<SEC-DOCUMENT>0001213900-22-022912.txt : 20220502
<SEC-HEADER>0001213900-22-022912.hdr.sgml : 20220502
<ACCEPTANCE-DATETIME>20220502081441
ACCESSION NUMBER:		0001213900-22-022912
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220502
DATE AS OF CHANGE:		20220502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nano-X Imaging Ltd.
		CENTRAL INDEX KEY:			0001795251
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39461
		FILM NUMBER:		22879501

	BUSINESS ADDRESS:	
		STREET 1:		COMMUNICATIONS CENTER
		CITY:			NEVE ILAN
		STATE:			L3
		ZIP:			9085000
		BUSINESS PHONE:		972-02-547-6333

	MAIL ADDRESS:	
		STREET 1:		COMMUNICATIONS CENTER
		CITY:			NEVE ILAN
		STATE:			L3
		ZIP:			9085000
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2021_nanoximaging.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 02 05:16:16 UTC 2022 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nnox="http://www.nanox.vision.com/20211231" xmlns:pf0="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 14pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 12pt">UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
WASHINGTON, D.C. 20549</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 16pt Times New Roman, Times, Serif; margin: 0; text-align: center">FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">20-F</ix:nonNumeric></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">(Mark One)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement">&#9744;</ix:nonNumeric> <b>REGISTRATION
STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">OR</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric> <b>ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric>,
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">OR</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric> <b>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">OR</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric> <b>SHELL
COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Date of event requiring this shell company
report</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">For the transition period from&#160; &#160;
&#160; &#160; &#160; to&#160; &#160;
&#160; &#160; &#160; </p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Commission file number <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-38024</ix:nonNumeric></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 14pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName">NANO-X IMAGING LTD</ix:nonNumeric></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Exact name of Registrant as specified
in its charter)</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">N/A<br/>
(Translation of Registrant&#8217;s name into English)</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">State of Israel<br/>
(Jurisdiction of incorporation or organization)</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">Communication Center</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Neve Ilan</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Israel</ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">9085000</ix:nonNumeric><br/>
(Address of principal executive offices)</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName">Erez Meltzer</ix:nonNumeric>, <b>Chief Executive Officer</b><br/>
Telephone: +972 02 5360360<br/>
Facsimile: <ix:nonNumeric contextRef="c1" name="dei:CityAreaCode">+972</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber">02 544 5214</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1">Communication Center</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown">Neve Ilan</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode">9085000</ix:nonNumeric><br/>
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Securities registered or to be registered
pursuant to Section 12(b) of the Act.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom"> <td style="width: 32%; border-bottom: Black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Title of each class</b></p></td> <td style="width: 2%">&#160;</td> <td style="width: 32%; border-bottom: Black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Trading Symbol</b></p></td> <td style="width: 2%">&#160;</td> <td style="width: 32%; border-bottom: Black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Name of each exchange on which registered</b></p></td></tr>
<tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><b>Ordinary Shares, par value NIS 0.01 per share</b></ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><b>NNOX</b></ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>The <span><ix:nonNumeric contextRef="c0" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric>
Stock Market LLC</span></b></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate the number of outstanding shares of each of the issuer&#8217;s
classes of capital or common stock as of the close of the period covered by the annual report: <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">51,791,441</ix:nonFraction> Ordinary Shares as of December
31, 2021</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. Yes &#9744;
<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If this report is an annual or transition report, indicate by check
mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note&#8212;Checking the box above will not relieve any registrant
required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those
sections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> &#9746; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> &#9746;
No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large accelerated
filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top"> <td style="width: 20%"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Large accelerated filer</ix:nonNumeric></td> <td style="width: 30%">&#9746;</td> <td style="width: 25%">Accelerated filer</td> <td style="width: 25%">&#9744;</td></tr>
<tr style="vertical-align: top"> <td>Non-accelerated filer</td> <td>&#9744;</td> <td>Emerging growth company</td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0">If an emerging growth company that prepares its financial statements
in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act.
&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0">&#8224; The term &#8220;new or revised financial accounting standard&#8221;
refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5,
2012.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has filed a report
on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued
its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark which basis of accounting the registrant
has used to prepare the financial statements included in this annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top"> <td style="width: 15%"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric> &#9746;</td> <td style="width: 70%">International Financial Reporting Standards as issued by the International Accounting Standards Board &#9744;</td> <td style="width: 15%; text-align: center">Other &#9744;</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">If &#8220;Other&#8221; has been checked in response to the previous
question, indicate by check mark which financial statement item the registrant has elected to follow. Item 17 &#9744;
Item 18 &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0">If this is an annual report, indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744;
No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING
THE PAST FIVE YEARS)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by checkmark whether the registrant has filed all documents
and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution
of securities under a plan confirmed by a court. Yes &#9744; No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="width: 1.25in">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 6%; text-align: center"><b>Page</b></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_001">PART I</a></td>
    <td>&#160;</td>
    <td style="text-align: center">1</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 1.</td>
    <td style="text-indent: 0pt"><a href="#a_002">Identity of Directors, Senior Management and Advisors</a></td>
    <td style="text-align: center">1</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 2.</td>
    <td style="text-indent: 0pt"><a href="#a_003">Offer Statistics and Expected Timetable</a></td>
    <td style="text-align: center">1</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 3.</td>
    <td style="text-indent: 0pt"><a href="#a_004">Key Information</a></td>
    <td style="text-align: center">1</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 4.</td>
    <td style="text-indent: 0pt"><a href="#a_005">Information on the Company</a></td>
    <td style="text-align: center">52</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 5.</td>
    <td style="text-indent: 0pt"><a href="#a_006">Operating and Financial Review and Prospects</a></td>
    <td style="text-align: center">78</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 6.</td>
    <td style="text-indent: 0pt"><a href="#a_007">Directors, Senior Management and Employees</a></td>
    <td style="text-align: center">94</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 7.</td>
    <td style="text-indent: 0pt"><a href="#a_008">Major Shareholders and Related Party Transactions</a></td>
    <td style="text-align: center">108</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 8.</td>
    <td style="text-indent: 0pt"><a href="#a_009">Financial Information</a></td>
    <td style="text-align: center">112</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 9.</td>
    <td style="text-indent: 0pt"><a href="#a_010">Offer and Listing</a></td>
    <td style="text-align: center">113</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 10.</td>
    <td style="text-indent: 0pt"><a href="#a_011">Additional Information</a></td>
    <td style="text-align: center">113</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 11.</td>
    <td style="text-indent: 0pt"><a href="#a_012">Qualitative and Quantitative Disclosures About Market Risk</a></td>
    <td style="text-align: center">128</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 12.</td>
    <td style="text-indent: 0pt"><a href="#a_013">Description of Securities Other than Equity Securities</a></td>
    <td style="text-align: center">128</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">&#160;</td>
    <td style="text-indent: 0pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_014">PART II</a></td>
    <td>&#160;</td>
    <td style="text-align: center">129</td></tr>
<tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 13.</td>
    <td style="text-indent: 0pt"><a href="#a_015">Defaults, Dividend Arrearages and Delinquencies</a></td>
    <td style="text-align: center">129</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 14.</td>
    <td style="text-indent: 0pt"><a href="#a_016">Material Modifications to the Rights of Security Holders and Use of Proceeds</a></td>
    <td style="text-align: center">129</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 15.</td>
    <td style="text-indent: 0pt"><a href="#a_017">Controls and Procedures</a></td>
    <td style="text-align: center">129</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 16.</td>
    <td style="text-indent: 0pt"><a href="#a_018">[Reserved]</a></td>
    <td style="text-align: center">132</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt; width: 1.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16A.</span></td>
    <td><a href="#v_027">Audit Committee Financial Expert</a></td>
    <td style="text-align: center; width: 6%">132</td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16B.</span></td>
    <td><a href="#v_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics</span></a></td>
    <td style="text-align: center">132</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16C.</span></td>
    <td><a href="#v_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services</span></a></td>
    <td style="text-align: center">132</td></tr>

<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt; width: 1.25in">Item 16D.</td>
    <td style="text-indent: 0pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><a href="#a_019">Exemptions from the Listing Standards for Audit Committees</a></p></td>
    <td style="text-align: center; width: 6%">132</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 16E.</td>
    <td style="text-indent: 0pt"><a href="#a_020">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></td>
    <td style="text-align: center">132</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 16F.</td>
    <td style="text-indent: 0pt"><a href="#a_021">Change in Registrant&#8217;s Certifying Accountant</a></td>
    <td style="text-align: center">132</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 16G.</td>
    <td style="text-indent: 0pt"><a href="#a_022">Corporate Governance</a></td>
    <td style="text-align: center">133</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 16H.</td>
    <td style="text-indent: 0pt"><a href="#a_023">Mine Safety Disclosure</a></td>
    <td style="text-align: center">133</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 16I.</td>
    <td style="text-indent: 0pt"><a href="#I_001">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></a></td>
    <td style="text-align: center">133</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">&#160;</td>
    <td style="text-indent: 0pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_027">PART III</a></td>
    <td>&#160;</td>
    <td style="text-align: center">134</td></tr>
<tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 17.</td>
    <td style="text-indent: 0pt"><a href="#a_029">Financial Statements</a></td>
        <td style="text-align: center">134</td></tr>
<tr style="vertical-align: top; ">
    <td style="padding-left: 35pt">Item 18.</td>
    <td style="text-indent: 0pt"><a href="#a_025">Financial Statements</a></td>
    <td style="text-align: center">134</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 35pt">Item 19.</td>
    <td style="text-indent: 0pt"><a href="#a_026">Exhibits</a></td>
    <td style="text-align: center">134</td></tr>
</table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">INTRODUCTION</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NANO-X IMAGING LTD was incorporated under the laws
of the State of Israel on December&#160;20, 2018 and commenced operations on September&#160;3, 2019. Unless the context otherwise requires,
all references to &#8220;Nanox,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and similar designations
refer to NANO-X IMAGING LTD, an Israeli company, and its consolidated subsidiaries. Unless derived from our financial statements or otherwise
noted, the terms &#8220;shekels&#8221; and &#8220;NIS&#8221; refer to New&#160;Israeli Shekels, the lawful currency of the State of Israel,
the terms &#8220;dollar&#8221; or &#8220;$&#8221; refer to U.S. dollars, the lawful currency of the United States, &#8220;and &#8220;KRW&#8221;
refers to Korean Won, the lawful currency of South Korea.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">FORWARD-LOOKING
STATEMENTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This annual report on Form 20-F contains
forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available
to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these
statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from
any future results, levels of activity, performance or achievements stated in or implied by these forward-looking statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All statements that are not historical facts
contained in this annual report on Form 20-F are forward-looking statements. These forward-looking statements include information
about possible or assumed future results of our business, financial condition, results of operations, prospects, liquidity, plans
and objectives. In some cases, you can identify forward-looking statements by terminology such as &#8220;can,&#8221; &#8220;might,&#8221;
&#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
&#8220;should,&#8221; &#8220;plan,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221;
&#8220;potential,&#8221; or the negative of these terms or other similar expressions. Forward-looking statements are based on information
we have when those statements are made or our management&#8217;s good faith belief as of that time with respect to future events,
and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in or suggested by the forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the initiation, timing, progress and results of our research and development,
manufacturing and commercialization activities with respect to our X-ray source technology or the Nanox.ARC and the Nanox.CLOUD, which
comprise the Nanox System;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to successfully demonstrate the feasibility of our technology for commercial applications;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our expectations regarding the necessity of, timing of filing for, and receipt of, regulatory clearances or approvals regarding
our technology, the Nanox.ARC and the Nanox.CLOUD;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to secure and maintain required U.S. Food and Drug Administration (the &#8220;FDA&#8221;) clearance and similar approvals from regulatory agencies worldwide and comply
with applicable quality standards and regulatory requirements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to manufacture the Nanox.ARC, if cleared, at substantially lower costs compared to medical imaging systems that
use a legacy analog X-ray source;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our expectations regarding the deployment schedule to meet our target
minimum installed base of our first Nanox Systems and final deployment of 15,000 Nanox Systems;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the pricing structure of our products and services, if such products and services receive regulatory clearance or approval;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the implementation of our business models;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to successfully integrate the business of companies that we acquire and to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired company to grow and manage growth profitably and retain its key employees;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our expectations regarding collaborations with third-parties and their potential benefits;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to enter into and maintain our arrangements with third-party manufacturers and suppliers;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to conduct business globally;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our expectations regarding when certain patents may be issued and the protection and enforcement of our intellectual property
rights;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to operate our business without infringing the intellectual property rights and proprietary technology of third
parties;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>regulatory developments in the United States and other jurisdictions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the rate and degree of market acceptance of our technology and our products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>development relating to our competitors and the medical imaging industry;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our estimates of the adoption of the Medical Screening as Service (&#8220;MSaaS&#8221;)
based model by market participants;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our estimates regarding the market opportunities for our technology and our products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to attract, motivate and retain key executive managers;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to comply with data protection laws, regulations and similar rules and to establish and maintain adequate cyber-security
and data protection;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to obtain third-party payor coverage or reimbursement of our Nanox System;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our expectation regarding the maintenance of our foreign private issuer status;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the ongoing impact of the COVID-19 pandemic, including mitigation efforts
and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to the development,
deployment and regulatory clearance of the Nanox Systems;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the costs incurred with respect to and the outcome of the securities class-action litigation we are currently subject to and
any similar or other claims and litigation we may be subject to in the future; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our success at managing other risks and uncertainties, including those listed under &#8220;Item 3. Key Information&#8212;D.
Risk Factors.&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many important factors, in addition to the factors
described above and in other sections of this annual report on Form 20-F, could adversely impact our business and financial performance.
The forward-looking statements contained in this annual report on Form 20-F speak only as of the date of this annual report on Form 20-F
and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in
this annual report on Form 20-F entitled &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; and &#8220;Item 5. Operating and
Financial Review and Prospects&#8221; and elsewhere in this annual report on Form 20-F. Because forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should
not rely on these forward-looking statements as predictions of future events. Moreover, we operate in an evolving environment. New risks
and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties, nor can
we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results
to differ materially from estimates or forward-looking statements. We qualify all of our forward-looking statements by these cautionary
statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements after the date of
this annual report on Form 20-F to conform these statements to actual results or to changes in our expectations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PART I</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_002"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in">Item 1.</td><td>Identity of Directors, Senior Management and Advisors</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_003"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in">Item 2.</td><td>Offer Statistics and Expected Timetable</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_004"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in">Item 3.</td><td>Key Information</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. [Reserved]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">B. Capitalization
and Indebtedness</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">C. Reasons for
the Offer and Use of Proceeds</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">D. Risk Factors</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risk Factors Summary</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><i>&#160;</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><i>Risks Related to Our Business</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">We are a development-stage company with limited operating history. We expect to incur significant additional losses in the future and may never be able to effectuate our business plan or achieve significant revenues or reach profitability. Therefore, at this stage of our business, potential investors have a high probability of losing their entire investment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Our efforts may never demonstrate the feasibility of our digital X-ray source technology, including both the micro-electro-mechanical systems (&#8220;MEMs&#8221;) X-ray chips and tubes, for commercial applications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Two of our business models depend on the successful commercial application of the Nanox.CLOUD, which is subject to numerous
risks and uncertainties.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We are highly dependent on the successful development, marketing and sale of our X-ray source technology and the related products
and services.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Products utilizing our technology may need to be approved or cleared by the FDA and similar regulatory agencies worldwide.
We may not receive, or may be delayed in receiving, the necessary approval or clearance for our future products, which would adversely
affect business, financial condition, results of operations and prospects.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We may need to obtain additional financing to fund our future operations. If we are unable to obtain such financing, we may
be unable to complete the development and commercialization of our technology and our products and services.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>The success of our primary business model, the Subscription Model, is subject to numerous risks and uncertainties.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We may not be successful in tailoring our X-ray source to the specific systems of other medical imaging companies under our
Licensing Model, and/or entering into licensing agreements on terms favorable to us.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>To the extent that we license our X-ray source technology to other medical imaging companies, the products integrating our
technology may need to be approved or cleared by the FDA or similar regulatory agencies.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">We recently completed the acquisitions of Nanox AI (formerly known as Zebra),
USARAD and the assets of MDWEB.&#160;&#160;Our failure to successfully, and in a timely manner, integrate the acquired businesses and
assets or any future acquisition and/or new lines of businesses could have an adverse effect on our business, financial condition, and
results of operations.&#160;&#160;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business
and our financial results and could cause a disruption to the development or deployment of the Nanox System.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our industry is highly competitive and is subject to technological change, which may result in new products or solutions that
are superior to our technology or other future products we may bring to market from time to time. If we are unable to anticipate
or keep pace with changes in the marketplace and the direction of technological innovation and customer demands, our technology
may become less useful or obsolete and our operating results will suffer.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We expect to depend on third parties to manufacture the Nanox.ARC and to supply certain component parts. Our reliance on third-party
manufacturers and suppliers involves certain risks that may result in, among others, increased costs, quality or compliance issues,
or failure to timely manufacture the Nanox.ARC, any of which could materially harm our business.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We may experience development or manufacturing problems and higher costs, or delays that could limit our revenue, if any, or
increase our losses.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We may not be able to successfully execute our business models.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">We have a limited operating history. If we successfully commercially launch the Nanox System, and it does not achieve widespread market acceptance, we will not be able to generate the revenue necessary to support our business.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We plan to do business globally, including in certain countries where we might have limited resources and would be subject
to additional regulatory burdens and other risks and uncertainties.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Because the Nanox System is still in the development stage, it is not yet approved for third-party payor coverage or reimbursement.
If in the future we are approved for and are otherwise able to commercialize it, but are unable to obtain adequate reimbursement
or insurance coverage from third-party payors, we may not be able to generate significant revenue, in which case we may need to
obtain additional financing.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Recent changes in the United States related to payment policies for imaging procedures could have a negative impact on the
utilization of our imaging services.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Billing complexities associated with obtaining payment or reimbursement may negatively affect our revenue, cash flow and profitability.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Any collaborative and MSaaS arrangements that we have established or may establish in the future may not be successful or we
may otherwise not realize the anticipated benefits from these collaborations. We do not control third parties with whom we have
or may have collaborative or MSaaS arrangements, and we will rely on them to achieve results which may be significant to us. In
addition, any current or future collaborative and MSaaS arrangements may place the development and commercialization of our technology
outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">We could become subject to product liability claims, product recalls, warranty claims and professional malpractice liability claims that could be expensive, divert management&#8217;s attention and harm our business reputation and financial results.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We are highly dependent on key members of our executive management team. Our inability to retain these individuals could impede
our business plan and growth strategies, which could have a negative impact on our business and the value of your investment.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>The mishandling or the perceived mishandling of sensitive information, or the occurrence of data security breaches, could harm
our business.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Our  ability to generate revenue from our teleradiology services and
AI solutions, as well as the other imaging offerings that we are developing will depend in large part on referrals from physicians.&#160;&#160;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">If we lose a significant number of our radiologists, our revenue from our teleradiology services and financial results could be adversely affected.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Exchange rate fluctuations between the U.S. dollar, the New Israeli Shekel and the KRW and inflation may negatively affect our results of operations, and we may not be able to hedge our currency exchange risks successfully.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">We  are currently subject to securities class-action litigation and&#160;U.S.
Securities and Exchange Commission (&#8220;SEC&#8221;) inquiry and may be subject to similar or other claims, litigation and investigations
in the future, all of which will require significant management attention, could result in significant legal expenses and may result
in unfavorable outcomes, all or any of which could have a material adverse impact on our financial condition and results of operations,
harm our reputation or otherwise negatively impact our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>If significant tariffs or other restrictions related to &#8220;trade wars&#8221; are placed on Chinese imports or any related
counter-measures are taken by China, our revenue and results of operations may be materially harmed.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our business may be impacted by changes in general economic conditions.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">Our business, financial condition and results of operations may be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine or any other geopolitical tensions.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">We do not expect to carry any business interruption insurance or any other insurance (except for director and officer, property, product liability, malpractice and clinical trials insurance). As a result, we may incur uninsured losses, increasing the possibility that you would lose your entire investment in our company.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Certain of our directors and/or officers may have interests that compete with ours.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our management team has limited experience managing a public company.</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Our Intellectual Property</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to
ensure their protection.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Patent terms may be inadequate to protect our competitive position on our future products for an adequate amount of time.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Claims that our technology or our future products or the sale or use of our future products infringe the patents or other intellectual
property rights of third parties could result in costly litigation or could require substantial time and money to resolve, even
if litigation is avoided.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment
and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we
or our future licensors do not comply with these requirements.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We may be subject to claims that our employees, consultants or advisers have wrongfully used or disclosed alleged trade secrets
of their former employers or claims asserting ownership of what we regard as our own intellectual property.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets
of interest and our business may be adversely affected.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our rights to develop and commercialize our products may be subject to the terms and conditions of licenses and sublicenses
granted to us by third parties.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We may be required to pay certain milestones and royalties and fulfill other obligations under our license agreements with
third-party licensors.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>If we choose to license our technology to third parties, this could result in disputes or otherwise limit our future operations.</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Government Regulation</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our product candidates and operations are subject to extensive government regulation and oversight both in the United States
and abroad, and our failure to comply with applicable requirements could harm our business.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We may not receive, or may be delayed in receiving, the necessary clearances or approvals for our future products, and failure
to timely obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial
penalties, and might require us to recall or withdraw a product from the market.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our products must be manufactured in accordance with federal, state and foreign regulations, and we could be forced to recall
our devices or terminate production if we fail to comply with these regulations.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">The misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product
liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in
the promotion of these uses, any of which could be costly to our business.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required
to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial
condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either
voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other
healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational
harm and diminished profits and future earnings.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Changes in laws or regulations relating to data protection, or any actual or perceived failure by us to comply with such laws
and regulations or our privacy policies, could materially and adversely affect our business or could lead to government enforcement
actions and significant penalties against us, and adversely impact our operating results.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>If we do not obtain and maintain international regulatory registrations, clearances or approvals for our products, we will
be unable to market and sell our products outside of the United States.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly for us to obtain regulatory
clearances or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Healthcare reform laws could adversely affect our products and financial condition.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their
ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being
developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact our business.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Employee Matters</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Under applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent
our competitors from benefiting from the expertise of some of our former employees.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We may not be able to attract and retain the highly skilled employees we need to support our planned growth.</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Owning Our Ordinary
Shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our share price may be volatile, and you may lose all or part of your investment.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>As a foreign private issuer, we are exempt from certain requirements that apply to domestic issuers and we are permitted to
follow certain home country corporate governance practices instead of applicable SEC and Nasdaq requirements, which may result
in less protection than is accorded to shareholders under rules applicable to domestic issuers.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We may lose our foreign private issuer status which would then require us to comply with the Exchange Act&#8217;s domestic
reporting regime and cause us to incur significant legal, accounting and other expenses.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We have not paid dividends in the past and have no immediate plans to pay dividends.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>We incur significant increased costs as a result of operating as a public company that reports to the SEC and our management
may be required to devote substantial time to meet compliance obligations.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Shares eligible for future sale may adversely affect the market for our ordinary shares and the issuance of additional ordinary
shares as a result of the exercise of our outstanding warrants and options will dilute the percentage ownership of our other shareholders.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>The purchase price of the ordinary shares may not reflect our actual value.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Our management conducted an evaluation of the effectiveness of our internal
control over financial reporting and concluded that our internal control over financial reporting was not effective as of December 31,
2021. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report
our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting,
which would harm our business and the trading price of our ordinary shares.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">We may be a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. Holders of our ordinary shares.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Our Operations in Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Conditions in Israel could materially and adversely affect our business.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>The termination or reduction of tax and other incentives that the Israeli government provides to Israeli companies may increase
our costs and taxes.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>It may be difficult to enforce a U.S. judgment against us, our officers and directors named in this annual report on Form 20-F
in Israel or the United States, or to assert U.S. securities laws claims in Israel or serve process on our officers and directors.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Your rights and responsibilities as our shareholder will be governed by Israeli law, which may differ in some respects from
the rights and responsibilities of shareholders of U.S. corporations.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Our amended and restated articles of association contains exclusive forum provisions for certain claims, which could limit
our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Provisions of our amended and restated articles of association and Israeli law and tax considerations may delay, prevent or
make difficult an acquisition of us, which could prevent a change of control and negatively affect the price of our ordinary shares.</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Our Business</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are a development-stage company with limited operating history.
We expect to incur significant additional losses in the future and may never be able to effectuate our business plan or achieve significant
revenue or reach profitability. Therefore, at this stage of our business, potential investors have a high probability of losing their
entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development-stage
company, and are subject to all of the risks inherent in the establishment of a new business enterprise. While we began to generate revenue
in the year ended December 31, 2021 through the sale of teleradiology services and the sale of AI solutions, following the completion
of the acquisitions of Nano-X AI Ltd (&#8220;Nanox AI&#8221;) (formerly known as Zebra Medical Vision Ltd. (&#8220;Zebra&#8221;)), USARAD
Holdings, Inc., a Delaware corporation (&#8220;USARAD&#8221;) and the assets of MDWEB, LLC (&#8220;MDWEB&#8221;) in November 2021, we
have a limited operating history and an unproven business plan upon which investors may evaluate our prospects. We have not yet demonstrated
the feasibility of our digital X-ray source technology, including both the MEMs X-ray chips and tubes, for commercial applications. Although
we have produced a working prototype of the Nanox.ARC and developed a prototype of the Nanox.CLOUD, we have not produced any of the approximately
15,000&#160;Nanox.ARC&#160;units planned for the initial global deployment. We engaged Dagesh P.K. Ltd. (&#8220;Dagesh&#8221;) to manufacture
the first Nanox.ARC units in Israel on a purchase order basis that we expect will be used for the acceptance tests under our MSaaS agreements,
demonstrations, regulatory approvals and for the initial global deployment, among other purposes. Even if we are able to manufacture the
Nanox.ARC, we may not be able to do so at the low costs needed to support our business models, including the Subscription Model, which
is our primary business model. We may not receive, or may be delayed in receiving, the necessary approval or clearance for the Nanox.ARC
or our future products. We also have not entered into any commercial arrangement for the licensing of our X-ray source under the Licensing
Model.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, even if our technology becomes
commercially viable, our business models may not generate sufficient revenue necessary to support our business. We estimate that
effectively stimulating market interest in our Nanox System will require deploying at least 5,000 to 10,000 Nanox.ARC units. In
addition, we estimate that a minimum installed base of at least 1,000 Nanox.ARC units will be needed to support our business during
the initial deployment, assuming we enter into at least one licensing agreement on commercially reasonable terms. We may never
achieve any of these thresholds for units deployed in the near-to-mid-term at any level or at all, which may cause our business
to fail. The Subscription Model is based on selling the Nanox System at low cost or no cost using a pay-per-scan pricing structure,
which is pioneering for medical imaging companies and is subject to numerous risks. The medical imaging industry is also highly
competitive and our technology, products, services or business models may not achieve widespread market acceptance. If we are unable
to address any issues mentioned above, or encounter other problems, expenses, difficulties, complications, and delays in connection
with the starting and expansion of our business, our entire business may fail, in which case you may lose your entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a history of net losses
and negative cash flow from operations since inception and we expect such losses and negative cash flows from operations to continue in
the foreseeable future. As of December 31, 2021 and 2020, we had working capital of approximately $42.1&#160;million and $215.3 million,
respectively, and shareholders&#8217; equity of approximately $292.1&#160;million and $230.7 million, respectively. For the years ended
December&#160;31, 2021, 2020 and 2019, we incurred net losses of approximately $61.8 million, $43.8&#160;million and $22.6 million, respectively.
As of December 31, 2021 and 2020, we had an accumulated deficit of approximately $146.2&#160;million and $84.4&#160;million, respectively,
and negative cash flow from operations of $38.1&#160;million, $21.5&#160;million and $5.5 million for the years ended December&#160;31,
2021, 2020 and 2019, respectively. We anticipate our losses will continue to increase from current levels because we expect to incur additional
costs related to developing our business, including research and development costs, manufacturing costs, employee-related costs, costs
related to acquisitions, costs of complying with government regulations, intellectual property development and prosecution costs, marketing
and promotion costs, capital expenditures, general and administrative expenses (including litigation costs), and costs associated with
operating as a public company.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our ability to generate significant revenue from
our operations and, ultimately, achieve profitability will depend on, among others, whether we can complete the development and commercialization
of our technology, our future products and our services, including our X-ray source technology, the Nanox.ARC and the Nanox.CLOUD, whether
we can manufacture the Nanox.ARC on a commercial scale in such amounts and at such costs as we anticipate, and whether we can achieve
market acceptance of our products, services and business models. We may never generate significant revenue or operate on a profitable
basis. Even if we achieve profitability, we may not be able to sustain it.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Our efforts may never demonstrate
the feasibility of our digital X-ray source technology, including both the MEMs X-ray chips and tubes, for commercial applications.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have developed our X-ray source technology,
including both the MEMs X-ray chips and tubes, and a working prototype of the Nanox.ARC. Even though we believe our X-ray source, which
we refer to as the Nanox.SOURCE, has achieved commercial applicability, our technology has not been tested over extended periods of time
and therefore no meaningful data exists regarding the durability, safety and effectiveness of our X-ray source over extended periods.
Although we have produced a working prototype of the Nanox.ARC, we may not be able to successfully integrate our X-ray source into the
Nanox.ARC or any medical imaging system. In addition, there is no precedent for commercialization of technology like ours. Even with
a fully functional prototype, the commercial scale production and deployment of Nanox.ARC will require significant additional development,
sales and marketing efforts, and we may not be able to ensure the effectiveness, accuracy, consistency and safety of the Nanox.ARC in
commercial settings. Any unanticipated technical or other problems and the possible insufficiency of funds and other resources needed
to complete the development and commercialization of our X-ray source, the Nanox.ARC or the Nanox.CLOUD may result in delays and cause
us to incur additional expenses that would increase our losses. If our X-ray source is not commercially feasible now or in the long term,
our business may fail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 7pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Two of our business models depend
on the successful commercial application of the Nanox.CLOUD, which is subject to numerous risks and uncertainties.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: #FEFEFE">In addition
to the Nanox.ARC, we have also developed, and continue to improve, the Nanox.CLOUD, a companion cloud software designed to deliver MSaaS.
The continued development and commercialization of the Nanox.CLOUD has a number of risks, including:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the Nanox.CLOUD requires a considerable investment of technical, financial, and legal resources, which may not be available
to us;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>it may require separate regulatory clearances or approvals;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">it may not be technically viable to integrate the Nanox.CLOUD with the businesses of our potential customers and collaborators, such as local operators, radiologists, cloud storage providers, medical artificial intelligence (&#8220;AI&#8221;)&#160;software providers and others;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>market acceptance of the MSaaS model is affected by a variety of factors, including security, reliability, scalability, customization,
performance, customer preference, patients&#8217; concerns with entrusting a third party to store and manage their health data,
public concerns regarding privacy and compliance with restrictive laws or regulations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our cloud-based service may raise concerns among our customer base, including concerns regarding changes to pricing over time,
service availability, information security of a cloud-based solution and access to medical images while offline;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the Nanox.CLOUD may be subject to computer system failures, infrastructure failures, cyber-attacks or other security breaches;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>incorrect or improper implementation or use of the Nanox.CLOUD by third-party cloud-service providers under our Sales Model
could result in customer dissatisfaction and harm our business and reputation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>undetected software errors or flaws in the Nanox.CLOUD could harm our reputation or decrease market acceptance of the MSaaS
model; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>we may incur higher costs than we expected as we expand our cloud-based services.</td></tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we are unable to successfully develop
and commercialize the Nanox.CLOUD, our business, financial condition, results of operations and prospects could be negatively impacted.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>We are highly dependent on the successful
development, marketing and sale of our X-ray source technology and the related products and services.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our core digital X-ray source technology
is the basis of our business. The Nanox.ARC currently under development is being designed to integrate our X-ray source technology
into a medical imaging device for commercial use. As a result, the success of our business plan is highly dependent on our ability
to develop, manufacture and commercialize our X-ray source technology and related products and services, such as the Nanox.ARC
and the Nanox.CLOUD, and our failure to do so could cause our business to fail. Successful commercialization of medical imaging
devices is a complex and uncertain process, dependent on the efforts of management, manufacturers, local operators, integrators,
medical professionals, third-party payors, as well as general economic conditions, among other factors. Any factor that adversely
impacts the development and commercialization of our X-ray source technology or related products and services, including the Nanox.ARC,
the Nanox.CLOUD and the Nanox System, will have a negative impact on our business, financial condition, results of operations and
prospects. Some potential factors include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to achieve sufficient market acceptance by hospitals and clinics, providers of medical imaging services, medical
professionals such as radiologists, third-party payors and others in the medical community;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to compete with existing medical imaging technology companies;</td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-size: 7pt">&#160;<span style="font-family: Times New Roman, Times, Serif">&#160;</span></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to establish, maintain and expand our sales, marketing and distribution networks;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to obtain and/or maintain necessary regulatory approvals; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to effectively protect our intellectual property.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our inability to successfully obtain clearance
or approval for and subsequently commercialize our X-ray source technology or related products and services, and/or successfully
develop and commercialize additional products or any enhancements to the products which we may develop would have a material adverse
effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Products utilizing our technology
may need to be approved or cleared by the FDA and similar regulatory agencies worldwide. We may not receive, or may be delayed
in receiving, the necessary approval or clearance for our future products, which would adversely affect business, financial condition,
results of operations and prospects.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We continue to implement a multi-step approach to the regulatory clearance
process. As a first step, we submitted a 510(k)&#160;premarket notification to an accredited Review Organization under the FDA&#8217;s
510(k) Third&#160;Party Review Program (the &#8220;Third Party Review Program&#8221;) for a single-source version of the Nanox.ARC, known
as the Nanox Cart X-Ray System. On April 1, 2021, we received clearance from the FDA to market our Nanox Cart X-Ray System. On June 17,
2021, we submitted a 510(k) premarket notification application to the FDA for the first version of our multi-source Nanox.ARC 3-D digital
tomosynthesis system. On August 12, 2021, we received a request for additional information from the FDA concerning the first submission
of our multi-source system. On January 10, 2022, we withdrew our first submission of our multi-source system. On January 12, 2022, we
submitted to&#160;the FDA a Q-submission for the second&#160;version of&#160;our&#160;multi-source Nanox.ARC 3-D digital tomosynthesis
system. The Q-submission program provides submitters an opportunity to have early collaboration and discussions about medical device submissions,
through a request for feedback from and/or a meeting with the FDA regarding a potential or planned medical device submission. We believe
that using this approach will assist to expedite and optimize the regulatory clearance process. The second version of&#160;the Nanox.ARC
is an improved and enhanced version that was designed, among other things,&#160;to address certain deficiencies raised by the FDA during
their review of the first submission from June 2021. We continue to communicate with the FDA and we expect the next step in this process
to be the submission of a supplement to the Q-submission followed a formal 510(k) application to the FDA for the multi-source Nanox.ARC.
If cleared by the FDA, we expect to commercialize the multi-source Nanox.ARC and we may seek alternatives for commercialization of our
Nanox Cart X-Ray System. However, the review process may be more costly and time consuming than we expect and we may not ultimately be
successful in completing the review process and our 510(k) premarket notification for the multi-source Nanox.ARC may not be cleared by
the FDA in a timely manner or at all. We may also need to seek approval from foreign regulatory authorities. We believe the digital X-ray
source falls within a category of radiology vacuum tubes converting electrical input power into X-rays that utilize the same energy levels,
radiation types and throughputs as already existing and approved X-ray tubes applied in a wide range of radiology medical procedures.
As a result, we expect that there will be no novel claim or methodology related to the X-ray radiation produced by the digital X-ray source;
however, regulatory agencies may not agree. To date, we have not had any discussion with the FDA or other regulatory authorities regarding
the regulatory pathways for the novel digital X-ray source. Efforts to achieve required governmental clearances and approvals could be
costly and time consuming, and we may not be able to obtain any such required clearances or approvals in accordance with our anticipated
timeline or in a cost-efficient manner. Any delay or failure to obtain necessary regulatory clearances or approvals could have a material
negative impact on our ability to generate revenues. Even if the products containing our technology receive the required regulatory clearance
or approval, such products will remain subject to extensive regulatory requirements. If we fail to comply with the regulatory requirements
of the FDA and other applicable U.S. and foreign regulatory authorities, or previously unknown problems with any approved commercial products,
manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the cost of compliance with
new laws or regulations governing our technology or future products could adversely affect our business, financial condition, results
of operations and prospects. New laws or regulations may impose restrictions or obligations on us that could force us to redesign
our technology or other future products or services, and may impose restrictions that are not possible or practicable to comply
with, which could cause our business to fail. See &#8220;&#8212;Risks Related to Government Regulation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>We may need to obtain additional
financing to fund our future operations. If we are unable to obtain such financing, we may be unable to complete the development
and commercialization of our technology and our products and services.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our operations have consumed substantial amounts
of cash since inception. Our net losses were $61.8&#160;million, $43.8&#160;million and $22.6 million for the years ended December&#160;31,
2021, 2020 and 2019, respectively. In addition, significant resources were invested in the development of our X-ray source technology
prior to us acquiring the technology. We anticipate that our future cash requirements will continue to be significant. While we began
to generate revenue in the year ended December 31, 2021, we expect that we will need to obtain additional financing to implement our
business plan as described in this annual report on Form 20-F. Specifically, although we believe our cash on hand is sufficient to complete
the manufacture, shipping, installation and deployment of a significant number of Nanox.ARC units, as well as to support the continued
research and development of the Nanox.ARC and the ongoing development of the Nanox.CLOUD, we may need to raise additional funds for such
purposes. Such financings could include equity financing, which may be dilutive to shareholders, or debt financing, which would likely
restrict our ability to borrow from other sources. In addition, such securities may contain rights, preferences or privileges senior
to those of the rights of our current shareholders. Additional funds may not be available when we need them, on terms attractive to us,
or at all. If adequate funds are not available on a timely basis, we may be required to curtail the development of our technology, products
or services, or materially delay, curtail, reduce or terminate our research and development and commercialization activities. We could
be forced to sell or dispose of our rights or assets. Any inability to raise adequate funds on commercially reasonable terms could have
a material adverse effect on our business, financial condition, results of operation and prospects, including the possibility that a
lack of funds could cause our business to fail and liquidate with little or no return to investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We operate in a capital intensive, high-cost industry
that requires significant amounts of capital to fund operations. We incur capital expenditures to, among other things, manufacture and
commercially deploy our Nanox Systems. To the extent we are unable to generate sufficient cash from our operations or we are unable to
structure or obtain financing, we may be unable to meet our capital expenditure requirements to support the maintenance and continued
growth of our operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>The success of our primary business
model, the Subscription Model, is subject to numerous risks and uncertainties.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect the Subscription Model to be our
primary business model and the key to achieving our vision of increasing early-detection of medical conditions that are discoverable
by X-ray. Even if we are able to successfully implement our Sales Model and/or our Licensing Model, the sustainability of our general
business plan depends substantially on the sustainability of our Subscription Model. We believe that effectively stimulating market
interest in our Nanox System will require deploying 5,000 to 10,000 Nanox.ARC units. In addition, we estimate that a minimum installed
base of at least 1,000 Nanox.ARC units will be needed to support our business during the initial deployment, assuming we enter
into at least one licensing agreement on commercially reasonable terms. The success of our Subscription Model will also depend
on each device, once deployed, performing a sufficient number of scans per day to be fully utilized. We may not be successful in
achieving these goals for various reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the process of manufacturing and deploying the Nanox System is a complex, multi-step process that depends on factors outside
our control, and could cause us to expend significant time and resources prior to earning associated revenues;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the manufacturing cost of the Nanox.ARC may be higher than we expect, may increase significantly, or may increase at a higher
rate than anticipated, and we may not be able to set or timely adjust our pay-per-scan pricing to compensate for any increased
costs;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the manufacturing of the Nanox.ARC may take longer than we expected, and we may have insufficient manufacturing capacity and
experience delays in the manufacturing and deployment of the Nanox System, which would have a negative impact on the timing of
our revenues;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>deployment and full utilization of the Nanox System may not be achieved or may take substantially longer than we expect, and
we may not be able to deploy a sufficient number of units of the Nanox System to support our business or to effectively stimulate
market interest;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>a Nanox System may perform fewer scans per day than our estimates due to a number of factors, including low market acceptance
rate, technical failures and downtime, service disruptions, outages or other performance problems, which would have a negative
impact on our revenues and our ability to recover costs;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the implementation, integration and testing of the Nanox.CLOUD with our potential customers and collaborators can be complex,
time-consuming and expensive for them, which may have a negative impact on the timing of our revenues;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the inability or unwillingness of potential customers to invest in the required safety infrastructure, including customary
X-ray shielding, to allow the Nanox.ARC to be safety operated;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>as part of the Subscription Model, we will be responsible for maintenance of the Nanox System units we deploy, which may be
more costly and time-consuming than we expect;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our customers may not be able to find or retain a sufficient number of radiologists to review the images generated by the Nanox
System, especially as we deploy additional Nanox Systems and the volume of scans increases;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the portion of our pay-per-scan pricing allocated to our collaborators may not be acceptable to them, either now or in the
future, and pricing negotiations with such collaborators may be a complex and time-consuming process;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the availability of insurance coverage and the level of reimbursement for the Nanox.ARC provided by third-party payors may
not be sufficient for our customers;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our pay-per-scan pricing may not be sufficient to recover our costs and may not be adjusted in a timely manner, which could
negatively affect our revenues or cause our revenues and results of operations to vary significantly from period to period;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>we may be unsuccessful in maintaining our target price per scan because we do not control the price charged by local operators
and higher prices may adversely affect market acceptance of the Nanox System; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>regulatory authorities may challenge our Subscription Model altogether, and impose significant civil, criminal, and administrative
penalties, damages, fines, and/or exclusion from government funded healthcare programs, which could adversely affect our revenues
and results of operations.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of the above factors may negatively
affect the implementation of our Subscription Model, or cause our Subscription Model to fail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>We may not be successful in tailoring
our X-ray source to the specific systems of other medical imaging companies under our Licensing Model, and/or entering into licensing
agreements on terms favorable to us.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under our proposed Licensing Model, we expect
to be engaged to tailor our X-ray source to other medical imaging companies&#8217; or manufacturers&#8217; of other X-ray devices specific
systems to replace the legacy X-ray source or to license our X-ray source technology to them to develop new types of imaging systems,
and we expect to receive a one-time, non-recurring licensing fee upfront, as well as recurring royalty payments for each imaging system
sold by such companies. We expect customization to be a complex and multi-step process that varies for each project, which will require
significant research and testing activities. We may also not be able to demonstrate the feasibility, functionality or safety of our technology
in other medical imaging systems, meet the potential licensees&#8217; design and manufacturing requirements, or satisfy their marketing
and product needs. In addition, we may not be successful in entering into licensing agreements with favorable terms as a result of a
numbers of factors, many of which are outside of our control, including willingness of, and the resources available to, other medical
imaging companies to in-license our novel X-ray source technology, our ability to agree with a potential partner on the value of our
technology, or on the related terms, as well as the availability of other technologies at lower cost or other alternative technologies
at the time. We have not entered into any licensing agreements to date. Any of the above factors may negatively affect the implementation
of our Licensing Model, or cause our Licensing Model to fail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>To the extent that we license our
X-ray source technology to other medical imaging companies, the products integrating our technology may need to be approved or
cleared by the FDA or similar regulatory agencies.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA or similar regulatory agencies may require
products developed by other medical imaging companies under the Licensing Model to go through lengthier or more rigorous processes than
we expected. These products may also be subject to regulations by governmental agencies in other jurisdictions, or regulation by other
federal, state and local agencies. In addition, we may not have control with respect to any such further regulatory approval strategies
or process. If such products do not receive, or are delayed in receiving, the necessary clearances or approvals, or if the performance
of one or more clinical trials are required in connection with such clearances or approvals, the prospects of our Licensing Model may
be materially affected, which could have a material adverse impact on our business and our revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We recently completed the acquisitions of Nanox AI (formerly
known as Zebra), USARAD and the assets of MDWEB. Our failure to successfully, and in a timely manner, integrate the acquired businesses
and assets or any future acquisition and/or new lines of businesses could have an adverse effect on our business, financial condition
and results of operations. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In November 2021, we completed the acquisitions
of Nanox AI (formerly known as Zebra), a deep-learning machine analytics company, USARAD, a leading provider of teleradiology services,
and the assets of MDWEB, a decentralized marketplace connecting imaging facilities with radiologists. We began to generate revenue in
the year ended December 31, 2021 through the sale of teleradiology services and AI solutions, following the completion of these acquisitions.
However, we may never realize the expected synergies, business opportunities and growth prospects in connection with these or any future
acquisitions and/or joint ventures. We may not be able to capitalize on the expected business opportunities, assumptions underlying estimates
of expected cost savings may be inaccurate or general industry and business conditions may deteriorate. In addition, integrating operations
may require significant efforts and expense on our part. We are dependent on few key employees to operate these businesses. Personnel
may leave or be terminated because of an acquisition. Our management may have its attention diverted while trying to integrate an acquisition.
If these factors limit our ability to integrate the operations of these or any future acquisition successfully or on a timely basis, our
expectations of future results of operations, including certain cost savings and synergies as a result of these or any future acquisition,
may not be met. The failure to successfully manage these risks in the implementation of these recent or any future acquisition and any
new lines of business could have a material, adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>A pandemic, epidemic or outbreak
of an infectious disease, such as COVID-19, may materially and adversely affect our business and our financial results and could
cause a disruption to the development or deployment of the Nanox System.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Public health crises such as pandemics or similar
outbreaks could adversely impact our business. Beginning in 2019, a novel strain of a virus named SARS-CoV-2 (severe acute respiratory
syndrome coronavirus 2), or coronavirus, which causes COVID-19, has spread to most countries across the world, including Israel and all
50 states within the U.S. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including
government-imposed quarantines, travel restrictions and other public health safety measures. The COVID-19 pandemic has adversely impacted
our operations in various ways. For example, due to travel restrictions as a result of the COVID-19 pandemic, our engineers had limited
ability to make work-related trips to Korea or Israel to test and optimize the Nanox.ARC and to begin MEMs X-ray chip manufacturing in
Korea. Our potential business partners also had limited ability to make on-site visits to our facilities or attend industry conferences
and meetings in person to experience the Nanox.ARC, which has negatively impacted our business development and deployment activities.
Due, in part, to travel restrictions as a result of the COVID-19 pandemic, we decided to manufacture the first Nanox.ARC units in Israel
on a purchase order basis from Dagesh that we expect will be used for the acceptance tests under our MSaaS agreements, demonstrations,
regulatory approvals and for the initial global deployment, among other purposes. The external labs we work with have been affected by
COVID-19, resulting in delays in our timeline for obtaining regulatory clearance and approval. Our FDA and other regulatory approvals
and clearances have been delayed due to prioritization of vaccines for COVID-19. COVID-19 has also caused shutdowns or disruptions of
business for our manufacturers and suppliers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The extent to which the COVID-19 pandemic impacts
our operations or those of our third-party partners will depend on future developments, which are highly uncertain and cannot be predicted
with confidence, including the duration of the pandemic, new information that will emerge concerning the severity of the coronavirus
and the actions to contain the coronavirus or treat its impact, further mutations or related variants of the virus (or even the threat
or perception that this could occur), among others. In addition, if any treatment or vaccine for COVID-19 is ineffective or underutilized,
any impact on our business may be prolonged. The continued spread of COVID-19 globally could adversely impact our development, manufacture
or deployment of the Nanox System, which could adversely affect our ability to obtain regulatory clearance and approval for and to commercialize
the Nanox System, increase our operating expenses and have a material adverse effect on our financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These and other factors arising from the
COVID-19 pandemic could worsen in countries that are afflicted with the coronavirus. Any of these factors, and other factors related
to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operations
and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the
United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize
the Nanox System.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Our industry is highly competitive
and is subject to technological change, which may result in new products or solutions that are superior to our technology or other
future products we may bring to market from time to time. If we are unable to anticipate or keep pace with changes in the marketplace
and the direction of technological innovation and customer demands, our technology may become less useful or obsolete and our operating
results will suffer.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The medical imaging industry is rapidly evolving and subject to intense
and increasing competition. To compete successfully and to be able to establish and maintain a competitive position in current and future
technologies, we will need to demonstrate the advantages of our technology over well-established alternative solutions, products and technologies,
such as computed tomography (&#8220;CT&#8221;), as well as newer methods of medical imaging and early detection. We believe that effectively
stimulating market interest for the Nanox System will require deploying 5,000 to 10,000 Nanox.ARC units. To achieve this, we will need
to raise or develop financial resources, technical expertise, marketing, distribution or support capabilities and we may not be successful
in doing so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Also, companies offering traditional medical
imaging systems, such as General Electric, Siemens, Philips, Hologic, Varian, Fuji, Toshiba and Hitachi, may be better established
in the market than we are, have greater corporate, financial, operational, sales and marketing resources than we do, or have more
experience in research and development than we have. In particular, the field emission technology has been used by a wide range
of leading market players in an attempt to create an alternative digital source of X-ray, the most well-known attempt being the
use of carbon nano tubes as the base materials for a potential field emission-based solution. In addition, early-detection technologies
developed by other companies, such as blood testing and DNA screening, may also reduce the attractiveness of our technology for
early detection or render it obsolete. Successful developments of these or other technologies by competitors resulting in new approaches
for medical imaging, including technologies, products or services that are more effective or commercially attractive, could make
our technology less useful or obsolete. We may also face opposition from certain industry leaders, who may have political influence
and the ability to delay deployment of the Nanox System in certain geographical areas.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, as the market expands, we expect
the entry of additional competitors, such as cloud computing companies or leading IT companies, who may have longer operating histories,
more extensive international operations, greater name recognition, and/or substantially greater technical, marketing and financial
resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our competitive position also depends on
our ability to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>generate widespread awareness, acceptance and adoption of our technology and future products or services;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>develop new or enhanced technologies or features that improve the convenience, efficiency, safety or perceived safety, and
productivity of our technology and future products or services;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>properly identify customer needs and deliver new products or services or product enhancements to address those needs;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>limit the time required from prototype development to commercial production;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>limit the timing and cost of regulatory approvals;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>attract and retain qualified personnel and collaborators;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>protect our inventions with patents or otherwise develop proprietary products and processes; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>secure sufficient capital resources to expand both our continued research and development, and sales and marketing efforts.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With respect to our AI imaging solutions, there
are a number of companies that currently offer AI radiology solutions, such as Aidoc and VIZ.AI, which, to our knowledge, focus on life
threatening and urgent cases. In addition, legacy healthcare technology companies are expected in the future to increase development efforts
in the field of AI imaging solutions. For example, Siemens Healthineers has developed AI-Rad Companion, which provides automatic post-processing
of imaging datasets through AI-powered algorithms for Siemens CTs. The AI medical imaging market is new and competition from new market
players may develop in the next few years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With respect to our teleradiology services, the
teleradiology market is highly competitive, rapidly evolving and fragmented, and is subject to changing technology and market dynamics.
The market has recently experienced and is expected to continue to experience competitive pricing pressure and radiologist compensation
pressure. We compete directly with both large and small-scale service providers who offer local, regional and national coverage operations.
We believe that our principal competitors are Envision Physician Services and Radiology Partners. We compete to attract and retain relationships
with customers and radiologists in different ways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our technology is not, or our future
products or services are not, competitive based on these or other factors, our business would be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>We expect to depend on third parties
to manufacture the Nanox.ARC and to supply certain component parts. Our reliance on third-party manufacturers and suppliers involves
certain risks that may result in, among others, increased costs, quality or compliance issues, or failure to timely manufacture
the Nanox.ARC, any of which could materially harm our business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If cleared, we expect to rely on third-party manufacturers
and suppliers for the commercial production of the multi-source Nanox.ARC. We are currently evaluating and testing glass-based and ceramics-based
X-ray tubes to determine which tubes will be used in the Nanox.ARC. Once a determination is made, we intend to enter into agreements with
third-party manufacturers for such tubes based on, among other things, cost effectiveness. In May 2020, we entered into a three-year contract
manufacturing agreement with FoxSemicon Integrated Technology, Inc., a subsidiary of Foxconn (&#8220;FITI&#8221;) to manufacture the multi-source
Nanox.ARC. Under the contract manufacturing agreement with FITI, FITI will negotiate and contract with other parties for the supply of
the various other components of the Nanox.ARC in accordance with the pre-approved supplier list and on the terms to be agreed upon by
both parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">However, due, in part, to travel restrictions as
a result of the COVID-19 pandemic, we decided to manufacture the first Nanox.ARC units in Israel and we engaged Dagesh to manufacture
Nanox.ARC units in Israel on a purchase order basis that we expect will be used for the acceptance tests under our MSaaS agreements, demonstrations,
regulatory approvals and for the initial global deployment, among other purposes. Although we expect to formalize our arrangement in writing,
we have not yet done so, and we may not establish a formal agreement or be able to enforce the obligations under such arrangements. As
we further expand our business in connection with the commercialization of our technology, we expect to seek to engage several manufacturers
of the Nanox.ARC. If any of our manufacturers or suppliers breach their agreements, are unable to meet their contractual or quality requirements,
or become unwilling to perform for any reason, we may be unable, or may be unable in a timely manner, to locate alternative acceptable
manufacturers or suppliers and enter into favorable agreements with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our dependence on third-party manufacturers and
suppliers involves a number of risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>insufficient capacity or delays in meeting our demand;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>inadequate manufacturing yields, inferior quality and excessive costs;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>inability to manufacture products that meet the agreed upon specifications;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>inability to obtain an adequate supply of materials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>inability to comply with the relevant regulatory requirements for the manufacturing process;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>limited warranties on products supplied to us;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>inability or failure to comply with our contractual obligations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>potential increases in prices; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>increased exposure to potential misappropriation of our intellectual property.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recently commenced the manufacture of the MEMs
X-ray chips at our new fabrication facility in Korea, which is expected to meet our currently anticipated needs. However, we may not be
successful in mass production of the MEMs X-ray chips at the facility or have sufficient capacity to manufacture the MEMs X-ray chips
as our business expands. In addition, we rely on third parties to supply the raw materials and certain component parts. Disruptions of
our relationships with such suppliers could negatively impact our production for an extended period of time. Any inability to acquire
sufficient quantities of any raw materials or components in a timely manner from these third-party suppliers could have a material negative
impact on our business. We may need to enhance or redesign our MEMs X-ray chip to generate licensing revenue from it or for it to be functional
for certain medical imaging applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, if we change the manufacturer of a
critical component of our products, we will be required to verify that the new manufacturer maintains facilities, procedures and operations
that comply with our quality and applicable regulatory requirements, which could further impede our ability to manufacture our products
in a timely manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Transitioning to a new supplier could be
time-consuming and expensive, may result in interruptions in our operations and product delivery, could affect the performance
specifications of our products or could require that we modify the design of those systems. If the change in manufacturer results
in a significant change to any product, a new 510(k) clearance or approval from the FDA or similar international regulatory authorization
may be necessary before we implement the change, which could cause substantial delays. The occurrence of any of these events could
harm our ability to meet the demand for our products in a timely or cost-effective manner. See &#8220;&#8212;Risks Related to Government
Regulation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>We may experience development or
manufacturing problems and higher costs, or delays that could limit our revenue, if any, or increase our losses.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Developing manufacturing procedures for
new products requires developing specific production processes for those products. Developing such processes could be time consuming,
and any unexpected difficulty in doing so can delay the introduction of the Nanox.ARC. Moreover, difficulties associated with adapting
our technology and product design to the proprietary process technology and design rules of outside manufacturers can lead to reduced
yields. Since low yields may result from either design or process technology failures, yield problems may not be effectively determined
or resolved until an actual product exists that can be analyzed and tested to identify process sensitivities relating to the design
rules that are used. As a result, yield problems may not be identified until well into the production process, and resolution of
yield problems may require cooperation between our manufacturers and us. This risk could be compounded by the offshore location
of our manufacturers, increasing the effort and time required to identify, communicate and resolve manufacturing yield problems.
Manufacturing defects that we do not discover during the manufacturing or testing process may lead to costly product recalls. These
risks may lead to increased costs or delayed product delivery, which would harm our profitability and customer relationships. Furthermore,
our, our manufacturers&#8217; or our suppliers&#8217; production processes and assembly methods may have to change to accommodate
any significant, future expansion of our manufacturing capacity, which may increase the manufacturing costs, delay production of
our products, reduce our product margin, require supplemental filings with the FDA or other regulatory authorities, any of which
may adversely impact our business. If we are unable to keep up with demand for our products by successfully manufacturing and shipping
our products in a timely manner, our revenue could be impaired, and market acceptance for our products could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may not be able to successfully execute our business models.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are pursuing three simultaneous business models to maximize the commercial potential of our X-ray source technology, each of which requires
significant time and resources, in particular, our primary business model, the Subscription Model. We are a company with limited operating
history and we may not have the necessary resources, expertise and experience to successfully execute any of our business models on a
global scale, such as obtaining the necessary approvals or clearances from the regulatory agencies of our target markets. Our ability
to execute our models is dependent on a number of factors, including the ability of our senior management team to execute our models,
our ability to engage local operators and integrators in different geographic regions, our ability to begin or maintain our pace of product
development, manufacturing and commercialization, our ability to meet the changing needs of the medical imaging market, and the ability
of our employees to perform at a high-level. If we are unable to execute our models, if our models do not drive the growth that we anticipate,
or if our market opportunity is not as large as we have estimated, it could adversely affect our business and our prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history. If we successfully commercially launch the Nanox System, and it does not achieve widespread market
acceptance, we will not be able to generate the revenue necessary to support our business.</i></b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a limited operating history and while we began the marketing of our AI solutions and teleradiology services following the recent
acquisitions in November 2021, we have no history of marketing our X-ray source technology, the Nanox.ARC or the Nanox.CLOUD. We may
fail to generate significant interest in our X-ray source technology or the Nanox System or the imaging products using our technology,
or any other product we may develop. These and other factors, including the following, may affect the rate and level of market acceptance:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectiveness
                                            of the sales and marketing efforts of us, and our partners such as the local partners;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perception
    by medical professionals and patients of the convenience, safety, efficiency and benefits of the Nanox System or products using our
    technology, compared to competing methods of medical imaging, such as the time and skill required to read the tomographic images
    produced by the Nanox.ARC and our X-ray source;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">opposition
    from certain industry leaders, which may limit our ability to promote the Nanox System and to penetrate into the medical imaging
    market in certain geographical areas;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            existence of established medical imaging technology;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">willingness
                                            of market participants to accept the MSaaS model;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    changing and volatile U.S. and global economic environments, including as a result of the COVID-19 pandemic, the military conflict
    between Russia and Ukraine, the global response to it and any negative impact on the global economy and capital markets resulting
    from the conflict or any other geopolitical tensions, or inflation;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
                                            of market introduction of competing products, and the sales and marketing initiatives of
                                            such products;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">press
                                            and blog coverage, social media coverage, and other publicity and public relations factors
                                            by others;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
                                            of financing or other resources to successfully develop and commercialize our technology
                                            and implement our business plan;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            level of commitment and support that we receive from our partners, such as local operators,
                                            cloud storage providers and medical AI software providers, as well as medical professionals
                                            such as radiologists; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">coverage
                                            determinations and reimbursement levels of third party payors.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
cleared or approved for marketing by the FDA or other regulatory agencies, depending on the approved clinical indication, the Nanox System
will be competing with existing and future imaging products and similar offerings. The technology underlying our X-ray source and the
Nanox System may be perceived as inferior or inaccurate and patients may be unwilling to undergo medical screening using the Nanox.ARC
or other products using our technology. Moreover, patients and medical professionals may be unwilling to depart from the current medical
imaging technology. Medical professionals tend to be slow to change their medical diagnostic practices because of perceived liability
risks arising from the use of new technology or products, and they may not recommend medical imaging using the Nanox.ARC or other products
using our technology until there is long-term clinical evidence to convince them to alter or modify their existing imaging methods. Our
efforts to educate patients, radiologists and other members of the medical community on the benefits of our products require significant
resources and may not be successful. Our efforts to educate the marketplace may require more resources than are required by conventional
technologies marketed by our competitors. In particular, gaining market acceptance for our products in nascent markets, such as Africa,
China, India, and certain countries in Latin America, could be challenging. Moreover, in the event that the Nanox System or other products
using our technology are the subject of guidelines, clinical studies or scientific publications that are unfavorable or damaging, or
otherwise call into question their benefits, we may have difficulty in convincing market participants to adopt our products. In addition,
medical professionals, patients, providers of medical imaging services and third-party payors may not adopt or reimburse the use of the
Nanox System in the near term or at all. If we are unable to achieve or maintain an adequate level of market acceptance, we may not generate
significant revenue or become profitable and our business, financial condition, results of operations and prospects would be significantly
harmed.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
plan to do business globally, including in certain countries where we might have limited resources and would be subject to additional
regulatory burdens and other risks and uncertainties.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to do business globally, including in North America and certain countries in Asia, Europe, Africa, Latin America and Australia.
Commercialization of our X-ray source technology, the Nanox.ARC or the Nanox System in foreign markets, either directly or through third
parties, is subject to additional risks and uncertainties, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reimbursement
                                            and insurance coverage;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to find agencies, dealers or distributors in specific countries or regions;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to directly control commercial activities of third parties;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
                                            resources to be deployed to a specific jurisdiction;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            burden of complying with complex and changing regulatory, tax, accounting and legal requirements;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">different
                                            medical imaging practice and customs in foreign countries affecting acceptance in the marketplace;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">import
                                            or export licensing and other requirements;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">longer
                                            accounts receivable collection times;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">longer
                                            lead times for shipping;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">language
                                            barriers for technical training;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
                                            protection of intellectual property rights in some foreign countries;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
                                            currency exchange rate fluctuations; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interpretations
                                            of contractual provisions governed by foreign laws in the event of a contract dispute.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
we are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C.
&#167; 201, the U.S. Travel Act, the USA PATRIOT Act, the United Kingdom Bribery Act 2010, the Proceeds of Crime Act 2002, Chapter 9
(sub-chapter 5) of the Israeli Penal Law, 1977, the Israeli Prohibition on Money Laundering Law&#8211;2000 and possibly other anti-bribery
and anti-money laundering laws in countries outside of the United States in which we conduct our activities. As we engage finders to
obtain MSaaS agreements in certain countries, we and our finders may have direct or indirect interactions with officials and employees
of government agencies or state-owned or affiliated entities. We may be held liable for the corrupt or other illegal activities of these
third-party business partners and intermediaries, our employees, representatives, contractors, partners and agents, even if we do not
explicitly authorize such activities. As we expand our international business, our risks under these laws may increase.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also may sell the Nanox.ARC, the Nanox.CLOUD or the Nanox System to government entities, which are subject to a number of challenges
and risks. Any actual or perceived privacy, data protection, or data security incident, or even any perceived defect with regard to our
practices or measures in these areas, may negatively impact public sector demand for our products. Government entities may also have
statutory, contractual or other legal rights to terminate contracts with us for convenience or due to a default, and any such termination
may adversely affect our future results of operations. Governments routinely investigate and audit government contractors&#8217; administrative
processes, and any unfavorable audit could result in the government refusing to continue buying our subscriptions, a reduction of revenue,
or fines or civil or criminal liability if the audit uncovers improper or illegal activities. In addition, sales of the Nanox.ARC, the
Nanox.CLOUD or the Nanox System in foreign markets could also be adversely affected by the imposition of governmental controls, political
and economic instability, war, conflicts, civil unrest and other hostilities, trade restrictions and changes in tariffs, any of which
may adversely affect our business, financial condition, results of operations and prospects.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Because
the Nanox System is still in the development stage, it is not yet approved for third-party payor coverage or reimbursement. If in the
future we are approved for and are otherwise able to commercialize it, but are unable to obtain adequate reimbursement or insurance coverage
from third-party payors, we may not be able to generate significant revenue, in which case we may need to obtain additional financing.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because the Nanox System is still in the development
stage, it is not yet approved for third-party payor coverage or reimbursement. Coding and coverage determinations as well as reimbursement
levels and conditions are important to the commercial success of an imaging product or offering. The future availability of insurance
coverage and reimbursement for newly approved medical devices is highly uncertain, and our future business will be greatly impacted by
the level of reimbursement provided by third-party payors. In the United States, third-party payors decide which imaging products and
services they will cover, how much they will pay and whether they will continue reimbursement. Third-party payors may not cover or provide
adequate reimbursement for the Nanox System or the imaging services using the Nanox System, assuming we are able to fully develop and
obtain all regulatory approvals and clearances to market it in the United States or other geographies. To date, we have not had any discussions
with any third-party payors, including any regulatory agencies administering any government funded healthcare programs, regarding the
coding, coverage or reimbursement for imaging services using the Nanox System. Accordingly, unless government and other third-party payors
provide coverage and reimbursement for our services, patients and healthcare providers may choose not to use them, which would cause investors
to lose their entire investment. A primary trend in the United States healthcare industry and elsewhere is cost containment. Government
authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular
products and services. Reimbursement may not be available, or continue to be available, for the Nanox System or the imaging services using
the Nanox System, other products or systems using our X-ray source technology, our AI solutions, teleradiology services, the Nanox.MARKETPLACE
or any other products or services we may develop or offer in the future, or even if reimbursement is available, such reimbursement may
not be adequate. We also will be subject to foreign reimbursement policies in the international markets we expect to enter. Decisions
by health insurers or other third-party payors in these markets not to cover, or to discontinue reimbursing, our products could materially
and adversely affect our business. If such decisions are made, they could also have a negative impact on our ability to generate revenues,
in which case we may need to obtain additional financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
changes in the United States related to payment policies for imaging procedures could have a negative impact on the utilization of our
imaging services.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, over the past several years, the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), the federal agency
responsible for administering the Medicare program, has implemented numerous changes to payment policies for imaging procedures in both
the hospital setting and non-hospital settings, which include physician offices and freestanding imaging facilities. Some of these changes
have had a negative impact on utilization of imaging services. Examples of these changes include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limiting
                                            payments for imaging services in physician offices and free-standing imaging facility settings
                                            based upon rates paid to hospital outpatient departments;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reducing
                                            payments for certain imaging procedures when performed together with other imaging procedures
                                            in the same family of procedures on the same patient on the same day in the physician office
                                            and free-standing imaging facility setting;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
                                            significant revisions to the methodology for determining the practice expense component of
                                            the Medicare payment applicable to the physician office and free-standing imaging facility
                                            setting which results in a reduction in payment; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revising
                                            payment policies and reducing payment amounts for imaging procedures performed in the hospital
                                            outpatient setting.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also expect increased regulation and oversight of advanced diagnostic testing. One provision in the Protecting Access to Medicare Act
requires CMS to develop appropriate use criteria (&#8220;AUC&#8221;) that professionals must consult when ordering advanced diagnostic
imaging services (which include magnetic resonance imaging (&#8220;MRI&#8221;), CT, nuclear medicine (including position emission tomography)
and other advanced diagnostic imaging services that the Secretary of the Department of Health and Human Services (&#8220;HHS&#8221;)
may specify). Under this provision, payment is to be made to the furnishing professional for an applicable advanced diagnostic imaging
service only if the claim indicates that the ordering professional consulted a qualified clinical decision support mechanism, as identified
by HHS, as to whether the ordered service adheres to the applicable AUC. To the extent that these types of changes have the effect of
reducing the aggregate number of diagnostic medical imaging procedures performed in the United States, our business, results of operations,
financial condition and cash flows would be adversely affected. Currently, the payment penalty phase for the AUC program is scheduled
to begin on the later of January 1, 2023 or the January 1 that follows the declared end of the public health emergency for COVID-19.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Billing
complexities associated with obtaining payment or reimbursement may negatively affect our revenue, cash flow and profitability.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for our imaging-based offerings is, and is expected to be, provided by individual patients and from a variety of payors, such as commercial
insurance carriers, managed care organizations and governmental programs. Each payor typically has different billing requirements, and
the billing requirements of many payors have become increasingly stringent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
the factors complicating our customers&#8217; ability to bill and receive reimbursement from third-party payors are:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
                                            among payors as to which party is responsible for payment;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disparity
                                            in coverage among various payors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disparity
                                            in information and billing requirements among payors; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorrect
                                            or missing billing information, which is required to be provided by the ordering physician.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we may be required to seek new billing
codes for imaging services using the Nanox System or any other imaging-based offering that we may provide, and regulatory authorities
may not approve the creation of separate codes. Additionally, even if we are successful, existing or future billing codes or the payment
amounts associated with such codes may change in the future.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
billing complexities, and the related uncertainty in obtaining payment for our imaging-based offerings, could negatively affect our revenue,
cash flow and profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Any
collaborative and MSaaS arrangements that we have established or may establish in the future may not be successful or we may otherwise
not realize the anticipated benefits from these collaborations. We do not control third parties with whom we have or may have collaborative
or MSaaS arrangements, and we will rely on them to achieve results which may be significant to us. In addition, any current or future
collaborative and MSaaS arrangements may place the development and commercialization of our technology outside our control, may require
us to relinquish important rights or may otherwise be on terms unfavorable to us.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into certain, and expect to enter into additional, collaborative arrangements and MSaaS agreements with respect to the research,
development, manufacture and commercialization of our technology with different relevant industry participants, including, among others,
local operators, integrators, radiologists, cloud storage providers and medical AI software providers and third-party payors. See &#8220;Item
4. Information on the Company&#8212;B. Business Overview&#8212; MSaaS Agreements.&#8221; Any future potential collaborative or MSaaS
arrangements may require us to rely on external consultants, advisors and experts for assistance in several key functions, including
research and development, manufacturing, regulatory, intellectual property, commercialization and distribution. We cannot and will not
control these third parties, but we may rely on them to achieve results, which may be significant to us. Relying upon these collaborative
arrangements subjects us to a number of risks, including:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to control the amount and timing of resources that our collaborators may
                                            devote to our technology;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should
                                            a collaborator fail to comply with applicable laws, rules or regulations when performing
                                            services for us, we could be held liable for such violations;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            collaborators may have a shortage of qualified personnel, particularly radiologists who can
                                            review the medical images generated by the Nanox System, especially as we deploy additional
                                            Nanox Systems and the volume of scans increases;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be required to relinquish important rights, such as marketing and distribution rights;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
                                            combinations or significant changes in a collaborator&#8217;s business strategy may adversely
                                            affect a collaborator&#8217;s willingness or ability to complete its obligations under any
                                            arrangement;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            collaborators may default on their payments to us or fail to deliver standby letters of credit
                                            or financial guarantees, and it may be time consuming and difficult to enforce such payment
                                            obligations and obligations to provide standby letters of credit and financial guarantees
                                            in various jurisdictions, and we may be unsuccessful in enforcing such obligations;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            collaborative arrangements are subject to conditionality, including receipt of regulatory
                                            clearance and material compliance with acceptance test protocol, among other things, for
                                            the Nanox.ARC;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
                                            certain circumstances, a collaborator could move forward with a competing product developed
                                            either independently or in collaboration with others, including our competitors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            current or future collaborators may utilize our proprietary information in a way that could
                                            expose us to competitive harm;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            collaborators could obtain ownership or other control over intellectual property that is
                                            material to our business; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborative
                                            arrangements are often terminated or allowed to expire or remain unformalized by a written
                                            agreement, which could delay the ability to commercialize our technology.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if disputes arise between us and any of our collaborators, it could result in the delay or termination of the development,
manufacturing or commercialization of products containing our technology, lead to protracted and costly legal proceedings, or cause collaborators
to act in their own interest, which may not be in our interest. As a result, the collaborative arrangements that we may enter into, may
not achieve their intended goals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these scenarios materialize, they could have a material adverse effect on our business, financial condition, results of operations
and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also may have other future products where it is desirable or essential to enter into agreements with a collaborator who has greater financial
resources or different expertise than us, but for which we are unable to find an appropriate collaborator or are unable to do so on favorable
terms. If we fail to enter into such collaborative agreements on favorable terms, it could materially delay or impair our ability to
develop and commercialize, and increase the costs of development and commercialization of, our technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could become subject to product liability claims, product recalls, warranty claims and professional malpractice liability claims that
could be expensive, divert management&#8217;s attention and harm our business reputation and financial results.</i></b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business exposes us to potential liability risks that are inherent in the marketing and sale of products used in patient care. We may
be held liable if the Nanox System or if any other product that integrates our X-ray source technology causes injury or death or is found
otherwise unsuitable during usage. The Nanox System currently under development incorporates sophisticated components and computer software.
Complex software can contain errors, particularly when first introduced. In addition, new products or enhancements may contain undetected
errors or performance problems that, despite testing, are discovered only after installation. Patients could allege or possibly prove
defects of our products or other products that integrate our technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
product liability claim, regardless of its merit or eventual outcome, could result in significant legal defense costs and divert management&#8217;s
attention. Regardless of merit or eventual outcome, liability claims may result in:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
                                            demand for the Nanox System;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
                                            to our reputation;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            of related litigation;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
                                            monetary awards to patients and others;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
                                            of revenue; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inability to commercialize future products.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may be subject to professional liability claims, including, without limitation, for improper use or malfunction of our diagnostic
imaging software.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the radiologists that provide our teleradiology services may occasionally subject us to malpractice claims. Claims, suits or complaints
relating to services provided by these radiologists may be asserted against us in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these outcomes may have an adverse effect on our business, financial condition and results of operations, and may increase the volatility
of our share price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
coverage limits of our insurance policies we may choose to purchase to cover related risks may not be sufficient to cover future claims.
If sales of the Nanox System or other products integrating our technology increase or we suffer future product liability claims or malpractice
claims, we may be unable to maintain product liability insurance or malpractice insurance at satisfactory rates or with adequate amounts
or at all. A product liability claim, any product recalls or excessive warranty claims, whether arising from defects in design or manufacture
or otherwise, could negatively affect our sales or require a change in the design or manufacturing process, any of which could harm our
relationship with our customers and partners, and have a material adverse impact on our reputation and business, financial condition,
results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Nanox System or other products integrating our technology are defective, we, our future customers or partners may be
required to notify regulatory authorities and/or to recall the products. See &#8220;&#8212;Risks Related to Government Regulation&#8212;Our
products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to
the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and
results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at
the direction of the FDA or another governmental authority, could have a negative impact on us.&#8221; Any recall would divert management&#8217;s
attention and financial resources and harm our reputation with customers, patients, medical professionals and third-party payors. A recall
involving the Nanox System would be particularly harmful to our business. The adverse publicity resulting from any of these actions could
adversely affect the perception of our customers or partners. These investigations or recalls, especially if accompanied by unfavorable
publicity, could result in our incurring substantial costs, losing revenues and damaging our reputation, each of which would harm our
business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are highly dependent on key members of our executive management team. Our inability to retain these individuals could impede our business
plan and growth strategies, which could have a negative impact on our business and the value of your investment.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to implement our business plan depends on the continued services of key members of our senior management. In particular, and
to a critical extent, we are dependent on the continued efforts and services of the members of management named under &#8220;Item 6.
Directors, Senior Management and Employees.&#8221; If we lose the services of such key members of our management team, we would likely
be forced to expend significant time and money in the pursuit of replacement individuals, which may result in a delay in the implementation
of our business plan and plan of operations. We may not be able to find satisfactory replacements on terms that would not be unduly expensive
or burdensome to us. We do not currently carry a key-man life insurance policy that would assist us in recouping our costs in the event
of the death or disability of a member of our management team. The loss of members of our management team, or our inability to attract
or retain other qualified individuals, could have a material adverse effect on our business, results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
mishandling or the perceived mishandling of sensitive information, or the occurrence of data security breaches, could harm our business.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our business operations will enable us to accumulate a significant amount of highly sensitive and/or confidential information,
including medical images and other medical and personal information. While employee contracts generally contain standard confidentiality
provisions, our employees, customers or collaborators may not properly handle or process sensitive or confidential data. The improper
handling of sensitive or confidential data, or even the perception of such mishandling (whether or not valid), or other security lapses
by us, our customers or collaborators, could reduce demand for our offerings or otherwise expose us to financial or reputational harm
or legal liability.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any security breach, including personal data breaches, or incident, including cybersecurity incidents, that we experience could
result in unauthorized access to, misuse of, or unauthorized acquisition of the sensitive or confidential information and data (including
medical information), the loss, corruption, or alteration of this data, interruptions in our operations, or damage to our systems. Any
such incidents could expose us to claims, litigation, regulatory or other governmental investigations, administrative fines and potential
liability. An increasing number of digital platforms have disclosed breaches of their security, some of which have involved sophisticated
and highly targeted attacks on portions of their services. Because the techniques used to obtain unauthorized access, disable or degrade
service, or sabotage systems change frequently and often are not foreseeable or recognized until launched against a target, we may be
unable to anticipate these techniques or to implement adequate preventative measures. If an actual or perceived breach of our security
occurs, public perception of the effectiveness of our security measures and brand could be harmed and our results of operations could
be negatively affected. Data security breaches and other incidents may also result from non-technical means (e.g., actions by employees
or contractors). Any compromise of our security could result in a violation of applicable security, privacy or data protection, consumer
and other laws, regulatory or other governmental investigations, enforcement actions, and legal and financial exposure, including potential
contractual liability. Any such compromise could also result in damage to our reputation and a loss of confidence in our security and
privacy or data protection measures. Any of these effects could materially and adversely affect our business, financial condition and
results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to execute our business strategy depends, in part, on the continued and uninterrupted performance of our information technology
systems, which support our operations. Despite the implementation of security measures, our internal computer systems, and those of third
parties on which we rely, are vulnerable to damage from, among others, computer viruses, malware, natural disasters, terrorism, war,
telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the internet, attachments to emails, persons inside
our organization, or persons with access to systems inside our organization or similar disruptive problems. The risk of a security breach
or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists,
has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.
If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development
programs. Any such security breach may compromise information stored on our networks and may result in significant data losses or theft
of personally identifiable information. A cybersecurity breach could also hurt our reputation by adversely affecting the patients&#8217;
perception of the security of their information. A number of proposed and enacted federal, state and international laws and regulations
obligate companies to notify individuals of security breaches involving particular personally identifiable information, which could result
from breaches experienced by us or by third parties, including collaborators, vendors, contractors or other organizations with which
we expect to form strategic relationships. In addition, a cybersecurity attack could result in other negative consequences, including
disruption of our internal operations, increased cyber security protection costs, lost revenue, regulatory actions or litigations.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our ability to generate revenue from our teleradiology services
and AI solutions, as well as the other imaging offerings that we are developing, will depend in large part on referrals from physicians.
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will depend on referrals of patients from unaffiliated
physicians and other third parties who have no contractual obligations to refer patients to us for our teleradiology services and AI solutions,
as well as the other imaging offerings that we are developing. If these physicians and other third parties do not refer patients to us,
our ability to generate revenue from our teleradiology services and AI solutions, as well as the other imaging offerings that we are developing
would be adversely affected. Further, we&#160;currently derive substantially all of our revenue from our teleradiology services from fees
charged for the diagnostic imaging services performed by radiologists. If physicians and other third parties were to discontinue referring
patients to our radiologists, our revenue from our teleradiology services would decrease and our financial results could be adversely
affected.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we lose a significant number of our radiologists, our revenue from our teleradiology services and financial results could be adversely
affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a shortage of qualified radiologists in some of the regional markets that we serve. In addition, competition in recruiting radiologists
may make it difficult for us to maintain adequate levels of radiologists. If a significant number of radiologists terminate their relationships
with us and we cannot recruit sufficient qualified radiologists, our ability to generate revenue from teleradiology services and our
financial results could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exchange
rate fluctuations between the U.S. dollar, the New Israeli Shekel and the KRW and inflation may negatively affect our results of operations,
and we may not be able to hedge our currency exchange risks successfully.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. dollar is our functional and reporting currency. However, a portion of our operating expenses, including personnel and facilities
related expenses, are incurred in NIS and KRW. As a result, we are exposed to the risks that the NIS and KRW may appreciate relative
to the U.S. dollar, or, if the NIS and KRW instead devalues relative to the U.S. dollar, that the inflation rate in Israel or Korea may
exceed such rate of devaluation of the NIS or KRW, or that the timing of such devaluation may lag behind inflation in Israel or Korea.
In any such event, the dollar cost of our operations in Israel or Korea would increase and our dollar-denominated results of operations
would be adversely affected. Given our general lack of currency hedging arrangements to protect us from fluctuations in the exchange
rates of the NIS and KRW and other foreign currencies in relation to the U.S. dollar (and/or from inflation of such foreign currencies),
we may be exposed to adverse effects from such movements. Our exchange rate exposure may change over time as our business evolves and
could result in increased costs or reduced revenue and could affect our actual cash flow. Changes in the relative values of currencies
occur regularly and, in some instances, may have a significant impact on our operating results. The rate of inflation in Israel or Korea
or in currency exchange rates may materially change and we might not be able to effectively mitigate these risks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are currently subject to securities class-action litigation and an SEC inquiry and may be subject to similar or other claims, litigation
and investigations in the future, all of which will require significant management attention, could result in significant legal expenses
and may result in unfavorable outcomes, all or any of which could have a material adverse impact on our financial condition and results
of operations, harm our reputation or otherwise negatively impact our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are, and may in the future become, subject to litigation or claims
arising in or outside the ordinary course of business that could negatively affect our business operations and financial condition, including
securities class actions and shareholder derivative actions, both of which are typically expensive to defend. Such claims and litigation
proceedings may be brought by third parties, including our customers, competitors, advisors, service providers, partners or collaborators,
employees, and governmental or regulatory bodies. For example, we currently have two securities class-action complaints pending against
us and certain current officers and a director, asserting violations of federal securities laws and seeking unspecified damages. We believe
these lawsuits are without merit and intend to defend this case vigorously. In addition, the Division of Enforcement of the SEC is conducting
an investigation to determine whether there had been any violations of the federal securities laws, and the duration and outcome of this
matter cannot be predicted at this time. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Legal Proceedings.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outcome of any litigation and SEC inquiry, regardless of its merits, is inherently uncertain and may differ substantially from our expectations.
Any claims and lawsuits, and the disposition of such claims and lawsuits, or SEC inquiry could be time-consuming and expensive to resolve,
divert management attention and resources, and lead to attempts on the part of other parties to pursue similar claims. We may not be
able to determine the amount of any potential losses and other costs we may incur due to the inherent uncertainties of litigation and
settlement negotiations. In the event we are required or decide to pay amounts in connection with any claims, lawsuits or SEC inquiry,
such amounts could be significant and could have a material adverse impact on our liquidity, business, financial condition and results
of operations. In addition, depending on the nature and timing of any such dispute, a resolution of a legal matter could materially affect
our future operating results, our cash flows or both.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
significant tariffs or other restrictions related to &#8220;trade wars&#8221; are placed on Chinese imports or any related counter-measures
are taken by China, our revenue and results of operations may be materially harmed.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nanox.ARC production process is expected to involve manufacturers and/or suppliers in China for the production of certain components
of the Nanox.ARC. If significant tariffs or other restrictions are placed by the United States government on Chinese imports or any related
counter-measures are taken by China, our business, financial condition and results of operations may be materially harmed. Throughout
2018 and 2019, former President Trump called for substantial changes to foreign trade policy with China and raised, and proposed to further
raise in the future, tariffs on several Chinese goods in order to reverse what he perceived as unfair trade practices that have negatively
impacted U.S. businesses. The announcement of such tariffs has triggered retaliatory actions from foreign governments, including China,
and may trigger retaliatory actions by other foreign governments, resulting in a &#8220;trade war.&#8221; On January 15, 2020, the United
States and China signed the Phase One Deal, which took effect on February 14, 2020, agreeing to the rollback of tariffs, expansion of
trade purchases and renewed commitments on intellectual property, technology transfer and currency practices deescalating the trade war.
U.S. President Biden has stated that there are no immediate plans to cancel the Phase One Deal, but the administration is expected to
make changes to the U.S.-China tariff policies. If any forms of duties or tariffs are imposed on the Nanox.ARC or its components, we
may be required to charge higher prices in the United States than we expect, which may result in fewer customers and harm our operating
performance. Alternatively, we or our contractors may seek manufacturers and/or suppliers outside of China, resulting in significant
costs and disruption to our operations and business. Our business could also be impacted by retaliatory trade measures taken by China
or other countries in response to existing or future tariffs, causing us to raise prices or make changes to our operations, any of which
could materially harm our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
business may be impacted by changes in general economic conditions.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to risks arising from changes in domestic and global economic conditions, including adverse economic conditions in
markets in which we operate, which may harm our business. For example, the current COVID-19 pandemic has caused significant volatility
and uncertainty in U.S. and international markets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our future customers significantly reduce spending in areas in which our technology and products are utilized, or prioritize other expenditures
over our technology and products, our business, financial condition, results of operations and prospects would be materially adversely
affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disruption
to the global economy could also result in a number of follow-on effects on our business, including a possible slow-down resulting from
lower customer expenditures; inability of customers to pay for products, solutions or services on time, if at all; an increase in the
amount of accounts receivable we are required to write off; more restrictive export regulations which could limit our potential customer
base; negative impact on our liquidity, financial condition and share price, which may impact our ability to raise capital in the market,
obtain financing and secure other sources of funding in the future on terms favorable to us.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the occurrence of catastrophic events, such as hurricanes, storms, earthquakes, tsunamis, floods, medical epidemics and other
catastrophes that adversely affect the business climate in any of our markets could have a material adverse effect on our business, financial
condition and results of operations. Some of our operations are located in areas that have been in the past, and may be in the future,
susceptible to such occurrences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business, financial condition and results of operations may be materially adversely affected by any negative impact on the global economy
and capital markets resulting from the conflict in Ukraine or any other geopolitical tensions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the military conflict
between Russia and Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops was reported. Although
the length and impact of the ongoing military conflict is highly unpredictable, the ongoing conflict in Ukraine have led, and could lead,
to market disruptions, including significant volatility in commodity prices, credit and capital markets. As a result, sanctions and penalties
have been levied by the United States, European Union and other countries against Russia. Russian military actions and the resulting
sanctions could have a negative impact on supply chains, our MSaaS agreements relating to Russia and Belarus or the region and adversely
affect the global economy and financial markets. Any of the abovementioned factors could affect our business, prospects, financial condition
and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict,
but could be substantial. Any such disruptions may also magnify the impact of other risks described in this Annual Report on Form 20-F.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect to carry any business interruption insurance or any other insurance (except for director and officer, property, product
liability, malpractice and clinical trials insurance). As a result, we may incur uninsured losses, increasing the possibility that you
would lose your entire investment in our company.</i></b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our products and services are in the medical imaging
field and so may be subject to claims. We are not immune from product liability or other product claim risks, and we may not be able to
maintain insurance on acceptable terms against such risks or that such insurance will be sufficient to protect us against potential claims
or that insurance will be available in the future in amounts sufficient to protect us. A product liability claim, malpractice or other
claim, as well as any claims for uninsured liabilities or in excess of insured liabilities, could have a material adverse effect on our
business, financial condition, results of operations and prospects.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
of our directors and/or officers may have interests that compete with ours.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our directors currently own, operate and manage other entities, which may have similar or different objectives than ours. Such activities
could detract from the time these people have to allocate to our affairs. We lease office space to an entity of which Ran Poliakine,
the chairman of our board of directors, serves as a member of senior management, Richard Stone, a director, serves as a director and
Anat Kaphan, our Chief Innovation Officer, serves as a consultant. Each of Ran Poliakine and Richard Stone is also a significant shareholder
in such entity. See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;B. Related Party Transactions&#8212;Agreements
with Directors and Officers&#8212;Relationship with Illumigyn Ltd.&#8221; Additionally, we lease office space to an entity of which each
of Ran Poliakine and Richard Stone is a shareholder of its parent company. See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;B.
Related Party Transactions&#8212;Agreements With Directors and Officers&#8212;Relationship with Wellsense Technologies, Ltd.&#8221; The
terms of such agreements may not be as favorable to us as those that could be obtained from a third party. Moreover, certain of our directors
and officers are affiliated with our current shareholders, and may have different interests than other shareholders. For additional information
regarding related party transactions and potential conflicts of interest, see &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;B.
Related Party Transactions.&#8221; Under the Israeli Companies Law, 5759-1999 (the&#160;&#8220;Companies Law&#8221;), office holders
must promptly disclose to us any direct or indirect personal interest (within the meaning of the Companies Law) that he or she may have
and all related material information or documents known to him or her relating to any existing or proposed transaction by us. In addition,
we have adopted a code of ethics and conduct that requires our employees, officers and directors to disclose any situation that reasonably
would be expected to give rise to a conflict of interest.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
management team has limited experience managing a public company.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
members of our management team have limited experience managing a publicly traded company, interacting with public company investors
and complying with the increasingly complex laws pertaining to public companies in the United States. Our management team may not successfully
or efficiently manage our operations a public company subject to significant regulatory oversight and reporting obligations under the
U.S. federal securities laws and the continuous scrutiny of securities analysts and investors. These obligations and constituents require
significant attention from our senior management and could divert their attention away from the day-to-day management of our business,
which could adversely affect our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Our Intellectual Property</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>It
is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their
protection.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon a combination of patents and trade secrets to protect the intellectual property related to our proprietary technologies. Our
success depends significantly on our ability to obtain and maintain intellectual property protection with respect to our technology and
products. Patents and other proprietary rights provide uncertain protections, and we may be unable to protect our intellectual property
for reasons including those that result from complex factual and legal issues such as those that create uncertainty as to the validity,
scope and enforceability of any particular patent that we hold or for which we have applied. As a result, we may be unsuccessful in defending
our patents and other proprietary rights against third-party challenges, which could have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we are attempting to obtain patent coverage for our technology where available and where we believe appropriate, there are aspects of
the technology for which patent coverage may never be sought or received. Additionally, we have obtained, and may in the future obtain,
certain intellectual property related to our technology from third parties, and we cannot be certain that such third parties took the
necessary actions to maintain such rights or that the transfer of such rights to us was proper and effective. We may, as a result, be
subject to claims challenging the ownership or enforceability of such rights. Furthermore, we may not possess the resources to, or for
other reasons may not choose to, pursue patent protection on every invention or in any or every country where we may eventually decide
to sell our future products. Our ability to prevent others from making or selling duplicate or similar technologies will be impaired
for those technologies with respect to which, and in those countries where, we have no patent protection. In addition, there is no assurance
that all potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from
issuing from a pending patent application or later invalidate or narrow the scope of an issued patent. Even if patents do successfully
issue and even if such patents cover our technology, third parties may challenge their validity, enforceability or scope, which may result
in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to these patents or any other patents owned
by or licensed to us could deprive us of rights necessary for the successful commercialization of our technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, for patents that do issue based on our applications or future applications, any issued patents may not provide us with any
competitive advantages. Competitors may be able to design around our patents and develop products that provide outcomes comparable or
superior to ours. Any changes we make to our product or any future products, including designs that may be required for commercialization
or that cause them to have what we view as more advantageous properties, may not be covered by patents and patent applications we have
licensed or own, and we may be required to file new applications and/or seek other forms of protection for any such altered products
if any such protection is available. In addition, the patent prosecution process is expensive, time-consuming and complicated, and we
and our current or future licensors, licensees or collaborators may not be able to prepare, file, prosecute and maintain all necessary
or desirable patents or patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current or
future licensors, licensees or collaborators will fail to identify patentable aspects of inventions before it is too late to obtain patent
protection for them. In addition, if we choose to and are able to secure patent protection in countries outside the U.S., the laws of
some foreign countries may not protect our intellectual property rights to the same extent as do the laws of the United States. For instance,
the legal systems of some countries, including India, China and other developing countries, do not favor the enforcement of patents and
other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation
of our other intellectual property rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to
grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions
and enforce our intellectual property rights, and more generally could affect the value of our intellectual property. Our efforts to
seek patent protection for our technology could be negatively impacted by any such changes, which could have a material adverse effect
on our existing patent rights and our ability to protect and enforce our intellectual property in the future. In particular, our ability
to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will
depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may come to believe that third parties are infringing on, or otherwise violating, our patents or other proprietary rights. To prevent
infringement or unauthorized use, we may need to file infringement and/or misappropriation suits, which are very expensive and time-consuming,
could result in meritorious counterclaims against us and would distract management&#8217;s attention. Also, in an infringement or misappropriation
proceeding, a court may decide that one or more of our patents is invalid, unenforceable, or both, in which case third parties may be
able to use our technology without paying license fees or royalties. Even if the validity of our patents is upheld, a court may refuse
to stop the other party from using the technology at issue on the grounds that the other party&#8217;s activities are not covered by
our patents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patents, we rely on trade secrets to protect our technology; however, the policies we use to protect our trade secrets may
not be effective in preventing misappropriation of our trade secrets by others. In addition, confidentiality agreements executed by our
employees, consultants and advisors may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary
information in the event of unauthorized use or disclosure. Litigating a trade secret claim is expensive and time consuming, and the
outcome may be unexpected. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover,
our competitors may independently develop knowledge, methods and know-how that allow them to create substantially similar products or
services without misappropriating our trade secrets. If we are unable to protect our trade secrets, we may be unable to prevent competitors
from using our own inventions and intellectual property to compete against us, and our business may be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
terms may be inadequate to protect our competitive position on our future products for an adequate amount of time.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and
the protection it affords, is limited. Even if patents covering our future products are obtained, once the patent life has expired, we
may be open to competition from competitive products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the amount of time required for the development, testing and regulatory review of new products, patents protecting our future products
might expire before or shortly after we or our future partners commercialize those products. As a result, our owned and licensed patent
portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours for
a sufficient amount of time, and, as a result, we may not be able to obtain adequate protection from our patent portfolio against competition,
in spite of the time and effort invested in the commercialization of our future products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Claims
that our technology or our future products or the sale or use of our future products infringe the patents or other intellectual property
rights of third parties could result in costly litigation or could require substantial time and money to resolve, even if litigation
is avoided.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our industry is characterized by competing intellectual property, we may be subject to legal actions for violating the intellectual property
rights of others, including claims that former employees, collaborators or third parties have an interest in our patents, trade secrets
or other intellectual property. For example, we may have inventorship or ownership disputes arising from conflicting obligations of employees,
consultants or others who are involved in developing our technology or our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also may be required to participate in interference, derivation or opposition proceedings that concern disputes regarding priority of
inventions disclosed in our patents. Determining whether a product infringes a patent, as well as priority of inventions and other patent-related
disputes, involves complex legal and factual issues and the outcome is often uncertain. We have not conducted any significant search
of patents issued to third parties, and third-party patents containing claims covering our technology or methods that predate our patents
may exist. Because of the number of patents issued and patent applications filed in our technical areas or fields (including some pertaining
specifically to medical imaging technologies), our competitors or other third parties may assert that our technology and the methods
we employ in the use of products incorporating our technology are covered by United States or foreign patents held by them. In addition,
because patent applications can take many years to issue and because publication schedules for pending applications vary by jurisdiction,
there may be applications now pending of which we are unaware, and which may result in issued patents that our technology or other future
products would infringe. Also, because the claims of published patent applications can change between publication and patent grant, there
may be published patent applications that may ultimately issue with claims that we infringe.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the number of competitors in the market for medical imaging technologies increases, and as the number of patents issued in this area
grows, the possibility of patent infringement claims against us increases. Some of our competitors may be able to sustain the costs of
complex patent litigation more effectively than we can, including if they have substantially greater resources. Defending against such
litigation is costly and time consuming, and would distract our management from our business. In addition, any uncertainties resulting
from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary
to continue our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that we become subject to a patent infringement or other intellectual property lawsuit and if the relevant patents or other
intellectual property were upheld as valid and enforceable and we were found to infringe or violate those rights or the terms of a license
to which we are a party, we could be prevented from selling any infringing products of ours unless we could obtain a license or were
able to redesign the product to avoid infringement. If we were unable to obtain a license or successfully redesign, we might be prevented
from selling our technology or other future products. If we are able to redesign, we may need to invest substantial resources in the
redesign process. If there is an allegation or determination that we have infringed the intellectual property rights of a competitor
or other person, we may be required to pay damages, or a settlement or ongoing royalties, or we may be required to enter into cross-licenses
with our competitors. In any of these circumstances, we may be unable to sell our products at competitive prices or at all, and our business,
financial condition, results of operations and prospects could be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may be required to indemnify our customers and distributors against claims relating to the infringement of intellectual
property rights of third parties related to our products. Third parties may assert infringement claims against our customers or distributors.
These claims may require us to initiate or defend protracted and costly litigation on behalf of our customers or distributors, regardless
of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of our customers or distributors,
or may be required to obtain licenses for the products or services they use. If we cannot obtain all necessary licenses on commercially
reasonable terms, our distributors may be forced to stop distributing our products or services, and our customers may be forced to stop
using our products or services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be compromised by disclosure during discovery. There could also be public announcements of the
results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of
our ordinary shares. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect
on the price of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Obtaining
and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we or our future licensors do not
comply with these requirements.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other government fees on a patent and patent application are due to be paid
to the patent offices and agencies in several stages over the lifetime of the patent and patent application. The U.S. Patent and Trademark
Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and
other similar provisions during the patent application process. In certain circumstances, we may be required to rely on our licensing
partners to take the necessary action to comply with these requirements with respect to patents or other intellectual property they have
licensed to us. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the
applicable rules, there are situations in which noncompliance, which could include failure to respond to official actions within prescribed
time limits, non-payment of fees and failure to properly legalize and submit formal documents, can result in abandonment or lapse of
the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event,
our competitors may be able to enter the market and compete with our products, which would have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may be subject to claims that our employees, consultants or advisers have wrongfully used or disclosed alleged trade secrets of their
former employers or claims asserting ownership of what we regard as our own intellectual property</b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our employees, consultants and advisers, including our senior management, were previously employed at other companies that may have
proprietary rights related to our business. Some of these employees, consultants and advisers, including members of our senior management,
executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try
to ensure that such individuals do not use the proprietary information or know-how of others in their work for us, we may be subject
to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information,
of any such individual&#8217;s former employer. We are not aware of any such disclosures, or threatened or pending claims related to
these matters, but in the future, litigation may be necessary to defend against such claims. If we fail in defending any such claims,
we may lose valuable intellectual property rights or personnel, in addition to possibly paying monetary damages and being enjoined from
conducting our business as contemplated. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
a licensor, collaborator, employee, consultant, adviser or other third party may dispute our or our licensor&#8217;s ownership of certain
intellectual property rights. We seek to address these concerns in our contractual agreements; however, we may not have contractual arrangements
with the party in question and/or such provisions may not be effective. If these provisions prove to be ineffective, we may not be able
to achieve our business objectives. If we or our licensors fail in defending any such claims, we may have to pay monetary damages and
may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property, which could adversely
impact our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unregistered trademarks or trade names are valuable assets and may be challenged, infringed, circumvented or declared generic or determined
to infringe third party&#8217;s marks. We may not be able to protect our rights to these trademarks and trade names, which may be necessary
to build name recognition among potential collaborators or customers in our markets of interest. At times, competitors may adopt trade
names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In
addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that
incorporate variations of our unregistered trademarks or trade names. We have not conducted any registrability studies for possible future
trademarks to assess whether such marks would be successfully registered. Over the long term, if we are unable to establish name recognition
based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. In
addition, we may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide
guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames
by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to
enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual
property may be ineffective and could result in substantial costs and diversion of resources and adversely affect our competitive position,
business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
rights to develop and commercialize our products may be subject to the terms and conditions of licenses and sublicenses granted to us
by third parties.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on licenses and sublicenses to certain patent rights and other intellectual property from third parties that are important or necessary
to the development of our products, including the software modules that we expect to integrate into the Nanox.CLOUD. These and other
licenses may not provide exclusive rights to use such intellectual property in all relevant fields of use and in all territories in which
we may wish to develop or commercialize our products and the underlying patents may fail to provide the intended exclusivity. As a result,
we may not be able to prevent competitors from developing and commercializing competitive products in the markets that we hope to address.
Moreover, we would not own at least some of the underlying intellectual property rights related to these products, and as a result our
rights would be subject to the continuation and compliance with the terms of those agreements. If such in-licenses were terminated, competitors
would have the freedom to develop, seek regulatory approval of, and to market, products similar or identical to ours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, these license agreements may not grant us the right to control the preparation, filing, prosecution or maintenance of patents
and patent applications covering our products. Therefore, we cannot be certain that these patents and patent applications will be prepared,
filed, prosecuted or maintained in a manner consistent with the best interests of our business. If our current or future licensing partners
fail to file, prosecute or maintain such patents, including the payment of applicable fees, or otherwise lose rights to those patents
or patent applications, the intellectual property we have licensed or exclusivity we have been granted may be reduced or eliminated,
and our right to develop and commercialize any of our future products that are subject of such licensed rights, and our ability to prevent
competitors from developing or commercializing such products, could be adversely affected. In addition, even where we have the right
to control patent prosecution and maintenance of patents and patent applications we have licensed from third parties, we may still be
adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the
date upon which we assumed control over patent prosecution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of such license agreements, the licensors may also have the right to control enforcement of our licensed patents or defense
of any claims asserting the invalidity or unenforceability of these patents. Even if we are permitted to pursue the enforcement or defense
of our licensed patents, we may require the cooperation of our future licensors or collaboration partners and any other applicable patent
owners and we cannot be certain that such cooperation will be provided to us. We also cannot be certain that our licensors will allocate
sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the
licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent
us from continuing to license intellectual property that we may need to operate our business. If we lose any of our licensed intellectual
property, our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our licensors
are not the sole and exclusive owners of the patents we in-license. If other third parties have ownership rights to our in-licensed patents,
they may be able to license such patents to our competitors, and our competitors could market competing products and technologies. In
addition, if our licensors have not obtained adequate rights from these third parties, we may need to obtain additional rights from these
third parties or we could be prevented from developing and commercializing the related products. This could have a material adverse effect
on our competitive position, business, financial conditions, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate
the license agreements, in which event we may have to cease developing, manufacturing or marketing any product covered by these agreements
and we may face other additional penalties or be required to grant our licensors additional rights. In addition, we may seek to obtain
additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in
a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties (potentially including
our competitors) to receive licenses to a portion of the intellectual property that is subject to our existing licenses. Any of these
events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may be required to pay certain milestones and royalties and fulfill other obligations under our license agreements with third-party licensors.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be required to pay milestones and royalties related to our development or commercialization activities of our products utilizing
the technologies licensed or sublicensed from third parties under license agreements we may enter into with them. These payments could
adversely affect our overall profitability related to any future products that we may seek to develop or commercialize. In order to maintain
our license rights under our license agreements, we may need to meet certain specified milestones or fulfill certain obligations, including
to devote a certain amount of resources, in the development of our products. Failure to satisfy such obligations could result in the
termination of our rights under such agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we choose to license our technology to third parties, this could result in disputes or otherwise limit our future operations.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also in the future, as one of our strategies, deploy our technology into the market and license patents and other intellectual proprietary
rights to third parties. Disputes with our licensees may arise, including regarding the scope and content of these licenses. Additionally,
a licensee may use our intellectual property without our permission, dispute our ownership of certain intellectual property rights or
argue that our intellectual property does not cover our product. Regardless of whether we pursue legal action to enforce any such dispute,
a dispute with a licensee or customer over intellectual property rights may damage our relationship with that licensee or customer and
may also harm our reputation in the industry. Our ability to expand into additional fields with our technologies also may be restricted
by licenses or other rights we may grant to third parties in the future, including if the licenses are exclusive, the licensee is assigned
ownership of intellectual property that we develop or rights of first negotiation or refusal are granted.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
Related to Government Regulation</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
product candidates and operations are subject to extensive government regulation and oversight both in the United States and abroad,
and our failure to comply with applicable requirements could harm our business.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the Nanox.ARC and other future products we develop to be regulated by the FDA as medical devices. Our product candidate is subject
to extensive regulation in the United States and elsewhere, including by the FDA and its foreign counterparts, the U.S. Department of
Justice (the &#8220;DOJ&#8221;) and the U.S. Department of Health and Human Services-Office of the Inspector General. The FDA and foreign
regulatory agencies regulate, among other things, with respect to medical devices: design, development and manufacturing; testing, labeling,
content and language of instructions for use and storage; clinical trials; product safety; establishment registration and device listing;
marketing, sales and distribution; pre-market clearance and approval; conformity assessment procedures; record keeping procedures; advertising
and promotion; recalls and field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries
and malfunctions that, if they were to occur, could lead to death or serious injury; post-market approval studies; and product import
and export.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations our product candidate is subject to are complex and have tended to become more stringent over time. Regulatory changes could
result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales
for any approved product. Failure to comply with applicable regulations could jeopardize our ability to sell our future products, if
cleared or approved, and result in enforcement actions such as: warning or untitled letters; fines; injunctions; consent decrees; civil
penalties; customer notifications; termination of distribution; recalls or seizures of products; administrative detention of medical
devices believed to be adulterated or misbranded; delays in the introduction of products into the market; operating restrictions; total
or partial suspension of production; refusal to grant future clearances or approvals for new products, new intended uses or modifications
to our products; withdrawals or suspensions of current approvals, resulting in prohibitions on sales of our products; and in the most
serious cases, criminal prosecution or penalties. The occurrence of any of these events would have a material adverse effect on our business,
financial condition and results of operations and could result in shareholders losing their entire investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may not receive, or may be delayed in receiving, the necessary clearances or approvals for our future products, and failure to timely
obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, before we can market a new medical device, or a new use of, new claim for or significant modification to an existing
product, we must first receive either clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;)
or approval of a pre-market approval application (a &#8220;PMA&#8221;) from the FDA, unless an exemption applies. In the 510(k) clearance
process, before a device may be marketed, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to
a legally-marketed &#8220;predicate&#8221; device, which includes a device that has been previously cleared through the 510(k) process,
a device that was legally marketed prior to May&#160;28, 1976 (pre-amendments device), a device that was originally on the U.S. market
pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be &#8220;substantially equivalent,&#8221; the proposed
device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate
device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate
device. Clinical data are sometimes required to support substantial equivalence. In the process of obtaining PMA approval, the FDA must
determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited
to, technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that
are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modifications
to products that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to products
cleared through a 510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive,
lengthy and uncertain. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but can last longer. The process
of obtaining a PMA is generally much more costly and uncertain than the 510(k) clearance process and generally takes from one to three&#160;years,
or even longer, from the time the application is submitted to the FDA. In addition, a PMA generally requires the performance of one or
more clinical trials. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to
obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances
or approvals, they may include significant limitations on the indicated uses for the device or other restrictions or requirements, which
may limit the market for the device.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, we continue to implement a multi-step approach to the regulatory clearance process. As a first step, we submitted
a 510(k) premarket notification for the Nanox Cart X-Ray System, a single-source version of the Nanox.ARC, to an accredited Review Organization
under the Third Party Review Program in January 2020. On April 1, 2021, we received clearance from the FDA to market our Nanox Cart X-Ray
System. On June 17, 2021, we submitted a 510(k) premarket notification application to the FDA for the first version of our multi-source
Nanox.ARC 3-D digital tomosynthesis system. On August 12, 2021, we received a request for additional information from the FDA concerning
the first submission of our multi-source system. On January 10, 2022, we withdrew our first submission of our multi-source system. On
January 12, 2022, we submitted to&#160;the FDA a Q-submission for the second&#160;version of&#160;our&#160;multi-source Nanox.ARC 3-D
digital tomosynthesis system. The Q-submission program provides submitters an opportunity to have early collaboration and discussions
about medical device submissions, through a request for feedback from and/or a meeting with the FDA regarding a potential or planned
medical device submission. We believe that using this approach will assist to expedite and optimize the regulatory clearance process.
The second version of&#160;the Nanox.ARC was designed, among other things,&#160;to address certain deficiencies raised by the FDA during
their review of the first submission from June 2021. We continue to communicate with the FDA and we expect the next step in this process
to be a submission of a supplement to the Q-submission followed by a formal 510(k) application to the FDA for the multi-source Nanox.ARC.
If cleared by the FDA, we expect to commercialize the multi-source Nanox.ARC and we may seek alternatives for commercialization of our
Nanox Cart X-Ray System. However, the review process may be more costly and time consuming than we expect and we may not ultimately be
successful in completing the review process and our 510(k) premarket notification may not be cleared by the FDA in a timely manner or
at all. If cleared, any modification to these systems that has not been previously cleared may require us to submit a new 510(k) premarket
notification and obtain clearance, or submit a PMA and obtain FDA approval prior to implementing the change. Specifically, any modification
to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its
intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every manufacturer
to make this determination in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with
our decisions regarding whether new clearances or approvals are necessary. We may make modifications or add additional features in the
future that we believe do not require a new 510(k) clearance or approval of a PMA. If the FDA disagrees with our determination and requires
us to submit new 510(k) notifications or PMA applications for modifications to our previously cleared products for which we have concluded
that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain
clearance or approval, and we may be subject to significant regulatory fines or penalties. If the FDA requires us to go through a lengthier,
more rigorous examination for future products or modifications to existing products than we had expected, product introductions or modifications
could be delayed or canceled, which could adversely affect our ability to grow our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA can delay, limit or deny clearance or approval of a medical device for many reasons, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity
                                            or notified body that our product candidates are safe or effective for their intended uses
                                            or are substantially equivalent to a predicate device;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            disagreement of the FDA or the applicable foreign regulatory body with the design or implementation
                                            of our clinical trials or the interpretation of data from pre-clinical studies or clinical
                                            trials;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">serious
                                            and unexpected adverse effects experienced by participants in our clinical trials;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            data from our pre-clinical studies and clinical trials may be insufficient to support clearance
                                            or approval, where required;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to demonstrate that the clinical and other benefits of the device outweigh the
                                            risks;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            manufacturing process or facilities we use may not meet applicable requirements; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential for approval policies or regulations of the FDA or applicable foreign regulatory
                                            bodies to change significantly in a manner rendering our clinical data or regulatory filings
                                            insufficient for clearance or approval.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to sell our products in member countries of the European Economic Area (&#8220;EEA&#8221;), our products must comply with the essential
requirements of the EU Medical Devices Directive (Council Directive 93/42/EEC). Compliance with these requirements is a prerequisite
to be able to affix the Conformit&#233; Europ&#233;ene (&#8220;CE&#8221;) mark to our products, without which they cannot be sold
or marketed in the EEA. To demonstrate compliance with the essential requirements we must undergo a conformity assessment procedure,
which varies according to the type of medical device and its classification. Except for low-risk medical devices (Class&#160;I non-sterile,
non-measuring devices), where the manufacturer can issue a European Community (&#8220;EC&#8221;) Declaration of Conformity based on a
self-assessment of the conformity of its products with the essential requirements of the EU Medical Devices Directive, a conformity assessment
procedure requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or
a Notified Body. Depending on the relevant conformity assessment procedure, the Notified Body would typically audit and examine the technical
file and the quality system for the manufacture, design and final inspection of our devices. The Notified Body issues a certificate of
conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer
and their conformity with the essential requirements. This certificate entitles the manufacturer to affix the CE mark to its medical
devices after having prepared and signed a related EC Declaration of Conformity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based,
among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions
of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use,
that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended
performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. If we fail to
remain in compliance with applicable European laws and directives, we would be unable to continue to affix the CE mark to our products,
which would prevent us from selling them within the EEA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Failure
to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might
require us to recall or withdraw a product from the market.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we receive regulatory clearance or approval of the Nanox.ARC or other future products, we will remain subject to ongoing and pervasive
regulatory requirements governing, among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion,
import, export, registration, and listing of devices. For example, we will be required to submit periodic reports to the FDA as a condition
of 510(k) clearance. These reports include information about failures and certain adverse events associated with the device after its
clearance. Failure to submit such reports, or failure to submit the reports in a timely manner, could result in enforcement action by
the FDA. Following its review of the periodic reports, the FDA might ask for additional information or initiate further investigation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations to which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions
on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have
obtained the proper regulatory clearance or approval to market a device, we have ongoing responsibilities under FDA regulations and applicable
foreign laws and regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply
with applicable regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities, which
may include any of the following sanctions:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled
                                            letters or warning letters;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                            injunctions, consent decrees and civil penalties;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls,
                                            termination of distribution, administrative detention, or seizure of our products;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer
                                            notifications or repair, replacement or refunds;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
                                            restrictions or partial suspension or total shutdown of production;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            in or refusal to grant our requests for future clearances or approvals or foreign marketing
                                            authorizations of new products, new intended uses, or modifications to existing products;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals
                                            or suspensions of product clearances or approvals, resulting in prohibitions on sales of
                                            our products;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
                                            refusal to issue certificates to foreign governments needed to export products for sale in
                                            other countries; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
                                            prosecution.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on
our reputation, business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA or state or foreign authorities may change their clearance and approval policies, adopt additional regulations or revise
existing regulations, or take other actions, which may prevent or delay clearance or approval of our future products under development
on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain
new clearances or approvals, increase the costs of compliance or restrict our ability to maintain any approvals we are able to obtain.
For example, the FDA has announced steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k)
of the FDCA. For more information, see &#8220;&#8212;Legislative or regulatory reforms in the United States or the EU may make it more
difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture, market or distribute our
products after clearance or approval is obtained.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
products must be manufactured in accordance with federal, state and foreign regulations, and we could be forced to recall our devices
or terminate production if we fail to comply with these regulations.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
methods used in, and the facilities used for, the manufacture of our products must comply with the Quality System Regulation (&#8220;QSR&#8221;),
which is a complex regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls,
quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing and shipping of medical devices. As
manufacturers of electron radiation-emitting products, we are also responsible for compliance with the radiological health regulations
and certain radiation safety performance standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we are required to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and
applicable regulatory requirements. The FDA enforces the QSR through periodic announced or unannounced inspections of medical device
manufacturing facilities, which may include the facilities of subcontractors. Our products are also subject to similar state regulations
and various laws and regulations of foreign countries governing manufacturing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
third-party manufacturers may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery
of our products. In addition, failure to comply with applicable FDA or state or foreign requirements or later discovery of previously
unknown problems with our products or manufacturing processes could result in, among other things: warning letters or untitled letters;
fines, injunctions or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension
of production or distribution; administrative or judicially imposed sanctions; the FDA&#8217;s refusal to grant pending or future clearances
or approvals for our products; clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us,
our suppliers or our employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these actions could significantly and negatively affect supply of our products. If any of these events occurs, our reputation could
be harmed, we could be exposed to product liability claims and we could lose customers and experience reduced sales and increased costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability
suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of
these uses, any of which could be costly to our business.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and promotion of our future products that obtains approval in the United States may be heavily scrutinized by the FDA, the DOJ, HHS,
state attorneys general, members of Congress, and the public. In addition, advertising and promotion of any future product that obtains
approval outside of the United States will be heavily scrutinized by comparable foreign regulatory authorities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that, if cleared or approved, our products, including the multi-source Nanox.ARC, will be cleared by the requisite regulatory
authorities for specific indications. We expect to train our marketing personnel and direct sales force to not promote our devices for
uses outside of the FDA-approved indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician
from using our devices off-label, when in the physician&#8217;s independent professional medical judgment he or she deems it appropriate.
There may be increased risk of injury to patients if physicians attempt to use our devices off-label. Furthermore, the use of our devices
for indications other than those approved by the FDA or approved by any foreign regulatory body may not effectively treat such conditions,
which could harm our reputation in the marketplace among healthcare providers and patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA or any state or foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label
use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including
the issuance or imposition of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure,
civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action
under other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label
use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages,
fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. We may become
subject to such actions and, if we are not successful in defending against such actions, those actions may have a material adverse effect
on our business, financial condition and results of operations. Equivalent laws and potential consequences exist in foreign jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if our products are cleared or approved, healthcare providers may misuse our products or use improper techniques if they are
not adequately trained, potentially leading to injury and an increased risk of product liability. If our devices are misused or used
with improper technique, we may become subject to costly litigation by our customers or their patients. As described above, product liability
claims could divert management&#8217;s attention from our core business, be expensive to defend and result in sizeable damage awards
against us that may not be covered by insurance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0in"><b>Our products may cause or contribute
to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to
do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations.
The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of
the FDA or another governmental authority, could have a negative impact on us.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Nanox.ARC or our other future products
receive clearance or approval, we will be subject to the FDA&#8217;s medical device reporting regulations and similar foreign regulations,
which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more
of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction
were to recur, could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the
date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we
become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event,
especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from
the use of the product. If we fail to comply with our reporting obligations, the FDA or other regulatory bodies could take action,
including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties,
revocation of our device clearance or approval, seizure of our products or delay in clearance or approval of future products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA and foreign regulatory bodies have
the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture
of a product or in the event that a product poses an unacceptable risk to health. The FDA&#8217;s authority to require a recall
must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also
choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could
occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design
deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other
errors may occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Depending on the corrective action we take
to redress a product&#8217;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new clearances
or approvals for the device before we may market or distribute the corrected device. Seeking such clearances or approvals may delay
our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with
our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions,
administrative penalties or civil or criminal fines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Companies are required to maintain certain
records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections
for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations,
it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement
could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales.
Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication
of our time and capital, distract management from operating our business and may harm our reputation and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Our relationships with customers
and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations,
which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and
future earnings.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Physicians, other healthcare providers,
and third-party payors will play a primary role with respect to any future products for which we obtain marketing approval. Our
arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws
and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute
our product. Restrictions under applicable federal and state healthcare laws and regulations include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>The U.S. federal healthcare program Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either
the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made,
in whole or in part, under federal healthcare programs such as Medicare and Medicaid. Although there are a number of statutory
exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are
drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend medical devices, including
certain discounts, or engaging consultants as speakers or consultants, may be subject to scrutiny if they do not fit squarely within
the exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback
liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants. Liability may
be established without a person or entity having actual knowledge of the federal Anti-Kickback Statute or specific intent to violate
it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Due to the breadth of these laws, the
narrowness of statutory exceptions and regulatory safe harbors available, and the range of interpretations to which they are subject,
it is possible that some of our current or future practices might be challenged under one or more of these laws, including, without
limitation, our proposed Subscription Model, and our advisory, consulting and royalty agreements with certain physicians who receive
compensation, in part, in the form of stock or stock options.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>The federal civil False Claims Act prohibits, among other things, any person from knowingly presenting, or causing to be presented,
a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used, a false
record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly
avoiding, decreasing, or concealing an obligation to pay money to the federal government. In recent years, several healthcare companies
have faced enforcement actions under the federal False Claims Act for, among other things, allegedly providing free product to
customers with the expectation that the customers would bill federal programs for the product or causing false claims to be submitted
because of the company&#8217;s marketing the product for unapproved, and thus non-reimbursable, uses. False Claims Act liability
is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of
tens of thousands of dollars per false claim or statement. Healthcare companies also are subject to other federal false claims
laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health
benefit programs.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information
Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), imposes criminal and civil liability for knowingly
and willfully executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or
covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare
benefits, items or services. In addition, HIPAA, as amended by HITECH, and their respective implementing regulations impose obligations,
including mandatory contractual terms, on covered healthcare providers, health plans, as well as their business associates, with
respect to safeguarding the privacy, security and transmission of individually identifiable health information.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>The Physician Payment Sunshine Act, implemented as the Open Payments program, requires manufacturers of certain products reimbursed
by Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to track and report to the federal government payments
and transfers of value that they make to physicians and teaching hospitals, certain other healthcare professionals beginning in
2022, group purchasing organizations, and ownership interests held by physicians and their families, and provides for public disclosures
of these data. Manufacturers are required to submit annual reports to the government and failure to do so may result in civil monetary
penalties for all payments, transfers of value and ownership or investment interests not reported in an annual submission, and
may result in liability under other federal laws and regulations.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Federal law prohibiting certain physician self-referrals, known as the Stark Law, prohibits a physician from referring Medicare or Medicaid patients to an entity for certain &#8220;designated health services&#8221; if the physician has a prohibited financial relationship with that entity, unless an exception applies. Certain radiology services are considered &#8220;designated health services&#8221; under the Stark Law.&#160;&#160;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Many states have adopted laws and regulations analogous to the federal laws cited above, including state anti-kickback and
false claims laws, which may apply to items or services reimbursed under Medicaid and other state programs or, in several states,
regardless of the payer. Several states have enacted legislation requiring medical device companies to, among other things, establish
marketing compliance programs; file periodic reports with the state, including reports on gifts and payments to individual health
care providers; make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities; and/or register
their sales representatives. Some states prohibit specified sales and marketing practices, including the provision of gifts, meals,
or other items to certain health care providers.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Efforts to ensure that our business arrangements
with third parties will comply with applicable healthcare laws and regulations involve substantial costs. Additionally, it is possible
that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations
or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in
violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil,
criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and
Medicaid, and the curtailment or restructuring of our operations. Exclusion, suspension and debarment from government funded healthcare
programs would significantly impact our ability to commercialize, sell or distribute any product. If any of the physicians or other
providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject
to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Changes in laws or regulations relating
to data protection, or any actual or perceived failure by us to comply with such laws and regulations or our privacy policies,
could materially and adversely affect our business or could lead to government enforcement actions and significant penalties against
us, and adversely impact our operating results.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect to receive health information
and other highly sensitive or confidential information and data of patients and other third parties (e.g., healthcare providers
who refer patients for scans), which we expect to compile and analyze. Collection and use of this data might raise privacy and
data protection concerns, which could negatively impact our business. There are numerous federal, state and international laws
and regulations regarding privacy, data protection, information security, and the collection, storing, sharing, use, processing,
transfer, disclosure, and protection of personal information and other data, and the scope of such laws and regulations may change,
be subject to differing interpretations, and may be inconsistent among countries and regions we intend to operate in (e.g., the
United States, the European Union and Israel), or conflict with other laws and regulations. The regulatory framework for privacy
and data protection worldwide is, and is likely to remain for the foreseeable future, uncertain and complex, and this or other
actual or alleged obligations may be interpreted and applied in a manner that we may not anticipate or that is inconsistent from
one jurisdiction to another and may conflict with other rules or practices including ours. Further, any significant change to applicable
laws, regulations, or industry practices regarding the collection, use, retention, security, or disclosure of data, or their interpretation,
or any changes regarding the manner in which the consent of relevant users for the collection, use, retention, or disclosure of
such data must be obtained, could increase our costs and require us to modify our services and candidate products, possibly in
a material manner, which we may be unable to complete, and may limit our ability to store and process patients&#8217; data or develop
new services and features.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In particular, we will be subject to U.S. data
protection laws and regulations (i.e., laws and regulations that address privacy and data security) at both the federal and state levels.
The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus
on privacy and data security issues. Numerous federal and state laws, including state data breach notification laws, state health information
privacy laws, and federal and state consumer protection laws, govern the collection, use, and disclosure of health-related and other personal
information. Failure to comply with such laws and regulations could result in government enforcement actions and create liability for
us (including the imposition of significant civil or criminal penalties), private litigation and/or adverse publicity that could negatively
affect our business. For instance, California enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;) on June&#160;28, 2018,
which took effect on January&#160;1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy
and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as
a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights
Act (&#8220;CPRA&#8221;), recently passed in California. The CPRA will impose additional data protection obligations on covered businesses,
including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for
certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations
and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January
1, 2023, and additional compliance investment and potential business process changes may be required. The CCPA and the CPRA may increase
our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we expect to obtain health
information that is subject to privacy and security requirements under HITECH and its implementing regulations. The Privacy Standards
and Security Standards under HIPAA establish a set of standards for the protection of individually identifiable health information
by health plans, health care clearinghouses and certain health care providers, referred to as Covered Entities, and the business
associates with whom Covered Entities enter into service relationships pursuant to which individually identifiable health information
may be exchanged. Notably, whereas HIPAA previously directly regulated only Covered Entities, HITECH makes certain of HIPAA&#8217;s
privacy and security standards also directly applicable to Covered Entities&#8217; business associates. As a result, both Covered
Entities and business associates are now subject to significant civil and criminal penalties for failure to comply with Privacy
Standards and Security Standards. As part of our normal operations, we expect to collect, process and retain personal identifying
information regarding patients, including as a business associate of Covered Entities, so we expect to be subject to HIPAA, including
changes implemented through HITECH, and we could be subject to criminal penalties if we knowingly obtain or disclose individually
identifiable health information in a manner that is not authorized or permitted by HIPAA. A data breach affecting sensitive personal
information, including health information, also could result in significant legal and financial exposure and reputational damages
that could potentially have an adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">HIPAA requires Covered Entities (like many
of our potential customers) and business associates, like us, to develop and maintain policies and procedures with respect to protected
health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect
such information. HITECH expands the notification requirement for breaches of patient-identifiable health information, restricts
certain disclosures and sales of patient-identifiable health information and provides for civil monetary penalties for HIPAA violations.
HITECH also increased the civil and criminal penalties that may be imposed against Covered Entities and business associates and
gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA
and its implementing regulations and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Additionally,
certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent or broader
in scope than HIPAA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Internationally, many jurisdictions have or are considering enacting
privacy or data protection laws or regulations relating to the collection, use, storage, transfer, disclosure and/or other processing
of personal data, as well as certification requirements for the hosting of health data specifically. Such laws and regulations may include
data hosting, data residency or data localization requirements (which generally require that certain types of data collected within a
certain country be stored and processed within that country), data export restrictions, international transfer laws (which prohibit or
impose conditions upon the transfer of such data from one country to another), or may require companies to implement privacy or data protection
and security policies, enable users to access, correct and delete personal data stored or maintained by such companies, inform individuals
of security breaches that affect their personal data or obtain individuals&#8217; consent to use their personal data. For example, European
legislators adopted the European Union&#8217;s General Data Protection Regulation (2016/679) (&#8220;GDPR&#8221;), which became effective
on May&#160;25, 2018, and are now in the process of finalizing the ePrivacy Regulation to replace the European ePrivacy Directive (Directive
2002/58/EC as amended by Directive 2009/136/EC). The GDPR, supplemented by national laws and further implemented through binding guidance
from the European Data Protection Board, imposes more stringent European Union data protection requirements and provides for significant
penalties for noncompliance. Further, following the United Kingdom&#8217;s withdrawal from the European Economic Area (&#8220;EEA&#8221;)
and the European Union (&#8220;EU&#8221;), and the expiry of the transition period, companies have to comply with both the GDPR and the
GDPR as incorporated into United Kingdom (&#8220;UK&#8221;) national law (the &#8220;UK GDPR&#8221;), the latter regime having the ability
to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. Our processing of large amounts of health data and
other highly sensitive data (referred to as &#8220;special category data&#8221; in the GDPR/UK GDPR) exposes us to further compliance
risk. We carry out data protection impact assessments (&#8220;DPIAs&#8221;) in connection with our high-risk processing activities and
implement appropriate safeguards and mechanisms to ensure adequate protection of the personal data, in order to comply with GDPR/UK GDPR.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Transfers of personal data between countries and
regions we intend to operate in (e.g., the EU, the UK, the U.S. and Israel) are subject to stringent regulation under the GDPR/UK GDPR,
and transfers of personal data out of the EEA/UK to third countries (that is, countries without an adequacy decision) must be made pursuant
to a valid data transfer mechanism. Common mechanisms for transfers to third countries (including the U.S.) are the latest version of
the EU&#8217;s Standard Contractual Clauses pursuant to Regulation (EU) 2016/679, introduced in 2021 (&#8220;SCCs&#8221;) and, for transfers
out of the UK, the International Data Transfer Agreement (&#8220;IDTA&#8221;) or the UK Addendum to the SCCs. In addition to the use of
a valid data transfer mechanism, transfer impact assessments must now be carried out in respect of planned transfers of personal data
from the EEA/UK to third countries including the U.S., and failure to do so may expose us to further compliance risk. The EU has, however,
adopted an adequacy decision in respect of Israel and transfers of personal data can therefore be made from the EEA/UK without the use
of additional safeguards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Whilst the European Commission and the U.S. Department
of Commerce had previously negotiated the EU-U.S. Privacy Shield (&#8220;Privacy Shield&#8221;), a self-certification mechanism for data
transfers from the EEA to the U.S., the status of transfers of data from the EEA/UK to the U.S. is currently uncertain following the 2020
decision of the Court of Justice of the European Union (&#8220;CJEU&#8221;) in Data Protection Commissioner v Facebook Ireland and Maximillian
Schrems (commonly known as &#8220;Schrems II&#8221;). Prior to the Schrems II ruling, a company that was self-certified could import personal
data from the EEA, provided it abided by the terms of the Privacy Shield. In Schrems II, however, the CJEU struck down the Privacy Shield,
effective immediately. A replacement for the Privacy Shield has not yet been finalized (although the EU and the U.S. have reached an agreement
in principle for a Trans-Atlantic Data Privacy Framework) and transfers must now be carried out pursuant to a valid data transfer mechanism
and accompanied by transfer impact assessments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Virtually every jurisdiction in which we
expect to operate has established its own data security and privacy legal framework with which we must, and our target customers
will need to, comply, including the rules and regulation mentioned above. We may also need to comply with varying and possibly
conflicting privacy laws and regulations in other jurisdictions. As a result, we could face regulatory actions, including significant
fines or penalties, adverse publicity and possible loss of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While we are preparing to implement various
measures intended to enable us to comply with applicable privacy or data protection laws, regulations and contractual obligations,
these measures may not always be effective and do not guarantee compliance. Any failure or perceived failure by us to comply with
our contractual or legal obligations or regulatory requirements relating to privacy, data protection, or information security may
result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer advocacy
groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and
otherwise materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens
imposed by, the laws, regulations, and policies that are applicable to the businesses of our customers or partners may limit the
adoption and use of, and reduce the overall demand for, our products and services. Additionally, if third parties we work with
violate applicable laws, regulations, or agreements, such violations may put the data we have received at risk, could result in
governmental investigations or enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy
groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and
otherwise materially and adversely affect our reputation and business. Further, public scrutiny of, or complaints about, technology
companies or their data handling or data protection practices, even if unrelated to our business, industry or operations, may lead
to increased scrutiny of technology companies, including us, and may cause government agencies to enact additional regulatory requirements,
or to modify their enforcement or investigation activities, which may increase our costs and risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>If we do not obtain and maintain
international regulatory registrations, clearances or approvals for our products, we will be unable to market and sell our products
outside of the United States.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sales of our products outside of the United
States are subject to foreign regulatory requirements that vary widely from country to country. Approval procedures vary among
countries and can involve additional testing. The time required to obtain approval outside of the United States may differ substantially
from that required to obtain FDA approval. In addition, the FDA regulates exports of medical devices from the United States. While
the regulations of some countries may not impose barriers to marketing and selling our products or only require notification, others
require that we obtain the clearance or approval of a specified regulatory body. Complying with foreign regulatory requirements,
including obtaining registrations, clearances or approvals, can be expensive and time-consuming, and we may not receive regulatory
clearances or approvals in each country in which we plan to market our products or we may be unable to do so on a timely basis.
The time required to obtain registrations, clearances or approvals, if required by other countries, may be longer than that required
for FDA clearance or approval, and requirements for such registrations, clearances or approvals may significantly differ from FDA
requirements. If we modify our products, we may need to apply for additional regulatory clearances or approvals before we are permitted
to sell the modified product. In addition, we may not continue to meet the quality and safety standards required to maintain the
authorizations that we have received. If we are unable to maintain our authorizations in a particular country, we will no longer
be able to sell the applicable product in that country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regulatory clearance or approval by the
FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, and registration, clearance
or approval by one or more foreign regulatory authorities does not ensure registration, clearance or approval by regulatory authorities
in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance or approval
in one country may have a negative effect on the regulatory process in others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Legislative or regulatory reforms
in the United States or the EU may make it more difficult and costly for us to obtain regulatory clearances or approvals for our
products or to manufacture, market or distribute our products after clearance or approval is obtained.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, legislation is drafted
and introduced in Congress that could significantly change the statutory provisions governing the regulation of medical devices.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations,
or take other actions, which may prevent or delay approval or clearance of our future products under development or impact our
ability to modify our currently cleared products on a timely basis. Over the last several years, the FDA has proposed reforms to
its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period,
or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November
2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under
Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing
the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices
that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared
on the basis of demonstrated substantial equivalence to predicate devices that are more than 10&#160;years old. In May 2019, the
FDA solicited public feedback on these proposals. The FDA requested public feedback on whether it should consider certain actions
that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k)
clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such
proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional
regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance, or
restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">More recently, in September 2019, the FDA
finalized guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers
of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway
by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need,
in the case of applicable products, for manufacturers to compare the safety and performance of their medical devices to specific
predicate devices in the clearance process. The FDA intends to develop and maintain a list device types appropriate for the &#8220;safety
and performance based&#8221; pathway and will continue to develop product-specific guidance documents that identify the performance
criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible. The FDA
may establish performance criteria for classes of devices for which we or our competitors seek or currently have received clearance,
and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain new 510(k)
clearances or otherwise create competition that may negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, FDA regulations and guidance
are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new statutes,
regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any
future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute our products.
We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted
or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to
obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional
record keeping.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA&#8217;s and other regulatory authorities&#8217;
policies may change and additional government regulations may be promulgated that could prevent, limit or delay regulatory clearance
or approval of our future products. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes
in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance,
we may lose any marketing approval or clearance that we may have obtained and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April&#160;5, 2017, the European Parliament
passed the Medical Devices Regulation (Regulation 2017/745), which repeals and replaces the EU Medical Devices Directive. Unlike
directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable,
i.e., without the need for adoption of EEA member state laws implementing them, in all EEA member states and are intended to eliminate
current differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation, among other things,
is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices
and ensure a high level of safety and health while supporting innovation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Medical Devices Regulation will, however,
only become applicable three years after publication (in 2020). Once applicable, the new regulations will, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>strengthen the rules on placing devices on the market and reinforce surveillance once they are available;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>establish explicit provisions on manufacturers&#8217; responsibilities for follow-up regarding the quality, performance and
safety of devices placed on the market;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification
number;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products
available in the EU; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">strengthened rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts
before they are placed on the market.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These modifications may have an effect on
the way we conduct our business in the EEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Healthcare reform laws could adversely
affect our products and financial condition.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the past several years, the U.S. healthcare
industry has been subject to an increase in governmental regulation at both the federal and state levels. Efforts to control healthcare
costs, including limiting access to care, alternative delivery models and changes in the methods used to determine reimbursement scenarios
and rates, are ongoing at the federal and state government levels. From time to time, changes designed to contain healthcare costs have
been implemented, some of which have resulted in decreased reimbursement rates for diagnostic imaging services that may impact our business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2010, former President Obama signed
into law the Patient Protection and Affordable Care Act, and the Health Care and Education Reconciliation Act of 2010 (collectively,
the &#8220;ACA&#8221;), which included measures that significantly changed the way healthcare is financed by both governmental
and private insurers. While a primary goal of these healthcare reform efforts was to expand coverage to more individuals, it also
involved additional regulatory mandates and other measures designed to constrain medical costs. The ACA significantly impacts the
medical device industry. Among other things, the ACA:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Imposes an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United
States, which, through a series of legislative amendments, was suspended, effective January&#160;1, 2016 and subsequently repealed
altogether on December&#160;20, 2019;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Establishes a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness
research in an effort to coordinate and develop such research; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Implements Medicare payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians
and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment
models.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the ACA and related healthcare
reform laws, regulations and initiatives have significantly increased regulation of managed care plans and decreased reimbursement
under Medicare managed care. Moreover, to alleviate budget shortfalls, states have reduced or frozen payments to Medicaid managed
care plans. We cannot accurately predict the complete impact of these healthcare reform initiatives, but they could lead to a decreased
demand for medical devices and other outcomes that could adversely impact our business and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some of the provisions of the ACA have yet to be
fully implemented, and certain provisions have been subject to judicial and Congressional challenges. For example, the Tax Cuts and Jobs
Act enacted on December&#160;22, 2017, or TCJA, eliminated the shared responsibility payment for individuals who fail to maintain minimum
essential coverage under section 5000A of the Internal Revenue Code of 1986, commonly referred to as the &#8220;individual mandate,&#8221;
effective January&#160;1, 2019. On December&#160;14, 2018, a U.S.&#160;District Court Judge in the Northern District of Texas, or the
Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because
it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. This decision was subsequently
appealed, and on December&#160;18, 2019, the U.S. Court of Appeals for the Fifth Circuit affirmed the decision of the district court that
the individual mandate, as amended by the TCJA, was unconstitutional. This decision was appealed to the U.S. Supreme Court, and on June
17, 2021, the Supreme Court held that state and individual plaintiffs did not have standing to challenge the individual mandate provision
of the ACA; in so holding, the Supreme Court did not consider larger constitutional questions about the validity of this provision or
the validity of the ACA in its entirety, and other efforts to challenge, repeal or replace the ACA, or portions thereof, will affect our
future products or our business. It is possible that the ACA, as currently enacted or as it may be amended in the future, and other healthcare
reform measures that may be adopted in the future, could have an adverse effect on our industry generally and on our ability to commercialize
our future products and achieve profitability.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Disruptions at the FDA and other
government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy
key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or
commercialized in a timely manner or at all, which could negatively impact our business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The ability of the FDA to review and clear
or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory,
and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events
that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated
in recent years as a result. In addition, government funding of other government agencies that fund research and development activities
is subject to the political process, which is inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Disruptions at the FDA and other agencies
may also slow the time necessary for new medical devices or modifications to cleared or approved medical devices to be reviewed
and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several
years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory
agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Separately, in response to the COVID-19 pandemic,
on March&#160;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March&#160;18,
2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&#160;10,
2020 the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based
prioritization system. More recently, the FDA announced on February 2, 2022 that beginning on February 7, 2022, it would resume domestic
surveillance inspections across all commodities and was proceeding with additional foreign surveillance inspections. Regulatory authorities
outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged
government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their
regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory
authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Employee Matters</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b><i>Under applicable employment laws,
we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from
the expertise of some of our former employees.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our employment agreements generally include
covenants not to compete. These agreements prohibit our employees, if they cease working for us, from competing directly with us
or working for our competitors for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions
in which our employees work at all or for a sufficient duration of time to prevent members of our management team from competing
with us. For example, Israeli courts have required employers seeking to enforce covenants not to compete to demonstrate that the
competitive activities of a former employee will harm one of a limited number of material interests of the employer, such as the
secrecy of a company&#8217;s confidential commercial information or the protection of its intellectual property. In Israel, if
we cannot demonstrate that such an interest will be harmed, we may be unable to prevent our competitors from benefiting from the
expertise of our former employees or consultants and our competitiveness may be diminished.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>We may not be able to attract and
retain the highly skilled employees we need to support our planned growth.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To continue to execute our business and
our growth plan, we must attract and retain highly qualified personnel. Competition for these personnel is intense. We may not
be successful in attracting and retaining qualified personnel. If we fail to attract new personnel or fail to retain and motivate
our current personnel, our business, financial condition, results of operations and future growth prospects could be severely harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Owning Our Ordinary
Shares</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Our share price may be volatile,
and you may lose all or part of your investment.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market price for our shares may be volatile
and subject to wide fluctuations in response to factors including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>actual or anticipated fluctuations in results of operations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>actual or anticipated changes in our growth rate relative to our competitors, as well as announcements by us or our competitors
of significant business developments, changes in relationships with our target customers, manufacturers or suppliers, acquisitions
or expansion plans;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>failure to meet or exceed financial estimates and projections of the investment community or that we provide to the public,
as well as variance in our financial performance from the expectations of market analysts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>issuance of new or updated research reports or short reports by securities analysts or other market participants;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>additions or departures of key management or other personnel;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">our involvement in litigations and investigations, including the securities class-action, shareholder derivative actions and the SEC investigation;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain
patent protection for our technology;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>announcement or expectation of additional debt or equity financing efforts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>sales of our ordinary shares or other securities by us, our insiders or our other shareholders, or the perception that these
sales may occur in the future;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the trading volume of our ordinary shares;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>market conditions in our industry;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>changes in the estimation of the future size and growth rate of our markets; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>general economic, market or political conditions in the United States or elsewhere.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In particular, the market prices of pre-commercial-stage
companies like ours have been highly volatile due to factors, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to develop and commercialize our technology and future products or services;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>developments or disputes concerning our product&#8217;s intellectual property rights;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our or our competitors&#8217; technological innovations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>fluctuations in the valuation of companies perceived by investors to be comparable to us;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital
commitments, new technologies or patents;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>failure to complete significant transactions or collaborate with vendors in manufacturing our product; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>proposals for legislation that would place restrictions on the price of medical therapies.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These and other market and industry factors
may cause the market price and demand for our ordinary shares to fluctuate substantially, regardless of our actual operating performance,
which may limit or prevent investors from readily selling their ordinary shares and may otherwise negatively affect the liquidity
of our ordinary shares. In addition, the stock market in general, and Nasdaq Global Market and emerging growth companies in particular,
have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance
of these companies. Such broad market fluctuations, and other factors (such as variations in quarterly and yearly operating results,
general trends in the medical imaging industry, and changes in state, federal or other applicable regulations affecting us and
our industry) may adversely affect the market price of our ordinary shares, if a market for them develops.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the past, when the market price of shares
has been volatile, holders of those shares have instituted securities class action litigation against the company that issued the
shares. If any of our shareholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a
lawsuit could also divert resources and the time and attention of our management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>As a foreign private issuer, we
are exempt from certain requirements that apply to domestic issuers and we are permitted to follow certain home country corporate
governance practices instead of applicable SEC and Nasdaq requirements, which may result in less protection than is accorded to
shareholders under rules applicable to domestic issuers.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We report under the Exchange Act as a non-U.S.
company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act, we are exempt
from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (1) the sections of
the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the
Exchange Act, (2) the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading
activities and liability for insiders who profit from trades made in a short period of time and (3) the rules under the Exchange
Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information,
although we intend to furnish comparable quarterly information on Form 6-K. In addition, foreign private issuers are not required
to file their annual report on Form 20-F until 120 days after the end of each fiscal year, while U.S. domestic issuers that are
accelerated filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year and U.S.
domestic issuers that are large accelerated filers are required to file their annual report on Form 10-K within 60 days after the
end of each fiscal year. Foreign private issuers are also exempt from Regulation FD, which is intended to prevent issuers from
making selective disclosures of material information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, as a foreign private issuer, we are
permitted to follow certain home country corporate governance practices instead of those otherwise required under the listing rules of
the Nasdaq Stock Market for domestic issuers. For instance, we follow home country practice in Israel with regard to, among other things,
director nomination procedure, approval of compensation of officers, and quorum at shareholder meetings. In addition, we follow our home
country law, instead of the listing rules of the Nasdaq Stock Market, which require that we obtain shareholder approval for certain dilutive
events, such as for the establishment or amendment of certain equity based compensation plans, an issuance that will result in a change
of control of the company, certain transactions other than a public offering involving issuances of a 20% or more interest in the company
and certain acquisitions of the stock or assets of another company. As foreign private issuer we are also permitted to follow home country
practice in Israel with regard to composition of the board of directors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a result of all of the above, you may
not have the same protections afforded to shareholders of a company that is not a foreign private issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>We may lose our foreign private
issuer status which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to incur
significant legal, accounting and other expenses.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As discussed above, we are a foreign private
issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the
Exchange Act applicable to U.S. domestic issuers. We will remain a foreign private issuer until our board determines that we no
longer meet the qualification set forth in Securities Act Rule 405 and Exchange Act Rule 3b-4, with such determinations to be made
on an annual basis as of the end of our second fiscal quarter. In order to maintain our current status as a foreign private issuer,
either (a) a majority of our ordinary shares must be either directly or indirectly owned of record by non-residents of the United
States or (b)(i)&#160;a majority of our executive officers or directors must not be U.S. citizens or residents, (ii)&#160;more
than 50 percent of our assets cannot be located in the United States and (iii)&#160;our business must be administered principally
outside the United States. If we lose this status, we would be required to comply with the Exchange Act reporting and other requirements
applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We
may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The
regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable
to a U.S. domestic issuer may be significantly higher than the costs we would incur as a foreign private issuer. As a result, we
expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some
activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable
to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance,
and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations
could also make it more difficult for us to attract and retain qualified members of our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>We have not paid dividends in the
past and have no immediate plans to pay dividends.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to reinvest all of our future earnings,
to the extent we have earnings, in order to develop and commercialize our technology and products and to cover operating costs, finance
operations and to otherwise become and remain competitive. We have never declared or paid any dividends on our ordinary shares and we
do not plan to pay any cash dividends with respect to our securities in the foreseeable future. As we are a development-stage company
with limited operating history, we may not be able to generate, at any time, sufficient surplus cash that would be available for distribution
to the holders of our ordinary shares as a dividend. Therefore, you should not expect to receive cash dividends on the ordinary shares
we are offering. Consequently, investors may need to rely on sales of their ordinary shares after price appreciation, which may never
occur, as the only way to realize any future gains on their investment. In addition, the Companies Law imposes restrictions on our ability
to declare and pay dividends. See &#8220;Item 8. Financial Information&#8212;A. Consolidated Statements and Other Financial Information&#8212;Dividend
Policy&#8221; for additional information. Payment of dividends may also be subject to Israeli withholding taxes. See &#8220;Item &#8220;10.
Additional Information&#8212;E. Taxation&#8212;<i>Taxation of Our Shareholders&#8212;Dividends&#8221; </i>for additional information.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We incur significant increased costs as a result of operating
as a public company that reports to the SEC and our management is required to devote substantial time to meet compliance obligations.</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a public company reporting to the SEC,
we incur significant legal, insurance, director compensation, accounting and other expenses that we did not incur as a private
company. We are subject to reporting requirements of the Exchange Act and the Sarbanes-Oxley Act, as well as rules subsequently
implemented by the SEC that impose significant requirements on public companies, including requiring establishment and maintenance
of effective disclosure and financial controls and changes in corporate governance practices. In addition, the Dodd-Frank Wall
Street Reform and Consumer Protection Act (the &#8220;Dodd-Frank Act&#8221;) imposes various other requirements on public companies.
There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that may increase
our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue
strain on our personnel, systems and resources. Our management and other personnel may need to devote a substantial amount of time
to these compliance initiatives. In addition, we expect these rules and regulations to make it more difficult and more expensive
for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage
or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult and expensive
for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also incur costs associated with corporate governance
requirements, including requirements under rules implemented by the SEC and the Nasdaq Global Market, and provisions of Israeli corporate
law applicable to public companies. These rules and regulations have and will continue to increase our legal and financial compliance
costs, introduce costs such as investor relations and stock exchange listing fees, and make some activities more time-consuming and costly.
Our board and other personnel continue to devote a substantial amount of time to these initiatives. To the extent we are not in compliance
with the Companies Law or Nasdaq Global Market rules, we may be subject to additional costs or delisting. We are continuously evaluating
and monitoring developments with respect to these rules, and we cannot estimate the amount of additional costs we may incur or the timing
of such costs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect to incur additional expenses and devote
increased management effort toward ensuring compliance with the auditor attestation requirements of Section 404 of the Sarbanes Oxley
Act (and the rules and regulations of the SEC thereunder) because we no longer qualify as an &#8220;emerging growth company.&#8221; We
cannot estimate the amount of additional costs we may incur as a result of being a public company or the timing of such costs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to Section 404 of the Sarbanes-Oxley Act
and the related rules adopted by the SEC and the Public Company Accounting Oversight Board, starting with this annual report, our management
is required to report on the effectiveness of our internal control over financial reporting. To maintain the effectiveness of our disclosure
controls and procedures and our internal control over financial reporting, we expect that we will need to continue enhancing existing,
and implement new, financial reporting and management systems, procedures and controls to manage our business effectively and support
our growth in the future. The process of evaluating our internal control over financial reporting requires an investment of substantial
time and resources, including by our Chief Financial Officer and other members of our senior management. As a result, this process may
divert internal resources and take a significant amount of time and effort to complete. In addition, we no longer qualify as an &#8220;emerging
growth company&#8221; under the JOBS Act and lost the ability to rely on the exemptions related thereto discussed above and our independent
registered public accounting firm must attest to the effectiveness of our internal control over financial reporting under Section 404.
Irrespective of compliance with Section 404, any failure of our internal controls could have a material adverse effect on our stated results
of operations and harm our reputation. As a result, we may experience higher than anticipated operating expenses, as well as higher independent
auditor fees during and after the implementation of these changes. If we are unable to implement any of the required changes to our internal
control over financial reporting effectively or efficiently or are required to do so earlier than anticipated, it could adversely affect
our operations, financial reporting and/or results of operations and could result in an adverse opinion on internal controls from our
independent auditors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Shares eligible for future sale
may adversely affect the market for our ordinary shares and the issuance of additional ordinary shares as a result of the exercise
of our outstanding warrants and options will dilute the percentage ownership of our other shareholders.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">From time to time, certain of our shareholders
are eligible to sell all or some of their ordinary shares by means of ordinary brokerage transactions in the open market pursuant to Rule
144, promulgated under the Securities Act, subject to certain limitations. In general, pursuant to Rule 144, non-affiliate shareholders
may sell freely after six&#160;months subject only to the current public information requirement (which disappears after one year). Of
the 52,080,400 ordinary shares outstanding as of March 31, 2022, approximately 42,308,506 ordinary shares have been registered under the
Securities Act and are freely transferable by persons other than our &#8220;affiliates&#8221; without restriction or additional registration;
the remaining shares outstanding have not been registered under the Securities Act and may be offered or sold only pursuant to an effective
registration statement or pursuant to an available exemption from the registration requirements. As of March 31, 2022, approximately 46,263,964
of our ordinary&#160;shares are held by &#8220;non-affiliates&#8221; and are freely tradable without restriction pursuant to Rule 144.
In addition, a certain shareholder has the ability to cause us to register the resale of its shares issuable upon exercise of certain
warrants under the Registration Rights Agreement (as defined below). See &#8220;Item 10. Additional Information&#8212;C. Material Contracts&#8221;
for a description of the registration rights. Any substantial sale of our ordinary shares pursuant to Rule 144 or pursuant to any resale
prospectus may have a material adverse effect on the market price of our ordinary shares.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, as of March 31, 2022, there were two
outstanding warrants to purchase a total of 2,312,443 ordinary shares, with exercise prices ranging from $18.00 per share to $20.87 per
share. As of March 31, 2022, there were 5,134,540 ordinary shares issuable upon the exercise of options to purchase ordinary shares outstanding
under our 2019 Equity Incentive Plan (as defined below), at a weighted average exercise price of $12.17 per share, and 1,800,703 additional
ordinary shares reserved for future issuance under our 2019 Equity Incentive Plan. The warrants are exercisable immediately and expire
on various dates. More convertible securities may be granted in the future to the Company&#8217;s officers, directors, employees or consultants
or as part of future financings. The exercise of outstanding stock options and warrants will dilute the percentage ownership of the Company&#8217;s
other shareholders.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>The purchase price of the ordinary
shares may not reflect our actual value.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The price of our ordinary shares may not
be indicative of our actual value or any future market price for our securities. This price may not accurately reflect the value
of the ordinary shares or the value that potential investors will realize upon their disposition of ordinary shares. The price
does not necessarily bear any relationship to our assets, earnings, book value per share or other generally accepted criteria of
value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If equity research analysts discontinue
research or reports about us or our business or if they issue unfavorable commentary or downgrade our ordinary shares, or if other
market participants such as short sellers issue unfavorable reports about us, the price of our ordinary shares could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The trading market for our ordinary shares
relies in part on the research and reports that equity research analysts publish about us and our business. The analysts&#8217;
estimates are based upon their own opinions and are often different from our estimates or expectations. If our results of operations
are below the estimates or expectations of public market analysts and investors, the price of our ordinary shares could decline.
Moreover, the price of our ordinary shares could decline if one or more securities analysts downgrade our ordinary shares or if
those analysts issue other unfavorable commentary or cease publishing reports about us or our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our management conducted an evaluation of the effectiveness of
our internal control over financial reporting and concluded that our internal control over financial reporting was not effective as of
December 31, 2021. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately
report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting,
which would harm our business and the trading price of our ordinary shares.</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Effective internal controls over financial reporting
are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures are designed
to prevent fraud. Our management is required to assess the effectiveness of our internal controls and procedures and disclose changes
in these controls on an annual basis and our independent registered public accounting firm is required to attest to the effectiveness
of our internal controls over financial reporting pursuant to Section 404.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any failure to implement required new or
improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations.
In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered
public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material
weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further
attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information,
which could have a negative effect on the trading price of our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management conducted an evaluation of the effectiveness
of our internal control over financial reporting and concluded that our internal control over financial reporting was not effective as
of December 31, 2021 due to a lack of sufficient number of financial reporting personnel with an appropriate level of knowledge, experience
and training commensurate with our financial reporting requirements, resulting in a failure to maintain an effective control environment
and a failure of segregation of duties, and also concluded that our disclosure controls and procedures were not effective as of December
31, 2021 due to material weaknesses in our internal control over financial reporting, all as described in Item 15, &#8220;Controls and
Procedures&#8221; of this annual report. As defined in Regulation&#160;12b-2 under the Exchange Act, a &#8220;material weakness&#8221;
is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility
that a material misstatement of our annual financial statements will not be prevented, or detected on a timely basis.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While management has continued the process of
remediating the material weaknesses, as described in Item 15, &#8220;Controls and Procedures,&#8221; if significant deficiencies or
other material weaknesses are identified in our internal control over financial reporting that we cannot remediate in a timely
manner, investors and others may lose confidence in the reliability of our financial statements and the trading price of our shares
and ability to obtain any necessary equity or debt financing could suffer. The material weaknesses will not be considered remediated
until we have completed implementing the necessary controls and applicable.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have made, and will continue to make, changes
in these and other areas. In any event, the process of determining whether our existing internal controls are compliant with Section 404
and sufficiently effective will require the investment of substantial time and resources, including by our chief financial officer and
other members of our senior management. As a result, this process may divert internal resources and take a significant amount of time
and effort to complete. In addition, we cannot predict the outcome of this process and whether we will need to implement remedial actions
in order to implement effective controls over financial reporting. The determination of whether or not our internal controls are sufficient
and any remedial actions required could result in us incurring additional costs that we did not anticipate, including the hiring of outside
consultants. We may also fail to complete our evaluation, testing and any required remediation needed to comply with Section 404 in a
timely fashion. Irrespective of compliance with Section 404, any additional failure of our internal controls could have a material adverse
effect on our stated results of operations and harm our reputation. As a result, we may experience higher than anticipated operating expenses,
as well as higher independent auditor fees during and after the implementation of these changes. If we are unable to implement any of
the required changes to our internal control over financial reporting effectively or efficiently or are required to do so earlier than
anticipated, it could adversely affect our operations, financial reporting or results of operations and could result in an adverse opinion
on internal controls from our independent auditors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, if we are unable to certify
that our internal control over financial reporting is effective and in compliance with Section 404, we may be subject to sanctions
or investigations by regulatory authorities, such as the SEC or stock exchanges, and we could lose investor confidence in the accuracy
and completeness of our financial reports, which could hurt our business, the price of our ordinary shares and our ability to access
the capital markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be a passive foreign investment company (&#8220;PFIC&#8221;)
for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. Holders of our ordinary
shares.</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A non-U.S. corporation will be a PFIC for
any taxable year if either (1) at least 75% of its gross income for such year consists of certain types of passive income; or (2)
at least 50% of the value of its assets (generally determined based on an average of the quarterly values of the assets) during
such year is attributable to assets that produce passive income or are held for the production of passive income. For this purpose,
cash and assets readily convertible into cash are categorized as passive assets and our goodwill and other unbooked intangibles
will generally be taken into account in determining our asset value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although subject to uncertainty, we believe that
it is likely that we were not classified as a PFIC for the taxable year that ended December 31, 2021. We believe, however, that we were
technically a PFIC for the 2020 taxable year, and that we may again be classified as a PFIC in the future, which could result in adverse
U.S. federal income tax consequences to U.S. shareholders. Our PFIC status for the current taxable year ending December 31, 2022 will
not be determinable until after the close of the taxable year. There can be no assurance that we will not be a PFIC for the current or
any future taxable year.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If we were classified as a PFIC for any
taxable year during which a U.S. Holder (as defined below) holds our ordinary shares, certain adverse U.S. federal income tax consequences
could apply to such U.S. Holder. See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;U.S. Federal Income Tax Considerations.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Our Operations in Israel</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Conditions in Israel could materially
and adversely affect our business.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our executive offices are located in Neve
Ilan, Israel. In addition, a number of our officers and directors are residents of Israel. Accordingly, political, economic and
military conditions in Israel and the surrounding region may directly affect our business and operations. Since the establishment of
the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries, as well as
terrorist acts committed within Israel by hostile elements. In recent years, Israel has been engaged in sporadic armed conflicts
with Hamas, an Islamist terrorist group that controls the Gaza Strip, with Hezbollah, an Islamist terrorist group that controls
large portions of southern Lebanon, and with Iranian-backed military forces in Syria. Some of these hostilities were accompanied by
missiles being fired from the Gaza Strip against civilian targets in various parts of Israel, and negatively affected business
conditions in Israel. In addition, Iran has threatened to attack Israel, may be developing nuclear weapons and has targeted
cyber-attacks against Israeli entities. In addition, Iran has threatened to attack Israel, may be developing nuclear weapons and has
targeted cyber-attacks against Israeli entities. Iran also has a strong influence among extremist groups in the region, including
Hamas in Gaza, Hezbollah in Lebanon and various rebel militia groups in Any hostilities involving Israel or the interruption or
curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations. Any
armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions and could
harm our results of operations and could make it more difficult for us to raise capital. In addition, the political and security
situation in Israel may result in parties with whom we have agreements involving performance in Israel claiming that they are not
obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We currently do not, and we do not expect
to, carry any commercial insurance that covers losses resulting from events associated with war and terrorism. Although the Israeli
government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot
be assured that this government coverage will be maintained or, if maintained, that it will be sufficient to compensate us fully
for damages incurred and the government may cease providing such coverage or the coverage might not suffice to cover potential
damages. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political
instability in the region would likely negatively affect business conditions and could harm our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Further, in the past, the State of Israel
and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel
and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial
condition or the expansion of our business. A campaign of boycotts, divestment and sanctions has been undertaken against Israel,
which could also adversely impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, many Israeli citizens are obligated
to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age of 40 (or older
for certain reservists) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist
activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve
duty call-ups in the future. Our operations could be disrupted by such call-ups, which may include the call-up of members of our
management. Such disruption could materially adversely affect our business, prospects, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>The termination or reduction of
tax and other incentives that the Israeli government provides to Israeli companies may increase our costs and taxes.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Israeli government currently provides
tax and capital investment incentives to Israeli companies, as well as grant and loan programs relating to research and development
and marketing and export activities (see &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;Israeli Tax Considerations
and Government Programs&#8221;). In recent years, the Israeli government has reduced the benefits available under these programs
and the Israeli governmental authorities may in the future further reduce or eliminate the benefits of these programs. We may take
advantage of these benefits and programs in the future; however, there can be no assurance that such benefits and programs will
be available to us. If we qualify for such benefits and programs and fail to meet the conditions thereof, the benefits could be
canceled and we could be required to refund any benefits we might already have enjoyed and become subject to penalties. Additionally,
if we qualify for such benefits and programs and they are subsequently terminated or reduced, it could have an adverse effect on
our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>It may be difficult to enforce a
U.S. judgment against us, our officers and directors named in this annual report on Form 20-F in Israel or the United States, or
to assert U.S. securities laws claims in Israel or serve process on our officers and directors.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many of our directors and officers are not
residents of the United States and a significant portion of their and our assets are located outside the United States. Service
of process upon us or our non-U.S. resident directors and officers may be difficult to obtain within the United States. We have
been informed by our legal counsel in Israel that it may be difficult to assert claims under U.S. securities laws in original actions
instituted in Israel or obtain a judgment based on the civil liability provisions of U.S. federal securities laws. Israeli courts
may refuse to hear a claim based on a violation of U.S. securities laws against us or our directors and officers because Israel
may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may
determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable
U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be
governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Additionally, Israeli
courts might not enforce judgments obtained in the United States against us or our directors and officers, which may make it difficult
to collect on judgments rendered against us or our directors and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Moreover, an Israeli court will not enforce
a non-Israeli judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts
(subject to exceptional cases), if its enforcement is likely to prejudice the sovereignty or security of the State of Israel, if
it was obtained by fraud or in the absence of due process, if it is at variance with another valid judgment that was given in the
same matter between the same parties, or if a suit in the same matter between the same parties was pending before a court or tribunal
in Israel at the time the foreign action was brought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Your rights and responsibilities
as our shareholder will be governed by Israeli law, which may differ in some respects from the rights and responsibilities of shareholders
of U.S. corporations.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are incorporated under Israeli law. The
rights and responsibilities of holders of our ordinary shares are governed by our amended and restated articles of association
and the Companies Law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders
in typical U.S. corporations. In particular, pursuant to the Companies Law, each shareholder of an Israeli company has to act in
good faith and in a customary manner in exercising his or her rights and fulfilling his or her obligations toward the company and
other shareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at the
general meeting of shareholders on amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized
share capital, mergers and certain transactions requiring shareholders&#8217; approval under the Companies Law. In addition, under
Israeli law, a controlling shareholder of an Israeli company or a shareholder who knows that it possesses the power to determine
the outcome of a shareholder vote or who has the power to appoint or prevent the appointment of a director or officer in the company
or has other powers toward the company has a duty of fairness toward the company. However, Israeli law does not define the substance
of this duty of fairness. There is little case law available in Israel to assist in understanding the implications of these provisions
that govern shareholder behavior.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Our amended and restated articles
of association contains exclusive forum provisions for certain claims, which could limit our shareholders&#8217; ability to obtain
a favorable judicial forum for disputes with us or our directors, officers or employees.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended and restated articles of association
provides that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the
exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the &#8220;Federal Forum
Provision&#8221;). Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware
holding that such provisions are facially valid under Delaware law. While there can be no assurance that U.S. federal or state
courts or Israeli courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should
be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our shareholders to enforce
any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. Section
27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created
by the Exchange Act or the rules and regulations thereunder and the Federal Forum Provision does not apply to suits brought to
enforce any duty or liability created by the Exchange Act. Accordingly, actions by our shareholders to enforce any duty or liability
created by the Exchange Act or the rules and regulations thereunder must also be brought in federal court. Our shareholders will
not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any person or entity purchasing or otherwise
acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to the Federal Forum
Provision. This provision may limit our shareholders&#8217; ability to bring a claim in a judicial forum they find favorable for
disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers
and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated
articles of association to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving
such action in other jurisdictions, which could harm our business, operating results and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Provisions of our amended and restated
articles of association and Israeli law and tax considerations may delay, prevent or make difficult an acquisition of us, which
could prevent a change of control and negatively affect the price of our ordinary shares.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Israeli corporate law regulates mergers,
requires tender offers for acquisitions of shares if such acquisitions cause the acquirer to hold more than specified thresholds,
requires special approvals for certain transactions involving directors, officers or significant shareholders and regulates other
matters that may be relevant to these types of transactions. For example, under Israeli law, a merger may not be consummated unless
at least 50 days have passed from the date that a merger proposal was filed by each merging company with the Israel Registrar of
Companies and at least 30 days have passed from the date that the shareholders of both merging companies approved the merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to our shareholders, especially for those shareholders whose country of residence
for tax purposes does not have a tax treaty with Israel which exempts such shareholders from Israeli tax. For example, Israeli
tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law
allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions,
including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of
shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions,
the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has
occurred. In order to benefit from the tax deferral, a pre-ruling from the Israeli Tax Authority may be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">These provisions of Israeli law and Israeli
tax laws may delay, prevent or make difficult a merger with, or an acquisition of us, or all or a significant portion of our assets,
which could prevent a change of control and may make it more difficult for a third party to acquire us, even if doing so would
be beneficial to our shareholders. These provisions may limit the price that investors may be willing to pay in the future for
our ordinary shares and therefore depress the price of our shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended and restated articles of association
provide that our directors (other than external directors) are elected on a staggered basis, such that a potential acquirer cannot
readily replace our entire board of directors at a single annual general shareholder meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_005"></a></div><div><a id="c_001"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in">Item 4.</td><td>Information on the Company</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 20pt"></td><td style="width: 20pt; text-align: left">A.</td><td style="text-align: justify">History and Development of the Company</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NANO-X IMAGING LTD was incorporated under
the laws of the State of Israel on December&#160;20, 2018 and commenced operations on September&#160;3, 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Substantially all of our assets at the time of
commencement of our operations were acquired or assigned (the &#8220;Asset Purchase&#8221;) from our predecessor company, Nanox Imaging
PLC (&#8220;Nanox Gibraltar&#8221;), a Gibraltar public company, under an Asset Purchase Agreement, dated as of September&#160;3, 2019
and as amended on December&#160;3, 2019 and December&#160;31, 2019, between Nanox Gibraltar and us. Pursuant to the Asset Purchase Agreement,
substantially all of the assets of Nanox Gibraltar, including all patents, patent applications and all other intellectual property rights,
but not including the shares of Nanox Japan, Inc., a wholly owned subsidiary of Nanox Gibraltar (&#8220;Nanox Japan (predecessor)&#8221;),
were sold to the Company for an aggregate consideration of $13.3 million, reflecting the fair market value of the transferred assets,
which was estimated to be $6.1 million (excluding cash) based on an independent valuation report, plus the cash balance less $200,000,
which cash amount totaled $7.2 million as of the date of the Asset Purchase Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In January 2020, the board
of directors of the Company and the board of directors and shareholders of Nanox Gibraltar approved the issuance of shares in accordance
with the terms of the Asset Purchase Agreement described above. As a result, 1,109,245 of the Company&#8217;s ordinary shares were issued
to Nanox Gibraltar, representing an aggregate consideration of approximately $17.8 million, and the Company has no further obligations
to Nanox Gibraltar under the Asset Purchase Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 2, 2021, the Company completed the
acquisition of 100% of the shares of USARAD Holdings, Inc., a Delaware corporation (&#8220;USARAD&#8221;), pursuant to the terms of the
Stock Purchase Agreement, dated October 25, 2021, among the Company, USARAD, Dr. Michael Yuz, other holders of capital stock of USARAD
and holders of USARAD options. USARAD <span>is a U.S.-based teleradiology company with over 300 U.S. certified
radiologists in its network</span>. At closing, the Company (through a wholly-owned subsidiary) purchased 100% of the shares of USARAD
on a fully diluted basis for $7,300,000 in cash and 496,545 ordinary shares. In addition, upon the successful achievement of certain milestones
related to profitability, EBITDA and other operational performance metrics, the Company undertook to pay additional cash consideration
in the amount of up to $2,000,000 and stock consideration in the amount of up to $6,500,000 at a per share value determined by the average
of: (i) the volume weighted average closing share price of the 30 trading days prior to the relevant milestone completion, and (ii) the
volume weighted average closing share price of the 30 trading days ending on August 6, 2021.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 3, 2021, the Company completed the
acquisition of the platform and other assets of MDWEB, pursuant to the terms of the Asset Purchase Agreement, dated October 21, 2021,
between the Company and MDWEB, a USARAD-related company. Pursuant to the acquisition, we acquired the MDW platform, now known as the Nanox.MARKETPLACE,
a decentralized marketplace connecting imaging facilities with radiologists. At closing, the Company issued 64,715 ordinary shares to
MDWEB. In addition, upon the successful achievement of certain milestones related to technical integration of the Nanox.MARKETPLACE with
the Nanox.CLOUD and achieving certain other operational targets, the Company undertook to pay additional stock consideration in the amount
of up to $1,500,000 at a per share value determined by the average of: (i) closing price of the 30 trading days ending on the applicable
milestone&#8217;s achievement date: and (ii) the volume weighted average closing share price of the 30 trading days prior to the closing
date.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 4, 2021, the Company consummated its
purchase of 100% of the equity of Zebra Medical Vision Ltd., an Israeli company (&#8220;Zebra&#8221;) pursuant to the terms of the Agreement
and Plan of Merger, dated August 9, 2021, as amended, among the Company, Zebra and Perryllion Ltd., as representative of Zebra&#8217;s
equity holders. Zebra, now known as Nanox AI, is a leading medical AI developer, with eight FDA-cleared and 11 CE-marked AI solutions
for medical imaging. At closing, the Company issued 3,249,142 ordinary shares of the Company and committed to issue 70,211 employee options
to the equity holders of Zebra, which represented (a) the basic purchase price of $100,000,000; minus (b) certain transaction costs; plus
(c) deferred closing consideration in the amount of $3,333,333 as a result of Zebra entering into a designated commercial agreement prior
to closing; plus (d) $6,300,000 as a result of Zebra achieving a designated milestone of obtaining a new FDA clearance for its population
health product. In addition, Zebra entered into one of the two additional designated commercial agreements within six months of the execution
of the agreement, and, pursuant to the agreement, the Company will pay a deferred closing consideration in the amount of $3,333,333 in
shares for such agreement. The deferred closing consideration will paid in the Company&#8217;s shares in the amount of the relevant installment
payment divided by the average closing price of the 30 trading days ending on the applicable agreement signing date. Further, if Zebra
will have achieved the agreed milestones related to obtaining certain FDA clearances and security certifications, completing certain technology
integration or achieving certain revenue and employee retention targets over the next three years, the Company undertook to pay additional
consideration, by way of issuing additional ordinary shares of the Company to be calculated based on the number of milestones actually
achieved and the respective consideration apportioned to each milestone. Assuming the achievement of all milestones, the additional consideration
will be in the amount of up to $77,700,000. Each of these milestone installments would be paid in the Company&#8217;s shares in the amount
of the relevant installment payment divided by the average closing price of the 30 trading days ending on the applicable milestone&#8217;s
achievement date. Zebra&#8217;s name was changed to Nanox AI Ltd. and it operates under the new name. On January 19, 2022, we issued 89,286
additional shares to the former shareholders of Nanox AI due to partial achievement of a milestone that occurred post-closing.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located at
Communications Center, Neve Ilan, Israel 9085000, and our telephone number is +972 02 5360360. Our website address is <span style="text-decoration:underline">http://www.nanox.vision</span>.
The information contained therein or connected thereto shall not be deemed to be incorporated into this annual report on Form 20-F. Our
agent for service of process in the United States is CT Corporation System.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"> Public Offerings</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In August 2020, we completed our initial public
offering of 10,555,556 ordinary shares at a public offering price of $18 per share, including 1,376,812 additional ordinary shares purchased
by the underwriters at the public offering price, less the underwriting discount, pursuant to the exercise in full of their option to
purchase additional ordinary shares. Our ordinary shares are listed on the NASDAQ Global Market under the symbol &#8220;NNOX.&#8221;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 10, 2021, certain of our shareholders
sold an aggregate of 3,091,635 ordinary shares in a public offering pursuant to an Underwriting Agreement by and among us, Cantor Fitzgerald
&amp; Co., acting as representative of the underwriters, and the selling shareholders named therein (the &#8220;Selling Shareholders&#8221;).
We did not receive any of the proceeds from the sale of ordinary shares offered by the Selling Shareholders.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">B. Business Overview</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Overview</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Early detection saves lives&#8212;and we at Nanox
are focused on applying our proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable
across the globe. We are developing a holistic imaging solution, which includes the Nanox System, comprised of the Nanox.ARC using our
novel MEMs X-ray source technology, and the Nanox.CLOUD, a companion cloud software, integrated with AI solutions and teleradiology services.
Our vision is to increase early detection of medical conditions that are discoverable by X-ray by improving access to imaging, reducing
imaging costs and enhancing imaging efficiency, which we believe is key to increasing early prevention and treatment, improving health
outcomes and, ultimately, saving lives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our imaging solution is designed as a modular open
system, and we intend in the future to explore the expansion of the solution to include additional components, which may be developed
by us or third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our holistic imaging solution is currently comprised
of the following four principal components:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>The Nanox System</i></b>. As a first step
to producing a new class of accessible and affordable medical imaging systems, we focused on identifying and developing a novel digital
X-ray source, which we refer to as the Nanox.SOURCE. Our X-ray source is based on a novel digital MEMs semiconductor cathode that we believe
can achieve the same functionalities as legacy X-ray analog cathodes, while allowing for lower-cost production than existing medical imaging
systems. We have been developing this technology over nine years towards the goal of commercial applicability. This novel digital X-ray
source is the basis of core technology in the imaging system we are developing, and we believe it also has the potential to replace the
legacy X-ray source in other existing imaging systems. Our technology aims to disrupt medical imaging by providing accessibility and affordability
on a global scale. Our goal is to enable medical institutions and other significant medical players to either employ our solutions as
a closed end-to-end system or to adopt a modular approach to our technologies, by acquiring or licensing our different components and
integrating our technologies into their specific product.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nanox System includes two integrated components&#8212;hardware
(Nanox.ARC), a medical imaging system incorporating our novel digital X-ray source, and software (Nanox.CLOUD). We have developed a working
prototype of the multi-source Nanox.ARC. Subject to receiving regulatory clearance, the version of the Nanox.ARC that we expect to introduce
to the market will be a 3D tomosynthesis imaging system. Tomosynthesis is an imaging technique used for early detection, that is designed
to produce a high-resolution, 3D, X-ray image reconstruction of the scanned human body part for review by a professional diagnostics expert.
In parallel, we have developed, and continue to improve, the Nanox.CLOUD, a companion cloud-based software to which scanned images may
be securely uploaded to the cloud system. By integrating the Nanox.CLOUD with the Nanox.ARC, we believe the Nanox System could provide
a streamlined process and end-to-end medical imaging service, including services such as image repository, radiologist matching, online
and offline diagnostics review and annotation, connectivity to diagnostic assistive AI systems, billing, monitoring and reporting.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If cleared by the FDA and/or similar regulatory
agencies in other jurisdictions, we plan to market and deploy the Nanox System globally at a substantially lower cost than currently available
medical imaging systems, such as legacy X-ray and Computerized Tomography (&#8220;CT&#8221;) systems, because our digital X-ray source
will allow the Nanox.ARC to have a simpler structure without the costly cooling equipment used in legacy X-ray systems or the complex
rotating mechanism used in CT devices. See &#8220;&#8212;Our Technology&#8212;The Nanox System.&#8221; We believe that the Nanox System
could increase the accessibility and affordability of early-detection medical imaging systems worldwide, substantially reduce wait-times
for imaging results and increase early detection rates compared to currently employed imaging process protocol.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We continue to implement a multi-step approach
to the regulatory clearance process for the Nanox System. On April 1, 2021, we received clearance from the FDA to market our Nanox Cart
X-Ray System, a single-source version of the Nanox.ARC. On June 17, 2021, we submitted a 510(k) premarket notification application to
the FDA for the first version of our multi-source Nanox.ARC 3-D digital tomosynthesis system. On August 12, 2021, we received a request
for additional information from the FDA concerning the first submission of our multi-source system. On January 10, 2022, we withdrew our
first submission of our multi-source system. On January 12, 2022, we submitted to&#160;the FDA a Q-submission for the second&#160;version
of&#160;our&#160;multi-source Nanox.ARC 3-D digital tomosynthesis system. The Q-submission program provides submitters an opportunity
to have early collaboration and discussions about medical device submissions, through a request for feedback from and/or a meeting with
the FDA regarding a potential or planned medical device submission and we believe that using this approach will assist to expedite and
optimize the regulatory clearance process for the Nanox.ARC. The second version of&#160;the Nanox.ARC is an improved and enhanced version
that was designed, among other things,&#160;to address certain deficiencies raised by the FDA during their review of the first submission
from June 2021. We continue to communicate with the FDA and we expect the next step in this process to be the submission of a supplement
to the Q-submission followed by a formal 510(k) application to the FDA for the multi-source Nanox.ARC. If cleared by the FDA and authorized
by similar regulatory agencies in other jurisdictions, our goal is to finalize deployment of the initial 15,000 Nanox Systems by the end
of 2024. In parallel, we are preparing for shipments of the first units of the Nanox System. See &#8220;Item 3. Key Information&#8212;D.
Risk Factors&#8212;<i>Products utilizing our technology may need to be approved or cleared by the FDA and similar regulatory agencies
worldwide. We may not receive, or may be delayed in receiving, the necessary approval or clearance for our future products, which would
adversely affect business, financial condition, results of operations and prospects</i>.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect that the Nanox System will enable us
to accumulate a significant number of medical images, which have the potential to be used by collaborators, such as medical AI-analytics
companies, through machine learning algorithms to increase the probability of early disease detection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Nanox.MARKETPLACE. </i></b>Nanox.MARKETPLACE
(formerly known as the MDW platform), which we acquired from MDWEB in November 2021, is our proprietary decentralized marketplace that
connects imaging facilities with radiologists and enables radiologists to provide, and customers to obtain, remote interpretations of
imaging data. The platform was designed by radiologists for the imaging industry. The radiologists connecting to Nanox.MARKETPLACE include
those radiologists who are part of our network and provide teleradiology services through USARAD, as well as other radiologists, all of
whom undergo an accreditation process that we perform and are required to be certified by the American Board of Radiology. Based primarily
on customer location and area of specialization, radiologists will be matched to conduct the imaging interpretation. The radiologist receives
payment through the platform from the customer upon the delivery of the imaging interpretation. The Nanox.MARKETPLACE service is currently
offered on a standalone basis. In the future, we plan to incorporate the Nanox.MARKETPLACE into the Nanox System, such that images that
were generated by the Nanox.ARC and uploaded to the Nanox.CLOUD, can be streamlined and referred through the Nanox.MARKETPLACE to radiologists
for remote reading.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>AI Imaging Solutions</i></b>. Following our
acquisition of Zebra, renamed Nanox AI, in November 2021, we offer FDA approved AI-based software imaging solutions to hospitals, health
maintenance organizations (&#8220;HMOs&#8221;), integrated delivery networks (&#8220;IDNs&#8221;), pharmaceutical companies and insurers,
that are designed to identify or predict undiagnosed or underdiagnosed medical conditions, through the mining of data included in images
of existing CT scans. We currently offer AI imaging population health solutions aimed at identifying underlying osteoporosis and cardiovascular
disease. We are also conforming these AI imaging population health solutions to be implemented as an additional service in the Nanox System,
once deployed. With our AI imaging population health solutions, we aim to further our mission to enable preventative healthcare through
early detection. We also continue to maintain certain legacy contracts for AI imaging triage solutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, following the acquisition of Nanox
AI, we have begun to develop an AI imaging solution that is designed to identify whether certain common abnormalities are presented in
images generated by Nanox.ARC and to determine if follow up diagnostic imaging or treatment is required. This AI imaging solution is currently
being developed for application in imaging of the chest and extremities. Ultimately, we expect to integrate this AI imaging solution,
which we refer to as Robodiology, into the Nanox System. Subject to completion of the development and receipt of requisite regulatory
approvals, we plan to offer this AI imaging solution as an optional service to our MSaaS partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Teleradiology Services</i></b>. Following
our acquisition of USARAD in November 2021, we offer teleradiology&#160;services to customers in the U.S. market and an additional seven
countries by U.S.-based radiologists, certified by the American Board of Radiology. We offer imaging interpretation services for radiology
practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities and multi-specialty physician groups and USARAD
contracts directly with these customers. In addition, we provide second opinion radiology readings, primarily to imaging centers. We have
a network of over 300 independent radiologists, all of whom have undergone an accreditation process by us, and we provide our teleradiology
services to over 500 imaging centers. We allocate images that we receive from our customers, through our picture archiving and documentation
system, to radiologists in our network based on the radiologist&#8217;s area of specialization. Payment is made by the customer directly
to us monthly based on the number of monthly readings and we pay the radiologist a predetermined fixed fee per reading.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, our teleradiology services are offered
as a standalone product through USARAD. In the future, we plan to incorporate our teleradiology services as part of our Nanox System offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Limitation of Current Medical Imaging Solutions and Our Market Opportunity</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The main categories of
current medical imaging systems that use X-ray sources include legacy X-ray systems, CT, mammography, fluoroscopy and angiogram. The
analog X-ray source used by these systems produces X-rays by accelerating electrons to high energies, causing them to hit a metal
target from which the X-rays are emitted. This requires a significant amount of electrical energy to be transferred to the X-ray
tube. Due to the heat generated by this process, one of the most complex mechanical challenges is cooling the analog X-ray source.
In addition, for CTs, the mechanical structure is even more complex because the analog X-ray source needs to rotate in a heavy
gantry at high speed. We believe these are key factors leading to the high cost and complexity of existing medical imaging systems,
which in turn significantly limits the availability of medical imaging for early detection globally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to a report from the Pan American Health
Organization and World Health Organization (&#8220;WHO&#8221;) in 2012, approximately two-thirds of the world population did not have
access to medical imaging. Further, many people with access to medical imaging face substantial wait times for scanning. For example,
in Canada, access to medical imaging procedures is a growing problem with months of reported wait times for MRI and CT screening. Long
wait times not only negatively impact patient outcomes but also add significant costs to the Canadian healthcare system each year due
to delays in detection and treatment. Wait times for a CT scan can be longer than six weeks in Scotland, over 12 months in Ireland, and
in the UK, tens of thousands of suspected cancer patients face month-long wait times to discover whether they have a particular illness
due to delays in analyzing scans and X-rays.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, most market participants, including
medical imaging manufacturing companies, medical imaging providers and radiologists, among others, have not provided the same level of
end-to-end medical imaging services. One of the reasons is that the scanning process is currently not integrated with the diagnostics
process, which contributes to extended wait times for image diagnostics by experts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">According to a report of Fortune Business Insights
from January 2022, the global medical imaging market size was $36.19 billion in 2020, and the market is expected to grow from $37.97 billion
in 2021 to $56.53 billion in 2028 at a CAGR of 5.8% in the 2021-2028 period. The X-ray equipment segment held a dominant market share
in 2020, accounting for 33.9% of the global medical imaging market share in such period. Further, according to such report, increasing
use of advanced AI-enabled diagnostic equipment for the rapid diagnosis and predictive analysis in developed countries is one of the major
factors anticipated to contribute to the rising product demand during the forecast period. Currently, only a handful of players operating
in the market are providing AI-enabled imaging technologies to the healthcare industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Nanox Ecosystem</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The Nanox System</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are developing the Nanox System, which has two
integrated components &#8212; hardware (Nanox.ARC) and software (Nanox.CLOUD). The Nanox.ARC, a 3D tomosynthesis imaging system, is designed
to integrate our proprietary and novel digital X-ray source, known as Nanox.SOURCE. Our X-ray source is based on a novel digital MEMs
semiconductor cathode that we believe can achieve the same functionalities as legacy X-ray analog cathodes, while allowing for lower-cost
production than existing medical imaging systems. We have been developing this technology over nine years towards the goal of commercial
applicability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our technology aims to disrupt the medical imaging
market by providing accessibility and affordability on a global scale. Our goal is to enable medical institutions and other significant
medical players to either employ our solutions as a closed end-to-end system or to adopt a modular approach to our technologies, by acquiring
or licensing our different components and integrating our technologies into their specific product.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Legacy Analog X-ray Source and Limitations
of Existing Medical Imaging Systems</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The X-ray tube technology has essentially remained
unchanged since its inception in 1895. For any type of imaging system to generate X-rays, the system must use X-ray tubes as a source
for the X-rays. The X-ray tube converts electrical power into X-rays by accelerating electrons to high energies, causing them to hit a
metal target from which the X-rays are emitted. X-rays can only be produced if the X-ray tube is energized, which has historically required
a significant amount of electrical energy to be transferred to the X-ray tube. However, only a small amount of the energy deposited into
the X-ray tube is actually converted into X-rays; the majority of the energy turns into heat. This is called a thermionic (heat-based)
mode of operation where a metal filament needs to be heated up to approximately 2,000&#176;C to generate the electron stream (a &#8220;cathode&#8221;)
that will hit a metal target (an &#8220;anode&#8221;) to generate the photon-based X-ray stream resulting from that high-energy impact.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Heating the filament to approximately 2,000&#176;C
requires the mechanical cathode support systems to withstand high temperatures within a high vacuum, high voltage environment. Tungsten
was introduced into the X-ray tube in 1903 for its properties of a high melting point and ductility. The tungsten filaments still used
today are critical components of X-ray tubes, but they limit the lifetime of the X-ray tube due to the progressive evaporation of filament
material under these high temperatures. At temperatures of up to 2,000&#176;C, the filament evaporates in hot spots close to the peak temperature
locations which over time can cause a catastrophic failure of the filament.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that the use of the legacy analog X-ray
source is one of the key factors for the high cost of existing medical imaging systems. The main categories of medical imaging systems
that use X-ray sources include legacy X-ray systems, CT (3D&#160;cross-sectional 360&#176; &#8220;slicing&#8221; X-ray imaging), mammography
(2D and 3D breast X-ray imaging), fluoroscopy (real-time X-ray video imaging) and angiogram (blood vessels, contrast X-ray imaging). CT
scanners, for example, are complex diagnostic imaging systems that use X-rays to take images of a patient&#8217;s internal structures
and organs. Due to the limitations of the analog X-ray source described above, general radiographic X-ray tubes are not well suited for
use in a CT scanner. CT scanners instead use a specialized X-ray tube designed to withstand the excessive amount of heat produced by continuous
energization. This X-ray tube is located in the gantry, which is the largest part of a CT scanner and consists of the X-ray detectors,
the mechanical supports and the scanner housing. Due to the heat generated by this process, one of the most complex mechanical challenges
is cooling the analog X-ray source while rotating it in a heavy gantry at high-speed. One solution used is the rotating anode, where a
tungsten metal disk rotates at high revolutions per minute so the electron beam hits a different spot on the disk on a continuous basis
to prevent the concentration of heat in one spot on the disk and reduce the likelihood of overheating or burning. In addition, CT scanners
require a long continuous exposure time to create 3D images of the patient&#8217;s body using multiple X-ray images, which means that
the X-ray tube must be continually energized and that patients are continuously exposed to radiation throughout that period. As a result
of these complexities, most high-quality X-ray tubes for a CT scanner weigh between approximately 50 and 100 kilograms with the cooling
mechanism and generally cost up to $150,000 each.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Our Novel Digital X-ray Source</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Realizing that the X-ray tube technology has essentially
not changed in more than 100&#160;years and remains a significant source of complexity and cost-driver of existing X-ray-based medical
imaging systems, we developed a novel digital X-ray source that we believe addresses these drawbacks and will enable a new class of medical
imaging systems that can be produced at a significantly lower cost than the existing systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our technology has its roots in field emission
display (&#8220;FED&#8221;) technology. FED technology was originally developed by Sony with other technology partners, for television
screens and monitors, offering a novel way of lighting screen pixels compared to traditional cathode-ray tubes that were based on a one-source
electron gun beam. The field emission display innovation used multiple nano-scale electron guns to achieve a much higher quality image
with significantly reduced motion blur effects. In 2009, after having invested substantial resources in the development of this technology
for over a decade including through a joint venture called Field Emission Technologies, Inc. (&#8220;FET&#8221;), Sony ceased development
of the project.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 2009, FET dissolved and transferred certain
assets to FET Japan Inc. (&#8220;FETJ&#8221;). Scientists on our team, who worked at FETJ, applied their expertise to develop non-display
related applications, including our X-ray source technology. In 2011, our predecessor company acquired certain non-display related know-how
from FETJ and certain members of the FETJ technical team joined us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After acquiring the technology, we spent over eight
years developing a digital X-ray source for the medical imaging industry that could be produced on a commercial scale. Our X-ray source
is a MEMs-based semiconductor cathode that achieves electron emission by a non-thermionic low-voltage trigger to approximately 100&#160;million
nano-scale molybdenum cones that act as multiple electron &#8220;guns,&#8221; instead of a single heated filament. The cathode is housed
in a customized X-ray tube.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe our X-ray source has the following technological
advantages over the analog X-ray source:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Reduced duration of radiation exposure</i>.
Our X-ray source uses a digital chip that is designed to provide better control and enables near-instantaneous on/off toggling of the
electron beam. This source control also enables a precise &#8220;stop and start&#8221; operation, which we believe can potentially result
in significantly reduced duration of radiation exposure compared to an analog X-ray source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>X-ray source KvP/mA decoupling. </i>Our X-ray
source is designed to create imaging using one X-ray source chip because there is complete independence and separation between the strength
of X-ray penetration and the amount of photons for illumination (referred to as &#8220;KvP / mA&#8221;). KvP represents the speed of electrons
that gives the X-ray its penetrating power, and higher KvP means the X-rays can penetrate higher density materials such as bones. mA represents
the amount of photons or brightness levels of the X-ray image. For legacy X-ray sources, KvP / mA ratios were codependent in a linear
relationship and each X-ray source could only produce one set of KvP / mA combinations dedicated for a particular use (for example, either
tissue images or bone images, but not both simultaneously). We believe our X-ray source technology can produce multi-spectral imaging
from one X-ray source, which allows for variable energy levels to be controlled during one scan. Therefore, one source chip can be used
for multiple types of scans, such as head-scans, abdomen, mammography and angiograms, involving both soft and hard tissues at variable
densities, simultaneously. We believe this multi-spectral imaging could also be applied to real-time video imaging. Our latest working
prototype uses up to120 KvP / mA, and we intend to commercialize the multi-source Nanox.ARC with a range of 40 - 120 KvP / mA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Longer lifetime</i>. Our X-ray source is based
on a field of multiple electron guns on our MEMs-based cathode that spread the load of electron generation among many &#8220;producers&#8221;
compared to a single filament that heats to a high temperature in the analog X-ray tube. As a result, our digital X-ray source is designed
to produce an electron beam from different locations on the chip towards the anode during each duty cycle without the need for the complex,
high precision rotating mechanism. In addition, the near instant on/off toggling feature of our digital X-ray source is designed to allow
us to reduce the duration of each operation. As a result, we believe our medical imaging system will have higher stability and a longer
lifetime, with a longer mean time between failures&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Simplified hardware structure</i>. Because our
chip-based X-ray source and tube are designed to be quickly triggered electronically, we are able to have multiple stationary-anode tubes
arranged around the patient as opposed to one larger tube that rotates around the patient. We believe this could reduce the complexity
and cost of the Nanox.ARC compared to legacy CT devices. This current approach to increase durability of the tungsten anode in imaging
devices, the rotating anode mechanism requires both a significant increase in tube size and mechanical component cost to allow for the
complex movements of the tube. In contrast, we believe by using our X-ray source we will be able to significantly reduce the size of X-ray
tubes and simplify the structure of our medical imaging system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe our X-ray source has the potential to replace the legacy
X-ray source in other existing imaging systems, as well as the X-ray source in systems used in other industries, such as security scanners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Nanox System</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have developed a working prototype of the multi-source
Nanox.ARC, a medical device that integrates our proprietary and novel X-ray source. Subject to receiving regulatory clearance, the version
of the multi-source Nanox.ARC that we expect to introduce to the market is expected to be a 3D tomosynthesis imaging system that produces
a 3D reconstruction of the scanned human body part. The Nanox.ARC, using our X-ray source, is being designed to produce partial and full-body
scans, with remote operation capability, and to have a full kVp/mA energy throughout range as per industry standards, multi-spectral imaging
range, as well as quiet operation, cloud connectivity and standard compliance safety mechanisms. It is being designed for easy setup and
operation with multiple stationary X-ray tubes arranged around the patient. The substantial majority of operational software that we anticipate
will be used to run the Nanox.ARC will be cloud-computing based and integrated with the Nanox.CLOUD, as further explained below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the Nanox.ARC, we have developed
the Nanox.CLOUD, a companion cloud software that will allow for the delivery of medical screening as a service. With the Nanox.CLOUD,
we anticipate that the high-cost components of existing medical imaging systems, such as analytics and computing software that are traditionally
installed via multiple licenses on-premise and on a per-system basis, will become centralized through the cloud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe this will significantly reduce on-going
software and IT licensing costs and enable a wide range of functionalities, such as multiple AI diagnostics and remote support. By integrating
the Nanox.CLOUD with the Nanox.ARC, we believe the Nanox System could provide a streamlined process and end-to-end medical imaging service,
including services such as image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity
to diagnostic assistive AI systems, billing, monitoring and reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe the Nanox System, if successfully developed,
will streamline the entire medical screening process ranging from scanning to support diagnostics, and solve the bottleneck of imaging-to-diagnostics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also expect to be able to offer the Nanox System
for a substantially lower cost than existing medical imaging systems, which we believe is key to achieving our goal of making early-detection
medical imaging systems more accessible globally. We believe our novel X-ray source is crucial to our ability to substantially reduce
the manufacturing cost of the Nanox.ARC. Our digital X-ray source generates X-ray radiation that is measurably identical in all key metrics
to the X-ray radiation generated by existing analog X-ray sources, but without creating the high temperature that results from the filament
used in the analog X-ray tube, thereby eliminating the need for the costly cooling equipment. In addition, our digital X-ray source is
designed to enable the Nanox.ARC to have multiple stationary tubes arranged around the patient, which allows for a more simplified structure,
as opposed to requiring the heavy, complex, high-precision rotating mechanisms used in legacy CT devices. As a result, we expect that
if we achieve the expected scale, we will be able to offer the Nanox System at a substantially lower cost than the cost of existing medical
imaging systems based on analog X-ray sources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As we continue to develop the Nanox System, we
continue to implement a multi-step approach to the regulatory clearance process. On June 17, 2021, we submitted a 510(k) premarket notification
application to the FDA for the first version of our multi-source Nanox.ARC 3-D digital tomosynthesis system. On August 12, 2021, we received
a request for additional information from the FDA concerning the first submission of our multi-source system. On January 10, 2022, we
withdrew our first submission of our multi-source system. On January 12, 2022, we submitted to&#160;the FDA a Q-submission for the second&#160;version
of&#160;our&#160;multi-source Nanox.ARC 3-D digital tomosynthesis system. The second version of&#160;the Nanox.ARC is an improved and
enhanced version that was designed, among other things,&#160;to address certain deficiencies raised by the FDA during their review of
the first submission from June 2021. We continue to communicate with the FDA and we expect the next step in this process to be the submission
of a supplement to the Q-submission, followed by a formal 510(k) application to the FDA for the multi-source Nanox.ARC. If cleared by
the FDA and authorized by similar regulatory agencies in other jurisdictions, our goal is to finalize deployment of the initial 15,000
Nanox Systems by the end of 2024. In parallel, we are preparing for shipments of the first units of the Nanox System. To date, we have
not obtained feedback from the FDA regarding the regulatory pathways for the novel digital X-ray source or the Nanox.CLOUD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If cleared by the FDA, we expect to commercialize
the multi-source Nanox.ARC and we may seek alternatives for commercialization of our Nanox Cart X-Ray System.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect that the Nanox System will enable us to accumulate a significant
number of medical images, which have the potential to be used by collaborators, such as medical AI-analytics companies, through machine
learning algorithms to increase the probability of early disease detection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Business Model</span></i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to commercialize our X-ray source technology
through three simultaneous business models: (i)&#160;the Subscription Model, (ii)&#160;the Sales Model and (iii)&#160;the Licensing Model.
We expect the Subscription Model to be our primary business model for the X-ray source technology and the key vehicle to achieving our
vision of increasing early detection of medical conditions that are discoverable by X-ray.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The Subscription Model (MSaaS Model)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foundation of the Subscription Model is our
integrated offering of the Nanox.ARC and the Nanox.CLOUD, which we refer to as the Nanox System. Under the Subscription Model, which we
also refer to as the MSaaS model (Medical Software as a Service), we expect to sell the Nanox System, if cleared or approved by the requisite
regulatory authorities, at low cost or to provide the system at no cost, and to receive a portion of the proceeds from each scan as the
right-to-use licensing fee, and potentially additional fees for usage of the Nanox.MARKETPLACE, AI capability and teleradiology services,
with the remaining amount allocated among our partners, including the local operators, radiologists, cloud storage providers, medical
AI software providers and others, on a case by case basis. While the actual pricing charged by local operators may be greater than our
suggested retail price, the retail price per scan in all markets other than the United States is still expected to be substantially less
than the global average. In the United States, we expect the retail price to represent a significant reduction compared to the average
cost of a CT scan. We expect the Nanox System will be operated by local operators independent from us, but we would contract with third
parties to provide the day-to-day maintenance of the Nanox System.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While we believe our novel X-ray source could provide
existing market participants with the paradigm shift needed for preventive healthcare disruption, we also believe existing market participants
are not likely to undertake the change-leadership route and will be slow to adopt the MSaaS model. Accordingly, our goal is to produce
and deploy approximately 15,000 Nanox Systems broadly across the globe by the end of 2024 to jumpstart the MSaaS-based medical imaging
market, including in the United States and certain countries in Asia, Europe, Africa, Latin America and Australia. We estimate that effectively
stimulating market interest in our Nanox System will require deploying 5,000 to 10,000 Nanox Systems. We believe that this strategy will
help initiate market disruption and accelerate the adoption of our novel X-ray source technology by traditional industry leaders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>The Sales Model</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In certain countries, such as China, we intend
to commercialize our X-ray source technology using the Sales Model to accommodate specific local regulatory requirements. Under this model,
we expect to sell the Nanox System, if cleared or approved by the requisite regulatory authorities, for a one-time charge. We expect this
retail price to be higher than the upfront sales price under the Subscription Model but still substantially lower than the cost of existing
medical imaging systems. If required by applicable regulatory requirements in any jurisdiction, we may enter into arrangements with third-party
cloud vendors, on a case-by-case basis, which will be responsible for providing the cloud services (instead of the Nanox.CLOUD) and will
be paid separately by the owner-operators of the Nanox Systems. In addition, we expect to contract with third-party service providers
to provide maintenance services for the Nanox Systems at the owner-operators&#8217; own costs.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>The Licensing Model (OEM Model)</i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While we believe the medical imaging industry will
eventually migrate towards the recurring revenue-based MSaaS model, we expect certain leading market participants will be slower to adopt
this model. For these market participants, we expect to provide an intermediate solution through which they will adopt our X-ray source
technology for their existing systems. Under the Licensing Model, which we also refer to as the OEM (Original Equipment Manufacturer)
model, we would be engaged to tailor our X-ray source to the specific systems of medical imaging device manufacturers or other X-ray device
manufacturers or to license our X-ray source technology to them to develop new types of imaging systems for a one-time licensing fee upfront
for the X-ray source, as well as recurring royalty payments for each system sold that incorporates our X-ray source. The licensees would
be responsible for the operation of the medical imaging systems integrating our X-ray source. Although we expect to initially rely on
the Licensing Model, in part, we view the Licensing Model as a transitional phase, aimed at maximizing the commercial value of our technology
and strategic buy-in from market participants to our vision through partnership and commercial relationships.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FUJIFILM Corporation was the first medical imaging
device manufacturer to participate in our licensing model. On May&#160;21, 2019, Nanox Gibraltar, our predecessor company, entered into
a Right of First Negotiation Agreement with FUJIFILM Corporation. Under the terms of such agreement, the parties agreed to exclusively
negotiate in good faith the terms and conditions of a potential commercial agreement until December&#160;31, 2019. The terms of the commercial
agreement are intended to cover the exclusive, worldwide licensing of certain patents and know-hows related to mammography medical devices
and solutions owned by us to FUJIFILM Corporation to develop, manufacture, market, distribute, operate and use mammography equipment and
services (the &#8220;field of use&#8221;). Under the Right of First Negotiation Agreement, if such commercial agreement was not entered
into by December&#160;31, 2019, and if during a period of six months following such date (i.e., until June 30, 2020) we became involved
in any negotiation to enter into an agreement for the grant of license of the patents covered by the agreement in the field of use to
any third party, FUJIFILM Corporation had a right of first negotiation with respect to such proposed transaction under terms and conditions
no less favorable to us than those proposed or offered by or to such third party. We assumed all of Nanox Gibraltar&#8217;s obligations
under the Right of First Negotiation Agreement upon the transfer of Nanox Gibraltar&#8217;s assets to us. While a commercial agreement
was not executed, we and FUJIFILM Corporation are continuing to collaborate towards the potential development by FUJIFILM Corporation
of a future product based on our technology.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Nanox.MARKETPLACE</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Nanox.MARKETPLACE (formerly known as the MDW platform),
which we acquired from MDWEB in November 2021, is our proprietary decentralized marketplace that connects imaging facilities with radiologists
and enables radiologists to provide, and customers to obtain, remote interpretations of imaging data. The platform was designed by radiologists
for the imaging industry. The radiologists connecting to Nanox.MARKETPLACE include those radiologists who are part of our network and
provide teleradiology services through USARAD, as well as other radiologists, all of whom undergo an accreditation process that we perform
and are required to be certified by the American Board of Radiology. Based primarily on customer location and area of specialization,
radiologists will be matched to conduct the imaging interpretation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Nanox.MARKETPLACE has created a payments system
through which the radiologist receives on demand payment from the customer, via the platform, upon the delivery of the imaging interpretation.
The customer can order an image interpretation on an as-need basis, through the web-based platform, without any special hardware or technical
knowledge.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nanox.MARKETPLACE service is currently offered
on a standalone basis. In the future, we plan to incorporate the Nanox.MARKETPLACE into the Nanox System, such that images that were generated
by the Nanox.ARC and uploaded to the Nanox.CLOUD, can be streamlined and referred through the Nanox.MARKETPLACE to radiologists for remote
reading.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>AI Imaging Solutions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Nanox AI (previously known
as Zebra Medical) that we acquired in November 2021, has developed machine learning platforms, based on its database of over 500 million
imaging scans, which facilitate the development of AI medical imaging solutions. Nanox AI has FDA approval for eight radiology AI solutions,
CE mark in Europe for 11 radiology AI solutions and regulatory approvals in other countries for its radiology AI solutions. Nanox AI has
been granted dozens of patents in the field of radiology AI. Nanox AI gathers underutilized image data from a CT scan and helps medical
service providers focus on patients that, upon findings generated by use of our AI solutions, require additional medical attention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following our acquisition of Nanox AI, we offer
FDA approved AI-based software imaging solutions to hospitals, HMOs, IDNs, pharmaceutical companies and insurers that are designed to
identify or predict undiagnosed or underdiagnosed medical conditions, through the mining of data included in images of existing CT scans.
We currently offer AI imaging population health solutions aimed at identifying underlying osteoporosis and cardiovascular disease. We
are also conforming these AI imaging population health solutions to be implemented as an additional service in the Nanox System, once
deployed. With our AI imaging population health solutions, we aim to further our mission to enable preventative healthcare through early
detection. We also continue to maintain certain legacy contracts for AI imaging triage solutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, following the acquisition of Nanox AI, we have begun
to develop an AI imaging solution that is designed to identify whether certain common abnormalities are presented in images generated
by Nanox.ARC and to determine if follow up diagnostic imaging or treatment is required. This AI imaging solution is currently being developed
for application in imaging of the chest and extremities. Ultimately, we expect to integrate this AI imaging solution, which we refer
to as Robodiology, into the Nanox System. Subject to completion of the development and receipt of requisite regulatory approvals, we
plan to offer this AI imaging solution as an optional service to our MSaaS partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Teleradiology Services</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following our acquisition of USARAD in November
2021, we offer teleradiology services to customers in the U.S market as well as seven additional countries. We provide radiologic interpretations
or reads for emergency, routine, and subspecialty care cases through the utilization of our scalable communications network, incorporating
encrypted servers and broadband Internet connections with workflow management and clinical applications software. Our radiologists&#8217;
network is comprised of U.S.-based radiologists, certified by the American Board of Radiology. We have a network of over 300 independent
radiologists, all of whom have undergone an accreditation process by us and we provide our services to over 500 imaging centers. We allocate
images that we receive from our customers, through our picture archiving and documentation system, to radiologists in our network based
on the radiologist&#8217;s area of specialization. Payment is made by the customer directly to us monthly based on the number of monthly
readings and we pay the radiologist a predetermined fixed fee per reading.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We offer imaging interpretation services for radiology
practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities and multi-specialty physician groups and USARAD
contracts directly with these customers. In addition, we provide second opinion radiology readings. We believe this service offers our
customers a solution to improve service levels, streamline underlying practice economics and enhance physician efficiency without sacrificing
the quality of patient care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, our teleradiology services are offered
as a standalone product through USARAD. In the future, we plan to incorporate our teleradiology services as part of our Nanox System offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Sales and Marketing</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>X-Ray Technology</i>.</b> We plan to commercialize
our X-ray technology using the three simultaneous business models described above broadly across the globe in the next few years, including
in the United States and certain countries in Asia, Europe, Africa, Latin America, and Australia. Our sales and marketing strategy varies
depending on specific geographical regions, as different regions generally require different marketing approaches.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In most countries, other than the United States,
we expect to primarily market through local partnerships with strong national branding and operational market participants in the target
region. These local partners would be engaged in deploying and operating our medical imaging systems, training and recruiting a local
medical professional workforce to operate the systems and providing medical imaging diagnostics for the systems&#8217; scan results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States, we expect to deploy the
Nanox System primarily through our local subsidiaries. In countries other than United States, we also expect to engage local value-added
resellers or integrators in different geographic regions to facilitate the local integration of our systems with health maintenance organizations,
electronic health record systems, payment methods and insurance coverage companies. We estimate that it will take approximately three
to six months of integration and localization efforts before we can generate sales in a given region.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>AI Solutions</i>. </b>We currently focus
our sales and marketing efforts for our AI solutions in the U.S. and UK markets and target large hospitals, HMOs, IDNs, pharmaceutical
companies and insurers. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Teleradiology Services and Nanox.MARKETPLACE</i></b>.
We currently focus our sales and marketing efforts for our teleradiology services and Nanox.MARKETPLACE in the U.S. market and target
daytime costumers, which include urgent care facilities, stand-alone imaging facilities and outpatient imaging centers, as well as night-time
and weekend customers, comprised of hospitals and community hospitals (state and local government).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following the completion of our recent acquisitions,
we are continuing to explore the potential synergies and the expansion of our offerings. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing and Supply of the Nanox.ARC</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have optimized the MEMs proprietary manufacturing
process and initially used our own equipment in the clean rooms located at the University of Tokyo to manufacture the MEMs X-ray chip.
We recently commenced manufacture of the MEMs X-ray chips at our new fabrication facility in Korea, which is expected to meet our currently
anticipated manufacturing needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are currently evaluating and testing glass-based
and ceramics-based X-ray tubes to determine which tubes will be used in the Nanox.ARC. Once a determination is made, we intend to enter
into agreements with third-party manufacturers for such tubes based on, among other things, cost effectiveness. We also expect to rely
on third-party manufacturers for the commercial production of the other components of the Nanox.ARC, if cleared or approved by the requisite
regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In May 2020, we entered into a three-year contract
manufacturing agreement with FITI for mass production of the multi-source Nanox.ARC. Under the contract manufacturing agreement, FITI
will negotiate and subcontract with other third parties for the commercial supply of the components of the Nanox.ARC in accordance with
the pre-approved supplier list and on the terms to be agreed upon by both parties, except for the MEMs X-ray chip and X-ray tube. As we
further expand our business in connection with the commercialization of our X-ray technology, we also expect to seek to engage alternative
manufacturers of the Nanox.ARC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">However, due, in part, to travel restrictions
as a result of the COVID-19 pandemic, we decided to manufacture the first Nanox.ARC units in Israel and commencing we engaged Dagesh
to manufacture Nanox.ARC units in Israel on a purchase order basis. We expect that these units will be used for the acceptance tests
under our MSaaS agreements, demonstrations, regulatory approvals and for the initial global deployment, among other purposes. We
expect to enter into a formal agreement with Dagesh for the manufacture of these Nanox.ARC units.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>MSaaS Agreements for the Nanox System</b></p><div>
</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into 11 MSaaS agreements to deploy
6,500 Nanox Systems in 17 regions, including in Europe, South and Central America, Asia, Australia, New Zealand, Russia and Africa, as
detailed in the table below. Under the terms of each agreement, we grant the other party a limited, non-transferable, exclusive, sub-licensable
right to access and operate the Nanox System in the region indicated for such party. We undertake to provide the specified number of Nanox
Systems to each entity as indicated in the table below based on agreed shipment schedules, subject to local regulatory approval and material
compliance with acceptance test protocol (the &#8220;conditions precedent&#8221;). The other party undertakes to deploy the systems to
provide a minimum number of scans per year (generally based on 7 scans per day and 23 days per month) on a pay-per-scan basis, and to
pay a minimum annual fee (including payments to our partners) in the amount indicated in the table below. The MSaaS agreements require
each of our counterparties to deliver to us a standby letter of credit or financial guarantee in the amount equal to the minimum annual
fee in favor of us after receipt of the conditions precedent. However, there can be no guaranty that our counterparties will be able to
obtain such letters of credit or financial guarantees.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nanox Systems provided under each agreement
will remain our property, and the other party will only have a limited license to use the Nanox Systems. In addition, we must approve
in writing any sublicense granted under this agreement. We undertake to provide billing, radiology and maintenance services and to provide
training for a local medical professional workforce to operate the Nanox.ARC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each agreement will be in effect for multiple
years, ranging from three to seven years from the date of the applicable agreement, and is renewable for an additional multi-year term
with both parties&#8217; mutual consent as indicated in the table below. Each agreement may be terminated by notice of the non-breaching
party in case of a material breach of a party&#8217;s material obligations, or by either party in case of the bankruptcy or insolvency
of the other party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; border-bottom: black 1.5pt solid">
    <p style="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><b>&#160;</b></p>
    <p style="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>Entity</b></p></td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Date of MSaaS<br/>
Agreement</b></span></td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Region</b></span></td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of<br/>
Nanox<br/>
Systems to<br/>
be Provided</b></span></td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Minimum Annual <br/>
Fee (approximate)</b></span></td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Initial<br/>
Term</b></span></td>
    <td style="white-space: nowrap; text-align: center">&#160;</td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Renewal <br/>
Term</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 34%"><span style="font-size: 10pt">The Gateway Group, Ltd.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 10%; text-align: center"><span style="font-size: 10pt">February 11, 2020</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%"><span style="font-size: 10pt">Australia, New Zealand and Norway</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: right">&#160;</td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">1,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%"><span style="font-size: 10pt">$58 million</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-size: 10pt">3 years</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center"><span style="font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">Golden Vine International Company, Ltd.</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">May 28, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Taiwan and Singapore</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Up to $29 million</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years*</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">Promedica Bioelectronics s.r.l</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">May 29, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Italy</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$29 million</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4 years</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">JSC Roel Group</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">May 29, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Russian Federation</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$12.6 million</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">Clarity Medical Solution, a division of &#8220;Grodnobioproduct&#8221; LLC</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">June 4, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Belarus</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">100</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$3.7 million</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">Gold Rush</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">June 16, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">South Africa</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">500</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$15.5 million</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">LATAM Business Development Group Ltd.</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">July 6, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Brazil</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$4.8 million (9 million Letter of Credit) in Year 1 $14.5 million in Year 2 $24.2 million in Year 3***</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">6 years</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">3 years</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">APR 1998 S.L</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">July 25, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Spain</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">420</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$11.4 million</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">5 years**</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">SPI Medical</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">August 23, 2020</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Mexico and Guatemala</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">630</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$17.1 million****</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">7 years</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">N/A</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">Eileeno Pharma</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">July 6, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Nigeria</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$4.6 million in year 1 to $30.4 million in year 4</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4 years</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4 years</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt">International Clinics</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">October 27, 2021</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chile, Peru and Bolivia</span></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">350</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$2.0 million in year 1 to $9.5 million in year 4</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4 years</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">4 years</span></td></tr>
  <tr>
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><span style="font-size: 10pt">TOTAL</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: right"><span style="font-size: 10pt">6,500</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Minimum of $187.5 million*****</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.5in">*</td><td>The MSaaS Agreement with Golden Vine International Company, Ltd. may also
                                            be terminated by either party upon notice stipulating that the notifying party has come to
                                            the conclusion, based on market evidence, that there is no business merit for the Nanox.ARC
                                            in Taiwan or Singapore.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.5in">**</td><td>The MSaaS Agreement with APR 1998 S.L. may also be terminated by the service
                                            provider at the end of a six-month trial period by sending within five days a formal notice
                                            to the Company if trial results are not satisfactory.</td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.5in">***</td><td>The enforceability of the standby letter of credit from LATAM Business
                                            Development Group Ltd. in our favor is also conditioned upon the parties finalizing within
                                            90 days of the date of the agreement or prior to receipt of regulatory approval, in mutually
                                            agreed form, the terms and conditions of the statement of work, the system requirement specifications
                                            and the service level agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&#160;</p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 0.5in; font-size: 10pt"><span style="font-size: 10pt">****</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">According to the agreement, SPI issued a performance bond purchased from Aseguradora Aserta, S.A. de C.V., Grupo Financiero Aserta, a top financial institution of Mexico, in favor of us in the amount of approximately $17.1&#160;million, which was effective through October&#160;31, 2021 and guaranteed the exclusivity of the MSaaS agreement between SPI and us prior to the satisfaction of certain conditions, including receipt of regulatory approval and compliance with acceptance test protocol, and upon satisfaction of those conditions, was to be converted into a financial guarantee that guarantees the minimum annual service fee to us.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0%">&#160;</td>
    <td style="width: 0.5in; font-size: 10pt"><span style="font-size: 10pt">*****</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">The total amount includes payments to be received by our partners. The total amount payable to us would be approximately $145&#160;million excluding the payments to our partners.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-indent: -27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe our MSaaS business model has the potential
to expand the total size of the X-ray-based medical imaging market. We plan to measure the success of our MSaaS business model by annual
capacity for Above-the-Line (&#8220;ATL&#8221;) scans which represent the increased capacity of imaging care we can provide to people
that originally had no meaningful access to medical imaging. As we expand our operations and deploy more units of the Nanox Systems in
an increasing number of countries using the MSaaS model, we expect our ATL scans metric to increase accordingly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Collaboration Agreements</i></b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We enter into collaboration agreements in the ordinary
course of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For example, we previously entered into a collaboration
agreement, dated September&#160;8, 2019, with Hadasit Medical Research Services and Development Ltd., a wholly owned subsidiary of the
Hadassah Medical Organization, to collaborate with respect to our medical imaging technology and resulting medical images devices, by
way of (among other things) joint research and development projects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, on June&#160;4, 2020, we entered into
a collaboration agreement with SK Telecom, pursuant to which we and SK&#160;Telecom continue to explore and engage in good faith to develop
a definitive agreement for the deployment of 2,500 Nanox Systems in South Korea and Vietnam, and we have established a wholly-owned subsidiary
in South Korea with the support of SK Telecom for the purpose of manufacturing MEMs X-ray chips for the Nanox.ARC. The agreement has now
expired according to its terms, but we continue to assess collaboration opportunities with SK Telecom.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also entered into several non-exclusive collaboration
agreements with certain AI partners and image transfer partners, which we may utilize to complement our in-house AI capabilities, including
those developed by the companies we recently acquired in November 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Given that the Nanox.CLOUD and the Nanox.MARKETPLACE
are designed with the capability to receive scans from different imaging sources, in addition to the Nanox.ARC, we intend to explore additional
collaboration opportunities in the near future. For example, we recently invested $1.0 million for approximately 1% of the shares of Remedi
co Ltd. (&#8220;Remedi&#8221;), a Korean radiation specialist company in radiography and therapy based on X-ray components. Remedi is
a privately owned company, and we have an ongoing collaboration in the development of the high voltage power supply for Nanox.ARC. We
are in advanced negotiation with Remedi to explore the possibility of connecting Remedi&#8217;s two-dimensional (&#8220;2D&#8221;) imaging
systems to the Nanox.CLOUD and the Nanox.MARKETPLACE, creating a mobile 2D X-ray system that enables remote readings of scans with AI-powered
imaging analysis and a global teleradiology solution. Subject to the completion of the negotiation and successful integration of the 2D
system, we aim to distribute this system to our MSaaS customers.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Competition</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Several large companies, such as General
Electric, Siemens, Philips, Hologic, Varian, Fuji, Toshiba and Hitachi currently dominate the medical imaging market. High regulatory,
distribution, manufacturing and service-related long-term contractual costs represent significant barriers to entry for any new
player. We expect that the existing market participants will remain key players in the future and we aim to form alliances with
several of these leading market participants, including through licensing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Over time, we anticipate that the evolution in
the industry will bring new players into the market. Digital healthcare disruptors such as cloud computing companies or leading IT companies
may enter the industry and we believe that they may become partners over time through our Subscription Model.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a general matter, we view competition
on two levels:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Competing digital X-ray sources with same or better attributes; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>Competing enterprises operating an MSaaS business model.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In terms of digital X-ray sources, the field emission
display technology is known and a wide range of industry leaders have used it to attempt to create an alternative, digital source of X-ray.
To our knowledge, the most well-known attempt to achieve a commercial grade, stable digital X-ray source was the use of carbon nano tubes
(&#8220;CNT&#8221;) as the base material for a potential field emission-based solution, and at least one company has recently commercialized
an X-ray system based on a CNT solution and there are several other companies currently in the process of developing this technology.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In terms of the MSaaS business model, we currently
seek a first-mover advantage by introducing the Subscription Model, as the main pre-requisite for this model is the low cost of the X-ray
source (when manufactured at scale). However, the primary competition comes from established market participants. While in developing
countries we are experiencing keen interest, the United States and other Western regions already have major market participants that are
well entrenched in the market with strong political influence and the ability to delay deployment of our systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With respect to our AI imaging solutions, there
are a number of companies that currently offer AI radiology solutions, such as Aidoc and VIZ.AI, which, to our knowledge, are focused
on life threatening and urgent cases. In addition, legacy healthcare technology companies are expected in the future to increase development
efforts in the field of AI imaging solutions. For example, Siemens Healthineers has developed AI-Rad Companion, which provides automatic
post-processing of imaging datasets through AI-powered algorithms for Siemens CTs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With respect to our teleradiology services, the
teleradiology market is highly competitive, rapidly evolving, and fragmented, and is subject to changing technology and market dynamics.
The market has recently experienced and is expected to continue to experience competitive pricing pressure and radiologist compensation
pressure. We compete directly with both large and small-scale service providers who offer local, regional and national coverage operations.
We believe that our principal competitors are Envision Physician Services and Radiology Partners. We compete to attract and retain relationships
with customers and radiologists in different ways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Security and Data Privacy</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nanox System is being designed and developed
with personal privacy, data security and protection in mind as a top priority for all development parties. Medical imaging information
and other health information is highly personal and sensitive and thus regarded as a prime target for hacks and malicious theft.
As part of our normal operations, we expect to collect, process and retain personal identifying information regarding patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe we will likely be subject to
U.S. rules and regulations governing data protection, including HIPAA. See&#8220;&#8212;Government Regulation&#8212;Healthcare
Regulatory Laws&#8212;Data Privacy and Security.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we believe we will likely be subject
to the GDPR and UK GDPR to the extent that our business involves personal data of persons within the EEA and the UK. Data protection
legislation, including the GDPR/UK GDPR, regulates the manner in which we may hold and communicate personal data of our employees and
patients (including, in our case, sensitive health data). We are likely to be defined as a &#8220;Data Controller&#8221; with respect
to the personal data of patients that we intend to collect and are therefore likely to be subject to a number of key legal obligations
under the GDPR/UK GDPR. In addition to reflecting existing requirements that already existed under the old data protection regime, such
as, among other things, requirements to provide users with a &#8220;fair processing notice&#8221; if we process their data, ensure that
inaccurate data is corrected, only retain data for so long as is necessary and not transfer data outside the EEA/UK to jurisdictions
which do not ensure an adequate level of protection of personal data without taking certain safeguards, the GDPR/UK GDPR also implemented
new, more stringent operational and procedural requirements for our use of personal data. These include expanded prior information requirements
in light of the transparency principle to tell patients how we may use their personal data, increased controls on profiling such persons,
increased rights for patients to access, control and delete their personal data and mandatory data breach notification requirements.
In addition, there are significantly increased administrative fines of the greater of &#8364;20&#160;million and 4% of global turnover
(as well as the right to compensation for financial or non-financial damages claimed by any individuals under Article 82 of the GDPR/UK
GDPR). Further, following the United Kingdom&#8217;s withdrawal from the European Economic Area and the European Union, and the expiry
of the transition period, companies have to comply with both the GDPR and the UK GDPR, the latter regime having the ability to separately
fine up to the greater of &#163;17.5 million or 4% of global turnover.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Separate from, and in addition to, the GDPR/UK
GDPR requirements, certification requirements for the hosting of health data will vary by jurisdiction (and may or may not apply to hosts
of health data). As the Nanox System is projected to operate in various EEA countries, we may be required to comply with other national
healthcare regulations or regulatory requirements. For example, in France, there is a procedure as of April&#160;1, 2018, for hosts of
health data to obtain a prior certification with the competent certification body.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are dedicated to making our systems and software
both HIPAA and GDPR/UK GDPR compliant. We intend to submit our systems to an independent external audit on a regular basis as required
by HHS. We also intend to develop our privacy protocols to comply with the GDPR/UK GDPR. In addition, we are undertaking intendant measures
to ensure a high-level of imaging data encryption, complete separation between the imaging data and personal information (anonymization)
as well as three-factor authentication procedures during on-boarding and usage of the Nanox System. We also intend to undertake to perform
periodic Pen-Tests by external cyber security professionals and publish the results of such audits publicly and without delay on our
website and via public relations channels.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Government Regulation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Nanox System and our operations will
be subject to extensive regulation by the FDA, and other federal and state authorities in the United States, as well as comparable
authorities in foreign jurisdictions. The Nanox.ARC will be subject to regulation as medical devices and radiation-emitting devices
in the United States under the FDCA, as implemented and enforced by the FDA, and under comparable regulatory schemes in foreign
jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>FDA Regulation of Medical Devices</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA regulates the development, design, non-clinical
and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket
clearance or approval, adverse event reporting, advertising, promotion, marketing and distribution, and import and export of medical
devices to ensure that medical devices distributed within the United States are safe and effective for their intended uses or are substantially
equivalent to a predicate device and otherwise meet the requirements of the FDCA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">FDA Premarket Clearance and Approval
Requirements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to certain exceptions, each medical
device commercially distributed in the United States requires either FDA clearance of a 510(k) premarket notification, or approval
of a PMA application. Under the FDCA, medical devices are classified into one of three classes&#8212;Class&#160;I, Class&#160;II
or Class&#160;III&#8212;depending on the degree of risk associated with each medical device and the extent of manufacturer and
regulatory control needed to ensure its safety and effectiveness. Class&#160;I includes devices with the lowest risk to the patient
and are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices,
which include compliance with the applicable portions of QSR, facility registration and product listing, reporting of adverse medical
events and truthful and non-misleading labeling, advertising and promotional materials. Class&#160;II devices are subject to the
FDA&#8217;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the
device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance
documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While most Class&#160;I devices are exempt
from the 510(k) premarket notification requirement, manufacturers of most Class&#160;II devices are required to submit to the FDA
a premarket notification under Section 510(k) of the FDCA requesting permission to commercially distribute the device. The FDA&#8217;s
permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance.
Devices deemed by the FDA to pose the greatest risks, such as life sustaining, life supporting or some implantable devices, or
devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed
device, are placed in Class&#160;III, requiring approval of a PMA. Some pre-amendment devices are unclassified, but are subject
to the FDA&#8217;s premarket notification and clearance process in order to be commercially distributed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">510(k) Clearance Marketing Pathway</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect the Nanox.ARC will be a Class&#160;II
device subject to premarket notification and clearance under section 510(k) of the FDCA. To obtain 510(k) clearance, we must submit to
the FDA a premarket notification submission demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a predicate
device already on the market. A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device
that was legally marketed prior to May&#160;28, 1976 (pre-amendments device), and for which a PMA is not required, a device that has
been reclassified from Class&#160;III to Class&#160;II or I, or a device that was found substantially equivalent through the 510(k) process.
The FDA&#8217;s 510(k) clearance process usually takes from three to twelve months, but often takes longer. The FDA may require additional
information, including clinical data, to make a determination regarding substantial equivalence. In addition, the FDA collects user fees
for certain medical device submissions and annual fees and for medical device establishments. For fiscal year 2022, the standard user
fee for a 510(k) premarket notification application is $12,745.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the FDA agrees that the device is substantially
equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If
the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device is
automatically designated as a Class&#160;III device. The device sponsor must then fulfill more rigorous PMA requirements, or can
request a risk-based classification determination for the device in accordance with the &#8220;<i>de novo</i>&#8221; process, which
is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate
device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After a device receives 510(k) marketing
clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change
or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or <i>de
novo</i> reclassification. The FDA requires each manufacturer to determine whether the proposed change requires submission of a
510(k), a <i>de novo</i> request or a PMA in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s
determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing
and/or request the recall of the modified device until 510(k) marketing clearance or until PMA approval is obtained or a <i>de
novo</i> request is granted. Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Over the last several years, the FDA has
proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and
a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products.
For example, in November 2018, the FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket
notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals
to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially
sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list
of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than
10&#160;years old. In May 2019, the FDA solicited public feedback on these proposals. The FDA requested public feedback on whether
it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were
used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may
work with Congress to implement such proposals through legislation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">More recently, in September 2019, the FDA finalized
guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain,
well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device
meets objective safety and performance criteria established by the FDA, thereby obviating the need, in the case of applicable products,
for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process.
The FDA maintains a list of device types appropriate for the &#8220;safety and performance based&#8221; pathway and will continue to
develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing
methods recommended in the guidance documents, where feasible. Also in September 2019, the FDA finalized guidance describing its current
approach to the &#8220;Special 510(k)&#8221; program, which provides an optional pathway for certain well-defined device modifications
where a manufacturer modifies its own legally marketed device, and design control procedures produce reliable results that can form,
in addition to other 510(k) content requirements, the basis for substantial equivalence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">PMA Approval Pathway</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Class&#160;III devices require PMA approval before
they can be marketed, although some pre-amendment Class&#160;III devices for which the FDA has not yet required a PMA are cleared through
the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must
demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies
and human clinical trials. The PMA must also contain a full description of the device and its components, a full description of the methods,
facilities and controls used for manufacturing and proposed labeling. Following receipt of a PMA, the FDA determines whether the application
is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180 days under the FDCA
to complete its review of a PMA, although in practice, the FDA&#8217;s review often takes significantly longer, and can take up to several
years. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations
to the FDA as to the approvability of the device. The FDA may or may not accept the panel&#8217;s recommendation. In addition, the FDA
will generally conduct a pre-approval inspection of the applicant or its third-party manufacturers&#8217; or suppliers&#8217; manufacturing
facility or facilities to ensure compliance with the QSR. PMA devices are also subject to the payment of user fees, which for fiscal
year 2022 includes a standard application fee of $374,858 and an annual establishment registration fee of $5,672.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA will approve the new device for
commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that
there is reasonable assurance that the device is safe and effective for its intended use(s). The FDA may approve a PMA with post-approval
conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling,
promotion, sale and distribution and collection of long-term follow-up data from patients in the clinical study that supported
PMA approval or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form
of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data
for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow
certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of those patients.
Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the
approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain changes to an approved device, such
as changes in manufacturing facilities, methods or quality control procedures, or changes in the design performance specifications,
which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission
of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from
the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain
other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended
use, mode of operation, and technical basis of operation, or when the design change is so significant that a new generation of
the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating
a reasonable assurance of safety and effectiveness. We do not expect any of our products to be marketed pursuant to a PMA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Clinical Trials</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Clinical trials are almost always required
to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of devices to determine
safety and effectiveness must be conducted in accordance with the FDA&#8217;s investigational device exemption (&#8220;IDE&#8221;)
regulations which govern investigational device labeling, prohibit promotion of the investigational device and specify an array
of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a
&#8220;significant risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application
to the FDA, which must become effective prior to commencing human clinical trials. If the device under evaluation does not present
a significant risk to human health, then the device sponsor is not required to submit an IDE application to the FDA before initiating
human clinical trials, but must still comply with abbreviated IDE requirements when conducting such trials. A significant risk
device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted,
used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise
preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application must
be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans
and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the
FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies
or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional
approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Regardless of the degree of risk presented
by the medical device, clinical studies must be approved by, and conducted under the oversight of, an Institutional Review Board
(&#8220;IRB&#8221;) for each clinical site. The IRB is responsible for the initial and continuing review of the IDE, and may pose
additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human
clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the
FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval
for the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such
as monitoring the investigation, ensuring that the investigators obtain informed consent and labeling and record-keeping requirements.
Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does
become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of
the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before
a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or
the rights, safety or welfare of human subjects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During a study, the sponsor is required
to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and
providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on
the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the
clinical study are also subject to FDA regulations and must obtain patient informed consent, rigorously follow the investigational
plan and study protocol, control the disposition of the investigational device and comply with all reporting and recordkeeping
requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time
for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Post-market Regulation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">After a device is cleared or approved for
marketing, numerous and pervasive regulatory requirements continue to apply. These include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>establishment registration and device listing with the FDA;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control,
documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>labeling regulations and FDA prohibitions against the promotion of investigational products, or the promotion of &#8220;off-label&#8221;
uses of cleared or approved products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>requirements related to promotional activities;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>clearance or approval of product modifications to 510(k)-cleared devices that could significantly affect safety or effectiveness
or that would constitute a major change in intended use of one of our cleared devices, or approval of certain modifications to
PMA-approved devices;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused
or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely
to cause or contribute to a death or serious injury, if the malfunction were to recur;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections
and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA
that may present a risk to health;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that
is in violation of governing laws and regulations; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public
health or to provide additional safety and effectiveness data for the device.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our manufacturing processes are required
to comply with the applicable portions of the QSR, which cover the methods and the facilities and controls for the design, manufacture,
testing, production, processes, controls, quality assurance, labeling, packaging, distribution, installation and servicing of finished
devices intended for human use. The QSR also requires, among other things, maintenance of a device master file, device history
file and complaint files. As a manufacturer, we will be subject to periodic scheduled or unscheduled inspections by the FDA. Our
failure to maintain compliance with the QSR requirements could result in the shut-down of, or restrictions on, our manufacturing
operations and the recall or seizure of our products, which would have a material adverse effect on our business. The discovery
of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing
severity or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician
in the practice of medicine, could result in restrictions on the device, including the removal of the product from the market or
voluntary or mandatory device recalls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA has broad regulatory compliance
and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety
of compliance or enforcement actions, which may result in any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>recalls, withdrawals or administrative detention or seizure of our products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>operating restrictions or partial suspension or total shutdown of production;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>withdrawing 510(k) clearances or PMA approvals that have already been granted;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>refusal to grant export approvals for our products; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>criminal prosecution.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="text-indent: 0; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Teleradiology</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The healthcare industry is highly regulated. Our
ability to operate profitably will depend in part upon the ability of us, our affiliated radiologists, and our customers to obtain and
maintain all necessary licenses and other approvals to comply with applicable healthcare regulations. We believe healthcare regulations
will continue to change. Therefore, we monitor developments in healthcare law and we are likely to be required to modify our operations
from time to time as the business and regulatory environment changes. Although we believe that we are operating in compliance with applicable
federal and state laws we cannot assure you that review of our business by courts or regulatory authorities will not result in determination
that could adversely affect our operations or that the healthcare regulatory environment will not change in way that restricts our operations.
Future changes in healthcare regulation are difficult to predict and may constrain or require us to restructure our operations which could
negatively impact our business and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Physician Licensure Laws.</i></b> The practice
of medicine including the practice of radiology and teleradiology is subject to state licensure laws regulations and approvals Physicians
located in one state who provide professional medical services to patients located in another state via telemedicine system must ordinarily
hold valid license to practice medicine in both the state where the physician is located and the state in which the patient is located.
We have established a system for ensuring that our affiliated radiologists are appropriately licensed under applicable state law. If
we are unable to obtain proper physician licenses or hospital credentials on behalf of our affiliated radiologists or if our affiliated
radiologists lose those licenses or credentials our business financial condition and results of operations may be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Corporate Practice of Medicine.</i></b> Generally
corporate practice of medicine laws prohibits anyone but duly licensed physician from exercising control over the medical judgments or
decisions rendered by another physician. Given that general prohibition some states permit business corporation to hold directly or indirectly
customer contracts for the provision of medical services including radiology and teleradiology and to own medical practice that provides
such services provided that only physicians exercise control over the medical judgments or decisions of other physicians. Moreover, the
laws of such states prohibit anyone but a physician who is duly licensed in such state from owning any interest in medical practice that
is incorporated or doing business in such state or the state of incorporation. Failure to comply with these laws could have material
and adverse consequences including the judicially sanctioned refusal of third-party payers to pay for services rendered, the absolute
right of customers to immediately repudiate the contract for services, malpractice claims against the provider, and possibly the hospital
based upon violation of statute designed to protect the public as well as civil or criminal penalties. We believe that we are following
the corporate practice of medicine laws in each state in which our affiliated radiologists provide medical services. Each of these are
duly licensed or qualified as a medical practice in the states where such license or qualification is required. We do not exercise control
over the medical judgments or decisions of our affiliated radiologists. While we believe we follow the requirements of the corporate
practice of medicine laws in each state where our affiliated radiologists provide services these laws and their interpretations are continually
evolving and may change in the future. Moreover, these laws and their interpretations are generally enforced by state courts and regulatory
agencies that have broad discretion in their enforcement. If our arrangements with our affiliated radiologists or our customers are found
to violate state laws prohibiting the practice of medicine by general business corporations or fee splitting, our business financial
condition and ability to operate in those states could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Fee Splitting.</b> Many states have also enacted
laws prohibiting physicians from splitting fees derived from the practice of medicine with anyone else. We believe that the management
administrative technical and other nonmedical services we provide to each of our affiliated radiologists for service fee does not constitute
fee splitting. Our belief notwithstanding, these laws and their interpretations also vary from state to state and are also enforced by
state courts and regulatory authorities that have broad discretion in their enforcement. If our arrangements with our affiliated radiologists
or our customers are found to violate state laws prohibiting the practice of medicine by general business corporations or fee splitting
our business financial condition and ability to operate in those states could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Medicare and Medicaid Reimbursement Programs.
</b>As of December 31, 2021, all our affiliated radiologists are located within the United States and are therefore eligible to submit
to Medicare and state Medicaid programs for reimbursement for services performed. Where our affiliated radiologists provide final reads
that are reimbursable under these programs, our business model generally provides that we are still paid service fees by our customers
who accept reassignment and bear the risk of loss of reimbursement when collecting from payers. As a result, our service fees do not
fluctuate, or change based solely on changes in Medicare or Medicaid reimbursement levels. Medicare reimbursement rules generally provide
that the proper Medicare carrier to pay physicians&#8217; claims is the Medicare carrier for the region in which the physician or practice
providing the service is located rather than the Medicare carrier for the region in which the patient receiving the services is located.
Many of our affiliated radiologists are located in a Medicare region that is different from the Medicare region in which the patients
and treating hospitals are located. It may be necessary for our customers to enroll with additional Medicare carriers to properly submit
claims for reimbursement. The Center for Medicare and Medicaid Services or CMS has stated that for certain interpretation services provided
to certain customers, reimbursement will be based upon the location of the interpreting physician, yet that reimbursement will be made
by the Medicare carrier for the region in which the patient and facility are located. Whether this policy will be expanded to other types
of interpretation services and facilities is unclear. See &#8220;Risk Factors Medicare and Medicaid rules governing reassignment of payments
could affect our customers&#8217; ability to collect fees for services provided by our affiliated radiologists and our ability to market
our services to our customers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Federal False Claims Act. </i></b> The Federal
False Claims Act provides in part that the federal government may bring lawsuit against any person whom it believes has knowingly presented
or caused to be presented false or fraudulent request for payment from the federal government or who has knowingly made false statement
or knowingly used false record to have claim approved. The Federal False Claims Act further provides that lawsuits brought under that
act may be initiated in the name of the United States by an individual who was the original source of the allegations known as the relator.
Actions brought under the Federal False Claims Act are sealed by the court at the time of filing. Under the Federal False Claims Act we
may be liable if we or one of our customers submitted false claim. If we were found to have violated these rules and regulations and as
result submitted or caused our customers to submit a false claim, any sanctions imposed under the Federal False Claims Act could result
in substantial fines and penalties or exclusion from participation in federal and state healthcare programs which could have material
adverse effect on our business and financial condition. If we are excluded from participation in federal or state healthcare programs
our customers who participate in those programs could not do business with us. Federal regulatory and law enforcement authorities regularly
review and enforce activities with respect to Medicare and Medicaid fraud and abuse regulations and other reimbursement laws and regulations
including laws and regulations that govern our activities and the activities of teleradiologists. These increased enforcement activities
may have direct or indirect adverse effect on our business financial condition and results of operations. Additionally, some state statutes
contain prohibitions similar to and possibly even more restrictive than the Federal False Claims Act. These state laws may also empower
state administrators to adopt regulations restricting financial relationships or payment arrangements involving healthcare providers under
which person benefits financially by referring patient to another person. We believe that we are operating in compliance with these laws.
However, if we are found to have violated such laws, our business results of operations and financial condition would be harmed.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Federal and State Anti-kickback Prohibitions</i></b>.
Various federal and state laws govern financial arrangements among healthcare providers. The federal anti-kickback law prohibits the
knowing and willful offer payment solicitation or receipt of any form of remuneration in return for or with the purpose to induce the
referral of Medicare Medicaid or other federal healthcare program patients or in return for or with the purpose to induce the purchase
lease or order of items or services that are covered by Medicare Medicaid or other federal healthcare programs. Similarly, many state
laws prohibit the solicitation of payment or receipt of remuneration in return for or to induce the referral of patients to private as
well as government programs. Violation of these anti-kickback laws may result in substantial civil or criminal penalties for individuals
or entities and/or exclusion from participating in federal or state healthcare programs. We believe that we are operating in compliance
with applicable federal and state anti-kickback laws and that our contractual arrangements with our customers are structured in manner
that is compliant with such laws. Enforcement of federal and state anti-kickback laws could affect our business operations or financial
condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Physician Self-Referral Prohibitions</i></b><i>.</i>
The federal physician self-referral statute known as the Stark Statute prohibits physicians from making referrals for certain designated
health services including radiology services to any entity with which the physician has financial relationship unless there is an exception
in the statute that allows the referral. The entity that receives a prohibited referral from a physician may not submit the bill to Medicare
for that service. Federal courts have ruled that violation of the Stark statute as well as violation of the federal anti-kickback law
described above can serve as the basis for Federal False Claims Act suit. Many state laws prohibit physician referrals to entities with
which the physician has financial interest or require that the physician provide the patient notice of the physician&#8217;s financial
relationship before making the referral. Violation of the Stark statute can result in substantial civil penalties for both the referring
physician and any entity that submits claim for healthcare service made pursuant to prohibited referral. We believe that all our customer
arrangements are in compliance with the Stark statute. However, these laws could be interpreted in manner inconsistent with our operations.
Federal or state self-referral regulation could impact our arrangements with certain customers.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Medicare Anti-Markup Rule</i></b><i>. </i>
CMS has certain anti-markup rules relating to diagnostic tests paid for by the Medicare program. The anti-markup rules are generally
applicable where physician or other supplier bills for the technical component or professional component of diagnostic test that was
ordered by the physician or other supplier or ordered by party related to such physician or other supplier through common ownership or
control and the diagnostic test is performed by physician that does not share practice with the billing physician or other supplier.
If the anti-markup rule applies to diagnostic test, then the reimbursement provided by Medicare to billing physician or other supplier
for that transaction may be limited. Because our affiliated radiologists do not order diagnostic tests and no party under common control
with either us or our affiliated radiologists orders diagnostic, tests we believe that the anti-markup rule does not apply to the professional
services our affiliated radiologists perform. However, this rule could be subject to an interpretation that affects the amounts either
we or our customers may be reimbursed by Medicare for professional diagnostic interpretations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>Health Insurance Portability and Accountability
Act of 1996</i></b><i>. </i> HIPAA authorizes the imposition of civil money penalties against entities that employ or enter contracts
with individuals or entities who have been excluded from participation in the Medicare or Medicaid programs. We perform background checks
on our affiliated radiologists, and we do not believe that we engage or contract with any excluded individuals or entities. However,
finding that we have violated this provision of HIPAA could have material adverse effect on our business and financial condition. HIPAA
also establishes several separate criminal penalties for making false or fraudulent claims to insurance companies and other non-governmental
payers of healthcare services. These provisions are intended to punish some of the same conduct in the submission of claims to private
payers as the Federal False Claims Act covers in connection with governmental health programs. We believe that our services have not
historically been provided in way that would place either our clients or ourselves at risk of violating the HIPAA anti-fraud statutes
including those in which we may be considered to receive an indirect reimbursement because of the reassignment by us to our customers
of the right to collect for final reads. We have entered into agreements, and may in the future enter into agreements with hospitals
that are subject to an integrity order by the U.S Department of Health and Human Services Office of the Inspector General, or HHS-OIG,
that requires the hospital to ensure that each subcontractor to the hospital fully complies with HIPAA and the terms of the integrity
order, including written policies and procedures assuring compliance and subjects each subcontractor to audit at the determination of
the HHS-OIG. We could be vulnerable to prosecution under these statutes if any of our customers deliberately or recklessly submits claims
that contain false misleading or incomplete information. In addition, the administrative simplification provisions of HIPAA require the
promulgation of regulations establishing national standards for among other things, certain electronic healthcare transactions the use
and disclosure of certain individually identifiable patient health information and the security of the electronic systems maintaining
this information. These are commonly known as the HIPAA transaction and code set standards privacy standards and security standards respectively.
The administrative provisions of HIPAA direct the federal government to adopt national electronic standards for automated transfer of
certain healthcare data among healthcare payers plans and providers. HIPAA is designed to enable the entire healthcare industry to communicate
electronic data using single set of standards. We are a covered entity under HIPAA and as such we must operate in compliance with the
electronic transaction code standards, privacy standards, and security standards. We are also a business associate under HIPAA because
we perform services for or on behalf of other covered entities. We have developed policies, procedures. and systems for handling patient
health information that we believe, are following the requirements of HIPAA.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Radiological Devices</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We and our products will also be regulated
by the FDA under the Electronic Product Radiation Control provisions of the FDCA because the Nanox.ARC contains radiation emitting
components, and because we assemble these components during manufacturing and service activities. The Electronic Product Radiation
Control provisions require radiation-producing products to comply with certain regulations and applicable performance standards.
Manufacturers are required to certify in product labeling and reports to the FDA that their products comply with all necessary
standards as well as maintain manufacturing, testing and sales records for their products. The Electronic Product Radiation Control
provisions also require manufacturers to report product defects and affix appropriate labeling to covered products. Failure to
comply with these requirements could result in enforcement action by the FDA, which can include any of the sanctions described
above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Healthcare Regulatory Laws</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Within the United States, our products and
our customers will be subject to extensive regulation by a wide range of federal and state agencies that govern business practices
in the medical device industry. These laws include federal and state anti-kickback, fraud and abuse, false claims, transparency
and anti-corruption statutes and regulations. Internationally, other governments also impose regulations in connection with their
healthcare reimbursement programs and the delivery of healthcare items and services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">U.S. federal healthcare fraud and abuse
laws will generally apply to our activities, among other reasons because we expect that our products will be covered under federal
healthcare programs such as Medicare and Medicaid. The Anti-Kickback Statute is particularly relevant because of its broad applicability.
Specifically, the Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving or providing
remuneration, directly or indirectly, in exchange for, or to induce, either the referral of an individual, or the furnishing, arranging
for or recommending a good or service for which payment may be made in whole or part under federal healthcare programs, such as
the Medicare and Medicaid programs. Almost any financial interaction with a healthcare provider, patient or customer will implicate
the Anti-Kickback Statute. Statutory exceptions and regulatory safe harbors protect certain interactions if specific requirements
are met. However, only those interactions that represent fair market value exchanges generally are protected by a safe harbor or
exception. The government can exercise enforcement discretion in taking action against unprotected activities. Further, a person
or entity does not need to have actual knowledge of the Anti-Kickback Statute or specific intent to violate it in order to have
committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation
of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal
civil money penalties statute. Penalties for Anti-Kickback Statute violations may include both criminal penalties such as imprisonment
and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other federal healthcare programs.
Exclusion would mean that diagnostic tests using our products would no longer be eligible for reimbursement under federal healthcare
programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many states have adopted laws similar to
the Anti-Kickback Statute. Some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed
by any payor, not only federal healthcare programs. Insurance companies may also bring a private cause of action for treble damages
against a manufacturer for a pattern of causing false claims to be filed under the federal Racketeer Influenced and Corrupt Organizations
Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Another development affecting the healthcare
industry is the increased use of the federal Civil False Claims Act and, in particular, actions brought pursuant to the False Claims
Act&#8217;s &#8220;whistleblower&#8221; or &#8220;qui tam&#8221; provisions. The False Claims Act imposes liability on any person
or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a
federal healthcare program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf
of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any
monetary recovery. In recent years, the number of suits brought against healthcare providers by private individuals has increased
dramatically. In addition, various states have enacted false claim laws analogous to the Civil False Claims Act, although many
of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The federal Health Insurance Portability
and Accountability Act of 1996, or HIPAA, among other things, created two new federal crimes: healthcare fraud and false statements
relating to healthcare matters. The HIPAA healthcare fraud statute prohibits, among other things, knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors. A violation of this statute
is a felony and may result in fines, imprisonment and/or exclusion from government-sponsored programs. The HIPAA false statements
statute prohibits, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making
any materially false, fictitious or fraudulent statement or representation in connection with the delivery of or payment for healthcare
benefits, items or services. A violation of this statute is a felony and may result in fines and/or imprisonment. Similar to the
federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statutes or specific intent to
violate them in order to have committed a violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Laws and regulations have also been enacted
by the federal government and various states to regulate the sales and marketing practices of medical device and pharmaceutical
manufacturers. The laws and regulations generally limit financial interactions between manufacturers and healthcare providers,
require pharmaceutical and medical device companies to comply with voluntary compliance standards issued by industry associations
and the relevant compliance guidance promulgated by the U.S. federal government and/or require disclosure to the government and/or
public of financial interactions (so-called &#8220;sunshine laws&#8221;). Many of these laws and regulations contain ambiguous
requirements or require administrative guidance for implementation. Manufacturers must adopt reasonable interpretations of requirements
if there is ambiguity and those interpretations could be challenged. Given the lack of clarity in laws and their implementation,
our activities could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Coverage and Reimbursement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Over the past few years, the growth rate
of advanced imaging volumes has slowed in part due to additional patient-related cost-sharing programs and an increasing trend
of third-party payors intensifying their utilization management efforts, for example, through benefit managers who require prior
authorizations to control the growth rate of imaging services generally. We expect that these trends will continue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">By way of example, in the United States,
the Protecting Access to Medicare Act of 2014 required CMS, in conjunction with medical specialty societies, to adopt AUC for certain advanced diagnostic imaging services, including MRI, CT, nuclear medicine (including
position emission tomography). Beginning in 2022, payment will be made to the furnishing professional for an applicable advanced
diagnostic imaging service only if the claim indicates that the ordering professional consulted a qualified clinical decision support
mechanism, as identified by HHS, as to whether the ordered service adheres to the applicable AUC. Applicable settings include physician
offices, hospital outpatient departments, including emergency departments, ambulatory surgical centers and independent diagnostic
testing facilities. Advanced imaging services ordered by certain physicians identified as having outlier-ordering partners will
be subject to prior authorization for applicable imaging services provided to Medicare beneficiaries. The outlier methodology used
by CMS will be subject to future notice and comment rulemaking before the prior authorization component is implemented. We cannot
predict the full impact of this project.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Third-party payors may impose limits on
coverage or reimbursement for diagnostic imaging services, including denying reimbursement for tests that do not follow recommended
diagnostic procedures or can only be billed using an unlisted or miscellaneous code. To the extent our customers will depend on
third-party payors, unfavorable coding, coverage and reimbursement policies may constrict the profit margins of our provider customers,
which may force us to lower our fees to attract and retain customers. If we are required to request new billing codes that more
precisely identify and describe our imaging services, coverage is limited or reimbursement rates are inadequate, a healthcare provider
might find it financially unattractive to own our diagnostic imaging systems. It is possible that third-party payor coding, coverage
and reimbursement policies will affect the need or prices for our products in the future, which could significantly affect our
financial performance and our ability to conduct our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Healthcare Reform</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the United States and certain foreign
jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the
healthcare system. In March 2010, the ACA was signed into law and substantially changed the way healthcare is financed by both
governmental and private insurers in the United States. The ACA contains a number of provisions, including those governing enrollment
in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the ACA imposed, among other
things, a new federal excise tax on the sale of certain medical devices, which, through a series of legislative amendments, was
suspended, effective January&#160;1, 2016, and subsequently repealed altogether on December&#160;20, 2019, provided incentives
to programs that increase the federal government&#8217;s comparative effectiveness research and implemented payment system reforms
including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination,
quality and efficiency of certain healthcare services through bundled payment models.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since its enactment, there have been judicial
and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA
in the future. By way of example, in 2017, Congress enacted the TCJA, which eliminated the tax-based shared responsibility payment imposed
by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred
to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a Texas U.S. District Court Judge ruled that the individual mandate
is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the TCJA, the remaining provisions
of the ACA are invalid as well. On December&#160;18, 2019, the U.S. Court of Appeals for the 5th Circuit ruled that the individual mandate
was unconstitutional. This decision was appealed to the U.S. Supreme Court, and on June 17, 2021, the Supreme Court held that state and
individual plaintiffs did not have standing to challenge the individual mandate provision of the ACA; in so holding, the Supreme Court
did not consider larger constitutional questions about the validity of this provision or the validity of the ACA in its entirety. It
is unclear how these decisions, future decisions, subsequent appeals, and other efforts to repeal and replace the ACA will impact the
ACA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other legislative changes have been proposed and
adopted in the United States since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal
year, which was temporarily suspended from May 1, 2020 through March 31, 2022, followed by a 1% reduction in effect from April 2022 through
June 2022 with the full 2% reduction resuming thereafter, and reduced payments to several types of Medicare providers. We believe the
overall escalating cost of medical products and services being paid for by the government and private health insurance has led to, and
will continue to lead to, increased pressures on the healthcare and medical device industry to reduce the costs of products and services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Data Privacy and Security</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Medical device companies may be subject
to U.S. federal and state and foreign health information privacy, security and data breach notification laws, which may govern
the collection, use, disclosure and protection of health-related and other personal information. In the United States, HIPAA imposes
privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#8220;covered
entities&#8221; (health plans, health care clearinghouses and certain health care providers), and their respective business associates,
individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a
service for or on behalf of a covered entity. HIPAA and its respective implementing regulations, including the final omnibus rule
published on January&#160;25, 2013, impose specified requirements relating to the privacy, security and transmission of individually
identifiable health information. HIPAA mandates the reporting of certain breaches of health information to HHS, affected individuals
and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of
unsecured protected health information (&#8220;PHI&#8221;), a complaint about privacy practices or an audit by HHS, may be subject
to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if
required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance.
The Health Information Technology For Economic and Clinical Health Act also increased the civil and criminal penalties that may
be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority
to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s
fees and costs associated with pursuing federal civil actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Even when HIPAA does not apply, according
to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure
constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act,
15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the
sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools
to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that
merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar
to what is required by the HIPAA Security Rule.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, certain state and non-U.S. laws,
such as the GDPR/UK GDPR, govern the privacy and security of health information in certain circumstances, some of which are more stringent
or broader in scope than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating
compliance efforts. Further, &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that
create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered
entity, are also subject to certain HIPAA privacy and security standards. Failure to comply with these laws, where applicable, can result
in the imposition of significant civil and/or criminal penalties and private litigation. For example, California enacted the CCPA, which
went into effect January&#160;1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides
new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also
creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with
a data breach. Although the law includes limited exceptions, including for PHI maintained by a covered entity or business associate,
it may regulate or impact our expected processing of personal information depending on the context. Further, the California Privacy Rights
Act (CPRA), recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including
additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain
uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could
result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023,
and additional compliance investment and potential business process changes may be required. In Europe, the GDPR went into effect in
May 2018 and introduces strict requirements for processing the personal data of individuals within the EEA. Companies that must comply
with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements
and potential fines for noncompliance of up to &#8364;20&#160;million or 4% of the annual global revenues of the noncompliant company,
whichever is greater. Relatedly, following the United Kingdom&#8217;s withdrawal from the European Economic Area and the European Union,
and the expiry of the transition period, companies have to comply with both the UK GDPR and the GDPR, the latter regime having the ability
to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The State of Israel has also implemented data protection
laws and regulations, including the Israeli Protection of Privacy Law of 1981.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Foreign Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As we plan to market and deploy our Nanox
System broadly across the globe, we will be subject to regulations applicable to medical and radiation-emitting devices in the
jurisdictions in which we operate, which regulations vary among countries. While some countries&#8217; regulations may not impose
barriers to marketing and selling our products or only require certain notification, others may require that we obtain the clearance,
registration or approval of a specified regulatory body. Process for obtaining such clearance, registration or approvals may involve
additional testing and time. Furthermore, complying with foreign regulatory requirements can be expensive and time-consuming, and
we will need to seek for regulatory clearances or approvals in each country in which we plan to market our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, depending on the country, if
we modify our products, we may need to apply for additional regulatory clearances or approvals before we are permitted to sell
the modified product. Also, for maintaining our authorizations in a particular country, we will need to continue meeting quality
and safety standards required in such country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Finally, while regulatory clearance or approval
by the FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, registration or regulatory
clearance or approval in one country, or denial thereof, may have effects on the regulatory process in others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Legal Proceedings</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">From time to time, we may
become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject
to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In September 2020, two securities
class action complaints were filed in the United States District Court for the Eastern District of New York against the Company and certain
current officers and a director, which were subsequently consolidated and captioned as <i>White v. Nano-X Imaging Ltd. et al</i>, Case
No. 1:20-cv-04355, alleging violations of securities laws on behalf of all persons and entities that purchased or otherwise acquired the
Company&#8217;s publicly traded securities between August 21, 2020 and September 15, 2020, and seeking unspecified damages. On December
7, 2020, proposed lead plaintiffs submissions were fully briefed and remain outstanding. The Company has not accrued any losses other
than legal fees with connection with this lawsuit. The Company&#8217;s position is that this lawsuit has no merit and it intends to defend
its position vigorously.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On October 5, 2021, a class action complaint was
filed in the United States District Court for the Eastern District of New York against the Company and certain of its officers, captioned
<i>McLaughlin v. Nano-X Imaging Ltd. et al</i>, Case No. 1:21-cv-05517. On January 25, 2022, Magistrate Judge Peggy Kuo appointed Davian
Holdings Limited as Lead Plaintiff in the McLaughlin v. Nano-X Imaging Ltd. et al, Case No. 1:21-cv-05517. On April 12, 2022 and in the
same case, the Lead Plaintiff filed an amended complaint, which alleges that defendants violated the federal securities laws in connection
with certain disclosures concerning the cost of the Nanox.ARC system as well as the comparison of the Nanox.ARC to CT scanners. Lead Plaintiff
seeks to represent a class of investors who purchased the Company&#8217;s publicly-traded securities between August 21, 2020 and November
17, 2021. The Company has not yet responded to the amended complaint and intends to defend these actions vigorously. The Company has
not accrued any losses other than legal fees with connection with this lawsuit. The Company&#8217;s position is that the lawsuit has no
merit and it intends to defend its position vigorously.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On October 28, 2021, a complaint was filed in the
United States District Court for the Central District of California against the Company, the Company&#8217;s recently-formed Delaware
subsidiary and Nanox Gibraltar PLC (&#8220;Gibraltar&#8221;) from which the Company received certain assets, as well as Mr. Ran Poliakine
and certain other unidentified parties, alleging several causes of action including breach of a consulting agreement between the plaintiff
and Gibraltar that was entered into in 2015. The plaintiff&#8217;s demand is for a payment of unpaid consulting fees from Gibraltar in
the amount of approximately $1 million and approximately $29.5 million from the Company relating to his claimed entitlement to warrants
in Gibraltar. The Company&#8217;s position is that the complaint against the Company has no merit, because, among other reasons, as it
was not a party to the agreement with the plaintiff and it is not Gibraltar&#8217;s legal successor for any liabilities that Gibraltar
may owe to the plaintiff. The Company intends to defend its position vigorously.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Division of Enforcement of the SEC notified
the Company that it is conducting an investigation to determine whether there had been any violations of the federal securities laws.
The Company has been providing documents and information to the SEC and has received a subpoena from the SEC requesting that the Company
provide documents and other information relating to the development cost of the Company&#8217;s Nanox.ARC prototypes, as well as the Company&#8217;s
estimate for the cost of assembling the final Nanox.ARC product at scale, among other things. The Company is cooperating with the SEC
in responding to its requests. The duration and outcome of this matter cannot be predicted at this time.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are unable to estimate a range of loss, if any, that could result
were there to be&#160;an adverse final outcome in any of the above cases or the SEC investigation. If an unfavorable outcome were to occur,
it is possible that the impact could be material to our results of operations in the period in which any such outcome becomes probable
and estimable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">C. Organizational Structure</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NANO-X IMAGING LTD, an Israeli Company (&#8220;Nanox
IL&#8221;), was incorporated on December&#160;20, 2018 and commenced its operations on September&#160;3, 2019.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September&#160;19, 2019, Nanox IL established
Nanox Imaging Inc., a wholly owned subsidiary in Japan.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September&#160;25, 2020, Nanox IL established
Nano-X Korean Inc., a wholly owned subsidiary in Korea.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 4, 2021, Nanox IL purchased all the
shares of Nano-X AI Ltd. (&#8220;Nanox AI&#8221;), an Israeli company formerly named Zebra Medical Vision Ltd. Nanox AI has a wholly
owned Delaware subsidiary named Nanox-X AI Inc.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 13, 2021, Nanox IL established Nano-X
Imaging Inc (&#8220;Nanox Inc.&#8221;), a wholly owned Delaware subsidiary. On November 2, 2021, Nanox Inc. completed the acquisition
of 100% of the shares of USARAD Holdings, Inc. (&#8220;USARAD&#8221;), a Delaware corporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 30, 2011, Nanox Inc. established a
new wholly-owned Delaware subsidiary, Nano-X MDW Inc, which owns the platform and other assets purchased by us from MDWEB, LLC on November
3, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 23, 2021, USARAD established another
wholly-owned Delaware subsidiary Nanox RAD Inc., which is not active yet.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>D. Property, Plants and Equipment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located in
a leased facility in Neve Ilan, Israel. We lease approximately 550&#160;square meters (approximately 5,920 square feet) of office space
and warehouses. The original lease expired in December&#160;2021, and we have exercised the option to extend our lease for an additional
24 months until December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We also lease approximately
620 square meters (approximately 6,670 square feet) of office space in Neve Ilan, Israel, that may be used for offices and technical development.
The lease expires in June 2023. In November 2020, we leased an additional approximately 370 square meters (approximately 3,980 square
feet) of office space in Neve Ilan, Israel. This lease also expires in June 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2022, we signed a new agreement to lease
a space of 105 square meters (approximately 1,130 square feet) of office space in Neve Ilan until February 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Nanox Japan (predecessor)
leases additional facilities of approximately 740 square feet of lab space and approximately 190 square feet of space in a clean room
at the premises of the University of Tokyo for research and development activities. The lease automatically renews on a semi-annual basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Nanox Imaging Inc. leases office space of approximately 2,300 square
feet in Fort Lee, New Jersey. The monthly rent payment for this agreement is approximately $6,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In December 2020, we purchased approximately 11,889
square meters of land in Yongin, Geonggi province, Korea, on which we built our fabrication facility for approximately $6.2 million, which
is operational.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Nanox AI leases approximately 841 square meters
of office space under an operating lease agreement that expires on November 30, 2024. The monthly rent payment for this agreement is approximately
$12,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.75in; text-align: left"><span style="font-size: 10pt"><b>Item 4A</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Unresolved Staff Comments</b></span></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">&#160;</p><div>

</div><div><a id="a_006"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in">Item 5.</td><td>Operating and Financial Review and Prospects</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following discussion and analysis of our financial
condition and results of operations should be read in conjunction with our audited consolidated financial statements and the related
notes included elsewhere in this annual report on Form 20-F. This discussion contains forward-looking statements based upon current expectations
that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements
as a result of various factors, including those discussed in the section titled &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221;
and in other parts of this annual report on Form 20-F. Our consolidated financial statements have been prepared in accordance with U.S.
GAAP. The functional currency of NANO-X IMAGING LTD is the U.S. dollar.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. Operating Results</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Overview</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Early detection saves lives&#8212;and we at Nanox
are focused on applying our proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable
across the globe. We are developing a holistic imaging solution, which includes the Nanox System, comprised of the Nanox.ARC using our
novel MEMs X-ray source technology, and the Nanox.CLOUD, a companion cloud software, integrated with AI solutions and teleradiology services.
Our vision is to increase early detection of medical conditions that are discoverable by X-ray by improving access to imaging, reducing
imaging costs and enhancing imaging efficiency, which we believe is key to increasing early prevention and treatment, improving health
outcomes and, ultimately, saving lives.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our imaging solution is designed as a modular
open system, and we intend in the future to explore the expansion of the solution to include additional components, which may be developed
by us or third parties.If cleared, we plan to market and deploy the Nanox System broadly across the globe at a substantially lower cost
compared to currently available medical imaging systems, such as CT. We believe that, if cleared, our technology&#8217;s relatively low
cost will enable us to increase accessibility and affordability of early-detection medical imaging systems globally, substantially reduce
wait-times for imaging results and increase early detection rates compared to currently employed imaging process protocol.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have devoted substantially all of our financial
resources to acquiring the base technology for our X-ray source and related know-how, conducting research and development activities,
organizing and staffing our company, developing our business plan, securing related intellectual property rights and raising capital.
Historically, we have funded our operations primarily with proceeds from the sale of our ordinary shares and warrants (after September&#160;3,
2019) and those of our predecessor company (prior to September&#160;3, 2019). During the years ended December 31, 2021, 2020 and 2019,
we received net cash proceeds of $7.4 million, $240.4&#160;million and $14.0 million, respectively, from the sales of our and our predecessor&#8217;s
ordinary shares. &#160;In the year ended December 31, 2021, we began to generate revenues through the sale of teleradiology services and
the sale of AI solutions, following the completion of the merger with Zebra, renamed Nanox AI Ltd., and the acquisitions of USARAD and
the assets of MDWEB in November 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have incurred significant operating losses since
our inception. Our ability to achieve profitability depends on the successful development and commercialization of our technology and
our products. We incurred net losses of $61.8&#160;million, $43.8&#160;million and $22.6 million for the years ended December&#160;31,
2021, 2020 and 2019, respectively. As of December 31, 2021 and 2020, we had an accumulated deficit of $146.2&#160;million and $84.4&#160;million,
respectively. We expect to continue to incur significant expenses for at least the next several years as we advance the Nanox System through
further development and regulatory approval. If we obtain marketing clearance or approval for the multi-source Nanox.ARC, we expect to
incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. In addition, we continue
to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and
other expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our goal is to jumpstart the MSaaS-based medical
imaging market by producing and deploying an initial wave of approximately 15,000 Nanox.ARC units by the end of 2024. We estimate that
effectively stimulating market interest in our Nanox System will require deploying at least 5,000 to 10,000 Nanox.ARC units. In addition,
we believe that a minimum installed base of at least 1,000 Nanox.ARC units will be required to support our business during the initial
wave of deployment, assuming we enter into at least one licensing agreement on commercially reasonable terms. We expect to incur significant
expenses for the manufacture, installation, deployment and maintenance of the Nanox System. As&#160;a result, we may need substantial
funding to support our continuing operations and pursue our business strategy before we can generate significant revenues. Until such
time as we can generate significant revenue from product sales, we expect to finance our operations through the sale of equity, debt financings
or other capital sources, including collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third
parties. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms,
or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back
or discontinue the development and commercialization of one or more of our products or delay our pursuit of potential in-licenses or acquisitions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2021, we had marketable
securities, cash and cash equivalents of $156.6&#160;million. We believe that our cash on hand and cash equivalents
will enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months from the date
of issuance of the financial statements. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust
our capital resources sooner than we expect. See &#8220;Item 5. Operating and Financial Review and Prospects&#8212;B. Liquidity and
Capital Resources.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Acquisitions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 2, 2021, the Company completed the
acquisition of 100% of the shares of USARAD, pursuant to the terms of the Stock Purchase Agreement, dated October 25, 2021, among the
Company, USARAD, Dr. Michael Yuz, other holders of capital stock of USARAD and holders of USARAD options. USARAD <span>is
a U.S. based teleradiology company with over 300 U.S. certified radiologists in its organization</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 3, 2021, the Company completed the
acquisition of the platform and other assets of MDWEB, pursuant to the terms of the Asset Purchase Agreement, dated October 21, 2021,
between the Company and MDWEB, a USARAD-related company. Pursuant to the acquisition, we acquired the MDW platform, now known as the Nanox.MARKETPLACE,
a decentralized marketplace connecting imaging facilities with radiologists.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 4, 2021, the Company consummated its
merger with Zebra pursuant to the terms of the Agreement and Plan of Merger, dated August 9, 2021, as amended, among the Company, Zebra
and Perryllion Ltd., as representative of Zebra&#8217;s equity holders. Zebra, now known as Nanox AI Ltd., is a leading medical AI developer,
with ten FDA-cleared and 11 CE-marked AI solutions for medical imaging.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For additional information
regarding these acquisitions, including the consideration that we paid and is payable in connection with these acquisitions, see &#8220;Item
4. Information on the Company&#8212;A. History and Development of the Company.&#8221; In the year ended December 31, 2021, following the
completion of these acquisitions, we began to generate revenues through the sale of teleradiology services and the sale of AI solutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Asset Purchase</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were formed on December&#160;20, 2018. Pursuant
to the Asset Purchase Agreement, as amended on December&#160;3, 2019 and December&#160;31, 2019, substantially all of the assets of Nanox
Gibraltar, including all patents, patent applications and all other intellectual property rights, but not including the shares of Nanox
Japan (predecessor), were sold to us for an aggregate consideration of $13.3&#160;million, reflecting the fair market value of the transferred
assets, which was estimated to be $6.1&#160;million (excluding cash) based on an independent valuation report, plus the cash balance less
$200,000, which cash amount totaled $7.2&#160;million as of the date of the Asset Purchase Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Asset Purchase Agreement,
the consideration for the transferred assets will be paid only on the occurrence of one of the following events: (a) the closing of a
transaction involving the sale of all or substantially all of our assets; (b) the acquisition of us by, or the merger of us with, another
entity, consolidation, reorganization, recapitalization, sale, assignment or disposal by us of all or substantially all of our issued
and outstanding shares; (c) the transfer, sale, lease, grant or other disposition of or the grant of an exclusive license over all or
substantially all of our assets, including, but not limited to, intellectual property, with the same economic effect to that of a sale
and/or cessation of its business; (d)&#160;any other transaction, except for a financing round, following which our shareholders prior
to the closing of such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity; (e)&#160;the
closing of our first underwritten public offering pursuant to a registration statement under the Securities Act or the Securities Law
(or under equivalent securities law of another jurisdiction) or any other securities laws world-wide with the same effects and results;
and (f) an equity financing by us at a minimum pre-money valuation of $100.0&#160;million, with proceeds to us of at least $30.0&#160;million.
In the events of (e)&#160;or (f) above, we will have the option to pay the consideration in cash or by the issuance to Nanox Gibraltar
of our securities of the same series to be issued upon such event, in an amount reflecting a 25% discount on the price per share to be
determined in connection with (e) and (f) above. If we elect to pay such consideration in cash, Nanox Gibraltar will have the right, at
its sole discretion and in good faith, to reject such payment in cash, and require that we pay such consideration in the form of our securities
in such amount and with such discount described above. In connection with this, we recorded a related party liability in an amount of
$17.8&#160;million in its financial statements as of and for the year ended December&#160;31, 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In January 2020, our board of directors and the
board of directors and shareholders of Nanox Gibraltar approved the issuance of shares in accordance with the terms of the Asset Purchase
Agreement described above. As a result, 1,109,245 of our ordinary shares were issued to Nanox Gibraltar, representing an aggregate consideration
of approximately $17.8&#160;million, and we have no further obligations to Nanox Gibraltar under the Asset Purchase Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Components of Our Results of Operations</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We began to generate revenues in year ended December
31, 2021, through the sale of teleradiology services and the sale of AI solutions, following the completion of the merger with Zebra,
renamed Nanox AI Ltd., and the acquisitions of USARAD and the assets of MDWEB in November 2021. The majority of our revenues are derived
from our teleradiology services, which consist primarily of fees received from various payors based on established billing rates, and
also of fees from hospitals and healthcare providers. We recognize revenue in the period in which performance obligations are satisfied
by providing services to customers, and record the amount of revenue that reflects the consideration that we expect to receive in exchange
for those services. We have not generated any revenue to date from sales of the Nanox System.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cost of Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cost of revenue consists of the cost of the sale
of teleradiology services and the cost of the sale of AI solutions. Cost of the sale of teleradiology services mainly consists of the
cost of radiologists and the cost of picture archiving and communication software (a medical imaging technology used to securely store
and digitally transmit electronic images and clinical reports). The cost of the sale of AI solutions mainly consists of the cost of labor
and amortization of intangible assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><b>Operating Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Research and Development Expenses</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses consist primarily
of costs incurred in connection with the research and development of our products. These expenses include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>expenses incurred in connection with the development of our products,
                                            including payments made pursuant to agreements with third parties, such as outside consultants
                                            related to process development and manufacturing activities, as well as patent registrations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>costs of components and materials, including payments made pursuant
                                            to agreements with third parties;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>costs of laboratory supplies incurred for each program;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>facilities, depreciation and other expenses, including direct
                                            or allocated expenses for rent and maintenance of facilities, as well as insurance costs;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>costs related to compliance with regulatory requirements; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>employee-related expenses, including salaries, related benefits
                                            and share-based compensation expenses for employees engaged in research and development activities.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recognize external development costs based
on an evaluation of the progress to completion of specific tasks using information provided to us by our suppliers and service providers.
Upfront payments, milestone payments (other than those deemed contingent consideration in a business combination) and annual maintenance
fees under license agreements are expensed in the period in which they are incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development activities are central
to our business. We expect that our research and development expenses will increase substantially over the next several years as we continue
development of the Nanox System. We expect to continue to devote a substantial portion of our resources to the Nanox.ARC multi-source
system, the Nanox.CLOUD, the Nanox.MARKETPLACE, our AI solutions and our underlying technology for the foreseeable future.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The successful development and commercialization
of our products are highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts
that will be necessary to complete the development of any of our products. This uncertainty is due to the numerous risks and uncertainties
associated with product development and commercialization, including the uncertainty of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the timing and progress of development activities;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to maintain our current research and development
                                            programs and to establish new ones;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the receipt of regulatory approvals from applicable regulatory
                                            authorities without the need for independent clinical trials or validation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the timing, receipt and terms of any marketing approvals from
                                            applicable regulatory authorities;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>our ability to establish new licensing or collaboration arrangements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>the performance of our future collaborators, if any;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>establishing commercial manufacturing capabilities or making
                                            arrangements with third-party manufacturers;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>obtaining, maintaining, defending and enforcing patent claims
                                            and other intellectual property rights;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">launching commercial sales of our products, including the Nanox.ARC the Nanox.CLOUD software and our AI solutions, whether alone or in collaboration with others; and</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>maintaining a continued acceptable safety profile of the products
                                            following approval.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any changes in the outcome of any of these variables
with respect to the development of our products could result in a significant change in the costs and timing associated with the development
of these products. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials or other testing
beyond what we currently expect, we could be required to expend significant additional financial resources and time to complete development
of our products. We may never obtain regulatory approval for any of our products and third parties may never obtain regulatory approvals
for any products containing our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Marketing, General and Administrative Expenses</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Marketing expenses consist of public relations
and general marketing expenses. General and administrative expenses consist primarily of salaries, related benefits and share-based compensation
expense for personnel in executive, finance and administrative functions. General and administrative expenses also include facilities,
depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance, as
well as professional fees for legal, patent, consulting, investor and public relations, accounting and audit services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We anticipate that our marketing, general and administrative
expenses will increase as we increase our headcount to support our continued research and development activities and commercialization
of our products. We also incur accounting, audit, legal, regulatory, compliance, directors&#8217; and officers&#8217; liability insurance
and investor and public relations costs associated with being a public company.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Results of Operations</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. Dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">REVENUE</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,304</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">COST OF REVENUE</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,816</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">GROSS LOSS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,512</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">OPERATING EXPENSES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,717</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sales and Marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,033</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,445</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,556</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,709</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,298</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,182</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL OPERATING EXPENSES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,046</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,923</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">OPERATING LOSS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61,558</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,923</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,571</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><b>FINANCIAL INCOME (EXPENSES),</b> net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(288</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">108</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">OPERATING LOSS BEFORE INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(61,846</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,815</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,563</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">INCOME TAX BENEFIT</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">NET LOSS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(61,798</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(43,815</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(22,563</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">BASIC AND DILUTED LOSS PER SHARE</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1.28</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(1.23</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(0.90</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><b>THE WEIGHTED AVERAGE OF THE NUMBER OF ORDINARY SHARES</b>
    (in thousands)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">48,216</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">35,654</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25,181</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61,798</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,815</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,563</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Unrealized loss from available- for-sale securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(607</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total other comprehensive loss:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(607</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL COMPREHENSIVE LOSS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62,405</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,815</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,563</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comparison of the years ended December 31, 2021 and 2020</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0; text-indent: 0.5in">The table below summarizes the results
of operations for the years ended December 31, 2021 and 2020, respectively:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Revenue</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our revenue incurred
during the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">($ in thousands)</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Teleradiology services</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%">AI</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">270</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the year ended December 31, 2021, we reported
revenue of $ 1.3 million, compared to none for the year ended December 31, 2020. During the year ended December 31, 2021, we generated
revenues through the sale of teleradiology services in the amount of $1.0 million and the sale of AI solutions in the amount of $0.3 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Cost of Revenue</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our cost of revenue
incurred during the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">($ in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Teleradiology services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>AI</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,816</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,816</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the year ended December 31, 2021, we reported
cost of revenue of $2.8 million, compared to none for the year ended December 31, 2020. During the year ended December 31, 2021, we incurred
cost of revenue through the sale of teleradiology services in the amount of $1.0 million and the sale of AI solutions in the amount of
$1.8 million.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Gross Loss </i></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our gross loss incurred
from each segment during the periods presented:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold">($ in thousands)</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Teleradiology services</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#160;&#160;&#160;-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%">AI</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,546</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,512</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the year ended December 31, 2021, we reported
a gross loss of $1.5 million, compared to no profit or loss for the year ended December 31, 2020. Our gross profit from teleradiology
services for the year ended December 31, 2021 was $0.0 million. Our gross loss from our AI solutions for the year ended December 31,
2021 was $1.5 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>


</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Research and Development Expenses</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our research and development
expenses incurred during the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">($ in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Research and Development Expenses:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Salaries and wages</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,091</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,384</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D - professional services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,072</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,647</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,755</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,122</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,210</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses increased by
$7.9 million to $17.1 million for the year ended December&#160;31, 2021 from $9.2 million for the year ended December 31, 2020. The increase
in research and development expenses was primarily attributable to the increase of $1.7 million due to the merger with Zebra, renamed
Nanox AI, and increases in salaries and wages and professional services as we continue to expand our research and development activities
relating to the Nanox System.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Sales and</i>&#160;<i>Marketing Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our sales and marketing
expenses incurred during the periods presented:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">($ in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Sales and Marketing Expenses:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Salaries and wages</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,711</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">733</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,442</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,252</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketing and business development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,460</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,033</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,445</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Sales and marketing expenses decreased to $7.0&#160;million
for the year ended December&#160;31, 2021, from $12.4 million for the year ended December 31, 2020. The decrease in sales and marketing
expenses was primarily attributable to a decrease in share-based compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and Administrative Expenses</i></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below summarizes our general and administrative
expenses incurred during the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">($ in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">General and Administrative Expenses:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Salaries and wages</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,159</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,847</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,145</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Directors&#8217; and officers&#8217; insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,445</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,812</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Professional services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,449</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,476</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">671</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Rent and Maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">821</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">620</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and Amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,924</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">516</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">34,709</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,268</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses increased
to $34.7 million for the year ended December&#160;31, 2021, from $22.3 million for the year ended December 31, 2020. The increase in
general and administrative expenses was primarily attributable to the merger with Zebra, renamed Nanox AI, and the acquisitions of USARAD
and the assets of MDWEB, an increase in our head count in connection with the expansion of our management team and the overall organization
infrastructure, an increase of approximately $1.9 million in legal fees primarily due to the SEC inquiry and class-actions, an increase
of $2.4 million in our directors&#8217; and officers&#8217; liability insurance premium and transaction expenses in connection with the
merger with Zebra, renamed Nanox AI, and the acquisitions of USARAD and the assets of MDWEB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Other Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other expenses were $1.2 million for the year ended
December&#160;31, 2021, and none for the year ended December 31, 2020. The increase in other expenses was primarily attributable to the
relocation of our fabrication facility from its temporary location to its permanent location in South Korea.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Comparison
of the years ended December 31, 2020 and 2019</i></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the results of operations for the years ended December 31, 2020 and 2019, respectively, together with the changes
in those items in dollars:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">($ in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Operating expenses</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,210</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,717</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Marketing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,445</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,556</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,268</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,298</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,923</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,571</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial (income) expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(108</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(43,815</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(22,563</td><td style="text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our research and development expenses incurred during the periods presented:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    Ended December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2019</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development Expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($
    in thousands)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
    - salaries and wages</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,091</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">437</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,384</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">661</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
    - professional services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,647</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,450</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">169</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,210</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,717</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased by $6.5 million to $9.2 million for the year ended December 31, 2020 from $2.7 million for the year
ended December 31, 2019. The increase in research and development expenses was primarily attributable to increases in salaries and wages,
share-based compensation and professional services as we continue to expand our research and development activities relating to the Nanox
System.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketing
Expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our marketing expenses incurred during the periods presented:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b>Year
    Ended December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2019</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
    Expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($
    in thousands)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
    &#8211; salaries and wages</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">733</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
    and business development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,460</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">739</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,252</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">617</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,445</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
expenses increased by $10.9 million to $12.4 million for the year ended December 31, 2020 from $1.6 million for the year ended December
31, 2019. The increase in marketing expenses was primarily attributable to increases in salaries and wages, share-based compensation
(of which $6.1 million related to the amendment to a certain business development agreement with two of our finders, as discussed in
&#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Commercial Agreements&#8212;MSaaS Agreements&#8221;), and
professional services as we continue to expand our business and to build management infrastructure to move toward the commercial stage
of our business.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our general and administrative expenses incurred during the periods presented:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<b>Year
    Ended December 31,</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2019</b>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and Administrative Expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($
    in thousands)</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G&amp;A
    &#8211; salaries and wages</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,847</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">461</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,145</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,967</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executives
    and officers&#8217; insurance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,812</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">---</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    fee</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">534</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G&amp;A
    &#8211; professional services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,449</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,470</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">671</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">417</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
    and Maintenance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">143</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    and Amortization</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">208</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">345</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">274</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,268</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,298</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses increased by $4.0 million to $22.3 million for the year ended December 31, 2020 from $18.3 million for the
year ended December 31, 2019. The increase in general and administrative expenses was primarily attributable to increases in salaries
and wages, executives&#8217; insurance and professional services as we continue to expand our business and to build management infrastructure
to move toward the commercial stage of our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently
Issued Accounting Pronouncements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations
is disclosed in Note 2 to our audited consolidated financial statements, included elsewhere in this annual report on Form 20-F.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Liquidity and Capital Resources</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
our inception and prior to November 2021, we did not generate any revenue from product sales or otherwise and have incurred significant
operating losses and negative cash flows from our operations. We began to generate revenues in the year ended December 31, 2021 through
the sale of teleradiology services and the sale of AI solutions, following the completion of the merger with Zebra, renamed Nanox AI
Ltd., and the acquisitions of USARAD and the assets of MDWEB in November 2021. We have not generated any revenue to date from sales of
the Nanox System. Historically, we have funded our operations primarily with proceeds from the sale of our and our predecessor company&#8217;s
ordinary shares.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
Flows</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding our cash flows for the periods presented:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">($
    in thousands)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(38,071</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21,487</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,524</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in investing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(116,320</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,937</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(125</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,379</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">240,991</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,861</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    change in cash and cash equivalents and restricted cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(147,012</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">205,567</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,212</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Cash used in Operating Activities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December&#160;31, 2021, 2020 and 2019, net cash used in operating activities was $38.1&#160;million, $21.5&#160;million
and $5.5 million, respectively, resulting from our net loss of $61.8&#160;million, $43.8&#160;million and $22.6 million, respectively,
adjusted for stock-based compensation changes of $18.8 million, $24.8&#160;million and $16.2&#160;million, respectively, amortization
of intangible assets of $1.8 million in the year ended December 31, 2021, non-cash charges of $0.4 million, $0.1 million and $0.1 million,
in the years ended December 31, 2021, 2020 and 2019, respectively, and changes in components of working capital of $2.6&#160;million,
($1.6)&#160;million and $0.7&#160;million for the years ended December 31, 2021, 2020 and 2019. The&#160;increase in cash used in operating
activities was primarily due to activities related to our business expansion.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Cash used in Investing Activities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December&#160;31, 2021, 2020 and 2019, net cash used in investment activities was $116.3&#160;million, $13.9 million
and $0.1 million, respectively. The increase in cash used in investing activities during the year ended December 31, 2021 was primarily
due to purchase of marketable securities, the completion of our fabrication facility in Korea and the acquisition of USARAD, as part
of the preparation for the commencement of full manufacturing activity.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Cash provided by Financing Activities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December&#160;31, 2021, 2020 and 2019, net cash provided by financing activities was $7.4&#160;million, $241&#160;million
and $13.9 million, respectively, primarily due to proceeds from the issuance of ordinary shares and warrants, net of issuance costs and
from the issuance of ordinary shares upon exercise of options and warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Contractual
Obligations</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
long-term contractual obligations mainly consist of our lease agreements for our offices and other facilities in Israel, Japan and the
United States. For details regarding these lease agreements, see &#8220;Item 4. Information on the Company&#8212;D. Property, Plants
and Equipment.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are party to a lease agreement for the lease of vehicles for certain of our employees, which remains in effect until June
30, 2023. The monthly payment under this agreement is approximately $12,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, we had non-current operating leases liabilities of $1.8 million. For additional details regarding our operating
lease agreements, see Note 7 to our audited consolidated financial statements, which are included in this annual report.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Funding
Requirements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of
the Nanox System and seek marketing approval for this product. In addition, we incur additional costs associated with operating as a
public company. Our expenses will also increase if, and as, we:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                            regulatory approvals for any additional products;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                            to discover and develop additional products;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                            a manufacturing, sales, marketing, medical affairs and distribution infrastructure to commercialize
                                            the Nanox System for which we may obtain marketing approval and intend to commercialize on
                                            our own or jointly;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
                                            additional quality control and scientific personnel;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
                                            our operational, financial and management systems and increase personnel, including personnel
                                            to support our clinical development, manufacturing and commercialization efforts and our
                                            operations as a public company;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate
    our manufacturing facility in South Korea for the purpose of manufacturing MEMs X-ray chips;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
                                            expand and protect our intellectual property portfolio; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire
                                            or in-license other products and technologies.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our cash on hand and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements
for at least the next twelve months from the date of issuance of the financial statements. We have based this estimate on assumptions
that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with manufacture, research, development and commercialization of products, we are
unable to estimate the exact amount of our working capital requirements. Our&#160;future funding requirements will depend on, and could
increase significantly as a result of, many factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope, progress, results and costs of researching and developing the Nanox System;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs, timing and outcome of regulatory review of the Nanox.ARC;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of future activities, including product sales, medical affairs, marketing, manufacturing
                                            and distribution, for the Nanox System for which we receive marketing approval;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial
                                            manufacturing, shipping, installation and deployment of the Nanox System and sufficient inventory
                                            to support commercial launch;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            revenue, if any, received from commercial sale of the Nanox System, should the Nanox.ARC
                                            receive marketing approval;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            cost and timing of hiring new employees to support our continued growth;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of preparing, filing and prosecuting patent applications, maintaining and enforcing
                                            our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability to establish and maintain collaborations on favorable terms, if at all;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs incurred with respect to and the outcome of the securities litigations and SEC investigation we are currently subject to and
    any similar or other claims, litigation and investigations we may be subject to in the future; and</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing, receipt and amount of sales of the Nanox System, if any.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
change in any of these or other variables with respect to the development of any of our products could significantly change the costs
and timing associated with the development of that product. Further, our operating plans may change in the future, and we may need additional
funds to meet operational needs and capital requirements associated with such operating plans.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of public
or private equity offerings, debt financings, collaborations, strategic partnerships or marketing, distribution or licensing arrangements
with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership
interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect
your rights as an ordinary shareholder. Debt financing and preferred equity financing, if available, may involve agreements that include
restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures
or declaring dividends. In addition, debt financing would result in increased fixed payment obligations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise funds through collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties,
we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or products or grant licenses
on terms that may not be favorable to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to raise additional funds when needed, we may be required to delay, reduce or eliminate our product development or future
commercialization efforts, or grant rights to develop and market products that we would otherwise prefer to develop and market ourselves.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
Research and Development, Patents and Licenses, etc.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development Expenses</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are charged to the statement of operations as incurred and consist primarily of personnel, materials and supplies
for research and development activities. See &#8220;Item 5. Operating and Financial Review and Prospects&#8212;A. Operating Results&#8212;Critical
Accounting Policies and Significant Judgments and Estimates&#8212;Research and Development Expenses.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
Property</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 31, 2022, we
and our subsidiaries had 22 issued patents in the United States and 11 provisional or pending U.S.&#160;patent applications. We also
had three patents issued in Israel, four patents pending in Israel, five pending patent applications in the European Patent Office and
two pending Patent Cooperation Treaty patent applications, which are the counterparts of our U.S. patent applications. As of March 31,
2022, we had three patents issued in each of Japan and China, two patents pending in each of Japan and China, 11 pending patent applications
in Korea and six pending patent applications in Hong Kong. Our issued patents generally expire between the years 2032 and 2034, and some
are directed to various features and combinations of features of the Nanox.ARC and the others for AI and teleradiology. We also have
six trademarks granted and one trademark pending in Israel.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to continue filing for patents on new technologies as they are developed and to actively pursue any infringement upon our patents.
We believe that our know-how and trade secrets represent de facto barriers to potential competition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
Trend Information</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a development-stage company and cannot predict with any degree of accuracy the outcome of our research and development efforts. As
such, we cannot predict with any degree of accuracy any significant trends, uncertainties or events that are reasonably likely to have
a material effect on our net loss, liquidity or capital resources, or cause financial information to not be indicative of future operating
results or financial condition. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are described
in this &#8220;Item 5. Operating and Financial Review and Prospects.&#8221;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>E. Critical Accounting Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our consolidated financial statements are prepared
in accordance with generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;). The preparation of our consolidated
financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates
on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates
under different assumptions or conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While our significant accounting policies are
described in more detail in Note 2 to our audited consolidated financial statements appearing elsewhere in this annual report on Form
20-F, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation
of our consolidated financial statements.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates in the Preparation of Financial Statements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those
estimates and such differences may have a material impact on our consolidated financial statements. As applicable to the consolidated
financial statements, the most significant estimates relate to assets acquired and liabilities assumed through business combination,
goodwill impairment, useful lives of intangible assets, deferred taxes and share-based payments. <b>&#160;&#160;</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Functional
Currency</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. dollar is the currency of the primary economic environment in which our and our subsidiaries&#8217; operations are conducted. A&#160;substantial
portion of the operational costs are denominated in U.S. dollars. Accordingly, our functional currency is the U.S. dollar (&#8220;primary
currency&#8221;).</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign currency assets and
liabilities are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date. Equity
accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the
income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the
period. Currency transaction gains and losses are presented in financial income and expenses, net.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
Combination </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We allocate the fair value of
consideration transferred in a business combination to the assets acquired, liabilities assumed, and non-controlling interests in the
acquired business based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the
business combination and are expensed as incurred. The excess of the fair value of the consideration transferred plus the fair value
of any non-controlling interest in the acquiree over the fair value of the assets acquired, liabilities assumed in the acquired business
is recorded as goodwill. The fair value of the consideration transferred may include a combination of cash, equity securities, earn out
payments and deferred payments. The allocation of the consideration transferred in certain cases may be subject to revision based on
the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative
impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. We include
the results of operations of the businesses that we have acquired in our consolidated results prospectively from the respective dates
of acquisition. We record obligations in connection with our business combinations at fair value on the acquisition date. Each reporting
period thereafter, we revalue earn-out liabilities and record the changes in their fair value in the consolidated statements of operations
and comprehensive loss. Changes in the fair value of earn-out liabilities can result from adjustments to the discount rates, our shares
price, sales and profitability targets. This fair value measurement represents Level 3 measurements, as it is based on significant inputs
not observable in the market. Significant judgment is required in determining the assumptions utilized as of the acquisition date and
for each subsequent period. Accordingly, changes in the assumptions described above could have a material impact on the our consolidated
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Marketable Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">All highly liquid investments
are classified as marketable securities and have been classified and accounted for as available-for-sale. We classify our marketable
securities as either short-term or long-term based on each instrument&#8217;s underlying contractual maturity date. Unrealized gains
and losses on marketable debt securities classified as available-for-sale are recognized in other comprehensive income/(loss).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Property
and Equipment, Net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated on a straight-line basis over the following
estimated useful lives:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers
    and electronic equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15&#8211;33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    furniture and lab equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machines
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    Improvement </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction
    in progress </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Goodwill</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill
reflects the excess of the consideration transferred plus the fair value of any non-controlling interest in the acquiree at the business
combination date over the fair values of the identifiable net assets acquired. Goodwill is an asset representing the future economic
benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
We allocate goodwill to our reporting units based on the reporting unit expected to benefit from the business combination. &#160;&#160;The
primary items that generate goodwill include the value of the synergies between the acquired companies and us and the acquired assembled
workforce, neither of which qualifies for recognition as an intangible asset. ASC 350, &#8220;Intangibles - Goodwill and other&#8221;
(&#8220;ASC 350&#8221;) requires goodwill to be tested for impairment at the reporting unit level at least annually or between annual
tests in certain circumstances and written down when impaired. ASC 350 allows an entity to first assess qualitative factors to determine
whether it is necessary to perform the two-step quantitative goodwill impairment test. If the qualitative assessment does not result
in a more likely than not indication of impairment, no further impairment testing is required. If it does result in a more likely than
not indication of impairment, the quantitative goodwill impairment test two-step impairment test is performed. Alternatively, ASC 350
permits an entity to bypass the qualitative assessment for any reporting unit and proceed directly to performing the quantitative first
step of the goodwill impairment test. The provisions of the accounting standard for goodwill allow us to first assess qualitative factors
to determine whether it is necessary to perform the next goodwill impairment quantitative test. Examples of events or circumstances that
may be indicative of impairment include but are not limited to: macroeconomic and industry conditions, overall financial performance
and adverse changes in legal, regulatory, market share and other relevant entity specific events. The carrying value of each reporting
unit is determined by assigning the assets and liabilities, including the existing goodwill, to those reporting units. When necessary,
we record charges for impairments of goodwill for the amount by which the carrying amount exceeds the fair value of these assets.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Intangible Assets, net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definite
life intangible assets are amortized using the straight-line method over their estimated period of useful life. Amortization of acquired
developed technology, trade names, customer relationships and patents are recorded under cost of revenues and selling and marketing expenses.
In addition, the remaining amortization period for the impaired asset would be reassessed and, if necessary, revised. Intangible assets
with estimable useful lives are amortized over their respective estimated useful lives to their estimated residual values and reviewed
periodically for impairment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of Long-Lived Assets</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
long-lived assets are reviewed for impairment in accordance with ASC No. 360, &#8220;Property, Plant and Equipment,&#8221; whenever events
or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The recoverability of assets to be
held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated
by such assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the
carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2021 and 2020, no impairment
triggering events were identified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal
and Other Contingencies</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are involved in claims and other legal proceedings that arise from time to time in the ordinary course of business. We record accruals
for these types of contingencies to the extent that we conclude their occurrence is probable and that the related liabilities are estimable.
When accruing these costs, we will recognize an accrual in the amount within a range of loss that is the best estimate within the range.
When no amount within the range is a better estimate than any other amount, we accrue for the minimum amount within the range. We record
anticipated recoveries under existing insurance contracts that are virtually certain of occurring at the gross amount that is expected
to be collected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
review the adequacy of the accruals on a periodic basis and may determine to alter our reserves at any time in the future if we believe
it would be appropriate to do so. As such accruals are based on management&#8217;s judgment as to the probability of losses and, where
applicable, actuarially determined estimates, accruals may materially differ from actual verdicts, settlements or other agreements made
with regards to such contingencies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue Recognition </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The majority of our revenues
are derived from our teleradiology services fees received from various payors based on established billing rates. Revenues are derived
directly from hospitals and healthcare providers. We recognize revenue in the period in which the performance obligation is satisfied.
We record the amount of revenue that reflects the consideration that we expect to receive in exchange for those services. We apply the
following five-step model in order to determine this amount: (i)&#160;identification of the contract with a customer; (ii)&#160;identification
of the promised services in the contract and determination of whether they represent performance obligations, including whether they
are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) we satisfy
each performance obligation. We record deferred revenue for any upfront payments received in advance of our performance obligations being
satisfied. These contract liabilities consist principally of unearned teleradiology service fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses are charged
to the statement of operations as incurred and consist primarily of personnel, materials and supplies for research and development activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Income Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%; font-size: 10pt">&#160;</td>
    <td style="width: 3%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td>
    <td style="width: 94%; text-align: left; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    account for income taxes in accordance with ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC&#160;740&#8221;). ASC 740 prescribes
    the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between
    the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be
    in effect when the differences are expected to reverse. We provide a valuation allowance, if necessary, to reduce deferred tax assets
    to their estimated realizable value if it is more likely than not that a portion or all of the deferred tax assets will not be realized,
    based on the weight of available positive and negative evidence. Deferred tax liabilities and assets are classified as non-current
    in accordance with ASU&#160;2015-17.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td>
    <td style="width: 92%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes that
    would apply in the event of disposal of investments in foreign subsidiaries have not been taken into account in computing the deferred
    income taxes, as it is our intent and ability to hold these investments.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td>
    <td style="width: 92%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We account
    for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain
    tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the
    weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position
    will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the
    tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement.
    We accrue interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%; text-align: left">&#160;</td>
    <td style="width: 4%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td>
    <td style="width: 92%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowances
    are provided unless it is more likely than not that the deferred tax asset will be realized. In the determination of the appropriate
    valuation allowances, we consider future reversals of existing taxable temporary differences, the most recent projections of future
    business results, prior earnings history, carryback and carry forward and prudent tax strategies that may enhance the likelihood
    of realization of a deferred tax asset. Assessments for the realization of deferred tax assets made at a given balance sheet date
    are subject to change in the future, particularly if earnings of a subsidiary are significantly higher or lower than expected, or
    if we take operational or tax positions that could impact the future taxable earnings of a subsidiary.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share-Based
Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
measure and recognize share-based compensation expense in our consolidated financial statements based on the grant date fair value for
all share-based payment awards made to non-employees, employees, officers and directors. We recognize the grant date fair value of the
award as an expense based on the straight-line method over the requisite service periods in our consolidated statements of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimated the grant date fair value of share options for the years ended December 31, 2021, 2020 and 2019 using the Black-Scholes option-pricing
model. Our use of the Black-Scholes option-pricing model requires the input of highly subjective assumptions, including estimated fair
value of our ordinary share price, expected share price volatility and expected term.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
    Fair Value of Share Price. Because our shares were not publicly traded prior to our initial public offering, we estimated the fair
    value of options granted to non-employees, employees, officers and directors at the date of grant using a number of objective and
    subjective factors consistent with the methodologies outlined in the American Institute of Certified Public Accountants Practice
    Aid, Valuation of Privately-Held-Companies Equity Securities Issued as Compensation, and based on independent third-party valuations
    that we obtained on a periodic basis. Following our initial public offering, our ordinary shares are publicly traded, and therefore
    we currently base the value of our ordinary shares on their market price.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free
    Interest Rate. We base the risk-free interest rate on the implied yield on currently available U.S. treasury bonds with a remaining
    term equal to the expected life of our options.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    Yield. We base dividend yield on our historical experience and expectation of no future dividend payouts. We have historically not
    paid cash dividends and have no foreseeable plans to pay cash dividends in the future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Volatility. We base expected share price volatility on the historical volatility of the ordinary shares of comparable companies that
    are publicly traded.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    Term. The expected term of options granted represents the period of time that options granted are expected to be outstanding. As
    we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected
    term was determined using the simplified method, which takes into consideration the option&#8217;s contractual life and the vesting
    periods.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
changes in these highly subjective assumptions would significantly impact our share-based compensation expense.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Measurement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements,
the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three
broad levels, which are described as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value
hierarchy gives the highest priority to Level 1 inputs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level
3 inputs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable
inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules
and regulations of the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
                                            6.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors,
                                            Senior Management and Employees</b></span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
Directors and Senior Management</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning our executive officers and directors, including their ages, as of April 1, 2022:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
    Officers</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ran
    Poliakine </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founder,
    Chairman of the Board</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez
    Meltzer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ran
    Daniel</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Dara </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Manager Source &amp; Services Division</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ofir
    Koren </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Manager Nanox.ARC Division</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pini
    Ben Elazar</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Manager Nanox AI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tamar
    Aharon Cohen </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Marketing Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guy
    Yoskovitz</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Clinical Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gali
    Yahav Attias</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    of Staff </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anat
    Kaphan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Innovation Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orit
    Wimpfheimer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer and Vice President Product Nanox AI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee
    Directors</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Floyd
    Katske </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard
    Stone </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noga
    Kainan </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    Suesskind </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez
    Alroy </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Officers</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Erez
Meltzer</b> has served as a member of our board of directors since December 2019 and in January 2022, assumed the role of our Chief Executive
Officer. Mr.&#160;Meltzer served as the Executive Chairman of the board of directors of Hadassah Medical and University Center from 2014
to 2020. Since 2008, Mr.&#160;Meltzer has served as a teaching professor at the Tel Aviv Faculty of Medicine in the area of crisis management.
Mr. Meltzer served as Executive Vice Chairman and Chief Executive Officer of Gadot Chemicals &amp; Shipping Group from 2008 to 2013.
Prior to that, Mr. Meltzer served as Chief Executive Officer of Africa-Israel Ltd from 2006 to 2008 and President and Chief Executive
Officer of Netafim Ltd from 2001 to 2006. Mr.&#160;Meltzer also served as Chief Executive Officer of Creo Scitex from 1996 to 2001. Mr.
Meltzer serves as a director of Turpaz Industries Ltd (TASE), Eltek Ltd. (NASDAQ) and Hadasit Bio Holdings Ltd. (TASE) as well as of
a number of private companies.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Ran Daniel</b> has served as our Chief Financial
Officer since August 2021. Mr.&#160;Daniel has extensive experience working as a chief financial officer in both rapidly growing companies
and publicly traded companies. Mr.&#160;Daniel served as the chief financial officer of the IDH Group from 2012 until 2014, the chief
financial officer of Elie Tahari family office from 2014 to 2016, the chief financial officer of Blue Sphere Corporation from 2016 to
2018 and Chief Financial Officer at Cuentas from 2018 to present. Mr. Daniel is licensed as a Certified Public Accountant in the United
States and Israel, Chartered Financial Analyst (CFA) and is admitted to practice law in the State of New York. Mr. Daniel holds a Bachelor
of Economics, a Bachelor of Accounting and an MBA in Finance from the Hebrew University of Jerusalem, as well as a Graduate Degree in
Law from the University of Bar-Ilan.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>James
Dara</b> has served as our General Manager Source &amp; Services Division since January 2022, after having served as our Chief Operating
Officer beginning in January 2021. Prior to joining us, Mr.&#160;Dara served as President of myCharge from 2012 to 2020. Prior to myCharge,
Mr.&#160;Dara served as Vice President of Business Development for Powermat Technologies Ltd. from 2009 to 2014 and as Interim CEO and
Vice President of Business Development of Wellsense Technologies Ltd. from 2009 to 2015. From 2003 to 2009, Mr.&#160;Dara served as Chief
Sales Officer, Senior Vice President and General Manager of North America for Braintech Inc. In addition, from 1998 to 2002, Mr.&#160;Dara
served as a Sales Manager and Sales Engineer for ITW Shakeproof Group. Mr.&#160;Dara received his Bachelor of Science degree in Mechanical
Engineering from Michigan State University, and his Master&#8217;s degree in Finance from Walsh University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ofir
Koren </b>has served as our General Manager Nanox.ARC Division since January 2022, after having served as our Chief Technology Officer
beginning in January 2021. Prior to joining us, Mr.&#160;Koren served as General Manager Israel and Vice President of Research &amp;
Development and Regulatory at ReWalk Robotics from 2013 to 2021. From 2012 to 2013, Mr.&#160;Koren served as Research &amp; Development
Manager for ReWalk Robotics. Prior to ReWalk Robotics, Mr.&#160;Koren served as General Manager at RuggedCOM from 2009 to 2012. From
2007 to 2009, Mr.&#160;Koren served as Vice President of Research &amp; Development at Alvarion. Mr.&#160;Koren served as Research &amp;
Development Director at Alvarion from 2004 to 2007. Mr.&#160;Koren received his Bachelor of Science degree in Electrical Engineering
from Tel Aviv University, and he holds an M.B.A. degree from Heriot-Watt University.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Tamar Aharon Cohen</b> has served as our Chief
Marketing Officer since January 2021. Prior to joining us, Ms.&#160;Aharon Cohen served as the Chief Executive Officer of Tempo Beverages
Cyprus Ltd. from 2017 to 2021. Ms.&#160;Aharon Cohen served as a Marketing Manager and a Division Manager at Tempo Beverages Ltd. from
2010 to 2017. From 2006 to 2010, Ms.&#160;Aharon Cohen served as a Marketing Manager for L&#8217;Or&#233;al Israel. Ms.&#160;Aharon
Cohen holds a LLB degree, a B.A. degree in Management and an executive M.B.A. degree, all from Tel Aviv University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Guy Yoskovitz</b> has served as our Chief Clinical
Officer since January 2022. Prior to that, Dr. Yoskovitz served as our VP Clinical Innovation, reporting to the Chief Product Officer,
beginning in November 2019. Prior to joining the company and from 2014, Dr. Yoskovitz served as Head of International Ventures &amp; Deputy
Director of Research, Innovation and International Affairs Authority, and as a lecturer, at Holon Institute of Technology, Israel. Dr
Yoskovitz holds a PhD in Human Genetics from the Faculty of Biology, University of Barcelona; an MSc degree in Medical Sciences from the
School of Graduate Studies, The Faculty of Medicine, Tel Aviv University, Israel; and a BSc degree in Computational Biology from Bar Ilan
university, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Pini Ben Elazar</b> has served as General Manager
Nanox AI since March 2022. Mr. Ben Elazar brings 25 years of strategic and commercial expertise in the healthcare industry. Mr. Ben Elazar
previously served on the board of Zebra Medical. From 2003 to March 2022, Mr. Ben Elazar has served as Chief Executive Officer of Mor
Research Applications, a technology transfer organization of Clalit Health Services, the largest health maintenance organization in Israel
and the second-largest&#160;HMO&#160;in the world. Mr. Ben Elazar holds an MBA degree from Johnson &amp; Wales University, Providence,
RI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Gali Yahav Attias</b> has served as our Chief
of Staff since December 2022 and commencing May 2022, she is expected to also serve as Vice President Corporate Resources. Ms. Yahav
Attias first joined our company as project manager in August 2021. From 2007 to 2021, Ms. Yahav Attias served as the secretary of the
Board and the external audit committee and the compliance officer of Hadassah Medical and University Center. From 2014 to 2017, Ms. Yahav
Attias also served as the executive liaison of the government recovery agreement implementation in Hadassah Medical Center. Ms. Yahav
Attias holds a B.A. degree in Social Sciences and Humanities from the Open University of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anat
Kaphan</b> has served as our Chief Innovation Officer since January 2022, after having served as our Vice President of Product Marketing
from September 2019. Prior to joining us, Ms.&#160;Kaphan served as Vice President of Product and Marketing at Mazor Robotics Ltd. from
2015 to 2018, and General Manager at Essence Group from 2014 to 2015. She also served as Marketing Director at Phillips from 2011 to
2014. Prior to that, Ms.&#160;Kaphan served as Business Development Director at Lumenis from 2001 to 2011 and Product Manager at Elscint
Ltd. from 1991 to 2001. Ms.&#160;Kaphan holds an M.B.A. in International marketing from Tel Aviv University and received her bachelor&#8217;s
degree in Economics and Accounting from Haifa University</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Orit Wimpfheimer</b> has served as our Chief Medical Officer and Vice President Product Nanox AI since January 2022. Dr. Wimpfheimer
previously held the position of Chief Medical Officer and Head of Product Strategy at Zebra Medical Vision, until its acquisition by
the Company. Dr. Wimpfheimer is the co-founder of Remote Radiology International, with over 20 years of experience in the radiology field.
Dr Wimpfheimer received her MD degree from Albert Einstein College of Medicine and completed her diagnostic radiology residency at New
York Presbyterian Hospital in New York.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Employee
Directors</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ran
Poliakine</b>, our founder, has served as a member of our board of directors since our inception and has served as the Chairman of the
Board of Directors since the closing of our initial public offering. Mr.&#160;Poliakine served as our Chief Executive Officer from September
2019 until January 2022, and has served as Chief Executive Officer of Nanox Gibraltar from August 2018 until November 2019. Prior to
that, Mr.&#160;Poliakine served as Chief Strategy Officer of Nanox Gibraltar from June 2015 to August 2018. Mr.&#160;Poliakine is a serial
entrepreneur and has founded numerous companies over the past two decades, including SixAI Ltd. (&#8220;SixAI&#8221;) and its two controlled
subsidiaries 634 Ai Ltd. (&#8220;634 Ai&#8221;) and Musashi Ai Ltd., Powermat Technologies Ltd., Wellsense, Inc., Wellsense Technologies
Ltd., Tap Systems, Inc. and Illumigyn Ltd. (&#8220;Illumigyn&#8221;). Mr.&#160;Poliakine is the chief executive officer and a member
of the board of directors of SixAI, the chairman of the board of directors and a senior advisor to Illumigyn, and a member of the board
of directors of Powermat Technologies Ltd., 634 Ai and CLKIM Ltd.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Floyd Katske</b> has served as a member of our board of directors since February 2020.&#160;Dr.
Katske is a&#160;urologic&#160;surgeon&#160;who graduated&#160;with honors from the George Washington University School of Medicine&#160;and
then&#160;trained in urology at the University of California, Los Angeles.&#160;Dr. Katske served as the&#160;Chief&#160;of&#160;Urology&#160;at
the UCLA/OliveView&#160;Medical Center and the Chief of Surgery and Chief of Staff at the Henry Mayo Newhall Hospital in Los Angeles.&#160;&#160;In
1997,&#160;Dr. Katskewas&#160;elected&#160;the&#160;President of the California&#160;Urological Association&#160;- the largest such professional
organization in the United States.&#160;Dr Katske&#160;has published more than 60 academic papers on various fields of surgery and urology.&#160;Dr.
Katske currently sits on the Board of Directors of Triurol Inc,&#160;and is the President of the Hutton Family Foundation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Richard
Stone</b> has served as a member of our board of directors since November 2019. Professor Stone has taught at Columbia University Law
School since 1974, and became Professor Emeritus in 2018. Professor Stone has taught courses in several fields of business law, specializing
in federal income taxation. From 1969 to 1973, Professor Stone served in the United States Justice Department as Assistant to the Solicitor
General of the United States. Beginning in 1981, Professor Stone began providing consulting to private and public technology start-ups,
primarily in the biotechnology field. Professor Stone co-founded several biotechnology companies, including Lev Pharmaceuticals, Siga
Technologies and OptMed. In 2007, Professor Stone began working primarily with Israeli technology companies, mostly in the medical space.
Professor Stone is a member of the board of directors of OptMed, Inc., Espro Information Technologies, Quality In Flow, LabStyle Innovations
and Illumigyn. Professor Stone received his bachelor&#8217;s degree, Magna Cum Laude, from Harvard College, and his Juris Doctor degree,
Magna Cum Laude, from Harvard Law School.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Noga Kainan</b> has served as a member of our
board of directors since February 2021.&#160;Ms. Kainan established in 2008 the forum for owners, chairpersons and CEOs of the leading
companies in the Israeli economy. Ms. Kainan also serves as chairperson of the CFO Forum, which brings together the CFOs of the leading
companies in the economy, since she established it in 1997. Ms. Kainan&#8217;s public activities include membership in committees in the
Israeli Prime Minister&#8217;s Office, member in the Board of Trustees of Bar Ilan University, the College of Management in Israel, and
the council of NGO for IDF soldiers&#8217; welfare. Ms. Kainan heads an association that she founded to promote the integration of autistic
students in academia. Ms. Kainan served as a director of the following companies traded on the Tel Aviv Stock Exchange: Bizportal Ltd.,
Poalim I.B.I &#8211; Managing &amp; Underwriting Ltd. and Analyst Provident Funds Ltd. Ms. Kainan also served as director at Oil Refineries
Ltd. before the company was listed on the Tel Aviv Stock Exchange. Ms. Kainan served as a representative at the International Association
of Financial Executives Institutes (IAFEI). Ms.&#160; Kainan, co-authored &#8220;Israel - Success Story,&#8221; translated to English
under the name: &#8220;Israel - Island of Success.&#8221; Ms. Kainan has a bachelor&#8217;s degree in art and literature from Haifa University
and an M.B.A. degree from Tel Aviv University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Dan Suesskind</b> has served as a member of
our board of directors since February 2021. Mr. Suesskind served as the Chief Financial Officer of Teva Pharmaceutical Industries Ltd.
(&#8220;Teva&#8221;) from 1977 to 2008 and as a director of Teva for several periods of time until 2018. Mr. Suesskind also served as
a director of the following companies: Israel Corporation Ltd., Redhill Biopharma Ltd., Syneron Medical Ltd., Migdal Ltd., Ness Technologies
Inc., The First International Bank of Israel, First International Selective Investment &#8211; Portfolio Management Company Ltd., LanOptics
Ltd., ESC Medical Systems and the Hadassah Medical Center in Jerusalem. Mr. Suesskind is currently a director of Nextar Chempharma Solutions
Ltd., Sanotize Research and Development Corp., Imed Infinity Medical Limited partnership (TASE) and The Jerusalem Foundation. Mr. Suesskind&#8217;s
public activities include membership in the Investment Committee of the Israeli Academy of Sciences and Humanities, the Ben Gurion University
and the Jerusalem Foundation. Mr. Suesskind is a member of the Board of Trustees of the Hebrew University of Jerusalem and of the Board
of Trustees of the Ben Gurion University. Mr. Suesskind has a bachelor&#8217;s degree in economics and political science from the Hebrew
University of Jerusalem and an M.B.A. degree from the University of Massachusetts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Erez
Alroy</b> was appointed by our board of directors to serve as a member of our board of directors as of March 31, 2022. From 2014 and
until 2020, Mr. Alroy was a major shareholder and the chairman of Migvan Engineering and Technology. For almost 20 years, Mr. Alroy held
various positions in the Shahal group, including 15 years as chief executive officer of SHL Telemedicine (SIX: SHLTN). Currently Mr.
Alroy is a private investor and holds several board positions, including SHL Telemedicine Ltd. and Merhavia Holdings and Investments
Ltd. (TASE), an investment firm that invests mainly in life science and healthcare companies. Mr. Alroy holds an MBA degree from the
Hebrew University of Jerusalem.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Compensation</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
of Executive Officers and Directors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies,
including the requirement applicable to emerging growth companies to disclose the compensation of our chief executive officer and other
two most highly compensated executive officers on an individual, rather than an aggregate, basis. The aggregate compensation, including
share-based compensation, paid or expensed by us to our executive officers and directors for the year ended December&#160;31, 2021 was
approximately $9.2&#160;million. In addition, approximately $0.3 million in the aggregate was set aside or accrued to provide pension,
severance, retirement or similar benefits or expenses. This amount does not include business travel, relocation, professional and business
association dues, meals and expenses reimbursed to officers, and other benefits commonly reimbursed or paid by companies in Israel, on
the same basis for all full-time employees generally.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the salary expenses and social benefit costs of our five most highly compensated office holders (as defined in
the Companies Law) during or with respect to the year ended December&#160;31, 2021. We refer to the five individuals for whom disclosure
is provided herein as our &#8220;Covered Executives.&#8221; For purposes of the table and the summary below, &#8220;compensation&#8221;
includes base salary, bonuses, equity-based compensation, retirement or termination payments, and any benefits or perquisites such as
car, phone and social benefits, as well as any undertaking to provide such compensation in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="18" style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Information
                                            Regarding the Covered Executive(1)</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    and Principal Position(2)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base<br/>
    Salary</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits
    and<br/> Perquisites&#160;(3)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Variable<br/>
    Compensation&#160;(4)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity-Based<br/>
    Compensation&#160;(5)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ran
    Poliakine, Chairman of the Board and Former Chief Executive Officer(6)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">720,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">237,600</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">180,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,238,872</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,376,472</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ofir
    Koren Head of the Nanox.ARC Division</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">279,372</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92,193</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,836</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">567,763</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">960,164</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Dara, Head of Source and Services Division</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">230,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,897</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">567,763</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">904,661</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itzhak
    Maayan, Former Chief Financial Officer(7)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">221,850</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,211</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49,536</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">575,287</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">919,884</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tamar
    Aharon Cohen, Chief Marketing Officer</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">214,353</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,736</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">187,490</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">488,193</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,665,575</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">508,637</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">388,706</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,137,176</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,650,094</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 3pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    accordance with Israeli law, all amounts reported in the table are in terms of cost to our Company, as recorded in our financial
    statements for the year ended December&#160;31, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash compensation amounts denominated in currencies other than the U.S. dollar were converted into U.S. dollars at the average conversion rate for the year ended December&#160;31, 2021.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reported in this column include benefits and perquisites, including those mandated by applicable law. Such benefits and perquisites
    may include, to the extent applicable to each executive, payments, contributions and/or allocations for pension, severance, vacation,
    car or car allowance, convalescence pay, payments for social security, tax gross-up payments and other benefits and perquisites consistent
    with our guidelines, regardless of whether such amounts have actually been paid to the executive. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reported in this column refer to Variable Compensation such as incentives and earned or paid bonuses as recorded in our financial
    statements for the year ended December&#160;31, 2021. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    reported in this column represent the expense recorded in our financial statements for the year ended December&#160;31, 2021 with
    respect to equity-based compensation, reflecting also equity awards made in previous years which have vested during the current year.
    Assumptions and key variables used in the calculation of such amounts are described in Note 12 to our audited consolidated financial
    statements, which are included in this annual report. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ran
    Poliakine ceased to serve as our Chief Executive Officer on December 31, 2021, although his formal notice period ends on June 30,
    2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Itzhak
    Maayan ceased to serve as our Chief Financial Officer in October 2021.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
pay each of our non-employee directors a cash fee of $36,000 per year plus an additional annual fee for service on a board committee
of $7,500 per each committee (or $15,000 for the chairperson of a committee). In addition, according to our Compensation Policy, our
non-employee directors receive, upon appointment or election to the board of directors, options to purchase our ordinary shares with
an economic value at the date of grant of $580,723, vesting quarterly over a period of four years, with full acceleration upon consummation
of an M&amp;A Transaction (as defined in our 2019 Equity Incentive Plan).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
as of January 1, 2021, we appointed Erez Meltzer as a &#8220;Designated Director,&#8221; as defined in and pursuant to our Compensation
Policy, and paid him additional compensation in such capacity, consisting of cash compensation of $80,000 per year and $200,000 in equity-based
compensation per year in the form of RSUs to be granted in four equal quarterly installments, calculated according to the fair market
value of our ordinary shares on the last trading day of each such quarter. Mr. Meltzer ceased to serve as a Designated Director on December
31, 2021, effective as of his appointment as our Chief Executive Officer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directorship
Agreements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into directorship agreements with each of our directors, pursuant to which such directors serve on our board of directors.
Pursuant to these agreements, each director was granted options under our 2019 Equity Incentive Plan. For information regarding the beneficial
ownership of our ordinary shares by our directors, see &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;A. Major
Shareholders.&#8221; .</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
Agreements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into written employment agreements with all of our executive officers. These agreements provide for notice periods of varying
duration for termination of the agreement by us or by the relevant executive officer, during which time the executive officer will continue
to receive base salary and benefits. These agreements also contain customary provisions regarding non-competition, confidentiality of
information and assignment of inventions. However, the enforceability of the non-competition provisions may be limited under applicable
law. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to Employee Matters&#8212;Under applicable employment
laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefitting
from the expertise of some of our former employees&#8221; for a further description of the enforceability of non-competition clauses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Ran Poliakine, our founder, a director and our former Chief Executive Officer. Pursuant to
the agreement, if the Company terminates Ran Poliakine&#8217;s employment and waives his obligation to perform services during the notice
period of 180 days, Ran Poliakine will be entitled to receive payments of his base salary and social benefits in lieu of notice for the
waived period, up to the full notice period for an immediate termination. The agreement provided Ran Poliakine with a gross monthly base
salary equal to $40,000 which was increased to $60,000 upon the consummation of our initial public offering in August 2000. Mr. Poliakine
resigned from his position as Chief Executive Officer effective as of January 1, 2022 and his employment will terminate after the 180
days&#8217; notice period. Mr. Poliakine continues to serve as chairman of our board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Mr. Meltzer, who has served as a director since December 2019, in connection with his appointment
as our Chief Executive Officer, effective as of January 1, 2022. Under the agreement, Mr. Meltzer is entitled to a gross annual salary
of US$900,000. In addition, Mr. Meltzer is entitled to an annual bonus (discretionary and based on measurable criteria) of US$900,000,
with a guaranteed bonus of at least US$450,000 for the 2022 fiscal year if his employment is continued through the entire fiscal year,
with the possibility to withdraw an advance payment on account of the 2022 annual bonus, subject to full recourse (clawback) if the bonus
is not earned. Under the agreement, we and Mr. Meltzer is required to provide six months&#8217; prior notice of employment termination
and we are required to provide 270 days&#8217; notice if we terminate the employment during the first year of employment (except for
&#8220;Cause&#8221; as defined in his employment agreement, in which case no prior notice will be required). If we terminate Mr. Meltzer&#8217;s
employment and waive his obligation to perform services during the notice period, Mr. Meltzer will be entitled to receive payments of
his base salary, social benefits and a company car in lieu of notice for the waived period, up to the full notice period for an immediate
termination. In connection with his appointment as our Chief Executive Officer, we granted Mr. Meltzer options to purchase 300,000 ordinary
shares at an exercise price of US$23.84 under our 2019 Equity Incentive Plan, which vest equally on a quarterly basis over 16 quarters
commencing effective as of January 1, 2022, subject to the continuous engagement by us at each vesting date. These options will have
full acceleration in case of consummation of a Deemed Liquidation (as such term is defined under our 2019 Equity Incentive Plan). &#160;The
above equity compensation is in addition to Mr. Meltzer&#8217;s equity compensation as a director. Mr. Meltzer does not receive additional
cash compensation as a director.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
Incentive Plan</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 3, 2019, we adopted the 2019 Equity Incentive Plan and its U.S. sub-Plan (the &#8220;2019 Equity Incentive Plan&#8221; or &#8220;Plan&#8221;).
The 2019 Equity Incentive Plan is intended to afford an incentive to any of our and our affiliates&#8217; employees, directors, officers,
consultants, advisors and any other person or entity who provides services to us, to continue as service providers, to increase their
efforts on our and our affiliates&#8217; behalf and to promote our success, by providing such persons with opportunities to acquire a
proprietary interest in us. The U.S. sub-Plan applies to our and any of our affiliates&#8217; employees, directors, officers, consultants,
advisors and any other person or entity who provides services to us who are subject to United States federal income tax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue under the 2019 Equity Incentive Plan and its U.S. sub-Plan up to 8,041,936 of our ordinary shares, subject to adjustment if
particular capital changes affect our share capital or such other number as our board of directors may determine from time to time. Ordinary
shares subject to outstanding awards under the 2019 Equity Incentive Plan and its U.S. sub-Plan that subsequently expire, or are cancelled,
forfeited or terminated for any reason before being exercised will be automatically, and without any further action, returned to the
share reserve under the Plan and will again be available for grant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>During the year ended December
31, 2021, our directors and officers were granted</span> a total of options to purchase an aggregate of 320,510 ordinary shares, with
a weighted average exercise price of $45.81 per share, and 7,917 RSUs under our 2019 Equity Incentive Plan. <span>As
of December 31, 2021, options to purchase 1,247,852 ordinary shares granted to our executive officers and directors under our 2019 Equity
Incentive Plan, at a weighted average exercise price of $13.85, and 2,953 RSUs granted under the 2019 Equity Incentive Plan, were outstanding.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a description of our compensation policy, see &#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;Compensation
Committee.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
Board Practices</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
of Directors</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors currently consists of&#8201;seven directors. Four of our directors qualify as independent directors under the corporate
governance standards of the Nasdaq corporate governance rules and the independence requirements of Rule&#160;10A-3 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our amended and restated articles of association, the number of directors on our board of directors will be no less than five and no
more than ten. The minimum and maximum number of directors may be changed, at any time and from time to time, by vote of our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are divided into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible, of
one-third of the total number of directors constituting the entire board of directors. At each annual general meeting of our shareholders,
the election or re-election of directors following the expiration of the term of office of the directors of that class of directors will
be for a term of office that expires on the third annual general meeting following such election or re-election, such that from 2021
and after, at each annual general meeting, the term of office of only one class of directors will expire. Each director holds office
until the third annual general meeting of our shareholders and until his or her successor is duly appointed, unless the tenure of such
director expires earlier pursuant to the Companies Law or unless removed from office as described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are divided among three classes as follows: the Class&#160;I directors, consisting of Erez Meltzer and Richard Stone, will
hold office until our annual general meeting of shareholders to be held in 2024; the Class&#160;II directors, consisting of Erez Alroy,
Floyd Katske and Noga Kainan, will hold office until our annual general meeting of shareholders to be held in 2022; and the Class&#160;III
directors, consisting of Ran Poliakine and Dan Suesskind, will hold office until our annual general meeting of shareholders to be held
in 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the directors shall be elected by a vote of the holders of a majority of the voting power present and voting at that meeting (excluding
abstentions). Each director will hold office until the annual general meeting of our shareholders for the year in which his or her term
expires, unless the tenure of such director expires earlier pursuant to the Companies Law or unless he or she is removed from office.
Under our amended and restated articles of association, the approval of the holders of at least sixty-six and two-thirds percent or more
of the votes cast by those shareholders voting in person or by proxy (including by voting deed) is required to remove any of our directors
from office (excluding abstentions).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
our amended and restated articles of association, our board of directors may appoint directors to fill vacancies on our board of directors,
including if the number of directors is below the maximum number of directors who may serve as provided in our amended and restated articles,
for a term of office equal to the remaining period of the term of office of the director(s) whose office(s) has been vacated, or in case
of a vacancy due to the number of directors serving being less than the maximum number stated in our amended and restated articles, the
board of directors shall determine at the time of appointment the class to which the additional director shall be assigned.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Israeli law, the chief executive officer or a relative of the chief executive officer of a public company may not serve as the chairman
of the board of directors of the company and the chairman or a relative of the chairman may not be vested with the authority of the chief
executive officer, in each case, unless approved by a special majority of our shareholders as required under the Companies Law. The shareholders&#8217;
approval can be provided for a period of five years following an initial public offering, and subsequently, for additional periods of
up to three years. In addition, a person who is subordinated, directly or indirectly, to the chief executive officer may not serve as
the chairman of the board of directors; the chairman of the board of directors may not be vested with authorities that are granted to
persons who are subordinated to the chief executive officer; and the chairman of the board of directors may not serve in any other position
in the company or in a controlled subsidiary, but he or she may serve as a director or chairman of a controlled subsidiary. Prior to
our initial public offering, we obtained our shareholders&#8217; approval that Mr.&#160;Ran Poliakine may serve as both our chairman
of the board of directors and chief executive officer for a period of up to five years from the closing of our initial public offering.
Mr. Poliakine retired from the position of Chief Executive Officer effective as of January 2022 and continues to serve as chairman of
our board of directors.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Companies Law, our board of directors must determine the minimum number of directors who are required to have financial
and accounting expertise. Under applicable regulations, a director with financial and accounting expertise is a director who, by reason
of his or her education, professional experience and skill, has a high level of proficiency in and understanding of business accounting
matters and financial statements. He or she must be able to thoroughly comprehend the financial statements of the company and initiate
debate regarding the manner in which financial information is presented. In determining the number of directors required to have such
expertise, the board of directors must consider, among other things, the type and size of the company and the scope and complexity of
its operations. Our board of directors has determined that we require at least one director with the requisite financial and accounting
expertise and that Erez Meltzer has such expertise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our office holders (including directors).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External
Directors</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, companies incorporated under the laws of the State of Israel, whose shares are publicly traded, including companies
with shares listed on the Nasdaq, are required to appoint at least two external directors within three months of the closing of the initial
public offering. While we exceeded the three-month period, our shareholders approved the appointment of two external directors, Noga
Kainan and Dan Suesskind as external directors in February 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
pursuant to regulations promulgated under the Companies Law, companies with shares traded on certain U.S. stock exchanges, including
the Nasdaq Global Market, may, subject to certain conditions, &#8220;opt out&#8221; from the Companies Law requirements to appoint external
directors and related Companies Law rules concerning the composition of the audit committee and compensation committee of the board of
directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 28, 2022, in accordance with these regulations, our board of directors elected to &#8220;opt out&#8221; from the Companies Law
requirement to appoint external directors and related Companies Law rules concerning the composition of the audit committee and
compensation committee of the board of directors, effective as of March 31, 2022. Under these regulations, the exemptions from such
Companies Law requirements will continue to be available to us so long as: (i) we do not have a &#8220;controlling
shareholder&#8221; (as such term is defined under the Companies Law), (ii) our shares are traded on certain U.S. stock exchanges,
including the Nasdaq Global Market, and (iii) we comply with the director independence requirements and the audit committee and
compensation committee composition requirements under U.S. laws (including applicable Nasdaq rules) applicable to U.S. domestic
issuers. Our directors who were previously designated as external directors, Noga Kainan and Dan Suesskind shall continue to serve
to serve as &#8220;ordinary&#8221; (non-external) directors, as Class II and Class III directors, respectively, until the end of the
term of their respective class.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
Committee</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Companies
Law Requirements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with regulations promulgated under the Companies Law described above, on March 28, 2022, our board of directors elected to
&#8220;opt out&#8221; from the Companies Law requirement to appoint external directors and related rules concerning the composition of
the audit committee and compensation committee, effective as of March 31, 2022. Under such exemption, among other things, the composition
of our audit committee must comply with the requirements of SEC and Nasdaq rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nasdaq
Listing Requirements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Nasdaq corporate governance rules, we are required to maintain an audit committee consisting of at least three independent directors,
all of whom are financially literate, none of whom has participated in the preparation of our or any of our subsidiary&#8217;s financial
statements at any time during the prior three years and one of whom has accounting or related financial management expertise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with U.S. law and Nasdaq requirements, our audit committee is responsible for the appointment, compensation and oversight
of the work of our independent auditors and for assisting our board of directors in monitoring our financial statements, the effectiveness
of our internal controls and our compliance with legal and regulatory requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee consists of Noga Kainan, Dan Suesskind and Richard Stone. Noga Kainan serves as chairperson of the audit committee. Our
board of directors has determined, in its business judgment, that Noga Kainan is an audit committee financial expert as defined by the
SEC rules and has the requisite financial experience as defined by the Nasdaq corporate governance rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the members of the audit committee is required to be &#8220;independent&#8221; as such term is defined in Rule&#160;10A-3(b)(1) under
the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
Committee Role</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted an audit committee charter setting forth the responsibilities of the audit committee consistent with the
rules of the SEC and the Nasdaq corporate governance rules, as well as the requirements for such committee under the Companies Law, which
include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            the retention and termination of our independent registered public accounting firm to the
                                            board of directors in accordance with Israeli law;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            to the board of directors in accordance with Israeli law the appointment, compensation, retention
                                            and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit
                                            report or performing other audit services;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            the terms of audit and non-audit services to be provided by the independent registered public
                                            accounting firm for pre-approval by our board of directors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            the engagement or termination of the person filling the office of our internal auditor;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            with management and our independent directors our financial statements prior to their submission
                                            to the SEC; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                            of certain transactions with office holders and controlling shareholders, as described below,
                                            and other related party transactions.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, under the Companies Law, the role
of the audit committee includes the identification of irregularities in our business management, among other things, by consulting with
the internal auditor or our independent auditors and suggesting an appropriate course of action to the board of directors. The audit
committee is also required to adopt procedures with respect to processing of employees&#8217; complaints in connection with deficiencies
in the management of the company, and the appropriate means of protection afforded to such employees. In addition, the audit committee
or the board of directors, as set forth in the articles of association of the company, is required to approve the yearly or periodic
work plan proposed by the internal auditor, and where the board of directors approves such work plan, to examine such work plan before
its submission to the board of directors and propose amendments thereto. The audit committee is required to assess the company&#8217;s
internal audit system and the performance of its internal auditor. The Companies Law also requires that the audit committee assess the
scope of the work and compensation of the company&#8217;s external auditor. In addition, the audit committee is required to determine
whether certain related party actions and transactions are &#8220;material&#8221; or &#8220;extraordinary&#8221; for the purpose of the
requisite approval procedures under the Companies Law and whether certain transactions with a controlling shareholder will be subject
to a competitive procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The audit committee charter states that in fulfilling
its role the committee is empowered to conduct or authorize investigations into any matters within its scope of responsibilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Approval of Transactions with Related Parties</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The approval of the audit committee is required
to effect specified actions and transactions with office holders and controlling shareholders and their relatives, or in which they have
a personal interest. The audit committee may not approve an action or a transaction with a controlling shareholder or with an office holder
unless, among other things, at the time of approval the audit committee meets the composition requirements under the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Companies Law requires that an office holder
promptly disclose to the board of directors any personal interest that he or she may have, and all related material information known
to him or her concerning any existing or proposed transaction with the company. A personal interest includes an interest of any person
in an act or transaction of a company, including a personal interest of one&#8217;s relative or of a corporate body in which such person
or a relative of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appoint
at least one director or the general manager, but excluding a personal interest stemming solely from one&#8217;s ownership of shares in
the company. A personal interest includes the personal interest of a person for whom the office holder holds a voting proxy or the personal
interest of the office holder with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such shareholder
has no personal interest in the matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If it is determined that an office holder has a
personal interest in a non-extraordinary transaction, meaning any transaction that is in the ordinary course of business, on market terms
or that is not likely to have a material impact on the company&#8217;s profitability, assets or liabilities, approval by the board of
directors is required for the transaction, unless the company&#8217;s articles of association provide for a different method of approval.
Any such transaction that is adverse to the company&#8217;s interests may not be approved by the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Approval first by the company&#8217;s audit
committee and subsequently by the board of directors is required for an extraordinary transaction (meaning, any transaction that is not
in the ordinary course of business, not on market terms or that is likely to have a material impact on the company&#8217;s profitability,
assets or liabilities) in which an office holder has a personal interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A director and any other office holder who has
a personal interest in a transaction which is considered at a meeting of the board of directors or the audit committee may generally (unless
it is with respect to a transaction which is not an extraordinary transaction) not be present at such a meeting or vote on that matter
unless a majority of the directors or members of the audit committee, as applicable, have a personal interest in the matter. If a majority
of the members of the audit committee or the board of directors have a personal interest in the approval of such a transaction then all
of the directors may participate in deliberations of the audit committee or board of directors, as applicable, with respect to such transaction
and vote on the approval thereof and, in such case, shareholder approval is also required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Certain disclosure and approval requirements apply
under Israeli law to certain transactions with controlling shareholders, certain transactions in which a controlling shareholder has a
personal interest and certain arrangements regarding the terms of service or employment of a controlling shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Compensation Committee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with regulations promulgated under
the Companies Law described above, on March 28, 2022, our board of directors elected to &#8220;opt out&#8221; from the Companies Law requirement
to appoint external directors and related rules concerning the composition of the audit committee and compensation committee, effective
as of March 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Nasdaq corporate governance rules, we
are required to maintain a compensation committee consisting of at least two directors, each of whom is an independent director within
the meaning of the Nasdaq corporate governance rules. Our compensation committee currently complies with the provisions of Nasdaq corporate
governance rules relating to composition requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The compensation committee consists of Dan Suesskind,
Noga Kainan and Erez Alroy, and assists the board of directors in determining compensation for our directors and officers. Dan Suesskind
serves as chairperson of the compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><i>Compensation Committee Role</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with the Companies Law, the roles
of the compensation committee are, among others, as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>to recommend to the board of directors the compensation policy for
                                            directors and officers, and, once every three years, or five years from a company&#8217;s
                                            initial public offering, to recommend to the board of directors, whether the compensation
                                            policy that had been approved should be extended for a longer period of time;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>to recommend to the board of directors updates to the compensation
                                            policy, from time to time, and examine its implementation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>to decide whether to approve the terms of office and employment of
                                            directors and officers that require approval of the compensation committee; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td>to decide whether the compensation terms of the chief executive officer,
                                            which were determined pursuant to the compensation policy, will be exempted from approval
                                            by the shareholders because such approval would harm the ability to engage the chief executive
                                            officer.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the roles mentioned above, our
compensation committee may also make recommendations to our board of directors regarding the awarding of employee equity grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Compensation Policy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In general, under the Companies Law, a public
company must have a compensation policy approved by the board of directors after receiving and considering the recommendations of the
compensation committee. In addition, the compensation policy requires the approval of the general meeting of the shareholders. In public
companies such as our company, shareholder approval by a majority vote of the ordinary shares present and voting at a meeting of shareholders
called for such purpose is required, provided that either: (i)&#160;such majority includes the majority of the votes of those shareholders
who are non-controlling shareholders and shareholders who do not have a personal interest in the approval of the compensation policy,
who voted at the meeting (excluding abstentions) or (ii)&#160;the total number of votes against the proposal among the shareholders mentioned
in clause (i)&#160;does exceed 2% of the voting rights in the company. Under special circumstances, the board of directors may approve
the compensation policy despite the objection of the shareholders on the condition that the compensation committee and then the board
of directors decide, on the basis of detailed arguments and after discussing again the compensation policy, that approval of the compensation
policy, despite the objection of the meeting of shareholders, is in the best interests of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">However, if a company initially offering its securities
to the public, adopts a compensation policy in advance of its initial public offering, and describes the compensation policy in the prospectus
relating to the offering, or adopts a compensation policy within nine months from the date the company becomes a public company, then
the compensation policy is deemed a validly adopted policy in accordance with the Companies Law requirements described above and will
be valid for a term of five years from the date such company becomes a public company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The compensation policy must be based on certain
considerations, include certain provisions and needs to reference certain matters as set forth in the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The compensation policy must serve as the basis
for decisions concerning the financial terms of employment or engagement of office holders, including exculpation, insurance, indemnification
or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain
factors, including advancement of the company&#8217;s objectives, business plan and long-term strategy, and creation of appropriate incentives
for office holders. It must also consider, among other things, the company&#8217;s risk management, size and the nature of its operations.
The compensation policy must furthermore consider the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            education, skills, experience, expertise and accomplishments of the relevant office holder;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            office holder&#8217;s position, responsibilities and prior compensation agreements with him
                                            or her;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ratio between the cost of the terms of employment of an office holder and the cost of the
                                            employment of other employees of the company, including employees employed through contractors
                                            who provide services to the company, in particular the ratio between such cost, the average
                                            and median salary of the employees of the company, as well as the impact of such disparities
                                            on the work relationships in the company;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the terms of employment include variable components &#8212; the possibility of reducing variable
                                            components at the discretion of the board of directors and the possibility of setting a limit
                                            on the exercise value of non-cash variable equity-based components; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            the terms of employment include severance compensation &#8212; the term of employment or
                                            office of the office holder, the terms of his or her compensation during such period, the
                                            company&#8217;s performance during the such period, his or her individual contribution to
                                            the achievement of the company goals and the maximization of its profits and the circumstances
                                            under which the office holder is leaving the company.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation policy must also include, with regard to variable components:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            the exception of office holders who are subordinate to the chief executive officer, determining
                                            the variable components on long-term performance basis and on measurable criteria; however,
                                            the company may determine that an immaterial part of the variable components of the compensation
                                            package of an office holder shall be awarded based on non-measurable criteria, if such amount
                                            is not higher than three monthly salaries per annum while taking into account the office
                                            holder&#8217;s contribution to the company;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ratio between variable and fixed components, as well as the limit of the values of variable
                                            components at the time of their grant.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-size: 10pt">a condition under which the
office holder will return to the company, according to conditions to be set forth in the compensation policy, any amounts paid as part
of his or her terms of employment, if such amounts were paid based on information later to be discovered to be wrong, and such information
was than re-presented in the company&#8217;s financial statements;</span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-size: 10pt">the minimum holding or vesting
period of variable equity-based components, while taking into consideration long-term incentives; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-size: 10pt">a limit to retirement grants.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our compensation policy was approved by the board
of directors and the shareholders on February 9, 2021, and will be in effect for a period of five years from the date of approval. Our
compensation policy is designed to promote retention and motivation of directors and executive officers, incentivize superior individual
excellence, align the interests of our directors and executive officers with our long-term performance and provide a risk management
tool. To that end, a portion of an executive officer&#8217;s compensation package is targeted to reflect our short and long-term goals,
as well as the executive officer&#8217;s individual performance. On the other hand, our compensation policy includes measures designed
to reduce the executive officer&#8217;s incentives to take excessive risks that may harm us in the long-term, such as limits on the value
of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive
officer and minimum vesting periods for equity-based compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our compensation policy also addresses our executive
officers&#8217; individual characteristics (such as his or her respective position, education, scope of responsibilities and contribution
to the attainment of our goals) as the basis for compensation variation among our executive officers, and considers the internal ratios
between compensation of our executive officers and directors and other employees. Pursuant to our compensation policy, the compensation
that may be granted to an executive officer may include: base salary, annual bonuses and other cash bonuses (such as relocation, signing
and special bonuses) as well as change of control related bonuses, equity-based compensation, benefits and retirement and termination
of employment arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&#8217;s base salary (or
to the total annual compensation in the case of the special bonus for special achievements).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An annual cash bonus may be awarded to executive
officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may be granted to our
executive officers, other than our chief executive officer, will be based on performance objectives and a discretionary evaluation of
the executive officer&#8217;s overall performance by our chief executive officer, subject to minimum thresholds. Furthermore, the performance
objectives will be recommended by our chief executive officer and approved by our compensation committee (and, if required by law, by
our board of directors).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The performance measurable objectives of our chief
executive officer, which will be determined annually by our compensation committee and board of directors, will include the weight to
be assigned to each achievement in the overall evaluation. A less significant portion of the chief executive officer&#8217;s annual cash
bonus may be based on a discretionary evaluation of the chief executive officer&#8217;s overall performance by the compensation committee
and the board of directors based on quantitative and qualitative criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The equity-based compensation under our compensation
policy for our executive officers is designed in a manner consistent with the underlying objectives in determining the base salary and
the annual cash bonus, with its main objectives being to enhance the alignment between the executive officers&#8217; interests with our
long-term interests and those of our shareholders and to strengthen the retention and the motivation of executive officers in the long
term. Our compensation policy entitles our executive officers to compensation in the form of share options or other equity-based awards,
such as restricted share units, in accordance with our share incentive plan then in place (subject to the compensation committee&#8217;s
approval or the approval of the board of directors). All equity-based incentives granted to executive officers shall be subject to vesting
periods in order to promote long-term retention of the awarded executive officers. The equity-based compensation may be granted from
time to time and will be individually determined and awarded according to the performance, educational background, prior business experience,
qualifications, role and the personal responsibilities of the executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, our compensation policy contains
compensation recovery provisions which allows us under certain conditions to recover bonuses paid in excess, enables our chief executive
officer to approve an immaterial change in the terms of employment of an executive officer (provided that the changes of the terms of
employment are in accordance with our compensation policy) and allows us to exculpate, indemnify and insure our executive officers and
directors, subject to certain limitations set forth thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our compensation policy also governs the compensation
of the members of our board of directors and determines that the compensation of the directors shall be in accordance with the Companies
Regulations (Rules Regarding the Compensation and Expenses of an External Director), 5760-2000, as amended by the Companies Regulations
(Relief for Public Companies Traded in Stock Exchange Outside of Israel), 5760-2000, or the compensation of directors regulations, as
such regulations may be amended from time to time, provided, however, that under special circumstances such as in the case of a professional
director, an expert director or a director who has particular stature or added value and makes a unique contribution to the Company,
such director&#8217;s compensation may be different than the compensation of all other directors. Our directors may also be entitled
to receive equity-based compensation in the form of restricted shares, restricted share units or share options subject to an annual maximum
and to a vesting period in order to promote long-term retention of the awarded director, subject to the approval of our shareholders,
as required under the Companies Law. Furthermore, the chairman of our board of directors may be entitled to a higher base compensation
or equity-based compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Approval of Compensation of Directors and Executive Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Directors. </i>Under the Companies Law, the
compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board of directors and,
unless exempted under regulations promulgated under the Companies Law, the approval of the shareholders at a general meeting. If the compensation
of our directors is inconsistent with our stated compensation policy, then those provisions that must be included in the compensation
policy according to the Companies Law must have been considered by the compensation committee and board of directors, and shareholder
approval will also be required, provided that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such
matter, present and voting at such meeting, are voted in favor of the compensation package, excluding abstentions; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such matter and who vote
against the compensation package does not exceed two percent (2%) of the aggregate voting rights in the Company.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Executive
officers other than the Chief Executive Officer. </i> The Companies Law requires the approval of the compensation of a p</span>ublic
company&#8217;s executive officers (other than the Chief Executive Officer) in the following order: (i) the compensation committee, (ii)
the company&#8217;s board of directors, and(iii) if such compensation arrangement is inconsistent with the company&#8217;s stated compensation
policy, the company&#8217;s shareholders (by a special majority vote as discussed above with respect to the approval of director compensation).
However, if the shareholders of the company do not approve a compensation arrangement with an executive officer that is inconsistent
with the company&#8217;s stated compensation policy, the compensation committee and board of directors may override the shareholders&#8217;
decision if each of the compensation committee and the board of directors provide detailed reasons for their decision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An amendment to an existing arrangement with an
office holder who is not the Chief Executive Officer, or a director requires only the approval of the compensation committee, if the compensation
committee determines that the amendment is not material in comparison to the existing arrangement. However, according to regulations promulgated
under the Companies Law, an amendment to an existing arrangement with an office holder (who is not a director) who is subordinate to the
Chief Executive Officer shall not require the approval of the compensation committee if (i) the amendment is approved by the Chief Executive
Officer and the company&#8217;s compensation policy provides that a non-material amendment to the terms of service of an office holder
(other than the Chief Executive Officer) may be approved by the Chief Executive Officer and (ii) the engagement terms are consistent with
the company&#8217;s compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Chief Executive Officer</i>. Under the Companies
Law, the compensation of a public company&#8217;s Chief Executive Officer is required to be approved by: (i) the company&#8217;s compensation
committee; (ii) the company&#8217;s board of directors, and (iii) the company&#8217;s shareholders (by a special majority vote as discussed
above with respect to the approval of director compensation). However, if the shareholders of the company do not approve the compensation
arrangement with the Chief Executive Officer, the compensation committee and board of directors may override the shareholders&#8217;
decision if each of the compensation committee and the board of directors provide a detailed report for their decision. The approval
of each of the compensation committee and the board of directors should be in accordance with the company&#8217;s stated compensation
policy; however, in special circumstances, they may approve compensation terms of a Chief Executive Officer that are inconsistent with
such policy provided that they have considered those provisions that must be included in the compensation policy according to the Companies
Law and that shareholder approval was obtained (by a special majority vote as discussed above with respect to the approval of director
compensation). In addition, the compensation committee may waive the shareholder approval requirement with regards to the approval of
the engagement terms of a candidate for the Chief Executive Officer position, if they determine that the compensation arrangement is
consistent with the company&#8217;s stated compensation policy and that the Chief Executive Officer did not have a prior business relationship
with the company or a controlling shareholder of the company and that subjecting the approval of the engagement to a shareholder vote
would impede the company&#8217;s ability to employ the Chief Executive Officer candidate. In the event that the Chief Executive Officer
also serves as a member of the board of directors, his or her compensation terms as Chief Executive Officer will be approved in accordance
with the rules applicable to approval of compensation of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">D. Employees</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December&#160;31, 2021, we had 186 employees,
of which 138 employees are based in Israel, six employees based in Japan, 25 employees based in the United States and 17 employees based
in Korea. We have never experienced any employment-related work stoppages and believe our relationship with our employees is good. The
following table sets out our total number of employees by function for the last three years.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Area of Activity</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">General and Administrative</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">76</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and Development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Sales and Marketing</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left"><sup>(1)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">186</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">(1)</td><td>Total does not include subcontractors.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our human capital resources objectives include, as applicable, identifying,
recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes
of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based
compensation awards, in order to increase shareholder value and the success of our company by motivating such individuals to perform to
the best of their abilities and achieve our objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">E. Share Ownership</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For information regarding the beneficial ownership
of our ordinary shares by our directors and executive officers, see &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;A.
Major Shareholders.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_008"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in">Item 7.</td><td>Major Shareholders and Related Party Transactions</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">A. Major Shareholders</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth information with
respect to the beneficial ownership of our ordinary shares as of March 31, 2022 by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">each person or entity known by us to own beneficially more than 5% of our outstanding ordinary shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">each of our directors and executive officers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">all of our directors and executive officers as a group; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">each selling shareholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The beneficial ownership of our ordinary shares is determined in accordance
with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting
power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose
of or to direct the disposition of the security. In determining beneficial ownership percentages, we deem ordinary shares that a shareholder
has the right to acquire, including the ordinary shares issuable pursuant to options or warrants that are currently exercisable or exercisable
within 60 days of March 31, 2022, if any, to be outstanding and to be beneficially owned by the person with such right to acquire additional
ordinary shares for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the
purpose of computing the percentage ownership of any other person. The percentage of ordinary shares beneficially owned prior to or after
the offering is based on 52,080,400 ordinary shares outstanding as of March 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except where otherwise indicated, we believe,
based on information furnished to us by such owners, that the beneficial owners of the ordinary shares listed below have sole investment
and voting power with respect to such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">None of our shareholders have different voting
rights from other shareholders. To the best of our knowledge, we are not owned or controlled, directly or indirectly, by another corporation
or by any foreign government. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our
company.</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise noted below, the address for
each beneficial owner is c/o Communications Center, Neve Ilan, Israel 9085000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; font-style: italic">5% or greater shareholders</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">SK square Co., Ltd. and SK Square Americas, Inc. (formerly known as SK Telecom TMT Investment Corp.)(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,869,909</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.22</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Ran Poliakine(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,504,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.23</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; font-style: italic; text-align: left">Executive Officers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Erez Meltzer(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">James Dara (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Ran Daniel</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Ofir Koren (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Gali Yahav</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Guy Yoskovitz (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,575</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Tamar Aharon Cohen (7)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Pini Ben Elazar</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Anat Kaphan (8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,952</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Orit Wimpfheimer (9)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,589</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; font-style: italic">Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Ran Poliakine(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,504,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.23</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Erez Meltzer(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,034</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Noga Kainan(10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Floyd Katske (11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,928</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Richard Stone (12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">379,898</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Dan Suesskind (13)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,344</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Erez Alroy</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; font-style: italic; text-align: left">All directors and executive officers as a group (16 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,102,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.74</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.35in">*</td><td>Amount represents less than 1% of outstanding ordinary shares.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: left"><span style="font-size: 10pt; ">Based solely
on the </span><span style="font-size: 10pt">Schedule 13G filed by SK square Co., Ltd. and SK Square Americas, Inc. with the SEC on February
14, 2022, consisting of (i) 2,607,466 ordinary shares and (ii) a warrant to purchase 2,262,443 ordinary shares held by SK Square Americas,
Inc., a wholly owned subsidiary of SK square. Co., Ltd.</span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: left"><span style="font-size: 10pt">Represents (i) 2,873,389 ordinary
shares and (ii) options to purchase 630,896 ordinary shares exercisable within 60 days of March 31, 2022.</span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: left"><span style="font-size: 10pt; ">Represents
(i) 4,964 ordinary shares, (ii) options to purchase 20,117 ordinary shares exercisable within 60 days of March 31, 2022 and (iii) 2,953
RSUs that vest within 60 days of March 31, 2022.</span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: left"><span style="font-size: 10pt; ">Represents
options to purchase 26,833 ordinary shares exercisable within 60 days of March 31, 2022.</span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: left"><span style="font-size: 10pt; ">Represents
options to purchase 26,833 ordinary shares exercisable within 60 days of March 31, 2022.</span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0%"></td>
    <td style="width: 34px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Represents </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) 13,575 ordinary shares and (ii) <span>options to purchase 40,000 ordinary shares exercisable within 60 days of March 31, 2022.</span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(7)</span></td><td style="text-align: left"><span style="font-size: 10pt; ">Represents
options to purchase 10,083 ordinary shares exercisable within 60 days of March 31, 2022.</span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(<span>8</span>)</span></td><td style="text-align: left"><span style="font-size: 10pt; ">Represents
options to purchase 25,952 ordinary shares </span><span style="font-size: 10pt">exercisable within 60 days of March 31, 2022<span>.</span></span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(9)</span></td><td style="text-align: left"><span style="font-size: 10pt; ">Represents
options to purchase 6,589 ordinary shares </span><span style="font-size: 10pt">exercisable within 60 days of March 31, 2022<span>.</span></span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(10)</span></td><td style="text-align: left"><span style="font-size: 10pt; ">Represents
options to purchase 2,344 ordinary shares </span><span style="font-size: 10pt">exercisable within 60 days of March 31, 2022<span>.</span></span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt; ">(11)</span></td><td style="text-align: left"><span style="font-size: 10pt; ">Represents
(i) options to purchase 17,602 ordinary shares exercisable within 60 days of March 31, 2022 and (iii) 18,326 RSUs that vest within 60
days of March 31, 2022.</span></td>
</tr></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Represents
</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) 317,042 ordinary shares and <span>(ii)
options to purchase 62,856 ordinary shares exercisable within 60 days of March 31, 2022</span>.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(13)</span></td><td style="text-align: justify"><span style="font-size: 10pt; ">Represents
options to purchase 2,344 ordinary shares exercisable within 60 days of March 31, 2022.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To our knowledge, other than as disclosed in the
table above, our other filings with the SEC and this Annual Report, there has been no significant change in the percentage ownership held
by any major shareholder since January 1, 2019. The major shareholders listed above do not have voting rights with respect to their ordinary
shares that are different from the voting rights of other holders of our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span>As of March
31, 2022, according to the records of Continental Stock Transfer &amp; Trust Co., approximately 3,685,102 (or 7.1%) of our outstanding
ordinary shares are held by 28 record holders in the United States, not including Cede
&amp; Co., the nominee of the Depository Trust Company, in whose name all shares held in &#8220;street name&#8221; are held in the United
States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">B. Related
Party Transactions</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our policy is to enter into transactions with related
parties on terms that, on the whole, are no more favorable, or no less favorable, than those available from unaffiliated third parties.
Based on our experience in the business sectors in which we operate and the terms of our transactions with unaffiliated third parties,
we believe that all of the transactions described below met this policy standard at the time they occurred. The following is a description
of material transactions, or series of related material transactions, since January&#160;1, 2021, to which we were or will be a party
and in which the other parties included or will include our directors, executive officers, holders of more than 5% of our voting securities
or any member of the immediate family of any of the foregoing persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Relationship
With SKT</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On June&#160;17, 2019, Nanox
Gibraltar entered into a Strategic Share Purchase Agreement with SK Telecom TMT Investment Corp. (&#8220;SKT&#8221;), Pureun Partners
Asset Management Co., Ltd. and EBEST-PPAM Fund No. 9 (collectively, the &#8220;SKT Entities&#8221;), pursuant to which Nanox Gibraltar
sold 2,262,443 ordinary shares to the SKT Entities for an aggregate purchase price of approximately $5.0&#160;million. In connection
with such transaction, Nanox Gibraltar also issued a warrant to SKT to acquire 2,262,443 ordinary shares at an exercise price of $20.87
per share (the &#8220;Warrant&#8221;).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the transactions described above, Nanox Gibraltar also entered into an investor rights agreement with the SKT Entities
(the &#8220;Investor Rights Agreement&#8221;). The agreement provides for the rights to nominate a member of our board of directors,
as well as certain registration rights. The rights under the Investor Rights Agreement terminated upon the closing of our initial public
offering. The SKT Entities became parties to the Registration Rights Agreement prior to the closing of our initial public offering. See
&#8220;Item 10. Additional Information&#8212;C. Material Contracts&#8212;Registration Rights Agreements&#8221; for detailed description
of the registration rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On June&#160;4, 2020, we entered into a Share Purchase
Agreement with SKT, pursuant to which we sold 1,250,000&#160;ordinary shares to SKT for an aggregate purchase price of $20.0&#160;million.
In connection with such agreement, we amended the Warrant to extend the exercise period to the earlier of June&#160;17, 2025 or an exit
event, which event does not include an initial public offering, and we amended the Investor Rights Agreement which grants SKT the right
to appoint Mr.&#160;Jung Ho Park (or another person designated by SKT) as a director for a term of three years. In addition, we granted
Mr.&#160;Park options to purchase 100,000 of our ordinary shares, vesting in equal quarterly installments over a period of four years,
at an exercise price of $16.00 per ordinary share. In the event that SKT nominates any replacement director, any such director may receive
options with the same terms, but the aggregate number of options granted to all such directors together shall not exceed 100,000. Mr.
Park resigned from our Board of Directors in December 2021, at which time his unvested options to purchase 68,750 ordinary shares expired;
however, new options to purchase the same number of ordinary shares (i.e., 68,750 shares) may be granted to any successor director, if
nominated by SKT.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Furthermore, on June&#160;4, 2020, we entered into
a collaboration agreement with SK Telecom Co., Ltd. (&#8220;SK Telecom&#8221;), pursuant to which we and SK Telecom continue to explore
and engage in good faith to develop a definitive agreement for the deployment of 2,500 Nanox Systems in South Korea and Vietnam. With
the support of SK Telecom we established a wholly-owned subsidiary in South Korea, which in turn established our new fabrication facility
in Korea for the manufacturing of MEMs X-ray chips for the Nanox.ARC. The collaboration agreement expired on December&#160;31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we signed an agreement with Dr. Ilung Kim, who previously
served as President of SK Telecom, dated December&#160;16, 2019, for the provision of consulting services to us. Under the agreement,
we granted Dr. Kim options to purchase 1,206,290 of our ordinary shares at an exercise price of $2.21 per ordinary share. 301,572 of the
options were vested as of the grant date and the remaining 904,718 options will vest in equal monthly installments over a period of three&#160;years
from the vesting commencement date (September&#160;1, 2019). All unvested options will be fully accelerated immediately prior to the closing
of a Deemed Liquidation (as defined in the Equity Incentive Plan). The vested options are exercisable until the earlier of (a) the second
anniversary of termination of the engagement between us and Dr.&#160;Kim or (b) the tenth anniversary from the date of grant. Effective
as of July 1, 2021, the consulting agreement was replaced by an employment agreement with Dr. Kim in connection with appointment as the
chief executive officer of our Korean subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Agreements
With Directors and Officers</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of each material contract, other than material contracts entered into in the ordinary course of business, to which
we are or have been a party, for the two years immediately preceding the date of this Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Relationship With Illumigyn Ltd.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since December&#160;1, 2019, Illumigyn has sub-leased
approximately 165 square meters of private office space, including access to shared public spaces, from us in Neve Ilan, Israel. Mr.&#160;Poliakine
currently serves as a member of senior management of Illumigyn through a service provider agreement and is a significant shareholder
primarily through indirect holdings, and he served as a member of the board of directors of Illumigyn until August 2019. In addition,
Mr.&#160;Richard Stone is a significant shareholder in, and serves as a member of the board of directors of Illumigyn and Anat Kaphan,
our Chief Innovation Officer, also serves as a consultant to Illumigyn. Since December 1, 2019, Illumigyn pays approximately $12,000
per month. During the years ended December 31, 2021 and 2020, the Company received from Illumigyn approximately $125,000 and $163,000,
respectively, under the sub lease.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><i>Relationship with SixAI Ltd.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-indent: 40.5pt">On April&#160;16, 2020, we entered into
a service agreement (the &#8220;Service Agreement&#8221;) with SixAI, pursuant to which SixAI shall provide Nanox with certain software
development and mechanical engineering services. The Service Agreement was effective as of March&#160;1, 2020 and was extended by mutual
agreement of the parties several times until terminated on December 31, 2021. Mr.&#160;Poliakine currently serves as a member of the
board of directors of SixAI and is a controlling shareholder of SixAI. During the years ended December 31, 2021 and 2020, the Company
recorded an expense of $240,000 and $355,000, respectively, relating to this agreement.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b><i>Relationship with Wellsense Technologies,
Ltd.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since February 2020, Wellsense Technologies, Ltd.
(&#8220;Wellsense Technologies&#8221;) has sub-leased approximately 165 square meters of private office space, including access to shared
public spaces, from us in Neve Ilan, Israel. Wellsense Technologies, Ltd. pays approximately $7,000 per month. Each of Ran Poliakine
and Richard Stone is a shareholder of the parent company of Wellsense Technologies. During the years ended December 31, 2021 and 2020,
the Company received from Wellsense Technologies approximately $66,000 and $59,000, respectively, under the sub lease.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Service
Agreement</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2021, our shareholders approved the
entry into an agreement with Floyd Katske, effective as of October 1, 2020, whereby Floyd Katske will assist the Chief Executive Officer
and us with various tasks given his medical knowledge, expertise and experience, as may be requested from time-to-time by our Chief Executive
Officer. These tasks are in addition and unrelated to his role as a director. We have agreed to pay Floyd Katske with respect to such
services $200 per hour, against an invoice. The services will be limited to 100 hours in any calendar month, according to hours approved
by the Chairman. In addition, we agreed to pay Floyd Katske cash compensation consisting of RSUs granted in each calendar quarter, in
the amount calculated by dividing (i) two times the cash compensation paid during such quarter as aforesaid by (ii) the fair market value
of our ordinary shares on the last trading day of such quarter. All tax consequences will be borne by Floyd Katske. The agreement may
be terminated by 14 days&#8217; written notice by either party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Designated
Director</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.45pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under our compensation policy, we designated Erez
Meltzer as a &#8220;Designated Director,&#8221; effective as of January 1, 2021, due to his stature, added value and extraordinary contribution
to us, including throughout our initial public offering process and thereafter. As a Designated Director, Erez Meltzer received additional
cash compensation (in addition to the annual base compensation and annual equity compensation paid to him for service as a director)
of $80,000 per year, and of $200,000 in equity-based compensation in the form of RSUs to be granted in quarterly installments, calculated
according to the fair market value of our ordinary shares on the last trading day of such quarter. Mr. Meltzer ceased to serve as a Designated
Director on December 31, 2021, effective as of his appointment as our Chief Executive Officer.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Directorship
Agreements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into directorship agreements with
each of our directors (other than Erez Alroy, who was recently appointed as a director and with whom we expect to enter into a similar
directorship agreement), pursuant to which such directors will serve on our board of directors. Pursuant to these agreements, each director
was granted options under our 2019 Equity Incentive Plan in the number and terms set out under &#8220;Item 6. Directors, Senior Management
and Employees&#8212;B. Compensation&#8212;Equity Incentive Plan.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Equity
Incentive Plans</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">For
a description of our equity incentive plans with members of our board of directors and executive officers, see &#8220;Item 6. Directors,
Senior Management and Employees&#8212;B. Compensation&#8212;Equity Incentive Plan.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Directors and Officers Insurance Policy and Indemnification and
Exculpation Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our amended and restated articles of association
permit us to exculpate, indemnify and insure each of our directors and officers to the fullest extent permitted by the Companies Law.
We have obtained directors&#8217; and officers&#8217; liability insurance which covers each of our executive officers and directors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have entered into agreements with each of our current directors and officers exculpating them from a breach of their duty of care to
us to the fullest extent permitted by law, and undertaking to indemnify them to the fullest extent permitted by law including, with respect
to liabilities resulting from our initial public offering, to the extent that these liabilities are not covered by insurance, all subject
to limited exceptions. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to
events determined as foreseeable by the board of directors based on our current or expected activities. The maximum aggregate amount
of indemnification that we may pay to our directors and officers based on such indemnification agreement shall not exceed the greater
of (i)&#160;in relation to indemnity in connection with an offering to the public of our securities, the aggregate amount of proceeds
from the sale by us and/or any of our shareholders in connection with such public offering, (ii) 25% of our total shareholders&#8217;
equity pursuant to our most recent financial statements as of the time of the actual payment of indemnification, and (iii) $50&#160;million
(in each case as may be increased from time to time by shareholders&#8217; approval). Such indemnification amounts are in addition to
any insurance amounts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">However,
in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy
and therefore unenforceable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Registration
Rights Agreements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into a registration rights agreement
(the &#8220;Registration Rights Agreement&#8221;) that entitles certain holders of our ordinary shares and other securities convertible
into or exchangeable for ordinary shares, including SK Square Americas, Inc. (formerly known as SK Telecom TMT Investment Corp.), to
certain piggyback registration rights. See &#8220;Item 10. Additional Information&#8212;C. Material Contracts&#8212;Registration Rights
Agreements.&#8221;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">C.
Interests of Experts and Counsel</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_009"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 8.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Financial
                                            Information</span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A.
Consolidated Financial Statements and Other Financial Information</span> &#160; &#160; </p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt; font-style: normal; font-weight: normal">See
&#8220;Item 18. Financial Statements.&#8221;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Legal
Proceedings</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-size: 10pt">See
&#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Legal Proceedings.&#8221;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Dividend
Policy</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have never declared or paid any cash dividends on our ordinary shares and we anticipate that, for the foreseeable future, we will retain
any future earnings to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay
cash dividends for at least the next several years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The distribution of dividends may also be limited
by the Companies Law, which permits the distribution of dividends only out of retained earnings or earnings derived over the two most
recent fiscal years, whichever is higher, provided that there is no reasonable concern that payment of a dividend will prevent a company
from satisfying its existing and foreseeable obligations as they become due. In the event that we do not have retained earnings or earnings
generated over the two most recent years legally available for distribution, we must seek the approval of the court in order to distribute
a dividend, and the court may approve our request if it is convinced that there is no reasonable concern that the payment of a dividend
will prevent us from satisfying our existing and foreseeable obligations as they become due. Our amended and restated articles of association
provide that dividends will be paid at the discretion of, and upon resolution by, our board of directors, subject to the provision of
the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">B. Significant
Changes</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Except
as disclosed elsewhere in this annual report on Form 20-F, we have not experienced any significant changes since the date of our audited
consolidated financial statements included in this annual report on Form 20-F.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_010"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 9.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Offer and
                                            Listing</span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">A. Offer
and Listing Details</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
ordinary shares have been listed on the NASDAQ Global Market since August 20, 2020 under the symbol &#8220;NNOX.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">B. Plan
of Distribution</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">C. Markets</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
ordinary shares have been listed on the NASDAQ Global Market since August 20, 2020 under the symbol &#8220;NNOX.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">D. Selling
Shareholders</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">E. Dilution</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">F. Expenses
of the Issue</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_011"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 10.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Additional
                                            Information</span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">A. Share
Capital</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">B. Memorandum
and Articles of Association</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
copy of our amended and restated articles of association is attached as Exhibit 1.1 to this Annual Report.&#160;Our registration number
with the Israeli Registrar of Companies is 515942076. Our registration number may be changed by the Israeli Registrar of Companies to
indicate that we are a public company. The following are summaries of material provisions of our current amended and restated articles
of association that became effective immediately prior to the completion of our initial public offering in August 2020, insofar as they
relate to the material terms of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Objects
of Our Company</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
purpose as set forth in our amended and restated articles of association is to engage in any lawful activity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Board
of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">See
&#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Borrowing Powers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Companies Law and our amended articles
of association, our board of directors may exercise all powers and take all actions that are not required under law or under our amended
and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Ordinary
Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2021, we had 51,791,441 ordinary shares outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Dividends</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have never declared or paid any cash dividends on our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. See &#8220;Item
8. Financial Information&#8212;A. Consolidated Statements and Other Financial Information&#8212;Dividend Policy&#8221; for more information
with respect to the requirements under Israeli law for the declaration and payment of dividends to our shareholders. Under the Companies
Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company
unless the company&#8217;s articles of association provide otherwise. Our amended and restated articles of association do not require
shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Voting
Rights</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
of our ordinary shares have identical voting and other rights in all respects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Holders
of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general
meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="text-indent: 0.5in; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><i>Quorum.</i> <span style="font-family: Times New Roman, Times, Serif">In
any meeting of shareholders, we will follow the quorum requirements for general meetings as set forth in our amended and restated articles
of association, instead of one-third of the issued share capital as required under the Nasdaq Marketplace Rules. Pursuant to our amended
and restated articles of association, the quorum required for our general meetings of shareholders will consist of at least two shareholders
present in person or by proxy (including by voting deed) and holding shares conferring in the aggregate at least 25% of the voting power
of the Company. A meeting adjourned for lack of a quorum will generally be adjourned to the same day of the following week at the same
time and place, or to such other day, time or place as indicated by our board of directors if so specified in the notice of the meeting.
At the reconvened meeting, subject to a limited exception, any number of shareholders present in person or by proxy shall constitute
a lawful quorum.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Vote
requirements.</i> An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple
majority of the votes attaching to the ordinary shares cast at a meeting, while a special resolution requires the affirmative vote
of no less than two-thirds of the votes attaching to the ordinary shares cast at a meeting. Both ordinary resolutions and special
resolutions may also be passed by a unanimous written resolution signed by all the shareholders of our company, as permitted by the
Companies Law and our amended and restated memorandum and articles of association. A special resolution will be required for
important matters such as a change of name or making changes to our amended and restated memorandum and articles of association.
Holders of the ordinary shares may, among other things, divide or combine their shares by ordinary resolution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Transfer
of Ordinary Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association,
unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares
are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended
and restated articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are,
or have been, in a state of war with Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the event of our liquidation, after satisfaction of liabilities to creditors and other payments due as per applicable law, our assets
will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive
dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential
rights that may be authorized in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Redemption of Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may, subject to applicable law, issue redeemable
shares or other securities and redeem the same with such terms and conditions as the board of directors may deem fit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Modifications
of Rights of Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Companies Law and our amended and restated articles of association, the rights attached to any class of share, such as voting, liquidation
and dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a
separate class meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in our amended and
restated articles of association, in addition to the ordinary majority vote of all classes of voting shares voting together as a single
class.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Issuance
of Additional Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may, upon a resolution of the shareholders at a General Meeting, from time to time, increase our share capital by the creation of new
shares. Any such increase shall be in such amount and shall be divided into shares of such nominal amounts or without nominal amounts,
and such shares shall confer such rights and preferences, and shall be subject to such restrictions, as the resolution approving the
creation of such shares shall provide. Except to the extent otherwise provided in the resolution creating such new shares, such new shares
shall be subject to all the provisions applicable to the shares of the original capital. Without prejudice to any special rights previously
conferred upon the holders of existing shares in the Company, the Company may, from time to time, provide for shares with such preferred
or deferred rights or rights of redemption or other special rights and/or such restrictions, whether in regard to dividends, voting,
repayment of share capital or otherwise, as may be stipulated in the resolution pursuant to which such shares are created.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Access
to Corporate Records</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the Companies Law, shareholders generally have the right to review minutes of our general meetings, our shareholders register and material
shareholders register, our amended and restated articles of association, our annual audited financial statements and any document that
we are required by law to file publicly with the Israeli Registrar of Companies or the Israel Securities Authority. In addition, any
shareholder who specifies the purpose of their request may request to be provided with any document related to an action or transaction
requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe
it has not been made in good faith or if such denial is necessary to protect our interests or protect a trade secret or patent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Exchange controls</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are currently no Israeli currency control
restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the ordinary shares or interest or other payments
to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Acquisitions under Israeli Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Full Tender Offer.</i><span style="font-family: Times New Roman, Times, Serif">A
person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&#8217;s voting
rights or issued and outstanding share capital is required by the Companies Law to make a tender offer to all of the company&#8217;s
shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public
Israeli company and who would as a result hold over 90% of the voting rights or issued and outstanding share capital of a certain class
of shares is required to make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all
of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and
outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal
interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by
operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of
the issued and outstanding share capital of the company or of the applicable class of shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Upon
a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder
accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to
determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However,
under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be
entitled to petition the Israeli court as described above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
the full tender offer was not accepted in accordance with the above alternatives, the acquirer may not acquire shares of the company
that will increase its holdings to more than 90% of the company&#8217;s issued and outstanding share capital or of the applicable class
from shareholders who accepted the tender offer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Special Tender Offer</i>. The Companies Law
provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of
the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply
if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Companies Law provides that an
acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser
would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds
more than 45% of the voting rights in the company, subject to certain exceptions. A special tender offer must be extended to all shareholders
of a company but the offeror is not required to purchase shares representing more than 5% of the voting power attached to the company&#8217;s
outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated only if (i)
at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by the offeror and (ii) the number
of shares tendered by shareholders who accept the offer exceeds the number of shares whose holders objected to the offer (excluding the
purchaser and its controlling shareholders, holders of 25% or more of the voting rights in the company or any person having a personal
interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives and entities under such
person&#8217;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common
control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the
target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the
purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer. Shares purchased in
contradiction to the tender offer rules under the Companies Law, will have no rights and will become dormant shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; "><i>Merger</i>. The Companies
Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under
the Companies Law are met, by a majority vote of each party&#8217;s shares, and, in the case of the target company, a majority vote of
each class of its shares voted on the proposed merger at a shareholders meeting. For purposes of the shareholder vote, unless a court
rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at the shareholders meeting
that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds
(or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party,
vote against the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder or if the controlling
shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval that governs
all extraordinary transactions with controlling shareholders. If the transaction would have been approved by the shareholders of a merging
company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may
still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger
is fair and reasonable, taking into account the value to the parties to the merger and the consideration offered to the shareholders of
the target company. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if
it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the
obligations of the merging entities, and may further give instructions to secure the rights of creditors. In addition, a merger may not
be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party
with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders
of each party. Israeli tax law treats some acquisitions, such as share for share exchanges between an Israeli company and a foreign company,
less favorably than U.S. tax laws. For example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges
his ordinary shares for shares in another corporation to taxation prior to the sale of the shares received in such share-for-share swap.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Anti-takeover measures</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Companies Law allows us to create and issue
shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights with respect
to voting, distributions or other matters and shares having preemptive rights. No preferred shares are currently authorized under our
amended and restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares,
such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover
or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization
and designation of a class of preferred shares will require an amendment to our amended and restated articles of association, which requires
the prior approval of the holders of a majority of the voting power attaching to our issued and outstanding shares represented at a general
meeting. The convening of the meeting, the shareholders entitled to participate and the majority vote required to be obtained at such
a meeting will be subject to the requirements set forth in the Companies Law and our amended articles of association as described above
under &#8220;&#8212;Voting Rights.&#8221; In addition, we have a classified board structure, which will effectively limit the ability
of any investor or potential investor or group of investors or potential investors to gain control of our board of directors, as disclosed
under &#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>General
Meetings of Shareholders and Shareholder Proposals</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later
than 15 months after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders
are referred to in our amended and restated articles of association as special meetings. Our board of directors may call special meetings
whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides
that our board of directors is required to convene a special general meeting upon the written request of (i)&#160;any two or more of
our directors or one-quarter or more of the members of our board of directors or (ii)&#160;one or more shareholders holding, in the aggregate,
either (a) 5% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b) 5% or more of our outstanding
voting power.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors
include a matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter
at the general meeting. Our amended and restated articles of association contain procedural guidelines and disclosure items with respect
to the submission of shareholder proposals for shareholder meetings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">C.
Material Contracts</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent Acquisition Transactions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 2, 2021, the Company completed the
acquisition of 100% of the shares of USARAD, pursuant to the terms of the Stock Purchase Agreement, dated October 25, 2021, among the
Company, USARAD, Dr. Michael Yuz, other holders of capital stock of USARAD, and holders of USARAD options</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 3, 2021, the Company completed the
acquisition of the platform and other assets of MDWEB, pursuant to the terms of the Asset Purchase Agreement, dated October 21, 2021,
between the Company and MDWEB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On November 4, 2021, the Company, consummated the
merger pursuant to the terms of the Agreement and Plan of Merger, dated August 9, 2021, as amended, among the Company, Zebra (now known
as Nanox AI), and Perryllion Ltd., as representative of Zebra&#8217;s equity holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0">For details regarding these agreements, see &#8220;Item 4. Information
on the Company&#8212;A. History and Development of the Company&#8221;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">FoxSemicon
Integrated Technology, Inc. Manufacturing Agreement</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On May&#160;26, 2020, we entered into a Contract
Manufacturing Agreement with FITI. Under the terms of the agreement, FITI agrees to manufacture, package, distribute and ship, and we
agree to purchase, certain products and procurement and assembly services, including a minimum of 1,000 Nanox Systems per year. We agree
to provide FITI with a rolling forecast of our estimated monthly purchases, which FITI will use to prepare its supply chain to cover the
material and manufacturing needs. Subsequently, we will send purchase orders to FITI for certain products and services. Prices for the
products will be agreed by the parties at least 90 days prior to the first expected delivery date. FITI will be entitled to order materials
in accordance with an approved supplier list and on the terms that the parties agree upon on a quarterly basis, and FITI must obtain our
prior written consent if it procures materials from other suppliers. FITI may also purchase materials from us to support orders pursuant
to our requests. The parties also agree to enter into a quality agreement, which will set forth the manufacturing standards applicable
to FITI. The agreement will be in effect for three years from the date of the agreement and is renewable for successive terms of one year
unless or until either party notifies the other in writing of its intention not to renew with 90 days&#8217; prior notice. The agreement
has not yet been implemented. The agreement may be terminated by notice of the non-breaching party in case of a material breach of a party&#8217;s
material obligations, or by either party in case of the bankruptcy or insolvency of the other party.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Warrant Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of March 31, 2022, there were two outstanding
warrants, which are currently exercisable: (i) a warrant issued upon the consummation of our initial public offering to A-Labs Advisory
&amp; Finance Ltd., which provided to us strategic consulting services, to purchase 50,000 ordinary shares, with an exercise price of
$18 per share; and (ii) the warrant issued to SK Square Americas, Inc. (formerly known as SK Telecom TMT Investment Corp.) to purchase
2,262,443 ordinary shares, with an exercise price of $20.87 per share, as described above under &#8220;Item 7. Major Shareholders and
Related Party Transactions&#8212;B. Related Party Transactions&#8212;Relationship With SKT.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Registration
Rights Agreements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into the Registration Rights Agreement
with shareholders who held 14,533,835 of our ordinary shares and other securities convertible into or exchangeable for ordinary shares;
however, some of these shares have been sold on the market, and the registration rights are no longer applicable. As of the date of this
annual report, the registration rights apply to 2,607,466 shares held by SK Square Americas, Inc. (formerly known as SK Telecom TMT Investment
Corp.).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the terms of the Registration Rights Agreement,
and subject to the limitations specified therein, if we register our ordinary shares under the Securities Act for sale to the public,
either for our own account or for the account of other security holders or both, the holders of registrable securities are entitled to
notice of the intended registration and to include any or all of their registrable securities in the registration. The right of holders
of registrable securities to include shares in an underwritten offering is subject to the right of the underwriters to limit the number
of shares included in such offering. Holders of registrable securities are generally required to pay all expenses of registration, including
the fees and disbursements of its counsel and all underwriting discounts and commissions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, as of March 31, 2022, SK Square Americas,
Inc., as a holder of a warrant to purchase an aggregate of 2,262,443 ordinary shares, is entitled to piggyback registration rights under
the terms of such warrant substantially similar to the registration rights described in the preceding paragraph.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">D.
Exchange Controls</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of
the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of certain countries that
have been, or are considered to be, in a state of war with Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">E.
Taxation</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Israeli
Tax Considerations and Government Programs</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>General
Corporate Tax Structure in Israel</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Israeli resident companies are generally subject
to corporate tax, currently at the rate of 23% of a company&#8217;s taxable income. Capital gains derived by an Israeli resident company
are subject to tax at the regular corporate tax rate.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
Israeli tax legislation, a corporation will be considered as an &#8220;Israeli resident company&#8221; if it meets one of the following:
(i)&#160;it was incorporated in Israel; or (ii)&#160;the control and management of its business are exercised in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Tax
Benefits and Grants for Research and Development</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Israeli
tax law allows, under certain conditions, a tax deduction for expenditures related to scientific research and development projects, including
capital expenditures, for the year in which they are incurred. Expenditures are deemed related to scientific research and development
projects, if:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">The
                                            expenditures are approved by the relevant Israeli government ministry, determined by the
                                            field of research; or</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">The research and development is for the promotion of the company and is carried out by or on behalf of the company seeking such tax deduction, or that the expenditure is made by a person that carries out the research and does not own an enterprise which is engaged in the field of research, or that such expenditure constitutes a participation in a research carried out by another person, in both cases, subject to the fulfillment of certain criteria set forth in the Israeli tax law. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The amount of such deductible
expenses is reduced by the sum of any funds received through government grants for the financing of such scientific research and development
projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested
in an asset depreciable under the general depreciation rules of the Ordinance. Capital Expenditures for scientific research incurred by
a company for the promotion or development of the company, which do not meet the above conditions, are deductible in equal amounts over
three years.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may apply to the Israeli Innovation Authority (the &#8220;IIA&#8221;), for approval to allow a tax deduction for research
and development expenses during the year incurred. There can be no assurance that such application will be accepted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Law
for the Encouragement of Capital Investments, 5719-1959</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Law for the Encouragement of Capital Investments, 5719-1959 (the &#8220;Investment Law&#8221;), provides certain incentives for capital
investments in production facilities (or other eligible assets) by &#8220;Industrial Enterprises&#8221; (as defined under the Investment
Law). The benefits available under the Investment Law are subject to the fulfillment of conditions stipulated therein. If a company does
not meet these conditions, it may be required to refund the amount of tax benefits, as adjusted by the Israeli consumer price index,
and interest, or other monetary penalties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Tax
Benefits Subsequent to the 2005 Amendment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
amendment to the Investment Law, which became effective as of April&#160;1, 2005, or the 2005 Amendment, changed certain provisions of
the Investment Law. An eligible investment program under the 2005 Amendment qualifies for benefits as a &#8220;Benefited Enterprise.&#8221;
Prior to the 2005 Amendment, investment programs under the Investment Law were called &#8220;Approved Enterprises.&#8221; The extent
of the tax benefits available under the 2005 Amendment to qualifying income of a Benefited Enterprise depend on, among other things,
the geographic location of the Benefited Enterprise in Israel. The location will also determine the period for which tax benefits are
available. Such tax benefits include an exemption from corporate tax on undistributed income for a period of between two to ten years,
depending on the geographic location of the Benefited Enterprise in Israel, and a reduced corporate tax rate of between 10% and the applicable
corporate tax rate for the remainder of the benefits period, depending on the level of foreign investment in the company in each year
during the benefits period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are not entitled to tax benefits under the 2005 Amendment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Tax
Benefits Under the 2011 Amendment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Investment Law was significantly amended as of January&#160;1, 2011, or the 2011 Amendment. The 2011 Amendment introduced new benefits
to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
2011 Amendment introduced new tax benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise,&#8221;
in accordance with the definition of such terms in the Investment Law. The definition of a Preferred Company, includes, inter alia, a
company incorporated in Israel that (1) is not wholly owned by a government entity, (2) owns a Preferred Enterprise and (3) is controlled
and managed from Israel and is subject to further conditions set forth in the Investment Law. Moreover, a Preferred Company needs to
meet certain conditions stipulated in the Investment Law such as being an industrial company (including a minimum threshold of 25% export).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to the income attributed to its Preferred Enterprise,
unless the Preferred Enterprise is located in development area &#8220;A,&#8221; in which case the rate will be 7.5%. Our operations are
currently not located in development area &#8220;A.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Dividends
distributed from income which is attributed to a &#8220;Preferred Enterprise&#8221; will be subject to withholding tax at the following
rates: (i)&#160;Israeli resident individuals&#8212;20% and (ii)&#160;non-Israeli residents&#8212;20%, subject to a reduced tax rate under
the provisions of an applicable double tax treaty and subject to the receipt in advance of valid certificate from the Israeli Tax Authority,
or the ITA. If such dividends are paid to an Israeli company, no tax is required to be withheld. However, if such dividends are subsequently
distributed by such Israeli company to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may
be provided in an applicable tax treaty will apply.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
provisions of the 2011 Amendment do not apply to existing &#8220;Benefited Enterprises&#8221; or &#8220;Approved Enterprises,&#8221;
which will continue to be entitled to the tax benefits under the Investment Law, as in effect prior to the 2011 Amendment, unless the
company owning such enterprises had made an election to apply the provisions of the 2011 Amendment (such election cannot be later rescinded),
which is to be filed with the ITA, not later than the date prescribed for the filing of the company&#8217;s annual Israeli tax return
for the respective year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are currently not entitled to tax benefits under the 2011 Amendment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Tax
Benefits Under the 2017 Amendment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additional
amendments to the Investment Law became effective in January 2017, or the 2017 Amendment. The 2017 Amendment provides new tax benefits
for two types of &#8220;Technological Enterprises,&#8221; as described below, and is in addition to the other existing tax benefit programs
under the Investment Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
2017 Amendment provides that a technological company satisfying certain conditions may qualify as a &#8220;Preferred Technological Enterprise&#8221;
and thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technological Income,&#8221; as defined
in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technological Enterprise located in development area &#8220;A.&#8221;
In addition, a Preferred Technological Company will enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of
certain &#8220;Benefited Intangible Assets&#8221; (as defined in the Investment Law) to a related foreign company if the Benefited Intangible
Assets were acquired from a foreign company on or after January&#160;1, 2017, for at least NIS 200&#160;million, and the sale receives
prior approval from the IIA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
2017 Amendment further provides that a technological company satisfying certain conditions may qualify as a &#8220;Special Preferred
Technological Enterprise&#8221; and thereby enjoy a reduced corporate tax rate of 6% on &#8220;Preferred Technological Income&#8221;
regardless of the company&#8217;s geographic location within Israel. In addition, a Special Preferred Technological Enterprise will enjoy
a reduced corporate tax rate of 6% on capital gain derived from the sale of certain &#8220;Benefited Intangible Assets&#8221; to a related
foreign company if the Benefited Intangible Assets were either developed by an Israeli company or acquired from a foreign company on
or after January&#160;1, 2017, and the sale received prior approval from the IIA. A Special Preferred Technological Enterprise that acquires
Benefited Intangible Assets from a foreign company for more than NIS 500&#160;million may be eligible for these benefits for a period
of at least ten years, subject to certain approvals as specified in the Investment Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Dividends
distributed by a Preferred Technological Enterprise or a Special Preferred Technological Enterprise, paid out of Preferred Technological
Income or income attributed to production are generally subject to withholding tax at the rate of 20% or such lower rate, as may be provided
in an applicable tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).
However, if such dividends are paid to an Israeli company, no tax is required to be withheld. However, if such dividends are subsequently
distributed by such Israeli company to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may
be provided in an applicable tax treaty will apply. If dividends paid out of Preferred Technological Income are distributed to a foreign
company and other conditions are met, the withholding tax rate will be 4% (or a lower rate under a tax treaty, if applicable, subject
to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are currently not entitled to tax benefits under the 2017 Amendment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Taxation
of Our Shareholders</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Capital
Gains</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Capital gain tax is imposed on the disposition
of capital assets by an Israeli resident for tax purposes, and on the disposition of such assets by a non-Israeli resident for tax purposes
if those assets are (i)&#160;located in Israel; (ii)&#160;are shares or a right to a share in an Israeli resident corporation, or (iii)&#160;located
outside of Israel which mainly represent, directly or indirectly, rights to assets, property or inventory located in Israel. The Ordinance
distinguishes between &#8220;Real Capital Gain&#8221; and the &#8220;Inflationary Surplus.&#8221; Real Capital Gain is the excess of the
total capital gain over Inflationary Surplus computed generally on the basis of the increase in the Israeli consumer price index or, in
certain circumstances, a foreign currency exchange rate, between the date of purchase and the date of disposition. The inflationary surplus
accumulated from and after December 31, 1993, is exempt from any capital gains tax in Israel while the real gain is taxed at the applicable
rate discussed below.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Real Capital Gain accrued by individuals on the
sale of our ordinary shares will be taxed at the rate of 25%. However, if the individual shareholder is a &#8220;Controlling Shareholder&#8221;
(i.e., a person who holds, directly or indirectly, alone or together with another, 10% or more of one of the Israeli resident company&#8217;s
&#8220;means of control,&#8221; which includes, among other things, the right to receive profits of the company, voting rights, the rights
to receive proceeds upon the company&#8217;s liquidation and the right to appoint a director) at the time of sale or at any time during
the preceding 12-month period, such capital gain will be taxed at the rate of 30%. Furthermore, where an individual claimed real interest
expenses and linkage differentials on securities, the capital gain on the sale of the securities will taxed at a rate of 30% (exclusive
of excess tax described below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Real Capital Gain derived by corporations will
be generally subject to the corporate tax rate (23% in 2022).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Individual and corporate shareholder dealing in
securities in Israel are taxed at the tax rates applicable to business income&#8212;23% for corporations in 2022 and a marginal tax rate
of up to 47% (in 2022) for individuals, not including excess tax (described below). Notwithstanding the foregoing, Real Capital Gain derived
from the sale of our ordinary shares by a non-Israeli shareholder may be exempt under the Ordinance from Israeli taxation provided that
the following cumulative conditions are met: (i)&#160;the shares were purchased upon or after the registration of the shares on the stock
exchange, (ii)&#160;the seller does not have a permanent establishment in Israel to which the derived capital gain is attributable, (iii)&#160;if
the seller is a corporation, no more than 25% of its means of control are held, directly and indirectly, alone or together with another
by Israeli residents, and (iv)&#160;if the seller is a corporation, there is no Israeli resident that is entitled to 25% or more of the
revenues or profits of the corporation, directly or indirectly. In addition, such exemption would not be available to a person whose capital
gains from selling or otherwise disposing of the securities are deemed to be business income. In addition, this exemption shall not be
relevant to the part of the capital gains allocable to the holding period before the shares were listed for trading on the stock exchange
(however, such portion might also be exempt from tax in Israel if certain criteria are met).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the sale of shares may be exempt from Israeli capital gain tax under the provisions of an applicable tax treaty. For example,
the Convention between the Government of the United States and the Government of the State of Israel with respect to Taxes of Income,
as amended, or the U.S.-Israel Double Tax Treaty, exempts U.S.&#160;residents for the purposes of the treaty from Israeli capital gain
tax in connection with such sale, provided (i)&#160;the U.S.&#160;resident owned, directly or indirectly, less than 10% of the Israeli
resident company&#8217;s voting power at any time within the 12-month period preceding such sale; (ii)&#160;the seller, being an individual,
is present in Israel for a period or periods of less than 183 days during the taxable year; and (iii)&#160;the capital gain from the
sale was not derived through a permanent establishment of the U.S. resident in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Shareholders
may be liable for Israeli tax on the sale of their ordinary shares and the payment of the consideration may be subject to withholding
of Israeli tax. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding
at the time of sale. For example, in transactions involving a sale of all of the shares of an Israeli resident company, in the form of
a merger or otherwise, the ITA may require from shareholders who are not liable for Israeli tax to sign declarations in forms specified
by this authority or obtain a specific exemption from the ITA to confirm their status as a non-Israeli resident, and, in the absence
of such declarations or exemptions, may require the purchaser of the shares to withhold taxes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
purchaser, the Israeli stockbrokers or financial institutions through which the shares are held is obligated, subject to the above mentioned
exemptions, to withhold tax on the amount of consideration paid upon the sale of the shares (or on the Real Capital Gain on the sale,
if known) at the rate of 25% in respect of an individual and 23% in respect of a corporation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon the sale of securities traded on a stock exchange,
a detailed return, including a computation of the tax due, generally need to be filed and an advanced payment must be paid on January
31 and July 31 of every calendar year in respect of sales of securities made within the previous six months. However, if all tax due was
withheld according to applicable provisions of the Ordinance and regulations promulgated thereunder the aforementioned return need not
be filed and no advance payment must be paid. Capital gain is also reportable on the annual income tax return.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Dividends</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have never paid cash dividends. A distribution
of dividends to a Preferred Enterprise to an Israeli resident individual, will generally be subject to withholding tax at a rate of 25%
or 30% if the dividend recipient is a &#8220;Controlling Shareholder&#8221; (as defined above) at the time of distribution or at any
time during the preceding 12-month period. If the recipient of the dividend is an Israeli resident corporation, such dividend will be
exempt from income tax provided the income from which such dividend is distributed was derived or accrued within Israel (although, if
such dividends are subsequently distributed to non-Israeli individuals or a non-Israeli company, withholding tax at a rate of 25% or
such lower rate as may be provided if an applicable tax treaty will apply (subject to the receipt in advance of a valid tax certificate
from the ITA allowing for a reduced tax rate)).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
non-Israeli resident (either individual or corporation) is generally subject to Israeli withholding tax on the receipt of dividends at
the rate of 25% (30% if the dividends recipient is a &#8220;Controlling Shareholder&#8221; (as defined above), at the time of distribution
or at any time during the preceding 12-month period); those rates are subject to a reduced tax rate under the provisions of an applicable
double tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate). Under the
U.S.-Israel Double Tax Treaty, the following withholding rates will apply in respect of dividends distributed by an Israeli resident
company to a U.S. resident: (i)&#160;if the U.S. resident is a corporation which holds during that portion of the taxable year which
precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding
voting shares of the Israeli resident paying corporation and not more than 25% of the gross income of the Israeli resident paying corporation
for such prior taxable year (if any) consists of certain type of interest or dividends&#8212;the tax rate is 12.5%, (ii)&#160;if both
the conditions mentioned in (i)&#160;above are met and the dividend is paid from an Israeli resident company&#8217;s income which was
entitled to a reduced tax rate applicable to an Approved Enterprise, Benefited Enterprise or Preferred Enterprise&#8212;the tax rate
is 15% if a certificate for a reduced withholding tax rate would be provided in advance from the ITA and (iii)&#160;in all other cases,
the tax rate is 25%. The aforementioned rates under the U.S.-Israel Double Tax Treaty will not apply if the dividend income was derived
through a permanent establishment of the U.S. resident in Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A non-Israeli resident who receives dividends from
which tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect to such income, provided that
(i)&#160;such income was not generated from business conducted in Israel by the taxpayer and (ii)&#160;the non-Israeli resident is not
subject to Excess Tax in Israel, and; (iii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax
return is required to be filed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Excess
Tax</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Individuals who are subject to tax in Israel (whether
such individual is an Israeli resident or non-Israeli resident) are also subject to an additional tax on annual income exceeding a certain
threshold (NIS 663,240, for 2022), which amount is linked to the Israeli consumer price index and therefore is usually adjusted on an
annual basis, at a rate of 3%, including, but not limited to, income derived from dividends, interest and capital gains.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Estate
and Gift Tax</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Israeli
law presently does not impose estate tax or in general gift taxes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">U.S.
Federal Income Tax Considerations</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following discussion is a summary of U.S. federal income tax considerations generally applicable to the ownership and disposition of
our ordinary shares. This summary applies only to investors that are U.S. Holders (as defined below) that hold our ordinary shares as
&#8220;capital assets&#8221; (generally, property held for investment) under the U.S.&#160;Internal Revenue Code of 1986, as amended
(the &#8220;Code&#8221;). This discussion is based upon U.S. federal tax law as in effect on the date of this annual report on Form 20-F
and on U.S. Treasury regulations in effect or, in some cases, proposed, as of the date of this annual report on Form 20-F, as well as
judicial and administrative interpretations thereof available on or before such date. All of the foregoing authorities are subject to
differing interpretations or change, which change could apply retroactively and could affect the tax considerations described below.
No ruling has been sought from the Internal Revenue Service, or the IRS, with respect to any U.S. federal income tax considerations described
below, and there can be no assurance that the IRS or a court will not take a contrary position. This discussion, moreover, does not address
the U.S. federal estate, gift, alternative minimum tax considerations, the Medicare tax on certain net investment income, any withholding
or information reporting requirements, or any state, local and non-U.S. tax considerations relating to the ownership or disposition of
our ordinary shares. The following summary does not address all aspects of U.S. federal income taxation that may be important to particular
investors in light of their individual circumstances or to persons in special tax situations such as:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">banks
and other financial institutions;</span></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">insurance
companies;</span></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">pension
plans;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">cooperatives;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">regulated
investment companies;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">real
estate investment trusts;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">broker-dealers;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">traders
that elect to use a mark-to-market method of accounting;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">certain
former U.S. citizens or long-term residents;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">tax-exempt
entities (including private foundations);</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">holders
who acquire our ordinary shares pursuant to any employee share option or otherwise as compensation;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">investors
that will hold our ordinary shares as part of a straddle, hedge, conversion, constructive sale or other integrated transaction for U.S.
federal income tax purposes;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">persons
holding our ordinary shares in connection with a trade or business outside the United States;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">persons
that actually or constructively own 10% or more of our stock (by vote or value);</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">investors
that have a functional currency other than the U.S. dollar; and</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">partnerships
or other entities classified as partnerships for U.S. federal income tax purposes, or persons holding our ordinary shares through such
entities, all of whom may be subject to tax rules that differ significantly from those discussed below.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Investors are urged to consult their tax advisors
about the application of the U.S. federal income tax rules to their particular circumstances as well as the state, local, non-U.S. and
other tax consequences to them of the ownership and disposition of our ordinary shares.</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>General</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of our ordinary shares that is, for U.S.&#160;federal
income tax purposes:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">an individual
who is a citizen or resident of the United States;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">a corporation
(or other entity treated as a corporation for U.S. federal income tax purposes) created in, or organized under the law of, the United
States or any state thereof or the District of Columbia;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">an estate
the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">a trust
(A) the administration of which is subject to the primary supervision of a U.S. court and which has one or more U.S. persons who have
the authority to control all substantial decisions of the trust or (B) that has otherwise validly elected to be treated as a U.S. person
under the Code.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) is a beneficial owner of our ordinary shares,
the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership.
Partnerships holding our ordinary shares and their partners are urged to consult their tax advisors regarding the ownership and disposition
of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Dividends</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any cash distributions (including the amount of
any Israeli tax withheld) paid on our ordinary shares out of our current or accumulated earnings and profits, as determined under U.S.
federal income tax principles, will generally be includible in the gross income of a U.S. Holder as dividend income on the day actually
or constructively received by the U.S. Holder. Because we do not intend to determine our earnings and profits on the basis of U.S. federal
income tax principles, any distribution we pay will generally be treated as a &#8220;dividend&#8221; for U.S. federal income tax purposes.
Dividends received on our ordinary shares will not be eligible for the dividends received deduction allowed to corporations in respect
of dividends received from U.S. corporations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Individuals
and other non-corporate U.S. Holders may be subject to tax at the lower capital gains tax rate applicable to &#8220;qualified dividend
income,&#8221; provided that certain conditions are satisfied, including that (1) the ordinary shares on which the dividends are paid
are readily tradable on an established securities market in the United States, or we are eligible for the benefit of the U.S.-Israel
Double Tax Treaty, (2) we are neither classified as a PFIC nor treated as such with respect to a U.S. Holder (as discussed below) for
the taxable year in which the dividend is paid or the preceding taxable year, and (3) certain holding period and other requirements are
met. Our ordinary shares are listed and traded on the Nasdaq Global Market. Thus, we believe that our ordinary shares will generally
be considered to be readily tradable on an established securities market in the United States. There can be no assurance that the ordinary
shares will continue to be considered readily tradable on an established securities market in later years. U.S. Holders are urged to
consult their tax advisors regarding the availability of the lower rate for dividends paid with respect to our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For U.S. foreign tax credit purposes, dividends
received on our ordinary shares will generally be treated as income from foreign sources and will generally constitute passive category
income. A U.S. Holder may be subject to Israeli withholding taxes on dividends paid on our ordinary shares. See &#8220;&#8212;Israeli
Tax Considerations and Government Programs&#8212;Taxation of Our Shareholders&#8212;Dividends.&#8221; Subject to certain conditions and
limitations, a U.S. Holder eligible under the U.S.-Israel Double Tax Treaty may be eligible to claim a foreign tax credit in respect of
any Israeli income taxes paid or withheld with respect to dividends on our ordinary shares to the extent such taxes are nonrefundable
under the U.S.-Israel Double Tax Treaty. Alternatively, a U.S.&#160;Holder who does not elect to claim a foreign tax credit for foreign
tax withheld may instead claim a deduction for U.S. federal income tax purposes in respect of such withholding, but only for a year in
which such holder elects to do so for all creditable foreign income taxes paid or accrued in the relevant taxable year. The rules governing
the foreign tax credit are complex and each U.S.&#160;Holder is urged to consult its tax advisor regarding the availability of the foreign
tax credit under its particular circumstances.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Sale
or Other Disposition</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A U.S. Holder will generally recognize gain or
loss upon the sale or other disposition of our ordinary shares in an amount equal to the difference between the amount realized upon
the disposition and the U.S. Holder&#8217;s adjusted tax basis in such ordinary shares. The gain or loss will generally be capital gain
or loss and individuals and other non-corporate U.S. Holders who have held the ordinary shares for more than one year will generally
be eligible for reduced tax rates. The deductibility of a capital loss may be subject to limitations. Any such gain that the U.S. Holder
recognizes may be subject to Israeli income tax and will generally be U.S. source fain, which may limit a U.S. Holder&#8217;s ability
to claim a foreign tax credit for any such Israeli income tax imposed on such gain. U.S. Holders that are eligible for the benefits of
the U.S.-Israel Double Tax Treaty may apply the U.S.-Israel Double Tax Treaty to treat such gain as exempt from Israeli tax, provided
certain requirements are met. Pursuant to recently issued Treasury regulations, however, if a U.S. Holder is not eligible for the benefits
of the U.S.-Israel Double Tax Treaty or does not elect to apply the U.S.-Israel Double Tax Treaty, then such holder may not be able to
claim a foreign tax credit arising from any Israeli tax imposed on the sale or other disposition of our ordinary shares. The rules regarding
foreign tax credits and the deductibility of foreign taxes are complex. U.S. Holders should consult their tax advisors regarding the
availability of a foreign tax credit or deduction in light of their particular circumstances, including their eligibility for benefits
under the U.S.-Israel Double Tax Treaty and the potential impact of the recently issued Treasury regulations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Passive
Foreign Investment Company Considerations</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
non-U.S. corporation, such as our company, will be classified as a PFIC for U.S. federal income tax purposes for any taxable year, if
either (i) 75% or more of its gross income for such year consists of certain types of passive income or (ii) 50% or more of the value
of its assets (generally determined on the basis of a quarterly average) during such year is attributable to assets that produce or are
held for the production of passive income. For this purpose, cash and assets readily convertible into cash are generally classified as
passive assets and goodwill and other unbooked intangibles associated with active business activities may generally be classified as
non-passive assets. Passive income generally includes, among other things, dividends, interest, royalties and rents (other than certain
royalties and rents derived in the active conduct of a trade or business and not derived from a related person), and gains from the disposition
of passive assets. We will be treated as owning a proportionate share of the assets and earning a proportionate share of the income of
any other corporation in which we own, directly or indirectly, at least 25% (by value) of the stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Whether
we are, or will be, classified as a PFIC is a factual determination made annually that will depend, in part, upon the composition of
our income and assets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on an analysis of our income and the value
of our assets, we believe that we were not a PFIC for the taxable year ended December 31, 2021, although no assurance can be given due
to the highly factual nature of such analysis. Our PFIC status for the current taxable year ending December 31, 2022 will not be determinable
until after the close of the year, and it is possible that we may be classified as a PFIC for the current taxable year and for future
taxable years. We believe that we were technically a PFIC for the 2020 taxable year. No assurance can be given with respect to our PFIC
status for the current taxable year or any future taxable year, however. The determination of whether we are or will become a PFIC is
uncertain, because it is a fact-intensive inquiry made on an annual basis that depends, in part, on the composition of our income and
assets. Fluctuations in the market price of our ordinary shares may influence whether we are classified as a PFIC for the current or
subsequent taxable years because the value of our assets for the purpose of the asset test may be determined by reference to the market
price of our ordinary shares from time to time. The composition of our income and assets may also be affected by how, and how quickly,
we use our liquid assets. Under circumstances where our revenue from activities that produce passive income increases relative to our
revenue from activities that produce non-passive income, or where we determine not to deploy cash for active purposes, our risk of being
classified as a PFIC will substantially increase.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
because there are uncertainties in the application of the relevant rules, it is possible that the IRS may challenge our classification
of certain income or assets as non-passive, or our valuation of our goodwill and other unbooked intangibles, each of which may increase
the likelihood of us becoming classified as a PFIC for the current or subsequent taxable years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares, unless the U.S. Holder makes a
mark-to-market election (as described below), the U.S. Holder will generally be subject to special tax rules on (i)&#160;any excess distribution
that we make to the U.S. Holder (which generally means any distribution paid during a taxable year to a U.S. Holder that is greater than
125% of the average annual distributions paid in the three preceding taxable years or, if shorter, the U.S. Holder&#8217;s holding period
for the ordinary shares), and (ii)&#160;any gain realized on the sale or other disposition of our ordinary shares. In addition, dividends
paid in respect of our ordinary shares would not be eligible for the lower tax rate described under &#8220;&#8212;Dividends&#8221; above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif">Under
the PFIC rules:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">the excess
distribution or gain will be allocated ratably over the U.S. Holder&#8217;s holding period for the ordinary shares;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">the amount
allocated to the taxable year of the excess distribution, sale or other disposition and to any taxable years in the U.S. Holder&#8217;s
holding period prior to the first taxable year in which we are classified as a PFIC (each, a &#8220;pre-PFIC year&#8221;), will be taxable
as ordinary income;</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">the amount
allocated to each prior taxable year, other than a pre-PFIC year, will be subject to tax at the highest tax rate in effect for individuals
or corporations, as appropriate, for that year; and</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">the interest
charge generally applicable to underpayments of tax will be imposed on the tax attributable to each prior taxable year, other than a
pre-PFIC year.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares, we generally will continue to
be treated as a PFIC with respect to such U.S. Holder for all succeeding years during which the holder holds our ordinary shares. However,
if we cease to meet the threshold requirements for PFIC status, provided that the U.S. Holder has not made a mark-to-market election,
as described below, such holder may avoid some of the adverse effects of the PFIC regime by making a &#8220;deemed sale&#8221; election
with respect to our ordinary shares held by such U.S. Holder. If such election is made, the U.S. Holder will be deemed to have sold our
ordinary shares it holds on the last day of the last taxable year in which we were classified as a PFIC at their fair market value and
any gain from such deemed sale will be taxed under the PFIC rules described above. After the deemed sale election, so long as we do not
become classified as a PFIC in a subsequent taxable year, the ordinary shares with respect to which such election was made will not be
treated as shares in a PFIC and the U.S. Holder will not be subject to the PFIC rules described above with respect to any &#8220;excess
distribution&#8221; received from us or any gain from an actual sale or other disposition of the ordinary shares. The rules dealing with
deemed sale elections are very complex. U.S. Holders of our ordinary shares are strongly urged to consult their tax advisors as to the
possibility and consequences of making a deemed sale election if we cease to be classified as a PFIC and such election becomes available
to such holders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we are classified as a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares and any subsidiary we own is also
classified as a PFIC, such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of the lower-tier PFIC
for purposes of the application of these rules. As a result, such U.S. Holder may incur liability for the deferred tax and interest charge
described above if either (1) we receive any excess distribution from, or dispose of all or part of our interest in, the lower-tier PFIC
or (2) the U.S. Holder disposes of all or part of our ordinary shares. It is possible that any subsidiary we own would be a PFIC for
the current taxable year or future taxable years. U.S. Holders are urged to consult their tax advisors regarding the application of the
PFIC rules to any subsidiary we own.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
an alternative to the foregoing rules, a U.S. Holder of &#8220;marketable stock&#8221; (as defined below) in a PFIC may make a mark-to-market
election with respect to such stock. If a U.S. Holder makes this election with respect to our ordinary shares, the holder will generally
(i)&#160;include as ordinary income for each taxable year that we are classified as a PFIC the excess, if any, of the fair market value
of the ordinary shares held at the end of the taxable year over the adjusted tax basis of such ordinary shares and (ii)&#160;deduct as
an ordinary loss in each such taxable year the excess, if any, of the adjusted tax basis of the ordinary shares over the fair market
value of such ordinary shares held at the end of the taxable year, but such deduction will only be allowed to the extent of the amount
previously included in income as a result of the mark-to-market election. The U.S. Holder&#8217;s adjusted tax basis in the ordinary
shares would be adjusted to reflect any income or loss resulting from the mark-to-market election. If a U.S. Holder makes a mark-to-market
election in respect of our ordinary shares and we cease to be classified as a PFIC, the holder will not be required to take into account
the gain or loss described above during any period that we are not classified as a PFIC. If a U.S. Holder makes a mark-to-market election,
any gain such U.S. Holder recognizes upon the sale or other disposition of our ordinary shares in a year when we are classified as a
PFIC will be treated as ordinary income and any loss will be treated as ordinary loss, but such loss will only be treated as ordinary
loss to the extent of the net amount previously included in income as a result of the mark-to-market election.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
mark-to-market election is available only for &#8220;marketable stock,&#8221; which is stock that is regularly traded on a qualified
exchange or other market, as defined in applicable U.S. Treasury regulations. Our ordinary shares are listed on the Nasdaq Global Market
and should be treated as regularly traded for purposes of the mark-to-market rules. While we anticipate that our ordinary shares will
continue to qualify as being regularly traded, no assurances may be given in this regard. If any subsidiary we own is, or becomes, classified
as a PFIC, the mark-to-market election will likely not be available with respect to the shares of such subsidiary that are treated as
owned by a U.S.&#160;Holder. Consequently, a U.S. Holder could be subject to the PFIC rules with respect to income of a lower-tier PFIC
the value of which had already been taken into account indirectly via mark-to-market adjustments. U.S. Holders are urged to consult their
tax advisors as to the availability and desirability of a mark-to-market election, as well as the impact of such election on interests
in any lower-tier PFIC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Alternatively,
a U.S. shareholder of a PFIC may avoid the PFIC tax consequences described above in respect of its shares of PFIC stock by making a timely
&#8220;qualified electing fund,&#8221; or QEF, election. To comply with the requirements of a QEF election, such shareholder must receive
certain information from the PFIC. Because we do not intend to provide information necessary for U.S. Holders to make QEF elections,
such election will not be available to U.S. Holders of our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
a U.S. Holder owns our ordinary shares during any taxable year that we are classified as a PFIC, the holder must generally file an annual
IRS Form 8621 regarding distributions received on, and any gain realized on the disposition of, our ordinary shares. U.S. Holders are
urged to consult their tax advisor regarding our PFIC status and the U.S. federal income tax consequences of owning and disposing of
our ordinary shares if we are, or become, classified as a PFIC, including the possibility of making a mark-to-market or deemed sale election.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>The summary of U.S. federal income tax consequences
set out above is for general informational purposes only. Investors are urged to consult their tax advisors about the application of
the U.S. federal income tax rules to their particular circumstances as well as the state, local, non-U.S. and other tax consequences
to them of the ownership and disposition of our ordinary shares.</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">F.
Dividends and Paying Agents</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">G.
Statement by Experts</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">H.
Documents on Display</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have previously filed with the SEC a registration statement on Form F-1 (File No. 333-240209), as amended, and a registration statement
on Form F-1 (File No. 333-252860), as amended, each with respect to our ordinary shares. As allowed by the SEC, in Item 19 of this annual
report on Form 20-F, we incorporate by reference certain information we previously filed with the SEC. This means that we can disclose
important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference
is considered to be part of this annual report on Form 20-F.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are subject to the periodic reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we are required
to file reports and other information with the SEC. The SEC maintains a website at www.sec.gov that contains reports and other information
regarding registrants that file electronically with the SEC. Our annual report on Form 20-F and other information submitted by us to
the SEC may be accessed through this website.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a foreign private issuer, we are exempt from
the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal
shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In
addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC
as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we are required to file
with the SEC, within four months after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on
Form 20-F containing financial statements audited by an independent registered public accounting firm, and submit to the SEC, on Form
6-K, unaudited quarterly financial information for the first three quarters of each fiscal year.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
maintain a corporate website at http://www.nanox.vision. In accordance with NASDAQ Stock Market Rule 5250(d), we will post this annual
report on Form 20-F on our website. Information contained on our website is not incorporated by reference into this annual report on
Form 20-F. In addition, we will provide hardcopies of our annual report on Form 20-F free of charge to shareholders upon request.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">I.
Subsidiary Information</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_012"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 11.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Qualitative
                                            and Quantitative Disclosures About Market Risk</span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Interest
Rate Risk</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2021, we had cash equivalents
consisting primarily of U.S. dollar bank deposits. Our&#160;primary exposure to market risk is interest income sensitivity, which is affected
by changes in the general level of U.S. interest rates. Consequently, changes in market interest rates would not have a material impact
on our financial position or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2021, we had no debt outstanding and are therefore
not exposed to interest rate risk with respect to the cost of servicing and repaying debt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Inflation-related
Risks</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not believe that the rate of inflation in
Israel has had a material impact on our business to date, however, our costs in Israel will increase if the inflation rate in Israel
exceeds the devaluation of the NIS against the U.S. dollar or if the timing of such devaluation lags behind inflation in Israel. Similarly,
our costs in Korea will increase if the inflation rate in Korea exceeds the devaluation of the KRW against the U.S. dollar or if the
timing of such devaluation lags behind inflation in Korea.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Foreign
Currency Exchange Risk</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The U.S. dollar is our functional
and reporting currency. However, a portion of our operating expenses, including personnel and facilities related expenses, are incurred
in NIS and KRW. As a result, our statements of operations and cash flows could be adversely affected in the future due to changes in
foreign exchange rates. If the NIS and KRW appreciate relative to the U.S. dollar, the dollar cost of our operations in Israel or Korea
would increase, respectively, and our dollar-denominated results of operations would be adversely affected. However, as we have cash
and cash equivalents denominated in U.S. dollars, we believe that changes in foreign currency exchange rates would not have a material
impact on our financial position or results of operations.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_013"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 12.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Description
                                            of Securities Other than Equity Securities</span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A.
Debt Securities</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">B.
Warrants and Rights</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">C.
Other Securities</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">D.
American Depositary Shares</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">PART
II</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_015"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 13.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Defaults,
                                            Dividend Arrearages and Delinquencies</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 14.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Material
                                            Modifications to the Rights of Security Holders and Use of Proceeds</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Initial Public Offering</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 25, 2020, we completed an initial public
offering in the United States on Nasdaq of our ordinary shares, par value NIS 0.01 per share, pursuant to a Registration Statement on
Form F-1, as amended (File No. 333-240209), which became effective on August 20, 2020. Cantor Fitzgerald &amp; Co., Oppenheimer &amp;
Co. Inc., Berenberg and CIBC Capital Markets acted as joint book-runners. National Securities Corporation acted as co-manager for the
offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We issued and sold 10,555,556 ordinary shares at
a public offering price of $18 per share, including 1,376,812 additional ordinary shares purchased by the underwriters at the public offering
price, less the underwriting discount, pursuant to the exercise in full of their option to purchase additional ordinary shares. Following
the sale of our ordinary shares in connection with the initial public offering, the offering terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The gross proceeds of the shares sold (including
the over-allotment option) was approximately $190.0 million. The total expenses of the offering, including underwriting discounts and
commissions, were approximately $20.8 million. The net proceeds we received from the offering (including the over-allotment option) were
approximately $169.2 million. No payments for such expenses were made directly or indirectly to (i)&#160;any of our directors, officers
or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii)&#160;any of our affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There has been no material change in the expected use of the net proceeds
from our initial public offering as described in our final prospectus filed with the SEC on August 24, 2020 pursuant to Rule 424(b)<span>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_017"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 15.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Controls
                                            and Procedures</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Disclosure
                                            Controls and Procedures</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Management
of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the
Company&#8217;s disclosure controls and procedures as of December&#160;31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company&#8217;s disclosure
controls and procedures are designed to ensure that information required to be disclosed by the issuer in the reports that it files or
submits under the Exchange Act of 1934, as amended, is recorded, processed, summarized and reported, within the time periods specified
in the Commission&#8217;s rules and forms, and that such information is accumulated and communicated to management of the Company, including
its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Based on their evaluation,
as of the end of the period covered by this Annual Report on Form 20-F, the Company&#8217;s Chief Executive Officer and Chief Financial
Officer have concluded that the Company&#8217;s disclosure controls and procedures were not effective due to material weaknesses in the
Company&#8217;s internal control over financial reporting described below.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">(b)</td><td style="text-align: justify">Management&#8217;s Annual Report on Internal Control Over Financial
Reporting</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our management
is responsible for establishing and maintaining adequate internal control over financial reporting as described in Rules 13a-15(f) and
15d-15(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Internal control over financial reporting is defined
as a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, or persons performing
similar functions, and effected by the Company&#8217;s board of directors, management and other personnel, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles and includes those policies and procedures that: (1) pertain to the maintenance of records that
in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer, (2) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management
and directors of the issuer and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of the issuer&#8217;s assets that could have a material effect on the financial statements.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in our conditions, or that the degree
of compliance with our policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our management, under the
supervision and participation of our Chief Executive Officer and our Chief Financial Officer, has conducted an assessment of the effectiveness
of our internal control over financial reporting as of December&#160;31, 2021 using criteria established in <i>Internal Control &#8212;
Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A material weakness is a deficiency,
or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material
misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Based on this assessment, management has concluded
that we did not maintain effective internal control over financial reporting as of December&#160;31, 2021, due to a lack of sufficient
number of financial reporting personnel with an appropriate level of knowledge, experience and training commensurate with our financial
reporting requirements. This control deficiency contributed to the following additional control deficiencies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">We did not maintain effective internal controls to ensure
processing and reporting of valid transactions is complete, accurate and timely. Specifically, we have not implemented a sufficient level
of formal policies, procedures and documentation that define how transactions across the business cycles are initiated, recorded, processed,
reported, documented, appropriately authorized and approved.</td>
</tr></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.3pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">We did not maintain effective internal control that assure
appropriate segregation of duties is maintained. Certain financial personnel had incompatible duties that allowed for the creation, review
and processing of certain financial data without independent review and authorization. This material weakness affects substantially all
financial statement accounts.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Each of these control deficiencies did not result
in material misstatements of the consolidated financial statements; however, each of the control deficiencies described above could result
in a misstatement that would result in a material misstatement of the annual or interim consolidated financial statements that would
not be prevented or detected. Accordingly, our management has determined that these control deficiencies constitute material weaknesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Remediation Efforts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
management, with the oversight of the Audit Committee of the Board of Directors, has continued the process of remediating the material
weakness. In connection with the remediation process, we have continued to make further progress in implementing a broad range of changes
</span>to our internal control over financial reporting to remediate the material weaknesses described in this item. We are committed
to maintaining a strong internal control environment, including enhancing and supplementing the <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">finance
team and resources with an appropriate level of knowledge and experience in internal control over financial reporting requirements. Our
actions to address the material weaknesses include:</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enhancing
                                            and supplementing the finance team with resources with knowledge and experience in internal
                                            control over financing reporting commensurate with our financial reporting requirements,
                                            including with responsibility for design and implementation of internal controls, increasing
                                            the number of roles, providing Company-sponsored training programs related to internal control
                                            over financial reporting.</span></td>
</tr></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 38.5pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designing
                                            and implementing additional formal policies, procedures and documentation to ensure transactions
                                            are properly initiated, recorded, processed, reported, appropriately authorized and approved,
                                            including enhancing our internal review procedures.</span></td>
</tr></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 38.5pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making
                                            improvements to maintain the appropriate level of segregation of duties including defining
                                            new finance personnel roles as well as designing and implementing additional independent
                                            review and authorization and compensating controls.</span></td>
</tr></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 38.5pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continue
                                            implementing a new Enterprise Resource Planning system to support efficient automated controls
                                            and manual controls that are dependent on system reports.</span></td>
</tr></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-indent: 0.5in">We believe we have made substantial progress
in accordance with our remediation plan. The material weaknesses will not be considered remediated until we have completed implementing
the necessary controls and applicable controls operate for a sufficient period of time and management has concluded, through testing,
that these controls are operating effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-indent: 0.5in">We cannot determine when our remediation
plan will be fully completed, and we cannot provide any assurance that these remediation efforts will be successful or that our internal
control over financial reporting will be effective as a result of these efforts.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Attestation
                                            Report of the Registered Public Accounting Firm</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-indent: 0.5in">Our internal control
over financial reporting as of December&#160;31, 2021 has been audited by&#160;Kesselman &amp; Kesselman, an independent registered public
accounting firm in&#160;Israel&#160;and a member of PricewaterhouseCoopers International Limited, as stated in their report which is
included under &#8220;Item 18&#8212;Financial Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; ">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(d)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Changes
                                            in Internal Control Over Financial Reporting</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
were no changes in our internal control over financial reporting during the period covered by this annual report on Form 20-F that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_018"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 16.</span></td><td><span style="font-family: Times New Roman, Times, Serif">[Reserved]</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="v_027"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(a)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Audit Committee
                                            Financial Expert</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Noga
Kainan, an independent director and a member of our audit committee, is an audit committee financial expert.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="v_028"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(b)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Code of
                                            Ethics</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have adopted a code of ethics and conduct, which is applicable to all of our directors, officers and employees. We have made our code
of ethics publicly available on our website.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="v_029"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(c)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Principal
                                            Accountant Fees and Services</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the aggregate fees
by categories specified below in connection with certain professional services rendered by Kesselman &amp; Kesselman, Certified Public
Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, our independent registered public accounting firm,
for the periods indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year Ended<br/>
December 31,</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 76%"><span style="font-size: 10pt">Audit Fees<sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">376,000</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right; width: 9%"><span style="font-size: 10pt">608,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Audit-Related Fees<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Tax Fees<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">10,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">19,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Other Fees<sup>(4)</sup></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">386,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">627,000</span></td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 3pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: left"><span style="font-size: 10pt">&#8220;Audit Fees&#8221; represents
the aggregate fees billed or accrued for the interim reviews and audit of our annual financial statements. This category also includes
services that generally the independent accountant provides, such as consents and assistance with and review of documents filed with
the SEC as well as fees related to audits in connection with our initial public offering in August 2020 and our secondary public offering
in February 2021.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8220;Audit-Related
                                            Fees&#8221; represents the aggregate fees billed or accrued for assurance and related services
                                            that are reasonably related to the performance of the audit or review of our financial statements
                                            and not reported under &#8220;Audit Fees.&#8221;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#8220;Tax Fees&#8221;
                                            represents the aggregate fees billed or accrued for professional tax services rendered by
                                            our independent registered public accounting firm for tax compliance and tax advice on actual
                                            or contemplated transactions.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#8220;All Other
                                            Fees&#8221; represents the aggregate fees billed or accrued for services rendered by our
                                            independent registered public accounting firm other than services reported under &#8220;Audit
                                            Fees,&#8221; &#8220;Audit-related Fees&#8221; and &#8220;Tax Fees.&#8221;</span></td></tr></table><div>




</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Audit
Committee Pre-Approval Policies and Procedures</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Audit Committee has adopted a policy pursuant to which we will not engage our auditors to perform any non-audit services unless the audit
committee pre-approves the service.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_019"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 16D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Exemptions
                                            from the Listing Standards for Audit Committees</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_020"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 16E.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Purchases
                                            of Equity Securities by the Issuer and Affiliated Purchasers</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_021"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 16F.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Change
                                            in Registrant&#8217;s Certifying Accountant</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_022"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 16G.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Corporate
                                            Governance</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
a foreign private issuer, we are permitted to follow certain Israeli corporate governance practices instead of the Nasdaq corporate governance
rules, provided that we disclose which requirements we are not following and the equivalent Israeli requirement. Pursuant to the &#8220;foreign
private issuer exemption&#8221;:</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">we comply with Israeli law with respect to quorum requirements. In accordance with the Companies Law, our amended and restated articles
of association provide that a quorum of two or more shareholders holding at least 25% of the voting rights in person or by proxy is required
for commencement of business at a general shareholder meeting. The quorum set forth in our amended and restated articles of association
with respect to an adjourned meeting shall, subject to a limited exception, consist of one or more shareholders present in person or
by proxy (including by voting deed), regardless of the number or percentage of our outstanding shares held by them;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">we
follow Israeli corporate governance practices instead of the Nasdaq requirements with regard to the nomination committee and director
nomination procedures. The nominations for directors, which are presented to our shareholders by our board of directors, are generally
made by the board of directors itself, in accordance with the provisions of our amended and restated articles of association and the
Companies Law. With the exception of directors elected by our board of directors due to a vacancy, in accordance with the staggered nomination
as described under &#8220;Item 6. Directors, Senior Management and Employees&#8212;C. Board Practices&#8212;Board of Directors,&#8221;
we intend to elect our directors to hold office until the annual general meeting of our shareholders that occurs in the third year following
his or her election and until his or her successor shall be elected and qualified;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">we
                                            intend to adopt and approve material changes to equity incentive plans in accordance with
                                            the Companies Law, which does not impose a requirement of shareholder approval for such actions.
                                            In addition, we intend to follow Israeli corporate governance practice, which requires shareholder
                                            approval prior to an issuance of securities in connection with equity-based compensation
                                            of officers, directors, employees or consultants only under certain circumstances, in lieu
                                            of Nasdaq Marketplace Rule 5635(c);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">as
                                            opposed to making periodic reports to shareholders and proxy solicitation materials available
                                            to shareholders in the manner specified by the Nasdaq corporate governance rules, the Companies
                                            Law does not require us to distribute periodic reports directly to shareholders, and the
                                            generally accepted business practice in Israel is not to distribute such reports to shareholders
                                            but to make such reports available through a public website. We will only mail such reports
                                            to shareholders upon request. As a foreign private issuer, we are generally exempt from the
                                            SEC&#8217;s proxy solicitation rules; and</span></td></tr></table><div>

</div><div><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">we
                                            follow Israeli corporate governance practices instead of Nasdaq requirements to obtain shareholder
                                            approval for all corporate actions requiring such approval under the requirements of the
                                            Companies Law such as (i)&#160;transactions with directors concerning the terms of their
                                            service or indemnification, exemption and insurance for their service (or for any other position
                                            that they may hold at our company), (ii)&#160;extraordinary transactions with controlling
                                            shareholders, (iii)&#160;terms of employment or other engagement of the controlling shareholder
                                            of the company or such controlling shareholder&#8217;s relative, (iv)&#160;private placements
                                            that will result in a change of control, (v)&#160;certain transactions, other than a public
                                            offering, involving issuances of a 20% or greater interest in us and (vi)&#160;certain acquisitions
                                            of the stock or assets of another company.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Otherwise,
we intend to comply with the rules generally applicable to U.S. domestic companies listed on the Nasdaq. We may in the future decide
to use the foreign private issuer exemption with respect to some or all of the other Nasdaq corporate governance rules. We also intend
to comply with Israeli corporate governance requirements under the Companies Law applicable to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_023"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 16H.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Mine Safety
                                            Disclosure</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><div><a id="I_001"></a></div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 16I.</b></span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-left: 0.5in; margin-top: 0; margin-bottom: 0">Not
applicable.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_027"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">PART
III</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_029"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 17.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Financial
                                            Statements</span></td></tr></table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">We
have elected to provide financial statements pursuant to Item 18.&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_025"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><span style="font-family: Times New Roman, Times, Serif">Item 18.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Financial
                                            Statements</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements of Nano-X Imaging Ltd. are included at the end of this annual report on Form 20-F.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_026"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="width: 0"></td>
    <td style="width: 0.75in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 19.</b></span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits</b></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 10%"><b>Exhibit No.</b></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 89%"><b>Description</b></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">1.1*</p></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1795251/000114036120018404/nt10006151x9_ex3-2.htm">Form of Amended and Restated Articles of Association of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Registration Statement on Form F-1/A (File No. 333-240209) filed on August&#160;14, 2020 with the SEC)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">2.1&#8224;</td>
    <td>&#160;</td>
    <td><a href="f20f2021ex2-1_nanox.htm">Description of Securities Registered under Section 12 of the Exchange Act</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">4.1&#8224;</td>
    <td>&#160;</td>
    <td><a href="f20f2021ex4-1_nanox.htm">Asset Purchase Agreement, dated November&#160;3, 2021, among MDWEB, LLC, Nano-X Imaging. and Nano-X Imaging Ltd.</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">4.2&#8224;</td>
    <td>&#160;</td>
    <td><a href="f20f2021ex4-2_nanox.htm">Agreement and Plan of Merger, dated August 9, 2021, among Nano-X Imaging Ltd, Zebra Medical Vision Ltd. and PerryLLion Ltd.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">4.3&#8224;</td>
    <td>&#160;</td>
    <td><a href="f20f2021ex4-3_nanox.htm">First Amendment to the Agreement and Plan of Merger, dated August 9, 2021, among Nano-X Imaging Ltd, Zebra Medical Vision Ltd. and PerryLLion Ltd.</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">4.4<span style="font-size: 10pt">&#8224;</span></td>
    <td>&#160;</td>
    <td><a href="f20f2021ex4-4_nanox.htm">Stock Purchase Agreement dated November 2, 2021 by and among&#160;Dr. Michael Yuz, Dr.
    Michael Yuz as the representative of Sellers, USARAD Holdings, Inc. and Nano-X Imaging Ltd</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">4.5<span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001795251/000114036120017084/nt10006151x8_ex4-5.htm">Form of warrants to purchase ordinary shares issued to A-Labs Finance and Advisory Ltd. (incorporated by reference to Exhibit 4.5 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&#160;30, 2020 with the SEC)</a></td></tr>

<tr style="vertical-align: top; ">
    <td style="text-align: center">4.6<span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001795251/000114036120017084/nt10006151x8_ex4-6.htm">Warrant to purchase ordinary shares, dated September&#160;2, 2019, issued to SK Telecom TMT Investment Corp. (incorporated by reference to Exhibit 4.6 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&#160;30, 2020 with the SEC)</a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">4.7*</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001795251/000114036120017084/nt10006151x8_ex4-7.htm">Amendment to Warrant to purchase ordinary shares, dated June&#160;4, 2020, issued to SK Telecom TMT Investment Corp. (incorporated by reference to Exhibit 4.7 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&#160;30, 2020 with the SEC)</a></td></tr>
<tr style="vertical-align: top; ">
    <td style="text-align: center">4.8<span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex10-1.htm">Contract Manufacturing Agreement, dated May&#160;26, 2020, by and between the Registrant and FoxSemicon Integrated Technology, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&#160;30, 2020 with the SEC)</a></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1795251/000114036120018404/nt10006151x9_ex10-2.htm">Registration Rights Agreement by and among the Registrant and the certain shareholders named therein (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form F-1/A (File No. 333-240209) filed on August&#160;14, 2020 with the SEC)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex10-3.htm">2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&#160;30, 2020 with the SEC)</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1795251/000114036120017084/nt10006151x8_ex10-4.htm">U.S. Sub-Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-240209) filed on July&#160;30, 2020 with the SEC)</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12*</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1795251/000114036120018404/nt10006151x9_ex10-5.htm">Form of Indemnification Agreement between the Registrant and each director and executive officer (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form F-1/A (File No. 333-240209) filed on August&#160;14, 2020 with the SEC)</a></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">4.13<span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001795251/000114036120030050/brhc10018522_ex99-1.htm">Compensation Policy for Executive Officers and Directors (incorporated by reference to Exhibit A to the Proxy Statement filed as Exhibit 99.1 to the Registrant&#8217;s Form 6-K (File No. 001-39461) filed on December 31, 2020 with the SEC)</a></td></tr>
<tr style="vertical-align: top; ">
    <td style="text-align: center">4.14<span style="font-size: 10pt">*</span></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001795251/000114036120030050/brhc10018522_ex99-1.htm">Equity Compensation Plan for Executive Officers and Directors (incorporated by reference to Exhibit B to the Proxy Statement filed as Exhibit 99.1 to the Registrant&#8217;s Form 6-K (File No. 333-001-39461) filed on December 31, 2020 with the SEC)</a></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 10%">8.1&#8224;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 89%"><a href="f20f2021ex8-1_nanox.htm">List of subsidiaries of the Registrant</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">12.1<span style="font-size: 10pt">&#8224;</span></td>
    <td>&#160;</td>
    <td><a href="f20f2021ex12-1_nanox.htm">Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">12.2<span style="font-size: 10pt">&#8224;</span></td>
    <td>&#160;</td>
    <td><a href="f20f2021ex12-2_nanox.htm">Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">13.1&#177;</td>
    <td>&#160;</td>
    <td><a href="f20f2021ex13-1_nanox.htm">Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">13.2&#177;</td>
    <td>&#160;</td>
    <td><a href="f20f2021ex13-2_nanox.htm">Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">15.1&#8224;</td>
    <td>&#160;</td>
    <td><span><a href="f20f2021ex15-1_nanox.htm">Consent of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.) a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting firm.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">101.INS</td>
    <td>&#160;</td>
    <td>XBRL Instance Document</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">101.SCH</td>
    <td>&#160;</td>
    <td>XBRL Taxonomy Extension Schema Document</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">101.CAL</td>
    <td>&#160;</td>
    <td>XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">101.DEF</td>
    <td>&#160;</td>
    <td>XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center">101.LAB</td>
    <td>&#160;</td>
    <td>XBRL Taxonomy Extension Label Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: center">101.PRE</td>
    <td>&#160;</td>
    <td>XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
  </table><div>
</div><p style="margin: 0"></p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 40%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0"></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td><span style="font-family: Times New Roman, Times, Serif">Previously filed.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#8224;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Filed herewith.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#177;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Furnished
                                            herewith.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
reviewing the agreements included as exhibits to this annual report on Form 20-F, please remember they are included to provide you with
information regarding their terms and are not intended to provide any other factual or disclosure information about us or the other parties
to the agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties
have been made solely for the benefit of the other parties to the applicable agreement and:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">should
                                            not in all instances be treated as categorical statements of fact, but rather as a way of
                                            allocating the risk to one of the parties if those statements prove to be inaccurate;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">have
                                            been qualified by disclosures that were made to the other party in connection with the negotiation
                                            of the applicable agreement, which disclosures are not necessarily reflected in the agreement;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">may
                                            apply standards of materiality in a way that is different from what may be viewed as material
                                            to you or other investors; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">were
                                            made only as of the date of the applicable agreement or such other date or dates as may be
                                            specified in the agreement and are subject to more recent developments.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Accordingly,
these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">SIGNATURES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">NANO-X
IMAGING LTD hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized
the undersigned to sign this annual report on Form 20-F on its behalf.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt">NANO-X IMAGING LTD</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Erez Meltzer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="width: 31%"><span style="font-size: 10pt">Erez Meltzer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 2, 2022</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED FINANCIAL STATEMENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INDEX</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 90%; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><b>Page</b></td></tr>
<tr style="vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><b><a href="#n_001">Report of Independent Registered Public Accounting Firm (PCAOB name: <ix:nonNumeric contextRef="c0" name="dei:AuditorName">Kesselman &amp; Kesselman C.P.A.s</ix:nonNumeric> and PCAOB ID:&#160;<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">1309</ix:nonNumeric>)</a></b></td> <td style="text-align: center">F-2 &#8211; F-3</td></tr>
<tr style="vertical-align: top; "> <td style="text-align: left">&#160;</td> <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><a href="#fin_002"><b>Consolidated Balance Sheets</b></a></td> <td style="text-align: center">F-4</td></tr>
<tr style="vertical-align: top; "> <td style="text-align: left">&#160;</td> <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><a href="#fin_003"><b>Consolidated Statements of Operations</b></a></td> <td style="text-align: center">F-5</td></tr>
<tr style="vertical-align: top; "> <td style="text-align: left">&#160;</td> <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><a href="#fin_004"><b>Consolidated Statements of Changes in Shareholders&#8217; Equity (Capital Deficiency)</b></a></td> <td style="text-align: center">F-6</td></tr>
<tr style="vertical-align: top; "> <td style="text-align: left">&#160;</td> <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><a href="#fin_005"><b>Consolidated Statements of Cash Flows</b></a></td> <td style="text-align: center">F-7</td></tr>
<tr style="vertical-align: top; "> <td style="text-align: left">&#160;</td> <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: left"><a href="#fin_006"><b>Notes to the Consolidated Financial Statements</b></a></td> <td style="text-align: center">F-8 &#8211; F-42</td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>


</div><!-- Field: Page; Sequence: 142; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="n_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; "><img alt="" src="image_007.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Report of Independent Registered Public
Accounting Firm </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">To the Board of Directors and Shareholders
of Nano-X Imaging Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Opinions on the Financial Statements
and Internal Control over Financial Reporting</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">We have audited the accompanying
consolidated balance sheets of Nano-X Imaging Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020,
and the related consolidated statements of operations, of changes in shareholders&#8217; equity and of cash flows for each of the three
years in the period ended December 31, 2021, including the related notes (collectively referred to as the &#8220;consolidated financial
statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2021, based on criteria
established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">In our opinion, the consolidated
financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December
31, 2021 and 2020<b>, </b>and the results of its operations and its cash flows for each of the three years in the period ended December
31, 2021 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company
did not maintain, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria
established in <i>Internal Control - Integrated Framework</i> (2013) issued by the COSO because material weaknesses in internal control
over financial reporting existed as of that date. The Company (i) lacked a sufficient number of financial reporting personnel with an
appropriate level of knowledge, experience and training commensurate with the Company&#8217;s financial reporting requirements, which
contributed to additional material weaknesses as the Company (ii) did not design and maintain effective internal controls to ensure processing
and reporting of transactions are complete, accurate, and timely and did not implement a sufficient level of formal policies, procedures
and documentation that define how transactions across all the business cycles are initiated, recorded, processed, reported, documented,
appropriately authorized and approved, (iii) did not design and maintain effective internal controls to ensure appropriate segregation
of duties is maintained, and (iv) did not design and maintain effective internal controls over certain information technology ("IT")
general controls for applications used in the preparation of the Company&#8217;s consolidated financial statements. A material weakness
is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility
that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material
weaknesses referred to above are described in Management's Report on Internal Control over Financial Reporting appearing in Item 15A.
We considered these material weaknesses in determining the nature, timing, and extent of audit tests applied in our audit of the 2021
consolidated financial statements, and our opinion regarding the effectiveness of the Company&#8217;s internal control over financial
reporting does not affect our opinion on those consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Basis for Opinions</i></b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">The Company's management
is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for
its assessment of the effectiveness of internal control over financial reporting, included in appearing under Item 15A. Our responsibility
is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting
based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">We conducted our audits
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance
about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective
internal control over financial reporting was maintained in all material respects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">Our audits of the consolidated
financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements,
whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial
statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial
reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal
control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances.
We believe that our audits provide a reasonable basis for our opinions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "></p><div>

</div><!-- Field: Page; Sequence: 143; Options: NewSection; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Definition and Limitations of Internal
Control over Financial Reporting</i></b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">A company&#8217;s internal
control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s
internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that,
in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management
and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">Because of its inherent
limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Critical Audit Matters</i></b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">The critical audit matter
communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or
required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated
financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit
matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating
the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which
it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><i>Purchase Price Allocation - Nanox AI Ltd.
(formally Zebra Medical Vision Ltd.)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">As described in Note
3a, the Company completed the acquisition of 100% of Nanox AI Ltd. (formally Zebra Medical Vision Ltd.) on November 4, 2021 for total
consideration of $129.3 million. The consideration was given by issuing the Company&#8217;s ordinary shares in an amount of $88.5 million
as well additional contingent payments estimated at a fair value of $40.8 million that is payable in additional shares upon achievement
of certain milestones. Management applied significant judgment in estimating the fair value of the intangible assets acquired, which included
cash flow projections and the discount rate used in respect of the intangible assets recorded. In addition significant assumptions were
made with respect to the contingent consideration recorded that included the achievement and timing of the milestones.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">The principal considerations
for our determination that performing procedures relating to the acquisition of Nanox AI Ltd. is a critical audit matter are (i) there
was a high degree of auditor judgment and subjectivity in applying procedures relating to the fair value measurement of intangible assets
acquired, the contingent consideration recorded due to the significant amount of judgment by management when developing the estimates;
(ii) significant audit effort was required in evaluating the significant assumptions relating to the estimates, such as the achievement
of certain milestones and the related timing of the contingent payments, as well as the cash flow projections and the discount rate used
with respect of the intangible assets recorded; and (iii) the audit effort involved the use of professionals with specialized skill and
knowledge.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">Addressing the matter
involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial
statements. These procedures included, among others, (i) reading the share purchase agreements; (ii) testing management&#8217;s process
for estimating the fair value of intangible assets; and (iii) testing management&#8217;s cash flow projections used to estimate the fair
value of the intangible assets, using professionals with specialized skill and knowledge to assist in doing so. Testing management&#8217;s
process included evaluating the appropriateness of the valuation methods and the reasonableness of significant assumptions, including
the cash flow projections and the discount rate for the intangible assets and contingent consideration. Evaluating the reasonableness
of the projections involved considering the past performance of the acquired businesses, as well as economic and industry forecasts. The
discount rate was evaluated by considering the cost of capital of comparable businesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">/s/Kesselman &amp; Kesselman</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">Certified Public Accountants (Isr.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">A member firm of PricewaterhouseCoopers International
Limited</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation">Tel-Aviv, Israel</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">May 2, 2022</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">We have served as the Company&#8217;s auditor
since 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><!-- Field: Page; Sequence: 144; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED BALANCE SHEETS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2020</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center">U.S. Dollars in thousands</td><td style="font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">66,645</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">213,468</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Marketable Securities - short term</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd">22,066</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts receivables net of allowance for credit losses of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" unitRef="usd"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" unitRef="usd">137</ix:nonFraction></ix:nonFraction> and o thousand as of December&#160;31, 2021 and December 31,2020, respectively.</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" unitRef="usd">1,051</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Prepaid expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd">3,129</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd">4,788</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other current assets</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd">1,966</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd">1,537</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL CURRENT ASSETS</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">94,857</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">219,793</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Restricted cash</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd">127</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd">316</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Property and equipment, net</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">37,435</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">14,020</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Operating lease right-of-use asset</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">1,725</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">1,359</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Marketable Securities - long term</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesNoncurrent" scale="3" unitRef="usd">67,845</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Intangible assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" unitRef="usd">101,826</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-indent: -9pt; padding-left: 0.25in">Goodwill</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" unitRef="usd">58,298</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other non-current assets</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd">1,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd">661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL NON-CURRENT ASSETS</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">268,313</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">16,356</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">TOTAL ASSETS</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">363,170</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">236,149</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: center; text-indent: -9pt; padding-left: 9pt">Liabilities and Shareholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Accounts payable</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd">3,134</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd">435</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Accrued expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd">3,611</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd">1,931</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Loan from a Government Agency</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="3" unitRef="usd">145</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Deferred revenue</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">247</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Contingent short term earnout liability</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd">42,471</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Current maturities of operating lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">881</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">519</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other current
    liabilities</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd">2,262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd">1,595</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL CURRENT LIABILITIES</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">52,751</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">4,480</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Non-current operating lease liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">950</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">923</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Long term loan</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLongTermDebtNoncurrent" scale="3" unitRef="usd">3,796</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Non-current deferred revenue</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">415</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Contingent long-term earnout liability</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" unitRef="usd">5,814</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Deferred tax liability</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" unitRef="usd">7,063</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other long-term liabilities</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" unitRef="usd">233</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL NON-CURRENT LIABILITIES</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">18,271</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL LIABILITIES</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">71,022</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">5,403</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">COMMITMENTS AND CONTINGENCIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">SHAREHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Ordinary Shares, par value NIS <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">0.01</ix:nonFraction></ix:nonFraction> per share <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></ix:nonFraction> authorized at December 31, 2021 and December 31 2020, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">51,791,441</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">46,100,173</ix:nonFraction></ix:nonFraction> issued and outstanding at September 30, 2021 and December 31, 2020, respectively</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">149</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">131</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">438,820</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">315,031</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Accumulated other comprehensive deficit</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd">607</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">146,214</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">84,416</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL SHAREHOLDERS&#8217; EQUITY</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">292,148</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">230,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">363,170</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">236,149</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes are an integral part
of these consolidated financial statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 145; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF OPERATIONS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. Dollars in thousands</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">REVENUE</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">1,304</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">COST OF REVENUE</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" unitRef="usd">2,816</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">GROSS LOSS</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" sign="-" unitRef="usd">1,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">OPERATING EXPENSES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">17,122</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">9,210</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">2,717</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Sales and Marketing</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd">7,033</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd">12,445</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd">1,556</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">34,709</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">22,268</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">18,298</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Other expenses</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd">1,182</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL OPERATING EXPENSES</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">60,046</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">43,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd">22,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">OPERATING LOSS</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">61,558</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">43,923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">22,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><b>FINANCIAL INCOME (EXPENSES),
    </b>net</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" sign="-" unitRef="usd">288</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" unitRef="usd">108</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">OPERATING LOSS BEFORE INCOME TAXES</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">61,846</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">43,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">22,563</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">INCOME TAX BENEFIT</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">NET LOSS</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">61,798</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">43,815</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">22,563</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">BASIC AND DILUTED LOSS PER SHARE</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">1.28</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">1.23</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.90</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"><b>THE WEIGHTED AVERAGE OF THE NUMBER OF ORDINARY
    SHARES</b> (in thousands)</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">48,216</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">35,654</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">25,181</ix:nonFraction></td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">NET LOSS</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">61,798</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">43,815</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">22,563</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Other comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Unrealized loss from available-for-sale securities</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="3" sign="-" unitRef="usd">607</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total other comprehensive loss:</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd">607</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL COMPERHENSIVE LOSS</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd">62,405</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd">43,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" sign="-" unitRef="usd">22,563</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes are an integral part
of these consolidated financial statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 146; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY (CAPITAL DEFICIENCY)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Ordinary shares</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt"><b>Accumulated</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of<br/>
shares</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Additional<br/>
paid-in<br/>
capital</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>other<br/>
comprehensive<br/>
deficit</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Accumulated<br/>
deficit</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>U.S. Dollars in thousands</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 28%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>BALANCE AT JANUARY 1, 2019</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">21,924,208</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">58</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">11,596</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16"><span style="font-size: 10pt">-</span></div></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">18,038</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">6,384</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>CHANGES DURING 2019:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Issuance of ordinary shares and warrants, net of issuance costs</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" scale="0" unitRef="shares">4,762,656</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" scale="3" unitRef="usd">16</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" scale="3" unitRef="usd">14,022</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" scale="3" unitRef="usd">14,038</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Issuance of ordinary shares to employees and non-employees upon exercise of warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">454,166</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">1</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">136</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">137</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Issuance of ordinary shares to investors upon exercise of warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" scale="0" unitRef="shares">9,050</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19"><span style="font-size: 10pt">*</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" scale="3" unitRef="usd">25</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" scale="3" unitRef="usd">25</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Share-based compensation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#160;</div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">16,245</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">16,245</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Additional consideration with respect to an assets purchase agreement, see&#160;&#160;note 9a</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23"><span style="font-size: 10pt">-&#160;</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" scale="3" sign="-" unitRef="usd">10,276</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24"><span style="font-size: 10pt">-&#160;</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" scale="3" sign="-" unitRef="usd">10,276</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Net loss for the year</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">&#160;</div></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#160;</div></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">22,563</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">22,563</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>BALANCE AT DECEMBER 31, 2019</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">27,150,080</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">75</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">31,748</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">40,601</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">8,778</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>CHANGES DURING 2020:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Issuance of ordinary shares and warrants, net of issuance costs</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" scale="0" unitRef="shares">4,624,500</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" scale="3" unitRef="usd">14</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" scale="3" unitRef="usd">70,999</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" scale="3" unitRef="usd">71,013</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Initial public offering of ordinary shares, net of offering costs</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">10,555,556</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">31</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">169,136</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">169,167</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Issuance of ordinary shares to employees and non-employees upon exercise of warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">997,863</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">3</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">497</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">500</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Issuance of ordinary shares to investors upon exercise of warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" scale="0" unitRef="shares">1,662,929</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" scale="3" unitRef="usd">5</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" scale="3" unitRef="usd">125</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31"><span style="font-size: 10pt">-&#160;</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" scale="3" unitRef="usd">130</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Share-based compensation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#160;</div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">24,781</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#160;</div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">24,781</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Conversion of related party liability to shareholders&#8217; equity, see note 9a</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">1,109,245</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd">3</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd">17,745</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-&#160;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd">17,748</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Net loss for the year</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">43,815</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">43,815</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>BALANCE AT DECEMBER 31, 2020</b></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">46,100,173</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">131</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">315,031</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35"><span style="font-size: 10pt">-</span></div></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">84,416</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">230,746</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>CHANGES DURING 2021:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Issuance of ordinary shares upon exercise of warrants</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares" scale="0" unitRef="shares">780,920</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants" scale="3" unitRef="usd">2</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants" scale="3" unitRef="usd">265</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants" scale="3" unitRef="usd">267</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Issuance of ordinary shares to employees and non-employees upon exercise of options</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares" scale="0" unitRef="shares">1,099,946</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" scale="3" unitRef="usd">3</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" scale="3" unitRef="usd">3,330</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" scale="3" unitRef="usd">3,333</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Issuance of ordinary shares due to business combination and assets acquisition (refer to Note 3)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin" scale="0" unitRef="shares">3,810,402</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" scale="3" unitRef="usd">13</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" scale="3" unitRef="usd">101,497</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40"><span style="font-size: 10pt">-&#160;</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" scale="3" unitRef="usd">101,510</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Share-based compensation</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">18,697</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">18,697</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Unrealized loss from available-for-sale securities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd">607</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45"><span style="font-size: 10pt">--</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" sign="-" unitRef="usd">607</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -9pt"><span style="font-size: 10pt">Net loss for the year</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46"><span style="font-size: 10pt">-</span></div></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#160;</div></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#160;</div></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">61,798</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">61,798</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>BALANCE AT DECEMBER 31, 2021</b></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">51,791,441</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">149</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">438,820</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">607</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">146,214</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">292,148</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(*)</span></td><td style="text-align: left"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-size: 10pt">Less than 1 thousand US dollars.</span></ix:footnote></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes are an integral part
of these consolidated financial statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 147; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. Dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.25in; padding-left: 27pt">Net loss for the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">61,798</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">43,815</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">22,563</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 27pt">Adjustments required to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">18,806</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">24,781</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">16,245</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" unitRef="usd">1,768</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.5in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">524</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">208</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">53</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Impairment of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" sign="-" unitRef="usd">214</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Deferred income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" sign="-" unitRef="usd">116</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Amortization of premium on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" scale="3" unitRef="usd">216</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Changes in operating assets and liabilities, net of effects of businesses acquired:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" unitRef="usd">40</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" sign="-" unitRef="usd">1,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" unitRef="usd">4,478</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" unitRef="usd">1,564</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Related party prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses" scale="3" sign="-" unitRef="usd">1,081</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Other non-current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd">374</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd">522</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd">139</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd">1,721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd">103</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd">393</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Operating lease assets and liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IncreaseDecreaseOperatingLease" scale="3" unitRef="usd">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IncreaseDecreaseOperatingLease" scale="3" unitRef="usd">83</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Accrued expenses and other liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd">719</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd">2,359</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" unitRef="usd">970</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.5in">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" unitRef="usd">179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.5in">Other long-term liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" unitRef="usd">233</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 27pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">38,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">21,487</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">5,524</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.25in; padding-left: 0.25in">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 27pt">Cash paid for business combinations, net of cash and restricted cash acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" unitRef="usd">2,859</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 27pt">Investment in marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesRealizedGainLoss" scale="3" unitRef="usd">90,303</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 27pt">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">23,158</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">13,937</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 27pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">116,320</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">13,937</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.25in; padding-left: 0.25in">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Proceeds from long term loan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="3" unitRef="usd">3,796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Proceeds from issuance of ordinary shares and warrants, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" scale="3" unitRef="usd">71,013</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" scale="3" unitRef="usd">14,038</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Proceeds from initial public offering of ordinary shares, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" unitRef="usd">169,348</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Proceeds from issuance of ordinary shares upon exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd">267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd">630</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd">162</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in">Issuance of ordinary shares to employees and non-employees upon exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">3,316</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">Deferred offering costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfFinancingCosts" scale="3" unitRef="usd">339</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">7,379</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">240,991</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">13,861</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.25in; padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -0.25in; padding-left: 0.25in">NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">147,012</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">205,567</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">8,212</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.25in; padding-left: 0.25in">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE YEAR</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">213,784</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">8,217</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">66,772</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">213,784</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">8,217</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.25in; padding-left: 0.25in">SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Unpaid offering costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nnox:UnpaidOfferingCosts" scale="3" unitRef="usd">858</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">issuance of ordinary shares to investor upon exercise of warrants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nnox:issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" scale="3" unitRef="usd">200</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Fair value of ordinary shares issued as consideration for purchase of assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" scale="3" unitRef="usd">1,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Fair value of ordinary shares issued as consideration for business combinations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" scale="3" unitRef="usd">100,010</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Fair value of contingent consideration assumed in business combinations</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:FairValueOfContingentConsiderationAssumedInBusinessCombinations" scale="3" unitRef="usd">47,194</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Fair value of contingent consideration assumed in purchase of assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IssuanceOfSharesInConsiderationOfAssets" scale="3" unitRef="usd">1,091</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Right-of-use assets obtained in exchange for new operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" scale="3" unitRef="usd">194</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" scale="3" unitRef="usd">1,085</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" scale="3" unitRef="usd">548</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Additional consideration with respect to an assets purchase agreement</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" scale="3" unitRef="usd">10,276</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.25in; padding-left: 0.25in">Conversion of related party liability to shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity" scale="3" unitRef="usd">17,748</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 6pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">(*)</span></td>
    <td><span style="font-size: 10pt">Less than 1 thousand US dollars.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt; text-indent: -7pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The accompanying notes are an integral part
of these consolidated financial statements</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_NatureOfOperations-c0_cont_1" escape="true" name="us-gaap:NatureOfOperations"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_2" id="_NatureOfOperations-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; font-size: 12pt">&#160;</td>
    <td style="width: 0.25in; font-size: 12pt"><span style="font-size: 10pt"><b>a.</b></span></td>
    <td style="text-align: left; font-size: 12pt"><span style="font-size: 10pt">Nano-X Imaging Ltd, an Israeli Company (hereinafter &#8220;the Company&#8221; or &#8220;Nanox IL&#8221;), was incorporated on December 20, 2018 and commenced its operations on September 3, 2019.</span></td></tr>
  </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_3" id="_NatureOfOperations-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On September 19, 2019, Nanox IL established
Nanox Imaging Inc. (hereinafter &#8220;Nanox Japan&#8221;), a wholly owned subsidiary in Japan.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_4" id="_NatureOfOperations-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On September 25, 2020, Nanox IL established
Nano-X Korea Inc. (hereinafter &#8220;Nanox Korea&#8221;), a wholly owned subsidiary in Korea.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_5" id="_NatureOfOperations-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On September 30, 2021, Nanox IL established
Nanox Imaging Inc. (hereinafter &#8220;Nanox U.S.&#8221;), a wholly owned subsidiary in the United States. On the same date, Nanox U.S. established Nanox MDW Inc. (hereinafter &#8220;Nanox MDW&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_6" id="_NatureOfOperations-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On November 2, 2021, Nanox U.S. completed the acquisition of <ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the
shares of USARAD Holdings, Inc. (refer to Note 3).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_7" id="_NatureOfOperations-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On November 4, 2021, the Company, completed
the merger with Zebra Medical Vision Ltd (refer to Note 3).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_8" id="_NatureOfOperations-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company together with its subsidiaries,
develops a commercial-grade tomographic imaging device with a digital X-ray source, provides teleradiology services and develops artificial
intelligence applications designed to be used in real-world medical imaging applications. The Company&#8217;s solution, referred to as
the Nanox Multi Source System, has two integrated components &#8211; &#8220;Nanox.ARC&#8221; and &#8220;Nanox. CLOUD&#8221;. Nanox.ARC
is a medical tomographic imaging system incorporating the Company&#8217;s novel digital X-ray source. Nanox. CLOUD is a platform which
employs a matching engine to match medical images to radiologists, provides image repository, connectivity to diagnostic assistive
AI systems, billing and reporting. On April 1, 2021, the Company received clearance from the FDA to market the Company&#8217;s Nanox
Cart X-Ray System. In addition, the Company is in the process to receive clearance from the FDA to market the Company&#8217;s Nanox Multi
Source System.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_9" id="_NatureOfOperations-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company has experienced net losses
and negative cash flows from operations since its inception. The&#160;Company anticipates such losses will continue until its product
candidates reach commercial profitability. In August 2020, the Company completed an IPO on Nasdaq with net proceeds received from the
IPO of approximately $<ix:nonFraction contextRef="c37" decimals="-6" format="ixt:num-dot-decimal" name="nnox:InitialPublicOfferingNetProceeds" scale="6" unitRef="usd">169</ix:nonFraction> million. Based on the Company&#8217;s financing activities during the year ended December 31, 2021, the Company
has sufficient funds for its plans for the next twelve months from the issuance of these financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"></p><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_10" id="_NatureOfOperations-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.</b></span></td>
    <td><span style="font-size: 10pt">Current Impact of COVID-19</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_11" id="_NatureOfOperations-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Following the December 2019 outbreak of
Coronavirus (COVID-19) in China, it has spread into most countries across the world, including Israel, Japan and all 50 states within
the U.S. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed
quarantines, travel restrictions and other public health safety measures. The COVID-19 pandemic has adversely impacted the Company&#8217;s
operations in various ways. For example, the Company&#8217;s engineers are unable to make work-related trips to Korea or Israel to test
and optimize the Nanox.ARC. The potential business partners are unable to make on-site visits to the Company&#8217;s facilities or attend
industry conferences and meetings to experience the Nanox.ARC, which has negatively impacted the Company&#8217;s business development
and deployment activities. The external labs the Company works with have also been affected by COVID-19, resulting in delays in the Company&#8217;s
timelines for obtaining regulatory approval. COVID-19 has also caused shutdowns or disruptions of business for our manufactures and suppliers.
The continued spread of COVID-19 globally could adversely impact the Company&#8217;s development, manufacture, or deployment of the Nanox
Systems, which could adversely affect the Company&#8217;s ability to obtain regulatory approval for and to commercialize the Nanox Systems,
increase the operating expenses and have a material adverse effect on the Company&#8217;s financial results.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>


</div><div>


</div><!-- Field: Page; Sequence: 149; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><ix:continuation continuedAt="_NatureOfOperations-c0_cont_12" id="_NatureOfOperations-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.75in; font-size: 10pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>c.</b></span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">Current Impact of geopolitical tensions and the start of the military conflict between Russia and Ukraine</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_NatureOfOperations-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">U.S. and global markets are experiencing
volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and
Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops was reported. Although the length and impact
of the ongoing military conflict is highly unpredictable, the ongoing conflict in Ukraine could lead to market disruptions, including
significant volatility in commodity prices, credit and capital markets. As a result, sanctions and penalties have been levied by the United
States, European Union and other countries against Russia. Russian military actions and the resulting sanctions could have a negative
impact on supply chains, the Company&#8217;s MSaaS agreements relating to Russia and Belarus or the region and adversely affect the global
economy and financial markets. Any of the abovementioned factors could affect the Company&#8217;s business, prospects, financial condition,
and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict,
but could be substantial.</p></ix:continuation><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Our consolidated financial statements are prepared in accordance
with generally accepted accounting principles in the United States (hereinafter -&#8220;U.S GAAP&#8221;). The preparation of our consolidated
financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates
on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates
under different assumptions or conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">In particular, a number of estimates have
been and will continue to be affected by the ongoing COVID-19 pandemic. The severity, magnitude and duration, as well as the economic
consequences, of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. As a result, the accounting estimates
and assumptions may change over time in response to COVID-19. Such changes could have&#160;an&#160;additional&#160;impact on&#160;the
Company&#8217;s long-lived asset and intangible asset valuation; inventory valuation; and the allowance for expected credit losses.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-indent: -1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>a.&#160;</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Use of estimates in the preparation of financial statements</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.75in"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The preparation of the consolidated financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company&#8217;s
consolidated financial statements. As applicable to these consolidated financial statements, the most significant estimates relate to
assets acquired and liabilities assumed through business combination, goodwill impairment, useful lives of intangible assets, deferred
taxes and share-based payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.&#160;</b></span></td> <td><span style="font-size: 10pt"><b>Functional currency</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in">The U.S. dollar is the currency of the primary economic environment
in which the operations of the Company and its subsidiaries is conducted. A substantial portion of the operational costs are denominated
in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar (&#8220;primary currency&#8221;). Foreign currency
assets and liabilities are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date.
Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result
of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during
the period. Currency transaction gains and losses are presented in financial income and expenses, net.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>


</div><!-- Field: Page; Sequence: 150; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" continuedAt="_BusinessCombinationsPolicy-c0_cont_1" escape="true" name="us-gaap:BusinessCombinationsPolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="text-align: left; width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Combinations</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedAt="_BusinessCombinationsPolicy-c0_cont_2" id="_BusinessCombinationsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company allocates the fair value of
consideration transferred in a business combination to the assets acquired, liabilities assumed, and non-controlling interests in the
acquired business based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the
business combination and are expensed as incurred. The excess of the fair value of the consideration transferred plus the fair value of
any non-controlling interest in the acquiree over the fair value of the assets acquired, liabilities assumed in the acquired business
is recorded as goodwill. The fair value of the consideration transferred may include a combination of cash, equity securities, earn out
payments and deferred payments. The allocation of the consideration transferred in certain cases may be subject to revision based on the
final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative
impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company
includes the results of operations of the businesses that it has acquired in its consolidated results prospectively from the respective
dates of acquisition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation continuedAt="_BusinessCombinationsPolicy-c0_cont_3" id="_BusinessCombinationsPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company records obligations in
connection with its business combinations at fair value on the acquisition date. Each reporting period thereafter, the Company revalues
earn-out liabilities and records the changes in their fair value in the consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation id="_BusinessCombinationsPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Changes in the fair value of earn-out liabilities can result from adjustments
to the discount rates, the Company&#8217;s shares price, sales and profitability targets. This fair value measurement represent Level
3 measurements, as they are based on significant inputs not observable in the market. Significant judgment is required in determining
the assumptions utilized as of the acquisition date and for each subsequent period. Accordingly, changes in the assumptions described
above could have a material impact on the Company&#8217;s consolidated results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>d.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Cash and cash equivalents </b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company considers as cash equivalents all short-term,
highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase
that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_MarketableSecuritiesPolicy-c0_cont_1" escape="true" name="us-gaap:MarketableSecuritiesPolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>e.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Marketable Securities</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation id="_MarketableSecuritiesPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">All highly liquid investments are classified
as marketable securities and have been classified and accounted for as available-for-sale. Investment in securities consists of debt
securities classified as available-for-sale and recorded at fair value. The Company classifies its marketable securities as either short-term
or long-term based on each instrument&#8217;s underlying contractual maturity date. Unrealized gains and losses on marketable debt securities
classified as available-for-sale are reported net of the related tax effect in other comprehensive income/(loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>f.</b></span></td><td style="text-align: left"><b>Accounts receivables</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_2" id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Accounts receivable are presented net of the allowance for expected credit loss and consists of short term receivables that arise in the normal course of business. The Company performs ongoing credit evaluations of its customer&#8217;s financial condition and typically requires no collateral from its customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>



</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation continuedAt="_TradeAndOtherAccountsReceivablePolicy-c0_cont_3" id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company adopted the Current Expected
Credit Losses (&#8220;CECL&#8221;) guidance effective January 1, 2020. The Company maintains the allowance for estimated losses resulting
from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime
expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable
forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness,
historical levels of credit losses, and future expectations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Changes in the allowance for&#160;credit losses&#160;are recognized
in, general and administrative expenses. Accounts receivables are written-off against the allowance for&#160;credit losses&#160;when management
deems the accounts are no longer collectible.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </b>(continued):</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>g.</b></span></td> <td><span style="font-size: 10pt"><b>Property&#160;and&#160;equipment,&#160;net</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Property and equipment are stated at cost, net of accumulated
depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful lives:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c0" escape="true" name="nnox:ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers and electronic equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c38" name="nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription">15</ix:nonNumeric>-<ix:nonNumeric contextRef="c39" name="nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription">33</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office furniture and lab equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c40" name="nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription">6</ix:nonNumeric>-<ix:nonNumeric contextRef="c41" name="nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription">20</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Vehicles</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c42" name="nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription">33</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equipment and machinery</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c43" name="nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription">10</ix:nonNumeric>-<ix:nonNumeric contextRef="c44" name="nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription">20</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold Improvement</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c45" name="nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Land</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c46" name="nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription">N/A</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The depreciable life of leasehold improvements is limited
by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>h.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b><i>Intangible Assets, net</i></b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_2" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b><i>Goodwill</i></b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_3" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Goodwill reflects the excess of the consideration transferred plus
the fair value of any non-controlling interest in the acquiree at the business combination date over the fair values of the identifiable
net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination
that are not individually identified and separately recognized. The Company allocates goodwill to its reporting units based on the reporting
unit expected to benefit from the business combination. &#160;&#160;The primary items that generate goodwill include the value of the
synergies between the acquired companies and the Company and the acquired assembled workforce, neither of which qualifies for recognition
as an intangible asset. ASC 350, &#8220;Intangibles - Goodwill and other&#8221; (&#8220;ASC 350&#8221;) requires goodwill to be tested
for impairment at the reporting unit level at least annually or between annual tests in certain circumstances and written down when impaired.
ASC 350 allows an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative
goodwill impairment test. If the qualitative assessment does not result in a more likely than not indication of impairment, no further
impairment testing is required. If it does result in a more likely than not indication of impairment, the quantitative goodwill impairment
test two-step impairment test is performed. Alternatively, ASC 350 permits an entity to bypass the qualitative assessment for any reporting
unit and proceed directly to performing the quantitative first step of the goodwill impairment test.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_4" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The provisions of the accounting standard for goodwill allow the Company
to first assess qualitative factors to determine whether it is necessary to perform the next goodwill impairment quantitative test. Examples
of events or circumstances that may be indicative of impairment include but are not limited to: macroeconomic and industry conditions,
overall financial performance and adverse changes in legal, regulatory, market share and other relevant entity specific events. The carrying
value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill, to those reporting
units. When necessary, the Company records charges for impairments of goodwill for the amount by which the carrying amount exceeds the
fair value of these assets. No goodwill impairment charge was recorded in 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"> </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 198.25pt">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_5" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b><i>other Intangible Assets, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Definite life intangible assets are amortized using the straight-line
method over their estimated period of useful life. Amortization of acquired developed technology, image big data, market platform, trade
names, customer relationships and radiologist relationships are recorded under cost of revenues and selling and marketing expenses. In
addition, the remaining amortization period for the impaired asset would be reassessed and, if necessary, revised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>i.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Impairment&#160;of&#160;long-lived&#160;assets </b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company tests long-lived assets for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets
is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated
by the asset or asset group. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company
recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future
discounted cash flows.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:nonNumeric contextRef="c0" continuedAt="_SeverancePayPolicyTextBlock-c0_cont_1" escape="true" name="nnox:SeverancePayPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>j.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Severance&#160;pay</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedAt="_SeverancePayPolicyTextBlock-c0_cont_2" id="_SeverancePayPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Israeli labor law generally requires severance pay be granted
upon dismissal of an employee or upon termination of employment under certain other circumstances. Pursuant to Section 14 of the Severance
Compensation Act, 1963 (&#8220;Section 14&#8221;), all of the Company&#8217;s employees in Israel are entitled to monthly deposits, at
a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments under Section 14 relieve the Company from
any future severance payment obligation with respect to those employees and, as such, the Company may only utilize the insurance policies
for the purpose of disbursement of severance pay. As a result, the Company does not recognize an asset nor liability for these employees.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation id="_SeverancePayPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In 2021 and 2020, all of the employees
of the Company and its subsidiary in Israel are subject to Section 14 of the Severance Law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 153; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:nonNumeric contextRef="c0" continuedAt="_LegalAndOtherContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="nnox:LegalAndOtherContingenciesPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>k.</b></span></td> <td><span style="font-size: 10pt"><b>Legal&#160;and other&#160;contingencies</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation continuedAt="_LegalAndOtherContingenciesPolicyTextBlock-c0_cont_2" id="_LegalAndOtherContingenciesPolicyTextBlock-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Certain conditions, such as legal proceedings, may exist as
of the date the consolidated financial statements are issued that may result in a loss to the Company, but that will only be resolved
when one or more future events occur or fail to occur. In assessing loss contingencies related to legal proceedings that are pending
against the Company or unasserted claims that may result in such proceedings, the Company&#8217;s management evaluates with its legal
advisors the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought
or expected to be sought. Such assessment inherently involves an exercise of judgment. Legal fees are expensed as incurred.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation id="_LegalAndOtherContingenciesPolicyTextBlock-c0_cont_2"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Management applies the guidance in ASC 450-20-25 when assessing losses
resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss would be incurred
and the amount of the liability can be estimated, then the Company records an accrued expense in the Company&#8217;s consolidated financial
statements based on its best estimate. Loss contingencies considered to be remote by management are generally not disclosed unless material.
For additional information see note 11.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>l.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Revenue Recognition</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; text-indent: -0.75in">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The majority of the Company&#8217;s revenues are derived from radiology
services fees received from various payors based on established billing rates. Revenues are derived directly from hospitals and healthcare
providers. The Company recognizes revenue in the period in which the performance obligation is satisfied. The Company records the amount
of revenue that reflects the consideration that it expects to receive in exchange for those services. The Company applies the following
five-step model in order to determine this amount: (i)&#160;identification of the contract with a customer; (ii)&#160;identification of
the promised services in the contract and determination of whether they represent performance obligations, including whether they are
distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">The Company records deferred revenue for any upfront payments received
in advance of the Company&#8217;s performance obligations being satisfied. These contract liabilities consist principally of unearned
radiology service fee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 154; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>m.</b></span></td> <td><span style="font-size: 10pt"><b>Research and development expenses</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Research and development expenses are charged to the statement
of operations as incurred and consist primarily of personnel, materials and supplies for research and development activities.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>n.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Income&#160;tax </b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.75in">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 1in">&#160;</td>
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income
    Taxes&#8221; (&#8220;ASC&#160;740&#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability
    account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and
    are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
    provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely
    than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative
    evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU&#160;2015-17.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 96px">&#160;</td>
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not
    been taken into account in computing the deferred income taxes, as it is the Company&#8217;s intent and ability to hold these investments.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_4" id="_IncomeTaxPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 96px; font-size: 10pt">&#160;</td> <td style="text-align: left; width: 24px; font-size: 10pt"><span style="font-size: 10pt">3)</span></td> <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nnox:TaxBenefitPercentage" scale="-2" unitRef="pure">50</ix:nonFraction>% (cumulative probability) likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 96px; font-size: 10pt">&#160;</td>
    <td style="text-align: left; width: 24px; font-size: 10pt"><span style="font-size: 10pt">4)</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Valuation allowances are provided unless it is more likely
than not that the deferred tax asset will be realized. In the determination of the appropriate valuation allowances, the Company considers
future reversals of existing taxable temporary differences, the most recent projections of future business results, prior earnings history,
carryback and carry forward and prudent tax strategies that may enhance the likelihood of realization of a deferred tax asset. Assessments
for the realization of deferred tax assets made at a given balance sheet date are subject to change in the future, particularly if earnings
of a subsidiary are significantly higher or lower than expected, or if the Company takes operational or tax positions that could impact
the future taxable earnings of a subsidiary.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><b>o<span style="font-size: 10pt">.</span></b></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Share-based compensation</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company accounts for share-based compensation under
ASC 718, &#8220;Compensation - Stock Compensation,&#8221; which requires the measurement and recognition of compensation expense
based on estimated fair values for all share-based payment awards made to non-employees, employees, officers and directors. ASC 718
requires companies to estimate the fair value of equity-based payment awards on the date of grant. The Company uses the
Black-Scholes-Merton option-pricing model as part of such estimation.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Prior to the adoption of ASU 2018-07, warrants issued to consultants
and other non-employees, as compensation for services provided to the Company, were accounted for based upon the fair value of the warrants.
The fair value of the warrants granted was measured on a final basis at the end of the related service period and was recognized over
the related service period using the straight-line method. After the adoption of ASU 2018-07, the measurement date for non-employee awards
is the date of the grant. The compensation expense for non-employees is recognized without changes in the fair value of the award, over
the requisite service period, which is the vesting period of the respective award using the straight line. The Company adopted ASU 2018-07
as of January 1, 2019 with no impact on its consolidated financial statements as all of the Company&#8217;s awards were fully vested
at the adoption date.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company recognizes compensation expenses for its stock-based
option awards and RSUs on a straight-line basis over the requisite service period (primarily a four-year period). The Company accounts
for forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 155; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in; font-size: 10pt">&#160;</td> <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>p.</b></span></td> <td style="font-size: 10pt"><span style="font-size: 10pt"><b>Loss&#160;per&#160;share</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Basic earnings per share is computed by dividing net income
(loss) attributable to holders of ordinary shares of the Company by the weighted average number of ordinary shares outstanding for each
reporting period.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In computing the Company&#8217;s diluted earnings per share,
the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary shares and the potential dilutive
ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding include the dilutive effect of in-the-money
options using the treasury stock method.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company did not take into account
any dilutive instruments, such as investor warrants , share-based payments and earn-out liability - contingently issuable ordinary shares
, since their effect, on a fully diluted basis, is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>q.</b></span></td> <td><span style="font-size: 10pt"><b>Fair&#160;value&#160;measurement</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Fair value is based on the price that would be received from
the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that
prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 96px">&#160;</td>
    <td style="text-align: left; width: 48px"><span style="font-size: 10pt">Level 1:</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Level 2: </span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Level 3: </span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></td></tr>
  </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.75in"><b>&#160;</b></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In determining fair value, the Company utilizes valuation techniques
that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty
credit risk in its assessment of fair value.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The Company&#8217;s financial instruments consist mainly of
cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities. The fair value
of these financial instruments approximates their carrying values.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Money market funds (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd">29,697</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd">29,697</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="nnox:LongTermMarketableSecurities" scale="3" unitRef="usd">89,911</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="nnox:LongTermMarketableSecurities" scale="3" unitRef="usd">89,911</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">119,608</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">119,608</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long term loan (**)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:LongTermDebt" scale="3" unitRef="usd">3,796</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:LongTermDebt" scale="3" unitRef="usd">3,796</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="3" unitRef="usd">42,471</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="3" unitRef="usd">42,471</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent long-term earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" scale="3" unitRef="usd">5,814</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" scale="3" unitRef="usd">5,814</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt"></td>
    <td style="border-bottom: Black 4pt double; text-align: left"></td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">-</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">52,081</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd">52,081</ix:nonFraction></p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span>The Company classifies AFS securities
within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair value</span></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:continuation continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2" id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span>(*)</span></td><td style="text-align: left"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span>As of&#160;</span>December
31, 2021,&#160;<span>approximately $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd">29,697</ix:nonFraction> thousand of debt securities were classified under &#8220;Cash
and Cash equivalents&#8221; in the consolidated balance sheets as such securities met all applicable classification criteria.</span></ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"></p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_2"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(**)</td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span>Since the loan was
originated in September 2021, the fair value of the long term loan approximates its carrying value.</span></ix:footnote></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>




</div><!-- Field: Page; Sequence: 156; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>r.</b></span></td> <td><span style="font-size: 10pt"><b>Concentration&#160;of&#160;Credit Risks</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Financial instruments that potentially subject the
Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, marketable securities
and accounts receivable.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The Company&#8217;s cash and cash equivalents and restricted
cash are invested with major banks in Israel, United States, Korea and Japan. Generally, these investments may be redeemed upon demand
and the Company believes that the financial institutions that hold the Company&#8217;s cash balances are financially sound and, accordingly,
bear minimal risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"><b>&#160;</b>&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:nonNumeric contextRef="c0" continuedAt="_DeferredOfferingCostsPolicyTextBlock-c0_cont_1" escape="true" name="nnox:DeferredOfferingCostsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>s.</b></span></td> <td><span style="font-size: 10pt"><b>Offering&#160;Costs </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:continuation id="_DeferredOfferingCostsPolicyTextBlock-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Deferred offering costs directly relating to the Company&#8217;s
private and initial public offering, were capitalized and offset against proceeds upon the consummation of the private and IPO transactions
in shareholders&#8217; equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>t.</b></span></td> <td><span style="font-size: 10pt"><b>Leases</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">On January 1, 2019 the Company adopted
ASU No. 2016-02, Leases (&#8220;Topic 842&#8221;), The Company determines if an arrangement is a lease at inception. Balances related
to operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current maturities of operating leases liabilities
and Non-current operating leases liabilities in the consolidated balance sheets.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">The Company also elected not separating lease components
from non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated
lease payments in the consolidated statements of operations on a straight-line basis over the lease term.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">ROU assets represent the Company&#8217;s right to use an underlying
asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease.
Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over
the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that
the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily
determined. As the Company&#8217;s leases do not provide an implicit rate, the Company&#8217;s uses its estimated incremental borrowing
rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for
lease payments is recognized on a straight-line basis over the lease term (see also note 7).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"></p><div>




</div><!-- Field: Page; Sequence: 157; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The Company presents unrecognized tax benefits as a reduction
to deferred tax asset where a net operating loss, a similar tax loss, or a tax credit carryforward that are available, under the tax law
of the applicable jurisdiction, to offset any additional income taxes that would result from the settlement of a tax position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 72px; padding-right: 0.8pt">&#160;</td> <td style="vertical-align: top; width: 24px; padding-right: 0.8pt"><span style="font-size: 10pt"><b>u.</b></span></td> <td style="vertical-align: top"><span style="font-size: 10pt"><b>Segment reporting</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">ASC 280, &#8220;Segment Reporting,&#8221; establishes standards
for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate
financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources
and in assessing performance. The Company&#8217;s chief operating decision maker is the Company&#8217;s Chief Executive Officer (the &#8220;CODM&#8221;),
who makes resource allocation decisions and assesses performance based on financial information prepared on a consolidated basis, accompanied
by disaggregated information about revenues, gross profit and operating loss by the three identified reportable segments. The Company&#8217;s
business includes three operating segments based on the services that the Company provides. The three segments are composed from the Nanox.Arc
segment, AI solutions and the Radiology services division segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt"><b>v.&#160;</b></span></td> <td><span style="font-size: 10pt"><b>Newly issued and recently adopted accounting pronouncements:</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><b><i>Accounting Pronouncements Adopted in Current year</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><b><i>&#160;</i></b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_79" id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">. In December 2019, the FASB issued ASU 2019-12, Income Taxes (&#8220;Topic
740&#8221;): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions
to the general principles and simplification of areas such as franchise taxes, step-up in tax basis goodwill, separate entity financial
statements and interim recognition of enactment of tax laws or rate changes. The guidance was effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted this guidance
since January 1, 2021, with no material impact on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_80" id="_SignificantAccountingPoliciesTextBlock-c0_cont_79"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">In October 2021, the FASB issued ASU
2021-08 &#8220;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;,
which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer
on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing
contract assets and contract liabilities at the same amounts recorded by the acquire. The guidance should be applied prospectively to
acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that
have not yet been issued. The Company early adopted ASU 2021-08 since January 1, 2021, with no material impact on its consolidated financial
statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><i>&#160;</i></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_81" id="_SignificantAccountingPoliciesTextBlock-c0_cont_80"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><i>Recently issued accounting pronouncements, not yet adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_81"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">In August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211;
Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic
815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective
for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years.&#160;The Company will adopt this
guidance effective January 1, 2022, with no material impact on its consolidated financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><!-- Field: Page; Sequence: 158; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CertainTransactionsTextBlock-c0_cont_1" escape="true" name="nnox:CertainTransactionsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; BUSINESS COMBINATION AND OTHER TRANSACTION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_2" id="_CertainTransactionsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">a.</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">The acquisition of Nanox AI Ltd (formerly Zebra Medical Vision Ltd.).</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_3" id="_CertainTransactionsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On November 4, 2021(&#8220;the merger date&#8221;), the Company,
completed the merger (&#8220;the Nanox AI transaction&#8221;) pursuant to the terms of the Agreement and Plan of Merger, dated August
9, 2021 (with certain amendments), among the Company, Zebra Medical Vision Ltd. (&#8220;Zebra&#8221;) and Perryllion Ltd., as representative
of Zebra&#8217;s equity holders. At November 4, 2021 the Company issued <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">3,249,142</ix:nonFraction> ordinary shares of the Company and committed to issue
<ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="nnox:EmployeeOptionsAndRestrictedStockUnits" scale="0" unitRef="shares">70,211</ix:nonFraction> employee options and restricted stock units&#160;to the equity holders of Zebra with an estimated fair value at the closing date
of $<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd">88,510</ix:nonFraction> thousand, representing $<ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="nnox:OutstandingSharesPerShare" scale="0" unitRef="usdPershares">26.57</ix:nonFraction> per share in consideration for the fully outstanding shares on a fully diluted basis of Zebra.
<ix:nonNumeric contextRef="c0" name="nnox:ServicePeriodsDecription">Out of which $<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="3" unitRef="usd">315</ix:nonFraction> thousand was allocated to the purchase consideration and $<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="nnox:PurchaseConsideration" scale="3" unitRef="usd">970</ix:nonFraction>&#160;thousand was allocated to future services and continued
employment and shall be expensed over remaining service periods of up to 4 years.</ix:nonNumeric> The fair value of ordinary shares issued by the Company
was determined using the Company&#8217;s closing trading price on the merger date. The consideration represented (a) the basic purchase
price minus (b) certain transaction costs; plus (c) contingent consideration as a result of Zebra entering into a designated commercial
agreement prior to closing; plus (d) additional contingent consideration as a result of Zebra achieving a designated milestone of obtaining
a new FDA clearance for its population health product and additional consideration as a result of Zebra achieving designated milestones
as further described below. In addition, if Zebra enters into any of the two additional designated commercial agreements within 6 months
of the agreement execution date (August 9, 2021), then the Company will pay a deferred closing consideration in the amount of $<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="nnox:DeferredClosingConsideration" scale="3" unitRef="usd">3,333</ix:nonFraction> thousand
in shares for each agreement. The deferred closing consideration would be paid in the Company&#8217;s shares in the amount of the relevant
instalment payment divided by the average closing price of the 30 trading days ending on the applicable agreement signing date. Further,
if Zebra achieves the agreed milestones related to obtaining certain FDA clearances and security certifications, completing certain technology
integration, or achieving certain revenue and employee retention targets over the next three years, the Company will pay additional consideration
in the amount of up to $<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AdditionalConsideration" scale="3" unitRef="usd">77,700</ix:nonFraction> thousand. Each of these milestone instalments would be paid in the Company&#8217;s shares in the amount
of the relevant instalment payment divided by the average closing price of the 30 trading days ending on the applicable milestone&#8217;s
achievement date. Zebra changed its name to Nanox AI ltd. and Zebra Medical Vision Inc. (a fully owned subsidiary of Zebra, which is incorporated
under the laws if the State of Delaware) changed its name to Nanox AI Inc.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 72pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_4" id="_CertainTransactionsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The Nanox AI transaction was accounted in accordance with ASC 805,
&#8220;Business Combinations&#8221;, using the acquisition method of accounting with the Company as the acquirer.&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_5" id="_CertainTransactionsTextBlock-c0_cont_4"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The following table summarizes the fair value of the consideration
transferred to Nanox AI shareholders for the Nanox AI transaction:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_6" id="_CertainTransactionsTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueConsiderationTransferred-c0_cont_1" escape="true" name="nnox:ScheduleOfFairValueConsiderationTransferred"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">U.S.$<br/> in thousand</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 89%; text-align: left">Issuance of ordinary shares, options and RSUs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">88,510</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" scale="3" unitRef="usd">38,129</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent long term earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" scale="3" unitRef="usd">2,660</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total consideration</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationAsset" scale="3" unitRef="usd">129,299</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:nonNumeric></ix:continuation><div>




</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_7" id="_CertainTransactionsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">In accordance with ASC 805, the estimated
contingent consideration&#160;as of the Nanox AI transaction date was&#160;included in the purchase price. The total contingent payments
could reach to a maximum aggregate amount of up to $<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="nnox:MaximumAggregateAmount" scale="3" unitRef="usd">77,700</ix:nonFraction> thousand, all shall be settled through the issuance of ordinary shares.&#160;The
Company determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash
flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement
within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected
from the success of achievements of several achievement and payment of milestone events; the time and resources needed to achieve those
milestones and the risk adjusted discount rate for fair value measurement. A probability of success factor was used in the fair value
calculation to reflect inherent regulatory and commercial risk of the contingent payments. The weighted average discount rate, applied
on the relative fair value of the contingent consideration liabilities, was&#160;<ix:nonFraction contextRef="c54" decimals="2" format="ixt:num-dot-decimal" name="nnox:FairValuePercentage" scale="-2" unitRef="pure">19</ix:nonFraction>%. The contingent consideration is evaluated quarterly,
or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements
of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material
changes to the contingent consideration liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><!-- Field: Page; Sequence: 159; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; BUSINESS COMBINATION AND OTHER TRANSACTION </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_8" id="_CertainTransactionsTextBlock-c0_cont_7"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The allocation of the purchase price to assets acquired and
liabilities assumed, including measurement period adjustments (, is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_9" id="_CertainTransactionsTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Allocation<br/> of Purchase<br/> Price</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">(U.S. $ in thousands)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; text-align: left">Cash, cash equivalents and Restricted&#160;Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd">6,956</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts Receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" unitRef="usd">99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd">430</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsCurrent" scale="3" unitRef="usd">79,816</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" unitRef="usd">51,243</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssets" scale="3" unitRef="usd">1,693</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalAssetsAcquired" scale="3" unitRef="usd">140,237</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd">3,413</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="nnox:ContingentShortTermEarnoutLiability" scale="3" unitRef="usd">38,129</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent long-term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="nnox:ContingentLongtermEarnoutLiability" scale="3" unitRef="usd">2,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Convertible note (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="nnox:ConvertibleNote" scale="3" unitRef="usd">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other labilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd">4,525</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="3" unitRef="usd">51,727</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="nnox:NetAssetsAcquired" scale="3" unitRef="usd">88,510</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_10" id="_CertainTransactionsTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">A 3 years Convertible Loan Agreement, dated August 9, 2021 between
the Company and Nanox AI in the amount of $3 million, which bears an annual interest of 6% and shall be automatically converted into the
Nanox AI&#8217;s Preferred C Shares, at a price per share of $23.42. This loan is eliminated in the Consolidated financial statements.</p></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_11" id="_CertainTransactionsTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"><ix:nonNumeric contextRef="c54" name="nnox:DescriptionOfNetAssets">The allocation of the purchase price to net assets acquired and liability
assumed resulted in the recognition of intangible asset related to technology of $27,316 thousand which will be expensed over remaining
service periods of 10 years, Image Big Data of $52,500 thousand which will be expensed over remaining service periods of 10 years, and
goodwill of $51,243 thousand, which is primarily attributed to the expected synergies from combining the operations of Zebra&#8217;s AI
solutions with the Company tomographic imaging systems. As such, the goodwill will be assigned to the operational segment of AI solutions.</ix:nonNumeric>&#160;The
goodwill amount is not deductible for tax purposes. The fair value&#160;estimate of the developed technology is determined using a variation
of the income approach known as the &#8220;Multi-Period Excess Earnings Approach&#8221;. This valuation technique estimates the fair value
of an asset based on market participants&#8217; expectations of the cash flows an asset would generate over its remaining useful life.&#160;The
net cash flows were discounted to present value. Due to the timing of the transaction closing date, the fair values assigned to assets
acquired and liabilities assumed are preliminary, based on management&#8217;s estimates and assumptions and may be subject to change as
additional information is received. We expect to finalize the valuation as soon as practicable, but not later than <ix:nonNumeric contextRef="c54" format="ixt-sec:durwordsen" name="nnox:AcquisitionDate">one year</ix:nonNumeric> from the acquisition
date. Refer to notes 2c and 2h.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_12" id="_CertainTransactionsTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The amount of the acquisition-related costs
was approximately $<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="3" unitRef="usd">310</ix:nonFraction> which was recognized as an expense in the general and administration expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; BUSINESS COMBINATION AND OTHER TRANSACTION </b>(continued):</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_13" id="_CertainTransactionsTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The results of operations of Nanox AI
have been included in the consolidated financial statements since the date of the acquisition. The amounts of revenues and net loss related
to Nanox AI that are included in the Company&#8217;s consolidated statements of operations for the period starting from the merger date
to&#160;December 31, 2021, are $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenuesNetOfInterestExpense" scale="3" unitRef="usd">270</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:NetLoss" scale="3" unitRef="usd">4,157</ix:nonFraction> thousand, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_14" id="_CertainTransactionsTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The following unaudited pro forma information
presents the combined results of operations of the Company and Nanox AI as if the acquisition of Nanox AI had been completed on January
1, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_15" id="_CertainTransactionsTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The unaudited pro forma results include adjustments primarily related
to amortization of the acquired intangible assets and share-based compensation associated with option grants as referenced above, as of
January 1,2020. The unaudited pro forma results do not reflect any cost saving synergies from operating efficiencies, or the effect of
the incremental costs incurred from integrating Nanox AI. Accordingly, these unaudited pro forma results are presented for informational
purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the
acquisition of Nanox AI had occurred at the beginning of 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_16" id="_CertainTransactionsTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" escape="true" name="pf0:CondensedStatementOfComprehensiveIncomeTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<br/> December&#160;31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<br/> December&#160;31, 2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="7" style="text-align: center">US$ in thousand</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">2,363</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">1,550</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">87,045</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">69,875</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_17" id="_CertainTransactionsTextBlock-c0_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">The acquisition of USARAD Holding Inc.&#160;&#160;(the &#8220;USARAD transaction&#8221;)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_18" id="_CertainTransactionsTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">On November 2, 2021 (the &#8220;USARAD closing
date&#8221;), the Company completed the acquisition of <ix:nonFraction contextRef="c56" decimals="2" format="ixt:num-dot-decimal" name="nnox:AcquisitionOfSharesPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the shares of USARAD Holdings, Inc., a Delaware corporation (&#8220;USARAD&#8221;),
pursuant to the terms of the Stock Purchase Agreement, dated October 25, 2021, among the Company, USARAD, Dr. Michael Yuz, other holders
of capital stock of USARAD, and holders of USARAD options. At the USARAD closing date, Nanox U.S. purchased <ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="nnox:PurchaseOfSharesPercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the shares of USARAD
on a fully diluted basis for $<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAcquiredFromAcquisition" scale="3" unitRef="usd">7,147</ix:nonFraction> thousand in cash and <ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="nnox:OrdinaryShare" scale="0" unitRef="shares">496,545</ix:nonFraction> of the Company&#8217;s ordinary shares with an estimated fair value of
$<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" unitRef="usd">11,500</ix:nonFraction> thousand. The number of ordinary shares issued by the Company was determined using the average closing trading price during the
30 trading days preceding to the closing date. The total consideration was approximately $<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="3" unitRef="usd">18,647</ix:nonFraction> thousand. In addition, upon the successful
achievement of certain milestones related to profitability, EBITDA and other operational performance-based earnouts over <ix:nonNumeric contextRef="c56" format="ixt-sec:duryear" name="nnox:OtherOperationalPerformancebasedEarnoutsOver">2</ix:nonNumeric> years, the
Company will pay additional cash consideration in the amount of up to $<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AdditionalCashConsideration" scale="3" unitRef="usd">2,000</ix:nonFraction> thousand and stock consideration in the amount of up to $<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="3" unitRef="usd">6,500</ix:nonFraction>
thousand at a per share value determined by the average of i) the volume weighted average closing share price of the 30 trading days prior
to the relevant milestone completion, and (ii) the volume weighted average closing share price of the 30 trading days ending on August
6, 2021.. Revenue in the amount of $<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="nnox:OtherRevenue" scale="3" unitRef="usd">1,034</ix:nonFraction> and net loss in the amount of $<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="nnox:OtherNetLoss" scale="3" unitRef="usd">358</ix:nonFraction> thousand of the acquiree included in the Company&#8217;s
consolidated statements of operations for the year ended at December 31,2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><!-- Field: Page; Sequence: 161; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; BUSINESS COMBINATION AND OTHER TRANSACTION </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_19" id="_CertainTransactionsTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The USARAD transaction was accounted in
accordance with ASC 805, &#8220;Business Combinations&#8221;, using the acquisition method of accounting with the Company as the acquirer.&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_20" id="_CertainTransactionsTextBlock-c0_cont_19"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The following table summarizes the fair value of the consideration
transferred to USARAD shareholders for the USARAD transaction:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_21" id="_CertainTransactionsTextBlock-c0_cont_20"><ix:continuation id="_ScheduleOfFairValueConsiderationTransferred-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. $ in thousands</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash payments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness" scale="3" unitRef="usd">7,147</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">11,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration at estimated fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" scale="3" unitRef="usd">6,405</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total consideration</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationContingentConsiderationAsset" scale="3" unitRef="usd">25,052</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_22" id="_CertainTransactionsTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">In accordance with ASC 805, the estimated
contingent consideration&#160;as of the USARAD transaction date was&#160;included in the purchase price. The total contingent payments
could reach to a maximum aggregate amount of up to $<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="nnox:MaximumAggregateAmount" scale="3" unitRef="usd">8,500</ix:nonFraction> thousand.&#160;Approximately <ix:nonFraction contextRef="c58" decimals="4" format="ixt:num-dot-decimal" name="nnox:SettledInCashPercentage" scale="-2" unitRef="pure">23.52</ix:nonFraction>% of the payments shall be settled in cash,
and <ix:nonFraction contextRef="c58" decimals="4" format="ixt:num-dot-decimal" name="nnox:IssuanceOfOrdinarySharePercentage" scale="-2" unitRef="pure">76.47</ix:nonFraction>% shall be settled through the issuance of ordinary shares.&#160;The estimated fair value of the contingent consideration is
based on management&#8217;s assessment&#160;of whether, and at what level, the financial metrics will be achieved, and the present value
factors associated&#160;with the timing of the payments.&#160;This fair value measurement&#160;is based on significant unobservable inputs
in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the fair value of contingent consideration
will be recorded in&#160;operating expenses. Additional payment&#160;of $<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AdditionalPayment" scale="3" unitRef="usd">144</ix:nonFraction> thousand may be paid to USARAD&#8217;s shareholders if an
approval of the PPP loan by the Federal Government will occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_23" id="_CertainTransactionsTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The allocation of the purchase price
to assets acquired and liabilities assumed is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_24" id="_CertainTransactionsTextBlock-c0_cont_23"><ix:continuation id="_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Allocation of Purchase Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(U.S. $ in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">332</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts Receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" unitRef="usd">912</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsCurrent" scale="3" unitRef="usd">21,187</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" unitRef="usd">7,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssets" scale="3" unitRef="usd">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalAssetsAcquired" scale="3" unitRef="usd">29,519</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loan from a government agency</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="3" unitRef="usd">144</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other labilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd">557</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd">3,766</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="nnox:ContingentShortTermEarnoutLiability" scale="3" unitRef="usd">3,453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent long term earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="nnox:ContingentLongTermEarnoutLiability" scale="3" unitRef="usd">2,952</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="3" unitRef="usd">10,872</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="nnox:NetAssetsAcquired" scale="3" unitRef="usd">18,647</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><!-- Field: Page; Sequence: 162; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>NOTE 3 &#8211; BUSINESS COMBINATION AND OTHER TRANSACTION </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_25" id="_CertainTransactionsTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; "><ix:nonNumeric contextRef="c58" name="us-gaap:ImpairedIntangibleAssetDescription">The allocation of the purchase price
to net assets acquired and liability assumed resulted in the recognition of intangible asset related to retained radiologists of $17,770
thousand, customers&#8217; relationship of $1,322 thousand, trademark of $2,095 thousand and goodwill of $7,055 thousand. As such, the
goodwill will be assigned to the operational segment of radiology services. The intangible asset relates to retained radiologists has
a useful-life of 11.17 years, the intangible asset relates to customers&#8217; relationship has a useful-life of 6.17 years and the intangible
asset relates to the trademark has a useful-life of 12.17 years.</ix:nonNumeric>&#160; This fair value measurement is based on significant unobservable
inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration
is based on several factors, such as: the cash flows projected from the success of achievements of several achievement and payment of
milestone events; the time and resources needed to achieve those milestones and the risk adjusted discount rate for fair value measurement.
A probability of success factor was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent
payments. The weighted average discount rate, calculated based on the relative fair value of the contingent consideration liabilities,
was&#160;<ix:nonFraction contextRef="c58" decimals="3" format="ixt:num-dot-decimal" name="nnox:FairValueOfContingentConsiderationLiabilities" scale="-2" unitRef="pure">21.9</ix:nonFraction>%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair
value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly
the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. Due
to the timing of the transaction closing date, the fair values assigned to assets acquired and liabilities assumed are preliminary, based
on management&#8217;s estimates and assumptions and may be subject to change as additional information is received. We expect to finalize
the valuation as soon as practicable, but not later than <ix:nonNumeric contextRef="c58" format="ixt-sec:durwordsen" name="nnox:AcquisitionDate">one year</ix:nonNumeric> from the acquisition date. Refer to notes 2c and 2h.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_26" id="_CertainTransactionsTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">During 2021,
USARAD executed the standard loan documents required for securing a loan from the SBA under its Paycheck Protection Program Loan (&#8220;PPP&#8221;)
assistance program in light of the impact of the COVID-19 pandemic on the Company&#8217;s business.&#160;Pursuant to that certain Loan
Authorization and Agreement, the principal amount of the PPP Loan is $<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="nnox:PrincipalAmountOfThePPPLoan" scale="3" unitRef="usd">144</ix:nonFraction>, with proceeds to be used for working capital purposes. Interest
accrues at the rate of <ix:nonFraction contextRef="c60" decimals="4" format="ixt:num-dot-decimal" name="nnox:InterestAccruesRate" scale="-2" unitRef="pure">1.00</ix:nonFraction> % per annum and the term of the loan is <ix:nonNumeric contextRef="c58" format="ixt-sec:durwordsen" name="nnox:LoanTerm">five years</ix:nonNumeric>. After the completion of the acquisition USARAD applied
for forgiveness of the loan. Per to the terms of the Stock Purchase Agreement, the Company will pay the forgiven amounts to the former
shareholders of USARAD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_27" id="_CertainTransactionsTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">The amount of the acquisition-related costs was approximately
$<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="3" unitRef="usd">198</ix:nonFraction> which was recognized as an expense in the general and administration expenses.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_28" id="_CertainTransactionsTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">Pro forma results of operations related
to the USARAD acquisition have not been prepared because they are not material to the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_29" id="_CertainTransactionsTextBlock-c0_cont_28"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>c.</b></span></td>
    <td style="text-align: left"><span style="font-size: 10pt">The Assets acquisition of MDWEB LLC.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CertainTransactionsTextBlock-c0_cont_30" id="_CertainTransactionsTextBlock-c0_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On November 3, 2021, the Company
completed the acquisition of the market platform and other assets of MDWEB, LLC (&#8220;MDWEB&#8221;), pursuant to the terms of the Asset
Purchase Agreement, dated October 21, 2021, between the Company and MDWEB. At the same date, <ix:nonNumeric contextRef="c62" name="nnox:AssetsAcquisitionDescription">the Company issued 64,715 of its ordinary
shares to MDWEB with an estimated fair value of $1,500 thousand. In addition, upon the successful achievement of certain milestones related
to technical integration of MDW platform with Nanox Cloud and achieving certain other operational targets, the Company will pay additional
stock consideration in the amount of up to $1,500 thousand at a per share value determined by the average closing price of the 30 trading
days ending on the applicable milestone&#8217;s achievement date. In addition, upon the successful achievement of certain milestones and
other operational performance-based earnouts over 2 years, the Company will pay stock consideration in the amount of up to $1,500 thousand
at a per share value determined by the average closing price of : (i) closing price of the 30 trading days ending on the applicable milestone&#8217;s
achievement date: and (ii) the volume weighted average closing share price of the 30 trading days prior to the closing date.</ix:nonNumeric> .</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_CertainTransactionsTextBlock-c0_cont_30"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">The Company will amortize the intangible assets on a straight-line
basis over their expected useful life of <ix:nonNumeric contextRef="c63" format="ixt-sec:durmonth" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">48</ix:nonNumeric> months. Refer to note 2h.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><!-- Field: Page; Sequence: 163; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE&#160;4 &#8212; GOODWILL&#160;&amp;
INTANGIBLE ASSETS, NET:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_2" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Goodwill</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_3" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The following table presents
the changes in the carrying amount of goodwill and the intangible assets as of December 31, 2021 (U.S. dollars in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_4" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfGoodwillTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">Goodwill from acquisition of Zebra</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" unitRef="usd">51,243</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Goodwill from acquisition of USARAD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="3" unitRef="usd">7,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" unitRef="usd">58,298</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_5" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><i>Intangible assets </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_6" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_5"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The acquired intangible assets has an estimated fair value
as of December 31, 2021 of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue" scale="0" unitRef="usd">101,826</ix:nonFraction> thousand. The Identifiable intangible assets were recorded as follows (U.S. dollars in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_7" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center"><b>&#160;</b></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Useful Life<br/>
(in Years)</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Amount as&#160;of<br/>
the merger/<br/>
acquisition<br/>
date</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Amortization<br/>
expense for<br/>
the period</b></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Amount as<br/>
of December 31,<br/>
2021</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="nnox:FiniteLivedIntangibleAssetNet" scale="3" unitRef="usd">27,316</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AmortizationExpenseForThePeriod" scale="3" unitRef="usd">455</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" unitRef="usd">26,861</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Image big data</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="nnox:FiniteLivedIntangibleAssetNet" scale="3" unitRef="usd">52,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AmortizationExpenseForThePeriod" scale="3" unitRef="usd">875</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" unitRef="usd">51,625</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Market platform</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c75" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">4</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="nnox:FiniteLivedIntangibleAssetNet" scale="3" unitRef="usd">2,591</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AmortizationExpenseForThePeriod" scale="3" unitRef="usd">108</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" unitRef="usd">2,483</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Radiologist relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c77" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">11.17</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="nnox:FiniteLivedIntangibleAssetNet" scale="3" unitRef="usd">17,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AmortizationExpenseForThePeriod" scale="3" unitRef="usd">265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" unitRef="usd">17,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade name</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c79" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">12.17</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="nnox:FiniteLivedIntangibleAssetNet" scale="3" unitRef="usd">2,095</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AmortizationExpenseForThePeriod" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" unitRef="usd">2,066</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><ix:nonNumeric contextRef="c81" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">6.17</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="nnox:FiniteLivedIntangibleAssetNet" scale="3" unitRef="usd">1,322</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AmortizationExpenseForThePeriod" scale="3" unitRef="usd">36</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" unitRef="usd">1,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="nnox:FiniteLivedIntangibleAssetNet" scale="3" unitRef="usd">103,594</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:AmortizationExpenseForThePeriod" scale="3" unitRef="usd">1,768</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIntangibleAssetsNet" scale="3" unitRef="usd">101,826</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_8" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Intangible assets with estimable useful lives are amortized over their
respective estimated useful lives to their estimated residual values and reviewed periodically for impairment. Amortization expenses were
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FilmMonetizedOnItsOwnAmortizationExpense" scale="0" unitRef="usd">1,768</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FilmMonetizedOnItsOwnAmortizationExpense" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FilmMonetizedOnItsOwnAmortizationExpense" scale="0" unitRef="usd">0</ix:nonFraction> for the years ended December 31, 2021 and December 31, 2020 and December 31, 2019, respectively.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_9" id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Amortization of intangible
assets for each of the next five years and thereafter is expected to be as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_GoodwillAndIntangibleAssetsDisclosureTextBlock-c0_cont_9"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><span style="font-size: 10pt">2022</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" scale="3" unitRef="usd">10,607</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" scale="3" unitRef="usd">10,607</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" scale="3" unitRef="usd">10,607</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" scale="3" unitRef="usd">10,499</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">2026 and thenafter</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" unitRef="usd">59,506</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" unitRef="usd">101,826</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><div>

</div><!-- Field: Page; Sequence: 164; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5  - PROPERTY AND EQUIPMENT, NET:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Composition of property and equipment grouped by major classifications
is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="nnox:ScheduleOfPropertyPlantAndEquipmentTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers and electronic equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="nnox:PercentageOfPropertyPlantAndEquipment" scale="-2" unitRef="pure">10</ix:nonFraction>-<ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="nnox:PercentageOfPropertyPlantAndEquipment" scale="-2" unitRef="pure">33</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office furniture and lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="nnox:PercentageOfPropertyPlantAndEquipment" scale="-2" unitRef="pure">6</ix:nonFraction>-<ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="nnox:PercentageOfPropertyPlantAndEquipment" scale="-2" unitRef="pure">20</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Vehicles</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c88" decimals="2" format="ixt:num-dot-decimal" name="nnox:PercentageOfPropertyPlantAndEquipment" scale="-2" unitRef="pure">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Machines</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c89" decimals="2" format="ixt:num-dot-decimal" name="nnox:PercentageOfPropertyPlantAndEquipment" scale="-2" unitRef="pure">10</ix:nonFraction>-<ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="nnox:PercentageOfPropertyPlantAndEquipment" scale="-2" unitRef="pure">20</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold Improvement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c91" decimals="2" format="ixt:num-dot-decimal" name="nnox:PercentageOfPropertyPlantAndEquipment" scale="-2" unitRef="pure">10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Land</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-102">N/A</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars <br/> in thousands)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Office furniture and lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">648</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">820</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Computers and electronic equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">1,109</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">151</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Equipment and machinery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">2,766</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c98" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">1762</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Leasehold improvement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c91" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">544</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">132</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Land &#8211; See b below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">6,314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">6,297</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Production line in construction &#8211; See b below</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">26,790</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">5,318</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">38,303</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">14,364</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">868</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">344</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">37,435</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">14,020</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>a.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt">Total depreciation in respect of property and equipment were approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="3" unitRef="usd">524</ix:nonFraction> thousand, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="3" unitRef="usd">208</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="3" unitRef="usd">53</ix:nonFraction> thousand for the years ended December 31, 2021, 2020 and 2019, respectively.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: left">&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">&#160;</td> <td style="text-align: left"><span style="font-size: 10pt"><b>b.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt">In December 2020, Nanox Korea purchased a land for approximately $<ix:nonFraction contextRef="c83" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForPurchaseOfOtherAssets1" scale="6" unitRef="usd">6.3</ix:nonFraction> million upon which it intends
to build a fabrication facility. In 2021, Nanox Korea completed the construction of the permanent fabrication plant.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CashEquivalentsAndRestrictedCashTextBlock-c0_cont_1" escape="true" name="nnox:CashEquivalentsAndRestrictedCashTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>NOTE 6 - CASH, CASH
EQUIVALENTS AND RESTRICTED CASH:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CashEquivalentsAndRestrictedCashTextBlock-c0_cont_2" id="_CashEquivalentsAndRestrictedCashTextBlock-c0_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The following table provides a reconciliation of cash, cash
equivalents and restricted cash reported on the consolidated balance sheet that sum to the same total amount as shown in the consolidated
statement of cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CashEquivalentsAndRestrictedCashTextBlock-c0_cont_3" id="_CashEquivalentsAndRestrictedCashTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">66,645</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">213,468</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted bank deposit (1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_6_fact" name="nnox:RestrictedBankDeposit" scale="3" unitRef="usd">127</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_7_fact" name="nnox:RestrictedBankDeposit" scale="3" unitRef="usd">316</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -11.5pt; padding-left: 11.5pt">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd">66,772</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" unitRef="usd">213,784</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>





</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"></p><div>

</div><ix:continuation id="_CashEquivalentsAndRestrictedCashTextBlock-c0_cont_3"><ix:continuation id="_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: left"><ix:footnote id="ix_4_footnote" xml:lang="en-US">As of December&#160;31, 2021, the Company&#8217;s restricted
cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit is presented at cost including accrued
interest. This bank deposit is used as security for credit card use and collateralizing the Company&#8217;s lease contracts</ix:footnote></td>
</tr></table></ix:continuation></ix:continuation><div>

</div><p style="margin-top: 0; margin-bottom: 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7  - LEASES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_2" id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">As of December 31, 2021, the Company has several operating
lease agreements for its car and facilities, as follows:</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_3" id="_LesseeOperatingLeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During the fourth quarter of 2019, the Company entered into
an office lease agreement. This agreement was through December 31, 2021 with an option by the Company to extend the period for an additional
24 months. The Company exercised the option.&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_4" id="_LesseeOperatingLeasesTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The monthly rent payment is approximately $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseAndRentalExpense" scale="3" unitRef="usd">13</ix:nonFraction> thousand. <ix:nonNumeric contextRef="c104" name="nnox:LeaseTermDescription">During
June 2020, the Company entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023.</ix:nonNumeric> The
monthly rent payment for this agreement is approximately $<ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseAndRentalExpense" scale="3" unitRef="usd">15</ix:nonFraction> thousand. <ix:nonNumeric contextRef="c105" name="nnox:LeaseTermDescription">During November 2020the Company signed an additional lease agreement,
for leasing another office complex through June 30, 2023.</ix:nonNumeric> The monthly rent payment for this agreement is approximately $<ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseAndRentalExpense" scale="3" unitRef="usd">12</ix:nonFraction> thousand. <ix:nonNumeric contextRef="c5" name="nnox:LeaseTermDescription">On
December 31,2021, the Company exercised its option to extend the lease for additional period of 24 months.</ix:nonNumeric></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_5" id="_LesseeOperatingLeasesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The Company leases vehicles to some of its employees. <ix:nonNumeric contextRef="c105" name="nnox:LeasesTermDescription">The
lease agreement is effective through June 30, 2023 and the monthly payment for this agreement is approximately $<ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="nnox:VehiclesLeasePayments" scale="3" unitRef="usd">12</ix:nonFraction> thousand.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_6" id="_LesseeOperatingLeasesTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">Nanox Korea leases 3 vehicles to some
employees. These lease agreements are effective through November 2023 to February 2024 and the monthly payment for these agreements is
approximately $ <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="3" unitRef="usd">5</ix:nonFraction> thousand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_7" id="_LesseeOperatingLeasesTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"><ix:nonNumeric contextRef="c0" name="nnox:FabricationFacilityAndResearchDevelopmentalCenterDescription">In 2021 Nanox Korea leased approximately
390 square meters of space for a temporary fabrication facility and approximately 200 square meters of space for a research and development
center in Korea.</ix:nonNumeric> During 2021 this lease ended due to the transfer of the temporary fabrication facility to the Company&#8217;s permanent
fabrication facility in Yongin, Geonggi province.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_8" id="_LesseeOperatingLeasesTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Nanox AI leases its offices in Israel under operating lease
agreement which expires in November 22 2024. Nanox AI has an option to extend the period for an additional 24 months through November
2026. &#160;Nanox AI concluded that it is not reasonably certain that it will exercise the renewal option. Accordingly, such renewal option
was not included in determining the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 54pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_9" id="_LesseeOperatingLeasesTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The monthly rent payment for this agreement is approximately
$<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="usd">12</ix:nonFraction> thousand and the management fee is $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ManagementFeeExpense" scale="3" unitRef="usd">4</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_10" id="_LesseeOperatingLeasesTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents the effects on the amounts relating
to the Company&#8217;s total lease costs:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_11" id="_LesseeOperatingLeasesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars <br/> In thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating lease cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Fixed payments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd">653</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd">276</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd">65</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalOperatingLeaseCost" scale="3" unitRef="usd">701</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalOperatingLeaseCost" scale="3" unitRef="usd">341</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7  - LEASES </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_12" id="_LesseeOperatingLeasesTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents supplemental cash flow information
related to operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_13" id="_LesseeOperatingLeasesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S.&#160;Dollars<br/> in&#160;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S.&#160;Dollars<br/> in&#160;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd">507</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd">169</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Right-of-use assets obtained in exchange for lease obligations (non-cash):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">194</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">1,085</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_14" id="_LesseeOperatingLeasesTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents supplemental balance sheet information
related to operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_15" id="_LesseeOperatingLeasesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock-c0_cont_1" escape="true" name="nnox:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating leases:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd">1,725</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd">1,359</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current maturities of operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="nnox:CurrentMaturitiesOfOperatingLeases" scale="3" unitRef="usd">881</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="nnox:CurrentMaturitiesOfOperatingLeases" scale="3" unitRef="usd">519</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-current operating leases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="nnox:NoncurrentOperatingLeases" scale="3" unitRef="usd">950</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="nnox:NoncurrentOperatingLeases" scale="3" unitRef="usd">923</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" unitRef="usd">1,831</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" unitRef="usd">1,442</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_16" id="_LesseeOperatingLeasesTextBlock-c0_cont_15"><ix:continuation id="_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Weighted average remaining lease term</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.14</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.67</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">5.70</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">5.83</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>




</div><!-- Field: Page; Sequence: 167; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7  - LEASES </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_17" id="_LesseeOperatingLeasesTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents maturities of operating lease liabilities:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">December&#160;31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars <br/> in thousands)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd">961</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd">745</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="nnox:LesseeOperatingLeaseLiabilityPaymentsDueYearFours" scale="3" unitRef="usd">245</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2025 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd">1,951</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="nnox:PresentValueOfLeaseLiabilities" scale="3" unitRef="usd">1,831</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DeferredRevenuesDisclosureTextBlock-c0_cont_1" escape="true" name="nnox:DeferredRevenuesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 &#8211; DEFERRED REVENUE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DeferredRevenuesDisclosureTextBlock-c0_cont_2" id="_DeferredRevenuesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The following table represents the changes in
deferred revenue for the year ended December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DeferredRevenuesDisclosureTextBlock-c0_cont_3" id="_DeferredRevenuesDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DeferredRevenueByArrangementDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deferred<br/> Revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Increase due to the business combinations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nnox:IncreaseDueToTheBusinessCombinations" scale="0" unitRef="usd">483</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in deferred revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nnox:DeferredRevenuesTotal" scale="0" unitRef="usd">179</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at December 31, 2021 (*)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:DeferredRevenue" scale="0" unitRef="usd">662</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation id="_DeferredRevenuesDisclosureTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Includes $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">415</ix:nonFraction> thousand under long term deferred revenue in
the Company&#8217;s consolidated balance sheets as of December 31, 2021.</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_1" escape="true" name="nnox:RelatedPartyLiabilityTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9   - RELATED PARTIES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_2" id="_RelatedPartyLiabilityTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">As of December
31, 2019, the Company recorded a Related Party Liability in an amount of $<ix:nonFraction contextRef="c19" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" scale="6" unitRef="usd">17.8</ix:nonFraction> million, which represents the fair value of the shares
that have been issued to Nanox PLC, based on the last financing round of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: left; text-indent: -28.35pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_3" id="_RelatedPartyLiabilityTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"><ix:nonNumeric contextRef="c106" name="us-gaap:DebtInstrumentDescription">During January 2020, subject to entering into a share purchase
agreement in the aggregate amount of at least $6 million, and a pre-money valuation of more than $100 million, the Company&#8217;s Board approved
the issuance and allotment of 1,109,245 ordinary shares to Nanox PLC with the purchase price of $12.00 per share, which reflects a discount
of 25% from the price of the last financing round of the Company. As a result, on January 30, 2020 the related party liability was settled
into equity</ix:nonNumeric>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p></ix:continuation><div>
</div><div>

</div><!-- Field: Page; Sequence: 168; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9  - RELATED PARTIES  </b>(continued):

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_4" id="_RelatedPartyLiabilityTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Related party balances at December 31, 2021 and December
31, 2020 consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_5" id="_RelatedPartyLiabilityTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="nnox:ScheduleOfRelatedPartyTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Dollars in thousands)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">(a) Due from Illumigyn</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalDueFromRelatedParties" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalDueFromRelatedParties" scale="3" unitRef="usd">27</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">(b) Due from Wellsense Technologies Ltd.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalDueFromRelatedParties" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalDueFromRelatedParties" scale="3" unitRef="usd">14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(c) Due from Six-Eye Interactive</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalDueFromRelatedParties" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalDueFromRelatedParties" scale="3" sign="-" unitRef="usd">5</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">(c) Due from Six AI ltd.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalDueFromRelatedParties" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total from related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalDueFromRelatedParties" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="nnox:TotalDueFromRelatedParties" scale="3" unitRef="usd">36</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_6" id="_RelatedPartyLiabilityTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.</b></span></td>
    <td><span style="font-size: 10pt"><b>Related parties transactions:</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_7" id="_RelatedPartyLiabilityTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars in thousands)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Research and development &#8211; see d below</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd">80</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd">355</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd">154</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">General and administrative &#8211; See c, e and f below</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:OtherGeneralAndAdministrativeExpenses" scale="3" unitRef="usd">191</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nnox:OtherGeneralAndAdministrativeExpenses" scale="3" unitRef="usd">167</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nnox:OtherGeneralAndAdministrativeExpenses" scale="3" sign="-" unitRef="usd">5,824</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_8" id="_RelatedPartyLiabilityTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>c.</b></td><td style="text-align: left"><b>Six-Eye Interactive agreements for services</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_9" id="_RelatedPartyLiabilityTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On June 1 2015, Nanox PLC entered into
a consulting agreement with Six-Eye, a company owned by Ran Poliakine, the Company&#8217;s former Chief Executive Officer and one of major
shareholders, pursuant to which Ran Poliakine agreed to provide services as Chief Strategy Officer and a member of the Executive Committee
to Nanox PLC. On May 1, 2017, Nanox PLC entered into a services agreement with Six-Eye for the supply of ongoing services, which include
research and development services, general and financial management (including accountancy), office management services and operational
and supply services. According to the agreement between the parties, Nanox PLC reimburses Six-Eye for its actual direct expenses plus
a <ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" unitRef="pure">12</ix:nonFraction>% surplus charge. The agreements were terminated in September 2019. During the year ended December 31 2019 the total expenses to Six-Eye
were $<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">679</ix:nonFraction> thousand. In addition to the services provided by Six-Eye during 2019, Six-Eye also paid directly to third-party consultants
and suppliers on behalf of the Company in the amount of approximately $<ix:nonFraction contextRef="c108" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="3" unitRef="usd">1,015</ix:nonFraction> thousand prior to the completion of the Company&#8217;s equity
financing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 1in; text-align: left"></p></ix:continuation><div>
</div><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_10" id="_RelatedPartyLiabilityTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="text-align: left; width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>d<span style="font-family: Times New Roman, Times, Serif">.</span></b></td><td style="text-align: left"><b>Six AI Ltd Service agreement</b></td>
</tr></table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_11" id="_RelatedPartyLiabilityTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On April 16, 2020, the Company entered into an agreement with
SixAI Ltd. (hereinafter-&#8220;SixAI&#8221;) a company controlled by Ran Poliakine, the Company&#8217;s former Chief Executive Officer
for certain software development and mechanical engineering services. The service agreement was effective as of March 1, 2020 and has
been extended by mutual agreement of the parties several times, until terminated at December 31, 2021. During the years ended December
31, 2021 and 2020, the Company recorded an expense of $<ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">80</ix:nonFraction> and $<ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">355</ix:nonFraction> thousand, respectively. Mr. Poliakine currently serves as a member
of the board of directors of SixAI and Mr. Poliakine is a significant shareholder of SixAI.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 1in; text-align: left"></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_12" id="_RelatedPartyLiabilityTextBlock-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="text-align: left; width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>e.</b></td><td style="text-align: left"><b>Illumigyn Ltd.</b></td>
</tr></table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_13" id="_RelatedPartyLiabilityTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Illumigyn Ltd (hereinafter &#8211;
&#8220;Illumigyn&#8221;) is a company in which Ran Poliakine, the Company&#8217;s former Chief Executive Officer, is a significant shareholder
primarily through indirect holdings. Since November 1 2019, Illumigyn sub-leased in transaction approximately <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqm">1,800</ix:nonFraction> square feet of private
office space, including access to shared public spaces, from the office spaces which the Company leases in Neve Ilan, Israel. Illumigyn
pays approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:PaysApproximately" scale="3" unitRef="usd">12</ix:nonFraction> thousand per month. During the years ended December 31, 2021 and 2020, the Company received approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseIncome" scale="3" unitRef="usd">125</ix:nonFraction>
and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseIncome" scale="3" unitRef="usd">163</ix:nonFraction> thousand, respectively in relation to the sub lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 1in; text-align: left"><b>&#160;</b></p></ix:continuation><div>


</div><div>



</div><!-- Field: Page; Sequence: 169; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9 - RELATED PARTY LIABILITY (</b>continued):<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_14" id="_RelatedPartyLiabilityTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>f.</b></td><td style="text-align: left"><b>Wellsense Technologies Ltd.</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;

</p></ix:continuation><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_15" id="_RelatedPartyLiabilityTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 72pt; text-align: left">Wellsense Technologies Ltd.(hereinafter
&#8211; &#8220;Wellsense&#8221;) is a company in which Ran Poliakine, the Company&#8217;s former Chief Executive Officer, and Richard
Stone, a member of the Company&#8217;s board of directors, are shareholders. Since February 2020, Wellsense has sub-leased private office
space, including access to shared public spaces, from the Company in Neve Ilan, Israel. Wellsense pays approximately $<ix:nonFraction contextRef="c112" decimals="-2" format="ixt:num-dot-decimal" name="us-gaap:LeaseIncome" scale="3" unitRef="usd">7.0</ix:nonFraction> thousand per
month. During the years ended December 31, 2021 and 2020, the Company received $66 and $59 thousand, respectively in relation to the sub
lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_16" id="_RelatedPartyLiabilityTextBlock-c0_cont_15"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>g.</b></td><td style="text-align: left"><b>Employment Agreements</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_17" id="_RelatedPartyLiabilityTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The Company has entered into an employment
agreement with Ran Poliakine, the Company&#8217;s founder, Chairman of the Board of Directors, and former Chief Executive Officer. Pursuant
to the agreement, if the Company terminates Ran Poliakine&#8217;s employment and waives his obligation to perform services during the
notice period of 180 days, Ran Poliakine will be entitled to receive payments of his base salary and social benefits in lieu of notice
for the waived period, up to the full notice period for an immediate termination. The agreement provides Ran Poliakine with a gross monthly
base salary equal to $<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesAndWages" scale="3" unitRef="usd">40</ix:nonFraction> which was increased to $<ix:nonFraction contextRef="c114" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesAndWages" scale="3" unitRef="usd">60</ix:nonFraction> upon the consummation of the Company&#8217;s initial public offering.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_18" id="_RelatedPartyLiabilityTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">On September 27, 2021, <ix:nonNumeric contextRef="c115" name="nnox:EmploymentAgreementDescription">the Company and
Erez Meltzer entered into an employment agreement, pursuant to which Mr. Meltzer agreed to serve as the Company&#8217;s new Chief Executive
Officer (&#8220;The Meltzer Employment Agreement&#8221;). The Meltzer Employment Agreement commenced and became effective as of January
1, 2022 and shall continue for an indefinite period until it is terminated by either party. Pursuant to the terms of the Meltzer Employment
Agreement, Mr. Meltzer will receive an annual base salary of nine hundred thousand dollars ($900) per year, and will be eligible for an
annual incentive payment of up to one hundred percent (100%) of his base salary, which of them $450 will be guaranteed for the 2022 fiscal
year if his employment is continued through the entire fiscal year, with the possibility to withdraw an advance payment on account of
the 2022 annual bonus, subject to full recourse (clawback) if the bonus is not earned; Mr. Meltzer will be entitled to customary social
benefits under Israeli law and practice pursuant to which the Company shall insure the CEO with a manager&#8217;s insurance policy or
a pension fund, or a combination of both (whereby each will apply partially), all according to his election; &#160;Mr. Meltzer will be
granted options to purchase 300,000 Ordinary Shares (the &#8220;Options&#8221;) which will vested equally over a period of 48 months as
long as Mr. Melter will be employed by the Company. The Options shall be subject to the Company&#8217;s 2019 Equity Incentive plan and,
to the extent possible, be granted pursuant to Section 102 of the Israeli Income Tax Ordinance, 5721-1961. The exercise price of the Options
shall be $23.84 per share, a share price equals to the 30-day average of the Company&#8217;s share price on NASDAQ, prior to the date
of approval of the CEO&#8217;s employment agreement by the Board on September 27, 2021. Such amount may be paid by the CEO by way of a
cashless exercise mechanism; The agreement calls for a 6 months&#8217; mutual notice of termination and 270 days if the Company provides
notice during the first year of employment (except for &#8220;Cause&#8221; as defined in the employment agreement, in which case no prior
notice will be required);</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyLiabilityTextBlock-c0_cont_19" id="_RelatedPartyLiabilityTextBlock-c0_cont_18"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 24px; font-size: 10pt; text-align: left"><span style="font-size: 10pt"><b>h.</b></span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt"><b>Service Agreement</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_RelatedPartyLiabilityTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In February 2021, the shareholders of the Company approved
the entry into an agreement with Floyd Katske, effective as of October 1, 2020, whereby Floyd Katske will assist the Chief Executive Officer
and the Company with various tasks given his medical knowledge, expertise and experience, as may be requested from time-to-time by the
Company&#8217;s Chief Executive Officer. These tasks are in addition and unrelated to his role as a member of the board of directors of
the Company. Floyd Katske will be paid with respect to such services $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UtilitiesOperatingExpenseProductsAndServices" scale="0" unitRef="usd">200</ix:nonFraction> per hour, against an invoice. The services will be limited to
100 hours in any calendar month, according to hours approved by the Chairman. In addition, Floyd Katske will be paid cash compensation
consisting of RSUs granted in each calendar quarter, in the amount calculated by dividing (i) two times the cash compensation paid during
such quarter as aforesaid by (ii) the fair market value of our ordinary shares on the last trading day of such quarter. All tax consequences
will be borne by Floyd Katske. The agreement may be terminated by 14 days&#8217; written notice by either party. During the year ended
December 31, 2021, the Company recorded an expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd">168</ix:nonFraction> with regards to the cash payment and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromDepositOnLoan" scale="3" unitRef="usd">473</ix:nonFraction> thousand with regards to the RSUs
portion of Floyds&#8217; fees.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>




</div><!-- Field: Page; Sequence: 170; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 &#8211; LONG TERM LOAN </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9pt">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">During September 2021, Nanox Korea entered
into a <ix:nonNumeric contextRef="c124" format="ixt-sec:duryear" name="us-gaap:LongTermDebtTerm">3</ix:nonNumeric> years Loan agreement with a Korean Bank, according to which the Bank granted the Company a loan in the amount of $<ix:nonFraction contextRef="c124" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="6" unitRef="usd">3.8</ix:nonFraction> million.
The loan bears an annual interest at a rate of 3 months KORIBOR and <ix:nonFraction contextRef="c124" decimals="5" format="ixt:num-dot-decimal" name="nnox:AnnualInterestRate" scale="-2" unitRef="pure">1.149</ix:nonFraction> % , whereas interest payments are due on a monthly basis and
the principal is due in the end of the loan term. The bank received a floating charge on the Company&#8217;s asset.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; ">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 - COMMITMENTS AND CONTINGENCIES</b>:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; ">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">From time to time, The Company may become
involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent
uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">in September 2020, two securities class
action complaints were filed in the United States District Court for the Eastern District of New York against the Company and certain
current officers and a director, which were subsequently consolidated and captioned as <i>White v. Nano-X Imaging Ltd. et al</i>, Case
No. 1:20-cv-04355, alleging violations of securities laws on behalf of all persons and entities that purchased or otherwise acquired the
Company&#8217;s publicly traded securities between August 21, 2020 and September 15, 2020, and seeking unspecified damages. On December
7, 2020, proposed lead plaintiffs submissions were fully briefed and remain outstanding. As of December 31, 2021, the Company has not
accrued any losses other than legal fees with connection to the above referenced complaints. The Company&#8217;s position is that the
complaint has no merit and it will defend its position vigorously.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On October 5, 2021, a class action complaint
was filed in the United States District Court for the Eastern District of New York against the Company and certain of its officers, captioned
McLaughlin v. Nano-X Imaging Ltd. et al, Case No. 1:21-cv-05517. The plaintiff asserts claims on behalf of persons and entities that purchased
or otherwise acquired the Company&#8217;s securities between June 17, 2021 and August 18, 2021, seeking unspecified damages. The plaintiff
alleges that the defendants made materially false and misleading statements concerning the Company&#8217;s business, operations and compliance
policies beginning on June 17, 2021, based on the Company&#8217;s U.S. Food and Drug Administration submissions. As of December 31, 2021,
the Company has not accrued any losses other than legal fees with connection to the above referenced complaint. The Company&#8217;s position
that the complaint has no merit and will defend its position vigorously.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On October 28, 2021, a complaint was filed
in the United States District Court for the Central District of California against the Company, the Company&#8217;s recently-formed Delaware
subsidiary and Nanox Gibraltar PLC (&#8220;Gibraltar&#8221;) from which the Company received certain assets, as well as Mr. Ran Poliakine
and certain other unidentified parties, alleging several causes of action including breach of a consulting agreement between plaintiff
and Gibraltar that was entered into in 2014. The plaintiff&#8217;s demand is for a payment of unpaid consulting fees from Gibraltar in
the amount of approximately $<ix:nonFraction contextRef="c125" decimals="-6" format="ixt:num-dot-decimal" name="nnox:ConsultingFees" scale="6" unitRef="usd">1</ix:nonFraction> million and approximately $<ix:nonFraction contextRef="c125" decimals="-5" format="ixt:num-dot-decimal" name="nnox:EntitlementToWarrantsAmount" scale="6" unitRef="usd">29.5</ix:nonFraction> million from the Company relating to his claimed entitlement to warrants
in Gibraltar. The Company&#8217;s position is that the complaint against the Company has no merit, among other reasons, as it was not
a party to the agreement with the plaintiff and it is not Gibraltar&#8217;s legal successor for any liabilities that Gibraltar may owe
to the plaintiff, and it intends to defend its position vigorously.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Division of Enforcement of the U.S.
Securities &amp; Exchange Commission (the &#8220;SEC&#8221;) has notified the Company that it is conducting an investigation to determine
whether there had been any violations of the federal securities laws. The Company has been providing documents and information and has
now received a subpoena from the SEC requesting that the Company provide documents and other information relating to the development cost
of the Company&#8217;s Nanox.ARC prototypes, as well as the Company&#8217;s estimate for the cost of assembling the final Nanox.ARC product
at scale. The Company is cooperating with the SEC in responding to its requests. The duration and outcome of this matter cannot be predicted
at this time.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;&#160;</p><div>




</div><!-- Field: Page; Sequence: 171; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>a.</b></span></td>
    <td><span style="font-size: 10pt"><b>Share capital</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Each holder of the Company&#8217;s ordinary
shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available
and declared by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). Since inception, the Company has not declared any dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The following table presents the number of authorized and issued and
outstanding shares as of each reporting date for each class of shares:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="nnox:ScheduleOfIssuedAndOutstandingTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Authorized</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Issued and Outstanding</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Authorized</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Issued and Outstanding</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 51%; text-align: left">Ordinary shares</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c32" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c32" decimals="INF" format="ixt:num-dot-decimal" name="nnox:OrdinarySharesIssuedAndOutstanding" scale="0" unitRef="shares">51,791,441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="nnox:OrdinarySharesIssuedAndOutstanding" scale="0" unitRef="shares">46,100,173</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">Total</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="nnox:OrdinarySharesIssuedAndOutstanding" scale="0" unitRef="shares">51,791,441</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="nnox:OrdinarySharesIssuedAndOutstanding" scale="0" unitRef="shares">46,100,173</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.</b></span></td>
    <td><span style="font-size: 10pt"><b>Share based compensation </b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><span style="text-decoration:underline">Share based compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On September 3, 2019, the Company&#8217;s
Board resolved to adopt an equity incentive plan (the &#8220;Plan&#8221;). Based on such Plan, each option will be exercisable for one
ordinary share of the Company and will become exercisable at such terms and during such periods, as the Board shall determine. <ix:nonNumeric contextRef="c126" name="nnox:DescriptionOfSharebasedCompensationExpenses">Pursuant
to the Plan (and further increase of option pool approved by the Board), 8,041,936 ordinary shares of NIS 0.01 par value of the Company
are reserved for issuance upon the exercise of the same amount of awards to be granted to some of the Company&#8217;s employees, directors
and consultants.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">As of December 31, 2021, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockOtherSharesOutstanding" scale="0" unitRef="shares">1,841,838</ix:nonFraction> ordinary shares reserved for the
equity incentive plan. The Board also approved the Plan for the purpose of selecting the capital gains tax track, under Section 102 of
the Israeli Income Tax Ordinance, for options granted to the Company&#8217;s Israeli employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>




</div><!-- Field: Page; Sequence: 172; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: left"><span style="text-decoration:underline">Share-based compensation to non-employees</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The following table summarizes share-based awards to non-employees
for the period ended December 31, 2021 and December 31, 2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended <br/> December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended <br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">payment</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">payment</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">3,372,626</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.27</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">3,410,406</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c19" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.89</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">180,319</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">40.12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">1,327,957</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">13.70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">1,043,142</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.66</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">*(1,267,012</div></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">8.94</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">118,954</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">10.18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" unitRef="shares">66,606</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">16.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares">98,725</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.92</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nnox:NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" scale="0" unitRef="shares">2,324,243</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.17</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nnox:NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" scale="0" unitRef="shares">3,372,626</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.27</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,618,777</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.35</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">2,191,042</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.67</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: left"><span style="font-size: 10pt">Out
of which <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" unitRef="shares">404,704</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" unitRef="shares">1,027,151</ix:nonFraction> awards were exercised on a cashless basis in 2021 and 2020, respectively.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The fair value of each granted award is estimated at the date
of grant using the Black- Scholes option-pricing model. The assumptions used for the year ended December 31, 2021 and year ended at December
31, 2020 are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/>
December&#160;31,<br/>
2021</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/>
December&#160;31,<br/>
2020</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Dividend yield</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 12%; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 12%; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c113" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">50.27</ix:nonFraction>% - <ix:nonFraction contextRef="c114" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">52.71</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c129" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">57.34</ix:nonFraction>%-<ix:nonFraction contextRef="c130" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">44.40</ix:nonFraction>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c113" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.66</ix:nonFraction>% - <ix:nonFraction contextRef="c114" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.61</ix:nonFraction>%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c129" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.27</ix:nonFraction>%-<ix:nonFraction contextRef="c130" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.61</ix:nonFraction>%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Contractual term (years)</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c113" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">0</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c114" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c129" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">5</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="c130" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The expected volatility is based on the historical volatility
of comparable companies. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term
of the awards granted in dollar terms. The Company does not have sufficient historical exercise data to provide a reasonable basis upon
which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified
method, which takes into consideration the option&#8217;s contractual life and the vesting periods (for non-employees, the expected term
is equal to the option&#8217;s contractual life.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 173; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY </b>(continued):</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: left">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in">The following table summarizes information concerning outstanding
and exercisable awards as of December 31, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards outstanding</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards exercisable</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>awards</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>award</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>outstanding</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>exercisable</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>price</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right; width: 18%"><span style="font-size: 10pt"><ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.92</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><span style="font-size: 10pt"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">192,927</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><ix:nonNumeric contextRef="c138" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">0.04</span></ix:nonNumeric></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><span style="font-size: 10pt"><ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">192,927</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><ix:nonNumeric contextRef="c139" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">0.04</span></ix:nonNumeric></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.21</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c140" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">1,769,513</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c141" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">7.89</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c140" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,288,236</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c142" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">7.89</span></ix:nonNumeric></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">16.00</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c143" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">161,484</ix:nonFraction></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c144" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">5.43</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c143" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">114,477</ix:nonFraction></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c145" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.22</ix:nonNumeric></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">23.19</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c146" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">21,000</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c147" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">9.78</span></ix:nonNumeric></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c149" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">23.84</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c149" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">30,000</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c150" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">9.88</span></ix:nonNumeric></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">30.93</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c152" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">20,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c153" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">8.81</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c152" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">20,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c154" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">8.81</span></ix:nonNumeric></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">30.66</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c155" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">12,000</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c156" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">9.53</span></ix:nonNumeric></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">40.21</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c158" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">17,319</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c159" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">9.19</span></ix:nonNumeric></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c158" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">3,137</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c160" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">9.19</span></ix:nonNumeric></td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">49.68</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">100,000</ix:nonFraction></span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c162" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">9.05</span></ix:nonNumeric></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">
</p></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt"></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><ix:continuation continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_2" id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2020</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Awards outstanding</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">award</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.01</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right"><ix:nonFraction contextRef="c165" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">186,815</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right"><ix:nonNumeric contextRef="c166" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">0.33</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right"><ix:nonFraction contextRef="c165" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">186,815</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right"><ix:nonNumeric contextRef="c166" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">0.33</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c168" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">269,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c169" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.18</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c168" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">269,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c169" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">1.18</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">2,191,349</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c172" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.22</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,188,914</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c172" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.22</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">16.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">444,748</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c175" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.89</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">283,933</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c175" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.89</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">18.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">260,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c178" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.86</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c177" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">260,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c178" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.86</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">30.93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c181" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.81</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c181" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.81</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><!-- Field: Page; Sequence: 174; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY </b>(continued):</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: left">Share-based compensation to employees, officers and directors</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 1in; text-align: left">During 2021, the Company granted to certain employees, officers and
directors awards to purchase <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" unitRef="shares">1,418,665</ix:nonFraction> of the Company&#8217;s ordinary shares for an average exercise price of $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">27.57</ix:nonFraction>. Most of the awards
agreement term is <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric> years unless the agreement is terminated, <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="nnox:AgreementTerminateTerm"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="nnox:VestingPeriod">4</ix:nonNumeric></ix:nonNumeric> years vesting period with a one-year cliff.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 81pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21"><ix:nonNumeric contextRef="c208" escape="true" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended </td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payment awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">exercise<br/>
 price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payment<br/>
 awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">exercise<br/>
 price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">2,381,125</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c209" decimals="2" format="ixt:num-dot-decimal" name="nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" scale="0" unitRef="usdPershares">4.14</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,667,267</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c210" decimals="2" format="ixt:num-dot-decimal" name="nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" scale="0" unitRef="usdPershares">2.21</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">1,418,665</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">27.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">730,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">13.53</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Issued due to business combination</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" scale="0" unitRef="shares">117,536</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="nnox:IssuedDueToBusinessCombination" scale="0" unitRef="usdPershares">0.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">837,724</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="nnox:StockIssuedDuringPeriodSharesStockOptionsForfeited" scale="0" unitRef="shares">318,672</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">19.69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="nnox:NumberOfSharebasedPaymentAwardsCancelled" scale="0" sign="-" unitRef="shares">16,876</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Outstanding at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">2,760,930</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" scale="0" unitRef="usdPershares">15.85</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">2,381,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c209" decimals="2" format="ixt:num-dot-decimal" name="nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" scale="0" unitRef="usdPershares">4.14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">845,356</ix:nonFraction></p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="nnox:WeightedAverageExercisePriceExercisableAtEndOfYear" scale="0" unitRef="usdPershares">3.58</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,061,778</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="nnox:WeightedAverageExercisePriceExercisableAtEndOfYear" scale="0" unitRef="usdPershares">2.80</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 81pt">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The fair value of each granted award is
estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used as of December 31, 2021 and 2020 are
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23"><ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Dividend yield</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c131" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c132" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Expected volatility</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c133" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">50.27</ix:nonFraction>%-<ix:nonFraction contextRef="c134" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">51.84</ix:nonFraction>%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c135" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">45.11</ix:nonFraction>%-<ix:nonFraction contextRef="c136" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">55.97</ix:nonFraction>%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Risk-free interest rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c133" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.66</ix:nonFraction>%-<ix:nonFraction contextRef="c134" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.61</ix:nonFraction>%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c135" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.23</ix:nonFraction>%-<ix:nonFraction contextRef="c136" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.61</ix:nonFraction>%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Contractual term (years)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c131" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c132" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">10</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY </b>(continued):</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The expected volatility is based on the
historical volatility of comparable companies. The risk-free interest rate assumption is based on observed interest rates appropriate
for the expected term of the awards granted in dollar terms. The Company does not have sufficient historical exercise data to provide
a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined
using the simplified method, which takes into consideration the option&#8217;s contractual life and the vesting periods. The following
table summarizes information concerning outstanding and exercisable awards as of December 31, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25"><ix:continuation continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_3" id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards outstanding</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards exercisable</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>awards</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>awards</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>outstanding</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>exercisable</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>price</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 18%; text-align: center"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.00</ix:nonFraction>-<ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.01</ix:nonFraction></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 17%; text-align: center"><div style="-sec-ix-hidden: hidden-fact-122"><span style="font-size: 10pt">120,757*)</span></div></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 17%; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 17%; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c185" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">73,679</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 17%; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: center; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.21</ix:nonFraction></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c186" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">1,130,143</ix:nonFraction></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c187" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">7.95</span></ix:nonNumeric></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c188" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">716,448</ix:nonFraction></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c189" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">7.95</span></ix:nonNumeric></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c190" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">16.00</ix:nonFraction></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c190" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">88,500</ix:nonFraction></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c191" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">7.48</span></ix:nonNumeric></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c192" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">35,791</ix:nonFraction></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c193" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">6.09</span></ix:nonNumeric></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$<ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">17.63</ix:nonFraction>-$<ix:nonFraction contextRef="c195" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">64.61</ix:nonFraction></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c196" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">1,421,530</ix:nonFraction></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c197" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">9.68</span></ix:nonNumeric></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c198" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">19,438</ix:nonFraction></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c199" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-size: 10pt">8.98</span></ix:nonNumeric></td>
    <td style="text-align: center">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*)</td><td style="text-align: left">Including <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">47,793</ix:nonFraction> RSUs that were granted to the employees of
Nanox AI at the completion of the merger and <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="nnox:ConsiderationForServicesShares" scale="0" unitRef="shares">3,221</ix:nonFraction> RSUs that were issued in consideration for services.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27"><ix:continuation id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2020</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Awards outstanding</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 18%; text-align: center">$<ix:nonFraction contextRef="c200" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.21</ix:nonFraction></td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center"><ix:nonFraction contextRef="c200" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">1,995,625</ix:nonFraction></td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center"><ix:nonNumeric contextRef="c201" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.05</ix:nonNumeric></td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center"><ix:nonFraction contextRef="c200" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,019,695</ix:nonFraction></td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center"><ix:nonNumeric contextRef="c201" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.05</ix:nonNumeric></td><td style="width: 1%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td style="text-align: center">$<ix:nonFraction contextRef="c202" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">16.00</ix:nonFraction></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c202" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">205,000</ix:nonFraction></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c203" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.62</ix:nonNumeric></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c202" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">37,917</ix:nonFraction></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c203" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.62</ix:nonNumeric></td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c204" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">26.56</ix:nonFraction>-$<ix:nonFraction contextRef="c205" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">59.20</ix:nonFraction></span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c206" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">180,500</ix:nonFraction></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c207" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.93</ix:nonNumeric></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonFraction contextRef="c206" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">4,167</ix:nonFraction></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><ix:nonNumeric contextRef="c207" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.93</ix:nonNumeric></td><td style="text-align: center">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3)</span></td><td style="text-align: left"><span style="font-size: 10pt">Share-based compensation expenses</span></td>
</tr></table><p style="margin: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Cost of revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherCostOfOperatingRevenue" scale="3" unitRef="usd">51</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" unitRef="usd">3,248</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" unitRef="usd">3,384</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentInProcess" scale="3" unitRef="usd">661</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and Marketing (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd">2,442</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd">9,252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd">617</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">13,065</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">12,145</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">14,967</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" scale="3" unitRef="usd">18,806</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" scale="3" unitRef="usd">24,781</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross" scale="3" unitRef="usd">16,245</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>



</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: left">On October 26, 2020, the Company entered into an amendment to
a business development agreement (&#8220;the Agreement&#8221;) dated February 4, 2020 with two service providers pursuant to which the
Company paid an aggregate one-time payment of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValueAddedTaxReceivableNoncurrent" scale="3" unitRef="usd">400</ix:nonFraction> thousand plus VAT and issued to them warrants to purchase an aggregate of <ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="nnox:PurchaseAggregateShares" scale="0" unitRef="shares">650,000</ix:nonFraction>
ordinary shares at an exercise price of $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares">18</ix:nonFraction> per share with a graded vesting ending 10 weeks following the grant date (subject to a standard
cashless exercise provision). As a result, the Company recorded an expense of $<ix:nonFraction contextRef="c0" decimals="1" format="ixt:num-dot-decimal" name="nnox:RecordedAnExpense" scale="0" unitRef="usd">6.1</ix:nonFraction> million for the warrants granted. The service providers
waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities
undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company&#8217;s systems
and the issuance of warrants.</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 176; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 - INCOME TAX:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>a.</b></span></td>
    <td><span style="font-size: 10pt"><b>Basis of taxation</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Current tax is calculated with
reference to the profit of the Company and its subsidiaries in their respective countries of operation. Set out below are details in respect
of the significant jurisdictions where the Company and its subsidiaries operate and the factors that influenced the current and deferred
taxation in those jurisdictions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in"><b>Israel</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company and Nanox AI Ltd are taxed
under the laws of the State of Israel at a corporate tax rate of <ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">23</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">In 2021, 2020 and 2019, the Company is
at a loss position and therefore has no corporate tax liability. As of December&#160;31, 2021, 2020 and 2019, the Company has a carry
forward loss of approximately $<ix:nonFraction contextRef="c215" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd">56.3</ix:nonFraction>&#160;million, $<ix:nonFraction contextRef="c216" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd">32.3</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c217" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd">2.3</ix:nonFraction>&#160;million, respectively. Such carry forward loss has
no expiration date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">In 2021, 2020 and 2019, Nanox AI Ltd.
is at a loss position and therefore has no corporate tax liability. As of December&#160;31, 2021, 2020 and 2019, Nanox AI Ltd. has a
carry forward loss of approximately $<ix:nonFraction contextRef="c214" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure">61.9</ix:nonFraction>&#160;million, $<ix:nonFraction contextRef="c218" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure">45.3</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c219" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure">17.6</ix:nonFraction>&#160;million, respectively. Such carry forward loss
has no expiration date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in"></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in"><b>United States</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The principal federal tax rate applicable to the U.S. subsidiaries
is <ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="nnox:FederalTaxRatePercentage" scale="-2" unitRef="pure">21</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b><i>Korea</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Nanox Korea is subject to a Corporate
income tax with accordance with the Korean tax law. The tax rate ranges between <ix:nonFraction contextRef="c221" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">10</ix:nonFraction>% to <ix:nonFraction contextRef="c222" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">25</ix:nonFraction>%, depending on the companies&#8217; taxable
income. In Addition, Nanox Korea is subject to a Local income tax of <ix:nonFraction contextRef="c223" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitRef="pure">10</ix:nonFraction>%. In 2021, Nanox Korea was at a loss position and therefore had
no corporate tax liability. As of December&#160;31, 2021 and 2020, Nanox Korea has a carry forward loss of approximately $<ix:nonFraction contextRef="c224" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd">7.1</ix:nonFraction>&#160;million
and $<ix:nonFraction contextRef="c225" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd">0.2</ix:nonFraction>&#160;million, respectively. Such carry forward loss has <ix:nonNumeric contextRef="c223" format="ixt-sec:duryear" name="nnox:CarryForwardLossYears">15</ix:nonNumeric> years expiration date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b><i>Japan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_13" id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Nanox Inc. is subject to national corporate income tax, and enterprise
tax, which, in the aggregate resulted in effective tax rate of approximately <ix:nonFraction contextRef="c226" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">33.59</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in; text-align: left"><b>&#160;</b></p></ix:continuation><div>


</div><div>




</div><!-- Field: Page; Sequence: 177; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 - INCOME TAX </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>



</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_14" id="_IncomeTaxDisclosureTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.</b></span></td>
    <td><span style="font-size: 10pt"><b>Income (loss) Before Income Taxes:</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_15" id="_IncomeTaxDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Income (loss) before income
taxes consisted of the following for the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_16" id="_IncomeTaxDisclosureTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfIncomelossBeforeIncomeTaxesConsisted-c0_cont_1" escape="true" name="nnox:ScheduleOfIncomelossBeforeIncomeTaxesConsisted"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year&#160;Ended&#160;December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Domestic (Israel)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">56,609</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">43,449</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">22,588</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" unitRef="usd">5,237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" unitRef="usd">366</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" sign="-" unitRef="usd">25</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss before income taxes</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" unitRef="usd">61,846</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" unitRef="usd">43,815</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" unitRef="usd">22,563</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:nonNumeric></ix:continuation><div>




</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_17" id="_IncomeTaxDisclosureTextBlock-c0_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>c.</b></span></td><td style="text-align: left"><span style="font-size: 10pt"><b>Income tax expenses consisted
of the following for the periods indicated:</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_18" id="_IncomeTaxDisclosureTextBlock-c0_cont_17"><ix:continuation continuedAt="_ScheduleOfIncomelossBeforeIncomeTaxesConsisted-c0_cont_2" id="_ScheduleOfIncomelossBeforeIncomeTaxesConsisted-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year&#160;Ended&#160;December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Domestic (Israel)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">57</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" sign="-" unitRef="usd">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Income tax expenses</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" unitRef="usd">48</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_19" id="_IncomeTaxDisclosureTextBlock-c0_cont_18"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>d.</b></span></td><td style="text-align: left"><span style="font-size: 10pt"><b>Taxes on Income:</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>



</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_20" id="_IncomeTaxDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Taxes on income for the years ended December&#160;31, 2021, 2020 and
2019 were comprised of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_21" id="_IncomeTaxDisclosureTextBlock-c0_cont_20"><ix:continuation id="_ScheduleOfIncomelossBeforeIncomeTaxesConsisted-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S.&#160;dollars&#160;in&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">Domestic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Foreign</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" sign="-" unitRef="usd">68</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="nnox:CurrentTotal" scale="3" sign="-" unitRef="usd">68</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 27pt">Domestic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" unitRef="usd">57</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" unitRef="usd">59</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd">116</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Provision for income taxes</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="nnox:ProvisionForIncomeTaxes" scale="3" unitRef="usd">48</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation></ix:continuation><div>




</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>NOTE 13 - INCOME TAX </b>(continued):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_22" id="_IncomeTaxDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">A reconciliation our theoretical income tax expense to actual income
tax expense is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_23" id="_IncomeTaxDisclosureTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss before taxes on income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" unitRef="usd">61,846</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" unitRef="usd">43,815</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossAttributableToParent" scale="3" unitRef="usd">22,563</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Statutory tax rate in Israel</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Theoretical tax benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" unitRef="usd">14,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" unitRef="usd">10,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" unitRef="usd">5,189</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase (decrease) in taxes resulting from:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Effect of different tax rates applicable in foreign jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" unitRef="usd">110</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating losses and other temporary differences for which valuation allowance was provided</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">6,174</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">7,235</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">701</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Permanent differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="3" unitRef="usd">8,113</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="3" unitRef="usd">2,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="3" unitRef="usd">4,480</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Actual tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" scale="3" sign="-" unitRef="usd">48</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_24" id="_IncomeTaxDisclosureTextBlock-c0_cont_23"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>e.</b></span></td>
    <td><span style="font-size: 10pt"><b>Deferred tax assets </b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_25" id="_IncomeTaxDisclosureTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in">Nanox IL&#8217;s deferred tax asset as of December 31,
2021 and December 31, 2020 was related to tax losses accumulated and carryforward. The reconciling item
between the statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax
benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_26" id="_IncomeTaxDisclosureTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The components of the Company&#8217;s deferred tax
assets and liabilities as of December&#160;31, 2021 and 2020 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_27" id="_IncomeTaxDisclosureTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S.&#160;dollars&#160;in&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 27pt">Tax loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">30,234</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">7,480</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd">4,010</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd">1,213</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Employee and payroll accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" unitRef="usd">304</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" unitRef="usd">96</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitRef="usd">109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">34,657</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">8,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd">21,775</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" unitRef="usd">12,882</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" unitRef="usd">8,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less valuation allowance for deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="nnox:LessValuationAllowanceForDeferredTaxAssets" scale="3" sign="-" unitRef="usd">12,882</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="nnox:LessValuationAllowanceForDeferredTaxAssets" scale="3" sign="-" unitRef="usd">8,789</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>NOTE 13 - INCOME TAX </b>(continued):</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_28" id="_IncomeTaxDisclosureTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Significant judgment is required
in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company
considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible
tax planning strategies. The Company reassess its valuation allowance periodically and if future evidence allows for a partial or full
release of the valuation allowance, a tax benefit will be recorded accordingly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_29" id="_IncomeTaxDisclosureTextBlock-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">As of December&#160;31, 2021, and 2020, the Company has recorded a
full valuation allowance of $<ix:nonFraction contextRef="c227" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">12,882</ix:nonFraction> and $<ix:nonFraction contextRef="c228" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">8,789</ix:nonFraction> thousand with regard to its deferred taxes (which is mainly tax loss carryforwards temporary
differences due to unallowed research and development expenses) generated in Israel, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_29"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S.&#160;dollars in&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Valuation allowance, December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">8,789</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Increase due to business combination</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nnox:IncreaseDueToBusinessCombinationinShares" scale="3" unitRef="usd">2,530</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Increase</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenuePeriodIncreaseDecrease" scale="3" unitRef="usd">1,563</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Valuation allowance, December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">12,882</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&#160;</p><div>




</div><!-- Field: Page; Sequence: 180; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentsOfOperationsTextBlock-c0_cont_1" escape="true" name="nnox:SegmentsOfOperationsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 - SEGMENTS OF OPERATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentsOfOperationsTextBlock-c0_cont_2" id="_SegmentsOfOperationsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">The Company reports segment information based on the &#8220;management&#8221;
approach. The management approach designates the internal reporting used by management for making decisions and assessing performance
as the source of the Company&#8217;s reportable operating segments. The Company manages its business primarily on a service basis. The
management approach designates the internal reporting used by management for making decisions and assessing performance as the source
of the Company&#8217;s reportable segments. The Company&#8217;s reportable segments consist of the Nanox ARC, Radiology services division
and AI solutions divisions. Each one is managed separately to better align with the Company&#8217;s customers and distribution partners
and the unique market dynamics of each segment. Operating income for each segment includes net sales to third parties, related cost of
sales and operating expenses directly attributable to the segment. Operating loss for each segment excludes other income and expense and
certain expenses managed outside the reportable segments. Costs excluded from segment operating income include various corporate expenses
such as income taxes. The Company does not include intercompany transfers between segments for management reporting</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentsOfOperationsTextBlock-c0_cont_3" id="_SegmentsOfOperationsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">The accounting policies of the various segments are the same as those
described in Note 2, &#8220;Summary of Significant Accounting Policies.&#8221; The Company evaluates the performance of its reportable
operating segments based on net sales and operating loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentsOfOperationsTextBlock-c0_cont_4" id="_SegmentsOfOperationsTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock-c0_cont_1" escape="true" name="nnox:ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Nanox. ARC</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Radiology Services</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>AI Solutions</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,034</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">270</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">1,304</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Segment operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">56,875</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">530</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">4,153</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">61,558</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="nnox:FinancialIncome" scale="0" unitRef="usd">288</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" sign="-" unitRef="usd">61,846</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation and amortization expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">458</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">441</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">1,393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">2,292</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">18,433</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">336</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">18,806</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SegmentsOfOperationsTextBlock-c0_cont_5" id="_SegmentsOfOperationsTextBlock-c0_cont_4"><ix:continuation continuedAt="_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock-c0_cont_2" id="_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Nanox. ARC</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Radiology Services</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>AI Solutions</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%">Segment operating loss</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(<ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">43,923</ix:nonFraction></td><td style="text-align: left; width: 1%">)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">43,923</ix:nonFraction></td><td style="text-align: left; width: 1%">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="nnox:FinancialExpense" scale="0" unitRef="usd">108</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" sign="-" unitRef="usd">43,815</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">208</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">208</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">24,781</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">24,781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "></p><div>

</div><!-- Field: Page; Sequence: 181; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 - SEGMENTS OF OPERATIONS</b> (continued):</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><div>

</div><ix:continuation continuedAt="_SegmentsOfOperationsTextBlock-c0_cont_6" id="_SegmentsOfOperationsTextBlock-c0_cont_5"><ix:continuation id="_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Nanox. ARC</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Radiology Services</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>AI Solutions</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%">Segment operating loss</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">22,571</ix:nonFraction></td><td style="text-align: left; width: 1%">)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(<ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">22,571</ix:nonFraction></td><td style="text-align: left; width: 1%">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="nnox:FinancialIncome" scale="0" unitRef="usd">8</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" sign="-" unitRef="usd">22,563</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="0" unitRef="usd">53</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">16,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd">16,245</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SegmentsOfOperationsTextBlock-c0_cont_7" id="_SegmentsOfOperationsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For the&#160;year ended December&#160;31, 2021, the Company&#8217;s
revenues in the United States of America constitutes approximately <ix:nonFraction contextRef="c241" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure">98</ix:nonFraction>% of the Company&#8217;s total revenue. For the year ended December
31, 2021 no individual customer exceeded <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>% of our total revenue or total accounts receivables.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SegmentsOfOperationsTextBlock-c0_cont_8" id="_SegmentsOfOperationsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and Equipment by Geography</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SegmentsOfOperationsTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="nnox:ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year&#160;Ended<br/>
December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Israel</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">3,381</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">2,065</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">South Korea</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">33,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">11,675</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unites States</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Japan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">196</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">280</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">37,435</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">14,020</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><!-- Field: Page; Sequence: 182; Value: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NANO-X IMAGING LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO THE FINANCIAL STATEMENTS (continued)</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 </b>- <b>LOSS PER SHARE:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>a.</b></span></td>
    <td><span style="font-size: 10pt"><b>Basic</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_3" id="_EarningsPerShareTextBlock-c0_cont_2"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Basic loss per share is calculated by dividing the loss attributable
to the Company&#8217;s owners by the weighted average number of ordinary shares in issue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.9pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_4" id="_EarningsPerShareTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2019</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 67%; padding-bottom: 1.5pt"><span style="font-size: 10pt">Net loss attributable to Company&#8217;s owners</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" unitRef="usd">61,798</ix:nonFraction></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" unitRef="usd">43,815</ix:nonFraction></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" unitRef="usd">22,563</ix:nonFraction></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">The weighted average of the number of ordinary shares (in thousands)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nnox:TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" scale="0" unitRef="shares">48,216</ix:nonFraction>&#160;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nnox:TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" scale="0" unitRef="shares">35,654</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="nnox:TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" scale="0" unitRef="shares">25,181</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt"><b>Basic and diluted loss per share</b></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nnox:BasicAndDilutedLossPerShare" scale="0" sign="-" unitRef="usdPershares">1.28</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="nnox:BasicAndDilutedLossPerShare" scale="0" sign="-" unitRef="usdPershares">1.23</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="nnox:BasicAndDilutedLossPerShare" scale="0" sign="-" unitRef="usdPershares">0.90</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.9pt">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_5" id="_EarningsPerShareTextBlock-c0_cont_4"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">For the calculation of loss per share, the Company used the
net loss attributable to Company&#8217;s owners divided by the weighted average number of the Company&#8217;s ordinary shares for the
years ended December 31, 2021, 2020 and 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_6" id="_EarningsPerShareTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.</b></span></td>
    <td><span style="font-size: 10pt"><b>Diluted</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.8pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">As of December 31, 2021, and 2020 the Company had <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="nnox:BasicAndDilutedShare" scale="0" unitRef="shares">2,505,370</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="nnox:BasicAndDilutedShare" scale="0" unitRef="shares">3,173,186</ix:nonFraction>
warrants, respectively and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="nnox:WarrantsShares" scale="0" unitRef="shares">4,842,342</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="nnox:WarrantsOption" scale="0" unitRef="shares">4,673,104</ix:nonFraction> options, respectively. As of December 31, 2019, the Company had <ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="nnox:WarrantsShares" scale="0" unitRef="shares">5,548,649</ix:nonFraction>&#160;warrants
and <ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="nnox:WarrantsOption" scale="0" unitRef="shares">3,654,464</ix:nonFraction> options. These warrants and awards were not considered when calculating diluted loss per share since their effect is anti-dilutive.
In addition, contingently issuable ordinary shares that are issuable based on certain conditions (see Note 3) are not included in the
potential dilutive shares in calculating the diluted loss per share.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.9pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 16 - SUBSEQUENT EVENTS:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 19, 2022, the Company issued <ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="nnox:AdditionalSharesIssued" scale="0" unitRef="shares">89,286</ix:nonFraction>
additional shares to the former shareholders of Nanox AI due to partial achievement of a milestone that occurred post-closing.&#160;The
fair value of the shares at the issuance date was $<ix:nonFraction contextRef="c260" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsFairValueDisclosure" scale="3" unitRef="usd">952</ix:nonFraction>.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In March 2022, the Company leased and addition space of 105 square
meters in Neve Ilan for a period of <ix:nonNumeric contextRef="c261" format="ixt-sec:duryear" name="nnox:LeasedAdditionTerm">3</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_4" id="_SubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On March 28, 2022, the Board of Directors of the
Company nominated Mr. Erez Alroy as a member of the Board of the Company. Mr. Alroy replaces Mr. Fenig who retires from his membership
at the Board of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_4"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On January 25, 2022, Magistrate Judge Peggy Kuo appointed Davian Holdings
Limited as Lead Plaintiff in the McLaughlin v. Nano-X Imaging Ltd. et al, Case No. 1:21-cv-05517. On April 12, 2022 and in the same case,
the Lead Plaintiff filed an amended complaint, which alleges that defendants violated the federal securities laws in connection with certain
disclosures concerning the cost of the Nanox.Arc system as well as the comparison of the Nanox.Arc to CT scanners. Lead Plaintiff seeks
to represent a class of investors who purchased the Company&#8217;s publicly-traded securities between August 21, 2020 and November 17,
2021. The Company has not yet responded to the amended complaint and intends to defend these actions vigorously.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-42</p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0 auto; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-3" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:CostOfRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="us-gaap:CostOfRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-7" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-8" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-9" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-10" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-11" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-12" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-13" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-14" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-15" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-16" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-17" name="nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-19" name="nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-20" name="nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-21" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-22" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-23" name="nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-24" name="nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-26" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-27" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-28" name="nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-29" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-30" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-31" name="nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-32" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-33" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-34" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-35" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-36" name="nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-37" name="nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-38" name="nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-39" name="nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-40" name="nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-41" name="nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-42" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-43" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-44" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-45" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-46" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-47" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-48" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-49" name="us-gaap:GainLossOnDispositionOfAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-50" name="us-gaap:GainLossOnDispositionOfAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-51" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-52" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-53" name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-54" name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-55" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-56" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-57" name="nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-58" name="nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-59" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-60" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-61" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-62" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-63" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-64" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-65" name="us-gaap:MarketableSecuritiesRealizedGainLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-66" name="us-gaap:MarketableSecuritiesRealizedGainLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-67" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-68" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-69" name="nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-70" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-71" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-72" name="us-gaap:PaymentsOfFinancingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-73" name="us-gaap:PaymentsOfFinancingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-74" name="nnox:UnpaidOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-75" name="nnox:UnpaidOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-76" name="nnox:issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-77" name="nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-78" name="nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-79" name="nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-80" name="nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-81" name="nnox:FairValueOfContingentConsiderationAssumedInBusinessCombinations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-82" name="nnox:FairValueOfContingentConsiderationAssumedInBusinessCombinations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-83" name="nnox:IssuanceOfSharesInConsiderationOfAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-84" name="nnox:IssuanceOfSharesInConsiderationOfAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-85" name="nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-86" name="nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-87" name="nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-88" name="nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-89" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-90" name="nnox:LongTermMarketableSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-91" name="nnox:LongTermMarketableSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-92" name="us-gaap:Assets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-93" name="us-gaap:Assets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-94" name="us-gaap:LongTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-95" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-96" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-97" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c48" id="hidden-fact-98" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-99" name="us-gaap:Liabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-100" name="us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_3_footnote" xml:lang="en-US">A 3 years Convertible Loan Agreement, dated August 9, 2021 between the Company and Nanox AI in the amount of $3 million, which bears an annual interest of 6% and shall be automatically converted into the Nanox AI&#8217;s Preferred C Shares, at a price per share of $23.42. This loan is eliminated in the Consolidated financial statements.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of the purchase price to assets acquired and liabilities assumed-->
<ix:nonFraction contextRef="c67" id="hidden-fact-101" name="us-gaap:Goodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-102" name="nnox:PercentageOfPropertyPlantAndEquipment" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-103" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-104" name="nnox:LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-105" name="us-gaap:DeferredRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_5_footnote" xml:lang="en-US">Includes $415 thousand under long term deferred revenue in the Company&#8217;s consolidated balance sheets as of December 31, 2021.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of Deferred Revenue-->
<ix:nonFraction contextRef="c123" id="hidden-fact-106" name="nnox:TotalDueFromRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-107" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-108" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-109" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-110" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-111" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-112" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-113" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c146" id="hidden-fact-114" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c148" id="hidden-fact-115" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c149" id="hidden-fact-116" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c151" id="hidden-fact-117" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c155" id="hidden-fact-118" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c157" id="hidden-fact-119" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c161" id="hidden-fact-120" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c163" id="hidden-fact-121" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c184" id="hidden-fact-122" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c209" id="hidden-fact-123" name="us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c212" id="hidden-fact-124" name="nnox:IssuedDueToBusinessCombination" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c212" id="hidden-fact-125" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c212" id="hidden-fact-126" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c212" id="hidden-fact-127" name="nnox:StockIssuedDuringPeriodSharesStockOptionsForfeited" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c212" id="hidden-fact-128" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c211" id="hidden-fact-129" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c211" id="hidden-fact-130" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c212" id="hidden-fact-131" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c212" id="hidden-fact-132" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c211" id="hidden-fact-133" name="nnox:NumberOfSharebasedPaymentAwardsCancelled" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c211" id="hidden-fact-134" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-135" name="us-gaap:OtherCostOfOperatingRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-136" name="us-gaap:OtherCostOfOperatingRevenue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_6_footnote" xml:lang="en-US">On October 26, 2020, the Company entered into an amendment to a business development agreement (&#8220;the Agreement&#8221;) dated February 4, 2020 with two service providers pursuant to which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company&#8217;s systems and the issuance of warrants.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of share-based compensation expenses-->
<ix:nonFraction contextRef="c233" id="hidden-fact-137" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c234" id="hidden-fact-138" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c233" id="hidden-fact-139" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c234" id="hidden-fact-140" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c233" id="hidden-fact-141" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c234" id="hidden-fact-142" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c235" id="hidden-fact-143" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c236" id="hidden-fact-144" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c237" id="hidden-fact-145" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c236" id="hidden-fact-146" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c237" id="hidden-fact-147" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c236" id="hidden-fact-148" name="nnox:CurrentTotal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c237" id="hidden-fact-149" name="nnox:CurrentTotal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c236" id="hidden-fact-150" name="nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c237" id="hidden-fact-151" name="nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c236" id="hidden-fact-152" name="nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c237" id="hidden-fact-153" name="nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c239" id="hidden-fact-154" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c240" id="hidden-fact-155" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c236" id="hidden-fact-156" name="nnox:ProvisionForIncomeTaxes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c237" id="hidden-fact-157" name="nnox:ProvisionForIncomeTaxes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-158" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-159" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-160" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-161" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-162" name="us-gaap:DeferredTaxAssetsOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-163" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-164" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c242" id="hidden-fact-165" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c247" id="hidden-fact-166" name="us-gaap:OperatingIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c248" id="hidden-fact-167" name="us-gaap:OperatingIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c247" id="hidden-fact-168" name="us-gaap:DepreciationAndAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c248" id="hidden-fact-169" name="us-gaap:DepreciationAndAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c247" id="hidden-fact-170" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c248" id="hidden-fact-171" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c251" id="hidden-fact-172" name="us-gaap:OperatingIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c252" id="hidden-fact-173" name="us-gaap:OperatingIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c251" id="hidden-fact-174" name="us-gaap:DepreciationAndAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c252" id="hidden-fact-175" name="us-gaap:DepreciationAndAmortization" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c251" id="hidden-fact-176" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c252" id="hidden-fact-177" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c256" id="hidden-fact-178" name="us-gaap:PropertyPlantAndEquipmentOtherNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001795251</ix:nonNumeric>
<ix:nonFraction contextRef="c0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="pure" xsi:nil="true"></ix:nonFraction><!--From Schedule of options valued using a Black-Scholes pricing model with assumptions with text ''-->
<ix:nonFraction contextRef="c0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="pure" xsi:nil="true"></ix:nonFraction><!--From Schedule of options valued using a Black-Scholes pricing model with assumptions with text ''-->
</ix:hidden>
<ix:references><link:schemaRef xlink:href="nnox-20211231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship fromRefs="ix_0_fact" toRefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromRefs="hidden-fact-89 ix_1_fact ix_2_fact" toRefs="ix_1_footnote"></ix:relationship>
<ix:relationship fromRefs="hidden-fact-94 ix_3_fact ix_4_fact" toRefs="ix_2_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_5_fact" toRefs="ix_3_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_6_fact ix_7_fact" toRefs="ix_4_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_8_fact" toRefs="ix_5_footnote"></ix:relationship>
<ix:relationship fromRefs="ix_9_fact ix_10_fact ix_11_fact" toRefs="ix_6_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:NasdaqMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-01</xbrli:startDate>
    <xbrli:endDate>2020-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-01</xbrli:startDate>
    <xbrli:endDate>2021-11-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-01</xbrli:startDate>
    <xbrli:endDate>2021-11-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nnox:BusinessAcquisitionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-27</xbrli:startDate>
    <xbrli:endDate>2021-11-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:PPPLoanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nnox:BusinessAcquisitionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:MDWEBLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-29</xbrli:startDate>
    <xbrli:endDate>2021-11-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:MDWEBLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nnox:ZebraMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nnox:USARADMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nnox:ImageBigDataMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nnox:ImageBigDataMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nnox:RadiologistRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nnox:RadiologistRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ComputersAndElectronicEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ComputersAndElectronicEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:OfficeFurnitureAndLabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:OfficeFurnitureAndLabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ComputersAndElectronicEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ComputersAndElectronicEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ProductionLineInConstructionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ProductionLineInConstructionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-02</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-11-02</xbrli:startDate>
    <xbrli:endDate>2020-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="nnox:AgreementAxis">nnox:SharePurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxPLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:NanoxJapanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-05-01</xbrli:startDate>
    <xbrli:endDate>2017-05-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxPLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:NanoxJapanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:SixAIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:SixAIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-11-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:WellseseTechnologiesLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2021-10-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-01</xbrli:startDate>
    <xbrli:endDate>2019-09-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nHxU+FkdcNBNYw6Vah1sITLF0AKIKqceszsygtSRj8AWpstzvXG3UpvsP0Kw1wBZdplajBi7sgUTevj2rFJUOTGGfUu3CQIgrK0mVSIM3kwlRiqrKvhbNG3uIEF/fWpfidhF66n81K/X] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndNineteenHundredthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndNineteenHundredthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndNineteenHundredthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndEightyfourHundredthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndEightyfourHundredthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndEightyfourHundredthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ThirtyPointNineThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ThirtyPointNineThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ThirtyPointNineThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:thirtyAndSixtysixHundredthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:thirtyAndSixtysixHundredthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:thirtyAndSixtysixHundredthsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:fortyAndTwentyoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:fortyAndTwentyoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:fortyAndTwentyoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:FortynineAndSixtyeightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:FortynineAndSixtyeightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:FortynineAndSixtyeightMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ZeroPointZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ZeroPointZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ZeroPointZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneEightZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneEightZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneEightZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OnePointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OnePointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OnePointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwentSixPointFiveSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwentSixPointFiveSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwentSixPointFiveSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwentSixPointFiveSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RegulatoryAssetAxis">us-gaap:DeferredFuelCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RegulatoryAssetAxis">us-gaap:DeferredFuelCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomelossBeforeIncomeTaxesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomelossBeforeIncomeTaxesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomelossBeforeIncomeTaxesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomeTaxExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomeTaxExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomeTaxExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxARCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:RadiologyServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:AISolutionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TotalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxARCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:RadiologyServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:AISolutionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TotalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxARCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:RadiologyServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:AISolutionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TotalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">currency:KRW</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">currency:KRW</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-01-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795251</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">pf0:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="sqm">
  <xbrli:measure>utr:sqm</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>f20f2021ex2-1_nanox.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Description of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">As of
December 31, 2021, NANO-X IMAGING LTD had one class of securities registered under Section 12 of the Securities Exchange Act of 1934,
as amended (the &ldquo;<B>Exchange Act</B>&rdquo;): our ordinary shares. References herein to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our&rdquo;
and the &ldquo;Company&rdquo; refer to NANO-X IMAGING LTX and not to any of its subsidiaries. The following description may not contain
all of the information that is important to you, and we therefore refer you to our amended and restated articles of association (our &ldquo;<B>Articles</B>&rdquo;),
a copy of which is filed with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;) as an exhibit to this annual report
on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Registration Number and
Purposes of the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our registration number with
the Israeli Registrar of Companies is 515942076. Our purpose as set forth in our amended and restated articles of association is to engage
in any lawful activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Share capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our authorized share capital
consists of 100,000,000 ordinary shares, par value NIS 0.01 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">All
of our outstanding ordinary shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not
have any preemptive rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Transfer of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our fully paid ordinary shares
are issued in registered form and may be freely transferred under our Articles, unless the transfer is restricted or prohibited by another
instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary
shares by non-residents of Israel is not restricted in any way by our Articles or the laws of the State of Israel, except for ownership
by nationals of some countries that are, or have been, in a state of war with Israel.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Limitation of Liability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The liability of each shareholder
for the Company&rsquo;s obligations is limited to the unpaid sum, if any, owing to the Company in consideration for the issuance of the
shares held by such shareholder. If at any time the Company shall issue shares with no nominal value, the liability of the Shareholders
shall be limited to the payment of the amount which the Shareholders should have paid the Company in respect of each share in accordance
with the conditions of such issuance and was not paid to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our ordinary shares do not have
cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at a shareholders
meeting have the power to elect our directors (except the External Directors (as defined in the Israel Companies Law, 5759-1999 (the &ldquo;<B>Companies
Law</B>&rdquo;)), to the extent elected).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under our Articles, the number
of directors on our board of directors must be no less than five and no more than ten (in each case including at least two External Directors,
as defined in the Companies Law, to the extent appointed). Subject to the aforesaid, the number of directors shall be determined, from
time to time, by a majority of the Directors then in office; provided that no determination in respect of a decrease in the number of
directors shall shorten the term of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The vote required to appoint
a Director is a simple majority vote (other than the External Directors, to the extent elected). In addition, under our Articles, our
board of directors may elect new directors to fill vacancies (whether such vacancy is due to a director no longer serving or due to the
number of directors serving being less than the maximum required in our Articles), provided that the total number of directors shall not,
at any time, exceed ten. Our Articles provide that the term of a director appointed by our board of directors to fill any vacancy will
be for the remaining term of office of the director(s) whose office(s) have been vacated, or in case of a vacancy due to the number of
Directors serving being less than the maximum number stated in the Articles, the Board shall determine at the time of appointment the
class pursuant to the Articles to which the additional Director shall be assigned. Furthermore, under our Articles, our directors (other
than the External Directors, to the extent elected), are divided into three classes with staggered three-year terms, in a way that at
each Annual General Meeting the term of office of only one class of Directors will expire. Each class of directors consists, as nearly
as possible, of 1/3 of the total number of directors constituting the entire board of directors (other than External Directors, to the
extent elected).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Dividend and Liquidation
Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have never declared or paid
any cash dividends on our ordinary shares and we anticipate that, for the foreseeable future, we will retain any future earnings to support
operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends for at least the
next several years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We may declare a dividend to
be paid to the holders of our ordinary shares in proportion to their respective shareholdings. The distribution of dividends may also
be limited by the Companies Law, which permits the distribution of dividends only out of retained earnings or earnings derived over the
two most recent fiscal years, whichever is higher, provided that there is no reasonable concern that payment of a dividend will prevent
a company from satisfying its existing and foreseeable obligations as they become due. In the event that we do not have retained earnings
or earnings generated over the two most recent years legally available for distribution, we must seek the approval of the court in order
to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable concern that the payment of
a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. Our Articles provide that dividends
will be paid at the discretion of, and upon resolution by, our board of directors, subject to the provisions of the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In the event of our liquidation,
after satisfaction of liabilities to creditors and other payments due as per applicable law, our assets will be distributed to the holders
of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by
the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Exchange Controls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or
other payments to non-residents of Israel, except for shareholders who are subject of certain countries that have been, or are considered
to be, in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Shareholder Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under Israeli law, we are required
to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date
of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred to in our amended
and restated articles of association as special meetings. Our board of directors may call special meetings whenever it sees fit, at such
time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors
is required to convene a special general meeting upon the written request of (i) any two or more of our directors or one-quarter or more
of the members of our board of directors or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding
issued shares and 1% or more of our outstanding voting power or (b) 5% or more of our outstanding voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under Israeli law, one or more
shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include a matter
in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the general
meeting. Our Articles contain procedural guidelines and disclosure items with respect to the submission of shareholder proposals for
shareholder meetings.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Subject to the provisions of
the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the
shareholders of record on a date to be decided by the board of directors, which may be between four and twenty one days prior to the meeting
or between twenty right and forty days prior to the date of the meeting, depending on the type of meeting and whether written proxies
are being used. Furthermore, the Companies Law requires that resolutions regarding, among other things, the following matters must be
passed at a general meeting of our shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">amendments to our amended and
restated articles of association;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">appointment or termination of
our auditors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">election of directors (unless
otherwise determined in our Articles);</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approval of certain related
party transactions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">increases or reductions of our
authorized share capital;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a merger; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">the exercise of our board of
directors&rsquo; powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its
powers is required for our proper management.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under our Articles, we are required
to give notice to our registered shareholders not less than 21 days prior to the meeting. The Companies Law requires that a notice of
any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda
of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related
parties, or an approval of a merger, or as otherwise required under applicable law, notice must be provided at least 35 days prior to
the meeting. Under the Companies Law, shareholders of a public company are not permitted to take action by written consent in lieu of
a meeting. Under Companies Law, whenever we cannot convene or conduct a general meeting in the manner prescribed under the law or our
articles of association, the court may, upon our, shareholders&rsquo; or directors&rsquo; request, order that we convene and conduct a
general meeting in the manner the court deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">All of our ordinary shares have
identical voting and other rights in all respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><I>Quorum Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to our Articles, holders
of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general
meeting. In any meeting of shareholders, we will follow the quorum requirements for general meetings as set forth in our Articles, instead
of one-third of the issued share capital as required under the Nasdaq Marketplace Rules. Pursuant to our Articles, the quorum required
for our general meetings of shareholders will consist of at least two shareholders present in person or by proxy (including by voting
deed) and holding shares conferring in the aggregate at least 25% of the voting power of the Company. A meeting adjourned for lack of
a quorum will generally be adjourned to the same day of the following week at the same time and place, or to such other day, time or place
as indicated by our board of directors if so specified in the notice of the meeting. At the reconvened meeting, subject to a limited exception,
any number of shareholders present in person or by proxy shall constitute a lawful quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><I>Vote Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our Articles provide that all
resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our Articles. Pursuant
to our Articles, an amendment to our Articles regarding any change of the composition or election procedures of our directors and the
removal of a director from office will require a special shareholders majority of at least two-thirds of the voting power represented
at the meeting in person or by proxy and voting thereon. Under the Companies Law, among others, each of (i) the approval of an extraordinary
transaction with a controlling shareholder and (ii) the terms of employment or other engagement of the controlling shareholder of the
company or such controlling shareholder&rsquo;s relative (even if such terms are not extraordinary) requires special approval and certain
transactions with respect to remuneration of our officers and directors, the approval and extension of a compensation policy and certain
deviations therefrom require further approvals. Under our Articles, any change to the rights and privileges of the holders of any class
of our shares requires a simple majority at a separate meeting of the class so affected (or such other percentage of the relevant class
that may be set forth in the governing documents relevant to such class), in addition to the ordinary majority vote of all classes of
shares voting together as a single class at a shareholder meeting. Another exception to the simple majority vote requirement is a resolution
for an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, that governs
the settlement of debts and reorganization of a company, which requires the approval of holders of 75% of the voting rights represented
at the meeting, in person, by proxy or by voting deed and voting on the resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><I>Access to Corporate Records</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under the Companies Law, shareholders
generally have the right to review minutes of our general meetings, our shareholders register and material shareholders register, our
amended and restated articles of association, our annual audited financial statements and any document that we are required by law to
file publicly with the Israeli Registrar of Companies or the Israel Securities Authority. In addition, any shareholder who specifies the
purpose of their request may request to be provided with any document related to an action or transaction requiring shareholder approval
under the related party transaction provisions of the Companies Law. We may deny this request if we believe it has not been made in good
faith or if such denial is necessary to protect our interests or protect a trade secret or patent.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><I>Modification of Class
Rights</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Under the Companies Law and
our Articles, the rights attached to any class of share, such as voting, liquidation and dividend rights, may be amended by adoption
of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance
with the rights attached to such class of shares, as set forth in our Articles, in addition to the ordinary majority vote of all classes
of voting shares voting together as a single class.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Acquisitions under Israeli
Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.45pt; background-color: white"><I>Full
Tender Offer</I>. A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target
company&rsquo;s voting rights or issued and outstanding share capital is required by the Companies Law to make a tender offer to all of
the company&rsquo;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire
shares of a public Israeli company and who would as a result hold over 90% of the voting rights or issued and outstanding share capital
of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the relevant class for the
purchase of all of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5%
of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not
have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to
the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less
than 2% of the issued and outstanding share capital of the company or of the applicable class of shares. Upon a successful completion
of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer
or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender
offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli
court as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If the full tender offer was
not accepted in accordance with the above alternatives, the acquirer may not acquire shares of the company that will increase its holdings
to more than 90% of the company&rsquo;s issued and outstanding share capital or of the applicable class from shareholders who accepted
the tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.45pt; background-color: white"><I>Special
Tender Offer</I>. The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special
tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company.
This requirement does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the
Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result
of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder
of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions. A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to the company&rsquo;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender
offer may be consummated only if (i) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired
by the offeror and (ii) the number of shares tendered by shareholders who accept the offer exceeds the number of shares whose holders
objected to the offer (excluding the purchaser and its controlling shareholders, holders of 25% or more of the voting rights in the company
or any person having a personal interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives
and entities under such person&rsquo;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling
it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase
of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the
offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.
Shares purchased in contradiction to the tender offer rules under the Companies Law, will have no rights and will become dormant shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 28.35pt; background-color: white"><I>Merger</I>.
The Companies Law permits merger transactions if approved by each party&rsquo;s board of directors and, unless certain requirements described
under the Companies Law are met, by a majority vote of each party&rsquo;s shares, and, in the case of the target company, a majority
vote of each class of its shares voted on the proposed merger at a shareholders meeting. For purposes of the shareholder vote, unless
a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at the shareholders
meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who
holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other
party, vote against the merger. If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder or if the
controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval
that governs all extraordinary transactions with controlling shareholders. If the transaction would have been approved by the shareholders
of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above,
a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds
that the merger is fair and reasonable, taking into account the value to the parties to the merger and the consideration offered to the
shareholders of the target company. Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent
the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable
to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors. In addition,
a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was
filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved
by the shareholders of each party. Israeli tax law treats some acquisitions, such as share for share exchanges between an Israeli company
and a foreign company, less favorably than U.S. tax laws. For example, Israeli tax law may, under certain circumstances, subject a shareholder
who exchanges his ordinary shares for shares in another corporation to taxation prior to the sale of the shares received in such share-for-share
swap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Anti-Takeover Measures
under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Companies Law allows us to
create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred
rights with respect to voting, distributions or other matters and shares having preemptive rights. No preferred shares are currently authorized
under our Articles. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending
on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders
from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred
shares will require an amendment to our Articles, which requires the prior approval of the holders of a majority of the voting power attaching
to our issued and outstanding shares represented at a general meeting. The convening of the meeting, the shareholders entitled to participate
and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law and
our Articles as described above under &ldquo;&mdash;Voting Rights.&rdquo; In addition, we have a classified board structure, which will
effectively limit the ability of any investor or potential investor or group of investors or potential investors to gain control of our
board of directors, as disclosed under &ldquo;Item 6. Directors, Senior Management and Employees&mdash;C. Board Practices.&rdquo;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Borrowing Powers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the Companies Law
and our Articles, our board of directors may exercise all powers and take all actions that are not required under law or under our amended
and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Changes in Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our Articles enable us to increase
or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution
duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital, such as the
declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board
of directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Choice of Forum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our Articles provide that the
federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving
any complaint asserting a cause of action arising under the Securities Act (the &ldquo;<B>Federal Forum Provision</B>&rdquo;). While there
can be no assurance that U.S. federal or state courts or Israeli courts will follow the holding of the Delaware Supreme Court which recently
found that such provisions are facially valid under Delaware law or determine that the Federal Forum Provision should be enforced in a
particular case, application of the Federal Forum Provision means that suits brought by our shareholders to enforce any duty or liability
created by the Securities Act must be brought in federal court and cannot be brought in state court. The Federal Forum Provision does
not apply to suits brought to enforce any duty or liability created by the Exchange Act. Section 27 of the Exchange Act creates exclusive
federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations
thereunder. Accordingly, actions by our shareholders to enforce any duty or liability created by the Exchange Act or the rules and regulations
thereunder also must be brought in federal court. Our shareholders will not be deemed to have waived our compliance with the federal securities
laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in any
of our securities shall be deemed to have notice of and consented to the Federal Forum Provision. This provision may limit a shareholder&rsquo;s
ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers or other employees, which
may discourage lawsuits against us and our directors, officers and other employees.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Establishment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We were incorporated under the
laws of the State of Israel on December 20, 2018. We are registered with the Israeli Registrar of Companies in Jerusalem.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The transfer agent and registrar
for our ordinary shares is Continental Stock Transfer &amp; Trust Co.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our ordinary shares are listed
on The Nasdaq Global Market under the symbol &lsquo;&lsquo;NNOX.&rsquo;&rsquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>f20f2021ex4-1_nanox.htm
<DESCRIPTION>ASSET PURCHASE AGREEMENT, DATED NOVEMBER 3, 2021, AMONG MDWEB, LLC, NANO-X IMAGING. AND NANO-X IMAGING LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><I>Execution Version</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSET PURCHASE AGREEMENT</B><BR>
<BR>
by and among<BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>MDWEB, LLC (doing business as MDW, LLC)<BR>
</B><BR>
</FONT>and<BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>Nano-X Imaging, INC.</B></FONT><BR>
<BR>
and<BR>
<BR>
<FONT STYLE="text-transform: uppercase"><B>Nano-X Imaging Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated as of October 21, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Page</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>1.</TD>
    <TD COLSPAN="2">Definitions.</TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 7%">1.1.</TD>
    <TD STYLE="width: 79%">Certain Matters of Construction</TD>
    <TD STYLE="text-align: center; width: 7%">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>1.2.</TD>
    <TD>Certain Definitions</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>2.</TD>
    <TD COLSPAN="2">The Transaction</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>2.1.</TD>
    <TD>Purchase and Sale of the Assets</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>2.2.</TD>
    <TD>Excluded Assets</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>2.3.</TD>
    <TD>Purchase Price</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>2.4.</TD>
    <TD>Excluded Liabilities</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>2.5.</TD>
    <TD>The Closing</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>2.6.</TD>
    <TD>Closing Deliveries and Payments</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>2.7.</TD>
    <TD>Purchase Price Adjustment</TD>
    <TD STYLE="text-align: center">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>2.8.</TD>
    <TD>Earn Out</TD>
    <TD STYLE="text-align: center">17</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>2.9.</TD>
    <TD>Tax Treatment; Purchase Price Allocation</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>3.</TD>
    <TD COLSPAN="2">Representations and Warranties of the Company.</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>3.1.</TD>
    <TD>Power and Authorization</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>3.2.</TD>
    <TD>Organization</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>3.3.</TD>
    <TD>No Violation or Approval; Consents</TD>
    <TD STYLE="text-align: center">20</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>3.4.</TD>
    <TD>Assets</TD>
    <TD STYLE="text-align: center">20</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>3.5.</TD>
    <TD>Financial Statements, Etc</TD>
    <TD STYLE="text-align: center">21</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>3.6.</TD>
    <TD>Ordinary Course of Business; No Material Adverse Effect</TD>
    <TD STYLE="text-align: center">21</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>3.7.</TD>
    <TD>Taxes</TD>
    <TD STYLE="text-align: center">21</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>3.8.</TD>
    <TD>Operations in Conformity with Laws</TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>3.9.</TD>
    <TD>Intellectual Property</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>3.10.</TD>
    <TD>Assigned Contracts</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>3.11.</TD>
    <TD>Transactions with Affiliates</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>3.12.</TD>
    <TD>Litigation</TD>
    <TD STYLE="text-align: center">28</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>3.13.</TD>
    <TD>Brokers</TD>
    <TD STYLE="text-align: center">28</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>3.14.</TD>
    <TD>Customers and Suppliers</TD>
    <TD STYLE="text-align: center">28</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>3.15.</TD>
    <TD>Regulatory Matters</TD>
    <TD STYLE="text-align: center">28</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>3.16.</TD>
    <TD>Data Privacy</TD>
    <TD STYLE="text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>3.17.</TD>
    <TD>Stock Consideration</TD>
    <TD STYLE="text-align: center">29</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>TABLE OF CONTENTS</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>(continued)</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Page</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>4.</TD>
    <TD COLSPAN="2">Representations and Warranties of the Buyer.</TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 7%">4.1.</TD>
    <TD STYLE="width: 79%">Organization</TD>
    <TD STYLE="text-align: center; width: 7%">30</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>4.2.</TD>
    <TD>Authorization</TD>
    <TD STYLE="text-align: center">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>4.3.</TD>
    <TD>No Violation or Approval; Consents</TD>
    <TD STYLE="text-align: center">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>4.4.</TD>
    <TD>Valid Issuance of Stock Consideration</TD>
    <TD STYLE="text-align: center">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>4.5.</TD>
    <TD>Litigation</TD>
    <TD STYLE="text-align: center">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>4.6.</TD>
    <TD>Brokers</TD>
    <TD STYLE="text-align: center">32</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>5.</TD>
    <TD COLSPAN="2">Conditions Precedent to the Obligations of the Buyer.</TD>
    <TD STYLE="text-align: center">32</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>5.1.</TD>
    <TD>Representations and Warranties</TD>
    <TD STYLE="text-align: center">32</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>5.2.</TD>
    <TD>Performance of Obligations</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>5.3.</TD>
    <TD>Compliance Certificate</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>5.4.</TD>
    <TD>Injunctions</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>5.5.</TD>
    <TD>Escrow Agreement</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>5.6.</TD>
    <TD>Personnel</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>5.7.</TD>
    <TD>Secretary&rsquo;s Certificate</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>5.8.</TD>
    <TD>Consents</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>5.9.</TD>
    <TD>Non-competition Agreements</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>5.10.</TD>
    <TD>USARAD Stock Purchase Agreement</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>5.11.</TD>
    <TD>Assets</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>6.</TD>
    <TD COLSPAN="2">Conditions Precedent to Obligations of the Company</TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>6.1.</TD>
    <TD>Representations and Warranties</TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>6.2.</TD>
    <TD>Performance of Obligations</TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>6.3.</TD>
    <TD>Compliance Certificate</TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>6.4.</TD>
    <TD>Injunctions</TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>6.5.</TD>
    <TD>Escrow Agreement</TD>
    <TD STYLE="text-align: center">34</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>7.</TD>
    <TD COLSPAN="2">Covenants of the Parties</TD>
    <TD STYLE="text-align: center">35</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>7.1.</TD>
    <TD>Conduct of Business Prior to Closing</TD>
    <TD STYLE="text-align: center">35</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>7.2.</TD>
    <TD>Confidentiality; Announcements</TD>
    <TD STYLE="text-align: center">37</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>7.3.</TD>
    <TD>No Solicitation</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>7.4.</TD>
    <TD>Preparation for Closing</TD>
    <TD STYLE="text-align: center">39</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>TABLE OF CONTENTS</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>(continued)</B></P>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Page</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 7%">7.5.</TD>
    <TD STYLE="width: 79%">Tax Matters</TD>
    <TD STYLE="text-align: center; width: 7%">39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>7.6.</TD>
    <TD>Notification</TD>
    <TD STYLE="text-align: center">39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>7.7.</TD>
    <TD>Share Lock-Up and Sale Restrictions</TD>
    <TD STYLE="text-align: center">40</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>7.8.</TD>
    <TD>Further Assurances</TD>
    <TD STYLE="text-align: center">40</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>8.</TD>
    <TD COLSPAN="2">Indemnification</TD>
    <TD STYLE="text-align: center">41</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>8.1.</TD>
    <TD>Survival</TD>
    <TD STYLE="text-align: center">41</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>8.2.</TD>
    <TD>Indemnity by the Company</TD>
    <TD STYLE="text-align: center">41</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>8.3.</TD>
    <TD>Indemnity by the Buyer</TD>
    <TD STYLE="text-align: center">42</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>8.4.</TD>
    <TD>Notification of Certain Claims</TD>
    <TD STYLE="text-align: center">43</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>8.5.</TD>
    <TD>Calculation of Losses</TD>
    <TD STYLE="text-align: center">44</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>8.6.</TD>
    <TD>Matters Involving Third Parties</TD>
    <TD STYLE="text-align: center">44</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>8.7.</TD>
    <TD>Materiality</TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>8.8.</TD>
    <TD>No Contribution</TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>8.9.</TD>
    <TD>Investigation</TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>8.10.</TD>
    <TD>Escrow</TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>8.11.</TD>
    <TD>Tax Treatment</TD>
    <TD STYLE="text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>8.12.</TD>
    <TD>Acknowledgement by the Buyer</TD>
    <TD STYLE="text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>8.13.</TD>
    <TD>Manner of Payment</TD>
    <TD STYLE="text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>8.14.</TD>
    <TD>Payment Process</TD>
    <TD STYLE="text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>9.</TD>
    <TD COLSPAN="2">Termination.</TD>
    <TD STYLE="text-align: center">48</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>9.1.</TD>
    <TD>Termination</TD>
    <TD STYLE="text-align: center">47</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-variant: small-caps">9.2.</FONT></TD>
    <TD>Effect of Termination</TD>
    <TD STYLE="text-align: center">49</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>10.</TD>
    <TD COLSPAN="2">Miscellaneous.</TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>10.1.</TD>
    <TD>Notices</TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>10.2.</TD>
    <TD>Expenses of Transaction</TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>10.3.</TD>
    <TD>Entire Agreement</TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>10.4.</TD>
    <TD>Severability</TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>10.5.</TD>
    <TD>Amendment</TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>10.6.</TD>
    <TD>Parties in Interest</TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>10.7.</TD>
    <TD>Assignment</TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>10.8.</TD>
    <TD>Governing Law</TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>10.9.</TD>
    <TD>Consent to Jurisdiction</TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-variant: small-caps">10.10.</FONT></TD>
    <TD>Waiver of Jury Trial</TD>
    <TD STYLE="text-align: center">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-variant: small-caps">10.11.</FONT></TD>
    <TD>Reliance</TD>
    <TD STYLE="text-align: center">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>10.12.</TD>
    <TD>Specific Enforcement</TD>
    <TD STYLE="text-align: center">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>10.13.</TD>
    <TD>No Waiver</TD>
    <TD STYLE="text-align: center">52</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>10.14.</TD>
    <TD>Negotiation of Agreement</TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>10.15.</TD>
    <TD>Disclosure Schedules</TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>10.16.</TD>
    <TD>Third Party Beneficiaries</TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>10.17.</TD>
    <TD>Headings</TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>10.18.</TD>
    <TD>Counterparts; Electronic Signature</TD>
    <TD STYLE="text-align: center">53</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; width: 100%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 2.1A &ndash; Assets</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 2.1B &ndash; Assumed Liabilities</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule 2.8.2 &ndash; Earn Out Milestones</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure Schedules</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; width: 100%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
A&nbsp;&nbsp;&nbsp;Form of Escrow Agreement</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
B&nbsp;&nbsp;&nbsp;Form of Non-Competition Agreement</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>ASSET PURCHASE
AGREEMENT</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Asset Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is made as of October 21, 2021, by and among MDWEB, LLC (doing business as MDW, LLC), a New York
limited liability company (the &ldquo;<U>Company</U>&rdquo;), NANO-X IMAGING, INC. (the &ldquo;<U>Buyer</U>&rdquo;) and Nano-X Imaging
Ltd., a company organized under the laws of the State of Israel (the &ldquo;<U>Parent</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Whereas</FONT>,
the Company owns and desires to sell certain assets, and the Buyer desires to acquire all of the Assets, all on the terms and subject
to the conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Whereas</FONT>,
the Buyer is a wholly-owned subsidiary of the Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Whereas</FONT>,
the condition and inducement to the Buyer&rsquo;s willingness to enter into this Agreement, the individuals listed on <U>Schedule &lrm;5.9</U>
are, concurrently with the execution of this Agreement, executing and delivering Non-Competition Agreements in the form of Exhibit B (the
&ldquo;<U>Non-Competition Agreements</U>&rdquo;), that will each become effective as of the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">WHEREAS, for U.S. federal
income Tax (as defined below) purposes, the parties intend that the consummation of the transactions contemplated hereby qualifies as
a &ldquo;reorganization&rdquo; within the meaning of Section 368(a) of the Code (as defined below), and that this Agreement be, and is
hereby, adopted as a plan of reorganization within the meaning of Section 368(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Now,
therefore</FONT>, in consideration of these premises, the covenants set forth herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">1. Definitions.</P>

<P STYLE="text-align: left; font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.1. <U>Certain
Matters of Construction</U>. For purposes of this Agreement, except as specified otherwise or the context otherwise requires, the words
&ldquo;hereof&rdquo;, &ldquo;herein&rdquo;, &ldquo;hereunder&rdquo; and words of similar import will refer to this Agreement as a whole
and not to any particular Section or provision of this Agreement, and reference to a particular Section of this Agreement will include
all subsections thereof. The word &ldquo;party&rdquo; will refer to the Company, the Buyer or the Parent. The word &ldquo;including&rdquo;
means including without limitation. The word &ldquo;will&rdquo; has the same meaning as the word &ldquo;shall&rdquo;. Definitions will
be equally applicable to both the singular and plural forms of the terms defined, and references to the masculine, feminine or neuter
gender will include each other gender. All references in this Agreement to any Section, Exhibit or Schedule will, unless otherwise specified,
be deemed to be a reference to a Section, Exhibit or Schedule of or to this Agreement, in each case as such may be amended in accordance
herewith, all of which are made a part of this Agreement. All references in this Agreement to monetary amounts will, unless otherwise
specified, be to United States dollars. Any Legal Requirement defined or referred to herein or in any agreement or instrument that is
referred to herein shall include any modification, amendment or re-enactment thereof, and any Legal Requirement substituted therefore,
in each case as of the time of inquiry, representation or covenant and all rules, regulations and statutory instruments issued or related
to such Legal Requirement. Any reference to a Governmental Authority shall be deemed also to refer to any successor thereto unless the
context requires otherwise. A reference to any agreement (including this Agreement) or Contract, is, unless otherwise specified, to the
agreement or Contract as amended, modified, supplemented or replaced at the time of inquiry, representation or covenant. Although the
same or similar subject matters may be addressed in different provisions of this Agreement, the parties intend that, except as reasonably
apparent on the face of the Agreement or as expressly provided in this Agreement, each such provision will be read separately, be given
independent significance and not be construed as limiting any other provision of this Agreement (whether or not more general or more specific
in scope, substance or content). References to a Person are also to its successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1.2. <U>Certain
Definitions</U>. For purposes of this Agreement, the following terms will have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Acquisition
Transaction</U>&rdquo; means, other than the Contemplated Transactions, any Person&rsquo;s (other than Buyer&rsquo;s) offer, proposal
or inquiry relating to, or any indication of interest in: (a)&nbsp;any merger, consolidation or other form of business combination with
or involving the Company, (b)&nbsp;the sale, license, disposition or acquisition of all or any material portion of the business or assets
of the Company, including the grant of any license to any Intellectual Property of the Company, other than non-exclusive licenses granted
to customers of the Company in the ordinary course of business, (c)&nbsp;the issuance, grant, disposition or acquisition of any membership
interests or other equity participations of the Company (other than the issuance of equity to employees of the Company), or (d)&nbsp;any
other transaction that would be inconsistent with or that would reasonably be likely to have an adverse effect upon any of the Contemplated
Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
means any criminal, judicial, administrative or arbitral action, audit, charge, claim, complaint, demand, grievance, hearing, known inquiry
or investigation, litigation, mediation, proceeding, citation, summons, subpoena or suit, whether civil, criminal, administrative, judicial
or investigative, whether public or private, commenced, brought, conducted or heard by or before, or otherwise involving any Governmental
Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means, as to any Person, any other Person controlling, controlled by or under common control with such Person. For the purposes of this
definition, &ldquo;controlling&rdquo;, &ldquo;controlled&rdquo; and &ldquo;control&rdquo; mean the possession, directly or indirectly,
of the power to direct the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Agreement</U>&rdquo;
is defined in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Anti-bribery
Laws</U>&rdquo; is defined in <U>Section &lrm;3.8.2.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Assets</U>&rdquo;
is defined in <U>Section &lrm;2.1.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Assigned
Contract</U>&rdquo; is defined in <U>Section&nbsp;&lrm;3.10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Assumed
Liabilities</U>&rdquo; is defined in in <U>Section &lrm;2.3.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Balance
Sheet Time</U>&rdquo; means 11:59&nbsp;p.m. New York time on the Business Day immediately preceding the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Basis</U>&rdquo;
means any past or present fact, situation, circumstance, status, condition, activity, practice, plan, occurrence, event, incident, action,
failure to act or transaction that could form the basis for any specific consequence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Business</U>&rdquo;
means the businesses conducted by the Company and its direct and indirect Subsidiaries as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by Legal Requirement
to be closed in New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Buyer</U>&rdquo;
is defined in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Buyer
Failure to Close</U>&rdquo; is defined in <U>Section &lrm;&lrm;9.1.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Buyer
Fundamental Representations</U>&rdquo; means the representations and warranties set forth in <U>Sections&nbsp;&lrm;4.1</U> (Organization),
<U>&lrm;4.2</U> (Authorization) and <U>&lrm;4.6</U> (Brokers).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Buyer
Indemnified Parties</U>&rdquo; is defined in <U>Section &lrm;8.2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Claim
Dispute Notice</U>&rdquo; is defined in <U>Section &lrm;8.4.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Claim
Notice</U>&rdquo; is defined in <U>Section &lrm;&lrm;&lrm;8.4.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
is defined in <U>Section &lrm;2.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Closing
Stock Consideration</U>&rdquo; is defined in <U>Section 2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; is defined in <U>Section &lrm;2.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Closing
Statement</U>&rdquo; is defined in <U>Section &lrm;2.7.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Code</U>&rdquo;
means the Internal Revenue Code of 1986, as amended, and the applicable Treasury regulations issued thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Company</U>&rdquo;
is defined in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Company
Authorizations</U>&rdquo; is defined in <U>Section &lrm;3.8.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><I>&ldquo;</I><U>Company
Benefit Plans</U><I>&rdquo;</I> means all Employee Benefit Plans maintained or contributed to by the Company or under which the Company
has or is reasonably likely to have any obligations (other than obligations to make current wage or salary payments or sales commissions
terminable on notice of 30 days or less) or liabilities, actual or contingent, in respect of, or which otherwise cover, any of the current
or former officers, employees or independent contractors of the Company who provide services in respect of the Business or their dependents
or beneficiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Company
Failure to Close</U>&rdquo; is defined in <U>Section &lrm;9.1.7.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Company
Fundamental Representations</U>&rdquo; means the representations and warranties set forth in <U>Sections &lrm;3.1</U> (Power and Authorization),
<U>&lrm;3.2</U> (Organization), <U>3.4.2</U> (Assets), <U>3.7</U> (Taxes) and <U>&lrm;3.13</U> (Brokers).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Company
Indemnified Parties</U>&rdquo; is defined in <U>Section&nbsp;&lrm;8.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Company
Intellectual Property</U>&rdquo; shall mean the Intellectual Property owned by or licensed to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Company&rsquo;s
Knowledge</U>&rdquo; means the actual knowledge of Michael Averbach, and Sergey Fradkov, in each case after reasonable internal inquiry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Company
Registered IP</U>&rdquo; is defined in <U>Section &lrm;&lrm;&lrm;3.9.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Contemplated
Transactions</U>&rdquo; means the transactions contemplated by this Agreement and the Escrow Agreement that are anticipated to be consummated
at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Continuing
Business</U>&rdquo; means the business of the Company and its Subsidiaries existing immediately prior to the Closing, as such business
is operated by the Continuing Business Company following the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;Continuing
Business <U>Company</U>&rdquo; means the Buyer, any successor to the Buyer, or any Person into which the Buyer may be merged, or which
acquires all or substantially all of the assets or stock of the Buyer, carrying out the Continuing Business following the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Contract</U>&rdquo;
means any legally binding contract, agreement, lease, license, sublicense, option, understanding, covenant-not-to-sue, promise, undertaking
or other binding arrangement, purchase order, instrument, note or other document or instrument, whether oral or written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Customer
Deliverables</U>&rdquo; shall mean (A) the products that the Company or any of its Subsidiaries currently produces, markets, sells or
licenses and (B) the services that the Company or any of its Subsidiaries currently provides.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the various disclosure schedules to this Agreement that are being delivered by on or behalf of the Company
on the date hereof in connection with the representations and warranties in <U>Section &lrm;3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Dispute
Notice</U>&rdquo; is defined in <U>Section&nbsp;&lrm;2.7.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Dispute
Submission Notice</U>&rdquo; is defined in <U>Section&nbsp;&lrm;2.7.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Disputed
Item</U>&rdquo; is defined in <U>Section&nbsp;&lrm;2.7.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Earn Out</U>&rdquo;
is defined in <U>Section &lrm;2.3.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Earn Out
Amount</U>&rdquo; is defined in <U>Section &lrm;2.8.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Earn Out
Dispute Notice</U>&rdquo; is defined in <U>Section &lrm;2.8.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Earn Out
Dispute Submission Notice</U>&rdquo; is defined in <U>Section &lrm;2.8.4(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;Earn Out
Maximum Amount&rdquo; is defined in Section &lrm;2.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Earn Out
Payment Date</U>&rdquo; is defined in <U>Section&nbsp;&lrm;2.8.2(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Earn Out
Period</U>&rdquo; means the First Earn Out Period, the Second Earn Out Period, and the Third Earn Out Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Earn Out
Statement</U>&rdquo; is defined in <U>Section&nbsp;2.8.1.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Escrow
Account</U>&rdquo; is defined in <U>Section&nbsp;&lrm;2.6.1(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Escrow
Agreement</U>&rdquo; means an escrow agreement in substantially the form of Exhibit A, to be entered into on or prior to the Closing Date
by the Buyer, the Company, the Parent, and the Escrow Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Escrow
Amount</U>&rdquo; means Closing Stock Consideration valued at $225,000, and calculated based on the volume weighted average closing share
price of Parent ordinary shares on the Nasdaq Stock Market over the 30 trading days prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Escrow
Funds</U>&rdquo; means, as of any date of determination, the excess (if any) of the Escrow Amount (including accrued interest or earnings
thereon) over the sum of all distributions and other payments to any Person from the Escrow Account paid pursuant to the terms of the
Escrow Agreement on or prior to such date of determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Escrow
Termination Date</U>&rdquo; is defined in <U>Section&nbsp;&lrm;8.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Estimated
Closing Statement</U>&rdquo; is defined in <U>Section&nbsp;&lrm;2.7.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Estimated
Working Capital Amount</U>&rdquo; is defined in <U>Section&nbsp;&lrm;2.7.5(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Excluded
Assets</U>&rdquo; is defined in <U>Section&nbsp;&lrm;2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Excluded
Liabilities</U>&rdquo; is defined in in <U>Section &lrm;2.4.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Expiration
Date</U>&rdquo; is defined in <U>Section&nbsp;&lrm;9.1.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
is defined in <U>Section&nbsp;&lrm;&lrm;&lrm;3.15.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>FDA Application
Integrity Policy</U>&rdquo; is defined in <U>Section&nbsp;&lrm;&lrm;&lrm;3.15.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Final
Working Capital Amount</U>&rdquo; is defined in <U>Section&nbsp;&lrm;2.7.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Financial
Controls</U>&rdquo; is defined in <U>Section &lrm;3.5.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Financial
Statements</U>&rdquo; is defined in <U>Section &lrm;3.5.1.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>First
Earn Out Period</U>&rdquo; means the three (3) consecutive calendar months immediately following the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Governmental
Authority</U>&rdquo; means any national, supranational, foreign, provincial, federal, state, municipal or local government, including
any political subdivision thereof, or governmental, regulatory or administrative authority, agency, body, branch, bureau, instrumentality
or commission, and any department, court, tribunal or judicial body, agency or official of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Government
Contract</U>&rdquo; means any Contract, prime contract, subcontract, teaming agreement or arrangement, joint venture, basic ordering agreement,
blanket purchase agreement, letter agreement, grant, cooperative agreement, purchase order, delivery order, task order, change order or
other commitment or funding vehicle between the Company or any of its Subsidiaries and (a)&nbsp;any Governmental Authority, (b)&nbsp;any
prime contractor to a Governmental Authority or (c)&nbsp;any subcontractor (of any tier) in connection with or with respect to any Contract
described in clause&nbsp;(a) or (b), and any modification of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Governmental
Order</U>&rdquo; means any ruling, award, decision, injunction, judgment, determination, assessment, agreement, order, decree, writ or
other requirement entered, issued or made by any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Income
Tax</U>&rdquo; means any Tax measured in whole or in part by income or gains (or similar Tax imposed in lieu thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
means with respect to any Person, and without duplication, all outstanding obligations of such Person on a consolidated basis (a)&nbsp;in
respect of indebtedness for borrowed money (including all accrued interest thereon, and any prepayment, breakage or similar charges payable
in connection with the discharge of such indebtedness), (b)&nbsp;evidenced by notes, debentures or similar instruments, (c)&nbsp;in respect
of any earn out or other deferred purchase price for the acquisition by such Person of any business, property or other Person, but excluding
any ordinary trade accounts payable or accruals incurred in the ordinary course of business which are captured in the accounts payable
and/or accrued expenses of the Company, (d)&nbsp;in respect of letters of credit, solely to the extent drawn upon by third parties, (e)&nbsp;as
lessee under leases that would be required to be recorded as capital leases in accordance with GAAP and (f)&nbsp;with respect to guarantees
of obligations of the types described in clauses&nbsp;(a) through (e) above of any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Indemnified
Party</U>&rdquo; means with respect to any claim for indemnification pursuant to <U>Section&nbsp;&lrm;8</U>, each Buyer Indemnified Party
or Company Indemnified Party asserting such claim (or on whose behalf such claim is asserted) under <U>Section&nbsp;&lrm;8.2</U> or <U>&lrm;8.3</U>,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Indemnifying
Party</U>&rdquo; means, with respect to any claim for indemnification pursuant to <U>Section&nbsp;&lrm;8</U>, the party or parties against
whom such claim has been asserted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Independent
Referee</U>&rdquo; means Yoel Beniluz, PhD; <U>provided</U> that, if Yoel Beniluz, PhD is unable or unwilling to serve as Independent
Referee, and the Buyer and the Company are unable to agree on another independent and nationally recognized firm with expertise in disputes
of the type contemplated by <U>Section&nbsp;&lrm;2.7</U> within fifteen (15) Business Days of receiving notice that Yoel Beniluz, PhD
will not serve as Independent Referee, the Buyer and the Company shall each nominate such a firm, and the two firms so nominated shall
nominate a third such firm, with such third firm to serve as the Independent Referee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Insurance
Policies</U>&rdquo; is defined in <U>Section&nbsp;&lrm;8.5.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Insurance
Proceeds</U>&rdquo; is defined in <U>Section&nbsp;&lrm;8.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Intellectual
Property</U>&rdquo; means all: (A) granted patents, pending patent applications, and all related continuation, continuation-in-part, divisional,
reissue and re-examinations thereof, utility models, statutory invention registrations and design patents; (B) trademarks, service marks,
trade dress, Internet domain names, logos, trade names and corporate names and registrations and applications for registration thereof;
(C) copyrights and registrations and applications for registration thereof; (D) computer software, data and documentation; (E) inventions,
trade secrets and confidential business information, whether patentable or non-patentable and whether or not reduced to practice, know-how,
manufacturing and product processes and techniques, research and development information, unpublished copyrightable works, financial,
marketing and business data, pricing and cost information, business and marketing plans and customer and supplier lists and information;
(F) other proprietary rights relating to any of the foregoing (including remedies against infringements thereof and rights of protection
of interest therein under the laws of all jurisdictions); and (G) copies and tangible embodiments thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Interim
Financial Statements</U>&rdquo; is defined in <U>Section &lrm;3.5.1.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Internal
Systems</U>&rdquo; shall mean any hardware, software, data, equipment, technology or internal systems used by or on behalf of the Company
or its Subsidiaries to produce the Customer Deliverables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Legal
Requirement</U>&rdquo; means, with respect to any Person, any national, supranational, federal, state, provincial, municipal or local,
statute, law, ordinance, code, rule, resolution, constitution, notice, administrative interpretation, regulation, Governmental Order ,
regulatory requirement, interpretation, stipulation, determination, or regulation issued, enacted, implemented or otherwise put into law
by or under the authority of a Governmental Authority and applicable to such Person or any of its Affiliates or any of their respective
properties, assets, officers, directors, general partners, members, managers, trustees, employees, consultants or agents (in connection
with such officer&rsquo;s, director&rsquo;s, general partner&rsquo;s, member&rsquo;s, manager&rsquo;s, employee&rsquo;s, consultant&rsquo;s
or agent&rsquo;s activities on behalf of such Person or any of its Affiliates).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Liabilities</U>&rdquo;
means any and all liabilities, Indebtedness, claims, commitments, deficiencies and obligations of any kind, whether accrued or fixed,
absolute or contingent, matured or unmatured, determined or undeterminable, on- or off-balance sheet or required to be recorded on a balance
sheet prepared in accordance with GAAP, including those arising under any Legal Requirement, Action or Government Order and those arising
under any Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Liability
Claim</U>&rdquo; means an indemnification claim by or on behalf of an Indemnified Party for Losses that it believes are or may be recoverable
pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;&lrm; &lrm;8</FONT></U>, other than in respect of a Third-Party Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Lien</U>&rdquo;
means any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, claim, option, right of first refusal, preemptive
right, community property interest, conditional or installment sale agreement, encumbrance, charges or other claims of third parties of
any kind, or restriction of any nature (including any restriction on the voting of any security, any restriction on the transfer of any
security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset
and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Losses</U>&rdquo;
means the amount of any losses, damages, awards, fines, penalties, expenses or fees (including reasonable fees and expenses of counsel),
costs (including costs of investigation, arbitration and court costs), deficiencies, claims, demands, Liabilities, judgments, or Taxes
of any nature, whether or not involving any Action, including any costs of defending any Actions or enforcing a Buyer Indemnified Party&rsquo;s
or Company Indemnified Party&rsquo;s rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; means any effect, change, event, development or circumstance that, considered together with all other effects,
changes, events, developments or circumstances is materially adverse to the Business, Assets, Liabilities, financial condition or results
of operations of the Company and its Subsidiaries, taken as a whole; <U>provided</U>, <U>however</U>, that any such change, effect, event,
development or circumstance caused by or resulting from any of the following shall not be considered, and shall not be taken into account
in determining the existence of, a &ldquo;Material Adverse Effect&rdquo;: (i) the announcement, pendency or consummation of the Contemplated
Transactions, including the impact of any of the foregoing on relationships with customers, suppliers, sales representatives, or employees,
(ii)&nbsp;conditions affecting the global economy or the financial, credit, commodities or capital markets as a whole, or generally affecting
the industries in which the Company conducts its business, (iii)&nbsp;any change in financial, banking, or securities markets (including
any disruption thereof and any decline in the price of any security or any market index), (iv)&nbsp;any change in, adoption of, or change
in the interpretation of any applicable Legal Requirement or GAAP, (v)&nbsp;any national or international political or social conditions,
including the engagement or continuation by the United States in hostilities or the escalation thereof, whether or not pursuant to the
declaration of a national emergency or war, or the occurrence or the escalation of any military or terrorist attack upon the United States,
or any of its territories, possessions, or diplomatic or consular offices or upon any military installation, equipment or personnel of
the United States, (vi)&nbsp;pandemics, epidemics, disease outbreaks, earthquakes, hurricanes, tornados, floods or other natural disasters
or acts of God, (vii)&nbsp;the failure by the Company to meet any revenue or earnings projections, forecasts or predictions (provided,
that clause (vii) shall not prevent a determination that any effect or change underlying such failure has resulted in a Material Adverse
Effect, to the extent such change or effect is not otherwise excluded from this definition of Material Adverse Effect), (viii)&nbsp;any
action taken by, or with the written consent of, the Buyer or any of its Affiliates with respect to the Contemplated Transactions or with
respect to the Company or (ix) any matter of which Buyer is aware on the date hereof; except, in the case of the foregoing clauses&nbsp;(ii),
(iii), (v) and (vi), to the extent such changes or effects would have a disproportionate effect on the Company compared to other Persons
in the industries and geographic regions in which the Company conducts its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Minor
Claims</U>&rdquo; is defined in <U>Section &lrm;8.2.2(a)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Non-Competition
Agreements</U>&rdquo; is defined in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Open Source
Materials</U>&rdquo; shall mean all software or other material that is distributed as &ldquo;free software&rdquo;, &ldquo;open source
software&rdquo; or under a similar licensing or distribution model, including without limitation the GNU General Public License (GPL),
GNU Lesser General Public License (LGPL), Mozilla Public License (MPL), BSD Licenses, the Artistic License, the Netscape Public License,
the Sun Community Source License (SCSL), the Sun Industry Standards License (SISL) and the Apache License.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Organizational
Documents</U>&rdquo; means, with respect to any Person (other than an individual), the certificate or articles of incorporation, organization
or formation of such Person and any limited liability company, operating or partnership agreement, by-laws or similar documents or agreements
relating to the legal organization of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Parties</U>&rdquo;
is defined in <U>Section &lrm;1.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Permits</U>&rdquo;
means all permits, certificates, licenses, franchises, consents, approvals and authorizations from Governmental Authorities that are necessary
to the conduct of the Company&rsquo;s business or operations as presently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Permitted
Liens</U>&rdquo; means (a)&nbsp;Liens for Taxes, not yet due and payable or the amount or validity of which is being contested in good
faith, and for which adequate reserves have been established on the Financial Statements, (b)&nbsp;landlords&rsquo;, warehousepersons&rsquo;,
mechanics&rsquo;, materialmens&rsquo; or carriers&rsquo; Liens to secure claims for labor, material or supplies and other similar Liens,
(c)&nbsp;Liens incurred or deposits or pledges made in connection with, or to secure payment of, workers&rsquo; compensation, unemployment
insurance, old age pension programs mandated under applicable Legal Requirements or other social security regulations, (d)&nbsp;zoning,
building, entitlement and other land use regulations or restrictions, (e)&nbsp;the interests of the lessors and sublessors of any leased
properties, (f)&nbsp;easements, rights of way and other imperfections of title or encumbrances that do not materially interfere with the
present use of the property related thereto, (g)&nbsp;restrictions on the ownership or transfer of securities arising under applicable
Legal Requirements, (h)&nbsp;Liens disclosed on the Interim Financial Statements or in the notes thereto or securing liabilities reflected
on the Interim Financial Statements, or (i) the lien on all of the Company&rsquo;s tangible and intangible personal property in favor
of the SBA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means any natural person or any corporation, partnership, limited liability company, other legal entity or Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Personal
Information</U>&rdquo; is defined in <U>Section &lrm;3.16.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Post-Closing
Reduction Amount</U>&rdquo; is defined in <U>Section &lrm;2.7.5(a).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Proprietary
Information</U>&rdquo; means any information related to the Company, the Buyer or the Parent, including any information related to their
respective business, organization, financial situation, operations, purchasing and sales activities, Intellectual Property, source codes,
information relating to services, operating processes, procedures, price lists, customer lists, technology, designs, and specifications,
or other proprietary information of the business of the Company, the Buyer or the Parent, this Agreement, the Contemplated Transactions,
and the existence of this Agreement and the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Purchase
Price</U>&rdquo; is defined in <U>Section&nbsp;&lrm;2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Records</U>&rdquo;
means all files, documents, ledgers, papers, books and records and similar information (whether in paper, electronic or other tangible
or intangible form) of the Company that are used or held for use by Company in, or necessary for the conduct of, the Business, including
all technical information, operating and production records, service records, service protocols, documentation of service methodologies,
quality control records, blueprints, drawings, technical plans, research and development notebooks and files, customer data, mailing lists,
warranty information, product testing reports, manuals, engineering and scientific data, catalogs, advertising and other marketing materials,
brochures, sales and promotional literature, standard forms of documents, business plans, budgets, price lists, customer lists and lists
of suppliers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Reference
Balance Sheet</U>&rdquo; is defined in <U>Section&nbsp;&lrm;3.5.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Reference
Balance Sheet Date</U>&rdquo; is defined in <U>Section&nbsp;&lrm;3.5.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Representative</U>&rdquo;
means, with respect to any Person, any director, partner, manager, officer, employee, or Controlling Person of such Person and any agent,
consultant, legal, accounting, financial or other advisor or other representative authorized by such Person to represent or act on behalf
of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>SBA</U>&rdquo;
means The Small Business Administration, an Agency of the U.S. Government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Schedules
Notice</U>&rdquo; is defined in <U>Section&nbsp;&lrm;7.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Second
Earn Out Period</U>&rdquo; means the twelve (12) consecutive calendar months immediately following the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Stock
Consideration</U>&rdquo; means Closing Stock Consideration and Earn Out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
of any Person means another Person, of which at least a majority of the securities or stock having by their terms ordinary voting power
to elect a majority of the board of directors, other Persons performing similar functions, or the right to appoint or elect a general
partner, is owned or controlled directly or indirectly by such first Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Tax</U>&rdquo;
means (i) any United States federal, state or local, or any foreign, income, franchise, profits, gross receipts, license, ad valorem,
net worth, value added, sales, use, real or personal property, payroll, withholding, employment, social security, excise, environmental,
customs duties, stamp, registration, alternative and add-on minimum tax, special assessment or other governmental and quasi-governmental
charges payable to any Taxing Authority and including all interest, penalties, additional taxes and additions to tax imposed with respect
thereto., whether disputed or not, (ii) Liability for the payment of any amounts of the type described in clause (i) of this sentence
as a result of being a member of an affiliated, consolidated, combined, unitary or aggregate group for any taxable period, (iii) Liability
under any state abandonment or unclaimed property, escheat or similar Legal Requirement, and (iv) Liability for the payment of any amounts
of the type described in clause (i), (ii) or (iii) of this sentence as a result of being a transferee of or successor to any person or
as a result of any express or implied obligation to indemnify or pay any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Tax Returns</U>&rdquo;
means returns, reports, forms and information statements required to be filed with a Taxing Authority reporting liability for Taxes, including
any schedules or attachments thereto and including any amendment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Taxing
Authority</U>&rdquo; means any United States, federal, state, local or any foreign or other governmental agency responsible for the imposition,
assessment or collection of any Tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Third
Earn Out Period</U>&rdquo; means the twenty four (24) consecutive calendar months immediately following the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Third
Party Claim</U>&rdquo; is defined in <U>Section&nbsp;&lrm;&lrm;8.6.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Transaction
Expenses</U>&rdquo; means all fees, costs and expenses incurred or otherwise payable by the Company in connection with the negotiation,
documentation and consummation of the Contemplated Transactions, including such fees and expenses of counsel to the Company, counsel to
the Company and any other professional fees and expenses, in each case to the extent incurred but unpaid as of the Closing (and excluding
any fees, costs and expenses paid or payable by the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Transfer</U>&rdquo;
is defined in <U>Section&nbsp;&lrm;2.8.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Transfer
Taxes</U>&rdquo; means all transfer, documentary, sales, use, stamp, registration and other such Taxes, and any conveyance fees or recording
charges, in each case incurred by Buyer, the Company or any Affiliate thereof in connection with the transactions contemplated by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Unaudited
Financial Statements</U>&rdquo; is defined in <U>Section &lrm;3.5.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Worker</U>&rdquo;
means any current or former officer, director, employee (regular, temporary, part-time or otherwise), consultant, project worker, agent
or individual independent contractor of the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&ldquo;<U>Working
Capital</U>&rdquo; means the sum of all current Assets acquired, <U>minus</U> the sum of all current liabilities assumed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">2. The
Transaction.</P>

<P STYLE="text-align: left; font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.1. <U>Purchase
and Sale of the Assets</U>. Upon the terms and subject to the satisfaction of the conditions contained in this Agreement, at the Closing
the Company will sell, convey, assign, transfer and deliver to Buyer, and Buyer will purchase and acquire from the Company, free and clear
of all liens and encumbrances whatsoever, other than Permitted Liens, all of the Company&rsquo;s right, title and interest in and to the
assets listed on <U>Schedule 2.1A</U> (the &ldquo;<U>Assets</U>&rdquo;), and Buyer shall assume, by an undertaking in a form and substance
reasonably satisfactory to the Buyer, as of the Closing Date, only those liabilities specifically listed on <U>Schedule 2.1.B</U> but
only to the extent that such liabilities and obligations thereunder are required to be performed after the Closing Date and do not relate
to any breach, default, or violation by the Company on or prior to the Closing Date (&ldquo;<U>Assumed Liabilities</U>&rdquo;) in exchange
for the consideration described in this Agreement. Buyer does not assume any liability of the Company other than those specifically listed
on <U>Schedule 2.1.B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.2. <U>Excluded
Assets</U>. Anything in <U>Section 2.1</U> to the contrary notwithstanding, there shall be excluded from the assets, properties, rights
and business to be transferred to Buyer hereunder all of (a) the Company&rsquo;s bank accounts (but not the funds in the accounts), (b)
the Company&rsquo;s corporate minute books and membership interests records, (c) books of account and other records of the Company which
are required by law to be kept in the Company&rsquo;s possession, including but not limited to Tax Returns, (d) all assets and rights
of the Company in and with respect to Company Benefit Plans, (e) all claims, causes of action, payment rights, audit rights, and all other
rights relating to the Excluded Liabilities; (f) contracts or agreements not expressly included as Assigned Contracts; and (g) real estate
(collectively, the &ldquo;<U>Excluded Assets</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.3. <U>Purchase
Price</U>. The sole consideration to be paid to the Company for the Assets will be (i) at the Closing such number of ordinary shares
of the Parent to be issued upon Closing valued at $1,500,000, and calculated based on the volume weighted average closing share
price of Parent ordinary shares on the Nasdaq Stock Market over the 30 trading days prior to the Closing (the &ldquo;<U>Closing
Stock Consideration</U>&rdquo;) plus (ii) up to such number of ordinary shares of the Parent valued at up to $1,500,000 (the
&ldquo;<U>Earn Out Maximum Amount</U>&rdquo;), calculated based on the following: (A) one-half shall be calculated based on the
volume weighted average closing share price of Parent ordinary shares on the Nasdaq Stock Market over the 30 trading days prior to
the Closing and (ii) one-half shall be calculated based on the volume weighted average closing share price of Parent ordinary shares
on the Nasdaq Stock Market over the 30 trading days prior to the relevant Earn Out milestone completion, in the form of an earn out
(the &ldquo;<U>Earn Out</U>&rdquo;) payable as described below (subsections (i) and (ii) are together referred to as the
&ldquo;<U>Purchase Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) The
Purchase Price shall be subject to adjustment in accordance with the terms of this Agreement, including in accordance with <U>Section&nbsp;&lrm;2.7</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.4. <U>Excluded
Liabilities</U>. Except for the Assumed Liabilities and anything else in this Agreement to the contrary notwithstanding, the Company shall
be responsible for (i) all liabilities and obligations arising out of goods or services provided by the Company and accruing prior to
the Closing Date, (ii) resulting from any failure of timely payment or performance by the Company or any breach by the Company of the
Assigned Contracts occurring prior to the Closing Date, (iii) all or any liabilities arising prior to the Closing Date, or (iv) not expressly
assumed by Buyer under this Agreement, and Buyer shall not assume, or in any way be liable or responsible for, any liabilities or obligations
of the Company except as specifically provided in <U>Section 2.1</U> (the &ldquo;<U>Excluded Liabilities&rdquo;)</U>. Without limiting
the generality of the foregoing, Buyer shall not assume the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt">(a) </FONT>any
liability or obligation under contracts and other agreements to which the Company is a party or by or to which it or its assets, properties
or rights are bound or subject other than the Assigned Contracts (subject to the limitation on assumption set forth in <U>Section 2.1</U>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt">(b) </FONT>any
liability or obligation arising out of (i) any Taxes for which the Company is responsible or any Taxes arising in connection with the
Business or the Assets (or ownership thereof) for any taxable period or portion thereof ending on or prior to the Closing Date, (ii) a
breach of default by the Company prior to the Closing Date under any contract or agreement, any tortious or negligent conduct by the Company
whether prior to, on or after the Closing Date, (iii) any liability or obligation of the Company to any of its employees, agents or contractors,
including without limitation, any employee benefit, accrued salaries and related payroll expenses, commission, or bonus (whether or not
accrued), severance, change of control payment, or other liability related to the termination of any employee prior to, on or after the
Closing Date and any liability attributable to the Company&rsquo;s classification of a person as an exempt or non-exempt employee except
to the extent such liability relates to employment of any such persons by the Buyer in the period of time after the Closing Date, or (iv)
cancellations of, or returns on, sales made by the Company to the extent such cancellations or returns are not Assumed Liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt">(c) </FONT>any
liability or obligation of The Company with respect to any of the Company Employee Benefit Plans, in each case, including any liability
or obligation with respect to such Employee Benefit Plan and any liability for any payments of any kind whatsoever under the Employee
Retirement Income Security Act of 1974, as amended, or any comparable laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt">(d) </FONT>any
liability or obligation owed by the Company to any Affiliate of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt">(e) </FONT>any
liability or obligation of the Company arising out of or in connection with the preparation of this Agreement and the consummation and
performance of the Contemplated Transactions whether or not such transactions are consummated, including, but not limited to, (i) any
Tax liability of the Company so arising or (ii) any liability to which the Company may become subject as a result of the fact that the
transactions contemplated by this Agreement are being effected without compliance with the provisions of any bulk sales act or any similar
statute as enacted in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: left">The Company shall discharge and satisfy in full
when due all liabilities and obligations not expressly assumed by Buyer pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.5. <U>The
Closing</U>. Subject to the terms and conditions hereof, the closing of the purchase and sale of the Assets pursuant to this Agreement
(the &ldquo;<U>Closing</U>&rdquo;) shall take place by electronic document transfer (<I>i</I>.<I>e</I>., .pdf signature pages and fully
executed documents exchanged via email) as promptly as practicable following, but in no event later than the third (3<SUP>rd</SUP>) Business
Day following, the satisfaction or waiver of each of the conditions set forth in <U>Sections&nbsp;&lrm;5</U> and <U>&lrm;6</U> hereof
(other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of such
conditions at Closing), or at such other time and place as the Buyer and the Company may agree in writing (the day on which the Closing
takes place, the &ldquo;<U>Closing Date</U>&rdquo;). Subject to the provisions of <U>Section 9.15</U>, the failure of any party to consummate
the Closing on the date and time determined pursuant to this <U>Section&nbsp;&lrm;2.5</U> shall not result in the termination of this
Agreement and shall not relieve such party of any obligation under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.6. <U>Closing
Deliveries and Payments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.6.1. <U>Buyer
Closing Deliveries and Payments</U>. At the Closing, the Buyer and the Parent shall deliver or cause to be delivered to the Company the
following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) the
Closing Stock Consideration, <I>minus</I> the Escrow Amount;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) to
the Escrow Agent, the Escrow Amount (the &ldquo;<U>Escrow Account</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(c) the
Escrow Agreement, duly executed by the Buyer and the Parent, and the various certificates, agreements, instruments and documents required
to be delivered by the Buyer and the Parent at or prior to the Closing referred to in <U>Section &lrm;6</U>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(d) all
other agreements, documents, instruments or writings as may be required to be delivered by the Buyer, at or prior to the Closing pursuant
to the terms of this Agreement, or as may reasonably be requested by the Company or its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.6.2. <U>Company
Closing Deliveries</U>. At the Closing, the Company shall deliver or cause to be delivered to the Buyer the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) a
bill of sale duly executed by the Company for all the personal property included in the list of Assets, in form and substance reasonably
satisfactory to the Buyer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) an
assignment for all of the Assets and Assumed Liabilities that are intangible personal property (i.e., contracts, intellectual property,
etc.) being assigned by the Company to Buyer, executed by the Buyer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(c) all
consents, waivers or approvals required in order to effectuate the sale of the Assets, including but not limited to any key customer consents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(d) list
of the Company&rsquo;s customers, including names, email addresses, addresses and telephone numbers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(e) the
Escrow Agreement, duly executed by the Company, and any other agreements, documents, instruments or certificates required to be delivered
by the Company at or prior to the Closing pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;&lrm;</FONT>5</U>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(f) all
other agreements, documents, instruments or writings as may be required to be delivered by the Company, at or prior to the Closing pursuant
to the terms of this Agreement, or as may reasonably be requested by Buyer or its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.7. <U>Purchase
Price Adjustment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.7.1. <U>Estimated
Closing Statement</U>. The Company will in good faith prepare and deliver, or cause to be prepared and delivered, to the Buyer not later
than five (5) Business Days prior to the Closing Date a written statement (the &ldquo;<U>Estimated Closing Statement</U>&rdquo;) setting
forth in reasonable detail the Company&rsquo;s good faith estimate of Working Capital (&ldquo;<U>Estimated Working Capital</U>&rdquo;).
The Estimated Closing Statement shall be accompanied by a certificate of the Company and the Chief Executive Officer of the Company certifying
that the estimates therein have been calculated in accordance with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.7.2. <U>Closing
Statement</U>. As promptly as practicable, but in any event within ninety (90) days after the Closing Date, the Buyer will in good faith
prepare or cause to be prepared, and will provide to the Company, a written statement (the &ldquo;<U>Closing Statement</U>&rdquo;) setting
forth in reasonable detail the Buyer&rsquo;s proposed determinations of Working Capital, as of the Balance Sheet Time. The Closing Statement
will solely be based on facts and circumstances as they exist prior to Closing and disregard any financing or other arrangements entered
into by the Buyer or any of its Affiliates in connection with the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.7.3. <U>Dispute
Notice</U>. The Closing Statement will be final, conclusive and binding on the parties unless the Company provides a written notice (a
&ldquo;<U>Dispute Notice</U>&rdquo;) to the Buyer no later than forty-five (45) days after delivery of the Closing Statement setting forth
in reasonable detail any item(s) or amount(s) on the Closing Statement that are disputed by the Company (each, a &ldquo;<U>Disputed Item</U>&rdquo;).
Any item or amount on the Closing Statement to which no dispute is raised in the Dispute Notice will be final, conclusive and binding
on the parties. Without limiting the generality of the foregoing, a Dispute Notice may not be based on (i) developments occurring after
the Closing Date unless the Closing Statement contains information related to developments occurring after the Closing Date, or (ii) items
that are the subject of an asserted indemnification claim pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;&lrm;</FONT>8</U>.
The Buyer shall provide the Company and its Representatives with access to, and the opportunity to make copies of, the work papers and
other materials used or considered by the Buyer in the preparation of the Closing Statement, and reasonable access to personnel and Representatives
of the Buyer who assisted or were consulted in the preparation of the Closing Statement; provided, that, in each case such provision and
access shall be (i) for the purpose of reviewing the Closing Statement and to prepare any Dispute Notice and (ii) during normal business
hours and in a manner that does not interfere with the normal business operations of the Buyer or the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.7.4. <U>Resolution
of Disputes</U>. The Buyer and the Company will attempt to resolve the Disputed Items in good faith during the twenty (20) day period
following delivery of the Dispute Notice and all such discussions will (unless otherwise agreed by the Buyer and the Company) be governed
by Rule&nbsp;408 of the Federal Rules of Evidence and any comparable applicable state rule. Disputed Items resolved in writing by the
Company and the Buyer within the twenty (20) day period will be final, conclusive and binding on the parties. If the Buyer and the Company
are unable to resolve all Disputed Items in the Dispute Notice within such twenty (20) day period, either the Buyer or the Company may
provide written notice to the other (the &ldquo;<U>Dispute Submission Notice</U>&rdquo;) that such party is submitting any remaining Disputed
Items for resolution to the Independent Referee. The Buyer and the Company shall enter into a customary engagement letter with the Independent
Referee. The Buyer and the Company will use their commercially reasonable efforts to cause the Independent Referee to render its decision
as soon as practicable (but in any event within thirty (30) days) after the submission to the Independent Referee of their respective
proposed final calculations of the Disputed Items (which the Buyer and the Company shall submit to the Independent Referee not later than
ten (10) days following the giving of the Dispute Submission Notice). Each of the Buyer and the Company shall use reasonable best efforts
to comply with all reasonable requests by the Independent Referee for access to their respective work papers, information, books, records
and similar items, personnel and Representatives (provided, that such access and compliance is during normal business hours and does not
interfere with the normal business operations of the Buyer or the Company). The Independent Referee will review such final calculations
of the Disputed Items and render a final determination of all Disputed Items in accordance with this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>2.7</U>,
<U>provided</U> that the Independent Referee&rsquo;s final determination with respect to each Disputed Item shall be within the range
of the proposed final calculations of such Disputed Item as presented in the Buyer&rsquo;s Closing Statement pursuant to <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.7.2</U>
and the Dispute Notice pursuant to <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.7.3</U>. The Buyer and the Company each
shall be entitled to make a written submission to the Independent Referee (which need not be provided to the other party) in support of
its respective proposed final calculations of the submitted Disputed Items, <U>provided</U> that such submissions shall be submitted within
twenty (20) days after the submission to the Independent Referee of such proposed final calculations of the submitted Disputed Items.
The Independent Referee&rsquo;s determination will be (a)&nbsp;in writing and shall include a reasonably detailed statement of the basis
for the Independent Referee&rsquo;s decision, (b)&nbsp;furnished to each of the Buyer and the Company as soon as practicable (but in any
event within thirty (30) days) after the Company&rsquo;s and the Buyer&rsquo;s respective final calculations of the Disputed Items have
been submitted to the Independent Referee, (c)&nbsp;limited in scope to the Disputed Items and (d)&nbsp;final, conclusive and binding
on the parties, and judgment on such decision may be entered in any court of competent jurisdiction. The fees and expenses of the Independent
Referee shall be borne by (i)&nbsp;the Company, on the one hand, and (ii)&nbsp;the Buyer, on the other hand, based on the percentage that
the portion of the contested amount not awarded to each party bears to the amount actually contested by the parties in aggregate, and
such allocation of fees and expenses shall be calculated by the Independent Referee and such calculation shall be final and binding on
the parties. By way of illustration, (x)&nbsp;if the Buyer&rsquo;s calculations would have resulted in a $100,000 net payment to the Buyer,
and the Company&rsquo;s calculations would have resulted in a $100,000 net payment to the Company and the Independent Referee&rsquo;s
final determination results in an aggregate net payment of $50,000 to the Company, then the Buyer and the Company shall pay 75% and 25%,
respectively, of such fees and expenses and (y)&nbsp;if each of such parties&rsquo; calculations differs from the Independent Referee&rsquo;s
calculation by at least $100,000, the Buyer and the Company shall split such fees and expenses evenly. At any time the Buyer and the Company
may agree to settle any objections raised in the Dispute Notice, including any Disputed Items submitted to the Independent Referee, which
agreement shall be in writing and final, conclusive and binding upon all of the parties hereto with respect to the subject matter of any
such objection so resolved; <U>provided</U> that, the parties shall promptly provide a copy of such agreement to the Independent Referee
and instruct the Independent Referee not to resolve such Disputed Item, it being agreed that if the Independent Referee nonetheless resolves
such Disputed Item for any reason, the agreement of the parties shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.7.5. <U>Post-Closing
Purchase Price Adjustment</U>. As promptly as possible, but in any event no later than the fifth (5th) Business Day following the final
determination, in accordance with <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.7.3</U> and/or <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.7.4</U>,
of Working Capital (&ldquo;<U>Final Working Capital Amount</U>&rdquo;), a Purchase Price adjustment shall be made as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) if
the Final Working Capital Amount is less than the Estimated Working Capital Amount, then the Purchase Price will be reduced by an amount
equal to such shortfall (the &ldquo;<U>Post-Closing Reduction Amount</U>&rdquo;), and such Post-Closing Reduction Amount shall be released
to the Buyer from the Escrow Account (i) in the form of Closing Stock Consideration valued in accordance with <U>Section 2.3</U> hereof
and (ii) in accordance with the terms of the Escrow Agreement and otherwise subject to <U>Sections <FONT STYLE="font-size: 10pt">&lrm;&lrm;</FONT>8.2.1</U>
and <FONT STYLE="font-size: 10pt"><U>&lrm;&lrm;</U></FONT><U>8.10</U>; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) if
the Final Working Capital Amount is greater than the Estimated Working Capital Amount, then the Purchase Price will be increased by an
amount equal to such excess and the Buyer will transfer to the Escrow Agent additional Closing Stock Consideration equal to such excess
amount valued in accordance with Section 2.3 hereof within five (5) Business Days after the determination of such excess amount, and such
additional Closing Stock Consideration shall be held by the Escrow Agent in accordance with the terms of the Escrow Agreement and the
applicable terms herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.8. <U>Earn
Out</U>. The Company shall be entitled to receive the Earn Out as additional consideration as set forth in this <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.8.1. <U>Earn
Out Statement</U>. Within forty-five (45) days following the end of each Earn Out Period, Buyer will prepare and deliver to the Company
a statement (an &ldquo;<U>Earn Out Statement</U>&rdquo;) setting forth whether applicable non-economic milestones have been met for that
portion of the Earn Out Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.8.2. Payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) If
the Continuing Business achieves milestones for the relevant Earn Out Periods, as set forth in <U>Schedule 2.8.2(a)</U> and as reasonably
and in good faith confirmed by Buyer in the relevant Earn Out Statement, Parent shall issue to the Company the amounts attached to the
relevant milestone according to Schedule 2.8.2(a) (such calculated amounts are referred to as the &ldquo;<U>Earn Out Amount</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) The
Parent shall issue the relevant portion(s) of the Earn Out Amount within 10 days after the Company confirms that the Company will not
deliver an Earn Out Dispute Notice for the applicable Earn Out Period, if applicable, and if the Company disputes any element of an Earn
Out Statement , pursuant to <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.8.4</U>, then any payment shall be due on such
date as the Buyer and the Company resolve the dispute under <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.8.4</U> (a date
on which payment is due is referred to as a &ldquo;<U>Earn Out Payment Date</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.8.3. Reserved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.8.4. Disputes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) Company
may dispute any element of an Earn Out Statement by delivering written notice to Buyer of said disagreement, setting forth in detail the
particulars of such disagreement (a &ldquo;<U>Earn Out Dispute Notice</U>&rdquo;), within thirty (30) days after the receipt by Company
of an Earn Out Statement. During such thirty (30) day period, Company and any accountant or agent of Company shall have full access during
normal business hours (i) to the relevant books and records of, and the work papers prepared by, Buyer to the extent that they relate
to an Earn Out Statement or any calculation provided therewith, and (ii) to such historical financial information (to the extent in Buyer&rsquo;s
possession) relating to an Earn Out Statement or any calculation provided therewith as Company may reasonably request for the purpose
of reviewing an Earn Out Statement or any calculation provided therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) In
the event that Company did not provide such a Earn Out Dispute Notice within such thirty (30) day period, Company shall be deemed to have
accepted an Earn Out Statement and any calculation provided thereunder, which shall thereafter be final, binding, non-appealable and conclusive
for all purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(c) In
the event a Earn Out Dispute Notice is timely provided, Buyer and Company shall use their reasonable efforts for a period of thirty (30)
days (or such longer period as they shall mutually agree) from the date of receipt of such notice, to resolve such disagreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(d) If
the Buyer and the Company are unable to resolve the matters disputed in the Earn Out Dispute Notice within such 30-day period, either
the Buyer or the Company may provide written notice to the other (the &ldquo;<U>Earn Out Dispute Submission Notice</U>&rdquo;) that such
party is submitting any remaining matters disputed in the Earn Out Dispute Notice for resolution to the Independent Referee, subject to
<U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>2.8.4(e)</U>. The Buyer and the Company shall enter into a customary engagement letter
with the Independent Referee. The Buyer and the Company will use their commercially reasonable efforts to cause the Independent Referee
to render its decision as soon as practicable (but in any event within thirty (30) days) after the submission to the Independent Referee
of their respective proposed determinations (which the Buyer and the Company shall submit to the Independent Referee not later than ten
(10) days following the giving of the Earn Out Dispute Submission Notice). Each of the Buyer and the Company shall use reasonable best
efforts to comply with all reasonable requests by the Independent Referee for access to their respective work papers, information, books,
records and similar items, personnel and Representatives (<U>provided</U> that such access and compliance is during normal business hours
and does not interfere with the normal business operations of the Buyer or the Company). The Independent Referee will review such matters
disputed in the Earn Out Dispute Notice and render a final determination of the matters disputed in the Earn Out Dispute Notice in accordance
with this <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.8</U>. The Buyer and the Company each shall be entitled to make
a written submission to the Independent Referee (which need not be provided to the other party) in support of its respective proposed
final determinations of the matters disputed in the Earn Out Dispute Notice, <U>provided</U> that such submissions shall be submitted
within twenty (20) days after the submission to the Independent Referee of such proposed final determinations of the matters disputed
in the Earn Out Dispute Notice. The Independent Referee&rsquo;s determination will be (a)&nbsp;in writing and shall include a reasonably
detailed statement of the basis for the Independent Referee&rsquo;s decision, (b)&nbsp;furnished to each of the Buyer and the Company
as soon as practicable, and (c)&nbsp;final, conclusive and binding on the parties, and judgment on such decision may be entered in any
court of competent jurisdiction. The fees and expenses of the Independent Referee shall be borne by (i)&nbsp;the Company, on the one hand,
and (ii)&nbsp;the Buyer, on the other hand, based on the percentage that the portion of the contested amount not awarded to each party
bears to the amount actually contested by the parties in aggregate, and such allocation of fees and expenses shall be calculated by the
Independent Referee and such calculation shall be final and binding on the parties. By way of illustration, if the Buyer&rsquo;s calculations
would have resulted in an Earn Out Amount equal to a dollar value of Five Hundred Thousand Dollars ($500,000) due to the Company and the
Company&rsquo;s calculations would have resulted in an Earn Out Amount equal to a dollar value of Seven Hundred Thousand Dollars ($700,000)
due to the Company and the Independent Referee&rsquo;s final determination results in an Earn Out Amount equal to a dollar value of Six
Hundred Thousand Dollars ($600,000) due to the Company, then the Buyer shall pay fifty percent (50%) and the Company shall pay fifty percent
(50%) of such fees and expenses. At any time the Buyer and the Company may agree to settle the dispute, which agreement shall be in writing
and final, conclusive and binding upon all of the parties hereto with respect to the subject matter of any such objection so resolved;
<U>provided</U> that, the parties shall promptly provide a copy of such agreement to the Independent Referee and instruct the Independent
Referee not to resolve the dispute, it being agreed that if the Independent Referee nonetheless resolves the dispute for any reason, the
agreement of the parties shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(e) Notwithstanding
any provision of this Agreement to the contrary, the Independent Referee shall not have the power to resolve any dispute relating to <U>Section
2.8.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">2.8.5. The
rights of the Company to receive the Earn Out Amount (i) are solely contractual rights and are not securities for purposes of any federal
or state securities Laws, and shall confer upon the Company only the rights of general unsecured creditors; (ii) do not constitute an
investment or ownership interest in Buyer or the Parent; (iii) are an integral part of the consideration payable by the Buyer for the
Assets; (iv) will not be represented by any form of certificate or instrument; (v) do not give the Company any dividend rights, voting
rights, liquidation rights, preemptive rights or other rights as security holders of the Parent or the Buyer or any of their Affiliates;
(vi) are not redeemable; (vii) do not bear interest; and (viii) may not be sold, assigned, pledged, gifted, conveyed or otherwise transferred
(a &ldquo;<U>Transfer</U>&rdquo;), except by operation of law or pursuant to the laws of descent and distribution (with any Transfer in
violation of this <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.8.5</U> being null and void). The Parties agree to treat
the Earn Out Payment as consideration payable by the Buyer for the Assets for all tax purposes and consistent with Section 2.9 below,
except as and to the extent required by applicable Legal Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">2.9. <U>Tax
Treatment.</U> For U.S. federal income Tax purposes, the parties acknowledge and agree that the consummation of the transactions contemplated
hereunder are intended to qualify as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a)(1)(C) of the Code, and the regulations
promulgated thereunder, and that this Agreement will constitute a &ldquo;plan of reorganization&rdquo; for purposes of Sections 354 and
361 of the Code. The parties hereto covenant and agree to file all applicable Tax Returns consistent with this paragraph and not take
any position on any such Tax Return inconsistent with this paragraph unless otherwise required by applicable Legal Requirements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">3. Representations
and Warranties of the Company.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Except as provided in the
Disclosure Schedules (subject to <U>Section &lrm;&lrm;10.15)</U>, the Company represents and warrants to the Buyer as of the date hereof
and the Closing Date (unless the particular statement speaks expressly as of a particular date, in which case it is true and correct only
as of such date) as follows (in each case, except where context implies otherwise, with respect to the Company and its direct and indirect
Subsidiaries):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.1. <U>Power
and Authorization</U>. The Company has the limited liability company power and authority to execute and deliver this Agreement and to
perform its obligations hereunder. The Company has taken all company actions or proceedings required to be taken by or on the part of
the Company to authorize and permit the execution and delivery by the Company of this Agreement and the instruments required to be executed
and delivered by it pursuant hereto, and the performance by the Company of its obligations hereunder and the consummation by the Company
of the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company, and assuming the due authorization,
execution and delivery by each of the other parties hereto, constitutes the legal, valid and binding obligation of the Company, enforceable
against it in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.2. <U>Organization</U>.
The Company is (a)&nbsp;duly organized, validly existing and in good standing under the laws of the State of New York, and (b) the Company
has all requisite power and authority and all Permits necessary to own, lease and operate its properties and assets and to carry on its
businesses as currently conducted and as proposed to be conducted. The Company is duly qualified or licensed to do business and is in
good standing in each jurisdiction where the character of the properties owned, leased or licensed by it or the nature of its business
makes such qualification, licensing or good standing necessary, except where the failure to be so qualified or licensed or in good standing
has not had, and would not reasonably be expected to have, a Material Adverse Effect. The Company has made available to the Buyer true
and correct copies of the Company&rsquo;s Organizational Documents. The Company is not in violation of any of the provisions of its Organizational
Documents, and no changes thereto are pending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.3. <U>No
Violation or Approval; Consents</U>. Except as set forth in <U>Schedule&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>3.3</U>, none of
the execution and delivery of or its performance of its obligations under this Agreement by the Company or its consummation of the Contemplated
Transactions, will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.3.1. require
any consent, waiver, approval, clearance, permit, order or authorization of or from, or registration, declaration, notice or filing to
or with any Governmental Authority with respect to the Company or any Company Subsidiary or pursuant to any Legal Requirement applicable
to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.3.2. require
any consent of any third party to the sale by of the Assets or the assumption of the Assumed Liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.3.3. (1)
result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of
obligations under, create in any Person the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver
under, any Contract, Permit, Lien (other than Permitted Liens) or other arrangement to which the Company or its Subsidiary is a party
or by which the Company or its Subsidiary is bound or to which its assets are subject except in the case where such breach, default, or
acceleration would not have a Material Adverse Effect, or (2) result in the imposition of any Lien (other than Permitted Liens); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.3.4. result
in a breach or violation of, or default under, the Organizational Documents of the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.4. <U>Assets</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.4.1. <U>Sufficiency
of Assets</U>. The Assets constitute all of the assets, tangible and intangible, of any nature whatsoever, necessary to operate the technology
and products and services of the Business in the manner presently operated by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.4.2. <U>Title
and Related Matters</U>. The Company is the legal owner of, and has good, marketable and transferable title to, and the absolute power
and right to sell, assign, transfer and deliver, all of the Assets, free and clear of all Liens, except for Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.4.3. <U>Condition
of Assets to be Acquired</U>. All of the Assets are in good operating condition and repair (ordinary wear and tear excepted) and are adequate
for the uses to which they are being put, and none of such Assets are in need of maintenance or repairs except for ordinary, routine maintenance
and repairs that are not material in nature or cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.4.4. <U>Accounts
Receivable</U>. All accounts receivable that are reflected on Company&rsquo;s Reference Balance Sheet or on the accounting records of Company
as of the Closing Date represent or will represent valid obligations arising from sales actually made or services actually performed by
the Company in the ordinary course of business. There is no contest, claim, defense or right of setoff, under any contract with any account
debtor of an account receivable relating to the amount or validity of such account receivable. <U>Schedule 3.4</U> contains an aged list
of the accounts receivable, contract rights, and other rights to receive money of the Company as of August 31, 2021, showing separately
those receivables that have been outstanding for (a) 29 days or less, (b) 30 to 59 days, (c) 60 to 89 days, (d) 90 to 119 days and (e)
more than 119 days, and in each case showing the name of the account debtor, maker or obligor, the unpaid balance and the age of each
receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.5. <U>Financial
Statements, Etc</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.5.1. The
Company has furnished the Buyer with copies of: (a)&nbsp;the unaudited consolidated balance sheet of the Company as of December&nbsp;31,
2019 and December 31, 2020, and the related statements of income and cash flows of the Company for the fiscal year then ended (the &ldquo;<U>Unaudited
Financial Statements</U>&rdquo;) and (b) the unaudited balance sheet of the Company as of August 31, 2021 (respectively, the &ldquo;<U>Reference
Balance Sheet</U>&rdquo; and the &ldquo;<U>Reference Balance Sheet Date</U>&rdquo;) and the related statements of income and cash flows
of the Company for the fiscal year then ended (the &ldquo;<U>Interim Financial Statements</U>&rdquo; and, collectively with the Unaudited
Financial Statements, the &ldquo;<U>Financial Statements</U>&rdquo;). The Financial Statements present fairly in all material respects
the financial position of the Company and the results of operations of the Company and any of its Subsidiaries (taken as whole) as of
the respective dates thereof and for the periods covered thereby subject in the case of the Reference Balance Sheet to the absence of
footnote disclosures and other presentation items. Except as disclosed in <U>Schedule&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>3.5</U>,
neither the Company nor its Subsidiaries has any Liabilities (whether or not required to be reflected in the Financial Statements under
GAAP), except for Liabilities that (v) are reflected in or reserved against in the Reference Balance Sheet, (w)&nbsp;have arisen or incurred
after the date of the Reference Balance Sheet in the ordinary course of business (none of which results from, arises out of, relates to,
is in the nature of, or was covered by any breach of contract, breach of warranty, tort, infringement, or violation of Legal Requirement)
and are reflected in the calculation of the Estimated Working Capital Amount, (x)&nbsp;Liabilities arising pursuant to the terms of any
Contract for which the Company or any of its Subsidiaries is a party that have not yet been performed (<U>provided</U>, neither the Company
nor any of its Subsidiaries is in breach, violation, or non-compliance with such Contract), and (z) are included in Indebtedness or Transaction
Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.5.2. The
Company has in place systems and processes (including the maintenance of proper books and records) that are designed to (1)&nbsp;provide
reasonable assurances regarding the reliability of the Financial Statements and (2)&nbsp;in a timely manner accumulate and communicate
to the Company&rsquo;s principal executive officer and principal financial officer the type of information that would be required to be
disclosed in the Financial Statements (such systems and processes, the &ldquo;<U>Financial Controls</U>&rdquo;). None of the Company,
its Subsidiaries, their respective officers nor the Company&rsquo;s independent auditors has identified or been made aware of any complaint,
allegation, deficiency, assertion or claim, whether written or oral, regarding the Financial Controls or the Financial Statements that
has not been resolved. There have been no instances of fraud or intentional misrepresentation by any Worker, whether or not material,
that occurred during any period covered by the Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.6. <U>Ordinary
Course of Business; No Material Adverse Effect. </U>Since the Reference Balance Sheet Date: (a) the Company and its Subsidiaries have
operated in the ordinary course of business; and (b) no Material Adverse Effect has occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.7. <U>Taxes</U>.
Except in each case as set forth on <U>Schedule&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>3.7</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.1. The
Company and any of its Subsidiaries have timely filed, or have caused to be timely filed on their behalf (after giving effect to extensions),
all Tax Returns required to be filed by or with respect to the Company and each of its Subsidiaries. All such Tax Returns were true, correct
and complete in all material respects. All Taxes required to be paid by or with respect to the Company or its Subsidiaries (whether or
not shown as due and payable on any such Tax Return) have been paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.2. All
Taxes required to have been withheld and paid in connection with amounts paid by the Company or its Subsidiaries to any Worker, creditor,
equityholder, or other third party have been withheld and paid to the appropriate Taxing Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.3. Neither
the Company nor any of its Subsidiaries have been notified in writing by a Taxing Authority of any deficiency or other assessment, audit
or examination concerning Taxes of the Company or any of its Subsidiaries that, if determined adversely to the Company or its Subsidiaries,
would reasonably be expected to result in material Tax Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.4. <FONT STYLE="font-family: Times New Roman, Times, Serif">There
are no pending requests for rulings or determinations by or before a Taxing Authority relating to Taxes with respect to the Company or
any of its Subsidiaries. No power of attorney has been executed by or on behalf of the Company or any of its Subsidiaries with respect
to any matters relating to Taxes that is currently in force.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.5. There
has been no extension or waiver of any statute of limitations in respect of Taxes with respect to the Company or any of its Subsidiaries
that remains in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.6. <FONT STYLE="font-family: Times New Roman, Times, Serif">No
claim or nexus inquiry has been made by a Taxing Authority in a jurisdiction where the Company or any of its Subsidiaries does not file
Tax Returns that the Company or any of its Subsidiaries is or may be subject to taxation by that jurisdiction or that the Company or any
of its Subsidiaries has a duty to collect Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.7. None
of the assets of the Company or any of its Subsidiaries are currently subject to any Liens with respect to Taxes, other than Permitted
Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.8. Neither
the Company nor any of its Subsidiaries is a party to or bound by any Tax sharing agreement, <FONT STYLE="font-family: Times New Roman, Times, Serif">Tax
indemnity, or tax-allocation agreement</FONT> other than any such agreement not primarily related to Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.9. Neither
the Company nor any of its Subsidiaries has, or ever had, (during any taxable period remaining open for the assessment of Tax by any applicable
Taxing <FONT STYLE="font-family: Times New Roman, Times, Serif">Authority under its applicable statute of limitations), any place of business
or permanent establishment in any jurisdiction outside the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.10. Neither
the Company nor any of its Subsidiaries has obtained any consent or clearance from or <FONT STYLE="font-family: Times New Roman, Times, Serif">entered
into any settlement or arrangement with any Taxing Authority that would be binding on Buyer or result in a material Tax Liability for
Buyer for any Tax period (or portion thereof) ending after the Closing Date. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.11. <FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company and its Subsidiaries have properly and timely documented its transfer pricing methodology in compliance with Sections 482 and
6662 of the Code and any similar or comparable provision of applicable Legal Requirement. Neither the Company nor any of its Subsidiaries
is a party to any advance pricing agreement or any similar or comparable contract or agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.12. <FONT STYLE="font-family: Times New Roman, Times, Serif">Neither
the Company</FONT> nor any of its Subsidiaries has ever participated in an international boycott within the meaning of Section 999 of
the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.13. <FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Schedule
<FONT STYLE="font-size: 10pt">&lrm;</FONT>3.7.13</U> contains a true and complete list of all jurisdictions (whether foreign or domestic)
to</FONT> which any Tax is properly payable by the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">3.7.14 The Company
has in effect a valid election under Treasury Regulation Section 301.7701-3 to be classified as an association taxable as a C corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.7pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.8. <U>Operations
in Conformity with Laws</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.8.1. The
Company and each of its Subsidiaries have complied in all material respects with, are not in material violation of, and have not received,
nor to the Company&rsquo;s Knowledge is there any Basis for, any allegation or notice of material default or violation with respect to,
any Legal Requirement or Permits with respect to the conduct of its business, or the ownership or operation of its business. No event
has occurred, and no condition or circumstance exists, that might (with or without notice or lapse of time or both) constitute, or result
directly or indirectly in, a default under, a material breach or violation of, or a failure to comply with, any Legal Requirement or Permits
with respect to the conduct of the business of the Company or any of its Subsidiaries or the ownership or operation of the Company or
any of its Subsidiaries. The Company and its Subsidiaries owns or possess all Permits that are necessary to conduct the business of the
Company and its Subsidiaries as presently conducted and as proposed to be conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.8.2. None
of the Company, any of its Subsidiaries or any of their respective Representatives, or distributors while retained by the Company or any
other Person acting on behalf of any such Person have, with respect to the business of the Company or any of its Subsidiaries, (1) used
any funds for unlawful contributions, gifts, entertainment or other unlawful payments relating to any political activity or (2) made any
unlawful payment to any government official or employee or any political party or campaign or violated any provision of the U.S. Foreign
Corrupt Practices Act of 1977 or any other Legal Requirement applicable to the conduct of business with Governmental Authorities (collectively,
&ldquo;<U>Anti-bribery Laws</U>&rdquo;). The Company has made available to Buyer true, correct and complete copies of each Contract in
effect, if any, as of the date of this Agreement between the Company or any of its Subsidiaries, on the one hand, and any sales agent
or foreign representative thereof, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.8.3. Except
as set forth on <U>Schedule 3.8.3</U>, neither the Company nor any of its Subsidiaries has applied for or received, is or will be entitled
to or is or will be the beneficiary of any grant, subsidy or financial assistance from any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.8.4. The
Company and each of its Subsidiaries have at all times conducted their business in accordance with (1) all applicable U.S. export control
and economic sanctions laws, including the Export Administration Regulations, the Arms Export Control Act, the International Traffic in
Arms Regulations, and the various statutes, regulations, and executive orders administered by the U.S. Department of the Treasury, Office
of Foreign Assets Control; and (2) all other applicable import/export controls in other countries in which the Company conducts business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.8.5. <U>Schedule
3.8.5</U> sets forth the true, complete and accurate export control classifications applicable to the Company&rsquo;s or any of its Subsidiaries&rsquo;
products, services, software and technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.8.6. Each
Permit (i) under which the Company or any of its Subsidiaries currently operates or holds any interest in any of their assets, or (ii)
that is required for the operation of the Company&rsquo;s or any of its Subsidiaries&rsquo; businesses as presently conducted or the holding
of any such interest (collectively, the &ldquo;<U>Company Authorizations</U>&rdquo;) has been issued or granted to the Company or one
of its Subsidiaries, as applicable. The Company Authorizations are in full force and effect and constitute all Company Authorizations
required to permit the Company and each of its Subsidiaries to lawfully operate or conduct their businesses or hold any interest in their
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.9. <U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.1. <U>Schedule
3.9.1</U> (i) sets forth each granted patent, pending patent application, copyright registration or application therefor, and trademark,
service mark and domain name registration or application therefor owned by or purported to be owned by the Company or any of its Subsidiaries
(&ldquo;<U>Company Registered IP</U>&rdquo;) and any actions that must be taken within one hundred eighty (180) days after the date hereof
for the purposes of obtaining, maintaining, perfecting, preserving or renewing any of the foregoing, <U>including</U> the payment of any
registration, maintenance or renewal fees or the filing of documents, applications or certificates or any responses to office actions.
The Company or any of its Subsidiaries is the owner of the Company Registered IP free and clear of all Liens (other than Permitted Liens).
Each of the Company Registered IP is valid, enforceable and subsisting, all necessary registration, maintenance and renewal fees currently
due in connection with such Company Registered IP have been made and all necessary documents, recordations and certificates in connection
with such Company Registered IP have been filed with the relevant Governmental Authority. <U>Schedule 3.9.1(i)</U> sets forth an accurate
and complete list of all material Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries that
is not Company Registered IP. The Company or any of its Subsidiaries has not received any written notice challenging the legality, validity,
enforceability or ownership of any Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries. The
Company has not licensed any rights to or in U.S. Patent No. 10,803,985., other than to USARAD Holdings, Inc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.2. The
Company or its Subsidiaries exclusively and solely owns, free of any Liens other than non-exclusive licenses entered into in the ordinary
course of business, or has the right to use all Intellectual Property necessary (i) to use, manufacture, sell, offer for sale, import,
supply, perform, reproduce, display, market and distribute the Customer Deliverables and (ii) to use, make, perform, reproduce and operate
the Internal Systems. The Company and its Subsidiaries have taken all reasonable measures to protect the proprietary nature of each item
of Company Intellectual Property, and to maintain in confidence all trade secrets and confidential information, that it owns or uses.
No other person or entity has any rights to any of the Company Intellectual Property owned by or purported to be owned by the Company
or any of its Subsidiaries (except pursuant to agreements or licenses additionally specified in <U>Schedule 3.9.2</U>), and, to the Company&rsquo;s
Knowledge, no other person or entity is infringing, violating or misappropriating any of the Company Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.3. Except
as would not have a Material Adverse Effect, to the Company&rsquo;s Knowledge, the operation by the Company and its Subsidiaries of their
business, including the design, development, use, import, export, manufacture, licensing, sale, offering for sale, supply or other disposition
of the Customer Deliverables and/or the Internal Systems does not (i) infringe, violate or misappropriate the Intellectual Property rights
of any Person, or (ii) constitute unfair competition or trade practices under applicable laws. <U>Schedule 3.9.3</U> additionally lists
any unresolved complaint, claim or notice, or written threat thereof, received by the Company or any of its Subsidiaries alleging any
such infringement, violation or misappropriation; and the Company or any of its Subsidiaries have made available to Buyer complete and
accurate copies of all written documentation in the possession of the Company or any of its Subsidiaries relating to any such unresolved
complaint, claim, notice or threat. The Company and its Subsidiaries have made available to Buyer complete and accurate copies of all
written documentation in the Company&rsquo;s possession relating to current, unresolved claims or disputes known to the Company or any
of its Subsidiaries concerning any Company Intellectual Property. To the Company&rsquo;s Knowledge, no third party has threatened any
Action or claim against the Company or any of its Subsidiaries for the infringement, violation or misappropriation of any Intellectual
Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.4. Except
as described in <U>Schedule 3.9.4</U>, neither the Company nor any of its Subsidiaries has agreed to indemnify any person or entity against
any infringement, violation or misappropriation of any Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.5. <U>Schedule
3.9.5</U> identifies each item of Company Intellectual Property that is owned, in whole or in part, by a party other than the Company
or one of its Subsidiaries, and the license or agreement pursuant to which the Company or any of its Subsidiaries uses it (excluding off-the-shelf
software programs licensed by the Company or one of its Subsidiaries pursuant to &ldquo;shrink wrap&rdquo; or &ldquo;click through&rdquo;
licenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.6. Neither
the Company nor any of its Subsidiaries has disclosed the source code for any software developed by it, or other confidential information
constituting, embodied in or pertaining to such software, to any person or entity, except pursuant to the agreements listed in <U>Schedule
3.9.6</U>, and neither the Company nor its Subsidiaries have taken reasonable measures to prevent disclosure of such source code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.7. All
of the Intellectual Property incorporated in or used in conjunction with the Customer Deliverables and/or the Internal Systems have been
created by employees or agents of the Company and its Subsidiaries within the scope of their employment or engagement by the Company and
its Subsidiaries or by independent contractors of the Company and its Subsidiaries. Each Worker has executed written, valid and enforceable
agreements expressly assigning to the Company or its Subsidiaries all right, title and interest in and to any Intellectual Property conceived
of, created, developed or first reduced to practice in the course of such Worker&rsquo;s employment by or engagement with the Company
or one of its Subsidiaries. No portion of such Intellectual Property was jointly developed with any third party, except to the extent
all right, title and interest in and to such Intellectual Property held by such third party as a result of such joint development has
been assigned to the Company or its Subsidiaries. The Company and its Subsidiaries have paid, in full, all required compensation to employees,
agents or independent contractors in relation to all Intellectual Property owned or purported to be owned by the Company and its Subsidiaries,
and neither this Agreement nor any transactions contemplated by this Agreement will result in any further amounts being payable to any
Worker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.8. Except
as set forth in <U>Schedule 3.9.8</U>, neither the Company nor any of its Subsidiaries has (i) incorporated any Open Source Materials
into, or combined Open Source Materials with, any Customer Deliverables and/or Internal Systems, (ii) distributed Open Source Materials
in connection with any Customer Deliverables and/or Internal Systems, or (iii) used Open Source Materials in any manner that (A) creates,
or purports to create, obligations for the Company or any of its Subsidiaries with respect to software developed or distributed by the
Company or any of its Subsidiaries or (B) grants, or purports to grant, to any third party any rights or immunities under intellectual
property rights. Without limiting the generality of the foregoing, neither the Company nor any of its Subsidiaries has used any Open Source
Materials that require, as a condition of use, modification and/or distribution of such Open Source Materials, that other software incorporated
into, derived from or distributed with such Open Source Materials be (1) disclosed or distributed in source code form, (2) licensed for
the purpose of making derivative works, or (3) redistributable at no charge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.9. Neither
the Company nor any of its Subsidiaries is subject to any agreement with any standards body or other similar entity that would obligate
the Company or any of its Subsidiaries to grant licenses or rights to or otherwise impair its control, enforcement or use of any Intellectual
Property owned or purported to be owned by the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.10. There
is no Order or other prohibition or restriction, issued by a Governmental Entity, on the use, practice or exploitation of any Customer
Deliverables or the Internal Systems in any jurisdiction in which the Company or any of its Subsidiaries currently conducts, has conducted
or currently contemplates conducting business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.11. No
Governmental Entity, university, or other similar educational institution has provided or provides facilities or funding for the creation
or development of any Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries. No Governmental
Entity, university, or other similar educational institution have any rights in or with respect to any Intellectual Property owned or
purported to be owned by the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.12. The
Company and its Subsidiaries have (1) complied in all material respects with its privacy policies and guidelines, related contractual
obligations with customers and all Legal Requirements; and (2) taken all adequate and necessary measures to ensure that its data, including
but not limited to personal information, is protected against loss, damage, and unauthorized access, use, modification, or other misuse.
To the Company&rsquo;s Knowledge, there has been no (i) loss, damage, or unauthorized access, use, transmission, modification, or other
misuse of any such information by the Company or any of its Subsidiaries or any of its employees, or any agents or third parties; or (ii)
unauthorized access to any databases, computers, storage media (e.g., backup tapes), network devices, or other devices that process or
store personal information, whether hosted or operated by the Company or any of its Subsidiaries or any other Person on the Company&rsquo;s
or its Subsidiaries&rsquo; behalf. To the Company&rsquo;s Knowledge, no Person (including any Governmental Authority) has made any claim
or commenced any Action with respect to any alleged loss, damage, or unauthorized access, use, modification, or other misuse of any such
personal information by the Company or its Subsidiaries or any employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.9.13. <U>Schedule
3.9.13</U> sets forth all Intellectual Property owned by the Company and its Subsidiaries that is issued or registered or subject to pending
applications for issuance or registration in the name of the Company or any of its Subsidiaries. To the Company&rsquo;s Knowledge, the
Intellectual Property set forth on <U>Schedule 3.9.13</U> is valid, subsisting and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.10. <U>Assigned
Contracts</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.10.1. <U>Schedule 3.10.1</U> includes each contract included in the Assets and being assigned to and assumed by
Buyer (the &ldquo;<U>Assigned Contracts</U>&rdquo;). The Company has made available to the Buyer an accurate and complete copy of each
Assigned Contract. All Assigned Contracts are valid, binding against the Company or one of its Subsidiaries, as applicable, and in
full force and effect. The Company and its Subsidiaries are not, and, to the Company&rsquo;s Knowledge, no other party is in
material default under, or in material breach or violation of, any Assigned Contract, and (b)&nbsp;to the Company&rsquo;s Knowledge
no event has occurred on or prior to the date hereof (with or without notice, lapse of time or both) would constitute a material
default by the Company or any of its Subsidiaries under any Assigned Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.10.2. The
Assigned Contracts include all customer contracts; contracts with consultants, contracts relating to the Company&rsquo;s technology, products
and services, and IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.10.3. No
Assigned Contracts are Government Contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.11. <U>Transactions
with Affiliates</U>. Except as set forth on <U>Schedule&nbsp;3.11</U>, no Affiliate, officer, manager or director (or the equivalent)
of the Company or any of its Subsidiaries (nor any immediate family member of such Persons or any trust, partnership or company in which
any of such Persons has or has had an interest) has or has had, directly or indirectly, other than with respect to the payment of compensation
to officers, managers and directors (or the equivalent) in the ordinary course of business, (a)&nbsp;any interest in any third party which
furnished or sold, or furnishes or sells, services, products or technology that the Company or any of its Subsidiaries furnishes or sells,
or proposes to furnish or sell, (b)&nbsp;any interest in any third party that purchases from or sells or furnishes to the Company or any
of its Subsidiaries any goods or services or (c)&nbsp;any interest in any contract to which the Company or any of its Subsidiaries is
a party, except that ownership of no more than one percent of the outstanding voting stock of a publicly traded company shall not be deemed
to be an &ldquo;<U>interest in any third party</U>&rdquo; for purposes of this <U>Section 3.11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.12. <U>Litigation</U>.
Except as set forth on <U>Schedule&nbsp;3.12</U>, there is no Action pending or, to the Company&rsquo;s Knowledge, threatened against
the Company or any of its Subsidiaries, or any of their respective assets or property, including any Company Intellectual Property, or
any of their respective officers, managers or directors in their capacities as such. No Governmental Order has been or is outstanding
against the Company or any of its Subsidiaries, any of their respective assets or properties, or any of the Company&rsquo;s or its Subsidiaries&rsquo;
officers, managers or directors in their respective capacities as such. There is no Action pending or, to the Company&rsquo;s Knowledge,
threatened, against any Person who has a contractual right or a right pursuant to the Organizational Documents, other Legal Requirement
to indemnification from the Company related to any Basis existing prior to the Closing Date, nor is there any Basis therefor. There is
no Action pending or, to the Company&rsquo;s Knowledge, threatened based on a claim of breach of fiduciary duty by the Company&rsquo;s
directors or officers arising out of actions taken by the Company&rsquo;s managers, directors or officers prior to the Closing Date, nor
is there any Basis therefor. There is no Action by the Company or any of its Subsidiaries pending, threatened or contemplated against
any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.13. <U>Brokers</U>.
There are no brokerage commissions, finders&rsquo; fees or similar compensation payable in connection with the Contemplated Transactions
based on any arrangement or agreement made by or on behalf of the Company other than fees (if any) that will be paid by the Company and
its Affiliates and for which the Buyer and (after the Closing) the Company will have no responsibility to pay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.14. <U>Customers
and Suppliers</U>. <U>Schedule&nbsp;3.14</U> sets forth a list of the ten (10) largest customers of the Company (measured by aggregate
revenue) and five (5) largest suppliers of the Company (measured by aggregate payments) for the twelve (12) month period ending on the
Reference Balance Sheet Date. Since the Reference Balance Sheet Date, no customer or supplier listed on <U>Schedule&nbsp;3.14</U> has
provided written notice that it intends to cease doing business with or materially decrease the amount of business done with the Company
or materially alter the terms upon which it is willing to do business with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.15. <U>Regulatory
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">3.15.1. The
Company has not classified the items that it produces, designs, tests, manufactures, fabricates, or develops for purposes of U.S. export
controls (including hardware, software, technology). The Company does not produce, design, test, manufacture, fabricate, or develop any
items that are controlled for export under the Export Administration Regulations, 15 CFR Parts 730-744. The Company does not produce,
design, test, manufacture, fabricate, or develop any defense articles, technical data, or services subject to the International Traffic
in Arms Regulations, 22 CFR Parts 120-130. The Company is not registered under the ITAR with the U.S. Department of State&rsquo;s Directorate
of Defense Trade Controls. The Company does not have a facility clearance to do classified work for the U.S. Government. The Company does
not maintain or collect any &ldquo;sensitive personal data&rdquo; as that term is used in 31 CFR &sect; 800.248.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.16. <U>Data
Privacy</U>. In connection with its collection, storage, use and/or disclosure of any information that constitutes &ldquo;personal information,&rdquo;
&ldquo;personal data&rdquo; or &ldquo;personally identifiable information&rdquo; as defined in applicable laws (collectively &ldquo;<U>Personal
Information</U>&rdquo;) by or on behalf of the Company, the Company is and has been, to the Company&rsquo;s Knowledge, in compliance with
(i) all applicable laws (including, without limitation, the Health Insurance Portability and Accountability Act of 1996, as amended, and
laws relating to privacy, data security, telephone and text message communications, and marketing by email or other channels) in all relevant
jurisdictions, and (ii) the Company&rsquo;s privacy policies, by which the Company is bound. The Company maintains and has maintained
reasonable physical, technical, and administrative security measures and policies designed to protect all Personal Information owned,
stored, used, maintained or controlled by or on behalf of the Company from and against unlawful, accidental or unauthorized access, destruction,
loss, use, modification and/or disclosure. The Company is and has been, to the Company&rsquo;s Knowledge, in compliance in all material
respects with all laws relating to data loss, theft and breach of security notification obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.17. <U>Stock
Consideration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) The
Stock Consideration to be acquired by the Company will be acquired for investment for the Company&rsquo;s own account, not as a nominee
or agent, and not with a view to the resale or distribution of any part thereof, and that the Company has no present intention of selling,
granting any participation in, or otherwise distributing the same. Company does not presently have any contract, undertaking, agreement
or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of
the Stock Consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) The
Company understands that the Stock Consideration is &ldquo;restricted securities&rdquo; under applicable U.S. federal and state securities
laws and that, pursuant to these laws, the Company must hold the Stock Consideration for a period of six months until the Stock Consideration
is freely tradeable pursuant to Rule 144 promulgated pursuant to the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company understands that
the Stock Consideration has not been, and will not be, registered under the Securities Act, by reason of a specific exemption from the
registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and
the accuracy of the Company&rsquo;s representations as expressed herein. The Company understands that the Stock Consideration is &ldquo;restricted
securities&rdquo; under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Company must hold the
Stock Consideration for a period of six months until the Stock Consideration is freely tradeable pursuant to Rule 144 promulgated pursuant
to the Securities Act. The Company acknowledges that the Company has no obligation to register the Stock Consideration for resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) The
Company is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) The
Company understands that the Stock Consideration may be notated with one or all of the following legends:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;THE SHARES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN
CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT
OF 1933.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: left; text-indent: 0in">Plus, any legend required
by the securities laws of any state to the extent such laws are applicable to the Stock Consideration represented by the certificate,
instrument, or book entry so legended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">3.18. <U>No
Other Representations and Warranties</U>. Except for the representations and warranties contained in this Section 3 (including the related
portions of the Disclosure Schedules), neither Company nor any other Person has made or makes any other express or implied representation
or warranty, either written or oral, on behalf of the Company, including any representation or warranty as to the accuracy or completeness
of any information regarding the Business and the Assets furnished or made available to Buyer and its Representatives including management
presentations or in any other form in expectation of the Contemplated Transactions or as to the future revenue, profitability or success
of the Business, or any representation or warranty arising from statute or otherwise in law<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">4. Representations
and Warranties of the Buyer.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Buyer and Parent each
represent and warrant, severally, to the Company as of the date hereof and the Closing Date (unless the particular statement speaks expressly
as of a particular date, in which case it is true and correct only as of such date) as follows (in each case, except where context implies
otherwise, with respect to the Company and its Affiliates) as follows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.1. <U>Organization</U>.
The Buyer and Parent are each (a)&nbsp;a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization and (b)&nbsp;duly qualified or licensed to do business and is in good standing in each jurisdiction where the character
of the properties owned, leased or licensed by it or the nature of its business makes such qualification, licensing or good standing necessary,
except where the failure to be so qualified or licensed or in good standing has not had, and would not reasonably be expected to materially
impair or delay the Buyer&rsquo;s ability to consummate the Contemplated Transactions. The Buyer is a wholly-owned subsidiary of the Parent.
Parent is classified as a corporation for United States tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.2. <U>Authorization</U>.
Each of Buyer and the Parent has the corporate power and authority to execute and deliver this Agreement, the Escrow Agreement and the
instruments required to be executed and delivered by it pursuant hereto, to perform its obligations hereunder, to issue the Stock Consideration,
and to consummate the Contemplated Transactions. Each of the Buyer and the Parent has taken all corporate actions or proceedings required
to be taken by or on the part of the Buyer and the Parent to authorize and permit the execution and delivery by the Buyer and the Parent
of this Agreement, the Escrow Agreement and the instruments required to be executed and delivered by it pursuant hereto and the performance
by each of the Buyer and the Parent of its respective obligations hereunder and the consummation by the Buyer and the Parent of the contemplated
transactions, including issuance of the Stock Consideration. This Agreement has been (or in the case of the Escrow Agreement, will be)
duly executed and delivered by each of the Buyer the Parent, and assuming the due authorization, execution and delivery by each of the
other parties hereto or thereto, constitutes (or will constitute) the legal, valid and binding obligation of each of the Buyer and the
Parent, enforceable against the Buyer and the Parent in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.3. <U>No
Violation or Approval; Consents</U>. Except as set forth in <U>Schedule&nbsp;3.3</U>, neither the execution and delivery of or its performance
of its obligations under this Agreement by the Buyer or the Parent nor either of its consummation of the Contemplated Transactions will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">4.3.1. require
any consent, waiver, approval, clearance, permit, order or authorization of or from, or registration, declaration, notice or filing to
or with any Governmental Authority with respect to the Buyer or the Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">4.3.2. not
(1) except as set forth in <U>Schedule 4.3.2</U>, result in a breach of, constitute (with or without due notice or lapse of time or both)
a default under, result in the acceleration of obligations under, create in any Person the right to accelerate, terminate, modify or cancel,
or require any notice, consent or waiver under, any contract, lease, sublease, license, sublicense, franchise, permit, indenture, agreement
or mortgage for borrowed money, instrument of indebtedness, Lien (other than Permitted Liens) or other arrangement to which the Buyer
or the Parent is a party or by which the Buyer or the Parent is bound or to which its assets are subject, or (3) result in the imposition
of any Lien (other than Permitted Liens); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">4.3.3. result
in a material breach or violation of, or material default under, the Organizational Documents of the Buyer or the Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.4. <U>Valid
Issuance of Stock Consideration</U>. The Stock Consideration, when issued and delivered in accordance with the terms and for the consideration
set forth in this Agreement (including upon delivery to the Escrow Agent), will be validly issued and outstanding, fully paid and nonassessable
and free of restrictions on transfer other than restrictions on transfer under this Agreement, applicable state and federal securities
laws and liens or encumbrances created by or imposed by the Company. Assuming the accuracy of the representations of the Company in <U>Section
4</U> of this Agreement, the Stock Consideration will be issued in compliance with all applicable federal and state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.5. <U>Litigation</U>.
There is no Action pending or, to the knowledge of the Buyer and Parent, threatened against the Buyer, the Parent or any of their Affiliates
or any of their properties, asserts or business, that would prevent Buyer from (a)&nbsp;executing and delivering this Agreement, or (b)&nbsp;performing
Buyer&rsquo;s or Parent&rsquo;s obligations pursuant to, or observing any of the terms and provisions of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.6. <U>Brokers</U>.
There are no brokerage commissions, finders&rsquo; fees or similar compensation payable in connection with the Contemplated Transactions
based on any arrangement or agreement made by or on behalf of the Buyer or any of its Affiliates other than fees (if any) that will be
paid by the Buyer or its Affiliates and for which the Company and its Affiliates will have no responsibility to pay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.7 <U>Intended
Tax Treatment</U>. Neither Parent, Buyer nor any of their respective Affiliates has taken or agreed to take any action, and there exists
no fact or circumstance among Parent, Buyer, and their respective Affiliates that is reasonably likely to prevent or impede the consummation
of the transactions contemplated hereby from qualifying as a &ldquo;reorganization&rdquo; within the meaning of Section 368(a)(1)(C) of
the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.8 <U>Buyer;
Stock Consideration</U>. Buyer is a direct, wholly-owned Subsidiary of Parent. The Closing Stock Consideration and the Earnout (if any)
received by the Company consists and will consist solely of Parent&rsquo;s ordinary shares that entitle the holders to vote on Parent&rsquo;s
board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">4.9 <U>Independent
Investigation</U>. Buyer and the Parent have conducted their own independent investigation, review and analysis of the Business and the
Assets, and acknowledge that each has been provided adequate access to the personnel, properties, assets, premises, books and records,
and other documents and data of the Company for such purpose. The Buyer and Parent each acknowledges and agrees that: (a) in making its
decision to enter into this Agreement and to consummate the transactions contemplated hereby, each has relied solely upon its own investigation
and the express representations and warranties of the Company set forth in Section 3 of this Agreement (including related portions of
the Disclosure Schedules); and (b) neither Company nor any other Person has made any representation or warranty as to the Company, the
Business, the Assets or this Agreement, except as expressly set forth in Section 3 of this Agreement (including the related portions of
the Disclosure Schedules).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">5. Conditions
Precedent to the Obligations of the Buyer.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The obligation of the Buyer
to consummate the Closing is subject to the satisfaction or waiver on or prior to the Closing Date of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.1. <U>Representations
and Warranties</U>. (i)&nbsp;The Company Fundamental Representations and the representations set forth in clause (b) of <U>Section 3.6</U>
shall be true and correct in all respects at and as of the date hereof and the Closing Date with the same effect as though made at and
as of such date and (ii)&nbsp;the representations and warranties of the Company in this Agreement and any certificate or other writing
delivered pursuant hereto other than the Company Fundamental Representations shall be true and correct at and as of the date hereof and
the Closing Date with the same effect as though made at and as of such date, except, in the case of this clause&nbsp;(ii), where the failure
to be true and correct would not reasonably be expected to have a Material Adverse Effect (without giving effect to &ldquo;material,&rdquo;
&ldquo;in all material respects,&rdquo; &ldquo;Material Adverse Effect&rdquo; or similar phrases in the representations and warranties
that limit the representations and warranties); <U>provided</U>, <U>however</U>, that, with respect to clauses&nbsp;(i) and (ii) above,
representations and warranties that are made as of a particular date or period will be true and correct (in the manner set forth in clauses&nbsp;(i)
or (ii), as applicable) only as of such date or period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.2. <U>Performance
of Obligations</U>. The Company (including its Subsidiaries) will have complied with and performed in all material respects all covenants
and agreements required by this Agreement to be complied with or performed by the Company (including its Subsidiaries), respectively,
at or prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.3. <U>Compliance
Certificate</U>. The Company will have delivered to the Buyer a certificate dated as of the Closing Date, executed by an officer of the
Company, to the effect that each of the conditions specified above in <U>Sections&nbsp;5.1 and 5.2</U> has been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.4. <U>Injunctions</U>.
No Governmental Authority will have enacted, issued or promulgated any Legal Requirement (whether temporary, preliminary or permanent)
that remains in effect and that enjoins, makes illegal or otherwise prohibits the consummation of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.5. <U>Escrow
Agreement</U>. The Buyer will have received a copy of the Escrow Agreement, duly executed and delivered by the Company and the Escrow
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.6. <U>Personnel</U>.
Michael Averbach and Sergey Fradkov shall have executed employment agreements with the Buyer for a term of not less than one year post-Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.7. <U>Secretary&rsquo;s
Certificate</U>. The Company will have delivered to the Buyer a certificate of the Secretary of the Company, dated as of the Closing Date,
certifying as to and attaching (a) copies of resolutions duly adopted by the Board of Directors or Managers of the Company authorizing
the execution, delivery and performance of this Agreement and the other agreements contemplated hereby, and the consummation of the Contemplated
Transactions, including a certification that such resolutions shall not have been modified or rescinded as of the Closing Date, (b) the
certificate of formation (or equivalent other governing document) of the Company and each of its Subsidiaries certified by the Secretary
of State or similar Governmental Authority in its jurisdiction of organization, (c) the good standing of the Company and its Subsidiaries
in their respective jurisdictions of organization, including copies of good standing certificates (or equivalent documents) issued within
five (5) Business Days of the Closing Date by the Secretary of State or similar Governmental Authority in its jurisdiction of organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.8. <U>Consents</U>.
All actions, approvals, consents and waivers that are listed in <U>Schedule 5.8</U> shall have been taken or obtained, as applicable,
and evidence thereof shall have been delivered by the Company to the Buyer, in each case in a form and substance reasonably acceptable
to the Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.9. <U>Non-competition
Agreements</U>. The Non-competition Agreements shall be in effect and not have been repudiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.10. <U>USARAD
Stock Purchase Agreement</U>. The Stock Purchase Agreement by and among the Buyer, the Parent, USARAD Holding., Inc. and the other parties
named therein, dated as of October 2021, shall have closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5.11. <U>Assets</U>.
The Assets shall be free from any Lien, other than Permitted Liens, and freely transferable other than Permitted Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">6. Conditions
Precedent to Obligations of the Company.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The obligation of the Company
to consummate the Closing is subject to the satisfaction or waiver on or prior to the Closing Date of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.1. <U>Representations
and Warranties</U>. (i)&nbsp;The Buyer Fundamental Representations shall be true and correct in all respects at and as of the date hereof
and the Closing Date with the same effect as though made at and as of such date and (ii)&nbsp;the representations and warranties of the
Buyer and the Parent in this Agreement and any certificate or other writing delivered pursuant hereto other than those set forth in clause&nbsp;(i)
above shall be true and correct at and as of the date hereof and the Closing Date with the same effect as though made at and as of such
date, except, in the case of this clause&nbsp;(ii), where the failure to be true and correct would not reasonably be expected to have
a material adverse effect on the Buyer&rsquo;s ability to consummate the Closing (without giving effect to materiality, material adverse
effect or similar phrases in the representations and warranties that limit such representations and warranties); <U>provided</U>, <U>however</U>,
that, with respect to clauses&nbsp;(i) and (ii) above, representations and warranties that are made as of a particular date or period
will be true and correct (in the manner set forth in clauses&nbsp;(i) or (ii), as applicable) only as of such date or period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.2. <U>Performance
of Obligations</U>. The Buyer will have complied with and performed in all material respects all covenants and agreements required by
this Agreement to be complied with or performed by the Buyer at or prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.3. <U>Compliance
Certificate</U>. The Buyer will have delivered to the Company a certificate of the Buyer dated as of the Closing Date to the effect that
each of the conditions specified above in <U>Sections&nbsp;6.1</U> and <U>6.2</U> has been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.4. <U>Injunctions</U>.
No Governmental Authority will have enacted, issued or promulgated any Legal Requirement or Governmental Order (whether temporary, preliminary
or permanent) that remains in effect and that enjoins, makes illegal or otherwise prohibits the consummation of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.5. <U>Escrow
Agreement</U>. The Company will have received a copy of the Escrow Agreement, duly executed by the Buyer, the Parent and the Escrow Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.6 <U>Secretary&rsquo;s
Certificate of Buyer</U>. The Buyer will have delivered to the Company a certificate of the Secretary of the Buyer, dated as of the Closing
Date, certifying as to and attaching (a) copies of resolutions duly adopted by the Board of Directors or Managers of the Buyer authorizing
the execution, delivery and performance of this Agreement and the other agreements contemplated hereby, and the consummation of the Contemplated
Transactions, and including a certification that such resolutions shall not have been modified or rescinded as of the Closing Date, (b)
the certificate of formation (or equivalent other governing document) of the Buyer and each of its Subsidiaries certified by the Secretary
of State or similar Governmental Authority in its jurisdiction of organization, (c) the good standing of the Buyer in its jurisdiction
of organization, including copies of the good standing certificate (or equivalent documents) issued within five (5) Business Days of the
Closing Date by the Secretary of State or similar Governmental Authority in its jurisdiction of organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">6.7 <U>Secretary&rsquo;s
Certificate of the Parent</U>. The Parent will have delivered to the Company a certificate of the Secretary of the Parent, dated as of
the Closing Date, certifying as to and attaching (a) copies of resolutions duly adopted by the Board of Directors or Managers of the Parent
authorizing the execution, delivery and performance of this Agreement and the other agreements contemplated hereby, and the consummation
of the Contemplated Transactions, including the issuance of the Stock Consideration, and including a certification that such resolutions
shall not have been modified or rescinded as of the Closing Date, (b) the certificate of formation (or equivalent other governing document)
of the Parent certified by the Secretary of State or similar Governmental Authority in its jurisdiction of organization, (c) the good
standing of the Parent in its jurisdiction of organization, including copies of the good standing certificate (or equivalent documents)
issued within five (5) Business Days of the Closing Date by the Secretary of State or similar Governmental Authority in its jurisdiction
of organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">7. Covenants
of the Parties.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.1. <U>Conduct
of Business Prior to Closing</U>. From the date hereof until the Closing, the Company shall conduct its business in the ordinary course
consistent with past practice. Without limiting the generality of the foregoing, from the date hereof until the Closing Date, and except
as (i) expressly contemplated by this Agreement, (ii) required by Legal Requirement, or (iii) otherwise consented to in writing in advance
by Buyer (which consent shall not be unreasonably withheld, conditioned or delayed),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.1.1. the
Company shall, and shall cause its Subsidiaries to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) (A)
pay all of its debts and Taxes when due, except to the extent such debts or Taxes are being contested in good faith by appropriate proceedings,
and for which adequate reserves have been established, (B) pay or perform its other obligations when due, and (C) use commercially reasonable
efforts consistent with past practice to (1) preserve intact its present business organization, (2) keep available the services of its
present officers and key employees, and (3) preserve its relationships with customers, suppliers, licensors, licensees, and others having
business dealings with it;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) notify
Buyer of any change, occurrence or event not in the ordinary course of business of the Company, and of any change, occurrence or event
which, individually or in the aggregate with any other changes, occurrences and events, could reasonably be expected to have a Material
Adverse Effect or which is reasonably likely to cause any of the conditions in <U>Article 5</U> and <U>Article 6</U> not to be satisfied;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.1.2. the
Company shall not, and shall not permit its Subsidiaries to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) adopt
or propose any change in the Organizational Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) merge,
combine or consolidate with any other Person or acquire any amount of assets of any other Person (except for acquisitions of supplies
in the ordinary course of business consistent with past practices), subject to <U>Section 7.3</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(c) settle,
release, assign, or compromise any Action relating to an Asset, whether now pending or hereafter made or brought;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(d) commence
any Action against any Person relating to an Asset other than in such cases where it in good faith determines that failure to commence
an Action would result in the material impairment of a valuable aspect of the Asset, as long as the Company consults with Buyer before
the filing of such Action;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(e) sell,
assign, lease, license, transfer, abandon or otherwise dispose of, or mortgage, pledge or encumber any of the Assets, other than pursuant
to non-exclusive licenses to Company Intellectual Property entered into in the ordinary course of business pursuant to the sale of Company
products or services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(f) (A)
amend or modify in any material respect in a manner adverse to the Company or any of its Subsidiaries, or assign or consent to the termination
of, any contract that is an Assumed Liability, or (B) except for a new contract with a customer or potential customer entered into in
the ordinary course of business, enter into any new agreement which would be considered a material Contract if it had been entered into
prior to the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(g) fail
to maintain insurance in at least such amounts and against at least such risks and losses as are consistent in all material respects with
the Company&rsquo;s current practices, reduce the amount or scope of any coverage provided by existing insurance policies, permit any
existing insurance policy to lapse without being replaced by a commensurate insurance policy or reduce the amount or scope of indemnity
bonds issued at the request or for the benefit of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(h) make
or change any election in respect of Taxes, file any amendment to a Tax Return, enter into any closing agreement in respect of Taxes,
settle any claim or assessment in respect of Taxes, or consent to any extension or waiver of the limitation period applicable to any claim
or assessment in respect of Taxes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(i) make
any change in accounting practices or policies from those utilized in the preparation of the Financial Statements, make any change in
its invoicing practices, write off, write down or make any determination to write off or write down any of its assets; or make any material
change in its credit or allowance practices or policies; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(j) agree or
commit to do any of the foregoing. Notwithstanding the foregoing, the Company shall be permitted, after the date of this Agreement
and prior to Closing, to (x) make all required payments on Indebtedness and (y) utilize unrestricted cash to pay obligations of the
Company in the ordinary course of business prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.2. <U>Confidentiality;
Announcements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.2.1. The
Confidentiality Agreement shall continue in full force and effect in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.2.2. The
parties hereto will not, and will cause their Representatives not to, issue or cause the publication of any press release or other public
announcement or make any disclosure to any Person regarding (a)&nbsp;this Agreement, the Disclosure Schedule, the Contemplated Transactions,
or any discussions, memoranda, letters or agreements related to this Agreement or thereto, including any announcement to customers, suppliers
or other third parties having dealings with the Company, (b)&nbsp;the existence or terms of this Agreement or the Contemplated Transactions;
(c)&nbsp;the existence of discussions and negotiations between or among Buyer, the Company, or any of the respective Representatives of
Buyer or the Company; (d)&nbsp;the consummation of the Contemplated Transactions or (e)&nbsp;information about the business, properties,
financial condition or operations of the other parties hereto, in the case of each of clauses (a)&ndash;(e) without prior approval of
the other parties, except to the extent (x)&nbsp;disclosure is required by a party to its Tax, financial, legal or other professional
advisors or, if applicable, spouse, subject to a duty of confidentiality, for purposes of complying with such Company&rsquo;s Tax obligations
or other reporting obligations under Legal Requirements arising out of the Contemplated Transactions, or (y)&nbsp;disclosure is made by
the Company to its legal counsel, subject to a duty of confidentiality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.2.3. After
the Closing Date, the Company agrees and agrees to cause its Representatives to treat any and all Proprietary Information included in
the Assets as confidential and not disclose or make it available to any Person unless it is or has been:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) obtained
legally and freely from a third party without restriction as to the disclosure of such information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) made
public as required by applicable Legal Requirements; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(c) within
the public domain or later becomes part of the public domain as a result of acts by someone other than the Company or any Representative
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.2.4. To
the extent obliged to treat such Proprietary Information as confidential, the Company shall use the same degree of care as it uses with
regard to its own proprietary information to prevent disclosure, use, or publication of the Proprietary Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.2.5. In
the event that the Company or any of their respective Representatives becomes legally compelled to disclose any such Proprietary Information
other than as permitted by <U>Section&nbsp;7.2.3</U>, the Company shall provide Buyer with prompt written notice of such requirement so
that Buyer may seek a protective order or other remedy or waive compliance with <U>Section&nbsp;7.2.3</U>, and in the event that such
protective order or other remedy is not obtained, or Buyer waives compliance with <U>Section&nbsp;7.2.3</U>, furnish only that portion
of such Proprietary Information that is legally required to be provided and exercise its commercially reasonable efforts to obtain assurances
that confidential treatment will be accorded such Proprietary Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.3. <U>No
Solicitation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.3.1. From
the date hereof until the earlier of the termination of this Agreement pursuant to its terms and the Closing Date, the Company will not
directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) solicit,
initiate, knowingly encourage, facilitate or support any inquiry, proposal or offer with respect to, or the making, announcement, submission
or completion of any Acquisition Transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) participate
or engage in any discussions or negotiations with, or furnish or disclose any non-public information relating to the Company, or otherwise
cooperate with, facilitate or assist any Person in connection with an Acquisition Transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(c) approve,
endorse or recommend any Acquisition Transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(d) enter
into any letter of intent, agreement in principle, merger agreement, acquisition agreement, option agreement or other similar agreement
relating to an Acquisition Transaction; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(e) resolve,
propose or agree to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.3.2. Upon
execution of this Agreement, the Company will, and will cause its Representatives and Affiliates to, immediately cease and cause to be
terminated any existing direct or indirect discussions with any Person (other than Buyer)&nbsp;that relate to or are in respect of an
Acquisition Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.3.3. From
the date hereof until the earlier of the termination of this Agreement pursuant to its terms and the Closing Date, the Company will, and
will cause its Representatives and Affiliates to, promptly (and in no event later than 48&nbsp;hours after receipt thereof) notify Buyer
orally and in writing of any proposal, offer, inquiry or notice concerning an Acquisition Transaction or that would reasonably be expected
to lead to a proposal relating to any Acquisition Transaction, or any request for information from a Person in respect of an Acquisition
Transaction or that would reasonably be expected to lead to a proposal relating to any Acquisition Transaction (including the identity
of the Person making or submitting such proposal, offer or request, the material terms thereof and a copy of any written proposal, offer
or request) that is received by the Company, or any representative thereof. The Company will keep Buyer informed on a reasonably current
basis (and, in any event, within 48&nbsp;hours) of the status and details of any material modifications to any such proposal, offer or
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.4. <U>Preparation
for Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.4.1. Subject
to the terms and conditions hereof, each of the Company, the Buyer and the Parent agrees to use its reasonable best efforts to take, or
cause to be taken, all actions and to do, or cause to be done, all things necessary or desirable under applicable Legal Requirements to
consummate the Contemplated Transactions as promptly as practicable, including preparing and filing as promptly as practicable with the
applicable Governmental Authorities all documentation to effect all necessary filings, notices, petitions, statements, registrations,
submissions of information, applications, approvals and other documents necessary to consummate the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.4.2. Each
of the Company, the Buyer and the Parent will cooperate with one another (a)&nbsp;in determining whether any actions, consents, approvals
or waivers are required to be obtained from third parties, including with respect to any contracts that are an Assumed Liability, in connection
with the consummation of the Contemplated Transactions and (b)&nbsp;in taking such actions, furnishing documents and information required
in connection therewith and seeking to obtain in a timely manner any such actions, consents, approvals or waivers; provided, that (i)
nothing in this Agreement will obligate or be construed to obligate the Company to make or cause to be made any payment or concession
to any third party in order to obtain any such action, consent, approval or waiver under any Assigned Contract and (ii) the obtaining
of any such action, consent, approval or waiver shall not be a condition to any party&rsquo;s obligation to consummate the Closing, except
as provided in <U>Section 5.8.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.5. <U>Tax
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.5.1. <U>Transfer
Taxes</U>. The Buyer shall bear Liability for all Transfer Taxes in connection with the Contemplated Transactions, and shall file all
necessary Tax Returns and other documentation with respect to such Transfer Taxes. If required by applicable Law, the Company will join
in the execution of and/or file any such Tax Returns and other documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">7.5.2. <U>Forms
W-9 or W-8</U>. In connection with the requirements under the Escrow Agreement, prior to Closing, the Company will provide to Buyer and
the Escrow Agent completed and executed Internal Revenue Service Form W-9 or Form W-8, as applicable. Notwithstanding anything herein
to the contrary, the failure of the Company to provide a completed W-9 or W-8, if applicable, shall entitle the Escrow Agent and Buyer
to withhold any payments to be made to the Company until the completed W-9 or W-8 is provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.6. <U>Notification</U>.
From the date hereof until the Closing Date, the Company may disclose to the Buyer in writing (in the form of updated Disclosure Schedules)
(the &ldquo;<U>Schedules Notice</U>&rdquo;) any development, fact or circumstance, solely to the extent arising after the date hereof,
causing a breach of any of the representations and warranties contained in <U>Section&nbsp;3</U> hereof. Such Schedules Notice shall amend
and supplement the appropriate Disclosure Schedules delivered on the date hereof and attached hereto; <U>provided</U> that (A) if the
condition set forth in <U>Section&nbsp;5.1</U> would not be satisfied if the Disclosure Schedule were not so amended and supplemented,
then the Buyer will have the right to terminate this Agreement by providing written notice of such termination to the Company, and (B)
no information or Schedules Notice provided under this <U>Section 7.6</U> will, or will be deemed to, limit or modify or otherwise affect
any representation or warranty contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.7. <U>Share
Lock-Up and Sale Restrictions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) The
Company shall be subject to the minimum lock-up and resale restrictions, according to Nasdaq rules and regulations and applicable U.S.
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) The
Company shall not use any non-public information of Buyer or the Parent which has been received in connection with this Agreement to purchase,
sell, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer, dispose of any securities of the Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) The
Buyer and the Parent shall undertake the actions required to (i) cause the Parent to comply with all reporting requirements of the Securities
Exchange Act of 1934 and any other requirements in order for the Stock Consideration to become freely tradeable pursuant to Rule 144 promulgated
pursuant to the Securities Act and (ii) cause the transfer agent of the Parent&rsquo;s stock to remove the restricted stock legend on
the Stock Consideration so that the Stock Consideration becomes freely tradeable by the Company at such time as permitted under Rule 144.
The Buyer and the Parent shall bear all the costs related to the requirements of this Section 7.7(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.8. <U>SBA
Loan</U>. Company agrees that within six months following the Closing, it (i) will replace the collateral on the lien in favor of the
SBA (including through amendment or repayment in full of the relevant loan and security agreements), with collateral that is not an Asset
or Assigned Contract and (ii) will ensure that the existing UCC-1 filed by the SBA with the State of New York showing the Company as Debtor
is terminated or amended to remove as collateral all Assets or Assigned Contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.9. <U>Further
Assurances</U>. Each of the Company, the Buyer and the Parent, upon the request of the other from time to time after the Closing, and
at the expense of the requesting party but without further consideration, shall sign such documents and take such actions as may be necessary
or otherwise reasonably requested to effect, or make more fully effective, the consummation of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7.9 <U>Dividends;
Voting Rights</U>. In respect of the portion of the Closing Stock Consideration consisting of the Escrow Amount (such portion, the &ldquo;<U>Escrowed
Shares</U>&rdquo;), each of the Company, Buyer and Parent covenants and agrees that, at all times while the Escrowed Shares are held by
the Escrow Agent (a) all dividends declared on the Escrowed Shares shall be distributed currently to the Company (or its designee(s));
and (b) all voting rights in respect of the Escrowed Shares shall be exercisable by or on behalf of the Company (or its designee(s)).
Upon any Escrow Shares being returned to Parent in accordance with this Agreement and the Escrow Agreement, respectively, neither the
Company nor any of its designees, shareholders, successors, or assigns shall have any further rights in respect of such Escrow Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">8. Indemnification</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.1. <U>Survival</U>.
Except as set forth in this <U>Section <FONT STYLE="font-size: 10pt">&lrm; 8.1</FONT></U>, the representations and warranties of the parties
contained in this Agreement or in the certificate delivered pursuant to <U>Section 5.3</U> or <U>Section&nbsp;6.3</U>, and the covenants
and agreements of the parties hereto to the extent they, by their terms, contemplate or provide for performance prior to the Closing,
shall survive the Closing until the date that is twelve (12) months after the Closing Date (the &ldquo;<U>Escrow Termination Date</U>&rdquo;),
except that the Company Fundamental Representations and the Buyer Fundamental Representations shall survive the Closing until the sixth
(6<SUP>th</SUP>) anniversary of the Closing Date. The other covenants and agreements of the parties contained in this Agreement, or in
any certificate or other writing delivered pursuant hereto or in connection herewith, shall survive the Closing in accordance with their
terms. If an Indemnified Party delivers, before the expiration of the applicable survival period described in this <U>Section 8.1</U>,
a Claim Notice to the Indemnifying Party asserting a Liability Claim for a breach of a representation or warranty or covenant or agreement
made by or on behalf of the Indemnifying Party in or pursuant to this Agreement, then the representation, warranty or covenant will survive
the expiration of the applicable survival period described in this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8.1</U> and remain
in full force and effect with respect to such Liability Claim until the final resolution thereof. No Liability Claim may be made seeking
indemnification for breaches of any representations, warranties, covenants or agreements pursuant to this <U>Section&nbsp;8</U> unless
a Claim Notice in respect of such Liability Claim is provided to the applicable Indemnifying Party in accordance with this <U>Section&nbsp;8</U>
prior to the expiration of the applicable survival period described in this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.2. <U>Indemnity
by the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.2.1. From
and after the Closing, subject to the provisions of this <U>Section&nbsp;8</U>, the Company shall indemnify the Buyer and each of its
Affiliates and each of their respective Representatives, successors and assigns (collectively, the &ldquo;<U>Buyer Indemnified Parties</U>&rdquo;)
and hold them harmless from and against any and all Losses suffered or incurred by the Buyer Indemnified Parties to the extent arising
from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) any
breach of any of the representations and warranties of the Company in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3</U> as of
the date hereof or as of the Closing Date as if such representation and warranty were made on such date (unless the representation or
warranty states that it is made only as of a specified date, in which case, as of the specified date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) any
breach, or any failure to perform, any covenant or agreement in this Agreement (or in any certificate or other writing delivered by or
on behalf of the Company pursuant hereto) that is required by its terms to be complied with or performed by the Company or any of its
Subsidiaries prior to or at the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(c) any
amount by which the Post-Closing Reduction Amount exceeds the Escrow Amount, which shall be compensated in accordance with the terms of
Section 2.7.5(a) hereof; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(d) defending
any Third-Party Claim alleging the occurrence of facts or circumstances that, if true, regardless of the outcome of such defense, would
entitle a Buyer Indemnified Party to indemnification pursuant to the other provisions of this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.2.2. <U>Limitations
on Indemnification by Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) Except
with respect to any claims for indemnification for breach of any Company Fundamental Representation or fraud, the Buyer Indemnified Parties
will not be entitled to indemnification under <U>Section 8.2.1(a)</U>&nbsp;or <U>Section 8.2.1(d)</U> unless and until (i) with respect
to any individual item of Loss, such item is greater than $50,000 or until the aggregate items of Loss are greater than $75,000 (any individual
items of Loss that are less than or equal to $50,000 or aggregate items of Loss less than or equal to than $75,000 being &ldquo;<U>Minor
Claims</U>&rdquo;) and (ii) the item of Loss is in excess of the remaining Escrow Amount, <U>provided</U>, <U>however</U>, that the Buyer
shall also be entitled to set off and holdback any Losses that are reasonably determined by the mutual agreement of the Buyer and the
Company, with the agreement of MDW not to be unreasonably withheld or delayed, to be indemnifiable Losses from any Earn Out that Buyer
would otherwise be obligated to pay under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) The
maximum aggregate amount of indemnifiable Losses that may be recovered by the Buyer Indemnified Parties from the Company <FONT STYLE="background-color: yellow"><B></B></FONT>shall be equal to the Purchase Price, <U>provided</U>, <U>however</U>, that the Buyer shall also
be entitled to set off and holdback any Losses that are reasonably determined by the mutual agreement of the Buyer and the Company, with
the agreement of MDW not to be unreasonably withheld or delayed, to be indemnifiable Losses from any Earn Out that Buyer would otherwise
be obligated to pay under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.2.3. Notwithstanding
anything to the contrary contained in this Agreement (including the foregoing limitations and <U>Section 8.12</U>), nothing in this Agreement
will (a) prevent any Buyer Indemnified Party from bringing any Action based upon the fraud or willful misconduct of any Person, or (b)
limit the Losses recoverable by a Buyer Indemnified Party for an Action based upon fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.3. <U>Indemnity
by the Buyer and the Parent</U>. From and after the Closing, subject to the provisions of this <U>Section&nbsp;8</U>, the Buyer and the
Parent shall jointly and severally indemnify the Company and each of its Affiliates and each of their respective Representatives, successors
and assigns (collectively, the &ldquo;<U>Company Indemnified Parties</U>&rdquo;) and hold them harmless from and against any and all Losses
suffered or incurred by the Company Indemnified Parties to the extent arising from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) any
breach of any of the representations and warranties of the Buyer or the Parent in <U>Section 4</U> as of the date hereof or as of the
Closing Date as if such representation and warranty were made on such date (unless the representation or warranty states that it is made
only as of a specified date, in which case, as of the specified date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) any
breach, or any failure to perform, any covenant or agreement in this Agreement (or in any certificate or other writing delivered by or
on behalf of the Buyer pursuant hereto) that is required by its terms to be complied with or performed by the Buyer or any of its Affiliates
prior to or at the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(c) any
amount owed by Buyer to the Company (i) pursuant to Section 2.7.5(b) and (ii) with respect to any Transfer Taxes for which the Buyer is
responsible in accordance with Section &lrm;7.5.1.1; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(d) defending
any Third-Party Claim alleging the occurrence of facts or circumstances that, if true, regardless of the outcome of such defense, would
entitle a Company Indemnified Party to indemnification pursuant to the other provisions of this <U>Section 8.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.4. <U>Notification
of Certain Claims</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.4.1. If
an Indemnified Party desires to make a Liability Claim, then the Buyer (if such Indemnified Party is a Buyer Indemnified Party) or the
Company (if such Indemnified Party is a Company Indemnified Party), as the case may be, will deliver to the Company or Buyer, respectively,
a notice (any such notice delivered in accordance with the provisions of this <FONT STYLE="font-size: 10pt">&lrm;</FONT><U>Section <FONT STYLE="font-size: 10pt">&lrm;
8.4.1</FONT></U>, a &ldquo;<U>Claim Notice</U>&rdquo;): (i) describing the Liability Claim in reasonable detail (based upon the information
then possessed by the Buyer or the Company, as the case may be); and (ii) indicating the amount (estimated, if necessary and to the extent
feasible) of the Loss that has been or may be paid, suffered, sustained or accrued by the Indemnified Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.4.2. No
delay or failure in providing such Claim Notice will affect an Indemnified Party&rsquo;s rights or remedies or an Indemnifying Party&rsquo;s
obligations hereunder except to the extent that the Indemnifying Party is materially and adversely prejudiced thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.4.3. If
the Escrow Funds are available to satisfy the recovery of the claim asserted in such Claim Notice and have not been fully released from
the Escrow Account, at the time of delivery of any Claim Notice to the Company, a duplicate copy of such Claim Notice shall be delivered
to the Escrow Agent by or on behalf of the Buyer (on behalf of itself or any other Buyer Indemnified Party).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.4.4. If
the Company or the Buyer, as the case may be, in good faith objects to any claim made in any Claim Notice, then the Company or the Buyer,
as the case may be, shall deliver a written notice (a &ldquo;<U>Claim Dispute Notice</U>&rdquo;) to the Buyer or the Company, as the case
may be, during the 30-day period commencing upon receipt by the Company or Buyer, as the case may be, of the Claim Notice. The Claim Dispute
Notice will set forth in reasonable detail the principal basis for the dispute of any claim made in the applicable Claim Notice. If the
Company or the Buyer, as the case may be, does not deliver a Claim Dispute Notice hereunder prior to the expiration of such 30-day period,
then such claim for indemnification set forth in such Claim Notice shall be deemed to have been conclusively determined in favor of the
Indemnified Party that delivered the Claim Notice for purposes of this <U>Section <FONT STYLE="font-size: 10pt">&lrm; 8</FONT></U> on
the terms set forth in the Claim Notice and the applicable Indemnified Party will be indemnified for the amount of Losses set forth in
the Claim Notice pursuant to this <U>Section <FONT STYLE="font-size: 10pt">&lrm;&lrm; 8</FONT></U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.4.5. If
a Claim Dispute Notice is properly delivered hereunder, then the Buyer and the Company will attempt in good faith to resolve any such
objections raised in such Claim Dispute Notice. If the Buyer and the Company agree to a resolution of such objection, then a memorandum
setting forth the matters conclusively determined by Buyer and the Company will be prepared and signed by both parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.4.6. If
no such resolution can be reached during the 45-day period following receipt of a given Claim Dispute Notice hereunder, then upon the
expiration of such 45-day period, either the Buyer or the Company may bring suit to resolve the objection in accordance with <FONT STYLE="font-size: 10pt">&lrm;</FONT><U>Section
<FONT STYLE="font-size: 10pt">&lrm; 10.9</FONT>.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.4.7. The
Buyer is the sole and exclusive Person authorized to act for, bring Liability Claims on behalf of, or deliver a Dispute Notice on behalf
of, the Buyer Indemnified Parties under this Agreement, and the Company is the sole and exclusive Person authorized to act for, bring
Liability Claims on behalf of, or deliver a Claim Dispute Notice on behalf of, the Company Indemnified Parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.5. <U>Calculation
of Losses</U>. For purposes of determining the amount of any Losses subject to indemnification under this <U>Section&nbsp;8</U> (except
for indemnification pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8.2.1(c)</U> or <U>Section 8.3(c)</U>), the amount
of such Losses will be determined net of (a)&nbsp;any amounts taken into account as liabilities or reserves in the calculation of the
Final Working Capital Amount or any other adjustments to the Purchase Price set forth in <U>Section&nbsp;2.77</U>, and (b)&nbsp;the sum
of any amounts recovered under insurance policies providing coverage for such Losses (the &ldquo;<U>Insurance Policies</U>&rdquo;), net
of any actual out-of-pocket expenses incurred in collecting such amounts (&ldquo;<U>Insurance Proceeds</U>&rdquo;). In the event that
any Insurance Proceeds are received after payment for the related indemnification claim has been made pursuant to this <U>Section&nbsp;8</U>,
then the Indemnified Party shall pay to the Company or the Buyer, as the case may be, an amount equal to the amount of the reduction in
Losses that would have been applied pursuant to the first sentence of this <U>Section&nbsp;8.5</U> had such Insurance Proceeds been received
at the time such indemnification claim was made. Each Indemnified Party shall use commercially reasonable efforts to make claims under
its applicable Insurance Policies. Notwithstanding anything herein to the contrary, no disputed matter that would result in a breach of
a representation, warranty, covenant or agreement herein that is the subject of a Liability Claim made pursuant to this <U>Section&nbsp;8</U>
shall be raised to support any adjustment to Purchase Price pursuant to the terms of <U>Section&nbsp;2.7</U> in a manner that would circumvent
the monetary limitations set forth in this <U>Section&nbsp;8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.6. <U>Matters
Involving Third Parties</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.6.1. If
an Indemnified Party receives written notice of any Action that has been or may be brought or asserted by a third party against such Indemnified
Party and that may give rise to a Liability Claim under this <U>Section <FONT STYLE="font-size: 10pt">&lrm;&lrm;</FONT>8</U> (each, a
&ldquo;<U>Third-Party Claim</U>&rdquo;), such Indemnified Party will, promptly after receipt of notice of any such Third-Party Claim,
notify the Company of such Third-Party Claim where the Buyer Indemnified Party is the subject of the Third-Party Claim and notify the
Buyer where a Company Indemnified Party is the subject of the Third-Party Claim, in each case by the delivery of a notice regarding the
same, which shall be deemed a Claim Notice. The failure of an Indemnified Party to so notify the Indemnifying Party of the commencement
of any such Third-Party Claim will not limit any party&rsquo;s rights or relieve any party from Liability in connection therewith, except
to the extent that such failure materially and adversely affects the ability of the Indemnifying Party to defend its interests in such
Third-Party Claim (to the extent such Indemnifying Party has such right under this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.6.2. In
the event of any Third-Party Claim, the Indemnifying Party, upon written notice to the Indemnified Party, will have the right in its sole
discretion to assume and control the defense of any such Third-Party Claim; provided that the Indemnified Party and its counsel (at the
Indemnified Party&rsquo;s sole expense) may participate in (but not control the conduct of) the defense of such Claim unless such participation
would adversely affect any privilege of the Indemnified Party in respect of such Third-Party Claim. The Indemnifying Party will have the
right, in its sole discretion, to settle any Third-Party Claim, but no settlement of any such Third-Party Claim with third party claimants
will be determinative of the amount of Losses relating to such matter unless the Indemnified Party consents to such settlement. In the
event that the Indemnified Party has consented to any such settlement, the Indemnified Party will have no power or authority to object
under any provision of this <FONT STYLE="font-size: 10pt">&lrm;</FONT><U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8</U> to the
amount of Losses with respect to such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.6.3. If
the Indemnifying Party does not elect to control the defense of a Third-Party Claim in accordance with <FONT STYLE="font-size: 10pt">&lrm;</FONT><U>Section
8.6.2</U>, the Indemnified Party will assume control of the defense of the Third-Party Claim with counsel reasonably satisfactory to the
Indemnifying Party. In such event, the Indemnifying Party will be given the opportunity to participate at its own cost in, but not direct
or conduct, any defense of such Third-Party Claim, unless such participation would adversely affect any privilege of the Indemnified Party
in respect of such Third-Party Claim. The Indemnified Party will not settle any such Third-Party Claim without the consent of the Indemnifying
Party unless such settlement (i) provides solely for the payment of money in an amount that is less than the remaining Escrow Funds that
are not subject to any other Liability Claim, (ii) provides for a full release of the Indemnifying Party involved in such Third-Party
Claim and (iii) does not involve any admission by any Indemnifying Party of breach, violation or wrongdoing or involve any future covenants
of an Indemnifying Party, other than covenants of confidentiality relating to the terms of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.6.4. If
requested by the Buyer or the Company, as applicable, the other party will enter into a separate confidentiality or joint defense agreement
prior to participating in the defense of any Third-Party Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.6.5. The
party controlling the defense of a Third-Party Claim will (i) keep the non-controlling party reasonably advised of the status of such
Third-Party Claim and the defense thereof and will consider in good faith recommendations made by the non-controlling party with respect
thereto and (ii) make available to the non-controlling party any documents or materials in its possession or control that may be necessary
to understand the defense of such claim (subject to confidentiality obligations and the protection of the attorney-client privilege).
The non-controlling party will furnish the controlling party with such information as it may have with respect to such Third-Party Claim
(including copies of any summons, complaints or other proceedings which may have been served on such party and any written claim, demand,
invoice, billing or other document evidencing or asserting the same) and will otherwise reasonably cooperate with and assist the controlling
party in the defense of such Third-Party Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.7. <U>Materiality</U>.
For purposes of this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8</U>, and the determination of whether any representation,
warranty, covenant or agreement of a Person under this Agreement has been breached, and the calculation of any Losses suffered by the
other Person on account of such breach hereunder, each such representation, warranty, covenant or agreement qualified by words or phrases
such as &ldquo;material,&rdquo; &ldquo;in all material respects&rdquo; or &ldquo;Material Adverse Effect&rdquo; or any similar term shall
be read as if such qualification did not exist, except for <U>Section 3.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.8. <U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.9. <U>Investigation</U>.
The right to indemnification or any other remedy based on representations, warranties, covenants and agreements in this Agreement, or
any other document, certificate or other instrument required to be executed or delivered by any party under this Agreement will not be
affected by any investigation conducted (or capable of being conducted) by any Buyer Indemnified Party, Company Indemnified Party or any
other Person at any time, or any knowledge acquired (or capable of being acquired) by any Buyer Indemnified Party, Company Indemnified
Party or any other Person at any time, whether before or after the execution and delivery of this Agreement or the Closing, with respect
to the accuracy or inaccuracy of, or compliance with, any such representation, warranty, covenant or agreement, provided, however, that
the foregoing provision in no way affects the determination as to whether a breach occurred giving rise to an indemnification claim hereunder.
The waiver of any condition to Closing based upon the accuracy of any representation or warranty, or on the performance of or compliance
with any covenant or agreement, will not affect the right to indemnification or other remedy based on such representations, warranties,
covenants and agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.10. <U>Escrow</U>.
Escrow Amount shall be held by the Escrow Agent in the Escrow Account until released in accordance with <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>2.7</U>
and this <U>Section&nbsp;8</U> and the Escrow Agreement. From and after the Closing, the Escrow Amount will be available to compensate
the Buyer Indemnified Parties for Losses in accordance with this <U>Section&nbsp;8</U> and the Escrow Agreement. The Escrow Agreement
shall provide that following the Escrow Termination Date, the Escrow Agent shall release to the Company the remainder of the Escrow Funds,
other than such portion of the Escrow Funds as may be reasonably necessary as determined by the mutual agreement of the Buyer and the
Company, with the agreement of MDW not to be unreasonably withheld or delayed, to satisfy any unresolved or unsatisfied Liability Claims
specified in any Claim Notice delivered by the Buyer to the Company before the Escrow Termination Date (which will remain in the Escrow
Account, until such claims have been resolved or satisfied). In the event of a conflict between the Escrow Agreement and this Agreement,
the terms of this Agreement shall govern. The fees, costs and expenses of the Escrow Agent shall be paid 100% by the Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.11. <U>Intentionally
Omitted</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.12. <U>Acknowledgement
by the Buyer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.7pt; text-align: left">THE REPRESENTATIONS AND WARRANTIES
BY THE COMPANY SET FORTH IN <U>SECTION 3</U> OF THIS AGREEMENT CONSTITUTE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES OF THE
COMPANY TO THE BUYER IN CONNECTION WITH THIS AGREEMENT OR THE CONTEMPLATED TRANSACTIONS, WHETHER IN WRITING, ORALLY OR OTHERWISE, AND
THE BUYER UNDERSTANDS, ACKNOWLEDGES AND AGREES THAT ALL OTHER REPRESENTATIONS AND WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED
(INCLUDING ANY RELATING TO THE FUTURE OR HISTORICAL FINANCIAL CONDITION, RESULTS OF OPERATIONS, ASSETS OR LIABILITIES OF THE COMPANY OR
THE ACCURACY AND COMPLETENESS OF ANY INFORMATION SUPPLIED RELATING TO THE COMPANY), ARE SPECIFICALLY DISCLAIMED BY THE COMPANY AND ARE
NOT BEING RELIED UPON BY THE BUYER OR ANY OF ITS REPRESENTATIVES OR AFFILIATES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.13. <U>Manner
of Payment</U>. The Buyer Indemnified Party&rsquo;s right under this Agreement to recover Losses arising out of the matters set forth
in <U>Section 8.2.1</U>, subject in each case to the limitations in this <U>Section&nbsp;8</U>, will be from the following sources:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.13.1. For
Losses under <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8.2.1(a)</U>, from the Escrow Funds, subject to <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>8.13.2</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.13.2. For
Losses under <U>Section 8.2.1(a)</U> arising from breaches of representations and warranties of the Company that constitute Company Fundamental
Representations,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(a) first,
from the Escrow Funds;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(b) second,
from the Earn Out; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">(c) third,
directly from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">8.13.3. For
Losses under <U>Sections 8.2.1(b)</U> &ndash; <U>(d)<FONT STYLE="font-size: 10pt">&lrm;</FONT></U>, inclusive, first from the Escrow Funds,
and, to the extent such Losses exceed the difference of the Escrow Funds minus any amounts that are subject to Liability Claims submitted
by Buyer, second from the earn Out, and third directly from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8.14. <U>Payment
Process</U>. Any indemnification payment to be made by an Indemnifying Party pursuant to this <U>Section&nbsp;8</U> will be effected,
as applicable, either by (i) release of stock by the Escrow Agent in accordance with the terms hereof and the Escrow Agreement or (ii)
wire transfer of immediately available funds from the Indemnifying Party to the account designated by the Buyer or the Company (on behalf
of the Buyer Indemnified Parties or the Company Indemnified Parties, respectively) within five (5) Business Days after such Losses have
been determined by (a)&nbsp;a final, non-appealable order or judgment of a court of competent jurisdiction or (b)&nbsp;a written, executed
agreement between the Buyer and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">9. Termination.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">9.1. <U>Termination</U>.
The parties may not terminate this Agreement other than as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">9.1.1. This
Agreement may be terminated at any time prior to the Closing by mutual written consent of the Buyer and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">9.1.2. The
Buyer may terminate this Agreement by delivering written notice to the Company at any time prior to the Closing in the event (a)&nbsp;the
Company is in material breach of any covenant, representation or warranty contained in this Agreement, (b)&nbsp;the Buyer has notified
the Company of the breach in writing, (c)&nbsp;such breach would result in, or would be reasonably be expected to result in, the failure
of any condition set forth in <U>Section&nbsp;5</U> and (d)&nbsp;such breach is incapable of cure or has continued without cure for a
period of thirty (30) days after delivery of such notice of breach; <U>provided</U>, <U>however</U>, that the Buyer shall not have the
right to terminate this Agreement pursuant to this <U>Section&nbsp;9.1.2</U> if the Buyer is then in material breach of this Agreement
so as to cause any of the conditions set forth in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>6</U> to not be satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">9.1.3. The
Company may terminate this Agreement by the Company delivering written notice to the Buyer at any time prior to the Closing in the event
(a)&nbsp;the Buyer is in material breach of any covenant, representation or warranty contained in this Agreement, (b)&nbsp;the Company
has notified the Buyer of the breach in writing, (c)&nbsp;such breach would result in, or would be reasonably be expected to result in,
the failure of any condition set forth in <U>Section&nbsp;6</U> and (d)&nbsp;such breach is incapable of cure or has continued without
cure for a period of thirty (30) days after delivery of such notice of breach; <U>provided</U>, <U>however</U>, that the Company shall
not have the right to terminate this Agreement pursuant to this <U>Section&nbsp;9.1.3</U> if the Company is then in material breach of
this Agreement so as to cause the conditions set forth in <U>Section 5</U> to not be satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">9.1.4. The
Buyer, on the one hand, or the Company, on the other hand, may terminate this Agreement by providing written notice to the other at any
time on or after December 1, 2021 (the &ldquo;<U>Expiration Date</U>&rdquo;), if the Closing shall not have occurred by the Expiration
Date; <U>provided</U>, that neither party shall have the right to terminate this Agreement pursuant to this <U>Section&nbsp;9.1.4</U>
if that party&rsquo;s breach of any provision of this Agreement has caused or resulted in the failure of the Closing to be consummated
by the Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">9.1.5. Either
the Buyer, on the one hand, or the Company, on the other hand, may terminate this Agreement by delivering written notice to the other
if any Governmental Authority issues a Governmental Order permanently enjoining, restraining or otherwise prohibiting the Contemplated
Transactions and such Governmental Order shall have become final and non-appealable; <U>provided</U>, that the Person seeking to terminate
pursuant to this <U>Section&nbsp;9.1.5</U> has not breached its obligations under <U>Section&nbsp;7.3</U> so as to cause the issuance
of such Governmental Order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">9.1.6. The
Company may terminate this Agreement, with no need to allow any additional cure period, by the Company delivering written notice to the
Buyer at any time prior to the Closing in the event that the conditions set forth in <U>Section&nbsp;5</U> have been satisfied (other
than those conditions that by their nature are to be satisfied at the Closing), the Company has confirmed that the Company is prepared
to consummate the Closing and the Buyer fails to complete the Closing on the date the Closing should have occurred pursuant to <U>Section
2.5</U> (a &ldquo;<U>Buyer Failure to Close</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">9.1.7. The
Buyer may terminate this Agreement, with no need to allow any additional cure period, by delivering written notice to the Company at any
time prior to the Closing in the event that the conditions set forth in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>6</U> have
been satisfied (other than those conditions that by their nature are to be satisfied at the Closing), the Buyer has confirmed that it
is prepared to consummate the Closing and the Company fails to complete the Closing on the date the Closing should have occurred pursuant
to <U>Section 2.5</U> (a &ldquo;<U>Company Failure to Close</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">Notwithstanding anything to
the contrary in this Agreement, (i) the Buyer may not terminate this Agreement following any Buyer Failure to Close and (ii) the Company
may not terminate this Agreement following any Company Failure to Close. The party seeking to terminate this Agreement pursuant to <U>Sections&nbsp;9.1.2</U>,
<U>9.1.3</U>, <U>9.1.4</U>, <U>9.1.5 9.1.6</U> or 9.1.7 will give written notice of such termination to the other parties, including a
brief description of the basis on which such party is terminating this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">9.2. </FONT><U>Effect
of Termination</U>. If this Agreement is terminated pursuant to <U>Section&nbsp;9.1</U>, all rights and obligations of the parties hereunder
will terminate without any liability of any party or any Affiliate thereof; <U>provided</U>, <U>however</U>, that (a)&nbsp;the rights
and obligations of the parties under <U>Section&nbsp;7.2</U> (Confidentiality; Announcements), <U>Section&nbsp;8.12</U> (Acknowledgement
by the Buyer), this <U>Section&nbsp;9.2</U> (Effect of Termination), <U>Section&nbsp;1</U> (Definitions) and <U>Section&nbsp;10</U> (Miscellaneous),
and the Confidentiality Agreement, will, in each case, survive termination of this Agreement and remain valid and binding obligations
of the parties, and (b)&nbsp;nothing herein will relieve any party to this Agreement from liability (i)&nbsp;pursuant to the sections
specified in this <U>Section&nbsp;9.2</U> that survive such termination, (ii)&nbsp;subject to <U>Section&nbsp;8.12</U>, for fraud or (iii)&nbsp;for
any breach of any covenant or agreement contained herein occurring prior to such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">10. Miscellaneous.</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.1. <U>Notices</U>.
All notices, requests, demands, claims and other communications required or permitted hereunder will be in writing and will be sent by
personal delivery, nationally recognized overnight courier, facsimile or by e-mail (as a PDF). Any notice, request, demand, claim, or
other communication required or permitted hereunder will be deemed duly given, as applicable, (a)&nbsp;upon personal delivery, (b)&nbsp;on
the date that delivery is confirmed in the courier&rsquo;s systems when sent by courier delivery or (c)&nbsp;upon confirmation of receipt
when sent by facsimile or e-mail (as a PDF), addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to the Buyer or to the Parent to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nano-X Imaging, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6050 Braemoor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bloomfield Hills, MI 48301</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: jim.d@nanox.vision</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: James Dara</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">with a copy to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Crowell &amp; Moring, LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1001 Pennsylvania Ave., NW</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, DC 20004</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Facsimile number: (202) 628-5116</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: mkass@crowell.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Mark A. Kass</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to the Company to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">MDWeb LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">29 Cormorant Drive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hampton Bays, NY 11946<BR>
    Email: mja@mdw.io<BR>
    Attention: Michael Averbach</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">with a copy to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Joshpe Mooney Paltzik LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1407 Broadway, Suite 4002</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10018</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: mmooney@jmpllp.com<BR>
    Attention: Michael Mooney</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Any party may change the address to which notices,
requests, demands, claims, and other communications required or permitted hereunder are to be delivered by providing to the other parties
notice in the manner herein set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.2. <U>Expenses
of Transaction</U>. Whether or not the Contemplated Transactions are consummated, except as otherwise specifically provided for in this
Agreement, each of the parties hereto will assume and bear all expenses, costs and fees (including legal and accounting fees and expenses)
incurred by such party in connection with the preparation, negotiation and execution and performance of this Agreement and the Escrow
Agreement and the consummation of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.3. <U>Entire
Agreement</U>. The agreement of the parties that is comprised of this Agreement (including all Schedules and Exhibits hereto) and the
Escrow Agreement sets forth the entire agreement and understanding between the parties and their respective Affiliates with respect to
the subject matter thereof and supersedes any and all prior agreements, understandings, negotiations and communications (other than the
Confidentiality Agreement), whether oral or written, relating to the subject matter of this Agreement or the Escrow Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.4. <U>Severability</U>.
If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or under public
policy, all other conditions and provisions of this Agreement will nevertheless remain in full force and effect so long as the economic
and legal substance of the Contemplated Transactions are not affected in any manner adverse to any party. Upon such determination that
any term or other provision is invalid, illegal or incapable of being enforced, the Company and the Buyer will negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties as closely as possible to the end that the Contemplated Transactions
are fulfilled in accordance with the terms hereof to the greatest extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.5. <U>Amendment</U>.
This Agreement may be amended or modified, but only by an instrument in writing executed by each of the Buyer and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.6. <U>Parties
in Interest</U>. This Agreement will be binding upon and inure solely to the benefit of the parties hereto, and except as provided in
<U>Sections 8</U>, and <U>10.16</U>, nothing in this Agreement, express or implied, is intended to or will be construed to or will confer
upon any other Person any right, claim, cause of action, benefit or remedy of any nature whatsoever under or by reason of this Agreement,
including by way of subrogation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.7. <U>Assignment</U>.
This Agreement will be binding upon and inure to the benefit of and be enforceable by the successors and permissible assigns of the parties
hereto. This Agreement and any rights and obligations hereunder may not be assigned, hypothecated or otherwise transferred by any party
hereto (by operation of law or otherwise) without the prior written agreement of the Buyer and the Company, <U>provided</U> that, the
Buyer may assign and delegate any or all of its rights, interests and obligations under this Agreement (1) before or after the Closing
to any of its Affiliates and (2) after the Closing, to any Person, provided in each case that any such Affiliate or Person agrees in writing
to be bound by all of the terms of this Agreement, but no such assignment or delegation will relieve the Buyer of its obligations under
this Agreement if such assignee does not perform such obligation. Any purported assignment in breach of this <U>Section&nbsp;10.7</U>
shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.8. <U>Governing
Law</U>. This Agreement, and all claims arising in whole or in part out of, related to, based upon, or in connection herewith or the subject
matter hereof or the Contemplated Transactions will be governed by, construed and enforced in accordance with the laws of the State of
New York, without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any
other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.9. <U>Consent
to Jurisdiction</U>. Each party to this Agreement, by its execution hereof, hereby irrevocably (a)&nbsp;submits, except as provided in
<U>Section&nbsp;2.7</U>, to the exclusive jurisdiction of the state or federal courts located in Manhattan, New York, NY for the purpose
of any and all Actions arising in whole or in part out of, related to, based upon or in connection with this Agreement or the subject
matter hereof or the Contemplated Transactions, (b)&nbsp;waives to the extent not prohibited by applicable law, and agrees not to assert,
by way of motion, as a defense or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the
above-named courts, that its property is exempt or immune from attachment or execution, that any such action brought in one of the above-named
courts should be dismissed on grounds of improper venue or <I>forum non conveniens</I>, should be transferred to any court other than
one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other court other than one
of the above-named courts, or that this Agreement or any claims arising in whole or in part out of, related to, based upon, or in connection
herewith or the subject matter hereof may not be enforced in or by such court, (c)&nbsp;agrees not to commence any such Action other than
before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal
of any such Action to any court other than one of the above-named courts (subject in each case to clause&nbsp;(a) of this sentence) whether
on the grounds of inconvenient forum or otherwise, (d)&nbsp;consents to service of process in any such Action in any manner permitted
by the laws of the State of New York, (e)&nbsp;agrees that service of process made in accordance with clause&nbsp;(d) or made pursuant
to <U>Section&nbsp;10.1</U> will constitute good and valid service of process in any such Action, and (f)&nbsp;waives and agrees not to
assert (by way of motion, as a defense, or otherwise) in any such Action any claim that service of process made in accordance with clause&nbsp;(d)
or clause&nbsp;(e) does not constitute good and valid service of process. Notwithstanding the immediately preceding sentence, a party
may commence an Action in any other court to enforce an order or judgment issued by one of the courts described in the immediately preceding
sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">10.10. </FONT><U>Waiver
of Jury Trial</U>. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW WHICH CANNOT BE WAIVED, EACH OF THE PARTIES HERETO HEREBY WAIVES, AND
AGREES TO CAUSE EACH OF ITS SUBSIDIARIES TO WAIVE, AND COVENANTS THAT NEITHER IT NOR ANY OF ITS SUBSIDIARIES SHALL ASSERT (WHETHER AS
PLAINTIFF, DEFENDANT OR OTHERWISE) ANY RIGHT TO TRIAL BY JURY IN ANY FORUM IN RESPECT OF ANY ACTION DESCRIBED IN <U>SECTION&nbsp;10.9</U>.
ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS <U>SECTION&nbsp;10.10</U> WITH ANY COURT AS WRITTEN EVIDENCE OF THE
CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">10.11. </FONT><U>Reliance</U>.
Each of the parties hereto acknowledges that it has been informed by each other party that the provisions of <U>Sections&nbsp;10.9</U>
and <U>10.10</U> constitute a material inducement upon which such party is relying and will rely in entering into this Agreement, and
each such party agrees that any breach by such party of any of the provisions of <U>Sections&nbsp;10.9</U> or <U>10.10</U> above would
constitute a material breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.12. <U>Specific
Enforcement</U>. Each of the parties acknowledges and agrees that the other parties would be damaged immediately, extensively and irreparably
and no adequate remedy at law would exist in the event that any of the provisions of this Agreement were not performed in accordance with
their specific terms or were otherwise breached or violated. Accordingly, in addition to, and not in limitation of, any other remedy available
to any party, the parties agree that, without posting bond or similar undertaking, each of the other parties shall be entitled to an injunction
or injunctions to prevent breaches or violations of the provisions of this Agreement and to the remedy of specific performance of this
Agreement and the terms and provisions hereof. Subject to <U>Section&nbsp;8</U> hereof and the limitations set forth therein, such remedies,
and any and all other remedies provided for in this Agreement, will, however, be cumulative in nature and not exclusive and will be in
addition to any other remedies to which such party may be entitled. Each of the parties hereby acknowledges and agrees that injunctive
relief and/or specific performance will not cause an undue hardship to any party. Each party further agrees that, in the event of any
action for injunctive relief or for specific performance in respect of any breach or violation, or threatened breach or violation, of
this Agreement, it shall not assert the defense that a remedy at law would be adequate or that specific performance or injunctive relief
in respect of such breach or violation should not be available on any other grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.13. <U>No
Waiver</U>. No failure or delay on the part of any party hereto in the exercise of any right hereunder will impair such right or be construed
to be a waiver of, or acquiescence in, any breach of any representation, warranty, covenant or agreement herein, nor will any single or
partial exercise of any such right preclude any other or further exercise thereof or of any other right. No waiver of any provision of
this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar), or shall constitute
a continuing waiver unless otherwise expressly provided. No waiver of any right or remedy hereunder shall be valid unless the same shall
be in writing and signed by the party against whom such waiver is intended to be effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.14. <U>Negotiation
of Agreement</U>. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or
question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption
or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.15. <U>Disclosure
Schedules</U>. The inclusion of any information in the Disclosure Schedules will not be deemed an admission or acknowledgment that such
information is required to be listed in the Disclosure Schedules or that such items are material. The Disclosure Schedules are arranged
in sections corresponding to the subsections of <U>Section 3</U> contained in this Agreement, and the disclosure of an item in one section
of the Disclosure Schedules as an exception to a particular representation or warranty in such subsection of <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3</U>
will be deemed adequately disclosed as an exception with respect to all other representations and warranties in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3</U>
to the extent that the relevance of such item to such other representations and warranties in <U>Section 3</U> is reasonably apparent
on its face, notwithstanding the presence or absence of an appropriate cross-reference thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.16. <U>Third
Party Beneficiaries</U>. No provision of this Agreement is intended to confer upon any Person other than the parties hereto any rights
or remedies hereunder; <U>provided however</U>, that the following Persons are expressly intended as third party beneficiaries with respect
to the following specified sections of this Agreement and will have the right to enforce such specified sections against the parties to
this Agreement: with respect to <U>Section&nbsp;8</U>, the Persons who are the beneficiaries of the indemnification under such Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.17. <U>Headings</U>.
The headings contained in this Agreement are inserted only for reference as a matter of convenience and in no way define, limit or describe
the scope or intent of this Agreement, and will not affect in any way the construction, meaning or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10.18. <U>Counterparts;
Electronic Signature</U>. This Agreement may be executed in any number of counterparts, and by the different parties hereto in separate
counterparts, each of which will be deemed an original for all purposes and all of which together will constitute one and the same instrument.
This Agreement may be executed by facsimile or PDF signature by any party and such signature will be deemed binding for all purposes hereof
without delivery of an original signature being thereafter required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>The remainder of this page is intentionally
blank. Signatures follow.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">In
witness whereof</FONT>, the parties have caused this Asset Purchase Agreement to be executed under seal by their respective duly authorized
officers as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><B>THE BUYER:</B></TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>Nano-X Imaging, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/James Dara</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>James Dara</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>THE PARENT:</B></TD>
    <TD COLSPAN="2"><B>NANO-X IMAGING LTD.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> /s/ Ran Daniel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Ran Daniel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>THE COMPANY:</B></TD>
    <TD COLSPAN="2"><B>MDWEB, LLC (doing business as MDW, LLC)</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Michael Averbach</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Michael Averbach</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Signature Page to Asset
Purchase Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-indent: -3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-indent: -3in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">54</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-indent: -3in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-indent: -3in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>f20f2021ex4-2_nanox.htm
<DESCRIPTION>AGREEMENT AND PLAN OF MERGER, DATED AUGUST 9, 2021, AMONG NANO-X IMAGING LTD, ZEBRA MEDICAL VISION LTD. AND PERRYLLION LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 4.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AGREEMENT AND PLAN OF MERGER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
DATED AS OF</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
AUGUST <FONT STYLE="font-weight: normal">9</FONT>, 2021</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
BY AND AMONG</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NANO-X IMAGING LTD</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
ZEBRA MEDICAL VISION LTD.,</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
NEW ZEALAND MERGER SUB LTD,</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
AND</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR>
PERRYLLION LTD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1.25in; text-transform: uppercase; text-indent: -1.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1.25in; text-transform: uppercase; text-indent: -1.25in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1.25in; text-transform: uppercase; text-indent: -1.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article I DEFINITIONS AND RULES OF CONSTRUCTION</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: justify">Section 1.1</TD>
    <TD STYLE="width: 75%; text-align: justify">Defined Terms</TD>
    <TD STYLE="width: 8%; text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 1.2</TD>
    <TD STYLE="text-align: justify">Certain References</TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 1.3</TD>
    <TD STYLE="text-align: justify">Rules of Construction</TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article II THE MERGER</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.1</TD>
    <TD STYLE="text-align: justify">Reverse Subsidiary Merger</TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.2</TD>
    <TD STYLE="text-align: justify">Effective Time</TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.3</TD>
    <TD STYLE="text-align: justify">Conversion of Company Shares; Treatment of Company Outstanding Instruments and Treatment of Company Warrants</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.4</TD>
    <TD STYLE="text-align: justify">Escrow</TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.5</TD>
    <TD STYLE="text-align: justify">Charter, Bylaws, Directors and Officers</TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.6</TD>
    <TD STYLE="text-align: justify">Calculation of Merger Consideration</TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.7</TD>
    <TD STYLE="text-align: justify">Closing and Closing Payments</TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.8</TD>
    <TD STYLE="text-align: justify">Exchange of Certificates.</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.9</TD>
    <TD STYLE="text-align: justify">Closing Deliveries</TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.10</TD>
    <TD STYLE="text-align: justify">Post-Closing Payments</TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.11</TD>
    <TD STYLE="text-align: justify">Notice of a Failure to Achieve a Milestone</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.12</TD>
    <TD STYLE="text-align: justify">Disputes Regarding the Achievement of a Milestone</TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 2.13</TD>
    <TD STYLE="text-align: justify">Withholding</TD>
    <TD STYLE="text-align: center"></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article III REPRESENTATIONS AND WARRANTIES OF THE COMPANY</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.1</TD>
    <TD STYLE="text-align: justify">Organization, Existence and Good Standing</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.2</TD>
    <TD STYLE="text-align: justify">Power and Authority</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.3</TD>
    <TD STYLE="text-align: justify">Enforceability</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.4</TD>
    <TD STYLE="text-align: justify">Consents; Non-contravention</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.5</TD>
    <TD STYLE="text-align: justify">Capitalization</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.6</TD>
    <TD STYLE="text-align: justify">Subsidiaries</TD>
    <TD STYLE="text-align: center">16</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.7</TD>
    <TD STYLE="text-align: justify">Financial Statements</TD>
    <TD STYLE="text-align: center">16</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.8</TD>
    <TD STYLE="text-align: justify">Undisclosed Liabilities; Indebtedness</TD>
    <TD STYLE="text-align: center">17</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.9</TD>
    <TD STYLE="text-align: justify">Assets</TD>
    <TD STYLE="text-align: center">17</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.10</TD>
    <TD STYLE="text-align: justify">Taxes</TD>
    <TD STYLE="text-align: center">18</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.11</TD>
    <TD STYLE="text-align: justify">Conduct of Business</TD>
    <TD STYLE="text-align: center">21</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.12</TD>
    <TD STYLE="text-align: justify">Contracts</TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.13</TD>
    <TD STYLE="text-align: justify">Permits</TD>
    <TD STYLE="text-align: center">25</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center">(continued)</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 12%">Section 3.14</TD>
    <TD STYLE="text-align: justify; width: 75%">Litigation</TD>
    <TD STYLE="text-align: center; width: 8%">25</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.15</TD>
    <TD STYLE="text-align: justify">Compliance with Laws</TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.16</TD>
    <TD STYLE="text-align: justify">Real Property</TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.17</TD>
    <TD STYLE="text-align: justify">Environmental Matters</TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.18</TD>
    <TD STYLE="text-align: justify">Intellectual Property</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.19</TD>
    <TD STYLE="text-align: justify">Data Protection; Privacy</TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.20</TD>
    <TD STYLE="text-align: justify">Information Technology</TD>
    <TD STYLE="text-align: center">31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.21</TD>
    <TD STYLE="text-align: justify">Employee Benefits</TD>
    <TD STYLE="text-align: center">32</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.22</TD>
    <TD STYLE="text-align: justify">Employees; Labor</TD>
    <TD STYLE="text-align: center">33</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.23</TD>
    <TD STYLE="text-align: justify">Related Parties Transactions</TD>
    <TD STYLE="text-align: center">36</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.24</TD>
    <TD STYLE="text-align: justify">Customers; Suppliers</TD>
    <TD STYLE="text-align: center">37</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.25</TD>
    <TD STYLE="text-align: justify">Insurance</TD>
    <TD STYLE="text-align: center">37</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.26</TD>
    <TD STYLE="text-align: justify">Names; Officers and Bank Accounts</TD>
    <TD STYLE="text-align: center">37</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.27</TD>
    <TD STYLE="text-align: justify">Accounts Receivable</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.28</TD>
    <TD STYLE="text-align: justify">Brokers</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 3.29</TD>
    <TD STYLE="text-align: justify">Accredited Investors and Qualified Investors</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article IV REPRESENTATIONS AND WARRANTIES OF PURCHASER</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 4.1</TD>
    <TD STYLE="text-align: justify">Organization, Existence and Good Standing</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 4.2</TD>
    <TD STYLE="text-align: justify">Power and Authority</TD>
    <TD STYLE="text-align: center">38</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 4.3</TD>
    <TD STYLE="text-align: justify">Enforceability</TD>
    <TD STYLE="text-align: center">39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 4.4</TD>
    <TD STYLE="text-align: justify">Consents; Non-contravention</TD>
    <TD STYLE="text-align: center">39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 4.5</TD>
    <TD STYLE="text-align: justify">Brokers</TD>
    <TD STYLE="text-align: center">39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD STYLE="text-transform: uppercase">Article V</TD>
    <TD STYLE="text-transform: uppercase">COVENANTS OF THE COMPANY</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">41</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 5.1</TD>
    <TD STYLE="text-align: justify">Reasonable Access</TD>
    <TD STYLE="text-align: center">41</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 5.2</TD>
    <TD STYLE="text-align: justify">Third Party Consents</TD>
    <TD STYLE="text-align: center">41</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 5.3</TD>
    <TD STYLE="text-align: justify">Operation of the Business</TD>
    <TD STYLE="text-align: center">42</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 5.4</TD>
    <TD STYLE="text-align: justify">Certain Updates</TD>
    <TD STYLE="text-align: center">42</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 5.5</TD>
    <TD STYLE="text-align: justify">Exclusivity</TD>
    <TD STYLE="text-align: center">43</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 5.6</TD>
    <TD STYLE="text-align: justify">Shareholder Consent</TD>
    <TD STYLE="text-align: center">44</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 5.7</TD>
    <TD STYLE="text-align: justify">Termination of Shareholder Agreements and Related Party Agreements</TD>
    <TD STYLE="text-align: center">44</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 5.9</TD>
    <TD STYLE="text-align: justify">Benefit Plan Terminations</TD>
    <TD STYLE="text-align: center"></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center">(continued)</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article VI COVENANTS OF PURCHASER</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">44</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 12%">Section 6.1</TD>
    <TD STYLE="text-align: justify; width: 75%">Confidentiality Agreement</TD>
    <TD STYLE="text-align: center; width: 8%">44</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 6.2</TD>
    <TD STYLE="text-align: justify">Officers&rsquo; and Directors&rsquo; Liability</TD>
    <TD STYLE="text-align: center">44</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article VII JOINT COVENANTS</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">45</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 7.1</TD>
    <TD STYLE="text-align: justify">Commercially Reasonable Efforts</TD>
    <TD STYLE="text-align: center">45</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 7.2</TD>
    <TD STYLE="text-align: justify">Further Assurances</TD>
    <TD STYLE="text-align: center">45</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article VIII CONDITIONS TO CLOSING</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 8.1</TD>
    <TD STYLE="text-align: justify">Conditions to the Company&rsquo;s Obligations</TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 8.2</TD>
    <TD STYLE="text-align: justify">Conditions to Purchaser&rsquo;s and Merger Sub&rsquo;s Obligations</TD>
    <TD STYLE="text-align: center">46</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 8.3</TD>
    <TD STYLE="text-align: justify">Joint Conditions to the Parties&rsquo; Obligations</TD>
    <TD STYLE="text-align: center">48</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article IX INDEMNIFICATION</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">49</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 9.1</TD>
    <TD STYLE="text-align: justify">General; Survival</TD>
    <TD STYLE="text-align: center">49</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 9.2</TD>
    <TD STYLE="text-align: justify">The Equityholders&rsquo; Indemnification Obligations</TD>
    <TD STYLE="text-align: center">49</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 9.3</TD>
    <TD STYLE="text-align: justify">Individual Equityholder Indemnification</TD>
    <TD STYLE="text-align: center">51</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 9.4</TD>
    <TD STYLE="text-align: justify">Limitations on Indemnification Obligations</TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 9.5</TD>
    <TD STYLE="text-align: justify">Purchaser&rsquo;s Indemnification Obligations</TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 9.6</TD>
    <TD STYLE="text-align: justify">Notice and Determination of Claims</TD>
    <TD STYLE="text-align: center">54</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 9.7</TD>
    <TD STYLE="text-align: justify">Third Party Claims</TD>
    <TD STYLE="text-align: center">54</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 9.8</TD>
    <TD STYLE="text-align: justify">Obligations to Mitigate Damages</TD>
    <TD STYLE="text-align: center">55</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 9.9</TD>
    <TD STYLE="text-align: justify">Adjustment to Merger Consideration</TD>
    <TD STYLE="text-align: center">55</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 9.10</TD>
    <TD STYLE="text-align: justify">Indemnification Exclusive Remedy</TD>
    <TD STYLE="text-align: center">55</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article X Tax Matters</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">55</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 10.1</TD>
    <TD STYLE="text-align: justify">Preparation and Filing of Tax Returns</TD>
    <TD STYLE="text-align: center">55</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 10.2</TD>
    <TD STYLE="text-align: justify">Control of Audit or Tax Litigation</TD>
    <TD STYLE="text-align: center">56</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 10.3</TD>
    <TD STYLE="text-align: justify">Cooperation</TD>
    <TD STYLE="text-align: center">56</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 10.4</TD>
    <TD STYLE="text-align: justify">Transfer Taxes</TD>
    <TD STYLE="text-align: center">57</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 10.5</TD>
    <TD STYLE="text-align: justify">Tax Refunds</TD>
    <TD STYLE="text-align: center">57</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 10.6</TD>
    <TD STYLE="text-align: justify">Tax Sharing Agreements</TD>
    <TD STYLE="text-align: center">57</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article XI TERMINATION</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">58</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 11.1</TD>
    <TD STYLE="text-align: justify">General</TD>
    <TD STYLE="text-align: center">58</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 11.2</TD>
    <TD STYLE="text-align: justify">Right to Terminate</TD>
    <TD STYLE="text-align: center">58</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 11.3</TD>
    <TD STYLE="text-align: justify">Remedies Upon Termination</TD>
    <TD STYLE="text-align: center">59</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 11.4</TD>
    <TD STYLE="text-align: justify">Certain Other Effects of Termination</TD>
    <TD STYLE="text-align: center">60</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center">(continued)</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article XII EQUITYHOLDER REPRESENTATIVE</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify; width: 5%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 12%">Section 12.1</TD>
    <TD STYLE="text-align: justify; width: 75%">Appointment of the Equityholder Representative</TD>
    <TD STYLE="text-align: center; width: 8%">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 12.2</TD>
    <TD STYLE="text-align: justify">Authority of the Equityholder Representative</TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 12.3</TD>
    <TD STYLE="text-align: justify">Reliance</TD>
    <TD STYLE="text-align: center">61</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 12.4</TD>
    <TD STYLE="text-align: justify">Indemnification of the Equityholder Representative</TD>
    <TD STYLE="text-align: center">63</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 12.5</TD>
    <TD STYLE="text-align: justify">Expense Fund</TD>
    <TD STYLE="text-align: center">63</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article XIII ADDITIONAL COVENANTS</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">64</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 13.1</TD>
    <TD STYLE="text-align: justify">Limitation on Warranties; No Reliance</TD>
    <TD STYLE="text-align: center">64</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 13.2</TD>
    <TD STYLE="text-align: justify">Specific Reliance</TD>
    <TD STYLE="text-align: center">64</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 13.3</TD>
    <TD STYLE="text-align: justify">Disclosure Schedule</TD>
    <TD STYLE="text-align: center">64</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-transform: uppercase">Article XIV MISCELLANEOUS</TD>
    <TD STYLE="text-align: center; text-transform: uppercase">66</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.1</TD>
    <TD STYLE="text-align: justify">Transaction Expenses</TD>
    <TD STYLE="text-align: center">66</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.2</TD>
    <TD STYLE="text-align: justify">Publicity</TD>
    <TD STYLE="text-align: center">66</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.3</TD>
    <TD STYLE="text-align: justify">Notices</TD>
    <TD STYLE="text-align: center">67</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.4</TD>
    <TD STYLE="text-align: justify">Entire Agreement</TD>
    <TD STYLE="text-align: center">68</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.5</TD>
    <TD STYLE="text-align: justify">Non-Waiver</TD>
    <TD STYLE="text-align: center">68</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.6</TD>
    <TD STYLE="text-align: justify">Counterparts</TD>
    <TD STYLE="text-align: center">68</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.7</TD>
    <TD STYLE="text-align: justify">Delivery by Electronic Transmission</TD>
    <TD STYLE="text-align: center">68</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.8</TD>
    <TD STYLE="text-align: justify">Severability</TD>
    <TD STYLE="text-align: center">68</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.9</TD>
    <TD STYLE="text-align: justify">Applicable Law</TD>
    <TD STYLE="text-align: center">68</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.10</TD>
    <TD STYLE="text-align: justify">Binding Effect; Benefit</TD>
    <TD STYLE="text-align: center">68</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.11</TD>
    <TD STYLE="text-align: justify">Assignment</TD>
    <TD STYLE="text-align: center">69</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.12</TD>
    <TD STYLE="text-align: justify">Amendments</TD>
    <TD STYLE="text-align: center">69</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.13</TD>
    <TD STYLE="text-align: justify">Waiver of Trial by Jury</TD>
    <TD STYLE="text-align: center">69</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.14</TD>
    <TD STYLE="text-align: justify">Consent to Jurisdiction</TD>
    <TD STYLE="text-align: center">69</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.15</TD>
    <TD STYLE="text-align: justify">Specific Performance</TD>
    <TD STYLE="text-align: center">69</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.16</TD>
    <TD STYLE="text-align: justify">Conflicts Regarding Representation</TD>
    <TD STYLE="text-align: center">69</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Section 14.17</TD>
    <TD STYLE="text-align: justify">Governmental Reporting</TD>
    <TD STYLE="text-align: center">69</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>Section 14.18</TD>
    <TD>Headings</TD>
    <TD STYLE="text-align: center">69</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1.25in; text-transform: uppercase; text-indent: -1.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 17%">Annex A</TD>
    <TD STYLE="width: 75%">Defined Terms</TD>
    <TD STYLE="text-align: center; width: 8%">A-1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>Schedule 1.1</TD>
    <TD>Key Employees</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Schedule 2.9(b)(ii)</TD>
    <TD>Company&rsquo;s Service Providers</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>Schedule 4.4</TD>
    <TD>Purchaser Capitalization Table</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Schedule 5.2</TD>
    <TD>Required Consents</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2">Document Schedules</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Exhibit A</TD>
    <TD>Form of Voting Agreement</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>Exhibit B</TD>
    <TD>Merger Proposal</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Exhibit C</TD>
    <TD>Form of Payout Spreadsheet</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>Exhibit D</TD>
    <TD>Company Board Resolution</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Exhibit E</TD>
    <TD>Form of Company Counsel Legal Opinion</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>Exhibit F</TD>
    <TD>Form of Nano-X Counsel Legal Opinion</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Exhibit G</TD>
    <TD>Indemnification Agreements</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>Exhibit H</TD>
    <TD>Milestone Schedule</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>Exhibit I</TD>
    <TD>Post- Closing Articles of Association of the Surviving Corporation</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>Exhibit J</TD>
    <TD>Form of Convertible Loan Agreement</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AGREEMENT AND PLAN OF MERGER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS AGREEMENT AND PLAN OF
MERGER (this &ldquo;<U>Agreement</U>&rdquo;) is made as of August [&bull;], 2021, by and among Nano-X Imaging Ltd, an Israeli company
(&ldquo;<U>Purchaser</U>&rdquo;), New Zealand Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of Purchaser (&ldquo;<U>Merger
Sub</U>&rdquo;), Zebra Medical Vision Ltd., an Israeli company (the &ldquo;<U>Company</U>&rdquo;), and PerryLLion Ltd., solely in its
capacity as the representative of all Equityholders (the &ldquo;<U>Equityholder Representative</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A. The
parties hereto intend to enter into a transaction whereby Merger Sub will merge with and into the Company (the &ldquo;<U>Merger</U>&rdquo;),
with the Company surviving the merger, on the terms and subject to the conditions set forth in this Agreement and in accordance with the
provisions of Sections 314-327 of the Companies Law 5759-1999 of the State of Israel (together with the rules and regulations promulgated
thereunder, the &ldquo;<U>ICL</U>&rdquo;), following which Merger Sub will cease to exist, and the Company will become a wholly owned
subsidiary of Purchaser, on the terms and subject to the conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.  The
Board of Directors of the Company has: (i) determined that this Agreement, the Merger and the other transactions contemplated by this
Agreement are fair to, and in the best interests of, the Company and its shareholders; (ii) approved this Agreement, the Merger and the
other transactions contemplated hereby; and (iii) determined to recommend that the shareholders of the Company approve this Agreement,
the Merger and the other transactions contemplated hereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C. The
Boards of Directors of Purchaser and Merger Sub have each (i) approved this Agreement, the Merger and the other transactions contemplated
hereby, (ii) determined that this Agreement, the Merger and the other transactions contemplated by this Agreement are fair to, and in
the best interests of, Merger Sub and its sole shareholder, Purchaser; (iii) determined that, considering the financial position of the
merging companies, no reasonable concern exists that the Surviving Corporation will be unable to fulfill the obligations of Merger Sub
to its creditors; and (iv) determined to recommend that Purchaser, as the sole shareholder of Merger Sub, approves this Agreement, the
Merger and the other transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D. Simultaneously
with the execution and delivery of this Agreement, as a condition to Purchaser&rsquo;s entering into this Agreement and as an inducement
thereto, Purchaser, the Company and the Requisite Supporting Shareholders entered into a voting agreement (the &ldquo;<U>Voting Agreement</U>&rdquo;)
in the form of <U>Exhibit&nbsp;A</U> pursuant to which such shareholders have agreed to take specified actions in furtherance of the Merger
and providing their agreement to the terms and conditions of this Agreement, including (i) actions relating to the approval of the Merger
and adoption of this Agreement by the Company&rsquo;s shareholders, and (ii) providing their consent to the effectiveness of the indemnification
agreement, customary waivers of rights, customary representations concerning their shares and their rights to consummate the transactions
contemplated by the Merger and the limitations on sales stipulated therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E. Simultaneously
with the execution and delivery of this Agreement, Purchaser and the Company shall enter into a convertible loan agreement, in the form
attached hereto as <U>Exhibit&nbsp;J</U> (the &ldquo;<U>Convertible Loan Agreement</U>&rdquo;), pursuant to which Purchaser shall extend
to the Company, immediately following the execution of this Agreement, a convertible loan in the principal amount of $3,000,000, which,
in the case that this Agreement is terminated, will be converted into shares of the most senior class of shares of the Company, all, as
further stipulated in the Convertible Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">F</FONT>. <FONT STYLE="font-weight: normal">Simultaneously
with the execution of this Agreement, Purchaser, as the sole shareholder of Merger Sub, is adopting and approving this Agreement and the
transactions contemplated hereby, including the Merger.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AGREEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration of the mutual
representations, warranties, covenants and agreements set forth in this Agreement, and for other good and valid consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;I<U><BR>
DEFINITIONS AND RULES OF CONSTRUCTION</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;1.1 </FONT><U>Defined
Terms</U>. Certain capitalized terms used in this Agreement have the definitions set forth in the body of this Agreement. Any capitalized
terms used in this Agreement and not defined in the body of this Agreement have the meanings assigned to such terms in <U>Annex&nbsp;A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;1.2 </FONT><U>Certain
References</U>. Any reference in this Agreement to a statute refers to the statute, any amendments or successor legislation, and all regulations
promulgated thereunder, as in effect at the relevant time. Any reference in this Agreement to any United States federal or state action,
remedy, method of judicial proceeding, legal document, legal status, court, official or any legal concept or thing shall, in respect of
any jurisdiction other than a federal or state jurisdiction of the United States, be deemed to include what is most nearly approximate
under the laws of such other jurisdiction. Any reference to a contract, instrument or other document as of a given date means the contract,
instrument or other document as amended, supplemented and modified from time to time through such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;1.3 </FONT><U>Rules
of Construction</U>. Words in the singular shall be held to include the plural and vice versa. Words of one gender shall be held to include
the other genders as the context requires. The terms &ldquo;hereof,&rdquo; &ldquo;herein,&rdquo; &ldquo;hereunder,&rdquo; &ldquo;hereto&rdquo;
and &ldquo;herewith&rdquo; and words of similar import shall, unless otherwise stated, be construed to refer to this Agreement and not
to any particular provision of this Agreement. All article, section, paragraph, annex, exhibit and schedule references are to the articles,
sections, paragraphs, annexes, exhibits and schedules of this Agreement unless otherwise specified. The word &ldquo;including&rdquo; and
words of similar import when used in this Agreement shall mean &ldquo;including, without limitation&rdquo; unless otherwise specified.
The word &ldquo;or&rdquo; shall not be exclusive. All references herein to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; are to United States
dollars. All references herein to &ldquo;ILS&rdquo; are to Israeli New Shekels. Any accounting term used in this Agreement shall have,
unless otherwise specifically provided herein, the meaning customarily given such term in accordance with US GAAP, and all financial computations
hereunder will be computed, unless otherwise specifically provided herein, in accordance with US GAAP. All references herein to any period
of days shall mean the relevant number of calendar days unless otherwise specified. All references herein to a &ldquo;party&rdquo; or
&ldquo;parties&rdquo; are to a party or parties to this Agreement unless otherwise specified. For purposes of <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;III</U>,
the words &ldquo;made available,&rdquo; &ldquo;furnished,&rdquo; &ldquo;delivered&rdquo; or &ldquo;provided&rdquo; or terms of similar
import shall mean, with respect to any material, that a copy of such material has been (a)&nbsp;posted to the Data Room on or before 5:00
p.m. (Israel time)&nbsp;on the date that is two Business Days prior to the date of this Agreement, and (b)&nbsp;memorialized in electronic
format on a CD-ROM delivered to Purchaser promptly following the execution of this Agreement (but in no event later than three days thereafter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;II<U><BR>
THE MERGER</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.1 </FONT><U>Reverse
Subsidiary Merger</U>. Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the ICL, at the
Effective Time, Merger Sub (as the target company (Chevrat Ha&rsquo;Ya&rsquo;ad) in the Merger) shall be merged with and into the Company
(as the absorbing company (HaChevra Ha&rsquo;Koletet) in the Merger). As a result of the Merger, the separate corporate existence of Merger
Sub shall cease and the Company shall continue as the Surviving Corporation (the &ldquo;<U>Surviving Corporation</U>&rdquo;) and shall
(a) become wholly owned by Purchaser, (b) continue to be governed by the Laws of the State of Israel, (c) maintain a registered office
in the State of Israel, and (d) succeed to and assume all of the rights, properties and obligations of Merger Sub in accordance with the
ICL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.2 </FONT><U>Effective
Time</U>. As soon as practicable after the determination of the date on which the Closing is to take place, each of the Company and Merger
Sub shall (and Purchaser shall cause Merger Sub to), in coordination with each other, deliver to the Registrar of Companies of the State
of Israel (the &ldquo;<U>Companies Registrar</U>&rdquo;) a notice of the contemplated Merger and the proposed date of the Closing on which
the Companies Registrar is requested to issue a certificate evidencing the Merger in accordance with Section 323(5) of the ICL (the &ldquo;<U>Certificate
of Merger</U>&rdquo;) after notice that the Closing has occurred is served to the Companies Registrar, which the parties shall deliver
on the Closing Date. The Merger shall become effective upon the issuance by the Companies Registrar of the Certificate of Merger in accordance
with Section 323(5) of the ICL (the time at which the Merger becomes effective is referred to herein as the &ldquo;<U>Effective Time</U>&rdquo;).
For the avoidance of doubt, and notwithstanding any provision of this Agreement to the contrary, it is the intention of the parties hereto
that the Merger shall be declared effective and that the issuance by the Companies Registrar of the Certificate of Merger in accordance
with Section 323(5) of the ICL shall both occur on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.3 </FONT><U>Conversion
of Company Shares; Treatment of Company Options, Outstanding Instruments and Company Warrants</U>. At the Effective Time, by virtue of
the Merger and without any further action on the part of Purchaser, Merger Sub, the Company or any of their respective shareholders or
agents, subject to the terms set forth in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;II</U>, each Company Share
issued and outstanding immediately before the Effective Time will be transferred to the Purchaser, and each Company Warrant and Company
Outstanding Instrument will be cancelled, and the right of each Equityholder thereof shall convert into and represent only the right to
receive its respective amount in the Closing Consideration, Post-Closing Payment Amount (including, for the removal of a doubt, the Deferred
Closing Consideration) and Earn-out Payment Amount pursuant to the Payout Spreadsheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) All
Company Shares, Company Outstanding Instruments and Company Warrants converted in accordance with this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.3</U>
shall upon such conversion no longer be outstanding and shall automatically be cancelled, and each holder of a certificate or certificates
representing such Company Shares, Company Outstanding Instrument and Company Warrant shall cease to have any rights with respect to such
Company Shares, Company Outstanding Instrument or Company Warrant, as applicable, except the right to receive consideration in the value
specified above in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Treatment of Vested Company Options</U>. As of the Effective Time,
any Vested Company Option (including any Unvested Company Option which becomes vested on account of the transactions contemplated herein)
shall be converted, immediately prior to the Effective Time, on a cashless (net exercise) basis, into Company Shares, in a way that each
Company Option holder will be entailed to Company Shares, in a value that is net of its stated exercise price. It is clarified that the
aggregated exercise price of all option holders will be added and be part of the Closing Consideration and will be distributed in accordance
with the Payout Spreadsheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Treatment
of Unvested Company Options; Termination of all Company Options</U>. As of the Effective Time, any Unvested Company Option (including
any Company Option promised to any Person but not granted by the Company) shall be cancelled or otherwise terminated, while having the
right to receive that amount of options to purchase Ordinary Shares of Purchaser, as provided in the Payout Spreadsheet (which shall include
the specific terms of exercise price, vesting schedule etc.), which will assume, for the purpose of calculating the respective portion
of the Merger Consideration which is attributed to Unvested Company Options, the conversion of all of the Unvested Company Options into
Ordinary Shares of the Company, immediately prior to the Closing as set forth in the Payout Spreadsheet (the &ldquo;<U>Option Consideration</U>&rdquo;).
In the event that any portion of the Option Consideration will not be issued to the grantees thereof due to termination of employment
or otherwise (the &ldquo;<U>Options Shortfall Amount</U>&rdquo;), then the consideration payable to the Equity Holders shall increase
by an identical number of Ordinary Shares of Purchaser which is equal to the Options Shortfall Amount (such number of Ordinary Shares
of Purchaser, the &ldquo;<U>Option Consideration True Up</U>&rdquo;), and such Option Consideration True Up will be added, if applicable,
on a pro-rata basis, to the Consideration (and will be treated, for all intents and purposes, as part of the Consideration hereunder)
which shall be allocated between the Equity Holders in the manner set forth in the Payout Spreadsheet, on April 25, 2025. Prior to the
Closing, the Company shall have taken all actions, if any, necessary to cause the cancellation and termination of such Company Options
and the treatment of such Company Options in the manner described in this <U>Section 2.3</U>, including, solely to the extent so required,
providing any required notice to or obtaining a waiver of such notice from the holders of the Company Options pursuant to the documents
governing such Company Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) All
of the Ordinary Shares of Merger Sub, with each having NIS 0.01 par value, which are issued and outstanding immediately prior to the Effective
Time shall be converted into and become validly issued, fully paid and non-assessable shares of the Surviving Corporation, such that all
of the shares of the Surviving Corporation which are issued and outstanding immediately prior to the Effective Time shall, by virtue of
the Merger and such conversion, be held by the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.4 </FONT><U>Escrows</U>.
On the Closing Date, Purchaser Share Consideration valued at $10,000,000 based on the Purchaser Share Consideration Price (the &ldquo;<U>Indemnity
Escrow Amount</U>&rdquo;) will be deposited by Purchaser with Altshuler Shaham Trusts Ltd. (together with its successors and permitted
assigns, the &ldquo;<U>Escrow Agent</U>&rdquo;) in an escrow account (the &ldquo;<U>Indemnity Escrow Account</U>&rdquo;) in accordance
with the Escrow and Paying Agent Agreement in a form to be reasonably agreed between the Parties (the &ldquo;<U>Escrow and Paying Agent
Agreement</U>&rdquo;), to serve as a mechanism to satisfy certain indemnification and other obligations of the Equityholders pursuant
to (or otherwise permitted by) <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>. The Indemnity Escrow Amount, net
of the amount of any claims for indemnification that have been noticed or filed under <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>,
will be released to the Paying Agent following a 12-month period as of the Closing Date for distribution to the Equityholders in accordance
with the Payout Spreadsheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.5 </FONT><U>Articles
of Association, Directors and Officers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Articles
of Association</U>. At the Effective Time, the Articles of Association of Surviving Corporation, shall be the Articles of Association
in the form attached hereto as <U>Exhibit </U>I, until duly amended as provided therein, herein and by applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Directors</U>.
The parties shall take all actions necessary so that the directors of Merger Sub at the Effective Time shall, from and after the Effective
Time, be appointed and serve as the directors of the Surviving Corporation until the earlier of their resignation or removal or until
their respective successors are duly elected and qualified, as the case may be, in accordance with the Surviving Corporation&rsquo;s articles
of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Officers</U>.
At the Effective Time, the non-director officers of the Company immediately before the Effective Time shall be the non-director officers
of the Surviving Corporation, until the earlier of their resignation or removal or until their respective successors are duly elected
or appointed and qualified, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.6 </FONT><U>Calculation
of Merger Consideration</U>. Subject to the terms and conditions of this Agreement, the aggregate consideration to which the Equityholders
(including, for the removal of a doubt, the holders of all Company Options, whether Vested Company Options or Unvested Company Options
(taking into account the exchange thereof into equity securities of the Purchaser) shall be entitled pursuant to this Agreement (the &ldquo;<U>Merger
Consideration</U>&rdquo;) is an amount of Purchaser Share Consideration (valued at the Purchaser Share Consideration Price) equal to:
(a) $100,000,000; <I><U>minus</U></I> (b) the Option Consideration; (the aggregate consideration in subsections (a) and (b) constitutes
the &ldquo;<U>Closing Consideration</U>&rdquo;); <I><U>plus</U></I> (c) the Deferred Closing Consideration (as defined below), if and
as applicable; <I><U>plus</U></I> (d) up to $84,000,000 contingent upon the successful achievement of the Milestones (the &ldquo;<U>Earn-out
Consideration</U>&rdquo;); <I><U>plus</U></I> (e) if applicable according to the provisions of Section 2.3(b) hereof, the Option Consideration
True Up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.7 </FONT><U>Closing
and Closing Payments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
transactions contemplated by this Agreement shall be consummated (the &ldquo;<U>Closing</U>&rdquo;) remotely via email no later than three
Business Days after the satisfaction or, if permissible, waiver, of the conditions set forth in <U>Article&nbsp;VIII</U> (other than those
conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of such conditions), or
on such other date, or at such other time or place, as shall be mutually agreed upon by the Company and Purchaser (provided that such
date shall not be later than the date on which a merger approval certificate is issued by the Companies Registrar). The date on which
the Closing occurs in accordance with the preceding sentence is referred to in this Agreement as the &ldquo;<U>Closing Date</U>.&rdquo;
In lieu of an in-person Closing, the Closing may instead be accomplished by email (in PDF or similar format) transmission to the respective
offices of legal counsel for the parties of the requisite documents, duly executed where required, delivered upon actual confirmed receipt.
All proceedings to be taken and all documents to be executed and delivered by all parties at the Closing will be deemed to have been taken
and executed simultaneously, and no proceedings will be deemed to have been taken nor documents executed or delivered until all have been
taken, executed and delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Not
less than five Business Days prior to the anticipated Closing Date, the Company shall deliver to Purchaser a statement (the &ldquo;<U>Closing
Consideration Certificate</U>&rdquo;), certified by the Chief Executive Officer of the Company, setting forth: (i) the Company&rsquo;s
good faith calculation of the Closing Consideration, together with the Company&rsquo;s good faith estimates of the Closing Indebtedness
and Transaction Expense Amount, based upon the most recent ascertainable financial information and records of the Company and the Transaction
Expense Amount and (ii) the Payout Spreadsheet. The Closing Consideration Certificate shall be prepared in accordance with the terms of
this Agreement, and, to the extent not inconsistent therewith, US GAAP. Prior to the Closing, Purchaser (A) shall have an opportunity
to review with the Company and its representatives, and the Company shall provide Purchaser and its representatives reasonable access
during normal business hours and upon reasonable notice to, the records of the Company and such information used to prepare the Closing
Consideration Certificate and Payout Spreadsheet and its personnel, and (B) may object to all or any part of, the Closing Consideration
Certificate. The Company shall consider such objections in good faith, but the Company&rsquo;s reasonable good faith estimates of the
Closing Indebtedness and Transaction Expense Amount shall control for purposes of calculating the payments to be made at Closing pursuant
to this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.7</U> (it being understood that Purchaser does not waive its
rights with respect to any misrepresentation by the Company as more fully set forth in Section 9 herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Promptly
after the Closing Date and on the Effective Time, Purchaser shall make the following payments to the Persons indicated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i) an
amount in Purchaser Share Consideration (valued at the Purchaser Share Consideration Price) equal to the Indemnity Escrow Amount shall
be deposited with the Escrow Agent, to be held and distributed by the Escrow Agent pursuant to the terms and conditions of the Escrow
and Paying Agent Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii) an
amount of Purchaser Share Consideration (valued at the Purchaser Share Consideration Price) equal to the Closing Consideration minus (A)
the Indemnity Escrow Amount, and minus (B) the Expense Fund Amount, as set forth on the Payout Spreadsheet, shall be issued and deposited
with the Paying Agent for the benefit of and distribution to the Equityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <U>Required
Withholding</U>. Notwithstanding anything to the contrary hereunder, each of the Purchaser, its Subsidiaries, Merger Sub, the Company,
the Paying Agent and any of their respective agents (each a &ldquo;<U>Payor</U>&rdquo;) shall be entitled to deduct and withhold or cause
to be deducted and withheld from any consideration, or other amounts, payable or otherwise deliverable pursuant to, or in connection with,
this Agreement (including the Merger Consideration and payments set forth in <U>Section 2.3</U>) such amounts as required to be deducted
or withheld therefrom under the Ordinance, or under any provision of applicable state, local, Israeli or foreign Tax Law and if any amount
is required to be withheld from Purchaser Share Consideration pursuant to this Agreement, Purchaser shall pay such amount in cash through
the Paying Agent and reduce the relevant Purchaser Share Consideration. To the extent such amounts were so deducted or withheld and timely
remitted by each Payor to the applicable Governmental Entity in accordance with applicable Law, such amounts shall be treated for all
purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. Payor shall provide
as soon as reasonably possible to each Person with respect of whom the deduction and withholding was made, a document evidencing the amount
so withheld and remitted to the applicable Governmental Entity with respect to the payment made to such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) Notwithstanding
the foregoing, with respect to any Israeli Taxes, if the Paying Agent provides Purchaser, prior to the Closing Date, with an undertaking
as required under Section 6.2.4.3(c) of the Income Tax Circular 19/2018 (Transaction for Sale of Rights in a Corporation that includes
Consideration that will be transferred to the Seller at Future Dates) with respect to Israeli Tax, any consideration payable under this
Agreement at the Closing to each Equityholder shall be retained by the Paying Agent for the benefit of each such Equityholder for a period
of up to 180 days from Closing (or, with respect to the Escrow Amount and Expense Fund Amount, 90 days from the date on which such amount,
or any portion thereof, is released to the applicable Equityholder) or an earlier date required in writing by such Equityholder or as
otherwise requested by the ITA (the &ldquo;<U>Withholding Drop Date</U>&rdquo;) during which time no Payor shall make any payments to
any such Equityholder with respect to Company Shares or Company Convertible Instruments or withhold any amounts for Israeli Taxes from
the consideration pursuant to this Agreement, except as provided below (unless such Payor is otherwise instructed explicitly by the ITA),
and during which time each such Equityholder may obtain (or, if one already exists, present to the Paying Agent) a valid certificate,
ruling or other written instructions issued by the ITA regarding the withholding (or exemption from withholding) of Israeli Tax from the
consideration payable in respect thereof in accordance with this Article II or providing other instructions regarding such payments or
withholding, to the Purchaser&rsquo;s reasonable satisfaction (the &ldquo;<U>Valid Certificate</U>&rdquo;); for the avoidance of doubt,
each of the 104H Tax Ruling and the 104H Interim Ruling, is and shall be considered a Valid Certificate. If any such Equityholder delivers,
no later than 3 Business Days prior to the Withholding Drop Date a Valid Certificate to a Payor, then the deduction and withholding of
any Israeli Taxes shall be made only in accordance with the provisions of such Valid Certificate. If any Equityholder (i) does not provide
Payor with a Valid Certificate, by no later than 3 Business Days before the Withholding Drop Date, or (ii) submits a written request with
Payor to release such Equityholder&rsquo;s applicable consideration relevant thereto prior to the Withholding Drop Date but fails to submit
a Valid Certificate at or before such time, then the amount to be withheld from such consideration shall be as required under the Ordinance.
Such amount shall be delivered or caused to be delivered to the ITA by the relevant Payor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) Notwithstanding
anything else to the contrary in this Agreement, and unless instructed otherwise by the ITA in writing, for Israeli withholding Tax purposes,
the value of the Purchaser Share Consideration shall be determined based on the closing price of such share on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) In
the event that a Payor receives a demand from the ITA to withhold any amount in respect of any recipient and transfer it to the ITA prior
to the Withholding Drop Date, the Payor (i) shall notify such recipient of such matter promptly after receipt of such demand, and provide
such recipient with reasonable time (but in no event less than thirty (30) days, unless otherwise explicitly required by the ITA) to attempt
to delay such requirement or extend the period for complying with such requirement as evidenced by a written certificate, ruling or confirmation
from the ITA, and (ii) to the extent that any such certificate, ruling or confirmation is not timely provided by such recipient to the
Payor, transfer to the ITA any amount so demanded, including any interest, indexation and fines required by the ITA in respect thereof,
and such amounts shall be treated for all purposes of this Agreement as having been delivered and paid to such recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) the
provisions of the Israeli Income Tax Rulings shall apply and all applicable withholding procedures with respect to any Electing Holders
shall be made in accordance with the provisions of the Israeli Income Tax Rulings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) Notwithstanding
anything to the Contrary set forth herein, any withholding effected hereunder by the Purchaser, Merger Sub, Company, Paying Agent or Escrow
Agent shall be effected, at the election of Purchaser, either (i) through the sale of Purchaser Share Consideration held in the Indemnity
Escrow Account or from the Merger Consideration and remittance of the proceeds therefrom to the applicable Tax Authority in accordance
with applicable Laws or (ii) the forfeiture from the Indemnity Escrow Account of Purchaser Share Consideration and payment of the applicable
withholding amount to the applicable Tax Authority out of the Purchaser&rsquo;s cash resources; provided that in each case the calculation of
the number of shares of Purchaser Share Consideration to be so sold or forfeited shall be based on the Purchaser Share Consideration Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.8 </FONT><U>Exchange
of Certificates</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Following
the date hereof, the parties will engage Altshuler Shaham Trusts Ltd. (the &ldquo;<U>Paying Agent</U>&rdquo;), to act as Paying Agent
under this Agreement for the purpose of effecting the exchange of consideration for Company certificates that, immediately prior to the
Effective Time, represented Company Shares entitled to payment pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.3</U>.
Promptly following the Effective Time, the Paying Agent shall send to each Equityholder a Letter of Transmittal, together with instructions
for the completion and return thereof. The Paying Agent shall pay each holder of certificates representing Company Shares who has surrendered
his, her or its certificates representing such Company Shares, together with a duly executed and completed letter of transmittal substantially
in the form which will be reasonably agreed between the Parties (&ldquo;<U>Letter of Transmittal</U>&rdquo;), and, with respect to Company
Shareholders who are individuals and residents in a jurisdiction that follows the community property regime, a duly executed Spousal Consent,
the amount of Purchaser Share Consideration to which he, she or it is entitled under <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.3</U>
as of the Effective Time (to avoid doubt, excluding any Post-Closing Payment Amounts or Earn-out Payment Amounts), which amount shall
be transferred to the Paying Agent within two Business Days after the later of (A) the Effective Time and (B) the date on which the Paying
Agent receives such Equityholder&rsquo;s duly completed Letter of Transmittal, certificate(s) and other documents, if any, reasonably
required by the Paying Agent for the purposes of making such transfer (&ldquo;<U>Transmittal Documents</U>&rdquo;). Until so surrendered
and exchanged, each such certificate shall represent solely the right to receive the applicable portion of the Merger Consideration pursuant
to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.3</U>. Notwithstanding the foregoing, if any such certificate shall
have been lost, stolen or destroyed, then, upon the making of an affidavit of such fact and the granting of a standard indemnity with
respect thereto by the Person claiming such certificate to be lost, stolen or destroyed, the Paying Agent shall disburse, in exchange
for such lost, stolen or destroyed certificate, the applicable portion of the Merger Consideration to be paid in respect of the Company
Shares represented by such certificate pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.3</U>, as contemplated
by this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.8(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Any
portion of the Merger Consideration deposited with the Paying Agent pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.8(a)</U>
or <U>Section 2.10</U> below that remains unclaimed by the Equityholders one year after the Effective Time - with respect to the Closing
Consideration, or, one year after the Milestone Achievement Date &ndash; with respect to each payment of any Earn-out Payment Amount,
will be returned to the Surviving Corporation, and any Equityholder who has not delivered to the Paying Agent the applicable Letter of
Transmittal, Transmittal Documents and, as applicable, Share certificates (or in the event that any Share certificate has been lost, stolen
or destroyed, provided an affidavit in accordance with <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.8(a)</U>) in
each case prior to such time, will thereafter look only to the Surviving Corporation for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.9 </FONT><U>Closing
Deliveries</U>. At the Closing, the parties shall deliver the documents and instruments that are set forth in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) At
the Closing, Purchaser or Merger Sub, as applicable, shall execute and/or deliver or cause to be delivered to the Company (or such other
Person as indicated below) all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i) the
Escrow and Paying Agent Agreement, duly executed by Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii) a
certificate executed by Purchaser confirming that the conditions set forth in <U>Sections&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>8.1(a)</U>
and <U>8.1(b)</U> have been satisfied;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii) evidence
of the issuance to the Paying Agent of such portion of the Closing Consideration (in Purchaser Share Consideration) as set out in Section
2.7(c)(vi);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv) evidence
of the issuance of the Indemnity Escrow Amount to the Escrow Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v) an
opinion of Amit, Pollak Matalon &amp; Co. addressed to the Equity Holders and dated as of the Closing, substantially in the form of <U>Exhibit
</U>F attached hereto; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi) a
certificate of the Chief Executive Officer of the Purchaser, certifying as true, correct and complete, together with copies of, the following:
(A) each Organizational Document of the Purchaser and the Merger Sub, including each such party&rsquo;s Articles of Association; and (B)
the resolutions of each of the Purchaser&rsquo;s and the Merger Sub&rsquo;s boards of directors authorizing the execution, delivery and
performance of this Agreement and any other documents delivered by such party hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) At
the Closing the Company shall execute and/or deliver or cause to be delivered to Purchaser all of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i) the
Escrow and Paying Agent Agreement, duly executed by the Company and the Equityholder Representative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)
written acknowledgments pursuant to which the Persons, including those identified in <U>Schedule 2.9(b)(ii),</U> who performed services
for or on behalf of, or provided advice to the Company and who are entitled to compensation from the Company or the US Subsidiary, in
connection with this Agreement, any of the transactions contemplated by this Agreement or is otherwise owed any amount which is part of
the Transaction Expenses (calculated to include any amounts that only become payable if the Closing occurs) (the &ldquo;<U>Transaction
Expense Amount</U>&rdquo;) has been paid in full and is not (and will not be) owed any other amount by the Company or any Affiliate thereof
with respect to this Agreement any of the transactions contemplated by this Agreement or otherwise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii) a
certificate of the Chief Executive Officer of the Company certifying as true, correct and complete the following: (A) a copy of each Organizational
Document of the Company, including the Company Charter; (B) a copy of the resolutions of the Company&rsquo;s board of directors, in the
form of <U>Exhibit D</U> attached hereto, authorizing the execution, delivery and performance of this Agreement and any other documents
delivered by the Company hereunder, and (C) minutes or written resolutions evidencing the Shareholder Approval;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv) a
certificate executed by the Company confirming that the conditions set forth in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.2(a)</U>,
<FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.2(b)</U> and <U>Section 8.2(c)</U> have been satisfied and representing
and warranting to Purchaser the amount of Closing Indebtedness and the Transaction Expense Amount set forth in the Closing Consideration
Certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v) a
resignation letter, effective as of the Effective Time, of each director and/or officer of the Company that has been requested by Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi) the
Payout Spreadsheet, duly certified by, and the amounts set forth therein as payable in respect of the Ordinary Shares of the Company,
the Preferred C Shares, the Preferred B Shares, the Preferred A Shares, the Company Warrants and the Company Outstanding Instruments,
represented and warranted to by, the Chief Executive Officer of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii)
an opinion of Horn &amp; Co. addressed to the Purchaser and dated as of the Closing, in the form of <U>Exhibit E</U> attached hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii) transfer
to the Equityholder Representative of the Expense Fund Amount;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ix) evidence
reasonably satisfactory to Purchaser of the termination, effective prior to the Effective Time, of all Contracts between the Company and
a Related Party of the Company, including all Rights Agreements and all Shareholder Agreements, which do not by their terms terminate
automatically at Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.10 </FONT><U>Post-Closing
Payments; Deferred Closing Payments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Within
15 days of each Milestone Achievement Date with respect to a Milestone which has been successfully achieved, Purchaser shall pay an amount
in Purchaser Share Consideration (valued at the Purchaser Share Consideration Price) that is equal to, with respect to such Milestone
(subject to deduction in accordance with this Agreement), such percentage of the aggregate Earn-out Consideration listed next to such
Milestone in the Milestone Schedule (each such portion of the Earn-out Consideration to be paid upon the successful achievement of a Milestone,
the &ldquo;<U>Earn-out Payment Amount</U>&rdquo;). Each Earn-out Payment Amount shall be issued and deposited, within the said 15 days
of the Milestone Achievement Date, with the Paying Agent for the benefit of and distribution to the Equityholders pursuant to the updated
Payout Spreadsheet, <I><U>provided</U></I>, <I><U>however</U></I>, that the provisions of <U>Sections 2.7(d)</U> through <U>(i)</U>, shall
apply with respect to the payment and distribution of each Earn-out Payment Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Subject
to the execution of each Designated Commercial Agreement (a &ldquo;<U>Deferred Closing Payment Date</U>&rdquo;) defined below on or prior
to the lapse of the 6-month period following the date hereof (the &ldquo;<U>Deferred Closing Final Date</U>&rdquo;), the Purchaser shall
pay an amount, in Purchaser Share Consideration (valued at the Purchaser Share Consideration Price) that is equal to, an amount of $5,333,333.33,
for each of the Designated Commercial Agreements (as defined below), which results in an aggregate amount of up to $16,000,000 (prior
to the deductions specified below), which was duly executed (by all relevant parties) following the date hereof and prior to the Deferred
Closing Final Date. The Purchaser shall deduct $2,000,000 from each payment of $5,333,333.333 for a Designated Commercial Agreement (and
$6,000,000 in aggregate, assuming all Designated Commercial Agreements are executed (the &ldquo;<U>Deduction Amount</U>&rdquo;) on account
of certain Company&rsquo;s indebtedness and cash shortfall (the amount actually required to be paid under this sub-Section (b) shall be referred
hereto as the &ldquo;<U>Deferred Closing Consideration</U>&rdquo;. The Deferred Closing Consideration will be paid within 15 days of the
execution of each Designated Commercial Agreement in accordance with this Section 2.10(b) but in any event not prior to the Closing. It
is agreed that the Purchaser will deduct from the Earn-out Consideration any portion of the Deduction Amount not previously deducted due
to the failure to execute any or all of the Designated Commercial Agreements as specified above (the &ldquo;<U>Deduction Amount Shortfall</U>&rdquo;).
For illustration purposes, if two Designated Commercial Agreements are executed, the Deduction Amount Shortfall shall be $2,000,000. The
deduction of the Deduction Amount Shortfall shall be made from the Earn-out Consideration derived from all Milestones achieved following
the Deferred Closing Payment Date pro rata, such that upon achievement of each Milestone, Purchaser shall be entitled to deduct a percentage
of the Deduction Amount Shortfall equal to the percentage attributed to the applicable Milestone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purpose hereof, the term &ldquo;<U>Designated
Commercial Agreements</U>&rdquo; shall mean commercial agreements between the Company and (i) IHC Health Services, Inc., which provides
for software license and provision of services by the Company to IHC, (ii) DePuy Ireland Unlimited Company, which provides an amendment
to the existing Development and License Agreement dated December 9, 2019 to include a refinement of the product specification, feasibility
and the development milestones, and (iii) The Secretary of State for Health and Social Care, which provides for evaluation project funded
by the UK National Health Service, for utilization of AI-enabled vertebral fracture pathway to prevent osteoporotic fractures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.11 </FONT><U>Notice
of a Failure to Achieve a Milestone</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Within
7 days after each Milestone Target Date, Purchaser shall notify, along with the provisions supporting documentation if and to the extent
applicable or available, to the Equityholder Representative, on the achievement or non-achievement of the respective Milestone for which
such Milestone Target Date has been set (in the case that such notice refers to the non-achievement of such Milestone, it shall be referred
hereto as the &ldquo;<U>Milestone Failure Notification</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;2.12 </FONT><U>Disputes
Regarding the Achievement of a Milestone</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Equityholder Representative
shall have from the time upon which a Milestone Failure Notification is delivered to it until 5:00 p.m., Eastern time, on the date 21
days after the date of such delivery (the &ldquo;<U>Milestone Dispute Period</U>&rdquo; or the &ldquo;<U>Dispute Period</U>&rdquo;) to
dispute the non-achievement of a Milestone (the &ldquo;<U>Milestone Dispute</U>&rdquo; or the &ldquo;<U>Dispute</U>&rdquo;). In the case
that the Milestone Failure Notification was provided with respect to a Milestone, then the Equityholder Representative and its advisors
and representatives shall have reasonable access during regular business hours to the books and records (in electronic format, if available)
of the Company and the Surviving Corporation reasonably relevant to Purchaser&rsquo;s conclusion that the applicable Milestone has not
been successfully achieved. The Equityholder Representative and its representatives may make inquiries of Purchaser and the Company regarding
questions concerning, or disagreements with, the Milestone Failure Notification arising in their review thereof, and Purchaser shall use
its, and shall cause the Surviving Company to use its, commercially reasonable efforts to cooperate with and respond to such inquiries.
If the Equityholder Representative does not deliver to the Purchaser within the Milestone Dispute Period a written notice of the Milestone
Dispute that sets forth in reasonable detail the elements and amounts with which the Equityholder Representative disagrees (a &ldquo;<U>Milestone
Dispute Notice</U>&rdquo; or a &ldquo;<U>Dispute Notice</U>&rdquo;), the Milestone Failure Notification shall be deemed to have been accepted
and agreed to by the Equityholder Representative in the form in which it was delivered by Purchaser and it shall be final and binding
upon the parties. If Equityholder Representative delivers a Milestone Dispute Notice to the Purchaser within the Milestone Dispute Period,
Purchaser and the Equityholder Representative shall use reasonable efforts to resolve the Milestone Dispute and agree in writing upon
the final conclusion of the disputed Milestone within 30 days after delivery of such Milestone Dispute Notice (the &ldquo;<U>Milestone
Dispute Objection Period</U>&rdquo; or a &ldquo;<U>Dispute Objection Period</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) If
Purchaser agrees with the objection of the Equityholder Representative and Equityholder Representative&rsquo;s claims that a Milestone
has been successfully achieved, and expressly confirms such agreement by delivery of written notice of the same delivered to the Equityholder
Representative, then the agreement of the Purchaser and the Equityholder Representative that the Milestone referred to in the Milestone
Failure Notice has been achieved will be final and binding upon the parties. If Purchaser and the Equityholder Representative are unable
to resolve each element of the applicable Dispute within the applicable Dispute Objection Period, then Purchaser will, within 15 days
after expiration of the applicable Dispute Objection Period, notify the Equityholder Representative in writing of its disagreement, which
notice will set forth in reasonable detail the elements and amounts, if applicable, with which Purchaser disagrees (the &ldquo;<U>Dispute
Response</U>&rdquo;). If Purchaser does not deliver to the Equityholder Representative within such 15-day period a Dispute Response, then
the Milestone shall be deemed to have been achieved. If Purchaser timely delivers the Dispute Response, Purchaser and the Equityholder
Representative shall jointly engage the Israeli branch of an internationally recognized certified public accounting firm that has not
performed material accounting, tax or auditing services for Purchaser, the Equityholder Representative, or the Company during the three
years immediately prior to such engagement (the &ldquo;<U>Arbitrating Accountant</U>&rdquo;). If Purchaser and the Equityholder Representative
are unable to agree on the identity of the Arbitrating Accountant, the accountants designated by each of Purchaser and the Equityholder
Representative shall jointly select the Arbitrating Accountant. Each of Purchaser and the Equityholder Representative agrees to use its
commercially reasonable efforts to cooperate with the Arbitrating Accountant and to cause the Arbitrating Accountant to resolve any such
dispute as soon as practicable after the commencement of the Arbitrating Accountant&rsquo;s engagement. The Arbitrating Accountant&rsquo;s
function shall be to resolve each element of the Dispute that has not been resolved by Purchaser and the Equityholder Representative as
an accounting expert and not as an arbitrator, decide whether the Milestone has been achieved or not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) In
connection with the resolution of the Dispute, the Arbitrating Accountant will limit its review to the positions of the parties set out
in the Dispute Notice and the Dispute Response. The Arbitrating Accountant may, at its discretion, conduct a conference concerning the
Dispute, at which conference Purchaser and the Equityholder Representative shall have the right to present additional documents, materials
and other information and to have present their respective advisors, counsel and accountants; <U>provided</U> that, Purchaser and the
Equityholder Representative will be limited by their respective positions in the Dispute Notice and the Dispute Response; and <U>provided
</U>that, the Arbitrating Accountant shall not rely on or consider any other documents, materials, presentations or evidence regarding
the intent or agreement of the parties (other than the plain language of the Agreement) in making a determination. In connection with
the resolution of the Dispute, there shall be no other hearings or oral examinations, testimony, depositions, discovery or other similar
proceedings. Each of Purchaser and the Equityholder Representative shall make available to the other party and the Arbitrating Accountant,
as the case may be, such documents, books, records, work papers, facilities, personnel and other information as such party or the Arbitrating
Accountant may reasonably request to review the resolution which underlies the Milestone Failure Notice and to resolve the applicable
Dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) The
Arbitrating Accountant shall as promptly as possible, and in any event within 30 days after the date of its appointment, render its decision
on each element in the Dispute in writing to Purchaser and the Equityholder Representative, together with a resolution as to whether the
Milestone has been achieved or not. In resolving the Dispute, the Arbitrating Accountant shall be bound by the provisions of this Agreement
Each of the Arbitrating Accountant&rsquo;s decision, the revised calculation of the Merger Consideration (where applicable) and the decision
as to whether the Milestone has been achieved or not, shall be final and binding upon the parties, and judgment may be entered on the
award. The Arbitrating Accountant shall determine the proportion of its fees and expenses to be paid by the Equityholder Representative,
on the one hand, and Purchaser, on the other hand, based on the degree to which the Arbitrating Accountant has accepted the positions
of the respective parties. Notwithstanding the foregoing, each of Purchaser and Equityholder Representative (on behalf of the Equityholders
and which may be paid out of the Expense Fund to the extent available) will be responsible for paying the fees, costs and expenses of
their respective attorneys, accountants and other representatives in connection with the Dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;III<U><BR>
REPRESENTATIONS AND WARRANTIES OF THE COMPANY</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company hereby makes the
representations and warranties to Purchaser that are set forth in this <U>&lrm;Article&nbsp;III</U> as of the date hereof and as of the
Closing Date (except to the extent that such representations and warranties speak as of a specific date, in which case such representations
and warranties are and will be complete and accurate as of such specific date), except as set forth in the disclosure schedule provided
by Company to the Purchaser, as of the date hereof (the &ldquo;<U>Disclosure Schedules</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.1 </FONT><U>Organization,
Existence and Good Standing</U>. The Company is a corporation duly organized and validly existing under the laws of Israel and the Company
is not registered by the Companies Registrar under the status of a &ldquo;Violating Company&rdquo; in the meaning of Section 362a of the
provisions of the ICL, and it has not received any written notice or warning concerning any intention of the Companies Registrar to register
and/or declare the Company as a &ldquo;Violating Company&rdquo;. The Company is in good standing, under the laws of, and is licensed to
do business in, all jurisdictions where the nature of its business or the nature or location of its assets requires such qualification,
except such jurisdictions where the failure to be so qualified or licensed or in good standing would not, individually or in the aggregate,
(a) result in or be reasonably expected to have a Material Adverse Effect or (b) materially and adversely affect the ability of the Company
to consummate the transactions contemplated by this Agreement. The Company has heretofore made available to Purchaser complete and accurate
copies of all Organizational Documents of the Company as currently in effect (including all amendments made thereto at any time on or
before the date hereof) and the Company is not in default under or in violation of any provision thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.2 </FONT><U>Power
and Authority</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
Company has full power and authority to enter into, deliver, and perform this Agreement and the other Transaction Documents to which it
is a party. The execution, delivery and performance of this Agreement and the other Transaction Documents to which it is a party by the
Company and the consummation by the Company of the transactions contemplated by this Agreement and the other Transaction Documents to
which it is a party have been duly and validly approved by the board of directors of the Company and, upon receipt of the Shareholder
Approval, will have been duly and validly approved by the Shareholders. Other than the Shareholder Approval, no other proceedings are
necessary on the part of the Company to authorize the execution, delivery and performance of this Agreement and the other Transaction
Documents to which the Company is a party and the consummation by the Company of the transactions contemplated herein or therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The
Board of Directors of the Company has (i)&nbsp;determined that this Agreement, the Transaction Documents to which the Company is to be
a party and the consummation by the Company of the transactions contemplated hereby and thereby, including the Merger, are fair to, advisable
and in the best interests of the Shareholders of the Company, (ii)&nbsp;approved and adopted this Agreement, the Transaction Documents
to which the Company is to be a party and the consummation by the Company of the transactions contemplated hereby and thereby, including
the Merger, (iii) resolved to recommend approval and adoption of this Agreement and the Merger by the Shareholders and (iv)&nbsp;directed
that this Agreement and the Merger be submitted to the Shareholders for their approval and adoption immediately following the execution
hereof. The only votes or consents required to obtain the Shareholder Approval are set forth on <U>Schedule 3.2(b)</U>. Other than as
set forth on such <U>Schedule 3.2(b)</U>, no other proceedings or actions on the part of the Company or any of its Shareholders are necessary
to obtain the Shareholder Approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.3 </FONT><U>Enforceability</U>.
This Agreement has been duly authorized, executed and delivered by the Company and, assuming (i) due authorization, execution and delivery
by the other parties and (ii) the Shareholder Approval being obtained, constitutes a legal, valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms, except to the extent enforcement may be affected by Laws relating to bankruptcy,
reorganization, insolvency and creditors&rsquo; rights and by the availability of injunctive relief, specific performance and other equitable
remedies. At the Closing, the Transaction Documents to be executed and delivered by the Company will have been duly executed and delivered
by duly authorized officers or other signatories of the Company and, assuming (i) due authorization, execution and delivery by the other
parties thereto and (ii) the Shareholder Approval being obtained, will constitute valid and binding obligations of the Company, enforceable
in accordance with their terms, except to the extent enforcement may be affected by Laws relating to bankruptcy, reorganization, insolvency
and creditors&rsquo; rights and by the availability of injunctive relief, specific performance and other equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.4 </FONT><U>Consents;
Non-contravention</U>. The Company does not need to give any notice to, make any filing with or obtain any authorization, consent, Order
or approval of any Governmental Entity in connection with the execution and delivery of this Agreement and the other Transaction Documents
or the consummation of the transactions contemplated herein and therein. Except as set forth in <U>Schedule 3.4</U>, neither the execution,
delivery and performance of this Agreement and the other Transaction Documents, nor the consummation of the transactions contemplated
herein and therein will: (a) violate any provision of the Company&rsquo;s Organizational Documents; (b) require any consent of or notification
to any third party, conflict with, result in a breach of, or constitute a default or an event creating rights of acceleration, termination,
modification or cancellation or a loss of rights under, any Material Contract or material Permit to which the Company is a party, subject
or otherwise bound; (c) the Company&rsquo;s Knowledge, violate any Law or Order to which the Company or any of its assets or businesses
is subject or otherwise bound; or (d) result in the creation or imposition of any Lien (other than Permitted Liens) upon any of the assets
or businesses of the Company or any of the Company Shares, except with respect to (b), (c) and (d), where such breach, default, violation
or creation or imposition of any Lien (other than Permitted Liens) would not individually or in the aggregate result or be reasonably
expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.5 </FONT><U>Capitalization</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
authorized share capital of the Company consists solely of 8,500,000 Ordinary Shares of the Company, 3,000,000 Preferred C Shares, 1,300,000
Preferred B Shares and 1,500,000 Preferred A Shares. The issued and outstanding share capital of the Company consists solely of 1,577,289<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
Ordinary Shares of the Company, 1,353,248 Preferred C Shares, 734,947 Preferred B Shares, and 957,896 Preferred A Shares. There are no
shares of share capital of the Company of any other class authorized, issued or outstanding. All of the issued and outstanding Company
Shares have been validly issued, are fully paid and non-assessable, and, except as set forth on <U>Schedule&nbsp;3.5(a)(i)</U>, are not
subject to, nor were they issued in violation of, any purchase or call option, preemptive rights, rights of first refusal or similar right.
<U>Schedule 3.5(a)(ii)</U> sets forth, with respect to the Company Shares, the record and beneficial owners thereof as of the date hereof,
the number of each type of Company Shares held by each such owner (including the number of Ordinary Shares of the Company into which such
Company Shares are convertible), and whether any such Company Shares are unvested or subject to a repurchase option, risk of forfeiture
or other contractual right as of the date of this Agreement, and with respect to the Company Convertible Instruments, the Company Shares
which holders of the Company Convertible Instruments are entitled to receive upon conversion thereof pursuant to the consummation of the
transactions contemplated in this Agreement. Each Shareholder holds his, her or its Company Shares free and clear of all Liens. <U>Schedule
3.5(a)(iii)</U> sets forth the number of Ordinary Shares of the Company into which each Preferred C Share, Preferred B Share and Preferred
A Share, respectively, is convertible as of immediately prior to the Closing pursuant to the Company Charter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Slight
changes may be required due to options exercise</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Other
than the Company Convertible Instruments set forth in Schedule 3.5(b) and the Company Warrants, there are no outstanding subscriptions,
options, warrants, convertible securities, puts, calls, rights to subscribe, conversion rights, or other agreements, rights or commitments
of any character relating to the issued or unissued share capital or other securities of the Company by which the Company is bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) As
of the date of this Agreement, there exist no in-the-money outstanding Company Options issued to participants pursuant to the Company
Incentive Plan, which is the only option or equity compensation plan currently sponsored by the Company, other than as set forth in <U>Schedule
3.5(c)</U>. Other than as set forth in <U>Schedule 3.5(c)</U>, the Company Incentive Plan constitutes the only Contract of the Company
pursuant to which the Company has or may grant, make or issue options, calls, rights, convertible securities, commitments or agreements
of any character, written or oral, to which the Company is a party or by which the Company is bound, obligating the Company to issue,
deliver, sell, repurchase or redeem, or cause to be issued, delivered, sold, repurchased or redeemed, any shares of Ordinary Shares of
the Company. The Company has furnished to Purchaser complete and accurate copies of the forms of agreements and instruments relating to
or issued under the Company Incentive Plan, including all exhibit, attachments, amendments, modifications, and supplements thereto, as
well as complete and accurate copies of any individual agreements or instruments which deviate from the provided forms of agreements and
instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Except
as set forth on <U>Schedule 3.5(d)</U>, to the Company's Knowledge there are no voting trusts, voting agreements, investors rights agreements,
proxies, stockholder agreements or other agreements that may affect the voting or transfer of the Company Shares (including agreements
relating to rights of first refusal, &ldquo;co-sale&rdquo; rights, &ldquo;drag-along&rdquo; rights or registration rights) of any Company
Shares, or any other investor rights, including rights of participation (i.e., pre-emptive rights), voting, board observation, information
or operational covenants (collectively, the &ldquo;<U>Rights Agreements</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) The
Company is not subject to any obligation (contingent or otherwise) to repurchase or otherwise acquire or retire any of its Equity Interests.
No former holder of any Equity Interests of the Company has asserted any claim or rights against the Company or any Shareholder that remains
unresolved and, to the Company&rsquo;s Knowledge, no such claim is threatened. The Company has no right or obligation (contingent or otherwise)
to acquire any direct or indirect equity ownership in, or to make any investment (in the form of a loan, capital contribution or otherwise)
in any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) <U>Schedule
3.5(f)</U> sets forth all of the Indebtedness of the Company. The Company is not in default or otherwise in breach of any Contracts pursuant
to which Indebtedness was issued to the Company. Other than as set forth in Schedule 3.5(f), no holder of Indebtedness has any right (i)&nbsp;to
convert or exchange such Indebtedness for any Equity Interests of the Company or (ii)&nbsp;to vote for the election of directors of the
Company or to vote on any other matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) The
Purchaser Share Consideration issued to the holders of the Company Shares and Company Warrants under <U>Section 2.2</U> and as set forth
on the Payout Spreadsheet will be calculated and will be issued (when issued in accordance with and subject to the terms of this Agreement)
in accordance with and subject to all terms of the Organizational Documents of the Company as in effect on the date hereof and on and
as of the Effective Time, all applicable Laws and any other Contractual requirements on the part of the Company. No holder is entitled
to any treatment of its Company Shares and Company Warrants as applicable, other than as provided in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) Upon
and subject to Closing, any agreement pursuant to which holder of Company Warrants is granted a right to purchase any Company Shares,
and all Company Warrants held by holder of Company Warrants, shall be cancelled and have no further force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.6 </FONT><U>Subsidiaries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Except
for Zebra Medical Vision, Inc, a Delaware corporation and wholly owned Subsidiary of the Company (the &ldquo;<U>US Subsidiary</U>&rdquo;),
the Company does not have any Subsidiaries and except as set forth in Schedule 3.6(a) has never had any other Subsidiaries. Other than
with respect to the US Subsidiary, the Company does not own any Equity Interests or other securities of, or any equity, voting, financial
or ownership interest in, any entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The
Company owns, beneficially and of record, all of the issued and outstanding stock capital of the US Subsidiary, and all the rights thereto
free and clear of liens, claims, charges, encumbrances, restrictions, rights, options to purchase, proxies, voting trust or other voting
agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) All
issued and outstanding share capital of the US Subsidiary has been duly authorized, and is validly issued and outstanding and fully paid
and was issued in accordance with the registration and qualification provisions of all applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) The
US Subsidiary is duly organized, validly existing and in good standing under the applicable laws of the State of Delaware, and has full
corporate power and authority to own its assets and to conduct its business. The US Subsidiary is qualified to do business and the Company
is not aware of any reason or factor which may prevent the US Subsidiary from being in good standing wherever the nature of such US Subsidiary&rsquo;s
business is being conducted. The US Subsidiary has not taken or failed to take any action, which action or failure would preclude or prevent
it from conducting its business after the Closing Date in the manner heretofore conducted or as proposed to be conducted prior to the
Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) The
US Subsidiary does not own Equity Interests or other securities of, or any equity, voting, financial or ownership interest in, any entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) All
of the corporate rights in and to the US Subsidiary are held by, and vested in, the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) Any
representation provided in this Article III with respect to the Company shall, where applicable, be deemed to have been provided, <I>mutatis
mutandis</I>, with respect to the US Subsidiary, unless explicitly excluded herein (for purpose of clarification, the mere reference to
the Company itself (without adding a reference to the US Subsidiary) shall not be deemed an explicit exclusion for the purpose hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.7 </FONT><U>Financial
Statements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Attached
as <U>Schedule 3.7(a)</U> are complete and accurate copies of (i) the audited consolidated balance sheets and related statements of operations,
stockholders&rsquo; equity and cash flows (together with any notes thereto) of the Company as of and for the years ended December 31,
2018 and 2019 (the &ldquo;<U>Audited Financial Statements</U>&rdquo;), (ii) an unaudited consolidated balance sheet and related statements
of operations, stockholders&rsquo; equity and cash flows (together with any notes thereto) of the Company as of and for the years ended
December 31, 2020 (the &ldquo;<U>Unaudited Financial Statements</U>&rdquo;), and (iii) the unaudited but reviewed consolidated balance
sheet and related statements of operations, stockholders&rsquo; equity and cash flows (together with any notes thereto) of the Company
as of and for the 5-month period ended May 31, 2021 (the &ldquo;<U>Interim Financial Statements</U>&rdquo; and, together with the Audited
Financial Statements and the Unaudited Financial Statements, the &ldquo;<U>Financial Statements</U>&rdquo;). The Financial Statements
(A) are consistent with and derived from the monthly books and records of the Company, (B) were prepared in accordance with US GAAP consistently
applied through the periods covered thereby and (C) present fairly, in all material respects, the financial position of the Company as
of the dates thereof and the results of operations and cash flows of the Company for the periods covered by such statements, in accordance
with US GAAP consistently applied through the periods covered thereby, except as disclosed therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Complete
and accurate copies of the books of account, share record books, minute books, bank accounts, and other corporate records of the Company
in the Company&rsquo;s possession have been made available by the Company to Purchaser, and such books and records have been maintained
in accordance with good business practices. The minute books of the Company contain accurate and complete records of all material meetings
held, and material action taken, by the Shareholders, the Company&rsquo;s board of directors, and the committees of the Company&rsquo;s
board of directors, and no material meeting of the Shareholders, board of directors, or committee has been held for which minutes have
not been prepared and are not contained in such minute books. At the Closing, all of those books and records will be in the possession
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) The
Company maintains adequate internal accounting controls which ensure that (i)&nbsp;transactions are executed with management&rsquo;s authorization;
(ii)&nbsp;transactions are recorded as necessary to permit preparation of the Company&rsquo;s financial statements and to maintain accountability
for its assets; (iii)&nbsp;access to its assets is permitted only in accordance with management&rsquo;s authorization; (iv)&nbsp;the reporting
of its assets is compared with existing assets at regular intervals; and (v)&nbsp;accounts, notes and other receivables and inventory
are recorded accurately, and proper and adequate procedures are implemented to affect the collection and/or valuation thereof on a current
and timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.8 </FONT><U>Undisclosed
Liabilities; Indebtedness</U>. The Company does not have any Liabilities other than Liabilities: (a)&nbsp;set forth on the balance sheet
in the Interim Financial Statements and not discharged subsequent to the date of the Interim Financial Statements; (b) for Transaction
Expenses that will be paid by the Company at the Closing in accordance with the terms of this Agreement; (c)&nbsp;incurred by the Company
subsequent to the date of the Interim Financial Statements in the ordinary course of business consistent with past practices and not discharged
subsequent to the date of the Interim Financial Statements; or (d)&nbsp;with respect to future performance (and not breach) under the
executory portion of any Material Contract by which the Company is bound and that was entered into in the ordinary course of the business
consistent with past practices, in the cases of each of (c) and (d), none of which is or may reasonably be expected to be (individually
or in combination with any other Liability) material to the Company. The Company is not a party to, nor does the Company have any commitment
to become a party to, any joint venture, off-balance sheet partnership or any similar contract or any off-balance sheet arrangements where
the purpose or intended effect of such contract or arrangement is to avoid disclosure of any transaction involving, or liabilities of,
the Company in the Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.9 </FONT><U>Assets</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
Company is the sole owner of all right, title, and interest in and to all assets reflected as being owned by it in the Interim Financial
Statements and all other assets and property, real and personal, tangible and intangible owned, held or used by it, other than (i) any
property or assets leased to the Company or (ii) Intellectual Property licensed to the Company (collectively, the &ldquo;<U>Assets</U>&rdquo;
and, together with (A) all property or assets leased to the Company and (B) Intellectual Property licensed to the Company, the &ldquo;<U>Property</U>&rdquo;),
and, except as set forth on <U>Schedule 3.9(a)</U> and other than pursuant to the express terms of any license agreement pursuant to which
Intellectual Property is licensed to the Company, there exists no restriction on the use or transfer of the Property. Other than set forth
in <U>Schedule 3.9(a)</U>, no Property is in the possession of others and the Company does not hold any property on consignment. The Company
has (I) good title to all of the Assets owned by it, free and clear of all Liens, other than Permitted Liens, and (II) a valid leasehold
interest in all of the leased Property or a valid license right to use all of the licensed Property, free and clear of all Liens. Upon
the Closing, the Company shall continue to be vested with good title to, or a valid leasehold interest or license right interest in, the
Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) All
of the tangible Property has been maintained in accordance with normal industry practice, is in good operating condition and repair (subject
to normal wear and tear), and is suitable for the purposes for which it is presently used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.10 </FONT><U>Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
Company has properly completed and timely filed all income and other material Tax Returns required to be filed by it prior to the Closing
Date, has timely paid all material Taxes required to be paid by them (whether or not shown on any Tax Return), and has no material Liability
for Taxes in excess of the amounts so paid other than Taxes that are not yet due or that are being contested in good faith in appropriate
proceedings. All such Tax Returns were materially complete and accurate and have been prepared in material compliance with applicable
Law. There is no written claim for Taxes being asserted against the Company that has resulted in a Lien against any of the assets of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The
Company has made available to Purchaser true, correct and complete copies of (i) all material Tax Returns filed, examination reports and
statements of deficiencies, adjustments and proposed deficiencies and adjustments in respect of the Company, (ii) any audit report, ruling,
decision, closing or settlement agreement, technical advice memorandum, tax holiday or similar document issued since the inception of
each of the Company (or otherwise with respect to any audit or proceeding in progress) relating to Taxes of the Company, (iii) any examination
reports, and statements of deficiencies assessed against or agreed to by the Company, and (iv) all material written communications to,
or received by the Company from any Tax authority, and (v) all Tax opinions and legal memoranda and similar documents for the Company,
in each case under (ii) to (v), for all taxable periods or all tax years with respect to which the applicable statute of limitations has
not expired. No election has been made with respect to Taxes of the Company in any Tax return that has not been made available to Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) The
Financial Statements reflect all Liabilities for unpaid Taxes of the Company. The Company does not have any Liability for Taxes that is
not included in the Financial Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) There
is (i) no past or pending audit of, or Tax controversy associated with, any Tax Return of the Company that has been or is being conducted
by a Tax Authority, (ii) no other procedure, proceeding or contest of any refund or deficiency in respect of Taxes pending or on appeal
with any Governmental Entity, (iii) no extension of any statute of limitations on the assessment of any Taxes granted by the Company currently
in effect and (iv)&nbsp;no agreement to any extension of time for filing any Tax Return that has not been filed. No claim has ever been
made by any Governmental Entity in writing in a jurisdiction where the Company do not file Tax Returns that the Company is or may be subject
to taxation by that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) The
Company has complied in all material respects with all applicable Laws relating to the payment and withholding of Taxes, including from
payments made or deemed made to employees, suppliers, lenders, SAFEs or any other Persons (including, without limitation, with respect
to the <U>Company Convertible Instruments and any applicable withholding in connection with the conversion thereof) </U>and has duly and
timely withheld and paid over to the appropriate Tax Authority all amounts required to be so withheld and paid under all applicable Laws.
The Company is in compliance with, and its records contain all information and documents necessary to comply with, all applicable information
reporting and withholding requirements under all applicable Tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) The
Company has duly withheld and deducted all of the amounts required to be paid by the Company on account of the issuance of the shares
pursuant to convertible instruments, or was otherwise exempted from such requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) The
Company is duly registered for the purposes of Israeli value added tax and has complied in all material respects with all requirements
concerning value added Taxes (&ldquo;<U>VAT</U>&rdquo;). The Company (i) has not made any exempt transactions (as defined in the Israel
Value Added Tax law of 1975) and there are no circumstances by reason of which there might not be an entitlement to full credit of all
VAT chargeable or paid on inputs, supplies, and other transactions and imports made by it, (ii) has collected and timely remitted to the
relevant Tax Authority all output VAT which it is required to collect and remit under any applicable Law; and (iii) has not received a
refund for input VAT for which it is not entitled under any applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) The
Company is not subject to any restrictions or limitations pursuant to Part E2 of the Ordinance or pursuant to any Tax ruling made with
reference to the provisions of Part E2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) The
Company does not and has never participated or engaged in any transaction listed in Section 131(g) of the Ordinance and the Israeli Income
Tax Regulations (Reportable Tax Planning), 5767-2006 promulgated thereunder nor is it subject to reporting obligations under Sections
131D or 131E of the Ordinance or Sections 67C and 67D or similar provisions under the Israel Value Added Tax law of 1975.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) The
Company is not and has never been a real property corporation (Igud Mekarke&rsquo;in) within the meaning of this term under Section 1
of the Israeli Land Taxation Law (Appreciation and Acquisition), 5723-1963.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k) The
Company is a resident for Tax purposes solely in its country of incorporation, and the Company is not and has never been subject to Tax
in any jurisdiction other than its country of incorporation whether by virtue of having employees, a permanent establishment (within the
meaning of an applicable Tax treaty), any other place of business in such jurisdiction or by virtue of exercising management and control
in such jurisdiction. The Company is not, and has never been, treated as engaged in the conduct of a &ldquo;trade or business&rdquo; within
the United States for purposes of Sections 875, 882, 884 or 1446 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l) <U>Schedule&nbsp;3.10(k)</U>
of the Disclosure Schedules sets forth a true, correct and complete list of any Tax exemption, Tax holiday or other Tax-sharing arrangement
or order that the Company has in any jurisdiction, including the nature, amount and expiration date of such Tax exemption, Tax holiday
or other Tax-sharing arrangement. The Company is in compliance with all terms and conditions required to maintain such Tax exemption,
Tax holiday or other Tax-sharing arrangement or order of any relevant Governmental Entity and, to the Knowledge of the Company, the consummation
of the transactions contemplated hereby will not have any adverse effect on the continuing validity and effectiveness of any such Tax
exemption, Tax holiday or other Tax-sharing arrangement or order. The Company has never made any election to be treated or claimed any
benefits as &ldquo;Beneficial Enterprise&rdquo; (Mifaal Mutay) or otherwise nor did it take any position of being a &ldquo;Preferred Enterprise&rdquo;
(Mifaal Muadaf) or &ldquo;Preferred Technological Enterprise&rdquo; or otherwise under the Law for Encouragement of Capital Investments,
1959. The Company has not taken any position, or represented to any person, that it meets the requirements under the so called &ldquo;The
Angels Law&rdquo; pursuant to Section 20 of the 2011-2012 Economic Policy Law (Legislation Amendments), 2011 and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m) The
Company has made available to Purchaser all documentation relating to any applicable Tax incentives. The Company and is in compliance
with all the material requirements of all such Tax incentives and none of the incentives will be jeopardized by the consummation of the
Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n) The
Company has not been and will not be required to include any adjustment in Taxable income for any Tax period (or portion thereof) pursuant
to Section&nbsp;481 or 263A of the Code or any comparable provision under state, local or foreign Tax laws as a result of transactions,
events or accounting methods employed prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o) The
Company does not own any interest in any controlled foreign corporation pursuant to Section&nbsp;75B of the Ordinance, or other entity
the income of which is required to be included in the income of the Company. The Company is not and has never been a controlled foreign
corporation (as defined in Section&nbsp;957 of the Code) or passive foreign investment company (as defined in Section 1297 of the Code).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p) The
Company (i) is not a party to or bound by any Tax sharing, Tax indemnity, or Tax allocation agreement or (ii) does not have any Liability
or potential Liability to another party under any such agreement, other than customary provisions in any commercial agreement entered
into in the ordinary course of business that does not primarily relate to Tax matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(q) The
Company has not taken a position in any Tax Return that would reasonably be expected to result in the imposition of penalties under Section&nbsp;6662
of the Code (to the extent applicable) or any comparable provisions of state, local or foreign applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(r) The
Company has not participated in, and is not currently participating in, a &ldquo;Listed Transaction&rdquo; or a &ldquo;Reportable Transaction&rdquo;
within the meaning of Section&nbsp;6707A(c) of the Code or Treasury Regulation Section&nbsp;1.6011-4(b), or any transaction requiring
disclosure under a corresponding or similar provision of state, local, or foreign law (including Section&nbsp;131(g) of the Ordinance).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(s) Neither
the Company nor any predecessor of the Company is or has ever been a member of a consolidated, combined, unitary or aggregate group of
which the Company or any predecessor of the Company was not the ultimate parent corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(t) The
Company does not have any Liability for the Taxes of any Person (other than the Company) under Section&nbsp;1.1502-6 of the Treasury Regulations
(or any similar provision of state, local or foreign law), as a transferee or successor, by operation of applicable Law, by Contract or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(u) The
Company will not be required to include any item of income in, or exclude any item of deduction from, Taxable income for any Taxable period
(or portion thereof) ending after the Closing Date as a result of any (i) change in method of accounting for a Taxable period ending on
or prior to the Closing Date, (ii) &ldquo;closing agreement&rdquo; described in Section&nbsp;7121 of the Code (or any corresponding or
similar provision of state, local, or foreign Tax law) executed on or prior to the Closing Date, (iii) intercompany transactions (including
any intercompany transaction subject to section 367 or 482 of the Code) or any excess loss account described in Treasury Regulations under
Section&nbsp;1502 of the Code (or any corresponding or similar provision of state, local, or foreign Tax law) with respect to a transaction
occurring on or prior to the Closing Date, (iv) installment sale or open transaction disposition made on or prior to the Closing Date,
(v) election under Section 108(i) of the Code made on or prior to the Closing Date or (vi) prepaid amount received on or prior to the
Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v) Other
than as set forth in Schedule 3.10(u), the Company has not received any private letter ruling from the IRS (or any comparable Tax ruling
from any other Governmental Entity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(w) The
Company is not a party to any joint venture, partnership or other Contract or arrangement that could be treated as a partnership for U.S.
federal income Tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(x) The
Company has not received any official foreign government receipts for any Taxes paid by it to any foreign Tax Authorities for which receipts
have been provided or are customarily provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(y) The
Company is not, and it has never been, a &ldquo;United States real property holding corporation&rdquo; within the meaning of Section&nbsp;897
of the Code, and the Company is not subject to Section&nbsp;1.897-2(h) of the Treasury Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(z) The
Company has not constituted either a &ldquo;distributing corporation&rdquo; or a &ldquo;controlled corporation&rdquo; in a distribution
of share intended to qualify for Tax-free treatment under Section&nbsp;355 of the Code (i)&nbsp;in the two years prior to the Agreement
Date or (ii)&nbsp;in a distribution that could otherwise constitute part of a &ldquo;plan&rdquo; or &ldquo;series of related transactions&rdquo;
(within the meaning of Section&nbsp;355(e) of the Code) in conjunction with the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(aa) The Company has not
made any classification election pursuant to Section 301.7701-3 of the Treasury Regulations other than the elections described in <U>Section&nbsp;Error!
Reference source not found.</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(bb) The Company has not
made any election statements under Section 83(b) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(cc) The Company is not
a party to any &ldquo;nonqualified deferred compensation plans&rdquo; (within the meaning of Section&nbsp;409A of the Code). The Company
is under no obligation to provide any gross up, indemnification, reimbursement or other payment for any Taxes, including any excise or
additional Taxes, under Section&nbsp;409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(dd) The Company is not
subject to any transfer pricing laws and regulations. No Tax Authority has proposed, asserted or otherwise discussed with the Company
the possibility of a transfer pricing adjustment or failure to comply with any transfer pricing requirements. No transfer pricing adjustment
is reasonably expected to be proposed, asserted or raised by any Tax Authority with respect to the Company either before or after the
Closing Date (i)&nbsp;with respect to any transactions that occurred prior to the Closing Date or (ii)&nbsp;as a result of any transfer
pricing documentation being provided to any Tax Authority by the Company prior to Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ee) No individual classified
by the Company as a non-employee (such as, an independent contractor, leased employee or consultant) was or will be considered as an employee
of the Company by an applicable Tax Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies, and have always been compliant,
with the requirements of Section 85A of the Ordinance and the regulations promulgated thereunder in all material respects. All intercompany
transactions between the Company and the US Subsidiary have met in all material respects the requirements of Section 85A of the Ordinance
and the regulations promulgated thereunder (or any corresponding provision of applicable state, local or non-U.S. Tax Law)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.11 </FONT><U>Conduct
of Business</U>. Other than as set forth in <U>Schedule 3.11</U>, since December 31, 2020, (i) the Company has operated only in the ordinary
course of business consistent with past practice and there has not been or occurred any event, circumstance, change, effect or occurrence
that would have or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and (ii) the Company
has not:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) (i)
amended any of its Organizational Documents or (ii)&nbsp;merged or consolidated with, or acquired, by any means, the shares or assets
of any other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) taken
any action for its winding up, liquidation, dissolution or reorganization or for the appointment of a receiver, administrator or administrative
receiver, trustee or similar officer of all or any of its assets or revenues;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) made
any change in its authorized share capital, issued any shares of share of any class, or issued or become a party to any subscriptions,
warrants, rights, options, convertible securities or other agreements or commitments of any character relating to the issued or unissued
share capital of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) (i)&nbsp;declared,
set aside, established a record date for, made or paid any dividend or distribution (whether payable in cash, stock, property or a combination
thereof)&nbsp;with respect to any of its share capital, (ii)&nbsp;split, combined or reclassified any shares of the Company&rsquo;s share
capital or any other Equity Interests, (iii) purchased, redeemed or otherwise acquired any shares of the Company&rsquo;s share capital
or any other Equity Interests or any rights, warrants or options to acquire any such shares or other securities, or (iv)&nbsp;made any
other actual, constructive or deemed distribution in respect of any shares of the Company&rsquo;s share capital or other Equity Interests
or otherwise make any payment(s) to any Shareholder in its capacity as such;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) sold
or transferred any of its assets or property (including any Intellectual Property), except for sales of inventory and transfers of cash
in payment of trade payables in the usual and ordinary course of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) incurred
any Lien, other than Permitted Liens, on any of its material assets or properties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) suffered
any material loss, or any interruption in use, of any material assets or property of the Company that is not fully covered by insurance,
whether on account of fire, flood, riot, strike, act of God or otherwise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) settled
or compromised, or agreed to settle or compromise, any claim against the Company, or waived any material right of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) initiated
any Proceeding, settled or compromised, or agreed to settle or compromise, any Proceeding initiated by or on behalf of the Company (except
to the extent permitted by part (h) above);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) (i)
incurred, assumed, sold or guaranteed any Indebtedness, (ii) paid, repaid, discharged or satisfied any Indebtedness, (iii)&nbsp;amended
the terms of any Contract related to Indebtedness, (iv)&nbsp;made a loan or advance to any Person or (v) purchased any debt securities
of any Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k) made
any material change to its accounting methods or practices;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l) made
or changed any Tax election; changed any annual Tax accounting period; adopted or changed any method of Tax accounting; filed any amended
Tax Return; entered or changed into any litigation, settlement or final determination of any tax audit, claim, compromise, or other proceeding
or assessment involving the Company and any resolution of any Tax liability or claim for any refund of Taxes or entered into any closing
agreement (as described in Section 7121 of the Code or any corresponding or similar provision of state, local or non-U.S. Law); or surrendered
any right to claim a Tax refund, offset or other reduction in Tax liability;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m) sold,
assigned, transferred, leased, or exclusively licensed any material Intellectual Property of the Company, or, other than in the ordinary
course of business, granted non-exclusive licenses to any material Intellectual Property of the Company, disclosed any source code of
any Company Software to any Person, disclosed any other material confidential information included in Owned Intellectual Property to any
Person (other than to Purchaser and its Affiliates or pursuant to written, valid and binding non-disclosure agreements), or abandoned
or permitted to lapse or otherwise fail to maintain in full force and effect any applications or registrations for material Owned Intellectual
Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n) revalued
any of its assets, including writing down the value of inventory or writing-off notes or accounts receivable other than in the ordinary
course of business consistent with past practice or as required by US GAAP;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o) made
any material change in the Company&rsquo;s cash management practices, including accelerating billing of customers or collection of receivables
or delaying payment of any expenses or payables or taken any action with the intention of increasing the amount of Cash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p) (i)
entered into any Contract for the purchase or lease of any additional real property or (ii) terminated or provided a notice of non-renewal
of any lease of real property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(q) (i)
adopted or amended any (A) bonus, profit sharing, compensation, severance, share option, pension, retirement, deferred compensation, collective
bargaining agreement, neutrality agreement or other labor agreement with any labor union or other collective bargaining representative,
or (B) employment or other employee benefit plan, agreement, or arrangement for the benefit or welfare of any employee, officer, director
or independent contractor or former director, employee, officer or independent contractor, (ii) except for salary increases made in the
ordinary course of business consistent with past practice and not in excess of 2%, increased the compensation or benefits of any such
persons or paid any material benefit not required by an existing Benefit Plan, or (iii) except with respect to the approval of this Agreement,
taken any action that would, or would be reasonably likely to, result in the acceleration of vesting of any Company Option;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(r) (i)
terminated the employment of any manager, officer or employee, or the engagement of any consultant or contractor, except in the ordinary
course of business consistent with past practice or (ii) hired or terminated any employee, or engaged or terminated the engagement of
any consultant or contractor, with a base salary or annual compensation in excess of $75,000;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(s) recognized
any labor union or labor organization as the bargaining representative of any employees of the Company, or negotiated or agreed to any
collective bargaining agreement or other Contract with a labor union or labor organization;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(t) entered
into, amended, modified, terminated or received notice of termination of, or granted any waiver, release or assignment of any material
rights or claims under, any Material Contract or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(u) entered
into any commitment or agreement to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing representations and warranties shall
not be deemed to be breached solely by virtue of the entry by the Company into, or the Company&rsquo;s performance of, this Agreement
or its consummation of the transactions contemplated by this Agreement or by any action taken after the date hereof at the written direction
of or with the written consent of Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.12 </FONT><U>Contracts</U>.
<U>Schedule 3.12</U> contains a list of the following Contracts which the Company is a party to, bound by, or has any obligation under
(each Contract that is listed on <U>Schedule 3.12</U> and each Contract that is required to be listed on <U>Schedule 3.12</U>, but is
not so listed, a &ldquo;<U>Material Contract</U>&rdquo;), in each case as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Contracts
containing (i) any covenant that restricts or purports to restrict the Company&rsquo;s right to compete, directly or indirectly, with
any other Person in any geographic area, (ii) terms in which Company grants to a third party any &ldquo;most favored nations&rdquo; terms
or an exclusive right to purchase from Company with respect to any product or geographic area, (iii) terms in which Company grants any
&ldquo;right of first offer&rdquo; or &ldquo;right of first refusal&rdquo; to any other Person to acquire the Company or any assets or
business thereof, or (iv) any provision in which Company grants exclusivity in favor of any third party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Contracts
providing for an expenditure by the Company in excess of $50,000 in any given 12-month period or in excess of $100,000 in the aggregate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Company
Intellectual Property Agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Any
Contract pursuant to which the Company settled any dispute, or released or was released from any claim pertaining to, any Intellectual
Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) Contracts
providing for the Company&rsquo;s sale of products, the Company&rsquo;s provision of services, or the Company incurring warranty liability
(i) in excess of $50,000 in any given 12-month period annually, in any such case (ii) pursuant to which the Company has agreed to indemnify
or hold harmless the other party thereto for claims arising from any actions or inactions of a Person other than the Company or its Affiliates,
agents, employees, officers and representatives, or (iii)&nbsp;pursuant to which the other party thereto has the right to setoff amounts
owed to the Company against amounts claimed or owed against the other, or any Affiliate of any of them;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) Contracts
pursuant to which the Company is obligated to sell products or to provide services to third parties which (i) the Company knows is at
a price which would result in a net loss to the Company on the sale of such products or provision of such services, (ii)&nbsp;contain
terms or conditions which the Company knows it will be unable, in any material way, to satisfy or fulfill, (iii) do not contain a limitation
on the Company&rsquo;s liability for consequential damages, (iv) does not contain a cap on damages, or (v) provides that the Company pays
liquidated damages; in each case in accordance with the terms of such Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) Contracts
with any Material Customer or Material Supplier;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) leases
or subleases, either as lessee or sublessee or lessor or sublessor, of personal or real property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) Contracts
providing for an expenditure by the Company for the purchase, lease or sale of any real property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) Contracts
that are a profit-sharing, option, equity interest purchase, equity-based compensation, deferred compensation or other plan or material
arrangement for the benefit of, or relating to, current or former directors, officers, managers, independent contractors or employees
of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k) Contracts
pursuant to which any Transaction Expenses are payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l) Contracts
relating to Indebtedness or any Lien, including any loan or credit agreements, pledge agreements, notes, security agreements, mortgages,
debentures, indentures, or letters of credit;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m) Contracts
relating to the acquisition or disposition of a Person or business (i) during the last five years or (ii) pursuant to which the Company
has any continuing rights or obligations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n) Contracts
providing for indemnification of any officer, director, employee, or agent of the Company (other than commercial Contracts entered into
in the ordinary course of business with the Company&rsquo;s vendors, customers or partners);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o) Contracts
involving a partnership, joint venture or the sharing of profits or losses, and any stockholder or limited liability company agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p) collective
bargaining agreements, neutrality agreements, card-check agreements, or other Contracts of any kind with a labor union, works council,
or other labor organization with respect to any employee of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(q) Contracts
with any employee leasing or staffing company by which such employee leasing or staffing company&rsquo;s employees or contractors provide
services to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(r) Contracts
requiring payments from, or providing for payments to, the Company in excess of $50,000 per annum that are not cancelable by the Company
without penalty on 30 days&rsquo; notice or less that are not specifically described on any other Schedule to this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(s) Contracts
relating to any interest rate, currency, commodity derivatives, hedging, or similar transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(t) Contracts
with a Related Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(u) Contracts
containing continuing obligations of the Company relating to any resolution or settlement of any actual or threatened Proceeding; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v) Contracts
containing any revocable or irrevocable power of attorney granted to any Person for any purpose whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(w) Contracts
providing for Government Grants from any governmental authority;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has provided to
Purchaser a complete and accurate copy of each Material Contract, together with all amendments, exhibits, attachments and waivers thereto.
Each Material Contract is legal, valid, binding upon and enforceable against the Company in accordance with its terms and, to the Company&rsquo;s
Knowledge, the other parties thereto. The Company has not materially breached any Material Contract or received any written (or, to the
Company&rsquo;s Knowledge, verbal) notice alleging that a material breach or default by the Company has occurred thereunder and, to the
Company&rsquo;s Knowledge, no material breach or default by the other contracting parties has occurred thereunder. Except as set forth
on <U>Schedule&nbsp;3.12</U>, no event has occurred which, with the passage of time or the giving of notice, or both, would constitute,
a material default under or a violation of any Material Contract by the Company or, to the Company&rsquo;s Knowledge, any other party
to such Material Contract. Except as set forth on <U>Schedule&nbsp;3.12</U>, the Company has not received any written or, to the Company&rsquo;s
Knowledge, oral notification that any party to a Material Contract intends to cancel, terminate, materially adversely modify, refuse to
perform or refuse to renew such Material Contract (if such Material Contract is renewable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.13 </FONT><U>Permits</U>.
The Company possesses, and has possessed, all material Permits that are required under applicable Law or necessary in order for the Company
to conduct its business as presently conducted or then conducted, as applicable, the lack of which is could have a Material Adverse Effect.
The operation of the business of the Company as currently conducted is not, and has not been in violation of, nor is the Company in default
or in violation under any Permit, and no event has occurred which, with notice or the lapse of time or both, would constitute a default
or violation of any material terms, condition or provision of any Permit, except in each case where such default or violation of such
Permit would not reasonably be expected to be material to the Company. There are no actions pending or, to the Company&rsquo;s Knowledge,
threatened, that seek the revocation, cancellation or adverse modification of any Permit, except where such revocation, cancellation or
adverse modification of any Permit would not reasonably be expected to materially impair the ability of the Company to conduct the business
as presently conducted and perform its obligations hereunder. The Company has not received or been subject to any written notice, charge,
claim or assertion, or, to the Company&rsquo;s Knowledge, any other notice, charge, claim or assertion, in each case alleging violations
of any Permit, nor to the Company&rsquo;s Knowledge, has any such notice, charge, claim or assertion been threatened, except where the
receipt of such notice, charge, claim or assertion would not reasonably be expected to, individually or in the aggregate, materially impair
the ability of the Company to conduct its business as currently conducted or to perform its obligations hereunder. Except as set forth
on <U>Schedule&nbsp;3.13</U>, the business of the Company and its Subsidiaries does not involve the use or development of, or engagement
in, encryption technology, or other technology whose development, commercialization, marketing or export requires the Company or any of
its Subsidiaries&rsquo; to obtain a license from any Governmental Authority, including, without limitation, the Israeli Ministry of Defense
or an authorized body thereof pursuant to Section&nbsp;2(a) of the Declaration Regarding the Control of Commodities and Services (Engagement
in Encryption Means), 1974, or under any other Law regulating the development, commercialization, marketing, or export of technology,
knowledge, services or goods (including, without limitation, the Israeli Defense Export Control Law, 2007, the Israeli Order of Import
and Export (Control of Export of Dual Use Goods, Services and Technologies), 2006, or the Israeli Trading with the Enemy Ordinance, 1939).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.14 </FONT><U>Litigation</U>.
There are no, and there have not been since June 1, 2016, any Proceedings of any kind or nature, in law or equity, pending or, to the
Company&rsquo;s Knowledge, threatened (i) against the Company or any assets of the Company or used by the Company or any Person whose
liability for such Proceeding has been retained or assumed by the Company, either contractually or by operation of law; (ii) that challenges,
or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, any of the transactions contemplated
by this Agreement; or (iii)&nbsp;that relates to the ownership of any Company Shares, or any Company Option or other right to Company
Shares or other securities of the Company, or right to receive consideration as a result of this Agreement. To the Knowledge of the Company,
no event has occurred, and no claim, dispute or other condition or circumstance exists, that will or could reasonably be expected to,
give rise to or serve as a basis for the commencement of any such Proceeding. The Company is not a party to, or specifically subject to,
any Order or in receipt of a subpoena, civil investigative demand, warrant, or other type of request for documents or information by a
Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.15 </FONT><U>Compliance
with Laws</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
Company is, and at all times has been, in compliance in all material respects with all applicable Laws and Orders. The Company has not
received any written or, to the Company&rsquo;s Knowledge, oral notice of violation of any applicable Law or Order and, to the Company&rsquo;s
Knowledge, no investigation by any Governmental Entity is pending with respect to any actual or alleged violation of Law by the Company
or any of its officers, directors or employees (in their capacity as such).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Neither
the Company nor any of its Affiliates or any of its or their officers or directors, (in their capacity as such), nor to the Company&rsquo;s
Knowledge, any employees, consultants, contractors agents, or other Persons acting for or on behalf of the Company or any of its Affiliates
(i)&nbsp;has been or is designated on, or is owned or controlled by any Person that has been or is designated on, any list of any Governmental
Entity as Persons with whom U.S. Persons cannot transact, including the U.S. Office of Foreign Assets Control&rsquo;s Specially Designated
Nationals and Blocked Persons List, (ii)&nbsp;is a national of, organized under the Laws of, or resident in any country or territory which
is itself the subject of any economic sanctions by any Governmental Entity or (iii) has been convicted of a criminal offense that would
trigger exclusion pursuant to 42 USC 1320a-7(a) or is listed or has been listed by a Federal or State agency as currently suspended, debarred,
excluded, or otherwise ineligible for State or Federal healthcare program participation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Neither
the Company or any of its Affiliates, nor, to the Company&rsquo;s Knowledge, any Person acting or purporting to act on behalf of the Company
or any of its Affiliates or with respect to the business of the Company has at all times, directly or indirectly, (i) made or received
any payment which was not legal to make or receive, (ii) improperly given, offered, promised or authorized the giving of money or anything
of material value to any government official or employee (including officials or employees of state-owned or controlled businesses and
institutions), political party or campaign official, candidate for foreign political office, official or employee of a public international
organization, or any other person acting on behalf of any of the foregoing, or (iii) engaged in any conduct constituting a violation of
Sections 290-297 of the Israeli Penal Law 1977, the U.S. Foreign Corrupt Practices Act of 1977 and the regulations promulgated thereunder,
the UK Bribery Act of 2010, or any similar Law. No investigation or Proceeding relating to any payment described in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.15(c)</U>
that was made, or is alleged to have been made, by or on behalf of the business of the Company is pending before any Governmental Entity,
or, to the Company&rsquo;s Knowledge, is any such Proceeding threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.16 </FONT><U>Real
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as set forth on <U>Schedule&nbsp;3.16:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
Company does not own, and has never owned, any real property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The
Company does not currently lease any real property, and does not have any liabilities or obligations with respect to any lease (whether
current or former).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.17 </FONT><U>Environmental
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
Company is, and at all times has been, in compliance in all material respects with all applicable Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The
Company possesses all material environmental Permits that are required for the operation of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) The
Company has not received any notice, written or otherwise, from any Governmental Entity regarding any actual or alleged material violation
of any Environmental Laws, including any investigatory, remedial or corrective obligations relating to the Company or the Leased Real
Property arising under Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.18 </FONT><U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Schedule
3.18(a)(i)</U> sets forth a complete list of the following that are owned by the Company: (i) patented or registered Intellectual Property,
(ii) pending patent applications and applications for other registrations of Intellectual Property, (iii) material unregistered trademarks
and service marks, (iv) domain name registrations, (v) Company Software, (vi) inventions that are being tracked or considered for possible
patent filings, and (vii) social media accounts (all of the foregoing, together with all other Intellectual Property that the Company
owns or purports to own, being the&nbsp;&ldquo;<U>Owned Intellectual Property</U>&rdquo;). The Company possesses good, valid and legal
title to, and solely owns all right, title and interest in, all of the Owned Intellectual Property, free and clear of any and all Liens
except for Permitted Liens (<I><U>provided</U></I>, <I><U>however</U></I>, that the above representation shall apply, with respect to
items (ii), (iii) and (vi), subject to the Company&rsquo;s Knowledge). Without derogation from the aforesaid in this Section 3.18(a),
each item of Owned Intellectual Property is subsisting and with respect to the items listed in (i) and (iv), valid and enforceable. <U>Schedule
3.18(a)(ii)</U> sets forth a complete list of patent applications that have been filed by the Company that are now abandoned. <U>Schedule
3.18(a)(iii)</U> sets forth a complete list of written opinions or memoranda procured by the Company providing analysis or recommendations
regarding freedom to operate, patentability or other patent clearance or infringement analysis searches performed in respect of any Company
Software or product or service sold, licensed or otherwise provided by the Company (each a &ldquo;<U>Company Product</U>&rdquo;), including
any Company Product that employs any Company Software.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Schedule
3.18(b)</U> sets forth a complete list of all: (i) Contracts (other than ordinary course licenses of commercially available software granted
pursuant to shrinkwrap, click-wrap, or other standard license agreements requiring annual payments of less than $5,000) pursuant to which
the use by the Company of Intellectual Property is permitted by any Person, including as a beneficiary of a covenant not to sue or similar
covenant (the &ldquo;<U>Intellectual Property Licenses</U>&rdquo; and together with the Owned Intellectual Property, the &ldquo;<U>Company
Intellectual Property</U>&rdquo;), (ii) Contracts pursuant to which the Company licenses or sublicenses any Intellectual Property to any
Person (including by granting a covenant not to sue or similar restrictive covenant), other than (A) non-exclusive licenses granted to
vendors and other contractors solely for the purposes of providing services to Company and (B) non-exclusive licenses granted to customers
and distributors of Company in the ordinary course of business consistent with past practice, (iii) Contracts pursuant to which Company
settled any dispute, or released or was released from any claim pertaining to, any Intellectual Property and (iv) Contracts pursuant to
which any Owned Intellectual Property was developed for the Company or the Company&rsquo;s ownership of which was otherwise procured by
the Company (the Intellectual Property Licenses, together with the Contracts identified in items (ii) through (iv) above, the &ldquo;<U>Company
Intellectual Property Agreements</U>&rdquo;). All of the Company Intellectual Property Agreements are in full force and effect and are
valid and enforceable in accordance with their terms. The Company and, to the Company&rsquo;s Knowledge, each other Person that is party
to such Company Intellectual Property Agreement, is in material compliance with all terms and requirements of such Company Intellectual
Property Agreement. The consummation of the transactions contemplated by this Agreement will not extinguish, reduce or limit any rights
of the Company in any Owned Intellectual Property, under any Company Intellectual Property Agreement, or extinguish, reduce or limit any
obligations of any counterparty to any Company Intellectual Property Agreement under any such Company Intellectual Property Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Other
than as set forth in <U>Schedule&nbsp;3.18(c)</U>, the conduct of the Company&rsquo;s business as currently conducted or as previously
conducted, the exercise of the rights of the Company relating to the Company Intellectual Property, and the products and services offered
by or on behalf of the Company at any time (whether by sale, license or otherwise) infringe upon, misappropriate or otherwise violate
(or have infringed upon, misappropriated or otherwise violated) the Intellectual Property of any Person (<I><U>provided</U></I>, <I><U>however</U></I>,
that the above representation if provided, with respect to any Company Intellectual Property which is not (i) patented or registered Intellectual
Property, (ii) domain name registrations, and (iii) Company Software, is subject to the Company&rsquo;s Knowledge). Other than as set
forth in <U>Schedule&nbsp;3.18(c)</U>, the Company has not received any written notice of any claims, and, to the Company&rsquo;s Knowledge,
there are no pending claims, of any Persons relating to the scope, ownership, validity, enforceability or use of any of the Company Intellectual
Property. The Company has not been sued or charged as a defendant in any Proceeding alleging the Company&rsquo;s infringement, misappropriation,
or other violation of any Intellectual Property of any Person, nor has any written claim or demand been made against the Company nor,
to the Knowledge of the Company, otherwise been threatened against the Company (including by an &ldquo;invitation&rdquo; to license as
a means to avoid infringement or potential infringement) alleging the Company&rsquo;s infringement, misappropriation, or other violation
of any Intellectual Property of any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Other
than as set forth in <U>Schedule 3.18(d)</U>, to the Company&rsquo;s Knowledge, no Person is misappropriating, infringing, diluting or
otherwise violating any of the Owned Intellectual Property. No Intellectual Property or other proprietary right misappropriation, validity,
enforceability, infringement, dilution or violation actions or Proceedings have been brought or otherwise asserted against any Person
by the Company. The Company has taken commercially reasonable measures to maintain and protect Company Intellectual Property, including
to protect its rights in and the confidentiality of the source code of the Company Software, its other confidential information and trade
secrets and the confidential information and trade secrets of third parties that have been disclosed to the Company in confidence. In
respect of the confidential information and trade secrets of third parties, the Company has complied in all material respects with its
obligations to such third parties under any written confidentiality or non-disclosure agreements relating to such confidential information
and trade secrets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) The
Owned Intellectual Property, including any Software that is owned by the Company and that constitutes Owned Intellectual Property (the
&ldquo;<U>Company Software</U>&rdquo;), was (i)&nbsp;developed by employees of the Company within the scope of their employment who assigned
any Intellectual Property and related rights that they may have in or to such Owned Intellectual Property to the Company pursuant to valid
and enforceable written agreements; or (ii)&nbsp;developed by independent contractors who assigned any Intellectual Property or related
rights that they may have in or to such Owned Intellectual Property to the Company pursuant to valid and enforceable written agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) Except
as provided in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.18(f)</U>, no university, military, educational institution,
research center, Governmental Entity, entity owned or controlled by any Governmental Entity, hospitals, medical centers or other similar
institutions or organization (each, an &ldquo;<U>R&amp;D Sponsor</U>&rdquo;) has sponsored or provided funding to the Company or the Company&rsquo;s
Subsidiaries for any research and development conducted in connection with the business of the Company and the Company&rsquo;s Subsidiaries,
or has any claim of right to, ownership of or other Lien, or rights to royalties or other consideration on any Company Intellectual Property.
Neither the Company nor any of its Subsidiaries is a participant in any standards-setting activities or joined any standards setting or
similar organization that would affect the proprietary nature of any Company Intellectual Property or restrict the ability of the Company
or any of the Company&rsquo;s Subsidiaries to enforce, license or exclude others from using any Company Intellectual Property, in each
case, except as would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. To the Knowledge
of the Company, none of the employees, consultants or independent contractors of the Company or any of its Subsidiaries who is or was
involved in, or who has or will have contributed to, the creation or development of any of the Company Intellectual Property was, during
the time period in which such Person was engaged by the Company or any of its Subsidiaries, an employee of any R&amp;D Sponsor. Except
as provided in <FONT STYLE="font-size: 10pt">&lrm;</FONT>Section 3.18(f), all Company Software or any products or Intellectual Property
under development by Company or any of its Subsidiaries uses or incorporates Intellectual Property that was developed by the Company or
any of its Subsidiaries using funding provided by the IIA. <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.18(f)</U>
sets forth the amount of each Government Grant received by the Company or any of its Subsidiaries from any R&amp;D Sponsor and with respect
to each of such Government Grants provided by the IIA: (a) the Benefit Track Number; (b) the file number; (c) file approval date; (d)
aggregate amount received; (e) current royalty repayment rate in %; and (f) aggregate royalties repaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) R&amp;D
Sponsor Government Grants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) Except
as set forth in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.18(g)</U>, none of the Company and its Subsidiaries
has applied for, nor received any, Government Grant, from any R&amp;D Sponsor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) The
Company has duly paid all royalties due which apply to each specific Government Grant relevant to any Company Intellectual Property (whether
IIA Funded Intellectual Property or otherwise), and there have been no disputes or disagreements with the relevant R&amp;D Sponsor (whether
the IIA or otherwise) with respect to such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) The
Company submitted to each R&amp;D Sponsor (including the IIA) all the required notices with respect to each non-Israeli Person as required
pursuant to the R&amp;D Law, including the form of undertaking that the R&amp;D Law requires be signed by each such non-Israeli Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv) To
the Company's Knowledge and as evidence by written records, the Company is not required to pay any royalties on account of its development
and License Agreement with DePuy Ireland Unlimited Company, dated December 9, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v) No
Lien was ever created with respect to any IIA Funded Intellectual Property and no such IIA Funded Intellectual Property has ever been
put in escrow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi) The
Company is not, and has not, manufactured (whether by itself or by any other Person), or provided manufacturing rights to another, outside
of Israel in any fashion that uses or incorporates IIA Funded Intellectual Property and has not submitted any request to the IIA for permission
to do so. The Company has not transferred (including, but not limited to, by way of disclosure of such know-how, deposit in escrow or
granting license rights) any IIA Funded Intellectual Property, and has not submitted any request to the IIA for permission to do so. Furthermore,
the royalty repayment cap of any Government Grant relevant to the IIA Funded Intellectual Property has not been increased nor has the
royalty repayment rate (set forth in <U>Schedule 3.18(f)</U>) been increased &ndash; whether or not conditionally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii) The
Company has made available to the Purchaser all material letters of approval, certificates of completion, supplements or amendments thereto
for Government Grants received by the Company from any R&amp;D Sponsor and all material correspondence related thereto. In each application
submitted by or on behalf of the Company (including, without limitation, with respect to IIA Funded Intellectual Property), all material
information required by such application has been disclosed accurately and completely in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(viii) With
the exception of standard restrictions and obligations relating to the receipt of Government Grants from the IIA, there are no other undertakings,
restrictions or obligations of the Company or its Subsidiaries in connection with any Government Grant provided with respect to the IIA
Funded Intellectual Property. The Company is in compliance with the terms and conditions of all Government Grants received by the Company
from any R&amp;D Sponsor (including, without limitation, with respect to IIA Funded Intellectual Property) and the Company has duly and
timely fulfilled all the undertakings relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) The
Company does not use or employ in the conduct of its business as currently conducted (including in connection with the sale, license or
other provision of products or services to customers or other third parties) any Company Software or other Intellectual Property developed
for or provided to a customer of the Company by or on behalf of the Company that the Company has assigned or is obligated to assign to
such customer, other than as permitted by the Company&rsquo;s valid, binding and written agreement with such customer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) <U>Schedule
3.18(i)</U> is a complete and accurate list of all Contracts pursuant to which the Company has granted, or is obligated to grant in the
future, to any third party a license, option, or other right to use or acquire any source code of any Company Software or of any other
Software included in the Company Intellectual Property (&ldquo;<U>Company Source Code</U>&rdquo;), or has provided, disclosed, or made
available, or is obligated to provide, disclose, or make available in the future, to any third party any Company Source Code, including
any Contracts that provide for source code escrow arrangements (the &ldquo;<U>Source Code Licenses</U>&rdquo;).&nbsp; No Company Source
Code has been provided to employees or contractors of the Company except on a need-to-know basis.&nbsp; No Company Source Code has been
provided, disclosed, or made available to any third party except under a valid, binding, written confidentiality agreement or a Source
Code License listed on <U>Schedule 3.18(i)</U>, or has otherwise been provided, disclosed, or made available to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) The
Company has not incorporated into any Company Software, or otherwise used, linked, included or derived from or distributed with any Company
Software any Open Source Code in a manner that that (i) requires the Company to disclose to any third party any source code of any Company
Software; (ii) requires the Company to license a third party to create any derivative work based on any Company Software; (iii) requires
the Company to license, or restricts the Company from licensing, any Company Software to any third party; or (iv) requires the Company
to grant any patent rights including non-assertion or patent license obligations. The Company has complied in all material respects with
all obligations under each Open Source License to which the Company is subject, and <U>Schedule 3.18(i)</U> is a complete and accurate
list of all Open Source Code (or URLs to the applicable pages containing Open Source Code) that is used in, linked to or called by, incorporated
into, included or distributed with, or from which any Company Software is derived, and identifies the purpose for which such Open Source
Code is used, the Open Source License pursuant to which such Open Source Code is licensed, and the source from which such Open Source
Code was acquired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k) No
Company Software and, to the Company&rsquo;s Knowledge, no Software licensed to the Company, contain any time bomb, virus, worm, Trojan
horse, back door, drop dead device, or any other Software designed to disable any other Software or any computer or system automatically,
with the passage of time, under the positive control of any Person, or otherwise, to materially interfere with its normal operation, to
allow circumvention of security controls, or that is otherwise intended to cause damage to hardware, Software or data (collectively, &ldquo;<U>Malicious
Code</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l) All
Company Software and all other Software licensed to Company pursuant to an Intellectual Property License, that (i) is material to the
operation of the Company, (ii) is distributed, sold, licensed, sublicensed, marketed or otherwise provided to third parties by the Company,
(iii) is used or held for use by the Company in connection with its business, or (iv) is owned by the Company and used in the ordinary
course of business to provide Company&rsquo;s services is, (A) in the possession, custody and control of the Company or, with respect
to Software licensed to Company pursuant to an Intellectual Property License, Company&rsquo;s vendors, along with all hardware and software
tools, documentation, and other materials used by the Company to exploit the Company Software and such other Software in the ordinary
course of business, and such Company Software, other Software and related tools and materials will remain so immediately after Closing
and (B) has been catalogued and documented as reasonably necessary to enable competently skilled programmers and engineers to use, update
and enhance such items by readily using the existing source code, engineering drawings, machine settings and documentation (collectively,
the &ldquo;<U>Company Software Documentation</U>&rdquo;), and the Company Software Documentation is in the possession and control of the
Company. The source code of the Company Software is contained within a code repository identified on <U>Schedule 3.18(k)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m) No
Company Software or other Owned Intellectual Property is subject to any Order that restricts, impairs or otherwise imposes any obligation
with respect to the validity, enforceability, disclosure, use, enforcement, prosecution, maintenance, transfer, licensing or other exploitation
of Company Software or other Owned Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.19 </FONT><U>Data
Protection; Privacy</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
Company has established and maintains the policies relating to the data and information processed by or on behalf of the Company, including
by any third party on behalf of the Company (&ldquo;<U>Company Data</U>&rdquo;), as are set forth on <U>Schedule 3.19(a)</U> (&ldquo;<U>Company
Data Policies</U>&rdquo;). All such Company Data Policies comply with applicable Data Requirements. The Company has disclosed to Purchaser
complete and accurate copies of all Company Data Policies. The Company is in compliance with all Company Data Policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Except as set forth on
<U>Schedule 3.19(b)</U>: (i) the Company is in material compliance with all Data Requirements, (ii) the Company has not received any
written notice alleging any failure to comply with any applicable Data Requirements, and (iii) there is no Proceeding pending against
the Company by any Person with respect to any actual or alleged violation of any Data Requirements, or any Company Data or the Processing
thereof, and to the Company&rsquo;s Knowledge there is no reasonable basis for any such investigation, proceeding or other action. The
consummation of the transactions contemplated by this Agreement will not cause the Company to violate any Data Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) The
Company maintains commercially reasonable and appropriate technical, administrative, and physical safeguards and measures that are designed
to (i) ensure the availability, integrity, security, and confidentiality of the Company Information Systems and Company Data; (ii) protect
against any Security Incident; and (iii) protect against any anticipated threats or hazards to the security or integrity of Company Data
or Company Information Systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Except
as set forth on <U>Schedule 3.19(d)</U>, (i) there has been no Security Incident, (ii) the Company has not received any notice alleging
the occurrence of any Security Incident, (iii) no Person (including any Governmental Entity) has commenced any Proceeding with respect
to any Security Incident and (iv) the Company has not notified and, to the Company&rsquo;s Knowledge, there have been no facts or circumstances
that would require the Company to notify, any other Person (including any Governmental Entity) of any Security Incident or any violation
of any Data Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.20 </FONT><U>Information
Technology</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
Company has taken commercially reasonable steps to ensure the systems, devices, networks, and equipment, including hardware, computers,
servers, storage devices, workstations, peripherals, routers, hubs, switches, sensors, and other systems, devices or equipment, and all
Software operating on or in connection with such systems, devices, networks or equipment, that are used or held for use in the conduct
of the business of the Company (the &ldquo;<U>Company Information Systems</U>&rdquo;) are reasonably adequate for the operation of the
businesses of the Company as currently conducted[, and the Company has purchased a sufficient number of license seats for all Software
currently used by or on behalf of the Company. With respect to the Company Information Systems: (i) the Company has taken commercially
reasonable steps and implemented commercially reasonable procedures to ensure, or, in the case of Company Information Systems not controlled
or configured by the Company, has contractually required its vendor or contractor to implement commercially reasonable procedures to ensure,
that such Company Information Systems do not include any Malicious Code, which procedures include the use of antivirus software to protect
such Company Information Systems from becoming infected by any Malicious Code; (ii) except as set forth on <U>Schedule 3.20(a)</U>, to
the Company&rsquo;s Knowledge, there has not been any material malfunction or any material unplanned downtime or service interruption
in or affecting any Company Information System; (iii) the Company has taken commercially reasonable steps and implemented commercially
reasonable procedures to manage its licenses to all Software that is a component of the Company Information Systems controlled or configured
by the Company and ensure compliance with the terms of such licenses and have fully complied with all vendor-initiated audits of usage
of such Software; and (iv) the Company has taken commercially reasonable steps and implemented commercially reasonable procedures to mitigate
risks that the Company Information Systems will be used or accessed by persons other than Company employees, contractors or other authorized
personnel or other than in a manner in which such personnel are authorized to use or access the Company Information Systems. The Company
has taken commercially reasonable measures to provide for system redundancy and back-up of data and material information in a commercially
reasonable manner and has exerted commercially reasonable efforts to avoid disruption or interruption to the business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The
Company is not obligated to support or maintain any of the Company Software except pursuant to Contracts with customers in the ordinary
course of business or as set forth in <U>Schedule 3.20(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.21 </FONT><U>Employee
Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Schedule
3.21(a)</U> sets forth a complete and accurate list of all Benefit Plans. The Company has made available to Purchaser, with respect to
each Benefit Plan listed on <U>Schedule 3.21(a)</U> (to the extent applicable thereto), copies of the plan document, as currently in effect,
or, if such Benefit Plan is not in writing, a written description of the material terms of such Benefit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Each
Benefit Plan, including any related trust or other funding arrangement, has been established, maintained, funded, and administered, in
all material respects, in accordance with its terms and in compliance with applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Except
as would not reasonably be expected to result in a material Liability to the Company, all contributions, premiums and other payments required
to have been made by the Company to the Benefit Plans prior to the Closing Date have been (or will be) timely made or provided for prior
to the Closing in accordance with past practice. All insurance premiums have been paid in full, subject only to normal retrospective adjustments
in the ordinary course, with regard to the Benefit Plans for policy years or other applicable policy periods ending on or before the Closing
Date. Full payment has been made of all amounts due under each of the Benefit Plans and to each person employed or formerly employed by
the Company that are required under the terms of the Benefit Plans to have been paid, and all obligations regarding the Benefit Plans
required to be satisfied prior to the date hereof have been satisfied in all material respects in accordance with the terms of the Benefit
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Other
than as stated in the governing documents of such Benefit Plans made available to Purchaser or as required under Law, each Benefit Plan
may be amended, modified or terminated without advance notice to or consent by any employee or beneficiary, and without liability for
any payment or penalty, other than benefits accrued as of the date of such amendment, modification or termination and administrative expenses.
Except as set forth in such Benefit Plan, the Company has not (i) undertaken to maintain any Benefit Plan for a period of time or (ii)
announced its intention, or undertaken (whether or not legally bound), to modify (other than as required to maintain such Benefit Plan
in compliance with applicable Law) or terminate any Benefit Plan or adopt any arrangement or program which, once established, would come
within the definition of Benefit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) Except
as explicitly required by the terms of this Agreement or as set forth on <U>Schedule 3.21(e)</U>, neither the execution of this Agreement
nor the consummation of the transactions hereunder will (whether alone or together with any other event or events, including termination
of employment) (i) entitle any current or former Company officer, director, employee or independent contractor to any increase in any
compensation or benefits due under any Benefit Plan, (ii) accelerate the time at which any compensation, benefits or award may become
payable, vested or required to be funded in respect of any current or former Company officer, director, employee or independent contractor,
(iii) entitle any current or former Company officer, director, employee or independent contractor to any compensation or benefits or (iv)
require any contributions or payments to fund any obligations under any Benefit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) Except
as set forth on <U>Schedule&nbsp;3.21(f)</U>, there are no claims (other than routine claims for benefits, appeals of such claims and
domestic relations order proceedings) pending or, to the Company&rsquo;s Knowledge, threatened with respect to (or against the assets
of) any Benefit Plan that would reasonably be expected to result in a material liability to the Company. Except as set forth on <U>Schedule&nbsp;3.21(f)</U>,
to the Company&rsquo;s Knowledge, no Benefit Plan is, or was during the last three years, under audit or investigation by any Governmental
Authority, nor is any such plan the subject of an active filing under any voluntary compliance, amnesty, closing agreement or other similar
program sponsored by a Governmental Entity, and no completed audit, compliance filing or closing agreement has resulted in the imposition
of any material Tax, interest or penalty that has not been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.22 </FONT><U>Employees;
Labor</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) There
has not been, nor to the Company&rsquo;s Knowledge has there been a written threat of, any union organizing, labor strike, labor dispute,
walkout, slowdown, picketing, refusal to cross picket lines, stoppage or lockout pending concerning the Company or involving any employee
of the Company. The Company is not party to or bound by any collective bargaining agreement, Contract or other agreement or understanding,
or any duty to bargain, with a labor union, works council or other labor organization, and, to the Company&rsquo;s knowledge, no labor
union, works council or labor organization represents any employees of the Company in respect of their employment with the Company. There
is not pending any request or demand that the Company recognize any labor organization as the bargaining representative of any employees
of the Company, and no petition for election or unfair labor practice charge is pending or, to the Company&rsquo;s Knowledge, threatened
to be filed with any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Schedule
3.22 contains </U>a list of all the current Company Service Providers who receives an average monthly payment of more than US$ 1,000 as
of the date of this Agreement has been made available to the Purchaser via a virtual data room and correctly reflects (i) their dates
of employment; (ii)&nbsp;their job titles and positions; (iii) work location; (iv) employment classifications (including whether each
Company Service Provider is (A) full-time or part-time, (B) hourly or salaried and (C) an employee, contractor or intern); (v) classification
as exempt or non-exempt under applicable overtime, wage and hour regulation, including the Hours of Work and Rest Law, 1951; (vi)&nbsp;all
compensation and benefits to which each such person is entitled, including their hourly rate of compensation (in case of hourly workers),
monthly base salary or annual salary, any other compensation payable to them, whether in cash or otherwise (including housing allowances,
cash compensation payable pursuant to bonus, deferred compensation, travel allowances or commission arrangements), social benefits (including
<I>bituach menahalim</I> and <I>keren hishtalmut</I>), recuperation pay entitlement or other benefits, and each Company Employee Plan
in which they participate or are eligible to participate; (vi)&nbsp;the number of hours and days of sick time to which such persons are
entitled and which have accrued; (vii)&nbsp;the vacation days to which such persons are entitled, annual entitlement to vacation days
and their accrued and unpaid vacation days; (viii) length of notice period required in order to terminate their employment, if any; (ix)&nbsp;automobiles
and other benefits in kind; and (x) their respective contribution rates and the salary basis for such contributions and whether such persons
are subject to the arrangement set forth in Section 14 of the Israeli Severance Pay Law, 1963 (the &ldquo;<U>Section 14 Arrangement</U>&rdquo;)
(and, to the extent any such person is subject to the Section 14 Arrangement, an indication of whether such arrangement has been applied
to such person from the commencement date of his or her employment and on the basis of his or her entire salary); (xii) their most recent
compensation increase including the date and amount thereof; (xiii) whether such persons are on leave or scheduled to be on leave (and
if so, the category of leave, the date on which such leave commenced or will commence and the date of expected return to work) and (xiv)&nbsp;visa
status, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">Except as set forth on <U>Schedule&nbsp;3.22(b)</U>,
no promises or commitments have been made to any of the Company Service Providers, whether in writing or orally, with respect to any future
changes or additions to their compensation or benefits. All Company Service Providers are properly classified and to the Company's Knowledge,
no Company Service Provider which is not an employee of the Company or the US Subsidiary would not reasonably be expected to be reclassified
by any Governmental Entity as an employee of the Company or the US Subsidiary, and all such Persons&rsquo; agreements contain provisions
which state that no employer-employee relations exist between such Persons and the Company. No Company Service Providers who is not an
employee of the Company or the US Subsidiary is entitled to any rights under any applicable labor laws. All current and former Company
Service Providers have received all of their rights to which they are and were entitled according to applicable Laws and their contracts
with the Company. Except as set forth on <U>Schedule&nbsp;3.22(b)</U>, the Company does not engage any personnel through manpower agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Without
derogating from any of the above representations, the Company&rsquo;s liability towards Company&rsquo;s employees regarding severance
pay, accrued vacation and contributions to all Company Employee Plans are fully funded or, if not required by any source to be funded,
are accrued on the Company&rsquo;s financial statements as of the date of such financial statements. The Section 14 Arrangement was properly
applied for in accordance with the terms of the general permit issued by the Israeli Minister of Labor regarding all former and current
employees of the Company who reside in Israel based on their full salaries and from their commencement date of employment. All amounts
that the Company is legally or contractually required to either (i)&nbsp;deduct from its employees&rsquo; salaries and any other compensation
or benefit or to transfer to such employees&rsquo; Company Employee Plan or (ii) withhold from employees&rsquo; salaries and any other
compensation or benefit and to pay to any Governmental Entity as required by any Applicable Laws have in either case been duly deducted,
transferred, withheld and paid, and the Company does not have any outstanding obligation to make any such deduction, transfer, withholding
or payment (other than routine payments, deductions or withholdings to be timely made in the ordinary course of business and consistent
with past practice).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) The
Company is, at all times has been, in material compliance with all applicable Laws respecting labor and employment, employment practices,
and terms and conditions of employment. (i) each employee performing service for the Company has been classified properly as exempt or
non-exempt under applicable Law concerning wages and hours of employment, and (ii) each Person performing services for the Company as
a volunteer, contractor or other non-employee classification has been properly classified as such by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) All
payments to Company Service Providers made by the Company have been in payment of bona fide fees and commissions and not as bribes, kickbacks
or as otherwise illegal or improper payments. All such payments have been made directly to the parties providing the goods or services
for which such payments were made, and no such payment has been paid in a manner intended to avoid currency controls or any party&rsquo;s
Tax reporting or Tax payment obligations. The Company has properly, fairly and accurately reflected on its books and records: (i)&nbsp;all
compensation paid to and perquisites provided to or on behalf of its agents and employees; and (ii)&nbsp;all compensation and perquisites
that are due and payable or deferred and payable to such persons, but which have not been paid or provided at the Closing Date. Such compensation
and perquisites have been properly and accurately disclosed in the respective Financial Statements and other public or private reports,
records or filings of the Company, to the extent required by Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) The
Company has been, operated in compliance in all material respects with all Applicable Laws relating to employment, termination of employment
and labor matters, including but not limited to, discrimination in employment, terms and conditions of employment, worker classification
(including the proper classification of workers as independent contractors, consultants and advisors), wages, pay slips, working hours,
overtime and overtime payments, working during rest days, social benefits contributions, termination and severance payment and engaging
employees through services providers (including manpower employees and service providers in accordance with the Israeli Law for Strengthening
the Enforcement of Labor Laws-2011 ), collective bargaining, extension orders, civil rights, safety and health, immigration, work-authorization,
privacy issues, fringe benefits, employment practices and the collection and payment of withholding or social security taxes and any similar
tax. The Company does not have any outstanding obligations with respect to non-payment of wages. The Company did not receive written notice
of complaints, charges or claims against the Company, and there are no controversies, complaints, charges or claims pending or, to the
Knowledge of the Company, threatened, between the Company and any current or former Company&rsquo;s employees, based on, arising out of,
in connection with or otherwise relating to the employment or termination of employment or failure to employ by the Company, of any individual
or Company Service Providers, which controversies have resulted or would reasonably be expected to result in a Proceeding before any Governmental
Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) Except
as set forth on <U>Schedule 3.22(h)</U>, the Company has paid in full to each employee all wages, salaries, commissions, bonuses and other
compensation due to such Person as of the date hereof and as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) To
the Company&rsquo;s Knowledge, no current or former officer, director or employee of the Company is a party to, or is otherwise bound
by, any agreement or arrangement, including any confidentiality, non-competition, non-solicitation or proprietary rights agreement, between
such employee, officer or director and any other Person that in any way adversely affected, affects or may affect (i) the performance
of his or her duties as an employee, officer or director of the Company, or (ii) the ability of the Company to conduct business. Except
as set forth on <U>Schedule 3.22(h)</U>, no third party has notified the Company that any Person currently or formerly engaged or employed
by the Company (i) has violated any of the terms or conditions of any employment, non-competition, non-solicitation or non-disclosure
agreement that such Person has entered with any third party, (ii) has disclosed or utilized any trade secret or proprietary information
or documentation of any third party, or (iii) has interfered in the employment relationship between any third party and any of such third
party&rsquo;s present or former employees. The Company is not obligated to indemnify any Person for such Person&rsquo;s breach of any
terms or conditions of any employment, non-competition, non-solicitation or non-disclosure agreement that such Person has entered with
any third party. Each current and former employee of the Company has executed an employee confidentiality and inventions agreement substantially
in the form provided to Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) To
the Company&rsquo;s Knowledge, no allegations of sexual harassment or sexual misconduct have been made against (i) any officer or director
of the Company or (ii) any employee of the Company. The Company has not entered into any settlement agreement relating to the allegations
of sexual harassment or sexual misconduct by any director, officer or other employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) No
independent contractor of the Company has given notice that he or she intends to terminate or materially reduce his or her relationship
with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k) The
employment of each of the current Company Service Providers is terminable by the Company without cause, subject only to the terms of the
respective engagement agreement and applicable Legal Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l) All
of the employees of the Company which have been terminated prior to the date hereof shall not be employed by the Company as of the Closing
and the Company shall have performed a final settlement with each of them and paid all related amounts prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.23 </FONT><U>Related
Parties Transactions</U>. Other than set forth in <U>Schedule 3.23</U>, the Company (a) has not entered into any agreement, Contract,
arrangement or other transaction or business relationship with any Related Party other than employment agreements and Benefit Plans in
the ordinary course of an employment relationship consistent with the Company&rsquo;s practices and policies with respect to employees
generally, and (b)&nbsp;is not owed and does not owe any financial obligation to or from any Related Party (excluding employee compensation
and other ordinary incidents of employment in the ordinary course of business consistent with past practice and consistent with the Company&rsquo;s
practices and policies with respect to employees generally). No property or interest in any property (including designs and drawings concerning
machinery) that relates or pertains to or is or will be necessary in the present or currently contemplated future operation of the business
of the Company is owned by or leased by or to any Related Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.24 </FONT><U>Customers;
Suppliers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Schedule
3.24(a)</U> sets forth a complete and accurate list of the top 20 customers of the Company, determined based on revenue received from
such customers, for each of the 2019 and 2020 calendar years (each such customer, a &ldquo;<U>Material Customer</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Schedule
3.24(b)</U> sets forth a complete and accurate list of the top 20 suppliers to the Company, determined by dollar purchase volume (measured
by gross amount) as made by the Company during each of the 2019 and 2020 calendar years (each such supplier, a &ldquo;<U>Material Supplier</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Other
than as set forth in <U>Schedule 3.24(c)</U>, the Company has not received any written or, to the Company&rsquo;s Knowledge, oral notice
from any Material Customer or Material Supplier to the effect that, and the Company does not have any Knowledge that, any such Material
Customer or Material Supplier, (i) with respect to Material Customers, has ceased or materially reduced, or intends to cease or materially
reduce, doing business with or refuse or otherwise fail to purchase or pay for goods or services from the Company, or (ii) with respect
to Material Suppliers, has ceased or materially reduced, or intends to cease or materially reduce, doing business with or refuse or otherwise
fail to supply goods or services to the Company, in each case consistent with past practices. The Company has not received any written,
or, to the Company&rsquo;s Knowledge, oral, notice from any customer requesting a benefit, credit, compensation, reperformance or other
recourse on account of any alleged deficiency (including failure to meet timelines) relating to or arising from goods provided or services
performed by the Company for such customer, and the Company has no Knowledge of any such claim by any customer. The Company is not involved
in any material dispute with any Material Customer or Material Supplier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.25 </FONT><U>Insurance</U>.
<U>Schedule&nbsp;3.25(a)</U> sets forth a complete and accurate list of all insurance policies and programs maintained by or for the benefit
of the Company or in respect of its assets, liabilities, properties or businesses as of the date of this Agreement (the &ldquo;<U>Insurance
Policies</U>&rdquo;). All such Insurance Policies are in full force and effect and the Company is not in material default with respect
to its obligations thereunder. Except as set forth on <U>Schedule 3.25(b)</U>, all premiums with respect to the Insurance Policies have
been paid in full and the Company has not received any written notice of cancellation, material change in premium or denial of renewal
in respect of any of the Insurance Policies. The Company has provided to Purchaser true, correct and complete loss runs for all Insurance
Policies and a true, correct, and complete list of all open claims or circumstances with respect to which notice has been provided to
the insurer or managing general agent thereof. The Company has not made any claim against an Insurance Policy as to which the insurer
is denying coverage or defending the claim under a reservation of rights. To the Company&rsquo;s Knowledge, there presently exist no claims
or circumstances that are reasonably likely to give rise to claims under the Insurance Policies as to which notice has not been provided
in accordance with the terms of the applicable Insurance Policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.26 </FONT><U>Names;
Officers and Bank Accounts</U>. Except as set forth on <U>Schedule&nbsp;3.26(a)</U>, the Company has never used any name or names under
which it has invoiced account debtors, maintained records concerning its assets or otherwise conducted business, other than the exact
name set forth in its articles or certificate of incorporation (as amended to date). <U>Schedule&nbsp;3.26(b)</U> lists all of the managers,
directors, officers, bank accounts, safety deposit boxes and lock boxes (designating each authorized signatory with respect thereto) of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.27 </FONT><U>Accounts
Receivable</U>. All of the accounts receivable owing to the Company as reflected on the balance sheet set forth in the Interim Financial
Statements (to the extent not received since such date), net of applicable reserves, constitute valid and enforceable claims arising from
bona fide transactions for goods sold or services performed in the ordinary course of business. No material account debtor has refused
or threatened to refuse to pay, for any reason, any material obligations owed to the Company. All accounts receivable are, to the Company&rsquo;s
Knowledge, fully collectible and no account receivable is subject to any counterclaim, set-off, defense, security interest, claim, or
other encumbrance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.28 </FONT><U>Brokers</U>.
Neither the Company nor any of its Affiliates has dealt with or made any arrangement or agreement with any Person who is entitled to a
broker&rsquo;s commission, finder&rsquo;s fee, investment banker&rsquo;s fee or similar payment from the Company or any of its Affiliates
with respect to the transactions contemplated by this Agreement or introducing the parties to each other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;3.29 </FONT><U>Accredited
Investors and Qualified Investors</U>. Fewer than 35 of the Shareholders entitled to receive Purchaser Share Consideration pursuant to
<U>Section 2.3</U> are not Accredited Investors (as such term is defined under Reg. S) or otherwise exempted by virtue of Section 15A
of the Israeli Securities Law, 1968, and if any such Shareholder is not a natural person, such Shareholder was not organized solely for
the purpose of acquiring Ordinary Shares of Purchaser.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;IV<U><BR>
REPRESENTATIONS AND WARRANTIES OF PURCHASER</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Purchaser hereby makes the representations
and warranties to the Company that are set forth in this <U>&lrm;Article&nbsp;IV</U> as of the date hereof and as of the Closing Date
(except to extent that such representations and warranties speak as of a specific date, in which case such representations and warranties
are and will be complete and accurate as of such specific date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.1 </FONT><U>Organization
and Existence</U>. Purchaser is a corporation and Merger Sub is a corporation, and each is duly organized and validly existing under the
Laws of the state of its incorporation. Purchaser and Merger Sub have each qualified as a foreign corporation, and are in good standing,
under the Laws of all jurisdictions where the nature of their respective businesses or the nature or location of their respective assets
require such qualification and where the failure to so qualify would reasonably be expected to have a material adverse effect on the business,
operations (including results of operations), assets, liabilities, or financial condition of Purchaser or Merger Sub or on the ability
of the parties to consummate the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.2 </FONT><U>Power
and Authority</U>. Purchaser and Merger Sub each have full corporate power and authority to enter into and perform this Agreement and
all the other Transaction Documents to be executed or delivered by them in connection with the transactions contemplated by this Agreement.
The execution, delivery and performance of this Agreement and the other Transaction Documents to which each is a party by Purchaser and
Merger Sub and the consummation by Purchaser and Merger Sub of the transactions contemplated in this Agreement and the other Transaction
Documents to which Purchaser and Merger Sub are a party have been duly and validly approved by each of Purchaser&rsquo;s and Merger Sub&rsquo;s
boards of directors and by Merger Sub&rsquo;s sole shareholder. The approval of Purchaser&rsquo;s stockholders for Purchaser to execute
this Agreement and the other Transaction Documents to which Purchaser is a party or consummate the transactions contemplated by this Agreement
is either not required or has been duly given. Other than the adoption of this Agreement by Purchaser in its capacity as the sole shareholder
of Merger Sub, which shall occur on the date of this Agreement, no other Proceedings are necessary on the part of Purchaser or Merger
Sub to authorize the execution, delivery and performance of this Agreement and the other Transaction Documents by Purchaser or Merger
Sub and the consummation by Purchaser and Merger Sub of the transactions contemplated herein and therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.3 </FONT><U>Enforceability</U>.
This Agreement has been duly authorized, executed and delivered by duly authorized officers or other signatories of each of Purchaser
and Merger Sub, and the material terms of the Merger have been approved by Purchaser&rsquo;s board of directors and, assuming due authorization,
execution and delivery by the other parties, constitutes a legal, valid and binding obligation of Purchaser and Merger Sub, respectively,
enforceable against each of Purchaser and Merger Sub in accordance with its terms, except to the extent enforcement may be affected by
Laws relating to bankruptcy, reorganization, insolvency and creditors&rsquo; rights and by the availability of injunctive relief, specific
performance and other equitable remedies. At the Closing, the Transaction Documents to be executed and delivered by each of Purchaser
and Merger Sub will have been duly executed and delivered by duly authorized officers of Purchaser and Merger Sub, respectively, and,
assuming due authorization, execution and delivery by the other parties thereto, will constitute valid and binding obligations of each
of Purchaser and Merger Sub, enforceable in accordance with their terms, except to the extent enforcement may be affected by Laws relating
to bankruptcy, reorganization, insolvency and creditors' rights and by the availability of injunctive relief, specific performance and
other equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;4.4 <U>Capitalization</U><FONT STYLE="font-size: 10pt">&nbsp;</FONT>.
The issued and outstanding share capital of Purchaser, as of the date hereof on a Fully Diluted As Converted Basis is as set forth
on <U>Schedule 4.4</U>. Other than set forth in Schedule 4.4, as of the date hereof there are no outstanding warrants and/or options
to purchase shares of the Purchaser and there is no undertaking or understanding in connection with the issuance of any shares or
securities of the Purchaser. &quot;Fully Diluted As Converted Basis&quot; shall include all shares of Purchaser (whether ordinary
shares, preferred shares, or otherwise) which are issued and outstanding at the time, as well as all shares issuable assuming the
exercise, conversion or exchange into shares of all warrants, options, notes, debentures, or other rights, securities, agreements or
other commitments which by their terms are exchangeable, exercisable or convertible (taking into account anti-dilution or other
similar rights), directly or indirectly, for or into share capital of the Parent, whether or not vested, and whether outstanding,
promised or contingent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.5 </FONT><U>Consents;
Non-contravention</U>. Neither Purchaser nor Merger Sub needs to give any notice to, make any filing with or obtain any authorization,
consent, Order or approval of any Governmental Entity in connection with the execution and delivery of this Agreement and the other Transaction
Documents or the consummation of the transactions contemplated herein and therein. Neither the execution, delivery and performance of
this Agreement and the other Transaction Documents, nor the consummation of the transactions contemplated herein and therein: (a) will
violate any provision of the Organizational Documents of Purchaser or Merger Sub; (b) will violate any Law or Order to which Purchaser
or Merger Sub or any of Purchaser&rsquo;s or Merger Sub&rsquo;s assets or businesses is subject or otherwise bound; or (c) will result
in the creation or imposition of any Lien (other than Permitted Liens) upon any of the material assets or businesses of Purchaser or Merger
Sub.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.6 </FONT><U>Brokers</U>.
Neither Purchaser nor any of its Affiliates has dealt or made any arrangement or agreement with any Person who is entitled to a broker&rsquo;s
commission, finder&rsquo;s fee, investment banker&rsquo;s fee or similar payment with respect to the transactions contemplated by this
Agreement or introducing the parties to each other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.7 </FONT><U>SEC
Reports.</U> A true and complete copy of each annual, quarterly and other report, registration statement, and definitive proxy statement
filed by Purchaser with the SEC since January 1, 2020 and prior to the date hereof (the &ldquo;<U>Purchaser&rsquo;s SEC Documents</U>&rdquo;)
is available on the web site maintained by the SEC at http://www.sec.gov, other than portions in respect of which confidential treatment
was granted by the SEC. As of their respective filing dates, the Purchaser&rsquo;s SEC Documents complied in all material respects with
the requirements of the Securities Act and the Exchange Act, as the case may be, and the rules and regulations of the SEC promulgated
thereunder applicable to such Purchaser&rsquo;s SEC Documents, and none of the SEC Documents, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The financial statements of Purchaser included in the SEC
Documents comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect
thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with GAAP applied on a consistent
basis, except as may be otherwise specified in such financial statements or the notes thereto, and fairly present in all material respects
the financial position of Parent as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.8 </FONT><U>Share
Consideration</U>. The shares of Ordinary Shares of Purchaser to be issued by Purchaser as part the Merger Consideration have been duly
authorized, and upon consummation of the Merger and the issuance of such shares of Ordinary Shares of Purchaser pursuant to and in accordance
with the terms hereof, will be (a) validly issued, fully paid and non-assessable, and (b) issued in compliance with applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.9 </FONT><U>No
Other Representations</U>. Purchaser acknowledges and agrees that neither the Company nor any Equityholder is making any representation
or warranties whatsoever, express or implied, except for the representations and warranties contained in &lrm;Article&nbsp;III and any
representations and warranties contained in the Transaction Documents. Any claims Purchaser may have for breach of representation or warranty
of this Agreement shall be based solely on the representations and warranties of the Company as set forth in &lrm;Article&nbsp;III an
any representations and warranties contained in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.10 </FONT><U>No
Litigation</U>. There are no Proceedings pending or, to the Knowledge of Purchaser, threatened against Purchaser or Merger Sub or any
of their Affiliates, that are reasonably likely to prohibit or restrain the ability of Purchaser or Merger Sub to enter into this Agreement
or consummate the Merger and the other transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.11 </FONT><U>Purchaser
Material Contracts</U>. Purchaser has made available to the Company accurate and complete (except for applicable redactions thereto) copies
of all contract, including all amendments and purchase orders thereto (i) with the top 10 customers (including purchase orders), distributors
or suppliers of the Purchaser which whom the Purchaser has a contract (excluding the agreements relating to the land purchase and facility
construction in the Republic of Korea); (ii) Contracts pursuant to which the use by the Purchaser of Intellectual Property is permitted
by any Person; and (iii) Contracts pursuant to which the Purchaser licenses or sublicenses any Intellectual Property to any Person, other
than (A) non-exclusive licenses granted to vendors and other contractors solely for the purposes of providing services to Purchaser and
(B) non-exclusive licenses granted to customers of Purchaser in the ordinary course of business consistent with past practice, and (iv)
material contracts pursuant to which any Intellectual Property was developed for the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;4.12 </FONT><U>No
Operations of Merger Sub</U>. Merger Sub has been formed solely for the purpose of engaging in the Transaction and is not currently engaged
and, prior to the Effective Time will not have engaged in any other business activities and will have incurred no liabilities or obligations
other than as contemplated by this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;V<U><BR>
COVENANTS OF THE COMPANY</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;5.1 </FONT><U>Reasonable
Access</U>. During the period between the date hereof and the earlier to occur of the termination of this Agreement pursuant to and in
accordance with <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;XI</U> or the Closing (such period, the &ldquo;<U>Pre-Closing
Period</U>&rdquo;), upon reasonable advance notice from Purchaser, the Company shall give to Purchaser&rsquo;s officers, employees, agents,
attorneys, consultants, accountants and lenders reasonable access during normal business hours to all of the properties, books, Contracts,
documents, insurance policies, records and senior management of or with respect to the Company and shall furnish to Purchaser and such
Persons as Purchaser may designate from time to time in writing to the Company such information as Purchaser or such Persons may at any
time and from time to time reasonably request; <U>provided</U> that, the Company shall not be required to disclose any information to
Purchaser if such disclosure would, (a) in the reasonable judgment of the Company, violate applicable Law, or, (b) in the reasonable judgment
of outside counsel to the Company, jeopardize any attorney-client privilege; <U>provided </U>that, in any such event, the parties shall
cooperate with respect to alternative access or disclosure that would not result in such violation or loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;5.2 </FONT><U>Third
Party Consents</U>. During the Pre-Closing Period, the Company shall use its commercially reasonable efforts (including payment to any
third party of any costs or fees in connection with such consents or requests therefor to the extent required by the terms of the applicable
Contract) and make a good faith attempt, and Purchaser shall cooperate with the Company, to obtain the third party consents (which consents
shall be in form and substance reasonably satisfactory to Purchaser) to the consummation of the transactions contemplated by this Agreement
under or with respect to the Contracts, Permits and other instruments enumerated in <U>Schedule 5.2</U> (&ldquo;<U>Required Consents</U>&rdquo;)<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;5.3 </FONT><U>Operation
of the Business.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) During
the Pre-Closing Period, the Company shall (i) carry on its business in the ordinary course, except as otherwise required by this Agreement,
(ii) exercise commercially reasonable efforts to retain the services of the Key Employees, (iii) exercise commercially reasonable efforts
to maintain its books, accounts and records, perform all maintenance and repairs necessary to maintain its facilities and equipment, taken
as a whole, in good operating condition, maintain the insurance policies it currently has in place and otherwise conduct its business,
in each case in the same manner as it is currently conducted, (iv)&nbsp;pay its expenses and payables, and collect receivables in the
ordinary course of business consistent with past practice, (v) exercise commercially reasonable efforts to take all actions, obtain all
consents, and deliver all notices required under the terms of the Company&rsquo;s Organizational Documents in connection with entry into
this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby, (vi) comply
in all material respects with all Laws and Contracts applicable to its operations and business and maintain all Permits required for the
continuation of its operations and business, and (viii) use commercially reasonable efforts to preserve intact its corporate existence
and Owned Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) During
the Pre-Closing Period, the Company shall not take or omit to take any action that would be required to be disclosed on <U>Schedule 3.11</U>
without the prior written consent of Purchaser (which consent shall not be unreasonably withheld, delayed or conditioned).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;5.4 </FONT><U>Certain
Updates</U>. During the Pre-Closing Period, the Company shall promptly notify Purchaser of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Any
Material Adverse Effect or any other fact or circumstance which otherwise results in the Company determining that a condition to its obligations
to consummate the transactions contemplated hereby cannot be fulfilled;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Any
written notice or other written communication from or to any Governmental Entity in connection with the transactions contemplated hereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Any
written notice or other written communication from any Person alleging that the consent of such Person is or may be required in connection
with the transactions contemplated hereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Any
Proceeding commenced, threatened against, relating to or involving or otherwise affecting the Company that, if pending on the date hereof,
would have been required to have been disclosed pursuant to this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) (i)
The damage or destruction by fire or other casualty of any material asset or part thereof or (ii) any asset or part thereof becoming the
subject of any proceeding or threatened proceeding for the taking thereof or of any right relating thereto by condemnation, eminent domain
or other similar governmental action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company hereby acknowledges that Purchaser
does not and shall not waive any right it may have hereunder as a result of such notifications and any notification given pursuant to
this <U>&lrm;Section&nbsp;5.4</U> shall (i) not have any effect for purposes of determining satisfaction of the conditions set forth in
<U>&lrm;Section&nbsp;8.2</U> of this Agreement, (ii) not in any way limit Purchaser&rsquo;s exercise of its rights hereunder, including
those rights set forth in <U>&lrm;Article&nbsp;IX</U>; and (iii) not constitute an update or supplement to the Schedules for any purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;5.5 </FONT><U>Exclusivity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) During
the Pre-Closing Period, the Company hereby covenants and agrees that it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 28.35pt">(i) will
discontinue and cause to be terminated any activities or negotiations currently in process or under discussion with any Person regarding
any offer or proposal or indication of interest in a merger, consolidation or other business combination involving any Equity Interest
in, or a substantial portion of the assets of, the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 28.35pt">(ii) will
not, and will cause its employees, officers, directors, investment bankers, financial advisors, attorneys or other agents or authorized
representatives, directly or indirectly, not to: (A) solicit or encourage, or take any other action to facilitate, any inquiries or the
making of any proposal relating to, any Competing Transaction, (B) enter into discussions or negotiate with any Person with respect to
any Competing Transaction, or (C) endorse or agree to endorse any Competing Transaction. Promptly following the receipt of any inquiry,
proposal or other communication relating to a Competing Transaction (and in any event within two Business Days thereafter), the Company
will notify Purchaser of such receipt and provide a description, in reasonable detail, of all material terms of such inquiry or proposals.
For purposes of this Agreement, a &ldquo;<U>Competing Transaction</U>&rdquo; means any of the following: (I) any merger, consolidation,
share exchange, business combination, joint venture, partnership, or similar transaction (or series of transactions) involving the Company;
(II) any sale, lease, exchange, mortgage, pledge, transfer or other disposition of a material portion of the assets of the Company, (III)
any transaction contemplating either the issuance by the Company of share capital, or the acquisition (directly or indirectly) by any
Person of any of the Company&rsquo;s share capital (excluding in connection with the exercise of Company Convertible Instruments, Company
Warrants and Company Options outstanding as of the date of this Agreement in accordance with their terms), other than financing agreements,
which the Company shall be entitled to pursue during the Pre-Closing Period, <I><U>provided</U></I>, <I><U>that</U></I>, those financing
agreements will not contain any provisions that could interfere with the consummation of the transactions contemplated hereby and each
party to such financing agreements shall sign the Voting Agreement as a condition to providing financing to the Company; or (IV) any similar
transaction, in each case other than the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Prior
to execution of this Agreement, the Company has discontinued and caused to be terminated, and will continue during the Pre-Closing Period
to prevent and not provide or permit, any access to any data room (whether virtual or physical), including the Data Room, or other non-public
information with respect to the Company in connection with any Competing Transaction, or other due diligence activities on the part of
any Person other than Purchaser and its officers, directors, members, shareholders, affiliates, employees, agents, advisors (including
financial advisors, attorneys and accountants), consultants or other representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"></FONT></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;5.6 </FONT><U>Shareholder
Consent</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
Company shall obtain and deliver to Purchaser, simultaneously with the execution of this Agreement, the Voting Agreement executed by the
Requisite Supporting Shareholders. The materials submitted to the Shareholders in connection with seeking the Shareholder Approval shall
include the recommendation of the Company&rsquo;s Board of Directors in favor of the adoption of this Agreement and the transactions contemplated
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The
Company shall use commercially reasonable efforts to obtain an executed Voting Agreement from each Shareholder (in addition to the Requisite
Supporting Shareholders) as soon as possible after the date hereof, and in any case prior to the date of the Company Shareholders Meeting
referred to in Section 13.4 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;5.7 </FONT><U>Termination
of Shareholder Agreements and Related Party Agreements</U>. The Company shall, and shall cause the applicable Shareholders to, cause the
termination, effective as of no later than immediately prior to the Closing, of all shareholder agreements, investors&rsquo; rights agreements,
voting agreements, voting trusts, right of first refusal and co-sale agreements, management rights agreements and all other similar agreements
or contracts relating to the Company to which any of them may be party (the &ldquo;<U>Shareholders Agreements</U>&rdquo;), in each case,
without any liability to the Company. The Company shall cause the termination of all other Contracts between the Company and a Related
Party identified in <U>Schedule 5.7</U>, effective as of no later than immediately prior to the Closing, in each case, without any liability
to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;5.8 </FONT><U>Financial
Statements</U>. The Company shall make commercial reasonable efforts to deliver to the Purchaser by the Closing Date audited consolidated
balance sheets and related statements of operations, stockholders&rsquo; equity and cash flows (together with all notes thereto) of the
Company as of and for the year ended December 31, 2020, prepared in accordance with US GAAS; provided that, it is agreed that the Purchaser
shall not have the right to delay the Closing as a result of non-delivery of such materials on or before the Closing, and further provided
that the Purchaser will bear 50% of all pre-approved costs of the US GAAS audit, if the Closing does not occur.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;VI<U><BR>
COVENANTS OF PURCHASER</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section&nbsp;6.1 </FONT><U>Confidentiality
Agreement</U>. That certain Mutual Confidential Disclosure Agreement, dated March 3, 2021, between the Company and Purchaser (the &ldquo;<U>Confidentiality
Agreement</U>&rdquo;) shall remain in full force and effect in accordance with its terms, and shall survive the execution of this Agreement
notwithstanding the terms thereof (<U>provided</U> that, the parties acknowledge and agree that this Agreement constitutes a final &ldquo;definitive
agreement&rdquo; as referred to therein). The provisions of this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;6.1</U>
and the Confidentiality Agreement shall terminate upon the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section&nbsp;6.2 </FONT><U>Officers&rsquo;
and Directors&rsquo; Liability</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Prior
to the Effective Time, the Company shall procure and bind a tail insurance coverage policy (the &ldquo;<U>Tail Insurance Coverage</U>&rdquo;)
for the benefit of the officers, directors and other Persons who, as of the Closing Date, are covered by the Company&rsquo;s currently
effective directors&rsquo; and officers&rsquo; and other management liability insurance policy (such persons, the &ldquo;<U>Indemnified
Persons</U>&rdquo;), which shall provide the Indemnified Persons with coverage in respect of acts or omissions occurring at or prior to
the Effective Time for a period of six years following the Effective Time in an amount not less than, and that shall have other terms
not materially less favorable to the Indemnified Persons than, the directors&rsquo; and officers&rsquo; and other management liability
insurance coverage presently maintained by the Company. Purchaser shall cause the Surviving Corporation to maintain the Tail Insurance
Coverage in full force and effect and continue to honor the obligations thereunder until the sixth anniversary of the Effective Time.
The Indemnified Persons are third party beneficiaries of this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Purchaser
agrees to cause the Surviving Company to honor in accordance with their terms the provisions of the indemnification agreements listed
in <U>Exhibit </U>G hereto with respect to indemnification of officers, directors, employees and agents of the Company (including provisions
relating to contributions, advancement of expenses and the like if covered under such indemnification agreements) and agrees that prior
to the six year anniversary of the Effective Time, such rights shall not be modified or amended except as required by Law, unless such
modification or amendment expands the rights of the foregoing persons to indemnification (including with respect to contribution, advancement
of expenses and the like). Purchaser acknowledges that any claims for indemnification made by any such indemnified person on or prior
to the sixth anniversary of the Effective Time and covered under such indemnification agreements shall survive such sixth anniversary
until the final resolution thereof. The foregoing Persons, who may be identified within the Company&rsquo;s Organizational Documents,
are third party beneficiaries of this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Purchaser
agrees that as of the Closing and until the last Milestone Target Date (the &ldquo;<U>Milestones Period</U>&rdquo;), Purchaser will provide
the Company such financing and suitable workforce and other resources which are reasonably required in order for the Company to achieve
the Milestones, according to a plan which will be agreed by each of the Purchaser and the Company during the Pre-Closing Period.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;VII<U><BR>
JOINT COVENANTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section&nbsp;7.1 </FONT><U>Commercially
Reasonable Efforts</U>. During the Pre-Closing Period, each of the parties shall use all commercially reasonable efforts to take, or cause
to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to consummate the transactions contemplated
by this Agreement and the other Transaction Documents as soon as practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section&nbsp;7.2 </FONT><U>Further
Assurances</U>. From and after the Closing, the parties will execute such further documents, and perform such further acts, as may be
necessary to comply with this Agreement and the other Transaction Documents and consummate the transactions contemplated by this Agreement
and the other Transaction Documents.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;VIII<U><BR>
CONDITIONS TO CLOSING</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section&nbsp;8.1 </FONT><U>Conditions
to the Company&rsquo;s Obligations</U>. The obligation of the Company to close the transactions contemplated by this Agreement is subject
to the fulfillment (or waiver by the Company, to the extent permitted by Law) of each of the following conditions on or prior to the Closing
Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
representations and warranties made by Purchaser and Merger Sub in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IV</U>
of this Agreement shall be complete and accurate in all material respects (it being understood that, for purposes of determining the accuracy
of such representations and warranties in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.1<FONT STYLE="font-size: 10pt">&lrm;</FONT>(a)</U>,
all &ldquo;Material Adverse Effect&rdquo; and other materiality qualifications contained in such representations and warranties shall
be disregarded) as of the date of this Agreement and as of the Closing Date as though then made and as though the Closing Date was substituted
for the date of this Agreement throughout such representations and warranties (except, in each case, to the extent such representations
and warranties are made on and as of a specified date, in which case the same shall continue on the Closing Date to be so complete and
accurate as of the specified date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) All
covenants and agreements of Purchaser and Merger Sub to be performed hereunder through and including the Closing Date (including all covenants
and agreements Purchaser or Merger Sub would be required to perform at the Closing if the transactions contemplated by this Agreement
were consummated) shall have been fully performed or complied with in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Purchaser
and Merger Sub, as applicable, shall have delivered to Company each of the agreements, documents and instruments required to be delivered
pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.9(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) No
Material Adverse Effect on the Purchaser, and no event or circumstance that would reasonably be expected to result in a Material Adverse
Effect, shall have occurred between the date of this Agreement and the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) The
104H Interim Tax Ruling and an interim 102 Tax Ruling has been obtained from the ITA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section&nbsp;8.2 </FONT><U>Conditions
to Purchaser&rsquo;s and Merger Sub&rsquo;s Obligations</U>. The obligation of Purchaser and Merger Sub to close the transactions contemplated
by this Agreement is subject to the fulfillment (or waiver by Purchaser, to the extent permitted by Law) of each of the following conditions
on or prior to the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) (i)
The representations and warranties contained in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.1</U> (Organization;
Existence), <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.2</U> (Power and Authority), <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.3</U>
(Enforceability), clauses (a) and (c) of the second sentence of <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.4</U>
(Consents; Non-contravention), <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.5</U> (other than the last sentence
of <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.5(c)</U> and <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.5(f)</U>),
<FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.28</U> (Brokers) and <U>Section 3.29</U> (Accredited Investors and
Qualified Investors) shall be complete and accurate in all respects as of the date of this Agreement and shall be complete and accurate
in all respects as of the Closing Date as though then made and as though the Closing Date was substituted for the date of this Agreement
throughout such representations and warranties (except, in each case, to the extent such representations and warranties are made on and
as of a specified date, in which case the same shall continue on the Closing Date to be so complete and accurate as of the specified date),
other than, solely in the case of the representations and warranties contained in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;3.5</U>
(Capitalization), de minimis inaccuracies in the representations and warranties as of such date and (ii) all other representations and
warranties contained in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;III</U> shall be complete and accurate in all
material respects (it being understood that, for purposes of determining the material accuracy of such representations and warranties
in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.2<FONT STYLE="font-size: 10pt">&lrm;</FONT>(a)</U>, all &ldquo;Material
Adverse Effect&rdquo; and other materiality qualifications contained in such representations and warranties shall be disregarded) as of
the date of this Agreement and as of the Closing Date as though then made and as though the Closing Date was substituted for the date
of this Agreement throughout such representations and warranties (except, in each case, to the extent such representations and warranties
are made on and as of a specified date, in which case the same shall continue on the Closing Date to be so complete and accurate as of
the specified date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) All
covenants and agreements of the Company to be performed hereunder through and including the Closing Date (including all covenants and
agreements that the Company would be required to perform at the Closing if the transactions contemplated by this Agreement were consummated)
shall have been fully performed or complied with in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)
No Material Adverse Effect, and no event or circumstance that would reasonably be expected to result in a Material Adverse Effect, shall
have occurred between the date of this Agreement and the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) The
Company or the Equityholder Representative, as applicable, shall have delivered to Purchaser each of the documents required to be delivered
by it at the Closing pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.9(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) The
Shareholder Approval shall have been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) At
least 80% of the Key Employees has remained employed with the Company executed a retention agreement with Purchaser and the Company (the
&ldquo;<U>Key Employee Agreements</U>&rdquo;) (provided, however, that such percentage must include the Key Employee Employment Agreement
with all the Essential Key Employees, as defined in <U>Schedule 1.1</U>). Notwithstanding the foregoing, in the event that the Purchaser
has not provided the Company with the form and principle commercial terms of the Key Employee Agreements proposed to the Key Employees
by August 30, 2021, then the execution of the Key Employee Agreements shall not be a condition to Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) A
restrictive covenant Agreement with Mr. Eyal Toledano shall be executed in a form which will be agreed between the Purchaser and Mr. Eyal
Toledano and shall remain in full force and effect on and as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) All
of the Company Intellectual Property is free and clear of any Encumbrances other than Permitted Liens, and any Software which qualifies
as part of the Company Intellectual Property shall have demonstrated by a reputable third-party professional scan to be free of harmful
Open Source Code, to the full satisfaction of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) The
Company's Chief Executive Officer has confirmed in writing that the Company has (i) duly terminated any IIA grant programs which are inactive
as of the date hereof; (ii) duly submitted to the IIA all required reports and fillings (including final execution reports) with respect
to the Company's active grants, together with proof reasonably acceptable to the Purchaser that such reports were received by the IIA,
(iii) submitted all of the reports it is required to submit, up until the Closing, to Zebra Technologies Corporation, by virtue of its
settlement agreement between the Company and Zebra (dated July 30, 2020, and as amended) or otherwise that there are no outstanding claims
by Zebra Technologies Corporation with respect to non-submission of such reports by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchaser has received (i) the audited consolidated
balance sheets and related statements of operations, stockholders&rsquo; equity and cash flows (together with all notes thereto) of the
Company as of and for the years ended December 31, 2020, prepared in accordance with US GAAP and (ii) the unaudited but reviewed balance
sheet and related statements of operations, stockholders&rsquo; equity and cash flows (together with any notes thereto), but without comparative
figures to the equivalent period of 2020, of the Company for the 6-month period ended June 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section&nbsp;8.3 </FONT><U>Joint
Conditions to the Parties&rsquo; Obligations</U>. The obligations of the parties to close the transactions contemplated by this Agreement
are subject to the fulfillment of all of the following conditions on or prior to the Closing Date (any of which may only be waived in
writing by each of Purchaser and the Company, to the extent permitted by Law):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Israeli
Statutory Waiting Periods</U>. At least 50 days shall have elapsed after the filing of the Merger Proposal with the Companies Registrar
and at least 30 days shall have elapsed after the approval of the Merger by the shareholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>No
Legal Prohibition</U>. No Governmental Authority of competent jurisdiction shall have (i)&nbsp;enacted, issued or promulgated any Law
that is in effect and has the effect of making the Merger illegal or which has the effect of prohibiting or otherwise preventing the consummation
of the Merger, or (ii)&nbsp;issued or granted any Order that has the effect of making the Merger illegal or which has the effect of prohibiting
or otherwise preventing the consummation of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)
<U>ISA Approval</U>. The Purchaser has received exemption from the Israeli Securities Authority according to Section 15D of the Israeli
Securities Law, 1968.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;IX<U><BR>
INDEMNIFICATION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section&nbsp;9.1 </FONT><U>General;
Survival</U>. The representations and warranties of the parties contained in this Agreement and in any certificate delivered by the Company
hereunder (including, for the removal of a doubt, any certificate issued by an officer of the Company as part of the Closing deliverables)
shall survive the execution and delivery of this Agreement and the Closing (and shall not merge into any instrument of conveyance). No
claim for indemnification arising out of breaches of the representations and warranties contained herein or in any certificate delivered
by the Company hereunder shall be brought more than 12 months after the Closing Date, except for claims in respect of the (i) Fundamental
Representations, which claims shall survive and may be brought until the date that is 6 years after the Closing Date, (ii) representations
under <U>Section 3.18 </U>(Intellectual Property), which claims shall survive and may be brought until the date that is 36 months after
the Closing Date; <I><U>provided that</U></I>, notwithstanding the foregoing, claims arising out of the representations and warranties
contained in <FONT STYLE="font-size: 10pt"><B><U>&lrm;</U></B></FONT><U>Section&nbsp;3.10</U> (Taxes) may be brought until 60 days after
the expiration of the applicable statute of limitation (including any extensions or tollings thereof). The respective covenants, agreements
and obligations of the parties set forth in this Agreement or any Transaction Document shall survive the Closing in accordance with their
respective terms, and if no specific term is specified, in perpetuity. No claim for breach of any representation or warranty contained
in this Agreement or in any certificate delivered by the Company hereunder may be made, and no obligation to indemnify for such claim
will arise, unless the claim is asserted in accordance with this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>
prior to the applicable survival termination date as set forth in this <FONT STYLE="font-size: 10pt">&lrm;</FONT><U>Section&nbsp;9.1</U>,
<I><U>provided, </U>however, </I>that if, at any time on or prior to the applicable survival termination date, any Purchaser Indemnitees
delivers to the Shareholders&rsquo; Representative a Claim Notice, then the claim asserted in such Claim Notice shall survive the applicable
survival termination date until such time as such claim is fully and finally resolved. It is the express intent of the parties that the
survival of the representations, warranties covenants and agreements in this Agreement and in any certificate delivered by the Company
hereunder (and the associated right to bring a claim for a breach of such representations, warranties covenants and agreements) is shorter
than the statute of limitations that would otherwise have been applicable to such representations, warranties covenants and agreements,
and, by contract, the applicable statute of limitations with respect to such representations, warranties covenants and agreements (and
the associated right to bring a claim for a breach of such representations, warranties covenants and agreements) are hereby reduced so
they end on the applicable survival termination date set forth in this <U>Section&nbsp;9.1</U>. Each of the parties acknowledges that
this Agreement results from arm&rsquo;s-length negotiations among the parties and embodies the justifiable expectations of sophisticated
parties derived from arm&rsquo;s-length negotiations; Purchaser and the Company specifically acknowledge that neither Purchaser nor the
Company has any special relationship with the other party that would justify any expectation beyond that of an ordinary buyer and an ordinary
seller in an arm&rsquo;s-length transaction, and there are no grounds for the tolling of any applicable statute of limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section&nbsp;9.2 </FONT><U>The
Equityholders&rsquo; Indemnification Obligations</U>. Subject to the other provisions of this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>,
from and after the Closing, by virtue of the Merger and, as applicable, by virtue of the execution of the Voting Agreements, the Equityholders
shall indemnify and hold harmless (and shall pay and compensate, regardless of whether such matters arise from Third Party Claims or direct
claims), Purchaser and its Affiliates (including, from and after the Closing, the Surviving Corporation) and the directors, officers,
managers, employees, shareholders, representatives, successors and assigns of each of them in their capacities as such (&ldquo;<U>Purchaser
Indemnitees</U>&rdquo;) for, from and against any and all Damages sustained or to be sustained by any Purchaser Indemnitee caused by,
arising out of, or resulting from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) any
inaccuracy in or breach of any representation or warranty made by the Company to Purchaser herein or in any certificate required to be
delivered by the Company hereunder, other than the Fundamental Representations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) any
inaccuracy in or breach of any Fundamental Representation made by the Company to Purchaser herein, or any certificate required to be delivered
by the Company hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) any
breach by the Company of, or any failure of the Company to comply with, any of the covenants or agreements under this Agreement to be
performed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) any
Indebtedness of the Company immediately prior to the Closing and any Transaction Expenses, solely to the extent that the same were not
included as deductions in the calculation of the Merger Consideration as finally determined pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.12</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) any
claims or threatened claims by current or former equity or debt holders of the Company of any kind or nature whatsoever, in their capacity
as an equity or debt holder or any other capacity, in each case whether absolute or contingent, liquidated or unliquidated, known or unknown,
and whether arising under any agreement or understanding (other than any claims (i) by current or former equity holders of the Company
against any current or former director of the Company alleging breach of fiduciary duty of such director in connection with such director&rsquo;s
decision to vote in favor of approving this Agreement and the transactions contemplated hereby and (ii) for breach by Purchaser or Merger
Sub of this Agreement and/or any of the other agreements executed and delivered by Purchaser or Merger Sub in connection herewith), including
any claim or threatened claim relating to, caused by, arising out of, or resulting from the failure of the Payout Spreadsheet to be accurate
and complete in all respects at the Closing or otherwise with respect to the allocation of the Merger Consideration, and, in each case,
any failure of the Merger Consideration and the allocation thereof as set forth in the Payout Spreadsheet to have been determined in accordance
with applicable Law, all applicable Contracts, and the Organizational Documents of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) any
Taxes or Damages payable with respect to Taxes claimed or assessed against the Purchaser, the Surviving Corporation, or Affiliates of
either of them for (i) any Pre-Closing Tax Period or the portion of a Straddle Period ending on the Closing Date, including on account
of the withholding, or necessity to withhold, Taxes on account of the conversion of any convertible instrument (including the Company
Outstanding Instruments), (ii) any Tax period with respect to any Taxes of any member of an affiliated, consolidated, combined or unitary
group of which the Company is or was a member on or prior to the Closing Date, (iii)&nbsp;any Tax period with respect to any Taxes of
any Person imposed on the Company as a transferee or successor in respect of a transaction or event occurring before the Closing, by Law,
Contract, or otherwise, and (iv) any Tax period attributable to Unrecognized Tax Items or as a result of the transactions contemplated
by this Agreement, except (in each case) to the extent and in such amount as such Taxes and Damages payable with respect to Taxes were
taken into account (A)&nbsp;in the Transaction Expense Amount, or (B) the Closing Indebtedness (each as finally determined pursuant to
<FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.12</U>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) any
fraud committed by or on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Equityholders&rsquo; indemnity
obligations pursuant to this <FONT STYLE="font-size: 10pt">&lrm;</FONT>Section&nbsp;9.2 shall be joint and several to the extent of the
Indemnity Escrow Amount and, after such time as no Purchaser Shares remain in the Indemnity Escrow Amount, such obligation shall be several
and not joint obligations of the Equityholders, in accordance with and to the extent of their respective Indemnifying Pro Rata Shares
of the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section
9.3&#9;</FONT><U>Limitations on Indemnification Obligations</U>. The parties&rsquo; indemnification obligations are subject to the
following limitations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The
Equityholders shall not have any liability under <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.2(a)</U> unless and
until the aggregate amount of the Damages incurred by the Purchaser Indemnitees exceeds $200,000 (the &ldquo;<U>Equityholder Threshold</U>&rdquo;),
in which case the Equityholders shall be required to pay all Damages, including the amount of the Equityholder Threshold, to the Purchaser
Indemnitees. In addition, Purchaser Indemnitees will not be entitled to assert any individual claim under <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.3(a)</U>
unless the Damages related to such individual claim exceed $10,000 (the &ldquo;<U>Per Claim Threshold</U>&rdquo;) and any such claim that
does not result in Damages in excess of the Per Claim Threshold will not count towards the calculation of the Equityholder Threshold;
<I><U>provided</U></I>, <I><U>that</U></I>, Damages resulting from, arising out of, imposed upon or incurred by any Purchaser Indemnitee
by reason of a breach of or inaccuracy in any of the Fundamental Representations shall not be counted towards the calculation of the Equityholder
Threshold and/or any Per Claim Threshold; <I><U>provided</U></I>, <I><U>that</U></I>, for the avoidance of doubt, whenever multiple claims
exist that arise out of the same set of facts or circumstances, such multiple claims shall be aggregated to constitute a single &ldquo;individual
claim&rdquo; for purposes of the preceding clause (for example, the failure to withhold taxes for all employees would not constitute a
separate item for each employee, but would be deemed a single individual item giving rise to a single Damage in the aggregate amount of
such failures); <I><U>provided</U></I>, <I><U>that</U></I>, to avoid doubt, once such Damages exceed the Per Claim Threshold, Purchaser
Indemnitees may assert such claim and all such Damages, from the first dollar thereof shall be recoverable hereunder and shall count towards
the calculation of the Equityholder Threshold; and <I><U>provided</U></I>, <I><U>that</U></I>, neither the Equityholder Threshold nor
the Per Claim Threshold shall apply to claims of willful misconduct or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The
Equityholders shall not have any liability under <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.2(a)</U>, for any
Damages in excess of the Indemnity Escrow Amount; <I><U>provided</U></I>, <I><U>that</U></I>, the limitation described in this <U>Section
9.3(b)</U> shall not apply in the case of willful misconduct or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)
(i) the aggregate amount of Damages that may be recovered by Purchaser Indemnitees under <U>Sections 9.2(b)</U> and (c), inclusive, shall
be an amount equal to the Merger Consideration, and (ii) no individual Equityholder shall be liable to the Purchaser Indemnitees hereunder
in excess of the amount of Merger Consideration actually received by such Equityholder hereunder (including such Equityholder&rsquo;s
portion of the Escrow Amount, Expense Fund and amounts payable pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;1.1</U>
hereof); <I><U>provided</U></I>, <I><U>that</U></I>, the limitations described in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.3(c)</U>
shall not apply to a particular Equityholder in the case of gross negligence, willful misconduct or fraud by such Equityholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Notwithstanding
anything contained herein or elsewhere to the contrary, any qualifications relating to materiality, including the terms &ldquo;material,&rdquo;
&ldquo;Material Adverse Effect,&rdquo; or monetary thresholds contained in the representations and warranties (or definitions contained
in the representations and warranties) set forth in this Agreement shall be disregarded for purposes of the indemnification provisions
hereof, including for purposes of determining whether or not a breach of a representation or warranty has occurred, determining whether
the thresholds in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U> have been surpassed and/or determining
the amount of any Damages incurred as a result of any breach of a representation or warranty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) No
information or knowledge acquired, or investigations conducted, by Purchaser or its representatives, of the Company or any of its businesses,
assets, liabilities or otherwise, shall in any way limit, or constitute a waiver of, or a defense to, any claim for indemnification or
other claim by Purchaser or any Purchaser Indemnitee under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) Neither
the Equityholder Representative nor any Equityholder shall have any claim for contribution from or against the Company as a result of
any indemnification or other payments made to any Purchaser Indemnitee pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) Notwithstanding
anything herein to the contrary, Purchaser Indemnitees shall not be entitled to recover under <FONT STYLE="font-size: 10pt">&lrm;</FONT>Section&nbsp;9.3:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">any exemplary and punitive Damages (except to the extent
the same are payable to a third party or result from, or arise in connection with, willful misconduct or fraud);</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">any Damages taken into account and actually reflected as a
reduction in the calculation of the Closing Consideration;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">any Damages with respect to any amount actually received by
any Indemnified Party under applicable insurance policies or third party indemnification provisions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) Purchaser
Indemnitees shall not be entitled to recover any Damages relating to any matter arising under one provision of this Agreement to the extent
that Purchaser Indemnitees have already recovered such Damages with respect to such matter pursuant to another provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) Subject
to <FONT STYLE="font-size: 10pt">&lrm;</FONT>Section&nbsp;9.5 any indemnifiable Damages owed to Purchaser or any Purchaser Indemnitee
pursuant to <U>Section 9.3</U> hereunder shall first be settled out of the Indemnity Escrow Account to the extent of the then-remaining
Indemnity Escrow Amount and then, to the extent that such Damages exceed the then available portion of the Indemnity Escrow Account (for
the sake of clarity, the available portion of the Indemnity Escrow Account shall not include any portions that are subject to a previously
submitted Claim Notice) or indemnification for such Damages is due after termination of the Indemnity Escrow Account, any such indemnifiable
Damages shall be, at the sole and absolute discretion of each Equityholder, either settled in share of Ordinary Shares of Purchaser in
an amount of Purchaser Share Consideration based on such Equityholder&rsquo;s Indemnifying Pro Rata Share or paid in cash directly by
the Equityholders in accordance with such Equityholder&rsquo;s Indemnifying Pro Rata Share. Except as set forth in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.3</U>,
no Purchaser Indemnitee shall have any obligation to first submit, seek to collect or to actually collect upon any coverage under any
applicable policy of insurance as a precondition to asserting claim for indemnification hereunder, including for purposes of <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.2</U>
hereof; <I><U>provided that</U></I>, in the event that a Purchaser Indemnitee determines in good faith that it is reasonably likely to
incur Damages for which it may be entitled to indemnification hereunder, Purchaser shall be entitled to submit a Claim Notice in accordance
with <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.6</U> for indemnification of reasonably anticipated Damages in
advance of the actual incurrence by any such Persons of the same, whether to preserve such Person&rsquo;s rights to assert a claim prior
to the expiration of an applicable survival period with regard to the underlying matter, to preserve such Person&rsquo;s rights under
the Escrow and Paying Agent Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is agreed that the number of Ordinary Shares
of Purchaser which will be paid to a Purchaser Indemnity in order to settle any indemnification obligation of the Equityholders under
&lrm;Section&nbsp;9.2 out of the Indemnity Escrow Amount, will be based on the Purchaser Share Consideration Price at Closing, regardless
of the market value of the Ordinary Shares of Purchaser at the time of such payment. However, it is hereby clarified that the number of
Ordinary Shares of Purchaser which will be paid to a Purchaser Indemnity in order to settle any indemnification obligation of the Equityholders
under &lrm;Section&nbsp;9.2 which is <I><U>not</U></I> out of the Indemnity Escrow Amount, will be based on the Purchaser Share Consideration
Price at the time of such settlement and payment, regardless of the market value of the Ordinary Shares of Purchaser at the time of the
Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;9.4&#9;</FONT><U>Purchaser&rsquo;s
Indemnification Obligations</U>. From and after the Closing Date, Purchaser shall indemnify and hold harmless (and shall pay and compensate,
regardless of whether such matters arise from Third Party Claims or direct claims) the Equityholder Representative, Equityholders and
their respective directors, managers, officers, members, shareholders, partners, agents, representatives, successors and assigns (&ldquo;<U>Equityholder
Indemnitees</U>&rdquo;) from and against all Damages sustained or to be sustained by any Equityholder Indemnitee caused by, arising out
of, or resulting from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) any
inaccuracy in or breach of any representation or warranty made by Purchaser to the Company herein or in any certificate required to be
delivered by Purchaser hereunder; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) any
breach by Purchaser or Merger Sub of, or any failure by Purchaser to comply with, any of the covenants or agreements under this Agreement
to be performed by Purchaser or Merger Sub at or prior to the Closing Date (including its obligations under this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;9.5&#9;</FONT><U>Notice
and Determination of Claims</U>. If any Indemnified Party believes that it has sustained or incurred any Damages, whether or not the applicable
dollar limitation specified by <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U> has been exceeded, such Indemnified
Party shall so notify the Indemnifying Party promptly in writing (the &ldquo;<U>Claim Notice</U>&rdquo;) specifying the basis hereunder
upon which the Indemnified Party&rsquo;s claim for indemnification is asserted and describing such Damages, the amount thereof, if known,
or a good faith estimate of the amount, and the method of computation of such Damages, all with reasonable particularity to the extent
then known. For the avoidance of doubt, all Damages caused by, arising out of, or resulting from the facts and circumstances set forth
in a Claim Notice shall be deemed reported at the time such Claim Notice was first delivered to the Indemnifying Party, regardless of
whether such Damages were known or knowable at the time of such delivery or whether or not all or any portion of such Damages had yet
been sustained by the Indemnified Party. Subject to the terms hereof, the Indemnifying Party shall, within 30 days of receipt of a Claim
Notice pursuant to this <U>Section 9.6</U>, either settle the amount of any valid claim, or, if the Indemnifying Party does not agree
to the amount of Damages claimed by the Indemnified Party, deliver written notice to the Indemnified Party disputing such claim in whole
or in part. In the event of any such dispute, the amount of indemnification to which a person shall be entitled under this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>
shall be determined: (a)&nbsp;by the written agreement between the parties; (b)&nbsp;by a final judgment or decree of any court of competent
jurisdiction; or (c)&nbsp;by any other means to which the parties shall agree in writing. The judgment or decree of a court shall be deemed
final when the time for appeal, if any, shall have expired and no appeal shall have been taken or when all appeals taken shall have been
finally determined. A failure by an Indemnified Party to give timely, complete or accurate notice as provided in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>
(including pursuant to this <U>Section 9.5</U> and <U>Section 9.6</U>) will not affect the rights or obligations of any party hereunder
except and only to the extent that, as a result of such failure, any party entitled to receive such notice was actually and materially
prejudiced as a result of such failure to give timely notice vis-&agrave;-vis its rights and obligations hereunder or otherwise. For purposes
of this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>, the Equityholder Representative has the full, and sole
and exclusive, authority to act, and shall act, on behalf of any Equityholder as either an Indemnifying Party or the Indemnified Party.
Without limiting the foregoing, any notice that a Purchaser Indemnitee shall be required to give to any Equityholder shall be satisfied
by the delivery of notice by the Purchaser Indemnitee to the Equityholder Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="text-transform: uppercase">Section&nbsp;9.6&#9;</FONT><U>Third
Party Claims</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Promptly
following the receipt of notice of a Third Party Claim, the party receiving the notice of the Third Party Claim shall notify the other
party of its existence setting forth with reasonable specificity the facts and circumstances of which such party has received notice and,
if the party giving such notice is an Indemnified Party, specifying the basis hereunder upon which the Indemnified Party&rsquo;s claim
for indemnification is asserted and describing such Damages, the amount thereof, if known, or a good faith estimate of the amount, and
the method of computation of such Damages, all with reasonable particularity, to the extent then known.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Subject
to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.6(d)</U>, if the Indemnifying Party provides written notice to the
Indemnified Party stating that the Indemnifying Party is irrevocably and unconditionally liable and responsible for the entire Third Party
Claim and any cost or expense arising out of the investigation, contest or settlement thereof (in each case, subject to the applicable
limitations contained in this Agreement) within ten days after the Indemnifying Party&rsquo;s receipt of written notice from the Indemnified
Party of such Third Party Claim, the Indemnifying Party shall have the right to conduct and control, through counsel of its choosing,
the defense, compromise and settlement of any Third Party Claim as to which indemnification is sought by any Indemnified Party from any
Indemnifying Party hereunder. In such event, the Indemnified Party may participate, through counsel chosen by it and at its own expense,
in the defense of any such Third Party Claim as to which the Indemnifying Party has so elected to conduct and control the defense thereof.
The Indemnified Party shall reasonably cooperate in connection with the defense, compromise or settlement of any Third Party Claim pursuant
to this <FONT STYLE="font-size: 10pt">&lrm;</FONT><U>Section&nbsp;9.6</U> and shall furnish such records, information and testimony and
attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested by the Indemnifying Party
in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) The
Indemnifying Party shall give the Indemnified Party written notice of the Indemnifying Party&rsquo;s intention to settle any Third Party
Claim at least ten days prior to the settlement of any such Third Party Claim. The Indemnifying Party shall not settle or compromise such
claim or demand without the prior written consent of the Indemnified Party, which shall not be unreasonably withheld, delayed or conditioned,
unless the Indemnified Party is given a full and complete release of any and all Liability by all relevant parties to such claim or demand,
there is no finding or admission of any violation of Law or any violation of the rights of any Person by any Indemnified Party and the
sole relief provided is monetary damages that are paid in full by the Indemnifying Party. The Indemnified Party shall have no liability
with respect to any compromise or settlement of any Third Party Claim effected without its consent when consent is required hereunder,
except where such consent is unreasonably delayed or conditions. Notwithstanding the foregoing to the contrary, the Indemnified Party
shall have the right to pay, settle or compromise any Third Party Claim for which the Indemnifying Party may have a liability under this
Agreement without the consent of the Indemnifying Party, <U>provided</U> that, in such event the Indemnified Party shall have no right
to indemnity therefor hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Notwithstanding
anything in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.6(b)</U> or <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.6(c)</U>
to the contrary, the Indemnified Party shall have the right to conduct and control, through counsel of its choosing at (which expenses
will be subject to indemnification hereunder), the defense, compromise and settlement of any Third Party Claim that (i) seeks an injunction
or other equitable relief against the Indemnified Party, (ii) relates to or arises in connection with any criminal matter, or (iii) in
Purchaser&rsquo;s good faith determination, could reasonably be expected to have a material adverse effect on Purchaser, the Company or
their respective businesses. Additionally, the Indemnifying Party shall lose its right to contest, defend, litigate and settle the Third
Party Claim if it shall fail to accept a tender of the defense of the Third Party Claim or if it shall fail to diligently contest the
Third Party Claim. In such event, the Indemnified Party shall have the right to conduct and control, through counsel of its choosing,
the defense, compromise or settlement of any such Third Party Claim; <U>provided</U> that, at least thirty days prior to any such settlement,
written notice of its intention to settle is given to the Indemnifying Party and the Indemnified Party in good faith considers any objections
of the Indemnifying Party. In the event that the Indemnified Party exercises its right to conduct and control any Third Party Claim in
accordance with this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.6(d)</U>, the Indemnifying Party will remain subject
to its obligations hereunder. Notwithstanding anything to the contrary contained herein, to the extent required by the insurer under any
applicable policy of insurance in connection with any claim made by a Purchaser Indemnitee thereunder, the conduct of the defense or prosecution
of any Third Party Claim will be assigned to counsel selected or approved by such insurer, or otherwise conducted in coordination with
the insurer such policy, in each case without prejudice to the rights of the parties hereunder, and the Equityholders, the Equityholder
Representative and the Purchaser Indemnitees will reasonably cooperate with the insurer under any applicable policy of insurance and such
counsel in the defense of the Third Party Claim and otherwise comply with the requirements of such policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) Notwithstanding
any provision of this <U>Section 9.7</U> to the contrary, any Third Party Claim relating to Taxes of the Company shall be governed by
the provisions of <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;X</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;9.7&#9;</FONT><U>Obligations
to Mitigate Damages</U>. Each Indemnified Party shall take, and shall cause all other Indemnified Parties to take, commercially reasonable
efforts to mitigate all Damages upon and after becoming aware of any event that could reasonably be expected to give rise to Damages.
In the event that an insurance or other recovery is made by any Indemnified Party with respect to any Damages for which any such Person
has been indemnified hereunder, then a refund equal to the aggregate amount of the recovery (net of costs and expenses actually incurred
in recovering such amounts) shall be made promptly to the Indemnifying Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;9.8&#9;</FONT><U>Adjustment
to Merger Consideration</U>. All indemnification payments made pursuant to this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>
shall be treated by the parties for all Tax purposes as an adjustment to the Merger Consideration unless otherwise required by Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;9.9&#9;</FONT><U>Indemnification
Exclusive Remedy</U>. Except for remedies that cannot be waived as a matter of Law and injunctive and provisional relief (including specific
performance), and except for the rights of the parties under <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.12</U>
(and without limitation of any such right), if the Closing occurs, indemnification pursuant to the provisions of this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>
shall be the sole and exclusive remedy of the parties with respect to any matters arising under or relating to this Agreement, any Transaction
Document (other than the Key Employee Employment Agreements and the Voting Agreements) and any closing document executed and delivered
pursuant to the provisions hereof and the transactions contemplated by this Agreement and the Transaction Documents (other than the Key
Employee Employment Agreements and the Voting Agreements), and the only legal action that may be asserted by any party with respect to
any matter that is the subject of this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U> shall be a contract action
to enforce, or to recover damages for the breach of, this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;IX</U>. Notwithstanding
the foregoing, the limitations set forth in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;9.9</U> shall not apply
to any claim arising out of or by virtue of willful misconduct or fraud of any party to this Agreement, or any person acting on their
behalf in connection with the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;9.10&#9;</FONT><U>Holdback;
Setoff</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Purchaser shall have
the right to holdback any payment of the Earn-out Consideration until all of the outstanding claims, for which a Claim Notice has been
provided as of the date of the applicable payment of the Earn-out Consideration, are settled. In addition, Purchaser shall have the right
to set off from the Earn-out Consideration any and all Damages to the Purchaser Indemnitees that such Purchaser Indemnitees are entitled
to be indemnified for, or be held harmless with respect thereto, under the provisions of this Article IX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;X<U><BR>
Tax Matters</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;10.1&#9;</FONT><U>Preparation
and Filing of Tax Returns</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Purchaser
shall prepare or cause to be prepared, at the Equityholders&rsquo; expense (to be funded by the Equityholder Representative out of the
Expense Fund on behalf of the Equityholders, to the extent available, and thereafter by the Equityholders directly), and timely file or
cause to be filed, all Tax Returns of the Company required to be filed after the Closing Date for any Pre-Closing Tax Period or any Straddle
Period. Purchaser shall permit Equityholder Representative to review and comment on each Tax Return described in the preceding sentence
that is either an Income Tax Return of which reflects any Tax liability in excess of the amount of such Taxes that is included in Closing
Indebtedness or Transaction Expenses (each as finally determined pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.12</U>)
and for which the Equityholders are responsible, and shall incorporate Equityholder Representative&rsquo;s reasonable comments into such
Tax Returns but only to the extent such comments could reasonably be expected to affect the indemnification obligations of the Equityholders
pursuant hereto. Except as otherwise required pursuant to applicable Law, or permitted with Equityholder Representative&rsquo;s consent
(which consent shall not be unreasonably withheld, conditioned, or delayed), all Tax Returns prepared pursuant to this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;10.1</U>
shall be prepared and filed in a manner consistent with past practices of the Company. Purchaser shall not amend or cause to be amended
any Tax Return of the Company for any Pre-Closing Tax Period or take any other action with respect to any such period that could reasonably
be expected to increase any indemnification obligations of the Equityholders hereunder, in each case, without the prior written consent
of the Equityholder Representative, which consent shall not be unreasonably withheld, conditioned, or delayed. The parties acknowledge
and agree that for U.S. federal Income Tax purposes, the taxable year of the Company will end at the end of the day on the Closing Date
and, to the extent applicable Tax Laws in other taxing jurisdictions so permit or require, the parties will elect to cause the taxable
year of the Company to terminate at the end of the day on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) All
Taxes payable with respect to Pre-Closing Tax Periods and the portion of the Straddle Period ending on the Closing Date, including the
Tax Returns prepared pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;10.1(a)</U>, shall be borne by the Equityholders
except to the extent and in such amount as such Taxes are included in Closing Indebtedness or Transaction Expenses (each as finally determined
pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.12</U>), and the Equityholder Representative, on behalf
of the Equityholders, shall pay such Taxes to Purchaser no later than seven Business Days prior to the due date for filing such Tax Returns.
For purposes of this Agreement, the portion of Taxes allocable to the portion of a Straddle Period ending on the Closing Date shall (i)
in the case of property, ad valorem and other Taxes imposed on a periodic basis, be deemed to be the amount of such Taxes for the entire
Straddle Period multiplied by a fraction the numerator of which is the number of days in the Straddle Period ending on (and including)
the Closing Date and the denominator of which is the number of days in the entire Straddle Period, and (ii) in the case of any other Taxes,
be deemed equal to the amount that would be payable if the relevant Straddle Period ended as of (and included) the Closing Date pursuant
to an interim closing-of-the-books. Any credits relating to a Straddle Period shall be taken into account as though the relevant Tax period
ended at the end of the day on the Closing Date. All determinations necessary to give effect to the allocations described in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;10.1(b)</U>
shall be made in a manner consistent with the prior practice of the Company, except for changes required by Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;10.2&#9;</FONT><U>Prohibited
Actions</U>. Purchaser shall not, and shall cause its Affiliates not to, without the prior written consent of the Equityholder Representative
(which consent shall not be unreasonably withheld, conditioned or delayed) amend any Tax Return, make, change or revoke any Tax election,
file any Tax Return in a jurisdiction in which Tax Returns have not previously been filed by that entity, initiate or enter into any voluntary
disclosure agreement or similar agreements, extend any applicable statute of limitations or take any other similar action outside the
ordinary course of business, in each case with respect to the Company and relating to any Pre-Closing Tax Period or Straddle Period, to
the extent that doing so could increase the liability of the Company for Taxes under applicable Law for which the Equityholders would
be liable under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;10.3&#9;</FONT><U>Control
of Audit or Tax Litigation</U>. After the Closing Date, Purchaser shall control any Proceedings that relates to Taxes or Tax Returns of
the Company (each a &ldquo;<U>Tax Controversy</U>&rdquo;) with respect to a Pre-Closing Tax Period or Straddle Period, and shall have
the right to employ counsel and other advisors of its choice; <I><U>provided that</U></I>, with respect to any such Tax Controversy, (a)
Purchaser shall promptly notify the Equityholder Representative of any such Tax Controversy; <I><U>provided that</U></I>, Purchaser&rsquo;s
failure or delay in notifying the Equityholder Representative of a Tax Controversy will not relieve Equityholders of any liability that
it may have to Purchaser under this Agreement, except to the extent that Equityholders are actually and materially prejudiced by such
failure or delay, (b) Purchaser shall allow the Equityholder Representative to participate in any such Tax Controversy at Equityholders&rsquo;
expense, and (c) Purchaser shall not settle or otherwise resolve any such Tax Controversy to the extent such settlement or resolution
would actually and materially increase the indemnification obligations of the Equityholders pursuant to <U>Section 9.3</U>) unless Purchaser
obtains Equityholder Representative&rsquo;s prior consent (which consent shall not be unreasonably withheld, delayed or conditioned).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;10.4&#9;</FONT><U>Cooperation</U>.
Purchaser, the Company and the Equityholder Representative (on behalf of Equityholders and to the extent in its possession) shall cooperate,
as and to the extent reasonably requested by the other party (including the furnishing, upon request and as promptly as practical, such
information, including reasonable access to books and records) in connection with the preparation and filing of any Tax Return and any
Tax Controversy, and each shall execute and deliver such powers of attorney and other documents as are necessary to carry out the intent
of this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;10.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;10.5&#9;</FONT><U>Transfer
Taxes</U>. All sales, use, transfer, real property transfer, documentary, recording, gains, share transfer and similar Taxes and fees,
and any deficiency, interest or penalty asserted with respect thereto, arising out of or in connection with the transactions effected
pursuant to this Agreement (collectively, &ldquo;<U>Transfer Taxes</U>&rdquo;) shall be borne by Purchaser. Purchaser and the Equityholders
shall reasonably cooperate in timely making all filings, Tax Returns, reports and forms as may be required with respect to all such Transfer
Taxes. Purchaser and the Equityholders agree to use commercially reasonable efforts to obtain any certificate, including a resale certificate,
or other document from any Governmental Entity as may be necessary to mitigate, reduce, or eliminate any Transfer Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;10.6&#9;</FONT><U>Tax
Refunds</U>. Any Tax refunds (including any interest in respect thereof) that are actually recognized (in cash or as a credit reducing
Taxes that would otherwise be due) by Purchaser, the Surviving Corporation, or their respective Affiliates, with respect to Taxes of the
Company arising in a Pre-Closing Tax Period or the portion of a Straddle Period ending on the Closing Date, in each case, to the extent
such Taxes were paid by the Company and such Tax refunds were not taken into account as an increase to the Merger Consideration, shall
be for the benefit of the Equityholders, and Purchaser shall pay or cause to be paid over to the Paying Agent for further distribution
to the Equityholders any such Tax refunds within 20 days after Purchaser&rsquo;s, the Surviving Corporation&rsquo;s, or their respective
Affiliate&rsquo;s actual receipt or entitlement thereof. Notwithstanding anything to the contrary herein, the amount of any payment Purchaser
makes or causes to be made pursuant to this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;10.6</U> shall be calculated
net of any reasonable costs (including Taxes) incurred by Purchaser, the Surviving Corporation, or their respective Affiliates, of obtaining,
distributing, or paying over the applicable Tax refund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;10.7&#9;</FONT><U>Tax
Sharing Agreements</U>. All Tax Sharing Agreements, other than this Agreement<U>,</U> shall be terminated as of the Closing and, after
the Closing, neither Purchaser nor the Surviving Corporation shall have any liability under any such Tax Sharing Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;10.8&#9;</FONT><U>104H
Tax Ruling</U>. The Company and the Equityholders (represented by the Equityholder Representative) shall prepare and file with the ITA,
no later than five (5) Business Days from the date of this Agreement, applications for rulings, which, among others, (i) are permitting
any Shareholders (other than with respect to their Company 102 Shares) who elect to become a party to such a tax ruling (each, an &ldquo;<U>Electing
Holder</U>&rdquo;), to defer any applicable Israeli Tax with respect to any consideration in Purchaser Share Consideration that such Electing
Holder will receive pursuant to this Agreement until the date set forth in Section 104H of the Ordinance (the <I>&ldquo;</I><U>104H Tax
Ruling</U><I>&rdquo;</I>; the 104H Tax Ruling may initially be issued by the ITA in the form of an interim pre-ruling, which shall be
referred hereto as the &ldquo;<U>104H Interim Tax Ruling</U>&rdquo;); and (ii) confirming, a as part of a &ldquo;102 ruling&rdquo;, that
the conversion of the Company Options into the assumed options to purchase Ordinary Shares of the Purchaser, and the conversion of Company
102 Shares into Ordinary Shares of the Purchaser, will not result in a requirement for an immediate Israeli tax payment, and that the
Israeli taxation will be deferred until the exercise of the options issued in exchange of the Company Options, or in the event of assumed
options which are Company 102 Options, until the earlier of: (x) the actual sale of the Ordinary Shares of Purchaser covered by the assumed
options, or the release of the assumed options and/or the Ordinary Shares of Purchaser covered by the assumed options from trust (the
&ldquo;<U>102 Tax Rulings</U>&rdquo;, and collectively with the 104H Tax Ruling and the 104H Interim Ruling, the &ldquo;<U>Israeli Income
Tax Rulings</U>&rdquo;). Purchaser shall cooperate with the Company, the Electing Holders and their Israeli counsel with respect to the
preparation and filing of such application and in the preparation of any written or oral submissions that may be necessary, proper or
advisable to obtain the Israeli Income Tax Rulings; provided that any costs associated with the application for the Israeli Income Tax
Rulings shall be paid by the Company or reduced as Transaction Expenses. Subject to the terms and conditions hereof, the Company and the
Equityholders shall use commercially reasonable efforts to promptly take, or cause to be taken, all action and to do, or cause to be done,
all things necessary, proper or advisable under applicable law to obtain the Israeli Income Tax Rulings, as promptly as practicable. For
the avoidance of doubt, the Company and the Electing Holders shall not make any application to the ITA with respect to any matter relating
to the Israeli Income Tax Rulings without first consulting with the Purchaser&rsquo;s Israeli legal counsel, granting Purchaser&rsquo;s
legal counsel the opportunity to review and comment on the draft application and obtaining the Purchaser&rsquo;s approval for those Israeli
Income Tax Rulings, and the Company and the Electing Holders shall inform Purchaser&rsquo;s counsel of the content of any material discussions
and meetings relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;XI<U><BR>
TERMINATION</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;11.1&#9;</FONT><U>General</U>.
The parties shall have the rights and remedies with respect to the termination and/or enforcement of this Agreement that are set forth
in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Article&nbsp;XI</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;11.2&#9;</FONT><U>Right
to Terminate</U>. This Agreement and the transactions contemplated by this Agreement may be terminated at any time prior to the Closing
by prompt notice given in accordance with <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;14.3</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) by
the mutual written consent of Purchaser and the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) by
either of such parties if the Closing shall not have occurred at or before 11:59&nbsp;p.m., Israeli time, on December 31, 2021; provided
that the right to terminate this Agreement under this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;11.2(b)</U> shall
not be available to any party whose failure to fulfill any of its obligations under this Agreement has been the principal cause of or
resulted in the failure of the Closing to occur on or prior to the aforesaid date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) by
Purchaser in the event of any material breach by the Company of any of its agreements, representations or warranties contained herein
such that the closing conditions set forth in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.2(a)</U> or <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.2(b)</U>,
as applicable, would not be satisfied, and the failure of the Company to cure such breach within thirty (30) days after receipt of notice
from Purchaser of such breach; <I><U>provided</U></I>, <I><U>that</U></I>, Purchaser is not then in breach of this Agreement so as to
cause a condition to the Closing set forth in either <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.1(a)</U> or <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.1(b)</U>
to not be satisfied as of the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) by
the Company in the event of any material breach by Purchaser or Merger Sub of any of Purchaser&rsquo;s or Merger Sub&rsquo;s agreements,
representations or warranties contained herein such that the closing conditions set forth in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.1(a)</U>
or <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.1(b)</U>, as applicable, would not be satisfied, and the failure
of Purchaser to cure such breach within 30 days after receipt of notice from Equityholder requesting such breach to be cured; <I><U>provided</U></I>,
<I><U>that</U></I>, the Company is not then in breach of this Agreement so as to cause a condition to the Closing set forth in either
<FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.2(a)</U> or <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;8.2(b)</U>
to not be satisfied as of the Closing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) by
Purchaser or the Company if there shall be in effect a final, non-appealable Order of a court of competent jurisdiction in effect precluding
consummation of the transactions contemplated by this Agreement; <U>provided</U> that, the right to terminate this Agreement under this
<FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;11.2(e)</U> shall not be available to any party whose failure to fulfill
any of its obligations under this Agreement has been the principal cause of or resulted in the Order; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;11.3&#9;</FONT><U>Remedies
Upon Termination</U>. If this Agreement is terminated pursuant to <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;11.2</U>,
each of the parties to this Agreement shall be relieved of their respective duties and obligations under this Agreement to the extent
that such duties and obligations would otherwise arise after the date of such termination, except as set forth in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;11.4</U>,
<U>Section 11.5</U>, <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;14.1</U>, <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;14.2</U>
or <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;14.3</U>, and no party to this Agreement shall have any claim against
any other party to this Agreement, unless the circumstances giving rise to the termination of this Agreement were caused by a party&rsquo;s
willful misconduct or fraud or willful and intentional breach of a representation, warranty or covenant set forth in this Agreement (which,
for the avoidance of doubt, will be deemed to include any failure by Purchaser to consummate the transactions contemplated hereby if obligated
to do so under this Agreement), in which event termination of this Agreement shall not be deemed or construed as limiting or denying any
legal or equitable right or remedy of the non-breaching parties. If following the termination of this Agreement any Proceeding is commenced
by any party to pursue any legal or equitable right or remedy against any other party whose willful misconduct or fraud or willful and
intentional breach of a representation, warranty or covenant herein results in the termination of this Agreement, all fees, costs and
expenses, including reasonable attorneys&rsquo; fees and court costs, incurred by the prevailing party in such Proceeding shall be reimbursed
by the losing party; <U>provided</U> that, if a party to such Proceeding prevails in part, and loses in part, the court, arbitrator or
other adjudicator presiding over such Proceeding shall award a reimbursement of the fees, costs and expenses incurred by such party on
an equitable basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;11.4&#9;</FONT><U>Certain
Other Effects of Termination</U>. In the event of the termination of this Agreement by either the Company or Purchaser as provided in
<FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;11.2</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) each
party, if so requested by the other party, will comply with the provisions of <U>Section 5</U> of the Confidentiality Agreement <I>mutatis
mutandis</I> with respect to all documents furnished to it by the other party (or any subsidiary, division, associate or Affiliate of
such other party) in connection with the transactions contemplated by this Agreement, whether so obtained before or after the execution
of this Agreement, and any copies thereof (except for copies of documents publicly available) that may have been made; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) the
Confidentiality Agreement shall remain in full force and effect in accordance with <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;6.1</U>
and survive termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;XII<U><BR>
EQUITYHOLDER REPRESENTATIVE</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;12.1&#9;</FONT><U>Appointment
of the Equityholder Representative</U>. By virtue of approval of the Merger and this Agreement or other appointment authorization documentation,
including the Voting Agreements, or by accepting any consideration payable hereunder, each of the Equityholders shall be deemed to have
agreed to irrevocably appoint the Equityholder Representative as such Equityholder&rsquo;s and the Equityholders&rsquo; attorney-in-fact
and exclusive agent in connection with the execution and performance of this Agreement as set forth in this <B><U>Error! Reference source
not found.</U></B> This power is irrevocable and coupled with an interest, and shall not be affected by the death, incapacity, illness,
dissolution or other inability to act of any Equityholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;12.2&#9;</FONT><U>Authority
of the Equityholder Representative</U>. Each Equityholder hereby irrevocably grants the Equityholder Representative full power and authority
to take such actions as it may deem necessary or appropriate in connection with, or to consummate, the transactions contemplated by this
Agreement, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) to
execute and deliver, on behalf of such Equityholder, and to accept delivery of, on behalf of such Equityholder, such documents as may
be deemed by the Equityholder Representative, in its sole discretion, to be appropriate to consummate this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) to
endorse and to deliver on behalf of such Equityholder, certificates representing the Company Shares to be sold by such Equityholder (if
a Shareholder) at the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) to
(i) dispute or refrain from disputing, on behalf of such Equityholder, any claim made by Purchaser under this Agreement or any other Transaction
Document; (ii) negotiate and compromise, on behalf of such Equityholder, any dispute that may arise under, and to exercise or refrain
from exercising any remedies available under, this Agreement or any other Transaction Document; and (iii) execute, on behalf of such Equityholder,
any settlement agreement, release or other document with respect to such dispute or remedy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) to
waive, on behalf of such Equityholder, any Closing condition contained in <U>Article&nbsp;VIII</U> of this Agreement and to give or agree
to, on behalf of such Equityholder, any and all consents, waivers, amendments or modifications, deemed by the Equityholder Representative,
in its sole discretion, to be necessary or appropriate, under this Agreement or any other Transaction Document, and, in each case, to
execute and deliver any documents that may be necessary or appropriate in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) to
enforce, on behalf of such Equityholder, any claim against Purchaser arising under this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) to
engage attorneys, accountants and agents at the expense of Equityholders, and to incur other out-of-pocket expenses related to the performance
of its services hereunder, and, as appropriate, to cause funds to be disbursed from the Expense Fund to fund such expenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) to
calculate the Pro Rata Share or Indemnifying Pro Rata Share of any Equityholder or Joining Equityholder at any time following the Effective
Time (and the Equityholder Representative shall prepare and provide such calculation to Purchaser within two Business Days of any request
by Purchaser, and Purchaser hall be entitled to conclusively rely on any such calculation for all purposes hereunder and under the Transaction
Documents);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) to
amend this Agreement (other than this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;12.2</U>) or any Transaction Document
or any of the instruments to be delivered to Purchaser by such Equityholder pursuant to this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) to
do or refrain from doing any further act or deed on behalf of any Equityholder or the Equityholders which the Equityholder Representative
deems necessary or appropriate in its sole discretion relating to the subject matter of this Agreement or the other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
the Equityholder Representative shall have no obligation to act on behalf of the Equityholders, except as expressly provided herein, in
the Escrow and Paying Agent Agreement and for purposes of clarity, there are no obligations of the Equityholder Representative in any
ancillary agreement, schedule, exhibit or the Disclosure Schedules. The Equityholder Representative shall be entitled to: (i) rely upon
the Payout Spreadsheet, (ii) rely upon any signature believed by it to be genuine, and (iii) reasonably assume that a signatory has proper
authorization to sign on behalf of the applicable Equityholder or other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything herein
to the contrary, the Equityholder Representative shall not be entitled to, and shall not, take any action that would or would be reasonably
expected to (A) cause any Equityholder&rsquo;s liability hereunder to exceed its respective portion of the Purchaser Share Consideration
due to the Equityholder, (B) result in the Purchaser Share Consideration due to any Equityholder being distributed in any manner other
than as set forth in this Agreement the Escrow and Paying Agent Agreement, or (C) result in an increase of any Equityholder&rsquo;s indemnity
or other obligations or liabilities under this Agreement (including, for the avoidance of doubt, any change to the nature of the indemnity
obligations), without (in each case) such Equitholders&rsquo; prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;12.3&#9;</FONT><U>Reliance</U>.
Each Equityholder hereby agrees to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) In
all matters in which action by the Equityholder Representative is required or permitted, the Equityholder Representative is authorized
to act on behalf of such Equityholder, notwithstanding any dispute or disagreement among the Equityholders or between any Equityholder
and the Equityholder Representative, and Purchaser shall be entitled to rely on any and all action taken by the Equityholder Representative
under this Agreement without any liability to, or obligation to inquire of, any Equityholder, notwithstanding any knowledge on the part
of Purchaser of any such dispute or disagreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) All
actions taken by the Equityholder Representative under this Agreement or the Escrow and Paying Agent Agreement shall be binding upon each
Equityholder and such Equityholder&rsquo;s successors as if expressly confirmed and ratified in writing by such Equityholder, and all
defenses which may be available to any Equityholder to contest, negate or disaffirm the action of the Equityholder Representative taken
in good faith under this Agreement or the Escrow and Paying Agent Agreement are waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Notice
to the Equityholder Representative, delivered in the manner provided in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;14.3</U>,
shall be deemed to be notice to any Equityholder and all Equityholders for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) The
power and authority of the Equityholder Representative, as described in this Agreement: (i) are coupled with an interest and shall be
irrevocable and survive the death, incompetence, bankruptcy or liquidation of any Equityholder and shall be binding on any successor thereto,
(ii) shall continue in force until all rights and obligations of Equityholders under this Agreement shall have terminated, expired or
been fully performed, and (iii) shall survive the delivery of an assignment by any Equityholder of the whole or any fraction of his, her
or its interest in the Indemnity Escrow Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) The
Equityholder Representative may resign at any time and a majority-in-interest of Equityholders (based on their respective Pro Rata Shares)
shall have the right, exercisable from time to time upon written notice delivered to the Equityholder Representative and Purchaser, to
remove the Equityholder Representative, with or without cause, and to appoint an Equityholder (or, in the case of an Equityholder that
is a corporation, partnership, limited liability company or trust, an officer, manager, employee or partner of such Equityholder) to fill
a vacancy caused by the death, resignation or removal of the Equityholder Representative. The immunities and rights to indemnification
shall survive the resignation or removal of the Equityholder Representative and the Closing and/or any termination of this Agreement and
the Escrow and Paying Agent Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)
If the Equityholder Representative resigns or is removed or otherwise ceases to function in his capacity as such for any reason whatsoever,
and no successor is appointed pursuant <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;12.2(e)</U> within 30 days, then
Purchaser shall have the right to appoint a reputable service provider as an Equityholder to act as the Equityholder Representative to
serve as described in this Agreement. The cost of such service provider will be borne by the Equityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;12.4&#9;</FONT><U>Indemnification
of the Equityholder Representative</U>. Each Equityholder shall severally, but not jointly, indemnify the Equityholder Representative
and defend and hold the Equityholder Representative harmless against any Damages (except such Damages resulting from the Equityholder
Representative&rsquo;s fraud or willful misconduct) that the Equityholder Representative may suffer or incur in connection with any action
or omission of the Equityholder Representative. Each Equityholder shall bear its Indemnifying Pro Rata Share of such Damages. Such Damages
may be recovered first, from the Expense Fund, second, from any distribution of the Indemnity Escrow Amount otherwise distributable to
the Equityholders at the time of distribution, and third, directly from the Equityholders. The Equityholder Representative shall not be
liable to any Equityholder with respect to any action or omission taken or omitted to be taken by the Equityholder Representative pursuant
to this <U>Article XII</U>, except for the Equityholder Representative&rsquo;s fraud or willful misconduct. The Equityholders acknowledge
that, as between the Equityholders and the Equityholder Representative, the Equityholder Representative shall not be required to expend
or risk its own funds or otherwise incur any financial liability in the exercise or performance of any of its powers, rights, duties or
privileges or pursuant to this Agreement, the Escrow and Paying Agent Agreement or the transactions contemplated hereby or thereby. Furthermore,
the Equityholder Representative shall not be required to take any action unless the Equityholder Representative has been provided with
funds, security or indemnities which, in its determination, are sufficient to protect the Equityholder Representative against the costs,
expenses and liabilities which may be incurred by the Equityholder Representative in performing such actions. The Equityholders shall
be responsible for ensuring that the Equityholder Representative can comply with Equityholder Representative&rsquo;s obligations under
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;12.5&#9;</FONT><U>Expense
Fund</U>. In accordance with <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.7(c)</U> on the Closing Date, Company
shall wire cash to the account of the Equityholder Representative in the amount of [$100,000] (the &ldquo;<U>Expense Fund Amount</U>&rdquo;).
The Expense Fund Amount shall be held by the Equityholder Representative as agent and for the benefit of the Equityholders in a segregated
client account and shall be used for the purposes of paying directly or reimbursing the Equityholder Representative for any expenses or
Damages of the Equityholder Representative incurred pursuant to this Agreement, the Escrow and Paying Agent Agreement or the Equityholder
Representative Engagement Agreement (the &ldquo;<U>Expense Fund</U>&rdquo;). The Equityholder Representative is not providing any investment
supervision, recommendations or advice and shall have no responsibility or liability for any loss of principal of the Expense Fund other
than as a result of its fraud or willful misconduct. The Equityholder Representative is not acting as a withholding agent or in any similar
capacity in connection with the Expense Fund, and has no tax reporting or income distribution obligations hereunder. The Equityholders
will not receive any interest on the Expense Fund and assign to the Equityholder Representative any such interest. The Equityholder Representative
may contribute funds to the Expense Fund from any consideration otherwise distributable to the Equityholders. As soon as reasonably determined
by the Equityholder Representative that the Expense Fund is no longer required to be withheld, and in any event not later than the date
on which all funds are released from the Indemnity Escrow Account, the Equityholder Representative shall distribute the then remaining
amount of the Expense Fund, if any, to the Paying Agent and the Surviving Corporation, as applicable, for further distribution to the
Equityholders based on their respective Indemnifying Pro Rata Shares in accordance with the same procedure set forth in <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;2.4</U>
for the payment to the Equityholders of amounts remaining in the Indemnity Escrow Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;XIII<U><BR>
ADDITIONAL COVENANTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;13.1&#9;</FONT><U>Limitation
on Warranties; No Reliance</U>. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE OTHER TRANSACTION
DOCUMENTS (WHICH, FOR THE AVOIDANCE OF DOUBT, ARE QUALIFIED BY THE DISCLOSURE SCHEDULE AND PURCHASER DISCLOSURE SCHEDULE), NONE OF THE
COMPANY, THE EQUITYHOLDERS OR THE EQUITYHOLDER REPRESENTATIVE IS MAKING OR WILL BE DEEMED TO HAVE MADE ANY OTHER REPRESENTATIONS OR WARRANTIES,
WRITTEN OR ORAL, COMMON LAW OR STATUTORY, EXPRESS OR IMPLIED (INCLUDING WITH RESPECT TO NON-INFRINGEMENT, MERCHANTABILITY OR SUITABILITY
OR FITNESS FOR ANY PARTICULAR PURPOSE), AS TO THE ACCURACY OR COMPLETENESS OF, OR THE DISTRIBUTION TO, OR USE BY, PURCHASER OF, ANY ADVICE,
DOCUMENT, OR OTHER INFORMATION REGARDING THE COMPANY SHARES, THE COMPANY OR THE BUSINESS, FINANCIAL CONDITION OR ASSETS (INCLUDING THE
CONDITION, VALUE, QUALITY OR SUITABILITY OF ANY ASSETS) OR LIABILITIES OF THE COMPANY, INCLUDING FORWARD-LOOKING STATEMENTS (ANY OF THE
FOREGOING, AN &ldquo;<U>EXTRA-CONTRACTUAL STATEMENT</U>&rdquo;). PURCHASER REPRESENTS, WARRANTS, AND ACKNOWLEDGES THAT, EXCEPT AS EXPRESSLY
PROVIDED IN THIS AGREEMENT OR ANY OF THE OTHER TRANSACTION DOCUMENTS, NONE OF THE COMPANY, ANY EQUITYHOLDER, OR THE EQUITYHOLDER REPRESENTATIVE,
OR ANY AGENT OR OTHER PERSON ACTING ON ANY OF THEIR BEHALVES HAS MADE, AND EACH OF THEM HEREBY EXPRESSLY DISCLAIM AND NEGATE, AND EACH
OF PURCHASER AND ITS AFFILIATES IS NOT RELYING ON, ANY EXTRA-CONTRACTUAL STATEMENT (INCLUDING ANY EXPRESS OR IMPLIED WARRANTY RELATING
TO THE COMPANY SHARES OR ANY ASSET (TANGIBLE, INTANGIBLE OR MIXED), INCLUDING IMPLIED WARRANTIES OF FITNESS, NON-INFRINGEMENT, MERCHANTABILITY
OR SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE). Notwithstanding anything to the contrary set forth herein, the foregoing representations
and agreements of Purchaser in this <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;13.1</U> assume the absence of willful
misconduct or fraud on the part of the Company, the Equityholders and their respective directors, managers, officers, affiliates, representatives
or advisors or any other Person in connection with the making of the representations, warranties or covenants under this Agreement, and
Purchaser is relying upon such absence of such willful misconduct or fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;13.2&#9;</FONT><U>Specific
Reliance</U>. The parties have specifically relied upon this <U>Article&nbsp;XIII</U>, together with the provisions of <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>Section&nbsp;14.4</U>,
in agreeing to the Merger Consideration and in agreeing to provide the specific representations and warranties set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;13.3&#9;</FONT><U>Company
Shareholders Meeting</U>. As soon as reasonably practicable following the date of this Agreement, but in no event later than the seventh
Business Day after the date hereof, the Company shall send a notice to convene a shareholder meeting of its shareholders to approve this
Agreement and the Merger in accordance with its Charter and the ICL to be held no later than 7 calendar days following the notice. No
later than three (3) days after the date of such approval, Merger Sub shall (in accordance with Section 317(b) of the ICL and the regulations
thereunder) inform the Companies Registrar of such approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 69; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;13.4&#9;</FONT><U>Merger
Proposal; Certificate of Merger</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Subject
to the ICL and the regulations promulgated thereunder, as promptly as practicable following the date hereof the Company and Merger Sub,
as applicable, shall take the following actions within the timeframes set forth herein; <U>provided</U>, <U>however</U>, that any such
actions or the timeframe for taking such action shall be subject to any amendment in the applicable provisions of the ICL and the regulations
promulgated thereunder (and in case of an amendment thereto, such amendment shall automatically apply so as to amend this Section accordingly):
(a) cause a merger proposal (in the Hebrew language) in the form of <U>Exhibit B</U> (the &ldquo;<U>Merger Proposal</U>&rdquo;) to be
executed in accordance with Section 316 of the ICL, (b) deliver the Merger Proposal to the Companies Registrar within three (3) days from
the calling of the shareholders meeting, (c) the Company shall cause a copy of the Merger Proposal to be delivered to its secured creditors,
if any, no later than three (3) days after the date on which the Merger Proposal is delivered to the Companies Registrar, (d) promptly
after the Company shall have complied with the preceding sentence and with clauses (i) and (ii) of this <FONT STYLE="font-size: 10pt">&lrm;</FONT>Section,
but in any event no more than three (3) days following the date on which such notice was sent to the creditors, the Company and Merger
Sub shall inform the Companies Registrar, in accordance with Section 317(b) of the ICL, that notice was given to their respective creditors,
if any, under Section 318 of the ICL (and regulations promulgated thereunder), (e) each of the Company and, if applicable, Merger Sub,
shall: (i) publish a notice to its creditors, stating that a Merger Proposal was submitted to the Companies Registrar and that the creditors
may review the Merger Proposal at the office of the Companies Registrar, Company&rsquo;s registered office or Merger Sub&rsquo;s registered
offices, as applicable, and at such other locations as the Company or Merger Sub, as applicable, may determine, in (A) two daily Hebrew
newspapers, on the day that the Merger Proposal is submitted to the Companies Registrar, (B) solely to the extent that the Company has
any &ldquo;Substantial Creditors&rdquo; (as such term is defined in the regulations promulgated under the ICL) outside of Israel, in a
popular newspaper in such applicable jurisdictions, as may be required by applicable Law; (ii) within four (4) business days from the
date of submitting the Merger Proposal to the Companies Registrar, send a notice by registered mail to all of the Substantial Creditors
that the Company or Merger Sub, as applicable, is aware of, in which it shall state that a Merger Proposal was submitted to the Companies
Registrar and that the creditors may review the Merger Proposal at such additional locations, if such locations were determined in the
notice referred to in the immediately preceding clause (i); and (iii) send to the Company&rsquo;s &ldquo;employees committee&rdquo; (Va&rsquo;ad
Ovdim) or display in a prominent place at the Company&rsquo;s premises a copy of the notice published in a daily Hebrew newspaper (as
referred to in clause (i)(A) of this Section, no later than three (3) business days following the day on which the Merger Proposal was
submitted to the Companies Registrar, (f) not later than three (3) days after the date on which the approval of the Company Shareholders
Meeting shareholders (to include the Requisite Supporting Shareholders) is received (the &ldquo;<U>Company Shareholder Approval</U>&rdquo;),
the Company shall (in accordance with Section 317(b) of ICL and the regulations thereunder) inform the Companies Registrar of such approval,
and (g) in accordance with the customary practice of the Companies Registrar, the Company and Merger Sub shall request, following coordination
with Merger Sub, that the Companies Registrar declare the Merger effective and issue the Certificate of Merger upon such date as the Company
and Merger Sub shall advise the Companies Registrar. For the avoidance of doubt, and notwithstanding any provision of this Agreement to
the contrary, it is the intention of the parties that the Merger shall be declared effective and the Certificate of Merger shall be issued
on the Closing Date, as a condition to the Closing taking place. For purposes of this <FONT STYLE="font-size: 10pt">&lrm;</FONT>Section,
&ldquo;business day&rdquo; shall have the meaning set forth in the Merger Regulations 5760-2000 promulgated under the ICL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 70; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Immediately
following the approval of this Agreement and the Merger by the Requisite Supporting Shareholders (it being agreed that the execution by
the Requisite Supporting Shareholders of the Voting Agreement shall be deemed as approval of the Merger by the Requisite Supporting Shareholders),
the sole shareholder of Merger Sub shall approve the Merger subject to the satisfaction or waiver (to the extent permitted hereunder)
of all the conditions to Closing (other than those that by their nature may only be satisfied or waived at Closing). No later than three
(3) days after the date of such approval, Merger Sub shall (in accordance with Section 317(b) of the ICL and the regulations thereunder)
inform the Companies Registrar of such approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;13.5&#9;</FONT><U>Tax
Rulings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) As
soon as practicable following the date of this Agreement but in no event later than five (5) days after the date hereof, the Company shall
instruct its Israeli counsel, advisors and accountants to prepare and file with the ITA an application for a ruling (which shall be confirmed
by Purchaser prior to its submission), or alternatively provide evidence that no withholding will be required with regard to the issuance
of the Merger Consideration to the Paying Agent, to the reasonable satisfaction of the Purchaser, that (A) exempts the applicable Payor
and its respective agents from any obligation to withhold Israeli Tax at the source from any consideration payable or otherwise deliverable
pursuant to this Agreement, including the Merger Consideration, or clarifying that no such obligation exists, or (B) clearly instructs
the applicable Payor and its respective agents on how such withholding at the source is to be executed, and in particular, with respect
to the classes or categories of holders of the Company Shares or Company Options from which Tax is to be withheld (if any) and the rate
or rates of withholding to be applied (the &ldquo;<U>Withholding Tax Ruling</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Each
of the Company and Purchaser shall cause their respective Israeli counsel, advisors and accountants to coordinate all activities, and
to cooperate with each other, with respect to the preparation and filing of such application and in the preparation of any written or
oral submissions that may be necessary, proper or advisable to obtain the Withholding Tax Ruling. The final text of the Withholding Tax
Ruling shall be subject to the prior written confirmation of Purchaser and its counsel and tax advisors, which consent shall not be unreasonably
withheld, conditioned or delayed. The Company and its Representatives shall not make any application to, or conduct any negotiation with,
the ITA with respect to matters relating to the Withholding Tax Ruling without prior coordination with Purchaser or its Representatives,
and will coordinate with Purchaser&rsquo;s Representatives their participation in all discussions and meetings with the ITA relating thereto.
Furthermore, the Company shall keep Purchaser and its agents and representatives informed, on a prompt basis (and, in any event, within
24 hours) of its receipt of any notice or information in connection with any of the above rulings or approvals. To the extent that the
Purchaser&rsquo;s Representatives elect not to participate in any such meeting or discussion, the Company&rsquo;s Representatives shall
promptly thereafter provide the Purchaser&rsquo;s Representatives a report of the discussions and/or meetings held with the ITA. Subject
to the terms and conditions hereof, the Company shall use commercially reasonable efforts to promptly take, or cause to be taken, all
action and to do, or cause to be done, all things necessary, proper or advisable under applicable Laws to obtain the Withholding Tax Ruling,
as promptly as practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;XIV<U><BR>
MISCELLANEOUS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.1&#9;</FONT><U>Transaction
Expenses</U>. Except as otherwise provided in this Agreement, each party shall bear all fees and expenses incurred by such party in connection
with, relating to or arising out of the negotiation, preparation, execution, delivery or performance of this Agreement or the consummation
of the transactions contemplated by this Agreement or any other Transaction Document, including financial advisors&rsquo;, attorneys&rsquo;,
accountants&rsquo; and other professional fees and expenses in connection with the transactions contemplated by this Agreement or any
other Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.2&#9;</FONT><U>Publicity</U>.
Up until the Closing, press releases and other publicity concerning the transactions contemplated by this Agreement shall be made only
with the prior written agreement of the Company and Purchaser, unless the Purchaser determines, in its reasonable discretion after consultation
with outside legal counsel, that it is required (or may be deemed required) by applicable Law or share exchange or listing rules to issue
or cause the publication of any press release or any public announcement with respect to the transactions contemplated by this Agreement,
in which event Purchaser shall make reasonable endeavors to provide an opportunity, subject to the limitations of the applicable Law and
the said rule, to the Company to review and comment upon such press release or public announcement in advance. Following the Closing,
(i) except as otherwise required by Law or applicable share exchange rules, no press releases or other publicity shall state the amount
of the Merger Consideration and (ii) neither the Equityholder Representative nor any Equityholder shall make any press release or public
announcement concerning the transactions contemplated by this Agreement without the prior written agreement of Purchaser, except to the
extent that any such release or announcement contains only statements that are consistent with previous statements made jointly or with
the approval with Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 71; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.3&#9;</FONT><U>Notices</U>.
All notices required or permitted to be given hereunder shall be in writing and may be delivered by hand, by email in .pdf format or similar
format, by nationally recognized private courier, or by registered mail; <U>provided</U> that, with respect to notices delivered to the
Equityholder Representative, such notices must be delivered solely via via email. Notices delivered by mail shall be deemed given three
Business Days after being deposited in the mail, postage prepaid, registered or certified mail, return receipt requested. Notices delivered
by hand shall be deemed delivered when actually delivered. Notices given by nationally recognized private courier shall be deemed delivered
on the date delivery is promised by the courier. Notices given by email shall be deemed given on the first Business Day following receipt.
All notices shall be addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">If to the Company (before the Closing)
or the Equityholder Representative:<BR>
<BR>
Zebra Medical Vision Ltd.<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Attn: Zohar Elhanani</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Email: zohar@zebra-med.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><B>[EQUITYHOLDER REPRESENTATIVE]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><B>[ADDRESS]</B><BR>
Attn: Amit Perry</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Email: amit@perryllion.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; background-color: white">with a copy (which will not constitute
notice) to:<BR>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Horn &amp; Co. Law Offices</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Investments Tower, Weizmann St. 2,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Floor 24, Tel Aviv 6423902 , Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attn.:&nbsp;Yuval Horn</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">E-mail: yhorn@hornlaw.co.il</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">If to any of the Company (following the Closing),
Purchaser, to each of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">Nano-X Imaging Ltd<BR>
Communications Centre,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Neve Ilan, Israel 9085000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: Ran Poliakine, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">E-mail: ran.p@nanox.vision</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">with a copy (which will not constitute
notice) to:<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -1.65pt">Amit, Pollak, Matalon &amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">APM House</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">18 Raoul Wallenberg St., 6th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">Tel Aviv 6971915, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">Facsimile: +972-3-5689001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">E-mail: ianr@apm.law and sbr@apm.law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">Attention: Ian Rostowsky, Adv. and Stephen
Rozen, Adv.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and/or to such other respective addresses and/or
addressees as may be designated by notice given in accordance with the provisions of this <U>&lrm;Section&nbsp;14.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 72; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.4 </FONT><U>Entire
Agreement</U>. This Agreement and the other Transaction Documents constitute the entire agreement between the parties respecting the transactions
contemplated hereby and thereby and supersede all prior or contemporaneous written agreements, arrangements, communications and understandings
and all prior and contemporaneous oral agreements, arrangements, communications and understandings among the parties with respect to the
transactions contemplated hereby or thereby, including any data room materials, bid letters, term sheets, summaries, issues lists or other
agreements or information. Each exhibit, schedule and the Disclosure Schedule shall be considered incorporated into this Agreement. Any
amendments, or alternative or supplementary provisions, to this Agreement, must be made in writing and duly executed by an authorized
representative or agent of each of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.5 </FONT><U>Non-Waiver</U>.
The failure in any one or more instances of a party to insist upon performance of any of the terms, covenants or conditions of this Agreement
or to exercise any right or privilege in this Agreement conferred, or the waiver by such party of any breach of any of the terms, covenants
or conditions of this Agreement, shall not be construed as a subsequent waiver of any such terms, covenants, conditions, rights or privileges,
but the same shall continue and remain in full force and effect as if no such forbearance or waiver had occurred. No waiver shall be effective
unless it is in writing and signed by an authorized representative of the waiving party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.6 </FONT><U>Counterparts</U>.
This Agreement may be executed and delivered by each party in separate counterparts, each of which when so executed and delivered shall
be deemed an original and all of which taken together shall constitute one and the same Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.7 </FONT><U>Delivery
by Electronic Transmission</U>. This Agreement and any other Transaction Document, and any amendments hereto or thereto, to the extent
signed and delivered by means of a facsimile machine or other electronic transmission, shall be treated in all manner and respects as
an original contract and shall be considered to have the same binding legal effects as if it were the original signed version thereof
delivered in person. No party hereto or to any such contract shall raise the use of a facsimile machine or other electronic transmission
to deliver a signature or the fact that any signature or contract was transmitted or communicated through the use of facsimile machine
or other electronic transmission as a defense to the formation of a contract and each such party forever waives any such defense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.8 </FONT><U>Severability</U>.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
Law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable Law or
rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction,
and, for purposes of such jurisdiction, such provision or portion thereof shall be struck from the remainder of this Agreement, which
shall remain in full force and effect. This Agreement shall be reformed, construed and enforced in such jurisdiction so as to best give
effect to the intent of the parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.9 </FONT><U>Applicable
Law</U>. This Agreement and any controversy related to or arising, directly or indirectly, out of, caused by or resulting from this Agreement
shall be governed and controlled as to validity, enforcement, interpretation, construction, effect and in all other respects by the internal
Laws of the State of Israel applicable to contracts made in that state, without giving effect to any choice of law or conflict of law
provision or rule that would cause the application of the Laws of any jurisdiction other than the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.10 </FONT><U>Binding
Effect; Benefit</U>. This Agreement shall inure to the benefit of and be binding upon the parties, and their successors and permitted
assigns. Nothing in this Agreement, express or implied, shall confer on any Person other than the parties, and their respective successors
and permitted assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement, including third-party beneficiary
rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.11 </FONT><U>Assignment</U>.
This Agreement shall not be assigned by the Company or the Equityholder Representative without the prior written consent of Purchaser.
This Agreement shall not be assigned by Purchaser or Merger Sub without the prior written consent of the Company; <U>provided</U> that,
either Purchaser or Merger Sub may assign the Agreement to a Controlled Affiliate of Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.12 </FONT><U>Amendments</U>.
This Agreement shall not be modified or amended except pursuant to an instrument in writing executed and delivered on behalf of each of
the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.13 </FONT><U>Consent
to Jurisdiction</U>. any Proceeding relating to this Agreement or the enforcement of any provision of this Agreement (including a Proceeding
based upon fraud or intentional misrepresentation) shall be brought or otherwise commenced exclusively in any court located in the district
of Tel Aviv, Israel. Each party to this Agreement and each Equityholder: (i)&nbsp;expressly and irrevocably consents and submits to the
jurisdiction of each court located in the district of Tel Aviv, Israel in connection with any such Proceeding; (ii)&nbsp;agrees that each
court located in the district of Tel Aviv, Israel shall be deemed to be a convenient forum; and (iii)&nbsp;agrees not to assert (by way
of motion, as a defense or otherwise), in any such Proceeding commenced in any court located in the district of Tel Aviv, Israel, any
claim that such party is not subject personally to the jurisdiction of such court, that such Proceeding has been brought in an inconvenient
forum, that the venue of such proceeding is improper or that this Agreement or the subject matter of this Agreement may not be enforced
in or by such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.14 </FONT><U>Specific
Performance</U>. The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance
with the terms hereof or were otherwise breached, including each party&rsquo;s right to consummate the transactions contemplated by this
Agreement. Accordingly, each of the parties agrees that the parties shall be entitled to specific performance of the terms hereof, including
an injunction or injunctions to prevent breaches of this Agreement and to otherwise enforce specifically the terms and provisions hereof
(including for specific performance of any transaction contemplated by this Agreement or any other Transaction Document) in any court
of competent jurisdiction, this being in addition to any other remedy to which such party is entitled at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Section&nbsp;14.15 </FONT><U>Conflicts
Regarding Representation</U>. Each of the parties acknowledges that (i) Amit, Pollak, Matalon &amp; Co (&ldquo;<U>APM</U>&rdquo;)
currently serves as counsel to the Purchaser, including in connection with the negotiation, preparation, execution and delivery of
this Agreement and the transactions contemplated thereby (the &ldquo;<U>Acquisition Engagement</U>&rdquo;), and in connection with
this Agreement and the transactions contemplated hereby, APM has not acted as counsel for any other Person.&nbsp;Only the Purchaser
shall be considered a client of APM in the Acquisition Engagement; and (ii) Horn &amp; Co. (&ldquo;Horn&rdquo;) currently serves as
counsel to the Company, including in connection with the Acquisition Engagement, and in connection with this Agreement and the
transactions contemplated hereby, Horn has not acted as counsel for any other Person. Only the Company shall be considered a client
of Horn in the Acquisition Engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the Equityholders
and the Company (prior to the Closing), on behalf of itself and its Affiliates (including, after the Closing, the Company) agrees, solely
with respect to any claim for indemnification made by or on behalf of any of them, not to invoke any attendant attorney-client privilege,
attorney work product protection or expectation of client confidentiality applicable to confidential communications between the Equityholder
Representative and the Company on the one hand, and APM, on the other hand, in the course of the Acquisition Engagement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the parties to this
Agreement consents to the arrangements in this <FONT STYLE="font-size: 10pt">&lrm;</FONT>Section&nbsp;14.15and waives any actual or potential
conflict of interest that may be involved in connection with APM&rsquo;s representation in the Acquisition Engagement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.16 </FONT><U>Governmental
Reporting</U>. Anything to the contrary in this Agreement notwithstanding, nothing in this Agreement shall be construed to mean that a
party hereto or other Person must make or file, or cooperate in the making or filing of, any return or report to any governmental authority
in any manner that such Person or such party reasonably believes or reasonably is advised is not in accordance with law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Section&nbsp;14.17 </FONT><U>Headings</U>.
The headings contained in this Agreement are for convenience of reference only and shall not affect the meaning or interpretation of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Pages Follow]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 74; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties have executed
this Agreement and Plan of Merger as of the date indicated in the first sentence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">PURCHASER:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt"><B>NANO-X IMAGING LTD</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt; width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 0pt; width: 36%">/s/ Ran Poliakine</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">Name:</TD>
    <TD STYLE="padding-bottom: 0pt">Ran Poliakine</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">Its:</TD>
    <TD STYLE="padding-bottom: 0pt">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">MERGER SUB:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt"><B>NEW ZEALAND MERGER SUB LTD.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 0pt"> /s/ Ran Poliakine</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">Name:</TD>
    <TD STYLE="padding-bottom: 0pt">Ran Poliakine</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">Its:</TD>
    <TD STYLE="padding-bottom: 0pt">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">THE COMPANY:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt"><B>ZEBRA MEDICAL VISION LTD.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 0pt">/s/ Zohar Elhanani</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">Name:&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">Zohar Elhanani&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">Its:</TD>
    <TD STYLE="padding-bottom: 0pt">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">EQUITYHOLDER REPRESENTATIVE:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt"><B>PERRRYLLION LTD.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 0pt">/s/ Amit Perry</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">Name:</TD>
    <TD STYLE="padding-bottom: 0pt"> Amit Perry</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0pt">Its:</TD>
    <TD STYLE="padding-bottom: 0pt"> Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[Signature Page - Agreement and Plan of Merger]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ANNEX A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Defined Terms</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Accredited Investor</U>&rdquo;
means a person that qualifies as an &ldquo;accredited investor&rdquo; as defined in the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
with respect to any Person means any other Person who directly or indirectly Controls, is Controlled by or is under common Control with
such Person, including, in the case of any Person who is an individual, his or her spouse, domestic partner any of his or her descendants
(lineal or adopted) or ancestors and any of their spouses or domestic partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Benefit Plan</U>&rdquo;
means any retirement, pension, profit sharing, deferred compensation, savings, bonus, incentive, cafeteria, medical, dental, vision, hospitalization,
life insurance, accidental death and dismemberment, medical expense reimbursement, dependent care assistance, tuition reimbursement, disability,
sick pay, paid time off, leave, holiday, vacation, employment, individual consulting, retention, severance, change of control, equity
purchase, equity option, restricted equity, phantom equity, equity appreciation rights, fringe benefit or other employee benefit plan,
program, agreement, or arrangement (including any &ldquo;employee benefit plan,&rdquo; as defined in Section 3(3) of ERISA) (a) sponsored,
maintained, contributed to, or required to be contributed to by the Company for the benefit of any current or former employee of the Company,
or (b) with respect to which the Company has, or would reasonably be expected to have, any liability, <U>provided</U> that, the term &ldquo;Benefit
Plan&rdquo; shall not include any plan, program or arrangement maintained or mandated by a Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means each day that is not a Saturday, Sunday or other day on which banking institutions located in Tel Aviv, Israel or in the State of
Michigan are authorized or obligated by law or executive order to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Cash</U>&rdquo;
means (a) all cash on hand in the Company&rsquo;s bank, lock box and other accounts (including cash resulting from the clearance of checks
deposited with the Company prior to the Closing Date, whether or not such clearance occurs before, on or after the Closing Date), plus
(b) the amount of all marketable securities owned by the Company, determined in accordance with US GAAP, in each case as of immediately
prior to the Closing, but in all events excluding any cash or cash equivalents of the Company that are not freely usable by Purchaser,
the Company or the Surviving Corporation because they are subject to restrictions, limitations on use or distribution by Law, Contract
or otherwise, including cash held outside the United States, cash held in escrow or as a security deposit or cash representing the amount
of any outstanding checks or wire transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Cause</U>&rdquo;
means any one of the following: (a) embezzlement; (b) theft; (c) criminal offence; (d) act involving moral turpitude; (e) breach of confidentiality
and/or non-competition undertakings contained in one&rsquo;s respective employment agreement with the Company and/or in any of the annexes
or schedules thereto; (f) severe disciplinary breach; (g) breach of one&rsquo;s fiduciary duties; (h) any other material breach by an
employee of the terms of his/her respective engagement agreement with the Company; or (i) any other act/or omission which under applicable
law enables severance payments or prior notice redemption to be entirely or partially denied by an employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Code</U>&rdquo; means the
Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company</U>&rdquo;
is defined in the Preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company 102 Options</U>&rdquo;
means Company Options subject to Section 102 of the Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company 102 Shares</U>&rdquo;
means Company Shares issued upon exercise of Company 102 Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Charter</U>&rdquo;
means the Third Amended and Restated Articles of Association of the Company, dated May 30, 2018 (as amended).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 76; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Incentive
Plan</U>&rdquo; means the Company Share Ownership and Option Plan (2014).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Options</U>&rdquo;
means options to purchase Ordinary Shares pursuant to the Company Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Service
Provider</U>&rdquo; means any current or former employee, worker, independent contractor, consultant, advisor, officer or director of
the Company or any Affiliate of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Shares</U>&rdquo;
means Ordinary Shares of the Company, Preferred A Shares, Preferred B Shares and Preferred C Shares, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Warrants</U>&rdquo;
means warrants convertible into Company Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Outstanding
Instruments</U>&rdquo; means together the outstanding Convertible Promissory Notes under the Note Purchase Agreement dated June 19, 2020
led by TELUS Corporation and the 3. SAFE (Simple Agreement for Future Equity) with aMoon 2 Fund Limited Partnership, dated August 17,
2020 (the &ldquo;<U>Company Convertible Instruments</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Contract</U>&rdquo;
means any binding contract (written or oral), agreement, arrangement, commitment, understanding, purchase order, lease, license, or other
legally binding agreement, and including all amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Control</U>&rdquo;
means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person,
whether through ownership of securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Damages</U>&rdquo;
means all assessments, levies, losses, damages, Liabilities, fines and penalties, whether or not arising out of Third Party Claims or
other Proceedings (including reasonable attorneys&rsquo; fees and expenses incurred in asserting, investigating or defending or settling
any of the foregoing or the enforcement of rights hereunder).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Data Requirements</U>&rdquo;
means the requirements of all applicable Contracts, Company Data Policies, and Laws, concerning the Processing of Company Data or the
confidentiality, nondisclosure, privacy, or security thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Data Room</U>&rdquo;
means the iDeals online data site located at https://www4.idealsvdr.com/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Environmental Laws</U>&rdquo;
means all federal, state and local statutes, regulations, ordinances, rules, regulations and policies having the force of law, and all
court orders and decrees and arbitration awards, and the common law, which pertain to environmental matters (including the pollution or
protection of the environment), worker health and safety or contamination of any type whatsoever (including those relating to the presence,
use, production, generation, handling, transportation, treatment, storage, disposal, distribution, labeling, testing, processing, discharge,
release, control or cleanup of Hazardous Materials).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>ERISA</U>&rdquo;
means the Employee Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Equity Interest</U>&rdquo;
means (a)&nbsp;any common, preferred, or other share capital, limited liability company interest, or membership interest, partnership
interest, or similar security; (b)&nbsp;any warrants, options, or other rights to, directly or indirectly, acquire any security described
in clause <U>(a)</U>; (c)&nbsp;any other security containing equity features, voting rights, or profit participation features; (d)&nbsp;any
security or instrument convertible or exchangeable, directly or indirectly, with or without consideration, into or for any security described
in <U>clauses&nbsp;(a)</U> through <U>(c)</U> above or another similar security (including convertible notes); and (e)&nbsp;any security
carrying any warrant or right to subscribe for or purchase any security described in <U>clauses&nbsp;(a)</U> through <U>(d)</U> above
or any similar security. Without limiting the foregoing, the Company Convertible Instruments shall be deemed &ldquo;Equity Interests&rdquo;
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Equityholders</U>&rdquo;
means the holders of Company Shares (excluding dormant shares), Company Warrants, Company Outstanding Instruments and Vested Company Options
immediately prior to the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
shall mean the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fundamental Representations</U>&rdquo;
means representations and warranties contained in <U>&lrm;Section&nbsp;3.1</U> (Organization, Existence and Good Standing), <U>&lrm;Section&nbsp;3.2</U>
(Power and Authority), <U>&lrm;Section&nbsp;3.3</U> (Enforceability), <U>&lrm;Section&nbsp;3.4</U> (Consents; Non-Contravention); <U>&lrm;Section&nbsp;3.5</U>
(Capitalization), <U>Section 3.6</U> (Subsidiaries) ), <U>Section 3.10</U> (Taxes), and <U>Section&nbsp;3.28</U> (Brokers).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Good Reason</U>&rdquo;
means any of the following with respect to an employee of the Company: (i) a reduction of more than 12% in an employee&rsquo;s salary
or monetary value of such employee&rsquo;s other material benefits, which is not applied in the same proportion to substantially all other
employees of similar position; (ii) any material breach by the Company of the employment agreement with the employee which was not remedied
within 15 days of the date on which the Company was notified, in writing, of such material breach by the employee; and (iii) a material
and adverse change (other than in circumstances constituting Cause) in employee's position, duties or responsibilities as they exist on
the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Governmental Entity</U>&rdquo;
means any nation, any state, any province or any municipal or other political subdivision thereof, and any agency, commission, department,
board, bureau, official, minister, tribunal or court, whether national, state, provincial, local, foreign or multinational, exercising
executive, legislative, judicial, regulatory or administrative functions of a nation, state, province or any municipal or other political
subdivision thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Government Grant</U>&rdquo;
shall mean any grant, incentive, qualification, subsidy, award, participation, exemption, status, cost sharing arrangement, reimbursement
arrangement or other benefit, relief or privilege, from the government of the State of Israel or any other governmental authority, or
judicial or arbitral body thereof, any outstanding application to receive the same filed by the Company, including, any material Tax or
other incentive granted to, provided or made available to, or enjoyed by the Company, under the Laws of the State of Israel, and further
including without limitation, by or on behalf of or under the authority of the IIA, the Investment Center, the BIRD Foundation or any
other bi/multi-national grant programs for research and development, the European Union, the Fund for Encouragement of Marketing Activities
of the Israeli Government or any other governmental authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Hazardous Material</U>&rdquo;
means any substance that is listed, defined, or regulated as a &ldquo;hazardous material,&rdquo; &ldquo;hazardous waste,&rdquo; &ldquo;hazardous
substance,&rdquo; or &ldquo;toxic substance,&rdquo; or that is otherwise regulated under any Environmental Law as an actual or potential
threat to health or the environment, including asbestos, polychlorinated biphenyls, any crude petroleum and its fractions or derivatives
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>IIA</U>&rdquo; means
the Israel Innovation Authority, previously known as the Research Committee of the Office of the Chief Scientist of the Israeli Ministry
of Economy and Industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>IIA Funded Intellectual
Property</U>&rdquo; means Intellectual Property, and any derivatives thereof, for which the Company or any of its Subsidiaries is the
recorded &ldquo;approval recipient&rdquo; (as such term is used in the R&amp;D Law) or for which the Company or any of its Subsidiaries
have obligations for vis-&agrave;-vis the IIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>IIA Status Letter</U>&rdquo;
means written approval from the IIA&rsquo;s Tmura fund with respect to the Company, in form and substance reasonably satisfactory to Purchaser,
setting forth as of the Effective Time (x) the Government Grants that were received by the Company from the IIA (as calculated pursuant
to the applicable Laws), (y) all interest and linkage accrued and fees thereon (as calculated pursuant to the applicable Laws), and (z)
royalties paid to the IIA on account of the Company&rsquo;s Government Grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Income Tax</U>&rdquo;
means any Tax imposed upon or measured by net income or gross income (excluding any Tax based solely on gross receipts).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
means, with respect to any Person, as of any date of determination, without duplication: (i) all indebtedness for borrowed money; (ii)
that portion of obligations with respect to capital leases that is properly classified as a liability on a balance sheet in conformity
with US GAAP; (iii) notes payable and drafts accepted representing extensions of credit whether or not representing obligations for borrowed
money (for the avoidance of doubt, excluding any trade accounts payable to any Person); (iv) guaranties securing indebtedness for borrowed
money; (v) all amounts under drawn outstanding letters of credit; (vi) all deferred compensation obligations, including (A) any underfunded
pension or post-retirement Liabilities and (B) all payment obligations under any retiree medical or deferred compensation plans; (vii)
all dividends and distributions payable to any shareholder of such Person and any other amounts owed to any shareholder of such Person
or such Person&rsquo;s Affiliate, other than employee compensation and other ordinary incidents of employment in the ordinary course of
business consistent with past practice and consistent with the Person&rsquo;s practices and policies with respect to employees generally;
(viii) all obligations issued or assumed as the deferred purchase price of property or services, all conditional sale obligations and
all obligations under any title retention agreement, including all obligations resulting from any holdback, performance bonus, earn-out
or other contingent payment arrangement in each case related to or arising out of any prior acquisition, business combination or similar
transaction, other than ongoing, ordinary-business trade debt in the amount not exceeding $50,000 in the aggregate; (ix) all obligations
under any interest rate, currency or other hedging agreement; (x) all Liabilities or obligations secured by Liens on any assets; (xi)
all Liabilities or obligations resulting from bank overdrafts; (xii) all unpaid Taxes for all Pre-Closing Tax Periods (and the portion
of any Straddle Periods ending on the Closing Date), (xiii) all Liabilities for any outstanding severance or consulting amounts owed to
any former (as of the Closing) employee, service provider or officer and any Taxes payable in connection therewith; and (xiv) all interest,
any premiums payable or any other costs or charges (including any prepayment penalties, termination fees, breakage costs, make-whole and
expense reimbursements) on any instruments or obligations described in clauses (i) through (xiii) hereof, all as the same may be payable
upon the complete and final payoff thereof, regardless of whether such payoff occurs prior to, simultaneous with or following the Closing.
For the avoidance of doubt, &ldquo;Indebtedness&rdquo; of the Company shall not include (A) deferred revenue of the Company incurred in
the ordinary course of business , (B) undrawn amounts under letters of credit, or (C) &ldquo;double trigger&rdquo; severance payments
to any employees of the Company arising not only as a result of the consummation of the transactions contemplated by this Agreement but
that also require a subsequent action by the Company, i.e. post-Closing termination by the Company, at the direction of Purchaser. Notwithstanding
the foregoing, to avoid double-counting, &ldquo;Indebtedness&rdquo; of the Company shall not include items to the extent that they are
taken into account in the final calculation of the Transaction Expense Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indemnified Party</U>&rdquo;
means, with respect to a particular matter, a Person who is entitled to indemnification from another party hereto pursuant to <U>&lrm;Article&nbsp;IX</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indemnifying Party</U>&rdquo;
means, with respect to a particular matter, a party hereto who is required to provide indemnification under <U>&lrm;Article&nbsp;IX</U>
to another Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indemnifying Pro
Rata Share</U>&rdquo; means, with respect to a particular Equityholder and at any time, the percentage corresponding to the fraction:
(a) the numerator of which is the aggregate amount of Merger Consideration actually paid or payable to such Equityholder at or prior to
such time, and (b) with a denominator equal to the total amount of Merger Consideration actually paid or payable to all Equityholders
at or prior to such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual Property</U>&rdquo;
means all intellectual property and industrial property rights, however arising, pursuant to the Laws of any jurisdiction throughout the
world, whether registered or unregistered, including any and all:(a)&nbsp;all patents and patent applications arising under the Laws of
any nation, state or jurisdiction (including any continuations, divisionals, continuations-in-part, provisionals, renewals, reissues,
re-examinations and applications for any of the foregoing); (b)&nbsp;all trademarks, service marks, trade names, slogans, logos, trade
dress, Internet domain names, URLs and similar designations of source or origin, in each case together with all goodwill, registrations
and applications for registration related to any of the foregoing; (c)&nbsp;all copyrights and copyrightable subject matter (including
any registration and applications for any of the foregoing); and (d)&nbsp;all trade secrets, know-how, proprietary processes, formula,
algorithms, models and methodologies, and other intellectual property or proprietary rights of any kind, whether arising under the Laws
of the United States or any other nation, state or jurisdiction; (e) Software; (f) mask works and registrations and applications for registration
thereof, (g) social media user names, identifiers, passwords, and profiles, and rights in telephone numbers, all goodwill associated therewith,
and all registrations and applications therefor; (h) rights of publicity and privacy; (i) shop rights; (j) all advertising and promotional
materials; and (k) websites (including the layout, design and contents of the web pages and underlying codes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>IRS</U>&rdquo; means
the Internal Revenue Service of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>ITA</U>&rdquo; shall
mean the Israeli Tax Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Joining Equityholder</U>&rdquo;
means each Equityholder who executes and delivers a Voting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Key Employee</U>&rdquo;
means each of the employees set forth on Schedule 1.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Knowledge</U>&rdquo;
means the actual knowledge, as of the applicable date, of any director or officer of the Company or the Purchaser, as applicable, after
reasonable inquiry. Such individual shall also be deemed to have actual knowledge of a particular fact, circumstance, event or other matter
in question if such knowledge would reasonably be expected to have been obtained by such individual in the ordinary course of the performance
of his duties as an officer or director of the Company or the Purchaser, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Law</U>&rdquo; means
any law, statute, ordinance, regulation, rule, code, treaty or other requirement having the force of law of any Governmental Entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liability</U>&rdquo;
or &ldquo;<U>liability</U>&rdquo; means any financial liability, debt, obligation, deficiency, interest, Tax, penalty, fine, demand, judgment,
claim, or other loss, cost or expense of any kind or nature whatsoever, whether asserted or unasserted, absolute or contingent, known
or unknown, accrued or unaccrued, liquidated or unliquidated, and whether due or become due and regardless of when asserted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means (i) any and all liens, claims, mortgages, security interests, rights, restrictions, limitations, easements, charges (whether floating
or fixed), assessments, levies, pledges and other encumbrances of every kind and nature whatsoever or other similar arrangements, (ii)
with respect to securities, any interest or equity of any Person (including any right to acquire, voting trust or agreement, option or
right of pre-emption or conversion, or any transfer restriction) or (iii) any agreement to create any of the above, in each case, whether
arising by agreement, operation of Law or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Adverse
Effect</U>&rdquo; means any event, effect, change, condition or development that, individually or in the aggregate with other such events,
effects, changes, conditions or developments, has, or would reasonably be expected to have a material adverse effect (a) on the business,
operations or financial condition of the Company or the Purchaser, as applicable or (b) upon the ability of the Company, the Equityholders
or the Equityholder Representative to perform any of their obligations under this Agreement or to consummate the transactions contemplated
hereby; <U>provided</U> that, none of the following will constitute or be taken into account in determining whether there has been a Material
Adverse Effect for purposes of clause (a) thereof: any event, circumstance, change, occurrence, fact, development or effect resulting
from or relating to (i) the taking of, or the failure to take, any action contemplated by this Agreement or any of the other Transaction
Documents that is specifically required to be taken or not taken hereunder or thereunder; (ii) changes after the date hereof in the general
economic conditions or political or social climate, including the engagement by the United States in hostilities, whether or not pursuant
to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack upon the United States or any
of its territories, possessions or diplomatic or consular offices or upon any military installation, equipment or personnel of the United
States; (iii) changes after the date hereof in the United States or global financial, securities, banking or commodity markets (including
any disruption thereof and any decline in the price of any security or any market index); (iv) the failure (in and of itself) by the Company
to meet any internal or other projections, budgets, plans or forecasts of its revenues, earnings or other financial performance or results
of operations (<U>provided</U> that, the underlying causes of such failure may be deemed to contribute to a Material Adverse Effect),
(v) changes, after the date hereof, generally applicable to the industries in which the Company operates; (vi) changes in US GAAP after
the date hereof; and (vii) natural disasters, pandemics, labor unrest, strikes, acts of wars, terrorism, sabotage and other &ldquo;acts
of God&rdquo;; <I><U>provided</U></I>, <I><U>that</U></I>, in the case of any event, effect, change, condition or development set forth
in the foregoing clauses (ii) through (iii) and (v) through (vii), inclusive, such events, effects, changes, conditions or developments
do not, individually or in the aggregate, disproportionately affect the business, operations or financial condition of the Company relative
to other companies operating in the industry in which the Company operates. It is hereby agreed that, with respect to the Purchaser only,
the definition of Material Adverse Effect shall also include shortfall of more than 20% in the non-cash assets presented in the audited
balance sheets and related statements of operations, stockholders&rsquo; equity and cash flows (together with any notes thereto) of the
Company as of and for the year ended December 31, 2020 compared to the information presented to the Purchaser in the Unaudited Financial
Statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone</U>&rdquo;
means the objective, milestone or acceptance criteria (in each case, whether technological criteria, commercial criteria, financial criteria
or otherwise) set out in the Milestone Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Achievement
Date</U>&rdquo; means, with respect to each Milestone, the date on which such Milestone has been successfully achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Schedule</U>&rdquo;
means the schedule enclosed hereto as <U>Exhibit H</U>, which delineates the description and terms of each Milestone, the Milestone Target
Date, and the percentage out of the total Earn-out Consideration to be paid on account of the successful achievement of such Milestone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Milestone Target
Date</U>&rdquo; means, with respect to each Milestone, the respective date on which such milestone needs to be achieved in order for such
achievement to qualify as a successful achievement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Open Source Code</U>&rdquo;
means software code subject to an Open Source License</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Open Source License</U>&rdquo;
means an &ldquo;open source,&rdquo; &ldquo;copyleft&rdquo; or other similar type of license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Order</U>&rdquo;
means any order, writ, injunction or decree of any Governmental Entity, arbitrator or mediator and any settlement agreement or compliance
agreement entered into in connection with any Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinance</U>&rdquo;
shall mean the Israeli Income Tax Ordinance [New Version], 1961, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary Shares
of the Company</U>&rdquo; means Ordinary Shares of the Company, par value ILS 0.01 each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary Shares
of Purchaser</U>&rdquo; means Ordinary Shares of Purchaser, par value ILS 0.01 each .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Organizational Documents</U>&rdquo;
means, with respect to a Person, the following documents that are presently in effect, including any amendments, modifications, or supplements
thereto: (a)&nbsp;the articles or certificate of incorporation, formation, organization, or association; (b)&nbsp;general or limited partnership
agreement; (c)&nbsp;limited liability company or operating agreement; (d)&nbsp;bylaws; and (e) any equityholders&rsquo; agreements, investor
rights agreements, voting agreements, voting trusts, joint venture agreements, registration rights agreements, or similar agreements relating
to the ownership of equity interests of such Person and to which such Person is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Payout Spreadsheet</U>&rdquo;
means a spreadsheet delivered by the Company to Purchaser at least three Business Days prior to Closing, in a form consistent with the
sample spreadsheet attached as <U>Exhibit C</U> and otherwise reasonably acceptable to Purchaser, which shall be updated as of the Closing
Date and shall set forth, as of the Closing Date: (i) the capitalization of the Company including: (A) a complete and accurate list of
the record holders of issued and outstanding Company Shares, number and kind of Company Shares held (including the number of Ordinary
Shares into which such shares are convertible) and the respective certificate numbers thereof, and such holders&rsquo; last known respective
addresses and email addresses; (B) a complete and accurate list of all outstanding Company Outstanding Instruments, including the name
of the Person with whom such Company Outstanding Instruments were made, the number and type of Company Shares issuable (in case of the
Company Convertible Instruments) upon the conversion of such Company Outstanding Instruments; and (C) a complete and accurate list of
all outstanding Company Warrants, including the name of the Person to whom such Company Warrants have been issued, the number and type
of Company Shares issuable upon the exercise of such Company Warrants, and the per share exercise price for each Company Warrant; and
(ii) the following information, calculated in accordance with applicable Law, the Organizational Documents of the Company and all other
Contractual requirements on the part of the Company: (1) the amount which each Equityholder is entitled to receive (subject to <U>&lrm;Section&nbsp;2.7</U>
and <U>&lrm;Section&nbsp;2.8</U>) pursuant to &lrm;Section&nbsp;2.3, (2) the formula for calculating, at any time, the portion of any
Post-Closing Payout Amounts that are payable in respect of each Company Share, Company Outstanding Instruments and Company Warrant, and
(3) the formula for calculating, at any time, the Pro Rata Share and Indemnifying Pro Rata Share of each Equityholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permits</U>&rdquo;
means all licenses, permits, registrations and government approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted Liens</U>&rdquo;
means: (a) statutory liens for Taxes not yet due but only to the extent an adequate reserve has been accrued as a current liability in
accordance with US GAAP and taken into account in Closing Indebtedness as finally determined pursuant to <U>&lrm;Section&nbsp;2.12</U>;
(b) statutory liens of landlords, carriers, warehousemen, mechanics and materialmen incurred in the ordinary course of business for sums
not yet due; (c) liens incurred or deposits made in the ordinary course of business in connection with workers&rsquo; compensation, unemployment
insurance and other types of social security or to secure the performance of tenders, statutory obligations, surety and appeal bonds,
bids, leases, government contracts, performance and return of money bonds and similar obligations; (d) minor irregularities of title that
are of record and do not, individually or in the aggregate, materially detract from the value or use of the Company&rsquo;s assets; and
(e) statutory liens mandated by IIA&rsquo;s applicable Laws with respect to the <U>IIA Funded Intellectual Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means any natural individual, corporation, partnership, limited liability company, joint venture, association, bank, trust company, trust
or other entity, whether or not legal entities, or any governmental entity, agency or political subdivision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Post-Closing Payment
Amounts</U>&rdquo; means, with respect to each Company Share, Company Outstanding Instrument and Company Warrant, the amounts that may
become payable in respect of such Company Share, Company Outstanding Instrument and Company Warrant from the Deferred Closing Consideration,
Indemnity Escrow Account, and the Expense Fund in accordance with <U>&lrm;Section&nbsp;2.4</U> or <U>&lrm;Section&nbsp;12.5</U>, respectively,
and, without duplication of the foregoing, any amounts that may become payable in respect of each Company Share, Company Outstanding Instrument
and Company Warrant after the Closing pursuant to <U>&lrm;Section&nbsp;1.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Closing Tax
Period</U>&rdquo; means any Tax period ending on or prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preferred A Shares</U>&rdquo;
means Series A Preferred Shares of the Company, par value ILS 0.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preferred B Shares</U>&rdquo;
means Series B Preferred Shares of the Company, par value ILS 0.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preferred C Shares</U>&rdquo;
means Series C Preferred Shares of the Company, par value ILS 0.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means any litigation (in law or in equity), arbitration, mediation, action, lawsuit, proceeding, compliant, charge, claim, demand, hearing,
inquiry, audit, examination, investigation or like matter before or by any Governmental Entity, whether administrative, judicial or arbitration
in nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Processing</U>&rdquo;
means, with respect to any data or information, collection, use, disclosure, transfer, transmission, storage, management, hosting, disposal,
retention, aggregation, analysis, curation, de-identification, or other handling or processing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pro Rata Share</U>&rdquo;
means, with respect to a particular Equityholder, the percentage corresponding to the fraction: (a) the numerator of which is the aggregate
amount of Merger Consideration actually paid or payable to such Equityholder at or prior to such time, and (b) the denominator of which
equals the total amount of Merger Consideration actually paid or payable to all Equityholders at or prior to such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser Share
Consideration</U>&rdquo; means unregistered Ordinary Shares of Purchaser, par value ILS 0.01 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser Share
Consideration Price</U>&rdquo; means (i) with respect to the Closing Consideration and the Deferred Closing Consideration paid at Closing,
an amount per share of Purchaser Share Consideration equal to the weighted average closing price of registered Ordinary Shares of Purchaser
(NASDAQ: NNOX) for the 90 trading days ending on the date hereof (as may be adjusted as appropriate to reflect any share splits, share
dividends, combinations, reorganizations, reclassifications or similar events), (ii) with respect to each payment of the Earn-out Consideration,
an amount per share of Purchaser Share Consideration equal to the average closing price of registered Ordinary Shares of Purchaser (NASDAQ:
NNOX) for the 30 trading days ending on the applicable Milestone Achievement Date (as may be adjusted as appropriate to reflect any share
splits, share dividends, combinations, reorganizations, reclassifications or similar events), and (iii) with respect to each payment of
the Deferred Closing Consideration which is not paid at Closing, an amount per share of Purchaser Share Consideration equal to the average
closing price of Ordinary Shares of Purchaser (NASDAQ: NNOX) for the 30 trading days ending on the applicable Deferred Closing Payment
Date (as may be adjusted as appropriate to reflect any share splits, share dividends, combinations, reorganizations, reclassifications
or similar events).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Related Party</U>&rdquo;
means, with respect to a Person, (a)&nbsp;any Affiliate of such Person, and any direct or indirect beneficial owner of 5% or more of the
equity securities or voting securities or other voting interests in such Person; (b)&nbsp;any member, manager, general partner, director,
officer, trustee, executor or receiver of such Person or Person described in <U>clause&nbsp;(a)</U> above or the estate of such Person
or any Person described in <U>clause&nbsp;(a)</U> above; (c)&nbsp;that is an individual, such individual&rsquo;s spouse, domestic partner
or immediate family member of such individual; and (d)&nbsp;any trust, family partnership, family limited partnership, family limited
liability company, or other entity established for the benefit of such Person or any Person described in any of <U>clauses&nbsp;(a)</U>
through <U>(c)</U> above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>R&amp;D Law</U>&rdquo;
shall mean the Israeli Encouragement of Research, Development and Technological Innovation in Industry Law, 5744-1984, including regulations,
directives and rules promulgated thereunder and decisions of any IIA research committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Requisite Supporting
Shareholders</U>&rdquo; means, (A) with respect to the Effective Date, Shareholders owning more than the minimum amount required under
the Company Charter and the applicable law, to include, at the minimum, (i) 50% of the issued and outstanding Company Shares (as calculated
on an as-converted to Company&rsquo;s Ordinary Shares basis), (ii) 66.66 % of the Company's issued and outstanding Preferred A Shares,
Preferred B Shares and Preferred C Shares (in aggregate), and (iii) the 50% of the issued and outstanding share capital each class of
Company Shares; and (B) with respect to the Closing, Shareholders owning more than the minimum amount required under the Company Charter
and the applicable law, to include, at the minimum, 80% of the issued and outstanding of each class of Company Shares (as calculated on
an as-converted to Company&rsquo;s Ordinary Shares basis).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC</U>&rdquo; shall
mean the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Security Incident</U>&rdquo;
means any actual or suspected loss, damage or unauthorized access to, or unauthorized acquisition, use, modification, denial or loss of
use of, destruction, compromise, disclosure or other misuse of, any Company Data or any Company Information Systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
shall mean the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shareholder</U>&rdquo;
means a holder of Company Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shareholder Approval</U>&rdquo;
means the approval of the holders owning a class and number of Company Shares sufficient to approve, authorize and adopt this Agreement,
the Merger, the other Transaction Documents to which the Company is a party and the other transactions contemplated hereby and thereby,
and to consummate the Merger and the other transactions contemplated hereby and thereby, as required under the ICL, the Company Organizational
Documents, the Shareholders Agreements and any applicable agreements between the Company, on the one hand, and any one or more Shareholders,
on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Software</U>&rdquo;
means all computer programs (including any and all software implementation of algorithms, models and methodologies whether in source code
or object code), databases and computations (including any and all data and collections of data), documentation (including user manuals
and training materials) relating to any of the foregoing and the content and information contained in any web sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Spousal Consent</U>&rdquo;
means, with respect to a Shareholder who is a married individual, the consent of the spouse of such Shareholder to the sale of such Shareholder&rsquo;s
Company Shares, in the form which will be reasonably agreed between the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Straddle Period</U>&rdquo;
means any Tax period that begins on or before and ends after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any corporation, limited liability company, partnership, association or other business entity of which (i) if a corporation, a majority
of the total voting power of shares of Share entitled (without regard to the occurrence of any contingency) to vote in the election of
directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by another Person, or (ii) if a limited
liability company, partnership, association or other business entity, a majority of the partnership or other similar ownership interest
thereof is at the time owned or controlled, directly or indirectly, by another Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Tax Returns</U>&rdquo;
means all returns, declarations, reports, estimates, claims for refund, information returns or statements, statements of foreign bank
and financial accounts, and other documents required to be filed by the Company in respect of any Taxes, including any schedules or attachments
thereto and including any amendment or supplement thereof, and the term &ldquo;<U>Tax Return</U>&rdquo; means any one of the foregoing
Tax Returns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Taxes</U>&rdquo;
means all taxes, charges, fees, levies, or other like assessments, including all federal, possession, province, state, city, county or
foreign (or governmental unit, agency, or political subdivision of any of the foregoing) corporate, net income, franchise, profits, alternative
or add-on minimum, gross income, gross receipts, real or personal property, ad valorem, net worth, sales, use, transfer, value added,
severance, stamp, gains, license, excise, environmental, premium, employment (including Social Security, unemployment insurance, employer
health and employee income tax withholding), withholding or minimum taxes, customs, duties, or any other tax, fee, levy or other like
assessment or charge of any kind whatsoever, together with any interest or any penalty, addition to tax or additional amount imposed by
any Governmental Entity, whether disputed or not, and including any obligations to pay Taxes of others, whether pursuant to Treasury Regulations
Section 1.1502-6 (or any similar provision of state, local, or non-U.S. Law), as a transferee, successor, by Contract, or otherwise, and
the term &ldquo;<U>Tax</U>&rdquo; means any one of the foregoing Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Third Party Claim</U>&rdquo;
means any action, lawsuit, proceeding, investigation, hearing, or like matter that is asserted or overtly threatened by a Person other
than the parties, their successors and permitted assigns, against any Indemnified Party or to which any Indemnified Party is subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction Documents</U>&rdquo;
means this Agreement and all the other agreements, certificates, instruments and other documents to be executed or delivered in connection
with the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction Expenses</U>&rdquo;
means (i)&nbsp;all Liabilities incurred by the Company in connection with the preparation, negotiation, execution and consummation of
the Merger, this Agreement and the other Transaction Documents and the transactions contemplated hereby and thereby, including the premium
of the Tail Insurance Coverage procured by the Company pursuant to <U>&lrm;Section&nbsp;6.2</U>, and (ii) all Liabilities and obligations
of the Company to any Person&nbsp;arising from change of control payments, commission agreements, stay bonuses, transaction bonuses, retention
agreements and similar arrangements or amounts payable as a result of the consummation of the Merger and the other transactions contemplated
hereby, and including, if applicable, the Company&rsquo;s share of employment Taxes with respect to such Liabilities and obligations,
but excluding any severance or other payments arising solely as a result of the termination of any employee of the Company by Purchaser,
the Surviving Corporation or any of their Affiliates on or after the Closing Date and excluding any expenses paid from the Expense Fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Unvested Company
Options</U>&rdquo; means Company Options which are not exercisable as of the date of the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Unrecognized Tax
Items</U>&rdquo; means the amount of any income or deductions disclosed with respect to <U>&lrm;Section&nbsp;3.10(b)</U> that is required
to be included or excluded, respectively, in taxable income for a Tax period or portion thereof beginning after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>US GAAP</U>&rdquo;
means the generally accepted accounting principles in the US.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>&ldquo;Vested Company Options</U>&rdquo;
means Company Options which are outstanding and exercisable vested as of the date of the Effective Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant Cancellation
Agreement</U>&rdquo; means an agreement duly executed by a holder of Company Warrants acknowledging and agreeing to the cancelation of
(a) any agreement pursuant to which such holder of Company Warrants is granted a right to purchase any Company Shares, and (b) all Company
Warrants held by such holder of Company Warrants, in form and substance reasonably acceptable to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Schedule 1.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Key Employees</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eyal Toledano*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Orit Wimpfheimer*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ayelet Akselrod-Ballin*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amit Oved</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Demi Goldberg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Guy Cohen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shmulik Ahituv</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ronen Gordon</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Shai Reshef</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Zohar Elhanani</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify"><I>are also defined as Essential Key Employees</I>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 85 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit H</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Milestone Schedule</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 17%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Objective</B></P></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 19%"><B>Milestone</B></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 52%"><B>Acceptance Criteria</B></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: center; width: 9%"><B>%</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1.a)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FDA clearance of the existing Company&rsquo;s&rsquo; Viewer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>FDA clearance </TD>
    <TD>&nbsp;</TD>
    <TD>Submission of company web-viewer for FDA within 6 months of closing, payment after FDA clearance is received</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1.b)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Security Certification SOC2</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>Renewal of SOC2 </TD>
    <TD>&nbsp;</TD>
    <TD>Approval of SOC2 renewal certification by year end 2022 </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1.c)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Security Certification ISO</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>Acceptance of ISO 27001 and 27799</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ISO auditor approval and ISO re-certification by year end 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(next audit is expected only May 2022)</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nanox ARC integration and FDA clearance to Zebra cloud</P></TD>
    <TD>&nbsp;</TD>
    <TD>Nanox ARC integration and FDA clearance to Zebra cloud</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nanox ARC fully integrated with Zebra Company&rsquo;s Cloud solution,
    including Existing Nanox Image Reconstruction algo and Nanox ARC base storage, within 9 months of closing.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FDA clearance for the integrated solution by year end 2023, Subject
    to NANOX existing reconstruction algorithm is provided at closing and its performance meets FDA predicate requirement</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(3)Current CPT code usage</TD>
    <TD>&nbsp;</TD>
    <TD>Health plans use the CPT code in 2022</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">The Company achieves the usage level defined by a major US payer (health insurance company) during 2022</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">(4) Current CPT code revenues</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>First billable transactions deliver at least 1M$ by year end 2023</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New CPT code</P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acceptance of a new code for Nanox procedures</P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acceptance notice from AMA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By year end 2023</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depending on Nanox providing:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FDA
    approval for Nanox Modality (ARC) procedure during 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3
    clinical peer reviewed accepted papers supporting Nanox Tomo CPT claims</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5%</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 86 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 17%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(6)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FDA - pop health</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%"><P STYLE="margin-top: 0; margin-bottom: 0">New FDA clearance for a Zebra population health product</P>
                           <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 52%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New Zebra product designated for population health is cleared by FDA
    by year end 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%">7.5%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(7)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FDA - X-Ray</P></TD>
    <TD>&nbsp;</TD>
    <TD>Extending zebra FDA clearance for <BR>
X-ray product to include Nanox <BR>
X-ray machine</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FDA clearance by March 2023</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Zebra shall provide data for development (tagged 1000/1000 positives
    negatives) by March 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to Nanox application for FDA approval of the Nano-X&rsquo;s
    technology during 2022*</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to Nanox providing for tuning 500/500 positive/negative until
    May 2022 and clinical validation 250/250 positive/negative until Aug 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7.5%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(8)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attainment of revenue goals</P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Achieve 90% of the revenue projections provided by Zebra management
    for 2022 ($9.311 million) and 70% for 2023 ($42.001 million).</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>Zebra audited annual report demonstrate that 90% of the revenue projections provided by Zebra management for 2022 ($9.311 million) and 70% for 2023 ($42.001 million).</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(9)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Employees retention</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">First year Team retention for 80% of all of the Company&rsquo;s employees
    as of the Closing (but to include 80% of all Key Employees and all of the Essential Key Employees) and 2nd and 3rd year Team retention
    of 70% of all of the Company&rsquo;s employees as of the Closing (but to include 70% of all Key Employees and all of the Essential Key
    Employees) (the &ldquo;<B>Retention Criteria</B>&rdquo;). Targets are accumulative and the measurement and payment will be done three
    years as of the Closing.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is hereby agreed that (i) if an employee&rsquo;s employment
by the Company is (a) terminated by the Company or Purchaser other than for Cause, or (b) terminated by the employee for Good Reason
within 30 days of the day on which the circumstances which give rise to the Good Reason had occurred, or (ii) if within 60 days after
an employee (not including, for the removal of a doubt, Essential Key Employees) left the Company for any reason (other than the termination
of his/her employment for Cause), the Company hires an equally competent employee (reasonably acceptable to the Purchaser ) instead of
such employee; then the employees noted in (i) and (ii) above shall be deemed as &lsquo;employed by the Company&rsquo; for the purpose
of determining whether the terms of the Retention Condition were satisfied.&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15%</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">If the Purchaser has decided to abandon
certain technology or product underlying a specific Milestone, causing that such Milestone cannot be achieved (the &ldquo;<U>Abandoned
Milestone</U>&rdquo;), the Purchaser shall promptly notify the Equityholders Representative of such decision and the Purchaser and the
Equityholders Representative will agree on a new milestone which is is useful for Purchaser and equivalent to the Abandoned Milestone,
and if no written agreement has been reached with respect to a new milestone within 90 days following such notice by Purchaser, the Earn-out
Payment Amount of the Abandoned Milestone shall be added, on a pro-rata basis, to all of the other Milestones (including those Milestone
that their respective &ldquo;Milestone Target Date&rdquo; has lapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Notwithstanding the above, if the Milestone cannot be achieved
because Purchaser does not receive the approval or does not submit the application in 2022 the parties will agree on equivalent milestones
for Company&rsquo;s components that are useful for Purchaser.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>5
<FILENAME>f20f2021ex4-3_nanox.htm
<DESCRIPTION>FIRST AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER, DATED AUGUST 9, 2021, AMONG NANO-X IMAGING LTD, ZEBRA MEDICAL VISION LTD. AND PERRYLLION LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.3</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN
OF MERGER</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amendment No. 1 to the
Agreement and Plan of Merger (the &ldquo;<U>Amendment</U>&rdquo;) is entered into on October __, 2021 by and among Nano-X Imaging Ltd,
New Zealand Merger Sub Ltd., Nano-X Ai Ltd. (formerly Zebra Medical Vision Ltd.), and PerryLLion Ltd., solely in its capacity as the representative
of all Equityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><B>WHEREAS</B>,</TD><TD STYLE="text-align: justify">the parties hereto (the &ldquo;<U>Parties</U>&rdquo;) have entered into that certain Agreement and Plan
of Merger, dated August 9, 2021, (the &ldquo;<U>Agreement</U>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><B>WHEREAS</B>,</TD><TD STYLE="text-align: justify">the Parties wish to amend and modify certain provision of the Agreement, as specified in this Amendment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><B>THEREFORE</B>, the
Parties agree to modify the Agreement as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capitalised terms used but not defined herein
shall bear the meaning attributed to such capitalised terms in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">The second paragraph of Section 2.3(a) of the Agreement shall
be amended to read as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&ldquo;<U>Treatment of Vested Company
Options</U>. As of the Effective Time, any Vested Company Option (including any Unvested Company Option which becomes vested on account
of the transactions contemplated herein) shall be converted, immediately prior to the Effective Time, into such number of Company Shares
which underlies the Vested Company Options, provided, however, that, as will be provided in the Payout Spreadsheet, such amount of Purchaser
Share Consideration for which the stated exercise price of each Vested Company Option would have been converted into according to the
terms of the Agreement (should it, and it only, have been converted into Company Shares) will be deducted from the Closing Consideration
attributed to each such Company Share which underlies such Vested Company Options, all, as further provide in the Payout Spreadsheet.&rdquo;.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The definition of &ldquo;<U>Designated Commercial Agreements</U>&rdquo; under Section 2.10(b) shall be amended to read as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&ldquo;commercial agreements between
the Company and (i) any integrated US Healthcare System (IDN) with over $2 billion of annual net patient revenue or leading commercial
payer involving Zebra&rsquo;s population health solutions for purpose of risk adjustment and/or cost savings or avoidance, (ii) DePuy Ireland
Unlimited Company, which provides an amendment to the existing Development and License Agreement dated December 9, 2019 to include a refinement
of the product specification, feasibility and the development milestones, and (iii) The Secretary of State for Health and Social Care,
which provides for evaluation project funded by the UK National Health Service, for utilization of AI-enabled vertebral fracture pathway
to prevent osteoporotic fractures&rdquo;.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">In Section 6.2(c), the words <I>&ldquo;during the Pre-Closing Period&rdquo;</I> shall be replaced by the words <I>&ldquo;within 60
days after Closing&rdquo;.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">The second paragraph of Section 8.2(i) of the Agreement shall be amended to read as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&ldquo;The Purchaser has received
the audited consolidated balance sheets and related statements of operations, stockholders&rsquo; equity and cash flows (together with
all notes thereto) of the Company as of and for the years ended December 31, 2020, prepared in accordance with US GAAP&rdquo;.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">To replace Exhibit H, the Milestone Schedule, with the updated Milestone Schedule that is attached as <B><U>Annex A hereto</U></B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">It is hereby agreed that, as request by the Altshuler Shaham Trusts Ltd. (the Escrow Agent and the Paying Agent under the Agreement),
(i) the Escrow and Paying Agent Agreement will be comprised of two separate agreements, one agreement with Altshuler Shaham Trusts Ltd.
in its capacity as the Escrow Agent (the &ldquo;<U>Escrow Agreement</U>&rdquo;), and a second agreement with Altshuler Shaham Trusts Ltd.
in its capacity as the Paying Agent (the &ldquo;<U>Paying Agent Agreement</U>&rdquo;), (ii) the Parties shall enter into an additional
(third) agreement with Altshuler Shaham Trusts Ltd., in its capacity as a trustee for the purpose of the 104H Interim Tax Ruling and the
104H Tax Ruling (the &ldquo;<U>104 Trustee Agreement</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">It is further agreed that all fees to
be paid at Closing to Paying Agent, Escrow Agent or otherwise to Altshuler Shaham Trusts Ltd. under the Escrow Agreement, Paying Agent
Agreement and the 104 Trustee Agreement, will be borne and paid equally by the Company and Purchaser, and, with respect to the Company,
its portion of such payments will be considered as Transaction Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Amendment shall be deemed for all intents
and purposes as an integral part of the Agreement and shall be governed by the terms and conditions of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the Parties have caused
this Amendment to be executed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><U>PURCHASER</U>:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>NANO-X IMAGING LTD</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 4%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 36%">/s/ Ran Daniel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify">Ran Daniel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Its:</TD>
    <TD STYLE="text-align: justify">Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><U>MERGER SUB</U>:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>NEW ZEALAND MERGER SUB LTD.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">/s/ Ran Daniel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify">Ran Daniel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Its:</TD>
    <TD STYLE="text-align: justify">Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><U>THE COMPANY</U>:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>ZEBRA MEDICAL VISION LTD.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">/s/ Zohar Elhanani</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD>
    <TD STYLE="text-align: justify">Zohar Elhanani</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Its:</TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><U>EQUITYHOLDER REPRESENTATIVE</U>:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><B>PERRRYLLION LTD.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">/s/ Amit Perry</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:&nbsp;</TD>
    <TD STYLE="text-align: justify">Amit Perry&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Its:</TD>
    <TD STYLE="text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Annex A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Updated Milestone Schedule</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 21%; text-align: left"><B>Objective</B></TD>
    <TD STYLE="text-align: center; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 21%; text-align: center"><B>Milestone</B></TD>
    <TD STYLE="text-align: center; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 40%; text-align: center"><B>Acceptance Criteria</B></TD>
    <TD STYLE="text-align: center; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center"><B>%</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(1.a)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">FDA clearance of the existing Company&rsquo;s&rsquo;
    Viewer</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">FDA clearance </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><I>Submission of Company web-viewer with the FDA within 6 months of closing, payment after FDA clearance is received, provided however, that if the product will be classified as Class 1 (and therefore, no submission nor clearance shall be required), the registration of the product will qualify for meeting acceptance criteria</I></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(1.b)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Security</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Certification SOC2</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Renewal of SOC2 </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Approval of SOC2 renewal certification by year end 2022 </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(1.c)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Security</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Certification ISO</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Acceptance of ISO 27001 and 27799</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ISO auditor approval and ISO re-certification
    by year end 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(next audit is expected only May 2022)</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(2)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Nanox ARC integration and FDA clearance
to Zebra cloud</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Nanox ARC integration and FDA clearance to Zebra cloud</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nanox ARC fully integrated with Zebra Company&rsquo;s
    Cloud solution, including Existing Nanox Image Reconstruction algo and Nanox ARC base storage, within 9 months of closing.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FDA clearance for the integrated solution by year
    end 2023, Subject to NANOX existing reconstruction algorithm is provided at closing and its performance meets FDA predicate requirement</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">(3) Current CPT code usage</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Health plans use the CPT code in 2022</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">The Company achieves the usage level defined by a major US payer (health insurance company) during 2022</P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">(4) Current CPT code revenues</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">First billable transactions deliver at least 1M$ by year end 2023</P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(5)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">New CPT code</P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acceptance of a new code for Nanox
procedures. Separately, an acceptance of a new code for a Zebra&rsquo;s population health product</P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acceptance notice from the AMA by year end 2023
    for each of the CPT codes.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nanox procedure code depends on Nanox providing:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FDA
    approval for Nanox Modality (ARC) procedure during 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3
    clinical peer reviewed accepted papers supporting Nanox Tomo CPT claims</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5% for the Nanox procedure code (2.5% for each CPT Code if a new Zebra CPT Code is attained)</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 21%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(6)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">FDA - pop health</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 21%"><P STYLE="margin-top: 0; margin-bottom: 0">New FDA clearance for a Zebra population health product</P>
                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New Zebra product designated for population health
    is cleared by FDA by year end 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 15%">7.5%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(7)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">FDA - X-Ray</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Extending zebra FDA clearance for <BR>
X-ray product to include Nanox <BR>
X-ray machine</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FDA clearance by March 2023</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Zebra shall provide data for development (tagged
    1000/1000 positives negatives) by March 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to Nanox application for FDA approval
    of the Nano-X&rsquo;s technology during 2022*</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to Nanox providing for tuning 500/500
    positive/negative until May 2022 and clinical validation 250/250 positive/negative until Aug 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7.5%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(8)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Attainment of revenue goals</P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Achieve 90% of the revenue projections provided
    by Zebra management for 2022 ($9.311 million) and 70% for 2023 ($42.001 million).</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Zebra audited annual report demonstrate that 90% of the revenue projections provided by Zebra management for 2022 ($9.311 million) and 70% for 2023 ($42.001 million).</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30%</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(9)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Employees retention</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">First year Team retention for 80% of all of the
    Company&rsquo;s employees as of the Closing (but to include 80% of all Key Employees and all of the Essential Key Employees) and 2nd and
    3rd year Team retention of 70% of all of the Company&rsquo;s employees as of the Closing (but to include 70% of all Key Employees and
    all of the Essential Key Employees) (the &ldquo;<B>Retention Criteria</B>&rdquo;). Targets are accumulative and the measurement and payment
    will be done three years as of the Closing.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is hereby agreed that (i) if an employee&rsquo;s
    employment by the Company is (a) terminated by the Company or Purchaser other than for Cause, or (b) terminated by the employee for Good
    Reason within 30 days of the day on which the circumstances which give rise to the Good Reason had occurred, or (ii) if within 60 days
    after an employee (not including, for the removal of a doubt, Essential Key Employees) left the Company for any reason (other than the
    termination of his/her employment for Cause), the Company hires an equally competent employee (reasonably acceptable to the Purchaser
    ) instead of such employee; then the employees noted in (i) and (ii) above shall be deemed as &lsquo;employed by the Company&rsquo; for
    the purpose of determining whether the terms of the Retention Condition were satisfied.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15%</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">- 6 -</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>6
<FILENAME>f20f2021ex4-4_nanox.htm
<DESCRIPTION>STOCK PURCHASE AGREEMENT DATED NOVEMBER 2, 2021 BY AND AMONG DR. MICHAEL YUZ ,DR. MICHAEL YUZ AS THE REPRESENTATIVE OF SELLERS, USARAD HOLDINGS, INC. AND NANO-X IMAGING LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit 4.4</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Execution
Version</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>STOCK
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">by
and among</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>USARAD
HOLDINGS, INC.,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>dr.
michael yuz,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THE
OTHER SELLERS LISTED ON THE SIGNATURE PAGE,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Seller
Representative,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NANO-X
IMAGING, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Nano-X
Imaging Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated
as of October 25, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Definitions</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">1.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Certain Matters of Construction</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">1.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Certain Definitions</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Transaction</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase and Sale of the Shares</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase Price</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">18</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">The Closing</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Closing Deliveries and Payments</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase Price Adjustment.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Earn Out</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Company Stock Options and Warrants</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">2.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Withholding</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Representations and Warranties of the Company and Yuz</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Power and Authorization</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Organization</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Capitalization; Subsidiaries</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">No Violation or Approval; Consents</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Financial Statements, Etc</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ordinary Course of Business; No Material Adverse Effect</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Taxes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.8.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Real Estate</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.9.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Operations in Conformity with Laws</FONT></TD>
    <TD STYLE="text-align: center">37</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Employee Plans</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.12.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Environmental Matters</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.13.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Material Contracts</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.14.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Government Contracts</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.15.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Transactions with Affiliates</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.16.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Litigation</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.17.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Insurance</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">46</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(continued)</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.18.</FONT></TD>
    <TD STYLE="width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Labor Matters</FONT></TD>
    <TD STYLE="text-align: center; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.19.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Brokers</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.20.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Customers and Suppliers</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.21.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory Matters</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.22.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Minutes</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.23.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Data Privacy</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">3.24.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">No Other Representations or Warranties</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Representations and Warranties of the Sellers</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Organization, Power and Standing</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">4.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorization; Enforceability</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">4.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Noncontravention</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">52</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ownership of Shares</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">52</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">4.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax and Legal Matters</FONT></TD>
    <TD STYLE="text-align: center">53</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">4.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Absence of Litigation</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">4.7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock Consideration</FONT></TD>
    <TD STYLE="text-align: center">54</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Representations and Warranties of the Buyer and Parent</FONT></TD>
    <TD STYLE="text-align: center">55</TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Organization</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">55</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Authorization</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">55</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">No Violation or Approval; Consents</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">55</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Valid Issuance of Stock Consideration</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Litigation</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Brokers</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital Structure</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.8.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Listing and Maintenance Requirements</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">SEC Reports</FONT></TD>
    <TD STYLE="text-align: center">57</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Investment Intent</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Independent Investigation</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">5.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Taxes and Tax Returns</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conditions Precedent to the Obligations of the Buyer</FONT></TD>
    <TD STYLE="text-align: center">58</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Representations and Warranties</FONT></TD>
    <TD STYLE="text-align: center">58</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(continued)</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.</FONT></TD>
    <TD STYLE="width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance of Obligations</FONT></TD>
    <TD STYLE="text-align: center; width: 7%">58</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Compliance Certificate</FONT></TD>
    <TD STYLE="text-align: center">58</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Injunctions</FONT></TD>
    <TD STYLE="text-align: center">58</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Escrow Agreement</FONT></TD>
    <TD STYLE="text-align: center">59</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Indebtedness</FONT></TD>
    <TD STYLE="text-align: center">59</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">FIRPTA</FONT></TD>
    <TD STYLE="text-align: center">59</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.8.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Personnel</FONT></TD>
    <TD STYLE="text-align: center">59</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.9.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Secretary&rsquo;s Certificate</FONT></TD>
    <TD STYLE="text-align: center">59</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.10.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Form W-9</FONT></TD>
    <TD STYLE="text-align: center">59</TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.11.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consents</FONT></TD>
    <TD STYLE="text-align: center">59</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.12.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-Competition</FONT></TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.13.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">MDW Unit Purchase Agreement</FONT></TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.14.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Company Intellectual Property</FONT></TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">6.15.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">PPP Escrow Agreement</FONT></TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">7.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Conditions Precedent to Obligations of the Sellers</FONT></TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Representations and Warranties</FONT></TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance of Obligations</FONT></TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">7.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Compliance Certificate</FONT></TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Injunctions</FONT></TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">7.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Escrow Agreement</FONT></TD>
    <TD STYLE="text-align: center">60</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Covenants of the Parties</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Access to Premises and Information</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Conduct of Business Prior to Closing</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Confidentiality; Announcements</FONT></TD>
    <TD STYLE="text-align: center">64</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">No Solicitation</FONT></TD>
    <TD STYLE="text-align: center">66</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Preparation for Closing</FONT></TD>
    <TD STYLE="text-align: center">67</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Business Records</FONT></TD>
    <TD STYLE="text-align: center">69</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors and Officers Indemnification and Insurance.</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">70</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax Matters</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">71</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.9.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Notification</FONT></TD>
    <TD STYLE="text-align: center">75</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(continued)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.10.</FONT></TD>
    <TD STYLE="width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Employee Matters</FONT></TD>
    <TD STYLE="text-align: center; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.11.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Share Lock-up and Sale Restrictions</FONT></TD>
    <TD STYLE="text-align: center">76</TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Further Assurances</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">77</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.13.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Release of Claims</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">77</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.14.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">PPP Loan</FONT></TD>
    <TD STYLE="text-align: center">79</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">8.15.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Stone Creek Consulting</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">80</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indemnification</FONT></TD>
    <TD STYLE="text-align: center">80</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Survival</FONT></TD>
    <TD STYLE="text-align: center">80</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Indemnity by the Sellers</FONT></TD>
    <TD STYLE="text-align: center">81</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Indemnity by the Buyer</FONT></TD>
    <TD STYLE="text-align: center">83</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Notification of Certain Claims</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">83</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Calculation of Losses</FONT></TD>
    <TD STYLE="text-align: center">85</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Matters Involving Third Parties</FONT></TD>
    <TD STYLE="text-align: center">85</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Materiality</FONT></TD>
    <TD STYLE="text-align: center">86</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.8.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">No Contribution</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">86</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.9.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Escrow</FONT></TD>
    <TD STYLE="text-align: center">86</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.10.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax Treatment</FONT></TD>
    <TD STYLE="text-align: center">87</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.11.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Acknowledgement by the Buyer</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">87</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.12.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Manner of Payment</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">87</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.13.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Payment Process</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">87</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">9.14.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Sellers&rsquo; Representative</FONT></TD>
    <TD STYLE="text-align: center">88</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Termination</FONT></TD>
    <TD STYLE="text-align: center">90</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Termination</FONT></TD>
    <TD STYLE="text-align: center">90</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">10.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Effect of Termination</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">91</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">Miscellaneous</FONT></TD>
    <TD STYLE="text-align: center">92</TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Notices</FONT></TD>
    <TD STYLE="text-align: center">92</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Expenses of Transaction</FONT></TD>
    <TD STYLE="text-align: center">93</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Entire Agreement</FONT></TD>
    <TD STYLE="text-align: center">93</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Severability</FONT></TD>
    <TD STYLE="text-align: center">93</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Amendment</FONT></TD>
    <TD STYLE="text-align: center">93</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(continued)</FONT></P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.6.</FONT></TD>
    <TD STYLE="width: 79%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Parties in Interest</FONT></TD>
    <TD STYLE="text-align: center; width: 7%">93</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.7.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Assignment</FONT></TD>
    <TD STYLE="text-align: center">93</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.8.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Governing Law</FONT></TD>
    <TD STYLE="text-align: center">94</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.9.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Consent to Jurisdiction</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">94</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.10.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Waiver of Jury Trial</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">94</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.11.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Reliance</FONT></TD>
    <TD STYLE="text-align: center">95</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.12.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Specific Enforcement</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">95</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.13.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">No Waiver</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">95</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.14.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Negotiation of Agreement</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">95</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.15.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Disclosure Schedules</FONT></TD>
    <TD STYLE="text-align: center">96</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.16.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">No Recourse Against Third Parties</FONT></TD>
    <TD STYLE="text-align: center">96</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.17.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Headings</FONT></TD>
    <TD STYLE="text-align: center">96</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">11.18.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Counterparts; Electronic Signature</FONT></TD>
    <TD STYLE="text-align: center">96</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif">Schedules</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
<TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Schedule
                                            2.2(c) &ndash; Allocation of Purchaser Price and Flow of Funds</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: left; background-color: White">
<TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Schedule&nbsp;2.5.1(a)
                                            &ndash; Sample Working Capital Calculation</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
<TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Schedule&nbsp;2.5.1(b)
                                            &ndash;Sample Closing Statement</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: left; background-color: White">
<TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Schedule
                                            2.6.1 &ndash; Earn Out Schedule</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
<TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Disclosure
                                            Schedules</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif">EXHIBITS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
<TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibit&nbsp;A&nbsp;&nbsp;&nbsp;Form
                                            of Escrow Agreement&nbsp;</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: left; background-color: White">
<TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibit
                                            B&nbsp;&nbsp;&nbsp;Form of Non-Competition Agreement</FONT></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Stock
PURCHASE AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Stock Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is made as of October 25, 2021, by and among (i)&nbsp;Dr. Michael Yuz
(&ldquo;<U>Yuz</U>&rdquo;), (ii)&nbsp;the other stockholders of capital stock of the Company listed on the signature page (the &ldquo;<U>Other
Stockholders</U>&rdquo; and together with Yuz, the &ldquo;<U>Stockholders</U>&rdquo;), (iii) the holders of vested options to purchase
Company Stock (as defined below) who are Accredited Investors (as defined below) listed on the signature page (each, an &ldquo;<U>Accredited
Optionholder</U>&rdquo; and together the &ldquo;<U>Accredited Optionholders</U>&rdquo;), (iv) the Warrantholders (as defined below),
which hold warrants to purchase Company Stock (as defined below) (each of Yuz and each of the Other Stockholders, Accredited Optionholders
and Warrantholders are referred to individually as a &ldquo;<U>Seller</U>&rdquo;, and together as the &ldquo;<U>Sellers</U>&rdquo;),
(v) Dr. Michael Yuz as the representative of Sellers under this Agreement (&ldquo;<U>Seller Representative</U>&rdquo;), (vi)&nbsp;USARAD
Holdings, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), (vii) NANO-X IMAGING, INC., a Delaware corporation (the &ldquo;<U>Buyer</U>&rdquo;),
and (viii) Nano-X Imaging Ltd., a company organized under the laws of the State of Israel (the &ldquo;<U>Parent</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">Whereas</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
the Stockholders are the record and beneficial owners of all of the shares of stock in the Company (the &ldquo;<U>Shares</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">Whereas</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
the Stockholders desire to sell and transfer all of the Shares to the Buyer, and the Buyer desires to acquire all of the Shares, all
on the terms and subject to the conditions set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">Whereas,
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">the Accredited Optionholders desire to cancel all Accredited Options
(as defined below) and the Warrantholders desire to cancel all Warrants (as defined below), in each case, in exchange for a portion of
the Purchase Price on the terms set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">Whereas</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
the Buyer is a wholly owned subsidiary of the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">Whereas</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
the condition and inducement to the Buyer&rsquo;s willingness to enter into this Agreement, the individuals listed on <U>Schedule 6.12
</U>are, concurrently with the execution of this Agreement, executing and delivering Non-Competition Agreements in the form of <U>Exhibit
B</U> (the &ldquo;<U>Non-Competition Agreements</U>&rdquo;), that will each become effective as of the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">Whereas</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
the Company and Parent entered into that certain binding letter of intent dated August 9, 2021 (the &ldquo;<U>LOI</U>&rdquo;) and, in
connection with entering into the LOI, the Parent deposited $750,000 with the Company (the &ldquo;<U>Deposit</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-variant: small-caps; font-weight: normal">Now,
therefore</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">, in consideration
of these premises, the covenants set forth herein and other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties agree as follows:</FONT></P>

<P STYLE="text-align: left; font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.
&nbsp;Definitions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.1.
&nbsp;<U>Certain Matters of Construction</U>. For purposes of this Agreement, except as specified otherwise or the context otherwise
requires, the words &ldquo;hereof&rdquo;, &ldquo;herein&rdquo;, &ldquo;hereunder&rdquo; and words of similar import will refer to this
Agreement as a whole and not to any particular Section or provision of this Agreement, and reference to a particular Section of this
Agreement will include all subsections thereof. The word &ldquo;party&rdquo; will refer to the Stockholders, the Accredited Optionholders,
the Warrantholders, the Company, the Buyer or the Parent. The word &ldquo;including&rdquo; means including without limitation. Definitions
will be equally applicable to both the singular and plural forms of the terms defined, and references to the masculine, feminine or neuter
gender will include each other gender. All references in this Agreement to any Section, Exhibit or Schedule will, unless otherwise specified,
be deemed to be a reference to a Section, Exhibit or Schedule of or to this Agreement, in each case as such may be amended in accordance
herewith, all of which are made a part of this Agreement. All references in this Agreement to monetary amounts will, unless otherwise
specified, be to United States dollars. Any Legal Requirement defined or referred to herein or in any agreement or instrument that is
referred to herein shall include any modification, amendment or re-enactment thereof, and any Legal Requirement substituted therefor,
in each case as of the time of inquiry, representation or covenant. Any reference to a Governmental Authority or statutory or regulatory
provisions shall be deemed also to refer to any successor thereto unless the context requires otherwise. A reference to any agreement
(including this Agreement) or Contract, is, unless otherwise specified, to the agreement or Contract as amended, modified, supplemented
or replaced at the time of inquiry, representation or covenant. Although the same or similar subject matters may be addressed in different
provisions of this Agreement, the parties intend that, except as reasonably apparent on the face of the Agreement or as expressly provided
in this Agreement, each such provision will be read separately, be given independent significance and not be construed as limiting any
other provision of this Agreement (whether or not more general or more specific in scope, substance or content). References to a Person
are also to its successors and permitted assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.2.
&nbsp;<U>Certain Definitions</U>. For purposes of this Agreement, the following terms will have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>401(k)
Plan</U>&rdquo; is defined in <U>Section 8.10.1.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Acquisition
Transaction</U>&rdquo; means, other than the transactions contemplated by this Agreement, any Person&rsquo;s (other than Buyer&rsquo;s
or Parent&rsquo;s) offer, proposal or inquiry relating to, or any indication of interest in: (a)&nbsp;any merger, consolidation or other
form of business combination with or involving the Company, (b)&nbsp;the sale, license, disposition or acquisition of all or any material
portion of the business or assets of the Company, including the grant of any license to any Intellectual Property of the Company, other
than non-exclusive licenses granted to customers of the Company in the ordinary course of business, (c)&nbsp;the issuance, grant, disposition
or acquisition of any Shares or other equity participations of the Company (other than the issuance of equity to employees of the Company),
or (d)&nbsp;any other transaction that would be inconsistent with or that would reasonably be likely to have an adverse effect upon any
of the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Accredited
Investor</U>&rdquo; means an accredited investor as defined in Rule 501 of Regulation D promulgated under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Accredited
Optionholder</U>&rdquo; is defined in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Accredited
Option</U>&rdquo; means each vested Company Stock Option held by an Accredited Optionholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Accredited
Option Payment</U>&rdquo; means the portion of the Cash Consideration allocable to the Accredited Optionholders in consideration of the
Accredited Options, net of the aggregate exercise price of all Accredited Options, and less the portions of the Deposit, Escrow Cash
Amount, and Seller Representative Fund Amount attributable to the Accredited Optionholders in consideration of the Accredited Options,
which amount will be distributed among the Accredited Optionholders, all in accordance with and as set forth on the Allocation Schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Action</U>&rdquo;
means any criminal, judicial, administrative or arbitral action, audit, charge, claim, complaint, demand, grievance, hearing, known inquiry
or investigation, litigation, mediation, proceeding, citation, summons, subpoena or suit, whether civil, criminal, administrative, judicial
or investigative, whether public or private, commenced, brought, conducted or heard by or before, or otherwise involving any Governmental
Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Affiliate</U>&rdquo;
means, as to any Person, any other Person controlling, controlled by or under common control with such Person. For the purposes of this
definition, &ldquo;controlling&rdquo;, &ldquo;controlled&rdquo; and &ldquo;control&rdquo; mean the possession, directly or indirectly,
of the power to direct the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Agreement</U>&rdquo;
is defined in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Anti-bribery
Laws</U>&rdquo; is defined in <U>Section 3.9.2.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Audited
Financial Statements</U>&rdquo; is defined in <U>Section 3.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Balance
Sheet Time</U>&rdquo; means 11:59&nbsp;p.m. New York time on the day immediately preceding the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Basis</U>&rdquo;
means any fact, condition or occurrence that forms the basis for any reasonably foreseeable specific consequence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Business</U>&rdquo;
means the businesses conducted by the Company and its direct and indirect Subsidiaries as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Business
Day</U>&rdquo; means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by Legal Requirement
to be closed in New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Buyer</U>&rdquo;
is defined in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Buyer
Failure to Close</U>&rdquo; is defined in <U>Section 10.1.6</U>.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Buyer
Fundamental Representations</U>&rdquo; means the representations and warranties set forth in <U>Sections&nbsp;5.1</U>, (Organization),
<U>5.2</U> (Authorization), <U>5.4</U> (Valid Issuance of Stock Consideration), <U>5.6</U> (Brokers), and <U>5.7</U> (Capital Structure).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Buyer
Indemnified Parties</U>&rdquo; is defined in <U>Section 9.2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Cash
Consideration</U>&rdquo; is defined in <U>Section 2.2(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Cash
on Hand</U>&rdquo; means all cash and cash equivalents (including short-term liquid investments with maturities of ninety (90) days or
less) of the Company (including any portion of the Deposit remaining as of the Closing), which will be calculated on a consolidated basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>CFR</U>&rdquo;
means the U.S. Code of Federal Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Claim
Dispute Notice</U>&rdquo; is defined in <U>Section 9.4.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Claim
Notice</U>&rdquo; is defined in <U>Section 9.4.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Closing</U>&rdquo;
is defined in <U>Section 2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Closing
Stock Consideration</U>&rdquo; is defined in <U>Section 2.2(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Closing
Date</U>&rdquo; is defined in <U>Section 2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Closing
Statement</U>&rdquo; is defined in <U>Section 2.5.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Closing
Stock Value</U>&rdquo; means the lower of (i) the volume weighted average price (as quoted by The Nasdaq Global Market) of Parent Stock
for the 30-Trading Day period ending two Business Days prior to the Closing, and (ii) the volume weighted average price (as quoted by
The Nasdaq Global Market) of Parent Stock for the 30-Trading Day period ending on August 6, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Code</U>&rdquo;
means the U.S. Internal Revenue Code of 1986, as amended, and the applicable Treasury Regulations issued thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Company</U>&rdquo;
is defined in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Company
Authorizations</U>&rdquo; is defined in <U>Section 3.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Company
Indebtedness</U>&rdquo; means the amount outstanding as of the Closing in respect of the Indebtedness of the Company excluding the PPP
Loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Company
Intellectual Property</U>&rdquo; shall mean the Intellectual Property owned by or licensed to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Company&rsquo;s
Knowledge</U>&rdquo; means the actual knowledge of Yuz, Jonathan Krutchik, Brian Phelan, and Elli Yuz, in each case, after reasonable
internal inquiry of his or her respective direct reports.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Company
Stock</U>&rdquo; means shares of the stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Company
Stock Options</U>&rdquo; means the outstanding options to purchase Company Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Company
Registered IP</U>&rdquo; is defined in <U>Section 3.11.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Confidentiality
Agreement</U>&rdquo; is defined in <U>Section 8.1.5.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Contemplated
Transactions</U>&rdquo; means the transactions contemplated by this Agreement and the Escrow Agreement that are anticipated to be consummated
at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Continuing
Business</U>&rdquo; means the business of the Company and its Subsidiaries existing immediately prior to the Closing, as such business
is operated by the Continuing Business Company following the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Continuing
Business Company</U>&rdquo; means the Company, any successor to the Company, or any Person into which the Company may be merged carrying
out the Continuing Business following the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Contract</U>&rdquo;
means any legally binding contract, agreement, lease, license, sublicense, option, understanding, covenant-not-to-sue, promise, undertaking
or other binding arrangement, purchase order, instrument, note or other document or instrument, whether oral or written (other than an
Employee Plan).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Customer
Deliverables</U>&rdquo; shall mean (a)&nbsp;the products that the Company or any of its Subsidiaries currently produces, markets, sells
or licenses and (b)&nbsp;the services that the Company or any of its Subsidiaries currently provides.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Deposit</U>&rdquo;
is defined in the Recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the various disclosure schedules to this Agreement that are being delivered by or on behalf of the Company
and the Sellers on the date hereof in connection with the representations and warranties in <U>Section 3</U> and <U>Section 4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Dispute
Notice</U>&rdquo; is defined in <U>Section&nbsp;2.5.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Dispute
Submission Notice</U>&rdquo; is defined in <U>Section&nbsp;2.5.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Disputed
Item</U>&rdquo; is defined in <U>Section&nbsp;2.5.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>D&amp;O
Indemnifiable Claim</U>&rdquo; is defined in <U>Section&nbsp;8.7.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>D&amp;O
Indemnified Person</U>&rdquo; is defined in <U>Section&nbsp;8.7.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>D&amp;O
Indemnifying Party</U>&rdquo; is defined in <U>Section&nbsp;8.7.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>D&amp;O
Tail Policy</U>&rdquo; is defined in <U>Section&nbsp;8.7.3.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Earn
Out</U>&rdquo; is defined in <U>Section 2.6.2(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Earn
Out Amount</U>&rdquo; is defined in <U>Section 2.6.2(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Earn
Out Dispute Notice</U>&rdquo; is defined in <U>Section 2.6.4(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Earn
Out Dispute Submission Notice</U>&rdquo; is defined in <U>Section 2.6.4(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Earn
Out Payment Date</U>&rdquo; is defined in <U>Section&nbsp;2.6.2(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Earn
Out Period</U>&rdquo; means the First Earn Out Period, the Second Earn Out Period, the Third Earn Out Period and the Post-FDA Clearance
Earn Out Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Earn
Out Schedule</U>&rdquo; means <U>Schedule 2.6.1</U> attached hereto and incorporated herein (the &ldquo;<U>Earn Out Schedule</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Earn
Out Statement</U>&rdquo; is defined in <U>Section&nbsp;2.6.1.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Earn
Out Stock Value</U>&rdquo; means the average of (i) the volume weighted average price (as quoted by The Nasdaq Global Market) of Parent
Stock for the 30-Trading Day period ending two Business Days prior to the final day of the relevant Earn Out Period, and (ii) the volume
weighted average price (as quoted by The Nasdaq Global Market) of Parent Stock for the 30-Trading Day period ending on August 6, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>EBITDA</U>&rdquo;
is defined in <U>Section&nbsp;2.6.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Economic
Milestone</U>&rdquo; means Milestones in Components A.1. or A.2. of the Earnout Schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Employee
Plan</U>&rdquo; means each (a) &ldquo;employee benefit plan&rdquo; as defined in Section 3(3) of ERISA, (b) each other employment, consulting,
indemnification, severance pay, salary continuation, pay in lieu of notice, bonus, incentive, retention, change in control compensation,
incentive stock, stock option, stock purchase or other equity or equity-based compensation, fringe benefit, employee loan, relocation,
health insurance, life insurance, disability insurance, retirement, provident fund, pension, profit sharing or deferred compensation
plans, contracts, programs, funds or arrangements of any kind, and (c) each other employee benefit plan, contract, program, fund or arrangement
(whether written or oral, funded or unfunded) and any trust, escrow or similar agreement related thereto, that is maintained, sponsored
or contributed to by the Company or any of its Subsidiaries or with respect to which the Company or any of its Subsidiaries has or may
have any Liability, contingent or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Employment
Practices</U>&rdquo; is defined in <U>Section&nbsp;3.18.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Environmental
Laws</U>&rdquo; means all applicable national, federal, state, provincial and local Legal Requirements relating to pollution or protection
of the environment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>ERISA</U>&rdquo;
means the Employee Retirement Income Security Act of 1974, as amended, and the regulations issued thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>ERISA
Affiliate</U>&rdquo; means any Person (whether or not incorporated) who, together with any other Person, is or has within the last four
years been considered, a single employer pursuant to Section 414 of the Code or Section 4001(b) of ERISA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Estimated
Cash on Hand Amount</U>&rdquo; is defined in <U>Section&nbsp;2.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Escrow
Account</U>&rdquo; is defined in <U>Section&nbsp;2.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Escrow
Agent</U>&rdquo; is defined as Continental Stock Transfer &amp; Trust Company, a New York corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Escrow
Agreement</U>&rdquo; means an escrow agreement in substantially the form of <U>Exhibit A</U>, to be entered into on or prior to the Closing
Date by the Buyer, the Seller Representative, the Parent, and the Escrow Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Escrow
Amount</U>&rdquo; means $2,325,000, consisting of the Escrow Cash Amount and the Escrow Stock Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Escrow
Cash Amount</U>&rdquo; means $600,000 in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Escrow
Funds</U>&rdquo; means, as of any date of determination, the excess (if any) of the Escrow Amount (including accrued interest or earnings
thereon) over the sum of all distributions and other payments to any Person from the Escrow Account paid pursuant to the terms of the
Escrow Agreement on or prior to such date of determination. For purposes of determining the value of the Escrow Funds, any shares of
Parent Stock will be valued on the basis of the Closing Stock Value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Escrow
Stock Amount</U>&rdquo; means the number of shares of Parent Stock with a value of approximately $1,725,000 (as adjusted as necessary
to avoid fractional shares), determined on the basis of the Closing Stock Value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Escrow
Termination Date</U>&rdquo; is defined in <U>Section&nbsp;9.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Estimated
Cash on Hand Amount</U>&rdquo; is defined in <U>Section&nbsp;2.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Estimated
Closing Statement</U>&rdquo; is defined in <U>Section&nbsp;2.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Estimated
Company Indebtedness</U>&rdquo; is defined in <U>Section&nbsp;2.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Estimated
Transaction Bonus Payments</U>&rdquo; is defined in <U>Section&nbsp;2.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Estimated
Transaction Expenses</U>&rdquo; is defined in <U>Section&nbsp;2.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Estimated
Working Capital Amount</U>&rdquo; is defined in <U>Section&nbsp;2.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Expiration
Date</U>&rdquo; is defined in <U>Section&nbsp;10.1.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>FDA</U>&rdquo;
is defined in <U>Section&nbsp;2.5.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>FDA
Application Integrity Policy</U>&rdquo; is defined in <U>Section&nbsp;2.5.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>FDA
Clearance</U>&rdquo; means approval or clearance from the FDA to market and sell the Nanox Arc or, with respect to any 510(k) application,
receipt of a letter from the FDA of substantial equivalence, for the relevant indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Final
Cash on Hand Amount</U>&rdquo; is defined in <U>Section&nbsp;2.5.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Final
Company Indebtedness</U>&rdquo; is defined in <U>Section&nbsp;2.5.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Final
Transaction Bonus Payments</U>&rdquo; is defined in <U>Section&nbsp;2.5.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Final
Transaction Expenses</U>&rdquo; is defined in <U>Section&nbsp;2.5.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Final
Working Capital Amount</U>&rdquo; is defined in <U>Section&nbsp;2.5.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Financial
Controls</U>&rdquo; is defined in <U>Section 3.5.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Financial
Statements</U>&rdquo; is defined in <U>Section 3.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>First
Earn Out Period</U>&rdquo; means the twelve (12) consecutive calendar months immediately following the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Fraud</U>&rdquo;
means actual and intentional fraud with the intent to deceive (and not constructive fraud, equitable fraud or negligent misrepresentation)
with respect to any representation or warranty set forth in this Agreement or the Disclosure Schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles, as in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Governmental
Authority</U>&rdquo; means any national, supranational, foreign, provincial, federal, state, municipal or local government, including
any political subdivision thereof, or governmental, regulatory or administrative authority, agency, body, branch, bureau, instrumentality
or commission, and any department, court, tribunal or judicial body, or agency of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Government
Contract</U>&rdquo; means any Contract, prime contract, subcontract, teaming agreement or arrangement, joint venture, basic ordering
agreement, blanket purchase agreement, letter agreement, grant, cooperative agreement, purchase order, delivery order, task order, change
order or other commitment or funding vehicle between the Company or any of its Subsidiaries and (a)&nbsp;any Governmental Authority,
(b)&nbsp;any prime contractor to a Governmental Authority or (c)&nbsp;any subcontractor (of any tier) in connection with or with respect
to any Contract described in clause&nbsp;(a) or (b), and any modification of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Governmental
Order</U>&rdquo; means any ruling, award, decision, injunction, judgment, determination, assessment, agreement, order, decree, writ or
other requirement entered, issued or made by any Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Hazardous
Substance</U>&rdquo; means &ldquo;hazardous substance&rdquo; (as defined in 42 U.S.C. &sect;&nbsp;9601(14)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>ICL</U>&rdquo;
means the Companies Law 5759-1999 of the State of Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Income
Tax</U>&rdquo; means any Tax measured in whole or in part by income or gains (or similar Tax imposed in lieu thereof).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Indebtedness</U>&rdquo;
means with respect to any Person, and without duplication, all outstanding obligations of such Person on a consolidated basis (a)&nbsp;in
respect of indebtedness for borrowed money (including all accrued interest thereon, and any prepayment, breakage or similar charges payable
in connection with the discharge of such indebtedness), including the PPP Loan, (b)&nbsp;evidenced by notes, debentures or similar instruments,
(c)&nbsp;in respect of any earn out or other deferred purchase price for the acquisition by such Person of any business, property or
other Person, but excluding any ordinary trade accounts payable or accruals incurred in the ordinary course of business which are captured
in the accounts payable and/or accrued expenses of the Company, (d)&nbsp;in respect of letters of credit, solely to the extent drawn
upon by third parties, (e)&nbsp;as lessee under leases that would be required to be recorded as capital leases in accordance with GAAP
and (f)&nbsp;with respect to guarantees of obligations of the types described in clauses&nbsp;(a) through (e) above of any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Indemnified
Taxes</U>&rdquo; means any Taxes of the Company or any of its Subsidiaries for a Pre-Closing Tax Period, including the portion of a Straddle
Period attributable to the Pre-Closing Tax Period as provided in <U>Section 8.8.4</U>; <U>provided</U>, <U>however</U>, that in no event
shall any Tax arising from any elections by or with respect to the Company or any Company Subsidiary under Code Sections 338 or 336(e)
with respect to any transactions contemplated by this Agreement be considered or treated as attributable to the Pre-Closing Tax Period
for any purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Indemnified
Party</U>&rdquo; means with respect to any claim for indemnification pursuant to <U>Section&nbsp;9</U>, each Buyer Indemnified Party
or Seller Indemnified Party asserting such claim (or on whose behalf such claim is asserted) under <U>Section&nbsp;9.2</U> or <U>9.3</U>,
as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Indemnifying
Party</U>&rdquo; means, with respect to any claim for indemnification pursuant to <U>Section&nbsp;9</U>, the party or parties against
whom such claim has been asserted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Indemnity
Agreement</U>&rdquo; is defined in <U>Section&nbsp;8.7.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Independent
Referee</U>&rdquo; means RSMUS LLP; <U>provided</U> that, if RSMUS LLP is unable or unwilling to serve as Independent Referee, and the
Buyer and the Seller Representative are unable to agree on another independent and nationally recognized firm with expertise in disputes
of the type contemplated by <U>Section&nbsp;2.5</U> within fifteen (15) Business Days of receiving notice that RSMUS LLP will not serve
as Independent Referee, the Buyer and the Seller Representative shall each nominate such a firm, and the two firms so nominated shall
nominate a third such firm, with such third firm to serve as the Independent Referee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Insurance
Policies</U>&rdquo; is defined in <U>Section&nbsp;9.5.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Insurance
Proceeds</U>&rdquo; is defined in <U>Section&nbsp;9.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Intellectual
Property</U>&rdquo; means all: (a) granted patents, pending patent applications, and all related continuation, continuation-in-part,
divisional, reissue and re-examinations thereof, utility models, statutory invention registrations and design patents; (b) trademarks,
service marks, trade dress, Internet domain names, logos, trade names and corporate names and registrations and applications for registration
thereof; (c) copyrights and registrations and applications for registration thereof; (d) computer software, data and documentation; (e)
inventions, trade secrets and confidential business information, whether patentable or non-patentable and whether or not reduced to practice,
know-how, manufacturing and product processes and techniques, research and development information, unpublished copyrightable works,
financial, marketing and business data, pricing and cost information, business and marketing plans and customer and supplier lists and
information; (f) other proprietary rights relating to any of the foregoing (including remedies against infringements thereof and rights
of protection of interest therein under the laws of all jurisdictions); and (g) copies and tangible embodiments thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Interim
Financial Statements</U>&rdquo; is defined in <U>Section 3.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Internal
Revenue Service</U>&rdquo; means the United States Internal Revenue Service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Internal
Systems</U>&rdquo; shall mean any hardware, software, data, equipment, technology or internal systems used by or on behalf of the Company
or its Subsidiaries to produce the Customer Deliverables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>IRCA</U>&rdquo;
is defined in <U>Section 3.18.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Leases</U>&rdquo;
is defined in <U>Section 3.13.1(h)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Legal
Requirement</U>&rdquo; means, with respect to any Person, any national, supranational, federal, state, provincial, municipal or local
statute, law, ordinance, code, rule, resolution, constitution, administrative regulation, Governmental Order, regulatory requirement,
stipulation, determination, or regulation issued, enacted, implemented or otherwise put into law by or under the authority of a Governmental
Authority and applicable to such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Liabilities</U>&rdquo;
means any and all liabilities, Indebtedness, claims, commitments, deficiencies and obligations of any kind, whether accrued or fixed,
absolute or contingent, matured or unmatured, determined or undeterminable, on- or off-balance sheet or required to be recorded on a
balance sheet prepared in accordance with GAAP, including those arising under any Legal Requirement, Action or Government Order and those
arising under any Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Liability
Claim</U>&rdquo; means an indemnification claim by or on behalf of an Indemnified Party for Losses that it believes are or may be recoverable
pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;&lrm; 9</FONT></U>, other than in respect of a Third-Party Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Lien</U>&rdquo;
means any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, claim, option, right of first refusal, preemptive
right, community property interest, conditional or installment sale agreement, encumbrance, charges or other claims of third parties
of any kind, or restriction of any nature (including any restriction on the voting of any security, any restriction on the transfer of
any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset
and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>LOI</U>&rdquo;
is defined in the Recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Losses</U>&rdquo;
means the amount of any reasonably foreseeable actual losses, damages, awards, fines, penalties, expenses or fees (including reasonable
fees and expenses of counsel), costs (including costs of investigation, arbitration and court costs), claims, demands, Liabilities, judgments,
or Taxes of any nature, whether or not involving any Action, including any costs of defending any Actions or enforcing a Buyer Indemnified
Party&rsquo;s or Seller Indemnified Party&rsquo;s rights under this Agreement, but excluding any punitive damages exemplary damages,
and damages based on &ldquo;multiple of earnings,&rdquo; &ldquo;multiple of cash flow&rdquo; or other similar valuation methodologies
based on a &ldquo;multiple&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Material
Adverse Effect</U>&rdquo; any effect, change, event, development or circumstance that, considered together with all other effects, changes,
events, developments or circumstances is or would reasonably be expected to be materially adverse to the business, assets, Liabilities,
condition (financial or otherwise) or results of operations of the Company and its Subsidiaries, taken as a whole; <U>provided</U>, <U>however</U>,
that any such change, effect, event, development or circumstance caused by or resulting from any of the following shall not be considered,
and shall not be taken into account in determining the existence of, a &ldquo;Material Adverse Effect&rdquo;: (a) the announcement, pendency
or consummation of the Contemplated Transactions, including the impact of any of the foregoing on relationships with customers, suppliers,
sales representatives, or Workers, (b)&nbsp;conditions affecting the global or national economy or the financial, credit, commodities
or capital markets as a whole, or generally affecting the industries in which the Company conducts its business, (c)&nbsp;any change
in financial, banking, or securities markets (including any disruption thereof and any decline in the price of any security or any market
index), (d)&nbsp;any change in, adoption of, or change in the interpretation of any applicable Legal Requirement or GAAP, (e)&nbsp;any
national or international political or social conditions, including the engagement or continuation by the United States in hostilities
or the escalation thereof, whether or not pursuant to the declaration of a national emergency or war, or the occurrence or the escalation
of any military or terrorist attack upon the United States, or any of its territories, possessions, or diplomatic or consular offices
or upon any military installation, equipment or personnel of the United States, (f)&nbsp;pandemics (including any Legal Requirement issued
in response to a pandemic), earthquakes, hurricanes, tornados, floods or other natural disasters, (g)&nbsp;the failure by the Company
to meet any revenue or earnings projections, forecasts or predictions (<U>provided</U>, that clause (g) shall not prevent a determination
that any effect or change underlying such failure has resulted in a Material Adverse Effect, to the extent such change or effect is not
otherwise excluded from this definition of Material Adverse Effect), or (h)&nbsp;any action taken by, or with the written consent of,
the Buyer or any of its Affiliates with respect to the Contemplated Transactions or with respect to the Company; except, in the case
of the foregoing clauses&nbsp;(b) or (c), to the extent such changes or effects would have a disproportionate effect on the Company compared
to other Persons in the industries and geographic regions in which the Company conducts its business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Material
Contract</U>&rdquo; is defined in <U>Section&nbsp;3.13.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Milestone</U>&rdquo;
means an Earn Out milestone, as set forth on the Earn Out Schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Nasdaq</U>&rdquo;
is defined in Section 5.4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>New
Litigation Claim</U>&rdquo; is defined in <U>Section 8.1.2.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>NIS</U>&rdquo;
means New Israeli Shekels, the lawful currency of the State of Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Non-accredited
Optionholder</U>&rdquo; is defined in <U>Section 2.7.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Non-Competition
Agreements</U>&rdquo; is defined in the Recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Non-Economic
Milestone</U>&rdquo; means any Milestone that is not an Economic Milestone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Open
Source Materials</U>&rdquo; shall mean all software or other material that is distributed as &ldquo;free software&rdquo;, &ldquo;open
source software&rdquo; or under a similar licensing or distribution model, including without limitation the GNU General Public License
(GPL), GNU Lesser General Public License (LGPL), Mozilla Public License (MPL), BSD Licenses, the Artistic License, the Netscape Public
License, the Sun Community Source License (SCSL), the Sun Industry Standards License (SISL) and the Apache License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Organizational
Documents</U>&rdquo; means, with respect to any Person (other than an individual), the certificate or articles of incorporation, organization
or formation of such Person and any limited liability company, operating or partnership agreement, by-laws or similar documents or agreements
relating to the legal organization of such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Other
Stockholders</U>&rdquo; is defined in the Recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Parent
Stock</U>&rdquo; means Parent&rsquo;s Ordinary Shares, NIS 0.01 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>parties</U>&rdquo;
is defined in <U>Section 1.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Permits</U>&rdquo;
means all permits, certificates, licenses, franchises, consents, approvals and authorizations from Governmental Authorities that are
necessary to the conduct of the Company&rsquo;s business or operations as presently conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Permitted
Liens</U>&rdquo; means (a)&nbsp;Liens for Taxes, not yet due and payable or the amount or validity of which is being contested in good
faith, and for which adequate reserves have been established on the Financial Statements in accordance with GAAP, (b)&nbsp;landlords&rsquo;
and warehousepersons&rsquo; Liens, as well as mechanics&rsquo;, materialmens&rsquo; or carriers&rsquo; Liens to secure claims for labor,
material or supplies and other similar Liens, (c)&nbsp;Liens incurred or deposits or pledges made in connection with, or to secure payment
of, workers&rsquo; compensation, unemployment insurance, old age pension programs mandated under applicable Legal Requirements or other
social security regulations, (d)&nbsp;zoning, building, entitlement and other land use regulations or restrictions, (e)&nbsp;the interests
of the lessors and sublessors of any leased properties, (f)&nbsp;easements, rights of way and other imperfections of title or encumbrances
that do not materially interfere with the present use of the property related thereto, (g)&nbsp;restrictions on the ownership or transfer
of securities arising under applicable Legal Requirements, or (h)&nbsp;Liens disclosed on the Interim Financial Statements or in the
notes thereto or securing liabilities reflected on the Interim Financial Statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Person</U>&rdquo;
means any natural person or any corporation, partnership, limited liability company, other legal entity or Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Post-Closing
Reduction Amount</U>&rdquo; is defined in <U>Section 2.5.5(a).</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Post-Closing
Tax Period</U>&rdquo; means any taxable period or portion thereof on or after the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Post-FDA
Clearance Earn Out Period</U>&rdquo; means the six (6) consecutive calendar months immediately following FDA Clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Potential
Claim</U>&rdquo; is defined in <U>Section 8.13.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>PPP
Escrow Account</U>&rdquo; is defined in <U>Section 2.4.1(g)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>PPP
Escrow Agent</U>&rdquo; means Wells Fargo Bank, N.A. or Continental Stock Transfer &amp; Trust Company, a New York corporation, as the
case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>PPP
Escrow Agreement</U>&rdquo; is defined in <U>Section 2.4.1(g)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>PPP
Escrow Amount</U>&rdquo; is defined in <U>Section 2.4.1(g)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>PPP
Funds</U>&rdquo; means the outstanding amount of the PPP Loan Agreement, including all interest and accrued thereon as of the Closing
Date and interest that would accrue thereon through October 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>PPP
Loan</U>&rdquo; means the funds received by the Company pursuant to the PPP Loan Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>PPP
Loan Agreement</U>&rdquo; means the Company&rsquo;s Promissory Note and Agreement issued to Wells Fargo Bank, N.A., and dated on or about
March 31, 2021, under the SBA Paycheck Protection Program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Pre-Closing
Tax Return</U>&rdquo; is defined in <U>Section 8.8.2(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Pre-Closing
Tax Period</U>&rdquo; means any taxable period ending before the Closing Date and the portion through the end of the day immediately
before the Closing Date for any Straddle Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Prohibited
Actions</U>&rdquo; is defined in <U>Section 2.6.5(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Proposed
Action</U>&rdquo; is defined in <U>Section 9.14.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Proprietary
Information</U>&rdquo; means any information related to the Company, Buyer or the Parent, including any information related to their
respective business, organization, financial situation, operations, purchasing and sales activities, Intellectual Property, source codes,
information relating to services, operating processes, procedures, price lists, customer lists, technology, designs, and specifications,
or other proprietary information of the business of the Company, Buyer or the Parent, this Agreement, the Contemplated Transactions,
and the existence of this Agreement and the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Purchase
Price</U>&rdquo; is defined in <U>Section&nbsp;2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Records</U>&rdquo;
means all files, documents, ledgers, papers, books and records and similar information (whether in paper, electronic or other tangible
or intangible form) of the Company that are used or held for use by the Company in, or necessary for the conduct of, the Business, including
all technical information, operating and production records, service records, service protocols, documentation of service methodologies,
quality control records, blueprints, drawings, technical plans, research and development notebooks and files, customer data, mailing
lists, warranty information, product testing reports, manuals, engineering and scientific data, catalogs, advertising and other marketing
materials, brochures, sales and promotional literature, standard forms of documents, business plans, budgets, price lists, customer lists
and lists of suppliers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Reference
Balance Sheet</U>&rdquo; is defined in <U>Section&nbsp;3.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Reference
Balance Sheet Date</U>&rdquo; is defined in <U>Section&nbsp;3.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Regulatory
Filings</U>&rdquo; is defined in <U>Section 8.5.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Released
Matter</U>&rdquo; is defined in <U>Section 8.13.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Released
Parties</U>&rdquo; is defined in <U>Section 8.13.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Releasing
Parties</U>&rdquo; is defined in <U>Section 8.13.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Representative</U>&rdquo;
means, with respect to any Person, any director, partner, manager, officer, employee, or Controlling Person of such Person and any agent,
consultant, legal, accounting, financial or other advisor or other representative authorized by such Person to represent or act on behalf
of such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Representative
Committee</U>&rdquo; is defined in <U>Section 9.14.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Representative
Committee Member</U>&rdquo; is defined in <U>Section 9.14.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Revenue</U>&rdquo;
is defined in <U>Section&nbsp;2.6.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Revenue
Statement</U>&rdquo; is defined in <U>Section&nbsp;2.6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Schedules
Notice</U>&rdquo; is defined in <U>Section&nbsp;8.9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>SEC</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>SEC
Reports</U>&rdquo; is defined in <U>Section 5.9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Second
Earn Out Period</U>&rdquo; means the twelve (12) consecutive calendar months immediately following first anniversary of the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Seller</U>&rdquo;
and &ldquo;<U>Sellers</U>&rdquo; are defined in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Seller
Affiliates</U>&rdquo; means, for purposes of Section <U>8.13.1</U>, such Seller&rsquo;s directors, officers, controlling Persons, employees,
and affiliated investment funds, if any, but does not include any of such Seller&rsquo;s or Seller&rsquo;s Affiliates&rsquo; portfolio
companies or limited partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Seller
Failure to Close</U>&rdquo; is defined in <U>Section 10.1.7.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Seller
Fundamental Representations</U>&rdquo; means the representations and warranties set forth in <U>Sections 3.1</U> (Power and Authorization),
<U>3.2</U> (Organization), 3.3 (Capitalization; Subsidiaries), <U>3.7</U> (Taxes), <U>3.19</U> (Brokers), <U>4.1</U> (Organization, Power
and Standing), <U>4.2</U> (Authorization; Enforceability) and <U>4.4</U> (Ownership of Shares).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Seller
Indemnified Parties</U>&rdquo; is defined in <U>Section&nbsp;9.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Seller
Representative</U>&rdquo; is defined in the Preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Seller
Representative Fund Amount</U>&rdquo; means an amount in cash equal to $25,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Shares</U>&rdquo;
is defined in the Recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Siemens</U>&rdquo;
means Siemens Healthineers Beteiligugen GmbH &amp; Co. KG.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Stock
Consideration</U>&rdquo; means Closing Stock Consideration and Stock Earn Out.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Stock
Earn Out</U>&rdquo; means shares of Parent Stock with a value of $6,500,000, calculated on the basis of the Earn Out Stock Value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Straddle
Period</U>&rdquo; means any taxable period that includes but does not end on the day immediately before the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Straddle
Period Tax Return</U>&rdquo; is defined in <U>Section 8.8.2(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Subsidiary</U>&rdquo;
of any Person means another Person, of which at least a majority of the securities or stock having by their terms ordinary voting power
to elect a majority of the board of directors, other Persons performing similar functions, or the right to appoint or elect a general
partner, is owned or controlled directly or indirectly by such first Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Tax</U>&rdquo;
or &ldquo;<U>Taxes</U>&rdquo; means any and all (a) United States federal, state or local, or any foreign, income, franchise, profits,
gross receipts, license, ad valorem, net worth, value added, sales, use, real or personal property, payroll, withholding, employment,
social security, excise, environmental, customs duties, stamp, registration, alternative and add-on minimum tax, special assessment or
other governmental and quasi-governmental charges in the nature of a tax payable to any Taxing Authority and including all interest,
penalties, additional taxes and additions to tax imposed with respect thereto., whether disputed or not, (b) Liability for the payment
of any amounts of the type described in clause (a) of this sentence as a result of being a member of an affiliated, consolidated, combined,
unitary or aggregate group for any taxable period, (c) Liability under any state abandonment or unclaimed property, escheat or similar
Legal Requirement, and (d) Liability for the payment of any amounts of the type described in clauses (a), (b) or (c) of this sentence
as a result of (1) being a transferee of or successor to any person or (2) any express or implied obligation to indemnify or pay any
other person for any such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Tax
Proceeding</U>&rdquo; is defined in <U>Section&nbsp;8.8.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Tax
Return</U>&rdquo; means any return, report, form, or information statement required to be filed with a Taxing Authority reporting liability
for Taxes, including any schedules or attachments thereto and including any amendment thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Taxing
Authority</U>&rdquo; means any United States, federal, state, local or any foreign or other governmental agency responsible for the imposition,
assessment or collection of any Tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Third
Earn Out Period</U>&rdquo; means the twelve (12) consecutive calendar months immediately following second anniversary of the Closing
Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Third-Party
Claim</U>&rdquo; is defined in <U>Section&nbsp;9.6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Trading
Day</U>&rdquo; means any day that The Nasdaq Global Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Transaction
Bonus Payments</U>&rdquo; means the bonus and other compensatory payments that become payable by the Company solely as a result of the
consummation of the Contemplated Transactions, and any employer portion of payroll Taxes related to such payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Transaction
Expenses</U>&rdquo; means all fees, costs and expenses incurred or otherwise payable by the Company in connection with the negotiation,
documentation and consummation of the Contemplated Transactions, including such fees and expenses of counsel to the Company, counsel
to the Sellers and any other professional fees and expenses, 50% of all premiums and other expenses associated with the D&amp;O Tail
Policy, in each case to the extent incurred but unpaid as of the Closing (and excluding the Transaction Bonus Payments and any fees,
costs and expenses paid or payable by the Sellers).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Transfer</U>&rdquo;
is defined in <U>Section 2.6.6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Transfer
Taxes</U>&rdquo; means any sales, use, transfer, value added, real property transfer, stamp, registration, documentary, recording or
similar duties or Taxes together with any interest thereon, penalties, fines, costs, fees, additions to Tax or additional amounts with
respect thereto incurred in connection with the Contemplated Transactions. For the avoidance of doubt, Transfer Taxes do not include
any Seller&rsquo;s Income Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Treasury
Regulations</U>&rdquo; means the final and temporary regulations promulgated by the United States Department of the Treasury under and
pursuant to the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Unaudited
Financial Statements</U>&rdquo; is defined in <U>Section 3.5.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Warrantholder</U>&rdquo;
means each of Siemens and Physician Fund LP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Warrants</U>&rdquo;
&ldquo;means the outstanding warrants to purchase Company Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Warrant
Payment</U>&rdquo; means the portion of the Cash Consideration allocable to the Warrantholders in respect of the Warrants, net of the
aggregate exercise price of all Warrants, and less the portions of the Deposit, Escrow Cash Amount, and Seller Representative Fund Amount
attributable to the Warrantholders in consideration of the Warrants, which amount will be distributed among the Warrantholders, all in
accordance with and as set forth on the Allocation Schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Worker</U>&rdquo;
means any current or former officer, director, employee (regular, temporary, part-time or otherwise), consultant, project worker, agent
or individual independent contractor of the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Working
Capital</U>&rdquo; means (a)&nbsp;the current assets of the Company (consisting solely of those asset account line items specified on
<U>Schedule&nbsp;2.5.1(a)</U>, excluding all Cash on Hand and current and deferred Income Tax assets), <I>minus</I> (b)&nbsp;the current
liabilities of the Company (consisting solely of liability account line items as specified on <U>Schedule&nbsp;2.5.1(a)</U>), excluding
any amounts payable in respect of Transaction Expenses, Transaction Bonus Payments, Company Indebtedness, PPP Loan, and current and deferred
Income Tax liabilities, in each case determined on a consolidated basis. Working Capital will be calculated using the accounting principles,
methods, and practices utilized in preparing the Financial Statements, applied on a consistent basis, applied in accordance with <U>Schedule&nbsp;2.5.1(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Working
Capital Target</U>&rdquo; means $353,209.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Yuz</U>&rdquo;
is defined in the Preamble.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.
&nbsp;The Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1.
&nbsp;<U>Purchase and Sale of the Shares</U>. At the Closing, and subject to the terms and conditions set forth in this Agreement, (a)
the Stockholders shall sell, transfer and deliver to the Buyer, free and clear of all Liens (other than Liens imposed by the Organizational
Documents of the Company and applicable securities laws) the Shares, (b) the Accredited Optionholder will cancel in full each such Accredited
Optionholder&rsquo;s Accredited Options pursuant to this Agreement in exchange for a portion of the Purchase Price; (c) the Warrantholders
will cancel in full each such Warrantholder&rsquo;s Warrants pursuant to this Agreement in exchange for a portion of the Purchase Price;
and (d) the Buyer shall purchase from the Stockholders the Shares and acknowledge the cancellation of the Accredited Options and the
Warrants, all in exchange for the consideration specified in <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.
&nbsp;<U>Purchase Price</U>. The aggregate consideration for the purchase and sale of the Shares pursuant to this Agreement will be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;an amount in cash (the &ldquo;<U>Cash Consideration</U>&rdquo;) calculated as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.1.
&nbsp;$7,000,000 in cash;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.2.
&nbsp;<I>minus</I> the Estimated Company Indebtedness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.3.
&nbsp;<I>minus</I> the amount of the Estimated Transaction Expenses to be paid at the Closing pursuant to <U>Section&nbsp;2.4.1(c)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.4.
&nbsp;<I>minus</I> the amount of the Estimated Transaction Bonus Payments to be paid pursuant to <U>Section&nbsp;2.4.1(d)</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.5.
&nbsp;<I>plus</I> the Estimated Cash on Hand Amount; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2.6.
&nbsp;<I>plus</I> the amount, if any, by which the Estimated Working Capital Amount exceeds the Working Capital Target; or <I>minus</I>
the amount, if any, by which the Estimated Working Capital Amount is less than the Working Capital Target;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Plus</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;Such number of shares of Parent Stock to be issued upon Closing valued at $11,500,000 (calculated based on the Closing Stock Value
(the &ldquo;<U>Closing Stock Consideration</U>&rdquo;; the aggregate consideration in <U>Sections 2.2(a)</U> and <U>(b)</U> is referred
to as the &ldquo;<U>Purchase Price</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Plus</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
&nbsp;The Earn Out Amount payable pursuant to <U>Section 2.6</U>, if earned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
&nbsp;The Cash Consideration and the Closing Stock Consideration, and the Earn Out Amount (if earned), and each Stockholder&rsquo;s,
Accredited Optionholder&rsquo;s, and Warrantholder&rsquo;s allocable share of the Escrow Amount, PPP Escrow Amount, and Seller Representative
Fund Amount will be allocated among the Stockholders, the Accredited Optionholders, and Warrantholders as set forth in <U>Schedule 2.2(c)
</U>(the &ldquo;<U>Allocation Schedule</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Purchase Price shall be subject to adjustment in accordance with the terms of this Agreement, including in accordance with <U>Section&nbsp;2.5</U>.
Although included in the Estimated Cash on Hand on the Estimated Closing Statement, the Deposit is a component of the Purchase Price
and is paid as part of the aggregate consideration for the purchase and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.3.
&nbsp;<U>The Closing</U>. Subject to the terms and conditions hereof, the closing of the purchase and sale of the Shares pursuant to
this Agreement (the &ldquo;<U>Closing</U>&rdquo;) shall take place by electronic document transfer (<I>i</I>.<I>e</I>., .pdf signature
pages and fully executed documents exchanged via email) as promptly as practicable following, but in no event later than the third (3rd)
Business Day following, the satisfaction or waiver of each of the conditions set forth in Sections 6 and 7 hereof (other than those conditions
that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of such conditions at Closing), or
at such other time and place as the Buyer and Seller Representative agree in writing (the day on which the Closing takes place, the &ldquo;<U>Closing
Date</U>&rdquo;). Subject to the provisions of Section 10, the failure of any party to consummate the Closing on the date and time determined
pursuant to this Section 2.3 shall not result in the termination of this Agreement and shall not relieve such party of any obligation
under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.4.
&nbsp;<U>Closing Deliveries and Payments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.4.1.
&nbsp;<U>Buyer Closing Deliveries and Payments</U>. At the Closing, the Buyer and Parent shall deliver or cause to be delivered the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;to the Stockholders, by wire transfer of immediately available funds to the accounts designated in writing by the Seller Representative
to the Buyer not less than five (5) Business Days prior to the Closing Date, an amount in cash equal to (i)&nbsp;the Cash Consideration,
<I>minus</I> (ii) (A) the Deposit, (B) the Escrow Cash Amount, (C) the Seller Representative Fund Amount; (D) the Accredited Option Payment,
(E) the Warrant Payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;to accounts specified by the Company at least three (3) Business Days prior to the Closing Date, by wire transfer of immediately
available funds, such cash amounts as are necessary to discharge in full any outstanding amount of Estimated Company Indebtedness, except
for the $75,000 contingent payment to Stone Creek Consulting, Inc., which will be payable pursuant to Section 8.15;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
&nbsp;to accounts specified by the Company at least three (3) Business Days prior to the Closing Date, by wire transfer of immediately
available funds, such cash amounts as are necessary to pay in full the Estimated Transaction Expenses;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
&nbsp;to the Company, for further processing through payroll, by wire transfer of immediately available funds to an account designated
in writing by the Company to the Buyer no less than five (5) Business Days prior to the Closing Date, such cash amounts as are necessary
to pay in full the Accredited Option Payment for further distribution to the Accredited Optionholders;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)
&nbsp;to the Warrantholders, by wire transfer of immediately available funds to the accounts designated in writing by the Seller Representative
to the Buyer not less than five (5) Business Days prior to the Closing Date, an amount in cash equal to the Warrant Payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)
&nbsp;to the Company, for further processing through payroll, by wire transfer of immediately available funds to an account designated
in writing by the Company to the Buyer no less than five (5) Business Days prior to the Closing Date, such cash amounts as are necessary
to pay in full each of the Estimated Transaction Bonus Payments;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)
&nbsp;to the Seller Representative, by wire transfer of immediately available funds, the Seller Representative Fund Amount;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)
&nbsp;to the Escrow Agent, by wire transfer of immediately available funds, the Escrow Cash Amount (the &ldquo;<U>Escrow Account</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)
&nbsp;to the Seller Representative, the Escrow Agreement, duly executed by the Buyer, the Parent and the Escrow Agent, and the various
certificates, agreements, instruments and documents required to be delivered by the Buyer and the Parent at or prior to the Closing referred
to in <U>Section 7</U>; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)
&nbsp;to the Stockholders, the Accredited Optionholders, and the Warrantholders, the Closing Stock Consideration, <I>minus</I> the Escrow
Stock Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.4.2.
&nbsp;<U>Company Closing Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;At the Closing, the Company shall deliver or cause to be delivered to the Buyer, the various certificates, agreements, instruments
and documents to be delivered by the Company at or prior to any Closing referred to in <U>Section&nbsp;6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;At or prior to the Closing, the Company will deliver to an escrow account (the &ldquo;<U>PPP Escrow Account</U>&rdquo;) under the
control of the PPP Escrow Agent, an amount equal to the PPP Escrow Funds (the &ldquo;<U>PPP Escrow Amount</U>&rdquo;), to be held and
released in accordance with the terms of the escrow agreement governing such escrow account (the &ldquo;<U>PPP Escrow Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.4.3.
&nbsp;<U>Stockholder Closing Deliveries</U>. At the Closing, the Stockholders shall deliver or cause to be delivered to the Buyer the
following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;Lost or destroyed share/certificate affidavits and stock powers for transfer of the Shares to the Buyer, in form and substance
reasonably satisfactory to the Buyer; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;the PPP Escrow Agreement, duly executed by the Company and the PPP Escrow Agent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
&nbsp;the Escrow Agreement, duly executed by the Seller Representative, and any other agreements, documents, instruments or certificates
required to be delivered by the Sellers or the Seller Representative at or prior to the Closing pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.5.
&nbsp;<U>Purchase Price Adjustment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.5.1.
&nbsp;<U>Estimated Balance Sheet and Estimated Closing Statement</U>. The Seller Representative will in good faith prepare and deliver,
or cause to be prepared and delivered, to the Buyer not later than three (3) Business Days prior to the Closing Date a written statement
(the &ldquo;<U>Estimated Closing Statement</U>&rdquo;) setting forth in reasonable detail the Company&rsquo;s good faith estimates of
(a)&nbsp;a consolidated balance sheet of the Company and its Subsidiaries as of the Closing Date, (b) (i) Transaction Expenses (listed
by payee) (the &ldquo;<U>Estimated Transaction Expenses</U>&rdquo;), (ii) Transaction Bonus Payments (listed by payee) (the &ldquo;<U>Estimated
Transaction Bonus Payments</U>&rdquo;), (iii) Company Indebtedness (the &ldquo;<U>Estimated Company Indebtedness</U>&rdquo;), (iv) Working
Capital (the &ldquo;<U>Estimated Working Capital Amount</U>&rdquo;), and (v) Cash on Hand (the &ldquo;<U>Estimated Cash on Hand Amount</U>&rdquo;),
in the case of clauses (iv) and (v), as of the Balance Sheet Time, and (c) on the basis of the foregoing, a calculation of the Purchase
Price. The Estimated Transaction Bonus Payments, Estimated Transaction Expenses, Estimated Company Indebtedness, Estimated Working Capital
Amount and Estimated Cash on Hand Amount set forth in the Estimated Closing Statement (x)&nbsp;will be prepared in accordance with the
definitions thereof and, solely in the case of the Estimated Company Indebtedness, Estimated Working Capital Amount and Estimated Cash
on Hand Amount, on a basis consistent with the preparation of the sample Closing Statement attached as <U>Schedule&nbsp;2.5.1(b)</U>
hereto (which, solely for illustrative purposes, assumes the Closing occurred on October 25, 2021) and (y)&nbsp;will solely be based
on facts and circumstances as they exist prior to Closing (except that the Estimated Transaction Bonus Payments and the Estimated Transaction
Expenses will be calculated assuming the occurrence of the Closing) and disregard any financing or other arrangements entered into by
the Buyer or any of its Affiliates in connection with the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.5.2.
&nbsp;<U>Closing Statement</U>. As promptly as practicable, but in any event within ninety (90) days after the Closing Date, the Buyer
will in good faith prepare or cause to be prepared, and will provide to the Seller Representative, a written statement (the &ldquo;<U>Closing
Statement</U>&rdquo;) setting forth in reasonable detail the Buyer&rsquo;s proposed determinations of (a)&nbsp;the consolidated balance
sheet of the Company and its Subsidiaries as of the Closing Date and (b) (i) Transaction Expenses, (ii) Transaction Bonus Payments, (iii)
Company Indebtedness, (iv) Working Capital and (v) Cash on Hand, in the case of clauses (iv) and (v), as of the Balance Sheet Time as
derived in accordance with the definitions therefor, and (c) on the basis of the foregoing, a calculation of the Purchase Price. The
Closing Statement (x)&nbsp;will be prepared in a manner consistent with the preparation of the sample Closing Statement attached as <U>Schedule
2.5.1(b)</U> hereto and (y)&nbsp;will solely be based on facts and circumstances as they exist prior to Closing (except that the Transaction
Bonus Payments and the Transaction Expenses will be calculated based on the occurrence of the Closing) and disregard any financing or
any financing or other arrangements entered into by the Buyer or any of its Affiliates in connection with the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.5.3.
&nbsp;<U>Dispute Notice</U>. The Closing Statement (and the proposed determinations of the Transaction Expenses, Transaction Bonus Payments,
Company Indebtedness, Working Capital and Cash on Hand reflected on the Closing Statement) will be final, conclusive and binding on the
parties unless the Seller Representative provides a written notice (a &ldquo;<U>Dispute Notice</U>&rdquo;) to the Buyer no later than
forty-five (45) days after delivery of the Closing Statement setting forth in reasonable detail any item(s) or amount(s) on the Closing
Statement that are disputed by the Seller Representative (each, a &ldquo;<U>Disputed Item</U>&rdquo;). Any item or amount on the Closing
Statement to which no dispute is raised in the Dispute Notice will be final, conclusive and binding on the parties. The Buyer shall provide,
and shall cause the Company to provide, the Seller Representative and its Representatives with access to, and the opportunity to make
copies of, the work papers and other materials used or considered by the Buyer in the preparation of the Closing Statement, and reasonable
access to personnel and Representatives of the Buyer and the Company who assisted or were consulted in the preparation of the Closing
Statement; <U>provided</U>, <U>that</U>, in each case such provision and access shall be (i) for the purpose of reviewing the Closing
Statement and to prepare any Dispute Notice and (ii) during normal business hours and in a manner that does not interfere with the normal
business operations of the Buyer or the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.5.4.
&nbsp;<U>Resolution of Disputes</U>. The Buyer and the Seller Representative will attempt to resolve the Disputed Items in good faith
during the twenty (20) day period following delivery of the Dispute Notice and all such discussions will (unless otherwise agreed by
the Buyer and the Seller Representative) be governed by Rule&nbsp;408 of the Federal Rules of Evidence and any comparable applicable
state rule. Disputed Items resolved in writing by the Seller Representative and the Buyer within the twenty (20) day period will be final,
conclusive and binding on the parties. If the Buyer and the Seller Representative are unable to resolve all Disputed Items in the Dispute
Notice within such twenty (20) day period, either the Buyer or the Seller Representative may provide written notice to the other (the
&ldquo;<U>Dispute Submission Notice</U>&rdquo;) that such party is submitting any remaining Disputed Items for resolution to the Independent
Referee. The Buyer and the Seller Representative shall enter into a customary engagement letter with the Independent Referee. The Buyer
and the Seller Representative will use their commercially reasonable efforts to cause the Independent Referee to render its decision
as soon as practicable (but in any event within thirty (30) days) after the submission to the Independent Referee of their respective
proposed final calculations of the Disputed Items (which the Buyer and the Seller Representative shall submit to the Independent Referee
not later than ten (10) days following the giving of the Dispute Submission Notice). Each of the Buyer and the Seller Representative
shall, and the Buyer shall cause the Company to, use reasonable best efforts to comply with all reasonable requests by the Independent
Referee for access to their respective work papers, information, books, records and similar items, personnel and Representatives (provided,
that such access and compliance is during normal business hours and does not interfere with the normal business operations of the Buyer
or the Company). The Independent Referee will review such final calculations of the Disputed Items and render a final determination of
all Disputed Items in accordance with this <U>Section 2.5</U>, <U>provided</U> that the Independent Referee&rsquo;s final determination
with respect to each Disputed Item shall be within the range of the proposed final calculations of such Disputed Item as presented in
the Buyer&rsquo;s Closing Statement pursuant to <U>Section&nbsp;2.5.2</U> and the Dispute Notice pursuant to <U>Section&nbsp;2.5.3</U>.
The Buyer and the Seller Representative each shall be entitled to make a written submission to the Independent Referee (which must be
provided to the other party) in support of its respective proposed final calculations of the submitted Disputed Items, <U>provided</U>
that such submissions shall be submitted within twenty (20) days after the submission to the Independent Referee of such proposed final
calculations of the submitted Disputed Items. The Independent Referee&rsquo;s determination will be (a)&nbsp;in writing and shall include
a reasonably detailed statement of the basis for the Independent Referee&rsquo;s decision, (b)&nbsp;furnished to each of the Buyer and
the Seller Representative as soon as practicable (but in any event within thirty (30) days) after the Seller Representative&rsquo;s and
the Buyer&rsquo;s respective final calculations of the Disputed Items have been submitted to the Independent Referee, (c)&nbsp;limited
in scope to the Disputed Items and (d)&nbsp;final, conclusive and binding on the parties, and judgment on such decision may be entered
in any court of competent jurisdiction. The fees and expenses of the Independent Referee shall be borne by (i)&nbsp;the Seller Representative,
on the one hand, and (ii)&nbsp;the Buyer, on the other hand, based on the percentage that the portion of the contested amount not awarded
to each party bears to the amount actually contested by the parties in aggregate, and such allocation of fees and expenses shall be calculated
by the Independent Referee and such calculation shall be final and binding on the parties. By way of illustration, (x)&nbsp;if the Buyer&rsquo;s
calculations would have resulted in a $1,000,000 net payment to the Buyer, and the Seller Representative&rsquo;s calculations would have
resulted in a $1,000,000 net payment to the Sellers and the Independent Referee&rsquo;s final determination results in an aggregate net
payment of $500,000 to the Sellers, then the Buyer and the Sellers shall pay 75% and 25%, respectively, of such fees and expenses and
(y)&nbsp;if each of such parties&rsquo; calculations differs from the Independent Referee&rsquo;s calculation by at least $1,000,000,
the Buyer and the Sellers shall split such fees and expenses evenly. At any time the Buyer and the Seller Representative may agree to
settle any objections raised in the Dispute Notice, including any Disputed Items submitted to the Independent Referee, which agreement
shall be in writing and final, conclusive and binding upon all of the parties hereto with respect to the subject matter of any such objection
so resolved; <U>provided</U> that, the parties shall promptly provide a copy of such agreement to the Independent Referee and instruct
the Independent Referee not to resolve such Disputed Item, it being agreed that if the Independent Referee nonetheless resolves such
Disputed Item for any reason, the agreement of the parties shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.5.5.
&nbsp;<U>Post-Closing Purchase Price Adjustment</U>. As promptly as possible, but in any event no later than the fifth (5<SUP>th</SUP>)
Business Day following the final determination, in accordance with <U>Section&nbsp;2.5.3</U> or <U>Section&nbsp;2.5.4</U>, of Transaction
Expenses, Transaction Bonus Payments, Company Indebtedness, Working Capital and Cash on Hand (respectively, the &ldquo;<U>Final Transaction
Expenses</U>&rdquo;, &ldquo;<U>Final Transaction Bonus Payments</U>&rdquo;, &ldquo;<U>Final Company Indebtedness</U>&rdquo;, &ldquo;<U>Final
Working Capital Amount</U>&rdquo; and &ldquo;<U>Final Cash on Hand Amount</U>&rdquo;), a Purchase Price adjustment shall be made as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;if (i)&nbsp;the sum of (A)&nbsp;the Final Working Capital Amount, <I>plus</I> (B)&nbsp;the Final Cash on Hand Amount, <I>minus
</I>(C)&nbsp;the Final Transaction Expenses, <I>minus</I> (D)&nbsp;the sum of the Final Transaction Bonus Payments, <I>minus</I> (E)&nbsp;the
Final Company Indebtedness is less than (ii)&nbsp;the sum of (A)&nbsp;the Estimated Working Capital Amount, <I>plus</I> (B)&nbsp;the
Estimated Cash on Hand Amount, <I>minus</I> (C)&nbsp;the Estimated Transaction Expenses, <I>minus</I> (D)&nbsp;the sum of the Estimated
Transaction Bonus Payments, <I>minus</I> (E)&nbsp;the Estimated Company Indebtedness, then the Purchase Price will be reduced by an amount
equal to such shortfall (the &ldquo;<U>Post-Closing Reduction Amount</U>&rdquo;), and such Post-Closing Reduction Amount shall be paid
to the Buyer solely from the Escrow Account and from no other source in accordance with the terms of the Escrow Agreement and otherwise
subject to <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT> 9.10</U>; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;if (i)&nbsp;the sum of (A)&nbsp;the Final Working Capital Amount, <I>plus</I> (B)&nbsp;the Final Cash on Hand Amount, <I>minus
</I>(C)&nbsp;the Final Transaction Expenses, <I>minus</I> (D)&nbsp;the sum of the Final Transaction Bonus Payments, <I>minus</I> (E)&nbsp;the
Final Company Indebtedness is greater than (ii)&nbsp;the sum of (A)&nbsp;the Estimated Working Capital Amount, <I>plus</I> (B)&nbsp;the
Estimated Cash on Hand Amount, <I>minus</I> (C)&nbsp;the Estimated Transaction Expenses, <I>minus</I> (D)&nbsp;the sum of the Estimated
Transaction Bonus Payments, <I>minus</I> (E)&nbsp;the Estimated Company Indebtedness, then the Purchase Price will be increased by an
amount equal to such excess and the Buyer will pay such excess amount to the Sellers (<U>provided</U> that compensatory payments shall
be made subject to the last sentence of <U>Section&nbsp;2.6</U>) within five (5) Business Days after the determination of such excess
amount by wire transfer of immediately available funds to the account specified by the Seller Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.6.
&nbsp;<U>Earn Out</U>. As additional consideration for the purchase of the Shares, Buyer will pay the Earn Out Amount if earned in accordance
with this <U>Section 2.6</U> (such payment, the &ldquo;<U>Earn Out</U>&rdquo;). The Earn Out, if earned, will be paid to the Sellers
and allocated among them as set forth in the Allocation Schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.6.1.
&nbsp;<U>Revenue Statement; Earn Out Statement</U>. Within forty-five (45) days following the end of each of the First Earn Out Period
and Second Earn Out Period, Buyer will prepare and deliver to the Seller Representative a statement (a &ldquo;<U>Revenue Statement</U>&rdquo;)
setting forth the Revenue and EBITDA for that portion of the First Earn Out Period and Second Earn Out Period, as applicable, along with
a statement setting forth whether the Economic Milestones have been met for that respective portion of the Earn Out Period. Within forty-five
(45) days following the end of each calendar quarter during each Earn Out Period, Buyer will prepare and deliver to the Seller Representative
an interim statement setting forth whether any Non-Economic Milestone was achieved during such period (each, an &ldquo;<U>Earn Out Statement</U>&rdquo;)
as if the Earn Out Period had ended at the end of such quarter; provided, however, that any failure to comply with this sentence will
not constitute a breach of this Agreement if Buyer cures such failure either (i) before receiving any written notice of such failure
from the Seller Representative, or (ii) within five Business Days after receiving a written notice of such failure from the Seller Representative.
Upon Seller Representative&rsquo;s determination that any Non-Economic Milestone has been achieved, the Seller Representative may notify
Buyer in writing of the achievement of such Non-Economic Milestone (a &ldquo;<U>Milestone Achievement Notice</U>&rdquo;), and unless
Buyer disputes in writing the achievement of such Milestone within thirty (30) days after receipt of the Seller Representative&rsquo;s
notice, Buyer shall pay to the Sellers the amount attached to the relevant Non-Economic Milestone as described in <U>Section 2.6.2</U>
below. If Buyer disputes the Milestone Achievement Notice, then Buyer will address such Non-Economic Milestone in the next Earnout Out
Statement, and the Seller Representative may accept or dispute such Earn Out Statement as otherwise provided in this <U>Section 2.6</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.6.2.
&nbsp;<U>Payments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;If the Continuing Business Company achieves any Milestone for the relevant Earn Out Period, as confirmed by (i) Buyer in the relevant
Revenue Statement or an Earn Out Statement, or (ii) Seller Representative, as to any Non-Economic Milestone, pursuant to a Milestone
Achievement Notice that Buyer does not dispute within thirty (30) days after receipt, Buyer shall pay to the Sellers, in accordance with
the Allocation Schedule, the amounts attached to the relevant Milestone according to the Earn Out Schedule (such calculated amounts are
referred to as the &ldquo;<U>Earn Out Amount</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;The Buyer shall pay the relevant portion(s) of the Earn Out Amount in accordance with the Allocation Schedule within fifteen (15)
days after the Seller Representative&rsquo;s notice, unless Seller Representative disputes any element of a Revenue Statement (or any
calculation provided therewith) or an Earn Out Statement, pursuant to <U>Section&nbsp;2.6.4</U>, in which case any payment shall be due
on such date as the Buyer and the Seller Representative resolve the dispute under <U>Section&nbsp;2.6.4</U> (a date on which payment
is due is referred to as a &ldquo;<U>Earn Out Payment Date</U>&rdquo;). Buyer shall pay the relevant portion of the Earn Out Amount in
accordance with the Allocation Schedule within fifteen (15) days after a Milestone Achievement Notice, unless Buyer disputes such Milestone
Achievement Notice, in which case any payment shall be due on such date as the Buyer and the Seller Representative resolve the dispute
under <U>Section&nbsp;2.6.4</U>. Any cash payment on a Earn Out Payment Date shall be made in accordance with the Allocation Schedule
via wire transfer of immediately available funds to an account designated in writing by each Seller, respectively, not less than five
(5) Business Days prior to the Earn Out Payment Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.6.3.
&nbsp;<U>Definitions</U>. For purposes of this <U>Section 2.6</U> and <U>Schedule 2.6.1</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;&ldquo;<U>Revenue</U>&rdquo; means the revenues recognized by the Continuing Business Company, in accordance with GAAP and reviewed
by the Parent&rsquo;s auditor, except that &ldquo;<U>Revenue</U>&rdquo; excludes (1) all governmental taxes, assessments, charges, duties,
withholding, refunds and tax reclaims relating to the utilization of the Continuing Business, and (2) all intercompany transactions between
the Buyer, the Company, the Parent or any of their respective Affiliates that are not associated with the Continuing Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;&ldquo;<U>EBITDA</U>&rdquo; means (a) net income after taxes for such period (excluding extraordinary gains or losses); <U>plus
</U>(b) any interest expense for such period; <U>plus</U> (c) income tax expense for such period; <U>plus</U> (d) depreciation and amortization
for such period; <U>plus or minus</U> (e) any other non-cash and non- recurring charges or gains which have been subtracted or added
in calculating net income after taxes for such period, recognized by the Continuing Business Company, in each case in accordance with
GAAP and reviewed by the Parent&rsquo;s auditor, during the relevant Earn Out Period. For the avoidance of doubt, it is acknowledged
that (i) any affiliate or intercompany transaction, service, allocation or charge (including with respect to MDW) that that are not associated
with the Continuing Business of the Company and negatively affects net income shall be excluded from the calculation of EBITDA and (ii)
all compensation for US employees and contractors of the Continuing Business Company shall be included in the calculation of EBITDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.6.4.
&nbsp;<U>Disputes</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;Seller Representative may dispute any element of a Revenue Statement (or any calculation provided therewith) or an Earn Out Statement
by delivering written notice to Buyer of said disagreement, setting forth in detail the particulars of such disagreement (a &ldquo;<U>Earn
Out Dispute Notice</U>&rdquo;), within thirty (30) days after the receipt by Seller Representative of a Revenue Statement or an Earn
Out Statement. During such thirty (30) day period, Seller Representative and any accountant or agent of Seller Representative shall have
full access during normal business hours (i) to the relevant books and records of, and the work papers prepared by, Buyer to the extent
that they relate to a Revenue Statement (or any calculation provided therewith) or an Earn Out Statement, and (ii) to such historical
financial information (to the extent in Buyer&rsquo;s possession or control) relating to a Revenue Statement (or any calculation provided
therewith) or an Earn Out Statement as Seller Representative may reasonably request for the purpose of reviewing a Revenue Statement
(or any calculation provided therewith) or an Earn Out Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;In the event that Seller Representative did not provide such a Earn Out Dispute Notice within such thirty (30) day period, Seller
Representative shall be deemed to have accepted a Revenue Statement <B>(</B>and any calculation provided thereunder) or an Earn Out Statement,
which shall thereafter be final, binding, non-appealable and conclusive for all purposes hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
&nbsp;In the event a Earn Out Dispute Notice is timely provided, Buyer and Seller Representative shall use their reasonable efforts for
a period of thirty (30) days (or such longer period as they shall mutually agree) from the date of receipt of such notice, to resolve
such disagreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
&nbsp;If the Buyer and the Seller Representative are unable to resolve the matters disputed in the Earn Out Dispute Notice within such
thirty (30) day period, either the Buyer or the Seller Representative may provide written notice to the other (the &ldquo;<U>Earn Out
Dispute Submission Notice</U>&rdquo;) that such party is submitting any remaining matters disputed in the Earn Out Dispute Notice for
resolution to the Independent Referee, subject to <U>Section 2.6.4(e)</U>. The Buyer and the Seller Representative shall enter into a
customary engagement letter with the Independent Referee. The Buyer and the Seller Representative will use their commercially reasonable
efforts to cause the Independent Referee to render its decision as soon as practicable (but in any event within thirty (30) days) after
the submission to the Independent Referee of their respective proposed calculations of Revenue and EBITDA (which the Buyer and the Seller
Representative shall submit to the Independent Referee not later than ten (10) days following the giving of the Earn Out Dispute Submission
Notice). Each of the Buyer and the Seller Representative shall, and the Buyer shall cause the Company to, use reasonable best efforts
to comply with all reasonable requests by the Independent Referee for access to their respective work papers, information, books, records
and similar items, personnel and Representatives (<U>provided</U> that such access and compliance is during normal business hours and
does not interfere with the normal business operations of the Buyer or the Company). The Independent Referee will review such final calculations
of the matters disputed in the Earn Out Dispute Notice and render a final determination of the matters disputed in the Earn Out Dispute
Notice in accordance with this <U>Section&nbsp;2.6</U>. The Buyer and the Seller Representative each shall be entitled to make a written
submission to the Independent Referee (which must be provided to the other party) in support of its respective proposed final calculations
of the matters disputed in the Earn Out Dispute Notice, <U>provided</U> that such submissions shall be submitted within twenty (20) days
after the submission to the Independent Referee of such proposed final calculations of the matters disputed in the Earn Out Dispute Notice.
The Independent Referee&rsquo;s determination will be (a)&nbsp;in writing and shall include a reasonably detailed statement of the basis
for the Independent Referee&rsquo;s decision, (b)&nbsp;furnished to each of the Buyer and the Seller Representative as soon as practicable,
and (c)&nbsp;final, conclusive and binding on the parties, and judgment on such decision may be entered in any court of competent jurisdiction.
The fees and expenses of the Independent Referee shall be borne 50% by the Seller Representative, on the one hand, and 50% by the Buyer,
on the other hand, unless the Independent Referee determines the Buyer&rsquo;s calculations set forth in the applicable Revenue Statement
are misstated by 5% or more, in which case the Buyer will pay 100% of the fees and expenses of the Independent Referee. At any time the
Buyer and the Seller Representative may agree to settle the dispute, which agreement shall be in writing and final, conclusive and binding
upon all of the parties hereto with respect to the subject matter of any such objection so resolved; <U>provided</U> that, the parties
shall promptly provide a copy of such agreement to the Independent Referee and instruct the Independent Referee not to resolve the dispute,
it being agreed that if the Independent Referee nonetheless resolves the dispute for any reason, the agreement of the parties shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)
&nbsp;Notwithstanding any provision of this Agreement to the contrary, the Independent Referee shall not have the power to resolve any
dispute relating to <U>Section 2.6.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.6.5.
&nbsp;<U>Operation of Business</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;During the Earn Out Period, each of the Buyer and Parent hereby covenants and agrees (i) to regularly discuss the operation of
the Continuing Business with Yuz, as long as Yuz is employed by the Buyer or its Affiliates; (ii) not to take, and to cause the Company
or any of its Affiliates not to take, any action that is intended to prohibit or otherwise limit the ability of the Sellers to earn the
Earn Out Amount; (iii) to operate the Continuing Business in good faith and not to take any actions in bad faith that would interfere
with the maintenance by the Company of existing customer relationships or the development by the Company of new customer relationships;
(iv) not to take any action, the purpose of which is to avoid achievement of any Earn-Out milestone that will result in an Earn Out Payment;
(v) not to impose or incur any affiliate or intercompany transaction, service, allocation or charge that is intended to, or which the
purpose is to, manipulate the results of operations of the Company in order to avoid the achievement of any Earn Out Payment, it being
understood that Buyer and Parent are free to take steps that in their discretion are desirable to integrate MDW, LLC and the Company
and neither Parent nor Buyer is required to invest any capital in the Continuing Business after the Closing except as otherwise expressly
set forth in the Earn Out Schedule; and (vi) during the First Earn Out Period and Second Earn Out Period, if the Parent or Buyer alter
the cost structure of the Company in a manner inconsistent with the conduct of the Business prior to the Closing such that there is a
resulting decrease in the EBITDA or Revenue of the Company, such decrease shall not be allocated against the Continuing Business Company's
EBITDA or Revenue calculations for purposes of the Earn Out and the EBITDA or Revenue will be calculated without reference to or inclusion
of such costs and expenses that resulted in the decrease in the EBITDA or Revenue of the Company (each action in subsections (ii) through
(vi) a &ldquo;<U>Prohibited Action</U>&rdquo;)<FONT STYLE="font-size: 10pt">. </FONT> Additionally, each of Buyer and Parent agrees that
it will not dispose of any material portion of the Continuing Business or the Company prior to the expiration of the Earn Out Period
(whether by merger, consolidation, sale of stock or assets, reorganization, recapitalization or otherwise), unless at the closing of
such disposition Buyer pays the maximum Earn Out Amount in full, regardless of the extent to which the Earn Out Amount has been earned.
Buyer agrees that if Buyer, the Company or their respective Affiliates materially breach the covenants and agreements contained in this
<U>Section 2.6</U>, then following written notice and the failure to cure within five (5) Business Days after receipt of notice, Buyer
will automatically be obligated to pay the maximum Earn Out Amount in full, regardless of the extent to which the Earn Out has been earned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;During the Earn Out Period, Buyer and the Company will permit each of Yuz, Elaine Yuz, Brian Phelan and Jonathan Krutchik to dedicate
substantially all of his or their time to the operation of the Continuing Business. Buyer will not direct Yuz, Elaine Yuz, Brian Phelan
or Jonathan Krutchik to dedicate their time to other aspects of the business of the Buyer or its Affiliates other than the Continuing
Business in a manner that would adversely impact the likelihood of achieving the maximum Earn Out.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
&nbsp;The Sellers each acknowledge and agree that (i) the Earn Out Amount is speculative and is subject to numerous factors, some of
which are outside the control of the Buyer and the Company, (ii) there is no assurance that the Sellers will receive any Earn Out Amount
and none of the Buyer, the Company or any of their respective Affiliates has promised or projected any Earn Out Amount, (iii) the Buyer,
the Company and their respective Affiliates owe no fiduciary duty to the Sellers other than those arising under applicable Law, and (iv)
the parties intend solely the express provisions of this Agreement to govern their contractual relationship with respect to any Earn
Out Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
&nbsp;Without limiting the generality of the foregoing, subject to the Buyer&rsquo;s agreement not to take any Prohibited Actions and
as otherwise expressly set forth in the Earn Out Schedule, none of the Buyer, the Company, nor any of their respective Affiliates shall
be required to operate the Company or the Continuing Business in any particular manner or expend any particular level of effort in conducting
the Continuing Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.6.6.
&nbsp;The rights of the Sellers to receive the Earn Out Amount (i) are solely contractual rights and are not securities for purposes
of any federal or state securities Laws, and shall confer upon the Sellers only the rights of general unsecured creditors; (ii) do not
constitute an investment or ownership interest in the Parent, Buyer or the Company; (iii) are an integral part of the consideration payable
by the Buyer for the Shares owned by the Sellers; (iv) will not be represented by any form of certificate or instrument; (v) do not give
any Seller any dividend rights, voting rights, liquidation rights, preemptive rights or other rights as security holders of the Parent,
the Buyer or any of their Affiliates; (vi) are not redeemable; (vii) do not bear interest; and (vii) except as provided in <U>Section
11.7</U>, may not be sold, assigned, pledged, gifted, conveyed or otherwise transferred (a &ldquo;<U>Transfer</U>&rdquo;), except to
an Affiliate or by operation of law or pursuant to the laws of descent and distribution (with any Transfer in violation of this <U>Section&nbsp;2.6.5
</U>being null and void). The Parties agree to treat the Earn Out Payment as consideration payable by the Buyer in exchange for the Shares
for all Tax purposes, except as and to the extent required by applicable Legal Requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.7.
&nbsp;<U>Company Stock Options and Warrants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.7.1.
&nbsp;Before the Closing, the Board of Directors of the Company shall adopt such resolutions or take such other actions as may be required
to effect the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;Authorize the Company to enter into an option cancellation agreement with each holder of vested Company Stock Options that is not
an Accredited Investor (each such investor, a &ldquo;<U>Non-Accredited Optionholder</U>,&rdquo; and each such Company Stock Option held
by a Non-Accredited Optionholder, a &ldquo;<U>Non-Accredited Option</U>&rdquo; ) as necessary to provide that (X) each such vested Non-Accredited
Option that is unexercised as of the Closing will be cancelled and converted immediately prior to the Closing into the right to receive
a Transaction Bonus Payment from the Company in an amount as set forth in and in accordance with the Allocation Schedule, and (Y) each
option to purchase Company Stock outstanding immediately prior to the Closing that is not a vested Company Stock Option shall terminate
at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;Authorize each Accredited Investor that holds a vested Company Stock Option to enter into this Agreement and receive a portion
of the Purchase Price in exchange for the termination and cancellation of his or her vested Accredited Option. Such Accredited Investor
will be entitled to receive a portion of the Purchase Price as set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.7.2.
&nbsp;Each Accredited Optionholder agrees that immediately prior to the Closing, the Company Stock Options held by such Accredited Optionholder
will be canceled and terminated, and such Accredited Optionholder has no further rights in or with respect to such Company Stock Options
other than the right to payment as provided in <U>Section 2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.7.3.
&nbsp;Each Warrantholder agrees that immediately prior to the Closing, the Warrants held by such Warrantholder will be canceled and terminated,
and such Warrantholder has no further rights in or with respect to such Warrants other than the right to payment as provided in <U>Section
2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.8.
&nbsp;<U>Withholding</U>. The Buyer, the Company and any other applicable withholding agent will be entitled to deduct and withhold or
cause to be deducted and withheld from any amounts payable or consideration otherwise deliverable to any Person pursuant to this Agreement
or any ancillary agreement any payroll Taxes or other amounts required under the Code or any applicable Tax Legal Requirement to be deducted
and withheld; <U>provided</U>, <U>however</U>, that before any such deduction or withholding is made (other than with respect to compensatory
payments for employment), the Buyer shall provide reasonable advance notice (and no less than four (4) Business Days&rsquo;) of such
withholding together with an explanation of the relevant Legal Requirement that requires such withholding, so as to provide such Person
with the opportunity to provide any forms or other documentation or take such other steps in order to avoid such deduction or withholding,
and (b)&nbsp;reasonably cooperate with any efforts of such Person to reduce or eliminate any such deduction or withholding. Any such
amounts deducted or withheld that are properly remitted to the appropriate Taxing Authorities will be treated for all purposes of this
Agreement as having been paid to the Person in respect of which such deduction and withholding was made. Notwithstanding any other provision
of this Agreement, all compensatory payments for services for employment subject to withholding that are contemplated by this Agreement
or the Escrow Agreement shall be payable through the Company&rsquo;s (or any applicable Subsidiary&rsquo;s) payroll in accordance with
applicable payroll procedures.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.
&nbsp;Representations and Warranties of the Company and Yuz.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as provided in the Disclosure Schedules (subject to <U>Section &lrm;11.15</U>), each of the Company and Yuz, severally and not jointly,
represents and warrants to the Buyer as of the date hereof and the Closing Date (unless the particular statement speaks expressly as
of a particular date, in which case it is true and correct only as of such date) as follows (in each case, except where context implies
otherwise, with respect to the Company and its direct and indirect Subsidiaries):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1.
&nbsp;<U>Power and Authorization</U>. The Company has the corporate power and authority to execute and deliver this Agreement and to
perform its obligations hereunder. The Company has taken all corporate actions or proceedings required to be taken by or on the part
of the Company or Sellers to authorize and permit the execution and delivery by the Company of this Agreement and the instruments required
to be executed and delivered by it pursuant hereto, and the performance by the Company of its obligations hereunder and the consummation
by the Company of the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company and the Seller Representative,
and assuming the due authorization, execution and delivery by each of the other parties hereto, constitutes the legal, valid and binding
obligation of the Company and the Seller Representative, enforceable against it and the Seller Representative in accordance with its
terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2.
&nbsp;<U>Organization</U>. The Company (a)&nbsp;is duly organized, validly existing and in good standing under the laws of the State
of Delaware, and (b) has all requisite power and authority and all Permits necessary to own, lease and operate its properties and assets
and to carry on its businesses as currently conducted and as proposed to be conducted. The Company is duly qualified or licensed to do
business and is in good standing in each jurisdiction where the character of the properties owned, leased or licensed by it or the nature
of its business makes such qualification, licensing or good standing necessary, except where the failure to be so qualified or licensed
or in good standing has not had, and would not reasonably be expected to have, a Material Adverse Effect. The Company has made available
to the Buyer true and correct copies of the Company&rsquo;s Organizational Documents. The Company is not in violation of any of the provisions
of its Organizational Documents, and no changes thereto are pending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3.
&nbsp;<U>Capitalization; Subsidiaries.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3.1.
&nbsp;<U>Title to Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
&nbsp;The entire authorized equity of, and other interest in, the Company consists of the Shares, which Shares are duly authorized, validly
issued, fully paid, nonassessable, and free of preemptive rights, and all such Shares are free and clear of any Lien other than Liens
imposed by the Company&rsquo;s Organizational Documents and applicable securities laws, and have not been issued in violation of any
Legal Requirement or contractual right, including preemptive rights (other than those created by virtue of this Agreement and the Organizational
Documents). Upon consummation of the Contemplated Transactions, Buyer shall own all of the Shares, free and clear of all Liens other
than Liens imposed by the Company&rsquo;s Organizational Documents and applicable securities laws and imposed on or permitted with respect
to third parties by the Buyer. Set forth on <U>Schedule 3.3.1(a)</U> is the name of each record owner of Shares and the number and type
of shares in the Company such Person holds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.6in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
&nbsp;Except as set forth on <U>Schedule 3.3.1(b)</U>, there are no outstanding or authorized options, warrants, convertible securities
or other rights, agreements, arrangements or commitments of any character relating to any equity in the Company or obligating any Seller
or the Company to issue or sell any equity (including the Shares), in the Company. Other than the Organizational Documents, there are
no voting trusts, proxies or other agreements or understandings in effect with respect to the voting or transfer of any of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3.2.
&nbsp;<U>Schedule&nbsp;3.3.2</U> sets forth the name of each Subsidiary of the Company, the jurisdiction of its incorporation or organization,
the direct owner(s) of the issued and outstanding equity securities of such Subsidiary and the percentage of the issued and outstanding
equity of such Subsidiary owned by such owner(s). Each such Subsidiary listed on <U>Schedule&nbsp;3.3.2</U> is a direct or indirect wholly
owned Subsidiary of the Company, and there are no outstanding options, warrants or other rights of any Person to acquire any shares or
any other equity securities of such direct and indirect Subsidiaries of the Company, or securities exercisable or exchangeable for, or
convertible into, equity securities of, or equity interests in, such direct and indirect Subsidiaries of the Company (in each case, other
than the Company or another direct or indirect Subsidiary of the Company). Except as set forth on <U>Schedule&nbsp;3.3.2</U> or in the
Organizational Documents of such entity, no Subsidiary is party to or bound by any voting or other similar agreement with respect to
any of such Subsidiary&rsquo;s equity securities. Neither the Company nor any of its Subsidiaries owns or holds the right or is obligated
to acquire any stock, partnership interest or joint venture interest or other equity ownership interest in any other Person, other than
as set forth on <U>Schedule&nbsp;3.3.2</U>. Each of the Subsidiaries listed on <U>Schedule&nbsp;3.3.2</U> is duly organized, validly
existing and is in good standing under the Legal Requirements of the jurisdiction of its incorporation or organization, has all requisite
power and authority and all Permits necessary to own, lease and operate its properties and assets and to carry on its businesses as currently
conducted. Each of the Subsidiaries listed on <U>Schedule&nbsp;3.3.2</U> is qualified to do business and in good standing in every jurisdiction
in which its ownership of property or the conduct of its businesses as currently conducted requires it to qualify, except where the failure
to be so qualified has not had, and would not be reasonably expected to have, a Material Adverse Effect. <U>Schedule&nbsp;3.3.2</U> also
lists (i)&nbsp;the officers and directors of the Company and each of its Subsidiaries, (ii)&nbsp;the jurisdictions in which the Company
and each of its Subsidiaries is qualified to do business, and (iii)&nbsp;the jurisdictions in which the Company or any of its Subsidiaries
has an office or facility, employed or engaged a Worker or conducted business. The Company has made available to the Buyer true and correct
copies of each Subsidiary&rsquo;s Organizational Documents as currently in effect, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4.
&nbsp;<U>No Violation or Approval; Consents</U>. Except as set forth in <U>Schedule&nbsp;3.4</U>, none of the execution and delivery
of or its performance of its obligations under this Agreement by the Company or its consummation of the Contemplated Transactions, will:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4.1.
&nbsp;require any consent, waiver, approval, clearance, permit, order or authorization of or from, or registration, declaration, notice
or filing to or with any Governmental Authority with respect to the Company or any Company Subsidiary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4.2.
&nbsp; (a) result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration
of obligations under, create in any Person the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver
under, any material Contract, Permit, Lien (other than Permitted Liens) or other arrangement to which the Company or its Subsidiary is
a party or by which the Company or its Subsidiary is bound or to which its assets are subject, or (b) result in the imposition of any
Lien (other than Permitted Liens); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4.3.
&nbsp;result in a breach or violation of, or default under, the Organizational Documents of the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.5.
&nbsp;<U>Financial Statements, Etc</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.5.1.
&nbsp;The Company has made available to the Buyer copies of: (a)&nbsp;the audited consolidated balance sheet of the Company as of December&nbsp;31,
2019 and December 31, 2020, and the related statements of income and cash flows of the Company for the fiscal year then ended (the &ldquo;<U>Audited
Financial Statements</U>&rdquo;), (b)&nbsp;the unaudited consolidated balance sheet of the Company as of June 30, 2021, and the related
statements of income and cash flows of the Company for the six (6) month period then ended (the &ldquo;<U>Unaudited Financial Statements</U>&rdquo;)
and (c)&nbsp;the unaudited balance sheet of the Company as of June 30, 2021 (respectively, the &ldquo;<U>Reference Balance Sheet</U>&rdquo;
and the &ldquo;<U>Reference Balance Sheet Date</U>&rdquo;) and the related statements of income and cash flows of the Company for the
six-month period then ended (the &ldquo;<U>Interim Financial Statements</U>&rdquo; and, collectively with the Audited Financial Statements
and Unaudited Financial Statements, the &ldquo;<U>Financial Statements</U>&rdquo;). The Financial Statements (i)&nbsp;have been prepared
in accordance with GAAP, consistently applied, and (ii)&nbsp;present fairly in all material respects the financial position of the Company
and the results of operations of the Company and any of its Subsidiaries (taken as whole) as of the respective dates thereof and for
the periods covered thereby subject in the case of the Reference Balance Sheet to the absence of footnote disclosures and other presentation
items. Except as disclosed in <U>Schedule&nbsp;3.5</U>, neither the Company nor its Subsidiaries has any Liabilities (whether or not
required to be reflected in the Financial Statements under GAAP), except for Liabilities that (v) are reflected in or reserved against
in the Reference Balance Sheet, (w)&nbsp;have arisen or incurred in the ordinary course of business since the date of the Reference Balance
Sheet (none of which results from, arises out of, relates to, is in the nature of, or was covered by any breach of contract, breach of
warranty, tort, infringement, or violation of Legal Requirement), (x) are reflected in the calculation of the Estimated Working Capital
Amount, (y)&nbsp;Liabilities arising pursuant to the terms of any Contract for which the Company or any of its Subsidiaries is a party
that have not yet been performed (<U>provided</U>, neither the Company nor any of its Subsidiaries is in breach, violation, or non-compliance
with such Contract), and (z) are included in Indebtedness or Transaction Expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.5.2.&nbsp;Neither
the Company nor its Subsidiary is a party to, or has any commitment to become a party to, any joint venture, off-balance sheet partnership
or any similar contract relating to any transaction or relationship between or among the Company or its Subsidiary, on the one hand,
and any unconsolidated affiliate, including any structured finance, special purpose or limited purpose Person on the other hand, or any
&ldquo;<U>off-balance sheet arrangement</U>&rdquo; (as defined in Item&nbsp;303(a) of Regulation&nbsp;S-K of the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.5.3.&nbsp;The
Company has in place systems and processes (including the maintenance of proper books and records) that are designed to (a)&nbsp;provide
reasonable assurances regarding the reliability of the Financial Statements and (b)&nbsp;in a timely manner accumulate and communicate
to the Company&rsquo;s principal executive officer and principal financial officer the type of information that would be required to
be disclosed in the Financial Statements (such systems and processes, the &ldquo;<U>Financial Controls</U>&rdquo;). The Company has in
place a revenue recognition policy consistent with GAAP. None of the Company, its Subsidiaries, their respective officers nor the Company&rsquo;s
independent auditors has identified or been made aware of any complaint, allegation, deficiency, assertion or claim, whether written
or oral, regarding the Financial Controls or the Financial Statements that has not been resolved. To the Company&rsquo;s Knowledge, there
have been no instances of fraud or intentional misrepresentation by any Worker that occurred during any period covered by the Financial
Statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.6.&nbsp;<U>Ordinary
Course of Business; No Material Adverse Effect</U>. Since the Reference Balance Sheet Date: (a) the Company and its Subsidiaries have
operated in the Ordinary Course of Business; and (b) no Material Adverse Effect has occurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.&nbsp;<U>Taxes</U>.
Except in each case as set forth on <U>Schedule&nbsp;3.7</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.1.&nbsp;The
Company and any of its Subsidiaries have filed, or have caused to be filed on their behalf (after giving effect to extensions), all Income
Tax and material other Tax Returns required to be filed by or with respect to the Company and each of its Subsidiaries. All such Tax
Returns were true, correct and complete in all material respects; <U>provided</U>, <U>however</U>, that regardless of what may be reported
on any such Tax Returns, no representation is made regarding (i)&nbsp;any carryovers of net operating losses, Tax credits, or charitable
contribution or other Tax benefits items that are available to the Company or that have been reported by the Company for any federal,
state, or other Tax purposes, or (ii)&nbsp;any limitation on use of the Company&rsquo;s net operating losses, capital losses, built-in
losses, Tax credits, charitable contributions, or other tax benefit carryovers that might apply either as of or after the Closing Date
under Sections 269, 382, 383, 384 or 1502 of the Code, any rules or regulations thereunder, or any other applicable limitations under
any Tax Legal Requirements. All material Taxes required to be paid by or with respect to the Company or its Subsidiaries (whether or
not shown as due and payable on any such Tax Return) have been paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.2.&nbsp;All
Taxes required to have been withheld and paid in connection with amounts paid by the Company or its Subsidiaries to any Worker, creditor,
stockholder, or other third party have been withheld and paid to the appropriate Taxing Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.3.&nbsp;Neither
the Company nor any of its Subsidiaries have been notified in writing by a Taxing Authority of any deficiency or other assessment, audit
or examination concerning Taxes of the Company or any of its Subsidiaries (i) that has not been fully resolved, and (ii) that, if determined
adversely to the Company or its Subsidiaries, would reasonably be expected to result in material Tax Liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.4.&nbsp;There
are no pending requests for rulings or determinations by or before a Taxing Authority relating to Taxes with respect to the Company or
any of its Subsidiaries. No power of attorney has been executed by or on behalf of the Company or any of its Subsidiaries with respect
to any matters relating to Taxes that is currently in force.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.5.&nbsp;There
has been no extension or waiver of any statute of limitations in respect of Taxes with respect to the Company or any of its Subsidiaries
that remains in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.6.&nbsp;No
written claim or, to the Company&rsquo;s Knowledge, any other claim or nexus inquiry has been made to the Company by a Taxing Authority
in a jurisdiction where the Company or any of its Subsidiaries does not file Tax Returns that the Company or any of its Subsidiaries
is or may be subject to taxation by that jurisdiction or that the Company or any of its Subsidiaries has a duty to collect Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.7.&nbsp;None
of the assets of the Company or any of its Subsidiaries are currently subject to any Liens with respect to Taxes, other than Permitted
Liens.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.8.&nbsp;Neither
the Company nor any of its Subsidiaries is a party to or bound by any Tax sharing agreement, Tax indemnity, or tax-allocation agreement
other than any such agreement not primarily related to Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.9.&nbsp;The
Company has no, and has never had, a Subsidiary other than XMRI.COM PLLC and USARAD PR LLC, which is, and has been since its formation,
an entity disregarded as separate from the Company under Treasury Regulations Section 301.7701-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.10.&nbsp;Neither
the Company nor any of its Subsidiaries has, or ever had, (during any taxable period remaining open for the assessment of Tax by any
applicable Taxing Authority under its applicable statute of limitations), any place of business or permanent establishment in any country
outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.11.&nbsp;Neither
the Company nor any of its Subsidiaries has obtained any consent or clearance from or entered into any settlement or arrangement with
any Taxing Authority that would be binding on the Buyer or result in a material Tax Liability for the Buyer for any Tax period (or portion
thereof) ending after the Closing Date. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.12.&nbsp;The
Company and its Subsidiaries have properly and timely documented its transfer pricing methodology in compliance with Sections 482 and
6662 of the Code and any similar or comparable provision of applicable Legal Requirement. Neither the Company nor any of its Subsidiaries
is a party to any advance pricing agreement with any Taxing Authority or any similar or comparable contract or agreement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.13.&nbsp;Neither
the Company nor any of its Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable
income for any period (or any portion thereof) ending after the Closing Date, as a result of any: (i) change in method of accounting
for a taxable period (or portion thereof) ending on or before the Closing Date, including under Section 481(a) of the Code or any similar
provision of applicable Legal Requirement; (ii) installment sale or other open transaction disposition made prior to the Closing Date;
(iii) prepaid amount received prior to the Closing Date; (iv) closing agreement described in Section 7121 of the Code or any similar
provision of applicable Legal Requirement executed prior to the Closing Date; or (v) intercompany transaction or excess loss account
described in Treasury Regulations Section 1.1502 (or any similar provision of applicable Legal Requirement) that occurs or arises before
the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.14.&nbsp;Neither
the Company nor any of its Subsidiaries (including any predecessor thereof) has (i) engaged in a &ldquo;listed transaction,&rdquo; as
defined in Section 6707A(c)(1) of the Code or Treasury Regulations Section 1.6011-4(b), (ii) ever been a member of a consolidated, combined,
unitary or aggregate group of corporations within the meaning of Section 1504 of the Code or any similar provision of applicable Tax
Legal Requirement (other than a group of which the Company is the common parent), or (iii) actual or potential Liability under Treasury
Regulations Section 1.1502-6 or any similar provision of applicable Tax Legal Requirement, as a transferee or successor, as a result
of any contractual obligation, or otherwise for any Taxes of any other Person. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.15.&nbsp;Neither
the Company nor any of its Subsidiaries has ever participated in an international boycott within the meaning of Section 999 of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.16.&nbsp;Neither
the Company nor any its Subsidiaries is, or at any time has been, subject to (i) the dual consolidated loss provisions of Section 1503(d)
of the Code or similar provision of other Tax Legal Requirement, or (ii) the overall foreign loss provisions of Section 904(f) of the
Code or similar provision of Tax Legal Requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.17.&nbsp;<U>Schedule
3.7.17</U> contains a true and complete list of all jurisdictions (whether foreign or domestic) to which any income Tax has been properly
payable by the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.7.18.&nbsp;Neither
the execution of this Agreement nor the consummation of the Contemplated Transactions could (whether in cash or property or vesting of
property) or will result in &ldquo;excess parachute payments&rdquo; within the meaning of Section 280G(b) of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
anything to the contrary in this Agreement, (i)&nbsp;this <U>Section&nbsp;3.7</U> contains the sole and exclusive representations and
warranties of Yuz, the Company and its Subsidiaries regarding Taxes, Tax Returns and other matters relating to Taxes, (ii)&nbsp;nothing
in this Agreement (including this <U>Section&nbsp;3.7</U>) shall be construed as providing a representation or warranty with respect
to the existence, amount, expiration date or limitations on (or availability of) any Tax attribute of the Company or any of its Subsidiaries
(including methods of accounting of the Company) and (iii)&nbsp;the Sellers shall have no Liability under this Agreement (including via
the Escrow Agreement) for any Taxes attributable to a Post-Closing Tax Period, for any Taxes that were taken into account in the Final
Working Capital Amount, or for any Taxes resulting from or attributable to actions taken by the Buyer, the Company, or any Affiliate
of the Buyer outside the ordinary course of business on the Closing Date but after the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.8.&nbsp;<U>Real
Estate</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.8.1.&nbsp;<U>Leases</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;Except
as set forth on <U>Schedule&nbsp;3.8.1(a)</U>, as of the date hereof, each of (i)&nbsp;the Leases is in full force and effect, is valid
and binding on the Company and its Subsidiaries, as applicable, and, to the Company&rsquo;s Knowledge, each of the other parties thereto,
enforceable in accordance with its terms (ii)&nbsp;the Company and any Subsidiary, as applicable, and, to the Company&rsquo;s Knowledge,
each of the other parties thereto, has performed all material obligations required to be performed by it under each Lease, and (iii)&nbsp;the
Company and any Subsidiary, as applicable, has not received any written notice of a breach of or default with respect to a Lease, nor
to the Company&rsquo;s Knowledge has any event or omission occurred which, with the giving of notice or the lapse of time, or both, would
constitute a breach or default under a Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.8.2.&nbsp;<U>Owned
Premises</U>. The Company does not own any real property. Neither the Company nor any of its Subsidiaries has sub-leased or sub-licensed,
or otherwise granted to any Person, the right to use or occupy any real property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.9.&nbsp;<U>Operations
in Conformity with Laws</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.9.1.&nbsp;Since
March 31, 2018, the Company and each of its Subsidiaries have complied in all material respects with, are not in material violation of,
and have not received any written allegation or notice of material default or violation with respect to, any Legal Requirement or Permits
with respect to the conduct of its business, or the ownership or operation of its business. To the Company&rsquo;s Knowledge, no event
has occurred, and no condition or circumstance exists, that might (with or without notice or lapse of time or both) constitute, or result
directly or indirectly in, a default under, a material breach or violation of, or a failure to comply with, any Legal Requirement or
Permits with respect to the conduct of the business of the Company or any of its Subsidiaries or the ownership or operation of the Company
or any of its Subsidiaries. The Company and its Subsidiaries owns or possess all Permits that are necessary to conduct the business of
the Company and its Subsidiaries as presently conducted and as proposed to be conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.9.2.&nbsp;To
the Company&rsquo;s Knowledge, none of the Company, any of its Subsidiaries or any of their respective Representatives, or distributors
while retained by the Company or any other Person acting on behalf of any such Person have, with respect to the business of the Company
or any of its Subsidiaries, (a) used any funds for unlawful contributions, gifts, entertainment or other unlawful payments relating to
any political activity or (b) made any unlawful payment to any government official or employee or any political party or campaign or
violated any provision of the U.S. Foreign Corrupt Practices Act of 1977 or any other Legal Requirement applicable to the conduct of
business with Governmental Authorities (collectively, &ldquo;<U>Anti-bribery Laws</U>&rdquo;). The Company has made available to Buyer
true, correct and complete copies of each Contract in effect, if any, as of the date of this Agreement between the Company or any of
its Subsidiaries, on the one hand, and any sales agent or foreign representative thereof, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.9.3.&nbsp;Neither
the Company nor any of its Subsidiaries has applied for or received, is or will be entitled to or is or will be the beneficiary of any
grant, subsidy or financial assistance from any Governmental Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.9.4.&nbsp;The
Company and each of its Subsidiaries have at all times conducted their business in all material respects in accordance with (a) all applicable
U.S. export control and economic sanctions laws, including the Export Administration Regulations, the Arms Export Control Act, the International
Traffic in Arms Regulations, and the various statutes, regulations, and executive orders administered by the U.S. Department of the Treasury,
Office of Foreign Assets Control; and (b) to the Company&rsquo;s Knowledge all other applicable import/export controls, in all material
respects, in other countries in which the Company conducts business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.9.5.&nbsp;<U>Schedule
3.9.5</U> sets forth the true, complete and accurate export control classifications applicable to the Company&rsquo;s or any of its Subsidiaries&rsquo;
products, services, software and technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.9.6.&nbsp;Each
Permit (i) under which the Company or any of its Subsidiaries currently operates or holds any interest in any of their assets, or (ii)
that is required for the operation of the Company&rsquo;s or any of its Subsidiaries&rsquo; businesses as presently conducted or the
holding of any such interest (collectively, the &ldquo;<U>Company Authorizations</U>&rdquo;) has been issued or granted to the Company
or one of its Subsidiaries, as applicable. The Company Authorizations are in full force and effect and constitute all Company Authorizations
required to permit the Company and each of its Subsidiaries to lawfully operate or conduct their businesses or hold any interest in their
assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.&nbsp;<U>Employee
Plans</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.1.&nbsp;<U>Schedule&nbsp;3.10.1
</U>sets forth a list of all Employee Plans. With respect to each Employee Plan, the Company has made available to Buyer true and correct
copies of (i) the current official Employee Plan documents, including all amendments thereto, or, in the case of an unwritten Employee
Plan, a written description thereof, and (ii) the most recent summary plan descriptions and any summaries of material modifications thereto,
and the past three annual reports and associated summary annual reports.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.2.&nbsp;Each
Employee Plan that is intended to be qualified under Section&nbsp;401(a) of the Code (i) has received a favorable determination or opinion
letter or filed for a determination or opinion letter from the IRS to the effect that the form of such plan is so qualified or the applicable
period for requesting such determination or opinion has not yet expired, and each trust created thereunder has been determined by the
IRS to be exempt from Tax under the provisions of Section 501(a) of the Code and (ii) to the Company&rsquo;s Knowledge, nothing has occurred
since the date of any such determination or prototype opinion letter that could reasonably be expected to give the IRS grounds to revoke
its qualified status under Section 401(a) of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.3.&nbsp;Each
Employee Plan has been established, maintained, operated and administered in compliance in all material respects with applicable Legal
Requirements. There have been no actions or omissions that would be non-exempt prohibited transactions under Section 406 of ERISA or
Section 4975 of the Code or material breaches of any of the duties imposed by ERISA on &ldquo;fiduciaries&rdquo; (within the meaning
of Section 3(21) of ERISA) with respect to the Employee Plans, which actions or omissions could reasonably be expected to result in any
Liability or excise tax being imposed on the Company under applicable Legal Requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.4.&nbsp;All
required contributions, assessments and premium payments on account of each Employee Plan have been timely paid by the applicable due
date or accrued in accordance with GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.5.&nbsp;With
respect to each Employee Plan, there are no pending (or, to the Company&rsquo;s Knowledge, threatened) Actions involving the Company
other than routine claims for benefits in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.6.&nbsp;None
of the Company, any of its Subsidiaries, or any of its or their ERISA Affiliates maintain, sponsor, participate in, contribute to or
have any obligation to contribute to, and at no time have such entities ever maintained, established, sponsored, participated in, contributed
to or been obligated to, or otherwise have or had any Liability with respect to (i) any &ldquo;defined benefit plan&rdquo; (as defined
in Section 3(35) of ERISA) that is subject to Title&nbsp;IV of ERISA, (ii)&nbsp;any &ldquo;multiemployer plan,&rdquo; (as defined in
Section&nbsp;3(37) of ERISA) or (iii) a &ldquo;multiple employer plan&rdquo; within the meaning of Section 210(a) of ERISA or Section
413(c) of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.7.&nbsp;Except
as set forth on <U>Schedule&nbsp;3.10.7</U> or as required under Section&nbsp;601 <I>et seq.</I> of ERISA or Section&nbsp;4980B of the
Code or any analogous state or local Legal Requirement, no Employee Plan provides benefits or coverage following retirement or other
termination of employment. With respect to each Employee Plan that is subject to Section 4980B of the Code, the Company and its Subsidiaries
have complied in all material respects with the continuation coverage requirements of Section 4980B of the Code and Part 6 of Subtitle
B of Title I of ERISA. No Employee Plan that provides health insurance or medical coverage is self-funded or self-insured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.8.&nbsp;Except
as set forth on <U>Schedule 3.10.8</U>, the consummation of the Contemplated Transactions will not, either alone or in combination with
another event (such as termination of employment), (a) result in any payment becoming due under any Employee Plan, (b) accelerate the
time of payment, funding or vesting of any benefits under any Employee Plan, (c) increase the amount of compensation or benefits due
under any Employee Plan, or (d) result in the forgiveness in whole or in part of, or accelerate the repayment date of, any outstanding
loans that exist under or as part of any Employee Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.10.9.&nbsp;Neither
the Company, nor any of its Subsidiaries, maintains an Employee Plan that is a nonqualified deferred compensation plan (within the meaning
of Section 409A(d)(1) of the Code).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.&nbsp;<U>Intellectual
Property</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.1.&nbsp;<U>Schedule
3.11.1</U> (i) sets forth each granted patent, pending patent application, copyright registration or application therefor, and trademark,
service mark and domain name registration or application therefor owned by or purported to be owned by the Company or any of its Subsidiaries
(&ldquo;<U>Company Registered IP</U>&rdquo;) and any actions that must be taken within one hundred eighty (180) days after the date hereof
for the purposes of obtaining, maintaining, perfecting, preserving or renewing any of the foregoing, <U>including</U> the payment of
any registration, maintenance or renewal fees or the filing of documents, applications or certificates or any responses to office actions.
The Company or any of its Subsidiaries is the owner of the Company Registered IP free and clear of all Liens (other than Permitted Liens).
Each of the Company Registered IP is valid, enforceable and subsisting, all necessary registration, maintenance and renewal fees currently
due in connection with such Company Registered IP have been made and all necessary documents, recordations and certificates in connection
with such Company Registered IP have been filed with the relevant Governmental Authority. <U>Schedule 3.11.1(ii)</U> sets forth an accurate
and complete list of all material Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries that
is not Company Registered IP. The Company or any of its Subsidiaries has not received any written notice challenging the legality, validity,
enforceability or ownership of any Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.2.&nbsp;The
Company or its Subsidiaries exclusively and solely owns, free of any Liens other than non-exclusive licenses entered into in the ordinary
course of business, or has the right to use all Intellectual Property necessary (i) to use, manufacture, sell, offer for sale, import,
supply, perform, reproduce, display, market and distribute the Customer Deliverables and (ii) to use, make, perform, reproduce and operate
the Internal Systems. The Company and its Subsidiaries have taken reasonable measures to protect the proprietary nature of each item
of Company Intellectual Property, and to maintain in confidence all trade secrets and confidential information, that it owns or uses.
To the Company&rsquo;s Knowledge, no other person or entity has any rights to any of the Company Intellectual Property owned by or purported
to be owned by the Company or any of its Subsidiaries (except pursuant to agreements or licenses additionally specified in <U>Schedule
3.11.2</U>), and, to the Company&rsquo;s Knowledge, no other person or entity is infringing, violating or misappropriating any of the
Company Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.3.&nbsp;To
the Company&rsquo;s Knowledge, the operation by the Company and its Subsidiaries of their business as currently conducted, including
the design, development, use, import, export, manufacture, licensing, sale, offering for sale, supply or other disposition of the Customer
Deliverables and/or the Internal Systems does not (i) infringe, violate or misappropriate the Intellectual Property rights of any Person,
or (ii) constitute unfair competition or trade practices under applicable laws. <U>Schedule 3.11.3</U> additionally lists any unresolved
complaint, claim or notice, or written threat thereof, received by the Company or any of its Subsidiaries alleging any such infringement,
violation or misappropriation; and the Company or any of its Subsidiaries have made available to Buyer complete and accurate copies of
all written documentation in the possession of the Company or any of its Subsidiaries relating to any such unresolved complaint, claim,
notice or threat. The Company and its Subsidiaries have made available to Buyer complete and accurate copies of all written documentation
in the Company&rsquo;s possession relating to current, unresolved claims or disputes known to the Company or any of its Subsidiaries
concerning any Company Intellectual Property. To the Company&rsquo;s Knowledge, no third party has threatened any Action or claim against
the Company or any of its Subsidiaries for the infringement, violation or misappropriation of any Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.4.&nbsp;Except
as described in <U>Schedule 3.11.4</U>, neither the Company nor any of its Subsidiaries has agreed to indemnify any person or entity
against any infringement, violation or misappropriation of any Intellectual Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.5.&nbsp;<U>Schedule
3.11.5</U> identifies each item of Company Intellectual Property that is licensed by the Company or one of its Subsidiaries from a third
party, and the respective license agreement pursuant to which the Company or any of its Subsidiaries uses such item (excluding off-the-shelf
software programs licensed by the Company or one of its Subsidiaries pursuant to &ldquo;shrink wrap&rdquo; or &ldquo;click through&rdquo;
licenses).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.6.&nbsp;Neither
the Company nor any of its Subsidiaries has disclosed the source code for any software developed by it, or other confidential information
constituting, embodied in or pertaining to such software, to any person or entity, except pursuant to the agreements listed in <U>Schedule
3.11.6</U>, and the Company or its Subsidiaries have taken reasonable measures to prevent disclosure of such source code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.7.&nbsp;All
of the Intellectual Property incorporated in the Customer Deliverables have been created by employees or agents of the Company or its
Subsidiaries within the scope of their employment or engagement by the Company and its Subsidiaries or by independent contractors of
the Company or its Subsidiaries. Each Worker who has created Intellectual Property within the scope of his or her employment or engagement
by the Company and its Subsidiaries has executed written, valid and enforceable agreements expressly assigning to the Company or its
Subsidiaries all right, title and interest in and to any Intellectual Property conceived of, created, developed or first reduced to practice
in the course of such Worker&rsquo;s employment by or engagement with the Company or one of its Subsidiaries. No portion of such Intellectual
Property was jointly developed with any third party, except to the extent all right, title and interest in and to such Intellectual Property
held by such third party as a result of such joint development has been assigned to the Company or its Subsidiaries. The Company and
its Subsidiaries have paid, in full, all required compensation to employees, agents or independent contractors in relation to all Intellectual
Property owned or purported to be owned by the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.8.&nbsp;Except
as set forth in <U>Schedule 3.11.8</U>, neither the Company nor any of its Subsidiaries has (i) incorporated any Open Source Materials
into, or combined Open Source Materials with, any Customer Deliverables and/or Internal Systems, (ii) distributed Open Source Materials
in connection with any Customer Deliverables and/or Internal Systems, or (iii) used Open Source Materials in any manner that (A) creates,
or purports to create, obligations for the Company or any of its Subsidiaries with respect to software developed or distributed by the
Company or any of its Subsidiaries or (B) grants, or purports to grant, to any third party any rights or immunities under intellectual
property rights. Without limiting the generality of the foregoing, neither the Company nor any of its Subsidiaries has used any Open
Source Materials that require, as a condition of use, modification and/or distribution of such Open Source Materials, that other software
incorporated into, derived from or distributed with such Open Source Materials be (1) disclosed or distributed in source code form, (2)
licensed for the purpose of making derivative works, or (3) redistributable at no charge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.9.&nbsp;To
the Company&rsquo;s Knowledge, neither the Company nor any of its Subsidiaries is subject to any agreement with any standards body or
other similar entity that would obligate the Company or any of its Subsidiaries to grant licenses or rights to or otherwise impair its
control, enforcement or use of any Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.10.&nbsp;To
the Company&rsquo;s Knowledge, there is no Governmental Order or other prohibition or restriction, issued by a Governmental Entity, on
the use, practice or exploitation of any Customer Deliverables or the Internal Systems in any jurisdiction in which the Company or any
of its Subsidiaries currently conducts business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.11.11.&nbsp;No
Governmental Entity, university, or other similar educational institution has provided or provides facilities or funding for the creation
or development of any Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries. No Governmental
Entity, university, or other similar educational institution have any rights in or with respect to any Intellectual Property owned or
purported to be owned by the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.12.&nbsp;<U>Environmental
Matters</U>. Except as set forth on <U>Schedule&nbsp;3.12</U> or as would not reasonably be expected to cause a Material Adverse Effect
to the Company, taken as a whole, (a)&nbsp;the Company is in compliance with all applicable Environmental Laws, (b)&nbsp;the Company
has all Permits required under applicable Environmental Laws and is in compliance with the respective requirements of such Permits, (c)&nbsp;there
is not now pending or, to the Company&rsquo;s Knowledge, threatened, any Action against the Company in connection with any past or present
noncompliance with such Environmental Laws and (d) to the Company&rsquo;s Knowledge, there have been no releases of Hazardous Substances
on or from any real property currently leased or operated by the Company or, to the Company&rsquo;s Knowledge, on or from any real property
formerly owned, leased or operated by the Company, for which release the Company reasonably could be expected to incur liability under
applicable Environmental Laws. Notwithstanding any other provisions in this Agreement, the representations and warranties included in
this <U>Section&nbsp;3.12</U> are the only representations and warranties made by the Company with respect to environmental matters,
including any and all matters with respect to Environmental Laws and Hazardous Substances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.13.&nbsp;<U>Material
Contracts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.13.1.&nbsp;<U>Schedule&nbsp;3.13.1
</U>sets forth a list of all material Contracts to which the Company is a party or by which it is bound (&ldquo;<U>Material Contracts</U>&rdquo;)
as of the date hereof, including without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;any
Contract which requires future expenditures by the Company in excess of $50,000 or which might result in payments to the Company in excess
of $50,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;any
distributor, sales representative or similar Contract that requires future expenditures by the Company in excess of $25,000 or that reasonably
would be expected to result in payments to the Company in excess of $25,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;any
Contract with any current or former stockholder, officer or director of the Company, or any &ldquo;<U>Affiliate</U>&rdquo; or &ldquo;<U>associate</U>&rdquo;
of such persons (as such terms are defined in the rules and regulations promulgated under the Securities Act), including without limitation
any Contract or other arrangement providing for the furnishing of services by, rental of real or personal property from, or otherwise
requiring payments to, any such person or entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;any
Contract for the disposition of any portion of the Company&rsquo;s assets (other than for the sale of Customer Deliverables in the ordinary
course of business);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;all
Contracts (other than purchase orders entered into in the ordinary course of business) for the purchase of inventory, raw materials,
supplies, goods, products or equipment, in each case which provides for aggregate payments to or by the Company in excess of $50,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;all
Contracts relating to equipment providing for aggregate rental payments in excess of $50,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&nbsp;all
Contracts or binding options to sell or lease (as lessor) any property or asset of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)&nbsp;any
Contract in accordance with which the Company is a lessor or lessee of any real property (the &ldquo;<U>Leases</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;all
Contracts (including Contracts with customers) that require individual or aggregate payments to the Company of more than $25,000 in any
calendar year for Customer Deliverables;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)&nbsp;all
Contracts between the Company and any of its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)&nbsp;all
Contracts pursuant to which the Company has an existing obligation to pay any amounts in respect of indemnification obligations, purchase
price adjustment, or otherwise, in connection with any merger, consolidation or other business combination or any acquisition or disposition
of a business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)&nbsp;any
commission, sales or agency Contract with any current Worker;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)&nbsp;any
Contract relating to Indebtedness, whether incurred, assumed, guaranteed or secured by any asset, and any guaranty of any obligation
for Indebtedness or other material guaranty;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)&nbsp;all
partnership, joint marketing, joint development or joint venture Contract to which the Company is a party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(o)&nbsp;any
Contract for the acquisition of the business or securities or other ownership interests of another party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(p)&nbsp;any
Contract under which the Company or any of its Subsidiaries is restricted from carrying on any business anywhere in the world or that
would, upon consummation of the Contemplated Transactions, restrict Buyer or any of its Affiliates from competing with any third party
or from engaging in any line of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(q)&nbsp;any
indemnification or other similar Contract pursuant to which the Company or any of its Subsidiaries is obligated to indemnify or advance
expenses on behalf of any current or former director, manager or officer of the Company in connection with any loss based on the fact
that such Person is or was a director, manager or officer of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(r)&nbsp;
any warranty or maintenance contract under which the Company or any of its Subsidiaries is obligated to provide services at a price fixed
before performance of such services, for which the fully burdened cost of complete performance by the Company or such Subsidiary currently
exceeds or is reasonably expected by the Company to exceed such price;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(s)&nbsp;any
hedging, futures, options or other derivative contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(t)&nbsp;any
agreement with any supplier of software, technology, hardware, components or services related to any Customer Deliverables or Internal
Systems;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(u)&nbsp;other
than leases of real property, any Contract that grants any third party a right of first refusal, first offer or similar right as to real
property owned by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)&nbsp;any
Contract that contains any &ldquo;most-favored nation&rdquo; or other exclusive rights of any type or scope in any line or lines of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(w)&nbsp;any
Contract pursuant to which any Person has licensed any Intellectual Property to the Company or any of its Subsidiaries, excluding any
off-the-shelf commercially available software licenses, or pursuant to which any Person or granted to the Company or any of its Subsidiaries
any covenant not to sue or right with respect to such Intellectual Property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(x)&nbsp;any
Contract pursuant to which Intellectual Property owned or purported to be owned by the Company is licensed by the Company or any of its
Subsidiaries to any Person or pursuant to which the Company or any of its Subsidiaries grants to any Person any covenant not to sue or
right with respect to any such Intellectual Property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(y)&nbsp;any
Contract pursuant to which Intellectual Property developed in connection with such agreement is jointly owned by Company and any third
party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(z)&nbsp;any
Contract under which the Company&rsquo;s or any of its Subsidiaries&rsquo; entrance into this Agreement or the consummation of the Contemplated
Transactions would give rise to, or trigger the application of, any rights of any third party or any obligations of the Company or any
of its Subsidiaries that would come into effect upon the consummation of the Contemplated Transactions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(aa)
any Contract that results in any person holding a power of attorney from the Company or any of its Subsidiaries; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(bb)
any Contract with any investment banker, broker, advisor or similar party, or any accountant, legal counsel or other party retained by
the Company or any of its Subsidiaries, in connection with this Agreement or the Contemplated Transactions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.13.2.&nbsp;The
Company has made available to the Buyer an accurate and complete copy of each Material Contract. All of such Contracts are valid, binding
against the Company or one of its Subsidiaries, as applicable, and in full force and effect. Except as set forth on <U>Schedule&nbsp;3.13.2
</U>hereto, (a)&nbsp;the Company and its Subsidiaries are not, and, to the Company&rsquo;s Knowledge, no other party is in material default
under, or in material breach or violation of, any Material Contract, and (b)&nbsp;to the Company&rsquo;s Knowledge no event has occurred
on or prior to the date hereof (with or without notice, lapse of time or both) that would constitute a material default by the Company
or any of its Subsidiaries under any Material Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.14.&nbsp;<U>Government
Contracts</U>. The Company and its Subsidiaries have no Government Contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.15.&nbsp;<U>Transactions
with Affiliates</U>. Except as set forth on <U>Schedule&nbsp;3.15</U>, no Affiliate, officer, manager or director (or the equivalent)
of the Company or any of its Subsidiaries (nor any immediate family member of such Persons or any trust, partnership or company in which
any of such Persons has or has had an interest) has or has had, directly or indirectly, other than with respect to the payment of compensation
to officers, managers and directors (or the equivalent) in the ordinary course of business, (a)&nbsp;any interest in any third party
which furnished or sold, or furnishes or sells, services, products or technology that the Company or any of its Subsidiaries furnishes
or sells, or proposes to furnish or sell, (b)&nbsp;any interest in any third party that purchases from or sells or furnishes to the Company
or any of its Subsidiaries any goods or services or (c)&nbsp;any interest in any contract to which the Company or any of its Subsidiaries
is a party, except that ownership of no more than one percent of the outstanding voting stock of a publicly traded company shall not
be deemed to be an &ldquo;<U>interest in any third party</U>&rdquo; for purposes of this <U>Section 3.15</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.16.&nbsp;<U>Litigation</U>.
Except as set forth on <U>Schedule&nbsp;3.16</U>, there is no Action pending or, to the Company&rsquo;s Knowledge, threatened against
the Company or any of its Subsidiaries, or any of their respective assets or property, including any Company Intellectual Property, or
any of their respective officers, managers or directors in their capacities as such. No Governmental Order (other than Governmental Orders
of general applicability) is outstanding against the Company or any of its Subsidiaries, any of their respective assets or properties,
or any of the Company&rsquo;s or its Subsidiaries&rsquo; officers, managers or directors in their respective capacities as such. The
Company has not received written notice of any Action pending, and to the Company&rsquo;s Knowledge, there is no Action pending or threatened
against any officer or director of the Company who has a contractual right or a right pursuant to the Organizational Documents or other
Legal Requirement to indemnification from the Company related to any Basis existing prior to the Closing Date. There is no Action pending
or, to the Company&rsquo;s Knowledge, threatened based on a claim of breach of fiduciary duty by the Company&rsquo;s directors or officers
arising out of actions taken by the Company&rsquo;s managers, directors or officers prior to the Closing Date. There is no Action by
the Company or any of its Subsidiaries pending, threatened or contemplated against any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.17.&nbsp;<U>Insurance</U>.
<U>Schedule&nbsp;3.17</U> sets forth a true, complete and correct list of all policies and indemnity bonds maintained by the Company
and its Subsidiaries for their benefit and includes the types of policies, insurers, forms of coverage, policy numbers, coverage dates,
annual premiums, and limits of liability as of the date hereof. True and complete copies of each listed policy have been made available
to the Buyer. All such policies are in full force and effect and shall remain in full force and effect. There is no material claim, notice
of circumstance, refusal of any coverage, limitation in coverage or rejection of any material claim, insurance carrier litigation or
dispute pending in connection with any of such policies or bonds. To the Company&rsquo;s Knowledge, there is no threatened termination
or invalidation of, or material premium increase with respect to, any of such policies or bonds. <U>Schedule&nbsp;3.17</U> sets forth
an accurate and complete list of all open claims filed by the Company or any of its Subsidiaries under any such policies or bonds. Neither
the Company nor any of its Subsidiaries is in default with respect to its obligations under any such insurance policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.18.&nbsp;<U>Labor
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.18.1.&nbsp;Neither
the Company nor any of its Subsidiaries has experienced any strike, walkout, lockout, work stoppage, or similar labor dispute, and, to
the Company&rsquo;s Knowledge, no such activities have been threatened, (b) to the Company&rsquo;s Knowledge, neither the Company nor
any of its Subsidiaries is subject to any labor grievance or any unfair labor practice charge or complaint, and no such grievance, charge
or complaint has been filed against the Company or any of its Subsidiaries, (c) to the Company&rsquo;s Knowledge, no union organizing
activities are underway or threatened with respect to Workers and no such activities have occurred, and (d) no collective bargaining
agreements are in effect with respect to Workers or are currently being negotiated by the Company or its Subsidiaries. Neither the Company
nor any of its Subsidiaries is a party to any collective bargaining agreement or any other labor-related agreement with any labor union,
labor organization, or works council. As of the date of this Agreement, (i) no such agreement is presently being negotiated, (ii) no
labor union, labor organization, or works council has made a pending demand for recognition or certification, and (iii) to the Company&rsquo;s
Knowledge, there are no representation or certification proceedings or petitions seeking a representation proceeding presently pending
or threatened in writing to be brought or filed with the National Labor Relations Board or any other labor relations tribunal or authority.
Neither the Company nor any of its Subsidiaries has any material duty to bargain with any labor organization or works council. To the
Company&rsquo;s Knowledge, there is no labor dispute, strike or work stoppage against the Company or any of its Subsidiaries pending
now, that has occurred in the past, or is now threatened that would reasonably be expected to interfere with the business activities
of the Company or any of its Subsidiaries. Except as set forth in <U>Schedule 3.18.1</U>, to the Company&rsquo;s Knowledge, the Company
and its Subsidiaries are, and at all times have been, in compliance in all material respects with all Legal Requirements governing the
employment of labor, including Legal Requirements relating to employment practices, wages, compensation, benefits, the payment of social
security and other state and federal Taxes, hours, classification of employees and independent contractors, affirmative action, collective
bargaining, discrimination, harassment, retaliation, civil rights, terms and conditions of employment, immigration, safety and health,
workers&rsquo; compensation, plant closings, and termination of service (&ldquo;<U>Employment Practices</U>&rdquo;), including the Age
Discrimination in Employment Act, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, ERISA, the Fair Labor Standards
Act (29 U.S.C. 201, et seq.), the Americans with Disabilities Act, the Occupational Safety and Health Act, the Family Medical and Leave
Act (29 U.S.C. 2601, et seq.), the National Labor Relations Act of 1935, The Worker Adjustment and Retraining Notification Act (29 U.S.C.
&sect; 2101), Executive Order 11246 and any other executive orders or regulations governing affirmative action, EEO and VETS-100 reporting
obligations, and the Immigration Nationality Act (8 U.S.C. 1324a, et seq.) and other applicable Legal Requirements of the jurisdictions
in which the Company or any of its Subsidiaries is qualified or do business. To the Company&rsquo;s Knowledge, all current employees
of the Company and its Subsidiaries who work in the United States are, and all former employees of the Company or any of its Subsidiaries
who worked in the United States whose employment terminated, voluntarily or involuntarily, were, legally authorized to work in the United
States. To the Company&rsquo;s Knowledge, the Company has completed and retained the necessary employment verification paperwork under
the Immigration Reform and Control Act of 1986 (&ldquo;<U>IRCA</U>&rdquo;) for the employees hired prior to the Closing Date. To the
Company&rsquo;s Knowledge, the Company is and has been in material compliance with both the employment verification provisions (including
the paperwork and documentation requirements) and the anti-discrimination provisions of IRCA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.18.2.&nbsp;Neither
the Company nor any of its Subsidiaries has any accrued but unpaid Liabilities relating to current or former Workers other than for compensation
or other employee benefits that has accrued since the last payroll pay date. To the Company&rsquo;s Knowledge, there are no material
claims, disputes, grievances, audits or controversies pending against the Company or any of its Subsidiaries or threatened or reasonably
anticipated against the Company or any of its Subsidiaries involving any Worker. Neither the Company nor any of its Subsidiaries is a
party to a conciliation agreement, consent decree or other agreement or order with any foreign, federal, state or local agency of any
Governmental Authority with respect to any Employment Practices. To the Company&rsquo;s Knowledge, there are no charges, Actions or formal
complaints relating to any Employment Practices threatened or pending before the Equal Employment Opportunity Commission, the National
Labor Relations Board, the U.S. Department of Labor, the U.S. Occupational Health and Safety Administration, the Workers&rsquo; Compensation
Appeals Board, or any other Governmental Entity against the Company or any of its Subsidiaries pertaining to any Worker. No current or
former Worker has filed a complaint or claim with the Company or any of its Subsidiaries with respect to Employment Practices. To the
Company&rsquo;s Knowledge, no current or former Worker has been involved in an accident in the course of his or her service with the
Company or any of its Subsidiaries that would have caused other than minor injury, nor has any such Person been exposed to material occupational
health hazards in the service of the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.18.3.&nbsp;<U>Schedule
3.18.3</U> sets forth a true, correct and complete list of the names (or, if required under privacy Legal Requirements, employee identification
number), of all Workers, showing each such Worker&rsquo;s current (i) position, (ii) status as full-time or part-time, (iii) if an employee,
his or her status as exempt or non-exempt (to the extent applicable under Legal Requirements), (iv) date of commencement of service,
(v) rate of cash compensation, (vi) any other unvested bonuses, (vii) material fringe benefits, (viii) primary work location and the
status of any required visa or work permit, (ix) accrued but unpaid vacation, sick leave or other paid time off, (x) accrued but unpaid
bonuses, (xi) severance or termination payment rights payable in excess of that required by applicable Legal Requirements, (xii) whether
such Worker is on a leave of absence or given written notice of the need for a leave of absence, (xiii) whether such person is on a performance
improvement plan, (xiv) employer and (xv) Worker classification as exempt or non-exempt. <FONT STYLE="font-size: 10pt">&lrm;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.18.4.&nbsp;To
the Company&rsquo;s Knowledge, no Worker is in violation of any employment contract, non-disclosure, confidentiality agreement, or consulting
agreement with the Company or any of its Subsidiaries. To the Company&rsquo;s Knowledge, no Worker is in violation of any non-competition
agreement, non-solicitation agreement or restrictive covenant with a former employer or service recipient relating to the right of any
such Worker to be employed by or provide services to the Company or any of its Subsidiaries because of the nature of the business conducted
or presently proposed to be conducted by it or to the use of trade secrets or proprietary information of others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.18.5.&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT><U>Schedule
3.18.5 </U>lists all employee manuals and handbooks, policy statements and agreements relating any Workers as of the date of this Agreement,
and the Company has delivered to Buyer accurate and complete copies of the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.19.&nbsp;<U>Brokers</U>.
There are no brokerage commissions, finders&rsquo; fees or similar compensation payable in connection with the Contemplated Transactions
based on any arrangement or agreement made by or on behalf of the Sellers or the Company other than fees (if any) that will (a)&nbsp;be
paid as contemplated by <U>Section&nbsp;2.4.1(c)</U> or (b)&nbsp;otherwise be paid by the Sellers and their respective Affiliates and
for which the Buyer and (after the Closing) the Company will have no responsibility to pay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.20.&nbsp;<U>Customers
and Suppliers</U>. <U>Schedule&nbsp;3.20</U> sets forth a list of the ten (10) largest customers of the Company (measured by aggregate
revenue) and five (5) largest suppliers of the Company (measured by aggregate payments) for the twelve (12) month period ending on the
Reference Balance Sheet Date. Since the Reference Balance Sheet Date, no customer or supplier listed on <U>Schedule&nbsp;3.20</U> has
provided written notice that it intends to cease doing business with or materially decrease the amount of business done with the Company
or materially alter the terms upon which it is willing to do business with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.21.&nbsp;<U>Regulatory
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.21.1.&nbsp;The
studies, tests, preclinical development and clinical trials, if any, conducted by or on behalf of the Company are being conducted in
all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional and scientific
standards for products or product candidates comparable to those being developed by the Company and all applicable laws and regulations,
including the Federal Food, Drug, and Cosmetic Act. The Company has not received any notices or correspondence from the U.S. Food and
Drug Administration (&ldquo;<U>FDA</U>&rdquo;) or any other governmental entity or any institutional review board or comparable authority
requiring the termination, suspension or material modification of any studies, tests, preclinical development or clinical trials conducted
by or on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.21.2.&nbsp;The
Company possesses all permits, licenses, registrations, certificates, authorizations, orders and approvals from the appropriate federal,
state or foreign regulatory authorities necessary to conduct its business as now conducted, including all such permits, licenses, registrations,
certificates, authorizations, orders and approvals required by the FDA. The Company has not received any notice of proceedings relating
to the suspension, modification, revocation or cancellation of any such permit, license, registration, certificate, authorization, order
or approval. Neither the Company nor, to the Company&rsquo;s Knowledge, any officer, employee or agent of the Company has been convicted
of any crime or engaged in any conduct that has previously caused or would reasonably be expected to result in (A) disqualification or
debarment by the FDA under 21 U.S.C. Sections 335(a) or (b), or any similar law, rule or regulation of any other governmental entities,
(B) debarment, suspension, or exclusion under any federal healthcare programs or by the General Services Administration, or (C) exclusion
under 42 U.S.C. Section 1320a-7 or any similar law, rule or regulation of any governmental entities. Neither the Company nor any of its
officers, employees, or, to the Company&rsquo;s Knowledge, any of its contractors or agents is the subject of any pending or threatened
investigation by FDA pursuant to its &ldquo;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&rdquo; policy
as stated at 56 Fed. Reg. 46191 (September&nbsp;10, 1991) (the &ldquo;<U>FDA Application Integrity Policy</U>&rdquo;) and any amendments
thereto, or by any other similar governmental entity pursuant to any similar policy. Neither the Company nor any of its officers, employees,
contractors, and agents has committed any act, made any statement or failed to make any statement that would reasonably be expected to
provide a basis for FDA to invoke the FDA Application Integrity Policy or for any similar governmental entity to invoke a similar policy.
Neither the Company nor any of its officers, employees, or to the Company&rsquo;s Knowledge, any of its contractors or agents has made
any materially false statements on, or material omissions from, any notifications, applications, approvals, reports and other submissions
to FDA or any similar governmental entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.21.3.&nbsp;The
Company is and has been in compliance with all applicable laws administered or issued by the FDA or any similar governmental entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.21.4.&nbsp;The
Company has not classified the items that it produces, designs, tests, manufactures, fabricates, or develops for purposes of U.S. export
controls (including hardware, software, technology). The Company does not produce, design, test, manufacture, fabricate, or develop any
items that are controlled for export under the Export Administration Regulations, 15 CFR Parts 730-744. The Company does not produce,
design, test, manufacture, fabricate, or develop any defense articles, technical data, or services subject to the International Traffic
in Arms Regulations, 22 CFR Parts 120-130 (&ldquo;<U>ITAR</U>&rdquo;). The Company is not registered under the ITAR with the U.S. Department
of State&rsquo;s Directorate of Defense Trade Controls. The Company does not have a facility clearance to do classified work for the
U.S. Government. The Company does not maintain or collect any &ldquo;sensitive personal data&rdquo; as that term is used within the context
of 31 CFR &sect; 800.248.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.22.&nbsp;<U>Minutes</U>.
The minutes of the meetings of the board of directors or managers and any committee thereof of the Company and the Company&rsquo;s Subsidiaries,
to the extent such minutes of meetings were memorialized, have been made available to the Buyer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.23.&nbsp;<U>Data
Privacy</U>. In connection with its collection, storage, use and/or disclosure of any information that constitutes &ldquo;personal information,&rdquo;
&ldquo;personal data&rdquo; or &ldquo;personally identifiable information&rdquo; as defined in applicable laws (collectively &ldquo;<U>Personal
Information</U>&rdquo;) by or on behalf of the Company, the Company is and has been, to the Company&rsquo;s Knowledge, in compliance
in all material respects with (i) all applicable laws (including, without limitation, the Health Insurance Portability and Accountability
Act of 1996, as amended, and laws relating to privacy, data security, telephone and text message communications, and marketing by email
or other channels) in all relevant jurisdictions, (ii) the Company&rsquo;s privacy policies, by which the Company is bound; and (iii)
any contractual obligations with its customers. The Company maintains and has maintained reasonable physical, technical, and administrative
security measures and policies designed to protect all Personal Information owned, stored, used, maintained or controlled by or on behalf
of the Company from and against unlawful, accidental or unauthorized access, destruction, loss, use, modification and/or disclosure.
The Company is and has been, to the Company&rsquo;s Knowledge, in compliance in all material respects with all laws relating to data
loss, theft and breach of security notification obligations. To the Company&rsquo;s Knowledge, there has been no (i) loss, damage, or
unauthorized access, use, transmission, modification, or other misuse of any such information by the Company or any of its Subsidiaries
or any of its Workers; or (ii) unauthorized access to any databases, computers, storage media (e.g., backup tapes), network devices,
or other devices that process or store personal information, whether hosted or operated by the Company or any of its Subsidiaries or
any other Person on the Company&rsquo;s or its Subsidiaries&rsquo; behalf. The Company has received no written notice that any Person
(including any Governmental Authority) has made any claim or commenced any Action, and to the Company&rsquo;s Knowledge no person has
made any claim or commenced any Action, against the Company with respect to any alleged loss, damage, or unauthorized access, use, modification,
or other misuse of any such personal information by the Company or its Subsidiaries or any Worker.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.24.&nbsp;<U>No
Other Representations or Warranties</U>. Except for the representations and warranties expressly set forth in this Agreement (including
the related portions of the Disclosure Schedules), none of the Company, Yuz, or any other Seller makes any representation or warranty
of any kind whatsoever, express or implied, to Buyer, and each of the Company, Yuz, and each other Seller hereby disclaims any such representation
or warranty, and notwithstanding the delivery or disclosures to Buyer, or any of its representatives or Affiliates of any documentation
or other information with respect to any one or more of the foregoing. None of the Company, Yuz, or any other Seller makes any representation
or warranty with respect to any projections, forecasts or other estimates, plans or budgets of future revenues, expenses or expenditures,
future results of operations (or any component thereof), future cash flows (or any component thereof) or future financial condition (or
any component thereof) of the Company or of the future business, operations or affairs of the Company, notwithstanding the delivery or
disclosures to Buyer, or any of its representatives or Affiliates of any documentation or other information with respect to any one or
more of the foregoing.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.&nbsp;Representations
and Warranties of the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as provided in the Disclosure Schedules (subject to <U>Section &lrm;11.15</U>), each Seller, severally and not jointly, and solely in
respect of such Seller and not in respect of any other Seller, represents and warrants to the Buyer as of the date hereof and the Closing
Date as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1.&nbsp;<U>Organization,
Power and Standing</U>. Such Seller, if a legal entity, is duly organized, validly existing and in good standing under the laws of the
state or country of its formation. Such Seller (or its trustee or trustees have) has the power and authority to execute and deliver this
Agreement, to perform its obligations hereunder and to consummate the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.2.&nbsp;<U>Authorization;
Enforceability</U>. If such Seller is not a natural person or a trust, the execution, delivery and performance by such Seller of this
Agreement and any agreement related to the Contemplated Transactions to which such Seller is a party have been duly authorized by all
requisite corporate or comparable organizational action on the part of such Seller, and no other proceedings or actions on the part of
such Seller are necessary to authorize the execution, delivery and performance by such Seller of this Agreement, any other agreement
to which such Seller is a party related to the Contemplated Transactions, and the consummation of the Contemplated Transactions. If such
Seller is a trust, (a) such Seller is a trust duly created under the Legal Requirements of the jurisdiction of its formation and is being
validly administered under all applicable Legal Requirements and (b) the trustee or trustees of such Seller are validly appointed as
the trustee, trustees, successor trustee or successor trustees of such Seller and each of them is validly qualified and competent to
act in capacity and is lawfully so acting. This Agreement and any other agreement to which such Seller is a party related to the Contemplated
Transactions, which have been duly executed and delivered by such Seller, and, assuming due authorization, execution and delivery by
the other parties hereto and thereto, represent the legal, valid and binding obligation of such Seller, enforceable against such Seller
in accordance with their respective terms, subject to the effect of (x) applicable bankruptcy, insolvency, reorganization, moratorium
and other similar Legal Requirement now and hereafter in effect relating to the rights of creditors generally and (y) rules of law and
equity governing specific performance, injunctive relief and other equitable remedies. No further authorizing action on the part of such
Seller is or will be required in connection with the consummation of the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.3.&nbsp;<U>Noncontravention</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;The
execution and delivery by such Seller of this Agreement, any other agreement that such Seller is a party related to the Contemplated
Transactions, and the performance by such Seller of its obligations hereunder and thereunder and the consummation of the Contemplated
Transactions by such Seller will not, (i) if such Seller is not a natural person, conflict with, or result in a violation of or default
under (with or without notice, lapse of time, or both), the memorandum or articles of association or incorporation, bylaws, partnership
agreement, shareholders agreement, declaration of trust or equivalent constitutional or authorizing documents of such Seller, (ii)(A)
conflict with, (B) result in a violation of or default under (with or without notice, lapse of time or both), (C) give rise to a right
of termination, cancellation, renegotiation or acceleration of any obligation or loss of any benefit under or (D) require any consent,
approval or waiver from any Person in accordance with the terms of any Contract or Permit of such Seller or pursuant to any Legal Requirement
applicable to such Seller, or (iii) result in the creation or imposition of any Lien with respect to, or otherwise have an adverse effect
upon, the Shares owned of record by such Seller or the ability of such Seller to consummate the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;No
Governmental Order, Permit or filing with or declaration or notification to, any Governmental Authority is required by or with respect
to such Seller in connection with the execution, delivery and performance of this Agreement or any agreement related to the Contemplated
Transactions by the Sellers or the consummation of the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4.&nbsp;<U>Ownership
of Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;In
respect of the Stockholders (and not the Accredited Optionholders or Warrantholders) only:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4.1.&nbsp;Such
Stockholder is the sole registered legal owner of the number of the Shares opposite such Stockholder&rsquo;s name set forth on <U>Schedule
4.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4.2.&nbsp;Except
pursuant to this Agreement, such Shares are not subject to any Liens (other than Liens pursuant to the Company&rsquo;s Organizational
Documents and applicable securities laws), and such Stockholder has not granted any rights to purchase, and has no obligation to transfer
the full legal and beneficial ownership of such Shares free from all Liens (other than Liens pursuant to the Company&rsquo;s Organizational
Documents and applicable securities laws) to Buyer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4.3.&nbsp;Such
Shares, together with any Accredited Options or Warrants set forth on <U>Schedule 4.4</U>, constitute all of the interest in the equity
of the Company owned, beneficially or of record, by such Stockholder, and except as set forth in <U>Schedule 4.4</U>, such Stockholder
has no other rights to acquire interest in the equity of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4.4.&nbsp;Upon
the Closing, Buyer will own such Shares free and clear of all Liens other than those arising hereunder (other than Liens pursuant to
the Company&rsquo;s Organizational Documents, applicable securities laws, or Liens imposed by or permitted with respect to third parties
by Buyer).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;In
respect of the Accredited Optionholders (and not the Stockholders or Warrantholders) only:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4.1.&nbsp;Such
Accredited Optionholder is the sole registered legal owner of the number of Accredited Options opposite such Accredited Optionholder&rsquo;s
name set forth on <U>Schedule&nbsp;4.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4.2.&nbsp;Such
Accredited Options, together with any Shares or Warrants set forth on <U>Schedule 4.4</U>, constitute all of the interest in the equity
of the Company owned, beneficially or of record, by such Accredited Optionholder, and except as set forth in <U>Schedule 4.4</U>, such
Accredited Optionholder has no other rights to acquire interest in the equity of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;In
respect of the Warrantholders (and not the Stockholders or Accredited Optionholders) only, such Warrantholder is the sole registered
legal owner of the number of Warrants opposite such Warrantholder&rsquo;s name set forth on <U>Schedule&nbsp;4.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.5.&nbsp;<U>Tax
and Legal Matters</U>. Such Seller acknowledges and agrees that such Seller had the opportunity to seek and was not prevented by the
Buyer, the Seller Representative or any other Seller from seeking independent legal and Tax advice before such Seller&rsquo;s execution
and delivery of this Agreement, and, if such Seller did not avail himself or itself of that opportunity before signing this Agreement,
that such Seller did so voluntarily without any undue pressure and agrees that such failure to obtain independent legal or Tax advice
will not be used by such Seller as a defense to the enforcement of such Seller&rsquo;s obligations under this Agreement. Such Seller
understands that he or it must rely solely on his or its own advisors and not on any statements or representations by the other Sellers,
the Seller Representative, the Buyer or any of their agents or attorneys, except for the representations and warranties of the Buyer
in <U>Article&nbsp;4</U>. Such Seller understands that such Seller (and not the Buyer or the Seller Representative) will be responsible
for such Seller&rsquo;s legal or Tax Liability that may arise as a result of the sale of such Seller&rsquo;s Shares hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.6.&nbsp;<U>Absence
of Litigation</U>. Such Seller is not subject to any pending or, to the knowledge of such Seller, threatened Action that would prevent
such Seller from (a)&nbsp;executing and delivering this Agreement or (b)&nbsp;performing such Seller&rsquo;s obligations pursuant to,
or observing any of the terms and provisions of, this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.7.&nbsp;<U>Stock
Consideration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;The
Stock Consideration to be acquired by the Seller will be acquired for investment for the Seller&rsquo;s own account, not as a nominee
or agent, and not with a view to the resale or distribution of any part thereof, and that the Seller has no present intention of selling,
granting any participation in, or otherwise distributing the same. Seller does not presently have any contract, undertaking, agreement
or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of
the Stock Consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;The
Seller understands that the Stock Consideration has not been, and will not be as of the Closing, registered under the Securities Act,
by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the
bona fide nature of the investment intent and the accuracy of the Seller&rsquo;s representations as expressed herein. The Seller understands
that the Stock Consideration is &ldquo;restricted securities&rdquo; under applicable U.S. federal and state securities laws and that,
pursuant to these laws, the Seller must hold the Stock Consideration indefinitely unless they are registered with the Securities and
Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available.
The Seller acknowledges that the Company has no obligation to register the Stock Consideration for resale. The Seller further acknowledges
that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not
limited to, the time and manner of sale, the holding period for the Stock Consideration, and on requirements relating to the Company
which are outside of the Seller&rsquo;s control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;Except
as provided in <U>Schedule 4.7</U>, the Seller is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;The
Seller understands that the Stock Consideration may be notated with one or all of the following legends:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;THE
SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH
A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER
THE SECURITIES ACT OF 1933.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Plus,
any legend required by the securities laws of any state to the extent such laws are applicable to the Stock Consideration represented
by the certificate, instrument, or book entry so legended.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.&nbsp;Representations
and Warranties of the Buyer and Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
of the Buyer and the Parent represents and warrants to the Sellers and the Company as of the date hereof and the Closing Date as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1.&nbsp;<U>Organization</U>.
(a)&nbsp;The Parent is a private company, duly organized and validly existing under the Laws of the State of Israel and is not a &ldquo;defaulting
company&rdquo; as defined under the ICL, (b)&nbsp;the Buyer is a corporation duly organized, validly existing and in good standing under
the laws of the jurisdiction of its organization and (c)&nbsp;each of the Buyer and the Parent is duly qualified or licensed to do business
and is in good standing in each jurisdiction where the character of the properties owned, leased or licensed by it or the nature of its
business makes such qualification, licensing or good standing necessary, except where the failure to be so qualified or licensed or in
good standing has not had, and would not reasonably be expected to materially impair or delay the Buyer&rsquo;s ability to consummate
the Contemplated Transactions. The Buyer is a wholly owned subsidiary of the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2.&nbsp;<U>Authorization</U>.
Each of Buyer and the Parent has the corporate power and authority to execute and deliver this Agreement, the Escrow Agreement and the
instruments required to be executed and delivered by it pursuant hereto, to perform its obligations hereunder, to issue the Stock Consideration,
and to consummate the Contemplated Transactions. Each of Buyer and the Parent has taken all corporate actions or proceedings required
to be taken by or on the part of the Buyer and the Parent to authorize and permit the execution and delivery by the Buyer and the Parent
of this Agreement, the Escrow Agreement and the instruments required to be executed and delivered by it pursuant hereto and the performance
by each of Buyer and the Parent of its respective obligations hereunder and the consummation by the Buyer and the Parent of the contemplated
transactions, including issuance of the Stock Consideration. This Agreement has been (or in the case of the Escrow Agreement, will be)
duly executed and delivered by each of the Buyer and the Parent, and assuming the due authorization, execution and delivery by each of
the other parties hereto or thereto, constitutes (or will constitute) the legal, valid and binding obligation of each of the Buyer and
the Parent, enforceable against the Buyer and the Parent in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3.&nbsp;<U>No
Violation or Approval; Consents</U>. Except as set forth in <U>Schedule&nbsp;3.4</U>, neither the execution and delivery of or its performance
of its obligations under this Agreement by the Buyer or the Parent nor either of their consummation of the Contemplated Transactions
will:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3.1.&nbsp;require
any consent, waiver, approval, clearance, permit, order or authorization of or from, or registration, declaration, notice or filing to
or with any Governmental Authority with respect to the Buyer or the Parent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3.2.&nbsp;not
(1) except as set forth in <U>Schedule 5.3.2</U>, result in a breach of, constitute (with or without due notice or lapse of time or both)
a default under, result in the acceleration of obligations under, create in any Person the right to accelerate, terminate, modify or
cancel, or require any notice, consent or waiver under, any contract, lease, sublease, license, sublicense, franchise, permit, indenture,
agreement or mortgage for borrowed money, instrument of indebtedness, Lien (other than Permitted Liens) or other arrangement to which
the Buyer or the Parent is a party or by which the Buyer or the Parent is bound or to which its assets are subject, or (3) result in
the imposition of any Lien (other than Permitted Liens); or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3.3.&nbsp;result
in a material breach or violation of, or material default under, the Organizational Documents of the Buyer or the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.4.&nbsp;<U>Valid
Issuance of Stock Consideration</U>. The Stock Consideration, when issued and delivered in accordance with the terms and for the consideration
set forth in this Agreement, will be validly issued, fully paid and nonassessable, not subject to preemptive rights, and free of restrictions
on transfer other than restrictions on transfer under applicable U.S. state and federal securities laws and this Agreement and pursuant
to any liens or encumbrances created by or imposed by a Seller. Assuming the accuracy of the representations of the Sellers in <U>Section
4</U> of this Agreement, the Stock Consideration will be issued in compliance with all applicable federal and state Laws and all applicable
rules of The Nasdaq Stock Market LLC (&ldquo;<U>Nasdaq</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5.&nbsp;<U>Litigation</U>.
There is no Action pending or, to the knowledge of the Buyer, threatened against the Buyer, the Parent or any of their Affiliates or
any of their properties, asserts or business, that would prevent Buyer or the Parent from (a)&nbsp;executing and delivering this Agreement,
or (b)&nbsp;performing Buyer&rsquo;s or the Parent&rsquo;s obligations pursuant to, or observing any of the terms and provisions of,
this Agreement. Neither Parent nor Buyer has received notice of and to their knowledge there is no SEC inquiry or investigation, other
governmental inquiry or investigation, or internal investigation pending or, to Parent&rsquo;s and Buyer&rsquo;s knowledge, threatened,
in each case regarding any accounting practices of the Parent or any of its Subsidiaries or any malfeasance by any officer or director
of Buyer, Parent, or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.6.&nbsp;<U>Brokers</U>.
There are no brokerage commissions, finders&rsquo; fees or similar compensation payable in connection with the Contemplated Transactions
based on any arrangement or agreement made by or on behalf of the Buyer, the Parent or any of their Affiliates other than fees (if any)
that will be paid by the Buyer, the Seller or their Affiliates and for which the Sellers and their Affiliates will have no responsibility
to pay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.7.&nbsp;<U>Capital
Structure</U>. The authorized share capital of the Parent consists of 100,000,000 ordinary shares, par value NIS 0.01 per share. As of
the date of this Agreement, 46,100,173 shares of Parent Stock were issued and outstanding (not including shares to be issued hereunder).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.8.&nbsp;<U>Listing
and Maintenance Requirements</U>. Parent Stock is registered pursuant to Section 12(b) of the Exchange Act, and the Parent has taken
no action designed to result in the termination of the registration of such Parent Stock under the Exchange Act nor has the Parent received
any notification that the SEC is contemplating terminating such registration. The Parent Stock is currently listed on The Nasdaq Global
Market and Parent is in compliance with all of the applicable rules and regulations of Nasdaq, subject to availing itself of any &ldquo;home
country&rdquo; exemption from such rules and regulations available to a &ldquo;foreign private issuer&rdquo; (as defined under the Exchange
Act and under the relevant rules and regulations of Nasdaq), except for any non-compliance that would not reasonably be expected to have,
individually or in the aggregate, a material adverse effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.9.&nbsp;<U>SEC
Reports</U>. The Parent has timely filed all reports, registration statements and other documents required to be filed by the Parent
under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) of the Exchange Act, for the two years preceding
the date hereof (or such shorter period as the Parent was required by law or regulation to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the &ldquo;<U>SEC
Reports</U>&rdquo;). As of the respective dates of their filing, all SEC Reports complied in all material respects with the applicable
requirements of all laws applicable to the Parent or to its securities, properties or business. To the Parent&rsquo;s knowledge, the
SEC Reports did not as of the time they were filed with the SEC contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they are made, not misleading. For purposes of this <U>Section 5.9</U>, &ldquo;knowledge&rdquo; means with respect to any fact, circumstance,
event or other matter in question, the actual knowledge of such fact, circumstance, event or other matter by executive management of
such entity, including its principal executive officer and the principal financial officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.10.&nbsp;<U>Investment
Intent</U>. The Buyer is acquiring the Shares for investment for its own account and not with a view to, or for sale in connection with,
any distribution of any part thereof. The Buyer acknowledges that the Shares and the sale thereof have not been registered under the
Legal Requirements of any jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.11.&nbsp;<U>Independent
Investigation</U>. Each of the Parent and the Buyer has conducted its own independent investigation, review and analysis of the business,
results of operations, prospects, condition (financial or otherwise) or assets of the Company, and acknowledges that it has been provided
access to the personnel, properties, assets, premises, books and records, and other documents and data of the Sellers and the Company
for such purpose. Without derogating from its reliance on the representations and warranties of the Company and Sellers in this Agreement,
each of the Parent and the Buyer acknowledges and agrees that: (a) in making its decision to enter into this Agreement and to consummate
the transactions contemplated hereby, each of the Parent and the Buyer has relied solely upon its own investigation and the express representations
and warranties of the Company and the Sellers set forth in Articles III and IV of this Agreement (including the related portions of the
Disclosure Schedules); and (b) none of the Sellers, the Company or any other Person has made any representation or warranty as to Sellers,
the Company or this Agreement, except as expressly set forth in Articles III and IV of this Agreement (including the related portions
of the Disclosure Schedules). Each of the Parent and the Buyer specifically disclaims that it is relying upon or had relied upon any
such other representations or warranties that may have been made by any Person, and acknowledges that the Company and the Sellers and
their respective Affiliates hereby specifically disclaim any such other representation or warranty made by any Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.12.&nbsp;<U>Taxes
and Tax Returns</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;Each
of the Parent and the Buyer has (i) filed (taking into account any applicable extensions) all income Tax Returns and other material Tax
Returns that were required to be filed on or prior to the date hereof and all such Tax Returns were correct and complete in all material
respects and (ii) paid all Taxes owed, whether or not shown on such Tax Returns, and each of their Subsidiaries has done so, except to
the extent that the failure to do so has not had, and would not reasonably be expected to have, a Material Adverse Effect on the Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;There
are no material liens for Taxes (other than Permitted Liens) on any assets of the Parent or the Buyer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;Neither
the Parent nor the Buyer is a party to any currently pending Tax audits or other administrative Tax proceedings in each case the outcome
of which could have a material adverse impact on Parent, Buyer, or their respective businesses or financial condition, or any currently
pending court proceedings or any other material dispute or claim concerning any material Tax liability of the Parent, the Buyer or any
of their Subsidiaries, in each case, for which written notice has been received. To the Parent&rsquo;s and Buyer&rsquo;s knowledge, there
are no material matters under discussion between the Parent, the Buyer or any of their Subsidiaries and any Taxing Authority.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.&nbsp;Conditions
Precedent to the Obligations of the Buyer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
obligation of the Buyer to consummate the Closing is subject to the satisfaction or waiver on or prior to the Closing Date of each of
the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1.&nbsp;<U>Representations
and Warranties</U>. (i)&nbsp;The Seller Fundamental Representations and the representations set forth in clause (b) of <U>Section 3.6
</U>shall be true and correct in all respects at and as of the date hereof and the Closing Date with the same effect as though made at
and as of such date and (ii)&nbsp;the representations and warranties of the Company and the Sellers in this Agreement and any certificate
or other writing delivered pursuant hereto other than the Seller Fundamental Representations shall be true and correct at and as of the
date hereof and the Closing Date with the same effect as though made at and as of such date, except, in the case of this clause&nbsp;(ii),
where the failure to be true and correct would not reasonably be expected to have a Material Adverse Effect (without giving effect to
&ldquo;material,&rdquo; &ldquo;in all material respects,&rdquo; &ldquo;Material Adverse Effect&rdquo; or similar phrases in the representations
and warranties that limit the representations and warranties); <U>provided</U>, <U>however</U>, that, with respect to clauses&nbsp;(i)
and (ii) above, representations and warranties that are made as of a particular date or period will be true and correct (in the manner
set forth in clauses&nbsp;(i) or (ii), as applicable) only as of such date or period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2.&nbsp;<U>Performance
of Obligations</U>. The Sellers and the Company (including its Subsidiaries) will have complied with and performed in all material respects
all covenants and agreements required by this Agreement to be complied with or performed by the Sellers or the Company (including its
Subsidiaries), respectively, at or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.3.&nbsp;<U>Compliance
Certificate</U>. The Seller Representative will have delivered to the Buyer a certificate dated as of the Closing Date, executed by an
officer of the Company and the Seller Representative, to the effect that each of the conditions specified above in <U>Sections&nbsp;6.1
and 6.2</U> has been satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4.&nbsp;<U>Injunctions</U>.
No Governmental Authority will have enacted, issued or promulgated any Legal Requirement (whether temporary, preliminary or permanent)
that remains in effect and that enjoins, makes illegal or otherwise prohibits the consummation of the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.5.&nbsp;<U>Escrow
Agreement</U>. The Buyer will have received a copy of the Escrow Agreement, duly executed and delivered by the Seller Representative
and the Escrow Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.6.&nbsp;<U>Indebtedness</U>.
The Company will have obtained, and delivered to the Buyer a copy of, pay-off letters or other similar documentation, in a form reasonably
acceptable to the Buyer, to the effect that there will be no outstanding amounts payable in respect of the Estimated Company Indebtedness
upon payment at the Closing of the amounts specified in such pay-off letters or similar documentation, which pay-off letters or similar
documentation shall include authorization of the release of all Liens upon the payment in full on the Closing Date of such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.7.&nbsp;<U>FIRPTA</U>.
The Company shall have delivered to the Buyer a statement from the Company certifying that Shares in the Company are not &ldquo;United
States real property interests&rdquo; (within the meaning of Section 897 of the Code), signed under penalties of perjury and otherwise
in form and substance as required by Treasury Regulations Sections 1.1445-2(c) and 1.897-2(h), together with the notice to the IRS required
by Treasury Regulations Section 1.897-2(h)(2), in each case a form reasonably acceptable to the Buyer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.8.&nbsp;<U>Personnel</U>.
Each of the Workers identified as &ldquo;Founders&rdquo; in <U>Schedule 6.8</U>, and all of the Workers identified as &ldquo;Key Employees&rdquo;
in <U>Schedule 6.8</U> shall have entered into new employment agreements with the Company effective as of immediately following the Closing,
which employment agreements will provide for the termination of their preexisting employment or consulting agreements with the Company
and employment term of not less than one year post-Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.9.&nbsp;<U>Secretary&rsquo;s
Certificate</U>. The Company will have delivered to the Buyer a certificate of the Secretary of the Company, dated as of the Closing
Date, (i) certifying as to and attaching (a) copies of resolutions duly adopted by the Board of Directors of the Company authorizing
the execution, delivery and performance of this Agreement and the other agreements contemplated hereby, and the consummation of the Contemplated
Transactions, including a certification that such resolutions shall not have been modified or rescinded as of the Closing Date, (b) the
certificate of formation (or equivalent other governing document) of the Company and each of its Subsidiaries certified by the Secretary
of State or similar Governmental Authority in its jurisdiction of organization, (c) the good standing of the Company and its Subsidiaries
in their respective jurisdictions of organization, including copies of good standing certificates (or equivalent documents) issued within
five (5) Business Days of the Closing Date by the Secretary of State or similar Governmental Authority in its jurisdiction of organization
and (ii) certifying as to the incumbency, names and signatures of the directors, managers, and officers (or functional equivalents) of
the Company and its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.10.&nbsp;<U>Forms
W-8/W-9</U>. The Buyer shall have received an IRS Form W-9 or an applicable version of IRS Form W-8 for each Seller, duly executed by
that Seller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.11.&nbsp;<U>Consents</U>.
All actions, approvals, consents and waivers that are listed in <U>Schedule 6.11</U> shall have been taken or obtained, as applicable,
and evidence thereof shall have been delivered by the Company to the Buyer, in each case in a form and substance reasonably acceptable
to the Buyer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.12.&nbsp;<U>Non-competition
Agreements</U>. The Non-competition Agreements shall be in effect and not have been repudiated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.13.&nbsp;<U>MDW
Asset Purchase Agreement</U>. The Asset Purchase Agreement by and among the Buyer, the Parent and MDW LLC, dated as of October 21, 2021,
shall have closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.14.&nbsp;<U>Company
Intellectual Property</U>. The Company&rsquo;s Intellectual Property shall be free from any Lien and freely transferable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.15.&nbsp;<U>PPP
Escrow Agreement</U>. The Buyer will have received a copy of the PPP Escrow Agreement, duly executed and delivered by the Company and
the PPP Escrow Agent.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.&nbsp;Conditions
Precedent to Obligations of the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
obligation of the Sellers to consummate the Closing is subject to the satisfaction or waiver on or prior to the Closing Date of each
of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.1.&nbsp;<U>Representations
and Warranties</U>. (i)&nbsp;The Buyer Fundamental Representations shall be true and correct in all respects at and as of the date hereof
and the Closing Date with the same effect as though made at and as of such date and (ii)&nbsp;the representations and warranties of the
Buyer in this Agreement and any certificate or other writing delivered pursuant hereto other than those set forth in clause&nbsp;(i)
above shall be true and correct at and as of the date hereof and the Closing Date with the same effect as though made at and as of such
date, except, in the case of this clause&nbsp;(ii), where the failure to be true and correct would not reasonably be expected to have
a material adverse effect on the Buyer&rsquo;s ability to consummate the Closing (without giving effect to materiality, material adverse
effect or similar phrases in the representations and warranties that limit such representations and warranties); <U>provided</U>, <U>however</U>,
that, with respect to clauses&nbsp;(i) and (ii) above, representations and warranties that are made as of a particular date or period
will be true and correct (in the manner set forth in clauses&nbsp;(i) or (ii), as applicable) only as of such date or period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.2.&nbsp;<U>Performance
of Obligations</U>. The Buyer will have complied with and performed in all material respects all covenants and agreements required by
this Agreement to be complied with or performed by the Buyer at or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.3.&nbsp;<U>Compliance
Certificate</U>. The Buyer will have delivered to the Sellers a certificate of the Buyer dated as of the Closing Date to the effect that
each of the conditions specified above in <U>Sections&nbsp;7.1</U> and <U>7.2</U> has been satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.4.&nbsp;<U>Injunctions</U>.
No Governmental Authority will have enacted, issued or promulgated any Legal Requirement or Governmental Order (whether temporary, preliminary
or permanent) that remains in effect and that enjoins, makes illegal or otherwise prohibits the consummation of the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.5.&nbsp;<U>Escrow
Agreement</U>. The Sellers will have received a copy of the Escrow Agreement, duly executed by the Buyer, the Parent and the Escrow Agent.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.&nbsp;Covenants
of the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1.&nbsp;<U>Access
to Premises and Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1.1.&nbsp;From
the date hereof until the Closing Date, the Company will promptly permit the Buyer and its Representatives to have reasonable access
during normal business hours to (i)&nbsp;all of the properties, books, contracts, commitments and records of the Company and any of its
Subsidiaries and (ii)&nbsp;all other information concerning the business, Intellectual Property, properties and personnel of Company
and its any of its Subsidiaries as Buyer may reasonably request. Buyer and its Representatives shall not unreasonably disrupt the personnel
and operations of the Company. Notwithstanding anything to the contrary contained in this <U>Section&nbsp;8.1</U>, the Company may withhold
any document (or portions thereof) or information (a)&nbsp;that may constitute privileged attorney-client communications or attorney
work product, or (b)&nbsp;if the provision of access to such document (or portion thereof) or information, as determined by the Company
in good faith, would reasonably be expected to conflict with applicable Legal Requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1.2.&nbsp;Subject
to Legal Requirements, until the earlier of the termination of this Agreement and the Closing Date, the Company shall promptly notify
Buyer of, and to confer from time to time as requested by Buyer, with one or more representatives of Buyer during ordinary business hours
to discuss, any material changes or developments in the operational matters of the Company and its Subsidiaries. If Buyer requests further
information or investigation of the basis of any potential violations of Legal Requirements, including Legal Requirements related to
export control and the Anti-bribery Laws, the Company shall cooperate with such request and shall make available any personnel or experts
engaged by the Company necessary to accommodate such request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1.3.&nbsp;The
Company shall (1)&nbsp;notify Buyer in writing promptly after learning of any Action by any Governmental Authority initiated by or against
the Company or any of its Subsidiaries, or known by the Company to be threatened against the Company, any of its Subsidiaries, or any
of their respective directors, officers, employees or members in their capacity as such (a &ldquo;<U>New Litigation Claim</U>&rdquo;);
(2)&nbsp;notify Buyer of ongoing material developments in any New Litigation Claim; and (3)&nbsp;consult in good faith with Buyer regarding
the conduct of the defense of any New Litigation Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1.4.&nbsp;No
information or knowledge obtained in any investigation in accordance with this <U>Section&nbsp;8.1</U> will affect, amend or supplement,
or be deemed to affect, amend or supplement, any representation or warranty contained in this Agreement, the Disclosure Schedule, the
conditions to the obligations of the parties to consummate the Contemplated Transactions or any party&rsquo;s rights hereunder (including
rights under <U>Article&nbsp;9</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.1.5.&nbsp;All
information exchanged pursuant to this <U>Section&nbsp;8.1</U> shall be subject to&nbsp;that certain confidentiality agreement by and
between Buyer and the Company, dated October 15, 2019 (the &ldquo;<U>Confidentiality Agreement</U>&rdquo;) and Buyer acknowledges and
agrees that it will abide by the terms of such Confidentiality Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2.&nbsp;<U>Conduct
of Business Prior to Closing</U>. From the date hereof until the Closing, the Company shall conduct its business in the ordinary course
consistent with past practice. Without limiting the generality of the foregoing, from the date hereof until the Closing Date, and except
as (i) expressly contemplated by this Agreement, (ii) required by Legal Requirement, or (iii) otherwise consented to in writing in advance
by Buyer (which consent shall not be unreasonably withheld, conditioned or delayed),</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2.1.&nbsp;the
Company shall, and shall cause its Subsidiaries to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;(i)
pay all of its debts and Taxes when due, except to the extent such debts or Taxes are being contested in good faith by appropriate proceedings,
and for which adequate reserves according to GAAP have been established, (ii) pay or perform its other obligations when due, and (iii)
use commercially reasonable efforts consistent with past practice to (1) preserve intact its present business organization, (2) keep
available the services of its present officers and key employees, and (3) preserve its relationships with customers, suppliers, licensors,
licensees, and others having business dealings with it; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;notify
Buyer of any change, occurrence or event not in the ordinary course of business of the Company, and of any change, occurrence or event
which, individually or in the aggregate with any other changes, occurrences and events, could reasonably be expected to have a Material
Adverse Effect or which is reasonably likely to cause any of the conditions in <U>Article 6</U> and <U>Article 7</U> not to be satisfied;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.2.2.&nbsp;the
Company shall not, and shall not permit its Subsidiaries to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;adopt
or propose any change in the Organizational Documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;merge,
combine or consolidate with any other Person or acquire any amount of assets of any other Person (except for acquisitions of supplies
in the ordinary course of business consistent with past practices), subject to <U>Section 8.4</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;except
(i) as expressly required by Legal Requirement, or (ii) to comply with any Employee Plan entered into prior to the date hereof and listed
on <U>Schedule 3.10.1</U> (to the extent complete and accurate copies of which have been heretofore made available to Buyer), (A) adopt,
enter into, terminate or amend any collective bargaining agreement or Employee Plan or any benefit or compensation arrangement that would
be an Employee Plan if it had been in existence on the date of this Agreement; (B) increase the compensation, bonus, fringe or other
benefits of, or pay any bonus of any kind or amount whatsoever to any Worker; (C) pay to any Worker any benefit or amount not required
under any Employee Plan; (D) grant or pay any equity or equity-based, change in control, severance or termination compensation or benefits
to, or increase in any manner the equity or equity-based, change in control, severance or termination compensation or benefits of, any
current or former Worker; (E) take any action to fund or in any other way secure the payment of compensation or benefits under any Employee
Plan; (F) take any action to accelerate the vesting or time of payment of any compensation or benefit under any Employee Plan; or (G)
hire any employee except in replacement of any Worker listed <U>Schedule 3.18.3</U> who is not a vice president or higher;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;settle,
release, assign, or compromise any Action, whether now pending or hereafter made or brought;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)&nbsp;commence
any Action against any Person other than in such cases where it in good faith determines that failure to commence an Action would result
in the material impairment of a valuable aspect of the Business, as long as the Company consults with Buyer before the filing of such
Action;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)&nbsp;(i)
declare, enter into, set aside, issue or pay any dividend or any distribution (in cash or in kind) to any equityholder of the Company,
(ii) directly or indirectly redeem, purchase or otherwise acquire any Share (other than repurchases of Shares from departing employees
in the ordinary course of business consistent with past practices), or (iii) enter into any subscriptions, options, warrants, puts, calls,
agreements, understandings, claims, or other commitments or rights of any type relating to the issuance, sale or transfer by the Company
of any securities of the Company, including securities which are convertible into or exchangeable for Company equity or other securities
of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)&nbsp;except
as contemplated by this Agreement or by the terms thereof, accelerate, amend or change the period of exercisability or vesting of Company
equity granted under the Employee Plans or the vesting of the securities purchased or purchasable under such options, awards or rights,
amend or change any other terms, including the exercise price or base value, of such options, awards or rights, or authorize cash payments
in exchange for any such option awards or rights or the securities purchased or purchasable under those options or rights or waive or
amend the right of repurchase applicable to any Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)&nbsp;sell,
assign, lease, license, transfer, abandon or otherwise dispose of, or mortgage, pledge or encumber any of its assets, other than pursuant
to non-exclusive licenses to Company Intellectual Property entered into in the ordinary course of business pursuant to the sale of Company
products or services;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)&nbsp;make
any loans or advances to, or any investments in or capital contributions to, any Person, or forgive or discharge in whole or in part
any outstanding loans or advances, other than advances to Workers for travel and other expenses in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)&nbsp;create,
incur, assume, or guarantee any indebtedness for borrowed money, other than borrowings that are included in Estimated Company Indebtedness
and that are pursuant to the Company&rsquo;s existing credit facilities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)&nbsp;(i)
amend or modify in any material respect in a manner adverse to the Company or any of its Subsidiaries, or assign or consent to the termination
of, any Material Contract, or (ii) except for a new contract with a customer or potential customer entered into in the ordinary course
of business, enter into any new agreement which would be considered a Material Contract if it had been entered into prior to the date
of this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)&nbsp;except
as contemplated by the Company&rsquo;s capital expenditure budget for its fiscal year ending December 31, 2021, which is attached hereto
as <U>Schedule 8.2.2(l)</U>, make any capital expenditures or commitments, capital additions or capital improvements or enter into any
capital leases;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)&nbsp;fail
to maintain insurance in at least such amounts and against at least such risks and losses as are consistent in all material respects
with the Company&rsquo;s current practices, reduce the amount or scope of any coverage provided by existing insurance policies, permit
any existing insurance policy to lapse without being replaced by a commensurate insurance policy or reduce the amount or scope of indemnity
bonds issued at the request or for the benefit of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)&nbsp;elect
or appoint any new non-employee members to the board of directors or similar governing body of the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(o)&nbsp;make
any material Tax election inconsistent with the Company&rsquo;s prior practices, change any material election in respect of Taxes, file
any amendment to a Tax Return, enter into any closing agreement in respect of Taxes, settle any claim or assessment in respect of Taxes,
or consent to any extension or waiver of the limitation period applicable to any claim or assessment in respect of Taxes;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(p)&nbsp;make
any change in accounting practices or policies from those utilized in the preparation of the Financial Statements, make any change in
its invoicing practices, write off, write down or make any determination to write off or write down any of its assets; or make any material
change in its credit or allowance practices or policies; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(q)&nbsp;agree
or commit to do any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the foregoing, the Company shall be permitted, after the date of this Agreement and prior to Closing, to (x) make all required payments
on Indebtedness and (y) utilize unrestricted cash to pay obligations of the Company in the ordinary course of business prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.3.&nbsp;<U>Confidentiality;
Announcements</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.3.1.&nbsp;The
Confidentiality Agreement shall continue in full force and effect in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.3.2.&nbsp;Each
party will not, and will make reasonable efforts to cause its Representatives not to, issue or cause the publication of any press release
or other public announcement or make any disclosure to any Person regarding (a)&nbsp;this Agreement, the Disclosure Schedule, the Contemplated
Transactions, or any discussions, memoranda, letters or agreements related to this Agreement or thereto, including any announcement to
employees, customers, suppliers or others having dealings with the Company, (b)&nbsp;the existence or terms of this Agreement or the
Contemplated Transactions; (c)&nbsp;the existence of discussions and negotiations between or among Buyer, the Company, and the Sellers,
or any of the respective Representatives of Buyer or the Company; (d)&nbsp;the consummation of the Contemplated Transactions or (e)&nbsp;information
about the business, properties, financial condition or operations of the Company, in the case of each of clauses (a)&ndash;(e) without
prior approval of Buyer, except, in the case of the Sellers, to the extent (x)&nbsp;disclosure is required by such Seller to his, her
or its Tax, financial, legal or other professional advisors or, if applicable, spouse, subject to a duty of confidentiality, for purposes
of complying with such Seller&rsquo;s Tax obligations or other reporting obligations under Legal Requirements arising out of the Contemplated
Transactions, or (y)&nbsp;disclosure is made by such Seller to his, her or its legal counsel, subject to a duty of confidentiality. No
party shall make any announcement or disclosure utilizing Siemens&rsquo;, or any of its Affiliate&rsquo;s, name, likeness, trade names,
trademarks, or service marks without the prior written consent of Siemens.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.3.3.&nbsp;After
the Closing Date, each Seller agrees and agrees to make reasonable efforts to cause its Representatives to treat any and all Proprietary
Information as confidential and not disclose or make it available to any Person unless it is or has been:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&nbsp;obtained
legally and freely from a third party without restriction as to the disclosure of such information;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)&nbsp;made
public as required by applicable Legal Requirements; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;within
the public domain or later becomes part of the public domain as a result of acts by someone other than any Seller or any Representative
of a Seller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.3.4.&nbsp;To
the extent obliged to treat Proprietary Information as confidential, each Seller and the Seller Representative shall use the same degree
of care as it uses with regard to its own proprietary information to prevent disclosure, use, or publication of the Proprietary Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.3.5.&nbsp;In
the event that a Seller or the Seller Representative or any of their respective Representatives becomes legally compelled to disclose
any Proprietary Information other than as permitted by <U>Section&nbsp;8.3.3</U>, such Seller or Seller Representative shall provide
Buyer with prompt written notice of such requirement so that Buyer may seek a protective order or other remedy or waive compliance with
<U>Section&nbsp;8.3.3</U>, and in the event that such protective order or other remedy is not obtained, or Buyer waives compliance with
<U>Section&nbsp;8.3.3</U>, furnish only that portion of such Proprietary Information that is legally required to be provided and exercise
its commercially reasonable efforts to obtain assurances that confidential treatment will be accorded such Proprietary Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.4.
<U>No Solicitation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.4.1.
From the date hereof until the earlier of the termination of this Agreement pursuant to its terms and the Closing Date, the Company and
the Sellers will not, and Sellers will use commercially reasonable efforts to cause its and their Representatives and Affiliates not
to, directly or indirectly:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
solicit, initiate, knowingly encourage, facilitate or support any inquiry, proposal or offer with respect to, or the making, announcement,
submission or completion of any Acquisition Transaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
participate or engage in any discussions or negotiations with, or furnish or disclose any non-public information relating to the Company,
or otherwise cooperate with, facilitate or assist any Person in connection with an Acquisition Transaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
approve, endorse or recommend any Acquisition Transaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
enter into any letter of intent, agreement in principle, merger agreement, acquisition agreement, option agreement or other similar agreement
relating to an Acquisition Transaction; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)
resolve, propose or agree to do any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.4.2.
Upon execution of this Agreement, the Company and each Seller will, and the Company shall use commercially reasonable efforts to cause
its and their Representatives and Affiliates to, immediately cease and cause to be terminated any existing direct or indirect discussions
with any Person (other than Buyer)&nbsp;that relate to or are in respect of an Acquisition Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.4.3.
From the date hereof until the earlier of the termination of this Agreement pursuant to its terms and the Closing Date, each Seller will,
and the Company shall use commercially reasonable efforts to cause its and their Representatives and Affiliates of the Company to, promptly
(and in no event later than 24&nbsp;hours after receipt thereof) notify Buyer orally and in writing of any proposal, offer, inquiry or
notice concerning an Acquisition Transaction or that would reasonably be expected to lead to a proposal relating to any Acquisition Transaction,
or any request for information from a Person in respect of an Acquisition Transaction or that would reasonably be expected to lead to
a proposal relating to any Acquisition Transaction (including the identity of the Person making or submitting such proposal, offer or
request, the material terms thereof and a copy of any written proposal, offer or request) that is received by the Company or any Seller,
or any representative thereof. The Sellers and the Company shall keep Buyer informed on a reasonably current basis (and, in any event,
within 24&nbsp;hours) of the status and details of any material modifications to any such proposal, offer or request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.5.
<U>Preparation for Closing</U>. Subject to the terms and conditions hereof, each of the Company, the Sellers, the Buyer and the Parent
agrees to use its reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary
or desirable under applicable Legal Requirements to consummate the Contemplated Transactions as promptly as practicable, including preparing
and filing as promptly as practicable with the applicable Governmental Authorities all documentation to effect all necessary filings,
notices, petitions, statements, registrations, submissions of information, applications and other documents necessary to consummate the
Contemplated Transactions. In furtherance (and not in limitation) of the foregoing:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.5.1.
<U>Regulatory Filings</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
Subject to the terms and conditions set forth in this Agreement, each of the parties agrees to use reasonable best efforts to take, or
cause to be taken, all actions that are necessary, proper or advisable to consummate and make effective, in the most expeditious manner
practicable, the Contemplated Transactions, including using reasonable best efforts to accomplish the following: (i)&nbsp;obtain all
required consents, approvals or waivers from third parties, including as required under any Material Contract and (ii)&nbsp;obtain all
necessary actions or nonactions, waivers, consents, approvals, orders and authorizations from Governmental Authorities, make all necessary
registrations, declarations and filings and take all reasonable best efforts to obtain an approval or waiver from, or to avoid any Action
by, any Governmental Authority, including making the Regulatory Filings (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
In connection with, and without limiting, the efforts referenced in <U>Section 8.5.1(a)</U> Buyer (and its respective Affiliates, if
applicable), on the one hand, and the Company (and the Company Subsidiaries, if applicable), on the other hand, shall promptly determine
whether any filings are required to be made with, and whether any other consents, approvals, permits or authorizations are required to
be obtained from, any Governmental Authority under any other applicable Legal Requirement in connection with the transactions contemplated
hereby, and if so, to prepare and file any such filings and to seek any such other consents, approvals, permits or authorizations (collectively,
the &ldquo;<U>Regulatory Filings</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
In connection with, and without limiting, the efforts referenced in <U>Section 8.5.1(a)</U> or the obligations of the parties under <U>Section
8.5.1(b)</U>,each of Buyer and the Company shall, to the extent permitted by applicable Legal Requirement and not prohibited by the applicable
Governmental Authority, (i)&nbsp;cooperate and coordinate with the other parties in the making of Regulatory Filings (including providing
copies, or portions thereof, of all such documents to the non-filing parties prior to filing and considering all reasonable additions,
deletions or changes suggested in connection therewith) and in connection with resolving any investigation, request or other inquiry
of any Governmental Authority with respect to any Regulatory Filing, (ii)&nbsp;supply the other parties with any information and reasonable
assistance that may be required or reasonably requested in connection with the making of any Regulatory Filing within a reasonable period,
and (iii)&nbsp;supply, within a reasonable period, any additional or supplemental information or assistance that may be required or requested
by any applicable Governmental Authority to which any such filing is made under any other applicable law, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
Buyer (and its Affiliates, if applicable), on the one hand, and the Company (and the Company Subsidiaries, if applicable), on the other
hand, shall, to the extent practicable and unless prohibited by applicable law or by the applicable Governmental Authority, promptly
inform the other parties of any material communication from any Governmental Authority regarding any of the Contemplated Transactions
in connection with any Regulatory Filings or investigations with, by or before any Governmental Authority relating to this Agreement,
including any Actions initiated by a private party. If any party or Subsidiary or other Affiliate thereof shall receive a request for
additional information or documentary material from any Governmental Authority with respect to a Regulatory Filing, then such party shall
use its reasonable best efforts to make, or cause to be made, as soon as reasonably practicable, an appropriate response in compliance
with such request. In connection with and without limiting the foregoing, to the extent reasonably practicable and unless prohibited
by applicable Legal Requirement or by the applicable Governmental Authority, the parties will (i)&nbsp;give each other reasonable advance
notice of all meetings with any Governmental Authority relating to the Contemplated Transactions, (ii)&nbsp;give each other an opportunity
to participate in each of such meetings, (iii)&nbsp;keep the other parties apprised with respect to any material communications with
any Governmental Authority regarding the Contemplated Transactions, (iv)&nbsp;cooperate in the filing of any analyses, presentations,
memoranda, briefs, arguments, opinions or other written communications explaining or defending the Contemplated Transactions, articulating
any regulatory or competitive argument or responding to requests or objections made by any Governmental Authority, (v)&nbsp;provide each
other with a reasonable advance opportunity to review and comment upon, and consider in good faith the views of the other with respect
to, all material written communications (including applications, analyses, presentations, memoranda, briefs, arguments and opinions)
with a Governmental Authority regarding the Contemplated Transactions, and (vi)&nbsp;provide each other (or counsel of each party, as
appropriate) with copies of all material written communications to or from any Governmental Authority relating to the Contemplated Transactions.
Any such disclosures, rights to participate or provisions of information by one party to the other may be made on a counsel-only basis
if allowed or required under applicable Legal Requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)
In connection with, and without limiting, the efforts referenced in <U>Section 8.5.1(a)</U> or the obligations of the parties under <U>Section
8.5.1(b)</U>, except as otherwise provided in this Agreement (including <U>Section&nbsp;8.5.1(f)</U> and <U>Section 8.5.1(g)</U>), each
of Buyer and the Company shall offer to take (and if such offer is accepted, to take or commit to take) all steps: (i)&nbsp;necessary
to obtain all consents, approvals or nonactions required to be obtained in connection with the consummation of the Contemplated Transactions;
and (ii)&nbsp;necessary to avoid or eliminate impediments under any Legal Requirement that may be asserted by any Governmental Authority
or other Person with respect to the Contemplated Transactions, in each case so as to enable the Closing to occur as promptly as practicable
following the date of this Agreement and, in any event, prior to the Expiration Date, and, if necessary, will participate in any Action
in order to defend against any Action by any Governmental Authority or private party to prevent or enjoin the consummation of the Contemplated
Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)
Notwithstanding anything to the contrary in this Agreement, none of the Company, Buyer or any of their respective Subsidiaries or Affiliates
shall be required to (and the Company may not, without the prior written consent of Buyer) become subject to, consent to, or offer or
agree to, or otherwise take any action with respect to, any requirement, condition, limitation, understanding, agreement or order to
(i)&nbsp;sell, license, assign, transfer, divest, hold separate or otherwise dispose of any assets, business or portion of business of
the Company, Buyer or any of their respective Subsidiaries or Affiliates, (ii)&nbsp;conduct, restrict, operate, invest or otherwise change
the assets, business or portion of business of the Company, Buyer, or any of their respective Subsidiaries or Affiliates in any manner,
or (iii)&nbsp; impose any restriction, requirement or limitation on the operation or control of the Business or portion of the business
of the Company, the Buyer or any of their respective Subsidiaries or Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)
Buyer shall not be required to accept any foreign ownership, Control or influence mitigation arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.5.2.
<U>Third Party Consents</U>. The Sellers and the Company will cooperate with one another (a)&nbsp;in determining whether any actions,
consents, approvals or waivers are required to be obtained from third parties to any Leases or Material Contracts, in connection with
the consummation of the Contemplated Transactions and (b)&nbsp;in taking such actions, furnishing documents and information required
in connection therewith and seeking to obtain in a timely manner any such actions, consents, approvals or waivers; provided, that (i)
nothing in this Agreement will obligate or be construed to obligate the Company or any Seller to make or cause to be made any payment
or concession to any third party in order to obtain any such action, consent, approval or waiver under any Lease or Material Contract
and (ii) the obtaining of any such action, consent, approval or waiver shall not be a condition to any party&rsquo;s obligation to consummate
the Closing, except as provided in <U>Section 6.11.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.6.
<U>Business Records</U>. The Buyer acknowledges that the Seller Representative may from time to time from and after the Closing require
access to the Records, and agrees that upon reasonable prior notice, it will, and will ensure that the Company will, during normal business
hours, provide the Seller Representative (and its Representatives) with either access to or copies of the Records. If the Company desires
to dispose of any such Records prior to the seventh (7<SUP>th</SUP>) anniversary of the Closing Date, the Company shall, prior to any
such disposition, notify the Sellers and provide to the Seller Representative (or, if applicable, its designee) and its Representative
a reasonable opportunity, at the Sellers&rsquo; expense, to make copies of or remove such Records. Notwithstanding anything to the contrary
herein, neither the Sellers nor the Seller Representative shall have access to or the right at any time to examine the Tax Returns, Tax
work papers, financial statements or books and records of Buyer or any of its Affiliates (other than the Pre-closing Tax Returns of Company
and any of its Subsidiaries, and in the case of information related to post-Closing periods, pro forma information containing only that
of, or separate Tax Returns for only, the Company and any of its Subsidiaries) in connection with any Third-Party Claim, Tax Proceeding,
similar claim or other dispute (whether among the parties or involving third parties) or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.7.
<U>Directors and Officers Indemnification and Insurance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.7.1.
The Buyer and the Company agree that all rights to indemnification, advancement of expenses and exculpation from liability for or in
connection with acts or omissions occurring at any time prior to or on the Closing Date that now exist in favor of any Person who prior
to or on the Closing Date is or was a current or former director, manager, officer or employee of the Company (or any Subsidiary thereof),
or who at the request of the Company (or any Subsidiary thereof) served prior to or on the Closing Date as a director, officer, member,
manager, employee, trustee or fiduciary of any other entity of any type (each a &ldquo;<U>D&amp;O Indemnified Person</U>&rdquo;), including
as provided in the Organizational Documents of the Company (or any Subsidiary thereof), or in any agreement between a D&amp;O Indemnified
Person and the Company (or any Subsidiary thereof) (an &ldquo;<U>Indemnity Agreement</U>&rdquo;), will survive the Closing and will continue
in full force and effect for the six (6) year period following the Closing Date. In furtherance (and not in limitation of) the foregoing,
for the six (6)-year period following the Closing Date, the Buyer will cause the Company to, and the Company will (a)&nbsp;maintain in
the Organizational Documents of the Company (any Subsidiary thereof) provisions with respect to indemnification, advancement of expenses
and exculpation from liability that in each such respect are at least as favorable to each D&amp;O Indemnified Person as those contained
in the Organizational Documents of the Company (or any Subsidiary thereof), as applicable, as in effect on the date hereof, which provisions
will not be amended, repealed or otherwise modified in any manner that would adversely affect the rights thereunder of any D&amp;O Indemnified
Person and (b)&nbsp;continue in existence each Indemnity Agreement without termination, revocation, amendment or other modification that
would adversely affect the rights thereunder of any D&amp;O Indemnified Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.7.2.
In addition to the other rights of each D&amp;O Indemnified Person provided for in this <U>Section&nbsp;8.7</U> and not in limitation
thereof, from and after the Closing, for the six (6) year period following the Closing Date, the Buyer shall, and shall cause the Company
(or each Subsidiary thereof) (each, a &ldquo;<U>D&amp;O Indemnifying Party</U>&rdquo;) to, indemnify and hold harmless (and release from
any liability to the Buyer or the Company or any Subsidiary thereof), each D&amp;O Indemnified Person against all losses, claims, damages,
liabilities, awards, orders, decrees, rulings, judgments, fines, penalties, settlement agreements, amounts paid in settlement, costs,
charges, expenses and fees (including attorneys&rsquo; and experts&rsquo; fees and expenses) based upon, arising out of, in respect of
or in connection with any threatened, pending or completed Action, based upon, arising out of, in respect of or in connection with any
actual or claimed acts or omissions occurring at any time prior to or on the Closing Date (including in respect of any actual or claimed
acts or omissions based upon, arising out of, in respect of or in connection with the negotiation or approval of this Agreement and the
consummation of the Contemplated Transactions) (each, a &ldquo;<U>D&amp;O Indemnifiable Claim</U>&rdquo;). Any D&amp;O Indemnifiable
Claim pending or asserted prior to or within the six (6) year period following the Closing Date shall continue to be covered by this
<U>Section&nbsp;8.7</U> until the later of such time that such D&amp;O Indemnifiable Claim is fully and finally disposed of with no further
exposure of a D&amp;O Indemnified Person of any kind or all settlement agreements, judgments, orders, awards, decrees or other rulings
in connection with such D&amp;O Indemnifiable Claim are fully and finally satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.7.3.
On or before the Closing Date, the Company will obtain for the Company at the Company&rsquo;s sole expense, and, for a six (6) year period
following the Closing Date, the Buyer will cause the Company to maintain in effect, with no lapse in coverage, one or more &ldquo;tail&rdquo;
or &ldquo;runoff&rdquo; directors&rsquo; and officers&rsquo; liability, and employment practices liability insurance policies covering
actual or claimed acts or omissions of any D&amp;O Indemnified Person occurring on or before the Closing Date, in each case on terms
with respect to coverage, retentions, amounts and other material terms at least as favorable to such D&amp;O Indemnified Persons as those
of such policies in effect on the date hereof (the &ldquo;<U>D&amp;O Tail Policy</U>&rdquo;). The cost of the D&amp;O Tail Policy will
be borne 50% by the Buyer, on the one hand, and 50% by the Sellers (which amount will be included among the Transaction Expenses).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.7.4.
If the Company (or any of its successors or assigns) (a)&nbsp;consolidates with or merges into any other Person and is not the continuing
or surviving corporation or entity of such consolidation or merger, or (b)&nbsp;transfers all or substantially all of its properties
and assets to any other Person (including by dissolution, liquidation, assignment for the benefit of creditors or similar action), then,
and in each such case, the Buyer will cause proper provision to be made so that such other Person fully assumes the obligations set forth
in this <U>Section&nbsp;8.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.7.5.
The provisions of this <U>Section&nbsp;8.7</U> shall survive the Closing. This <U>Section&nbsp;8.7</U> shall be for the irrevocable benefit
of, and shall be enforceable by, each D&amp;O Indemnified Person and his or her respective heirs, executors, administrators, estates,
successors and assigns, and each such Person shall be an express intended third party beneficiary of this Agreement for such purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8.
<U>Tax Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8.1.
<U>Transfer Taxes</U>. The Buyer, on one hand, and the Sellers, on the other hand, shall each bear one-half of the Liability for all
Transfer Taxes in connection with the Contemplated Transactions. The parties shall cooperate with each other in connection with the filing
of any Tax Returns relating to Transfer Taxes, including joining in the execution of any such Tax Return or other documentation where
necessary. The Buyer, on the one hand, and the Seller Representative and the Stockholders, on the other hand, shall, upon request of
the other party, use their commercially reasonable efforts to obtain any certificate or other document from any person as may be necessary
to mitigate, reduce or eliminate any Transfer Tax. Unless otherwise required by applicable law, the Seller Representative (on behalf
of the Sellers) shall be responsible for preparing and timely filing any Tax Return relating to Transfer Taxes and shall provide to the
Buyer copies of all filed Tax Returns relating to Transfer Taxes and evidence that all Transfer Taxes have been timely paid. To the extent
that the Buyer pays any portion of Transfer Taxes for which the Sellers are responsible under this <U>Section 8.8.1</U>, within three
(3) Business Days of receipt of the Buyer&rsquo;s written request and evidence of such payment, the Seller Representative (on behalf
of the Sellers) shall reimburse the Buyer for the Sellers&rsquo; allocable portion of the amount of such Transfer Taxes paid by the Buyer
on behalf of the Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8.2.
<U>Pre-Closing Tax Period Tax Returns</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
The Seller Representative shall timely prepare or cause to be timely prepared all income Tax Returns for the Company and its Subsidiaries
for Tax periods ending before the Closing Date and that are due on or after the Closing Date (each a &ldquo;<U>Pre-Closing Tax Return</U>&rdquo;).
Except as otherwise may be approved by the Buyer, all such income Tax Returns described in the previous sentence must be prepared (i)
in accordance with applicable Legal Requirements, and (ii) consistent with the past practices of the Company except as otherwise required
by applicable Legal Requirements. At least thirty (30) days prior to filing, the Seller Representative shall provide drafts of such income
Tax Returns to the Buyer for review and written comments, and the Seller Representative will consider such comments in good faith. The
Buyer shall prepare or cause to be prepared all other Tax Returns for the Company and its Subsidiaries to be filed after the Closing
Date, and, for any such Tax Returns for a Straddle Period (each such Tax Return, a &ldquo;<U>Straddle Period Tax Return</U>&rdquo;) or
that are a Pre-Closing Tax Return the Buyer shall provide drafts of such Tax Returns to the Seller Representative for review and written
comments at least thirty (30) days prior to filing, and the Buyer shall consider in good faith Seller Representative&rsquo;s reasonable
comments and proposed changes in the applicable Tax Return(s) (if in compliance with Legal Requirements and consistent with the Company&rsquo;s
past practice). Except as required by Legal Requirements, all Tax Returns described in this <U>Section 8.8.2(a)</U> shall be prepared
consistent with past practice. The Sellers shall be responsible for the full amount of Taxes shown due on any Pre-Closing Tax Return
and for the portion of the Taxes shown due on any Straddle Period Tax Return that are allocable under <U>Section 8.8.4</U> to the portion
of the Straddle Period ending on the Closing Date, except for any such Taxes included in the calculation of Working Capital. Within three
(3) Business Days of Seller Representative&rsquo;s receipt of the Buyer&rsquo;s written request, a copy of which will be delivered to
the Escrow Agent, the Escrow Agent will pay to the Buyer the amounts of Taxes for which the Sellers are responsible as described in the
proceeding sentence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
The parties agree that all losses, deductions, credits and any other Tax benefits available on account of the payment or incurrence of
the Transaction Expenses, the Transaction Bonus Payments, the payment of the Company Indebtedness, and the other transactions or payments
contemplated by this Agreement shall be reported in Pre-Closing Tax Periods to the greatest extent permitted by Legal Requirement, and
to the greatest extent required to be treated as a loss, deduction, credit or benefit on Tax Returns of an owner of the Company, shall
be reported as a loss, deduction, credit or benefit on the Sellers&rsquo; Tax Returns (rather than the Buyer&rsquo;s Tax Returns, or
the Company&rsquo;s Tax Returns for any period beginning on or after the Closing Date) to the extent permitted by Legal Requirement.
In addition, for any of the Transaction Expenses that are facilitative and might otherwise be required to be capitalized by the Company
under Treasury Regulations Section 1.263(a)-5, the parties to this Agreement agree, and agree to cause their Affiliates, to cause the
Company to make and apply, to the extent applicable, the &ldquo;safe harbor election&rdquo; described in IRS Revenue Procedure 2011-29,
2011-18 I.R.B. 746, with respect to all such expenses that are eligible for such election, unless and except as the Seller Representative
may otherwise agree.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
The Buyer shall cause the Company to join the Buyer&rsquo;s &ldquo;consolidated group&rdquo; (within the meaning of Treasury Regulations
Section 1.1502-1(h)) for purposes of U.S. federal Income Taxes and all other applicable Income Taxes effective as of the beginning of
the date following the Closing Date and, to the extent permitted by applicable Law, treat the day immediately before the Closing Date
as the last date of the taxable period for each other Tax period of the Company (the &ldquo;<U>Agreed Tax Treatment</U>&rdquo;). Each
party hereto shall file all Tax Returns consistently with the Agreed Tax Treatment and shall not take any position inconsistent therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8.3.
<U>Amended Returns; Tax Elections</U>. The Buyer shall not, and shall cause the Company and its Subsidiaries not to, (a)&nbsp;make any
amendment of any Tax Returns of the Company or any Subsidiary to the extent such Tax Return relates to any Pre-Closing Tax Period (including
any Straddle Period Tax Return) or to the extent such amendment would otherwise adversely affect any Stockholder or its direct or indirect
owners (including any indemnification liability under <U>Section 9.2</U>) without the Seller Representative&rsquo;s prior written consent
(not to be unreasonably withheld, conditioned or delayed) or (b)&nbsp;make any election that has retroactive effect to any Pre-Closing
Tax Period or that would otherwise materially increase the Tax Liability of any Stockholder or any Stockholder&rsquo;s direct or indirect
owners without such Stockholder&rsquo;s prior written consent (not to be unreasonably withheld, conditioned or delayed), in each case,
except as required by Legal Requirement; <U>provided</U>, <U>however</U>, that in all such cases above, if such amended Tax Return or
election could reasonably be expected to increase in any material respect the Tax liability of a Stockholder (including any indemnification
obligation with respect to Taxes pursuant to <U>Section 9.2</U>), it will be reasonable for the Seller Representative to withhold consent
(such consent not to be unreasonably withheld) from any such amendment or election proposed by or on behalf of the Buyer, to the extent
that the Tax Return filings of the Company or any Subsidiary, in the absence of filing such Tax Return or election, would be in accordance
with applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8.4.
<U>Straddle Periods</U>. In the case of any Straddle Period, the amount of any Taxes of the Company and its Subsidiaries not based upon
or measured by income, payroll, specific activities or events, the level of any item, gain, receipts, proceeds or profits or similar
items for the Pre-Closing Tax Period will be deemed to be the amount of such Taxes for the entire Tax period multiplied by a fraction,
the numerator of which is the number of days in the Tax period ending on the day immediately before the Closing Date and the denominator
of which is the number of days in such Straddle Period. The amount of any other Taxes for a Straddle Period that is included in the Pre-Closing
Tax Period will be determined based on an interim closing of the books as of the close of business on the day immediately before the
Closing Date (and for such purpose the taxable period of any partnership will be deemed to end as of the close of business on the day
immediately before the Closing Date); <U>provided</U>, <U>however</U>, that (i)&nbsp;any carryforward of charitable contribution deductions,
Tax credits, or other Tax attributes from a Tax Period ending before the Closing Date to a Straddle Period will be deemed to be used
fully in the portion of such Straddle Period ending on the day immediately before the Closing Date before being used in the portion of
such Straddle Period beginning on the Closing Date, (ii)&nbsp;Tax deductions related to Transaction Expenses, the Transaction Bonus Payments,
the payment of the Company Indebtedness, and the other transactions or payments contemplated by this Agreement that are allowed under
applicable Tax Law in a Straddle Period shall be allocated to the pre-Closing portion of the Straddle Period as provided in <U>Section
8.8.4</U>, and (iii)&nbsp;exemptions, allowances or deductions that are calculated on an annual basis will be allocated to the portion
of the Straddle Period ending on the day immediately before the Closing Date in the same proportion as the number of calendar days during
the Straddle Period through the day immediately before the Closing Date bears to the number of calendar days in the entire Straddle Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8.5.
<U>Tax Proceedings</U>. In the event of any audit, assessment, examination, claim or other controversy or proceeding relating to Taxes
or Tax Returns of the Company or any Subsidiary (a &ldquo;<U>Tax Proceeding</U>&rdquo;) with respect to or which includes any Pre-Closing
Tax Period, the Buyer shall inform the Seller Representative of such Tax Proceeding promptly; provided, however, that the failure or
delay by the Buyer to promptly provide notice of a Tax Proceeding will not affect the Buyer&rsquo;s right to indemnification hereunder
except to the extent the defense of such Tax Proceeding is prejudiced thereby or the delay increases the ultimate Tax (including any
interest and penalties) or other liability costs with respect to Tax Proceeding. To the extent that the Seller Representative provided
written acknowledgement of the Sellers&rsquo; Liability (to the extent attributable to the Pre-Closing Tax Period) to indemnify the Buyer
pursuant to <U>Section 9.2</U> for the Tax Liability at issue in the Tax Proceeding, the Buyer shall afford the Seller Representative
the opportunity to control, at the Sellers&rsquo; expense, the conduct of any such Tax Proceeding, with counsel or a Tax adviser of its
own choosing, and to settle or otherwise resolve such Tax Proceeding in such manner as the Seller Representative may deem appropriate;
<U>provided</U>, <U>however</U>, that the Seller Representative may not settle any such Tax Proceeding without the Buyer&rsquo;s consent
(which consent shall not be unreasonably withheld, conditioned or delayed). The Buyer shall have the right to reasonably be informed
of material developments in any such Tax Proceeding and participate in such Tax Proceeding at its own expense. In the event that the
Seller Representative does not assume control of such a Tax Proceeding, the Buyer may control the Tax Proceeding, but the Buyer may not
settle or otherwise resolve such Tax Proceeding without the Seller Representative&rsquo;s consent (which consent shall not be unreasonably
withheld).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8.6.
<U>Refunds</U>. Any refunds (or credits against Tax in lieu of a refund to which the Buyer or its Affiliates, including the Company or
its Subsidiaries, become entitled) of Taxes of the Company or its Subsidiaries attributable or relating to a Pre-Closing Tax Period,
including for a Straddle Period to the extent allocable to the portion of such Tax Period ending on the Closing Date in accordance with
<U>Section 8.8.4</U>, will be for the benefit of the Sellers. The Buyer will promptly pay over to the Sellers all Tax refunds or credits
received by the Buyer or its Affiliates (including the Company and its Subsidiaries) to which the Sellers are entitled under this <U>Section
8.8.6</U>, including all interest paid by a Taxing Authority with respect thereto, by wire transfer of immediately available funds in
accordance with wire information to be provided by the Seller Representative upon Buyer&rsquo;s request, which the Buyer shall pay within
ten (10) days after (i)&nbsp;the Buyer&rsquo;s (or its Affiliate&rsquo;s) receipt of any such refund, or (ii)&nbsp;the due date of the
Tax Return on which such credit is used or applied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8.7.
<U>Cooperation and Tax Record Retention</U>. The Buyer shall promptly furnish to the Seller Representative such information as the Seller
Representative may reasonably request with respect to Tax matters relating to the Company or any Subsidiary for any taxable period beginning
before the Closing Date, including by providing access to relevant books and records and making employees of the Buyer and the Company
and its Subsidiaries available to provide additional information and explanation of any materials provided hereunder. The Buyer and Seller
Representative shall cooperate with each other in connection with the preparation of any Tax Returns, in connection with any claim for
a refund or credit governed by <U>Section 8.8.4</U>, and in connection with any Tax Proceeding controlled by the Seller Representative
pursuant to <U>Section 8.8.5</U>. Notwithstanding anything else contained herein to the contrary, the Buyer shall retain all books and
records with respect to Tax matters pertinent to the Company and any of its Subsidiaries relating to any Pre-Closing Tax Period until
the expiration of the statute of limitations (taking into account any extensions thereof) applicable to such taxable periods, and to
abide by all record retention agreements entered into with any Taxing Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.8.8.
The parties agree that no election pursuant to Code Sections 338 or 336(e) will be made by the Buyer, the Company, or any of the Company&rsquo;s
Subsidiaries with respect to the transactions contemplated under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.9.
<U>Notification</U>. From the date hereof until the Closing Date, the Company or the Seller Representative may disclose to the Buyer
in writing (in the form of updated Disclosure Schedules) (the &ldquo;<U>Schedules Notice</U>&rdquo;) any development, fact or circumstance,
solely to the extent arising after the date hereof, causing a breach of any of the representations and warranties contained in <U>Sections&nbsp;3
</U>or <U>4</U> hereof. Such Schedules Notice shall amend and supplement the appropriate Disclosure Schedules delivered on the date hereof
and attached hereto; <U>provided</U> that (A) if the condition set forth in <U>Section&nbsp;6.1</U> would not be satisfied if the Disclosure
Schedule were not so amended and supplemented, then the Buyer will have the right to terminate this Agreement by providing written notice
of such termination to the Company, and (B) no information or Schedules Notice provided under this <U>Section 8.9</U> will, or will be
deemed to, limit or modify or otherwise affect any representation or warranty contained herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.10.
<U>Certain Employment and 401(k) Plan Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.10.1.
If requested by Buyer at least five days prior to the Closing Date, then effective no later than one Business Day prior to the Closing
Date, the Company will terminate any and all Employee Plans intended to include a cash or deferred arrangement qualifying under and described
in Code Section 401(k) (each, a &ldquo;<U>401(k) Plan</U>&rdquo;). If Buyer requests that a 401(k) Plan be terminated pursuant to the
preceding sentence, then no later than two (2) days prior to the Closing Date, the Company will provide Buyer with evidence that any
such 401(k) Plans have been terminated (effective as of no later than one (1) Business Day prior to and contingent upon the Closing Date)
pursuant to validly adopted resolutions of the Company&rsquo;s board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.10.2.
Effective from and after the Closing Date and for a period of one (1) year thereafter, with respect to employees of the Company who remain
employed by the Company (&ldquo;<U>Continuing Employees</U>&rdquo;), Buyer will cause the Company to continue to: (i) maintain base compensation
levels at least equal to the base compensation levels in place immediately prior to the Closing, (ii) provide such Continuing Employees
with eligibility for benefits that are no less favorable in the aggregate to the benefits available under current Employee Plans, (iii)
provide to such Continuing Employees health insurance coverage with deductibles and other terms, in the aggregate, no less favorable
than those being provided under the applicable Employee Plan prior to the Closing, and (iv) provide each Continuing Employee with employment
terms and conditions that are no less favorable, in the aggregate, to the terms and conditions of such employee&rsquo;s employment with
the Company prior to the Closing; provided, however, that nothing in the preceding or any other provision of this Agreement will obligate
Buyer to continue the employment of any employee after the Closing for any period of time or to continue any specific Employee Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.10.3.
Effective from and after the Closing Date, Continuing Employees will be given credit for eligibility and vesting purposes under the employee
benefit plans, programs, policies and arrangements maintained from time to time by Buyer or the Company, for such employees&rsquo; service
with the Company to the same extent and for the same purposes that such service was taken into account under a corresponding Employee
Plan as of the Closing Date; provided, however, that no such service will be credited to the extent that it would result in a duplication
of benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.10.4.
All provisions contained in this Agreement with respect to employee benefit plans or employee compensation are included for the sole
benefit of the parties hereto and do not create any right in any other Person, including any employee or former employee of the Company
or any participant or beneficiary in any Employee Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.11.
<U>Restrictive Legends and Sale Restrictions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
Sellers that receive shares of Stock Consideration shall be subject to resale restrictions according to Nasdaq rules and regulations
and applicable U.S. securities laws, and their Stock Consideration will bear restrictive legends as set forth in <U>Section 4.7(d)</U>
of this Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
Certificates evidencing the Stock Consideration shall not be required to contain legends as set forth in <U>Section 4.7(d)</U> of this
Agreement (i)&nbsp;while a registration statement, if any, covering the resale of the Stock Consideration is effective under the Securities
Act, (ii)&nbsp;following any sale of such shares pursuant to Rule&nbsp;144 under the Securities Act (&ldquo;<U>Rule 144</U>&rdquo;),
(iii) if the Stock Consideration is eligible for immediate sale under Rule 144 without any volume or manner-of-sale restrictions) or
(iv) if Sellers provide Parent with a legal opinion to the effect that such legends are not required under applicable requirements of
the Securities Act (including controlling judicial interpretations and pronouncements issued by the staff of the SEC). At such time as
Stock Consideration is eligible for immediate sale under Rule 144, Parent, at its sole expense, shall cause its counsel to issue a legal
opinion to Parent&rsquo;s transfer agent or the Sellers (if required by the Parent&rsquo;s transfer agent) to effectuate the removal
of all legends on certificates evidencing such Stock Consideration. Parent agrees that at such time as legends are no longer required
under this <U>Section 8.11(b)</U>, it will, no later than two (2) Business Days following the delivery by the Sellers to the Parent or
the Parent&rsquo;s transfer agent of a certificate representing the Stock Consideration , deliver or cause to be delivered to the Sellers
certificates representing Stock Consideration that are free from all restrictive and other legends (or, if such shares of Parent Stock
are represented in book-entry format, instruct the transfer agent to remove the restrictive legend from the applicable book entry).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
The Parent shall use commercially reasonable efforts to maintain the listing of all Parent Stock on The Nasdaq Global Market or any other
U.S. national securities exchange and automated quotation system, if any, upon which shares of Parent Stock are then listed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
Sellers shall not use any material non-public information of Buyer or the Parent which has been received in connection with this Agreement
to purchase, sell, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer, dispose of any securities
of the Parent in violation of applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.12.
<U>Further Assurances</U>. Each of the Sellers, the Buyer and the Parent, upon the request of the other from time to time after the Closing,
and at the expense of the requesting party but without further consideration, shall sign such documents and take such actions as may
be necessary or otherwise reasonably requested to effect, or make more fully effective, the consummation of the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.13.
<U>Release of Claims</U>. Upon and subject to the Closing and in consideration of the payments made to such Seller as set forth on the
Closing Statement and other good and valuable consideration, each Seller undertakes as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.13.1.
Except in respect of the Retained Claims, each Seller, on behalf of himself, herself, or itself, and his, her or its successors, assigns,
heirs, executors, legatees, administrators, beneficiaries, Representatives, and agents and any Seller Affiliates (the &ldquo;<U>Releasing
Parties</U>&rdquo;), fully, finally and irrevocably releases, acquits and forever discharges the Company, each other Stockholder, and
Buyer, each of their respective, Affiliates, successors and assigns, and the beneficiaries, heirs, executors, or Representatives, and
insurers of any of them (collectively, the &ldquo;<U>Released Parties</U>&rdquo;), along with the current and former officers and directors
of Company, from (a) any and all claims, counterclaims, suits, causes of action, damages, demands, and Liabilities (i) relating to the
allocation of the Purchase Price set forth in the Allocation Schedule, including the allocation among the Sellers of the liability for
the Purchase Price adjustment pursuant to <U>Section&nbsp;2.5.5</U>, each Seller&rsquo;s allocable share of the Escrow Amount, PPP Escrow
Amount, and Seller Representative Fund Amount, and the allocation of the Earn Out among the Sellers, all in accordance with the Allocation
Schedule; or (ii) relating to rights of first refusal or notice requirements provided in the Company&rsquo;s Organizational Documents
or other agreements governing the Company or the Sellers&rsquo; ability to engage in the sale of Shares or transactions similar to those
contemplated by this Agreement; and (b) any and all commitments, Actions, promises, agreements, controversies, debts, claims, counterclaims,
suits, causes of action, damages, demands, Liabilities, obligations, costs and expenses of every kind and nature whatsoever, whether
arising from any express, implied, oral, or written contract or agreement or otherwise, known or unknown, past, present or future, at
law or in equity, contingent or otherwise (a &ldquo;<U>Potential Claim</U>&rdquo;), that such Releasing Parties, or any of them, had,
has or may have had at any time in the past until and including the Closing, against the Released Parties, or any of them, for or by
reason of any matter, cause or thing whatsoever occurring at any time at or prior to the Closing with respect to the Company or its ownership
of securities issued by the Company (items (a) and (b) above, collectively the &ldquo;<U>Released Matters</U>&rdquo;), in all cases except
that the Released Matters do not include any Retained Claim as further described in <U>Section 8.13.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.13.2.
The Released Matters do not include, and nothing in this Agreement shall affect or be construed as a waiver or release by the Releasing
Parties of, any Potential Claim by such Releasing Parties arising from or relating to the Retained Claims. &ldquo;<U>Retained Claims</U>&rdquo;
means (a)&nbsp;fees, salary, reimbursement for expenses, bonuses, change of control payments, or other compensation or employment benefits
earned or accrued by or for the benefit of such Releasing Parties prior to the Closing in respect of services performed by such Seller
as an employee, manager or director of the Company and any of its Subsidiaries and (b)&nbsp;the payment of the consideration for the
Shares owned by such Stockholder, Accredited Options owned by such Accredited Optionholder, or Warrants owned by such Warrantholder,
as applicable and in each case pursuant to the Allocation Schedule, in each case on and subject to the terms and conditions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.13.3.
<U>No Transfer of Potential Claims</U>. Such Seller represents and warrants to the Released Parties that such Seller has made no assignment
or transfer of any of the Potential Claims for any Released Matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.13.4.
<U>Waiver of Unknown Claims</U>. With respect to any and all Potential Claims for any Released Matter, such Seller expressly waives and
relinquishes, and the other Releasing Parties shall be deemed to have expressly waived and relinquished, any and all provisions, rights
and benefits conferred by any Legal Requirement of any jurisdiction or principle of common law that provides that a general release does
not extend to claims that are unknown or unsuspected to the releasor at the time the releasor executes the release, even if knowledge
of such claims by the releasor would have materially affected his or her settlement with the debtor. Such Seller acknowledges that the
inclusion of such unknown Potential Claims herein was separately bargained for and was a key element of this <U>Section&nbsp;8.13</U>.
Such Seller acknowledges, and the other Releasing Parties shall be deemed to have acknowledged, that they may hereafter discover facts
which are different from or in addition to those that they may now know or believe to be true with respect to any and all Potential Claims
herein released and agree that all such unknown Potential Claims are nonetheless released and that this <U>Section&nbsp;8.13</U> shall
be and remain effective in all respects even if such different or additional facts are subsequently discovered. Furthermore, such Seller,
by signing this Agreement, hereby agrees to waive any and all rights of pre-emption or first refusal or other rights of or restrictions
of the Company on the transfer of any of the Shares conferred by the Organizational Documents or any Contract with respect to the transfers
of the Shares provided for in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.13.5.
<U>Covenant Not to Sue</U>. Such Seller hereby irrevocably covenants to refrain from and, if such Seller Controls any of the Releasing
Parties, to cause such Releasing Parties to refrain from, asserting any Potential Claim, or commencing, instituting or causing to be
commenced, any Action of any kind against any of the Released Parties, in any forum whatsoever (including any administrative agency),
that arises out of, relates in any way to, or is based upon, any of the Released Matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.13.6.
<U>Basis of Defense; Attorneys&rsquo; Fees</U>. This <U>Section 8.13</U> may be pleaded by the Released Parties as a full and complete
defense and may be used as the basis for an injunction against any action at law or equity instituted or maintained against them in violation
of this <U>Section 8.13</U>. In the event any Potential Claim is brought or maintained by such Seller or any Releasing Party against
the Released Parties in violation of this <U>Section 8.13 and a Released Party prevails</U>, such Seller shall be responsible for all
costs and expenses, including reasonable attorneys&rsquo; fees, incurred by the Released Parties in defending same</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.14.
<U>PPP Loan</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.14.1.
At Closing, the Company shall deposit the PPP Escrow Amount into the PPP Escrow Account in accordance with <U>Section 2.4.2(b)</U>, such
amount to be held and released in accordance with the PPP Escrow Agreement. In the event that a portion or all of the debt outstanding
under the PPP Loan is forgiven by the U.S. Small Business Administration or Wells Fargo Bank, N.A., as applicable, in accordance with
applicable Law and any portion of the PPP Escrow Amount deposited into the PPP Escrow Account pursuant to <U>Section 2.4.2(b)</U> hereof
is disbursed by the PPP Escrow Agent to the Company (following the Closing), Buyer or the Parent, the Buyer or the Parent promptly shall
pay all of such released amounts to the Sellers in accordance with the Allocation Schedule, which amounts will be payable to and among
the Stockholders and Warrantholders in accordance with the Allocation Schedule and to the Company for further distribution to and among
the Accredited Optionholders in accordance with the Allocation Schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.14.2.
Following the Closing, Buyer will reasonably cooperate with Seller Representative&rsquo;s efforts to establish an escrow account with
Wells Fargo Bank, N.A., as escrow agent, for purposes of administering the PPP Escrow Account pursuant to an escrow agreement containing
substantially similar terms as it relates to the PPP Escrow Account set forth in the PPP Escrow Agreement delivered at the Closing.&nbsp;
Upon agreeing to a mutually acceptable escrow agreement with Wells Fargo Bank, N.A., Buyer and Seller Representative will deliver a Joint
Instruction (as defined in the PPP Escrow Agreement delivered at Closing) to the Escrow Agent instructing the Escrow Agent to deliver
the PPP Escrow Account in full to Wells Fargo Bank, N.A., which will then become the PPP Escrow Agent under this Agreement and such escrow
agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.15.
<U>Stone Creek Consulting</U>. For purposes of calculating Estimated Company Indebtedness, the Company&rsquo;s $75,000 contingent liability
to Stone Creek Consulting will be treated as Estimated Company Indebtedness. Following the Closing, the Parent and Buyer will cause the
Company to pay to Stone Creek Consulting $75,000 if the applicable contingencies set forth in Letter Agreement dated July 1, 2021 are
satisfied. If within 150 days of the Closing, the contingencies are not satisfied, and the $75,000 payment does not become payable, unless
otherwise included as part of the Purchase Price Adjustment pursuant to Section 2.5, Parent and Buyer will cause the Company to pay $75,000
to the Sellers in accordance with the Allocation Schedule, which amounts will be payable to and among the Stockholders and Warrantholders
in accordance with the Allocation Schedule and to the Company for further distribution to and among the Accredited Optionholders in accordance
with the Allocation Schedule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.
Indemnification</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.1.
<U>Survival</U>. Except as set forth in this <U>Section <FONT STYLE="font-size: 10pt">&lrm; 9.1</FONT></U>, the representations and warranties
of the parties contained in this Agreement or in the certificate delivered pursuant to <U>Section 6.3</U> or <U>Section&nbsp;7.3</U>,
and the covenants and agreements of the parties hereto to the extent they, by their terms, contemplate or provide for performance prior
to the Closing, shall survive the Closing until the date that is twelve (12) months after the Closing Date (the &ldquo;<U>Escrow Termination
Date</U>&rdquo;), except that the Seller Fundamental Representations shall survive the Closing until the sixth (6<SUP>th</SUP>) anniversary
of the Closing Date and the representations and warranties in <U>Section 3.19</U> (Intellectual Property) shall survive the Closing until
the third (3<SUP>rd</SUP>) anniversary of the Closing Date. The other covenants and agreements of the parties contained in this Agreement,
or in any certificate or other writing delivered pursuant hereto or in connection herewith, shall survive the Closing in accordance with
their terms. If the Buyer delivers, before the expiration of the applicable survival period described in the first sentence of this <U>Section
9.1</U>, a Claim Notice to the Seller Representative asserting a Liability Claim for a breach of a representation or warranty or covenant
or agreement made by or on behalf of the Company or the Sellers in or pursuant to this Agreement, or if the Seller Representative delivers,
before the expiration of the applicable survival period described in the first sentence of this <U>Section 9.1</U>, a Claim Notice to
the Buyer asserting a Liability Claim for a breach of a representation or warranty or covenant or agreement made by or on behalf of Parent
or the Buyer in or pursuant to this Agreement, then the representation, warranty or covenant will survive the expiration of the applicable
survival period described in the first sentence of this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>9.1</U> and remain in full
force and effect with respect to such Liability Claim until the final resolution thereof. No Liability Claim may be made seeking indemnification
for breaches of any representations, warranties, covenants or agreements pursuant to this <U>Section&nbsp;9</U> unless a Claim Notice
in respect of such Liability Claim is provided to the applicable Indemnifying Party in accordance with this <U>Section&nbsp;9</U> prior
to the expiration of the applicable survival period described in the first sentence of this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>9.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.2.
<U>Indemnity by the Sellers</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.2.1.
From and after the Closing, subject to the provisions of this <U>Section&nbsp;9</U>, each Seller shall indemnify, severally but not jointly
pro rata in accordance with proceeds allocable to such person, as set forth in the Allocation Schedule, the Buyer and each of its Affiliates
and each of their respective Representatives, successors and assigns (collectively, the &ldquo;<U>Buyer Indemnified Parties</U>&rdquo;)
and hold them harmless from and against any and all Losses suffered or incurred by the Buyer Indemnified Parties to the extent arising
from:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
any breach of any of the representations and warranties of the Company in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
any breach, or any failure to perform, any covenant or agreement in this Agreement (or in any certificate or other writing delivered
by or on behalf of the Company pursuant hereto) that is required by its terms to be complied with or performed by the Company or any
of its Subsidiaries prior to or at the Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
any D&amp;O Indemnifiable Claims against any D&amp;O Indemnified Person, including such claims that are threatened or alleged;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
any Indemnified Taxes; <U>provided</U>, <U>however</U>, that notwithstanding anything to the contrary in this Agreement, (i)&nbsp;in
no event will the Sellers have any liability or indemnification obligation with respect to the amount, availability, or use of any Tax
assets of the Company or any of its Subsidiaries (including, but not limited to, carryovers of losses, deductions, or other Tax attributes
or the Tax basis of the Company&rsquo;s or Subsidiaries&rsquo; assets) in any taxable period beginning on or after the Closing Date that
are attributable to Pre-Closing Tax Periods; and (ii)&nbsp;the Buyer Indemnified Parties shall not be entitled to any indemnification,
and none of the Sellers will have any liability or obligation with respect to any indemnification, for or with respect to any Taxes or
other costs that might arise or accrue to the Company, any Subsidiary, or any other Person by reason of, or in connection with, any election
by or on behalf of the Company or any Subsidiary thereof pursuant to Sections 336(e) or 338 of the Code with respect to any transactions
contemplated by this Agreement; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)
any principal and unpaid interest for which the Company becomes liable under the PPP Loan Agreement that is not satisfied by the funds
deposited at the Closing into the PPP Escrow Account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.2.2.
From and after the Closing, subject to the provisions of this <U>Section <FONT STYLE="font-size: 10pt">&lrm; 9</FONT></U>, each Seller
shall indemnify, severally but not jointly, solely in respect of such Seller and not in respect of any other Seller, the Buyer Indemnified
Parties and hold them harmless from and against any and all Losses suffered or incurred by the Buyer Indemnified Parties to the extent
arising or resulting from:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
any breach of the representations and warranties of such Seller (and not in respect of any other Seller) in <U>Section <FONT STYLE="font-size: 10pt">&lrm;
4</FONT></U>; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
any breach of, or any failure to perform, any covenant or agreement of such Seller (and not any other Seller) in this Agreement (or in
any certificate or other writing delivered by or on behalf of such Seller pursuant hereto);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
Seller shall have any obligations under <U>Section 9.2.2</U> with respect to claims for Fraud unless the Seller knowingly participated
in such Fraud.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.2.3.
<U>Limitations on Indemnification by Sellers; Sources</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
Except with respect to claims for indemnification for breach of any Seller Fundamental Representation or Losses related to Fraud, the
Buyer Indemnified Parties will not be entitled to indemnification under <U>Section 9.2.1(a)</U> (i) for an individual claim unless and
until the Loss related to such individual claim is greater than $15,000; (ii) for any Loss unless and until the aggregate amount of Losses
exceeds $125,000 (the &ldquo;<U>Deductible</U>&rdquo;), at which time the Buyer Indemnified Parties will be entitled to recover any Losses
satisfying the requirements of this <U>Article 9</U>; and (iii) in excess of the Escrow Funds and Earn Out. Subject to <U>Section9.2.3(b)</U>,
the Buyer Indemnified Parties&rsquo; right under this <U>Section 9.2.3(a)</U> to recover such Losses is limited to recovery first from
the Escrow Funds and then from the Earn Out and from no other source.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
The maximum aggregate amount of indemnifiable Losses that may be recovered by the Buyer Indemnified Parties in respect of claims pursuant
to (i) <U>Section 9.2.1(a)</U> with respect to breaches of Seller Fundamental Representations only, (ii) <U>Sections 9.2.1(b)</U> - <U>9.2.1(d)<FONT STYLE="font-size: 10pt">&lrm;</FONT></U>,
inclusive, and (iii) <U>Section 9.2.2</U> shall be equal to the Purchase Price. Subject to <U>Section 9.2.3(c)</U>, the Buyer Indemnified
Parties&rsquo; right to recover Losses under this <U>Section 9.2.3(b)</U> will be from the following sources:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
With respect to Losses arising pursuant to <U>Section 9.2.1(a)</U> with respect to breaches of Seller Fundamental Representations only
and with respect to Losses arising pursuant to <U>Sections 9.2.1(b)</U> - <U>9.2.1(d)<FONT STYLE="font-size: 10pt">&lrm;</FONT></U>,
inclusive, first from the Escrow Funds, and to the extent the Escrow Funds are insufficient, second from the Earn Out, and to the extent
the Earn Out is insufficient, then directly from the Sellers severally and not jointly in accordance with their pro rata share of any
Losses in accordance with the Allocation Schedule, but only to the extent of the portion of the Purchase Price actually received by such
Seller;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)
With respect to Losses arising pursuant to <U>Section 9.2.2</U>, first from the applicable Seller&rsquo;s remaining allocable share of
the Escrow Funds, and then directly from the applicable Seller; <U>provided</U>, <U>that</U>, except in the case of Fraud in which such
Seller knowingly participated, no Seller will have any liability pursuant to <U>Section 9.2.2</U> in excess of the portion of the Purchase
Price actually received by such Seller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)
Any recovery for claims against the Earn Out pursuant to <U>Sections 9.2.3(a)</U> and <U>9.2.3(b)</U> will be made to the Buyer Indemnified
Party in a ratio of Parent Stock to cash equal to the ratio of Stock Earn Out to cash comprising the Earn Out Amount pursuant to <U>Section
2.6.2(a)</U>, (ii) any recovery of Parent Stock from the Earn Out will be valued on the basis of the Earn Out Stock Value, and (iii)
any recovery for claims against the Escrow Funds will be made in accordance with the requirements of <U>Section 9.9(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)
Except in the case of Fraud in which such Seller knowingly participated, no Seller will have any liability pursuant to <U>Section 9.2.1
</U>or <U>9.2.2</U> in excess of the portion of the Purchase Price actually received by such Seller, and no Seller will have any liability
pursuant to <U>Section 9.2.2</U> as a result of breaches by other Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.2.4.
Notwithstanding anything to the contrary contained in this Agreement (including the foregoing limitations), nothing in this Agreement
will (a) prevent any Buyer Indemnified Party from bringing any Action based upon the Fraud of any Person, or (b) limit the Losses recoverable
by such Buyer Indemnified Party in such Action, except that the maximum Losses recoverable by such Buyer Indemnified Party in respect
of Fraud by or on behalf of the Company is the Purchase Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.3.
<U>Indemnity by the Buyer and the Parent</U>. From and after the Closing, subject to the provisions of this <U>Section&nbsp;9</U>, each
of the Buyer and the Parent shall indemnify the Sellers and each of their Affiliate&rsquo;s Representatives and direct and indirect owners
and each of the respective successors and assigns of the foregoing (collectively, the &ldquo;<U>Seller Indemnified Parties</U>&rdquo;)
and hold them harmless from and against any and all Losses suffered or incurred by the Seller Indemnified Parties (a)&nbsp;to the extent
arising or resulting from any breach of (i)&nbsp;any representation, warranty, covenant or agreement of the Buyer or the Parent in this
Agreement or (ii)&nbsp;any covenant or agreement to be performed by the Company following the Closing, or (b)&nbsp;with respect to any
Transfer Taxes for which the Buyer is responsible in accordance with <U>Section&nbsp;8.8.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4.
<U>Notification of Certain Claims</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4.1.
If an Indemnified Party desires to make a Liability Claim, then the Buyer (if such Indemnified Party is a Buyer Indemnified Party) or
the Seller Representative (if such Indemnified Party is a Seller Indemnified Party), as the case may be, will deliver to the Seller Representative
or Buyer, respectively, a notice (any such notice delivered in accordance with the provisions of this <FONT STYLE="font-size: 10pt">&lrm;</FONT><U>Section
<FONT STYLE="font-size: 10pt">&lrm; 9.4.1</FONT></U>, a &ldquo;<U>Claim Notice</U>&rdquo;): (i) describing the Liability Claim in reasonable
detail (based upon the information then possessed by the Buyer or the Seller Representative, as the case may be); and (ii) indicating
the amount (estimated, if necessary and to the extent feasible) of the Loss that has been or may be paid, suffered, sustained or accrued
by the Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4.2.
No delay or failure in providing such Claim Notice will affect an Indemnified Party&rsquo;s rights or remedies or an Indemnifying Party&rsquo;s
obligations hereunder except to the extent that the Indemnifying Party is materially and adversely prejudiced thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4.3.
If the Escrow Funds are available to satisfy the recovery of the claim asserted in such Claim Notice and have not been fully released
from the Escrow Account, at the time of delivery of any Claim Notice to the Seller Representative, a duplicate copy of such Claim Notice
shall be delivered to the Escrow Agent by or on behalf of the Buyer (on behalf of itself or any other Buyer Indemnified Party).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4.4.
If the Seller Representative or the Buyer, as the case may be, in good faith objects to any claim made in any Claim Notice, then the
Seller Representative or the Buyer, as the case may be, shall deliver a written notice (a &ldquo;<U>Claim Dispute Notice</U>&rdquo;)
to the Buyer or the Seller Representative, as the case may be, during the 30-day period commencing upon receipt by the Seller Representative
or Buyer, as the case may be, of the Claim Notice. The Claim Dispute Notice will set forth in reasonable detail the principal basis for
the dispute of any claim made in the applicable Claim Notice. If the Seller Representative or the Buyer, as the case may be, does not
deliver a Claim Dispute Notice hereunder prior to the expiration of such 30-day period, then such claim for indemnification set forth
in such Claim Notice shall be deemed to have been conclusively determined in favor of the Indemnified Party that delivered the Claim
Notice for purposes of this <U>Section <FONT STYLE="font-size: 10pt">&lrm; 9</FONT></U> on the terms set forth in the Claim Notice and
the applicable Indemnified Party will be indemnified for the amount of Losses set forth in the Claim Notice pursuant to this <U>Section
<FONT STYLE="font-size: 10pt">&lrm;&lrm; 9</FONT></U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4.5.
If a Claim Dispute Notice is properly delivered hereunder, then the Buyer and the Seller Representative will attempt in good faith to
resolve any such objections raised in such Claim Dispute Notice. If the Buyer and the Seller Representative agree to a resolution of
such objection, then a memorandum setting forth the matters conclusively determined by Buyer and the Seller Representative will be prepared
and signed by both parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4.6.
If no such resolution can be reached during the 45-day period following receipt of a given Claim Dispute Notice hereunder, then upon
the expiration of such 45-day period, either the Buyer or the Seller Representative may bring suit to resolve the objection in accordance
with <FONT STYLE="font-size: 10pt">&lrm;</FONT><U>Section <FONT STYLE="font-size: 10pt">&lrm; 11.9</FONT></U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.4.7.
The Buyer is the sole and exclusive Person authorized to act for, bring Liability Claims on behalf of, or deliver a Dispute Notice on
behalf of, the Buyer Indemnified Parties under this Agreement, and the Seller Representative is the sole and exclusive Person authorized
to act for, bring Liability Claims on behalf of, or deliver a Claim Dispute Notice on behalf of, the Seller Indemnified Parties under
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.5.
<U>Calculation of Losses</U>. For purposes of determining the amount of any Losses subject to indemnification under this <U>Section&nbsp;9
</U>(except for indemnification pursuant to <U>Section 9.2.1(e)</U>), the amount of such Losses will be determined net of (a)&nbsp;any
amounts taken into account as liabilities or reserves in the calculation of the Final Working Capital Amount or any other adjustments
to the Purchase Price set forth in <U>Section&nbsp;2.5</U>, and (b)&nbsp;the sum of any amounts recovered by Buyer Indemnified Parties
under insurance policies providing covering for such Losses (the &ldquo;<U>Insurance Policies</U>&rdquo;), net of any actual out-of-pocket
expenses incurred in collecting such amounts (&ldquo;<U>Insurance Proceeds</U>&rdquo;). In the event that any Insurance Proceeds are
received after payment for the related indemnification claim has been made pursuant to this <U>Section&nbsp;9</U>, then the Indemnified
Party shall pay to the Sellers in accordance with the Allocation Schedule or the Buyer, as the case may be, an amount equal to the amount
of the reduction in Losses that would have been applied pursuant to the first sentence of this <U>Section&nbsp;9.5</U> had such Insurance
Proceeds been received at the time such indemnification claim was made. Each Indemnified Party shall use commercially reasonable efforts
to make claims under its applicable Insurance Policies. Notwithstanding anything herein to the contrary, no disputed matter that would
result in a breach of a representation, warranty, covenant or agreement herein that is the subject of a Liability Claim made pursuant
to this <U>Section&nbsp;9</U> shall be raised to support any adjustment to Purchase Price pursuant to the terms of <U>Section&nbsp;2.5
</U>in a manner that would circumvent the monetary limitations set forth in this <U>Section&nbsp;9</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.6.
<U>Matters Involving Third Parties</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.6.1.
If an Indemnified Party receives written notice of any Action that has been brought or may be brought or asserted by a third party against
such Indemnified Party and that will give rise to a Liability Claim under this Section 9 (each, a &ldquo;<U>Third-Party Claim</U>&rdquo;),
such Indemnified Party will notify the Seller Representative promptly after receipt of such notice of any such Third-Party Claim (if
a Buyer Indemnified Party is the subject of the Third-Party Claim), or notify the Buyer (if a Seller Indemnified Party is the subject
of the Third-Party Claim), in each case by the delivery of a notice regarding the Third-Party Claim, which will be deemed a Claim Notice.
The failure of an Indemnified Party to notify the Indemnifying Party of the commencement of any such Third-Party Claim will not limit
any party&rsquo;s rights or relieve any party from Liability in connection therewith, except to the extent that such failure materially
and adversely affects the ability of the Indemnifying Party to defend its interest in such Third-Party Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.6.2.
In the event of any Third-Party Claim, the Indemnifying Party, upon written notice to the Indemnified Party, will have the right in its
sole discretion to assume and control the defense of any such Third-Party Claim. In such event, the Indemnified Party will be given the
opportunity to participate at its own cost in, but not direct or conduct, any defense of such Third-Party Claim, unless such participation
would adversely affect any privilege of the Indemnifying Party in respect of such Third-Party Claim. The Indemnifying Party will not
settle any such Third-Party Claim without the consent of the Indemnified Party unless such settlement (i) provides solely for the payment
of money in an amount that is less than the remaining Escrow Funds that are not subject to any other Liability Claim, (ii) provides for
a full release of the Indemnified Parties involved in such Third-Party Claim and (iii) does not involve any admission by any Indemnified
Party of breach, violation or wrongdoing or involve any future covenants of an Indemnified Party, other than covenants of confidentiality
relating to the terms of such settlement. If requested by the Buyer, the Seller Representative will enter into a separate confidentiality
or joint defense agreement prior to participating in the defense of any Third-Party Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.6.3.
If the Indemnifying Party does not elect to control the defense of a Third-Party Claim in accordance with <FONT STYLE="font-size: 10pt">&lrm;</FONT><U>Section
9.6.2</U>, the Indemnified Party will assume control of the defense of the Third-Party Claim. The Indemnifying Party will have the right,
in its sole discretion, to settle any Third-Party Claim, but no settlement of any such Third-Party Claim with third party claimants will
be determinative of the amount of Losses relating to such matter unless the Indemnifying Party consents to such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.6.4.
The party controlling the defense of a Third-Party Claim will (i) keep the non-controlling party reasonably advised of the status of
such Third-Party Claim and the defense thereof and will consider in good faith recommendations made by the non-controlling party with
respect thereto and (ii) make available to the non-controlling party any documents or materials in its possession or control that may
be necessary to understand the defense of such claim (subject to confidentiality obligations and the protection of the attorney-client
privilege). The non-controlling party will furnish the controlling party with such information as it may have with respect to such Third-Party
Claim (including copies of any summons, complaints or other proceedings which may have been served on such party and any written claim,
demand, invoice, billing or other document evidencing or asserting the same) and will otherwise reasonably cooperate with and assist
the controlling party in the defense of such Third-Party Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.7.
<U>Materiality</U>. Solely for purposes of calculating any Losses suffered by the other Person on account of any breach of any representation,
warranty, covenant or agreement of a Person under this <U>Section 9</U>, each such representation, warranty, covenant or agreement qualified
by words or phrases such as &ldquo;material,&rdquo; &ldquo;in all material respects&rdquo; or &ldquo;Material Adverse Effect&rdquo; or
any similar term shall be read as if such qualification did not exist (except with respect to <U>Section 3.6</U> (Ordinary Course of
Business; No Material Adverse Effect) and the definition of &ldquo;Material Contracts&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.8.
<U>No Contribution</U>. None of the Sellers or the Seller Representative will have any right of contribution, right of indemnity or other
right or remedy against the Buyer or any of its Affiliates, the Company or any of its Subsidiaries, or any of their Representatives in
connection with any indemnification obligation or any other Liability to which such Person may become subject pursuant to or in connection
with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.9.
<U>Escrow</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)
Escrow Amount shall be held by the Escrow Agent in the Escrow Account until paid in accordance with <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>2.5
</U>and this <U>Section&nbsp;9</U> and the Escrow Agreement. From and after the Closing, the Escrow Amount will be available to compensate
the Buyer Indemnified Parties for Losses in accordance with this <U>Section&nbsp;9</U> and the Escrow Agreement. The Escrow Agreement
shall provide that following the Escrow Termination Date, the Escrow Agent shall pay to the Sellers, in accordance with the Allocation
Schedule, the remainder of the Escrow Funds no later than five (5) Business Days after the expiration of the Escrow Termination Date,
other than such portion of the Escrow Funds that is subject to pending but unresolved or unsatisfied Liability Claims specified in any
Claim Notice (the &ldquo;<U>Retained Amounts</U>&rdquo;). The Escrow Agreement shall provide that any Retained Amounts shall be released
to the Sellers, in accordance with the Allocation Schedule, no later than five (5) Business Days after the date of final resolution and
payment of the outstanding claim for indemnification. In the event of a conflict between the Escrow Agreement and this Agreement, the
terms of this Agreement shall govern. The fees, costs and expenses of the Escrow Agent shall be paid 50% by the Buyer and 50% by the
Sellers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)
Any portion of the Escrow Funds disbursed by the Escrow Agent to compensate the Buyer Indemnified Parties for Losses in accordance with
<U>Section&nbsp;9</U> or to be paid to the Sellers following the Escrow Termination Date in accordance with <U>Section 9.9(a)</U> shall
be made in a ratio of Parent Stock to cash equal to the ratio of the Escrow Stock Amount to the Escrow Cash Amount deposited with the
Escrow Agent at Closing. For purposes of determining the value of any distributions made pursuant to this <U>Section 9.9(b)</U>, shares
of the Parent Stock will be valued on the basis of the Closing Stock Value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.10.
<U>Tax Treatment</U>. The Buyer and the Sellers will treat any payment received pursuant to <U>Section&nbsp;2.5.5</U> and this <U>Section&nbsp;9
</U>as an adjustment to the purchase price for Tax and financial reporting purposes, except to the extent otherwise required by any Legal
Requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.11.
<U>Acknowledgement by the Buyer</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">THE
REPRESENTATIONS AND WARRANTIES BY THE COMPANY AND THE SELLERS SET FORTH IN <U>SECTIONS 3</U> AND <U>4</U> OF THIS AGREEMENT CONSTITUTE
THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND THE SELLERS, AS APPLICABLE, TO THE BUYER IN CONNECTION WITH
THIS AGREEMENT OR THE CONTEMPLATED TRANSACTIONS, WHETHER IN WRITING, ORALLY OR OTHERWISE, AND THE BUYER UNDERSTANDS, ACKNOWLEDGES AND
AGREES THAT ALL OTHER REPRESENTATIONS AND WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED (INCLUDING ANY RELATING TO THE FUTURE
OR HISTORICAL FINANCIAL CONDITION, RESULTS OF OPERATIONS, ASSETS OR LIABILITIES OF THE COMPANY OR THE ACCURACY AND COMPLETENESS OF ANY
INFORMATION SUPPLIED RELATING TO THE COMPANY), ARE SPECIFICALLY DISCLAIMED BY THE COMPANY AND THE SELLERS AND ARE NOT BEING RELIED UPON
BY THE BUYER OR ANY OF ITS REPRESENTATIVES OR AFFILIATES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.12.
Reserved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.13.
<U>Payment Process</U>. Any indemnification payment to be made by an Indemnifying Party pursuant to this <U>Section&nbsp;9</U> will be
effected by wire transfer of immediately available funds from the Indemnifying Party to the account designated by the Buyer or the Seller
Representative (on behalf of the Buyer Indemnified Parties or the Seller Indemnified Parties, respectively) within five (5) Business
Days after such Losses have been determined by (a)&nbsp;a final, non-appealable order or judgment of a court of competent jurisdiction
or (b)&nbsp;a written, executed agreement between the Buyer and the Seller Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.14.
<U>Seller Representative</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.14.1.
Subject to the requirements of <U>Section 9.14.2</U> below, by approval of this Agreement in accordance with the laws of the State of
Delaware, each Seller hereby irrevocably appoints Yuz, on an exclusive basis, as such Seller&rsquo;s true and lawful attorney-in-fact,
representative, agent and proxy, with full power of substitution or re-substitution, to act solely and exclusively, on behalf of such
Seller with respect to any and all matters relating to this Agreement and the Escrow Agreement, including (i) that the Parent Stock subject
to the Escrow Stock Amount initially may be titled in the name of the Stockholder Representative on behalf of the Sellers until released
from the Escrow Account, at which time the Parent Stock will be re-titled in the name of the Sellers in accordance with the Allocation
Schedule, (ii) to perform covenants, exercise rights and satisfy obligations of the Sellers herein, to communicate to, and receive all
communications and notices from the Buyer, (iii) to resolve with the Buyer and the Independent Referee the Closing Statement and the
calculation of any adjustment to the Purchase Price related thereto, (iv) to authorize deliveries to the Buyer Indemnified Parties of
cash or other property from the Escrow Account, or to object to related claims in accordance with the Escrow Agreement, (v) to consent
or agree to, negotiate, enter into settlements and compromises of, and comply with Governmental Orders with respect to any indemnification
claims or disputes under this Agreement, (vi) to authorize the release of the Seller Representative Fund Amount or otherwise control
the Seller Representative Fund Amount, and (vii) to do each and every act, implement any decision and exercise any and all rights which
the Sellers are permitted or required to do or exercise under this Agreement, except that (x) the Seller Representative may not receive
any funds payable hereunder on behalf of the Sellers, and if Seller Representative receives any such funds, it will promptly distribute
those funds to the applicable Sellers in accordance with the Allocation Schedule and (y) any action by on or the party of the Seller
Representative, including in respect of indemnification claims, disputes related to the release of escrow funds, or matters related to
the Earn-Out, that might impact the proceeds payable to Siemens or otherwise relates to any liability of Siemens also requires the written
consent of Siemens, which Siemens may grant or withhold in its discretion. If Yuz or any successor or replacement of his as Seller Representative
is ever unable and/or unwilling to act as a Seller Representative, the Persons holding a majority of the Shares to be sold pursuant to
this Agreement may select another representative or representatives to replace such Seller Representative(s) and such substituted representative
shall be deemed to be such Seller Representative(s) for all purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.14.2.
Subject to the approval requirements set forth in the proviso below, the Seller Representative is hereby authorized and empowered to
exclusively act as the representative of the Sellers, and to take all action deemed by the consent of the Seller Representative on behalf
of the Sellers required or permitted to be taken by the Seller Representative under this Agreement and/or the Escrow Agreement, including
with respect to any claims (including the settlement thereof) made by the Buyer for indemnification pursuant to this <U>Section&nbsp;9</U>;
<U>provided that</U>, prior to taking any action on behalf of the Sellers (including in respect of the use of the Seller Representative
Fund Amount) (a &ldquo;<U>Proposed Action</U>&rdquo;), the Seller Representative must first submit the Proposed Action to Siemens, Michael
Yuz and Brian Phelan (each, a &ldquo;<U>Representative Committee Member</U>&rdquo; and collectively, the &ldquo;<U>Representative Committee</U>&rdquo;)
for approval. A Proposed Action will be deemed approved by the Representative Committee and the Seller Representative may undertake such
Proposed Action if a majority of the Representative Committee Members vote to approve the Proposed Action. For the avoidance of doubt,
the Seller Representative may not undertake a Proposed Action if the Representative Committee does not approve such Proposed Action.
Each Representative Committee Member may approve a Proposed Action in writing, including electronically via email, and meetings of the
Representative Committee are not required. The Sellers shall be bound by all actions taken by the Seller Representative in its capacity
as such. Each Seller acknowledges and agrees that the Seller Representative shall for all purposes be deemed the sole authorized agent
of the Sellers until such time as the agency is terminated and no Seller shall have any right to act on its own behalf with respect to
any of the foregoing matters. The Seller Representative shall promptly, and in any event within five (5) Business Days thereof, provide
written notice to the Sellers of any action taken on behalf of the Sellers by the Seller Representative pursuant to the authority delegated
to the Seller Representative under this <U>Section 9.14</U>. The Seller Representative shall at all times act in its capacity as Seller
Representative in a manner that the Seller Representative believes to be in the best interest of the Sellers. The Sellers agree that
the Buyer Indemnified Parties shall be entitled to rely exclusively upon all actions taken or omitted to be taken by the Seller Representative
pursuant to this Agreement and any of the foregoing matters. Notwithstanding anything contained herein to the contrary, the Sellers shall
remain bound by their obligations under this Agreement, including under <U>Sections <FONT STYLE="font-size: 10pt">&lrm; 8</FONT></U>
and <FONT STYLE="font-size: 10pt"><U>&lrm; 9</U></FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.14.3.
Neither the Seller Representative (nor any of his Representatives, if applicable) nor the Representative Committee Members shall be liable
to any Person for any error of judgment, or any action taken, suffered or omitted to be taken, under this Agreement or the Escrow Agreement,
except in the case of his gross negligence, bad faith, fraud or willful misconduct. Each of the Seller Representative and the Representative
Committee Members, respectively, may consult with legal counsel, independent public accountants and other experts selected by them and
shall not be liable for any action taken or omitted to be taken in good faith in accordance with the advice of counsel, accountants or
experts. Neither the Seller Representative nor any Representative Committee Member, respectively, shall have any duty to ascertain or
to inquire as to the performance or observance of any of the terms, covenants or conditions of this Agreement or the Escrow Agreement.
As to any matters not expressly provided for in this Agreement or the Escrow Agreement, the Seller Representative and the Representative
Committee Members, respectively, shall not be required to exercise any discretion or take any action. Each Seller, severally in accordance
with its pro rata share of the Purchase Price, shall indemnify and hold harmless and reimburse the Seller Representative and the Representative
Committee Members from and against any and all Losses incurred by the Seller Representative and each Representative Committee Member,
respectively, in each case solely in his capacity as such, arising out of or resulting from any action taken or omitted to be taken by
the Seller Representative under this Agreement or the Escrow Agreement, other than such Losses arising out of or resulting from the Seller
Representative&rsquo;s gross negligence, bad faith, fraud or willful misconduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.14.4.
At the Closing, Buyer will deliver the Seller Representative Fund Amount to a bank account designated by the Seller Representative, which
will be controlled by the Seller Representative and used solely to pay the costs and expenses, if any, incurred by the Seller Representative
in the performance of his obligations as the Seller Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.14.5.
In all matters relating to this <U>Article&nbsp;9</U> and subject to the approval requirements of the Representative Committee, the Seller
Representative shall be the only party entitled to assert the rights of the Sellers, and the Seller Representative shall be permitted
to perform all of the obligations of the Sellers hereunder, provided that the Sellers shall remain bound by their obligations under this
Agreement including any payment obligations. Buyer shall be entitled to rely on all statements, representations, and decisions of the
Seller Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.
Termination.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1.
<U>Termination</U>.<B>]</B> The parties may not terminate this Agreement other than as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1.1.
This Agreement may be terminated at any time prior to the Closing by mutual written consent of the Buyer and the Seller Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1.2.
The Buyer may terminate this Agreement by delivering written notice to the Seller Representative at any time prior to the Closing in
the event (a)&nbsp;the Seller Representative, Sellers or the Company is in material breach of any covenant, representation or warranty
contained in this Agreement, (b)&nbsp;the Buyer has notified the Seller Representative of the breach in writing, (c)&nbsp;such breach
would result in, or would be reasonably be expected to result in, the failure of any condition set forth in <U>Section&nbsp;6</U> and
(d)&nbsp;such breach is incapable of cure or has continued without cure for a period of thirty (30) days after delivery of such notice
of breach; <U>provided</U>, <U>however</U>, that the Buyer shall not have the right to terminate this Agreement pursuant to this <U>Section&nbsp;10.1.2
</U>if the Buyer is then in material breach of this Agreement so as to cause any of the conditions set forth in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>7
</U>to not be satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1.3.
The Sellers may terminate this Agreement by the Seller Representative delivering written notice to the Buyer at any time prior to the
Closing in the event (a)&nbsp;the Buyer is in material breach of any covenant, representation or warranty contained in this Agreement,
(b)&nbsp;the Seller Representative have notified the Buyer of the breach in writing, (c)&nbsp;such breach would result in, or would be
reasonably be expected to result in, the failure of any condition set forth in <U>Section&nbsp;7</U> and (d)&nbsp;such breach is incapable
of cure or has continued without cure for a period of thirty (30) days after delivery of such notice of breach; <U>provided</U>, <U>however</U>,
that the Sellers shall not have the right to terminate this Agreement pursuant to this <U>Section&nbsp;10.1.3</U> if the Sellers, the
Seller Representative or the Company is then in material breach of this Agreement so as to cause the conditions set forth in <U>Section
<FONT STYLE="font-size: 10pt">&lrm;</FONT>7</U> to not be satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1.4.
The Buyer, on the one hand, or the Seller Representative, on the other hand, may terminate this Agreement by providing written notice
to the other at any time on or after December 15, 2021(the &ldquo;<U>Expiration Date</U>&rdquo;), if the Closing shall not have occurred
by the Expiration Date; <U>provided</U>, that neither party shall have the right to terminate this Agreement pursuant to this <U>Section&nbsp;10.1.4
</U>if that party&rsquo;s breach of any provision of this Agreement has caused or resulted in the failure of the Closing to be consummated
by the Expiration Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1.5.
Either the Buyer, on the one hand, or the Seller Representative on behalf of the Sellers, on the other hand, may terminate this Agreement
by delivering written notice to the other if any Governmental Authority issues a Governmental Order permanently enjoining, restraining
or otherwise prohibiting the Contemplated Transactions and such Governmental Order shall have become final and non-appealable; <U>provided</U>,
that the Person seeking to terminate pursuant to this <U>Section&nbsp;10.1.5</U> (or, in the case where the Seller Representative and
the Company are seeking to terminate, the Company, the Seller Representative and the Sellers) has not breached its obligations under
<U>Section&nbsp;8.4</U> so as to cause the issuance of such Governmental Order.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1.6.
The Sellers may terminate this Agreement, with no need to allow any additional cure period, by the Seller Representative delivering written
notice to the Buyer at any time prior to the Closing in the event that the conditions set forth in <U>Section&nbsp;6</U> have been satisfied
(other than those conditions that by their nature are to be satisfied at the Closing), the Sellers have confirmed that the Sellers and
the Company are prepared to consummate the Closing and the Buyer fails to complete the Closing on the date the Closing should have occurred
pursuant to <U>Section&nbsp;2.3</U> (a &ldquo;<U>Buyer Failure to Close</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.1.7.
The Buyer may terminate this Agreement, with no need to allow any additional cure period, by delivering written notice to the Seller
Representative at any time prior to the Closing in the event that the conditions set forth in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>7
</U>have been satisfied (other than those conditions that by their nature are to be satisfied at the Closing), the Buyer has confirmed
that it is prepared to consummate the Closing and the Sellers, the Company or the Seller Representative fails to complete the Closing
on the date the Closing should have occurred pursuant to <U>Section 2.3</U> (a &ldquo;<U>Seller Failure to Close</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
anything to the contrary in this Agreement, (i) the Buyer may not terminate this Agreement following any Buyer Failure to Close and (ii)
neither the Sellers, the Company, nor the Seller Representative may terminate this Agreement following any Seller Failure to Close. The
party seeking to terminate this Agreement pursuant to <U>Sections&nbsp;10.1.2</U>, <U>10.1.3</U>, <U>10.1.4</U>, <U>10.1.5 10.1.6</U>
or 10.1.7 will give written notice of such termination to the other parties (provided that any such notice on behalf of the Sellers shall
be provided by the Seller Representative), including a brief description of the basis on which such party is terminating this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">10.2.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Effect of Termination</U>. If this Agreement is terminated pursuant
to <U>Section&nbsp;10.1</U>, all rights and obligations of the parties hereunder will terminate without any liability of any party or
any Affiliate thereof; <U>provided</U>, <U>however</U>, that (a)&nbsp;the rights and obligations of the parties under <U>Section&nbsp;8.3
</U>(Confidentiality; Announcements), <U>Section&nbsp;9.11</U> (Acknowledgement by the Buyer), this <U>Section&nbsp;10.2</U> (Effect
of Termination), <U>Section&nbsp;1.2</U> (Definitions) and <U>Section&nbsp;11</U> (Miscellaneous), and the Confidentiality Agreement,
will, in each case, survive termination of this Agreement and remain valid and binding obligations of the parties, and (b)&nbsp;nothing
herein will relieve any party to this Agreement from liability (i)&nbsp;pursuant to the sections specified in this <U>Section&nbsp;10.2
</U>that survive such termination, (ii)&nbsp;subject to <U>Section&nbsp;9.11</U>, for fraud or (iii)&nbsp;for any breach of any covenant
or agreement contained herein occurring prior to such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.
Miscellaneous.</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.1.
<U>Notices</U>. All notices, requests, demands, claims and other communications required or permitted hereunder will be in writing and
will be sent by personal delivery, nationally recognized overnight courier, facsimile or by e-mail (as a PDF). Any notice, request, demand,
claim, or other communication required or permitted hereunder will be deemed duly given, as applicable, (a)&nbsp;upon personal delivery,
(b)&nbsp;on the date that delivery is confirmed in the courier&rsquo;s systems when sent by courier delivery or (c)&nbsp;upon confirmation
of receipt when sent by facsimile or e-mail (as a PDF), addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If to
    the Buyer or the Parent or, after the Closing, the Company, to:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nano-X
    Imaging Ltd.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Communications
    Center</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Neve
    Ilan, Israel 9085000</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Facsimile
    number: <B>[</B>&#9679;<B>]</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email:
    ilan.r@nanox.vision</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention:
    Ilan Rotem, General Counsel</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">with
    a copy (which will not constitute notice) to:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Crowell
    &amp; Moring, LLP</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">1001
    Pennsylvania Ave., NW</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Washington,
    DC 20004</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Facsimile
    number: (202) 628-5116</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email:
    mkass@crowell.com</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attention:
    Mark A. Kass</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If to
    the Sellers, or, prior to the Closing, to the Company, to:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">USARAD
    Holdings, Inc.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">3201
    N Federal Hwy.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Suite
    212</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ft. Lauderdale,
    FL 33306<BR>
    Email: myuz@secondopinions.com<BR>
    Attention: Michael Yuz, CEO</FONT></P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">with
    a copy (which will not constitute notice) to:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Wyrick
    Robbins Yates &amp; Ponton LLP</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">4101
    Lake Boone Trail, Suite 300</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Raleigh,
    North Carolina 27607</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">E-mail:
    dcreekman@wyrick.com<BR>
    Attention: David P. Creekman</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tobin
    Reyes, P.A.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">225 NE
    Mizner Blvd.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Suite
    510<BR>
    Boca Raton, Florida 33432</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email:
    mdebiase@tobinreyes.com<BR>
    Attention: Michael De Biase</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
party may change the address to which notices, requests, demands, claims, and other communications required or permitted hereunder are
to be delivered by providing to the other parties notice in the manner herein set forth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.2.
<U>Expenses of Transaction</U>. Whether or not the Contemplated Transactions are consummated, except as otherwise specifically provided
for in this Agreement, each of the parties hereto will assume and bear all expenses, costs and fees (including legal and accounting fees
and expenses) incurred by such party in connection with the preparation, negotiation and execution and performance of this Agreement
and the Escrow Agreement and the consummation of the Contemplated Transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.3.
<U>Entire Agreement</U>. The agreement of the parties that is comprised of this Agreement (including all Schedules and Exhibits hereto)
and the Escrow Agreement sets forth the entire agreement and understanding between the parties and their respective Affiliates with respect
to the subject matter thereof and supersedes any and all prior agreements, understandings, negotiations and communications (other than
the Confidentiality Agreement), whether oral or written, relating to the subject matter of this Agreement or the Escrow Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.4.
<U>Severability</U>. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule
of law or under public policy, all other conditions and provisions of this Agreement will nevertheless remain in full force and effect
so long as the economic and legal substance of the Contemplated Transactions are not affected in any manner adverse to any party. Upon
such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Sellers and the Buyer will
negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible to the end
that the Contemplated Transactions are fulfilled in accordance with the terms hereof to the greatest extent possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.5.
<U>Amendment</U>. This Agreement may be amended or modified, but only by an instrument in writing executed by each of the Buyer and the
Seller Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.6.
<U>Parties in Interest</U>. This Agreement will be binding upon and inure solely to the benefit of the parties hereto, and except as
provided in <U>Sections&nbsp;8.7</U>, <U>9</U>, and <U>11.16</U>, nothing in this Agreement, express or implied, is intended to or will
be construed to or will confer upon any other Person any right, claim, cause of action, benefit or remedy of any nature whatsoever under
or by reason of this Agreement, including by way of subrogation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.7.
<U>Assignment</U>. This Agreement will be binding upon and inure to the benefit of and be enforceable by the successors and permissible
assigns of the parties hereto. This Agreement and any rights and obligations hereunder may not be assigned, hypothecated or otherwise
transferred by any party hereto (by operation of law or otherwise) without the prior written agreement of the Buyer and the Seller Representative,
<U>provided</U> that, (a) the Buyer may assign and delegate any or all of its rights, interests and obligations under this Agreement
(1) before or after the Closing to any of its Affiliates and (2) after the Closing, to any Person, as long as any such Affiliate or Person
agrees in writing to be bound by all of the terms of this Agreement, but no such assignment or delegation will relieve the Buyer of its
obligations under this Agreement if such assignee does not perform such obligations, (b) the rights and obligations of the Seller Representative
may be assigned and delegated pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>9.14</U>, and (c) any Seller may Transfer
its rights to payment hereunder, including (for the avoidance of doubt) the right to receive any portion of the Earn Out Amount, if earned,
and Escrow Funds, to another Seller hereunder prior to and following the Closing. The Seller Representative will provide the Buyer with
an updated Allocation Schedule reflecting such Transfer within five (5) Business Days after any such transfer. Any purported assignment
in breach of this <U>Section&nbsp;11.7</U> shall be null and void.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.8.
<U>Governing Law</U>. This Agreement, and all claims arising in whole or in part out of, related to, based upon, or in connection herewith
or the subject matter hereof or the Contemplated Transactions will be governed by, construed and enforced in accordance with the laws
of the State of Delaware, without giving effect to any choice or conflict of law provision or rule that would cause the application of
the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.9.
<U>Consent to Jurisdiction</U>. Each party to this Agreement, by its execution hereof, hereby irrevocably (a)&nbsp;submits, except as
provided in <U>Section&nbsp;2.5</U>, to the exclusive jurisdiction of the Delaware Court of Chancery (or if, but only if, the Delaware
Court of Chancery declines to accept jurisdiction, the Superior Court of the State of Delaware or the United States District Court for
the District of Delaware) for the purpose of any and all Actions arising in whole or in part out of, related to, based upon or in connection
with this Agreement or the subject matter hereof or the Contemplated Transactions, (b)&nbsp;waives to the extent not prohibited by applicable
law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such Action, any claim that it is not subject personally
to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that any such action
brought in one of the above-named courts should be dismissed on grounds of improper venue or <I>forum non conveniens</I>, should be transferred
to any court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any
other court other than one of the above-named courts, or that this Agreement or any claims arising in whole or in part out of, related
to, based upon, or in connection herewith or the subject matter hereof may not be enforced in or by such court, (c)&nbsp;agrees not to
commence any such Action other than before one of the above-named courts nor to make any motion or take any other action seeking or intending
to cause the transfer or removal of any such Action to any court other than one of the above-named courts (subject in each case to clause&nbsp;(a)
of this sentence) whether on the grounds of inconvenient forum or otherwise, (d)&nbsp;consents to service of process in any such Action
in any manner permitted by the laws of the State of Delaware, (e)&nbsp;agrees that service of process made in accordance with clause&nbsp;(d)
or made pursuant to <U>Section&nbsp;11.1</U> will constitute good and valid service of process in any such Action, and (f)&nbsp;waives
and agrees not to assert (by way of motion, as a defense, or otherwise) in any such Action any claim that service of process made in
accordance with clause&nbsp;(d) or clause&nbsp;(e) does not constitute good and valid service of process. Notwithstanding the immediately
preceding sentence, a party may commence an Action in any other court to enforce an order or judgment issued by one of the courts described
in the immediately preceding sentence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">11.10.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Waiver of Jury Trial</U>. TO THE EXTENT NOT PROHIBITED BY APPLICABLE
LAW WHICH CANNOT BE WAIVED, EACH OF THE PARTIES HERETO HEREBY WAIVES, AND AGREES TO CAUSE EACH OF ITS SUBSIDIARIES TO WAIVE, AND COVENANTS
THAT NEITHER IT NOR ANY OF ITS SUBSIDIARIES SHALL ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE) ANY RIGHT TO TRIAL BY JURY IN
ANY FORUM IN RESPECT OF ANY ACTION DESCRIBED IN <U>SECTION&nbsp;11.9</U>. ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY
OF THIS <U>SECTION&nbsp;11.10</U> WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO
TRIAL BY JURY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">11.11.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Reliance</U>. Each of the parties hereto acknowledges that it has
been informed by each other party that the provisions of <U>Sections&nbsp;11.9</U> and <U>11.10</U> constitute a material inducement
upon which such party is relying and will rely in entering into this Agreement, and each such party agrees that any breach by such party
of any of the provisions of <U>Sections&nbsp;11.9</U> or <U>11.10</U> above would constitute a material breach of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.12.
<U>Specific Enforcement</U>. Each of the parties acknowledges and agrees that the other parties would be damaged immediately, extensively
and irreparably and no adequate remedy at law would exist in the event that any of the provisions of this Agreement were not performed
in accordance with their specific terms or were otherwise breached or violated. Accordingly, in addition to, and not in limitation of,
any other remedy available to any party, the parties agree that, without posting bond or similar undertaking, each of the other parties
shall be entitled to an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and to the remedy
of specific performance of this Agreement and the terms and provisions hereof. Subject to <U>Section&nbsp;9</U> hereof and the limitations
set forth therein, such remedies, and any and all other remedies provided for in this Agreement, will, however, be cumulative in nature
and not exclusive and will be in addition to any other remedies to which such party may be entitled. Each of the parties hereby acknowledges
and agrees that injunctive relief and/or specific performance will not cause an undue hardship to any party. Each party further agrees
that, in the event of any action for injunctive relief or for specific performance in respect of any breach or violation, or threatened
breach or violation, of this Agreement, it shall not assert the defense that a remedy at law would be adequate or that specific performance
or injunctive relief in respect of such breach or violation should not be available on any other grounds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.13.
<U>No Waiver</U>. No failure or delay on the part of any party hereto in the exercise of any right hereunder will impair such right or
be construed to be a waiver of, or acquiescence in, any breach of any representation, warranty, covenant or agreement herein, nor will
any single or partial exercise of any such right preclude any other or further exercise thereof or of any other right. No waiver of any
provision of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar), or shall
constitute a continuing waiver unless otherwise expressly provided. No waiver of any right or remedy hereunder shall be valid unless
the same shall be in writing and signed by the party against whom such waiver is intended to be effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.14.
<U>Negotiation of Agreement</U>. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event
an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and
no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.15.
<U>Disclosure Schedules</U>. The inclusion of any information in the Disclosure Schedules will not be deemed an admission or acknowledgment
that such information is required to be listed in the Disclosure Schedules or that such items are material. The Disclosure Schedules
are arranged in sections corresponding to the subsections of <U>Sections 3</U> and 4 contained in this Agreement, and the disclosure
of an item in one section of the Disclosure Schedules as an exception to a particular representation or warranty in such subsection of
<U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3 </U>or <U>Section 4</U> will be deemed adequately disclosed as an exception with
respect to all other representations and warranties in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3</U> or <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4
</U>to the extent that the relevance of such item to such other representations and warranties in <U>Section 3</U> or <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4
</U>is reasonably apparent on its face, notwithstanding the presence or absence of an appropriate cross-reference thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.16.
<U>Third Party Beneficiaries</U>. No provision of this Agreement is intended to confer upon any Person other than the parties hereto
any rights or remedies hereunder; <U>provided however</U>, that the following Persons are expressly intended as third party beneficiaries
with respect to the following specified sections of this Agreement and will have the right to enforce such specified sections against
the parties to this Agreement: with respect to <U>Section&nbsp;8.7</U>, the Persons who are the beneficiaries of the rights under such
Section; with respect to <U>Section&nbsp;9</U>, the Persons who are the beneficiaries of the indemnification under such Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.17.
<U>Headings</U>. The headings contained in this Agreement are inserted only for reference as a matter of convenience and in no way define,
limit or describe the scope or intent of this Agreement, and will not affect in any way the construction, meaning or interpretation of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.18.
<U>Counterparts; Electronic Signature</U>. This Agreement may be executed in any number of counterparts, and by the different parties
hereto in separate counterparts, each of which will be deemed an original for all purposes and all of which together will constitute
one and the same instrument. This Agreement may be executed by facsimile or PDF signature by any party and such signature will be deemed
binding for all purposes hereof without delivery of an original signature being thereafter required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>[</B><I>The
remainder of this page is intentionally blank. Signatures follow.</I><B>]</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">In
witness whereof</FONT>, the parties have caused this Stock Purchase Agreement to be executed under seal by their respective duly authorized
officers as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><B>THE BUYER:</B></TD>
    <TD COLSPAN="2"><B>NANO-X IMAGING, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ James Dara</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>James Dara</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>President</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>THE PARENT:</B></TD>
    <TD COLSPAN="2"><B>NANO-X IMAGING LTD.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Ran Daniel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Ran Daniel</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>THE COMPANY:</B></TD>
    <TD COLSPAN="2"><B>USARAD HOLDINGS, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Michael Yuz</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Michael Yuz, MD,MBA</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Signature
Page to Stock Purchase Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 104 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt"><B>THE SELLERS:</B></TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ MichaelYuz</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">Michael Yuz</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt"><B>Siemens Healthineers Beteiligungen GmbH &amp; Co. KG</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt; width: 35%">/s/ Sanders Gernot</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Name:&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Sanders Gernot</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Title:</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Hummel Roland</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Name:</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Hummel Roland</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">Title:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt"><B>Omphalos Venture Partners, LLC</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Mark Marlow</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Name:</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Mark Marlow</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Title:</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">President</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt"><B>Physician Fund LP</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">B. Bobby Bahram</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Name:</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">B. Bobby Bahram</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Title:</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font-size: 10pt">Manager of the Manager of the General Partner</FONT>&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Aleksandr Viventsov</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">Aleksandr Viventsov</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>SIGNATURE
PAGE TO STOCK PURCHASE AGREEMENT</I></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt"><B>KHBH, LLC</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt; width: 35%">/s/ Brian Harrington</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Name:</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Brian Harrington</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Title:</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Manager</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Brent Backhaus</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">Brent Backhaus</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Lorna Backhaus</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">Lorna Backhaus</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Victor Koros</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">Victor Koros</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">Brent and Lorna Backhaus, as Tenants by the Entirety</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Brent Backhaus </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">Brent Backhaus, TBE</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Lorna Backhaus </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">Lorna Backhaus, TBE</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Eduard Michel </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0pt; padding-left: 0pt">Eduard Michel</TD></TR>
  </TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; width: 60%; padding-left: 0pt"><B>THE ACCREDITED OPTIONHOLDERS:</B></TD>
    <TD STYLE="padding-right: 0pt; width: 40%; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Mark Marlow</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Mark Marlow</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Brian Phelan </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Brian Phelan</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Pradheep Shanker </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Pradheep Shanker, MD</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-right: 0pt; padding-left: 0pt">/s/ Elaine Yuz </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">Elaine Yuz</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><I>Signature
Page to Stock Purchase Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>7
<FILENAME>f20f2021ex8-1_nanox.htm
<DESCRIPTION>LIST OF SUBSIDIARIES OF THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 8.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsidiaries of the Registrant</B></FONT></P>



<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 32%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of Subsidiary</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; white-space: nowrap; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction of Incorporation</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The holding company</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X AI LTD&nbsp; </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ISRAEL</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X IMAGING LTD</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X KOREA INC</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KOREA</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X IMAGING LTD</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X IMAGING INC</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DELAWARE</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X IMAGING LTD</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X IMAGING INC</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAPAN</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X IMAGING LTD</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USARAD HOLDING INC</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DELAWARE</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X IMAGING INC</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANOX RAD INC</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DELAWARE </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USARAD HOLDING INC</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANOX MDW INC</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DELAWARE </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X IMAGING INC</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANOX AI INC</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DELAWARE</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NANO-X AI LTD</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>8
<FILENAME>f20f2021ex12-1_nanox.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHIEF EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Erez Meltzer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this annual report on Form
20-F of Nano-x Imaging Ltd.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">4. The registrant&rsquo;s other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">a) designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">c) evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">d) disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">5. The registrant&rsquo;s other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">a) all significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">b) any fraud, whether or not material, that involved
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Date:
    May 2, 2022</FONT></TD>
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">/s/
    Erez Meltzer</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Erez
    Meltzer</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Chief Executive
    Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>9
<FILENAME>f20f2021ex12-2_nanox.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHIEF FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Ran Daniel, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this annual report on Form
20-F of Nano-x Imaging Ltd.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">4. The registrant&rsquo;s other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">a) designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">b) Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">c) evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">d) disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">5. The registrant&rsquo;s other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">a) all significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">b) any fraud, whether or not material, that involved
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font: 11pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Date:
    May 2, 2022</FONT></TD>
    <TD STYLE="width: 60%; font: 11pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 11pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">/s/
    Ran Daniel</FONT></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Ran
    Daniel</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Chief
    Financial Officer</FONT></P></TD>
    <TD STYLE="font: 11pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>10
<FILENAME>f20f2021ex13-1_nanox.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
13.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this Annual Report on Form 20-F of Nano-x Imaging Ltd. (the &ldquo;Company&rdquo;) for the twelve-months ended December
31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), Ran Daniel, Chief Financial
Officer of the Company, hereby certifies, pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act
of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: May 2,
    2022</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Erez Meltzer </FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erez Meltzer</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>11
<FILENAME>f20f2021ex13-2_nanox.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In connection with this Annual Report on Form
20-F of Nano-x Imaging Ltd. (the &ldquo;Company&rdquo;) for the twelve-months ended December 31, 2021, as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), Ran Daniel, Chief Financial Officer of the Company, hereby certifies,
pursuant to 18 U.S.C. &sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(1) The Report fully complies with the requirements
of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(2) The information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Dated: May 2, 2022</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 36%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 60%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ Ran Daniel</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Ran Daniel</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>12
<FILENAME>f20f2021ex15-1_nanox.htm
<DESCRIPTION>CONSENT OF KESSELMAN & KESSELMAN, CERTIFIED PUBLIC ACCOUNTANTS (ISR.) A MEMBER FIRM OF PRICEWATERHOUSECOOPERS INTERNATIONAL LIMITED, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ex15-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">We hereby consent to the incorporation
by reference in the Registration Statement on Form S-8 (No. 333-248322) of Nano-X Imaging Ltd. of our report dated May 2, 2022 relating
to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal">/s/Kesselman &amp; Kesselman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal">May 2, 2022 </FONT></TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal">Certified Public Accountants (Isr.)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 10pt; font-weight: normal">A member firm of PricewaterhouseCoopers International Limited</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex15-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !^ )0# 2(  A$! Q$!_\0
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M1.CJ>A%3U6T^PM=*TZWL+*(16MM&(HHP2=J@8 R>:LT %%%% !1110 4444
M%%%% !7"^.OAO_PG4ZB[\0ZA;6*A<64(4Q;AGYB#U/-=U10!YQX-^$X\$ZBD
M^G>)]3:VW[YK-@HBF.,?,/Z^U>CT44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !] )0# 2(  A$! Q$!_\0
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MC&,\[<$9YZUV5% '!^&_A)X=\*:K%J.E7&J1R1G)C-V?+?@CYE &>M=Y110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex15-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !J M(# 2(  A$! Q$!_\0
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M!PPV R>.:2E3P.$P=;#N<YXBBJ?M:^)5+F25X<\Y33A&!]E"_M3C][$"S2*
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M3MD7#+WM_P 91CET;5T^'M+Z)[V\^O3'#\,/EYLUXDC=1YDN&<%*S;CS)/\
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M_5[!NU]9I<V>:\NJBW92=KJ-Y<OTVNH0%S&VZ,AV0%VBVD)"DQ<E96\I=K@
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M !>.B_:AXC6\X^(-I;:^-0\\ZJH1M)-_)HS-8MG_ &KQG_T(^%W_ -W1CO\
MZ'>^GEOKUU6'X8NKYKQ(E=7:X9P;:5U=V_M]7:C=I75VDKJ[<?M%M2M%7>9
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MIIIM.]VB O  "4?GI^ZC_O2K_P ]/6%OP9?4X56@8H K9=E49B3@L(CS^\.
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MC[1I^:=TUH[IL?L*<H>UA3P_L[735"C?:^DE%-/3=6:>JLTBX5( /F2<^_\
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M2;-51AM&,;O1?NZ3U>BT]EW:]1/+/ .TDC/&![X/RYS^-,**%9C&, '(ZD@
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MJO:2IMKJDUU,.3#OGM1H?NHRG/\ <47:$(RG-_!TA";OTM?H.,<0(&.K%?\
M5KP1ZY8''''&?:DVQ+EMI^1=_$:C@$#@ENO.?\>E0O?VZD,714:2,;W947=.
MTL:+EB,R%T6/RQ\WF.HQDFO+-$^/_P #_$_Q3\4_ KPY\8/A;KWQN\$Z+:>(
M?&OP<T3XA>$-6^*?@WPY?-I*V>O>*_ &G:S<>*?#NC74FM:9';:GK&EV=E=/
M?V26TTQN[42XMSFVJ-6>LJ=2$G6K33PRPD\15DX^T>B:BW)JT8-J7NMC<,,E
M*2IT4HR<&_84E:HJRPJ7-R*S^LRC%:I\S48N]F>O[EY^_P >Z^H']WWI ROE
M?GY9H^=A&0<'C R.?49]J:64-R&P<\CG)'S9 !)QD8&!G/\ #@C-?[1'$-SB
M1269_P#5EV"B:*(N4CWN%)D1MQ3")N>4QA6QLIRE4G3C.%TZCBK0OR24%AW=
M16KJ4\2KW3ERVT<$S648<U&/*[5(2;O*;3:@GLYM6O>\6FFG9IJY:^S+Z#_O
MA?\ XJ@VR@$X' S]Q?\ XJN.\<?$OP#\,/#C^,?B7XV\*?#GP?#?:'I=QXL\
M>^(M$\'>'+74_%&KZ=X>\,:;>:QXCOM-L;/4/$?B#5M.T#0[*YFBN=4UV]L]
M&LXY=3O;.UN.N%V&190',3 ,)&4)&8V#;'W.5W+(P5$5 TK&2-A'Y;AZVY-6
MU*K=Z+]_6M=Z*T>>RU:V1DZ-&*<I0P]HIR?[C#[)-O['9/\ I#A;H<=.02/W
M:]L_[7M2""/&<#MQY:]\^C>WK38[^&1E79(&94=7,;>6\<AG$313*&AEWK T
MC1Q22301/%)=10+(N2&]CG52BL5D!.Y5#HK!D0H[(S*L@=RH4DY,<@!^3-91
M49\\X5:KA0FZ=?\ ?UM*B^S=U-->^]GYD\E!2A!TL/SUTYT%["C[U-)-OX-=
M.J\B4V\:XR$Y_P!C_P"RH\A -P"\<CY,'.>/XCCGV/T/2F_:XPXC9),9A!D*
MIY6RX20PR"3>4</+&;4)&7G^T-%F(12QRN-=P@J"VUL(X0E=S*X78R ,3*K2
M.D"M")%>>1(D+,>'R5.:3=6;IM>ZO:U$[]+R]IJKV];FOL:*M:A133O?V-)>
MGV%:S5[II];JUTX1L>1_[)_5*0QD<-T/4?(>._1!^61]1UIK72'.X[ '=0'*
M)N$2!Y)8][*98D5AN>/> <C&5($@G3=Y3.@<Y 0R1A\JBNX"ABS&..2-WP"
MKJ<G-7JHV3?,DKWJ3;Z<V\W;2^O2UQN*;U:Y7NDVD_)_O&FFKIIIIIM6:NFS
MR8^NU<>OE_\ V=+Y$><;5!/K'_\ 94L=S 6*[U0E8W4/)""ZR3-!&R*)"Q62
M0*(WV[)#(BQLS[D6P5&<D\Y&.1VJ5&7.VYU/9M>[^^JIW>GQ<]V+V.'_ .?%
M#T]E2_\ E97^RI_L_P#? _QI1;*""-N001A #Q[\X^N#]*LT57LU_/6^=>LU
M\TYM-=TTTUHTTVF>QH_\^:*\U1I)KS34$TUT:::=FFFDU%Y9]3^8_P#B*0Q9
M!!)(((()&"#P0?D'!^HJ:BJMY_A%?BH)KU33[-.S5.$7HTVGHTY3::>C33FT
MTTVFFFFFTTTVG5^RH.BH/P)Q] :/LJ_[/XQC_$5:HI./,[N=7Y5JR_*9"H4(
MZ*A0_P#!%'_Y65OLR>B?]\?_ &5'V9.P3_OC'Z[CCZX/TJS11R_WZO\ X.J_
M_)A[&C_SYH_^":7_ ,K*WD>BH/<,?_B:7RF_V,=__P!808JQ12<$]Y5?_!U7
M_P"3&J4%M&.O_3NE_P#*BOY)]%_[Z;_XFCR<\$+@\'EC^A&#].]6**.1?S5?
M_!U7_P"3%[&G_+'_ , I?_*BK]E3_9_[X'^-'V5/]G_O@?XU:HH]FOYZW_@^
MM_\ + ]C1_Y\4/\ P32_^5E;[,GHG_?'_P!E2BV0$$!00<@A,$$="#NX([&K
M%%/E_OU?G5J-?-.337=--/9IIL/8T?\ GS17FJ-)->::@FGV:::=FFFDU%Y9
M_P">C_F?\:41D$'S'."#@DX/MUJ2BG]W_@,/_D!^R@M;2TU^.IT_[?"BBBF:
M"'=V('KG_P#4:0DA23U )X]ORIU(<8.>F#GZ4-JUGLM6]G9:O7T1-DFY7?FK
MNWR6RV*=S=PQQR"125P$;<J,F)0PRX9U!0 '?DCY<U_&%_P5I\2ZS\4_CSXS
M^%UQ^S7-^W!XC^&__!4N[^*'A#X'^*[70]5-I\ _@)_P2/\ V)?B]\4O &FW
M_BU=2_L+X:>(?B3\1+;Q!XS\">$6M4^(^H>*-:TO1/#WC+Q'XO31;S^SRXCB
M:*4MN/R[B%\T.=@;:%,*O-O.<*8D9P?N M@'\F?AO_P3X^'FN?MS?M)?MH?&
M+X?:Y8_%S0OCUH\O[+'Q"\,?%CQGX3TN\^"5W^Q9^R3X%\;7OB/X9_"[X@Z;
MX'\6W>K_ !C\'?%/P;XBD^,W@W7/&GB#P]X*^'^BZ@=4^&/@CX*1Z)QUZ3:P
MU>4J*GAL9A\5B:>(G4I4*F78:.+J8FG5G1E&M0IU:T<NI5L50<L10H2Q#H0G
M5G!+*I4Y4XR4G"K2Q5%2@ES1Q&(J8.GETE=-/DI2S";@TXUI4Z;E:,&I?G_>
M>*?V5_V-/ G[,_[4'[+?PA^"OQB_;1_X*1>-=/LO!7[46B?LIZIXFBT73M;^
M%]YKOB/5M#^#G[.?AB3XPV/PK\%>#?#%IX2M_@UX)\1Z#KTM\-)E^-WQ@OM5
MMO&7Q.U+V[X]?\% OV^/A%X1^%^I>-/@Y\(OV?;?Q'/XXL[KXU_%GX4_'KXA
M? WQ7J.D_$;3O!7P?TOXBI\(M9O_ !3^PC%\?O#NJ)XET_Q?\7-5^..E_!G4
MM4TGP/XF\-^.M6;6Y-'^QU_X)6?L*V/A0>"K3X8^.]$\.Z7\5;GXT>#=/\/_
M +17[2_AR?X/?$^]N_$UWJ.O? '4M!^,-AJ/[/B:U!XLUZ'Q!H'P1O\ X?\
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M$=,TWP3HVF_"GQKI<7PPU?QAJ'@&[T']I+]J/1=5\(V?C6W)\8^ _#FJZ/\
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M7?C'XF^+M$T[X8Z9X1\6>&=0^'6B_%>_B\=^,/#DD47B;PWIEXUQI6%\-O\
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M5O"4L6G^+["/2KB_\0^/?&NKZSXY\.QZ?XU\2:GK\]UK/B.]N+:PNX^/M?\
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MN;D^KP5)VBVUYY^PA^U9XI^//[(UY^T+^T'<_#3P/%X>\5_'G0M0^)6AK?\
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M?M"^'K>W\&>/]%\1^ M ^-FM:_\ $W3?!^N:[XU^.?Q2F\0>'-$\.:WH^F>
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MZ/U_"XK$76$RFE5I<M*ZJU:%&U#$)/E;JUJDJ=6I1D_>?-3IV:Y;_/O[.O\
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M]HE%QJ3S18:$*\HVIP?L^25.3<?HOXK?MN?M;^%?#OQ2^,G@+]E7X&77[/\
MX-OM%L_!OC/XW?M:?%[X0?$;XM?VOH?AN[T6#P+\'?!G[#'Q^BU&^\4>*?$\
M/@7P?I.F^.'\0^+/%=F=+M;"WGEMA)D^%?\ @H%^U/I'Q?\ V5_AQ^T;^PGI
MWP)'[5_BSQ%X/\*^&])_:AT;XV_'#X?ZSX3\(ZCXPUOQ;\2/A[X$^$T?PLLO
M@_%IVD:FS>/O#'[0?BK6;$:EX>M=9\#Z3JESJ&DZ-](>(/@G\0?C=\4M<;QK
M>:Y\)OA'\'=$G\)?L[Z?X;N_!M[XEU+XFZSH%I]K_:/G_M2W\?>&9KOX<6EW
M!H7P*T#Q9H-[!X<\4V7B[Q_XL\+Z[K4WP]?P/P/[(G_!.B;]D/QKJWB_2?VS
M/VL_C3!XGN;W4?'6A?'9?V5O%ES\0=3NK%-*LM7\8?$SPS^RMX)^.^JS:+$D
M%WHUDOQ:M["WO+:*'4(=4TN2?3I>>E4HPQ'-2AB?J^%PU'%T(XI5%7H8JM3X
MGP57+\=6HU6O:8G _P!GYIC9QHSEDM*GE>*P*Q>(S3&T</BHXNMED/:XC#SQ
MM:.#PN(JTJ<*5*IA:-2A.MC*5!-QI?5JE.675:?,_;2G.M)PO9_37Q*_; _9
M;^$7Q#\-?"+XK_M+?L]?##XI^-YM,B\'?#+XA_&;X<>"OB-XN77[_P#L;P^G
MACP-XG\0Z=XGUZXUS7-VB:5#IFCWC:CJ@^P6D<]PR1/\1_$C_@I)\2_AK\8?
M#/A[6OV3-<T#X*:Y^U%;_LKV?COXB_$2X^'7QB\9ZM8I_:/BOXX?![X":M\-
M[G3/B%^S%X+TZ*_UKQ)\7+KXQ>&+J#POH^M^,8/!]QX-T]M<;]2/$EMK$/A_
M7Y_#MOI4FNPZ)J<FA6NL3O!H<NM+9W1TZUU:2&U6:'1UU)8);FX4RW"0W-X8
MUC1$#?B%X%^!W[9/[1/[0?[&7QX^+/[*O@C]C+XY_!+78]9_;'_:(\,ZW\(?
MM7[3NFZ+X!\4^$M/^!_PBM/AE\5?C-\1O&O[/5_XA\5_\);I1_:7\2>#]:\$
MOX=T2[TKX?7.NWTTNB]&'A">:PA7A&6%G/%WM92C"KF%"%:%XQYU16 HT:N.
MA#G]E6J83&X252M5Q5&EIF'/2PL(86=3VDDZ+=5^TM&KB*4W6?PI8BC'FIT:
MMK4\/*5+V<[\\?UA^#W[5/[,W[2MKXEN_P!G/]HSX&?'FV\(36=OXMN_@K\6
MOA[\5(_",^I0W#:<GB4>"O$.N+H4MW]GN6MHM9%H9$M+J5E%O;3RI^=/QY_X
M*"_MC?L\?"S7OCWXW_8\_9^\+?"*U\6:]HWAC1/&O[8OQFT']H;Q7X>T?7=5
MCTS4[7X+:;^PAK_A'2?$.H?#K0M7^+%]X2N/C,^F^&? ]AJVJ>-O%OAJQ\+^
M+[KP]^QT=DT:!W\D>7' 6^ZX2.W<W"6X>6%@8K:552WE6.*4P,\DH:\C2Y/P
ME%\(_&'Q&\3_ !D^-W[0'PPO?&4-MX9^(OPO^!_[-"R^ ]2GTWX376@7^C>,
M+R\DUOQU:?#S4/BY^T??6\^D76M:GXRTGPSX:^&-QX)^'EQ=>'HI/B3XN\1Y
M8FA4A*4\)*-.HZ->DIUE*I2I^VQ<<>ZLH)PNJ>)IPEH[J@JM&*M-3C<*]2A[
M*->,L12C4IN<**4:M2$*D93A&;T4ZD5.$&TESRIN3Y8R/ _@Q_P4H\=>./B#
M^RW9?%/]FI?@S\(?VV?#WBKQ'^R_XMB^+]EXZ^)S:7X;\!2?%#3$^//P>T[X
M;Z3X:^$L?B;P-%?W_ABX\#_%_P",):\M['0?%H\*:S=QV,?N?[.W[0W[5'QR
MO? WQ U']GCX!^!OV:_B'I\WB;PGXVC_ &I?B1XB^..H^"M2TQM5\!:MJGP6
MN_V1?!W@O1=7\26+>'-2\0:0_P"T%K8T#2+F[03ZI>6ILKO\O/#/_!,_XQ^
M=5\3?M9?#'X0Z)H_B_X-_!CQ=\-_V*/V(OCS^T-\7?VD?"'AK3?BC=>'-/\
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MH?O;K#UL?*GGE-0<I0R2E7HM>WLG]47'_!5OX=O^TY\6O@IX/^'NL>)_A/\
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M  3D^'/QW^,7C/XX2?%?X]_"KQ5\1OV>K[]F3XI:;\(O&/@W0M&^)_PJ>_\
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MN@?$'Q#;:S;Z)?ZCJ&BZ3;Q2E]?Q[_P5=UCX2>&_@GXC^+/[,6HZ)/\ &_\
M9=^%/QL\$>'/!_Q'L_%OB?4/CO\ &/XG> _A;HW[,UOH^J^ /"YL[FXUKXG^
M%-5G^*&K36-LFCP>.);WPGIEOX4O[^3TCXB_\$B/V;_'^I?$!-.\3_%SX4>
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MW[V>Y&RR;.& (Y)'8,TS94,""0)%^\",@Y! &:IM7D()\L>7(A3)#-$QBMX
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M&B20 9QG?SQV#2=\#G"KQZ]:>S2,H5=H=E(!.<;MB8+8!.-Q)!Y..@STB%U
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MXJU.KSM**48>]:+:;MS+[5VTG?=63Z#%@9"C!]Q69I,?+$"L@*R!O(CB5][
M7#)*DFZ?(\P (R6B6.> <Y '09P,9XZ GWQBJCZA #"K"1/,E,2M(JQQY)NE
M0)*[B.=V:T=1;VKW%THDBFD@C@<RK.+F'>D._$C&4(&&"SPG]ZH4G</+RI+L
MOELLD;([!UR24>2,FYJFI\\6I-?%).,;I6<5)I*.R7N[)!;32SJ62E?6ZM9W
MC;JF[]WJUKHX0  #;G:<C)]"S#OG[SMGV/M@Q^0^QQA=[*Q4YP$<@ 8X)VC:
MO/7(S@U'_:$7G&#<=V[RTYC)DE"/++$D0<SEH(%CN'9HEB>*X@,$DS.55RWT
M;3- K!I$8^: T6(H_G59G)<?NGE1K="NYVG26,)_H]R81PIM)<J247!*+LN5
MP=.UNZA)P3Z1=D-)J[YHMN2FVXQ;YE-5+IWTO.*FU_,KZ"B";N5(R>,]M\I'
M;^XZCZ@\X H\B88P5&'R/F/W<P<' S]V.3@<9*^IPW[<FV*0[UCE>)/,D584
M1IWDA@5S,8_WLMPB6HM4#WB7$]O%+;QF3AZ7BL ?FY"$@A-I)$I>-9PQMI9(
M1#+YZ0SR&+8=V-T>\]G'F<M;N7-\3M?V\<1MM;VD4K?R7AL[F2HQ2BN=VC%1
MW5VE2]EJ[ZOV=U?>^N^A,T<C?+E0A9@=K,K[" !M90"KC^\""#R&S@BD;"3)
M$;0P*5 /E0P@N#YF$*M;ML$!9987W/NFWF2,*<&PUXBOM,4Y!#N'2,2HT<<2
MR/(OE,[G#.D*1;//EE;,,,D*O*J+J%LS,I9T=9%A960X$S+O\E77='*Z1AI)
MO)>1;>-)'N&B5&(KET::NG&4).24G*,FV^9M>]HW!73M3;A9IFGM(-64K:.*
M:TE=M-23U]].W+*UTM$K%>*Q>%SY<%G%&9M^(1Y1\MC*73:MO@D/(\^XOEYY
MI22@'SV_)9<G9#@(H&"V00X<C)7[HY*GKNQGBFB^@9S&I+." R$QQR1N8Y)@
MDD4LD<L;F./S%5T4O$XFCWPI-)&\W4?E"5,M&Q*J_P J MYRPKM\UD+J[-NB
M9%=9D :$R>9")4X+E:5TWS7DFE.4Y))5'-QDW5C%*G"I+F<::4&IQ22/9Q<G
M):-M6BK*$5;WJ<8)65*I.U6K"]JE5>T;3T$*$C 9@2" 2V,;FR"/E.,9('!
M'8YXA$3J2R[%!=6+8)+;75F!CC$*EW0$!V9PIQE' (*I?P-@[UVLSH'W)C=$
MQCF1BK-Y;03*;>97"&.XQ$P$C $6^A?(4;MC!'*E)%CEV[WAEV.WD31(49UF
M\O(D01&1F*KRQ5-4U5IR5.EAW[!\UY<M1?NZ*E*4FW[.K6;C=^].I+FYURQI
MN5G/EDN><5=ZV44KMNVRT3?6UKW+'FYW+@Y"Y!'&>2O7.<Y';U%9Z0LH95;#
M'$8";(XX"8HA(EM&L3%(GDCC<HS,29)3D$*&L"X@V&7>%51EF?Y%VA5D:17?
M:DD2)*I:6)GB#;D#%U9:K?;(HYE1HYV>5QA55&\N7:7$4Q\P"$M'$\B2RE+>
M39Y<4\DLD4<FL98A.M=T[TJ]K.$;QH^WIRC=-ZOZISMRWYO>:NK/5*DZ4I-\
MT)P<4W+?F4HOEE=-.TM&K-.S3ND/-G+ND833$,VY(_,N$ +"0.#()6 4[QM$
M<*!"BN!YF7*M9S.&1I6*EHRK'?NVH8B 1N!61#%NCF63<KNS!00";#7T"L4;
M>KY4(&0HLV_SF7R)F(@F/E02W$D<<K2P0*))TB# %[7404LPD5< EFB=0H8N
MI+!@& 0KF1L;8T997(BRXI4:48."C:'L_9Z2FFH*C*AI)34E)492CSJ7/>TU
M+VBC-8*5--O>3DY7E=M2E55:ZO))+VJC*UN6RY+<C<'GFRG+!Y)/FV J@DD*
MQL A,;L JW2QR#S+>XEA2XA(;!)GE:E-I=>25$J,249O,!9'VL#*"(O(D#S
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M6$P>*P^#G@\37]M%TYQ4TDJJ<H3CS*IJ[IRNG:Z:O;0_D/\ VF_^"M_[5_Q
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MOACQ/I'A-9OB]\3/$'QY\;^-K'Q)XATJZL]5L;3XF_ KX$ZEXNFM[_Q!\/\
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MYL=L^N3_ (4PB3!P5Z'J<?R4U)16[2=MU:VS:O:V^]UIKW5^Y"5NK>M]7?\
M38BVR=RI]^<]3Z@^HQSGD^@H*.0>5SZ\], >F<\'GW^M2T5DZ$)1<&ZEG!P;
MYW=ITY4VV[7YFI.7-O[2T_B2*YGV7R1 8WW9ROWB3G/<8XP.M*L;@\D8VJ,
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>nnox-20211231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 02 05:16:13 UTC 2022 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.nanox.vision.com/20211231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nnox="http://www.nanox.vision.com/20211231" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="nnox-20211231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nnox-20211231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nnox-20211231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nnox-20211231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet" id="nnox_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals" id="nnox_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement" id="nnox_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ShareholdersEquityType2or3" id="nnox_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statement of Changes in Shareholders&#8217; Equity (capital Deficiency)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ConsolidatedCashFlow" id="nnox_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/General" id="nnox_r_General">
        <link:definition>006 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SignificantAccountingPolicies" id="nnox_r_SignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransaction" id="nnox_r_BusinessCombinationandOtherTransaction">
        <link:definition>008 - Disclosure - Business Combination and Other Transaction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNet" id="nnox_r_GoodwillIntangibleAssetsNet">
        <link:definition>009 - Disclosure - Goodwill &amp; Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNet" id="nnox_r_PropertyandEquipmentNet">
        <link:definition>010 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash" id="nnox_r_CashCashEquivalentsandRestrictedCash">
        <link:definition>011 - Disclosure - Cash, Cash Equivalents and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/Leases" id="nnox_r_Leases">
        <link:definition>012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/DeferredRevenue" id="nnox_r_DeferredRevenue">
        <link:definition>013 - Disclosure - Deferred Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/RelatedParties" id="nnox_r_RelatedParties">
        <link:definition>014 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LongTermLoan" id="nnox_r_LongTermLoan">
        <link:definition>015 - Disclosure - Long Term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/CommitmentsandContingencies" id="nnox_r_CommitmentsandContingencies">
        <link:definition>016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ShareholdersEquity" id="nnox_r_ShareholdersEquity">
        <link:definition>017 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/IncomeTax" id="nnox_r_IncomeTax">
        <link:definition>018 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SegmentsofOperations" id="nnox_r_SegmentsofOperations">
        <link:definition>019 - Disclosure - Segments of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LossPerShare" id="nnox_r_LossPerShare">
        <link:definition>020 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SubsequentEvents" id="nnox_r_SubsequentEvents">
        <link:definition>021 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/AccountingPoliciesByPolicy" id="nnox_r_AccountingPoliciesByPolicy">
        <link:definition>022 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables" id="nnox_r_SignificantAccountingPoliciesTables">
        <link:definition>023 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables" id="nnox_r_BusinessCombinationandOtherTransactionTables">
        <link:definition>024 - Disclosure - Business Combination and Other Transaction (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables" id="nnox_r_GoodwillIntangibleAssetsNetTables">
        <link:definition>025 - Disclosure - Goodwill &amp; Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetTables" id="nnox_r_PropertyandEquipmentNetTables">
        <link:definition>026 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables" id="nnox_r_CashCashEquivalentsandRestrictedCashTables">
        <link:definition>027 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LeasesTables" id="nnox_r_LeasesTables">
        <link:definition>028 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/DeferredRevenueTables" id="nnox_r_DeferredRevenueTables">
        <link:definition>029 - Disclosure - Deferred Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/RelatedPartiesTables" id="nnox_r_RelatedPartiesTables">
        <link:definition>030 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ShareholdersEquityTables" id="nnox_r_ShareholdersEquityTables">
        <link:definition>031 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/IncomeTaxTables" id="nnox_r_IncomeTaxTables">
        <link:definition>032 - Disclosure - Income Tax (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SegmentsofOperationsTables" id="nnox_r_SegmentsofOperationsTables">
        <link:definition>033 - Disclosure - Segments of Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LossPerShareTables" id="nnox_r_LossPerShareTables">
        <link:definition>034 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/GeneralDetails" id="nnox_r_GeneralDetails">
        <link:definition>035 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails" id="nnox_r_SignificantAccountingPoliciesDetails">
        <link:definition>036 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable" id="nnox_r_ScheduleofpropertyandequipmentTable">
        <link:definition>037 - Disclosure - Significant Accounting Policies (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" id="nnox_r_ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable">
        <link:definition>038 - Disclosure - Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails" id="nnox_r_BusinessCombinationandOtherTransactionDetails">
        <link:definition>039 - Disclosure - Business Combination and Other Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable" id="nnox_r_ScheduleoffairvalueconsiderationtransferredTable">
        <link:definition>040 - Disclosure -  Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" id="nnox_r_ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable">
        <link:definition>041 - Disclosure -  Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable" id="nnox_r_ScheduleofacquisitionofNanoxAITable">
        <link:definition>042 - Disclosure -  Business Combination and Other Transaction (Details) - Schedule of acquisition of Nanox AI</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetDetails" id="nnox_r_GoodwillIntangibleAssetsNetDetails">
        <link:definition>043 - Disclosure - Goodwill &amp; Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable" id="nnox_r_ScheduleofgoodwillandtheintangibleassetsTable">
        <link:definition>044 - Disclosure - Goodwill &amp; Intangible Assets, Net (Details) - Schedule of goodwill and the intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable" id="nnox_r_ScheduleofintangibleassetsTable">
        <link:definition>045 - Disclosure - Goodwill &amp; Intangible Assets, Net (Details) - Schedule of intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable" id="nnox_r_ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable">
        <link:definition>046 - Disclosure - Goodwill &amp; Intangible Assets, Net (Details) - Schedule of Amortization of intangible assets for each of the next five years and thereafter</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails" id="nnox_r_PropertyandEquipmentNetDetails">
        <link:definition>047 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable" id="nnox_r_ScheduleofPercentageofpropertyandequipmentTable">
        <link:definition>048 - Disclosure - Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0" id="nnox_r_ScheduleofpropertyandequipmentTable0">
        <link:definition>049 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable" id="nnox_r_ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable">
        <link:definition>050 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LeasesDetails" id="nnox_r_LeasesDetails">
        <link:definition>051 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable" id="nnox_r_ScheduleofcompanystotalleasecostsTable">
        <link:definition>052 - Disclosure - Leases (Details) - Schedule of company's total lease costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable" id="nnox_r_ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable">
        <link:definition>053 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable" id="nnox_r_ScheduleofsupplementalbalancesheetinformationTable">
        <link:definition>054 - Disclosure - Leases (Details) - Schedule of supplemental balance sheet information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable" id="nnox_r_ScheduleofmaturitiesofoperatingleaseliabilitiesTable">
        <link:definition>055 - Disclosure - Leases (Details) - Schedule of maturities of operating lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/DeferredRevenueDetails" id="nnox_r_DeferredRevenueDetails">
        <link:definition>056 - Disclosure - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofDeferredRevenueTable" id="nnox_r_ScheduleofDeferredRevenueTable">
        <link:definition>057 - Disclosure - Deferred Revenue (Details) - Schedule of Deferred Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/RelatedPartiesDetails" id="nnox_r_RelatedPartiesDetails">
        <link:definition>058 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable" id="nnox_r_ScheduleofrelatedpartyTable">
        <link:definition>059 - Disclosure - Related Parties (Details) - Schedule of related party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable" id="nnox_r_ScheduleofrelatedpartiestransactionsTable">
        <link:definition>060 - Disclosure - Related Parties (Details) - Schedule of related parties transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LongTermLoanDetails" id="nnox_r_LongTermLoanDetails">
        <link:definition>061 - Disclosure - Long Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/CommitmentsandContingenciesDetails" id="nnox_r_CommitmentsandContingenciesDetails">
        <link:definition>062 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ShareholdersEquityDetails" id="nnox_r_ShareholdersEquityDetails">
        <link:definition>063 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nHxU+FkdcNBNYw6Vah1sITLF0AKIKqceszsygtSRj8AWpstzvXG3UpvsP0Kw1wBZdplajBi7sgUTevj2rFJUOTGGfUu3CQIgrK0mVSIM3kwlWl+4RGJ7ynzMoOtn9ec/Lw==] CSR-->
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable" id="nnox_r_ScheduleofissuedandoutstandingTable">
        <link:definition>064 - Disclosure - Shareholders' Equity (Details) - Schedule of issued and outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable" id="nnox_r_ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable">
        <link:definition>065 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based awards to employees, officers and directors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" id="nnox_r_ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable">
        <link:definition>066 - Disclosure - Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable" id="nnox_r_ScheduleofinformationconcerningoutstandingandexercisableawardsTable">
        <link:definition>067 - Disclosure - Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable" id="nnox_r_ScheduleofsharedbasedpaymentstoemployeesTable">
        <link:definition>068 - Disclosure - Shareholders' Equity (Details) - Schedule of shared - based payments to employees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable" id="nnox_r_ScheduleofsharebasedcompensationexpensesTable">
        <link:definition>069 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based compensation expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/IncomeTaxDetails" id="nnox_r_IncomeTaxDetails">
        <link:definition>070 - Disclosure - Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable" id="nnox_r_ScheduleofincomelossbeforeincometaxesconsistedTable">
        <link:definition>071 - Disclosure - Income Tax (Details) - Schedule of income (loss) before income taxes consisted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable" id="nnox_r_ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable">
        <link:definition>072 - Disclosure - Income Tax (Details) - Schedule of reconciliation our theoretical income tax expense to actual income tax expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="nnox_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>073 - Disclosure - Income Tax (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofvaluationallowanceprovidedportiondeferredTable" id="nnox_r_ScheduleofvaluationallowanceprovidedportiondeferredTable">
        <link:definition>074 - Disclosure - Income Tax (Details) - Schedule of valuation allowance provided portion deferred</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SegmentsofOperationsDetails" id="nnox_r_SegmentsofOperationsDetails">
        <link:definition>075 - Disclosure - Segments of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" id="nnox_r_ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable">
        <link:definition>076 - Disclosure - Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable" id="nnox_r_ScheduleofpropertyandequipmentbygeographyTable">
        <link:definition>077 - Disclosure - Segments of Operations (Details) - Schedule of property and equipment by geography</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/LossPerShareDetails" id="nnox_r_LossPerShareDetails">
        <link:definition>078 - Disclosure - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable" id="nnox_r_ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable">
        <link:definition>079 - Disclosure - Loss Per Share (Details) - Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/SubsequentEventsDetails" id="nnox_r_SubsequentEventsDetails">
        <link:definition>080 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nanox.vision.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract"/>
  <xs:element name="CertainTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CertainTransactionsAbstract"/>
  <xs:element name="ScheduleOfFairValueConsiderationTransferredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfFairValueConsiderationTransferredAbstract"/>
  <xs:element name="ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract"/>
  <xs:element name="ScheduleOfAcquisitionOfNanoxAiAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfAcquisitionOfNanoxAiAbstract"/>
  <xs:element name="ScheduleOfGoodwillAndTheIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfGoodwillAndTheIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract"/>
  <xs:element name="ScheduleOfPercentageOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfPercentageOfPropertyAndEquipmentAbstract"/>
  <xs:element name="CashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
  <xs:element name="ScheduleOfCompanysTotalLeaseCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract"/>
  <xs:element name="ScheduleOfSupplementalBalanceSheetInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract"/>
  <xs:element name="DeferredRevenuesDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DeferredRevenuesDisclosureAbstract"/>
  <xs:element name="ScheduleOfDeferredRevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfDeferredRevenueAbstract"/>
  <xs:element name="RelatedPartyLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RelatedPartyLiabilityAbstract"/>
  <xs:element name="ScheduleOfRelatedPartyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfRelatedPartyAbstract"/>
  <xs:element name="ScheduleOfRelatedPartiesTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfRelatedPartiesTransactionsAbstract"/>
  <xs:element name="ScheduleOfIssuedAndOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfIssuedAndOutstandingAbstract"/>
  <xs:element name="ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract"/>
  <xs:element name="ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract"/>
  <xs:element name="ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract"/>
  <xs:element name="ScheduleOfSharedBasedPaymentsToEmployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract"/>
  <xs:element name="ScheduleOfShareBasedCompensationExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfShareBasedCompensationExpensesAbstract"/>
  <xs:element name="ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract"/>
  <xs:element name="ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract"/>
  <xs:element name="SegmentsOfOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SegmentsOfOperationsAbstract"/>
  <xs:element name="ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentByGeographyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfPropertyAndEquipmentByGeographyAbstract"/>
  <xs:element name="ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract"/>
  <xs:element name="NonCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NonCurrentAssetsAbstract"/>
  <xs:element name="NonCurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NonCurrentLiabilitiesAbstract"/>
  <xs:element name="OtherComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OtherComprehensiveLossAbstract"/>
  <xs:element name="ChangesDuring2020Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ChangesDuring2020Abstract"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AssetsAbstract0"/>
  <xs:element name="OperatingLeaseCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OperatingLeaseCostAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract"/>
  <xs:element name="OperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OperatingLeasesAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_WeightedAverageDiscountRateAbstract"/>
  <xs:element name="ChangesDuringTheYearAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ChangesDuringTheYearAbstract"/>
  <xs:element name="ChangesDuringTheYearAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ChangesDuringTheYearAbstract0"/>
  <xs:element name="CurrentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CurrentAbstract"/>
  <xs:element name="DeferredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DeferredAbstract"/>
  <xs:element name="IncreaseDecreaseInTaxesResultingFromAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncreaseDecreaseInTaxesResultingFromAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DeferredTaxAssetsAbstract"/>
  <xs:element name="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
  <xs:element name="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares"/>
  <xs:element name="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants"/>
  <xs:element name="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares"/>
  <xs:element name="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6"/>
  <xs:element name="IssuanceOfOrdinarySharesUponExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants"/>
  <xs:element name="IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares"/>
  <xs:element name="IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions"/>
  <xs:element name="IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares"/>
  <xs:element name="IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets"/>
  <xs:element name="IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin"/>
  <xs:element name="IncreaseDecreaseRelatedPartyPrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses"/>
  <xs:element name="IncreaseDecreaseOperatingLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncreaseDecreaseOperatingLease"/>
  <xs:element name="ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
  <xs:element name="UnpaidOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_UnpaidOfferingCosts"/>
  <xs:element name="issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants"/>
  <xs:element name="FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets"/>
  <xs:element name="FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations"/>
  <xs:element name="FairValueOfContingentConsiderationAssumedInBusinessCombinations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations"/>
  <xs:element name="IssuanceOfSharesInConsiderationOfAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfSharesInConsiderationOfAssets"/>
  <xs:element name="RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities"/>
  <xs:element name="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements"/>
  <xs:element name="ConversionOfRelatedPartyLiabilityToShareholdersEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity"/>
  <xs:element name="GeneralTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_GeneralTable"/>
  <xs:element name="GeneralLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_GeneralLineItems"/>
  <xs:element name="CertainTransactionsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CertainTransactionsTextBlock"/>
  <xs:element name="CashEquivalentsAndRestrictedCashTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CashEquivalentsAndRestrictedCashTextBlock"/>
  <xs:element name="CashCashEquivalentsandRestrictedCashTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_CashCashEquivalentsandRestrictedCashTable"/>
  <xs:element name="CashCashEquivalentsandRestrictedCashLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CashCashEquivalentsandRestrictedCashLineItems"/>
  <xs:element name="DeferredRevenuesDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DeferredRevenuesDisclosureTextBlock"/>
  <xs:element name="RelatedPartyLiabilityTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RelatedPartyLiabilityTextBlock"/>
  <xs:element name="SegmentsOfOperationsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SegmentsOfOperationsTextBlock"/>
  <xs:element name="SeverancePayPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SeverancePayPolicyTextBlock"/>
  <xs:element name="LegalAndOtherContingenciesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_LegalAndOtherContingenciesPolicyTextBlock"/>
  <xs:element name="DeferredOfferingCostsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DeferredOfferingCostsPolicyTextBlock"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock"/>
  <xs:element name="ScheduleOfFairValueConsiderationTransferred" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfFairValueConsiderationTransferred"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock"/>
  <xs:element name="CashCashEquivalentsandRestrictedCashTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_CashCashEquivalentsandRestrictedCashTablesTable"/>
  <xs:element name="CashCashEquivalentsandRestrictedCashTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CashCashEquivalentsandRestrictedCashTablesLineItems"/>
  <xs:element name="ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
  <xs:element name="ScheduleOfRelatedPartyTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfRelatedPartyTableTextBlock"/>
  <xs:element name="ScheduleOfIssuedAndOutstandingTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfIssuedAndOutstandingTextBlock"/>
  <xs:element name="ShareholdersEquityTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityTablesTable"/>
  <xs:element name="ShareholdersEquityTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityTablesLineItems"/>
  <xs:element name="ScheduleOfIncomelossBeforeIncomeTaxesConsisted" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted"/>
  <xs:element name="ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
  <xs:element name="PropertyPlantAndEquipmentSalvageValuePercentageDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems"/>
  <xs:element name="LongTermMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_LongTermMarketableSecurities"/>
  <xs:element name="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable"/>
  <xs:element name="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems"/>
  <xs:element name="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"/>
  <xs:element name="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems"/>
  <xs:element name="TotalAssetsAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_TotalAssetsAcquired"/>
  <xs:element name="ContingentShortTermEarnoutLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_ContingentShortTermEarnoutLiability"/>
  <xs:element name="ContingentLongtermEarnoutLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_ContingentLongtermEarnoutLiability"/>
  <xs:element name="ConvertibleNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_ConvertibleNote"/>
  <xs:element name="NetAssetsAcquired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_NetAssetsAcquired"/>
  <xs:element name="ContingentLongTermEarnoutLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_ContingentLongTermEarnoutLiability"/>
  <xs:element name="FiniteLivedIntangibleAssetNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_FiniteLivedIntangibleAssetNet"/>
  <xs:element name="AmortizationExpenseForThePeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_AmortizationExpenseForThePeriod"/>
  <xs:element name="PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable"/>
  <xs:element name="PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems"/>
  <xs:element name="PercentageOfPropertyPlantAndEquipment" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_PercentageOfPropertyPlantAndEquipment"/>
  <xs:element name="RestrictedBankDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_RestrictedBankDeposit"/>
  <xs:element name="TotalOperatingLeaseCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_TotalOperatingLeaseCost"/>
  <xs:element name="CurrentMaturitiesOfOperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_CurrentMaturitiesOfOperatingLeases"/>
  <xs:element name="NoncurrentOperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_NoncurrentOperatingLeases"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentsDueYearFours" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter"/>
  <xs:element name="PresentValueOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_PresentValueOfLeaseLiabilities"/>
  <xs:element name="IncreaseDueToTheBusinessCombinations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncreaseDueToTheBusinessCombinations"/>
  <xs:element name="DeferredRevenuesTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_DeferredRevenuesTotal"/>
  <xs:element name="RelatedPartiesDetailsScheduleofrelatedpartyTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable"/>
  <xs:element name="RelatedPartiesDetailsScheduleofrelatedpartyLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems"/>
  <xs:element name="TotalDueFromRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_TotalDueFromRelatedParties"/>
  <xs:element name="OtherGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_OtherGeneralAndAdministrativeExpenses"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofissuedandoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems"/>
  <xs:element name="OrdinarySharesIssuedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_OrdinarySharesIssuedAndOutstanding"/>
  <xs:element name="NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
  <xs:element name="IssuedDueToBusinessCombination" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuedDueToBusinessCombination"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockOptionsForfeited" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited"/>
  <xs:element name="NumberOfSharebasedPaymentAwardsCancelled" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NumberOfSharebasedPaymentAwardsCancelled"/>
  <xs:element name="WeightedAverageExercisePriceExercisableAtEndOfYear" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_WeightedAverageExercisePriceExercisableAtEndOfYear"/>
  <xs:element name="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable"/>
  <xs:element name="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems"/>
  <xs:element name="CurrentTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_CurrentTotal"/>
  <xs:element name="DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
  <xs:element name="DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
  <xs:element name="ProvisionForIncomeTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_ProvisionForIncomeTaxes"/>
  <xs:element name="LessValuationAllowanceForDeferredTaxAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_LessValuationAllowanceForDeferredTaxAssets"/>
  <xs:element name="IncreaseDueToBusinessCombinationinShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncreaseDueToBusinessCombinationinShares"/>
  <xs:element name="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"/>
  <xs:element name="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems"/>
  <xs:element name="FinancialIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_FinancialIncome"/>
  <xs:element name="FinancialExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_FinancialExpense"/>
  <xs:element name="SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable"/>
  <xs:element name="SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems"/>
  <xs:element name="TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands"/>
  <xs:element name="BasicAndDilutedLossPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_BasicAndDilutedLossPerShare"/>
  <xs:element name="GeneralDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_GeneralDetailsTable"/>
  <xs:element name="GeneralDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_GeneralDetailsLineItems"/>
  <xs:element name="InitialPublicOfferingNetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_InitialPublicOfferingNetProceeds"/>
  <xs:element name="TaxBenefitPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_TaxBenefitPercentage"/>
  <xs:element name="BusinessCombinationandOtherTransactionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_BusinessCombinationandOtherTransactionDetailsTable"/>
  <xs:element name="BusinessCombinationandOtherTransactionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_BusinessCombinationandOtherTransactionDetailsLineItems"/>
  <xs:element name="EmployeeOptionsAndRestrictedStockUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_EmployeeOptionsAndRestrictedStockUnits"/>
  <xs:element name="OutstandingSharesPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_OutstandingSharesPerShare"/>
  <xs:element name="ServicePeriodsDecription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ServicePeriodsDecription"/>
  <xs:element name="PurchaseConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_PurchaseConsideration"/>
  <xs:element name="DeferredClosingConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_DeferredClosingConsideration"/>
  <xs:element name="AdditionalConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_AdditionalConsideration"/>
  <xs:element name="MaximumAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_MaximumAggregateAmount"/>
  <xs:element name="FairValuePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_FairValuePercentage"/>
  <xs:element name="DescriptionOfNetAssets" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DescriptionOfNetAssets"/>
  <xs:element name="AcquisitionDate" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AcquisitionDate"/>
  <xs:element name="NetLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_NetLoss"/>
  <xs:element name="AcquisitionOfSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AcquisitionOfSharesPercentage"/>
  <xs:element name="PurchaseOfSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_PurchaseOfSharesPercentage"/>
  <xs:element name="OrdinaryShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_OrdinaryShare"/>
  <xs:element name="OtherOperationalPerformancebasedEarnoutsOver" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OtherOperationalPerformancebasedEarnoutsOver"/>
  <xs:element name="AdditionalCashConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_AdditionalCashConsideration"/>
  <xs:element name="OtherRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_OtherRevenue"/>
  <xs:element name="OtherNetLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_OtherNetLoss"/>
  <xs:element name="SettledInCashPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SettledInCashPercentage"/>
  <xs:element name="IssuanceOfOrdinarySharePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IssuanceOfOrdinarySharePercentage"/>
  <xs:element name="AdditionalPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_AdditionalPayment"/>
  <xs:element name="FairValueOfContingentConsiderationLiabilities" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_FairValueOfContingentConsiderationLiabilities"/>
  <xs:element name="PrincipalAmountOfThePPPLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nnox_PrincipalAmountOfThePPPLoan"/>
  <xs:element name="InterestAccruesRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_InterestAccruesRate"/>
  <xs:element name="LoanTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_LoanTerm"/>
  <xs:element name="AssetsAcquisitionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AssetsAcquisitionDescription"/>
  <xs:element name="LeaseTermDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_LeaseTermDescription"/>
  <xs:element name="LeasesTermDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_LeasesTermDescription"/>
  <xs:element name="VehiclesLeasePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_VehiclesLeasePayments"/>
  <xs:element name="FabricationFacilityAndResearchDevelopmentalCenterDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription"/>
  <xs:element name="AgreementDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AgreementDomain"/>
  <xs:element name="RelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_RelatedPartiesDetailsTable"/>
  <xs:element name="RelatedPartiesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RelatedPartiesDetailsLineItems"/>
  <xs:element name="PaysApproximately" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_PaysApproximately"/>
  <xs:element name="EmploymentAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_EmploymentAgreementDescription"/>
  <xs:element name="AnnualInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_AnnualInterestRate"/>
  <xs:element name="ConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_ConsultingFees"/>
  <xs:element name="EntitlementToWarrantsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_EntitlementToWarrantsAmount"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="DescriptionOfSharebasedCompensationExpenses" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DescriptionOfSharebasedCompensationExpenses"/>
  <xs:element name="VestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_VestingPeriod"/>
  <xs:element name="AgreementTerminateTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AgreementTerminateTerm"/>
  <xs:element name="ConsiderationForServicesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ConsiderationForServicesShares"/>
  <xs:element name="PurchaseAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_PurchaseAggregateShares"/>
  <xs:element name="RecordedAnExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nnox_RecordedAnExpense"/>
  <xs:element name="IncomeTaxDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_IncomeTaxDetailsTable"/>
  <xs:element name="IncomeTaxDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncomeTaxDetailsLineItems"/>
  <xs:element name="FederalTaxRatePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_FederalTaxRatePercentage"/>
  <xs:element name="CarryForwardLossYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_CarryForwardLossYears"/>
  <xs:element name="SegmentsofOperationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_SegmentsofOperationsDetailsTable"/>
  <xs:element name="SegmentsofOperationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SegmentsofOperationsDetailsLineItems"/>
  <xs:element name="BasicAndDilutedShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_BasicAndDilutedShare"/>
  <xs:element name="WarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_WarrantsShares"/>
  <xs:element name="WarrantsOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nnox_WarrantsOption"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nnox_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SubsequentEventsDetailsLineItems"/>
  <xs:element name="AdditionalSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AdditionalSharesIssued"/>
  <xs:element name="LeasedAdditionTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_LeasedAdditionTerm"/>
  <xs:element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="nnox_AgreementAxis"/>
  <xs:element name="AISolutionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AISolutionsMember"/>
  <xs:element name="AwardsExercisableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AwardsExercisableMember"/>
  <xs:element name="AwardsOutstandingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_AwardsOutstandingMember"/>
  <xs:element name="BlackScholesOptionpricingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_BlackScholesOptionpricingMember"/>
  <xs:element name="BusinessAcquisitionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_BusinessAcquisitionMember"/>
  <xs:element name="ComputersAndElectronicEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ComputersAndElectronicEquipmentMember"/>
  <xs:element name="DueToMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DueToMember"/>
  <xs:element name="DueToOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DueToOneMember"/>
  <xs:element name="DueToThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DueToThreeMember"/>
  <xs:element name="DueToTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DueToTwoMember"/>
  <xs:element name="EmployeesOfficersAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_EmployeesOfficersAndDirectorsMember"/>
  <xs:element name="FortynineAndSixtyeightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_FortynineAndSixtyeightMember"/>
  <xs:element name="ImageBigDataMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ImageBigDataMember"/>
  <xs:element name="IncomeTaxExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncomeTaxExpensesMember"/>
  <xs:element name="IncomelossBeforeIncomeTaxesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_IncomelossBeforeIncomeTaxesMember"/>
  <xs:element name="MDWEBLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_MDWEBLLCMember"/>
  <xs:element name="NanoxAILtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NanoxAILtdMember"/>
  <xs:element name="NanoxARCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NanoxARCMember"/>
  <xs:element name="NanoxJapanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NanoxJapanMember"/>
  <xs:element name="NanoxPLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NanoxPLCMember"/>
  <xs:element name="NasdaqMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NasdaqMember"/>
  <xs:element name="NonemployeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_NonemployeesMember"/>
  <xs:element name="OfficeFurnitureAndLabEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OfficeFurnitureAndLabEquipmentMember"/>
  <xs:element name="OneEightZeroZeroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OneEightZeroZeroMember"/>
  <xs:element name="OneNinetyTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OneNinetyTwoMember"/>
  <xs:element name="OnePointZeroZeroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OnePointZeroZeroMember"/>
  <xs:element name="OneSixZeroZeroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_OneSixZeroZeroMember"/>
  <xs:element name="PPPLoanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_PPPLoanMember"/>
  <xs:element name="ProductionLineInConstructionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ProductionLineInConstructionMember"/>
  <xs:element name="RadiologistRelationshipsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RadiologistRelationshipsMember"/>
  <xs:element name="RadiologyServicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_RadiologyServicesMember"/>
  <xs:element name="SeventeenPointSixtyThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SeventeenPointSixtyThreeMember"/>
  <xs:element name="SharePurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SharePurchaseAgreementMember"/>
  <xs:element name="SixAIMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SixAIMember"/>
  <xs:element name="SixteenPointZeroZeroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_SixteenPointZeroZeroMember"/>
  <xs:element name="TaxesOnIncomeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_TaxesOnIncomeMember"/>
  <xs:element name="ThirtyPointNineThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ThirtyPointNineThreeMember"/>
  <xs:element name="TotalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_TotalMember"/>
  <xs:element name="TwentSixPointFiveSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_TwentSixPointFiveSixMember"/>
  <xs:element name="TwoPointTwoOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_TwoPointTwoOneMember"/>
  <xs:element name="TwoTwentyOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_TwoTwentyOneMember"/>
  <xs:element name="USARADHoldingIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_USARADHoldingIncMember"/>
  <xs:element name="USARADMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_USARADMember"/>
  <xs:element name="WellseseTechnologiesLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_WellseseTechnologiesLtdMember"/>
  <xs:element name="ZebraMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ZebraMember"/>
  <xs:element name="ZeroPointZeroZeroOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_ZeroPointZeroZeroOneMember"/>
  <xs:element name="fortyAndTwentyoneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_fortyAndTwentyoneMember"/>
  <xs:element name="thirtyAndSixtysixHundredthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_thirtyAndSixtysixHundredthsMember"/>
  <xs:element name="twentythreeAndEightyfourHundredthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_twentythreeAndEightyfourHundredthsMember"/>
  <xs:element name="twentythreeAndNineteenHundredthsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_twentythreeAndNineteenHundredthsMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nnox_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>nnox-20211231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 02 05:16:13 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedBalanceSheet" roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedIncomeStatement" roleURI="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedCashFlow" roleURI="http://www.nanox.vision.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable" roleURI="http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofpropertyandequipmentTable0" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_Goodwill" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBorrowings" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLongTermDebtNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4" weight="-1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nHxU+FkdcNBNYw6Vah1sITLF0AKIKqceszsygtSRj8AWpstzvXG3UpvsP0Kw1wBZdplajBi7sgUTevj2rFJUOTGGfUu3CQIgrK0mVSIM3kwlJSigdnCHUXv40CE1GxYCUg==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseOperatingLease" xlink:href="nnox-20211231.xsd#nnox_IncreaseDecreaseOperatingLease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nnox_IncreaseDecreaseOperatingLease" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:href="nnox-20211231.xsd#nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20211231.xsd#nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>nnox-20211231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 02 05:16:13 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedBalanceSheet" roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedIncomeStatement" roleURI="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ShareholdersEquityType2or3" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedCashFlow" roleURI="http://www.nanox.vision.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_General" roleURI="http://www.nanox.vision.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SignificantAccountingPolicies" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_BusinessCombinationandOtherTransaction" roleURI="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransaction"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_GoodwillIntangibleAssetsNet" roleURI="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_PropertyandEquipmentNet" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_CashCashEquivalentsandRestrictedCash" roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_Leases" roleURI="http://www.nanox.vision.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_DeferredRevenue" roleURI="http://www.nanox.vision.com/role/DeferredRevenue"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_RelatedParties" roleURI="http://www.nanox.vision.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LongTermLoan" roleURI="http://www.nanox.vision.com/role/LongTermLoan"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_CommitmentsandContingencies" roleURI="http://www.nanox.vision.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ShareholdersEquity" roleURI="http://www.nanox.vision.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_IncomeTax" roleURI="http://www.nanox.vision.com/role/IncomeTax"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SegmentsofOperations" roleURI="http://www.nanox.vision.com/role/SegmentsofOperations"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LossPerShare" roleURI="http://www.nanox.vision.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SubsequentEvents" roleURI="http://www.nanox.vision.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_AccountingPoliciesByPolicy" roleURI="http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SignificantAccountingPoliciesTables" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_BusinessCombinationandOtherTransactionTables" roleURI="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_GoodwillIntangibleAssetsNetTables" roleURI="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_PropertyandEquipmentNetTables" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LeasesTables" roleURI="http://www.nanox.vision.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_DeferredRevenueTables" roleURI="http://www.nanox.vision.com/role/DeferredRevenueTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_RelatedPartiesTables" roleURI="http://www.nanox.vision.com/role/RelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ShareholdersEquityTables" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_IncomeTaxTables" roleURI="http://www.nanox.vision.com/role/IncomeTaxTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SegmentsofOperationsTables" roleURI="http://www.nanox.vision.com/role/SegmentsofOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LossPerShareTables" roleURI="http://www.nanox.vision.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofpropertyandequipmentTable" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" roleURI="http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleoffairvalueconsiderationtransferredTable" roleURI="http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" roleURI="http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofacquisitionofNanoxAITable" roleURI="http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofgoodwillandtheintangibleassetsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofintangibleassetsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable" roleURI="http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofPercentageofpropertyandequipmentTable" roleURI="http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofpropertyandequipmentTable0" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable" roleURI="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofcompanystotalleasecostsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofsupplementalbalancesheetinformationTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofmaturitiesofoperatingleaseliabilitiesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofDeferredRevenueTable" roleURI="http://www.nanox.vision.com/role/ScheduleofDeferredRevenueTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofrelatedpartyTable" roleURI="http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofrelatedpartiestransactionsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofissuedandoutstandingTable" roleURI="http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofinformationconcerningoutstandingandexercisableawardsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofsharedbasedpaymentstoemployeesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofsharebasedcompensationexpensesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofincomelossbeforeincometaxesconsistedTable" roleURI="http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable" roleURI="http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofvaluationallowanceprovidedportiondeferredTable" roleURI="http://www.nanox.vision.com/role/ScheduleofvaluationallowanceprovidedportiondeferredTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" roleURI="http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofpropertyandequipmentbygeographyTable" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable" roleURI="http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_GeneralDetails" roleURI="http://www.nanox.vision.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SignificantAccountingPoliciesDetails" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_BusinessCombinationandOtherTransactionDetails" roleURI="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_GoodwillIntangibleAssetsNetDetails" roleURI="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_PropertyandEquipmentNetDetails" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LeasesDetails" roleURI="http://www.nanox.vision.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_DeferredRevenueDetails" roleURI="http://www.nanox.vision.com/role/DeferredRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_RelatedPartiesDetails" roleURI="http://www.nanox.vision.com/role/RelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LongTermLoanDetails" roleURI="http://www.nanox.vision.com/role/LongTermLoanDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_CommitmentsandContingenciesDetails" roleURI="http://www.nanox.vision.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ShareholdersEquityDetails" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_IncomeTaxDetails" roleURI="http://www.nanox.vision.com/role/IncomeTaxDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SegmentsofOperationsDetails" roleURI="http://www.nanox.vision.com/role/SegmentsofOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LossPerShareDetails" roleURI="http://www.nanox.vision.com/role/LossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SubsequentEventsDetails" roleURI="http://www.nanox.vision.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#DocumentAndEntityInformation" roleURI="http://www.nanox.vision.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NonCurrentAssetsAbstract" xlink:href="nnox-20211231.xsd#nnox_NonCurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="nnox_NonCurrentAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentAssetsAbstract" xlink:to="us-gaap_RestrictedCash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentAssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentAssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentAssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentAssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentAssetsAbstract" xlink:to="us-gaap_Goodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentAssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_ShortTermBorrowings" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NonCurrentLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_NonCurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="nnox_NonCurrentLiabilitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherLongTermDebtNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_Liabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_CostOfRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_GrossProfit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_EarningsPerShareBasic" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OtherComprehensiveLossAbstract" xlink:href="nnox-20211231.xsd#nnox_OtherComprehensiveLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="nnox_OtherComprehensiveLossAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OtherComprehensiveLossAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" xlink:href="nnox-20211231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:href="nnox-20211231.xsd#nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseOperatingLease" xlink:href="nnox-20211231.xsd#nnox_IncreaseDecreaseOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="nnox_IncreaseDecreaseOperatingLease" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20211231.xsd#nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_UnpaidOfferingCosts" xlink:href="nnox-20211231.xsd#nnox_UnpaidOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_UnpaidOfferingCosts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:href="nnox-20211231.xsd#nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" xlink:href="nnox-20211231.xsd#nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" xlink:href="nnox-20211231.xsd#nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations" xlink:href="nnox-20211231.xsd#nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfSharesInConsiderationOfAssets" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfSharesInConsiderationOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_IssuanceOfSharesInConsiderationOfAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:href="nnox-20211231.xsd#nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:href="nnox-20211231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:href="nnox-20211231.xsd#nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/General">
    <loc xlink:type="locator" xlink:label="nnox_GeneralLineItems" xlink:href="nnox-20211231.xsd#nnox_GeneralLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_GeneralTable" xlink:href="nnox-20211231.xsd#nnox_GeneralTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_GeneralLineItems" xlink:to="nnox_GeneralTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_GeneralLineItems" xlink:to="us-gaap_NatureOfOperations" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransaction">
    <loc xlink:type="locator" xlink:label="nnox_CertainTransactionsAbstract" xlink:href="nnox-20211231.xsd#nnox_CertainTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_CertainTransactionsTextBlock" xlink:href="nnox-20211231.xsd#nnox_CertainTransactionsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CertainTransactionsAbstract" xlink:to="nnox_CertainTransactionsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNet">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash">
    <loc xlink:type="locator" xlink:label="nnox_CashCashEquivalentsandRestrictedCashLineItems" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_CashCashEquivalentsandRestrictedCashTable" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_CashCashEquivalentsandRestrictedCashLineItems" xlink:to="nnox_CashCashEquivalentsandRestrictedCashTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_CashEquivalentsAndRestrictedCashTextBlock" xlink:href="nnox-20211231.xsd#nnox_CashEquivalentsAndRestrictedCashTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CashCashEquivalentsandRestrictedCashLineItems" xlink:to="nnox_CashEquivalentsAndRestrictedCashTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/DeferredRevenue">
    <loc xlink:type="locator" xlink:label="nnox_DeferredRevenuesDisclosureAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredRevenuesDisclosureTextBlock" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_DeferredRevenuesDisclosureAbstract" xlink:to="nnox_DeferredRevenuesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilityAbstract" xlink:href="nnox-20211231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilityTextBlock" xlink:href="nnox-20211231.xsd#nnox_RelatedPartyLiabilityTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartyLiabilityAbstract" xlink:to="nnox_RelatedPartyLiabilityTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LongTermLoan">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/IncomeTax">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SegmentsofOperations">
    <loc xlink:type="locator" xlink:label="nnox_SegmentsOfOperationsAbstract" xlink:href="nnox-20211231.xsd#nnox_SegmentsOfOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsOfOperationsTextBlock" xlink:href="nnox-20211231.xsd#nnox_SegmentsOfOperationsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsOfOperationsAbstract" xlink:to="nnox_SegmentsOfOperationsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_SeverancePayPolicyTextBlock" xlink:href="nnox-20211231.xsd#nnox_SeverancePayPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nnox_SeverancePayPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LegalAndOtherContingenciesPolicyTextBlock" xlink:href="nnox-20211231.xsd#nnox_LegalAndOtherContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nnox_LegalAndOtherContingenciesPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredOfferingCostsPolicyTextBlock" xlink:href="nnox-20211231.xsd#nnox_DeferredOfferingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nnox_DeferredOfferingCostsPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables">
    <loc xlink:type="locator" xlink:label="nnox_CertainTransactionsAbstract" xlink:href="nnox-20211231.xsd#nnox_CertainTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfFairValueConsiderationTransferred" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfFairValueConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CertainTransactionsAbstract" xlink:to="nnox_ScheduleOfFairValueConsiderationTransferred" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CertainTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CertainTransactionsAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables">
    <loc xlink:type="locator" xlink:label="nnox_CashCashEquivalentsandRestrictedCashTablesLineItems" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_CashCashEquivalentsandRestrictedCashTablesTable" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_CashCashEquivalentsandRestrictedCashTablesLineItems" xlink:to="nnox_CashCashEquivalentsandRestrictedCashTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CashCashEquivalentsandRestrictedCashTablesLineItems" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/DeferredRevenueTables">
    <loc xlink:type="locator" xlink:label="nnox_DeferredRevenuesDisclosureAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_DeferredRevenuesDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilityAbstract" xlink:href="nnox-20211231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfRelatedPartyTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfRelatedPartyTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartyLiabilityAbstract" xlink:to="nnox_ScheduleOfRelatedPartyTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartyLiabilityAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityTablesLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityTablesTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="nnox_ShareholdersEquityTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityTablesTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_EmployeesOfficersAndDirectorsMember" xlink:href="nnox-20211231.xsd#nnox_EmployeesOfficersAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nnox_EmployeesOfficersAndDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfIssuedAndOutstandingTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIssuedAndOutstandingTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="nnox_ScheduleOfIssuedAndOutstandingTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/IncomeTaxTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SegmentsofOperationsTables">
    <loc xlink:type="locator" xlink:label="nnox_SegmentsOfOperationsAbstract" xlink:href="nnox-20211231.xsd#nnox_SegmentsOfOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsOfOperationsAbstract" xlink:to="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsOfOperationsAbstract" xlink:to="nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:href="nnox-20211231.xsd#nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable">
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LongTermMarketableSecurities" xlink:href="nnox-20211231.xsd#nnox_LongTermMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="nnox_LongTermMarketableSecurities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_LongTermDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_Liabilities" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable">
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxAILtdMember" xlink:href="nnox-20211231.xsd#nnox_NanoxAILtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_NanoxAILtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_USARADHoldingIncMember" xlink:href="nnox-20211231.xsd#nnox_USARADHoldingIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_USARADHoldingIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationAsset" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable">
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxAILtdMember" xlink:href="nnox-20211231.xsd#nnox_NanoxAILtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_NanoxAILtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_USARADHoldingIncMember" xlink:href="nnox-20211231.xsd#nnox_USARADHoldingIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_USARADHoldingIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_IntangibleAssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_Goodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_OtherAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_TotalAssetsAcquired" xlink:href="nnox-20211231.xsd#nnox_TotalAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="nnox_TotalAssetsAcquired" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ContingentShortTermEarnoutLiability" xlink:href="nnox-20211231.xsd#nnox_ContingentShortTermEarnoutLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="nnox_ContingentShortTermEarnoutLiability" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ContingentLongTermEarnoutLiability" xlink:href="nnox-20211231.xsd#nnox_ContingentLongTermEarnoutLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="nnox_ContingentLongTermEarnoutLiability" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ContingentLongtermEarnoutLiability" xlink:href="nnox-20211231.xsd#nnox_ContingentLongtermEarnoutLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="nnox_ContingentLongtermEarnoutLiability" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ConvertibleNote" xlink:href="nnox-20211231.xsd#nnox_ConvertibleNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="nnox_ConvertibleNote" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_OtherLiabilities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NetAssetsAcquired" xlink:href="nnox-20211231.xsd#nnox_NetAssetsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="nnox_NetAssetsAcquired" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable">
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxAILtdMember" xlink:href="nnox-20211231.xsd#nnox_NanoxAILtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="nnox_NanoxAILtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_GoodwillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ZebraMember" xlink:href="nnox-20211231.xsd#nnox_ZebraMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nnox_ZebraMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_USARADMember" xlink:href="nnox-20211231.xsd#nnox_USARADMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="nnox_USARADMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ImageBigDataMember" xlink:href="nnox-20211231.xsd#nnox_ImageBigDataMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="nnox_ImageBigDataMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_MarketingRelatedIntangibleAssetsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RadiologistRelationshipsMember" xlink:href="nnox-20211231.xsd#nnox_RadiologistRelationshipsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="nnox_RadiologistRelationshipsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TradeNamesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FiniteLivedIntangibleAssetNet" xlink:href="nnox-20211231.xsd#nnox_FiniteLivedIntangibleAssetNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="nnox_FiniteLivedIntangibleAssetNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AmortizationExpenseForThePeriod" xlink:href="nnox-20211231.xsd#nnox_AmortizationExpenseForThePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="nnox_AmortizationExpenseForThePeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems" xlink:href="nnox-20211231.xsd#nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" xlink:href="nnox-20211231.xsd#nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems" xlink:to="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ComputersAndElectronicEquipmentMember" xlink:href="nnox-20211231.xsd#nnox_ComputersAndElectronicEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nnox_ComputersAndElectronicEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PercentageOfPropertyPlantAndEquipment" xlink:href="nnox-20211231.xsd#nnox_PercentageOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems" xlink:to="nnox_PercentageOfPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OfficeFurnitureAndLabEquipmentMember" xlink:href="nnox-20211231.xsd#nnox_OfficeFurnitureAndLabEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nnox_OfficeFurnitureAndLabEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ComputersAndElectronicEquipmentMember" xlink:href="nnox-20211231.xsd#nnox_ComputersAndElectronicEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nnox_ComputersAndElectronicEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ProductionLineInConstructionMember" xlink:href="nnox-20211231.xsd#nnox_ProductionLineInConstructionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nnox_ProductionLineInConstructionMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RestrictedBankDeposit" xlink:href="nnox-20211231.xsd#nnox_RestrictedBankDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="nnox_RestrictedBankDeposit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfCompanysTotalLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_OperatingLeaseCostAbstract" xlink:href="nnox-20211231.xsd#nnox_OperatingLeaseCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:to="nnox_OperatingLeaseCostAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OperatingLeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OperatingLeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nHxU+FkdcNBNYw6Vah1sITLF0AKIKqceszsygtSRj8AWpstzvXG3UpvsP0Kw1wBZdplajBi7sgUTevj2rFJUOTGGfUu3CQIgrK0mVSIM3kwl0Wj2oI/6NADgmYxjJIz+zg==] CSR-->
    <loc xlink:type="locator" xlink:label="nnox_TotalOperatingLeaseCost" xlink:href="nnox-20211231.xsd#nnox_TotalOperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:to="nnox_TotalOperatingLeaseCost" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:href="nnox-20211231.xsd#nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_OperatingLeasesAbstract" xlink:href="nnox-20211231.xsd#nnox_OperatingLeasesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="nnox_OperatingLeasesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_CurrentMaturitiesOfOperatingLeases" xlink:href="nnox-20211231.xsd#nnox_CurrentMaturitiesOfOperatingLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="nnox_CurrentMaturitiesOfOperatingLeases" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NoncurrentOperatingLeases" xlink:href="nnox-20211231.xsd#nnox_NoncurrentOperatingLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="nnox_NoncurrentOperatingLeases" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_WeightedAverageRemainingLeaseTermAbstract" xlink:href="nnox-20211231.xsd#nnox_WeightedAverageRemainingLeaseTermAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="nnox_WeightedAverageRemainingLeaseTermAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_WeightedAverageDiscountRateAbstract" xlink:href="nnox-20211231.xsd#nnox_WeightedAverageDiscountRateAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="nnox_WeightedAverageDiscountRateAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:href="nnox-20211231.xsd#nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter" xlink:href="nnox-20211231.xsd#nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:to="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PresentValueOfLeaseLiabilities" xlink:href="nnox-20211231.xsd#nnox_PresentValueOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:to="nnox_PresentValueOfLeaseLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofDeferredRevenueTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfDeferredRevenueAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfDeferredRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfDeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDueToTheBusinessCombinations" xlink:href="nnox-20211231.xsd#nnox_IncreaseDueToTheBusinessCombinations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfDeferredRevenueAbstract" xlink:to="nnox_IncreaseDueToTheBusinessCombinations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredRevenuesTotal" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfDeferredRevenueAbstract" xlink:to="nnox_DeferredRevenuesTotal" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable">
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems" xlink:to="nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DueToMember" xlink:href="nnox-20211231.xsd#nnox_DueToMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_DueToMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DueToOneMember" xlink:href="nnox-20211231.xsd#nnox_DueToOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_DueToOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DueToTwoMember" xlink:href="nnox-20211231.xsd#nnox_DueToTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_DueToTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DueToThreeMember" xlink:href="nnox-20211231.xsd#nnox_DueToThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_DueToThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_TotalDueFromRelatedParties" xlink:href="nnox-20211231.xsd#nnox_TotalDueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems" xlink:to="nnox_TotalDueFromRelatedParties" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfRelatedPartiesTransactionsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfRelatedPartiesTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfRelatedPartiesTransactionsAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OtherGeneralAndAdministrativeExpenses" xlink:href="nnox-20211231.xsd#nnox_OtherGeneralAndAdministrativeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfRelatedPartiesTransactionsAbstract" xlink:to="nnox_OtherGeneralAndAdministrativeExpenses" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OrdinarySharesIssuedAndOutstanding" xlink:href="nnox-20211231.xsd#nnox_OrdinarySharesIssuedAndOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" xlink:to="nnox_OrdinarySharesIssuedAndOutstanding" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ChangesDuringTheYearAbstract" xlink:href="nnox-20211231.xsd#nnox_ChangesDuringTheYearAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="nnox_ChangesDuringTheYearAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" xlink:href="nnox-20211231.xsd#nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_BlackScholesOptionpricingMember" xlink:href="nnox-20211231.xsd#nnox_BlackScholesOptionpricingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nnox_BlackScholesOptionpricingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OneNinetyTwoMember" xlink:href="nnox-20211231.xsd#nnox_OneNinetyTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_OneNinetyTwoMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_TwoTwentyOneMember" xlink:href="nnox-20211231.xsd#nnox_TwoTwentyOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_TwoTwentyOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OneSixZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_OneSixZeroZeroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_OneSixZeroZeroMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_twentythreeAndNineteenHundredthsMember" xlink:href="nnox-20211231.xsd#nnox_twentythreeAndNineteenHundredthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_twentythreeAndNineteenHundredthsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_twentythreeAndEightyfourHundredthsMember" xlink:href="nnox-20211231.xsd#nnox_twentythreeAndEightyfourHundredthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_twentythreeAndEightyfourHundredthsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ThirtyPointNineThreeMember" xlink:href="nnox-20211231.xsd#nnox_ThirtyPointNineThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ThirtyPointNineThreeMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_thirtyAndSixtysixHundredthsMember" xlink:href="nnox-20211231.xsd#nnox_thirtyAndSixtysixHundredthsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_thirtyAndSixtysixHundredthsMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_fortyAndTwentyoneMember" xlink:href="nnox-20211231.xsd#nnox_fortyAndTwentyoneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_fortyAndTwentyoneMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FortynineAndSixtyeightMember" xlink:href="nnox-20211231.xsd#nnox_FortynineAndSixtyeightMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_FortynineAndSixtyeightMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ZeroPointZeroZeroOneMember" xlink:href="nnox-20211231.xsd#nnox_ZeroPointZeroZeroOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_ZeroPointZeroZeroOneMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OneEightZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_OneEightZeroZeroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_OneEightZeroZeroMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OnePointZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_OnePointZeroZeroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_OnePointZeroZeroMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_TwoPointTwoOneMember" xlink:href="nnox-20211231.xsd#nnox_TwoPointTwoOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_TwoPointTwoOneMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_SixteenPointZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_SixteenPointZeroZeroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_SixteenPointZeroZeroMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_SeventeenPointSixtyThreeMember" xlink:href="nnox-20211231.xsd#nnox_SeventeenPointSixtyThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_SeventeenPointSixtyThreeMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_TwentSixPointFiveSixMember" xlink:href="nnox-20211231.xsd#nnox_TwentSixPointFiveSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="nnox_TwentSixPointFiveSixMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AwardsOutstandingMember" xlink:href="nnox-20211231.xsd#nnox_AwardsOutstandingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nnox_AwardsOutstandingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AwardsExercisableMember" xlink:href="nnox-20211231.xsd#nnox_AwardsExercisableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nnox_AwardsExercisableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NonemployeesMember" xlink:href="nnox-20211231.xsd#nnox_NonemployeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_NonemployeesMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NonemployeesMember" xlink:href="nnox-20211231.xsd#nnox_NonemployeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="nnox_NonemployeesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:href="nnox-20211231.xsd#nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuedDueToBusinessCombination" xlink:href="nnox-20211231.xsd#nnox_IssuedDueToBusinessCombination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_IssuedDueToBusinessCombination" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited" xlink:href="nnox-20211231.xsd#nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NumberOfSharebasedPaymentAwardsCancelled" xlink:href="nnox-20211231.xsd#nnox_NumberOfSharebasedPaymentAwardsCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_NumberOfSharebasedPaymentAwardsCancelled" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_WeightedAverageExercisePriceExercisableAtEndOfYear" xlink:href="nnox-20211231.xsd#nnox_WeightedAverageExercisePriceExercisableAtEndOfYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_WeightedAverageExercisePriceExercisableAtEndOfYear" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfShareBasedCompensationExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostOfOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_OtherCostOfOperatingRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable">
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomelossBeforeIncomeTaxesMember" xlink:href="nnox-20211231.xsd#nnox_IncomelossBeforeIncomeTaxesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_IncomelossBeforeIncomeTaxesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxExpensesMember" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_IncomeTaxExpensesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_TaxesOnIncomeMember" xlink:href="nnox-20211231.xsd#nnox_TaxesOnIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_TaxesOnIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_CurrentAbstract" xlink:href="nnox-20211231.xsd#nnox_CurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="nnox_CurrentAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_CurrentTotal" xlink:href="nnox-20211231.xsd#nnox_CurrentTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_CurrentAbstract" xlink:to="nnox_CurrentTotal" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="nnox_DeferredAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="nnox-20211231.xsd#nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_DeferredAbstract" xlink:to="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="nnox-20211231.xsd#nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_DeferredAbstract" xlink:to="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_DeferredAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ProvisionForIncomeTaxes" xlink:href="nnox-20211231.xsd#nnox_ProvisionForIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="nnox_ProvisionForIncomeTaxes" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="us-gaap_IncomeLossAttributableToParent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredTaxAssetsAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="nnox_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LessValuationAllowanceForDeferredTaxAssets" xlink:href="nnox-20211231.xsd#nnox_LessValuationAllowanceForDeferredTaxAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="nnox_LessValuationAllowanceForDeferredTaxAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofvaluationallowanceprovidedportiondeferredTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDueToBusinessCombinationinShares" xlink:href="nnox-20211231.xsd#nnox_IncreaseDueToBusinessCombinationinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:to="nnox_IncreaseDueToBusinessCombinationinShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenuePeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:to="us-gaap_DeferredRevenuePeriodIncreaseDecrease" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable">
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxARCMember" xlink:href="nnox-20211231.xsd#nnox_NanoxARCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_NanoxARCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RadiologyServicesMember" xlink:href="nnox-20211231.xsd#nnox_RadiologyServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_RadiologyServicesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AISolutionsMember" xlink:href="nnox-20211231.xsd#nnox_AISolutionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_AISolutionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_TotalMember" xlink:href="nnox-20211231.xsd#nnox_TotalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_TotalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FinancialExpense" xlink:href="nnox-20211231.xsd#nnox_FinancialExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="nnox_FinancialExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FinancialIncome" xlink:href="nnox-20211231.xsd#nnox_FinancialIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="nnox_FinancialIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable">
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems" xlink:to="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_KRW" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_KRW"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="currency_KRW" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable">
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" xlink:href="nnox-20211231.xsd#nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_BasicAndDilutedLossPerShare" xlink:href="nnox-20211231.xsd#nnox_BasicAndDilutedLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="nnox_BasicAndDilutedLossPerShare" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="nnox_GeneralDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_GeneralDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_GeneralDetailsTable" xlink:href="nnox-20211231.xsd#nnox_GeneralDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="nnox_GeneralDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_GeneralDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_GeneralDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NasdaqMember" xlink:href="nnox-20211231.xsd#nnox_NasdaqMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nnox_NasdaqMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_InitialPublicOfferingNetProceeds" xlink:href="nnox-20211231.xsd#nnox_InitialPublicOfferingNetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="nnox_InitialPublicOfferingNetProceeds" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_TaxBenefitPercentage" xlink:href="nnox-20211231.xsd#nnox_TaxBenefitPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nnox_TaxBenefitPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails">
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsTable" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_BusinessCombinationandOtherTransactionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessAcquisitionMember" xlink:href="nnox-20211231.xsd#nnox_BusinessAcquisitionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="nnox_BusinessAcquisitionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxAILtdMember" xlink:href="nnox-20211231.xsd#nnox_NanoxAILtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_NanoxAILtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_USARADHoldingIncMember" xlink:href="nnox-20211231.xsd#nnox_USARADHoldingIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_USARADHoldingIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_MDWEBLLCMember" xlink:href="nnox-20211231.xsd#nnox_MDWEBLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_MDWEBLLCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PPPLoanMember" xlink:href="nnox-20211231.xsd#nnox_PPPLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="nnox_PPPLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_EmployeeOptionsAndRestrictedStockUnits" xlink:href="nnox-20211231.xsd#nnox_EmployeeOptionsAndRestrictedStockUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_EmployeeOptionsAndRestrictedStockUnits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OutstandingSharesPerShare" xlink:href="nnox-20211231.xsd#nnox_OutstandingSharesPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_OutstandingSharesPerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ServicePeriodsDecription" xlink:href="nnox-20211231.xsd#nnox_ServicePeriodsDecription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_ServicePeriodsDecription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PurchaseConsideration" xlink:href="nnox-20211231.xsd#nnox_PurchaseConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_PurchaseConsideration" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredClosingConsideration" xlink:href="nnox-20211231.xsd#nnox_DeferredClosingConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_DeferredClosingConsideration" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalConsideration" xlink:href="nnox-20211231.xsd#nnox_AdditionalConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_AdditionalConsideration" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_MaximumAggregateAmount" xlink:href="nnox-20211231.xsd#nnox_MaximumAggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_MaximumAggregateAmount" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FairValuePercentage" xlink:href="nnox-20211231.xsd#nnox_FairValuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_FairValuePercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DescriptionOfNetAssets" xlink:href="nnox-20211231.xsd#nnox_DescriptionOfNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_DescriptionOfNetAssets" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AcquisitionDate" xlink:href="nnox-20211231.xsd#nnox_AcquisitionDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_AcquisitionDate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesNetOfInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesNetOfInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_RevenuesNetOfInterestExpense" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NetLoss" xlink:href="nnox-20211231.xsd#nnox_NetLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_NetLoss" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AcquisitionOfSharesPercentage" xlink:href="nnox-20211231.xsd#nnox_AcquisitionOfSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_AcquisitionOfSharesPercentage" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PurchaseOfSharesPercentage" xlink:href="nnox-20211231.xsd#nnox_PurchaseOfSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_PurchaseOfSharesPercentage" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OrdinaryShare" xlink:href="nnox-20211231.xsd#nnox_OrdinaryShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_OrdinaryShare" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OtherOperationalPerformancebasedEarnoutsOver" xlink:href="nnox-20211231.xsd#nnox_OtherOperationalPerformancebasedEarnoutsOver"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_OtherOperationalPerformancebasedEarnoutsOver" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalCashConsideration" xlink:href="nnox-20211231.xsd#nnox_AdditionalCashConsideration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_AdditionalCashConsideration" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OtherRevenue" xlink:href="nnox-20211231.xsd#nnox_OtherRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_OtherRevenue" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_OtherNetLoss" xlink:href="nnox-20211231.xsd#nnox_OtherNetLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_OtherNetLoss" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_SettledInCashPercentage" xlink:href="nnox-20211231.xsd#nnox_SettledInCashPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_SettledInCashPercentage" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharePercentage" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_IssuanceOfOrdinarySharePercentage" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalPayment" xlink:href="nnox-20211231.xsd#nnox_AdditionalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_AdditionalPayment" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairedIntangibleAssetDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairedIntangibleAssetDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_ImpairedIntangibleAssetDescription" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FairValueOfContingentConsiderationLiabilities" xlink:href="nnox-20211231.xsd#nnox_FairValueOfContingentConsiderationLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_FairValueOfContingentConsiderationLiabilities" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PrincipalAmountOfThePPPLoan" xlink:href="nnox-20211231.xsd#nnox_PrincipalAmountOfThePPPLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_PrincipalAmountOfThePPPLoan" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_InterestAccruesRate" xlink:href="nnox-20211231.xsd#nnox_InterestAccruesRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_InterestAccruesRate" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LoanTerm" xlink:href="nnox-20211231.xsd#nnox_LoanTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_LoanTerm" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AssetsAcquisitionDescription" xlink:href="nnox-20211231.xsd#nnox_AssetsAcquisitionDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_AssetsAcquisitionDescription" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="36" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FilmMonetizedOnItsOwnAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_OtherDepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseAndRentalExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LeaseTermDescription" xlink:href="nnox-20211231.xsd#nnox_LeaseTermDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="nnox_LeaseTermDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LeasesTermDescription" xlink:href="nnox-20211231.xsd#nnox_LeasesTermDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="nnox_LeasesTermDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_VehiclesLeasePayments" xlink:href="nnox-20211231.xsd#nnox_VehiclesLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="nnox_VehiclesLeasePayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForFees" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription" xlink:href="nnox-20211231.xsd#nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ManagementFeeExpense" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/DeferredRevenueDetails">
    <loc xlink:type="locator" xlink:label="nnox_DeferredRevenuesDisclosureAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_DeferredRevenuesDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesDetailsTable" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="nnox_RelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_RelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_RelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AgreementAxis" xlink:href="nnox-20211231.xsd#nnox_AgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_RelatedPartiesDetailsTable" xlink:to="nnox_AgreementAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AgreementDomain" xlink:href="nnox-20211231.xsd#nnox_AgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="nnox_AgreementAxis" xlink:to="nnox_AgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AgreementDomain_0" xlink:href="nnox-20211231.xsd#nnox_AgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="nnox_AgreementAxis" xlink:to="nnox_AgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_RelatedPartiesDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxJapanMember" xlink:href="nnox-20211231.xsd#nnox_NanoxJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="nnox_NanoxJapanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_SharePurchaseAgreementMember" xlink:href="nnox-20211231.xsd#nnox_SharePurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_AgreementDomain" xlink:to="nnox_SharePurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxPLCMember" xlink:href="nnox-20211231.xsd#nnox_NanoxPLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_NanoxPLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_SixAIMember" xlink:href="nnox-20211231.xsd#nnox_SixAIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_SixAIMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_WellseseTechnologiesLtdMember" xlink:href="nnox-20211231.xsd#nnox_WellseseTechnologiesLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nnox_WellseseTechnologiesLtdMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_OtherExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_AreaOfLand" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PaysApproximately" xlink:href="nnox-20211231.xsd#nnox_PaysApproximately"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="nnox_PaysApproximately" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_LeaseIncome" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_SalariesAndWages" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_EmploymentAgreementDescription" xlink:href="nnox-20211231.xsd#nnox_EmploymentAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="nnox_EmploymentAgreementDescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UtilitiesOperatingExpenseProductsAndServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UtilitiesOperatingExpenseProductsAndServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_UtilitiesOperatingExpenseProductsAndServices" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_CostsAndExpenses" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromDepositOnLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="us-gaap_PaymentsForProceedsFromDepositOnLoan" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LongTermLoanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTerm" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AnnualInterestRate" xlink:href="nnox-20211231.xsd#nnox_AnnualInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="nnox_AnnualInterestRate" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_ConsultingFees" xlink:href="nnox-20211231.xsd#nnox_ConsultingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="nnox_ConsultingFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_EntitlementToWarrantsAmount" xlink:href="nnox-20211231.xsd#nnox_EntitlementToWarrantsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="nnox_EntitlementToWarrantsAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_ShareholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_DescriptionOfSharebasedCompensationExpenses" xlink:href="nnox-20211231.xsd#nnox_DescriptionOfSharebasedCompensationExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_DescriptionOfSharebasedCompensationExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_VestingPeriod" xlink:href="nnox-20211231.xsd#nnox_VestingPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_VestingPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AgreementTerminateTerm" xlink:href="nnox-20211231.xsd#nnox_AgreementTerminateTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_AgreementTerminateTerm" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_ConsiderationForServicesShares" xlink:href="nnox-20211231.xsd#nnox_ConsiderationForServicesShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_ConsiderationForServicesShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ValueAddedTaxReceivableNoncurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_PurchaseAggregateShares" xlink:href="nnox-20211231.xsd#nnox_PurchaseAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_PurchaseAggregateShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_RecordedAnExpense" xlink:href="nnox-20211231.xsd#nnox_RecordedAnExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_RecordedAnExpense" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/IncomeTaxDetails">
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsTable" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="nnox_IncomeTaxDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_IncomeTaxDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAssetAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_IncomeTaxDetailsTable" xlink:to="us-gaap_RegulatoryAssetAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAssetDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="us-gaap_RegulatoryAssetDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAssetDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="us-gaap_RegulatoryAssetDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_IncomeTaxDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFuelCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFuelCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegulatoryAssetDomain" xlink:to="us-gaap_DeferredFuelCostsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_KR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KR" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_FederalTaxRatePercentage" xlink:href="nnox-20211231.xsd#nnox_FederalTaxRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="nnox_FederalTaxRatePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_CarryForwardLossYears" xlink:href="nnox-20211231.xsd#nnox_CarryForwardLossYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="nnox_CarryForwardLossYears" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SegmentsofOperationsDetails">
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsTable" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_SegmentsofOperationsDetailsLineItems" xlink:to="nnox_SegmentsofOperationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SegmentsofOperationsDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SegmentsofOperationsDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShareDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="nnox_BasicAndDilutedShare" xlink:href="nnox-20211231.xsd#nnox_BasicAndDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="nnox_BasicAndDilutedShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_WarrantsShares" xlink:href="nnox-20211231.xsd#nnox_WarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="nnox_WarrantsShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_WarrantsOption" xlink:href="nnox-20211231.xsd#nnox_WarrantsOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="nnox_WarrantsOption" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="nnox_SubsequentEventsDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nnox_SubsequentEventsDetailsTable" xlink:href="nnox-20211231.xsd#nnox_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="nnox_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nnox_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalSharesIssued" xlink:href="nnox-20211231.xsd#nnox_AdditionalSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="nnox_AdditionalSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_OtherAssetsFairValueDisclosure" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nnox_LeasedAdditionTerm" xlink:href="nnox-20211231.xsd#nnox_LeasedAdditionTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="nnox_LeasedAdditionTerm" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>nnox-20211231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 02 05:16:13 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">TOTAL NON-CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">GROSS LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">TOTAL OPERATING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">OPERATING LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Total other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">TOTAL COMPERHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE YEAR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, cash equivalents and Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of property and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="nnox_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract_lbl" xml:lang="en-US">Schedule of financial assets and liabilities measured fair value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract" xlink:to="nnox_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CertainTransactionsAbstract" xlink:href="nnox-20211231.xsd#nnox_CertainTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CertainTransactionsAbstract_lbl" xml:lang="en-US">Business Combination and Other Transaction [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CertainTransactionsAbstract" xlink:to="nnox_CertainTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfFairValueConsiderationTransferredAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfFairValueConsiderationTransferredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfFairValueConsiderationTransferredAbstract_lbl" xml:lang="en-US">Schedule of fair value consideration transferred [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfFairValueConsiderationTransferredAbstract" xlink:to="nnox_ScheduleOfFairValueConsiderationTransferredAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract_lbl" xml:lang="en-US">Schedule of the purchase price to assets acquired and liabilities assumed [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="nnox_ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfAcquisitionOfNanoxAiAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfAcquisitionOfNanoxAiAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfAcquisitionOfNanoxAiAbstract_lbl" xml:lang="en-US">Schedule of acquisition of Nanox AI [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfAcquisitionOfNanoxAiAbstract" xlink:to="nnox_ScheduleOfAcquisitionOfNanoxAiAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill &amp; Intangible Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfGoodwillAndTheIntangibleAssetsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfGoodwillAndTheIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfGoodwillAndTheIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule of goodwill and the intangible assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfGoodwillAndTheIntangibleAssetsAbstract" xlink:to="nnox_ScheduleOfGoodwillAndTheIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_lbl0" xml:lang="en-US">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl1" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfIntangibleAssetsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule of intangible assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfIntangibleAssetsAbstract" xlink:to="nnox_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract_lbl" xml:lang="en-US">Schedule of Amortization of intangible assets for each of the next five years and thereafter [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:to="nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPercentageOfPropertyAndEquipmentAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPercentageOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfPercentageOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of Percentage of property and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPercentageOfPropertyAndEquipmentAbstract" xlink:to="nnox_ScheduleOfPercentageOfPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_CashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20211231.xsd#nnox_CashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashEquivalentsAndRestrictedCashAbstract" xlink:to="nnox_CashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_lbl" xml:lang="en-US">Schedule of reconciliation of cash, cash equivalents and restricted cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfCompanysTotalLeaseCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract_lbl" xml:lang="en-US">Schedule of company&apos;s total lease costs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:to="nnox_ScheduleOfCompanysTotalLeaseCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to operating leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract_lbl" xml:lang="en-US">Schedule of supplemental balance sheet information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of maturities of operating lease liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredRevenuesDisclosureAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DeferredRevenuesDisclosureAbstract_lbl" xml:lang="en-US">Deferred Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredRevenuesDisclosureAbstract" xlink:to="nnox_DeferredRevenuesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfDeferredRevenueAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfDeferredRevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfDeferredRevenueAbstract_lbl" xml:lang="en-US">Schedule of Deferred Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfDeferredRevenueAbstract" xlink:to="nnox_ScheduleOfDeferredRevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Balance at December 31, 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredRevenue_lbl0" xml:lang="en-US">Balance at December 31, 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilityAbstract" xlink:href="nnox-20211231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartyLiabilityAbstract_lbl" xml:lang="en-US">Related Party Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartyLiabilityAbstract" xlink:to="nnox_RelatedPartyLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfRelatedPartyAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfRelatedPartyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfRelatedPartyAbstract_lbl" xml:lang="en-US">Schedule of related party [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfRelatedPartyAbstract" xlink:to="nnox_ScheduleOfRelatedPartyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfRelatedPartiesTransactionsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfRelatedPartiesTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfRelatedPartiesTransactionsAbstract_lbl" xml:lang="en-US">Schedule of related parties transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfRelatedPartiesTransactionsAbstract" xlink:to="nnox_ScheduleOfRelatedPartiesTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfIssuedAndOutstandingAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIssuedAndOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfIssuedAndOutstandingAbstract_lbl" xml:lang="en-US">Schedule of issued and outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfIssuedAndOutstandingAbstract" xlink:to="nnox_ScheduleOfIssuedAndOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract_lbl" xml:lang="en-US">Schedule of share-based awards to employees, officers and directors [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price, Outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract_lbl" xml:lang="en-US">Schedule of options valued using a Black-Scholes pricing model with assumptions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract" xlink:to="nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract_lbl" xml:lang="en-US">Schedule of information concerning outstanding and exercisable awards [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" xlink:to="nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract_lbl" xml:lang="en-US">Schedule of shared - based payments to employees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract" xlink:to="nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer&apos;s Equity, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of share-based payment awards, Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of share-based payment awards, Outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Number of share-based payment awards, Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:href="nnox-20211231.xsd#nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:to="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl0" xml:lang="en-US">Weighted average exercise price, Outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:to="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfShareBasedCompensationExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfShareBasedCompensationExpensesAbstract_lbl" xml:lang="en-US">Schedule of share-based compensation expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="nnox_ScheduleOfShareBasedCompensationExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract_lbl" xml:lang="en-US">Schedule of income (loss) before income taxes consisted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract" xlink:to="nnox_ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract_lbl" xml:lang="en-US">Schedule of reconciliation our theoretical income tax expense to actual income tax expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract_lbl" xml:lang="en-US">Schedule of valuation allowance provided portion deferred [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:to="nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Valuation allowance, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Valuation allowance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsOfOperationsAbstract" xlink:href="nnox-20211231.xsd#nnox_SegmentsOfOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SegmentsOfOperationsAbstract_lbl" xml:lang="en-US">Segments Of Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SegmentsOfOperationsAbstract" xlink:to="nnox_SegmentsOfOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract_lbl" xml:lang="en-US">Schedule of reportable operating segments based on net sales and operating loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract" xlink:to="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyAndEquipmentByGeographyAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentByGeographyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfPropertyAndEquipmentByGeographyAbstract_lbl" xml:lang="en-US">Schedule of property and equipment by geography [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentByGeographyAbstract" xlink:to="nnox_ScheduleOfPropertyAndEquipmentByGeographyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract_lbl" xml:lang="en-US">Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable Securities - short term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Accounts receivables net of allowance for credit losses of $137 and o thousand as of December 31, 2021 and December 31,2020, respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Accounts Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts receivables net, credit losses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NonCurrentAssetsAbstract" xlink:href="nnox-20211231.xsd#nnox_NonCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NonCurrentAssetsAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NonCurrentAssetsAbstract" xlink:to="nnox_NonCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xml:lang="en-US">Marketable Securities - long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Loan from a Government Agency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Contingent short term earnout liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturities of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other labilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_NonCurrentLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_NonCurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NonCurrentLiabilitiesAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NonCurrentLiabilitiesAbstract" xlink:to="nnox_NonCurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Non-current operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLongTermDebtNoncurrent_lbl" xml:lang="en-US">Long term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebtNoncurrent" xlink:to="us-gaap_OtherLongTermDebtNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Non-current deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl0" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Contingent long-term earnout liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary Shares, par value NIS 0.01 per share 100,000,000 authorized at December 31, 2021 and December 31 2020, 51,791,441 and 46,100,173 issued and outstanding at September 30, 2021 and December 31, 2020, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and Marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Segment operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">FINANCIAL INCOME (EXPENSES), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">THE WEIGHTED AVERAGE OF THE NUMBER OF ORDINARY SHARES (in thousands) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OtherComprehensiveLossAbstract" xlink:href="nnox-20211231.xsd#nnox_OtherComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OtherComprehensiveLossAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherComprehensiveLossAbstract" xlink:to="nnox_OtherComprehensiveLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xml:lang="en-US">Unrealized loss from available- for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">CHANGES DURING 2019:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl0" xml:lang="en-US">CHANGES DURING 2021:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of ordinary shares and warrants, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl" xml:lang="en-US">Issuance of ordinary shares and warrants, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of ordinary shares to employees and non-employees upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of ordinary shares to investors upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl" xml:lang="en-US">Issuance of ordinary shares to investors upon exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" xlink:href="nnox-20211231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6_lbl" xml:lang="en-US">Additional consideration with respect to an assets purchase agreement, see note 9a</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ChangesDuring2020Abstract" xlink:href="nnox-20211231.xsd#nnox_ChangesDuring2020Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ChangesDuring2020Abstract_lbl" xml:lang="en-US">CHANGES DURING 2020:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ChangesDuring2020Abstract" xlink:to="nnox_ChangesDuring2020Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Initial public offering of ordinary shares, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Initial public offering of ordinary shares, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of related party liability to shareholders&#8217; equity, see note 9a</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of related party liability to shareholders&#8217; equity, see note 9a (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants_lbl" xml:lang="en-US">Issuance of ordinary shares upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants" xlink:to="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares_lbl" xml:lang="en-US">Issuance of ordinary shares upon exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares" xlink:to="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions_lbl" xml:lang="en-US">Issuance of ordinary shares to employees and non-employees upon exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" xlink:to="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares_lbl" xml:lang="en-US">Issuance of ordinary shares to employees and non-employees upon exercise of options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares" xlink:to="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets_lbl" xml:lang="en-US">Issuance of ordinary shares due to business combination and assets acquisition (refer to Note 3)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin_lbl" xml:lang="en-US">Issuance of ordinary shares due to business combination and assets acquisition (refer to Note 3) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized loss from available- for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities, net of effects of businesses acquired:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseOperatingLease" xlink:href="nnox-20211231.xsd#nnox_IncreaseDecreaseOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IncreaseDecreaseOperatingLease_lbl" xml:lang="en-US">Operating lease assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseOperatingLease" xlink:to="nnox_IncreaseDecreaseOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xml:lang="en-US">Proceeds from long term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20211231.xsd#nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from issuance of ordinary shares and warrants, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:to="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from initial public offering of ordinary shares, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from issuance of ordinary shares upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Issuance of ordinary shares to employees and non-employees upon exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_UnpaidOfferingCosts" xlink:href="nnox-20211231.xsd#nnox_UnpaidOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_UnpaidOfferingCosts_lbl" xml:lang="en-US">Unpaid offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_UnpaidOfferingCosts" xlink:to="nnox_UnpaidOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:href="nnox-20211231.xsd#nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl" xml:lang="en-US">issuance of ordinary shares to investor upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:to="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" xlink:href="nnox-20211231.xsd#nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets_lbl" xml:lang="en-US">Fair value of ordinary shares issued as consideration for purchase of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" xlink:to="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" xlink:href="nnox-20211231.xsd#nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations_lbl" xml:lang="en-US">Fair value of ordinary shares issued as consideration for business combinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" xlink:to="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations" xlink:href="nnox-20211231.xsd#nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations_lbl" xml:lang="en-US">Fair value of contingent consideration assumed in business combinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations" xlink:to="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfSharesInConsiderationOfAssets" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfSharesInConsiderationOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfSharesInConsiderationOfAssets_lbl" xml:lang="en-US">Fair value of contingent consideration assumed in purchase of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfSharesInConsiderationOfAssets" xlink:to="nnox_IssuanceOfSharesInConsiderationOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:href="nnox-20211231.xsd#nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:to="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:href="nnox-20211231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl" xml:lang="en-US">Additional consideration with respect to an assets purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:href="nnox-20211231.xsd#nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl" xml:lang="en-US">Conversion of related party liability to shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:to="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">INCOME TAX BENEFIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Impairment of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_lbl" xml:lang="en-US">Amortization of premium on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:to="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:href="nnox-20211231.xsd#nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl" xml:lang="en-US">Related party prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:to="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Cash paid for business combinations, net of cash and restricted cash acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xml:lang="en-US">Investment in marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:to="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:href="nnox-20211231.xsd#nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl" xml:lang="en-US">Property and equipment, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:to="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of financial assets and liabilities measured fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AssetsAbstract0" xlink:href="nnox-20211231.xsd#nnox_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AssetsAbstract0_lbl" xml:lang="en-US">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AssetsAbstract0" xlink:to="nnox_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LongTermMarketableSecurities" xlink:href="nnox-20211231.xsd#nnox_LongTermMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LongTermMarketableSecurities_lbl" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LongTermMarketableSecurities" xlink:to="nnox_LongTermMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Contingent short term earnout liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US">Contingent long-term earnout liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_lbl0" xml:lang="en-US">Contingent long term earnout liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_CertainTransactionsTextBlock" xlink:href="nnox-20211231.xsd#nnox_CertainTransactionsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_CertainTransactionsTextBlock_lbl" xml:lang="en-US">BUSINESS COMBINATION AND OTHER TRANSACTION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CertainTransactionsTextBlock" xlink:to="nnox_CertainTransactionsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfFairValueConsiderationTransferred" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfFairValueConsiderationTransferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfFairValueConsiderationTransferred_lbl" xml:lang="en-US">Schedule of fair value consideration transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfFairValueConsiderationTransferred" xlink:to="nnox_ScheduleOfFairValueConsiderationTransferred_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_lbl" xml:lang="en-US">Cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:to="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl" xml:lang="en-US">Total consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:to="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xml:lang="en-US">Contingent consideration at estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of the purchase price to assets acquired and liabilities assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsCurrent_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsCurrent" xlink:to="us-gaap_IntangibleAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TotalAssetsAcquired" xlink:href="nnox-20211231.xsd#nnox_TotalAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_TotalAssetsAcquired_lbl" xml:lang="en-US">Total assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalAssetsAcquired" xlink:to="nnox_TotalAssetsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Less deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_ContingentShortTermEarnoutLiability" xlink:href="nnox-20211231.xsd#nnox_ContingentShortTermEarnoutLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ContingentShortTermEarnoutLiability_lbl" xml:lang="en-US">Contingent short term earnout liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ContingentShortTermEarnoutLiability" xlink:to="nnox_ContingentShortTermEarnoutLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ContingentLongtermEarnoutLiability" xlink:href="nnox-20211231.xsd#nnox_ContingentLongtermEarnoutLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ContingentLongtermEarnoutLiability_lbl" xml:lang="en-US">Contingent long-term earnout liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ContingentLongtermEarnoutLiability" xlink:to="nnox_ContingentLongtermEarnoutLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ConvertibleNote" xlink:href="nnox-20211231.xsd#nnox_ConvertibleNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ConvertibleNote_lbl" xml:lang="en-US">Convertible note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConvertibleNote" xlink:to="nnox_ConvertibleNote_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Total liabilities assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NetAssetsAcquired" xlink:href="nnox-20211231.xsd#nnox_NetAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NetAssetsAcquired_lbl" xml:lang="en-US">Net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NetAssetsAcquired" xlink:to="nnox_NetAssetsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Loan from a government agency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ContingentLongTermEarnoutLiability" xlink:href="nnox-20211231.xsd#nnox_ContingentLongTermEarnoutLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ContingentLongTermEarnoutLiability_lbl" xml:lang="en-US">Contingent long term earnout liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ContingentLongTermEarnoutLiability" xlink:to="nnox_ContingentLongTermEarnoutLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of acquisition of Nanox AI</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">GOODWILL &amp; INTANGIBLE ASSETS, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">Schedule of goodwill and the intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl" xml:lang="en-US">Goodwill from acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Weighted Average Useful Life (in Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FiniteLivedIntangibleAssetNet" xlink:href="nnox-20211231.xsd#nnox_FiniteLivedIntangibleAssetNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FiniteLivedIntangibleAssetNet_lbl" xml:lang="en-US">Amount as of the merger/ acquisition date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FiniteLivedIntangibleAssetNet" xlink:to="nnox_FiniteLivedIntangibleAssetNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AmortizationExpenseForThePeriod" xlink:href="nnox-20211231.xsd#nnox_AmortizationExpenseForThePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AmortizationExpenseForThePeriod_lbl" xml:lang="en-US">Amortization expense for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AmortizationExpenseForThePeriod" xlink:to="nnox_AmortizationExpenseForThePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">Amount as of December 31, 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Amortization of intangible assets for each of the next five years and thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">2026 and thenafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PercentageOfPropertyPlantAndEquipment" xlink:href="nnox-20211231.xsd#nnox_PercentageOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PercentageOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Percentage of property plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PercentageOfPropertyPlantAndEquipment" xlink:to="nnox_PercentageOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Total property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CashEquivalentsAndRestrictedCashTextBlock" xlink:href="nnox-20211231.xsd#nnox_CashEquivalentsAndRestrictedCashTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashEquivalentsAndRestrictedCashTextBlock" xlink:to="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RestrictedBankDeposit" xlink:href="nnox-20211231.xsd#nnox_RestrictedBankDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RestrictedBankDeposit_lbl" xml:lang="en-US">Restricted bank deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RestrictedBankDeposit" xlink:to="nnox_RestrictedBankDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of the compnay&apos;s total lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OperatingLeaseCostAbstract" xlink:href="nnox-20211231.xsd#nnox_OperatingLeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OperatingLeaseCostAbstract_lbl" xml:lang="en-US">Operating lease cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OperatingLeaseCostAbstract" xlink:to="nnox_OperatingLeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Fixed payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TotalOperatingLeaseCost" xlink:href="nnox-20211231.xsd#nnox_TotalOperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_TotalOperatingLeaseCost_lbl" xml:lang="en-US">Total operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalOperatingLeaseCost" xlink:to="nnox_TotalOperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information related to operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:href="nnox-20211231.xsd#nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations (non-cash):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:to="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental balance sheet information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:to="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OperatingLeasesAbstract" xlink:href="nnox-20211231.xsd#nnox_OperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OperatingLeasesAbstract_lbl" xml:lang="en-US">Operating leases:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OperatingLeasesAbstract" xlink:to="nnox_OperatingLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CurrentMaturitiesOfOperatingLeases" xlink:href="nnox-20211231.xsd#nnox_CurrentMaturitiesOfOperatingLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_CurrentMaturitiesOfOperatingLeases_lbl" xml:lang="en-US">Current maturities of operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CurrentMaturitiesOfOperatingLeases" xlink:to="nnox_CurrentMaturitiesOfOperatingLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NoncurrentOperatingLeases" xlink:href="nnox-20211231.xsd#nnox_NoncurrentOperatingLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NoncurrentOperatingLeases_lbl" xml:lang="en-US">Non-current operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NoncurrentOperatingLeases" xlink:to="nnox_NoncurrentOperatingLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_WeightedAverageRemainingLeaseTermAbstract" xlink:href="nnox-20211231.xsd#nnox_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WeightedAverageRemainingLeaseTermAbstract" xlink:to="nnox_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_WeightedAverageDiscountRateAbstract" xlink:href="nnox-20211231.xsd#nnox_WeightedAverageDiscountRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_WeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WeightedAverageDiscountRateAbstract" xlink:to="nnox_WeightedAverageDiscountRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:href="nnox-20211231.xsd#nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:to="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter" xlink:href="nnox-20211231.xsd#nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter_lbl" xml:lang="en-US">2025 and thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter" xlink:to="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total operating lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PresentValueOfLeaseLiabilities" xlink:href="nnox-20211231.xsd#nnox_PresentValueOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PresentValueOfLeaseLiabilities_lbl" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PresentValueOfLeaseLiabilities" xlink:to="nnox_PresentValueOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredRevenuesDisclosureTextBlock" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DeferredRevenuesDisclosureTextBlock_lbl" xml:lang="en-US">DEFERRED REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredRevenuesDisclosureTextBlock" xlink:to="nnox_DeferredRevenuesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDueToTheBusinessCombinations" xlink:href="nnox-20211231.xsd#nnox_IncreaseDueToTheBusinessCombinations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IncreaseDueToTheBusinessCombinations_lbl" xml:lang="en-US">Increase due to the business combinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDueToTheBusinessCombinations" xlink:to="nnox_IncreaseDueToTheBusinessCombinations_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredRevenuesTotal" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DeferredRevenuesTotal_lbl" xml:lang="en-US">Change in deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredRevenuesTotal" xlink:to="nnox_DeferredRevenuesTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartyLiabilityTextBlock" xlink:href="nnox-20211231.xsd#nnox_RelatedPartyLiabilityTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RelatedPartyLiabilityTextBlock_lbl" xml:lang="en-US">RELATED PARTIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartyLiabilityTextBlock" xlink:to="nnox_RelatedPartyLiabilityTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfRelatedPartyTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfRelatedPartyTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfRelatedPartyTableTextBlock_lbl" xml:lang="en-US">Schedule of related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfRelatedPartyTableTextBlock" xlink:to="nnox_ScheduleOfRelatedPartyTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TotalDueFromRelatedParties" xlink:href="nnox-20211231.xsd#nnox_TotalDueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_TotalDueFromRelatedParties_lbl" xml:lang="en-US">Total Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalDueFromRelatedParties" xlink:to="nnox_TotalDueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of related parties transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development &#8211; see d below</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">LONG TERM LOAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfIssuedAndOutstandingTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIssuedAndOutstandingTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfIssuedAndOutstandingTextBlock_lbl" xml:lang="en-US">Schedule of issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfIssuedAndOutstandingTextBlock" xlink:to="nnox_ScheduleOfIssuedAndOutstandingTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl" xml:lang="en-US">Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OrdinarySharesIssuedAndOutstanding" xlink:href="nnox-20211231.xsd#nnox_OrdinarySharesIssuedAndOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OrdinarySharesIssuedAndOutstanding_lbl" xml:lang="en-US">Issued and Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinarySharesIssuedAndOutstanding" xlink:to="nnox_OrdinarySharesIssuedAndOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of share-based awards to employees, officers and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ChangesDuringTheYearAbstract" xlink:href="nnox-20211231.xsd#nnox_ChangesDuringTheYearAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ChangesDuringTheYearAbstract_lbl" xml:lang="en-US">Changes during the year:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="nnox_ChangesDuringTheYearAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of share-based payment awards, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Granted employees shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price, Weighted average exercise price Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price. Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" xlink:href="nnox-20211231.xsd#nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear_lbl" xml:lang="en-US">Number of share-based payment awards, Outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" xlink:to="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of share-based payment awards, Exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Number of awards exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Black-Scholes option-pricing model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Contractual term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of information concerning outstanding and exercisable awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number of awards outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ChangesDuringTheYearAbstract0" xlink:href="nnox-20211231.xsd#nnox_ChangesDuringTheYearAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ChangesDuringTheYearAbstract0_lbl" xml:lang="en-US">Changes during the year:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="nnox_ChangesDuringTheYearAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl" xml:lang="en-US">Number of share-based payment awards, Issued due to business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuedDueToBusinessCombination" xlink:href="nnox-20211231.xsd#nnox_IssuedDueToBusinessCombination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuedDueToBusinessCombination_lbl" xml:lang="en-US">Issued due to business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuedDueToBusinessCombination" xlink:to="nnox_IssuedDueToBusinessCombination_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of share-based payment awards, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of share-based payment awards, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_NumberOfSharebasedPaymentAwardsCancelled" xlink:href="nnox-20211231.xsd#nnox_NumberOfSharebasedPaymentAwardsCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NumberOfSharebasedPaymentAwardsCancelled_lbl" xml:lang="en-US">Number of share-based payment awards, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NumberOfSharebasedPaymentAwardsCancelled" xlink:to="nnox_NumberOfSharebasedPaymentAwardsCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_WeightedAverageExercisePriceExercisableAtEndOfYear" xlink:href="nnox-20211231.xsd#nnox_WeightedAverageExercisePriceExercisableAtEndOfYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_WeightedAverageExercisePriceExercisableAtEndOfYear_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WeightedAverageExercisePriceExercisableAtEndOfYear" xlink:to="nnox_WeightedAverageExercisePriceExercisableAtEndOfYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of share-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostOfOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCostOfOperatingRevenue_lbl" xml:lang="en-US">Cost of revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostOfOperatingRevenue" xlink:to="us-gaap_OtherCostOfOperatingRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and Marketing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl" xml:lang="en-US">Share-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAX</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted_lbl" xml:lang="en-US">Schedule of income (loss) before income taxes consisted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted" xlink:to="nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CurrentAbstract" xlink:href="nnox-20211231.xsd#nnox_CurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_CurrentAbstract_lbl" xml:lang="en-US">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CurrentAbstract" xlink:to="nnox_CurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DeferredAbstract_lbl" xml:lang="en-US">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredAbstract" xlink:to="nnox_DeferredAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation our theoretical income tax expense to actual income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory tax rate in Israel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDecreaseInTaxesResultingFromAbstract" xlink:href="nnox-20211231.xsd#nnox_IncreaseDecreaseInTaxesResultingFromAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IncreaseDecreaseInTaxesResultingFromAbstract_lbl" xml:lang="en-US">Increase (decrease) in taxes resulting from:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseInTaxesResultingFromAbstract" xlink:to="nnox_IncreaseDecreaseInTaxesResultingFromAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Operating losses and other temporary differences for which valuation allowance was provided</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl" xml:lang="en-US">Actual tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredTaxAssetsAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredTaxAssetsAbstract" xlink:to="nnox_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Tax loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Employee and payroll accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LessValuationAllowanceForDeferredTaxAssets" xlink:href="nnox-20211231.xsd#nnox_LessValuationAllowanceForDeferredTaxAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LessValuationAllowanceForDeferredTaxAssets_lbl" xml:lang="en-US">Less valuation allowance for deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LessValuationAllowanceForDeferredTaxAssets" xlink:to="nnox_LessValuationAllowanceForDeferredTaxAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xml:lang="en-US">Acquired intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock_lbl" xml:lang="en-US">Schedule of valuation allowance provided portion deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock" xlink:to="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncreaseDueToBusinessCombinationinShares" xlink:href="nnox-20211231.xsd#nnox_IncreaseDueToBusinessCombinationinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IncreaseDueToBusinessCombinationinShares_lbl" xml:lang="en-US">Increase due to business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDueToBusinessCombinationinShares" xlink:to="nnox_IncreaseDueToBusinessCombinationinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenuePeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenuePeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenuePeriodIncreaseDecrease" xlink:to="us-gaap_DeferredRevenuePeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsOfOperationsTextBlock" xlink:href="nnox-20211231.xsd#nnox_SegmentsOfOperationsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SegmentsOfOperationsTextBlock_lbl" xml:lang="en-US">SEGMENTS OF OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SegmentsOfOperationsTextBlock" xlink:to="nnox_SegmentsOfOperationsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock_lbl" xml:lang="en-US">Schedule of reportable operating segments based on net sales and operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock" xlink:to="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FinancialIncome" xlink:href="nnox-20211231.xsd#nnox_FinancialIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FinancialIncome_lbl" xml:lang="en-US">Financial income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FinancialIncome" xlink:to="nnox_FinancialIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Loss before taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FinancialExpense" xlink:href="nnox-20211231.xsd#nnox_FinancialExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FinancialExpense_lbl" xml:lang="en-US">Financial expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FinancialExpense" xlink:to="nnox_FinancialExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment by geography</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock" xlink:to="nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" xlink:href="nnox-20211231.xsd#nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands_lbl" xml:lang="en-US">The weighted average of the number of ordinary shares (in thousands)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" xlink:to="nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_BasicAndDilutedLossPerShare" xlink:href="nnox-20211231.xsd#nnox_BasicAndDilutedLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_BasicAndDilutedLossPerShare_lbl" xml:lang="en-US">Basic and diluted loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BasicAndDilutedLossPerShare" xlink:to="nnox_BasicAndDilutedLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OtherGeneralAndAdministrativeExpenses" xlink:href="nnox-20211231.xsd#nnox_OtherGeneralAndAdministrativeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nnox_OtherGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative &#8211; See c, e and f below</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherGeneralAndAdministrativeExpenses" xlink:to="nnox_OtherGeneralAndAdministrativeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of share-based payment awards, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of share-based payment awards, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of share-based payment awards, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited" xlink:href="nnox-20211231.xsd#nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited_lbl" xml:lang="en-US">Number of share-based payment awards, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited" xlink:to="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic (Israel)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl" xml:lang="en-US">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl0" xml:lang="en-US">Loss before taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl0"/>
    <loc xlink:type="locator" xlink:label="nnox_CurrentTotal" xlink:href="nnox-20211231.xsd#nnox_CurrentTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nnox_CurrentTotal_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CurrentTotal" xlink:to="nnox_CurrentTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="nnox-20211231.xsd#nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="nnox-20211231.xsd#nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ProvisionForIncomeTaxes" xlink:href="nnox-20211231.xsd#nnox_ProvisionForIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nnox_ProvisionForIncomeTaxes_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ProvisionForIncomeTaxes" xlink:to="nnox_ProvisionForIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Theoretical tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Effect of different tax rates applicable in foreign jurisdictions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to Company&#8217;s owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers and electronic equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Equipment and machinery [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machines [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxAILtdMember" xlink:href="nnox-20211231.xsd#nnox_NanoxAILtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NanoxAILtdMember_lbl" xml:lang="en-US">Nanox AI Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NanoxAILtdMember" xlink:to="nnox_NanoxAILtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_USARADHoldingIncMember" xlink:href="nnox-20211231.xsd#nnox_USARADHoldingIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_USARADHoldingIncMember_lbl" xml:lang="en-US">USARAD Holding Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_USARADHoldingIncMember" xlink:to="nnox_USARADHoldingIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ZebraMember" xlink:href="nnox-20211231.xsd#nnox_ZebraMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ZebraMember_lbl" xml:lang="en-US">Zebra [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ZebraMember" xlink:to="nnox_ZebraMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_USARADMember" xlink:href="nnox-20211231.xsd#nnox_USARADMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_USARADMember_lbl" xml:lang="en-US">USARAD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_USARADMember" xlink:to="nnox_USARADMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillMember_lbl" xml:lang="en-US">Goodwill [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Developed technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ImageBigDataMember" xlink:href="nnox-20211231.xsd#nnox_ImageBigDataMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ImageBigDataMember_lbl" xml:lang="en-US">Image big data [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ImageBigDataMember" xlink:to="nnox_ImageBigDataMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketingRelatedIntangibleAssetsMember_lbl" xml:lang="en-US">Market platform [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:to="us-gaap_MarketingRelatedIntangibleAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RadiologistRelationshipsMember" xlink:href="nnox-20211231.xsd#nnox_RadiologistRelationshipsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RadiologistRelationshipsMember_lbl" xml:lang="en-US">Radiologist relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RadiologistRelationshipsMember" xlink:to="nnox_RadiologistRelationshipsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeNamesMember_lbl" xml:lang="en-US">Trade name [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ComputersAndElectronicEquipmentMember" xlink:href="nnox-20211231.xsd#nnox_ComputersAndElectronicEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ComputersAndElectronicEquipmentMember_lbl" xml:lang="en-US">Computers and electronic equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ComputersAndElectronicEquipmentMember" xlink:to="nnox_ComputersAndElectronicEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OfficeFurnitureAndLabEquipmentMember" xlink:href="nnox-20211231.xsd#nnox_OfficeFurnitureAndLabEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OfficeFurnitureAndLabEquipmentMember_lbl" xml:lang="en-US">Office furniture and lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OfficeFurnitureAndLabEquipmentMember" xlink:to="nnox_OfficeFurnitureAndLabEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ProductionLineInConstructionMember" xlink:href="nnox-20211231.xsd#nnox_ProductionLineInConstructionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ProductionLineInConstructionMember_lbl" xml:lang="en-US">Production line in construction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ProductionLineInConstructionMember" xlink:to="nnox_ProductionLineInConstructionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DueToMember" xlink:href="nnox-20211231.xsd#nnox_DueToMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DueToMember_lbl" xml:lang="en-US">Due to [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DueToMember" xlink:to="nnox_DueToMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DueToOneMember" xlink:href="nnox-20211231.xsd#nnox_DueToOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DueToOneMember_lbl" xml:lang="en-US">Due to One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DueToOneMember" xlink:to="nnox_DueToOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DueToTwoMember" xlink:href="nnox-20211231.xsd#nnox_DueToTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DueToTwoMember_lbl" xml:lang="en-US">Due to Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DueToTwoMember" xlink:to="nnox_DueToTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DueToThreeMember" xlink:href="nnox-20211231.xsd#nnox_DueToThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DueToThreeMember_lbl" xml:lang="en-US">Due to Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DueToThreeMember" xlink:to="nnox_DueToThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_BlackScholesOptionpricingMember" xlink:href="nnox-20211231.xsd#nnox_BlackScholesOptionpricingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_BlackScholesOptionpricingMember_lbl" xml:lang="en-US">Black- Scholes option-pricing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BlackScholesOptionpricingMember" xlink:to="nnox_BlackScholesOptionpricingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OneNinetyTwoMember" xlink:href="nnox-20211231.xsd#nnox_OneNinetyTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OneNinetyTwoMember_lbl" xml:lang="en-US">1.92 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OneNinetyTwoMember" xlink:to="nnox_OneNinetyTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TwoTwentyOneMember" xlink:href="nnox-20211231.xsd#nnox_TwoTwentyOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_TwoTwentyOneMember_lbl" xml:lang="en-US">2.21 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TwoTwentyOneMember" xlink:to="nnox_TwoTwentyOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OneSixZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_OneSixZeroZeroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OneSixZeroZeroMember_lbl" xml:lang="en-US">16.00 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OneSixZeroZeroMember" xlink:to="nnox_OneSixZeroZeroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_twentythreeAndNineteenHundredthsMember" xlink:href="nnox-20211231.xsd#nnox_twentythreeAndNineteenHundredthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_twentythreeAndNineteenHundredthsMember_lbl" xml:lang="en-US">23.19 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_twentythreeAndNineteenHundredthsMember" xlink:to="nnox_twentythreeAndNineteenHundredthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_twentythreeAndEightyfourHundredthsMember" xlink:href="nnox-20211231.xsd#nnox_twentythreeAndEightyfourHundredthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_twentythreeAndEightyfourHundredthsMember_lbl" xml:lang="en-US">23.84 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_twentythreeAndEightyfourHundredthsMember" xlink:to="nnox_twentythreeAndEightyfourHundredthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ThirtyPointNineThreeMember" xlink:href="nnox-20211231.xsd#nnox_ThirtyPointNineThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ThirtyPointNineThreeMember_lbl" xml:lang="en-US">30.93 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ThirtyPointNineThreeMember" xlink:to="nnox_ThirtyPointNineThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_thirtyAndSixtysixHundredthsMember" xlink:href="nnox-20211231.xsd#nnox_thirtyAndSixtysixHundredthsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_thirtyAndSixtysixHundredthsMember_lbl" xml:lang="en-US">30.66 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_thirtyAndSixtysixHundredthsMember" xlink:to="nnox_thirtyAndSixtysixHundredthsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_fortyAndTwentyoneMember" xlink:href="nnox-20211231.xsd#nnox_fortyAndTwentyoneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_fortyAndTwentyoneMember_lbl" xml:lang="en-US">40.21 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_fortyAndTwentyoneMember" xlink:to="nnox_fortyAndTwentyoneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FortynineAndSixtyeightMember" xlink:href="nnox-20211231.xsd#nnox_FortynineAndSixtyeightMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FortynineAndSixtyeightMember_lbl" xml:lang="en-US">49.68 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FortynineAndSixtyeightMember" xlink:to="nnox_FortynineAndSixtyeightMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ZeroPointZeroZeroOneMember" xlink:href="nnox-20211231.xsd#nnox_ZeroPointZeroZeroOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ZeroPointZeroZeroOneMember_lbl" xml:lang="en-US">0.01 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ZeroPointZeroZeroOneMember" xlink:to="nnox_ZeroPointZeroZeroOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OneEightZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_OneEightZeroZeroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OneEightZeroZeroMember_lbl" xml:lang="en-US">18.00 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OneEightZeroZeroMember" xlink:to="nnox_OneEightZeroZeroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OnePointZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_OnePointZeroZeroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OnePointZeroZeroMember_lbl" xml:lang="en-US">One Point Zero Zero [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OnePointZeroZeroMember" xlink:to="nnox_OnePointZeroZeroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TwoPointTwoOneMember" xlink:href="nnox-20211231.xsd#nnox_TwoPointTwoOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_TwoPointTwoOneMember_lbl" xml:lang="en-US">2.21 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TwoPointTwoOneMember" xlink:to="nnox_TwoPointTwoOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SixteenPointZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_SixteenPointZeroZeroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SixteenPointZeroZeroMember_lbl" xml:lang="en-US">16.00 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SixteenPointZeroZeroMember" xlink:to="nnox_SixteenPointZeroZeroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SeventeenPointSixtyThreeMember" xlink:href="nnox-20211231.xsd#nnox_SeventeenPointSixtyThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SeventeenPointSixtyThreeMember_lbl" xml:lang="en-US">17.63 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SeventeenPointSixtyThreeMember" xlink:to="nnox_SeventeenPointSixtyThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TwentSixPointFiveSixMember" xlink:href="nnox-20211231.xsd#nnox_TwentSixPointFiveSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_TwentSixPointFiveSixMember_lbl" xml:lang="en-US">26.56 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TwentSixPointFiveSixMember" xlink:to="nnox_TwentSixPointFiveSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AwardsOutstandingMember" xlink:href="nnox-20211231.xsd#nnox_AwardsOutstandingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AwardsOutstandingMember_lbl" xml:lang="en-US">Awards outstanding [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AwardsOutstandingMember" xlink:to="nnox_AwardsOutstandingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NonemployeesMember" xlink:href="nnox-20211231.xsd#nnox_NonemployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NonemployeesMember_lbl" xml:lang="en-US">Non-employees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NonemployeesMember" xlink:to="nnox_NonemployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AwardsExercisableMember" xlink:href="nnox-20211231.xsd#nnox_AwardsExercisableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AwardsExercisableMember_lbl" xml:lang="en-US">Awards exercisable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AwardsExercisableMember" xlink:to="nnox_AwardsExercisableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_EmployeesOfficersAndDirectorsMember" xlink:href="nnox-20211231.xsd#nnox_EmployeesOfficersAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_EmployeesOfficersAndDirectorsMember_lbl" xml:lang="en-US">Employees, Officers and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmployeesOfficersAndDirectorsMember" xlink:to="nnox_EmployeesOfficersAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomelossBeforeIncomeTaxesMember" xlink:href="nnox-20211231.xsd#nnox_IncomelossBeforeIncomeTaxesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IncomelossBeforeIncomeTaxesMember_lbl" xml:lang="en-US">Income (loss) Before Income Taxes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncomelossBeforeIncomeTaxesMember" xlink:to="nnox_IncomelossBeforeIncomeTaxesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxExpensesMember" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IncomeTaxExpensesMember_lbl" xml:lang="en-US">Income Tax Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncomeTaxExpensesMember" xlink:to="nnox_IncomeTaxExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TaxesOnIncomeMember" xlink:href="nnox-20211231.xsd#nnox_TaxesOnIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_TaxesOnIncomeMember_lbl" xml:lang="en-US">Taxes on Income [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TaxesOnIncomeMember" xlink:to="nnox_TaxesOnIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxARCMember" xlink:href="nnox-20211231.xsd#nnox_NanoxARCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NanoxARCMember_lbl" xml:lang="en-US">Nanox ARC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NanoxARCMember" xlink:to="nnox_NanoxARCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TotalMember" xlink:href="nnox-20211231.xsd#nnox_TotalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_TotalMember_lbl" xml:lang="en-US">Total [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalMember" xlink:to="nnox_TotalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RadiologyServicesMember" xlink:href="nnox-20211231.xsd#nnox_RadiologyServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RadiologyServicesMember_lbl" xml:lang="en-US">Radiology Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RadiologyServicesMember" xlink:to="nnox_RadiologyServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AISolutionsMember" xlink:href="nnox-20211231.xsd#nnox_AISolutionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AISolutionsMember_lbl" xml:lang="en-US">AI Solutions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AISolutionsMember" xlink:to="nnox_AISolutionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IL_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_KRW" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_KRW"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_KRW_lbl" xml:lang="en-US">South Korea [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_KRW" xlink:to="currency_KRW_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">Unites States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="country_US_lbl0" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <loc xlink:type="locator" xlink:label="country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_JP_lbl" xml:lang="en-US">Japan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AgreementAxis" xlink:href="nnox-20211231.xsd#nnox_AgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AgreementAxis" xlink:to="nnox_AgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAssetAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegulatoryAssetAxis_lbl" xml:lang="en-US">Regulatory Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="us-gaap_RegulatoryAssetAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xml:lang="en-US">Percentage of acquisition shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_InitialPublicOfferingNetProceeds" xlink:href="nnox-20211231.xsd#nnox_InitialPublicOfferingNetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_InitialPublicOfferingNetProceeds_lbl" xml:lang="en-US">Proceeds received from the IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_InitialPublicOfferingNetProceeds" xlink:to="nnox_InitialPublicOfferingNetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_TaxBenefitPercentage" xlink:href="nnox-20211231.xsd#nnox_TaxBenefitPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_TaxBenefitPercentage_lbl" xml:lang="en-US">Tax benefit percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TaxBenefitPercentage" xlink:to="nnox_TaxBenefitPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Ordinary shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_EmployeeOptionsAndRestrictedStockUnits" xlink:href="nnox-20211231.xsd#nnox_EmployeeOptionsAndRestrictedStockUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_EmployeeOptionsAndRestrictedStockUnits_lbl" xml:lang="en-US">Employee options and restricted stock units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmployeeOptionsAndRestrictedStockUnits" xlink:to="nnox_EmployeeOptionsAndRestrictedStockUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OutstandingSharesPerShare" xlink:href="nnox-20211231.xsd#nnox_OutstandingSharesPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OutstandingSharesPerShare_lbl" xml:lang="en-US">Outstanding shares per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OutstandingSharesPerShare" xlink:to="nnox_OutstandingSharesPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ServicePeriodsDecription" xlink:href="nnox-20211231.xsd#nnox_ServicePeriodsDecription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ServicePeriodsDecription_lbl" xml:lang="en-US">Service periods, decription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ServicePeriodsDecription" xlink:to="nnox_ServicePeriodsDecription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Total consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PurchaseConsideration" xlink:href="nnox-20211231.xsd#nnox_PurchaseConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PurchaseConsideration_lbl" xml:lang="en-US">Purchase consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseConsideration" xlink:to="nnox_PurchaseConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredClosingConsideration" xlink:href="nnox-20211231.xsd#nnox_DeferredClosingConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DeferredClosingConsideration_lbl" xml:lang="en-US">Deferred closing consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredClosingConsideration" xlink:to="nnox_DeferredClosingConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalConsideration" xlink:href="nnox-20211231.xsd#nnox_AdditionalConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AdditionalConsideration_lbl" xml:lang="en-US">Additional consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsideration" xlink:to="nnox_AdditionalConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_MaximumAggregateAmount" xlink:href="nnox-20211231.xsd#nnox_MaximumAggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_MaximumAggregateAmount_lbl" xml:lang="en-US">Maximum aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_MaximumAggregateAmount" xlink:to="nnox_MaximumAggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FairValuePercentage" xlink:href="nnox-20211231.xsd#nnox_FairValuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FairValuePercentage_lbl" xml:lang="en-US">Fair value percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValuePercentage" xlink:to="nnox_FairValuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DescriptionOfNetAssets" xlink:href="nnox-20211231.xsd#nnox_DescriptionOfNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DescriptionOfNetAssets_lbl" xml:lang="en-US">Description of net assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DescriptionOfNetAssets" xlink:to="nnox_DescriptionOfNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AcquisitionDate" xlink:href="nnox-20211231.xsd#nnox_AcquisitionDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AcquisitionDate_lbl" xml:lang="en-US">Acquisition date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AcquisitionDate" xlink:to="nnox_AcquisitionDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xml:lang="en-US">General and administration expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesNetOfInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesNetOfInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesNetOfInterestExpense_lbl" xml:lang="en-US">Amounts of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesNetOfInterestExpense" xlink:to="us-gaap_RevenuesNetOfInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NetLoss" xlink:href="nnox-20211231.xsd#nnox_NetLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NetLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NetLoss" xlink:to="nnox_NetLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AcquisitionOfSharesPercentage" xlink:href="nnox-20211231.xsd#nnox_AcquisitionOfSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AcquisitionOfSharesPercentage_lbl" xml:lang="en-US">Acquisition of shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AcquisitionOfSharesPercentage" xlink:to="nnox_AcquisitionOfSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PurchaseOfSharesPercentage" xlink:href="nnox-20211231.xsd#nnox_PurchaseOfSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PurchaseOfSharesPercentage_lbl" xml:lang="en-US">Purchase of shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseOfSharesPercentage" xlink:to="nnox_PurchaseOfSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OrdinaryShare" xlink:href="nnox-20211231.xsd#nnox_OrdinaryShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OrdinaryShare_lbl" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinaryShare" xlink:to="nnox_OrdinaryShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OtherOperationalPerformancebasedEarnoutsOver" xlink:href="nnox-20211231.xsd#nnox_OtherOperationalPerformancebasedEarnoutsOver"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OtherOperationalPerformancebasedEarnoutsOver_lbl" xml:lang="en-US">Other operational performance-based earnouts over</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherOperationalPerformancebasedEarnoutsOver" xlink:to="nnox_OtherOperationalPerformancebasedEarnoutsOver_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalCashConsideration" xlink:href="nnox-20211231.xsd#nnox_AdditionalCashConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AdditionalCashConsideration_lbl" xml:lang="en-US">Additional cash consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalCashConsideration" xlink:to="nnox_AdditionalCashConsideration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Stock consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OtherRevenue" xlink:href="nnox-20211231.xsd#nnox_OtherRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OtherRevenue_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherRevenue" xlink:to="nnox_OtherRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_OtherNetLoss" xlink:href="nnox-20211231.xsd#nnox_OtherNetLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_OtherNetLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherNetLoss" xlink:to="nnox_OtherNetLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SettledInCashPercentage" xlink:href="nnox-20211231.xsd#nnox_SettledInCashPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SettledInCashPercentage_lbl" xml:lang="en-US">Settled in cash percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SettledInCashPercentage" xlink:to="nnox_SettledInCashPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IssuanceOfOrdinarySharePercentage" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_IssuanceOfOrdinarySharePercentage_lbl" xml:lang="en-US">Issuance of ordinary share percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharePercentage" xlink:to="nnox_IssuanceOfOrdinarySharePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalPayment" xlink:href="nnox-20211231.xsd#nnox_AdditionalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AdditionalPayment_lbl" xml:lang="en-US">Additional payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalPayment" xlink:to="nnox_AdditionalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairedIntangibleAssetDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairedIntangibleAssetDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairedIntangibleAssetDescription_lbl" xml:lang="en-US">Intangible asset, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairedIntangibleAssetDescription" xlink:to="us-gaap_ImpairedIntangibleAssetDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FairValueOfContingentConsiderationLiabilities" xlink:href="nnox-20211231.xsd#nnox_FairValueOfContingentConsiderationLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FairValueOfContingentConsiderationLiabilities_lbl" xml:lang="en-US">Fair value of contingent consideration liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfContingentConsiderationLiabilities" xlink:to="nnox_FairValueOfContingentConsiderationLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PrincipalAmountOfThePPPLoan" xlink:href="nnox-20211231.xsd#nnox_PrincipalAmountOfThePPPLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PrincipalAmountOfThePPPLoan_lbl" xml:lang="en-US">Principal amount of the PPP Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PrincipalAmountOfThePPPLoan" xlink:to="nnox_PrincipalAmountOfThePPPLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_InterestAccruesRate" xlink:href="nnox-20211231.xsd#nnox_InterestAccruesRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_InterestAccruesRate_lbl" xml:lang="en-US">Interest accrues rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_InterestAccruesRate" xlink:to="nnox_InterestAccruesRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LoanTerm" xlink:href="nnox-20211231.xsd#nnox_LoanTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LoanTerm_lbl" xml:lang="en-US">Loan term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LoanTerm" xlink:to="nnox_LoanTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AssetsAcquisitionDescription" xlink:href="nnox-20211231.xsd#nnox_AssetsAcquisitionDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AssetsAcquisitionDescription_lbl" xml:lang="en-US">Assets acquisition, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AssetsAcquisitionDescription" xlink:to="nnox_AssetsAcquisitionDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Intangible assets on straight-line basis over expected useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_lbl" xml:lang="en-US">Estimated fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FilmMonetizedOnItsOwnAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense_lbl" xml:lang="en-US">Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense" xlink:to="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl" xml:lang="en-US">Purchase of land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LeaseTermDescription" xlink:href="nnox-20211231.xsd#nnox_LeaseTermDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LeaseTermDescription_lbl" xml:lang="en-US">Rent payment agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeaseTermDescription" xlink:to="nnox_LeaseTermDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LeasesTermDescription" xlink:href="nnox-20211231.xsd#nnox_LeasesTermDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LeasesTermDescription_lbl" xml:lang="en-US">Vehicles lease, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeasesTermDescription" xlink:to="nnox_LeasesTermDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_VehiclesLeasePayments" xlink:href="nnox-20211231.xsd#nnox_VehiclesLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_VehiclesLeasePayments_lbl" xml:lang="en-US">Vehicle lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_VehiclesLeasePayments" xlink:to="nnox_VehiclesLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payment for agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription" xlink:href="nnox-20211231.xsd#nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription_lbl" xml:lang="en-US">Fabrication facility and research developmental center description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription" xlink:to="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments for rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManagementFeeExpense_lbl" xml:lang="en-US">management fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeExpense" xlink:to="us-gaap_ManagementFeeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xml:lang="en-US">Related party liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Share purchase agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Direct expenses percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Expense amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nHxU+FkdcNBNYw6Vah1sITLF0AKIKqceszsygtSRj8AWpstzvXG3UpvsP0Kw1wBZdplajBi7sgUTevj2rFJUOTGGfUu3CQIgrK0mVSIM3kwlpib7tqz2Bar376KTTarp+w==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_lbl" xml:lang="en-US">Prior completion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Private office space (in Square Meters)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PaysApproximately" xlink:href="nnox-20211231.xsd#nnox_PaysApproximately"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PaysApproximately_lbl" xml:lang="en-US">pays approximately</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PaysApproximately" xlink:to="nnox_PaysApproximately_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseIncome_lbl" xml:lang="en-US">Relation to sub lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncome" xlink:to="us-gaap_LeaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Gross monthly base salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_EmploymentAgreementDescription" xlink:href="nnox-20211231.xsd#nnox_EmploymentAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_EmploymentAgreementDescription_lbl" xml:lang="en-US">Employment Agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmploymentAgreementDescription" xlink:to="nnox_EmploymentAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UtilitiesOperatingExpenseProductsAndServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UtilitiesOperatingExpenseProductsAndServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UtilitiesOperatingExpenseProductsAndServices_lbl" xml:lang="en-US">Services amount for per hour</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UtilitiesOperatingExpenseProductsAndServices" xlink:to="us-gaap_UtilitiesOperatingExpenseProductsAndServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Loan expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromDepositOnLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan_lbl" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:to="us-gaap_PaymentsForProceedsFromDepositOnLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US">Loan agreement term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AnnualInterestRate" xlink:href="nnox-20211231.xsd#nnox_AnnualInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AnnualInterestRate_lbl" xml:lang="en-US">Annual interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AnnualInterestRate" xlink:to="nnox_AnnualInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ConsultingFees" xlink:href="nnox-20211231.xsd#nnox_ConsultingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ConsultingFees_lbl" xml:lang="en-US">Consulting fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConsultingFees" xlink:to="nnox_ConsultingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_EntitlementToWarrantsAmount" xlink:href="nnox-20211231.xsd#nnox_EntitlementToWarrantsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_EntitlementToWarrantsAmount_lbl" xml:lang="en-US">Entitlement to warrants amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EntitlementToWarrantsAmount" xlink:to="nnox_EntitlementToWarrantsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DescriptionOfSharebasedCompensationExpenses" xlink:href="nnox-20211231.xsd#nnox_DescriptionOfSharebasedCompensationExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DescriptionOfSharebasedCompensationExpenses_lbl" xml:lang="en-US">Description of share-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DescriptionOfSharebasedCompensationExpenses" xlink:to="nnox_DescriptionOfSharebasedCompensationExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Awards were exercised on a cashless</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US">Employees, officers awards to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Average exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_VestingPeriod" xlink:href="nnox-20211231.xsd#nnox_VestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_VestingPeriod_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_VestingPeriod" xlink:to="nnox_VestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Awards agreement term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AgreementTerminateTerm" xlink:href="nnox-20211231.xsd#nnox_AgreementTerminateTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AgreementTerminateTerm_lbl" xml:lang="en-US">Agreement terminate term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AgreementTerminateTerm" xlink:to="nnox_AgreementTerminateTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ConsiderationForServicesShares" xlink:href="nnox-20211231.xsd#nnox_ConsiderationForServicesShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_ConsiderationForServicesShares_lbl" xml:lang="en-US">Consideration for services shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConsiderationForServicesShares" xlink:to="nnox_ConsiderationForServicesShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValueAddedTaxReceivableNoncurrent_lbl" xml:lang="en-US">Plus VAT (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:to="us-gaap_ValueAddedTaxReceivableNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PurchaseAggregateShares" xlink:href="nnox-20211231.xsd#nnox_PurchaseAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PurchaseAggregateShares_lbl" xml:lang="en-US">Purchase aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseAggregateShares" xlink:to="nnox_PurchaseAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RecordedAnExpense" xlink:href="nnox-20211231.xsd#nnox_RecordedAnExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_RecordedAnExpense_lbl" xml:lang="en-US">Recorded expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RecordedAnExpense" xlink:to="nnox_RecordedAnExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Carry forward loss (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_FederalTaxRatePercentage" xlink:href="nnox-20211231.xsd#nnox_FederalTaxRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_FederalTaxRatePercentage_lbl" xml:lang="en-US">Federal tax rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FederalTaxRatePercentage" xlink:to="nnox_FederalTaxRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CarryForwardLossYears" xlink:href="nnox-20211231.xsd#nnox_CarryForwardLossYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_CarryForwardLossYears_lbl" xml:lang="en-US">Carry forward loss years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CarryForwardLossYears" xlink:to="nnox_CarryForwardLossYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Total revenue percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_BasicAndDilutedShare" xlink:href="nnox-20211231.xsd#nnox_BasicAndDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_BasicAndDilutedShare_lbl" xml:lang="en-US">Basic and diluted share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BasicAndDilutedShare" xlink:to="nnox_BasicAndDilutedShare_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_WarrantsShares" xlink:href="nnox-20211231.xsd#nnox_WarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_WarrantsShares_lbl" xml:lang="en-US">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WarrantsShares" xlink:to="nnox_WarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_WarrantsOption" xlink:href="nnox-20211231.xsd#nnox_WarrantsOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_WarrantsOption_lbl" xml:lang="en-US">Warrants option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WarrantsOption" xlink:to="nnox_WarrantsOption_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AdditionalSharesIssued" xlink:href="nnox-20211231.xsd#nnox_AdditionalSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_AdditionalSharesIssued_lbl" xml:lang="en-US">Additional shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalSharesIssued" xlink:to="nnox_AdditionalSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsFairValueDisclosure_lbl" xml:lang="en-US">Fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsFairValueDisclosure" xlink:to="us-gaap_OtherAssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LeasedAdditionTerm" xlink:href="nnox-20211231.xsd#nnox_LeasedAdditionTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LeasedAdditionTerm_lbl" xml:lang="en-US">Leased addition term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeasedAdditionTerm" xlink:to="nnox_LeasedAdditionTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates in the preparation of financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Intangible Assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SeverancePayPolicyTextBlock" xlink:href="nnox-20211231.xsd#nnox_SeverancePayPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SeverancePayPolicyTextBlock" xlink:to="nnox_SeverancePayPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_LegalAndOtherContingenciesPolicyTextBlock" xlink:href="nnox-20211231.xsd#nnox_LegalAndOtherContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_LegalAndOtherContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Legal and other contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LegalAndOtherContingenciesPolicyTextBlock" xlink:to="nnox_LegalAndOtherContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_DeferredOfferingCostsPolicyTextBlock" xlink:href="nnox-20211231.xsd#nnox_DeferredOfferingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredOfferingCostsPolicyTextBlock" xlink:to="nnox_DeferredOfferingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Newly issued and recently adopted accounting pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Bisiness Acquisition [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NasdaqMember" xlink:href="nnox-20211231.xsd#nnox_NasdaqMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NasdaqMember_lbl" xml:lang="en-US">Nasdaq [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NasdaqMember" xlink:to="nnox_NasdaqMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessAcquisitionMember" xlink:href="nnox-20211231.xsd#nnox_BusinessAcquisitionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_BusinessAcquisitionMember_lbl" xml:lang="en-US">Business Acquisition [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BusinessAcquisitionMember" xlink:to="nnox_BusinessAcquisitionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PPPLoanMember" xlink:href="nnox-20211231.xsd#nnox_PPPLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_PPPLoanMember_lbl" xml:lang="en-US">PPP Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PPPLoanMember" xlink:to="nnox_PPPLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_MDWEBLLCMember" xlink:href="nnox-20211231.xsd#nnox_MDWEBLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_MDWEBLLCMember_lbl" xml:lang="en-US">MDWEB LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_MDWEBLLCMember" xlink:to="nnox_MDWEBLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SharePurchaseAgreementMember" xlink:href="nnox-20211231.xsd#nnox_SharePurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SharePurchaseAgreementMember_lbl" xml:lang="en-US">Share purchase agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SharePurchaseAgreementMember" xlink:to="nnox_SharePurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxPLCMember" xlink:href="nnox-20211231.xsd#nnox_NanoxPLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NanoxPLCMember_lbl" xml:lang="en-US">Nanox PLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NanoxPLCMember" xlink:to="nnox_NanoxPLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_NanoxJapanMember" xlink:href="nnox-20211231.xsd#nnox_NanoxJapanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_NanoxJapanMember_lbl" xml:lang="en-US">Nanox Japan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NanoxJapanMember" xlink:to="nnox_NanoxJapanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SixAIMember" xlink:href="nnox-20211231.xsd#nnox_SixAIMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_SixAIMember_lbl" xml:lang="en-US">SixAI [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SixAIMember" xlink:to="nnox_SixAIMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_WellseseTechnologiesLtdMember" xlink:href="nnox-20211231.xsd#nnox_WellseseTechnologiesLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nnox_WellseseTechnologiesLtdMember_lbl" xml:lang="en-US">Wellsese Technologies Ltd.[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WellseseTechnologiesLtdMember" xlink:to="nnox_WellseseTechnologiesLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_KR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_KR_lbl" xml:lang="en-US">Korea [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KR" xlink:to="country_KR_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFuelCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFuelCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFuelCostsMember_lbl" xml:lang="en-US">Deferred Taxes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFuelCostsMember" xlink:to="us-gaap_DeferredFuelCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_GeneralTable" xlink:href="nnox-20211231.xsd#nnox_GeneralTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_GeneralTable_lbl" xml:lang="en-US">General [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_GeneralTable" xlink:to="nnox_GeneralTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_GeneralLineItems" xlink:href="nnox-20211231.xsd#nnox_GeneralLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_GeneralLineItems_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_GeneralLineItems" xlink:to="nnox_GeneralLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CashCashEquivalentsandRestrictedCashTable" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashCashEquivalentsandRestrictedCashTable_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashCashEquivalentsandRestrictedCashTable" xlink:to="nnox_CashCashEquivalentsandRestrictedCashTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CashCashEquivalentsandRestrictedCashLineItems" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashCashEquivalentsandRestrictedCashLineItems_lbl" xml:lang="en-US">Cash Equivalents and Restricted Cash [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashCashEquivalentsandRestrictedCashLineItems" xlink:to="nnox_CashCashEquivalentsandRestrictedCashLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CashCashEquivalentsandRestrictedCashTablesTable" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashCashEquivalentsandRestrictedCashTablesTable_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashCashEquivalentsandRestrictedCashTablesTable" xlink:to="nnox_CashCashEquivalentsandRestrictedCashTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_CashCashEquivalentsandRestrictedCashTablesLineItems" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashCashEquivalentsandRestrictedCashTablesLineItems_lbl" xml:lang="en-US">Cash Equivalents and Restricted Cash Table[Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashCashEquivalentsandRestrictedCashTablesLineItems" xlink:to="nnox_CashCashEquivalentsandRestrictedCashTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityTablesTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityTablesTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityTablesTable" xlink:to="nnox_ShareholdersEquityTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityTablesLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityTablesLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityTablesLineItems" xlink:to="nnox_ShareholdersEquityTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of property and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" xlink:to="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable_lbl" xml:lang="en-US">Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable" xlink:to="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems_lbl" xml:lang="en-US">Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable_lbl" xml:lang="en-US">Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" xlink:to="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems_lbl" xml:lang="en-US">Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable_lbl" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl" xml:lang="en-US">Condensed Statement of Income Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xml:lang="en-US">Schedule of Goodwill [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillLineItems_lbl" xml:lang="en-US">Goodwill [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" xlink:href="nnox-20211231.xsd#nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable_lbl" xml:lang="en-US">Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" xlink:to="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems" xlink:href="nnox-20211231.xsd#nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems_lbl" xml:lang="en-US">Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems" xlink:to="nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable_lbl" xml:lang="en-US">Related Parties (Details) - Schedule of related party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable" xlink:to="nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems_lbl" xml:lang="en-US">Related Parties (Details) - Schedule of related party [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems" xlink:to="nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of issued and outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable" xlink:to="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of issued and outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:to="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xml:lang="en-US">Option Indexed to Issuer&apos;s Equity, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of shared - based payments to employees [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:to="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of shared - based payments to employees [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable_lbl" xml:lang="en-US">Income Tax (Details) - Schedule of income (loss) before income taxes consisted [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable" xlink:to="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems_lbl" xml:lang="en-US">Income Tax (Details) - Schedule of income (loss) before income taxes consisted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable_lbl" xml:lang="en-US">Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" xlink:to="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems_lbl" xml:lang="en-US">Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable_lbl" xml:lang="en-US">Segments of Operations (Details) - Schedule of property and equipment by geography [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable" xlink:to="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems_lbl" xml:lang="en-US">Segments of Operations (Details) - Schedule of property and equipment by geography [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems" xlink:to="nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_GeneralDetailsTable" xlink:href="nnox-20211231.xsd#nnox_GeneralDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_GeneralDetailsTable_lbl" xml:lang="en-US">General (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_GeneralDetailsTable" xlink:to="nnox_GeneralDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_GeneralDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_GeneralDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_GeneralDetailsLineItems_lbl" xml:lang="en-US">General (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_GeneralDetailsLineItems" xlink:to="nnox_GeneralDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsTable" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsTable_lbl" xml:lang="en-US">Business Combination and Other Transaction (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsTable" xlink:to="nnox_BusinessCombinationandOtherTransactionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_BusinessCombinationandOtherTransactionDetailsLineItems_lbl" xml:lang="en-US">Business Combination and Other Transaction (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="nnox_BusinessCombinationandOtherTransactionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_AgreementDomain" xlink:href="nnox-20211231.xsd#nnox_AgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AgreementDomain_lbl" xml:lang="en-US">Agreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AgreementDomain" xlink:to="nnox_AgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesDetailsTable" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartiesDetailsTable_lbl" xml:lang="en-US">Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartiesDetailsTable" xlink:to="nnox_RelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_RelatedPartiesDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartiesDetailsLineItems_lbl" xml:lang="en-US">Related Parties (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartiesDetailsLineItems" xlink:to="nnox_RelatedPartiesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsTable" xlink:to="nnox_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_ShareholdersEquityDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareholdersEquityDetailsLineItems" xlink:to="nnox_ShareholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAssetDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegulatoryAssetDomain_lbl" xml:lang="en-US">Regulatory Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAssetDomain" xlink:to="us-gaap_RegulatoryAssetDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsTable" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncomeTaxDetailsTable_lbl" xml:lang="en-US">Income Tax (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncomeTaxDetailsTable" xlink:to="nnox_IncomeTaxDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_IncomeTaxDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncomeTaxDetailsLineItems_lbl" xml:lang="en-US">Income Tax (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncomeTaxDetailsLineItems" xlink:to="nnox_IncomeTaxDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsTable" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SegmentsofOperationsDetailsTable_lbl" xml:lang="en-US">Segments of Operations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SegmentsofOperationsDetailsTable" xlink:to="nnox_SegmentsofOperationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SegmentsofOperationsDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SegmentsofOperationsDetailsLineItems_lbl" xml:lang="en-US">Segments of Operations (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SegmentsofOperationsDetailsLineItems" xlink:to="nnox_SegmentsofOperationsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SubsequentEventsDetailsTable" xlink:href="nnox-20211231.xsd#nnox_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SubsequentEventsDetailsTable" xlink:to="nnox_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nnox_SubsequentEventsDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SubsequentEventsDetailsLineItems" xlink:to="nnox_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_AcquisitionOfSharesPercentage_lbl0" xml:lang="en-US">Acquisition of shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AcquisitionOfSharesPercentage" xlink:to="nnox_AcquisitionOfSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_AdditionalCashConsideration_lbl0" xml:lang="en-US">Additional cash consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalCashConsideration" xlink:to="nnox_AdditionalCashConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_AdditionalConsideration_lbl0" xml:lang="en-US">The amount of additional consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsideration" xlink:to="nnox_AdditionalConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl0" xml:lang="en-US">Additional consideration with respect to an assets purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_AdditionalPayment_lbl0" xml:lang="en-US">Additional payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalPayment" xlink:to="nnox_AdditionalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_AdditionalSharesIssued_lbl0" xml:lang="en-US">Additional shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalSharesIssued" xlink:to="nnox_AdditionalSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_AgreementTerminateTerm_lbl0" xml:lang="en-US">Agreement terminate term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AgreementTerminateTerm" xlink:to="nnox_AgreementTerminateTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_AmortizationExpenseForThePeriod_lbl0" xml:lang="en-US">Amortization expense for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AmortizationExpenseForThePeriod" xlink:to="nnox_AmortizationExpenseForThePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_AnnualInterestRate_lbl0" xml:lang="en-US">Annual interest rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AnnualInterestRate" xlink:to="nnox_AnnualInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_BasicAndDilutedShare_lbl0" xml:lang="en-US">Basic and diluted share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BasicAndDilutedShare" xlink:to="nnox_BasicAndDilutedShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_CarryForwardLossYears_lbl0" xml:lang="en-US">Carry forward loss years.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CarryForwardLossYears" xlink:to="nnox_CarryForwardLossYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl0" xml:lang="en-US">The entire disclosure for cash equivalent and restricted cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashEquivalentsAndRestrictedCashTextBlock" xlink:to="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_CertainTransactionsTextBlock_lbl0" xml:lang="en-US">Certain Transactions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CertainTransactionsTextBlock" xlink:to="nnox_CertainTransactionsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ConsiderationForServicesShares_lbl0" xml:lang="en-US">Consideration for services shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConsiderationForServicesShares" xlink:to="nnox_ConsiderationForServicesShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ConsultingFees_lbl0" xml:lang="en-US">Consulting fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConsultingFees" xlink:to="nnox_ConsultingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ContingentLongTermEarnoutLiability_lbl0" xml:lang="en-US">Contingent long term earnout liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ContingentLongTermEarnoutLiability" xlink:to="nnox_ContingentLongTermEarnoutLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ContingentLongtermEarnoutLiability_lbl0" xml:lang="en-US">Contingent long-term earnout liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ContingentLongtermEarnoutLiability" xlink:to="nnox_ContingentLongtermEarnoutLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ContingentShortTermEarnoutLiability_lbl0" xml:lang="en-US">Contingent short term earnout liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ContingentShortTermEarnoutLiability" xlink:to="nnox_ContingentShortTermEarnoutLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl0" xml:lang="en-US">Conversion of related party liability to shareholders&#8217; equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:to="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ConvertibleNote_lbl0" xml:lang="en-US">The amount of convertible note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConvertibleNote" xlink:to="nnox_ConvertibleNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_DeferredClosingConsideration_lbl0" xml:lang="en-US">The amount of deferred closing consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredClosingConsideration" xlink:to="nnox_DeferredClosingConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_DeferredRevenuesTotal_lbl0" xml:lang="en-US">Deferred Revenues Total.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredRevenuesTotal" xlink:to="nnox_DeferredRevenuesTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_EmployeeOptionsAndRestrictedStockUnits_lbl0" xml:lang="en-US">Employee options and restricted stock units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmployeeOptionsAndRestrictedStockUnits" xlink:to="nnox_EmployeeOptionsAndRestrictedStockUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_EmploymentAgreementDescription_lbl0" xml:lang="en-US">Description of employment agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmploymentAgreementDescription" xlink:to="nnox_EmploymentAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_EntitlementToWarrantsAmount_lbl0" xml:lang="en-US">Entitlement to warrants amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EntitlementToWarrantsAmount" xlink:to="nnox_EntitlementToWarrantsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription_lbl0" xml:lang="en-US">Fabrication facility and research developmental center description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription" xlink:to="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations_lbl0" xml:lang="en-US">Fair value of contingent consideration assumed in business combinations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations" xlink:to="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_FairValueOfContingentConsiderationLiabilities_lbl0" xml:lang="en-US">Fair value of contingent consideration liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfContingentConsiderationLiabilities" xlink:to="nnox_FairValueOfContingentConsiderationLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations_lbl0" xml:lang="en-US">Fair value of ordinary shares issued as consideration for business combinations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" xlink:to="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets_lbl0" xml:lang="en-US">Fair value of ordinary shares issued as consideration for purchase of assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" xlink:to="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_FairValuePercentage_lbl0" xml:lang="en-US">The percentage of fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValuePercentage" xlink:to="nnox_FairValuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_FederalTaxRatePercentage_lbl0" xml:lang="en-US">Federal tax rate percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FederalTaxRatePercentage" xlink:to="nnox_FederalTaxRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_FinancialExpense_lbl0" xml:lang="en-US">Amount of financial expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FinancialExpense" xlink:to="nnox_FinancialExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_FinancialIncome_lbl0" xml:lang="en-US">Amount of financial income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FinancialIncome" xlink:to="nnox_FinancialIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_FiniteLivedIntangibleAssetNet_lbl0" xml:lang="en-US">Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FiniteLivedIntangibleAssetNet" xlink:to="nnox_FiniteLivedIntangibleAssetNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IncreaseDecreaseOperatingLease_lbl0" xml:lang="en-US">Operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseOperatingLease" xlink:to="nnox_IncreaseDecreaseOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl0" xml:lang="en-US">Related party prepaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:to="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IncreaseDueToBusinessCombinationinShares_lbl0" xml:lang="en-US">Increase due to business combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDueToBusinessCombinationinShares" xlink:to="nnox_IncreaseDueToBusinessCombinationinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IncreaseDueToTheBusinessCombinations_lbl0" xml:lang="en-US">Increase due to the business combinations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDueToTheBusinessCombinations" xlink:to="nnox_IncreaseDueToTheBusinessCombinations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_InitialPublicOfferingNetProceeds_lbl0" xml:lang="en-US">Initial public offering net proceeds .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_InitialPublicOfferingNetProceeds" xlink:to="nnox_InitialPublicOfferingNetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_InterestAccruesRate_lbl0" xml:lang="en-US">Interest accrues rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_InterestAccruesRate" xlink:to="nnox_InterestAccruesRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharePercentage_lbl0" xml:lang="en-US">Issuance of ordinary share percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharePercentage" xlink:to="nnox_IssuanceOfOrdinarySharePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl0" xml:lang="en-US">Issuance of ordinary shares and warrants, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl0" xml:lang="en-US">Issuance of ordinary shares and warrants, net of issuance shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl0" xml:lang="en-US">Issuance of ordinary shares to investors upon exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl0" xml:lang="en-US">Issuance of ordinary shares to investors upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants_lbl0" xml:lang="en-US">Issuance of ordinary shares upon exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants" xlink:to="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares_lbl0" xml:lang="en-US">Issuance of ordinary shares upon exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares" xlink:to="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuanceOfSharesInConsiderationOfAssets_lbl0" xml:lang="en-US">Issuance of shares in consideration of assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfSharesInConsiderationOfAssets" xlink:to="nnox_IssuanceOfSharesInConsiderationOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_IssuedDueToBusinessCombination_lbl0" xml:lang="en-US">Issued due to business combination.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuedDueToBusinessCombination" xlink:to="nnox_IssuedDueToBusinessCombination_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_LeaseTermDescription_lbl0" xml:lang="en-US">Description of lease term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeaseTermDescription" xlink:to="nnox_LeaseTermDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_LeasesTermDescription_lbl0" xml:lang="en-US">Lease agreement term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeasesTermDescription" xlink:to="nnox_LeasesTermDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_LongTermMarketableSecurities_lbl0" xml:lang="en-US">Long term marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LongTermMarketableSecurities" xlink:to="nnox_LongTermMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_MaximumAggregateAmount_lbl0" xml:lang="en-US">The amount of maximum aggregate amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_MaximumAggregateAmount" xlink:to="nnox_MaximumAggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_NetAssetsAcquired_lbl0" xml:lang="en-US">Net assets acquired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NetAssetsAcquired" xlink:to="nnox_NetAssetsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_NetLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NetLoss" xlink:to="nnox_NetLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear_lbl0" xml:lang="en-US">Number of share-based payment awards, Outstanding at end of year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" xlink:to="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_OrdinaryShare_lbl0" xml:lang="en-US">Number of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinaryShare" xlink:to="nnox_OrdinaryShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_OrdinarySharesIssuedAndOutstanding_lbl0" xml:lang="en-US">Number of shares issued and outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinarySharesIssuedAndOutstanding" xlink:to="nnox_OrdinarySharesIssuedAndOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_OtherGeneralAndAdministrativeExpenses_lbl0" xml:lang="en-US">Amount of general and administrative expense classified as other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherGeneralAndAdministrativeExpenses" xlink:to="nnox_OtherGeneralAndAdministrativeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_OtherNetLoss_lbl0" xml:lang="en-US">The value of net loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherNetLoss" xlink:to="nnox_OtherNetLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_OtherOperationalPerformancebasedEarnoutsOver_lbl0" xml:lang="en-US">Other operational performance-based earnouts over.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherOperationalPerformancebasedEarnoutsOver" xlink:to="nnox_OtherOperationalPerformancebasedEarnoutsOver_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_OtherRevenue_lbl0" xml:lang="en-US">The amount of other revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherRevenue" xlink:to="nnox_OtherRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_OutstandingSharesPerShare_lbl0" xml:lang="en-US">Outstanding shares per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OutstandingSharesPerShare" xlink:to="nnox_OutstandingSharesPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_PercentageOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Percentage of property plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PercentageOfPropertyPlantAndEquipment" xlink:to="nnox_PercentageOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_PresentValueOfLeaseLiabilities_lbl0" xml:lang="en-US">Present value of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PresentValueOfLeaseLiabilities" xlink:to="nnox_PresentValueOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_PrincipalAmountOfThePPPLoan_lbl0" xml:lang="en-US">Principal amount of the PPP Loan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PrincipalAmountOfThePPPLoan" xlink:to="nnox_PrincipalAmountOfThePPPLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl0" xml:lang="en-US">Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:to="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ProvisionForIncomeTaxes_lbl0" xml:lang="en-US">Provision for income taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ProvisionForIncomeTaxes" xlink:to="nnox_ProvisionForIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_PurchaseAggregateShares_lbl0" xml:lang="en-US">Purchase aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseAggregateShares" xlink:to="nnox_PurchaseAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_PurchaseConsideration_lbl0" xml:lang="en-US">Purchase consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseConsideration" xlink:to="nnox_PurchaseConsideration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_PurchaseOfSharesPercentage_lbl0" xml:lang="en-US">Purchase of shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseOfSharesPercentage" xlink:to="nnox_PurchaseOfSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl0" xml:lang="en-US">Recognition of operating lease right-of-use asset against operating lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:to="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_RecordedAnExpense_lbl0" xml:lang="en-US">Recorded an expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RecordedAnExpense" xlink:to="nnox_RecordedAnExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Property and equipment are stated at cost, net of accumulated depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:to="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_ServicePeriodsDecription_lbl0" xml:lang="en-US">Service periods, decription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ServicePeriodsDecription" xlink:to="nnox_ServicePeriodsDecription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_SettledInCashPercentage_lbl0" xml:lang="en-US">Settled in cash percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SettledInCashPercentage" xlink:to="nnox_SettledInCashPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_TaxBenefitPercentage_lbl0" xml:lang="en-US">Tax benefit percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TaxBenefitPercentage" xlink:to="nnox_TaxBenefitPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_TotalDueFromRelatedParties_lbl0" xml:lang="en-US">Total Due from related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalDueFromRelatedParties" xlink:to="nnox_TotalDueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_UnpaidOfferingCosts_lbl0" xml:lang="en-US">Unpaid offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_UnpaidOfferingCosts" xlink:to="nnox_UnpaidOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_VehiclesLeasePayments_lbl0" xml:lang="en-US">Vehicle lease Payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_VehiclesLeasePayments" xlink:to="nnox_VehiclesLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_VestingPeriod_lbl0" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_VestingPeriod" xlink:to="nnox_VestingPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_WarrantsOption_lbl0" xml:lang="en-US">Number of shares warrants option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WarrantsOption" xlink:to="nnox_WarrantsOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_WarrantsShares_lbl0" xml:lang="en-US">Number of shrares warrants shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WarrantsShares" xlink:to="nnox_WarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl0" xml:lang="en-US">Issuance of ordinary shares to investor upon exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:to="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares" xlink:to="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations_lbl1" xml:lang="en-US">FairValueOfContingentConsiderationAssumedInBusinessCombinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations" xlink:to="nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OtherRevenue_lbl1" xml:lang="en-US">OtherRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherRevenue" xlink:to="nnox_OtherRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AdditionalConsideration_lbl1" xml:lang="en-US">AdditionalConsideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsideration" xlink:to="nnox_AdditionalConsideration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_WellseseTechnologiesLtdMember_lbl0" xml:lang="en-US">WellseseTechnologiesLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WellseseTechnologiesLtdMember" xlink:to="nnox_WellseseTechnologiesLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DeferredRevenuesDisclosureTextBlock_lbl0" xml:lang="en-US">DeferredRevenuesDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredRevenuesDisclosureTextBlock" xlink:to="nnox_DeferredRevenuesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfSupplementalBalanceSheetInformationTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:to="nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NetAssetsAcquired_lbl1" xml:lang="en-US">NetAssetsAcquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NetAssetsAcquired" xlink:to="nnox_NetAssetsAcquired_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DueToThreeMember_lbl0" xml:lang="en-US">DueToThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DueToThreeMember" xlink:to="nnox_DueToThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets_lbl0" xml:lang="en-US">IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NoncurrentOperatingLeases_lbl0" xml:lang="en-US">NoncurrentOperatingLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NoncurrentOperatingLeases" xlink:to="nnox_NoncurrentOperatingLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AmortizationExpenseForThePeriod_lbl1" xml:lang="en-US">AmortizationExpenseForThePeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AmortizationExpenseForThePeriod" xlink:to="nnox_AmortizationExpenseForThePeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RadiologistRelationshipsMember_lbl0" xml:lang="en-US">RadiologistRelationshipsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RadiologistRelationshipsMember" xlink:to="nnox_RadiologistRelationshipsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ContingentShortTermEarnoutLiability_lbl1" xml:lang="en-US">ContingentShortTermEarnoutLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ContingentShortTermEarnoutLiability" xlink:to="nnox_ContingentShortTermEarnoutLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PurchaseOfSharesPercentage_lbl1" xml:lang="en-US">PurchaseOfSharesPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseOfSharesPercentage" xlink:to="nnox_PurchaseOfSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SeverancePayPolicyTextBlock_lbl0" xml:lang="en-US">SeverancePayPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SeverancePayPolicyTextBlock" xlink:to="nnox_SeverancePayPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OneSixZeroZeroMember_lbl0" xml:lang="en-US">OneSixZeroZeroMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OneSixZeroZeroMember" xlink:to="nnox_OneSixZeroZeroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RelatedPartyLiabilityTextBlock_lbl0" xml:lang="en-US">RelatedPartyLiabilityTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RelatedPartyLiabilityTextBlock" xlink:to="nnox_RelatedPartyLiabilityTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NonCurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">NonCurrentLiabilitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NonCurrentLiabilitiesAbstract" xlink:to="nnox_NonCurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl1" xml:lang="en-US">RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:to="nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares_lbl0" xml:lang="en-US">IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares" xlink:to="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharePercentage_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharePercentage" xlink:to="nnox_IssuanceOfOrdinarySharePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CurrentMaturitiesOfOperatingLeases_lbl0" xml:lang="en-US">CurrentMaturitiesOfOperatingLeases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CurrentMaturitiesOfOperatingLeases" xlink:to="nnox_CurrentMaturitiesOfOperatingLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_VestingPeriod_lbl1" xml:lang="en-US">VestingPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_VestingPeriod" xlink:to="nnox_VestingPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ZeroPointZeroZeroOneMember_lbl0" xml:lang="en-US">ZeroPointZeroZeroOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ZeroPointZeroZeroOneMember" xlink:to="nnox_ZeroPointZeroZeroOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_twentythreeAndNineteenHundredthsMember_lbl0" xml:lang="en-US">twentythreeAndNineteenHundredthsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_twentythreeAndNineteenHundredthsMember" xlink:to="nnox_twentythreeAndNineteenHundredthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AssetsAcquisitionDescription_lbl0" xml:lang="en-US">AssetsAcquisitionDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AssetsAcquisitionDescription" xlink:to="nnox_AssetsAcquisitionDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SegmentsOfOperationsTextBlock_lbl0" xml:lang="en-US">SegmentsOfOperationsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SegmentsOfOperationsTextBlock" xlink:to="nnox_SegmentsOfOperationsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncreaseDecreaseInTaxesResultingFromAbstract_lbl0" xml:lang="en-US">IncreaseDecreaseInTaxesResultingFromAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseInTaxesResultingFromAbstract" xlink:to="nnox_IncreaseDecreaseInTaxesResultingFromAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_WarrantsShares_lbl1" xml:lang="en-US">WarrantsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WarrantsShares" xlink:to="nnox_WarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_InterestAccruesRate_lbl1" xml:lang="en-US">InterestAccruesRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_InterestAccruesRate" xlink:to="nnox_InterestAccruesRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ChangesDuringTheYearAbstract0_lbl0" xml:lang="en-US">ChangesDuringTheYearAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ChangesDuringTheYearAbstract0" xlink:to="nnox_ChangesDuringTheYearAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter_lbl0" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter" xlink:to="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DescriptionOfNetAssets_lbl0" xml:lang="en-US">DescriptionOfNetAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DescriptionOfNetAssets" xlink:to="nnox_DescriptionOfNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfIssuedAndOutstandingTextBlock_lbl0" xml:lang="en-US">ScheduleOfIssuedAndOutstandingTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfIssuedAndOutstandingTextBlock" xlink:to="nnox_ScheduleOfIssuedAndOutstandingTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ContingentLongtermEarnoutLiability_lbl1" xml:lang="en-US">ContingentLongtermEarnoutLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ContingentLongtermEarnoutLiability" xlink:to="nnox_ContingentLongtermEarnoutLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_thirtyAndSixtysixHundredthsMember_lbl0" xml:lang="en-US">thirtyAndSixtysixHundredthsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_thirtyAndSixtysixHundredthsMember" xlink:to="nnox_thirtyAndSixtysixHundredthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_fortyAndTwentyoneMember_lbl0" xml:lang="en-US">fortyAndTwentyoneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_fortyAndTwentyoneMember" xlink:to="nnox_fortyAndTwentyoneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LeasesTermDescription_lbl1" xml:lang="en-US">LeasesTermDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeasesTermDescription" xlink:to="nnox_LeasesTermDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ConsultingFees_lbl1" xml:lang="en-US">ConsultingFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConsultingFees" xlink:to="nnox_ConsultingFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LeasedAdditionTerm_lbl0" xml:lang="en-US">LeasedAdditionTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeasedAdditionTerm" xlink:to="nnox_LeasedAdditionTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FederalTaxRatePercentage_lbl1" xml:lang="en-US">FederalTaxRatePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FederalTaxRatePercentage" xlink:to="nnox_FederalTaxRatePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ProvisionForIncomeTaxes_lbl1" xml:lang="en-US">ProvisionForIncomeTaxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ProvisionForIncomeTaxes" xlink:to="nnox_ProvisionForIncomeTaxes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OrdinarySharesIssuedAndOutstanding_lbl1" xml:lang="en-US">OrdinarySharesIssuedAndOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinarySharesIssuedAndOutstanding" xlink:to="nnox_OrdinarySharesIssuedAndOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OtherNetLoss_lbl1" xml:lang="en-US">OtherNetLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherNetLoss" xlink:to="nnox_OtherNetLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted_lbl0" xml:lang="en-US">ScheduleOfIncomelossBeforeIncomeTaxesConsisted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted" xlink:to="nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DueToMember_lbl0" xml:lang="en-US">DueToMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DueToMember" xlink:to="nnox_DueToMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfRelatedPartyTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfRelatedPartyTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfRelatedPartyTableTextBlock" xlink:to="nnox_ScheduleOfRelatedPartyTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncreaseDecreaseOperatingLease_lbl1" xml:lang="en-US">IncreaseDecreaseOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseOperatingLease" xlink:to="nnox_IncreaseDecreaseOperatingLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_WeightedAverageDiscountRateAbstract_lbl0" xml:lang="en-US">WeightedAverageDiscountRateAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WeightedAverageDiscountRateAbstract" xlink:to="nnox_WeightedAverageDiscountRateAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ConvertibleNote_lbl1" xml:lang="en-US">ConvertibleNote</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConvertibleNote" xlink:to="nnox_ConvertibleNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DeferredClosingConsideration_lbl1" xml:lang="en-US">DeferredClosingConsideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredClosingConsideration" xlink:to="nnox_DeferredClosingConsideration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LeaseTermDescription_lbl1" xml:lang="en-US">LeaseTermDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LeaseTermDescription" xlink:to="nnox_LeaseTermDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AcquisitionDate_lbl0" xml:lang="en-US">AcquisitionDate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AcquisitionDate" xlink:to="nnox_AcquisitionDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_BasicAndDilutedLossPerShare_lbl0" xml:lang="en-US">BasicAndDilutedLossPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BasicAndDilutedLossPerShare" xlink:to="nnox_BasicAndDilutedLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FortynineAndSixtyeightMember_lbl0" xml:lang="en-US">FortynineAndSixtyeightMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FortynineAndSixtyeightMember" xlink:to="nnox_FortynineAndSixtyeightMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PrincipalAmountOfThePPPLoan_lbl1" xml:lang="en-US">PrincipalAmountOfThePPPLoan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PrincipalAmountOfThePPPLoan" xlink:to="nnox_PrincipalAmountOfThePPPLoan_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ProductionLineInConstructionMember_lbl0" xml:lang="en-US">ProductionLineInConstructionMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ProductionLineInConstructionMember" xlink:to="nnox_ProductionLineInConstructionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_UnpaidOfferingCosts_lbl1" xml:lang="en-US">UnpaidOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_UnpaidOfferingCosts" xlink:to="nnox_UnpaidOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AwardsExercisableMember_lbl0" xml:lang="en-US">AwardsExercisableMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AwardsExercisableMember" xlink:to="nnox_AwardsExercisableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_MaximumAggregateAmount_lbl1" xml:lang="en-US">MaximumAggregateAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_MaximumAggregateAmount" xlink:to="nnox_MaximumAggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:to="nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OperatingLeasesAbstract_lbl0" xml:lang="en-US">OperatingLeasesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OperatingLeasesAbstract" xlink:to="nnox_OperatingLeasesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract_lbl0" xml:lang="en-US">RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:to="nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FinancialIncome_lbl1" xml:lang="en-US">FinancialIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FinancialIncome" xlink:to="nnox_FinancialIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_BlackScholesOptionpricingMember_lbl0" xml:lang="en-US">BlackScholesOptionpricingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BlackScholesOptionpricingMember" xlink:to="nnox_BlackScholesOptionpricingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SixteenPointZeroZeroMember_lbl0" xml:lang="en-US">SixteenPointZeroZeroMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SixteenPointZeroZeroMember" xlink:to="nnox_SixteenPointZeroZeroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DescriptionOfSharebasedCompensationExpenses_lbl0" xml:lang="en-US">DescriptionOfSharebasedCompensationExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DescriptionOfSharebasedCompensationExpenses" xlink:to="nnox_DescriptionOfSharebasedCompensationExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ComputersAndElectronicEquipmentMember_lbl0" xml:lang="en-US">ComputersAndElectronicEquipmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ComputersAndElectronicEquipmentMember" xlink:to="nnox_ComputersAndElectronicEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NumberOfSharebasedPaymentAwardsCancelled_lbl0" xml:lang="en-US">NumberOfSharebasedPaymentAwardsCancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NumberOfSharebasedPaymentAwardsCancelled" xlink:to="nnox_NumberOfSharebasedPaymentAwardsCancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SixAIMember_lbl0" xml:lang="en-US">SixAIMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SixAIMember" xlink:to="nnox_SixAIMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DueToTwoMember_lbl0" xml:lang="en-US">DueToTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DueToTwoMember" xlink:to="nnox_DueToTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OtherGeneralAndAdministrativeExpenses_lbl1" xml:lang="en-US">OtherGeneralAndAdministrativeExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherGeneralAndAdministrativeExpenses" xlink:to="nnox_OtherGeneralAndAdministrativeExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TwoTwentyOneMember_lbl0" xml:lang="en-US">TwoTwentyOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TwoTwentyOneMember" xlink:to="nnox_TwoTwentyOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RadiologyServicesMember_lbl0" xml:lang="en-US">RadiologyServicesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RadiologyServicesMember" xlink:to="nnox_RadiologyServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LessValuationAllowanceForDeferredTaxAssets_lbl0" xml:lang="en-US">LessValuationAllowanceForDeferredTaxAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LessValuationAllowanceForDeferredTaxAssets" xlink:to="nnox_LessValuationAllowanceForDeferredTaxAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock" xlink:to="nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_MDWEBLLCMember_lbl0" xml:lang="en-US">MDWEBLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_MDWEBLLCMember" xlink:to="nnox_MDWEBLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LongTermMarketableSecurities_lbl1" xml:lang="en-US">LongTermMarketableSecurities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LongTermMarketableSecurities" xlink:to="nnox_LongTermMarketableSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_EmployeesOfficersAndDirectorsMember_lbl0" xml:lang="en-US">EmployeesOfficersAndDirectorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmployeesOfficersAndDirectorsMember" xlink:to="nnox_EmployeesOfficersAndDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions_lbl0" xml:lang="en-US">IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" xlink:to="nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AnnualInterestRate_lbl1" xml:lang="en-US">AnnualInterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AnnualInterestRate" xlink:to="nnox_AnnualInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AssetsAbstract0_lbl0" xml:lang="en-US">AssetsAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AssetsAbstract0" xlink:to="nnox_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TotalMember_lbl0" xml:lang="en-US">TotalMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalMember" xlink:to="nnox_TotalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AdditionalSharesIssued_lbl1" xml:lang="en-US">AdditionalSharesIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalSharesIssued" xlink:to="nnox_AdditionalSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DeferredOfferingCostsPolicyTextBlock_lbl0" xml:lang="en-US">DeferredOfferingCostsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredOfferingCostsPolicyTextBlock" xlink:to="nnox_DeferredOfferingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_USARADHoldingIncMember_lbl0" xml:lang="en-US">USARADHoldingIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_USARADHoldingIncMember" xlink:to="nnox_USARADHoldingIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CurrentAbstract_lbl0" xml:lang="en-US">CurrentAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CurrentAbstract" xlink:to="nnox_CurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncomelossBeforeIncomeTaxesMember_lbl0" xml:lang="en-US">IncomelossBeforeIncomeTaxesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncomelossBeforeIncomeTaxesMember" xlink:to="nnox_IncomelossBeforeIncomeTaxesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AISolutionsMember_lbl0" xml:lang="en-US">AISolutionsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AISolutionsMember" xlink:to="nnox_AISolutionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AgreementTerminateTerm_lbl1" xml:lang="en-US">AgreementTerminateTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AgreementTerminateTerm" xlink:to="nnox_AgreementTerminateTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TotalDueFromRelatedParties_lbl1" xml:lang="en-US">TotalDueFromRelatedParties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalDueFromRelatedParties" xlink:to="nnox_TotalDueFromRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl1" xml:lang="en-US">issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:to="nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SettledInCashPercentage_lbl1" xml:lang="en-US">SettledInCashPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SettledInCashPercentage" xlink:to="nnox_SettledInCashPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited_lbl0" xml:lang="en-US">StockIssuedDuringPeriodSharesStockOptionsForfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited" xlink:to="nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NetLoss_lbl1" xml:lang="en-US">NetLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NetLoss" xlink:to="nnox_NetLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AdditionalPayment_lbl1" xml:lang="en-US">AdditionalPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalPayment" xlink:to="nnox_AdditionalPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NanoxJapanMember_lbl0" xml:lang="en-US">NanoxJapanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NanoxJapanMember" xlink:to="nnox_NanoxJapanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TwoPointTwoOneMember_lbl0" xml:lang="en-US">TwoPointTwoOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TwoPointTwoOneMember" xlink:to="nnox_TwoPointTwoOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PercentageOfPropertyPlantAndEquipment_lbl1" xml:lang="en-US">PercentageOfPropertyPlantAndEquipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PercentageOfPropertyPlantAndEquipment" xlink:to="nnox_PercentageOfPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_WeightedAverageExercisePriceExercisableAtEndOfYear_lbl0" xml:lang="en-US">WeightedAverageExercisePriceExercisableAtEndOfYear</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WeightedAverageExercisePriceExercisableAtEndOfYear" xlink:to="nnox_WeightedAverageExercisePriceExercisableAtEndOfYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription_lbl1" xml:lang="en-US">FabricationFacilityAndResearchDevelopmentalCenterDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription" xlink:to="nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock" xlink:to="nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OfficeFurnitureAndLabEquipmentMember_lbl0" xml:lang="en-US">OfficeFurnitureAndLabEquipmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OfficeFurnitureAndLabEquipmentMember" xlink:to="nnox_OfficeFurnitureAndLabEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesUponExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants" xlink:to="nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear_lbl1" xml:lang="en-US">NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" xlink:to="nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NanoxPLCMember_lbl0" xml:lang="en-US">NanoxPLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NanoxPLCMember" xlink:to="nnox_NanoxPLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl1" xml:lang="en-US">ConversionOfRelatedPartyLiabilityToShareholdersEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:to="nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfFairValueConsiderationTransferred_lbl0" xml:lang="en-US">ScheduleOfFairValueConsiderationTransferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfFairValueConsiderationTransferred" xlink:to="nnox_ScheduleOfFairValueConsiderationTransferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DueToOneMember_lbl0" xml:lang="en-US">DueToOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DueToOneMember" xlink:to="nnox_DueToOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfSharesInConsiderationOfAssets_lbl1" xml:lang="en-US">IssuanceOfSharesInConsiderationOfAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfSharesInConsiderationOfAssets" xlink:to="nnox_IssuanceOfSharesInConsiderationOfAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DeferredAbstract_lbl0" xml:lang="en-US">DeferredAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredAbstract" xlink:to="nnox_DeferredAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl1" xml:lang="en-US">IncreaseDecreaseRelatedPartyPrepaidExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:to="nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OutstandingSharesPerShare_lbl1" xml:lang="en-US">OutstandingSharesPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OutstandingSharesPerShare" xlink:to="nnox_OutstandingSharesPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NonemployeesMember_lbl0" xml:lang="en-US">NonemployeesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NonemployeesMember" xlink:to="nnox_NonemployeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TaxesOnIncomeMember_lbl0" xml:lang="en-US">TaxesOnIncomeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TaxesOnIncomeMember" xlink:to="nnox_TaxesOnIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FinancialExpense_lbl1" xml:lang="en-US">FinancialExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FinancialExpense" xlink:to="nnox_FinancialExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TwentSixPointFiveSixMember_lbl0" xml:lang="en-US">TwentSixPointFiveSixMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TwentSixPointFiveSixMember" xlink:to="nnox_TwentSixPointFiveSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_BasicAndDilutedShare_lbl1" xml:lang="en-US">BasicAndDilutedShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BasicAndDilutedShare" xlink:to="nnox_BasicAndDilutedShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfPropertyPlantAndEquipmentTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_EmploymentAgreementDescription_lbl1" xml:lang="en-US">EmploymentAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmploymentAgreementDescription" xlink:to="nnox_EmploymentAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ThirtyPointNineThreeMember_lbl0" xml:lang="en-US">ThirtyPointNineThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ThirtyPointNineThreeMember" xlink:to="nnox_ThirtyPointNineThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AcquisitionOfSharesPercentage_lbl1" xml:lang="en-US">AcquisitionOfSharesPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AcquisitionOfSharesPercentage" xlink:to="nnox_AcquisitionOfSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OperatingLeaseCostAbstract_lbl0" xml:lang="en-US">OperatingLeaseCostAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OperatingLeaseCostAbstract" xlink:to="nnox_OperatingLeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuedDueToBusinessCombination_lbl1" xml:lang="en-US">IssuedDueToBusinessCombination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuedDueToBusinessCombination" xlink:to="nnox_IssuedDueToBusinessCombination_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl0" xml:lang="en-US">ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:to="nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands_lbl0" xml:lang="en-US">TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" xlink:to="nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ZebraMember_lbl0" xml:lang="en-US">ZebraMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ZebraMember" xlink:to="nnox_ZebraMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SeventeenPointSixtyThreeMember_lbl0" xml:lang="en-US">SeventeenPointSixtyThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SeventeenPointSixtyThreeMember" xlink:to="nnox_SeventeenPointSixtyThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_InitialPublicOfferingNetProceeds_lbl1" xml:lang="en-US">InitialPublicOfferingNetProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_InitialPublicOfferingNetProceeds" xlink:to="nnox_InitialPublicOfferingNetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CertainTransactionsTextBlock_lbl1" xml:lang="en-US">CertainTransactionsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CertainTransactionsTextBlock" xlink:to="nnox_CertainTransactionsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ChangesDuringTheYearAbstract_lbl0" xml:lang="en-US">ChangesDuringTheYearAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ChangesDuringTheYearAbstract" xlink:to="nnox_ChangesDuringTheYearAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ServicePeriodsDecription_lbl1" xml:lang="en-US">ServicePeriodsDecription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ServicePeriodsDecription" xlink:to="nnox_ServicePeriodsDecription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl1" xml:lang="en-US">AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin_lbl0" xml:lang="en-US">IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6_lbl0" xml:lang="en-US">AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" xlink:to="nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_twentythreeAndEightyfourHundredthsMember_lbl0" xml:lang="en-US">twentythreeAndEightyfourHundredthsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_twentythreeAndEightyfourHundredthsMember" xlink:to="nnox_twentythreeAndEightyfourHundredthsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PurchaseAggregateShares_lbl1" xml:lang="en-US">PurchaseAggregateShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseAggregateShares" xlink:to="nnox_PurchaseAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_EmployeeOptionsAndRestrictedStockUnits_lbl1" xml:lang="en-US">EmployeeOptionsAndRestrictedStockUnits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EmployeeOptionsAndRestrictedStockUnits" xlink:to="nnox_EmployeeOptionsAndRestrictedStockUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NonCurrentAssetsAbstract_lbl0" xml:lang="en-US">NonCurrentAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NonCurrentAssetsAbstract" xlink:to="nnox_NonCurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FiniteLivedIntangibleAssetNet_lbl1" xml:lang="en-US">FiniteLivedIntangibleAssetNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FiniteLivedIntangibleAssetNet" xlink:to="nnox_FiniteLivedIntangibleAssetNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PresentValueOfLeaseLiabilities_lbl1" xml:lang="en-US">PresentValueOfLeaseLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PresentValueOfLeaseLiabilities" xlink:to="nnox_PresentValueOfLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FairValuePercentage_lbl1" xml:lang="en-US">FairValuePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValuePercentage" xlink:to="nnox_FairValuePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OtherComprehensiveLossAbstract_lbl0" xml:lang="en-US">OtherComprehensiveLossAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherComprehensiveLossAbstract" xlink:to="nnox_OtherComprehensiveLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NanoxARCMember_lbl0" xml:lang="en-US">NanoxARCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NanoxARCMember" xlink:to="nnox_NanoxARCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncreaseDueToTheBusinessCombinations_lbl1" xml:lang="en-US">IncreaseDueToTheBusinessCombinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDueToTheBusinessCombinations" xlink:to="nnox_IncreaseDueToTheBusinessCombinations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NanoxAILtdMember_lbl0" xml:lang="en-US">NanoxAILtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NanoxAILtdMember" xlink:to="nnox_NanoxAILtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_USARADMember_lbl0" xml:lang="en-US">USARADMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_USARADMember" xlink:to="nnox_USARADMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AwardsOutstandingMember_lbl0" xml:lang="en-US">AwardsOutstandingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AwardsOutstandingMember" xlink:to="nnox_AwardsOutstandingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OneNinetyTwoMember_lbl0" xml:lang="en-US">OneNinetyTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OneNinetyTwoMember" xlink:to="nnox_OneNinetyTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_NasdaqMember_lbl0" xml:lang="en-US">NasdaqMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_NasdaqMember" xlink:to="nnox_NasdaqMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PPPLoanMember_lbl0" xml:lang="en-US">PPPLoanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PPPLoanMember" xlink:to="nnox_PPPLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CurrentTotal_lbl0" xml:lang="en-US">CurrentTotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CurrentTotal" xlink:to="nnox_CurrentTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PurchaseConsideration_lbl1" xml:lang="en-US">PurchaseConsideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PurchaseConsideration" xlink:to="nnox_PurchaseConsideration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OneEightZeroZeroMember_lbl0" xml:lang="en-US">OneEightZeroZeroMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OneEightZeroZeroMember" xlink:to="nnox_OneEightZeroZeroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AgreementAxis_lbl0" xml:lang="en-US">AgreementAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AgreementAxis" xlink:to="nnox_AgreementAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RestrictedBankDeposit_lbl0" xml:lang="en-US">RestrictedBankDeposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RestrictedBankDeposit" xlink:to="nnox_RestrictedBankDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PaysApproximately_lbl0" xml:lang="en-US">PaysApproximately</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PaysApproximately" xlink:to="nnox_PaysApproximately_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_AdditionalCashConsideration_lbl1" xml:lang="en-US">AdditionalCashConsideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_AdditionalCashConsideration" xlink:to="nnox_AdditionalCashConsideration_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TotalAssetsAcquired_lbl0" xml:lang="en-US">TotalAssetsAcquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalAssetsAcquired" xlink:to="nnox_TotalAssetsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncomeTaxExpensesMember_lbl0" xml:lang="en-US">IncomeTaxExpensesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncomeTaxExpensesMember" xlink:to="nnox_IncomeTaxExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:to="nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CarryForwardLossYears_lbl1" xml:lang="en-US">CarryForwardLossYears</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CarryForwardLossYears" xlink:to="nnox_CarryForwardLossYears_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl1" xml:lang="en-US">IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:to="nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_IncreaseDueToBusinessCombinationinShares_lbl1" xml:lang="en-US">IncreaseDueToBusinessCombinationinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_IncreaseDueToBusinessCombinationinShares" xlink:to="nnox_IncreaseDueToBusinessCombinationinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_EntitlementToWarrantsAmount_lbl1" xml:lang="en-US">EntitlementToWarrantsAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_EntitlementToWarrantsAmount" xlink:to="nnox_EntitlementToWarrantsAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TaxBenefitPercentage_lbl1" xml:lang="en-US">TaxBenefitPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TaxBenefitPercentage" xlink:to="nnox_TaxBenefitPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:to="nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LoanTerm_lbl0" xml:lang="en-US">LoanTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LoanTerm" xlink:to="nnox_LoanTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ImageBigDataMember_lbl0" xml:lang="en-US">ImageBigDataMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ImageBigDataMember" xlink:to="nnox_ImageBigDataMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">WeightedAverageRemainingLeaseTermAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WeightedAverageRemainingLeaseTermAbstract" xlink:to="nnox_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_WarrantsOption_lbl1" xml:lang="en-US">WarrantsOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_WarrantsOption" xlink:to="nnox_WarrantsOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DeferredRevenuesTotal_lbl1" xml:lang="en-US">DeferredRevenuesTotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredRevenuesTotal" xlink:to="nnox_DeferredRevenuesTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_TotalOperatingLeaseCost_lbl0" xml:lang="en-US">TotalOperatingLeaseCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_TotalOperatingLeaseCost" xlink:to="nnox_TotalOperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl1" xml:lang="en-US">CashEquivalentsAndRestrictedCashTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_CashEquivalentsAndRestrictedCashTextBlock" xlink:to="nnox_CashEquivalentsAndRestrictedCashTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_RecordedAnExpense_lbl1" xml:lang="en-US">RecordedAnExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_RecordedAnExpense" xlink:to="nnox_RecordedAnExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_DeferredTaxAssetsAbstract" xlink:to="nnox_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ContingentLongTermEarnoutLiability_lbl1" xml:lang="en-US">ContingentLongTermEarnoutLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ContingentLongTermEarnoutLiability" xlink:to="nnox_ContingentLongTermEarnoutLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LegalAndOtherContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">LegalAndOtherContingenciesPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LegalAndOtherContingenciesPolicyTextBlock" xlink:to="nnox_LegalAndOtherContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OrdinaryShare_lbl1" xml:lang="en-US">OrdinaryShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OrdinaryShare" xlink:to="nnox_OrdinaryShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_BusinessAcquisitionMember_lbl0" xml:lang="en-US">BusinessAcquisitionMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_BusinessAcquisitionMember" xlink:to="nnox_BusinessAcquisitionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_VehiclesLeasePayments_lbl1" xml:lang="en-US">VehiclesLeasePayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_VehiclesLeasePayments" xlink:to="nnox_VehiclesLeasePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations_lbl1" xml:lang="en-US">FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" xlink:to="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OnePointZeroZeroMember_lbl0" xml:lang="en-US">OnePointZeroZeroMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OnePointZeroZeroMember" xlink:to="nnox_OnePointZeroZeroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_OtherOperationalPerformancebasedEarnoutsOver_lbl1" xml:lang="en-US">OtherOperationalPerformancebasedEarnoutsOver</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_OtherOperationalPerformancebasedEarnoutsOver" xlink:to="nnox_OtherOperationalPerformancebasedEarnoutsOver_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ConsiderationForServicesShares_lbl1" xml:lang="en-US">ConsiderationForServicesShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ConsiderationForServicesShares" xlink:to="nnox_ConsiderationForServicesShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours_lbl0" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueYearFours</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:to="nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets_lbl1" xml:lang="en-US">FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" xlink:to="nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_FairValueOfContingentConsiderationLiabilities_lbl1" xml:lang="en-US">FairValueOfContingentConsiderationLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_FairValueOfContingentConsiderationLiabilities" xlink:to="nnox_FairValueOfContingentConsiderationLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_SharePurchaseAgreementMember_lbl0" xml:lang="en-US">SharePurchaseAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_SharePurchaseAgreementMember" xlink:to="nnox_SharePurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_ChangesDuring2020Abstract_lbl0" xml:lang="en-US">ChangesDuring2020Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_ChangesDuring2020Abstract" xlink:to="nnox_ChangesDuring2020Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl1" xml:lang="en-US">PropertyPlantAndEquipmentSalvageValuePercentageDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:to="nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_lbl0" xml:lang="en-US">Acquired Finite-Lived Intangible Asset, Residual Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl0" xml:lang="en-US">Developed Technology Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Revenue, by Arrangement, Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl0" xml:lang="en-US">Marketable Securities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl0" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTerm_lbl0" xml:lang="en-US">Long-Term Debt, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl1" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl0" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_KRW_lbl0" xml:lang="en-US">Korea (South), Won</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_KRW" xlink:to="currency_KRW_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl0" xml:lang="en-US">Customer Relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense_lbl0" xml:lang="en-US">Film, Monetized on Its Own, Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense" xlink:to="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod_lbl0" xml:lang="en-US">Goodwill, Acquired During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl0" xml:lang="en-US">Contingent Consideration Classified as Equity, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl0" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl0" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl1" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl0" xml:lang="en-US">Excess Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl2" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Other Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl0" xml:lang="en-US">Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsFairValueDisclosure_lbl0" xml:lang="en-US">Other Assets, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsFairValueDisclosure" xlink:to="us-gaap_OtherAssetsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl0" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl0" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl1" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl0" xml:lang="en-US">Other Depreciation and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl1" xml:lang="en-US">Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl0" xml:lang="en-US">Vehicles [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl0" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairedIntangibleAssetDescription_lbl0" xml:lang="en-US">Impaired Intangible Asset, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairedIntangibleAssetDescription" xlink:to="us-gaap_ImpairedIntangibleAssetDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Income Tax Liabilities, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_lbl0" xml:lang="en-US">Cash Acquired in Excess of Payments to Acquire Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:to="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl1" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl0" xml:lang="en-US">Shares Granted, Value, Share-Based Payment Arrangement, before Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0" xml:lang="en-US">Short-Term Bank Loans and Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock_lbl0" xml:lang="en-US">Schedule of Valuation Allowance for Impairment of Recognized Servicing Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock" xlink:to="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl0" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsCurrent_lbl0" xml:lang="en-US">Intangible Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsCurrent" xlink:to="us-gaap_IntangibleAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl0" xml:lang="en-US">Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl0" xml:lang="en-US">Business Combination, Acquisition Related Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl0" xml:lang="en-US">Marketable Securities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1" xml:lang="en-US">Increase (Decrease) in Stockholders&apos; Equity [Roll Forward]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostOfOperatingRevenue_lbl0" xml:lang="en-US">Other Cost of Operating Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostOfOperatingRevenue" xlink:to="us-gaap_OtherCostOfOperatingRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl0" xml:lang="en-US">Payments of Financing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl1" xml:lang="en-US">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl0" xml:lang="en-US">Cash Acquired from Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl1" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_lbl1" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl2" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl0" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl1" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl0" xml:lang="en-US">Payments for Purchase of Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_lbl0" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_lbl0" xml:lang="en-US">Interest Income, Debt Securities, Held-to-Maturity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:to="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl0" xml:lang="en-US">Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl0" xml:lang="en-US">Other Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl1" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingRelatedIntangibleAssetsMember_lbl0" xml:lang="en-US">Marketing-Related Intangible Assets [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:to="us-gaap_MarketingRelatedIntangibleAssetsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseIncome_lbl0" xml:lang="en-US">Lease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncome" xlink:to="us-gaap_LeaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManagementFeeExpense_lbl0" xml:lang="en-US">Management Fee Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeExpense" xlink:to="us-gaap_ManagementFeeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl0" xml:lang="en-US">Other Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl0" xml:lang="en-US">Business Combination, Contingent Consideration, Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:to="us-gaap_BusinessCombinationContingentConsiderationAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl0" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValueAddedTaxReceivableNoncurrent_lbl0" xml:lang="en-US">Value Added Tax Receivable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:to="us-gaap_ValueAddedTaxReceivableNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl0" xml:lang="en-US">Short-Term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFuelCostsMember_lbl0" xml:lang="en-US">Deferred Fuel Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFuelCostsMember" xlink:to="us-gaap_DeferredFuelCostsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl0" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillMember_lbl0" xml:lang="en-US">Goodwill [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl0" xml:lang="en-US">Research and Development in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Other Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenuePeriodIncreaseDecrease_lbl0" xml:lang="en-US">Deferred Revenue, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenuePeriodIncreaseDecrease" xlink:to="us-gaap_DeferredRevenuePeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl0" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl0" xml:lang="en-US">Area of Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Other, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl0" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UtilitiesOperatingExpenseProductsAndServices_lbl0" xml:lang="en-US">Utilities Operating Expense, Products and Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UtilitiesOperatingExpenseProductsAndServices" xlink:to="us-gaap_UtilitiesOperatingExpenseProductsAndServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan_lbl0" xml:lang="en-US">Payments for (Proceeds from) Deposit on Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:to="us-gaap_PaymentsForProceedsFromDepositOnLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee Director Award Plan, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl0" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeNamesMember_lbl0" xml:lang="en-US">Trade Names [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl2" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_JP_lbl0" xml:lang="en-US">JAPAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl0" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl0" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_KR_lbl0" xml:lang="en-US">KOREA, REPUBLIC OF</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KR" xlink:to="country_KR_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebtNoncurrent_lbl0" xml:lang="en-US">Other Long-Term Debt, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebtNoncurrent" xlink:to="us-gaap_OtherLongTermDebtNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesNetOfInterestExpense_lbl0" xml:lang="en-US">Revenues, Net of Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesNetOfInterestExpense" xlink:to="us-gaap_RevenuesNetOfInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl0" xml:lang="en-US">ISRAEL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>nnox-20211231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon May 02 05:16:13 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedBalanceSheet" roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedIncomeStatement" roleURI="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ShareholdersEquityType2or3" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ConsolidatedCashFlow" roleURI="http://www.nanox.vision.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_General" roleURI="http://www.nanox.vision.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SignificantAccountingPolicies" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_BusinessCombinationandOtherTransaction" roleURI="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransaction"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_GoodwillIntangibleAssetsNet" roleURI="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_PropertyandEquipmentNet" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_CashCashEquivalentsandRestrictedCash" roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_Leases" roleURI="http://www.nanox.vision.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_DeferredRevenue" roleURI="http://www.nanox.vision.com/role/DeferredRevenue"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_RelatedParties" roleURI="http://www.nanox.vision.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LongTermLoan" roleURI="http://www.nanox.vision.com/role/LongTermLoan"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_CommitmentsandContingencies" roleURI="http://www.nanox.vision.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ShareholdersEquity" roleURI="http://www.nanox.vision.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_IncomeTax" roleURI="http://www.nanox.vision.com/role/IncomeTax"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SegmentsofOperations" roleURI="http://www.nanox.vision.com/role/SegmentsofOperations"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LossPerShare" roleURI="http://www.nanox.vision.com/role/LossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SubsequentEvents" roleURI="http://www.nanox.vision.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_AccountingPoliciesByPolicy" roleURI="http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SignificantAccountingPoliciesTables" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_BusinessCombinationandOtherTransactionTables" roleURI="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_GoodwillIntangibleAssetsNetTables" roleURI="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_PropertyandEquipmentNetTables" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LeasesTables" roleURI="http://www.nanox.vision.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_DeferredRevenueTables" roleURI="http://www.nanox.vision.com/role/DeferredRevenueTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_RelatedPartiesTables" roleURI="http://www.nanox.vision.com/role/RelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ShareholdersEquityTables" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_IncomeTaxTables" roleURI="http://www.nanox.vision.com/role/IncomeTaxTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SegmentsofOperationsTables" roleURI="http://www.nanox.vision.com/role/SegmentsofOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LossPerShareTables" roleURI="http://www.nanox.vision.com/role/LossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofpropertyandequipmentTable" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" roleURI="http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleoffairvalueconsiderationtransferredTable" roleURI="http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" roleURI="http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofacquisitionofNanoxAITable" roleURI="http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofgoodwillandtheintangibleassetsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofintangibleassetsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable" roleURI="http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofPercentageofpropertyandequipmentTable" roleURI="http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofpropertyandequipmentTable0" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable" roleURI="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofcompanystotalleasecostsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofsupplementalbalancesheetinformationTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofmaturitiesofoperatingleaseliabilitiesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofDeferredRevenueTable" roleURI="http://www.nanox.vision.com/role/ScheduleofDeferredRevenueTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofrelatedpartyTable" roleURI="http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofrelatedpartiestransactionsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofissuedandoutstandingTable" roleURI="http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofinformationconcerningoutstandingandexercisableawardsTable" roleURI="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofsharedbasedpaymentstoemployeesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofsharebasedcompensationexpensesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofincomelossbeforeincometaxesconsistedTable" roleURI="http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable" roleURI="http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofvaluationallowanceprovidedportiondeferredTable" roleURI="http://www.nanox.vision.com/role/ScheduleofvaluationallowanceprovidedportiondeferredTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" roleURI="http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofpropertyandequipmentbygeographyTable" roleURI="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable" roleURI="http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_GeneralDetails" roleURI="http://www.nanox.vision.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SignificantAccountingPoliciesDetails" roleURI="http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_BusinessCombinationandOtherTransactionDetails" roleURI="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_GoodwillIntangibleAssetsNetDetails" roleURI="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_PropertyandEquipmentNetDetails" roleURI="http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LeasesDetails" roleURI="http://www.nanox.vision.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_DeferredRevenueDetails" roleURI="http://www.nanox.vision.com/role/DeferredRevenueDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_RelatedPartiesDetails" roleURI="http://www.nanox.vision.com/role/RelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LongTermLoanDetails" roleURI="http://www.nanox.vision.com/role/LongTermLoanDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_CommitmentsandContingenciesDetails" roleURI="http://www.nanox.vision.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_ShareholdersEquityDetails" roleURI="http://www.nanox.vision.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_IncomeTaxDetails" roleURI="http://www.nanox.vision.com/role/IncomeTaxDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SegmentsofOperationsDetails" roleURI="http://www.nanox.vision.com/role/SegmentsofOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_LossPerShareDetails" roleURI="http://www.nanox.vision.com/role/LossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#nnox_r_SubsequentEventsDetails" roleURI="http://www.nanox.vision.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nnox-20211231.xsd#DocumentAndEntityInformation" roleURI="http://www.nanox.vision.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="NonCurrentAssetsAbstract" xlink:href="nnox-20211231.xsd#nnox_NonCurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="NonCurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_RestrictedCash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_Goodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_ShortTermBorrowings" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="NonCurrentLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_NonCurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="NonCurrentLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermDebtNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherLongTermDebtNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_Liabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_CostOfRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_GrossProfit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_EarningsPerShareBasic" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherComprehensiveLossAbstract" xlink:href="nnox-20211231.xsd#nnox_OtherComprehensiveLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OtherComprehensiveLossAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveLossAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveLossAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesUponExerciseOfWarrants" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesUponExerciseOfWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" xlink:href="nnox-20211231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseRelatedPartyPrepaidExpenses" xlink:href="nnox-20211231.xsd#nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="IncreaseDecreaseRelatedPartyPrepaidExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseOperatingLease" xlink:href="nnox-20211231.xsd#nnox_IncreaseDecreaseOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="IncreaseDecreaseOperatingLease" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" xlink:href="nnox-20211231.xsd#nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidOfferingCosts" xlink:href="nnox-20211231.xsd#nnox_UnpaidOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="UnpaidOfferingCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" xlink:href="nnox-20211231.xsd#nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" xlink:href="nnox-20211231.xsd#nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" xlink:href="nnox-20211231.xsd#nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfContingentConsiderationAssumedInBusinessCombinations" xlink:href="nnox-20211231.xsd#nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="FairValueOfContingentConsiderationAssumedInBusinessCombinations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesInConsiderationOfAssets" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfSharesInConsiderationOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="IssuanceOfSharesInConsiderationOfAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" xlink:href="nnox-20211231.xsd#nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" xlink:href="nnox-20211231.xsd#nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfRelatedPartyLiabilityToShareholdersEquity" xlink:href="nnox-20211231.xsd#nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ConversionOfRelatedPartyLiabilityToShareholdersEquity" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralTable" xlink:href="nnox-20211231.xsd#nnox_GeneralTable"/>
    <loc xlink:type="locator" xlink:label="GeneralLineItems" xlink:href="nnox-20211231.xsd#nnox_GeneralLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="GeneralTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralTable" xlink:to="GeneralLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralLineItems" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransaction">
    <loc xlink:type="locator" xlink:label="CertainTransactionsAbstract" xlink:href="nnox-20211231.xsd#nnox_CertainTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="CertainTransactionsTextBlock" xlink:href="nnox-20211231.xsd#nnox_CertainTransactionsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainTransactionsAbstract" xlink:to="CertainTransactionsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNet">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash">
    <loc xlink:type="locator" xlink:label="CashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20211231.xsd#nnox_CashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="CashCashEquivalentsandRestrictedCashTable" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashTable"/>
    <loc xlink:type="locator" xlink:label="CashCashEquivalentsandRestrictedCashLineItems" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndRestrictedCashAbstract" xlink:to="CashCashEquivalentsandRestrictedCashTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsandRestrictedCashTable" xlink:to="CashCashEquivalentsandRestrictedCashLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="CashEquivalentsAndRestrictedCashTextBlock" xlink:href="nnox-20211231.xsd#nnox_CashEquivalentsAndRestrictedCashTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsandRestrictedCashLineItems" xlink:to="CashEquivalentsAndRestrictedCashTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/DeferredRevenue">
    <loc xlink:type="locator" xlink:label="DeferredRevenuesDisclosureAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredRevenuesDisclosureTextBlock" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenuesDisclosureAbstract" xlink:to="DeferredRevenuesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedParties">
    <loc xlink:type="locator" xlink:label="RelatedPartyLiabilityAbstract" xlink:href="nnox-20211231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyLiabilityTextBlock" xlink:href="nnox-20211231.xsd#nnox_RelatedPartyLiabilityTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyLiabilityAbstract" xlink:to="RelatedPartyLiabilityTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LongTermLoan">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/IncomeTax">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SegmentsofOperations">
    <loc xlink:type="locator" xlink:label="SegmentsOfOperationsAbstract" xlink:href="nnox-20211231.xsd#nnox_SegmentsOfOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentsOfOperationsTextBlock" xlink:href="nnox-20211231.xsd#nnox_SegmentsOfOperationsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsOfOperationsAbstract" xlink:to="SegmentsOfOperationsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePayPolicyTextBlock" xlink:href="nnox-20211231.xsd#nnox_SeverancePayPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SeverancePayPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LegalAndOtherContingenciesPolicyTextBlock" xlink:href="nnox-20211231.xsd#nnox_LegalAndOtherContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LegalAndOtherContingenciesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredOfferingCostsPolicyTextBlock" xlink:href="nnox-20211231.xsd#nnox_DeferredOfferingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DeferredOfferingCostsPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables">
    <loc xlink:type="locator" xlink:label="CertainTransactionsAbstract" xlink:href="nnox-20211231.xsd#nnox_CertainTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueConsiderationTransferred" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfFairValueConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainTransactionsAbstract" xlink:to="ScheduleOfFairValueConsiderationTransferred" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainTransactionsAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables">
    <loc xlink:type="locator" xlink:label="CashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20211231.xsd#nnox_CashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="CashCashEquivalentsandRestrictedCashTablesTable" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashTablesTable"/>
    <loc xlink:type="locator" xlink:label="CashCashEquivalentsandRestrictedCashTablesLineItems" xlink:href="nnox-20211231.xsd#nnox_CashCashEquivalentsandRestrictedCashTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAndRestrictedCashAbstract" xlink:to="CashCashEquivalentsandRestrictedCashTablesTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsandRestrictedCashTablesTable" xlink:to="CashCashEquivalentsandRestrictedCashTablesLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsandRestrictedCashTablesLineItems" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/DeferredRevenueTables">
    <loc xlink:type="locator" xlink:label="DeferredRevenuesDisclosureAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenuesDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartiesTables">
    <loc xlink:type="locator" xlink:label="RelatedPartyLiabilityAbstract" xlink:href="nnox-20211231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfRelatedPartyTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyLiabilityAbstract" xlink:to="ScheduleOfRelatedPartyTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyLiabilityAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityTablesTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityTablesTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityTablesLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityTablesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeesOfficersAndDirectorsMember" xlink:href="nnox-20211231.xsd#nnox_EmployeesOfficersAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesOfficersAndDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesTable" xlink:to="ShareholdersEquityTablesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfIssuedAndOutstandingTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIssuedAndOutstandingTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="ScheduleOfIssuedAndOutstandingTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/IncomeTaxTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomelossBeforeIncomeTaxesConsisted" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfIncomelossBeforeIncomeTaxesConsisted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SegmentsofOperationsTables">
    <loc xlink:type="locator" xlink:label="SegmentsOfOperationsAbstract" xlink:href="nnox-20211231.xsd#nnox_SegmentsOfOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsOfOperationsAbstract" xlink:to="ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsOfOperationsAbstract" xlink:to="ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentSalvageValuePercentageDescription" xlink:href="nnox-20211231.xsd#nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems" xlink:to="PropertyPlantAndEquipmentSalvageValuePercentageDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:href="nnox-20211231.xsd#nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermMarketableSecurities" xlink:href="nnox-20211231.xsd#nnox_LongTermMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="LongTermMarketableSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_LongTermDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems" xlink:to="us-gaap_Liabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueConsiderationTransferredAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfFairValueConsiderationTransferredAbstract"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueConsiderationTransferredAbstract" xlink:to="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NanoxAILtdMember" xlink:href="nnox-20211231.xsd#nnox_NanoxAILtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="NanoxAILtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="USARADHoldingIncMember" xlink:href="nnox-20211231.xsd#nnox_USARADHoldingIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="USARADHoldingIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable" xlink:to="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract" xlink:to="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NanoxAILtdMember" xlink:href="nnox-20211231.xsd#nnox_NanoxAILtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="NanoxAILtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="USARADHoldingIncMember" xlink:href="nnox-20211231.xsd#nnox_USARADHoldingIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="USARADHoldingIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable" xlink:to="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_IntangibleAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_Goodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_OtherAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalAssetsAcquired" xlink:href="nnox-20211231.xsd#nnox_TotalAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="TotalAssetsAcquired" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentShortTermEarnoutLiability" xlink:href="nnox-20211231.xsd#nnox_ContingentShortTermEarnoutLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="ContingentShortTermEarnoutLiability" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentLongTermEarnoutLiability" xlink:href="nnox-20211231.xsd#nnox_ContingentLongTermEarnoutLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="ContingentLongTermEarnoutLiability" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentLongtermEarnoutLiability" xlink:href="nnox-20211231.xsd#nnox_ContingentLongtermEarnoutLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="ContingentLongtermEarnoutLiability" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNote" xlink:href="nnox-20211231.xsd#nnox_ConvertibleNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="ConvertibleNote" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_OtherLiabilities" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetAssetsAcquired" xlink:href="nnox-20211231.xsd#nnox_NetAssetsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="NetAssetsAcquired" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems" xlink:to="us-gaap_OtherCashEquivalentsAtCarryingValue" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAcquisitionOfNanoxAiAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfAcquisitionOfNanoxAiAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAcquisitionOfNanoxAiAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NanoxAILtdMember" xlink:href="nnox-20211231.xsd#nnox_NanoxAILtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="NanoxAILtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfIncomeCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfGoodwillAndTheIntangibleAssetsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfGoodwillAndTheIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGoodwillAndTheIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="us-gaap_GoodwillMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ZebraMember" xlink:href="nnox-20211231.xsd#nnox_ZebraMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="ZebraMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="USARADMember" xlink:href="nnox-20211231.xsd#nnox_USARADMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="USARADMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_GoodwillLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillAcquiredDuringPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImageBigDataMember" xlink:href="nnox-20211231.xsd#nnox_ImageBigDataMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="ImageBigDataMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketingRelatedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingRelatedIntangibleAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_MarketingRelatedIntangibleAssetsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RadiologistRelationshipsMember" xlink:href="nnox-20211231.xsd#nnox_RadiologistRelationshipsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="RadiologistRelationshipsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_TradeNamesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_CustomerRelationshipsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FiniteLivedIntangibleAssetNet" xlink:href="nnox-20211231.xsd#nnox_FiniteLivedIntangibleAssetNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizationExpenseForThePeriod" xlink:href="nnox-20211231.xsd#nnox_AmortizationExpenseForThePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationExpenseForThePeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPercentageOfPropertyAndEquipmentAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPercentageOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" xlink:href="nnox-20211231.xsd#nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems" xlink:href="nnox-20211231.xsd#nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPercentageOfPropertyAndEquipmentAbstract" xlink:to="PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ComputersAndElectronicEquipmentMember" xlink:href="nnox-20211231.xsd#nnox_ComputersAndElectronicEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="ComputersAndElectronicEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable" xlink:to="PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPropertyPlantAndEquipment" xlink:href="nnox-20211231.xsd#nnox_PercentageOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems" xlink:to="PercentageOfPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OfficeFurnitureAndLabEquipmentMember" xlink:href="nnox-20211231.xsd#nnox_OfficeFurnitureAndLabEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="OfficeFurnitureAndLabEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComputersAndElectronicEquipmentMember" xlink:href="nnox-20211231.xsd#nnox_ComputersAndElectronicEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="ComputersAndElectronicEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_VehiclesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProductionLineInConstructionMember" xlink:href="nnox-20211231.xsd#nnox_ProductionLineInConstructionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="ProductionLineInConstructionMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedBankDeposit" xlink:href="nnox-20211231.xsd#nnox_RestrictedBankDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="RestrictedBankDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfCompanysTotalLeaseCostsAbstract"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb4h6dwdYYWao3axeb5NffB2Z2yHr2fg2PJTRjl7ml768JvTYoEyRkMlu+ImljTqVRqFe1CEYJ+nHxU+FkdcNBNYw6Vah1sITLF0AKIKqceszsygtSRj8AWpstzvXG3UpvsP0Kw1wBZdplajBi7sgUTevj2rFJUOTGGfUu3CQIgrK0mVSIM3kwl+mFbOP34WfbVUQ7d3IELzA==] CSR-->
    <loc xlink:type="locator" xlink:label="OperatingLeaseCostAbstract" xlink:href="nnox-20211231.xsd#nnox_OperatingLeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:to="OperatingLeaseCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalOperatingLeaseCost" xlink:href="nnox-20211231.xsd#nnox_TotalOperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanysTotalLeaseCostsAbstract" xlink:to="TotalOperatingLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:href="nnox-20211231.xsd#nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract" xlink:to="RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesAbstract" xlink:href="nnox-20211231.xsd#nnox_OperatingLeasesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="OperatingLeasesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentMaturitiesOfOperatingLeases" xlink:href="nnox-20211231.xsd#nnox_CurrentMaturitiesOfOperatingLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="CurrentMaturitiesOfOperatingLeases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncurrentOperatingLeases" xlink:href="nnox-20211231.xsd#nnox_NoncurrentOperatingLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="NoncurrentOperatingLeases" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLeaseTermAbstract" xlink:href="nnox-20211231.xsd#nnox_WeightedAverageRemainingLeaseTermAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="WeightedAverageRemainingLeaseTermAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRateAbstract" xlink:href="nnox-20211231.xsd#nnox_WeightedAverageDiscountRateAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalBalanceSheetInformationAbstract" xlink:to="WeightedAverageDiscountRateAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:href="nnox-20211231.xsd#nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFours" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter" xlink:href="nnox-20211231.xsd#nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PresentValueOfLeaseLiabilities" xlink:href="nnox-20211231.xsd#nnox_PresentValueOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFours" xlink:to="PresentValueOfLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofDeferredRevenueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredRevenueAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfDeferredRevenueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDueToTheBusinessCombinations" xlink:href="nnox-20211231.xsd#nnox_IncreaseDueToTheBusinessCombinations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredRevenueAbstract" xlink:to="IncreaseDueToTheBusinessCombinations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredRevenuesTotal" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredRevenueAbstract" xlink:to="DeferredRevenuesTotal" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredRevenueAbstract" xlink:to="us-gaap_DeferredRevenue_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfRelatedPartyAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsScheduleofrelatedpartyTable" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsScheduleofrelatedpartyLineItems" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyAbstract" xlink:to="RelatedPartiesDetailsScheduleofrelatedpartyTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofrelatedpartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DueToMember" xlink:href="nnox-20211231.xsd#nnox_DueToMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DueToMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToOneMember" xlink:href="nnox-20211231.xsd#nnox_DueToOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DueToOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToTwoMember" xlink:href="nnox-20211231.xsd#nnox_DueToTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DueToTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToThreeMember" xlink:href="nnox-20211231.xsd#nnox_DueToThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DueToThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofrelatedpartyTable" xlink:to="RelatedPartiesDetailsScheduleofrelatedpartyLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="TotalDueFromRelatedParties" xlink:href="nnox-20211231.xsd#nnox_TotalDueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsScheduleofrelatedpartyLineItems" xlink:to="TotalDueFromRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartiesTransactionsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfRelatedPartiesTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartiesTransactionsAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherGeneralAndAdministrativeExpenses" xlink:href="nnox-20211231.xsd#nnox_OtherGeneralAndAdministrativeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartiesTransactionsAbstract" xlink:to="OtherGeneralAndAdministrativeExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIssuedAndOutstandingAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIssuedAndOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofissuedandoutstandingTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIssuedAndOutstandingAbstract" xlink:to="ShareholdersEquityDetailsScheduleofissuedandoutstandingTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofissuedandoutstandingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofissuedandoutstandingTable" xlink:to="ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesIssuedAndOutstanding" xlink:href="nnox-20211231.xsd#nnox_OrdinarySharesIssuedAndOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems" xlink:to="OrdinarySharesIssuedAndOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesDuringTheYearAbstract" xlink:href="nnox-20211231.xsd#nnox_ChangesDuringTheYearAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="ChangesDuringTheYearAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringTheYearAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" xlink:href="nnox-20211231.xsd#nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract" xlink:to="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BlackScholesOptionpricingMember" xlink:href="nnox-20211231.xsd#nnox_BlackScholesOptionpricingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="BlackScholesOptionpricingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable" xlink:to="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AwardsOutstandingMember" xlink:href="nnox-20211231.xsd#nnox_AwardsOutstandingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="AwardsOutstandingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AwardsExercisableMember" xlink:href="nnox-20211231.xsd#nnox_AwardsExercisableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="AwardsExercisableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NonemployeesMember" xlink:href="nnox-20211231.xsd#nnox_NonemployeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="NonemployeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OneNinetyTwoMember" xlink:href="nnox-20211231.xsd#nnox_OneNinetyTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="OneNinetyTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoTwentyOneMember" xlink:href="nnox-20211231.xsd#nnox_TwoTwentyOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="TwoTwentyOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneSixZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_OneSixZeroZeroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="OneSixZeroZeroMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="twentythreeAndNineteenHundredthsMember" xlink:href="nnox-20211231.xsd#nnox_twentythreeAndNineteenHundredthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="twentythreeAndNineteenHundredthsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="twentythreeAndEightyfourHundredthsMember" xlink:href="nnox-20211231.xsd#nnox_twentythreeAndEightyfourHundredthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="twentythreeAndEightyfourHundredthsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThirtyPointNineThreeMember" xlink:href="nnox-20211231.xsd#nnox_ThirtyPointNineThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ThirtyPointNineThreeMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="thirtyAndSixtysixHundredthsMember" xlink:href="nnox-20211231.xsd#nnox_thirtyAndSixtysixHundredthsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="thirtyAndSixtysixHundredthsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="fortyAndTwentyoneMember" xlink:href="nnox-20211231.xsd#nnox_fortyAndTwentyoneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="fortyAndTwentyoneMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FortynineAndSixtyeightMember" xlink:href="nnox-20211231.xsd#nnox_FortynineAndSixtyeightMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="FortynineAndSixtyeightMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ZeroPointZeroZeroOneMember" xlink:href="nnox-20211231.xsd#nnox_ZeroPointZeroZeroOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ZeroPointZeroZeroOneMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneEightZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_OneEightZeroZeroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="OneEightZeroZeroMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OnePointZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_OnePointZeroZeroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="OnePointZeroZeroMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoPointTwoOneMember" xlink:href="nnox-20211231.xsd#nnox_TwoPointTwoOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="TwoPointTwoOneMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SixteenPointZeroZeroMember" xlink:href="nnox-20211231.xsd#nnox_SixteenPointZeroZeroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="SixteenPointZeroZeroMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeventeenPointSixtyThreeMember" xlink:href="nnox-20211231.xsd#nnox_SeventeenPointSixtyThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="SeventeenPointSixtyThreeMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwentSixPointFiveSixMember" xlink:href="nnox-20211231.xsd#nnox_TwentSixPointFiveSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="TwentSixPointFiveSixMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSharedBasedPaymentsToEmployeesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSharedBasedPaymentsToEmployeesAbstract" xlink:to="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonemployeesMember" xlink:href="nnox-20211231.xsd#nnox_NonemployeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="NonemployeesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable" xlink:to="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" xlink:href="nnox-20211231.xsd#nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuedDueToBusinessCombination" xlink:href="nnox-20211231.xsd#nnox_IssuedDueToBusinessCombination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="IssuedDueToBusinessCombination" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockOptionsForfeited" xlink:href="nnox-20211231.xsd#nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsForfeited" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharebasedPaymentAwardsCancelled" xlink:href="nnox-20211231.xsd#nnox_NumberOfSharebasedPaymentAwardsCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="NumberOfSharebasedPaymentAwardsCancelled" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_0" xlink:href="nnox-20211231.xsd#nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceExercisableAtEndOfYear" xlink:href="nnox-20211231.xsd#nnox_WeightedAverageExercisePriceExercisableAtEndOfYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems" xlink:to="WeightedAverageExercisePriceExercisableAtEndOfYear" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedCompensationExpensesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfShareBasedCompensationExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCostOfOperatingRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostOfOperatingRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_OtherCostOfOperatingRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract" xlink:to="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IncomelossBeforeIncomeTaxesMember" xlink:href="nnox-20211231.xsd#nnox_IncomelossBeforeIncomeTaxesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="IncomelossBeforeIncomeTaxesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxExpensesMember" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="IncomeTaxExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxesOnIncomeMember" xlink:href="nnox-20211231.xsd#nnox_TaxesOnIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TaxesOnIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable" xlink:to="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentAbstract" xlink:href="nnox-20211231.xsd#nnox_CurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="CurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentTotal" xlink:href="nnox-20211231.xsd#nnox_CurrentTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAbstract" xlink:to="CurrentTotal" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="DeferredAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="nnox-20211231.xsd#nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredAbstract" xlink:to="DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="nnox-20211231.xsd#nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredAbstract" xlink:to="DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredAbstract" xlink:to="us-gaap_InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProvisionForIncomeTaxes" xlink:href="nnox-20211231.xsd#nnox_ProvisionForIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="ProvisionForIncomeTaxes" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems" xlink:to="us-gaap_IncomeLossAttributableToParent" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LessValuationAllowanceForDeferredTaxAssets" xlink:href="nnox-20211231.xsd#nnox_LessValuationAllowanceForDeferredTaxAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="LessValuationAllowanceForDeferredTaxAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofvaluationallowanceprovidedportiondeferredTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDueToBusinessCombinationinShares" xlink:href="nnox-20211231.xsd#nnox_IncreaseDueToBusinessCombinationinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:to="IncreaseDueToBusinessCombinationinShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenuePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenuePeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:to="us-gaap_DeferredRevenuePeriodIncreaseDecrease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"/>
    <loc xlink:type="locator" xlink:label="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract" xlink:to="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NanoxARCMember" xlink:href="nnox-20211231.xsd#nnox_NanoxARCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="NanoxARCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RadiologyServicesMember" xlink:href="nnox-20211231.xsd#nnox_RadiologyServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RadiologyServicesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AISolutionsMember" xlink:href="nnox-20211231.xsd#nnox_AISolutionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AISolutionsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalMember" xlink:href="nnox-20211231.xsd#nnox_TotalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TotalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable" xlink:to="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialExpense" xlink:href="nnox-20211231.xsd#nnox_FinancialExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="FinancialExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialIncome" xlink:href="nnox-20211231.xsd#nnox_FinancialIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="FinancialIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentByGeographyAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfPropertyAndEquipmentByGeographyAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable"/>
    <loc xlink:type="locator" xlink:label="SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentByGeographyAbstract" xlink:to="SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_KRW" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_KRW"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="currency_KRW" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_JP" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable" xlink:to="SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:href="nnox-20211231.xsd#nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" xlink:href="nnox-20211231.xsd#nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BasicAndDilutedLossPerShare" xlink:href="nnox-20211231.xsd#nnox_BasicAndDilutedLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract" xlink:to="BasicAndDilutedLossPerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsTable" xlink:href="nnox-20211231.xsd#nnox_GeneralDetailsTable"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_GeneralDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="GeneralDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NasdaqMember" xlink:href="nnox-20211231.xsd#nnox_NasdaqMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="NasdaqMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="GeneralDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialPublicOfferingNetProceeds" xlink:href="nnox-20211231.xsd#nnox_InitialPublicOfferingNetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsLineItems" xlink:to="InitialPublicOfferingNetProceeds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxBenefitPercentage" xlink:href="nnox-20211231.xsd#nnox_TaxBenefitPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="TaxBenefitPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails">
    <loc xlink:type="locator" xlink:label="CertainTransactionsAbstract" xlink:href="nnox-20211231.xsd#nnox_CertainTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationandOtherTransactionDetailsTable" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_BusinessCombinationandOtherTransactionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CertainTransactionsAbstract" xlink:to="BusinessCombinationandOtherTransactionDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NanoxAILtdMember" xlink:href="nnox-20211231.xsd#nnox_NanoxAILtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="NanoxAILtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="USARADHoldingIncMember" xlink:href="nnox-20211231.xsd#nnox_USARADHoldingIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="USARADHoldingIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MDWEBLLCMember" xlink:href="nnox-20211231.xsd#nnox_MDWEBLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MDWEBLLCMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BusinessAcquisitionMember" xlink:href="nnox-20211231.xsd#nnox_BusinessAcquisitionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PPPLoanMember" xlink:href="nnox-20211231.xsd#nnox_PPPLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="PPPLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsTable" xlink:to="BusinessCombinationandOtherTransactionDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeOptionsAndRestrictedStockUnits" xlink:href="nnox-20211231.xsd#nnox_EmployeeOptionsAndRestrictedStockUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="EmployeeOptionsAndRestrictedStockUnits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingSharesPerShare" xlink:href="nnox-20211231.xsd#nnox_OutstandingSharesPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="OutstandingSharesPerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ServicePeriodsDecription" xlink:href="nnox-20211231.xsd#nnox_ServicePeriodsDecription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="ServicePeriodsDecription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseConsideration" xlink:href="nnox-20211231.xsd#nnox_PurchaseConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="PurchaseConsideration" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredClosingConsideration" xlink:href="nnox-20211231.xsd#nnox_DeferredClosingConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="DeferredClosingConsideration" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalConsideration" xlink:href="nnox-20211231.xsd#nnox_AdditionalConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="AdditionalConsideration" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumAggregateAmount" xlink:href="nnox-20211231.xsd#nnox_MaximumAggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="MaximumAggregateAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValuePercentage" xlink:href="nnox-20211231.xsd#nnox_FairValuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="FairValuePercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfNetAssets" xlink:href="nnox-20211231.xsd#nnox_DescriptionOfNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="DescriptionOfNetAssets" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquisitionDate" xlink:href="nnox-20211231.xsd#nnox_AcquisitionDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="AcquisitionDate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesNetOfInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesNetOfInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_RevenuesNetOfInterestExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLoss" xlink:href="nnox-20211231.xsd#nnox_NetLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="NetLoss" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AcquisitionOfSharesPercentage" xlink:href="nnox-20211231.xsd#nnox_AcquisitionOfSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="AcquisitionOfSharesPercentage" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfSharesPercentage" xlink:href="nnox-20211231.xsd#nnox_PurchaseOfSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="PurchaseOfSharesPercentage" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShare" xlink:href="nnox-20211231.xsd#nnox_OrdinaryShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="OrdinaryShare" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherOperationalPerformancebasedEarnoutsOver" xlink:href="nnox-20211231.xsd#nnox_OtherOperationalPerformancebasedEarnoutsOver"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="OtherOperationalPerformancebasedEarnoutsOver" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalCashConsideration" xlink:href="nnox-20211231.xsd#nnox_AdditionalCashConsideration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="AdditionalCashConsideration" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherRevenue" xlink:href="nnox-20211231.xsd#nnox_OtherRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="OtherRevenue" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherNetLoss" xlink:href="nnox-20211231.xsd#nnox_OtherNetLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="OtherNetLoss" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SettledInCashPercentage" xlink:href="nnox-20211231.xsd#nnox_SettledInCashPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="SettledInCashPercentage" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharePercentage" xlink:href="nnox-20211231.xsd#nnox_IssuanceOfOrdinarySharePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="IssuanceOfOrdinarySharePercentage" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalPayment" xlink:href="nnox-20211231.xsd#nnox_AdditionalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="AdditionalPayment" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairedIntangibleAssetDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairedIntangibleAssetDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_ImpairedIntangibleAssetDescription" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfContingentConsiderationLiabilities" xlink:href="nnox-20211231.xsd#nnox_FairValueOfContingentConsiderationLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="FairValueOfContingentConsiderationLiabilities" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrincipalAmountOfThePPPLoan" xlink:href="nnox-20211231.xsd#nnox_PrincipalAmountOfThePPPLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="PrincipalAmountOfThePPPLoan" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestAccruesRate" xlink:href="nnox-20211231.xsd#nnox_InterestAccruesRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="InterestAccruesRate" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanTerm" xlink:href="nnox-20211231.xsd#nnox_LoanTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="LoanTerm" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AssetsAcquisitionDescription" xlink:href="nnox-20211231.xsd#nnox_AssetsAcquisitionDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="AssetsAcquisitionDescription" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationandOtherTransactionDetailsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FilmMonetizedOnItsOwnAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FilmMonetizedOnItsOwnAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_OtherDepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAndRentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseAndRentalExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeaseTermDescription" xlink:href="nnox-20211231.xsd#nnox_LeaseTermDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeaseTermDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeasesTermDescription" xlink:href="nnox-20211231.xsd#nnox_LeasesTermDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesTermDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VehiclesLeasePayments" xlink:href="nnox-20211231.xsd#nnox_VehiclesLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="VehiclesLeasePayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForFees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FabricationFacilityAndResearchDevelopmentalCenterDescription" xlink:href="nnox-20211231.xsd#nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="FabricationFacilityAndResearchDevelopmentalCenterDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_PaymentsForRent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ManagementFeeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/DeferredRevenueDetails">
    <loc xlink:type="locator" xlink:label="DeferredRevenuesDisclosureAbstract" xlink:href="nnox-20211231.xsd#nnox_DeferredRevenuesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredRevenuesDisclosureAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/RelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="RelatedPartyLiabilityAbstract" xlink:href="nnox-20211231.xsd#nnox_RelatedPartyLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsTable" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_RelatedPartiesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyLiabilityAbstract" xlink:to="RelatedPartiesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NanoxPLCMember" xlink:href="nnox-20211231.xsd#nnox_NanoxPLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="NanoxPLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SixAIMember" xlink:href="nnox-20211231.xsd#nnox_SixAIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="SixAIMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WellseseTechnologiesLtdMember" xlink:href="nnox-20211231.xsd#nnox_WellseseTechnologiesLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="WellseseTechnologiesLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NanoxJapanMember" xlink:href="nnox-20211231.xsd#nnox_NanoxJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="NanoxJapanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementAxis" xlink:href="nnox-20211231.xsd#nnox_AgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="AgreementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDomain" xlink:href="nnox-20211231.xsd#nnox_AgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="AgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SharePurchaseAgreementMember" xlink:href="nnox-20211231.xsd#nnox_SharePurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementAxis" xlink:to="SharePurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="RelatedPartiesDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_OtherExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_AreaOfLand" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaysApproximately" xlink:href="nnox-20211231.xsd#nnox_PaysApproximately"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="PaysApproximately" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_LeaseIncome" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesAndWages"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_SalariesAndWages" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmploymentAgreementDescription" xlink:href="nnox-20211231.xsd#nnox_EmploymentAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="EmploymentAgreementDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UtilitiesOperatingExpenseProductsAndServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UtilitiesOperatingExpenseProductsAndServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_UtilitiesOperatingExpenseProductsAndServices" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_CostsAndExpenses" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromDepositOnLoan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromDepositOnLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsLineItems" xlink:to="us-gaap_PaymentsForProceedsFromDepositOnLoan" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LongTermLoanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualInterestRate" xlink:href="nnox-20211231.xsd#nnox_AnnualInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="AnnualInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsultingFees" xlink:href="nnox-20211231.xsd#nnox_ConsultingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ConsultingFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EntitlementToWarrantsAmount" xlink:href="nnox-20211231.xsd#nnox_EntitlementToWarrantsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="EntitlementToWarrantsAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfSharebasedCompensationExpenses" xlink:href="nnox-20211231.xsd#nnox_DescriptionOfSharebasedCompensationExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="DescriptionOfSharebasedCompensationExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VestingPeriod" xlink:href="nnox-20211231.xsd#nnox_VestingPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="VestingPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementTerminateTerm" xlink:href="nnox-20211231.xsd#nnox_AgreementTerminateTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AgreementTerminateTerm" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsiderationForServicesShares" xlink:href="nnox-20211231.xsd#nnox_ConsiderationForServicesShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ConsiderationForServicesShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValueAddedTaxReceivableNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ValueAddedTaxReceivableNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAggregateShares" xlink:href="nnox-20211231.xsd#nnox_PurchaseAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="PurchaseAggregateShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecordedAnExpense" xlink:href="nnox-20211231.xsd#nnox_RecordedAnExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="RecordedAnExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/IncomeTaxDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxDetailsTable" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_IncomeTaxDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="country_KR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_KR" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_JP" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAssetAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsTable" xlink:to="us-gaap_RegulatoryAssetAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RegulatoryAssetDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="us-gaap_RegulatoryAssetDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFuelCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFuelCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="us-gaap_DeferredFuelCostsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsTable" xlink:to="IncomeTaxDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FederalTaxRatePercentage" xlink:href="nnox-20211231.xsd#nnox_FederalTaxRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsLineItems" xlink:to="FederalTaxRatePercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CarryForwardLossYears" xlink:href="nnox-20211231.xsd#nnox_CarryForwardLossYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsLineItems" xlink:to="CarryForwardLossYears" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SegmentsofOperationsDetails">
    <loc xlink:type="locator" xlink:label="SegmentsOfOperationsAbstract" xlink:href="nnox-20211231.xsd#nnox_SegmentsOfOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentsofOperationsDetailsTable" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SegmentsofOperationsDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_SegmentsofOperationsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsOfOperationsAbstract" xlink:to="SegmentsofOperationsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsTable" xlink:to="SegmentsofOperationsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsofOperationsDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/LossPerShareDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="BasicAndDilutedShare" xlink:href="nnox-20211231.xsd#nnox_BasicAndDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="BasicAndDilutedShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsShares" xlink:href="nnox-20211231.xsd#nnox_WarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="WarrantsShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOption" xlink:href="nnox-20211231.xsd#nnox_WarrantsOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="WarrantsOption" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="nnox-20211231.xsd#nnox_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="nnox-20211231.xsd#nnox_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="AdditionalSharesIssued" xlink:href="nnox-20211231.xsd#nnox_AdditionalSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AdditionalSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_OtherAssetsFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LeasedAdditionTerm" xlink:href="nnox-20211231.xsd#nnox_LeasedAdditionTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="LeasedAdditionTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.nanox.vision.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="nnox-20211231.xsd#nnox_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329154656792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NANO-X IMAGING LTD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NNOX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">51,791,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001795251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Communication Center<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Neve Ilan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">9085000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value NIS 0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Kesselman & Kesselman C.P.A.s<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Communication Center<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Neve Ilan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">9085000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Erez Meltzer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">02 544 5214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329157627592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 66,645<span></span>
</td>
<td class="nump">$ 213,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities - short term</a></td>
<td class="nump">22,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivables net of allowance for credit losses of $137 and o thousand as of December 31, 2021 and December 31,2020, respectively.</a></td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">3,129<span></span>
</td>
<td class="nump">4,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,966<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">94,857<span></span>
</td>
<td class="nump">219,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NonCurrentAssetsAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">37,435<span></span>
</td>
<td class="nump">14,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,725<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable Securities - long term</a></td>
<td class="nump">67,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">101,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">58,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">TOTAL NON-CURRENT ASSETS</a></td>
<td class="nump">268,313<span></span>
</td>
<td class="nump">16,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">363,170<span></span>
</td>
<td class="nump">236,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,134<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,611<span></span>
</td>
<td class="nump">1,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loan from a Government Agency</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Contingent short term earnout liability</a></td>
<td class="nump">42,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of operating lease liabilities</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,262<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">52,751<span></span>
</td>
<td class="nump">4,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NonCurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtNoncurrent', window );">Long term loan</a></td>
<td class="nump">3,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Non-current deferred revenue</a></td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Contingent long-term earnout liability</a></td>
<td class="nump">5,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">7,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL NON-CURRENT LIABILITIES</a></td>
<td class="nump">18,271<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">71,022<span></span>
</td>
<td class="nump">5,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares, par value NIS 0.01 per share 100,000,000 authorized at December 31, 2021 and December 31 2020, 51,791,441 and 46,100,173 issued and outstanding at September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">438,820<span></span>
</td>
<td class="nump">315,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive deficit</a></td>
<td class="num">(607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(146,214)<span></span>
</td>
<td class="num">(84,416)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">292,148<span></span>
</td>
<td class="nump">230,746<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 363,170<span></span>
</td>
<td class="nump">$ 236,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NonCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NonCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NonCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NonCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329154535160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivables net, credit losses (in Dollars) | $</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares, issued</a></td>
<td class="nump">51,791,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,100,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">51,791,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,100,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329154464760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUE</a></td>
<td class="nump">$ 1,304<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUE</a></td>
<td class="nump">2,816<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS LOSS</a></td>
<td class="num">(1,512)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,122<span></span>
</td>
<td class="nump">9,210<span></span>
</td>
<td class="nump">2,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and Marketing</a></td>
<td class="nump">7,033<span></span>
</td>
<td class="nump">12,445<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">34,709<span></span>
</td>
<td class="nump">22,268<span></span>
</td>
<td class="nump">18,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other expenses</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">60,046<span></span>
</td>
<td class="nump">43,923<span></span>
</td>
<td class="nump">22,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(61,558)<span></span>
</td>
<td class="num">(43,923)<span></span>
</td>
<td class="num">(22,571)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">FINANCIAL INCOME (EXPENSES), net</a></td>
<td class="num">(288)<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">OPERATING LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(61,846)<span></span>
</td>
<td class="num">(43,815)<span></span>
</td>
<td class="num">(22,563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX BENEFIT</a></td>
<td class="nump">48<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (61,798)<span></span>
</td>
<td class="num">$ (43,815)<span></span>
</td>
<td class="num">$ (22,563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">THE WEIGHTED AVERAGE OF THE NUMBER OF ORDINARY SHARES (in thousands) (in Shares)</a></td>
<td class="nump">48,216<span></span>
</td>
<td class="nump">35,654<span></span>
</td>
<td class="nump">25,181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">$ (61,798)<span></span>
</td>
<td class="num">$ (43,815)<span></span>
</td>
<td class="num">$ (22,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OtherComprehensiveLossAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized loss from available- for-sale securities</a></td>
<td class="num">(607)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss:</a></td>
<td class="num">(607)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">TOTAL COMPERHENSIVE LOSS</a></td>
<td class="num">$ (62,405)<span></span>
</td>
<td class="num">$ (43,815)<span></span>
</td>
<td class="num">$ (22,563)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OtherComprehensiveLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OtherComprehensiveLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329151094360">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Shareholders&#8217; Equity (capital Deficiency) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive deficit</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 11,596<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (18,038)<span></span>
</td>
<td class="num">$ (6,384)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,924,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts', window );">Issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">14,022<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares', window );">Issuance of ordinary shares and warrants, net of issuance costs (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,762,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of ordinary shares to employees and non-employees upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">454,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants', window );">Issuance of ordinary shares to investors upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares', window );">Issuance of ordinary shares to investors upon exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,245<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6', window );">Additional consideration with respect to an assets purchase agreement, see note 9a</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(10,276)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,563)<span></span>
</td>
<td class="num">(22,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">31,748<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(40,601)<span></span>
</td>
<td class="num">(8,778)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,150,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts', window );">Issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">70,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares', window );">Issuance of ordinary shares and warrants, net of issuance costs (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,624,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering of ordinary shares, net of offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">169,136<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering of ordinary shares, net of offering costs (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,555,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of ordinary shares to employees and non-employees upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">997,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants', window );">Issuance of ordinary shares to investors upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares', window );">Issuance of ordinary shares to investors upon exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,662,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">24,781<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of related party liability to shareholders&#8217; equity, see note 9a</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">17,745<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of related party liability to shareholders&#8217; equity, see note 9a (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,109,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,815)<span></span>
</td>
<td class="num">(43,815)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">315,031<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(84,416)<span></span>
</td>
<td class="nump">230,746<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,100,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants', window );">Issuance of ordinary shares upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">265<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares', window );">Issuance of ordinary shares upon exercise of warrants (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">780,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions', window );">Issuance of ordinary shares to employees and non-employees upon exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3,330<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares', window );">Issuance of ordinary shares to employees and non-employees upon exercise of options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,099,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets', window );">Issuance of ordinary shares due to business combination and assets acquisition (refer to Note 3)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">101,497<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">101,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin', window );">Issuance of ordinary shares due to business combination and assets acquisition (refer to Note 3) (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,810,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,697<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss from available- for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(607)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(61,798)<span></span>
</td>
<td class="num">(61,798)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 438,820<span></span>
</td>
<td class="num">$ (607)<span></span>
</td>
<td class="num">$ (146,214)<span></span>
</td>
<td class="nump">$ 292,148<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,791,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-size: 10pt">Less than 1 thousand US dollars.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and warrants, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and warrants, net of issuance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares to investors upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares to investors upon exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329155273032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="num">$ (61,798)<span></span>
</td>
<td class="num">$ (43,815)<span></span>
</td>
<td class="num">$ (22,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">18,806<span></span>
</td>
<td class="nump">24,781<span></span>
</td>
<td class="nump">16,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Impairment of property and equipment</a></td>
<td class="nump">214<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(116)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity', window );">Amortization of premium on marketable securities</a></td>
<td class="num">(216)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of businesses acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Accounts receivable</a></td>
<td class="num">(40)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,724<span></span>
</td>
<td class="num">(4,478)<span></span>
</td>
<td class="num">(1,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses', window );">Related party prepaid expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(374)<span></span>
</td>
<td class="num">(522)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,721<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncreaseDecreaseOperatingLease', window );">Operating lease assets and liabilities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(719)<span></span>
</td>
<td class="nump">2,359<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">179<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">233<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(38,071)<span></span>
</td>
<td class="num">(21,487)<span></span>
</td>
<td class="num">(5,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for business combinations, net of cash and restricted cash acquired</a></td>
<td class="num">(2,859)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Investment in marketable securities</a></td>
<td class="num">(90,303)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(23,158)<span></span>
</td>
<td class="num">(13,937)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(116,320)<span></span>
</td>
<td class="num">(13,937)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from long term loan</a></td>
<td class="nump">3,796<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts', window );">Proceeds from issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">71,013<span></span>
</td>
<td class="nump">14,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering of ordinary shares, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">169,348<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of ordinary shares upon exercise of warrants</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">630<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of ordinary shares to employees and non-employees upon exercise of options</a></td>
<td class="nump">3,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,379<span></span>
</td>
<td class="nump">240,991<span></span>
</td>
<td class="nump">13,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="num">(147,012)<span></span>
</td>
<td class="nump">205,567<span></span>
</td>
<td class="nump">8,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE YEAR</a></td>
<td class="nump">213,784<span></span>
</td>
<td class="nump">8,217<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR</a></td>
<td class="nump">66,772<span></span>
</td>
<td class="nump">213,784<span></span>
</td>
<td class="nump">8,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_UnpaidOfferingCosts', window );">Unpaid offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants', window );">issuance of ordinary shares to investor upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets', window );">Fair value of ordinary shares issued as consideration for purchase of assets</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations', window );">Fair value of ordinary shares issued as consideration for business combinations</a></td>
<td class="nump">100,010<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations', window );">Fair value of contingent consideration assumed in business combinations</a></td>
<td class="nump">47,194<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfSharesInConsiderationOfAssets', window );">Fair value of contingent consideration assumed in purchase of assets</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements', window );">Additional consideration with respect to an assets purchase agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity', window );">Conversion of related party liability to shareholders&#8217; equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17,748<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional consideration with respect to an assets purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of related party liability to shareholders&#8217; equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration assumed in business combinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of ordinary shares issued as consideration for business combinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of ordinary shares issued as consideration for purchase of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IncreaseDecreaseOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IncreaseDecreaseOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfSharesInConsiderationOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares in consideration of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfSharesInConsiderationOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognition of operating lease right-of-use asset against operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_UnpaidOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_UnpaidOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares to investor upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including amortization and accretion of premiums and discounts, on held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329161137352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_GeneralLineItems', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">GENERAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in; font-size: 12pt">&#160;</td>
    <td style="width: 0.25in; font-size: 12pt"><span style="font-size: 10pt"><b>a.</b></span></td>
    <td style="text-align: left; font-size: 12pt"><span style="font-size: 10pt">Nano-X Imaging Ltd, an Israeli Company (hereinafter &#8220;the Company&#8221; or &#8220;Nanox IL&#8221;), was incorporated on December 20, 2018 and commenced its operations on September 3, 2019.</span></td></tr>
  </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On September 19, 2019, Nanox IL established
Nanox Imaging Inc. (hereinafter &#8220;Nanox Japan&#8221;), a wholly owned subsidiary in Japan.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On September 25, 2020, Nanox IL established
Nano-X Korea Inc. (hereinafter &#8220;Nanox Korea&#8221;), a wholly owned subsidiary in Korea.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On September 30, 2021, Nanox IL established
Nanox Imaging Inc. (hereinafter &#8220;Nanox U.S.&#8221;), a wholly owned subsidiary in the United States. On the same date, Nanox U.S. established Nanox MDW Inc. (hereinafter &#8220;Nanox MDW&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On November 2, 2021, Nanox U.S. completed the acquisition of 100% of the
shares of USARAD Holdings, Inc. (refer to Note 3).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On November 4, 2021, the Company, completed
the merger with Zebra Medical Vision Ltd (refer to Note 3).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company together with its subsidiaries,
develops a commercial-grade tomographic imaging device with a digital X-ray source, provides teleradiology services and develops artificial
intelligence applications designed to be used in real-world medical imaging applications. The Company&#8217;s solution, referred to as
the Nanox Multi Source System, has two integrated components &#8211; &#8220;Nanox.ARC&#8221; and &#8220;Nanox. CLOUD&#8221;. Nanox.ARC
is a medical tomographic imaging system incorporating the Company&#8217;s novel digital X-ray source. Nanox. CLOUD is a platform which
employs a matching engine to match medical images to radiologists, provides image repository, connectivity to diagnostic assistive
AI systems, billing and reporting. On April 1, 2021, the Company received clearance from the FDA to market the Company&#8217;s Nanox
Cart X-Ray System. In addition, the Company is in the process to receive clearance from the FDA to market the Company&#8217;s Nanox Multi
Source System.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company has experienced net losses
and negative cash flows from operations since its inception. The&#160;Company anticipates such losses will continue until its product
candidates reach commercial profitability. In August 2020, the Company completed an IPO on Nasdaq with net proceeds received from the
IPO of approximately $169 million. Based on the Company&#8217;s financing activities during the year ended December 31, 2021, the Company
has sufficient funds for its plans for the next twelve months from the issuance of these financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.</b></span></td>
    <td><span style="font-size: 10pt">Current Impact of COVID-19</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Following the December 2019 outbreak of
Coronavirus (COVID-19) in China, it has spread into most countries across the world, including Israel, Japan and all 50 states within
the U.S. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed
quarantines, travel restrictions and other public health safety measures. The COVID-19 pandemic has adversely impacted the Company&#8217;s
operations in various ways. For example, the Company&#8217;s engineers are unable to make work-related trips to Korea or Israel to test
and optimize the Nanox.ARC. The potential business partners are unable to make on-site visits to the Company&#8217;s facilities or attend
industry conferences and meetings to experience the Nanox.ARC, which has negatively impacted the Company&#8217;s business development
and deployment activities. The external labs the Company works with have also been affected by COVID-19, resulting in delays in the Company&#8217;s
timelines for obtaining regulatory approval. COVID-19 has also caused shutdowns or disruptions of business for our manufactures and suppliers.
The continued spread of COVID-19 globally could adversely impact the Company&#8217;s development, manufacture, or deployment of the Nanox
Systems, which could adversely affect the Company&#8217;s ability to obtain regulatory approval for and to commercialize the Nanox Systems,
increase the operating expenses and have a material adverse effect on the Company&#8217;s financial results.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.75in; font-size: 10pt">&#160;</td>
    <td style="text-align: left; width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>c.</b></span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">Current Impact of geopolitical tensions and the start of the military conflict between Russia and Ukraine</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">U.S. and global markets are experiencing
volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and
Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops was reported. Although the length and impact
of the ongoing military conflict is highly unpredictable, the ongoing conflict in Ukraine could lead to market disruptions, including
significant volatility in commodity prices, credit and capital markets. As a result, sanctions and penalties have been levied by the United
States, European Union and other countries against Russia. Russian military actions and the resulting sanctions could have a negative
impact on supply chains, the Company&#8217;s MSaaS agreements relating to Russia and Belarus or the region and adversely affect the global
economy and financial markets. Any of the abovementioned factors could affect the Company&#8217;s business, prospects, financial condition,
and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict,
but could be substantial.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_GeneralLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_GeneralLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159068488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Our consolidated financial statements are prepared in accordance
with generally accepted accounting principles in the United States (hereinafter -&#8220;U.S GAAP&#8221;). The preparation of our consolidated
financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates
on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates
under different assumptions or conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">In particular, a number of estimates have
been and will continue to be affected by the ongoing COVID-19 pandemic. The severity, magnitude and duration, as well as the economic
consequences, of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. As a result, the accounting estimates
and assumptions may change over time in response to COVID-19. Such changes could have&#160;an&#160;additional&#160;impact on&#160;the
Company&#8217;s long-lived asset and intangible asset valuation; inventory valuation; and the allowance for expected credit losses.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-indent: -1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>a.&#160;</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Use of estimates in the preparation of financial statements</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.75in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The preparation of the consolidated financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company&#8217;s
consolidated financial statements. As applicable to these consolidated financial statements, the most significant estimates relate to
assets acquired and liabilities assumed through business combination, goodwill impairment, useful lives of intangible assets, deferred
taxes and share-based payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.&#160;</b></span></td> <td><span style="font-size: 10pt"><b>Functional currency</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in">The U.S. dollar is the currency of the primary economic environment
in which the operations of the Company and its subsidiaries is conducted. A substantial portion of the operational costs are denominated
in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar (&#8220;primary currency&#8221;). Foreign currency
assets and liabilities are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date.
Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result
of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during
the period. Currency transaction gains and losses are presented in financial income and expenses, net.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="text-align: left; width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Combinations</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company allocates the fair value of
consideration transferred in a business combination to the assets acquired, liabilities assumed, and non-controlling interests in the
acquired business based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the
business combination and are expensed as incurred. The excess of the fair value of the consideration transferred plus the fair value of
any non-controlling interest in the acquiree over the fair value of the assets acquired, liabilities assumed in the acquired business
is recorded as goodwill. The fair value of the consideration transferred may include a combination of cash, equity securities, earn out
payments and deferred payments. The allocation of the consideration transferred in certain cases may be subject to revision based on the
final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative
impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company
includes the results of operations of the businesses that it has acquired in its consolidated results prospectively from the respective
dates of acquisition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company records obligations in
connection with its business combinations at fair value on the acquisition date. Each reporting period thereafter, the Company revalues
earn-out liabilities and records the changes in their fair value in the consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Changes in the fair value of earn-out liabilities can result from adjustments
to the discount rates, the Company&#8217;s shares price, sales and profitability targets. This fair value measurement represent Level
3 measurements, as they are based on significant inputs not observable in the market. Significant judgment is required in determining
the assumptions utilized as of the acquisition date and for each subsequent period. Accordingly, changes in the assumptions described
above could have a material impact on the Company&#8217;s consolidated results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>d.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Cash and cash equivalents </b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company considers as cash equivalents all short-term,
highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase
that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>e.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Marketable Securities</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">All highly liquid investments are classified
as marketable securities and have been classified and accounted for as available-for-sale. Investment in securities consists of debt
securities classified as available-for-sale and recorded at fair value. The Company classifies its marketable securities as either short-term
or long-term based on each instrument&#8217;s underlying contractual maturity date. Unrealized gains and losses on marketable debt securities
classified as available-for-sale are reported net of the related tax effect in other comprehensive income/(loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>f.</b></span></td><td style="text-align: left"><b>Accounts receivables</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Accounts receivable are presented net of the allowance for expected credit loss and consists of short term receivables that arise in the normal course of business. The Company performs ongoing credit evaluations of its customer&#8217;s financial condition and typically requires no collateral from its customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company adopted the Current Expected
Credit Losses (&#8220;CECL&#8221;) guidance effective January 1, 2020. The Company maintains the allowance for estimated losses resulting
from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime
expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable
forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness,
historical levels of credit losses, and future expectations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Changes in the allowance for&#160;credit losses&#160;are recognized
in, general and administrative expenses. Accounts receivables are written-off against the allowance for&#160;credit losses&#160;when management
deems the accounts are no longer collectible.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>g.</b></span></td> <td><span style="font-size: 10pt"><b>Property&#160;and&#160;equipment,&#160;net</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Property and equipment are stated at cost, net of accumulated
depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful lives:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers and electronic equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">15-33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office furniture and lab equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">6-20</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Vehicles</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equipment and machinery</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">10-20</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold Improvement</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Land</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The depreciable life of leasehold improvements is limited
by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>h.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b><i>Intangible Assets, net</i></b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b><i>Goodwill</i></b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Goodwill reflects the excess of the consideration transferred plus
the fair value of any non-controlling interest in the acquiree at the business combination date over the fair values of the identifiable
net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination
that are not individually identified and separately recognized. The Company allocates goodwill to its reporting units based on the reporting
unit expected to benefit from the business combination. &#160;&#160;The primary items that generate goodwill include the value of the
synergies between the acquired companies and the Company and the acquired assembled workforce, neither of which qualifies for recognition
as an intangible asset. ASC 350, &#8220;Intangibles - Goodwill and other&#8221; (&#8220;ASC 350&#8221;) requires goodwill to be tested
for impairment at the reporting unit level at least annually or between annual tests in certain circumstances and written down when impaired.
ASC 350 allows an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative
goodwill impairment test. If the qualitative assessment does not result in a more likely than not indication of impairment, no further
impairment testing is required. If it does result in a more likely than not indication of impairment, the quantitative goodwill impairment
test two-step impairment test is performed. Alternatively, ASC 350 permits an entity to bypass the qualitative assessment for any reporting
unit and proceed directly to performing the quantitative first step of the goodwill impairment test.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The provisions of the accounting standard for goodwill allow the Company
to first assess qualitative factors to determine whether it is necessary to perform the next goodwill impairment quantitative test. Examples
of events or circumstances that may be indicative of impairment include but are not limited to: macroeconomic and industry conditions,
overall financial performance and adverse changes in legal, regulatory, market share and other relevant entity specific events. The carrying
value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill, to those reporting
units. When necessary, the Company records charges for impairments of goodwill for the amount by which the carrying amount exceeds the
fair value of these assets. No goodwill impairment charge was recorded in 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b><i>other Intangible Assets, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Definite life intangible assets are amortized using the straight-line
method over their estimated period of useful life. Amortization of acquired developed technology, image big data, market platform, trade
names, customer relationships and radiologist relationships are recorded under cost of revenues and selling and marketing expenses. In
addition, the remaining amortization period for the impaired asset would be reassessed and, if necessary, revised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>i.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Impairment&#160;of&#160;long-lived&#160;assets </b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company tests long-lived assets for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets
is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated
by the asset or asset group. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company
recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future
discounted cash flows.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>j.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Severance&#160;pay</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Israeli labor law generally requires severance pay be granted
upon dismissal of an employee or upon termination of employment under certain other circumstances. Pursuant to Section 14 of the Severance
Compensation Act, 1963 (&#8220;Section 14&#8221;), all of the Company&#8217;s employees in Israel are entitled to monthly deposits, at
a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments under Section 14 relieve the Company from
any future severance payment obligation with respect to those employees and, as such, the Company may only utilize the insurance policies
for the purpose of disbursement of severance pay. As a result, the Company does not recognize an asset nor liability for these employees.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In 2021 and 2020, all of the employees
of the Company and its subsidiary in Israel are subject to Section 14 of the Severance Law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>k.</b></span></td> <td><span style="font-size: 10pt"><b>Legal&#160;and other&#160;contingencies</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Certain conditions, such as legal proceedings, may exist as
of the date the consolidated financial statements are issued that may result in a loss to the Company, but that will only be resolved
when one or more future events occur or fail to occur. In assessing loss contingencies related to legal proceedings that are pending
against the Company or unasserted claims that may result in such proceedings, the Company&#8217;s management evaluates with its legal
advisors the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought
or expected to be sought. Such assessment inherently involves an exercise of judgment. Legal fees are expensed as incurred.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Management applies the guidance in ASC 450-20-25 when assessing losses
resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss would be incurred
and the amount of the liability can be estimated, then the Company records an accrued expense in the Company&#8217;s consolidated financial
statements based on its best estimate. Loss contingencies considered to be remote by management are generally not disclosed unless material.
For additional information see note 11.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>l.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Revenue Recognition</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; text-indent: -0.75in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The majority of the Company&#8217;s revenues are derived from radiology
services fees received from various payors based on established billing rates. Revenues are derived directly from hospitals and healthcare
providers. The Company recognizes revenue in the period in which the performance obligation is satisfied. The Company records the amount
of revenue that reflects the consideration that it expects to receive in exchange for those services. The Company applies the following
five-step model in order to determine this amount: (i)&#160;identification of the contract with a customer; (ii)&#160;identification of
the promised services in the contract and determination of whether they represent performance obligations, including whether they are
distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">The Company records deferred revenue for any upfront payments received
in advance of the Company&#8217;s performance obligations being satisfied. These contract liabilities consist principally of unearned
radiology service fee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>m.</b></span></td> <td><span style="font-size: 10pt"><b>Research and development expenses</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b>&#160;</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Research and development expenses are charged to the statement
of operations as incurred and consist primarily of personnel, materials and supplies for research and development activities.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>n.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Income&#160;tax </b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.75in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 1in">&#160;</td>
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income
    Taxes&#8221; (&#8220;ASC&#160;740&#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability
    account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and
    are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
    provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely
    than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative
    evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU&#160;2015-17.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 96px">&#160;</td>
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not
    been taken into account in computing the deferred income taxes, as it is the Company&#8217;s intent and ability to hold these investments.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 96px; font-size: 10pt">&#160;</td> <td style="text-align: left; width: 24px; font-size: 10pt"><span style="font-size: 10pt">3)</span></td> <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 96px; font-size: 10pt">&#160;</td>
    <td style="text-align: left; width: 24px; font-size: 10pt"><span style="font-size: 10pt">4)</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Valuation allowances are provided unless it is more likely
than not that the deferred tax asset will be realized. In the determination of the appropriate valuation allowances, the Company considers
future reversals of existing taxable temporary differences, the most recent projections of future business results, prior earnings history,
carryback and carry forward and prudent tax strategies that may enhance the likelihood of realization of a deferred tax asset. Assessments
for the realization of deferred tax assets made at a given balance sheet date are subject to change in the future, particularly if earnings
of a subsidiary are significantly higher or lower than expected, or if the Company takes operational or tax positions that could impact
the future taxable earnings of a subsidiary.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><b>o<span style="font-size: 10pt">.</span></b></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Share-based compensation</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company accounts for share-based compensation under
ASC 718, &#8220;Compensation - Stock Compensation,&#8221; which requires the measurement and recognition of compensation expense
based on estimated fair values for all share-based payment awards made to non-employees, employees, officers and directors. ASC 718
requires companies to estimate the fair value of equity-based payment awards on the date of grant. The Company uses the
Black-Scholes-Merton option-pricing model as part of such estimation.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Prior to the adoption of ASU 2018-07, warrants issued to consultants
and other non-employees, as compensation for services provided to the Company, were accounted for based upon the fair value of the warrants.
The fair value of the warrants granted was measured on a final basis at the end of the related service period and was recognized over
the related service period using the straight-line method. After the adoption of ASU 2018-07, the measurement date for non-employee awards
is the date of the grant. The compensation expense for non-employees is recognized without changes in the fair value of the award, over
the requisite service period, which is the vesting period of the respective award using the straight line. The Company adopted ASU 2018-07
as of January 1, 2019 with no impact on its consolidated financial statements as all of the Company&#8217;s awards were fully vested
at the adoption date.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company recognizes compensation expenses for its stock-based
option awards and RSUs on a straight-line basis over the requisite service period (primarily a four-year period). The Company accounts
for forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in; font-size: 10pt">&#160;</td> <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>p.</b></span></td> <td style="font-size: 10pt"><span style="font-size: 10pt"><b>Loss&#160;per&#160;share</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Basic earnings per share is computed by dividing net income
(loss) attributable to holders of ordinary shares of the Company by the weighted average number of ordinary shares outstanding for each
reporting period.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In computing the Company&#8217;s diluted earnings per share,
the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary shares and the potential dilutive
ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding include the dilutive effect of in-the-money
options using the treasury stock method.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company did not take into account
any dilutive instruments, such as investor warrants , share-based payments and earn-out liability - contingently issuable ordinary shares
, since their effect, on a fully diluted basis, is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>q.</b></span></td> <td><span style="font-size: 10pt"><b>Fair&#160;value&#160;measurement</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Fair value is based on the price that would be received from
the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that
prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 96px">&#160;</td>
    <td style="text-align: left; width: 48px"><span style="font-size: 10pt">Level 1:</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Level 2: </span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Level 3: </span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></td></tr>
  </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.75in"><b>&#160;</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In determining fair value, the Company utilizes valuation techniques
that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty
credit risk in its assessment of fair value.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The Company&#8217;s financial instruments consist mainly of
cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities. The fair value
of these financial instruments approximates their carrying values.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Money market funds (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,697</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,697</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">89,911</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">89,911</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">119,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">119,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long term loan (**)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,796</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,471</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,471</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent long-term earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,814</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,814</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt"/>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">-</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">52,081</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">52,081</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span>The Company classifies AFS securities
within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair value</span></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span>(*)</span></td><td style="text-align: left"><span>As of&#160;</span>December
31, 2021,&#160;<span>approximately $29,697 thousand of debt securities were classified under &#8220;Cash
and Cash equivalents&#8221; in the consolidated balance sheets as such securities met all applicable classification criteria.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(**)</td><td style="text-align: justify"><span>Since the loan was
originated in September 2021, the fair value of the long term loan approximates its carrying value.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>r.</b></span></td> <td><span style="font-size: 10pt"><b>Concentration&#160;of&#160;Credit Risks</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Financial instruments that potentially subject the
Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, marketable securities
and accounts receivable.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The Company&#8217;s cash and cash equivalents and restricted
cash are invested with major banks in Israel, United States, Korea and Japan. Generally, these investments may be redeemed upon demand
and the Company believes that the financial institutions that hold the Company&#8217;s cash balances are financially sound and, accordingly,
bear minimal risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"><b>&#160;</b>&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>s.</b></span></td> <td><span style="font-size: 10pt"><b>Offering&#160;Costs </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Deferred offering costs directly relating to the Company&#8217;s
private and initial public offering, were capitalized and offset against proceeds upon the consummation of the private and IPO transactions
in shareholders&#8217; equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>t.</b></span></td> <td><span style="font-size: 10pt"><b>Leases</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">On January 1, 2019 the Company adopted
ASU No. 2016-02, Leases (&#8220;Topic 842&#8221;), The Company determines if an arrangement is a lease at inception. Balances related
to operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current maturities of operating leases liabilities
and Non-current operating leases liabilities in the consolidated balance sheets.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">The Company also elected not separating lease components
from non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated
lease payments in the consolidated statements of operations on a straight-line basis over the lease term.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">ROU assets represent the Company&#8217;s right to use an underlying
asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease.
Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over
the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that
the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily
determined. As the Company&#8217;s leases do not provide an implicit rate, the Company&#8217;s uses its estimated incremental borrowing
rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for
lease payments is recognized on a straight-line basis over the lease term (see also note 7).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The Company presents unrecognized tax benefits as a reduction
to deferred tax asset where a net operating loss, a similar tax loss, or a tax credit carryforward that are available, under the tax law
of the applicable jurisdiction, to offset any additional income taxes that would result from the settlement of a tax position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 72px; padding-right: 0.8pt">&#160;</td> <td style="vertical-align: top; width: 24px; padding-right: 0.8pt"><span style="font-size: 10pt"><b>u.</b></span></td> <td style="vertical-align: top"><span style="font-size: 10pt"><b>Segment reporting</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">ASC 280, &#8220;Segment Reporting,&#8221; establishes standards
for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate
financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources
and in assessing performance. The Company&#8217;s chief operating decision maker is the Company&#8217;s Chief Executive Officer (the &#8220;CODM&#8221;),
who makes resource allocation decisions and assesses performance based on financial information prepared on a consolidated basis, accompanied
by disaggregated information about revenues, gross profit and operating loss by the three identified reportable segments. The Company&#8217;s
business includes three operating segments based on the services that the Company provides. The three segments are composed from the Nanox.Arc
segment, AI solutions and the Radiology services division segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt"><b>v.&#160;</b></span></td> <td><span style="font-size: 10pt"><b>Newly issued and recently adopted accounting pronouncements:</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><b><i>Accounting Pronouncements Adopted in Current year</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">. In December 2019, the FASB issued ASU 2019-12, Income Taxes (&#8220;Topic
740&#8221;): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions
to the general principles and simplification of areas such as franchise taxes, step-up in tax basis goodwill, separate entity financial
statements and interim recognition of enactment of tax laws or rate changes. The guidance was effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted this guidance
since January 1, 2021, with no material impact on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">In October 2021, the FASB issued ASU
2021-08 &#8220;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;,
which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer
on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing
contract assets and contract liabilities at the same amounts recorded by the acquire. The guidance should be applied prospectively to
acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that
have not yet been issued. The Company early adopted ASU 2021-08 since January 1, 2021, with no material impact on its consolidated financial
statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><i>Recently issued accounting pronouncements, not yet adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">In August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211;
Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic
815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective
for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years.&#160;The Company will adopt this
guidance effective January 1, 2022, with no material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329154540424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination and Other Transaction<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CertainTransactionsAbstract', window );"><strong>Business Combination and Other Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CertainTransactionsTextBlock', window );">BUSINESS COMBINATION AND OTHER TRANSACTION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; BUSINESS COMBINATION AND OTHER TRANSACTION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">a.</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">The acquisition of Nanox AI Ltd (formerly Zebra Medical Vision Ltd.).</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On November 4, 2021(&#8220;the merger date&#8221;), the Company,
completed the merger (&#8220;the Nanox AI transaction&#8221;) pursuant to the terms of the Agreement and Plan of Merger, dated August
9, 2021 (with certain amendments), among the Company, Zebra Medical Vision Ltd. (&#8220;Zebra&#8221;) and Perryllion Ltd., as representative
of Zebra&#8217;s equity holders. At November 4, 2021 the Company issued 3,249,142 ordinary shares of the Company and committed to issue
70,211 employee options and restricted stock units&#160;to the equity holders of Zebra with an estimated fair value at the closing date
of $88,510 thousand, representing $26.57 per share in consideration for the fully outstanding shares on a fully diluted basis of Zebra.
Out of which $315 thousand was allocated to the purchase consideration and $970&#160;thousand was allocated to future services and continued
employment and shall be expensed over remaining service periods of up to 4 years. The fair value of ordinary shares issued by the Company
was determined using the Company&#8217;s closing trading price on the merger date. The consideration represented (a) the basic purchase
price minus (b) certain transaction costs; plus (c) contingent consideration as a result of Zebra entering into a designated commercial
agreement prior to closing; plus (d) additional contingent consideration as a result of Zebra achieving a designated milestone of obtaining
a new FDA clearance for its population health product and additional consideration as a result of Zebra achieving designated milestones
as further described below. In addition, if Zebra enters into any of the two additional designated commercial agreements within 6 months
of the agreement execution date (August 9, 2021), then the Company will pay a deferred closing consideration in the amount of $3,333 thousand
in shares for each agreement. The deferred closing consideration would be paid in the Company&#8217;s shares in the amount of the relevant
instalment payment divided by the average closing price of the 30 trading days ending on the applicable agreement signing date. Further,
if Zebra achieves the agreed milestones related to obtaining certain FDA clearances and security certifications, completing certain technology
integration, or achieving certain revenue and employee retention targets over the next three years, the Company will pay additional consideration
in the amount of up to $77,700 thousand. Each of these milestone instalments would be paid in the Company&#8217;s shares in the amount
of the relevant instalment payment divided by the average closing price of the 30 trading days ending on the applicable milestone&#8217;s
achievement date. Zebra changed its name to Nanox AI ltd. and Zebra Medical Vision Inc. (a fully owned subsidiary of Zebra, which is incorporated
under the laws if the State of Delaware) changed its name to Nanox AI Inc.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 72pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The Nanox AI transaction was accounted in accordance with ASC 805,
&#8220;Business Combinations&#8221;, using the acquisition method of accounting with the Company as the acquirer.&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The following table summarizes the fair value of the consideration
transferred to Nanox AI shareholders for the Nanox AI transaction:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">U.S.$<br/> in thousand</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 89%; text-align: left">Issuance of ordinary shares, options and RSUs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">88,510</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,129</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent long term earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,660</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total consideration</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">129,299</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">In accordance with ASC 805, the estimated
contingent consideration&#160;as of the Nanox AI transaction date was&#160;included in the purchase price. The total contingent payments
could reach to a maximum aggregate amount of up to $77,700 thousand, all shall be settled through the issuance of ordinary shares.&#160;The
Company determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash
flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement
within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected
from the success of achievements of several achievement and payment of milestone events; the time and resources needed to achieve those
milestones and the risk adjusted discount rate for fair value measurement. A probability of success factor was used in the fair value
calculation to reflect inherent regulatory and commercial risk of the contingent payments. The weighted average discount rate, applied
on the relative fair value of the contingent consideration liabilities, was&#160;19%. The contingent consideration is evaluated quarterly,
or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements
of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material
changes to the contingent consideration liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The allocation of the purchase price to assets acquired and
liabilities assumed, including measurement period adjustments (, is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Allocation<br/> of Purchase<br/> Price</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">(U.S. $ in thousands)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; text-align: left">Cash, cash equivalents and Restricted&#160;Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,956</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts Receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,816</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,243</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,413</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,129</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent long-term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,660</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Convertible note (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other labilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,525</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,727</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">88,510</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">A 3 years Convertible Loan Agreement, dated August 9, 2021 between
the Company and Nanox AI in the amount of $3 million, which bears an annual interest of 6% and shall be automatically converted into the
Nanox AI&#8217;s Preferred C Shares, at a price per share of $23.42. This loan is eliminated in the Consolidated financial statements.</p></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The allocation of the purchase price to net assets acquired and liability
assumed resulted in the recognition of intangible asset related to technology of $27,316 thousand which will be expensed over remaining
service periods of 10 years, Image Big Data of $52,500 thousand which will be expensed over remaining service periods of 10 years, and
goodwill of $51,243 thousand, which is primarily attributed to the expected synergies from combining the operations of Zebra&#8217;s AI
solutions with the Company tomographic imaging systems. As such, the goodwill will be assigned to the operational segment of AI solutions.&#160;The
goodwill amount is not deductible for tax purposes. The fair value&#160;estimate of the developed technology is determined using a variation
of the income approach known as the &#8220;Multi-Period Excess Earnings Approach&#8221;. This valuation technique estimates the fair value
of an asset based on market participants&#8217; expectations of the cash flows an asset would generate over its remaining useful life.&#160;The
net cash flows were discounted to present value. Due to the timing of the transaction closing date, the fair values assigned to assets
acquired and liabilities assumed are preliminary, based on management&#8217;s estimates and assumptions and may be subject to change as
additional information is received. We expect to finalize the valuation as soon as practicable, but not later than one year from the acquisition
date. Refer to notes 2c and 2h.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The amount of the acquisition-related costs
was approximately $310 which was recognized as an expense in the general and administration expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The results of operations of Nanox AI
have been included in the consolidated financial statements since the date of the acquisition. The amounts of revenues and net loss related
to Nanox AI that are included in the Company&#8217;s consolidated statements of operations for the period starting from the merger date
to&#160;December 31, 2021, are $270 thousand and $4,157 thousand, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The following unaudited pro forma information
presents the combined results of operations of the Company and Nanox AI as if the acquisition of Nanox AI had been completed on January
1, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The unaudited pro forma results include adjustments primarily related
to amortization of the acquired intangible assets and share-based compensation associated with option grants as referenced above, as of
January 1,2020. The unaudited pro forma results do not reflect any cost saving synergies from operating efficiencies, or the effect of
the incremental costs incurred from integrating Nanox AI. Accordingly, these unaudited pro forma results are presented for informational
purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the
acquisition of Nanox AI had occurred at the beginning of 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<br/> December&#160;31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<br/> December&#160;31, 2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="7" style="text-align: center">US$ in thousand</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,363</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,550</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(87,045</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(69,875</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">The acquisition of USARAD Holding Inc.&#160;&#160;(the &#8220;USARAD transaction&#8221;)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">On November 2, 2021 (the &#8220;USARAD closing
date&#8221;), the Company completed the acquisition of 100% of the shares of USARAD Holdings, Inc., a Delaware corporation (&#8220;USARAD&#8221;),
pursuant to the terms of the Stock Purchase Agreement, dated October 25, 2021, among the Company, USARAD, Dr. Michael Yuz, other holders
of capital stock of USARAD, and holders of USARAD options. At the USARAD closing date, Nanox U.S. purchased 100% of the shares of USARAD
on a fully diluted basis for $7,147 thousand in cash and 496,545 of the Company&#8217;s ordinary shares with an estimated fair value of
$11,500 thousand. The number of ordinary shares issued by the Company was determined using the average closing trading price during the
30 trading days preceding to the closing date. The total consideration was approximately $18,647 thousand. In addition, upon the successful
achievement of certain milestones related to profitability, EBITDA and other operational performance-based earnouts over 2 years, the
Company will pay additional cash consideration in the amount of up to $2,000 thousand and stock consideration in the amount of up to $6,500
thousand at a per share value determined by the average of i) the volume weighted average closing share price of the 30 trading days prior
to the relevant milestone completion, and (ii) the volume weighted average closing share price of the 30 trading days ending on August
6, 2021.. Revenue in the amount of $1,034 and net loss in the amount of $358 thousand of the acquiree included in the Company&#8217;s
consolidated statements of operations for the year ended at December 31,2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The USARAD transaction was accounted in
accordance with ASC 805, &#8220;Business Combinations&#8221;, using the acquisition method of accounting with the Company as the acquirer.&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The following table summarizes the fair value of the consideration
transferred to USARAD shareholders for the USARAD transaction:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. $ in thousands</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash payments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,147</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration at estimated fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total consideration</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,052</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">In accordance with ASC 805, the estimated
contingent consideration&#160;as of the USARAD transaction date was&#160;included in the purchase price. The total contingent payments
could reach to a maximum aggregate amount of up to $8,500 thousand.&#160;Approximately 23.52% of the payments shall be settled in cash,
and 76.47% shall be settled through the issuance of ordinary shares.&#160;The estimated fair value of the contingent consideration is
based on management&#8217;s assessment&#160;of whether, and at what level, the financial metrics will be achieved, and the present value
factors associated&#160;with the timing of the payments.&#160;This fair value measurement&#160;is based on significant unobservable inputs
in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the fair value of contingent consideration
will be recorded in&#160;operating expenses. Additional payment&#160;of $144 thousand may be paid to USARAD&#8217;s shareholders if an
approval of the PPP loan by the Federal Government will occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The allocation of the purchase price
to assets acquired and liabilities assumed is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Allocation of Purchase Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(U.S. $ in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">332</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts Receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">912</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,187</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,519</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loan from a government agency</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other labilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,766</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,453</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent long term earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,952</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,872</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,647</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">The allocation of the purchase price
to net assets acquired and liability assumed resulted in the recognition of intangible asset related to retained radiologists of $17,770
thousand, customers&#8217; relationship of $1,322 thousand, trademark of $2,095 thousand and goodwill of $7,055 thousand. As such, the
goodwill will be assigned to the operational segment of radiology services. The intangible asset relates to retained radiologists has
a useful-life of 11.17 years, the intangible asset relates to customers&#8217; relationship has a useful-life of 6.17 years and the intangible
asset relates to the trademark has a useful-life of 12.17 years.&#160; This fair value measurement is based on significant unobservable
inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration
is based on several factors, such as: the cash flows projected from the success of achievements of several achievement and payment of
milestone events; the time and resources needed to achieve those milestones and the risk adjusted discount rate for fair value measurement.
A probability of success factor was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent
payments. The weighted average discount rate, calculated based on the relative fair value of the contingent consideration liabilities,
was&#160;21.9%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair
value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly
the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. Due
to the timing of the transaction closing date, the fair values assigned to assets acquired and liabilities assumed are preliminary, based
on management&#8217;s estimates and assumptions and may be subject to change as additional information is received. We expect to finalize
the valuation as soon as practicable, but not later than one year from the acquisition date. Refer to notes 2c and 2h.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">During 2021,
USARAD executed the standard loan documents required for securing a loan from the SBA under its Paycheck Protection Program Loan (&#8220;PPP&#8221;)
assistance program in light of the impact of the COVID-19 pandemic on the Company&#8217;s business.&#160;Pursuant to that certain Loan
Authorization and Agreement, the principal amount of the PPP Loan is $144, with proceeds to be used for working capital purposes. Interest
accrues at the rate of 1.00 % per annum and the term of the loan is five years. After the completion of the acquisition USARAD applied
for forgiveness of the loan. Per to the terms of the Stock Purchase Agreement, the Company will pay the forgiven amounts to the former
shareholders of USARAD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">The amount of the acquisition-related costs was approximately
$198 which was recognized as an expense in the general and administration expenses.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">Pro forma results of operations related
to the USARAD acquisition have not been prepared because they are not material to the Company&#8217;s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt"><b>c.</b></span></td>
    <td style="text-align: left"><span style="font-size: 10pt">The Assets acquisition of MDWEB LLC.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On November 3, 2021, the Company
completed the acquisition of the market platform and other assets of MDWEB, LLC (&#8220;MDWEB&#8221;), pursuant to the terms of the Asset
Purchase Agreement, dated October 21, 2021, between the Company and MDWEB. At the same date, the Company issued 64,715 of its ordinary
shares to MDWEB with an estimated fair value of $1,500 thousand. In addition, upon the successful achievement of certain milestones related
to technical integration of MDW platform with Nanox Cloud and achieving certain other operational targets, the Company will pay additional
stock consideration in the amount of up to $1,500 thousand at a per share value determined by the average closing price of the 30 trading
days ending on the applicable milestone&#8217;s achievement date. In addition, upon the successful achievement of certain milestones and
other operational performance-based earnouts over 2 years, the Company will pay stock consideration in the amount of up to $1,500 thousand
at a per share value determined by the average closing price of : (i) closing price of the 30 trading days ending on the applicable milestone&#8217;s
achievement date: and (ii) the volume weighted average closing share price of the 30 trading days prior to the closing date. .</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">The Company will amortize the intangible assets on a straight-line
basis over their expected useful life of 48 months. Refer to note 2h.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CertainTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CertainTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CertainTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Certain Transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CertainTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329259158808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill &amp; Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill &amp; Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL &amp; INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE&#160;4 &#8212; GOODWILL&#160;&amp;
INTANGIBLE ASSETS, NET:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Goodwill</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The following table presents
the changes in the carrying amount of goodwill and the intangible assets as of December 31, 2021 (U.S. dollars in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">Goodwill from acquisition of Zebra</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">51,243</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Goodwill from acquisition of USARAD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,298</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><i>Intangible assets </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The acquired intangible assets has an estimated fair value
as of December 31, 2021 of $101,826 thousand. The Identifiable intangible assets were recorded as follows (U.S. dollars in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center"><b>&#160;</b></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Useful Life<br/>
(in Years)</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Amount as&#160;of<br/>
the merger/<br/>
acquisition<br/>
date</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Amortization<br/>
expense for<br/>
the period</b></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Amount as<br/>
of December 31,<br/>
2021</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,316</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Image big data</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">51,625</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Market platform</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,591</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,483</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Radiologist relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">11.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,770</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,505</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade name</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">12.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,095</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,066</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">6.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,322</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,286</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">103,594</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,768</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">101,826</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Intangible assets with estimable useful lives are amortized over their
respective estimated useful lives to their estimated residual values and reviewed periodically for impairment. Amortization expenses were
$1,768 and $0 and $0 for the years ended December 31, 2021 and December 31, 2020 and December 31, 2019, respectively.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Amortization of intangible
assets for each of the next five years and thereafter is expected to be as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><span style="font-size: 10pt">2022</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">10,607</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">10,607</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">10,607</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">10,499</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">2026 and thenafter</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">59,506</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">101,826</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329154567352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5  - PROPERTY AND EQUIPMENT, NET:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Composition of property and equipment grouped by major classifications
is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers and electronic equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10-33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office furniture and lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">6-20</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Vehicles</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Machines</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10-20</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold Improvement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Land</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-102">N/A</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars <br/> in thousands)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Office furniture and lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">648</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">820</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Computers and electronic equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Equipment and machinery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,766</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1762</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Leasehold improvement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Land &#8211; See b below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,297</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Production line in construction &#8211; See b below</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,790</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,364</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(868</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,435</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,020</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>a.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt">Total depreciation in respect of property and equipment were approximately $524 thousand, $208 thousand and $53 thousand for the years ended December 31, 2021, 2020 and 2019, respectively.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: left">&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: left">&#160;</td> <td style="text-align: left"><span style="font-size: 10pt"><b>b.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt">In December 2020, Nanox Korea purchased a land for approximately $6.3 million upon which it intends
to build a fabrication facility. In 2021, Nanox Korea completed the construction of the permanent fabrication plant.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329158933480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CashCashEquivalentsandRestrictedCashLineItems', window );"><strong>Cash Equivalents and Restricted Cash [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CashEquivalentsAndRestrictedCashTextBlock', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>NOTE 6 - CASH, CASH
EQUIVALENTS AND RESTRICTED CASH:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&#160;</b></span></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">The following table provides a reconciliation of cash, cash
equivalents and restricted cash reported on the consolidated balance sheet that sum to the same total amount as shown in the consolidated
statement of cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">66,645</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,468</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted bank deposit (1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">316</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -11.5pt; padding-left: 11.5pt">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">66,772</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">213,784</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: left">As of December&#160;31, 2021, the Company&#8217;s restricted
cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit is presented at cost including accrued
interest. This bank deposit is used as security for credit card use and collateralizing the Company&#8217;s lease contracts</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CashCashEquivalentsandRestrictedCashLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CashCashEquivalentsandRestrictedCashLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CashEquivalentsAndRestrictedCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash equivalent and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CashEquivalentsAndRestrictedCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159004152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7  - LEASES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">As of December 31, 2021, the Company has several operating
lease agreements for its car and facilities, as follows:</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During the fourth quarter of 2019, the Company entered into
an office lease agreement. This agreement was through December 31, 2021 with an option by the Company to extend the period for an additional
24 months. The Company exercised the option.&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The monthly rent payment is approximately $13 thousand. During
June 2020, the Company entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023. The
monthly rent payment for this agreement is approximately $15 thousand. During November 2020the Company signed an additional lease agreement,
for leasing another office complex through June 30, 2023. The monthly rent payment for this agreement is approximately $12 thousand. On
December 31,2021, the Company exercised its option to extend the lease for additional period of 24 months.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The Company leases vehicles to some of its employees. The
lease agreement is effective through June 30, 2023 and the monthly payment for this agreement is approximately $12 thousand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">Nanox Korea leases 3 vehicles to some
employees. These lease agreements are effective through November 2023 to February 2024 and the monthly payment for these agreements is
approximately $ 5 thousand.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">In 2021 Nanox Korea leased approximately
390 square meters of space for a temporary fabrication facility and approximately 200 square meters of space for a research and development
center in Korea. During 2021 this lease ended due to the transfer of the temporary fabrication facility to the Company&#8217;s permanent
fabrication facility in Yongin, Geonggi province.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Nanox AI leases its offices in Israel under operating lease
agreement which expires in November 22 2024. Nanox AI has an option to extend the period for an additional 24 months through November
2026. &#160;Nanox AI concluded that it is not reasonably certain that it will exercise the renewal option. Accordingly, such renewal option
was not included in determining the lease term.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 54pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The monthly rent payment for this agreement is approximately
$12 thousand and the management fee is $4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents the effects on the amounts relating
to the Company&#8217;s total lease costs:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars <br/> In thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating lease cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Fixed payments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">653</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">276</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">701</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">341</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents supplemental cash flow information
related to operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S.&#160;Dollars<br/> in&#160;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S.&#160;Dollars<br/> in&#160;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;507</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">169</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Right-of-use assets obtained in exchange for lease obligations (non-cash):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">194</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,085</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents supplemental balance sheet information
related to operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating leases:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,359</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current maturities of operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">519</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-current operating leases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">950</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">923</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,831</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,442</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Weighted average remaining lease term</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.67</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.70</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.83</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The table below presents maturities of operating lease liabilities:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">December&#160;31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars <br/> in thousands)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">961</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">245</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2025 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,951</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,831</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159011960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredRevenuesDisclosureAbstract', window );"><strong>Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredRevenuesDisclosureTextBlock', window );">DEFERRED REVENUE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8 &#8211; DEFERRED REVENUE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">The following table represents the changes in
deferred revenue for the year ended December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deferred<br/> Revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Increase due to the business combinations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">483</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in deferred revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">179</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at December 31, 2021 (*)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">662</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Includes $415 thousand under long term deferred revenue in
the Company&#8217;s consolidated balance sheets as of December 31, 2021.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredRevenuesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredRevenuesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredRevenuesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredRevenuesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159000008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartyLiabilityAbstract', window );"><strong>Related Party Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartyLiabilityTextBlock', window );">RELATED PARTIES:</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9   - RELATED PARTIES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">As of December
31, 2019, the Company recorded a Related Party Liability in an amount of $17.8 million, which represents the fair value of the shares
that have been issued to Nanox PLC, based on the last financing round of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: left; text-indent: -28.35pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">During January 2020, subject to entering into a share purchase
agreement in the aggregate amount of at least $6 million, and a pre-money valuation of more than $100 million, the Company&#8217;s Board approved
the issuance and allotment of 1,109,245 ordinary shares to Nanox PLC with the purchase price of $12.00 per share, which reflects a discount
of 25% from the price of the last financing round of the Company. As a result, on January 30, 2020 the related party liability was settled
into equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Related party balances at December 31, 2021 and December
31, 2020 consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Dollars in thousands)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">(a) Due from Illumigyn</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">(b) Due from Wellsense Technologies Ltd.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(c) Due from Six-Eye Interactive</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">(c) Due from Six AI ltd.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total from related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.</b></span></td>
    <td><span style="font-size: 10pt"><b>Related parties transactions:</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars in thousands)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Research and development &#8211; see d below</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">80</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">355</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">154</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">General and administrative &#8211; See c, e and f below</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(191</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(167</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,824</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><b>c.</b></td><td style="text-align: left"><b>Six-Eye Interactive agreements for services</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On June 1 2015, Nanox PLC entered into
a consulting agreement with Six-Eye, a company owned by Ran Poliakine, the Company&#8217;s former Chief Executive Officer and one of major
shareholders, pursuant to which Ran Poliakine agreed to provide services as Chief Strategy Officer and a member of the Executive Committee
to Nanox PLC. On May 1, 2017, Nanox PLC entered into a services agreement with Six-Eye for the supply of ongoing services, which include
research and development services, general and financial management (including accountancy), office management services and operational
and supply services. According to the agreement between the parties, Nanox PLC reimburses Six-Eye for its actual direct expenses plus
a 12% surplus charge. The agreements were terminated in September 2019. During the year ended December 31 2019 the total expenses to Six-Eye
were $679 thousand. In addition to the services provided by Six-Eye during 2019, Six-Eye also paid directly to third-party consultants
and suppliers on behalf of the Company in the amount of approximately $1,015 thousand prior to the completion of the Company&#8217;s equity
financing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 1in; text-align: left"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="text-align: left; width: 0.75in"/><td style="width: 0.25in; text-align: left"><b>d<span style="font-family: Times New Roman, Times, Serif">.</span></b></td><td style="text-align: left"><b>Six AI Ltd Service agreement</b></td>
</tr></table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On April 16, 2020, the Company entered into an agreement with
SixAI Ltd. (hereinafter-&#8220;SixAI&#8221;) a company controlled by Ran Poliakine, the Company&#8217;s former Chief Executive Officer
for certain software development and mechanical engineering services. The service agreement was effective as of March 1, 2020 and has
been extended by mutual agreement of the parties several times, until terminated at December 31, 2021. During the years ended December
31, 2021 and 2020, the Company recorded an expense of $80 and $355 thousand, respectively. Mr. Poliakine currently serves as a member
of the board of directors of SixAI and Mr. Poliakine is a significant shareholder of SixAI.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="text-align: left; width: 0.75in"/><td style="width: 0.25in; text-align: left"><b>e.</b></td><td style="text-align: left"><b>Illumigyn Ltd.</b></td>
</tr></table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Illumigyn Ltd (hereinafter &#8211;
&#8220;Illumigyn&#8221;) is a company in which Ran Poliakine, the Company&#8217;s former Chief Executive Officer, is a significant shareholder
primarily through indirect holdings. Since November 1 2019, Illumigyn sub-leased in transaction approximately 1,800 square feet of private
office space, including access to shared public spaces, from the office spaces which the Company leases in Neve Ilan, Israel. Illumigyn
pays approximately $12 thousand per month. During the years ended December 31, 2021 and 2020, the Company received approximately $125
and $163 thousand, respectively in relation to the sub lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 1in; text-align: left"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><b>f.</b></td><td style="text-align: left"><b>Wellsense Technologies Ltd.</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 72pt; text-align: left">Wellsense Technologies Ltd.(hereinafter
&#8211; &#8220;Wellsense&#8221;) is a company in which Ran Poliakine, the Company&#8217;s former Chief Executive Officer, and Richard
Stone, a member of the Company&#8217;s board of directors, are shareholders. Since February 2020, Wellsense has sub-leased private office
space, including access to shared public spaces, from the Company in Neve Ilan, Israel. Wellsense pays approximately $7.0 thousand per
month. During the years ended December 31, 2021 and 2020, the Company received $66 and $59 thousand, respectively in relation to the sub
lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><b>g.</b></td><td style="text-align: left"><b>Employment Agreements</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">The Company has entered into an employment
agreement with Ran Poliakine, the Company&#8217;s founder, Chairman of the Board of Directors, and former Chief Executive Officer. Pursuant
to the agreement, if the Company terminates Ran Poliakine&#8217;s employment and waives his obligation to perform services during the
notice period of 180 days, Ran Poliakine will be entitled to receive payments of his base salary and social benefits in lieu of notice
for the waived period, up to the full notice period for an immediate termination. The agreement provides Ran Poliakine with a gross monthly
base salary equal to $40 which was increased to $60 upon the consummation of the Company&#8217;s initial public offering.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">On September 27, 2021, the Company and
Erez Meltzer entered into an employment agreement, pursuant to which Mr. Meltzer agreed to serve as the Company&#8217;s new Chief Executive
Officer (&#8220;The Meltzer Employment Agreement&#8221;). The Meltzer Employment Agreement commenced and became effective as of January
1, 2022 and shall continue for an indefinite period until it is terminated by either party. Pursuant to the terms of the Meltzer Employment
Agreement, Mr. Meltzer will receive an annual base salary of nine hundred thousand dollars ($900) per year, and will be eligible for an
annual incentive payment of up to one hundred percent (100%) of his base salary, which of them $450 will be guaranteed for the 2022 fiscal
year if his employment is continued through the entire fiscal year, with the possibility to withdraw an advance payment on account of
the 2022 annual bonus, subject to full recourse (clawback) if the bonus is not earned; Mr. Meltzer will be entitled to customary social
benefits under Israeli law and practice pursuant to which the Company shall insure the CEO with a manager&#8217;s insurance policy or
a pension fund, or a combination of both (whereby each will apply partially), all according to his election; &#160;Mr. Meltzer will be
granted options to purchase 300,000 Ordinary Shares (the &#8220;Options&#8221;) which will vested equally over a period of 48 months as
long as Mr. Melter will be employed by the Company. The Options shall be subject to the Company&#8217;s 2019 Equity Incentive plan and,
to the extent possible, be granted pursuant to Section 102 of the Israeli Income Tax Ordinance, 5721-1961. The exercise price of the Options
shall be $23.84 per share, a share price equals to the 30-day average of the Company&#8217;s share price on NASDAQ, prior to the date
of approval of the CEO&#8217;s employment agreement by the Board on September 27, 2021. Such amount may be paid by the CEO by way of a
cashless exercise mechanism; The agreement calls for a 6 months&#8217; mutual notice of termination and 270 days if the Company provides
notice during the first year of employment (except for &#8220;Cause&#8221; as defined in the employment agreement, in which case no prior
notice will be required);</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 72px; font-size: 10pt; text-align: left">&#160;</td>
    <td style="width: 24px; font-size: 10pt; text-align: left"><span style="font-size: 10pt"><b>h.</b></span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt"><b>Service Agreement</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In February 2021, the shareholders of the Company approved
the entry into an agreement with Floyd Katske, effective as of October 1, 2020, whereby Floyd Katske will assist the Chief Executive Officer
and the Company with various tasks given his medical knowledge, expertise and experience, as may be requested from time-to-time by the
Company&#8217;s Chief Executive Officer. These tasks are in addition and unrelated to his role as a member of the board of directors of
the Company. Floyd Katske will be paid with respect to such services $200 per hour, against an invoice. The services will be limited to
100 hours in any calendar month, according to hours approved by the Chairman. In addition, Floyd Katske will be paid cash compensation
consisting of RSUs granted in each calendar quarter, in the amount calculated by dividing (i) two times the cash compensation paid during
such quarter as aforesaid by (ii) the fair market value of our ordinary shares on the last trading day of such quarter. All tax consequences
will be borne by Floyd Katske. The agreement may be terminated by 14 days&#8217; written notice by either party. During the year ended
December 31, 2021, the Company recorded an expense of $168 with regards to the cash payment and $473 thousand with regards to the RSUs
portion of Floyds&#8217; fees.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartyLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartyLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartyLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartyLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159011960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG TERM LOAN</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10 &#8211; LONG TERM LOAN </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">During September 2021, Nanox Korea entered
into a 3 years Loan agreement with a Korean Bank, according to which the Bank granted the Company a loan in the amount of $3.8 million.
The loan bears an annual interest at a rate of 3 months KORIBOR and 1.149 % , whereas interest payments are due on a monthly basis and
the principal is due in the end of the loan term. The bank received a floating charge on the Company&#8217;s asset.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329158998888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 11 - COMMITMENTS AND CONTINGENCIES</b>:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">From time to time, The Company may become
involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent
uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">in September 2020, two securities class
action complaints were filed in the United States District Court for the Eastern District of New York against the Company and certain
current officers and a director, which were subsequently consolidated and captioned as <i>White v. Nano-X Imaging Ltd. et al</i>, Case
No. 1:20-cv-04355, alleging violations of securities laws on behalf of all persons and entities that purchased or otherwise acquired the
Company&#8217;s publicly traded securities between August 21, 2020 and September 15, 2020, and seeking unspecified damages. On December
7, 2020, proposed lead plaintiffs submissions were fully briefed and remain outstanding. As of December 31, 2021, the Company has not
accrued any losses other than legal fees with connection to the above referenced complaints. The Company&#8217;s position is that the
complaint has no merit and it will defend its position vigorously.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On October 5, 2021, a class action complaint
was filed in the United States District Court for the Eastern District of New York against the Company and certain of its officers, captioned
McLaughlin v. Nano-X Imaging Ltd. et al, Case No. 1:21-cv-05517. The plaintiff asserts claims on behalf of persons and entities that purchased
or otherwise acquired the Company&#8217;s securities between June 17, 2021 and August 18, 2021, seeking unspecified damages. The plaintiff
alleges that the defendants made materially false and misleading statements concerning the Company&#8217;s business, operations and compliance
policies beginning on June 17, 2021, based on the Company&#8217;s U.S. Food and Drug Administration submissions. As of December 31, 2021,
the Company has not accrued any losses other than legal fees with connection to the above referenced complaint. The Company&#8217;s position
that the complaint has no merit and will defend its position vigorously.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On October 28, 2021, a complaint was filed
in the United States District Court for the Central District of California against the Company, the Company&#8217;s recently-formed Delaware
subsidiary and Nanox Gibraltar PLC (&#8220;Gibraltar&#8221;) from which the Company received certain assets, as well as Mr. Ran Poliakine
and certain other unidentified parties, alleging several causes of action including breach of a consulting agreement between plaintiff
and Gibraltar that was entered into in 2014. The plaintiff&#8217;s demand is for a payment of unpaid consulting fees from Gibraltar in
the amount of approximately $1 million and approximately $29.5 million from the Company relating to his claimed entitlement to warrants
in Gibraltar. The Company&#8217;s position is that the complaint against the Company has no merit, among other reasons, as it was not
a party to the agreement with the plaintiff and it is not Gibraltar&#8217;s legal successor for any liabilities that Gibraltar may owe
to the plaintiff, and it intends to defend its position vigorously.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Division of Enforcement of the U.S.
Securities &amp; Exchange Commission (the &#8220;SEC&#8221;) has notified the Company that it is conducting an investigation to determine
whether there had been any violations of the federal securities laws. The Company has been providing documents and information and has
now received a subpoena from the SEC requesting that the Company provide documents and other information relating to the development cost
of the Company&#8217;s Nanox.ARC prototypes, as well as the Company&#8217;s estimate for the cost of assembling the final Nanox.ARC product
at scale. The Company is cooperating with the SEC in responding to its requests. The duration and outcome of this matter cannot be predicted
at this time.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329158960136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 12 - SHAREHOLDERS&#8217; EQUITY:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>a.</b></span></td>
    <td><span style="font-size: 10pt"><b>Share capital</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Each holder of the Company&#8217;s ordinary
shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available
and declared by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). Since inception, the Company has not declared any dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The following table presents the number of authorized and issued and
outstanding shares as of each reporting date for each class of shares:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Authorized</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Issued and Outstanding</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Authorized</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Issued and Outstanding</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 51%; text-align: left">Ordinary shares</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">100,000,000</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">51,791,441</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">100,000,000</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">46,100,173</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">Total</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">51,791,441</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,100,173</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.</b></span></td>
    <td><span style="font-size: 10pt"><b>Share based compensation </b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><span style="text-decoration:underline">Share based compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">On September 3, 2019, the Company&#8217;s
Board resolved to adopt an equity incentive plan (the &#8220;Plan&#8221;). Based on such Plan, each option will be exercisable for one
ordinary share of the Company and will become exercisable at such terms and during such periods, as the Board shall determine. Pursuant
to the Plan (and further increase of option pool approved by the Board), 8,041,936 ordinary shares of NIS 0.01 par value of the Company
are reserved for issuance upon the exercise of the same amount of awards to be granted to some of the Company&#8217;s employees, directors
and consultants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">As of December 31, 2021, 1,841,838 ordinary shares reserved for the
equity incentive plan. The Board also approved the Plan for the purpose of selecting the capital gains tax track, under Section 102 of
the Israeli Income Tax Ordinance, for options granted to the Company&#8217;s Israeli employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: left"><span style="text-decoration:underline">Share-based compensation to non-employees</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The following table summarizes share-based awards to non-employees
for the period ended December 31, 2021 and December 31, 2020:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended <br/> December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended <br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">payment</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">payment</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,372,626</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.27</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,410,406</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.89</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">180,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,327,957</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,043,142</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">*(1,267,012</div></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(118,954</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(66,606</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(98,725</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,324,243</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6.17</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,372,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.27</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,618,777</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.35</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,191,042</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.67</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: left"><span style="font-size: 10pt">Out
of which 404,704 and 1,027,151 awards were exercised on a cashless basis in 2021 and 2020, respectively.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The fair value of each granted award is estimated at the date
of grant using the Black- Scholes option-pricing model. The assumptions used for the year ended December 31, 2021 and year ended at December
31, 2020 are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/>
December&#160;31,<br/>
2021</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/>
December&#160;31,<br/>
2020</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Dividend yield</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 12%; text-align: center"><span style="font-size: 10pt">0</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 12%; text-align: center"><span style="font-size: 10pt">0</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">50.27% - 52.71%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57.34%-44.40%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">0.66% - 1.61%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.27%-1.61%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Contractual term (years)</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">0&#8211;10</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">5&#8211;10</span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The expected volatility is based on the historical volatility
of comparable companies. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term
of the awards granted in dollar terms. The Company does not have sufficient historical exercise data to provide a reasonable basis upon
which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified
method, which takes into consideration the option&#8217;s contractual life and the vesting periods (for non-employees, the expected term
is equal to the option&#8217;s contractual life.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in">The following table summarizes information concerning outstanding
and exercisable awards as of December 31, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards outstanding</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards exercisable</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>awards</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>award</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>outstanding</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>exercisable</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>price</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right; width: 18%"><span style="font-size: 10pt">1.92</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><span style="font-size: 10pt">192,927</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><span style="font-size: 10pt">0.04</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><span style="font-size: 10pt">192,927</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><span style="font-size: 10pt">0.04</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">2.21</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,769,513</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7.89</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,288,236</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7.89</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">16.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">161,484</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5.43</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">114,477</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.22</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">23.19</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">21,000</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.78</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">23.84</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">30,000</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.88</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">30.93</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">20,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">8.81</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">20,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">8.81</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">30.66</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">12,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.53</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">40.21</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">17,319</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.19</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,137</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.19</span></td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">49.68</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.05</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">
</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2020</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Awards outstanding</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">award</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">0.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">0.33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">1.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">269,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">269,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.18</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">2.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,191,349</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,188,914</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">16.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">444,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">283,933</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.89</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">18.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.86</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">30.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.81</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: left">Share-based compensation to employees, officers and directors</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 1in; text-align: left">During 2021, the Company granted to certain employees, officers and
directors awards to purchase 1,418,665 of the Company&#8217;s ordinary shares for an average exercise price of $27.57. Most of the awards
agreement term is 10 years unless the agreement is terminated, 4 years vesting period with a one-year cliff.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 81pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended </td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payment awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">exercise<br/>
 price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payment<br/>
 awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">exercise<br/>
 price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,381,125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,667,267</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.21</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,418,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">27.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">730,734</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.53</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Issued due to business combination</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(837,724</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(318,672</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,876</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Outstanding at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">2,760,930</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">15.85</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,381,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">845,356</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,061,778</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 81pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The fair value of each granted award is
estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used as of December 31, 2021 and 2020 are
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Dividend yield</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Expected volatility</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.27%-51.84%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45.11%-55.97%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Risk-free interest rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66%-1.61%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.23%-1.61%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Contractual term (years)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The expected volatility is based on the
historical volatility of comparable companies. The risk-free interest rate assumption is based on observed interest rates appropriate
for the expected term of the awards granted in dollar terms. The Company does not have sufficient historical exercise data to provide
a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined
using the simplified method, which takes into consideration the option&#8217;s contractual life and the vesting periods. The following
table summarizes information concerning outstanding and exercisable awards as of December 31, 2021 and 2020:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards outstanding</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards exercisable</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>awards</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>awards</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>outstanding</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>exercisable</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>price</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 18%; text-align: center"><span style="font-size: 10pt">$0.00-0.01</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 17%; text-align: center"><div style="-sec-ix-hidden: hidden-fact-122"><span style="font-size: 10pt">120,757*)</span></div></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 17%; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 17%; text-align: center"><span style="font-size: 10pt">73,679</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 17%; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: center; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$2.21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">1,130,143</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">7.95</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">716,448</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">7.95</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$16.00</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">88,500</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">7.48</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">35,791</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">6.09</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$17.63-$64.61</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">1,421,530</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">9.68</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">19,438</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8.98</span></td>
    <td style="text-align: center">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*)</td><td style="text-align: left">Including 47,793 RSUs that were granted to the employees of
Nanox AI at the completion of the merger and 3,221 RSUs that were issued in consideration for services.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2020</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Awards outstanding</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 18%; text-align: center">$2.21</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center">1,995,625</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center">9.05</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center">1,019,695</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center">9.05</td><td style="width: 1%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td style="text-align: center">$16.00</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">205,000</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">9.62</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">37,917</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">9.62</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$26.56-$59.20</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">180,500</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">9.93</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">4,167</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">9.93</td><td style="text-align: center">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3)</span></td><td style="text-align: left"><span style="font-size: 10pt">Share-based compensation expenses</span></td>
</tr></table><p style="margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Cost of revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">51</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">661</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and Marketing (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,442</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">617</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,065</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,145</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,806</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,781</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,245</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: left">On October 26, 2020, the Company entered into an amendment to
a business development agreement (&#8220;the Agreement&#8221;) dated February 4, 2020 with two service providers pursuant to which the
Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000
ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard
cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers
waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities
undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company&#8217;s systems
and the issuance of warrants.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329158920568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 13 - INCOME TAX:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>a.</b></span></td>
    <td><span style="font-size: 10pt"><b>Basis of taxation</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Current tax is calculated with
reference to the profit of the Company and its subsidiaries in their respective countries of operation. Set out below are details in respect
of the significant jurisdictions where the Company and its subsidiaries operate and the factors that influenced the current and deferred
taxation in those jurisdictions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in"><b>Israel</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company and Nanox AI Ltd are taxed
under the laws of the State of Israel at a corporate tax rate of 23%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">In 2021, 2020 and 2019, the Company is
at a loss position and therefore has no corporate tax liability. As of December&#160;31, 2021, 2020 and 2019, the Company has a carry
forward loss of approximately $56.3&#160;million, $32.3&#160;million and $2.3&#160;million, respectively. Such carry forward loss has
no expiration date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">In 2021, 2020 and 2019, Nanox AI Ltd.
is at a loss position and therefore has no corporate tax liability. As of December&#160;31, 2021, 2020 and 2019, Nanox AI Ltd. has a
carry forward loss of approximately $61.9&#160;million, $45.3&#160;million and $17.6&#160;million, respectively. Such carry forward loss
has no expiration date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in"><b>United States</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The principal federal tax rate applicable to the U.S. subsidiaries
is 21%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b><i>Korea</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Nanox Korea is subject to a Corporate
income tax with accordance with the Korean tax law. The tax rate ranges between 10% to 25%, depending on the companies&#8217; taxable
income. In Addition, Nanox Korea is subject to a Local income tax of 10%. In 2021, Nanox Korea was at a loss position and therefore had
no corporate tax liability. As of December&#160;31, 2021 and 2020, Nanox Korea has a carry forward loss of approximately $7.1&#160;million
and $0.2&#160;million, respectively. Such carry forward loss has 15 years expiration date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b><i>Japan</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left">Nanox Inc. is subject to national corporate income tax, and enterprise
tax, which, in the aggregate resulted in effective tax rate of approximately 33.59%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in; text-align: left"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.</b></span></td>
    <td><span style="font-size: 10pt"><b>Income (loss) Before Income Taxes:</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Income (loss) before income
taxes consisted of the following for the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year&#160;Ended&#160;December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Domestic (Israel)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(56,609</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(43,449</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(22,588</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,237</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(366</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss before income taxes</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(61,846</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(43,815</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(22,563</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>c.</b></span></td><td style="text-align: left"><span style="font-size: 10pt"><b>Income tax expenses consisted
of the following for the periods indicated:</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year&#160;Ended&#160;December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Domestic (Israel)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(57</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Income tax expenses</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(48</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>d.</b></span></td><td style="text-align: left"><span style="font-size: 10pt"><b>Taxes on Income:</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Taxes on income for the years ended December&#160;31, 2021, 2020 and
2019 were comprised of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S.&#160;dollars&#160;in&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">Domestic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Foreign</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 27pt">Domestic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(59</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Provision for income taxes</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(48</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">A reconciliation our theoretical income tax expense to actual income
tax expense is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss before taxes on income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(61,846</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(43,815</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(22,563</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Statutory tax rate in Israel</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Theoretical tax benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,077</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,189</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase (decrease) in taxes resulting from:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Effect of different tax rates applicable in foreign jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(110</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating losses and other temporary differences for which valuation allowance was provided</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,174</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">701</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Permanent differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,113</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,842</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,480</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Actual tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(48</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>e.</b></span></td>
    <td><span style="font-size: 10pt"><b>Deferred tax assets </b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in">Nanox IL&#8217;s deferred tax asset as of December 31,
2021 and December 31, 2020 was related to tax losses accumulated and carryforward. The reconciling item
between the statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax
benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The components of the Company&#8217;s deferred tax
assets and liabilities as of December&#160;31, 2021 and 2020 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S.&#160;dollars&#160;in&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 27pt">Tax loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,480</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,010</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,213</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Employee and payroll accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,657</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,789</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,775</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,882</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,789</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less valuation allowance for deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,882</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,789</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Significant judgment is required
in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company
considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible
tax planning strategies. The Company reassess its valuation allowance periodically and if future evidence allows for a partial or full
release of the valuation allowance, a tax benefit will be recorded accordingly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">As of December&#160;31, 2021, and 2020, the Company has recorded a
full valuation allowance of $12,882 and $8,789 thousand with regard to its deferred taxes (which is mainly tax loss carryforwards temporary
differences due to unallowed research and development expenses) generated in Israel, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S.&#160;dollars in&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Valuation allowance, December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,789</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Increase due to business combination</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,530</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Increase</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,563</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Valuation allowance, December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,882</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329158992984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsOfOperationsAbstract', window );"><strong>Segments Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsOfOperationsTextBlock', window );">SEGMENTS OF OPERATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 14 - SEGMENTS OF OPERATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">The Company reports segment information based on the &#8220;management&#8221;
approach. The management approach designates the internal reporting used by management for making decisions and assessing performance
as the source of the Company&#8217;s reportable operating segments. The Company manages its business primarily on a service basis. The
management approach designates the internal reporting used by management for making decisions and assessing performance as the source
of the Company&#8217;s reportable segments. The Company&#8217;s reportable segments consist of the Nanox ARC, Radiology services division
and AI solutions divisions. Each one is managed separately to better align with the Company&#8217;s customers and distribution partners
and the unique market dynamics of each segment. Operating income for each segment includes net sales to third parties, related cost of
sales and operating expenses directly attributable to the segment. Operating loss for each segment excludes other income and expense and
certain expenses managed outside the reportable segments. Costs excluded from segment operating income include various corporate expenses
such as income taxes. The Company does not include intercompany transfers between segments for management reporting</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">The accounting policies of the various segments are the same as those
described in Note 2, &#8220;Summary of Significant Accounting Policies.&#8221; The Company evaluates the performance of its reportable
operating segments based on net sales and operating loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Nanox. ARC</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Radiology Services</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>AI Solutions</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">270</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,304</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Segment operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56,875</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(530</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,153</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61,558</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61,846</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation and amortization expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,292</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,806</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Nanox. ARC</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Radiology Services</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>AI Solutions</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%">Segment operating loss</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(43,923</td><td style="text-align: left; width: 1%">)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(43,923</td><td style="text-align: left; width: 1%">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,815</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">24,781</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">24,781</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Nanox. ARC</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Radiology Services</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>AI Solutions</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%">Segment operating loss</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(22,571</td><td style="text-align: left; width: 1%">)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(22,571</td><td style="text-align: left; width: 1%">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,563</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,245</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">For the&#160;year ended December&#160;31, 2021, the Company&#8217;s
revenues in the United States of America constitutes approximately 98% of the Company&#8217;s total revenue. For the year ended December
31, 2021 no individual customer exceeded 10% of our total revenue or total accounts receivables.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and Equipment by Geography</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year&#160;Ended<br/>
December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Israel</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,381</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,065</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">South Korea</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,675</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unites States</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Japan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">37,435</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">14,020</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SegmentsOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SegmentsOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SegmentsOfOperationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SegmentsOfOperationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159035384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 15 </b>- <b>LOSS PER SHARE:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>a.</b></span></td>
    <td><span style="font-size: 10pt"><b>Basic</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Basic loss per share is calculated by dividing the loss attributable
to the Company&#8217;s owners by the weighted average number of ordinary shares in issue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.9pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2019</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 67%; padding-bottom: 1.5pt"><span style="font-size: 10pt">Net loss attributable to Company&#8217;s owners</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(61,798</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(43,815</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(22,563</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">The weighted average of the number of ordinary shares (in thousands)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">48,216&#160;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">35,654</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">25,181</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt"><b>Basic and diluted loss per share</b></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(1.28</span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(1.23</span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(0.90</span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">For the calculation of loss per share, the Company used the
net loss attributable to Company&#8217;s owners divided by the weighted average number of the Company&#8217;s ordinary shares for the
years ended December 31, 2021, 2020 and 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.</b></span></td>
    <td><span style="font-size: 10pt"><b>Diluted</b></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.8pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">As of December 31, 2021, and 2020 the Company had 2,505,370 and 3,173,186
warrants, respectively and 4,842,342 and 4,673,104 options, respectively. As of December 31, 2019, the Company had 5,548,649&#160;warrants
and 3,654,464 options. These warrants and awards were not considered when calculating diluted loss per share since their effect is anti-dilutive.
In addition, contingently issuable ordinary shares that are issuable based on certain conditions (see Note 3) are not included in the
potential dilutive shares in calculating the diluted loss per share.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329158915000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 16 - SUBSEQUENT EVENTS:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 19, 2022, the Company issued 89,286
additional shares to the former shareholders of Nanox AI due to partial achievement of a milestone that occurred post-closing.&#160;The
fair value of the shares at the issuance date was $952.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In March 2022, the Company leased and addition space of 105 square
meters in Neve Ilan for a period of 3 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On March 28, 2022, the Board of Directors of the
Company nominated Mr. Erez Alroy as a member of the Board of the Company. Mr. Alroy replaces Mr. Fenig who retires from his membership
at the Board of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On January 25, 2022, Magistrate Judge Peggy Kuo appointed Davian Holdings
Limited as Lead Plaintiff in the McLaughlin v. Nano-X Imaging Ltd. et al, Case No. 1:21-cv-05517. On April 12, 2022 and in the same case,
the Lead Plaintiff filed an amended complaint, which alleges that defendants violated the federal securities laws in connection with certain
disclosures concerning the cost of the Nanox.Arc system as well as the comparison of the Nanox.Arc to CT scanners. Lead Plaintiff seeks
to represent a class of investors who purchased the Company&#8217;s publicly-traded securities between August 21, 2020 and November 17,
2021. The Company has not yet responded to the amended complaint and intends to defend these actions vigorously.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329154610952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in the preparation of financial statements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>a.&#160;</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Use of estimates in the preparation of financial statements</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.75in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The preparation of the consolidated financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company&#8217;s
consolidated financial statements. As applicable to these consolidated financial statements, the most significant estimates relate to
assets acquired and liabilities assumed through business combination, goodwill impairment, useful lives of intangible assets, deferred
taxes and share-based payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>b.&#160;</b></span></td> <td><span style="font-size: 10pt"><b>Functional currency</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in">The U.S. dollar is the currency of the primary economic environment
in which the operations of the Company and its subsidiaries is conducted. A substantial portion of the operational costs are denominated
in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar (&#8220;primary currency&#8221;). Foreign currency
assets and liabilities are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date.
Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result
of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during
the period. Currency transaction gains and losses are presented in financial income and expenses, net.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: left">
<td style="text-align: left; width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c.</b></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Combinations</b></span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company allocates the fair value of
consideration transferred in a business combination to the assets acquired, liabilities assumed, and non-controlling interests in the
acquired business based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the
business combination and are expensed as incurred. The excess of the fair value of the consideration transferred plus the fair value of
any non-controlling interest in the acquiree over the fair value of the assets acquired, liabilities assumed in the acquired business
is recorded as goodwill. The fair value of the consideration transferred may include a combination of cash, equity securities, earn out
payments and deferred payments. The allocation of the consideration transferred in certain cases may be subject to revision based on the
final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative
impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company
includes the results of operations of the businesses that it has acquired in its consolidated results prospectively from the respective
dates of acquisition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company records obligations in
connection with its business combinations at fair value on the acquisition date. Each reporting period thereafter, the Company revalues
earn-out liabilities and records the changes in their fair value in the consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Changes in the fair value of earn-out liabilities can result from adjustments
to the discount rates, the Company&#8217;s shares price, sales and profitability targets. This fair value measurement represent Level
3 measurements, as they are based on significant inputs not observable in the market. Significant judgment is required in determining
the assumptions utilized as of the acquisition date and for each subsequent period. Accordingly, changes in the assumptions described
above could have a material impact on the Company&#8217;s consolidated results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>d.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Cash and cash equivalents </b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company considers as cash equivalents all short-term,
highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase
that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. </p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>e.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Marketable Securities</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">All highly liquid investments are classified
as marketable securities and have been classified and accounted for as available-for-sale. Investment in securities consists of debt
securities classified as available-for-sale and recorded at fair value. The Company classifies its marketable securities as either short-term
or long-term based on each instrument&#8217;s underlying contractual maturity date. Unrealized gains and losses on marketable debt securities
classified as available-for-sale are reported net of the related tax effect in other comprehensive income/(loss).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>f.</b></span></td><td style="text-align: left"><b>Accounts receivables</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Accounts receivable are presented net of the allowance for expected credit loss and consists of short term receivables that arise in the normal course of business. The Company performs ongoing credit evaluations of its customer&#8217;s financial condition and typically requires no collateral from its customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company adopted the Current Expected
Credit Losses (&#8220;CECL&#8221;) guidance effective January 1, 2020. The Company maintains the allowance for estimated losses resulting
from the inability of the Company&#8217;s customers to make required payments. The allowance represents the current estimate of lifetime
expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable
forecasts when appropriate. The estimate is a result of the Company&#8217;s ongoing evaluation of collectability, customer creditworthiness,
historical levels of credit losses, and future expectations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Changes in the allowance for&#160;credit losses&#160;are recognized
in, general and administrative expenses. Accounts receivables are written-off against the allowance for&#160;credit losses&#160;when management
deems the accounts are no longer collectible.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>g.</b></span></td> <td><span style="font-size: 10pt"><b>Property&#160;and&#160;equipment,&#160;net</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Property and equipment are stated at cost, net of accumulated
depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful lives:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers and electronic equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">15-33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office furniture and lab equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">6-20</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Vehicles</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equipment and machinery</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">10-20</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold Improvement</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Land</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The depreciable life of leasehold improvements is limited
by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>h.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b><i>Intangible Assets, net</i></b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b><i>Goodwill</i></b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Goodwill reflects the excess of the consideration transferred plus
the fair value of any non-controlling interest in the acquiree at the business combination date over the fair values of the identifiable
net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination
that are not individually identified and separately recognized. The Company allocates goodwill to its reporting units based on the reporting
unit expected to benefit from the business combination. &#160;&#160;The primary items that generate goodwill include the value of the
synergies between the acquired companies and the Company and the acquired assembled workforce, neither of which qualifies for recognition
as an intangible asset. ASC 350, &#8220;Intangibles - Goodwill and other&#8221; (&#8220;ASC 350&#8221;) requires goodwill to be tested
for impairment at the reporting unit level at least annually or between annual tests in certain circumstances and written down when impaired.
ASC 350 allows an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative
goodwill impairment test. If the qualitative assessment does not result in a more likely than not indication of impairment, no further
impairment testing is required. If it does result in a more likely than not indication of impairment, the quantitative goodwill impairment
test two-step impairment test is performed. Alternatively, ASC 350 permits an entity to bypass the qualitative assessment for any reporting
unit and proceed directly to performing the quantitative first step of the goodwill impairment test.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The provisions of the accounting standard for goodwill allow the Company
to first assess qualitative factors to determine whether it is necessary to perform the next goodwill impairment quantitative test. Examples
of events or circumstances that may be indicative of impairment include but are not limited to: macroeconomic and industry conditions,
overall financial performance and adverse changes in legal, regulatory, market share and other relevant entity specific events. The carrying
value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill, to those reporting
units. When necessary, the Company records charges for impairments of goodwill for the amount by which the carrying amount exceeds the
fair value of these assets. No goodwill impairment charge was recorded in 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b><i>other Intangible Assets, net</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Definite life intangible assets are amortized using the straight-line
method over their estimated period of useful life. Amortization of acquired developed technology, image big data, market platform, trade
names, customer relationships and radiologist relationships are recorded under cost of revenues and selling and marketing expenses. In
addition, the remaining amortization period for the impaired asset would be reassessed and, if necessary, revised.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>i.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Impairment&#160;of&#160;long-lived&#160;assets </b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company tests long-lived assets for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets
is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated
by the asset or asset group. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company
recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future
discounted cash flows.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>j.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Severance&#160;pay</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">Israeli labor law generally requires severance pay be granted
upon dismissal of an employee or upon termination of employment under certain other circumstances. Pursuant to Section 14 of the Severance
Compensation Act, 1963 (&#8220;Section 14&#8221;), all of the Company&#8217;s employees in Israel are entitled to monthly deposits, at
a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments under Section 14 relieve the Company from
any future severance payment obligation with respect to those employees and, as such, the Company may only utilize the insurance policies
for the purpose of disbursement of severance pay. As a result, the Company does not recognize an asset nor liability for these employees.</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In 2021 and 2020, all of the employees
of the Company and its subsidiary in Israel are subject to Section 14 of the Severance Law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LegalAndOtherContingenciesPolicyTextBlock', window );">Legal and other contingencies</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>k.</b></span></td> <td><span style="font-size: 10pt"><b>Legal&#160;and other&#160;contingencies</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Certain conditions, such as legal proceedings, may exist as
of the date the consolidated financial statements are issued that may result in a loss to the Company, but that will only be resolved
when one or more future events occur or fail to occur. In assessing loss contingencies related to legal proceedings that are pending
against the Company or unasserted claims that may result in such proceedings, the Company&#8217;s management evaluates with its legal
advisors the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought
or expected to be sought. Such assessment inherently involves an exercise of judgment. Legal fees are expensed as incurred.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Management applies the guidance in ASC 450-20-25 when assessing losses
resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss would be incurred
and the amount of the liability can be estimated, then the Company records an accrued expense in the Company&#8217;s consolidated financial
statements based on its best estimate. Loss contingencies considered to be remote by management are generally not disclosed unless material.
For additional information see note 11.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>l.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Revenue Recognition</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; text-indent: -0.75in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The majority of the Company&#8217;s revenues are derived from radiology
services fees received from various payors based on established billing rates. Revenues are derived directly from hospitals and healthcare
providers. The Company recognizes revenue in the period in which the performance obligation is satisfied. The Company records the amount
of revenue that reflects the consideration that it expects to receive in exchange for those services. The Company applies the following
five-step model in order to determine this amount: (i)&#160;identification of the contract with a customer; (ii)&#160;identification of
the promised services in the contract and determination of whether they represent performance obligations, including whether they are
distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">The Company records deferred revenue for any upfront payments received
in advance of the Company&#8217;s performance obligations being satisfied. These contract liabilities consist principally of unearned
radiology service fee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>m.</b></span></td> <td><span style="font-size: 10pt"><b>Research and development expenses</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b>&#160;</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Research and development expenses are charged to the statement
of operations as incurred and consist primarily of personnel, materials and supplies for research and development activities.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income tax</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt"><b>n.</b></span></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Income&#160;tax </b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.75in">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 1in">&#160;</td>
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">1)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">The Company accounts for income taxes in accordance with ASC 740, &#8220;Income
    Taxes&#8221; (&#8220;ASC&#160;740&#8221;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability
    account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and
    are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
    provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely
    than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative
    evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU&#160;2015-17.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 96px">&#160;</td>
    <td style="text-align: left; width: 0.25in"><span style="font-size: 10pt">2)</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not
    been taken into account in computing the deferred income taxes, as it is the Company&#8217;s intent and ability to hold these investments.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 96px; font-size: 10pt">&#160;</td> <td style="text-align: left; width: 24px; font-size: 10pt"><span style="font-size: 10pt">3)</span></td> <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 96px; font-size: 10pt">&#160;</td>
    <td style="text-align: left; width: 24px; font-size: 10pt"><span style="font-size: 10pt">4)</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 10pt">Valuation allowances are provided unless it is more likely
than not that the deferred tax asset will be realized. In the determination of the appropriate valuation allowances, the Company considers
future reversals of existing taxable temporary differences, the most recent projections of future business results, prior earnings history,
carryback and carry forward and prudent tax strategies that may enhance the likelihood of realization of a deferred tax asset. Assessments
for the realization of deferred tax assets made at a given balance sheet date are subject to change in the future, particularly if earnings
of a subsidiary are significantly higher or lower than expected, or if the Company takes operational or tax positions that could impact
the future taxable earnings of a subsidiary.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: left; width: 0.75in">&#160;</td> <td style="text-align: left; width: 0.25in"><b>o<span style="font-size: 10pt">.</span></b></td> <td style="text-align: left"><span style="font-size: 10pt"><b>Share-based compensation</b></span></td></tr> </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company accounts for share-based compensation under
ASC 718, &#8220;Compensation - Stock Compensation,&#8221; which requires the measurement and recognition of compensation expense
based on estimated fair values for all share-based payment awards made to non-employees, employees, officers and directors. ASC 718
requires companies to estimate the fair value of equity-based payment awards on the date of grant. The Company uses the
Black-Scholes-Merton option-pricing model as part of such estimation.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Prior to the adoption of ASU 2018-07, warrants issued to consultants
and other non-employees, as compensation for services provided to the Company, were accounted for based upon the fair value of the warrants.
The fair value of the warrants granted was measured on a final basis at the end of the related service period and was recognized over
the related service period using the straight-line method. After the adoption of ASU 2018-07, the measurement date for non-employee awards
is the date of the grant. The compensation expense for non-employees is recognized without changes in the fair value of the award, over
the requisite service period, which is the vesting period of the respective award using the straight line. The Company adopted ASU 2018-07
as of January 1, 2019 with no impact on its consolidated financial statements as all of the Company&#8217;s awards were fully vested
at the adoption date.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company recognizes compensation expenses for its stock-based
option awards and RSUs on a straight-line basis over the requisite service period (primarily a four-year period). The Company accounts
for forfeitures as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in; font-size: 10pt">&#160;</td> <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt"><b>p.</b></span></td> <td style="font-size: 10pt"><span style="font-size: 10pt"><b>Loss&#160;per&#160;share</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Basic earnings per share is computed by dividing net income
(loss) attributable to holders of ordinary shares of the Company by the weighted average number of ordinary shares outstanding for each
reporting period.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In computing the Company&#8217;s diluted earnings per share,
the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary shares and the potential dilutive
ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding include the dilutive effect of in-the-money
options using the treasury stock method.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">The Company did not take into account
any dilutive instruments, such as investor warrants , share-based payments and earn-out liability - contingently issuable ordinary shares
, since their effect, on a fully diluted basis, is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>q.</b></span></td> <td><span style="font-size: 10pt"><b>Fair&#160;value&#160;measurement</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Fair value is based on the price that would be received from
the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that
prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 96px">&#160;</td>
    <td style="text-align: left; width: 48px"><span style="font-size: 10pt">Level 1:</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Level 2: </span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left"><span style="font-size: 10pt">Level 3: </span></td>
    <td style="text-align: left"><span style="font-size: 10pt">Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></td></tr>
  </table><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.75in"><b>&#160;</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In determining fair value, the Company utilizes valuation techniques
that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty
credit risk in its assessment of fair value.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The Company&#8217;s financial instruments consist mainly of
cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities. The fair value
of these financial instruments approximates their carrying values.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Money market funds (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,697</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,697</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">89,911</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">89,911</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">119,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">119,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long term loan (**)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,796</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,471</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,471</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent long-term earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,814</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,814</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt"/>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">-</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">52,081</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">52,081</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span>The Company classifies AFS securities
within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair value</span></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span>(*)</span></td><td style="text-align: left"><span>As of&#160;</span>December
31, 2021,&#160;<span>approximately $29,697 thousand of debt securities were classified under &#8220;Cash
and Cash equivalents&#8221; in the consolidated balance sheets as such securities met all applicable classification criteria.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(**)</td><td style="text-align: justify"><span>Since the loan was
originated in September 2021, the fair value of the long term loan approximates its carrying value.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risks</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>r.</b></span></td> <td><span style="font-size: 10pt"><b>Concentration&#160;of&#160;Credit Risks</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Financial instruments that potentially subject the
Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, marketable securities
and accounts receivable.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The Company&#8217;s cash and cash equivalents and restricted
cash are invested with major banks in Israel, United States, Korea and Japan. Generally, these investments may be redeemed upon demand
and the Company believes that the financial institutions that hold the Company&#8217;s cash balances are financially sound and, accordingly,
bear minimal risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"><b>&#160;</b>&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredOfferingCostsPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>s.</b></span></td> <td><span style="font-size: 10pt"><b>Offering&#160;Costs </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Deferred offering costs directly relating to the Company&#8217;s
private and initial public offering, were capitalized and offset against proceeds upon the consummation of the private and IPO transactions
in shareholders&#8217; equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 0.25in"><span style="font-size: 10pt"><b>t.</b></span></td> <td><span style="font-size: 10pt"><b>Leases</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left">On January 1, 2019 the Company adopted
ASU No. 2016-02, Leases (&#8220;Topic 842&#8221;), The Company determines if an arrangement is a lease at inception. Balances related
to operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current maturities of operating leases liabilities
and Non-current operating leases liabilities in the consolidated balance sheets.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">The Company also elected not separating lease components
from non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated
lease payments in the consolidated statements of operations on a straight-line basis over the lease term.</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">ROU assets represent the Company&#8217;s right to use an underlying
asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease.
Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over
the lease term. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that
the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily
determined. As the Company&#8217;s leases do not provide an implicit rate, the Company&#8217;s uses its estimated incremental borrowing
rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for
lease payments is recognized on a straight-line basis over the lease term (see also note 7).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">The Company presents unrecognized tax benefits as a reduction
to deferred tax asset where a net operating loss, a similar tax loss, or a tax credit carryforward that are available, under the tax law
of the applicable jurisdiction, to offset any additional income taxes that would result from the settlement of a tax position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 72px; padding-right: 0.8pt">&#160;</td> <td style="vertical-align: top; width: 24px; padding-right: 0.8pt"><span style="font-size: 10pt"><b>u.</b></span></td> <td style="vertical-align: top"><span style="font-size: 10pt"><b>Segment reporting</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">ASC 280, &#8220;Segment Reporting,&#8221; establishes standards
for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate
financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources
and in assessing performance. The Company&#8217;s chief operating decision maker is the Company&#8217;s Chief Executive Officer (the &#8220;CODM&#8221;),
who makes resource allocation decisions and assesses performance based on financial information prepared on a consolidated basis, accompanied
by disaggregated information about revenues, gross profit and operating loss by the three identified reportable segments. The Company&#8217;s
business includes three operating segments based on the services that the Company provides. The three segments are composed from the Nanox.Arc
segment, AI solutions and the Radiology services division segment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly issued and recently adopted accounting pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt"><b>v.&#160;</b></span></td> <td><span style="font-size: 10pt"><b>Newly issued and recently adopted accounting pronouncements:</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><b><i>Accounting Pronouncements Adopted in Current year</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">. In December 2019, the FASB issued ASU 2019-12, Income Taxes (&#8220;Topic
740&#8221;): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions
to the general principles and simplification of areas such as franchise taxes, step-up in tax basis goodwill, separate entity financial
statements and interim recognition of enactment of tax laws or rate changes. The guidance was effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted this guidance
since January 1, 2021, with no material impact on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left">In October 2021, the FASB issued ASU
2021-08 &#8220;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;,
which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer
on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing
contract assets and contract liabilities at the same amounts recorded by the acquire. The guidance should be applied prospectively to
acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that
have not yet been issued. The Company early adopted ASU 2021-08 since January 1, 2021, with no material impact on its consolidated financial
statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"><i>Recently issued accounting pronouncements, not yet adopted</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt">In August 2020, the FASB issued ASU 2020-06 &#8220;Debt &#8211;
Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic
815 &#8211; 40).&#8221; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity, including convertible instruments and contracts on an entity&#8217;s own equity. The amendments to this guidance are effective
for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years.&#160;The Company will adopt this
guidance effective January 1, 2022, with no material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LegalAndOtherContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LegalAndOtherContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329154625832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers and electronic equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">15-33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office furniture and lab equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">6-20</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Vehicles</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Equipment and machinery</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">10-20</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold Improvement</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Land</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">N/A</span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities measured fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Balance as of <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Money market funds (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,697</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,697</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Marketable securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">89,911</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">89,911</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">119,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">119,608</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long term loan (**)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,796</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,471</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,471</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent long-term earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,814</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,814</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt"/>
    <td style="border-bottom: Black 4pt double; text-align: left"/><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">-</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">52,081</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">52,081</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0.25in; text-align: left"><span>(*)</span></td><td style="text-align: left"><span>As of&#160;</span>December
31, 2021,&#160;<span>approximately $29,697 thousand of debt securities were classified under &#8220;Cash
and Cash equivalents&#8221; in the consolidated balance sheets as such securities met all applicable classification criteria.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(**)</td><td style="text-align: justify"><span>Since the loan was
originated in September 2021, the fair value of the long term loan approximates its carrying value.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Property and equipment are stated at cost, net of accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329160083544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination and Other Transaction (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CertainTransactionsAbstract', window );"><strong>Business Combination and Other Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfFairValueConsiderationTransferred', window );">Schedule of fair value consideration transferred</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">U.S.$<br/> in thousand</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash payments</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 89%; text-align: left">Issuance of ordinary shares, options and RSUs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">88,510</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,129</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent long term earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,660</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total consideration</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">129,299</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. $ in thousands</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash payments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,147</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent consideration at estimated fair value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,405</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total consideration</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,052</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of the purchase price to assets acquired and liabilities assumed</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Allocation<br/> of Purchase<br/> Price</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">(U.S. $ in thousands)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; text-align: left">Cash, cash equivalents and Restricted&#160;Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,956</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts Receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,816</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,243</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,237</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,413</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,129</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent long-term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,660</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Convertible note (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other labilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,525</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,727</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">88,510</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Allocation of Purchase Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">(U.S. $ in thousands)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">332</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts Receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">912</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,187</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,519</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loan from a government agency</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other labilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,766</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent short term earnout liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,453</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Contingent long term earnout liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,952</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,872</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18,647</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pf0_CondensedStatementOfComprehensiveIncomeTableTextBlock', window );">Schedule of acquisition of Nanox AI</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<br/> December&#160;31, 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<br/> December&#160;31, 2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="7" style="text-align: center">US$ in thousand</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,363</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,550</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(87,045</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(69,875</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CertainTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CertainTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfFairValueConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfFairValueConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pf0_CondensedStatementOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pf0_CondensedStatementOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pf0_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159842088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill &amp; Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill &amp; Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill and the intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance as of December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-align: left">Goodwill from acquisition of Zebra</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">51,243</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Goodwill from acquisition of USARAD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,055</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58,298</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center"><b>&#160;</b></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Useful Life<br/>
(in Years)</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Amount as&#160;of<br/>
the merger/<br/>
acquisition<br/>
date</b></td><td style="white-space: nowrap; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><b>Amortization<br/>
expense for<br/>
the period</b></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><b>Amount as<br/>
of December 31,<br/>
2021</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27,316</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,861</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Image big data</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">51,625</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Market platform</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,591</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">108</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,483</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Radiologist relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">11.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,770</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,505</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trade name</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">12.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,095</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,066</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Customer relationships</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">6.17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,322</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,286</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">103,594</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,768</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">101,826</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Amortization of intangible assets for each of the next five years and thereafter</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><span style="font-size: 10pt">2022</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="font-size: 10pt">10,607</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">2023</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">10,607</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2024</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">10,607</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">2025</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">10,499</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">2026 and thenafter</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">59,506</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">101,826</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329158957064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers and electronic equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10-33</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Office furniture and lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">6-20</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Vehicles</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Machines</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">10-20</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Leasehold Improvement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Land</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-102">N/A</span></span></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars <br/> in thousands)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Office furniture and lab equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">648</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">820</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Computers and electronic equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Equipment and machinery</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,766</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1762</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Leasehold improvement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Vehicles</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Land &#8211; See b below</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,297</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Production line in construction &#8211; See b below</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,790</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,318</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,303</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,364</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(868</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,435</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,020</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159055112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CashCashEquivalentsandRestrictedCashTablesLineItems', window );"><strong>Cash Equivalents and Restricted Cash Table[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of reconciliation of cash, cash equivalents and restricted cash</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">66,645</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,468</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted bank deposit (1)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">316</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -11.5pt; padding-left: 11.5pt">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">66,772</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">213,784</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: left">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: left">As of December&#160;31, 2021, the Company&#8217;s restricted
cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit is presented at cost including accrued
interest. This bank deposit is used as security for credit card use and collateralizing the Company&#8217;s lease contracts</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CashCashEquivalentsandRestrictedCashTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CashCashEquivalentsandRestrictedCashTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329161738904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of the compnay's total lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars <br/> In thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating lease cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Fixed payments</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">653</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">276</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term lease cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating lease cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">701</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">341</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information related to operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended <br/> December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S.&#160;Dollars<br/> in&#160;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S.&#160;Dollars<br/> in&#160;thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating cash flows from operating leases</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;507</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">169</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Right-of-use assets obtained in exchange for lease obligations (non-cash):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">194</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,085</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock', window );">Schedule of supplemental balance sheet information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars<br/> in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating leases:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,725</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,359</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current maturities of operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">519</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-current operating leases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">950</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">923</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total operating lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,831</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,442</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Weighted average remaining lease term</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.67</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.70</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.83</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of operating lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">December&#160;31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars <br/> in thousands)</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">961</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">245</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">2025 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,951</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,831</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159324296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredRevenuesDisclosureAbstract', window );"><strong>Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Schedule of Deferred Revenue</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deferred<br/> Revenue</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Increase due to the business combinations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">483</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in deferred revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">179</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance at December 31, 2021 (*)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">662</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredRevenuesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredRevenuesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329160044904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartyLiabilityAbstract', window );"><strong>Related Party Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfRelatedPartyTableTextBlock', window );">Schedule of related party</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Dollars in thousands)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">(a) Due from Illumigyn</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">27</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">(b) Due from Wellsense Technologies Ltd.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(c) Due from Six-Eye Interactive</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">(c) Due from Six AI ltd.</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total from related parties</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">18</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related parties transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(U.S. Dollars in thousands)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 4pt">Research and development &#8211; see d below</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">80</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">355</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">154</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">General and administrative &#8211; See c, e and f below</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(191</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(167</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,824</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartyLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartyLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfRelatedPartyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfRelatedPartyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150988408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityTablesLineItems', window );"><strong>Shareholders' Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfIssuedAndOutstandingTextBlock', window );">Schedule of issued and outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2021</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2020</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Authorized</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Issued and Outstanding</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Authorized</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Issued and Outstanding</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 51%; text-align: left">Ordinary shares</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">100,000,000</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">51,791,441</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">100,000,000</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">46,100,173</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">Total</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">51,791,441</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,100,173</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock', window );">Schedule of share-based awards to employees, officers and directors</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended <br/> December 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended <br/> December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">payment</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">payment</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercise</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,372,626</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.27</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,410,406</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.89</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">180,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,327,957</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,043,142</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.66</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">*(1,267,012</div></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8.94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(118,954</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(66,606</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(98,725</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,324,243</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6.17</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3,372,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.27</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,618,777</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">3.35</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,191,042</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.67</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes option-pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/>
December&#160;31,<br/>
2021</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-size: 10pt"><b>Year ended<br/>
December&#160;31,<br/>
2020</b></span></td>
    <td style="white-space: nowrap; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><span style="font-size: 10pt">Dividend yield</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 12%; text-align: center"><span style="font-size: 10pt">0</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="white-space: nowrap; width: 12%; text-align: center"><span style="font-size: 10pt">0</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left"><span style="font-size: 10pt">Expected volatility</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">50.27% - 52.71%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57.34%-44.40%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">0.66% - 1.61%</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.27%-1.61%</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">Contractual term (years)</span></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center">0&#8211;10</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap; text-align: center"><span style="font-size: 10pt">5&#8211;10</span></td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Dividend yield</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt">Expected volatility</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50.27%-51.84%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45.11%-55.97%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Risk-free interest rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.66%-1.61%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.23%-1.61%</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Contractual term (years)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of information concerning outstanding and exercisable awards</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards outstanding</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards exercisable</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>awards</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>award</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>outstanding</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>exercisable</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>price</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right; width: 18%"><span style="font-size: 10pt">1.92</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><span style="font-size: 10pt">192,927</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><span style="font-size: 10pt">0.04</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><span style="font-size: 10pt">192,927</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: right; width: 17%"><span style="font-size: 10pt">0.04</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">2.21</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,769,513</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7.89</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">1,288,236</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">7.89</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">16.00</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">161,484</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">5.43</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">114,477</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.22</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">23.19</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">21,000</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.78</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">23.84</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">30,000</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.88</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">30.93</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">20,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">8.81</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">20,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">8.81</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">30.66</span></td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">12,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.53</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="font-size: 10pt">-</span></div></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">40.21</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">17,319</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.19</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">3,137</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.19</span></td>
    <td style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">49.68</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">100,000</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">9.05</span></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121"><span style="font-size: 10pt">-</span></div></td>
    <td style="text-align: right">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">
</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2020</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Awards outstanding</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Awards exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">award</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">0.33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">186,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 17%; text-align: right">0.33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">1.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">269,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">269,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.18</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">2.21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,191,349</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,188,914</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.22</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">16.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">444,748</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">283,933</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.89</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">$</td><td style="text-align: right">18.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.86</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: right">30.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.81</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>December 31, 2021</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards outstanding</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Awards exercisable</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Number of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Weighted</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>awards</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>awards</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>average</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>outstanding</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>exercisable</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>remaining</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>Exercise</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>at end of</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt"><b>contractual</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>price</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>year</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center; border-bottom: black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>life (years)</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 18%; text-align: center"><span style="font-size: 10pt">$0.00-0.01</span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 17%; text-align: center"><div style="-sec-ix-hidden: hidden-fact-122"><span style="font-size: 10pt">120,757*)</span></div></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 17%; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 17%; text-align: center"><span style="font-size: 10pt">73,679</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 17%; text-align: center"><span style="font-size: 10pt">-</span></td>
    <td style="text-align: center; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$2.21</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">1,130,143</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">7.95</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">716,448</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">7.95</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$16.00</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">88,500</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">7.48</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">35,791</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">6.09</span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">$17.63-$64.61</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">1,421,530</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">9.68</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">19,438</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">8.98</span></td>
    <td style="text-align: center">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31, 2020</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Awards outstanding</b></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Awards exercisable</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">awards</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">outstanding</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">exercisable</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">remaining</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">at end of</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">contractual</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">life (years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 18%; text-align: center">$2.21</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center">1,995,625</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center">9.05</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center">1,019,695</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 17%; text-align: center">9.05</td><td style="width: 1%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center">&#160;</td><td style="text-align: center">$16.00</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">205,000</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">9.62</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">37,917</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">9.62</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$26.56-$59.20</span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">180,500</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">9.93</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">4,167</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">9.93</td><td style="text-align: center">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Cost of revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">51</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,248</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">661</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and Marketing (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,442</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,252</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">617</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,065</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,145</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,967</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,806</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,781</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">16,245</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember', window );">Employees, Officers and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityTablesLineItems', window );"><strong>Shareholders' Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of issued and outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended </td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">share-based</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">average</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payment awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">exercise<br/>
 price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">payment<br/>
 awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">exercise<br/>
 price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,381,125</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.14</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,667,267</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.21</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes during the year:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,418,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">27.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">730,734</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.53</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Issued due to business combination</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(837,724</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(318,672</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.69</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,876</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Outstanding at end of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">2,760,930</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">15.85</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,381,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.14</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">845,356</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.58</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,061,778</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.80</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 81pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfIssuedAndOutstandingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfIssuedAndOutstandingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock awards granted to nonemployee directors that were outstanding at the beginning and end of the year, and the number of awards that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nnox_EmployeesOfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329161750152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted', window );">Schedule of income (loss) before income taxes consisted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year&#160;Ended&#160;December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Domestic (Israel)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(56,609</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(43,449</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(22,588</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,237</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(366</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Loss before income taxes</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(61,846</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(43,815</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(22,563</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year&#160;Ended&#160;December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Domestic (Israel)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(57</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Income tax expenses</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(48</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td colspan="2" style="font-size: 1pt">&#160;</td><td style="font-size: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S.&#160;dollars&#160;in&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">Domestic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Foreign</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">-</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 27pt">Domestic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(57</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(59</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(116</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt">&#160;</td>
    <td style="font-size: 1pt; text-align: left">&#160;</td><td style="font-size: 1pt; text-align: right">&#160;</td><td style="font-size: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Provision for income taxes</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(48</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation our theoretical income tax expense to actual income tax expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt">Loss before taxes on income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(61,846</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(43,815</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(22,563</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Statutory tax rate in Israel</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Theoretical tax benefit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,077</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,189</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Increase (decrease) in taxes resulting from:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Effect of different tax rates applicable in foreign jurisdictions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(110</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Operating losses and other temporary differences for which valuation allowance was provided</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,174</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,235</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">701</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Permanent differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,113</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,842</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,480</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Actual tax benefit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(48</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S.&#160;dollars&#160;in&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 27pt">Tax loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30,234</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,480</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,010</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,213</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">Employee and payroll accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,657</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,789</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,775</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Deferred tax assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,882</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,789</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Less valuation allowance for deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,882</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,789</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Deferred tax assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock', window );">Schedule of valuation allowance provided portion deferred</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S.&#160;dollars in&#160;thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%">Valuation allowance, December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,789</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Increase due to business combination</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,530</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Increase</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,563</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Valuation allowance, December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,882</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity by class in any valuation allowance for impairment of recognized servicing assets - including beginning and ending balances, aggregate additions charged and recoveries credited to operations, and aggregate write-downs charged against allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128311188&amp;loc=d3e122739-111746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329158967144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsOfOperationsAbstract', window );"><strong>Segments Of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock', window );">Schedule of reportable operating segments based on net sales and operating loss</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Nanox. ARC</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Radiology Services</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>AI Solutions</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">270</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,304</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Segment operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56,875</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(530</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,153</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61,558</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financial income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61,846</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation and amortization expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,292</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">336</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,806</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Nanox. ARC</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Radiology Services</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>AI Solutions</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%">Segment operating loss</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(43,923</td><td style="text-align: left; width: 1%">)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(43,923</td><td style="text-align: left; width: 1%">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,815</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">24,781</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">24,781</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Nanox. ARC</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Radiology Services</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>AI Solutions</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 52%">Segment operating loss</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(22,571</td><td style="text-align: left; width: 1%">)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">(22,571</td><td style="text-align: left; width: 1%">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,563</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,245</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock', window );">Schedule of property and equipment by geography</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year&#160;Ended<br/>
December&#160;31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Israel</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,381</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,065</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">South Korea</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,675</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Unites States</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Japan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">37,435</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">14,020</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SegmentsOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SegmentsOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159322072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year ended December 31,</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2021</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2019</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 67%; padding-bottom: 1.5pt"><span style="font-size: 10pt">Net loss attributable to Company&#8217;s owners</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(61,798</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(43,815</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid">&#160;</td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(22,563</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">The weighted average of the number of ordinary shares (in thousands)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">48,216&#160;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">35,654</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">25,181</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt"><b>Basic and diluted loss per share</b></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(1.28</span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(1.23</span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">(0.90</span></td>
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.9pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150975352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Nov. 02, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_NasdaqMember', window );">Nasdaq [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_InitialPublicOfferingNetProceeds', window );">Proceeds received from the IPO</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Bisiness Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_GeneralDetailsLineItems', window );"><strong>General (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Percentage of acquisition shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_GeneralDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_GeneralDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_InitialPublicOfferingNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering net proceeds .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_InitialPublicOfferingNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_NasdaqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_NasdaqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329250202136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TaxBenefitPercentage', window );">Tax benefit percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt securities</a></td>
<td class="nump">$ 29,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_TaxBenefitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax benefit percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_TaxBenefitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329157693240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and electronic equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and electronic equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and lab equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and lab equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Equipment and machinery [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Equipment and machinery [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold Improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription', window );">Property and equipment, percentage</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150731096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value - Fair Value [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 29,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LongTermMarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">89,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">119,608<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term loan</a></td>
<td class="nump">3,796<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent short term earnout liability</a></td>
<td class="nump">42,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Contingent long-term earnout liability</a></td>
<td class="nump">5,814<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">52,081<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LongTermMarketableSecurities', window );">Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term loan</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent short term earnout liability</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Contingent long-term earnout liability</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">29,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LongTermMarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">89,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">119,608<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent short term earnout liability</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Contingent long-term earnout liability</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LongTermMarketableSecurities', window );">Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term loan</a></td>
<td class="nump">3,796<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent short term earnout liability</a></td>
<td class="nump">42,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Contingent long-term earnout liability</a></td>
<td class="nump">5,814<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 52,081<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span>As of&#160;</span>December
31, 2021,&#160;<span>approximately $29,697 thousand of debt securities were classified under &#8220;Cash
and Cash equivalents&#8221; in the consolidated balance sheets as such securities met all applicable classification criteria.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span>Since the loan was
originated in September 2021, the fair value of the long term loan approximates its carrying value.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LongTermMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LongTermMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150016184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination and Other Transaction (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 04, 2021</div></th>
<th class="th"><div>Nov. 03, 2021</div></th>
<th class="th"><div>Nov. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsLineItems', window );"><strong>Business Combination and Other Transaction (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ServicePeriodsDecription', window );">Service periods, decription</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Out of which $315 thousand was allocated to the purchase consideration and $970&#160;thousand was allocated to future services and continued
employment and shall be expensed over remaining service periods of up to 4 years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total consideration</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PurchaseConsideration', window );">Purchase consideration</a></td>
<td class="nump">$ 970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesNetOfInterestExpense', window );">Amounts of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NetLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxAILtdMember', window );">Nanox AI Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsLineItems', window );"><strong>Business Combination and Other Transaction (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares issued (in Shares)</a></td>
<td class="nump">3,249,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_EmployeeOptionsAndRestrictedStockUnits', window );">Employee options and restricted stock units (in Shares)</a></td>
<td class="nump">70,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Estimated fair value</a></td>
<td class="nump">$ 88,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OutstandingSharesPerShare', window );">Outstanding shares per share (in Dollars per share)</a></td>
<td class="nump">$ 26.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredClosingConsideration', window );">Deferred closing consideration</a></td>
<td class="nump">$ 3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AdditionalConsideration', window );">Additional consideration</a></td>
<td class="nump">$ 77,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_MaximumAggregateAmount', window );">Maximum aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FairValuePercentage', window );">Fair value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DescriptionOfNetAssets', window );">Description of net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The allocation of the purchase price to net assets acquired and liability
assumed resulted in the recognition of intangible asset related to technology of $27,316 thousand which will be expensed over remaining
service periods of 10 years, Image Big Data of $52,500 thousand which will be expensed over remaining service periods of 10 years, and
goodwill of $51,243 thousand, which is primarily attributed to the expected synergies from combining the operations of Zebra&#8217;s AI
solutions with the Company tomographic imaging systems. As such, the goodwill will be assigned to the operational segment of AI solutions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AcquisitionDate', window );">Acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxAILtdMember', window );">Nanox AI Ltd [Member] | Business Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsLineItems', window );"><strong>Business Combination and Other Transaction (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">General and administration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember', window );">USARAD Holding Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsLineItems', window );"><strong>Business Combination and Other Transaction (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_MaximumAggregateAmount', window );">Maximum aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AcquisitionDate', window );">Acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AcquisitionOfSharesPercentage', window );">Acquisition of shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PurchaseOfSharesPercentage', window );">Purchase of shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OrdinaryShare', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OtherOperationalPerformancebasedEarnoutsOver', window );">Other operational performance-based earnouts over</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AdditionalCashConsideration', window );">Additional cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Stock consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OtherRevenue', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OtherNetLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SettledInCashPercentage', window );">Settled in cash percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.52%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuanceOfOrdinarySharePercentage', window );">Issuance of ordinary share percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AdditionalPayment', window );">Additional payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedIntangibleAssetDescription', window );">Intangible asset, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The allocation of the purchase price
to net assets acquired and liability assumed resulted in the recognition of intangible asset related to retained radiologists of $17,770
thousand, customers&#8217; relationship of $1,322 thousand, trademark of $2,095 thousand and goodwill of $7,055 thousand. As such, the
goodwill will be assigned to the operational segment of radiology services. The intangible asset relates to retained radiologists has
a useful-life of 11.17 years, the intangible asset relates to customers&#8217; relationship has a useful-life of 6.17 years and the intangible
asset relates to the trademark has a useful-life of 12.17 years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FairValueOfContingentConsiderationLiabilities', window );">Fair value of contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_InterestAccruesRate', window );">Interest accrues rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LoanTerm', window );">Loan term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember', window );">USARAD Holding Inc. [Member] | PPP Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsLineItems', window );"><strong>Business Combination and Other Transaction (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PrincipalAmountOfThePPPLoan', window );">Principal amount of the PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember', window );">USARAD Holding Inc. [Member] | Business Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsLineItems', window );"><strong>Business Combination and Other Transaction (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">General and administration expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_MDWEBLLCMember', window );">MDWEB LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsLineItems', window );"><strong>Business Combination and Other Transaction (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AssetsAcquisitionDescription', window );">Assets acquisition, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company issued 64,715 of its ordinary
shares to MDWEB with an estimated fair value of $1,500 thousand. In addition, upon the successful achievement of certain milestones related
to technical integration of MDW platform with Nanox Cloud and achieving certain other operational targets, the Company will pay additional
stock consideration in the amount of up to $1,500 thousand at a per share value determined by the average closing price of the 30 trading
days ending on the applicable milestone&#8217;s achievement date. In addition, upon the successful achievement of certain milestones and
other operational performance-based earnouts over 2 years, the Company will pay stock consideration in the amount of up to $1,500 thousand
at a per share value determined by the average closing price of : (i) closing price of the 30 trading days ending on the applicable milestone&#8217;s
achievement date: and (ii) the volume weighted average closing share price of the 30 trading days prior to the closing date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Intangible assets on straight-line basis over expected useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AcquisitionOfSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of shares percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AcquisitionOfSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AdditionalCashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional cash consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AdditionalCashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AdditionalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AdditionalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AdditionalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AdditionalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AssetsAcquisitionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AssetsAcquisitionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_BusinessCombinationandOtherTransactionDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_BusinessCombinationandOtherTransactionDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredClosingConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred closing consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredClosingConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DescriptionOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DescriptionOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_EmployeeOptionsAndRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee options and restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_EmployeeOptionsAndRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_FairValueOfContingentConsiderationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_FairValueOfContingentConsiderationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_FairValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_FairValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_InterestAccruesRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest accrues rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_InterestAccruesRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuanceOfOrdinarySharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary share percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuanceOfOrdinarySharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LoanTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LoanTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_MaximumAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_MaximumAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OrdinaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OrdinaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OtherNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of net loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OtherNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OtherOperationalPerformancebasedEarnoutsOver">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other operational performance-based earnouts over.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OtherOperationalPerformancebasedEarnoutsOver</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OutstandingSharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Outstanding shares per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OutstandingSharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PrincipalAmountOfThePPPLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount of the PPP Loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PrincipalAmountOfThePPPLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PurchaseOfSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of shares percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PurchaseOfSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ServicePeriodsDecription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Service periods, decription</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ServicePeriodsDecription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SettledInCashPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settled in cash percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SettledInCashPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedIntangibleAssetDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the finite or indefinite-lived intangible asset (excluding goodwill) that is impaired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedIntangibleAssetDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesNetOfInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income after deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesNetOfInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxAILtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_NanoxAILtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=nnox_BusinessAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=nnox_BusinessAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nnox_PPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nnox_PPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_MDWEBLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_MDWEBLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150876008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxAILtdMember', window );">Nanox AI Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems', window );"><strong>Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness', window );">Cash payments</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">88,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent short term earnout liability</a></td>
<td class="nump">38,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Contingent long term earnout liability</a></td>
<td class="nump">2,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationAsset', window );">Total consideration</a></td>
<td class="nump">129,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember', window );">USARAD Holding Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems', window );"><strong>Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness', window );">Cash payments</a></td>
<td class="nump">7,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares</a></td>
<td class="nump">11,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Contingent consideration at estimated fair value</a></td>
<td class="nump">6,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationAsset', window );">Total consideration</a></td>
<td class="nump">$ 25,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6411-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxAILtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_NanoxAILtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159222600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxAILtdMember', window );">Nanox AI Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems', window );"><strong>Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and Restricted Cash</a></td>
<td class="nump">$ 6,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts Receivables</a></td>
<td class="nump">99<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">430<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Intangible assets</a></td>
<td class="nump">79,816<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">51,243<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TotalAssetsAcquired', window );">Total assets acquired</a></td>
<td class="nump">140,237<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="nump">3,413<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ContingentShortTermEarnoutLiability', window );">Contingent short term earnout liability</a></td>
<td class="nump">38,129<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ContingentLongtermEarnoutLiability', window );">Contingent long-term earnout liability</a></td>
<td class="nump">2,660<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ConvertibleNote', window );">Convertible note</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other labilities</a></td>
<td class="nump">4,525<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">51,727<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NetAssetsAcquired', window );">Net assets acquired</a></td>
<td class="nump">88,510<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember', window );">USARAD Holding Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems', window );"><strong>Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts Receivables</a></td>
<td class="nump">912<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Intangible assets</a></td>
<td class="nump">21,187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,055<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TotalAssetsAcquired', window );">Total assets acquired</a></td>
<td class="nump">29,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Loan from a government agency</a></td>
<td class="nump">144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="nump">3,766<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ContingentShortTermEarnoutLiability', window );">Contingent short term earnout liability</a></td>
<td class="nump">3,453<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ContingentLongTermEarnoutLiability', window );">Contingent long term earnout liability</a></td>
<td class="nump">2,952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other labilities</a></td>
<td class="nump">557<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">10,872<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NetAssetsAcquired', window );">Net assets acquired</a></td>
<td class="nump">18,647<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 332<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">A 3 years Convertible Loan Agreement, dated August 9, 2021 between the Company and Nanox AI in the amount of $3 million, which bears an annual interest of 6% and shall be automatically converted into the Nanox AI&#8217;s Preferred C Shares, at a price per share of $23.42. This loan is eliminated in the Consolidated financial statements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ContingentLongTermEarnoutLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent long term earnout liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ContingentLongTermEarnoutLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ContingentLongtermEarnoutLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent long-term earnout liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ContingentLongtermEarnoutLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ContingentShortTermEarnoutLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent short term earnout liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ContingentShortTermEarnoutLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of convertible note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NetAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net assets acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NetAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_TotalAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_TotalAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxAILtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_NanoxAILtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_USARADHoldingIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329161677928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination and Other Transaction (Details) - Schedule of acquisition of Nanox AI - Nanox AI Ltd [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedStatementOfIncomeCaptionsLineItems', window );"><strong>Condensed Statement of Income Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 2,363<span></span>
</td>
<td class="nump">$ 1,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (87,045)<span></span>
</td>
<td class="num">$ (69,875)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedStatementOfIncomeCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedStatementOfIncomeCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=nnox_NanoxAILtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=nnox_NanoxAILtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329151118888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill &amp; Intangible Assets, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill &amp; Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue', window );">Estimated fair value</a></td>
<td class="nump">$ 101,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FilmMonetizedOnItsOwnAmortizationExpense', window );">Amortization Expense</a></td>
<td class="nump">$ 1,768<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FilmMonetizedOnItsOwnAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for capitalized film cost for film predominantly monetized on its own.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=SL120155244-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FilmMonetizedOnItsOwnAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329149926232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill &amp; Intangible Assets, Net (Details) - Schedule of goodwill and the intangible assets - Goodwill [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">58,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_GoodwillMember', window );">Zebra [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill from acquisition</a></td>
<td class="nump">51,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_GoodwillMember', window );">USARAD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill from acquisition</a></td>
<td class="nump">$ 7,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nnox_ZebraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nnox_ZebraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=nnox_USARADMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=nnox_USARADMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150764600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill &amp; Intangible Assets, Net (Details) - Schedule of intangible assets<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FiniteLivedIntangibleAssetNet', window );">Amount as of the merger/ acquisition date</a></td>
<td class="nump">$ 103,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AmortizationExpenseForThePeriod', window );">Amortization expense for the period</a></td>
<td class="nump">1,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Amount as of December 31, 2021</a></td>
<td class="nump">$ 101,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FiniteLivedIntangibleAssetNet', window );">Amount as of the merger/ acquisition date</a></td>
<td class="nump">$ 27,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AmortizationExpenseForThePeriod', window );">Amortization expense for the period</a></td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Amount as of December 31, 2021</a></td>
<td class="nump">$ 26,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nnox_ImageBigDataMember', window );">Image big data [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FiniteLivedIntangibleAssetNet', window );">Amount as of the merger/ acquisition date</a></td>
<td class="nump">$ 52,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AmortizationExpenseForThePeriod', window );">Amortization expense for the period</a></td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Amount as of December 31, 2021</a></td>
<td class="nump">$ 51,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember', window );">Market platform [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in Years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FiniteLivedIntangibleAssetNet', window );">Amount as of the merger/ acquisition date</a></td>
<td class="nump">$ 2,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AmortizationExpenseForThePeriod', window );">Amortization expense for the period</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Amount as of December 31, 2021</a></td>
<td class="nump">$ 2,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nnox_RadiologistRelationshipsMember', window );">Radiologist relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in Years)</a></td>
<td class="text">11 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FiniteLivedIntangibleAssetNet', window );">Amount as of the merger/ acquisition date</a></td>
<td class="nump">$ 17,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AmortizationExpenseForThePeriod', window );">Amortization expense for the period</a></td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Amount as of December 31, 2021</a></td>
<td class="nump">$ 17,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in Years)</a></td>
<td class="text">12 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FiniteLivedIntangibleAssetNet', window );">Amount as of the merger/ acquisition date</a></td>
<td class="nump">$ 2,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AmortizationExpenseForThePeriod', window );">Amortization expense for the period</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Amount as of December 31, 2021</a></td>
<td class="nump">$ 2,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Life (in Years)</a></td>
<td class="text">6 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FiniteLivedIntangibleAssetNet', window );">Amount as of the merger/ acquisition date</a></td>
<td class="nump">$ 1,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AmortizationExpenseForThePeriod', window );">Amortization expense for the period</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Amount as of December 31, 2021</a></td>
<td class="nump">$ 1,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AmortizationExpenseForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization expense for the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AmortizationExpenseForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_FiniteLivedIntangibleAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_FiniteLivedIntangibleAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nnox_ImageBigDataMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nnox_ImageBigDataMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_MarketingRelatedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nnox_RadiologistRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=nnox_RadiologistRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329161514680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill &amp; Intangible Assets, Net (Details) - Schedule of Amortization of intangible assets for each of the next five years and thereafter<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract', window );"><strong>Schedule of Amortization of intangible assets for each of the next five years and thereafter [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2022</a></td>
<td class="nump">$ 10,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2023</a></td>
<td class="nump">10,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2024</a></td>
<td class="nump">10,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2025</a></td>
<td class="nump">10,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2026 and thenafter</a></td>
<td class="nump">59,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 101,826<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329149962184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfOtherAssets1', window );">Purchase of land</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfOtherAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid to purchase other assets as part of operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPurchaseOfOtherAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329157667928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_ComputersAndElectronicEquipmentMember', window );">Computers and electronic equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems', window );"><strong>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PercentageOfPropertyPlantAndEquipment', window );">Percentage of property plant and equipment</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_ComputersAndElectronicEquipmentMember', window );">Computers and electronic equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems', window );"><strong>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PercentageOfPropertyPlantAndEquipment', window );">Percentage of property plant and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and lab equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems', window );"><strong>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PercentageOfPropertyPlantAndEquipment', window );">Percentage of property plant and equipment</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and lab equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems', window );"><strong>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PercentageOfPropertyPlantAndEquipment', window );">Percentage of property plant and equipment</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems', window );"><strong>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PercentageOfPropertyPlantAndEquipment', window );">Percentage of property plant and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machines [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems', window );"><strong>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PercentageOfPropertyPlantAndEquipment', window );">Percentage of property plant and equipment</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machines [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems', window );"><strong>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PercentageOfPropertyPlantAndEquipment', window );">Percentage of property plant and equipment</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems', window );"><strong>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PercentageOfPropertyPlantAndEquipment', window );">Percentage of property plant and equipment</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems', window );"><strong>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PercentageOfPropertyPlantAndEquipment', window );">Percentage of property plant and equipment</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PercentageOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PercentageOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_ComputersAndElectronicEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_ComputersAndElectronicEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159201512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - Schedule of property and equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 38,303<span></span>
</td>
<td class="nump">$ 14,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(868)<span></span>
</td>
<td class="num">(344)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">37,435<span></span>
</td>
<td class="nump">14,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_OfficeFurnitureAndLabEquipmentMember', window );">Office furniture and lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">648<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_ComputersAndElectronicEquipmentMember', window );">Computers and electronic equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Equipment and machinery [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">2,766<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">132<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">6,314<span></span>
</td>
<td class="nump">6,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_ProductionLineInConstructionMember', window );">Production line in construction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 26,790<span></span>
</td>
<td class="nump">$ 5,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_OfficeFurnitureAndLabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_OfficeFurnitureAndLabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_ComputersAndElectronicEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_ComputersAndElectronicEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_ProductionLineInConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nnox_ProductionLineInConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329161739192">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Schedule of reconciliation of cash, cash equivalents and restricted cash [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 66,645<span></span>
</td>
<td class="nump">$ 213,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RestrictedBankDeposit', window );">Restricted bank deposit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">127<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 66,772<span></span>
</td>
<td class="nump">$ 213,784<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of December&#160;31, 2021, the Company&#8217;s restricted
cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit is presented at cost including accrued
interest. This bank deposit is used as security for credit card use and collateralizing the Company&#8217;s lease contracts</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RestrictedBankDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RestrictedBankDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329157737800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent payment</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LeaseTermDescription', window );">Rent payment agreement, description</a></td>
<td class="text">During November 2020the Company signed an additional lease agreement,
for leasing another office complex through June 30, 2023.<span></span>
</td>
<td class="text">During
June 2020, the Company entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
December 31,2021, the Company exercised its option to extend the lease for additional period of 24 months.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LeasesTermDescription', window );">Vehicles lease, description</a></td>
<td class="text">The
lease agreement is effective through June 30, 2023 and the monthly payment for this agreement is approximately $12 thousand.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_VehiclesLeasePayments', window );">Vehicle lease payment</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment for agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription', window );">Fabrication facility and research developmental center description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In 2021 Nanox Korea leased approximately
390 square meters of space for a temporary fabrication facility and approximately 200 square meters of space for a research and development
center in Korea.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">management fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fabrication facility and research developmental center description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LeaseTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LeaseTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LeasesTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement term, description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LeasesTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_VehiclesLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vehicle lease Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_VehiclesLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159133816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of company's total lease costs - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OperatingLeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Fixed payments</a></td>
<td class="nump">$ 653<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TotalOperatingLeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 701<span></span>
</td>
<td class="nump">$ 341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OperatingLeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OperatingLeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_TotalOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_TotalOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329154400248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental cash flow information related to operating leases - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 507<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations (non-cash):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329242292968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of supplemental balance sheet information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OperatingLeasesAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,725<span></span>
</td>
<td class="nump">$ 1,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CurrentMaturitiesOfOperatingLeases', window );">Current maturities of operating leases</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NoncurrentOperatingLeases', window );">Non-current operating leases</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,831<span></span>
</td>
<td class="nump">$ 1,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 1 month 20 days<span></span>
</td>
<td class="text">2 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">5.83%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CurrentMaturitiesOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CurrentMaturitiesOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NoncurrentOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NoncurrentOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329154627384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of operating lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract', window );"><strong>Schedule of maturities of operating lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">$ 961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours', window );">2024</a></td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter', window );">2025 and thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">1,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PresentValueOfLeaseLiabilities', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PresentValueOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PresentValueOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159013624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Revenue (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredRevenuesDisclosureAbstract', window );"><strong>Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 415<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredRevenuesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredRevenuesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329161677768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue (Details) - Schedule of Deferred Revenue<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfDeferredRevenueAbstract', window );"><strong>Schedule of Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Balance at December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncreaseDueToTheBusinessCombinations', window );">Increase due to the business combinations</a></td>
<td class="nump">483<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredRevenuesTotal', window );">Change in deferred revenue</a></td>
<td class="nump">179<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Balance at December 31, 2021</a></td>
<td class="nump">$ 662<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $415 thousand under long term deferred revenue in the Company&#8217;s consolidated balance sheets as of December 31, 2021.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredRevenuesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenues Total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredRevenuesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IncreaseDueToTheBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase due to the business combinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IncreaseDueToTheBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329153648040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2021</div></th>
<th class="th"><div>May 17, 2017</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Related party liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Private office space (in Square Meters) | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PaysApproximately', window );">pays approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncome', window );">Relation to sub lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">$ 163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_EmploymentAgreementDescription', window );">Employment Agreement description</a></td>
<td class="text">the Company and
Erez Meltzer entered into an employment agreement, pursuant to which Mr. Meltzer agreed to serve as the Company&#8217;s new Chief Executive
Officer (&#8220;The Meltzer Employment Agreement&#8221;). The Meltzer Employment Agreement commenced and became effective as of January
1, 2022 and shall continue for an indefinite period until it is terminated by either party. Pursuant to the terms of the Meltzer Employment
Agreement, Mr. Meltzer will receive an annual base salary of nine hundred thousand dollars ($900) per year, and will be eligible for an
annual incentive payment of up to one hundred percent (100%) of his base salary, which of them $450 will be guaranteed for the 2022 fiscal
year if his employment is continued through the entire fiscal year, with the possibility to withdraw an advance payment on account of
the 2022 annual bonus, subject to full recourse (clawback) if the bonus is not earned; Mr. Meltzer will be entitled to customary social
benefits under Israeli law and practice pursuant to which the Company shall insure the CEO with a manager&#8217;s insurance policy or
a pension fund, or a combination of both (whereby each will apply partially), all according to his election; &#160;Mr. Meltzer will be
granted options to purchase 300,000 Ordinary Shares (the &#8220;Options&#8221;) which will vested equally over a period of 48 months as
long as Mr. Melter will be employed by the Company. The Options shall be subject to the Company&#8217;s 2019 Equity Incentive plan and,
to the extent possible, be granted pursuant to Section 102 of the Israeli Income Tax Ordinance, 5721-1961. The exercise price of the Options
shall be $23.84 per share, a share price equals to the 30-day average of the Company&#8217;s share price on NASDAQ, prior to the date
of approval of the CEO&#8217;s employment agreement by the Board on September 27, 2021. Such amount may be paid by the CEO by way of a
cashless exercise mechanism; The agreement calls for a 6 months&#8217; mutual notice of termination and 270 days if the Company provides
notice during the first year of employment (except for &#8220;Cause&#8221; as defined in the employment agreement, in which case no prior
notice will be required);<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UtilitiesOperatingExpenseProductsAndServices', window );">Services amount for per hour</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Loan expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromDepositOnLoan', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Gross monthly base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Gross monthly base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AgreementAxis=nnox_SharePurchaseAgreementMember', window );">Share purchase agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Share purchase agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During January 2020, subject to entering into a share purchase
agreement in the aggregate amount of at least $6 million, and a pre-money valuation of more than $100 million, the Company&#8217;s Board approved
the issuance and allotment of 1,109,245 ordinary shares to Nanox PLC with the purchase price of $12.00 per share, which reflects a discount
of 25% from the price of the last financing round of the Company. As a result, on January 30, 2020 the related party liability was settled
into equity<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxPLCMember', window );">Nanox PLC [Member] | Nanox Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Direct expenses percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expense amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior completion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_SixAIMember', window );">SixAI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expense amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">$ 355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_WellseseTechnologiesLtdMember', window );">Wellsese Technologies Ltd.[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsLineItems', window );"><strong>Related Parties (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncome', window );">Relation to sub lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_EmploymentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of employment agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_EmploymentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PaysApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PaysApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartiesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartiesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromDepositOnLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow from resulting from payment, receipt or drawdown of cash deposit to guarantee a loan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3095-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromDepositOnLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UtilitiesOperatingExpenseProductsAndServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense for products and services of regulated operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UtilitiesOperatingExpenseProductsAndServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AgreementAxis=nnox_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AgreementAxis=nnox_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxPLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_NanoxPLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_NanoxJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nnox_NanoxJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_SixAIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_SixAIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_WellseseTechnologiesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_WellseseTechnologiesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329157575368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties (Details) - Schedule of related party - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems', window );"><strong>Related Parties (Details) - Schedule of related party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TotalDueFromRelatedParties', window );">Total Due from related parties</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_DueToMember', window );">Due to [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems', window );"><strong>Related Parties (Details) - Schedule of related party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TotalDueFromRelatedParties', window );">Total Due from related parties</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_DueToOneMember', window );">Due to One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems', window );"><strong>Related Parties (Details) - Schedule of related party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TotalDueFromRelatedParties', window );">Total Due from related parties</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_DueToTwoMember', window );">Due to Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems', window );"><strong>Related Parties (Details) - Schedule of related party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TotalDueFromRelatedParties', window );">Total Due from related parties</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_DueToThreeMember', window );">Due to Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems', window );"><strong>Related Parties (Details) - Schedule of related party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TotalDueFromRelatedParties', window );">Total Due from related parties</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_TotalDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Due from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_TotalDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_DueToMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_DueToMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_DueToOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_DueToOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_DueToTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_DueToTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_DueToThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_DueToThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329161485944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - Schedule of related parties transactions - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfRelatedPartiesTransactionsAbstract', window );"><strong>Schedule of related parties transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development &#8211; see d below</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OtherGeneralAndAdministrativeExpenses', window );">General and administrative &#8211; See c, e and f below</a></td>
<td class="num">$ (191)<span></span>
</td>
<td class="num">$ (167)<span></span>
</td>
<td class="nump">$ 5,824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OtherGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OtherGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfRelatedPartiesTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfRelatedPartiesTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159962024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Loan (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Loan agreement term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Loan amount</a></td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AnnualInterestRate', window );">Annual interest rate</a></td>
<td class="nump">1.149%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AnnualInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AnnualInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329149918168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 28, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ConsultingFees', window );">Consulting fees</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_EntitlementToWarrantsAmount', window );">Entitlement to warrants amount</a></td>
<td class="nump">$ 29.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_EntitlementToWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entitlement to warrants amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_EntitlementToWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150633016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 03, 2019</div></th>
<th class="th"><div>Oct. 26, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DescriptionOfSharebasedCompensationExpenses', window );">Description of share-based compensation expenses</a></td>
<td class="text">Pursuant
to the Plan (and further increase of option pool approved by the Board), 8,041,936 ordinary shares of NIS 0.01 par value of the Company
are reserved for issuance upon the exercise of the same amount of awards to be granted to some of the Company&#8217;s employees, directors
and consultants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,841,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Awards were exercised on a cashless</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,704<span></span>
</td>
<td class="nump">1,027,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Employees, officers awards to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,418,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Average exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_VestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Awards agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AgreementTerminateTerm', window );">Agreement terminate term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted employees shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,319<span></span>
</td>
<td class="nump">1,327,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableNoncurrent', window );">Plus VAT (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_PurchaseAggregateShares', window );">Purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_RecordedAnExpense', window );">Recorded expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted employees shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ConsiderationForServicesShares', window );">Consideration for services shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AgreementTerminateTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement terminate term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AgreementTerminateTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ConsiderationForServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration for services shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ConsiderationForServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DescriptionOfSharebasedCompensationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DescriptionOfSharebasedCompensationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_PurchaseAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase aggregate shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_PurchaseAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_RecordedAnExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recorded an expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_RecordedAnExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_VestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_VestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due after one year of the balance sheet date (or one operating cycle), if longer of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329155271016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of issued and outstanding - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of issued and outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OrdinarySharesIssuedAndOutstanding', window );">Issued and Outstanding</a></td>
<td class="nump">51,791,441<span></span>
</td>
<td class="nump">46,100,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of issued and outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_OrdinarySharesIssuedAndOutstanding', window );">Issued and Outstanding</a></td>
<td class="nump">51,791,441<span></span>
</td>
<td class="nump">46,100,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_OrdinarySharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_OrdinarySharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329149869672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of share-based awards to employees, officers and directors - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract', window );"><strong>Schedule of share-based awards to employees, officers and directors [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share-based payment awards, Outstanding at beginning of year</a></td>
<td class="nump">3,372,626<span></span>
</td>
<td class="nump">3,410,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at beginning of year</a></td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ChangesDuringTheYearAbstract', window );"><strong>Changes during the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share-based payment awards, Granted</a></td>
<td class="nump">180,319<span></span>
</td>
<td class="nump">1,327,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 40.12<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of share-based payment awards, Exercised</a></td>
<td class="num">(1,043,142)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">$ 7.66<span></span>
</td>
<td class="nump">$ 8.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of share-based payment awards, Forfeited</a></td>
<td class="num">(118,954)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">$ 10.18<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of share-based payment awards, Expired</a></td>
<td class="num">(66,606)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="nump">$ 16.37<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of share-based payment awards, Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(98,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price. Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear', window );">Number of share-based payment awards, Outstanding at end of year</a></td>
<td class="nump">2,324,243<span></span>
</td>
<td class="nump">3,372,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at end of year</a></td>
<td class="nump">$ 6.17<span></span>
</td>
<td class="nump">$ 5.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share-based payment awards, Exercisable at end of year</a></td>
<td class="nump">1,618,777<span></span>
</td>
<td class="nump">2,191,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable at end of year</a></td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="nump">$ 5.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ChangesDuringTheYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ChangesDuringTheYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share-based payment awards, Outstanding at end of year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150647832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">50.27%<span></span>
</td>
<td class="nump">57.34%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Contractual term (years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">52.71%<span></span>
</td>
<td class="nump">44.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Contractual term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_BlackScholesOptionpricingMember', window );">Black- Scholes option-pricing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Contractual term (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_BlackScholesOptionpricingMember', window );">Black- Scholes option-pricing [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">50.27%<span></span>
</td>
<td class="nump">45.11%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_BlackScholesOptionpricingMember', window );">Black- Scholes option-pricing [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">51.84%<span></span>
</td>
<td class="nump">55.97%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nnox_BlackScholesOptionpricingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nnox_BlackScholesOptionpricingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329147511208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | 2.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">1,130,143<span></span>
</td>
<td class="nump">1,995,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 11 months 12 days<span></span>
</td>
<td class="text">9 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,019,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | 16.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">88,500<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 5 months 23 days<span></span>
</td>
<td class="text">9 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | 17.63 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">1,421,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | 17.63 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 17.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | 17.63 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">64.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | 26.56 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | 26.56 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 1.92 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">192,927<span></span>
</td>
<td class="nump">269,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">14 days<span></span>
</td>
<td class="text">1 year 2 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="nump">192,927<span></span>
</td>
<td class="nump">269,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 2.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">1,769,513<span></span>
</td>
<td class="nump">2,191,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
<td class="text">6 years 2 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="nump">1,288,236<span></span>
</td>
<td class="nump">1,188,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 16.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">161,484<span></span>
</td>
<td class="nump">444,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">5 years 5 months 4 days<span></span>
</td>
<td class="text">8 years 10 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="nump">114,477<span></span>
</td>
<td class="nump">283,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 23.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 23.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">9 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 23.84 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 23.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">9 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 30.93 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 30.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">8 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 30.66 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 30.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">9 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 40.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 40.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">17,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">9 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="nump">3,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 49.68 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 49.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">9 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 0.01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | 18.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Non-employees [Member] | One Point Zero Zero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number of awards outstanding at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember', window );">Awards outstanding [Member] | Maximum [Member] | 26.56 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="nump">73,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | 2.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="nump">716,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | 16.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="nump">35,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | 17.63 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">8 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of awards exercisable at end of year</a></td>
<td class="nump">19,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 1.92 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 2.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 16.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 23.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 23.84 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 30.93 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">8 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 30.66 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 40.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">9 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 49.68 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 0.01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | 18.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember', window );">Awards exercisable [Member] | Non-employees [Member] | One Point Zero Zero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nnox_AwardsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_TwoPointTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_TwoPointTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_SixteenPointZeroZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_SixteenPointZeroZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_SeventeenPointSixtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_SeventeenPointSixtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_TwentSixPointFiveSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_TwentSixPointFiveSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_NonemployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_NonemployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_OneNinetyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_OneNinetyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_TwoTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_TwoTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_OneSixZeroZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_OneSixZeroZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_twentythreeAndNineteenHundredthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_twentythreeAndNineteenHundredthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_twentythreeAndEightyfourHundredthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_twentythreeAndEightyfourHundredthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ThirtyPointNineThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ThirtyPointNineThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_thirtyAndSixtysixHundredthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_thirtyAndSixtysixHundredthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_fortyAndTwentyoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_fortyAndTwentyoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_FortynineAndSixtyeightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_FortynineAndSixtyeightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ZeroPointZeroZeroOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_ZeroPointZeroZeroOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_OneEightZeroZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_OneEightZeroZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_OnePointZeroZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=nnox_OnePointZeroZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nnox_AwardsExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329153608248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of shared - based payments to employees - Non-employees [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of shared - based payments to employees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share-based payment awards, Outstanding at beginning of year</a></td>
<td class="nump">2,381,125<span></span>
</td>
<td class="nump">1,667,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices', window );">Weighted average exercise price, Outstanding at beginning of year</a></td>
<td class="nump">$ 4.14<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share-based payment awards, Granted</a></td>
<td class="nump">1,418,665<span></span>
</td>
<td class="nump">730,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">$ 27.57<span></span>
</td>
<td class="nump">$ 13.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance', window );">Number of share-based payment awards, Issued due to business combination</a></td>
<td class="nump">117,536<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IssuedDueToBusinessCombination', window );">Issued due to business combination</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of share-based payment awards, Exercised</a></td>
<td class="num">(837,724)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Weighted average exercise price Exercised</a></td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited', window );">Number of share-based payment awards, Forfeited</a></td>
<td class="num">(318,672)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">$ 19.69<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of share-based payment awards, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_NumberOfSharebasedPaymentAwardsCancelled', window );">Number of share-based payment awards, Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(16,876)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of share-based payment awards, Outstanding at end of year</a></td>
<td class="nump">2,760,930<span></span>
</td>
<td class="nump">2,381,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices', window );">Weighted average exercise price, Outstanding at end of year</a></td>
<td class="nump">$ 15.85<span></span>
</td>
<td class="nump">$ 4.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of share-based payment awards, Exercisable at end of year</a></td>
<td class="nump">845,356<span></span>
</td>
<td class="nump">1,061,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_WeightedAverageExercisePriceExercisableAtEndOfYear', window );">Weighted average exercise price, Exercisable at end of year</a></td>
<td class="nump">$ 3.58<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IssuedDueToBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issued due to business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IssuedDueToBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_NumberOfSharebasedPaymentAwardsCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_NumberOfSharebasedPaymentAwardsCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_WeightedAverageExercisePriceExercisableAtEndOfYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_WeightedAverageExercisePriceExercisableAtEndOfYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=nnox_NonemployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=nnox_NonemployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329161335208">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of share-based compensation expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfShareBasedCompensationExpensesAbstract', window );"><strong>Schedule of share-based compensation expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostOfOperatingRevenue', window );">Cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 51<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,248<span></span>
</td>
<td class="nump">3,384<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSellingAndMarketingExpense', window );">Sales and Marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,442<span></span>
</td>
<td class="nump">9,252<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,065<span></span>
</td>
<td class="nump">12,145<span></span>
</td>
<td class="nump">14,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Share-based compensation expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18,806<span></span>
</td>
<td class="nump">$ 24,781<span></span>
</td>
<td class="nump">$ 16,245<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On October 26, 2020, the Company entered into an amendment to a business development agreement (&#8220;the Agreement&#8221;) dated February 4, 2020 with two service providers pursuant to which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company&#8217;s systems and the issuance of warrants.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfShareBasedCompensationExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfShareBasedCompensationExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostOfOperatingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other costs incurred during the reporting period related to other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostOfOperatingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling and marketing expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150589832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance (in Dollars)</a></td>
<td class="nump">$ 12,882<span></span>
</td>
<td class="nump">$ 8,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegulatoryAssetAxis=us-gaap_DeferredFuelCostsMember', window );">Deferred Taxes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance (in Dollars)</a></td>
<td class="nump">$ 12,882<span></span>
</td>
<td class="nump">8,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Carry forward loss (in Dollars)</a></td>
<td class="nump">$ 56,300<span></span>
</td>
<td class="nump">$ 32,300<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Tax credits</a></td>
<td class="nump">61.90%<span></span>
</td>
<td class="nump">45.30%<span></span>
</td>
<td class="nump">17.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FederalTaxRatePercentage', window );">Federal tax rate percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">Korea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Carry forward loss (in Dollars)</a></td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Tax credits</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CarryForwardLossYears', window );">Carry forward loss years</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">Korea [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">Korea [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsLineItems', window );"><strong>Income Tax (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">33.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CarryForwardLossYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carry forward loss years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CarryForwardLossYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_FederalTaxRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal tax rate percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_FederalTaxRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IncomeTaxDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IncomeTaxDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAssetAxis=us-gaap_DeferredFuelCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAssetAxis=us-gaap_DeferredFuelCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329147500840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Details) - Schedule of income (loss) before income taxes consisted - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_IncomelossBeforeIncomeTaxesMember', window );">Income (loss) Before Income Taxes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems', window );"><strong>Income Tax (Details) - Schedule of income (loss) before income taxes consisted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic (Israel)</a></td>
<td class="num">$ (56,609)<span></span>
</td>
<td class="num">$ (43,449)<span></span>
</td>
<td class="num">$ (22,588)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(5,237)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td>
<td class="num">(61,846)<span></span>
</td>
<td class="num">(43,815)<span></span>
</td>
<td class="num">(22,563)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_IncomeTaxExpensesMember', window );">Income Tax Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems', window );"><strong>Income Tax (Details) - Schedule of income (loss) before income taxes consisted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic (Israel)</a></td>
<td class="num">(57)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">9<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expenses</a></td>
<td class="num">(48)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_TaxesOnIncomeMember', window );">Taxes on Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems', window );"><strong>Income Tax (Details) - Schedule of income (loss) before income taxes consisted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic (Israel)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">68<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CurrentAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_CurrentTotal', window );">Total</a></td>
<td class="nump">68<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">(57)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="num">(116)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ProvisionForIncomeTaxes', window );">Provision for income taxes</a></td>
<td class="num">$ (48)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_CurrentTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_CurrentTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ProvisionForIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ProvisionForIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_IncomelossBeforeIncomeTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_IncomelossBeforeIncomeTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_IncomeTaxExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_IncomeTaxExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_TaxesOnIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_TaxesOnIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329157680008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Details) - Schedule of reconciliation our theoretical income tax expense to actual income tax expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract', window );"><strong>Schedule of reconciliation our theoretical income tax expense to actual income tax expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before taxes on income</a></td>
<td class="num">$ (61,846)<span></span>
</td>
<td class="num">$ (43,815)<span></span>
</td>
<td class="num">$ (22,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory tax rate in Israel</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax benefit</a></td>
<td class="num">$ (14,225)<span></span>
</td>
<td class="num">$ (10,077)<span></span>
</td>
<td class="num">$ (5,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Effect of different tax rates applicable in foreign jurisdictions</a></td>
<td class="num">(110)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Operating losses and other temporary differences for which valuation allowance was provided</a></td>
<td class="nump">6,174<span></span>
</td>
<td class="nump">7,235<span></span>
</td>
<td class="nump">701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Permanent differences</a></td>
<td class="nump">8,113<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
<td class="nump">4,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome', window );">Actual tax benefit</a></td>
<td class="num">$ (48)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329153609368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Tax (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">$ 30,234<span></span>
</td>
<td class="nump">$ 7,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development</a></td>
<td class="nump">4,010<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Employee and payroll accrued expenses</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">109<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">34,657<span></span>
</td>
<td class="nump">8,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Less deferred tax liabilities</a></td>
<td class="num">(21,775)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">12,882<span></span>
</td>
<td class="nump">8,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LessValuationAllowanceForDeferredTaxAssets', window );">Less valuation allowance for deferred tax assets</a></td>
<td class="num">$ (12,882)<span></span>
</td>
<td class="num">(8,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LessValuationAllowanceForDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LessValuationAllowanceForDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329155269720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Details) - Schedule of valuation allowance provided portion deferred<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract', window );"><strong>Schedule of valuation allowance provided portion deferred [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance, beginning balance</a></td>
<td class="nump">$ 8,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_IncreaseDueToBusinessCombinationinShares', window );">Increase due to business combination</a></td>
<td class="nump">2,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenuePeriodIncreaseDecrease', window );">Increase</a></td>
<td class="nump">1,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance, ending balance</a></td>
<td class="nump">$ 12,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_IncreaseDueToBusinessCombinationinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase due to business combination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_IncreaseDueToBusinessCombinationinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329250199480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segments of Operations (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsLineItems', window );"><strong>Segments of Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Total revenue percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsLineItems', window );"><strong>Segments of Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Total revenue percentage</a></td>
<td class="nump">98.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SegmentsofOperationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SegmentsofOperationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150268472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxARCMember', window );">Nanox ARC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems', window );"><strong>Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment operating loss</a></td>
<td class="num">(56,875)<span></span>
</td>
<td class="num">$ (43,923)<span></span>
</td>
<td class="num">$ (22,571)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">18,433<span></span>
</td>
<td class="nump">24,781<span></span>
</td>
<td class="nump">16,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_RadiologyServicesMember', window );">Radiology Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems', window );"><strong>Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment operating loss</a></td>
<td class="num">(530)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">441<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">37<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_AISolutionsMember', window );">AI Solutions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems', window );"><strong>Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment operating loss</a></td>
<td class="num">(4,153)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">1,393<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">336<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nnox_TotalMember', window );">Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems', window );"><strong>Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Segment operating loss</a></td>
<td class="num">(61,558)<span></span>
</td>
<td class="num">(43,923)<span></span>
</td>
<td class="num">(22,571)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FinancialExpense', window );">Financial expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_FinancialIncome', window );">Financial income</a></td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss before taxes on income</a></td>
<td class="num">(61,846)<span></span>
</td>
<td class="num">(43,815)<span></span>
</td>
<td class="num">(22,563)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">2,292<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">$ 18,806<span></span>
</td>
<td class="nump">$ 24,781<span></span>
</td>
<td class="nump">$ 16,245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_FinancialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of financial expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_FinancialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_FinancialIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of financial income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_FinancialIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_NanoxARCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_NanoxARCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_RadiologyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_RadiologyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_AISolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_AISolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nnox_TotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nnox_TotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329150803880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segments of Operations (Details) - Schedule of property and equipment by geography - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems', window );"><strong>Segments of Operations (Details) - Schedule of property and equipment by geography [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and Equipment</a></td>
<td class="nump">$ 37,435<span></span>
</td>
<td class="nump">$ 14,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems', window );"><strong>Segments of Operations (Details) - Schedule of property and equipment by geography [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and Equipment</a></td>
<td class="nump">3,381<span></span>
</td>
<td class="nump">2,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=currency_KRW', window );">South Korea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems', window );"><strong>Segments of Operations (Details) - Schedule of property and equipment by geography [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and Equipment</a></td>
<td class="nump">33,836<span></span>
</td>
<td class="nump">11,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Unites States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems', window );"><strong>Segments of Operations (Details) - Schedule of property and equipment by geography [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and Equipment</a></td>
<td class="nump">22<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems', window );"><strong>Segments of Operations (Details) - Schedule of property and equipment by geography [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and Equipment</a></td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=currency_KRW">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=currency_KRW</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329149923160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BasicAndDilutedShare', window );">Basic and diluted share</a></td>
<td class="nump">2,505,370<span></span>
</td>
<td class="nump">3,173,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_WarrantsShares', window );">Warrants</a></td>
<td class="nump">4,842,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,548,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_WarrantsOption', window );">Warrants option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,673,104<span></span>
</td>
<td class="nump">3,654,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_BasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and diluted share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_BasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_WarrantsOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares warrants option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_WarrantsOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_WarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shrares warrants shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_WarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329155354120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract', window );"><strong>Schedule of basic loss per share is calculated by dividing the loss attributable to the company&#8217;s owners [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to Company&#8217;s owners</a></td>
<td class="num">$ (61,798)<span></span>
</td>
<td class="num">$ (43,815)<span></span>
</td>
<td class="num">$ (22,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands', window );">The weighted average of the number of ordinary shares (in thousands)</a></td>
<td class="nump">48,216<span></span>
</td>
<td class="nump">35,654<span></span>
</td>
<td class="nump">25,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_BasicAndDilutedLossPerShare', window );">Basic and diluted loss per share</a></td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (0.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_BasicAndDilutedLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_BasicAndDilutedLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140329159087016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 19, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_AdditionalSharesIssued', window );">Additional shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nnox_LeasedAdditionTerm', window );">Leased addition term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_AdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_AdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_LeasedAdditionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_LeasedAdditionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nnox_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nnox_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nnox_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>f20f2021_nanoximaging_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nnox="http://www.nanox.vision.com/20211231"
  xmlns:pf0="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nnox-20211231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:NasdaqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-04</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-04</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nnox:BusinessAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-27</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-02</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:PPPLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">nnox:BusinessAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:USARADHoldingIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:MDWEBLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-11-03</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:MDWEBLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">nnox:NanoxAILtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nnox:ZebraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">nnox:USARADMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:ConsolidatedEntitiesAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nnox:ImageBigDataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nnox:ImageBigDataMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:MarketingRelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nnox:RadiologistRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">nnox:RadiologistRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ComputersAndElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ComputersAndElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:OfficeFurnitureAndLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:OfficeFurnitureAndLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ComputersAndElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ComputersAndElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ProductionLineInConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nnox:ProductionLineInConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2020-06-02</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2020-11-02</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nnox:AgreementAxis">nnox:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:NanoxJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-17</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxPLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nnox:NanoxJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:SixAIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:SixAIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:WellseseTechnologiesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-27</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:DueToThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-28</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-03</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-26</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:BlackScholesOptionpricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndNineteenHundredthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndNineteenHundredthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndNineteenHundredthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndEightyfourHundredthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndEightyfourHundredthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:twentythreeAndEightyfourHundredthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ThirtyPointNineThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ThirtyPointNineThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ThirtyPointNineThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:thirtyAndSixtysixHundredthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:thirtyAndSixtysixHundredthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:thirtyAndSixtysixHundredthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:fortyAndTwentyoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:fortyAndTwentyoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:fortyAndTwentyoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:FortynineAndSixtyeightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:FortynineAndSixtyeightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:FortynineAndSixtyeightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ZeroPointZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ZeroPointZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:ZeroPointZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneNinetyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneSixZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneEightZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneEightZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OneEightZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OnePointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OnePointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:OnePointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsExercisableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SeventeenPointSixtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwoPointTwoOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:SixteenPointZeroZeroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwentSixPointFiveSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwentSixPointFiveSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwentSixPointFiveSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nnox:AwardsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">nnox:TwentSixPointFiveSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">nnox:EmployeesOfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">nnox:NonemployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAssetAxis">us-gaap:DeferredFuelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAssetAxis">us-gaap:DeferredFuelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomelossBeforeIncomeTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomelossBeforeIncomeTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomelossBeforeIncomeTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomeTaxExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomeTaxExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:IncomeTaxExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TaxesOnIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxARCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:RadiologyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:AISolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxARCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:RadiologyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:AISolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:NanoxARCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:RadiologyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:AISolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nnox:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">currency:KRW</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">currency:KRW</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-19</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-19</instant>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:StatementScenarioAxis">pf0:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqm">
        <measure>utr:sqm</measure>
    </unit>
    <dei:DocumentType contextRef="c0">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0">001-38024</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">NANO-X IMAGING LTD</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="c0">Communication Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">Neve Ilan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0">IL</dei:EntityAddressCountry>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressPostalZipCode contextRef="c0">9085000</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName contextRef="c1">Erez Meltzer</dei:ContactPersonnelName>
    <dei:CityAreaCode contextRef="c1">+972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1">02 544 5214</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1 contextRef="c1">Communication Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1">Neve Ilan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c1">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c1">9085000</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="c0">Ordinary Shares, par value NIS 0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">NNOX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">51791441</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="c0">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:AuditorName contextRef="c0">Kesselman &amp; Kesselman C.P.A.s</dei:AuditorName>
    <dei:AuditorFirmId contextRef="c0">1309</dei:AuditorFirmId>
    <dei:AuditorLocation contextRef="c0">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">66645000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">213468000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c2" decimals="-3" unitRef="usd">22066000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c2" decimals="-3" unitRef="usd">137000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c3" decimals="-3" unitRef="usd">137000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c2" decimals="-3" unitRef="usd">1051000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c2" decimals="-3" unitRef="usd">3129000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="-3" unitRef="usd">4788000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">1966000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">1537000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">94857000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">219793000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCash contextRef="c2" decimals="-3" unitRef="usd">127000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c3" decimals="-3" unitRef="usd">316000</us-gaap:RestrictedCash>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">37435000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">14020000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">1725000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">1359000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:MarketableSecuritiesNoncurrent contextRef="c2" decimals="-3" unitRef="usd">67845000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c2" decimals="-3" unitRef="usd">101826000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c2" decimals="-3" unitRef="usd">58298000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">1057000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">661000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">268313000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">16356000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">363170000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">236149000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" unitRef="usd">3134000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">435000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">3611000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">1931000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings contextRef="c2" decimals="-3" unitRef="usd">145000</us-gaap:ShortTermBorrowings>
    <us-gaap:DeferredRevenueCurrent contextRef="c2" decimals="-3" unitRef="usd">247000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">42471000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">881000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">519000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">2262000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">1595000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">52751000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">4480000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">950000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" unitRef="usd">923000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLongTermDebtNoncurrent contextRef="c2" decimals="-3" unitRef="usd">3796000</us-gaap:OtherLongTermDebtNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c2" decimals="-3" unitRef="usd">415000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">5814000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c2" decimals="-3" unitRef="usd">7063000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c2" decimals="-3" unitRef="usd">233000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="-3" unitRef="usd">18271000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="-3" unitRef="usd">923000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" unitRef="usd">71022000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" unitRef="usd">5403000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="2" unitRef="ilsPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="2" unitRef="ilsPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="INF" unitRef="shares">51791441</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">51791441</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">46100173</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">46100173</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" unitRef="usd">149000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">131000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" unitRef="usd">438820000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">315031000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="-3" unitRef="usd">-607000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">-146214000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-84416000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">292148000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">230746000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">363170000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">236149000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">1304000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="-3" unitRef="usd">2816000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="-3" unitRef="usd">-1512000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">17122000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">9210000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" unitRef="usd">2717000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="-3" unitRef="usd">7033000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c4" decimals="-3" unitRef="usd">12445000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c5" decimals="-3" unitRef="usd">1556000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">34709000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">22268000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">18298000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">-1182000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" unitRef="usd">60046000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="-3" unitRef="usd">43923000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="-3" unitRef="usd">22571000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-61558000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-43923000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-22571000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c0" decimals="-3" unitRef="usd">-288000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c4" decimals="-3" unitRef="usd">108000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c5" decimals="-3" unitRef="usd">8000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" unitRef="usd">-61846000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="-3" unitRef="usd">-43815000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="-3" unitRef="usd">-22563000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">-48000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-61798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-43815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-22563000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-1.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">-1.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-0.9</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="INF" unitRef="shares">48216</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="INF" unitRef="shares">35654</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="INF" unitRef="shares">25181</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss contextRef="c0" decimals="-3" unitRef="usd">-61798000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="-3" unitRef="usd">-43815000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c5" decimals="-3" unitRef="usd">-22563000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax contextRef="c0" decimals="-3" unitRef="usd">-607000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c0" decimals="-3" unitRef="usd">-607000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="-3" unitRef="usd">-62405000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c4" decimals="-3" unitRef="usd">-43815000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c5" decimals="-3" unitRef="usd">-22563000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="0" unitRef="shares">21924208</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="-3" unitRef="usd">58000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" unitRef="usd">11596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" unitRef="usd">-18038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" unitRef="usd">-6384000</us-gaap:StockholdersEquity>
    <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares contextRef="c11" decimals="0" unitRef="shares">4762656</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares>
    <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts contextRef="c11" decimals="-3" unitRef="usd">16000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
    <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts contextRef="c12" decimals="-3" unitRef="usd">14022000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
    <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts contextRef="c5" decimals="-3" unitRef="usd">14038000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c11" decimals="0" unitRef="shares">454166</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c11" decimals="-3" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c12" decimals="-3" unitRef="usd">136000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c5" decimals="-3" unitRef="usd">137000</us-gaap:StockIssuedDuringPeriodValueOther>
    <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares
      contextRef="c11"
      decimals="0"
      id="ix_0_fact"
      unitRef="shares">9050</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares>
    <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants contextRef="c12" decimals="-3" unitRef="usd">25000</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants>
    <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants contextRef="c5" decimals="-3" unitRef="usd">25000</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c12" decimals="-3" unitRef="usd">16245000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c5" decimals="-3" unitRef="usd">16245000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6 contextRef="c12" decimals="-3" unitRef="usd">-10276000</nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6>
    <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6 contextRef="c5" decimals="-3" unitRef="usd">-10276000</nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" unitRef="usd">-22563000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-22563000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c15" decimals="0" unitRef="shares">27150080</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" unitRef="usd">75000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" unitRef="usd">31748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" unitRef="usd">-40601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" unitRef="usd">-8778000</us-gaap:StockholdersEquity>
    <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares contextRef="c20" decimals="0" unitRef="shares">4624500</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares>
    <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts contextRef="c20" decimals="-3" unitRef="usd">14000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
    <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts contextRef="c21" decimals="-3" unitRef="usd">70999000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
    <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts contextRef="c4" decimals="-3" unitRef="usd">71013000</nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20" decimals="0" unitRef="shares">10555556</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20" decimals="-3" unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c21" decimals="-3" unitRef="usd">169136000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c4" decimals="-3" unitRef="usd">169167000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c20" decimals="0" unitRef="shares">997863</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c20" decimals="-3" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c21" decimals="-3" unitRef="usd">497000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c4" decimals="-3" unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueOther>
    <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares contextRef="c20" decimals="0" unitRef="shares">1662929</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares>
    <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants contextRef="c20" decimals="-3" unitRef="usd">5000</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants>
    <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants contextRef="c21" decimals="-3" unitRef="usd">125000</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants>
    <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants contextRef="c4" decimals="-3" unitRef="usd">130000</nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c21" decimals="-3" unitRef="usd">24781000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">24781000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c20" decimals="0" unitRef="shares">1109245</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c20" decimals="-3" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c21" decimals="-3" unitRef="usd">17745000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c4" decimals="-3" unitRef="usd">17748000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:NetIncomeLoss contextRef="c23" decimals="-3" unitRef="usd">-43815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-43815000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c24" decimals="0" unitRef="shares">46100173</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" unitRef="usd">131000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" unitRef="usd">315031000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" unitRef="usd">-84416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">230746000</us-gaap:StockholdersEquity>
    <nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares contextRef="c28" decimals="0" unitRef="shares">780920</nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares>
    <nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants contextRef="c28" decimals="-3" unitRef="usd">2000</nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants>
    <nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants contextRef="c29" decimals="-3" unitRef="usd">265000</nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants>
    <nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants contextRef="c0" decimals="-3" unitRef="usd">267000</nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants>
    <nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares contextRef="c28" decimals="0" unitRef="shares">1099946</nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares>
    <nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions contextRef="c28" decimals="-3" unitRef="usd">3000</nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions>
    <nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions contextRef="c29" decimals="-3" unitRef="usd">3330000</nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions>
    <nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions contextRef="c0" decimals="-3" unitRef="usd">3333000</nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions>
    <nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin contextRef="c28" decimals="0" unitRef="shares">3810402</nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin>
    <nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets contextRef="c28" decimals="-3" unitRef="usd">13000</nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets>
    <nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets contextRef="c29" decimals="-3" unitRef="usd">101497000</nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets>
    <nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets contextRef="c0" decimals="-3" unitRef="usd">101510000</nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c29" decimals="-3" unitRef="usd">18697000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">18697000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c30" decimals="-3" unitRef="usd">-607000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c0" decimals="-3" unitRef="usd">-607000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" unitRef="usd">-61798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-61798000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c32" decimals="0" unitRef="shares">51791441</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" unitRef="usd">149000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" unitRef="usd">438820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" unitRef="usd">-607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" unitRef="usd">-146214000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">292148000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-61798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-43815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-22563000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">18806000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">24781000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="-3" unitRef="usd">16245000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="-3" unitRef="usd">1768000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" unitRef="usd">524000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c4" decimals="-3" unitRef="usd">208000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="-3" unitRef="usd">53000</us-gaap:Depreciation>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c0" decimals="-3" unitRef="usd">-214000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c0" decimals="-3" unitRef="usd">-116000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity contextRef="c0" decimals="-3" unitRef="usd">216000</us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c0" decimals="-3" unitRef="usd">40000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c0" decimals="-3" unitRef="usd">-1724000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c4" decimals="-3" unitRef="usd">4478000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c5" decimals="-3" unitRef="usd">1564000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses contextRef="c5" decimals="-3" unitRef="usd">-1081000</nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="-3" unitRef="usd">374000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c4" decimals="-3" unitRef="usd">522000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c5" decimals="-3" unitRef="usd">139000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" unitRef="usd">1721000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c4" decimals="-3" unitRef="usd">-103000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c5" decimals="-3" unitRef="usd">393000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <nnox:IncreaseDecreaseOperatingLease contextRef="c0" decimals="-3" unitRef="usd">23000</nnox:IncreaseDecreaseOperatingLease>
    <nnox:IncreaseDecreaseOperatingLease contextRef="c4" decimals="-3" unitRef="usd">83000</nnox:IncreaseDecreaseOperatingLease>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" unitRef="usd">-719000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="-3" unitRef="usd">2359000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="-3" unitRef="usd">970000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="-3" unitRef="usd">179000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="c0" decimals="-3" unitRef="usd">233000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-38071000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="-3" unitRef="usd">-21487000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="-3" unitRef="usd">-5524000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c0" decimals="-3" unitRef="usd">2859000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:MarketableSecuritiesRealizedGainLoss contextRef="c0" decimals="-3" unitRef="usd">90303000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">23158000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">13937000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="-3" unitRef="usd">125000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">-116320000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="-3" unitRef="usd">-13937000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="-3" unitRef="usd">-125000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c0" decimals="-3" unitRef="usd">3796000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts contextRef="c4" decimals="-3" unitRef="usd">71013000</nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
    <nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts contextRef="c5" decimals="-3" unitRef="usd">14038000</nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c4" decimals="-3" unitRef="usd">169348000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c0" decimals="-3" unitRef="usd">267000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c4" decimals="-3" unitRef="usd">630000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c5" decimals="-3" unitRef="usd">162000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" unitRef="usd">3316000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c5" decimals="-3" unitRef="usd">339000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">7379000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">240991000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="-3" unitRef="usd">13861000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">-147012000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="-3" unitRef="usd">205567000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="-3" unitRef="usd">8212000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">213784000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c19" decimals="-3" unitRef="usd">8217000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c10" decimals="-3" unitRef="usd">5000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">66772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">213784000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c19" decimals="-3" unitRef="usd">8217000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <nnox:UnpaidOfferingCosts contextRef="c5" decimals="-3" unitRef="usd">858000</nnox:UnpaidOfferingCosts>
    <nnox:issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants contextRef="c4" decimals="-3" unitRef="usd">200000</nnox:issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants>
    <nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets contextRef="c0" decimals="-3" unitRef="usd">1500000</nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets>
    <nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations contextRef="c0" decimals="-3" unitRef="usd">100010000</nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations>
    <nnox:FairValueOfContingentConsiderationAssumedInBusinessCombinations contextRef="c0" decimals="-3" unitRef="usd">47194000</nnox:FairValueOfContingentConsiderationAssumedInBusinessCombinations>
    <nnox:IssuanceOfSharesInConsiderationOfAssets contextRef="c0" decimals="-3" unitRef="usd">1091000</nnox:IssuanceOfSharesInConsiderationOfAssets>
    <nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities contextRef="c0" decimals="-3" unitRef="usd">194000</nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities>
    <nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities contextRef="c4" decimals="-3" unitRef="usd">1085000</nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities>
    <nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities contextRef="c5" decimals="-3" unitRef="usd">548000</nnox:RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities>
    <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements contextRef="c5" decimals="-3" unitRef="usd">10276000</nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements>
    <nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity contextRef="c4" decimals="-3" unitRef="usd">17748000</nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity>
    <us-gaap:NatureOfOperations contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 1 - GENERAL:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in; font-size: 12pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in; font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; font-size: 12pt"&gt;&lt;span style="font-size: 10pt"&gt;Nano-X Imaging Ltd, an Israeli Company (hereinafter &#x201c;the Company&#x201d; or &#x201c;Nanox IL&#x201d;), was incorporated on December 20, 2018 and commenced its operations on September 3, 2019.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;On September 19, 2019, Nanox IL established
Nanox Imaging Inc. (hereinafter &#x201c;Nanox Japan&#x201d;), a wholly owned subsidiary in Japan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;On September 25, 2020, Nanox IL established
Nano-X Korea Inc. (hereinafter &#x201c;Nanox Korea&#x201d;), a wholly owned subsidiary in Korea.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;On September 30, 2021, Nanox IL established
Nanox Imaging Inc. (hereinafter &#x201c;Nanox U.S.&#x201d;), a wholly owned subsidiary in the United States. On the same date, Nanox U.S. established Nanox MDW Inc. (hereinafter &#x201c;Nanox MDW&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;On November 2, 2021, Nanox U.S. completed the acquisition of 100% of the
shares of USARAD Holdings, Inc. (refer to Note 3).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;On November 4, 2021, the Company, completed
the merger with Zebra Medical Vision Ltd (refer to Note 3).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company together with its subsidiaries,
develops a commercial-grade tomographic imaging device with a digital X-ray source, provides teleradiology services and develops artificial
intelligence applications designed to be used in real-world medical imaging applications. The Company&#x2019;s solution, referred to as
the Nanox Multi Source System, has two integrated components &#x2013; &#x201c;Nanox.ARC&#x201d; and &#x201c;Nanox. CLOUD&#x201d;. Nanox.ARC
is a medical tomographic imaging system incorporating the Company&#x2019;s novel digital X-ray source. Nanox. CLOUD is a platform which
employs a matching engine to match medical images to radiologists, provides image repository, connectivity to diagnostic assistive
AI systems, billing and reporting. On April 1, 2021, the Company received clearance from the FDA to market the Company&#x2019;s Nanox
Cart X-Ray System. In addition, the Company is in the process to receive clearance from the FDA to market the Company&#x2019;s Nanox Multi
Source System.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company has experienced net losses
and negative cash flows from operations since its inception. The&#160;Company anticipates such losses will continue until its product
candidates reach commercial profitability. In August 2020, the Company completed an IPO on Nasdaq with net proceeds received from the
IPO of approximately $169 million. Based on the Company&#x2019;s financing activities during the year ended December 31, 2021, the Company
has sufficient funds for its plans for the next twelve months from the issuance of these financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Current Impact of COVID-19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Following the December 2019 outbreak of
Coronavirus (COVID-19) in China, it has spread into most countries across the world, including Israel, Japan and all 50 states within
the U.S. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed
quarantines, travel restrictions and other public health safety measures. The COVID-19 pandemic has adversely impacted the Company&#x2019;s
operations in various ways. For example, the Company&#x2019;s engineers are unable to make work-related trips to Korea or Israel to test
and optimize the Nanox.ARC. The potential business partners are unable to make on-site visits to the Company&#x2019;s facilities or attend
industry conferences and meetings to experience the Nanox.ARC, which has negatively impacted the Company&#x2019;s business development
and deployment activities. The external labs the Company works with have also been affected by COVID-19, resulting in delays in the Company&#x2019;s
timelines for obtaining regulatory approval. COVID-19 has also caused shutdowns or disruptions of business for our manufactures and suppliers.
The continued spread of COVID-19 globally could adversely impact the Company&#x2019;s development, manufacture, or deployment of the Nanox
Systems, which could adversely affect the Company&#x2019;s ability to obtain regulatory approval for and to commercialize the Nanox Systems,
increase the operating expenses and have a material adverse effect on the Company&#x2019;s financial results.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left; width: 0.75in; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 0.25in; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;Current Impact of geopolitical tensions and the start of the military conflict between Russia and Ukraine&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;U.S. and global markets are experiencing
volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and
Ukraine. On February 24, 2022, a full-scale military invasion of Ukraine by Russian troops was reported. Although the length and impact
of the ongoing military conflict is highly unpredictable, the ongoing conflict in Ukraine could lead to market disruptions, including
significant volatility in commodity prices, credit and capital markets. As a result, sanctions and penalties have been levied by the United
States, European Union and other countries against Russia. Russian military actions and the resulting sanctions could have a negative
impact on supply chains, the Company&#x2019;s MSaaS agreements relating to Russia and Belarus or the region and adversely affect the global
economy and financial markets. Any of the abovementioned factors could affect the Company&#x2019;s business, prospects, financial condition,
and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict,
but could be substantial.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c36" decimals="2" unitRef="pure">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <nnox:InitialPublicOfferingNetProceeds contextRef="c37" decimals="-6" unitRef="usd">169000000</nnox:InitialPublicOfferingNetProceeds>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Our consolidated financial statements are prepared in accordance
with generally accepted accounting principles in the United States (hereinafter -&#x201c;U.S GAAP&#x201d;). The preparation of our consolidated
financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates
on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates
under different assumptions or conditions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;In particular, a number of estimates have
been and will continue to be affected by the ongoing COVID-19 pandemic. The severity, magnitude and duration, as well as the economic
consequences, of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. As a result, the accounting estimates
and assumptions may change over time in response to COVID-19. Such changes could have&#160;an&#160;additional&#160;impact on&#160;the
Company&#x2019;s long-lived asset and intangible asset valuation; inventory valuation; and the allowance for expected credit losses.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-indent: -1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;a.&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Use of estimates in the preparation of financial statements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.75in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The preparation of the consolidated financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company&#x2019;s
consolidated financial statements. As applicable to these consolidated financial statements, the most significant estimates relate to
assets acquired and liabilities assumed through business combination, goodwill impairment, useful lives of intangible assets, deferred
taxes and share-based payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;b.&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Functional currency&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in"&gt;The U.S. dollar is the currency of the primary economic environment
in which the operations of the Company and its subsidiaries is conducted. A substantial portion of the operational costs are denominated
in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar (&#x201c;primary currency&#x201d;). Foreign currency
assets and liabilities are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date.
Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result
of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during
the period. Currency transaction gains and losses are presented in financial income and expenses, net.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="text-align: left; width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Business Combinations&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company allocates the fair value of
consideration transferred in a business combination to the assets acquired, liabilities assumed, and non-controlling interests in the
acquired business based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the
business combination and are expensed as incurred. The excess of the fair value of the consideration transferred plus the fair value of
any non-controlling interest in the acquiree over the fair value of the assets acquired, liabilities assumed in the acquired business
is recorded as goodwill. The fair value of the consideration transferred may include a combination of cash, equity securities, earn out
payments and deferred payments. The allocation of the consideration transferred in certain cases may be subject to revision based on the
final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative
impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company
includes the results of operations of the businesses that it has acquired in its consolidated results prospectively from the respective
dates of acquisition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company records obligations in
connection with its business combinations at fair value on the acquisition date. Each reporting period thereafter, the Company revalues
earn-out liabilities and records the changes in their fair value in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Changes in the fair value of earn-out liabilities can result from adjustments
to the discount rates, the Company&#x2019;s shares price, sales and profitability targets. This fair value measurement represent Level
3 measurements, as they are based on significant inputs not observable in the market. Significant judgment is required in determining
the assumptions utilized as of the acquisition date and for each subsequent period. Accordingly, changes in the assumptions described
above could have a material impact on the Company&#x2019;s consolidated results of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;d.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Cash and cash equivalents &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company considers as cash equivalents all short-term,
highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase
that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. &lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;e.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Marketable Securities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;All highly liquid investments are classified
as marketable securities and have been classified and accounted for as available-for-sale. Investment in securities consists of debt
securities classified as available-for-sale and recorded at fair value. The Company classifies its marketable securities as either short-term
or long-term based on each instrument&#x2019;s underlying contractual maturity date. Unrealized gains and losses on marketable debt securities
classified as available-for-sale are reported net of the related tax effect in other comprehensive income/(loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;f.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;Accounts receivables&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Accounts receivable are presented net of the allowance for expected credit loss and consists of short term receivables that arise in the normal course of business. The Company performs ongoing credit evaluations of its customer&#x2019;s financial condition and typically requires no collateral from its customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company adopted the Current Expected
Credit Losses (&#x201c;CECL&#x201d;) guidance effective January 1, 2020. The Company maintains the allowance for estimated losses resulting
from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime
expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable
forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness,
historical levels of credit losses, and future expectations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Changes in the allowance for&#160;credit losses&#160;are recognized
in, general and administrative expenses. Accounts receivables are written-off against the allowance for&#160;credit losses&#160;when management
deems the accounts are no longer collectible.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;g.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Property&#160;and&#160;equipment,&#160;net&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Property and equipment are stated at cost, net of accumulated
depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful lives:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;15-33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Vehicles&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Equipment and machinery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;10-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Land&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The depreciable life of leasehold improvements is limited
by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;h.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Goodwill reflects the excess of the consideration transferred plus
the fair value of any non-controlling interest in the acquiree at the business combination date over the fair values of the identifiable
net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination
that are not individually identified and separately recognized. The Company allocates goodwill to its reporting units based on the reporting
unit expected to benefit from the business combination. &#160;&#160;The primary items that generate goodwill include the value of the
synergies between the acquired companies and the Company and the acquired assembled workforce, neither of which qualifies for recognition
as an intangible asset. ASC 350, &#x201c;Intangibles - Goodwill and other&#x201d; (&#x201c;ASC 350&#x201d;) requires goodwill to be tested
for impairment at the reporting unit level at least annually or between annual tests in certain circumstances and written down when impaired.
ASC 350 allows an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative
goodwill impairment test. If the qualitative assessment does not result in a more likely than not indication of impairment, no further
impairment testing is required. If it does result in a more likely than not indication of impairment, the quantitative goodwill impairment
test two-step impairment test is performed. Alternatively, ASC 350 permits an entity to bypass the qualitative assessment for any reporting
unit and proceed directly to performing the quantitative first step of the goodwill impairment test.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The provisions of the accounting standard for goodwill allow the Company
to first assess qualitative factors to determine whether it is necessary to perform the next goodwill impairment quantitative test. Examples
of events or circumstances that may be indicative of impairment include but are not limited to: macroeconomic and industry conditions,
overall financial performance and adverse changes in legal, regulatory, market share and other relevant entity specific events. The carrying
value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill, to those reporting
units. When necessary, the Company records charges for impairments of goodwill for the amount by which the carrying amount exceeds the
fair value of these assets. No goodwill impairment charge was recorded in 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;b&gt;&lt;i&gt;other Intangible Assets, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Definite life intangible assets are amortized using the straight-line
method over their estimated period of useful life. Amortization of acquired developed technology, image big data, market platform, trade
names, customer relationships and radiologist relationships are recorded under cost of revenues and selling and marketing expenses. In
addition, the remaining amortization period for the impaired asset would be reassessed and, if necessary, revised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;i.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Impairment&#160;of&#160;long-lived&#160;assets &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The Company tests long-lived assets for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets
is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated
by the asset or asset group. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company
recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future
discounted cash flows.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;j.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Severance&#160;pay&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Israeli labor law generally requires severance pay be granted
upon dismissal of an employee or upon termination of employment under certain other circumstances. Pursuant to Section 14 of the Severance
Compensation Act, 1963 (&#x201c;Section 14&#x201d;), all of the Company&#x2019;s employees in Israel are entitled to monthly deposits, at
a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments under Section 14 relieve the Company from
any future severance payment obligation with respect to those employees and, as such, the Company may only utilize the insurance policies
for the purpose of disbursement of severance pay. As a result, the Company does not recognize an asset nor liability for these employees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In 2021 and 2020, all of the employees
of the Company and its subsidiary in Israel are subject to Section 14 of the Severance Law.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;k.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Legal&#160;and other&#160;contingencies&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Certain conditions, such as legal proceedings, may exist as
of the date the consolidated financial statements are issued that may result in a loss to the Company, but that will only be resolved
when one or more future events occur or fail to occur. In assessing loss contingencies related to legal proceedings that are pending
against the Company or unasserted claims that may result in such proceedings, the Company&#x2019;s management evaluates with its legal
advisors the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought
or expected to be sought. Such assessment inherently involves an exercise of judgment. Legal fees are expensed as incurred.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Management applies the guidance in ASC 450-20-25 when assessing losses
resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss would be incurred
and the amount of the liability can be estimated, then the Company records an accrued expense in the Company&#x2019;s consolidated financial
statements based on its best estimate. Loss contingencies considered to be remote by management are generally not disclosed unless material.
For additional information see note 11.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;l.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; text-indent: -0.75in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The majority of the Company&#x2019;s revenues are derived from radiology
services fees received from various payors based on established billing rates. Revenues are derived directly from hospitals and healthcare
providers. The Company recognizes revenue in the period in which the performance obligation is satisfied. The Company records the amount
of revenue that reflects the consideration that it expects to receive in exchange for those services. The Company applies the following
five-step model in order to determine this amount: (i)&#160;identification of the contract with a customer; (ii)&#160;identification of
the promised services in the contract and determination of whether they represent performance obligations, including whether they are
distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in"&gt;The Company records deferred revenue for any upfront payments received
in advance of the Company&#x2019;s performance obligations being satisfied. These contract liabilities consist principally of unearned
radiology service fee.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;m.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Research and development expenses&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Research and development expenses are charged to the statement
of operations as incurred and consist primarily of personnel, materials and supplies for research and development activities.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;n.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Income&#160;tax &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.75in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left; width: 1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;The Company accounts for income taxes in accordance with ASC 740, &#x201c;Income
    Taxes&#x201d; (&#x201c;ASC&#160;740&#x201d;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability
    account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and
    are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
    provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely
    than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative
    evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU&#160;2015-17.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left; width: 96px"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not
    been taken into account in computing the deferred income taxes, as it is the Company&#x2019;s intent and ability to hold these investments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 96px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left; width: 96px; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Valuation allowances are provided unless it is more likely
than not that the deferred tax asset will be realized. In the determination of the appropriate valuation allowances, the Company considers
future reversals of existing taxable temporary differences, the most recent projections of future business results, prior earnings history,
carryback and carry forward and prudent tax strategies that may enhance the likelihood of realization of a deferred tax asset. Assessments
for the realization of deferred tax assets made at a given balance sheet date are subject to change in the future, particularly if earnings
of a subsidiary are significantly higher or lower than expected, or if the Company takes operational or tax positions that could impact
the future taxable earnings of a subsidiary.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;b&gt;o&lt;span style="font-size: 10pt"&gt;.&lt;/span&gt;&lt;/b&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Share-based compensation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The Company accounts for share-based compensation under
ASC 718, &#x201c;Compensation - Stock Compensation,&#x201d; which requires the measurement and recognition of compensation expense
based on estimated fair values for all share-based payment awards made to non-employees, employees, officers and directors. ASC 718
requires companies to estimate the fair value of equity-based payment awards on the date of grant. The Company uses the
Black-Scholes-Merton option-pricing model as part of such estimation.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Prior to the adoption of ASU 2018-07, warrants issued to consultants
and other non-employees, as compensation for services provided to the Company, were accounted for based upon the fair value of the warrants.
The fair value of the warrants granted was measured on a final basis at the end of the related service period and was recognized over
the related service period using the straight-line method. After the adoption of ASU 2018-07, the measurement date for non-employee awards
is the date of the grant. The compensation expense for non-employees is recognized without changes in the fair value of the award, over
the requisite service period, which is the vesting period of the respective award using the straight line. The Company adopted ASU 2018-07
as of January 1, 2019 with no impact on its consolidated financial statements as all of the Company&#x2019;s awards were fully vested
at the adoption date.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The Company recognizes compensation expenses for its stock-based
option awards and RSUs on a straight-line basis over the requisite service period (primarily a four-year period). The Company accounts
for forfeitures as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;p.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Loss&#160;per&#160;share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Basic earnings per share is computed by dividing net income
(loss) attributable to holders of ordinary shares of the Company by the weighted average number of ordinary shares outstanding for each
reporting period.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;In computing the Company&#x2019;s diluted earnings per share,
the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary shares and the potential dilutive
ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding include the dilutive effect of in-the-money
options using the treasury stock method.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company did not take into account
any dilutive instruments, such as investor warrants , share-based payments and earn-out liability - contingently issuable ordinary shares
, since their effect, on a fully diluted basis, is anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;q.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair&#160;value&#160;measurement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Fair value is based on the price that would be received from
the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that
prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left; width: 96px"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 48px"&gt;&lt;span style="font-size: 10pt"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Level 2: &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Level 3: &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.75in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;In determining fair value, the Company utilizes valuation techniques
that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty
credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;The Company&#x2019;s financial instruments consist mainly of
cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities. The fair value
of these financial instruments approximates their carrying values.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Balance as of &lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Money market funds (*)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,697&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,697&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;89,911&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;89,911&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;119,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;119,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long term loan (**)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Contingent short term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent long-term earnout liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,814&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,814&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"/&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"/&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;52,081&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;52,081&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;span&gt;The Company classifies AFS securities
within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair value&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span&gt;As of&#160;&lt;/span&gt;December
31, 2021,&#160;&lt;span&gt;approximately $29,697 thousand of debt securities were classified under &#x201c;Cash
and Cash equivalents&#x201d; in the consolidated balance sheets as such securities met all applicable classification criteria.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(**)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span&gt;Since the loan was
originated in September 2021, the fair value of the long term loan approximates its carrying value.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;r.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Concentration&#160;of&#160;Credit Risks&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Financial instruments that potentially subject the
Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, marketable securities
and accounts receivable.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;The Company&#x2019;s cash and cash equivalents and restricted
cash are invested with major banks in Israel, United States, Korea and Japan. Generally, these investments may be redeemed upon demand
and the Company believes that the financial institutions that hold the Company&#x2019;s cash balances are financially sound and, accordingly,
bear minimal risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;s.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Offering&#160;Costs &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Deferred offering costs directly relating to the Company&#x2019;s
private and initial public offering, were capitalized and offset against proceeds upon the consummation of the private and IPO transactions
in shareholders&#x2019; equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;t.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left"&gt;On January 1, 2019 the Company adopted
ASU No. 2016-02, Leases (&#x201c;Topic 842&#x201d;), The Company determines if an arrangement is a lease at inception. Balances related
to operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current maturities of operating leases liabilities
and Non-current operating leases liabilities in the consolidated balance sheets.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;The Company also elected not separating lease components
from non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated
lease payments in the consolidated statements of operations on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;ROU assets represent the Company&#x2019;s right to use an underlying
asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease.
Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over
the lease term. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that
the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily
determined. As the Company&#x2019;s leases do not provide an implicit rate, the Company&#x2019;s uses its estimated incremental borrowing
rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for
lease payments is recognized on a straight-line basis over the lease term (see also note 7).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;The Company presents unrecognized tax benefits as a reduction
to deferred tax asset where a net operating loss, a similar tax loss, or a tax credit carryforward that are available, under the tax law
of the applicable jurisdiction, to offset any additional income taxes that would result from the settlement of a tax position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr&gt; &lt;td style="width: 72px; padding-right: 0.8pt"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 24px; padding-right: 0.8pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;u.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;ASC 280, &#x201c;Segment Reporting,&#x201d; establishes standards
for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate
financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources
and in assessing performance. The Company&#x2019;s chief operating decision maker is the Company&#x2019;s Chief Executive Officer (the &#x201c;CODM&#x201d;),
who makes resource allocation decisions and assesses performance based on financial information prepared on a consolidated basis, accompanied
by disaggregated information about revenues, gross profit and operating loss by the three identified reportable segments. The Company&#x2019;s
business includes three operating segments based on the services that the Company provides. The three segments are composed from the Nanox.Arc
segment, AI solutions and the Radiology services division segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;v.&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Newly issued and recently adopted accounting pronouncements:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&lt;b&gt;&lt;i&gt;Accounting Pronouncements Adopted in Current year&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;. In December 2019, the FASB issued ASU 2019-12, Income Taxes (&#x201c;Topic
740&#x201d;): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions
to the general principles and simplification of areas such as franchise taxes, step-up in tax basis goodwill, separate entity financial
statements and interim recognition of enactment of tax laws or rate changes. The guidance was effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted this guidance
since January 1, 2021, with no material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;In October 2021, the FASB issued ASU
2021-08 &#x201c;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;,
which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer
on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing
contract assets and contract liabilities at the same amounts recorded by the acquire. The guidance should be applied prospectively to
acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that
have not yet been issued. The Company early adopted ASU 2021-08 since January 1, 2021, with no material impact on its consolidated financial
statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&lt;i&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;In August 2020, the FASB issued ASU 2020-06 &#x201c;Debt &#x2013;
Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic
815 &#x2013; 40).&#x201d; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective
for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years.&#160;The Company will adopt this
guidance effective January 1, 2022, with no material impact on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;a.&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Use of estimates in the preparation of financial statements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.75in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The preparation of the consolidated financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results may differ from those estimates and such differences may have a material impact on the Company&#x2019;s
consolidated financial statements. As applicable to these consolidated financial statements, the most significant estimates relate to
assets acquired and liabilities assumed through business combination, goodwill impairment, useful lives of intangible assets, deferred
taxes and share-based payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;b.&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Functional currency&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in"&gt;The U.S. dollar is the currency of the primary economic environment
in which the operations of the Company and its subsidiaries is conducted. A substantial portion of the operational costs are denominated
in U.S. dollars. Accordingly, the functional currency of the Company is the U.S. dollar (&#x201c;primary currency&#x201d;). Foreign currency
assets and liabilities are translated into the primary currency using the exchange rates in effect on the consolidated balance sheet date.
Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result
of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during
the period. Currency transaction gains and losses are presented in financial income and expenses, net.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="text-align: left; width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Business Combinations&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company allocates the fair value of
consideration transferred in a business combination to the assets acquired, liabilities assumed, and non-controlling interests in the
acquired business based on their fair values at the acquisition date. Acquisition-related expenses are recognized separately from the
business combination and are expensed as incurred. The excess of the fair value of the consideration transferred plus the fair value of
any non-controlling interest in the acquiree over the fair value of the assets acquired, liabilities assumed in the acquired business
is recorded as goodwill. The fair value of the consideration transferred may include a combination of cash, equity securities, earn out
payments and deferred payments. The allocation of the consideration transferred in certain cases may be subject to revision based on the
final determination of fair values during the measurement period, which may be up to one year from the acquisition date. The cumulative
impact of revisions during the measurement period is recognized in the reporting period in which the revisions are identified. The Company
includes the results of operations of the businesses that it has acquired in its consolidated results prospectively from the respective
dates of acquisition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company records obligations in
connection with its business combinations at fair value on the acquisition date. Each reporting period thereafter, the Company revalues
earn-out liabilities and records the changes in their fair value in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Changes in the fair value of earn-out liabilities can result from adjustments
to the discount rates, the Company&#x2019;s shares price, sales and profitability targets. This fair value measurement represent Level
3 measurements, as they are based on significant inputs not observable in the market. Significant judgment is required in determining
the assumptions utilized as of the acquisition date and for each subsequent period. Accordingly, changes in the assumptions described
above could have a material impact on the Company&#x2019;s consolidated results of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;d.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Cash and cash equivalents &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company considers as cash equivalents all short-term,
highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase
that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. &lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;e.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Marketable Securities&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;All highly liquid investments are classified
as marketable securities and have been classified and accounted for as available-for-sale. Investment in securities consists of debt
securities classified as available-for-sale and recorded at fair value. The Company classifies its marketable securities as either short-term
or long-term based on each instrument&#x2019;s underlying contractual maturity date. Unrealized gains and losses on marketable debt securities
classified as available-for-sale are reported net of the related tax effect in other comprehensive income/(loss).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;f.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;Accounts receivables&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Accounts receivable are presented net of the allowance for expected credit loss and consists of short term receivables that arise in the normal course of business. The Company performs ongoing credit evaluations of its customer&#x2019;s financial condition and typically requires no collateral from its customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company adopted the Current Expected
Credit Losses (&#x201c;CECL&#x201d;) guidance effective January 1, 2020. The Company maintains the allowance for estimated losses resulting
from the inability of the Company&#x2019;s customers to make required payments. The allowance represents the current estimate of lifetime
expected credit losses over the remaining duration of existing accounts receivable considering current market conditions and supportable
forecasts when appropriate. The estimate is a result of the Company&#x2019;s ongoing evaluation of collectability, customer creditworthiness,
historical levels of credit losses, and future expectations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Changes in the allowance for&#160;credit losses&#160;are recognized
in, general and administrative expenses. Accounts receivables are written-off against the allowance for&#160;credit losses&#160;when management
deems the accounts are no longer collectible.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;g.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Property&#160;and&#160;equipment,&#160;net&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Property and equipment are stated at cost, net of accumulated
depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful lives:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;15-33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Vehicles&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Equipment and machinery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;10-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Land&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The depreciable life of leasehold improvements is limited
by the expected lease term, unless there is a transfer of title or a purchase option for the leased asset reasonably certain of exercise.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <nnox:ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;15-33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Vehicles&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Equipment and machinery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;10-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Land&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;</nnox:ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock>
    <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c38">15</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
    <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c39">33</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
    <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c40">6</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
    <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c41">20</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
    <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c42">33</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
    <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c43">10</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
    <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c44">20</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
    <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c45">10</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
    <nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription contextRef="c46">N/A</nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;h.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets, net&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Goodwill reflects the excess of the consideration transferred plus
the fair value of any non-controlling interest in the acquiree at the business combination date over the fair values of the identifiable
net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination
that are not individually identified and separately recognized. The Company allocates goodwill to its reporting units based on the reporting
unit expected to benefit from the business combination. &#160;&#160;The primary items that generate goodwill include the value of the
synergies between the acquired companies and the Company and the acquired assembled workforce, neither of which qualifies for recognition
as an intangible asset. ASC 350, &#x201c;Intangibles - Goodwill and other&#x201d; (&#x201c;ASC 350&#x201d;) requires goodwill to be tested
for impairment at the reporting unit level at least annually or between annual tests in certain circumstances and written down when impaired.
ASC 350 allows an entity to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative
goodwill impairment test. If the qualitative assessment does not result in a more likely than not indication of impairment, no further
impairment testing is required. If it does result in a more likely than not indication of impairment, the quantitative goodwill impairment
test two-step impairment test is performed. Alternatively, ASC 350 permits an entity to bypass the qualitative assessment for any reporting
unit and proceed directly to performing the quantitative first step of the goodwill impairment test.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The provisions of the accounting standard for goodwill allow the Company
to first assess qualitative factors to determine whether it is necessary to perform the next goodwill impairment quantitative test. Examples
of events or circumstances that may be indicative of impairment include but are not limited to: macroeconomic and industry conditions,
overall financial performance and adverse changes in legal, regulatory, market share and other relevant entity specific events. The carrying
value of each reporting unit is determined by assigning the assets and liabilities, including the existing goodwill, to those reporting
units. When necessary, the Company records charges for impairments of goodwill for the amount by which the carrying amount exceeds the
fair value of these assets. No goodwill impairment charge was recorded in 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;b&gt;&lt;i&gt;other Intangible Assets, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 76.5pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Definite life intangible assets are amortized using the straight-line
method over their estimated period of useful life. Amortization of acquired developed technology, image big data, market platform, trade
names, customer relationships and radiologist relationships are recorded under cost of revenues and selling and marketing expenses. In
addition, the remaining amortization period for the impaired asset would be reassessed and, if necessary, revised.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;i.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Impairment&#160;of&#160;long-lived&#160;assets &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The Company tests long-lived assets for impairment whenever events
or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. Recoverability of long-lived assets
is measured by comparing the carrying amount of the long-lived asset to the estimated undiscounted future cash flows expected to be generated
by the asset or asset group. If the sum of the expected undiscounted cash flow is less than the carrying amount of the asset, the Company
recognizes an impairment loss, which is the excess of the carrying amount over the fair value of the asset, using the expected future
discounted cash flows.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"/&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <nnox:SeverancePayPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;j.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Severance&#160;pay&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Israeli labor law generally requires severance pay be granted
upon dismissal of an employee or upon termination of employment under certain other circumstances. Pursuant to Section 14 of the Severance
Compensation Act, 1963 (&#x201c;Section 14&#x201d;), all of the Company&#x2019;s employees in Israel are entitled to monthly deposits, at
a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments under Section 14 relieve the Company from
any future severance payment obligation with respect to those employees and, as such, the Company may only utilize the insurance policies
for the purpose of disbursement of severance pay. As a result, the Company does not recognize an asset nor liability for these employees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In 2021 and 2020, all of the employees
of the Company and its subsidiary in Israel are subject to Section 14 of the Severance Law.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</nnox:SeverancePayPolicyTextBlock>
    <nnox:LegalAndOtherContingenciesPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;k.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Legal&#160;and other&#160;contingencies&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Certain conditions, such as legal proceedings, may exist as
of the date the consolidated financial statements are issued that may result in a loss to the Company, but that will only be resolved
when one or more future events occur or fail to occur. In assessing loss contingencies related to legal proceedings that are pending
against the Company or unasserted claims that may result in such proceedings, the Company&#x2019;s management evaluates with its legal
advisors the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought
or expected to be sought. Such assessment inherently involves an exercise of judgment. Legal fees are expensed as incurred.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Management applies the guidance in ASC 450-20-25 when assessing losses
resulting from contingencies. If the assessment of a contingency indicates that it is probable that a material loss would be incurred
and the amount of the liability can be estimated, then the Company records an accrued expense in the Company&#x2019;s consolidated financial
statements based on its best estimate. Loss contingencies considered to be remote by management are generally not disclosed unless material.
For additional information see note 11.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;</nnox:LegalAndOtherContingenciesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;l.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; text-indent: -0.75in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The majority of the Company&#x2019;s revenues are derived from radiology
services fees received from various payors based on established billing rates. Revenues are derived directly from hospitals and healthcare
providers. The Company recognizes revenue in the period in which the performance obligation is satisfied. The Company records the amount
of revenue that reflects the consideration that it expects to receive in exchange for those services. The Company applies the following
five-step model in order to determine this amount: (i)&#160;identification of the contract with a customer; (ii)&#160;identification of
the promised services in the contract and determination of whether they represent performance obligations, including whether they are
distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration;
(iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue when (or as) the Company
satisfies each performance obligation.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in"&gt;The Company records deferred revenue for any upfront payments received
in advance of the Company&#x2019;s performance obligations being satisfied. These contract liabilities consist principally of unearned
radiology service fee.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;m.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Research and development expenses&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Research and development expenses are charged to the statement
of operations as incurred and consist primarily of personnel, materials and supplies for research and development activities.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;n.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Income&#160;tax &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -0.75in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left; width: 1in"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;The Company accounts for income taxes in accordance with ASC 740, &#x201c;Income
    Taxes&#x201d; (&#x201c;ASC&#160;740&#x201d;). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability
    account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and
    are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company
    provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it is more likely
    than not that a portion or all of the deferred tax assets will not be realized, based on the weight of available positive and negative
    evidence. Deferred tax liabilities and assets are classified as non-current in accordance with ASU&#160;2015-17.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left; width: 96px"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Taxes that would apply in the event of disposal of investments in foreign subsidiaries have not
    been taken into account in computing the deferred income taxes, as it is the Company&#x2019;s intent and ability to hold these investments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 96px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;The Company accounts for uncertain tax positions in accordance with ASC 740-10. ASC 740-10 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative probability) likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits under taxes on income (tax benefit).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left; width: 96px; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Valuation allowances are provided unless it is more likely
than not that the deferred tax asset will be realized. In the determination of the appropriate valuation allowances, the Company considers
future reversals of existing taxable temporary differences, the most recent projections of future business results, prior earnings history,
carryback and carry forward and prudent tax strategies that may enhance the likelihood of realization of a deferred tax asset. Assessments
for the realization of deferred tax assets made at a given balance sheet date are subject to change in the future, particularly if earnings
of a subsidiary are significantly higher or lower than expected, or if the Company takes operational or tax positions that could impact
the future taxable earnings of a subsidiary.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <nnox:TaxBenefitPercentage contextRef="c0" decimals="2" unitRef="pure">0.50</nnox:TaxBenefitPercentage>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left; width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left; width: 0.25in"&gt;&lt;b&gt;o&lt;span style="font-size: 10pt"&gt;.&lt;/span&gt;&lt;/b&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Share-based compensation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The Company accounts for share-based compensation under
ASC 718, &#x201c;Compensation - Stock Compensation,&#x201d; which requires the measurement and recognition of compensation expense
based on estimated fair values for all share-based payment awards made to non-employees, employees, officers and directors. ASC 718
requires companies to estimate the fair value of equity-based payment awards on the date of grant. The Company uses the
Black-Scholes-Merton option-pricing model as part of such estimation.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Prior to the adoption of ASU 2018-07, warrants issued to consultants
and other non-employees, as compensation for services provided to the Company, were accounted for based upon the fair value of the warrants.
The fair value of the warrants granted was measured on a final basis at the end of the related service period and was recognized over
the related service period using the straight-line method. After the adoption of ASU 2018-07, the measurement date for non-employee awards
is the date of the grant. The compensation expense for non-employees is recognized without changes in the fair value of the award, over
the requisite service period, which is the vesting period of the respective award using the straight line. The Company adopted ASU 2018-07
as of January 1, 2019 with no impact on its consolidated financial statements as all of the Company&#x2019;s awards were fully vested
at the adoption date.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The Company recognizes compensation expenses for its stock-based
option awards and RSUs on a straight-line basis over the requisite service period (primarily a four-year period). The Company accounts
for forfeitures as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;p.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Loss&#160;per&#160;share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Basic earnings per share is computed by dividing net income
(loss) attributable to holders of ordinary shares of the Company by the weighted average number of ordinary shares outstanding for each
reporting period.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;In computing the Company&#x2019;s diluted earnings per share,
the denominator for diluted earnings per share is a computation of the weighted-average number of ordinary shares and the potential dilutive
ordinary shares outstanding during the period. Potential dilutive ordinary shares outstanding include the dilutive effect of in-the-money
options using the treasury stock method.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company did not take into account
any dilutive instruments, such as investor warrants , share-based payments and earn-out liability - contingently issuable ordinary shares
, since their effect, on a fully diluted basis, is anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;q.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair&#160;value&#160;measurement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Fair value is based on the price that would be received from
the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that
prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left; width: 96px"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 48px"&gt;&lt;span style="font-size: 10pt"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Level 2: &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Level 3: &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.75in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;In determining fair value, the Company utilizes valuation techniques
that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty
credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;The Company&#x2019;s financial instruments consist mainly of
cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities. The fair value
of these financial instruments approximates their carrying values.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Balance as of &lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Money market funds (*)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,697&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,697&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;89,911&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;89,911&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;119,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;119,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long term loan (**)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Contingent short term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent long-term earnout liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,814&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,814&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"/&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"/&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;52,081&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;52,081&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;span&gt;The Company classifies AFS securities
within Level 2 because it uses alternative pricing sources and models utilizing market observable inputs to determine their fair value&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span&gt;As of&#160;&lt;/span&gt;December
31, 2021,&#160;&lt;span&gt;approximately $29,697 thousand of debt securities were classified under &#x201c;Cash
and Cash equivalents&#x201d; in the consolidated balance sheets as such securities met all applicable classification criteria.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(**)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span&gt;Since the loan was
originated in September 2021, the fair value of the long term loan approximates its carrying value.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Balance as of &lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Money market funds (*)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,697&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29,697&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Marketable securities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;89,911&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;89,911&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;119,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;119,608&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Long term loan (**)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Contingent short term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,471&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent long-term earnout liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,814&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,814&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"/&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"/&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;52,081&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;52,081&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span&gt;(*)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span&gt;As of&#160;&lt;/span&gt;December
31, 2021,&#160;&lt;span&gt;approximately $29,697 thousand of debt securities were classified under &#x201c;Cash
and Cash equivalents&#x201d; in the consolidated balance sheets as such securities met all applicable classification criteria.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(**)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span&gt;Since the loan was
originated in September 2021, the fair value of the long term loan approximates its carrying value.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c48" decimals="-3" id="ix_1_fact" unitRef="usd">29697000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c49" decimals="-3" id="ix_2_fact" unitRef="usd">29697000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <nnox:LongTermMarketableSecurities contextRef="c48" decimals="-3" unitRef="usd">89911000</nnox:LongTermMarketableSecurities>
    <nnox:LongTermMarketableSecurities contextRef="c49" decimals="-3" unitRef="usd">89911000</nnox:LongTermMarketableSecurities>
    <us-gaap:Assets contextRef="c48" decimals="-3" unitRef="usd">119608000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c49" decimals="-3" unitRef="usd">119608000</us-gaap:Assets>
    <us-gaap:LongTermDebt contextRef="c50" decimals="-3" id="ix_3_fact" unitRef="usd">3796000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c49" decimals="-3" id="ix_4_fact" unitRef="usd">3796000</us-gaap:LongTermDebt>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c50" decimals="-3" unitRef="usd">42471000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c49" decimals="-3" unitRef="usd">42471000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c50" decimals="-3" unitRef="usd">5814000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c49" decimals="-3" unitRef="usd">5814000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c50" decimals="-3" unitRef="usd">52081000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c49" decimals="-3" unitRef="usd">52081000</us-gaap:Liabilities>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c2" decimals="-3" unitRef="usd">29697000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;r.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Concentration&#160;of&#160;Credit Risks&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Financial instruments that potentially subject the
Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, marketable securities
and accounts receivable.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;The Company&#x2019;s cash and cash equivalents and restricted
cash are invested with major banks in Israel, United States, Korea and Japan. Generally, these investments may be redeemed upon demand
and the Company believes that the financial institutions that hold the Company&#x2019;s cash balances are financially sound and, accordingly,
bear minimal risk.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <nnox:DeferredOfferingCostsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;s.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Offering&#160;Costs &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Deferred offering costs directly relating to the Company&#x2019;s
private and initial public offering, were capitalized and offset against proceeds upon the consummation of the private and IPO transactions
in shareholders&#x2019; equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;</nnox:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;t.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: left"&gt;On January 1, 2019 the Company adopted
ASU No. 2016-02, Leases (&#x201c;Topic 842&#x201d;), The Company determines if an arrangement is a lease at inception. Balances related
to operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current maturities of operating leases liabilities
and Non-current operating leases liabilities in the consolidated balance sheets.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;The Company also elected not separating lease components
from non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated
lease payments in the consolidated statements of operations on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;ROU assets represent the Company&#x2019;s right to use an underlying
asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease.
Operating lease ROU assets and liabilities are recognized as of the commencement date based on the present value of lease payments over
the lease term. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that
the Company will exercise that option. The discount rate for the lease is the rate implicit in the lease unless that rate cannot be readily
determined. As the Company&#x2019;s leases do not provide an implicit rate, the Company&#x2019;s uses its estimated incremental borrowing
rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for
lease payments is recognized on a straight-line basis over the lease term (see also note 7).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;The Company presents unrecognized tax benefits as a reduction
to deferred tax asset where a net operating loss, a similar tax loss, or a tax credit carryforward that are available, under the tax law
of the applicable jurisdiction, to offset any additional income taxes that would result from the settlement of a tax position.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr&gt; &lt;td style="width: 72px; padding-right: 0.8pt"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; width: 24px; padding-right: 0.8pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;u.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Segment reporting&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;ASC 280, &#x201c;Segment Reporting,&#x201d; establishes standards
for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate
financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources
and in assessing performance. The Company&#x2019;s chief operating decision maker is the Company&#x2019;s Chief Executive Officer (the &#x201c;CODM&#x201d;),
who makes resource allocation decisions and assesses performance based on financial information prepared on a consolidated basis, accompanied
by disaggregated information about revenues, gross profit and operating loss by the three identified reportable segments. The Company&#x2019;s
business includes three operating segments based on the services that the Company provides. The three segments are composed from the Nanox.Arc
segment, AI solutions and the Radiology services division segment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;v.&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Newly issued and recently adopted accounting pronouncements:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&lt;b&gt;&lt;i&gt;Accounting Pronouncements Adopted in Current year&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;. In December 2019, the FASB issued ASU 2019-12, Income Taxes (&#x201c;Topic
740&#x201d;): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions
to the general principles and simplification of areas such as franchise taxes, step-up in tax basis goodwill, separate entity financial
statements and interim recognition of enactment of tax laws or rate changes. The guidance was effective for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted this guidance
since January 1, 2021, with no material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;In October 2021, the FASB issued ASU
2021-08 &#x201c;Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;,
which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer
on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing
contract assets and contract liabilities at the same amounts recorded by the acquire. The guidance should be applied prospectively to
acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December 15, 2022, including
interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that
have not yet been issued. The Company early adopted ASU 2021-08 since January 1, 2021, with no material impact on its consolidated financial
statements.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&lt;i&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;In August 2020, the FASB issued ASU 2020-06 &#x201c;Debt &#x2013;
Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic
815 &#x2013; 40).&#x201d; This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities
and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. The amendments to this guidance are effective
for fiscal years beginning after December&#160;15, 2021, and interim periods within those fiscal years.&#160;The Company will adopt this
guidance effective January 1, 2022, with no material impact on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <nnox:CertainTransactionsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 3 &#x2013; BUSINESS COMBINATION AND OTHER TRANSACTION&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="font-size: 10pt"&gt;The acquisition of Nanox AI Ltd (formerly Zebra Medical Vision Ltd.).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;On November 4, 2021(&#x201c;the merger date&#x201d;), the Company,
completed the merger (&#x201c;the Nanox AI transaction&#x201d;) pursuant to the terms of the Agreement and Plan of Merger, dated August
9, 2021 (with certain amendments), among the Company, Zebra Medical Vision Ltd. (&#x201c;Zebra&#x201d;) and Perryllion Ltd., as representative
of Zebra&#x2019;s equity holders. At November 4, 2021 the Company issued 3,249,142 ordinary shares of the Company and committed to issue
70,211 employee options and restricted stock units&#160;to the equity holders of Zebra with an estimated fair value at the closing date
of $88,510 thousand, representing $26.57 per share in consideration for the fully outstanding shares on a fully diluted basis of Zebra.
Out of which $315 thousand was allocated to the purchase consideration and $970&#160;thousand was allocated to future services and continued
employment and shall be expensed over remaining service periods of up to 4 years. The fair value of ordinary shares issued by the Company
was determined using the Company&#x2019;s closing trading price on the merger date. The consideration represented (a) the basic purchase
price minus (b) certain transaction costs; plus (c) contingent consideration as a result of Zebra entering into a designated commercial
agreement prior to closing; plus (d) additional contingent consideration as a result of Zebra achieving a designated milestone of obtaining
a new FDA clearance for its population health product and additional consideration as a result of Zebra achieving designated milestones
as further described below. In addition, if Zebra enters into any of the two additional designated commercial agreements within 6 months
of the agreement execution date (August 9, 2021), then the Company will pay a deferred closing consideration in the amount of $3,333 thousand
in shares for each agreement. The deferred closing consideration would be paid in the Company&#x2019;s shares in the amount of the relevant
instalment payment divided by the average closing price of the 30 trading days ending on the applicable agreement signing date. Further,
if Zebra achieves the agreed milestones related to obtaining certain FDA clearances and security certifications, completing certain technology
integration, or achieving certain revenue and employee retention targets over the next three years, the Company will pay additional consideration
in the amount of up to $77,700 thousand. Each of these milestone instalments would be paid in the Company&#x2019;s shares in the amount
of the relevant instalment payment divided by the average closing price of the 30 trading days ending on the applicable milestone&#x2019;s
achievement date. Zebra changed its name to Nanox AI ltd. and Zebra Medical Vision Inc. (a fully owned subsidiary of Zebra, which is incorporated
under the laws if the State of Delaware) changed its name to Nanox AI Inc.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 72pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;The Nanox AI transaction was accounted in accordance with ASC 805,
&#x201c;Business Combinations&#x201d;, using the acquisition method of accounting with the Company as the acquirer.&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;The following table summarizes the fair value of the consideration
transferred to Nanox AI shareholders for the Nanox AI transaction:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S.$&lt;br/&gt; in thousand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 89%; text-align: left"&gt;Issuance of ordinary shares, options and RSUs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;88,510&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Contingent short term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent long term earnout liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,660&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total consideration&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;129,299&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;In accordance with ASC 805, the estimated
contingent consideration&#160;as of the Nanox AI transaction date was&#160;included in the purchase price. The total contingent payments
could reach to a maximum aggregate amount of up to $77,700 thousand, all shall be settled through the issuance of ordinary shares.&#160;The
Company determined the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash
flow analysis. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement
within the fair value hierarchy. The fair value of the contingent consideration is based on several factors, such as: the cash flows projected
from the success of achievements of several achievement and payment of milestone events; the time and resources needed to achieve those
milestones and the risk adjusted discount rate for fair value measurement. A probability of success factor was used in the fair value
calculation to reflect inherent regulatory and commercial risk of the contingent payments. The weighted average discount rate, applied
on the relative fair value of the contingent consideration liabilities, was&#160;19%. The contingent consideration is evaluated quarterly,
or more frequently, if circumstances dictate. Changes in the fair value of contingent consideration are recorded in consolidated statements
of income. Significant changes in unobservable inputs, mainly the probability of success and cash flows projected, could result in material
changes to the contingent consideration liabilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The allocation of the purchase price to assets acquired and
liabilities assumed, including measurement period adjustments (, is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Allocation&lt;br/&gt; of Purchase&lt;br/&gt; Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;(U.S. $ in thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-weight: bold; text-align: left"&gt;Cash, cash equivalents and Restricted&#160;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,956&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts Receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,816&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,693&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total assets acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Contingent short term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Contingent long-term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Convertible note (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other labilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,525&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities assumed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51,727&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;88,510&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"&gt;A 3 years Convertible Loan Agreement, dated August 9, 2021 between
the Company and Nanox AI in the amount of $3 million, which bears an annual interest of 6% and shall be automatically converted into the
Nanox AI&#x2019;s Preferred C Shares, at a price per share of $23.42. This loan is eliminated in the Consolidated financial statements.&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;The allocation of the purchase price to net assets acquired and liability
assumed resulted in the recognition of intangible asset related to technology of $27,316 thousand which will be expensed over remaining
service periods of 10 years, Image Big Data of $52,500 thousand which will be expensed over remaining service periods of 10 years, and
goodwill of $51,243 thousand, which is primarily attributed to the expected synergies from combining the operations of Zebra&#x2019;s AI
solutions with the Company tomographic imaging systems. As such, the goodwill will be assigned to the operational segment of AI solutions.&#160;The
goodwill amount is not deductible for tax purposes. The fair value&#160;estimate of the developed technology is determined using a variation
of the income approach known as the &#x201c;Multi-Period Excess Earnings Approach&#x201d;. This valuation technique estimates the fair value
of an asset based on market participants&#x2019; expectations of the cash flows an asset would generate over its remaining useful life.&#160;The
net cash flows were discounted to present value. Due to the timing of the transaction closing date, the fair values assigned to assets
acquired and liabilities assumed are preliminary, based on management&#x2019;s estimates and assumptions and may be subject to change as
additional information is received. We expect to finalize the valuation as soon as practicable, but not later than one year from the acquisition
date. Refer to notes 2c and 2h.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The amount of the acquisition-related costs
was approximately $310 which was recognized as an expense in the general and administration expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;The results of operations of Nanox AI
have been included in the consolidated financial statements since the date of the acquisition. The amounts of revenues and net loss related
to Nanox AI that are included in the Company&#x2019;s consolidated statements of operations for the period starting from the merger date
to&#160;December 31, 2021, are $270 thousand and $4,157 thousand, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;The following unaudited pro forma information
presents the combined results of operations of the Company and Nanox AI as if the acquisition of Nanox AI had been completed on January
1, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;The unaudited pro forma results include adjustments primarily related
to amortization of the acquired intangible assets and share-based compensation associated with option grants as referenced above, as of
January 1,2020. The unaudited pro forma results do not reflect any cost saving synergies from operating efficiencies, or the effect of
the incremental costs incurred from integrating Nanox AI. Accordingly, these unaudited pro forma results are presented for informational
purposes only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the
acquisition of Nanox AI had occurred at the beginning of 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Year Ended&lt;br/&gt; December&#160;31, 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Year Ended&lt;br/&gt; December&#160;31, 2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;US$ in thousand&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,363&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(87,045&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(69,875&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;The acquisition of USARAD Holding Inc.&#160;&#160;(the &#x201c;USARAD transaction&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;On November 2, 2021 (the &#x201c;USARAD closing
date&#x201d;), the Company completed the acquisition of 100% of the shares of USARAD Holdings, Inc., a Delaware corporation (&#x201c;USARAD&#x201d;),
pursuant to the terms of the Stock Purchase Agreement, dated October 25, 2021, among the Company, USARAD, Dr. Michael Yuz, other holders
of capital stock of USARAD, and holders of USARAD options. At the USARAD closing date, Nanox U.S. purchased 100% of the shares of USARAD
on a fully diluted basis for $7,147 thousand in cash and 496,545 of the Company&#x2019;s ordinary shares with an estimated fair value of
$11,500 thousand. The number of ordinary shares issued by the Company was determined using the average closing trading price during the
30 trading days preceding to the closing date. The total consideration was approximately $18,647 thousand. In addition, upon the successful
achievement of certain milestones related to profitability, EBITDA and other operational performance-based earnouts over 2 years, the
Company will pay additional cash consideration in the amount of up to $2,000 thousand and stock consideration in the amount of up to $6,500
thousand at a per share value determined by the average of i) the volume weighted average closing share price of the 30 trading days prior
to the relevant milestone completion, and (ii) the volume weighted average closing share price of the 30 trading days ending on August
6, 2021.. Revenue in the amount of $1,034 and net loss in the amount of $358 thousand of the acquiree included in the Company&#x2019;s
consolidated statements of operations for the year ended at December 31,2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The USARAD transaction was accounted in
accordance with ASC 805, &#x201c;Business Combinations&#x201d;, using the acquisition method of accounting with the Company as the acquirer.&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;The following table summarizes the fair value of the consideration
transferred to USARAD shareholders for the USARAD transaction:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S. $ in thousands&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Cash payments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,147&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Issuance of ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent consideration at estimated fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total consideration&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,052&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;In accordance with ASC 805, the estimated
contingent consideration&#160;as of the USARAD transaction date was&#160;included in the purchase price. The total contingent payments
could reach to a maximum aggregate amount of up to $8,500 thousand.&#160;Approximately 23.52% of the payments shall be settled in cash,
and 76.47% shall be settled through the issuance of ordinary shares.&#160;The estimated fair value of the contingent consideration is
based on management&#x2019;s assessment&#160;of whether, and at what level, the financial metrics will be achieved, and the present value
factors associated&#160;with the timing of the payments.&#160;This fair value measurement&#160;is based on significant unobservable inputs
in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the fair value of contingent consideration
will be recorded in&#160;operating expenses. Additional payment&#160;of $144 thousand may be paid to USARAD&#x2019;s shareholders if an
approval of the PPP loan by the Federal Government will occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;The allocation of the purchase price
to assets acquired and liabilities assumed is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Allocation of Purchase Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(U.S. $ in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;332&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts Receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;912&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total assets acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loan from a government agency&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other labilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Contingent short term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent long term earnout liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities assumed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,872&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,647&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; "&gt;The allocation of the purchase price
to net assets acquired and liability assumed resulted in the recognition of intangible asset related to retained radiologists of $17,770
thousand, customers&#x2019; relationship of $1,322 thousand, trademark of $2,095 thousand and goodwill of $7,055 thousand. As such, the
goodwill will be assigned to the operational segment of radiology services. The intangible asset relates to retained radiologists has
a useful-life of 11.17 years, the intangible asset relates to customers&#x2019; relationship has a useful-life of 6.17 years and the intangible
asset relates to the trademark has a useful-life of 12.17 years.&#160; This fair value measurement is based on significant unobservable
inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration
is based on several factors, such as: the cash flows projected from the success of achievements of several achievement and payment of
milestone events; the time and resources needed to achieve those milestones and the risk adjusted discount rate for fair value measurement.
A probability of success factor was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent
payments. The weighted average discount rate, calculated based on the relative fair value of the contingent consideration liabilities,
was&#160;21.9%. The contingent consideration is evaluated quarterly, or more frequently, if circumstances dictate. Changes in the fair
value of contingent consideration are recorded in consolidated statements of income. Significant changes in unobservable inputs, mainly
the probability of success and cash flows projected, could result in material changes to the contingent consideration liabilities. Due
to the timing of the transaction closing date, the fair values assigned to assets acquired and liabilities assumed are preliminary, based
on management&#x2019;s estimates and assumptions and may be subject to change as additional information is received. We expect to finalize
the valuation as soon as practicable, but not later than one year from the acquisition date. Refer to notes 2c and 2h.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; "&gt;During 2021,
USARAD executed the standard loan documents required for securing a loan from the SBA under its Paycheck Protection Program Loan (&#x201c;PPP&#x201d;)
assistance program in light of the impact of the COVID-19 pandemic on the Company&#x2019;s business.&#160;Pursuant to that certain Loan
Authorization and Agreement, the principal amount of the PPP Loan is $144, with proceeds to be used for working capital purposes. Interest
accrues at the rate of 1.00 % per annum and the term of the loan is five years. After the completion of the acquisition USARAD applied
for forgiveness of the loan. Per to the terms of the Stock Purchase Agreement, the Company will pay the forgiven amounts to the former
shareholders of USARAD.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; "&gt;The amount of the acquisition-related costs was approximately
$198 which was recognized as an expense in the general and administration expenses.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; "&gt;Pro forma results of operations related
to the USARAD acquisition have not been prepared because they are not material to the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;The Assets acquisition of MDWEB LLC.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"&gt;On November 3, 2021, the Company
completed the acquisition of the market platform and other assets of MDWEB, LLC (&#x201c;MDWEB&#x201d;), pursuant to the terms of the Asset
Purchase Agreement, dated October 21, 2021, between the Company and MDWEB. At the same date, the Company issued 64,715 of its ordinary
shares to MDWEB with an estimated fair value of $1,500 thousand. In addition, upon the successful achievement of certain milestones related
to technical integration of MDW platform with Nanox Cloud and achieving certain other operational targets, the Company will pay additional
stock consideration in the amount of up to $1,500 thousand at a per share value determined by the average closing price of the 30 trading
days ending on the applicable milestone&#x2019;s achievement date. In addition, upon the successful achievement of certain milestones and
other operational performance-based earnouts over 2 years, the Company will pay stock consideration in the amount of up to $1,500 thousand
at a per share value determined by the average closing price of : (i) closing price of the 30 trading days ending on the applicable milestone&#x2019;s
achievement date: and (ii) the volume weighted average closing share price of the 30 trading days prior to the closing date. .&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; "&gt;The Company will amortize the intangible assets on a straight-line
basis over their expected useful life of 48 months. Refer to note 2h.&lt;/p&gt;</nnox:CertainTransactionsTextBlock>
    <us-gaap:SharesIssued contextRef="c51" decimals="0" unitRef="shares">3249142</us-gaap:SharesIssued>
    <nnox:EmployeeOptionsAndRestrictedStockUnits contextRef="c52" decimals="0" unitRef="shares">70211</nnox:EmployeeOptionsAndRestrictedStockUnits>
    <us-gaap:FairValueNetAssetLiability contextRef="c51" decimals="-3" unitRef="usd">88510000</us-gaap:FairValueNetAssetLiability>
    <nnox:OutstandingSharesPerShare contextRef="c51" decimals="2" unitRef="usdPershares">26.57</nnox:OutstandingSharesPerShare>
    <nnox:ServicePeriodsDecription contextRef="c0">Out of which $315 thousand was allocated to the purchase consideration and $970&#160;thousand was allocated to future services and continued
employment and shall be expensed over remaining service periods of up to 4 years.</nnox:ServicePeriodsDecription>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c53" decimals="-3" unitRef="usd">315000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <nnox:PurchaseConsideration contextRef="c53" decimals="-3" unitRef="usd">970000</nnox:PurchaseConsideration>
    <nnox:DeferredClosingConsideration contextRef="c52" decimals="-3" unitRef="usd">3333000</nnox:DeferredClosingConsideration>
    <nnox:AdditionalConsideration contextRef="c52" decimals="-3" unitRef="usd">77700000</nnox:AdditionalConsideration>
    <nnox:ScheduleOfFairValueConsiderationTransferred contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S.$&lt;br/&gt; in thousand&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 89%; text-align: left"&gt;Issuance of ordinary shares, options and RSUs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;88,510&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Contingent short term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent long term earnout liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,660&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total consideration&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;129,299&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S. $ in thousands&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Cash payments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,147&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Issuance of ordinary shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent consideration at estimated fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total consideration&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,052&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;</nnox:ScheduleOfFairValueConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c54" decimals="-3" unitRef="usd">88510000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent contextRef="c64" decimals="-3" unitRef="usd">38129000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c64" decimals="-3" unitRef="usd">2660000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationAsset contextRef="c64" decimals="-3" unitRef="usd">129299000</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <nnox:MaximumAggregateAmount contextRef="c54" decimals="-3" unitRef="usd">77700000</nnox:MaximumAggregateAmount>
    <nnox:FairValuePercentage contextRef="c54" decimals="2" unitRef="pure">0.19</nnox:FairValuePercentage>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Allocation&lt;br/&gt; of Purchase&lt;br/&gt; Price&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;(U.S. $ in thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-weight: bold; text-align: left"&gt;Cash, cash equivalents and Restricted&#160;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,956&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts Receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,816&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51,243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,693&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total assets acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Contingent short term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,129&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Contingent long-term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,660&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Convertible note (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other labilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,525&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities assumed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51,727&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;88,510&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Allocation of Purchase Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;(U.S. $ in thousands)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;332&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts Receivables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;912&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total assets acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loan from a government agency&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other labilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Contingent short term earnout liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contingent long term earnout liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,952&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities assumed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,872&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,647&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c64" decimals="-3" unitRef="usd">6956000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c64" decimals="-3" unitRef="usd">99000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c64" decimals="-3" unitRef="usd">430000</us-gaap:OtherAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent contextRef="c64" decimals="-3" unitRef="usd">79816000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:Goodwill contextRef="c64" decimals="-3" unitRef="usd">51243000</us-gaap:Goodwill>
    <us-gaap:OtherAssets contextRef="c64" decimals="-3" unitRef="usd">1693000</us-gaap:OtherAssets>
    <nnox:TotalAssetsAcquired contextRef="c54" decimals="-3" unitRef="usd">140237000</nnox:TotalAssetsAcquired>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c64" decimals="-3" unitRef="usd">3413000</us-gaap:DeferredIncomeTaxLiabilities>
    <nnox:ContingentShortTermEarnoutLiability contextRef="c64" decimals="-3" unitRef="usd">38129000</nnox:ContingentShortTermEarnoutLiability>
    <nnox:ContingentLongtermEarnoutLiability contextRef="c64" decimals="-3" unitRef="usd">2660000</nnox:ContingentLongtermEarnoutLiability>
    <nnox:ConvertibleNote contextRef="c64" decimals="-3" id="ix_5_fact" unitRef="usd">3000000</nnox:ConvertibleNote>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c64" decimals="-3" unitRef="usd">4525000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilities contextRef="c64" decimals="-3" unitRef="usd">51727000</us-gaap:OtherLiabilities>
    <nnox:NetAssetsAcquired contextRef="c64" decimals="-3" unitRef="usd">88510000</nnox:NetAssetsAcquired>
    <nnox:DescriptionOfNetAssets contextRef="c54">The allocation of the purchase price to net assets acquired and liability
assumed resulted in the recognition of intangible asset related to technology of $27,316 thousand which will be expensed over remaining
service periods of 10 years, Image Big Data of $52,500 thousand which will be expensed over remaining service periods of 10 years, and
goodwill of $51,243 thousand, which is primarily attributed to the expected synergies from combining the operations of Zebra&#x2019;s AI
solutions with the Company tomographic imaging systems. As such, the goodwill will be assigned to the operational segment of AI solutions.</nnox:DescriptionOfNetAssets>
    <nnox:AcquisitionDate contextRef="c54">P1Y</nnox:AcquisitionDate>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c55" decimals="-3" unitRef="usd">310000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:RevenuesNetOfInterestExpense contextRef="c0" decimals="-3" unitRef="usd">270000</us-gaap:RevenuesNetOfInterestExpense>
    <nnox:NetLoss contextRef="c0" decimals="-3" unitRef="usd">4157000</nnox:NetLoss>
    <pf0:CondensedStatementOfComprehensiveIncomeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Year Ended&lt;br/&gt; December&#160;31, 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Year Ended&lt;br/&gt; December&#160;31, 2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;US$ in thousand&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,363&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(87,045&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(69,875&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;</pf0:CondensedStatementOfComprehensiveIncomeTableTextBlock>
    <us-gaap:Revenues contextRef="c65" decimals="-3" unitRef="usd">2363000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c66" decimals="-3" unitRef="usd">1550000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss contextRef="c65" decimals="-3" unitRef="usd">-87045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c66" decimals="-3" unitRef="usd">-69875000</us-gaap:NetIncomeLoss>
    <nnox:AcquisitionOfSharesPercentage contextRef="c56" decimals="2" unitRef="pure">1</nnox:AcquisitionOfSharesPercentage>
    <nnox:PurchaseOfSharesPercentage contextRef="c57" decimals="2" unitRef="pure">1</nnox:PurchaseOfSharesPercentage>
    <us-gaap:CashAcquiredFromAcquisition contextRef="c56" decimals="-3" unitRef="usd">7147000</us-gaap:CashAcquiredFromAcquisition>
    <nnox:OrdinaryShare contextRef="c57" decimals="0" unitRef="shares">496545</nnox:OrdinaryShare>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c57" decimals="-3" unitRef="usd">11500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c56" decimals="-3" unitRef="usd">18647000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <nnox:OtherOperationalPerformancebasedEarnoutsOver contextRef="c56">P2Y</nnox:OtherOperationalPerformancebasedEarnoutsOver>
    <nnox:AdditionalCashConsideration contextRef="c56" decimals="-3" unitRef="usd">2000000</nnox:AdditionalCashConsideration>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c56" decimals="-3" unitRef="usd">6500000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <nnox:OtherRevenue contextRef="c58" decimals="-3" unitRef="usd">1034000</nnox:OtherRevenue>
    <nnox:OtherNetLoss contextRef="c58" decimals="-3" unitRef="usd">358000</nnox:OtherNetLoss>
    <us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness contextRef="c58" decimals="-3" unitRef="usd">7147000</us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c58" decimals="-3" unitRef="usd">11500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure contextRef="c60" decimals="-3" unitRef="usd">6405000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationAsset contextRef="c60" decimals="-3" unitRef="usd">25052000</us-gaap:BusinessCombinationContingentConsiderationAsset>
    <nnox:MaximumAggregateAmount contextRef="c58" decimals="-3" unitRef="usd">8500000</nnox:MaximumAggregateAmount>
    <nnox:SettledInCashPercentage contextRef="c58" decimals="4" unitRef="pure">0.2352</nnox:SettledInCashPercentage>
    <nnox:IssuanceOfOrdinarySharePercentage contextRef="c58" decimals="4" unitRef="pure">0.7647</nnox:IssuanceOfOrdinarySharePercentage>
    <nnox:AdditionalPayment contextRef="c58" decimals="-3" unitRef="usd">144000</nnox:AdditionalPayment>
    <us-gaap:OtherCashEquivalentsAtCarryingValue contextRef="c60" decimals="-3" unitRef="usd">332000</us-gaap:OtherCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c60" decimals="-3" unitRef="usd">912000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:IntangibleAssetsCurrent contextRef="c60" decimals="-3" unitRef="usd">21187000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:Goodwill contextRef="c60" decimals="-3" unitRef="usd">7055000</us-gaap:Goodwill>
    <us-gaap:OtherAssets contextRef="c60" decimals="-3" unitRef="usd">33000</us-gaap:OtherAssets>
    <nnox:TotalAssetsAcquired contextRef="c58" decimals="-3" unitRef="usd">29519000</nnox:TotalAssetsAcquired>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c60" decimals="-3" unitRef="usd">144000</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c60" decimals="-3" unitRef="usd">557000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c60" decimals="-3" unitRef="usd">3766000</us-gaap:DeferredIncomeTaxLiabilities>
    <nnox:ContingentShortTermEarnoutLiability contextRef="c60" decimals="-3" unitRef="usd">3453000</nnox:ContingentShortTermEarnoutLiability>
    <nnox:ContingentLongTermEarnoutLiability contextRef="c60" decimals="-3" unitRef="usd">2952000</nnox:ContingentLongTermEarnoutLiability>
    <us-gaap:OtherLiabilities contextRef="c60" decimals="-3" unitRef="usd">10872000</us-gaap:OtherLiabilities>
    <nnox:NetAssetsAcquired contextRef="c60" decimals="-3" unitRef="usd">18647000</nnox:NetAssetsAcquired>
    <us-gaap:ImpairedIntangibleAssetDescription contextRef="c58">The allocation of the purchase price
to net assets acquired and liability assumed resulted in the recognition of intangible asset related to retained radiologists of $17,770
thousand, customers&#x2019; relationship of $1,322 thousand, trademark of $2,095 thousand and goodwill of $7,055 thousand. As such, the
goodwill will be assigned to the operational segment of radiology services. The intangible asset relates to retained radiologists has
a useful-life of 11.17 years, the intangible asset relates to customers&#x2019; relationship has a useful-life of 6.17 years and the intangible
asset relates to the trademark has a useful-life of 12.17 years.</us-gaap:ImpairedIntangibleAssetDescription>
    <nnox:FairValueOfContingentConsiderationLiabilities contextRef="c58" decimals="3" unitRef="pure">0.219</nnox:FairValueOfContingentConsiderationLiabilities>
    <nnox:AcquisitionDate contextRef="c58">P1Y</nnox:AcquisitionDate>
    <nnox:PrincipalAmountOfThePPPLoan contextRef="c59" decimals="-3" unitRef="usd">144000</nnox:PrincipalAmountOfThePPPLoan>
    <nnox:InterestAccruesRate contextRef="c60" decimals="4" unitRef="pure">0.01</nnox:InterestAccruesRate>
    <nnox:LoanTerm contextRef="c58">P5Y</nnox:LoanTerm>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c61" decimals="-3" unitRef="usd">198000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <nnox:AssetsAcquisitionDescription contextRef="c62">the Company issued 64,715 of its ordinary
shares to MDWEB with an estimated fair value of $1,500 thousand. In addition, upon the successful achievement of certain milestones related
to technical integration of MDW platform with Nanox Cloud and achieving certain other operational targets, the Company will pay additional
stock consideration in the amount of up to $1,500 thousand at a per share value determined by the average closing price of the 30 trading
days ending on the applicable milestone&#x2019;s achievement date. In addition, upon the successful achievement of certain milestones and
other operational performance-based earnouts over 2 years, the Company will pay stock consideration in the amount of up to $1,500 thousand
at a per share value determined by the average closing price of : (i) closing price of the 30 trading days ending on the applicable milestone&#x2019;s
achievement date: and (ii) the volume weighted average closing share price of the 30 trading days prior to the closing date.</nnox:AssetsAcquisitionDescription>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c63">P48M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;NOTE&#160;4 &#x2014; GOODWILL&#160;&amp;amp;
INTANGIBLE ASSETS, NET:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The following table presents
the changes in the carrying amount of goodwill and the intangible assets as of December 31, 2021 (U.S. dollars in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Goodwill from acquisition of Zebra&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;51,243&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Goodwill from acquisition of USARAD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,298&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;&lt;i&gt;Intangible assets &lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt"&gt;The acquired intangible assets has an estimated fair value
as of December 31, 2021 of $101,826 thousand. The Identifiable intangible assets were recorded as follows (U.S. dollars in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Useful Life&lt;br/&gt;
(in Years)&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Amount as&#160;of&lt;br/&gt;
the merger/&lt;br/&gt;
acquisition&lt;br/&gt;
date&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Amortization&lt;br/&gt;
expense for&lt;br/&gt;
the period&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Amount as&lt;br/&gt;
of December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,316&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Image big data&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;52,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;51,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Market platform&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Radiologist relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;11.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;12.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,066&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Customer relationships&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;6.17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,322&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;103,594&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,768&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;101,826&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Intangible assets with estimable useful lives are amortized over their
respective estimated useful lives to their estimated residual values and reviewed periodically for impairment. Amortization expenses were
$1,768 and $0 and $0 for the years ended December 31, 2021 and December 31, 2020 and December 31, 2019, respectively.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Amortization of intangible
assets for each of the next five years and thereafter is expected to be as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 89%"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,607&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,607&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,607&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,499&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;2026 and thenafter&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;59,506&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;101,826&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance as of December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Goodwill from acquisition of Zebra&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;51,243&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Goodwill from acquisition of USARAD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58,298&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c68" decimals="-3" unitRef="usd">51243000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c69" decimals="-3" unitRef="usd">7055000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill contextRef="c70" decimals="-3" unitRef="usd">58298000</us-gaap:Goodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue contextRef="c2" decimals="0" unitRef="usd">101826</us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Useful Life&lt;br/&gt;
(in Years)&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Amount as&#160;of&lt;br/&gt;
the merger/&lt;br/&gt;
acquisition&lt;br/&gt;
date&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Amortization&lt;br/&gt;
expense for&lt;br/&gt;
the period&lt;/b&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b&gt;Amount as&lt;br/&gt;
of December 31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,316&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Image big data&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;52,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;51,625&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Market platform&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,591&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Radiologist relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;11.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,770&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trade name&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;12.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,095&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,066&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Customer relationships&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;6.17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,322&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;103,594&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,768&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;101,826&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c71">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <nnox:FiniteLivedIntangibleAssetNet contextRef="c72" decimals="-3" unitRef="usd">27316000</nnox:FiniteLivedIntangibleAssetNet>
    <nnox:AmortizationExpenseForThePeriod contextRef="c71" decimals="-3" unitRef="usd">455000</nnox:AmortizationExpenseForThePeriod>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c72" decimals="-3" unitRef="usd">26861000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c73">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <nnox:FiniteLivedIntangibleAssetNet contextRef="c74" decimals="-3" unitRef="usd">52500000</nnox:FiniteLivedIntangibleAssetNet>
    <nnox:AmortizationExpenseForThePeriod contextRef="c73" decimals="-3" unitRef="usd">875000</nnox:AmortizationExpenseForThePeriod>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c74" decimals="-3" unitRef="usd">51625000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c75">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <nnox:FiniteLivedIntangibleAssetNet contextRef="c76" decimals="-3" unitRef="usd">2591000</nnox:FiniteLivedIntangibleAssetNet>
    <nnox:AmortizationExpenseForThePeriod contextRef="c75" decimals="-3" unitRef="usd">108000</nnox:AmortizationExpenseForThePeriod>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c76" decimals="-3" unitRef="usd">2483000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c77">P11Y2M1D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <nnox:FiniteLivedIntangibleAssetNet contextRef="c78" decimals="-3" unitRef="usd">17770000</nnox:FiniteLivedIntangibleAssetNet>
    <nnox:AmortizationExpenseForThePeriod contextRef="c77" decimals="-3" unitRef="usd">265000</nnox:AmortizationExpenseForThePeriod>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c78" decimals="-3" unitRef="usd">17505000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c79">P12Y2M1D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <nnox:FiniteLivedIntangibleAssetNet contextRef="c80" decimals="-3" unitRef="usd">2095000</nnox:FiniteLivedIntangibleAssetNet>
    <nnox:AmortizationExpenseForThePeriod contextRef="c79" decimals="-3" unitRef="usd">29000</nnox:AmortizationExpenseForThePeriod>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c80" decimals="-3" unitRef="usd">2066000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c81">P6Y2M1D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <nnox:FiniteLivedIntangibleAssetNet contextRef="c82" decimals="-3" unitRef="usd">1322000</nnox:FiniteLivedIntangibleAssetNet>
    <nnox:AmortizationExpenseForThePeriod contextRef="c81" decimals="-3" unitRef="usd">36000</nnox:AmortizationExpenseForThePeriod>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c82" decimals="-3" unitRef="usd">1286000</us-gaap:OtherIntangibleAssetsNet>
    <nnox:FiniteLivedIntangibleAssetNet contextRef="c2" decimals="-3" unitRef="usd">103594000</nnox:FiniteLivedIntangibleAssetNet>
    <nnox:AmortizationExpenseForThePeriod contextRef="c0" decimals="-3" unitRef="usd">1768000</nnox:AmortizationExpenseForThePeriod>
    <us-gaap:OtherIntangibleAssetsNet contextRef="c2" decimals="-3" unitRef="usd">101826000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:FilmMonetizedOnItsOwnAmortizationExpense contextRef="c0" decimals="0" unitRef="usd">1768</us-gaap:FilmMonetizedOnItsOwnAmortizationExpense>
    <us-gaap:FilmMonetizedOnItsOwnAmortizationExpense contextRef="c4" decimals="0" unitRef="usd">0</us-gaap:FilmMonetizedOnItsOwnAmortizationExpense>
    <us-gaap:FilmMonetizedOnItsOwnAmortizationExpense contextRef="c5" decimals="0" unitRef="usd">0</us-gaap:FilmMonetizedOnItsOwnAmortizationExpense>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 89%"&gt;&lt;span style="font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,607&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,607&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,607&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10,499&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;2026 and thenafter&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;59,506&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;101,826&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo contextRef="c2" decimals="-3" unitRef="usd">10607000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree contextRef="c2" decimals="-3" unitRef="usd">10607000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour contextRef="c2" decimals="-3" unitRef="usd">10607000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive contextRef="c2" decimals="-3" unitRef="usd">10499000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c2" decimals="-3" unitRef="usd">59506000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c2" decimals="-3" unitRef="usd">101826000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 5  - PROPERTY AND EQUIPMENT, NET:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;Composition of property and equipment grouped by major classifications
is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10-33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Vehicles&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Machines&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Land&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-102"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars &lt;br/&gt; in thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;648&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;820&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Equipment and machinery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1762&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Leasehold improvement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Land &#x2013; See b below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Production line in construction &#x2013; See b below&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,790&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,318&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,364&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(868&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;37,435&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total depreciation in respect of property and equipment were approximately $524 thousand, $208 thousand and $53 thousand for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;In December 2020, Nanox Korea purchased a land for approximately $6.3 million upon which it intends
to build a fabrication facility. In 2021, Nanox Korea completed the construction of the permanent fabrication plant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <nnox:ScheduleOfPropertyPlantAndEquipmentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10-33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;6-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Vehicles&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Machines&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;10-20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold Improvement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Land&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-102"&gt;N/A&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;</nnox:ScheduleOfPropertyPlantAndEquipmentTableTextBlock>
    <nnox:PercentageOfPropertyPlantAndEquipment contextRef="c84" decimals="2" unitRef="pure">0.10</nnox:PercentageOfPropertyPlantAndEquipment>
    <nnox:PercentageOfPropertyPlantAndEquipment contextRef="c85" decimals="2" unitRef="pure">0.33</nnox:PercentageOfPropertyPlantAndEquipment>
    <nnox:PercentageOfPropertyPlantAndEquipment contextRef="c86" decimals="2" unitRef="pure">0.06</nnox:PercentageOfPropertyPlantAndEquipment>
    <nnox:PercentageOfPropertyPlantAndEquipment contextRef="c87" decimals="2" unitRef="pure">0.20</nnox:PercentageOfPropertyPlantAndEquipment>
    <nnox:PercentageOfPropertyPlantAndEquipment contextRef="c88" decimals="2" unitRef="pure">0.33</nnox:PercentageOfPropertyPlantAndEquipment>
    <nnox:PercentageOfPropertyPlantAndEquipment contextRef="c89" decimals="2" unitRef="pure">0.10</nnox:PercentageOfPropertyPlantAndEquipment>
    <nnox:PercentageOfPropertyPlantAndEquipment contextRef="c90" decimals="2" unitRef="pure">0.20</nnox:PercentageOfPropertyPlantAndEquipment>
    <nnox:PercentageOfPropertyPlantAndEquipment contextRef="c91" decimals="2" unitRef="pure">0.10</nnox:PercentageOfPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars &lt;br/&gt; in thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Office furniture and lab equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;648&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;820&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Computers and electronic equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;151&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Equipment and machinery&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,766&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1762&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Leasehold improvement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;544&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Land &#x2013; See b below&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,297&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Production line in construction &#x2013; See b below&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,790&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,318&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,303&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,364&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(868&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;37,435&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c93" decimals="-3" unitRef="usd">648000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c94" decimals="-3" unitRef="usd">820000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c95" decimals="-3" unitRef="usd">1109000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c96" decimals="-3" unitRef="usd">151000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c97" decimals="-3" unitRef="usd">2766000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c98" decimals="-3" unitRef="usd">1762000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c91" decimals="-3" unitRef="usd">544000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c99" decimals="-3" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c88" decimals="-3" unitRef="usd">132000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c92" decimals="-3" unitRef="usd">6314000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c101" decimals="-3" unitRef="usd">6297000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c102" decimals="-3" unitRef="usd">26790000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c103" decimals="-3" unitRef="usd">5318000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" unitRef="usd">38303000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" unitRef="usd">14364000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" unitRef="usd">868000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">344000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">37435000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">14020000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c0" decimals="-3" unitRef="usd">524000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c4" decimals="-3" unitRef="usd">208000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c5" decimals="-3" unitRef="usd">53000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:PaymentsForPurchaseOfOtherAssets1 contextRef="c83" decimals="-5" unitRef="usd">6300000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
    <nnox:CashEquivalentsAndRestrictedCashTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-transform: uppercase"&gt;&lt;b&gt;NOTE 6 - CASH, CASH
EQUIVALENTS AND RESTRICTED CASH:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-transform: uppercase"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;The following table provides a reconciliation of cash, cash
equivalents and restricted cash reported on the consolidated balance sheet that sum to the same total amount as shown in the consolidated
statement of cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(U.S. Dollars&lt;br/&gt; in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;66,645&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,468&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted bank deposit (1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;316&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -11.5pt; padding-left: 11.5pt"&gt;Total cash, cash equivalents and restricted cash shown in the statement of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;66,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;213,784&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: left"&gt;As of December&#160;31, 2021, the Company&#x2019;s restricted
cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit is presented at cost including accrued
interest. This bank deposit is used as security for credit card use and collateralizing the Company&#x2019;s lease contracts&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</nnox:CashEquivalentsAndRestrictedCashTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(U.S. Dollars&lt;br/&gt; in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;66,645&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,468&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Restricted bank deposit (1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;127&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;316&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -11.5pt; padding-left: 11.5pt"&gt;Total cash, cash equivalents and restricted cash shown in the statement of cash flows&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;66,772&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;213,784&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(1)&lt;/td&gt;&lt;td style="text-align: left"&gt;As of December&#160;31, 2021, the Company&#x2019;s restricted
cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit is presented at cost including accrued
interest. This bank deposit is used as security for credit card use and collateralizing the Company&#x2019;s lease contracts&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">66645000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">213468000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <nnox:RestrictedBankDeposit contextRef="c0" decimals="-3" id="ix_6_fact" unitRef="usd">127000</nnox:RestrictedBankDeposit>
    <nnox:RestrictedBankDeposit contextRef="c4" decimals="-3" id="ix_7_fact" unitRef="usd">316000</nnox:RestrictedBankDeposit>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c2" decimals="-3" unitRef="usd">66772000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c3" decimals="-3" unitRef="usd">213784000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 7  - LEASES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;As of December 31, 2021, the Company has several operating
lease agreements for its car and facilities, as follows:&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;During the fourth quarter of 2019, the Company entered into
an office lease agreement. This agreement was through December 31, 2021 with an option by the Company to extend the period for an additional
24 months. The Company exercised the option.&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;The monthly rent payment is approximately $13 thousand. During
June 2020, the Company entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023. The
monthly rent payment for this agreement is approximately $15 thousand. During November 2020the Company signed an additional lease agreement,
for leasing another office complex through June 30, 2023. The monthly rent payment for this agreement is approximately $12 thousand. On
December 31,2021, the Company exercised its option to extend the lease for additional period of 24 months.&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;The Company leases vehicles to some of its employees. The
lease agreement is effective through June 30, 2023 and the monthly payment for this agreement is approximately $12 thousand.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;Nanox Korea leases 3 vehicles to some
employees. These lease agreements are effective through November 2023 to February 2024 and the monthly payment for these agreements is
approximately $ 5 thousand.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;In 2021 Nanox Korea leased approximately
390 square meters of space for a temporary fabrication facility and approximately 200 square meters of space for a research and development
center in Korea. During 2021 this lease ended due to the transfer of the temporary fabrication facility to the Company&#x2019;s permanent
fabrication facility in Yongin, Geonggi province.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;Nanox AI leases its offices in Israel under operating lease
agreement which expires in November 22 2024. Nanox AI has an option to extend the period for an additional 24 months through November
2026. &#160;Nanox AI concluded that it is not reasonably certain that it will exercise the renewal option. Accordingly, such renewal option
was not included in determining the lease term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 54pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;The monthly rent payment for this agreement is approximately
$12 thousand and the management fee is $4.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;The table below presents the effects on the amounts relating
to the Company&#x2019;s total lease costs:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars&lt;br/&gt; in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars &lt;br/&gt; In thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating lease cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Fixed payments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;653&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;276&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;701&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;341&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;The table below presents supplemental cash flow information
related to operating leases:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(U.S.&#160;Dollars&lt;br/&gt; in&#160;thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(U.S.&#160;Dollars&lt;br/&gt; in&#160;thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;507&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;169&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Right-of-use assets obtained in exchange for lease obligations (non-cash):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Operating leases&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;194&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,085&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;The table below presents supplemental balance sheet information
related to operating leases:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars&lt;br/&gt; in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars&lt;br/&gt; in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current maturities of operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;881&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Non-current operating leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;950&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;923&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,831&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,442&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.83&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;The table below presents maturities of operating lease liabilities:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars &lt;br/&gt; in thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;961&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2025 and thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,951&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,831&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseAndRentalExpense contextRef="c5" decimals="-3" unitRef="usd">13000</us-gaap:LeaseAndRentalExpense>
    <nnox:LeaseTermDescription contextRef="c104">During
June 2020, the Company entered into an additional office lease agreement, expanded the space leased in 2019, through June 30, 2023.</nnox:LeaseTermDescription>
    <us-gaap:LeaseAndRentalExpense contextRef="c104" decimals="-3" unitRef="usd">15000</us-gaap:LeaseAndRentalExpense>
    <nnox:LeaseTermDescription contextRef="c105">During November 2020the Company signed an additional lease agreement,
for leasing another office complex through June 30, 2023.</nnox:LeaseTermDescription>
    <us-gaap:LeaseAndRentalExpense contextRef="c105" decimals="-3" unitRef="usd">12000</us-gaap:LeaseAndRentalExpense>
    <nnox:LeaseTermDescription contextRef="c5">On
December 31,2021, the Company exercised its option to extend the lease for additional period of 24 months.</nnox:LeaseTermDescription>
    <nnox:LeasesTermDescription contextRef="c105">The
lease agreement is effective through June 30, 2023 and the monthly payment for this agreement is approximately $12 thousand.</nnox:LeasesTermDescription>
    <nnox:VehiclesLeasePayments contextRef="c105" decimals="-3" unitRef="usd">12000</nnox:VehiclesLeasePayments>
    <us-gaap:PaymentsForFees contextRef="c0" decimals="-3" unitRef="usd">5000</us-gaap:PaymentsForFees>
    <nnox:FabricationFacilityAndResearchDevelopmentalCenterDescription contextRef="c0">In 2021 Nanox Korea leased approximately
390 square meters of space for a temporary fabrication facility and approximately 200 square meters of space for a research and development
center in Korea.</nnox:FabricationFacilityAndResearchDevelopmentalCenterDescription>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="-3" unitRef="usd">12000</us-gaap:PaymentsForRent>
    <us-gaap:ManagementFeeExpense contextRef="c0" decimals="-3" unitRef="usd">4000</us-gaap:ManagementFeeExpense>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars&lt;br/&gt; in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars &lt;br/&gt; In thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating lease cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Fixed payments&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;653&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;276&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term lease cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;65&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating lease cost&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;701&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;341&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:LeaseCost contextRef="c0" decimals="-3" unitRef="usd">653000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c4" decimals="-3" unitRef="usd">276000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c0" decimals="-3" unitRef="usd">48000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c4" decimals="-3" unitRef="usd">65000</us-gaap:ShortTermLeaseCost>
    <nnox:TotalOperatingLeaseCost contextRef="c0" decimals="-3" unitRef="usd">701000</nnox:TotalOperatingLeaseCost>
    <nnox:TotalOperatingLeaseCost contextRef="c4" decimals="-3" unitRef="usd">341000</nnox:TotalOperatingLeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(U.S.&#160;Dollars&lt;br/&gt; in&#160;thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(U.S.&#160;Dollars&lt;br/&gt; in&#160;thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;507&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;169&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Right-of-use assets obtained in exchange for lease obligations (non-cash):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Operating leases&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;194&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,085&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" unitRef="usd">507000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c4" decimals="-3" unitRef="usd">169000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">194000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c4" decimals="-3" unitRef="usd">1085000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nnox:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars&lt;br/&gt; in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars&lt;br/&gt; in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,359&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current maturities of operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;881&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;519&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Non-current operating leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;950&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;923&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,831&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,442&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted average remaining lease term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.67&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.83&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;</nnox:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="-3" unitRef="usd">1725000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c4" decimals="-3" unitRef="usd">1359000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <nnox:CurrentMaturitiesOfOperatingLeases contextRef="c2" decimals="-3" unitRef="usd">881000</nnox:CurrentMaturitiesOfOperatingLeases>
    <nnox:CurrentMaturitiesOfOperatingLeases contextRef="c3" decimals="-3" unitRef="usd">519000</nnox:CurrentMaturitiesOfOperatingLeases>
    <nnox:NoncurrentOperatingLeases contextRef="c2" decimals="-3" unitRef="usd">950000</nnox:NoncurrentOperatingLeases>
    <nnox:NoncurrentOperatingLeases contextRef="c3" decimals="-3" unitRef="usd">923000</nnox:NoncurrentOperatingLeases>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c0" decimals="-3" unitRef="usd">1831000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c4" decimals="-3" unitRef="usd">1442000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P2Y1M20D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P2Y8M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="4" unitRef="pure">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="4" unitRef="pure">0.0583</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars &lt;br/&gt; in thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;961&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2025 and thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,951&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,831&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="-3" unitRef="usd">961000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c2" decimals="-3" unitRef="usd">745000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <nnox:LesseeOperatingLeaseLiabilityPaymentsDueYearFours contextRef="c2" decimals="-3" unitRef="usd">245000</nnox:LesseeOperatingLeaseLiabilityPaymentsDueYearFours>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="-3" unitRef="usd">1951000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="-3" unitRef="usd">120000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <nnox:PresentValueOfLeaseLiabilities contextRef="c2" decimals="-3" unitRef="usd">1831000</nnox:PresentValueOfLeaseLiabilities>
    <nnox:DeferredRevenuesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 8 &#x2013; DEFERRED REVENUE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;The following table represents the changes in
deferred revenue for the year ended December 31, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Deferred&lt;br/&gt; Revenue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Increase due to the business combinations&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;483&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in deferred revenue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;179&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2021 (*)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;662&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: left"&gt;Includes $415 thousand under long term deferred revenue in
the Company&#x2019;s consolidated balance sheets as of December 31, 2021.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</nnox:DeferredRevenuesDisclosureTextBlock>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Deferred&lt;br/&gt; Revenue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Increase due to the business combinations&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;483&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in deferred revenue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;179&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Balance at December 31, 2021 (*)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;662&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <nnox:IncreaseDueToTheBusinessCombinations contextRef="c2" decimals="0" unitRef="usd">483</nnox:IncreaseDueToTheBusinessCombinations>
    <nnox:DeferredRevenuesTotal contextRef="c0" decimals="0" unitRef="usd">179</nnox:DeferredRevenuesTotal>
    <us-gaap:DeferredRevenue contextRef="c2" decimals="0" id="ix_8_fact" unitRef="usd">662</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c2" decimals="-3" unitRef="usd">415000</us-gaap:DeferredRevenueNoncurrent>
    <nnox:RelatedPartyLiabilityTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9   - RELATED PARTIES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;As of December
31, 2019, the Company recorded a Related Party Liability in an amount of $17.8 million, which represents the fair value of the shares
that have been issued to Nanox PLC, based on the last financing round of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: left; text-indent: -28.35pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left"&gt;During January 2020, subject to entering into a share purchase
agreement in the aggregate amount of at least $6 million, and a pre-money valuation of more than $100 million, the Company&#x2019;s Board approved
the issuance and allotment of 1,109,245 ordinary shares to Nanox PLC with the purchase price of $12.00 per share, which reflects a discount
of 25% from the price of the last financing round of the Company. As a result, on January 30, 2020 the related party liability was settled
into equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;Related party balances at December 31, 2021 and December
31, 2020 consisted of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(Dollars in thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;(a) Due from Illumigyn&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;(b) Due from Wellsense Technologies Ltd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;(c) Due from Six-Eye Interactive&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;(c) Due from Six AI ltd.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total from related parties&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Related parties transactions:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars in thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt"&gt;Research and development &#x2013; see d below&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;80&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;355&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;154&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;General and administrative &#x2013; See c, e and f below&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(191&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(167&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,824&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;Six-Eye Interactive agreements for services&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;On June 1 2015, Nanox PLC entered into
a consulting agreement with Six-Eye, a company owned by Ran Poliakine, the Company&#x2019;s former Chief Executive Officer and one of major
shareholders, pursuant to which Ran Poliakine agreed to provide services as Chief Strategy Officer and a member of the Executive Committee
to Nanox PLC. On May 1, 2017, Nanox PLC entered into a services agreement with Six-Eye for the supply of ongoing services, which include
research and development services, general and financial management (including accountancy), office management services and operational
and supply services. According to the agreement between the parties, Nanox PLC reimburses Six-Eye for its actual direct expenses plus
a 12% surplus charge. The agreements were terminated in September 2019. During the year ended December 31 2019 the total expenses to Six-Eye
were $679 thousand. In addition to the services provided by Six-Eye during 2019, Six-Eye also paid directly to third-party consultants
and suppliers on behalf of the Company in the amount of approximately $1,015 thousand prior to the completion of the Company&#x2019;s equity
financing.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 1in; text-align: left"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="text-align: left; width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;d&lt;span style="font-family: Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;Six AI Ltd Service agreement&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;On April 16, 2020, the Company entered into an agreement with
SixAI Ltd. (hereinafter-&#x201c;SixAI&#x201d;) a company controlled by Ran Poliakine, the Company&#x2019;s former Chief Executive Officer
for certain software development and mechanical engineering services. The service agreement was effective as of March 1, 2020 and has
been extended by mutual agreement of the parties several times, until terminated at December 31, 2021. During the years ended December
31, 2021 and 2020, the Company recorded an expense of $80 and $355 thousand, respectively. Mr. Poliakine currently serves as a member
of the board of directors of SixAI and Mr. Poliakine is a significant shareholder of SixAI.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="text-align: left; width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;e.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;Illumigyn Ltd.&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Illumigyn Ltd (hereinafter &#x2013;
&#x201c;Illumigyn&#x201d;) is a company in which Ran Poliakine, the Company&#x2019;s former Chief Executive Officer, is a significant shareholder
primarily through indirect holdings. Since November 1 2019, Illumigyn sub-leased in transaction approximately 1,800 square feet of private
office space, including access to shared public spaces, from the office spaces which the Company leases in Neve Ilan, Israel. Illumigyn
pays approximately $12 thousand per month. During the years ended December 31, 2021 and 2020, the Company received approximately $125
and $163 thousand, respectively in relation to the sub lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 1in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;f.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;Wellsense Technologies Ltd.&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;

&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 72pt; text-align: left"&gt;Wellsense Technologies Ltd.(hereinafter
&#x2013; &#x201c;Wellsense&#x201d;) is a company in which Ran Poliakine, the Company&#x2019;s former Chief Executive Officer, and Richard
Stone, a member of the Company&#x2019;s board of directors, are shareholders. Since February 2020, Wellsense has sub-leased private office
space, including access to shared public spaces, from the Company in Neve Ilan, Israel. Wellsense pays approximately $7.0 thousand per
month. During the years ended December 31, 2021 and 2020, the Company received $66 and $59 thousand, respectively in relation to the sub
lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;g.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;b&gt;Employment Agreements&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;The Company has entered into an employment
agreement with Ran Poliakine, the Company&#x2019;s founder, Chairman of the Board of Directors, and former Chief Executive Officer. Pursuant
to the agreement, if the Company terminates Ran Poliakine&#x2019;s employment and waives his obligation to perform services during the
notice period of 180 days, Ran Poliakine will be entitled to receive payments of his base salary and social benefits in lieu of notice
for the waived period, up to the full notice period for an immediate termination. The agreement provides Ran Poliakine with a gross monthly
base salary equal to $40 which was increased to $60 upon the consummation of the Company&#x2019;s initial public offering.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: left"&gt;On September 27, 2021, the Company and
Erez Meltzer entered into an employment agreement, pursuant to which Mr. Meltzer agreed to serve as the Company&#x2019;s new Chief Executive
Officer (&#x201c;The Meltzer Employment Agreement&#x201d;). The Meltzer Employment Agreement commenced and became effective as of January
1, 2022 and shall continue for an indefinite period until it is terminated by either party. Pursuant to the terms of the Meltzer Employment
Agreement, Mr. Meltzer will receive an annual base salary of nine hundred thousand dollars ($900) per year, and will be eligible for an
annual incentive payment of up to one hundred percent (100%) of his base salary, which of them $450 will be guaranteed for the 2022 fiscal
year if his employment is continued through the entire fiscal year, with the possibility to withdraw an advance payment on account of
the 2022 annual bonus, subject to full recourse (clawback) if the bonus is not earned; Mr. Meltzer will be entitled to customary social
benefits under Israeli law and practice pursuant to which the Company shall insure the CEO with a manager&#x2019;s insurance policy or
a pension fund, or a combination of both (whereby each will apply partially), all according to his election; &#160;Mr. Meltzer will be
granted options to purchase 300,000 Ordinary Shares (the &#x201c;Options&#x201d;) which will vested equally over a period of 48 months as
long as Mr. Melter will be employed by the Company. The Options shall be subject to the Company&#x2019;s 2019 Equity Incentive plan and,
to the extent possible, be granted pursuant to Section 102 of the Israeli Income Tax Ordinance, 5721-1961. The exercise price of the Options
shall be $23.84 per share, a share price equals to the 30-day average of the Company&#x2019;s share price on NASDAQ, prior to the date
of approval of the CEO&#x2019;s employment agreement by the Board on September 27, 2021. Such amount may be paid by the CEO by way of a
cashless exercise mechanism; The agreement calls for a 6 months&#x2019; mutual notice of termination and 270 days if the Company provides
notice during the first year of employment (except for &#x201c;Cause&#x201d; as defined in the employment agreement, in which case no prior
notice will be required);&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;h.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Service Agreement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;In February 2021, the shareholders of the Company approved
the entry into an agreement with Floyd Katske, effective as of October 1, 2020, whereby Floyd Katske will assist the Chief Executive Officer
and the Company with various tasks given his medical knowledge, expertise and experience, as may be requested from time-to-time by the
Company&#x2019;s Chief Executive Officer. These tasks are in addition and unrelated to his role as a member of the board of directors of
the Company. Floyd Katske will be paid with respect to such services $200 per hour, against an invoice. The services will be limited to
100 hours in any calendar month, according to hours approved by the Chairman. In addition, Floyd Katske will be paid cash compensation
consisting of RSUs granted in each calendar quarter, in the amount calculated by dividing (i) two times the cash compensation paid during
such quarter as aforesaid by (ii) the fair market value of our ordinary shares on the last trading day of such quarter. All tax consequences
will be borne by Floyd Katske. The agreement may be terminated by 14 days&#x2019; written notice by either party. During the year ended
December 31, 2021, the Company recorded an expense of $168 with regards to the cash payment and $473 thousand with regards to the RSUs
portion of Floyds&#x2019; fees.&lt;/p&gt;</nnox:RelatedPartyLiabilityTextBlock>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty contextRef="c19" decimals="-5" unitRef="usd">17800000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:DebtInstrumentDescription contextRef="c106">During January 2020, subject to entering into a share purchase
agreement in the aggregate amount of at least $6 million, and a pre-money valuation of more than $100 million, the Company&#x2019;s Board approved
the issuance and allotment of 1,109,245 ordinary shares to Nanox PLC with the purchase price of $12.00 per share, which reflects a discount
of 25% from the price of the last financing round of the Company. As a result, on January 30, 2020 the related party liability was settled
into equity</us-gaap:DebtInstrumentDescription>
    <nnox:ScheduleOfRelatedPartyTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(Dollars in thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;(a) Due from Illumigyn&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;(b) Due from Wellsense Technologies Ltd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;(c) Due from Six-Eye Interactive&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;(c) Due from Six AI ltd.&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total from related parties&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</nnox:ScheduleOfRelatedPartyTableTextBlock>
    <nnox:TotalDueFromRelatedParties contextRef="c116" decimals="-3" unitRef="usd">3000</nnox:TotalDueFromRelatedParties>
    <nnox:TotalDueFromRelatedParties contextRef="c117" decimals="-3" unitRef="usd">27000</nnox:TotalDueFromRelatedParties>
    <nnox:TotalDueFromRelatedParties contextRef="c118" decimals="-3" unitRef="usd">11000</nnox:TotalDueFromRelatedParties>
    <nnox:TotalDueFromRelatedParties contextRef="c119" decimals="-3" unitRef="usd">14000</nnox:TotalDueFromRelatedParties>
    <nnox:TotalDueFromRelatedParties contextRef="c120" decimals="-3" unitRef="usd">1000</nnox:TotalDueFromRelatedParties>
    <nnox:TotalDueFromRelatedParties contextRef="c121" decimals="-3" unitRef="usd">-5000</nnox:TotalDueFromRelatedParties>
    <nnox:TotalDueFromRelatedParties contextRef="c122" decimals="-3" unitRef="usd">3000</nnox:TotalDueFromRelatedParties>
    <nnox:TotalDueFromRelatedParties contextRef="c2" decimals="-3" unitRef="usd">18000</nnox:TotalDueFromRelatedParties>
    <nnox:TotalDueFromRelatedParties contextRef="c3" decimals="-3" unitRef="usd">36000</nnox:TotalDueFromRelatedParties>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended December 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;(U.S. Dollars in thousands)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 4pt"&gt;Research and development &#x2013; see d below&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;80&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;355&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;154&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;General and administrative &#x2013; See c, e and f below&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(191&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(167&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,824&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 79.8pt"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">80000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">355000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c5" decimals="-3" unitRef="usd">154000</us-gaap:OtherResearchAndDevelopmentExpense>
    <nnox:OtherGeneralAndAdministrativeExpenses contextRef="c0" decimals="-3" unitRef="usd">191000</nnox:OtherGeneralAndAdministrativeExpenses>
    <nnox:OtherGeneralAndAdministrativeExpenses contextRef="c4" decimals="-3" unitRef="usd">167000</nnox:OtherGeneralAndAdministrativeExpenses>
    <nnox:OtherGeneralAndAdministrativeExpenses contextRef="c5" decimals="-3" unitRef="usd">-5824000</nnox:OtherGeneralAndAdministrativeExpenses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c107" decimals="2" unitRef="pure">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:OtherExpenses contextRef="c108" decimals="-3" unitRef="usd">679000</us-gaap:OtherExpenses>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax contextRef="c108" decimals="-3" unitRef="usd">1015000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherExpenses contextRef="c109" decimals="-3" unitRef="usd">80000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c110" decimals="-3" unitRef="usd">355000</us-gaap:OtherExpenses>
    <us-gaap:AreaOfLand contextRef="c111" decimals="0" unitRef="sqm">1800</us-gaap:AreaOfLand>
    <nnox:PaysApproximately contextRef="c0" decimals="-3" unitRef="usd">12000</nnox:PaysApproximately>
    <us-gaap:LeaseIncome contextRef="c0" decimals="-3" unitRef="usd">125000</us-gaap:LeaseIncome>
    <us-gaap:LeaseIncome contextRef="c4" decimals="-3" unitRef="usd">163000</us-gaap:LeaseIncome>
    <us-gaap:LeaseIncome contextRef="c112" decimals="-2" unitRef="usd">7000</us-gaap:LeaseIncome>
    <us-gaap:SalariesAndWages contextRef="c113" decimals="-3" unitRef="usd">40000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages contextRef="c114" decimals="-3" unitRef="usd">60000</us-gaap:SalariesAndWages>
    <nnox:EmploymentAgreementDescription contextRef="c115">the Company and
Erez Meltzer entered into an employment agreement, pursuant to which Mr. Meltzer agreed to serve as the Company&#x2019;s new Chief Executive
Officer (&#x201c;The Meltzer Employment Agreement&#x201d;). The Meltzer Employment Agreement commenced and became effective as of January
1, 2022 and shall continue for an indefinite period until it is terminated by either party. Pursuant to the terms of the Meltzer Employment
Agreement, Mr. Meltzer will receive an annual base salary of nine hundred thousand dollars ($900) per year, and will be eligible for an
annual incentive payment of up to one hundred percent (100%) of his base salary, which of them $450 will be guaranteed for the 2022 fiscal
year if his employment is continued through the entire fiscal year, with the possibility to withdraw an advance payment on account of
the 2022 annual bonus, subject to full recourse (clawback) if the bonus is not earned; Mr. Meltzer will be entitled to customary social
benefits under Israeli law and practice pursuant to which the Company shall insure the CEO with a manager&#x2019;s insurance policy or
a pension fund, or a combination of both (whereby each will apply partially), all according to his election; &#160;Mr. Meltzer will be
granted options to purchase 300,000 Ordinary Shares (the &#x201c;Options&#x201d;) which will vested equally over a period of 48 months as
long as Mr. Melter will be employed by the Company. The Options shall be subject to the Company&#x2019;s 2019 Equity Incentive plan and,
to the extent possible, be granted pursuant to Section 102 of the Israeli Income Tax Ordinance, 5721-1961. The exercise price of the Options
shall be $23.84 per share, a share price equals to the 30-day average of the Company&#x2019;s share price on NASDAQ, prior to the date
of approval of the CEO&#x2019;s employment agreement by the Board on September 27, 2021. Such amount may be paid by the CEO by way of a
cashless exercise mechanism; The agreement calls for a 6 months&#x2019; mutual notice of termination and 270 days if the Company provides
notice during the first year of employment (except for &#x201c;Cause&#x201d; as defined in the employment agreement, in which case no prior
notice will be required);</nnox:EmploymentAgreementDescription>
    <us-gaap:UtilitiesOperatingExpenseProductsAndServices contextRef="c0" decimals="0" unitRef="usd">200</us-gaap:UtilitiesOperatingExpenseProductsAndServices>
    <us-gaap:CostsAndExpenses contextRef="c0" decimals="0" unitRef="usd">168</us-gaap:CostsAndExpenses>
    <us-gaap:PaymentsForProceedsFromDepositOnLoan contextRef="c0" decimals="-3" unitRef="usd">473000</us-gaap:PaymentsForProceedsFromDepositOnLoan>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10 &#x2013; LONG TERM LOAN &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -9pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;During September 2021, Nanox Korea entered
into a 3 years Loan agreement with a Korean Bank, according to which the Bank granted the Company a loan in the amount of $3.8 million.
The loan bears an annual interest at a rate of 3 months KORIBOR and 1.149 % , whereas interest payments are due on a monthly basis and
the principal is due in the end of the loan term. The bank received a floating charge on the Company&#x2019;s asset.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebtTerm contextRef="c124">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:LongTermDebt contextRef="c124" decimals="-5" unitRef="usd">3800000</us-gaap:LongTermDebt>
    <nnox:AnnualInterestRate contextRef="c124" decimals="5" unitRef="pure">0.01149</nnox:AnnualInterestRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 11 - COMMITMENTS AND CONTINGENCIES&lt;/b&gt;:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52.5pt; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;From time to time, The Company may become
involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent
uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;in September 2020, two securities class
action complaints were filed in the United States District Court for the Eastern District of New York against the Company and certain
current officers and a director, which were subsequently consolidated and captioned as &lt;i&gt;White v. Nano-X Imaging Ltd. et al&lt;/i&gt;, Case
No. 1:20-cv-04355, alleging violations of securities laws on behalf of all persons and entities that purchased or otherwise acquired the
Company&#x2019;s publicly traded securities between August 21, 2020 and September 15, 2020, and seeking unspecified damages. On December
7, 2020, proposed lead plaintiffs submissions were fully briefed and remain outstanding. As of December 31, 2021, the Company has not
accrued any losses other than legal fees with connection to the above referenced complaints. The Company&#x2019;s position is that the
complaint has no merit and it will defend its position vigorously.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;On October 5, 2021, a class action complaint
was filed in the United States District Court for the Eastern District of New York against the Company and certain of its officers, captioned
McLaughlin v. Nano-X Imaging Ltd. et al, Case No. 1:21-cv-05517. The plaintiff asserts claims on behalf of persons and entities that purchased
or otherwise acquired the Company&#x2019;s securities between June 17, 2021 and August 18, 2021, seeking unspecified damages. The plaintiff
alleges that the defendants made materially false and misleading statements concerning the Company&#x2019;s business, operations and compliance
policies beginning on June 17, 2021, based on the Company&#x2019;s U.S. Food and Drug Administration submissions. As of December 31, 2021,
the Company has not accrued any losses other than legal fees with connection to the above referenced complaint. The Company&#x2019;s position
that the complaint has no merit and will defend its position vigorously.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;On October 28, 2021, a complaint was filed
in the United States District Court for the Central District of California against the Company, the Company&#x2019;s recently-formed Delaware
subsidiary and Nanox Gibraltar PLC (&#x201c;Gibraltar&#x201d;) from which the Company received certain assets, as well as Mr. Ran Poliakine
and certain other unidentified parties, alleging several causes of action including breach of a consulting agreement between plaintiff
and Gibraltar that was entered into in 2014. The plaintiff&#x2019;s demand is for a payment of unpaid consulting fees from Gibraltar in
the amount of approximately $1 million and approximately $29.5 million from the Company relating to his claimed entitlement to warrants
in Gibraltar. The Company&#x2019;s position is that the complaint against the Company has no merit, among other reasons, as it was not
a party to the agreement with the plaintiff and it is not Gibraltar&#x2019;s legal successor for any liabilities that Gibraltar may owe
to the plaintiff, and it intends to defend its position vigorously.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Division of Enforcement of the U.S.
Securities &amp;amp; Exchange Commission (the &#x201c;SEC&#x201d;) has notified the Company that it is conducting an investigation to determine
whether there had been any violations of the federal securities laws. The Company has been providing documents and information and has
now received a subpoena from the SEC requesting that the Company provide documents and other information relating to the development cost
of the Company&#x2019;s Nanox.ARC prototypes, as well as the Company&#x2019;s estimate for the cost of assembling the final Nanox.ARC product
at scale. The Company is cooperating with the SEC in responding to its requests. The duration and outcome of this matter cannot be predicted
at this time.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <nnox:ConsultingFees contextRef="c125" decimals="-6" unitRef="usd">1000000</nnox:ConsultingFees>
    <nnox:EntitlementToWarrantsAmount contextRef="c125" decimals="-5" unitRef="usd">29500000</nnox:EntitlementToWarrantsAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 12 - SHAREHOLDERS&#x2019; EQUITY:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;Each holder of the Company&#x2019;s ordinary
shares is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever funds are legally available
and declared by the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;). Since inception, the Company has not declared any dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The following table presents the number of authorized and issued and
outstanding shares as of each reporting date for each class of shares:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Authorized&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Issued and Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Authorized&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Issued and Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 51%; text-align: left"&gt;Ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;51,791,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;46,100,173&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;51,791,441&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,100,173&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Share based compensation &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&lt;span style="text-decoration:underline"&gt;Share based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;On September 3, 2019, the Company&#x2019;s
Board resolved to adopt an equity incentive plan (the &#x201c;Plan&#x201d;). Based on such Plan, each option will be exercisable for one
ordinary share of the Company and will become exercisable at such terms and during such periods, as the Board shall determine. Pursuant
to the Plan (and further increase of option pool approved by the Board), 8,041,936 ordinary shares of NIS 0.01 par value of the Company
are reserved for issuance upon the exercise of the same amount of awards to be granted to some of the Company&#x2019;s employees, directors
and consultants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;As of December 31, 2021, 1,841,838 ordinary shares reserved for the
equity incentive plan. The Board also approved the Plan for the purpose of selecting the capital gains tax track, under Section 102 of
the Israeli Income Tax Ordinance, for options granted to the Company&#x2019;s Israeli employees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: left"&gt;&lt;span style="text-decoration:underline"&gt;Share-based compensation to non-employees&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The following table summarizes share-based awards to non-employees
for the period ended December 31, 2021 and December 31, 2020:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;share-based&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;share-based&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;payment&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;payment&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,372,626&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.27&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,410,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.89&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Changes during the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;180,319&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,327,957&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,043,142&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;*(1,267,012&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(118,954&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(66,606&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(98,725&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,324,243&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.17&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,372,626&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.27&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,618,777&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.35&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,191,042&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.67&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Out
of which 404,704 and 1,027,151 awards were exercised on a cashless basis in 2021 and 2020, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The fair value of each granted award is estimated at the date
of grant using the Black- Scholes option-pricing model. The assumptions used for the year ended December 31, 2021 and year ended at December
31, 2020 are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt;
December&#160;31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt;
December&#160;31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 12%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 12%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;50.27% - 52.71%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;57.34%-44.40%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;0.66% - 1.61%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.27%-1.61%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Contractual term (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;0&#x2013;10&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5&#x2013;10&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The expected volatility is based on the historical volatility
of comparable companies. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term
of the awards granted in dollar terms. The Company does not have sufficient historical exercise data to provide a reasonable basis upon
which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified
method, which takes into consideration the option&#x2019;s contractual life and the vesting periods (for non-employees, the expected term
is equal to the option&#x2019;s contractual life.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in"&gt;The following table summarizes information concerning outstanding
and exercisable awards as of December 31, 2021 and 2020:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Awards outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Awards exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;awards&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;award&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;at end of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;contractual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;at end of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;contractual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;life (years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;life (years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 18%"&gt;&lt;span style="font-size: 10pt"&gt;1.92&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 17%"&gt;&lt;span style="font-size: 10pt"&gt;192,927&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 17%"&gt;&lt;span style="font-size: 10pt"&gt;0.04&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 17%"&gt;&lt;span style="font-size: 10pt"&gt;192,927&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 17%"&gt;&lt;span style="font-size: 10pt"&gt;0.04&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2.21&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,769,513&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.89&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,288,236&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.89&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;16.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;161,484&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.43&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;114,477&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.22&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;23.19&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.78&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;23.84&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.88&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30.93&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;20,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8.81&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;20,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8.81&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;12,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.53&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;40.21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;17,319&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.19&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,137&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.19&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;49.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.05&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Awards outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;Awards exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;awards&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;award&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;at end of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;at end of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;186,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;0.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;186,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;0.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;269,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;269,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,191,349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,188,914&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;444,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;283,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;30.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;2.&lt;/td&gt;&lt;td style="text-align: left"&gt;Share-based compensation to employees, officers and directors&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.3pt 0pt 1in; text-align: left"&gt;During 2021, the Company granted to certain employees, officers and
directors awards to purchase 1,418,665 of the Company&#x2019;s ordinary shares for an average exercise price of $27.57. Most of the awards
agreement term is 10 years unless the agreement is terminated, 4 years vesting period with a one-year cliff.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 81pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year ended &lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;share-based&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;share-based&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;payment awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;exercise&lt;br/&gt;
 price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;payment&lt;br/&gt;
 awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;exercise&lt;br/&gt;
 price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,381,125&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,667,267&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Changes during the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,418,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;27.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td style="text-align: right"&gt;730,734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Issued due to business combination&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(837,724&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(318,672&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,876&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2.21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;2,760,930&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;15.85&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,381,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4.14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;Exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;845,356&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.58&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,061,778&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 81pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The fair value of each granted award is
estimated at the date of grant using the Black- Scholes option-pricing model. The assumptions used as of December 31, 2021 and 2020 are
as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;Expected volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50.27%-51.84%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45.11%-55.97%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.66%-1.61%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.23%-1.61%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contractual term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The expected volatility is based on the
historical volatility of comparable companies. The risk-free interest rate assumption is based on observed interest rates appropriate
for the expected term of the awards granted in dollar terms. The Company does not have sufficient historical exercise data to provide
a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined
using the simplified method, which takes into consideration the option&#x2019;s contractual life and the vesting periods. The following
table summarizes information concerning outstanding and exercisable awards as of December 31, 2021 and 2020:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Awards outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Awards exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;awards&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;awards&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;at end of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;contractual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;at end of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;contractual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;life (years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;life (years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$0.00-0.01&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;&lt;span style="font-size: 10pt"&gt;120,757*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;73,679&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$2.21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;1,130,143&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;7.95&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;716,448&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;7.95&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$16.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;88,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;7.48&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;35,791&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6.09&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$17.63-$64.61&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;1,421,530&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;9.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;19,438&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;8.98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;*)&lt;/td&gt;&lt;td style="text-align: left"&gt;Including 47,793 RSUs that were granted to the employees of
Nanox AI at the completion of the merger and 3,221 RSUs that were issued in consideration for services.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Awards outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Awards exercisable&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;awards&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;awards&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;outstanding&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;remaining&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;exercisable&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;remaining&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;at end of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;contractual&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;at end of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;contractual&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;year&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;life (years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;year&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;life (years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: center"&gt;$2.21&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: center"&gt;1,995,625&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: center"&gt;9.05&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: center"&gt;1,019,695&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: center"&gt;9.05&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;$16.00&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;205,000&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;9.62&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;37,917&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;9.62&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$26.56-$59.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;180,500&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;9.93&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4,167&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;9.93&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Share-based compensation expenses&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(U.S. dollars in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Cost of revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;51&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;661&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sales and Marketing (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,065&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,145&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,967&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,806&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,781&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,245&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: left"&gt;On October 26, 2020, the Company entered into an amendment to
a business development agreement (&#x201c;the Agreement&#x201d;) dated February 4, 2020 with two service providers pursuant to which the
Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000
ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard
cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers
waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities
undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company&#x2019;s systems
and the issuance of warrants.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <nnox:ScheduleOfIssuedAndOutstandingTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Authorized&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Issued and Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Authorized&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Issued and Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 51%; text-align: left"&gt;Ordinary shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;51,791,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;46,100,173&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;51,791,441&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100,000,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,100,173&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;</nnox:ScheduleOfIssuedAndOutstandingTextBlock>
    <us-gaap:ExcessStockSharesAuthorized contextRef="c32" decimals="INF" unitRef="shares">100000000</us-gaap:ExcessStockSharesAuthorized>
    <nnox:OrdinarySharesIssuedAndOutstanding contextRef="c32" decimals="INF" unitRef="shares">51791441</nnox:OrdinarySharesIssuedAndOutstanding>
    <us-gaap:ExcessStockSharesAuthorized contextRef="c24" decimals="INF" unitRef="shares">100000000</us-gaap:ExcessStockSharesAuthorized>
    <nnox:OrdinarySharesIssuedAndOutstanding contextRef="c24" decimals="INF" unitRef="shares">46100173</nnox:OrdinarySharesIssuedAndOutstanding>
    <us-gaap:ExcessStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">100000000</us-gaap:ExcessStockSharesAuthorized>
    <nnox:OrdinarySharesIssuedAndOutstanding contextRef="c2" decimals="INF" unitRef="shares">51791441</nnox:OrdinarySharesIssuedAndOutstanding>
    <us-gaap:ExcessStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">100000000</us-gaap:ExcessStockSharesAuthorized>
    <nnox:OrdinarySharesIssuedAndOutstanding contextRef="c3" decimals="INF" unitRef="shares">46100173</nnox:OrdinarySharesIssuedAndOutstanding>
    <nnox:DescriptionOfSharebasedCompensationExpenses contextRef="c126">Pursuant
to the Plan (and further increase of option pool approved by the Board), 8,041,936 ordinary shares of NIS 0.01 par value of the Company
are reserved for issuance upon the exercise of the same amount of awards to be granted to some of the Company&#x2019;s employees, directors
and consultants.</nnox:DescriptionOfSharebasedCompensationExpenses>
    <us-gaap:CommonStockOtherSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">1841838</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;share-based&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;share-based&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;payment&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;payment&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,372,626&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.27&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,410,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.89&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Changes during the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;180,319&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,327,957&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13.70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,043,142&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.66&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;*(1,267,012&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(118,954&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(66,606&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(98,725&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,324,243&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.17&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,372,626&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.27&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,618,777&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.35&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,191,042&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.67&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="0" unitRef="shares">3372626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">5.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="0" unitRef="shares">3410406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c19" decimals="2" unitRef="usdPershares">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c0" decimals="0" unitRef="shares">180319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">40.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c4" decimals="0" unitRef="shares">1327957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">13.7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c0" decimals="0" unitRef="shares">1043142</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">7.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">8.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c0" decimals="0" unitRef="shares">118954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">10.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c0" decimals="0" unitRef="shares">66606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">16.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c4" decimals="0" unitRef="shares">98725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c4" decimals="2" unitRef="usdPershares">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <nnox:NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear contextRef="c0" decimals="0" unitRef="shares">2324243</nnox:NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">6.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <nnox:NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear contextRef="c4" decimals="0" unitRef="shares">3372626</nnox:NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">5.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c2" decimals="0" unitRef="shares">1618777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c3" decimals="0" unitRef="shares">2191042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">5.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="c0" decimals="0" unitRef="shares">404704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="c4" decimals="0" unitRef="shares">1027151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt;
December&#160;31,&lt;br/&gt;
2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt;
December&#160;31,&lt;br/&gt;
2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 72%"&gt;&lt;span style="font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 12%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; width: 12%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;50.27% - 52.71%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;57.34%-44.40%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;0.66% - 1.61%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.27%-1.61%&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Contractual term (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;0&#x2013;10&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;5&#x2013;10&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1.5pt"&gt;Expected volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;50.27%-51.84%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;45.11%-55.97%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.66%-1.61%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.23%-1.61%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Contractual term (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c4" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c113" decimals="4" unitRef="pure">0.5027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c114" decimals="4" unitRef="pure">0.5271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c129" decimals="4" unitRef="pure">0.5734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c130" decimals="4" unitRef="pure">0.444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c113" decimals="4" unitRef="pure">0.0066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c114" decimals="4" unitRef="pure">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c129" decimals="4" unitRef="pure">0.0027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c130" decimals="4" unitRef="pure">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c113">P0Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c114">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c129">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c130">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Awards outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Awards exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;awards&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;award&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;at end of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;contractual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;at end of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;contractual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;life (years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;life (years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 18%"&gt;&lt;span style="font-size: 10pt"&gt;1.92&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 17%"&gt;&lt;span style="font-size: 10pt"&gt;192,927&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 17%"&gt;&lt;span style="font-size: 10pt"&gt;0.04&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 17%"&gt;&lt;span style="font-size: 10pt"&gt;192,927&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; width: 17%"&gt;&lt;span style="font-size: 10pt"&gt;0.04&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2.21&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,769,513&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.89&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;1,288,236&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;7.89&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;16.00&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;161,484&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;5.43&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;114,477&lt;/p&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.22&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;23.19&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;21,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.78&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;23.84&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.88&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30.93&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;20,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8.81&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;20,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;8.81&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;30.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;12,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.53&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;40.21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;17,319&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.19&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;3,137&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.19&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;49.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;100,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;9.05&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Awards outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;Awards exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;awards&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;award&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;outstanding&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;exercisable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;at end of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;at end of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;contractual&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;life (years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;186,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;0.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;186,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;0.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;269,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;269,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,191,349&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,188,914&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;444,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;283,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;30.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Awards outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Awards exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;awards&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;awards&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;exercisable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;at end of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;contractual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;at end of&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;contractual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;life (years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;year&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;life (years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$0.00-0.01&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;&lt;span style="font-size: 10pt"&gt;120,757*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;73,679&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 17%; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$2.21&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;1,130,143&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;7.95&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;716,448&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;7.95&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$16.00&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;88,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;7.48&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;35,791&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;6.09&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;$17.63-$64.61&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;1,421,530&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;9.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;19,438&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;8.98&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Awards outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Awards exercisable&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;awards&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;awards&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;outstanding&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;remaining&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;exercisable&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;remaining&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;at end of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;contractual&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;at end of&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;contractual&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;year&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;life (years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;year&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;life (years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: center"&gt;$2.21&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: center"&gt;1,995,625&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: center"&gt;9.05&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: center"&gt;1,019,695&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 17%; text-align: center"&gt;9.05&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;$16.00&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;205,000&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;9.62&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;37,917&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;9.62&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$26.56-$59.20&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;180,500&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;9.93&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;4,167&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;9.93&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c137" decimals="2" unitRef="usdPershares">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c137" decimals="INF" unitRef="shares">192927</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c138">P0Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c137" decimals="INF" unitRef="shares">192927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c139">P0Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c140" decimals="2" unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c140" decimals="INF" unitRef="shares">1769513</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c141">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c140" decimals="INF" unitRef="shares">1288236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c142">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c143" decimals="2" unitRef="usdPershares">16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c143" decimals="INF" unitRef="shares">161484</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c144">P5Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c143" decimals="INF" unitRef="shares">114477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c145">P4Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c146" decimals="2" unitRef="usdPershares">23.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c146" decimals="INF" unitRef="shares">21000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c147">P9Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c149" decimals="2" unitRef="usdPershares">23.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c149" decimals="INF" unitRef="shares">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c150">P9Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c152" decimals="2" unitRef="usdPershares">30.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c152" decimals="INF" unitRef="shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c153">P8Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c152" decimals="INF" unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c154">P8Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c155" decimals="2" unitRef="usdPershares">30.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c155" decimals="INF" unitRef="shares">12000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c156">P9Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c158" decimals="2" unitRef="usdPershares">40.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c158" decimals="INF" unitRef="shares">17319</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c159">P9Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c158" decimals="INF" unitRef="shares">3137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c160">P9Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c161" decimals="2" unitRef="usdPershares">49.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c161" decimals="INF" unitRef="shares">100000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c162">P9Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c164" decimals="2" unitRef="usdPershares">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c165" decimals="INF" unitRef="shares">186815</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c166">P0Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c165" decimals="INF" unitRef="shares">186815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c166">P0Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c167" decimals="2" unitRef="usdPershares">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c168" decimals="INF" unitRef="shares">269714</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c169">P1Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c168" decimals="INF" unitRef="shares">269714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c169">P1Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c170" decimals="2" unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c171" decimals="INF" unitRef="shares">2191349</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c172">P6Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c171" decimals="INF" unitRef="shares">1188914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c172">P6Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c173" decimals="2" unitRef="usdPershares">16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c174" decimals="INF" unitRef="shares">444748</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c175">P8Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c174" decimals="INF" unitRef="shares">283933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c175">P8Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c176" decimals="2" unitRef="usdPershares">18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c177" decimals="INF" unitRef="shares">260000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c178">P3Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c177" decimals="INF" unitRef="shares">260000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c178">P3Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c179" decimals="2" unitRef="usdPershares">30.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c180" decimals="INF" unitRef="shares">20000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c181">P9Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c180" decimals="INF" unitRef="shares">1666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c181">P9Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="c0" decimals="0" unitRef="shares">1418665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c2" decimals="2" unitRef="usdPershares">27.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <nnox:AgreementTerminateTerm contextRef="c0">P4Y</nnox:AgreementTerminateTerm>
    <nnox:VestingPeriod contextRef="c0">P4Y</nnox:VestingPeriod>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="c208">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year ended &lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;share-based&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;share-based&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;payment awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;exercise&lt;br/&gt;
 price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;payment&lt;br/&gt;
 awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;exercise&lt;br/&gt;
 price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,381,125&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,667,267&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Changes during the year:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,418,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;27.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td style="text-align: right"&gt;730,734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Issued due to business combination&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(837,724&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(318,672&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(16,876&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2.21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;2,760,930&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;15.85&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,381,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4.14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;Exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;845,356&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3.58&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,061,778&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 27pt 0pt 81pt"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c209" decimals="0" unitRef="shares">2381125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices contextRef="c209" decimals="2" unitRef="usdPershares">4.14</nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c210" decimals="0" unitRef="shares">1667267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices contextRef="c210" decimals="2" unitRef="usdPershares">2.21</nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c211" decimals="0" unitRef="shares">1418665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c211" decimals="2" unitRef="usdPershares">27.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c212" decimals="0" unitRef="shares">730734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c212" decimals="2" unitRef="usdPershares">13.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance contextRef="c213" decimals="0" unitRef="shares">117536</us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance>
    <nnox:IssuedDueToBusinessCombination contextRef="c211" decimals="2" unitRef="usdPershares">0</nnox:IssuedDueToBusinessCombination>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c211" decimals="0" unitRef="shares">837724</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c211" decimals="2" unitRef="usdPershares">3.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <nnox:StockIssuedDuringPeriodSharesStockOptionsForfeited contextRef="c211" decimals="0" unitRef="shares">318672</nnox:StockIssuedDuringPeriodSharesStockOptionsForfeited>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c211" decimals="2" unitRef="usdPershares">19.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <nnox:NumberOfSharebasedPaymentAwardsCancelled contextRef="c212" decimals="0" unitRef="shares">-16876</nnox:NumberOfSharebasedPaymentAwardsCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c212" decimals="2" unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c213" decimals="0" unitRef="shares">2760930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices contextRef="c213" decimals="2" unitRef="usdPershares">15.85</nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c209" decimals="0" unitRef="shares">2381125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices contextRef="c209" decimals="2" unitRef="usdPershares">4.14</nnox:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c213" decimals="0" unitRef="shares">845356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <nnox:WeightedAverageExercisePriceExercisableAtEndOfYear contextRef="c211" decimals="2" unitRef="usdPershares">3.58</nnox:WeightedAverageExercisePriceExercisableAtEndOfYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c209" decimals="0" unitRef="shares">1061778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <nnox:WeightedAverageExercisePriceExercisableAtEndOfYear contextRef="c212" decimals="2" unitRef="usdPershares">2.8</nnox:WeightedAverageExercisePriceExercisableAtEndOfYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c131" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c132" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c133" decimals="4" unitRef="pure">0.5027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c134" decimals="4" unitRef="pure">0.5184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c135" decimals="4" unitRef="pure">0.4511</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c136" decimals="4" unitRef="pure">0.5597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c133" decimals="4" unitRef="pure">0.0066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c134" decimals="4" unitRef="pure">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c135" decimals="4" unitRef="pure">0.0023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c136" decimals="4" unitRef="pure">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c131">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c132">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c182" decimals="2" unitRef="usdPershares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c183" decimals="2" unitRef="usdPershares">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c185" decimals="INF" unitRef="shares">73679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c186" decimals="2" unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c186" decimals="INF" unitRef="shares">1130143</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c187">P7Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c188" decimals="INF" unitRef="shares">716448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c189">P7Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c190" decimals="2" unitRef="usdPershares">16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c190" decimals="INF" unitRef="shares">88500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c191">P7Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c192" decimals="INF" unitRef="shares">35791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c193">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c194" decimals="2" unitRef="usdPershares">17.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c195" decimals="2" unitRef="usdPershares">64.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c196" decimals="INF" unitRef="shares">1421530</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c197">P9Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c198" decimals="INF" unitRef="shares">19438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c199">P8Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c127" decimals="0" unitRef="shares">47793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <nnox:ConsiderationForServicesShares contextRef="c127" decimals="0" unitRef="shares">3221</nnox:ConsiderationForServicesShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c200" decimals="2" unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c200" decimals="INF" unitRef="shares">1995625</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c201">P9Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c200" decimals="INF" unitRef="shares">1019695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c201">P9Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c202" decimals="2" unitRef="usdPershares">16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c202" decimals="INF" unitRef="shares">205000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c203">P9Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c202" decimals="INF" unitRef="shares">37917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c203">P9Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c204" decimals="2" unitRef="usdPershares">26.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c205" decimals="2" unitRef="usdPershares">59.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c206" decimals="INF" unitRef="shares">180500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c207">P9Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c206" decimals="INF" unitRef="shares">4167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c207">P9Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(U.S. dollars in thousands)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Cost of revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;51&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;661&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Sales and Marketing (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,252&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,065&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,145&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,967&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,806&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,781&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,245&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:OtherCostOfOperatingRevenue contextRef="c0" decimals="-3" unitRef="usd">51000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="c0" decimals="-3" unitRef="usd">3248000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="c4" decimals="-3" unitRef="usd">3384000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess contextRef="c5" decimals="-3" unitRef="usd">661000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c0" decimals="-3" id="ix_9_fact" unitRef="usd">2442000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c4" decimals="-3" id="ix_10_fact" unitRef="usd">9252000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c5" decimals="-3" id="ix_11_fact" unitRef="usd">617000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">13065000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">12145000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">14967000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="c0" decimals="-3" unitRef="usd">18806000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="c4" decimals="-3" unitRef="usd">24781000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="c5" decimals="-3" unitRef="usd">16245000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:ValueAddedTaxReceivableNoncurrent contextRef="c2" decimals="-3" unitRef="usd">400000</us-gaap:ValueAddedTaxReceivableNoncurrent>
    <nnox:PurchaseAggregateShares contextRef="c128" decimals="0" unitRef="shares">650000</nnox:PurchaseAggregateShares>
    <us-gaap:WarrantExercisePriceIncrease contextRef="c128" decimals="0" unitRef="usdPershares">18</us-gaap:WarrantExercisePriceIncrease>
    <nnox:RecordedAnExpense contextRef="c0" decimals="1" unitRef="usd">6.1</nnox:RecordedAnExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 13 - INCOME TAX:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Basis of taxation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"&gt;Current tax is calculated with
reference to the profit of the Company and its subsidiaries in their respective countries of operation. Set out below are details in respect
of the significant jurisdictions where the Company and its subsidiaries operate and the factors that influenced the current and deferred
taxation in those jurisdictions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in"&gt;&lt;b&gt;Israel&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;The Company and Nanox AI Ltd are taxed
under the laws of the State of Israel at a corporate tax rate of 23%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;In 2021, 2020 and 2019, the Company is
at a loss position and therefore has no corporate tax liability. As of December&#160;31, 2021, 2020 and 2019, the Company has a carry
forward loss of approximately $56.3&#160;million, $32.3&#160;million and $2.3&#160;million, respectively. Such carry forward loss has
no expiration date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;In 2021, 2020 and 2019, Nanox AI Ltd.
is at a loss position and therefore has no corporate tax liability. As of December&#160;31, 2021, 2020 and 2019, Nanox AI Ltd. has a
carry forward loss of approximately $61.9&#160;million, $45.3&#160;million and $17.6&#160;million, respectively. Such carry forward loss
has no expiration date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in"&gt;&lt;b&gt;United States&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;The principal federal tax rate applicable to the U.S. subsidiaries
is 21%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;b&gt;&lt;i&gt;Korea&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"&gt;Nanox Korea is subject to a Corporate
income tax with accordance with the Korean tax law. The tax rate ranges between 10% to 25%, depending on the companies&#x2019; taxable
income. In Addition, Nanox Korea is subject to a Local income tax of 10%. In 2021, Nanox Korea was at a loss position and therefore had
no corporate tax liability. As of December&#160;31, 2021 and 2020, Nanox Korea has a carry forward loss of approximately $7.1&#160;million
and $0.2&#160;million, respectively. Such carry forward loss has 15 years expiration date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&lt;b&gt;&lt;i&gt;Japan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: left"&gt;Nanox Inc. is subject to national corporate income tax, and enterprise
tax, which, in the aggregate resulted in effective tax rate of approximately 33.59%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 1in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Income (loss) Before Income Taxes:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;Income (loss) before income
taxes consisted of the following for the periods indicated:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year&#160;Ended&#160;December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Domestic (Israel)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(56,609&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(43,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(22,588&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(366&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss before income taxes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(61,846&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(43,815&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(22,563&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;c.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Income tax expenses consisted
of the following for the periods indicated:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year&#160;Ended&#160;December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Domestic (Israel)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Income tax expenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(48&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: left"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;d.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Taxes on Income:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;Taxes on income for the years ended December&#160;31, 2021, 2020 and
2019 were comprised of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in"&gt;Domestic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Foreign&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 27pt"&gt;Domestic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(116&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(48&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;A reconciliation our theoretical income tax expense to actual income
tax expense is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loss before taxes on income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(61,846&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(43,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(22,563&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Statutory tax rate in Israel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Theoretical tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,077&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Increase (decrease) in taxes resulting from:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Effect of different tax rates applicable in foreign jurisdictions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(110&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Operating losses and other temporary differences for which valuation allowance was provided&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,174&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Permanent differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,113&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,480&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Actual tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(48&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;e.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Deferred tax assets &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in"&gt;Nanox IL&#x2019;s deferred tax asset as of December 31,
2021 and December 31, 2020 was related to tax losses accumulated and carryforward. The reconciling item
between the statutory tax rate of the Company and the effective tax rate is the change in valuation allowance in respect of tax
benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;The components of the Company&#x2019;s deferred tax
assets and liabilities as of December&#160;31, 2021 and 2020 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Tax loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,213&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Employee and payroll accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,789&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Less deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,775&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,789&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Less valuation allowance for deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12,882&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,789&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;Significant judgment is required
in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company
considered all available evidence, including past operating results, the most recent projections for taxable income, and prudent and feasible
tax planning strategies. The Company reassess its valuation allowance periodically and if future evidence allows for a partial or full
release of the valuation allowance, a tax benefit will be recorded accordingly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt 0pt 62.05pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;As of December&#160;31, 2021, and 2020, the Company has recorded a
full valuation allowance of $12,882 and $8,789 thousand with regard to its deferred taxes (which is mainly tax loss carryforwards temporary
differences due to unallowed research and development expenses) generated in Israel, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S.&#160;dollars in&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Valuation allowance, December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,789&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Increase due to business combination&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Increase&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,563&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Valuation allowance, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,882&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c214" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="c215" decimals="-5" unitRef="usd">56300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c216" decimals="-5" unitRef="usd">32300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c217" decimals="-5" unitRef="usd">2300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c214" decimals="3" unitRef="pure">0.619</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c218" decimals="3" unitRef="pure">0.453</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c219" decimals="3" unitRef="pure">0.176</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <nnox:FederalTaxRatePercentage contextRef="c220" decimals="2" unitRef="pure">0.21</nnox:FederalTaxRatePercentage>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c221" decimals="2" unitRef="pure">0.10</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c222" decimals="2" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c223" decimals="2" unitRef="pure">0.10</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:OperatingLossCarryforwards contextRef="c224" decimals="-5" unitRef="usd">7100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c225" decimals="-5" unitRef="usd">200000</us-gaap:OperatingLossCarryforwards>
    <nnox:CarryForwardLossYears contextRef="c223">P15Y</nnox:CarryForwardLossYears>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c226" decimals="4" unitRef="pure">0.3359</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <nnox:ScheduleOfIncomelossBeforeIncomeTaxesConsisted contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year&#160;Ended&#160;December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Domestic (Israel)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(56,609&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(43,449&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(22,588&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(366&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Loss before income taxes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(61,846&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(43,815&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(22,563&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year&#160;Ended&#160;December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Domestic (Israel)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Income tax expenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(48&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-142"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in"&gt;Domestic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Foreign&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;68&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -9pt; padding-left: 9pt"&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -9pt; padding-left: 27pt"&gt;Domestic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(57&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(59&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(116&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Provision for income taxes&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(48&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;</nnox:ScheduleOfIncomelossBeforeIncomeTaxesConsisted>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c229" decimals="-3" unitRef="usd">56609000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c230" decimals="-3" unitRef="usd">43449000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c231" decimals="-3" unitRef="usd">22588000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c229" decimals="-3" unitRef="usd">5237000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c230" decimals="-3" unitRef="usd">366000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c231" decimals="-3" unitRef="usd">-25000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossAttributableToParent contextRef="c229" decimals="-3" unitRef="usd">61846000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c230" decimals="-3" unitRef="usd">43815000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c231" decimals="-3" unitRef="usd">22563000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c232" decimals="-3" unitRef="usd">57000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c232" decimals="-3" unitRef="usd">-9000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c232" decimals="-3" unitRef="usd">48000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c235" decimals="-3" unitRef="usd">-68000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <nnox:CurrentTotal contextRef="c235" decimals="-3" unitRef="usd">-68000</nnox:CurrentTotal>
    <nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c235" decimals="-3" unitRef="usd">57000</nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c235" decimals="-3" unitRef="usd">59000</nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:InventoryNet contextRef="c238" decimals="-3" unitRef="usd">116000</us-gaap:InventoryNet>
    <nnox:ProvisionForIncomeTaxes contextRef="c235" decimals="-3" unitRef="usd">48000</nnox:ProvisionForIncomeTaxes>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Loss before taxes on income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(61,846&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(43,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(22,563&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Statutory tax rate in Israel&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Theoretical tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,077&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,189&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Increase (decrease) in taxes resulting from:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Effect of different tax rates applicable in foreign jurisdictions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(110&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Operating losses and other temporary differences for which valuation allowance was provided&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,174&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,235&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;701&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Permanent differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,113&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,480&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Actual tax benefit&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(48&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-161"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossAttributableToParent contextRef="c0" decimals="-3" unitRef="usd">61846000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c4" decimals="-3" unitRef="usd">43815000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c5" decimals="-3" unitRef="usd">22563000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c4" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="-3" unitRef="usd">14225000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c4" decimals="-3" unitRef="usd">10077000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="-3" unitRef="usd">5189000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c0" decimals="-3" unitRef="usd">110000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="-3" unitRef="usd">6174000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" unitRef="usd">7235000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="-3" unitRef="usd">701000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c0" decimals="-3" unitRef="usd">8113000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c4" decimals="-3" unitRef="usd">2842000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c5" decimals="-3" unitRef="usd">4480000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome contextRef="c0" decimals="-3" unitRef="usd">-48000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Tax loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30,234&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,010&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,213&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 27pt"&gt;Employee and payroll accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 27pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;109&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-162"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,657&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,789&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Less deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,775&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-163"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,789&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Less valuation allowance for deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12,882&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,789&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt"&gt;Deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-164"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12.5pt"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="-3" unitRef="usd">30234000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" unitRef="usd">7480000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c2" decimals="-3" unitRef="usd">4010000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="-3" unitRef="usd">1213000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c2" decimals="-3" unitRef="usd">304000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c3" decimals="-3" unitRef="usd">96000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther contextRef="c2" decimals="-3" unitRef="usd">109000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="-3" unitRef="usd">34657000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="-3" unitRef="usd">8789000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c2" decimals="-3" unitRef="usd">21775000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c2" decimals="-3" unitRef="usd">12882000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c3" decimals="-3" unitRef="usd">8789000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <nnox:LessValuationAllowanceForDeferredTaxAssets contextRef="c2" decimals="-3" unitRef="usd">-12882000</nnox:LessValuationAllowanceForDeferredTaxAssets>
    <nnox:LessValuationAllowanceForDeferredTaxAssets contextRef="c3" decimals="-3" unitRef="usd">-8789000</nnox:LessValuationAllowanceForDeferredTaxAssets>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c227" decimals="-3" unitRef="usd">12882000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c228" decimals="-3" unitRef="usd">8789000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;U.S.&#160;dollars in&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%"&gt;Valuation allowance, December 31, 2020&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,789&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Increase due to business combination&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Increase&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,563&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Valuation allowance, December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,882&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" unitRef="usd">8789000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <nnox:IncreaseDueToBusinessCombinationinShares contextRef="c0" decimals="-3" unitRef="usd">2530000</nnox:IncreaseDueToBusinessCombinationinShares>
    <us-gaap:DeferredRevenuePeriodIncreaseDecrease contextRef="c0" decimals="-3" unitRef="usd">1563000</us-gaap:DeferredRevenuePeriodIncreaseDecrease>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="-3" unitRef="usd">12882000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <nnox:SegmentsOfOperationsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 14 - SEGMENTS OF OPERATIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; "&gt;The Company reports segment information based on the &#x201c;management&#x201d;
approach. The management approach designates the internal reporting used by management for making decisions and assessing performance
as the source of the Company&#x2019;s reportable operating segments. The Company manages its business primarily on a service basis. The
management approach designates the internal reporting used by management for making decisions and assessing performance as the source
of the Company&#x2019;s reportable segments. The Company&#x2019;s reportable segments consist of the Nanox ARC, Radiology services division
and AI solutions divisions. Each one is managed separately to better align with the Company&#x2019;s customers and distribution partners
and the unique market dynamics of each segment. Operating income for each segment includes net sales to third parties, related cost of
sales and operating expenses directly attributable to the segment. Operating loss for each segment excludes other income and expense and
certain expenses managed outside the reportable segments. Costs excluded from segment operating income include various corporate expenses
such as income taxes. The Company does not include intercompany transfers between segments for management reporting&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; "&gt;The accounting policies of the various segments are the same as those
described in Note 2, &#x201c;Summary of Significant Accounting Policies.&#x201d; The Company evaluates the performance of its reportable
operating segments based on net sales and operating loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Nanox. ARC&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Radiology Services&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;AI Solutions&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;270&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,304&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Segment operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(56,875&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(530&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,153&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61,558&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financial income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss before taxes on income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61,846&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,292&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18,806&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Nanox. ARC&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Radiology Services&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;AI Solutions&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 52%"&gt;Segment operating loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;(43,923&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;(43,923&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss before taxes on income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43,815&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;24,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;24,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Nanox. ARC&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Radiology Services&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;AI Solutions&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 52%"&gt;Segment operating loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;(22,571&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;(22,571&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss before taxes on income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,563&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;For the&#160;year ended December&#160;31, 2021, the Company&#x2019;s
revenues in the United States of America constitutes approximately 98% of the Company&#x2019;s total revenue. For the year ended December
31, 2021 no individual customer exceeded 10% of our total revenue or total accounts receivables.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Property and Equipment by Geography&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year&#160;Ended&lt;br/&gt;
December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Israel&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,065&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;South Korea&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unites States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Japan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;37,435&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;14,020&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nnox:SegmentsOfOperationsTextBlock>
    <nnox:ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Nanox. ARC&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Radiology Services&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;AI Solutions&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-165"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;270&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,304&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Segment operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(56,875&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(530&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,153&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61,558&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Financial income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;288&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss before taxes on income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(61,846&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation and amortization expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,292&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;336&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;18,806&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Nanox. ARC&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Radiology Services&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;AI Solutions&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 52%"&gt;Segment operating loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;(43,923&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-166"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-167"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;(43,923&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss before taxes on income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43,815&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-168"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-169"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;24,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-170"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-171"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;24,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Nanox. ARC&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Radiology Services&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;AI Solutions&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 52%"&gt;Segment operating loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;(22,571&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-172"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-173"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;(22,571&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss before taxes on income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,563&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-174"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-175"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-176"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-177"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;16,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; "&gt;&#160;&#160;&lt;/p&gt;</nnox:ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock>
    <us-gaap:Revenues contextRef="c243" decimals="0" unitRef="usd">1034</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c244" decimals="0" unitRef="usd">270</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c245" decimals="0" unitRef="usd">1304</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss contextRef="c242" decimals="0" unitRef="usd">-56875</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c243" decimals="0" unitRef="usd">-530</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c244" decimals="0" unitRef="usd">-4153</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c245" decimals="0" unitRef="usd">-61558</us-gaap:OperatingIncomeLoss>
    <nnox:FinancialIncome contextRef="c245" decimals="0" unitRef="usd">288</nnox:FinancialIncome>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c245" decimals="0" unitRef="usd">-61846</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DepreciationAndAmortization contextRef="c242" decimals="0" unitRef="usd">458</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c243" decimals="0" unitRef="usd">441</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c244" decimals="0" unitRef="usd">1393</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c245" decimals="0" unitRef="usd">2292</us-gaap:DepreciationAndAmortization>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c242" decimals="0" unitRef="usd">18433</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c243" decimals="0" unitRef="usd">37</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c244" decimals="0" unitRef="usd">336</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c245" decimals="0" unitRef="usd">18806</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c246" decimals="0" unitRef="usd">-43923</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c249" decimals="0" unitRef="usd">-43923</us-gaap:OperatingIncomeLoss>
    <nnox:FinancialExpense contextRef="c249" decimals="0" unitRef="usd">108</nnox:FinancialExpense>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c249" decimals="0" unitRef="usd">-43815</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DepreciationAndAmortization contextRef="c246" decimals="0" unitRef="usd">208</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c249" decimals="0" unitRef="usd">208</us-gaap:DepreciationAndAmortization>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c246" decimals="0" unitRef="usd">24781</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c249" decimals="0" unitRef="usd">24781</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c250" decimals="0" unitRef="usd">-22571</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c253" decimals="0" unitRef="usd">-22571</us-gaap:OperatingIncomeLoss>
    <nnox:FinancialIncome contextRef="c253" decimals="0" unitRef="usd">8</nnox:FinancialIncome>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c253" decimals="0" unitRef="usd">-22563</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DepreciationAndAmortization contextRef="c250" decimals="0" unitRef="usd">53</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c253" decimals="0" unitRef="usd">53</us-gaap:DepreciationAndAmortization>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c250" decimals="0" unitRef="usd">16245</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c253" decimals="0" unitRef="usd">16245</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c241" decimals="2" unitRef="pure">0.98</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c2" decimals="2" unitRef="pure">0.10</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <nnox:ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year&#160;Ended&lt;br/&gt;
December&#160;31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Israel&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,065&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;South Korea&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Unites States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-178"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Japan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;196&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;37,435&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;14,020&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nnox:ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c215" decimals="0" unitRef="usd">3381</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c216" decimals="0" unitRef="usd">2065</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c254" decimals="0" unitRef="usd">33836</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c255" decimals="0" unitRef="usd">11675</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c241" decimals="0" unitRef="usd">22</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c257" decimals="0" unitRef="usd">196</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c258" decimals="0" unitRef="usd">280</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c2" decimals="0" unitRef="usd">37435</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c3" decimals="0" unitRef="usd">14020</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 15 &lt;/b&gt;- &lt;b&gt;LOSS PER SHARE:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;a.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Basic&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63.8pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;Basic loss per share is calculated by dividing the loss attributable
to the Company&#x2019;s owners by the weighted average number of ordinary shares in issue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.9pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 67%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Net loss attributable to Company&#x2019;s owners&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(61,798&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(43,815&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(22,563&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;The weighted average of the number of ordinary shares (in thousands)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;48,216&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;35,654&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;25,181&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Basic and diluted loss per share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1.28&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1.23&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(0.90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.9pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;For the calculation of loss per share, the Company used the
net loss attributable to Company&#x2019;s owners divided by the weighted average number of the Company&#x2019;s ordinary shares for the
years ended December 31, 2021, 2020 and 2019.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;b.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Diluted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81.8pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"&gt;As of December 31, 2021, and 2020 the Company had 2,505,370 and 3,173,186
warrants, respectively and 4,842,342 and 4,673,104 options, respectively. As of December 31, 2019, the Company had 5,548,649&#160;warrants
and 3,654,464 options. These warrants and awards were not considered when calculating diluted loss per share since their effect is anti-dilutive.
In addition, contingently issuable ordinary shares that are issuable based on certain conditions (see Note 3) are not included in the
potential dilutive shares in calculating the diluted loss per share.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Year ended December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 67%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Net loss attributable to Company&#x2019;s owners&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(61,798&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(43,815&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 8%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(22,563&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;The weighted average of the number of ordinary shares (in thousands)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;48,216&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;35,654&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;25,181&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Basic and diluted loss per share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1.28&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(1.23&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;(0.90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.9pt"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c0" decimals="-3" unitRef="usd">61798000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c4" decimals="-3" unitRef="usd">43815000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c5" decimals="-3" unitRef="usd">22563000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <nnox:TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands contextRef="c0" decimals="0" unitRef="shares">48216</nnox:TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands>
    <nnox:TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands contextRef="c4" decimals="0" unitRef="shares">35654</nnox:TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands>
    <nnox:TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands contextRef="c5" decimals="0" unitRef="shares">25181</nnox:TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands>
    <nnox:BasicAndDilutedLossPerShare contextRef="c0" decimals="2" unitRef="usdPershares">-1.28</nnox:BasicAndDilutedLossPerShare>
    <nnox:BasicAndDilutedLossPerShare contextRef="c4" decimals="2" unitRef="usdPershares">-1.23</nnox:BasicAndDilutedLossPerShare>
    <nnox:BasicAndDilutedLossPerShare contextRef="c5" decimals="2" unitRef="usdPershares">-0.9</nnox:BasicAndDilutedLossPerShare>
    <nnox:BasicAndDilutedShare contextRef="c0" decimals="0" unitRef="shares">2505370</nnox:BasicAndDilutedShare>
    <nnox:BasicAndDilutedShare contextRef="c4" decimals="0" unitRef="shares">3173186</nnox:BasicAndDilutedShare>
    <nnox:WarrantsShares contextRef="c2" decimals="0" unitRef="shares">4842342</nnox:WarrantsShares>
    <nnox:WarrantsOption contextRef="c3" decimals="0" unitRef="shares">4673104</nnox:WarrantsOption>
    <nnox:WarrantsShares contextRef="c19" decimals="0" unitRef="shares">5548649</nnox:WarrantsShares>
    <nnox:WarrantsOption contextRef="c19" decimals="0" unitRef="shares">3654464</nnox:WarrantsOption>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 16 - SUBSEQUENT EVENTS:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On January 19, 2022, the Company issued 89,286
additional shares to the former shareholders of Nanox AI due to partial achievement of a milestone that occurred post-closing.&#160;The
fair value of the shares at the issuance date was $952.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;In March 2022, the Company leased and addition space of 105 square
meters in Neve Ilan for a period of 3 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;On March 28, 2022, the Board of Directors of the
Company nominated Mr. Erez Alroy as a member of the Board of the Company. Mr. Alroy replaces Mr. Fenig who retires from his membership
at the Board of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;On January 25, 2022, Magistrate Judge Peggy Kuo appointed Davian Holdings
Limited as Lead Plaintiff in the McLaughlin v. Nano-X Imaging Ltd. et al, Case No. 1:21-cv-05517. On April 12, 2022 and in the same case,
the Lead Plaintiff filed an amended complaint, which alleges that defendants violated the federal securities laws in connection with certain
disclosures concerning the cost of the Nanox.Arc system as well as the comparison of the Nanox.Arc to CT scanners. Lead Plaintiff seeks
to represent a class of investors who purchased the Company&#x2019;s publicly-traded securities between August 21, 2020 and November 17,
2021. The Company has not yet responded to the amended complaint and intends to defend these actions vigorously.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <nnox:AdditionalSharesIssued contextRef="c259" decimals="0" unitRef="shares">89286</nnox:AdditionalSharesIssued>
    <us-gaap:OtherAssetsFairValueDisclosure contextRef="c260" decimals="-3" unitRef="usd">952000</us-gaap:OtherAssetsFairValueDisclosure>
    <nnox:LeasedAdditionTerm contextRef="c261">P3Y</nnox:LeasedAdditionTerm>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c5"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c5"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c4"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c5"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c4"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c5"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c4"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c5"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c8"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts
      contextRef="c13"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c13"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants
      contextRef="c11"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants
      contextRef="c13"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c11"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c13"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6
      contextRef="c11"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6
      contextRef="c13"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c17"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts
      contextRef="c22"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c22"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c22"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants
      contextRef="c22"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c20"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c22"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c22"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c26"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants
      contextRef="c30"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesUponExerciseOfWarrants
      contextRef="c31"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions
      contextRef="c30"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions
      contextRef="c31"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets
      contextRef="c30"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets
      contextRef="c31"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c28"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c30"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c31"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c31"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c30"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c4"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c5"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c4"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity
      contextRef="c4"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity
      contextRef="c5"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="c4"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="c5"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses
      contextRef="c0"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IncreaseDecreaseRelatedPartyPrepaidExpenses
      contextRef="c4"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="c4"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="c5"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="c4"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="c5"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="c4"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="c5"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="c4"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="c5"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="c4"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="c5"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts
      contextRef="c0"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c0"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c5"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="c0"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="c4"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:UnpaidOfferingCosts
      contextRef="c0"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:UnpaidOfferingCosts
      contextRef="c4"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants
      contextRef="c5"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets
      contextRef="c4"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets
      contextRef="c5"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations
      contextRef="c4"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations
      contextRef="c5"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:FairValueOfContingentConsiderationAssumedInBusinessCombinations
      contextRef="c4"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:FairValueOfContingentConsiderationAssumedInBusinessCombinations
      contextRef="c5"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfSharesInConsiderationOfAssets
      contextRef="c4"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:IssuanceOfSharesInConsiderationOfAssets
      contextRef="c5"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements
      contextRef="c0"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements
      contextRef="c4"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity
      contextRef="c0"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:ConversionOfRelatedPartyLiabilityToShareholdersEquity
      contextRef="c5"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="c47"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:LongTermMarketableSecurities
      contextRef="c47"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:LongTermMarketableSecurities
      contextRef="c50"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Assets
      contextRef="c47"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Assets
      contextRef="c50"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebt
      contextRef="c47"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="c47"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="c48"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent
      contextRef="c47"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent
      contextRef="c48"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="c47"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAcquiredInExcessOfPaymentsToAcquireBusiness
      contextRef="c54"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="c67"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:PercentageOfPropertyPlantAndEquipment
      contextRef="c92"
      id="hidden-fact-102"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c100"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter
      contextRef="c2"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenue
      contextRef="c3"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:TotalDueFromRelatedParties
      contextRef="c123"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c4"
      id="hidden-fact-107"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c4"
      id="hidden-fact-108"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c4"
      id="hidden-fact-109"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c4"
      id="hidden-fact-110"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c4"
      id="hidden-fact-111"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c0"
      id="hidden-fact-112"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-113"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c146"
      id="hidden-fact-114"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c148" id="hidden-fact-115" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c149"
      id="hidden-fact-116"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c151" id="hidden-fact-117" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c155"
      id="hidden-fact-118"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c157" id="hidden-fact-119" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c161"
      id="hidden-fact-120"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c163" id="hidden-fact-121" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c184"
      id="hidden-fact-122"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
      contextRef="c209"
      id="hidden-fact-123"
      unitRef="shares"
      xsi:nil="true"/>
    <nnox:IssuedDueToBusinessCombination
      contextRef="c212"
      id="hidden-fact-124"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c212"
      id="hidden-fact-125"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c212"
      id="hidden-fact-126"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <nnox:StockIssuedDuringPeriodSharesStockOptionsForfeited
      contextRef="c212"
      id="hidden-fact-127"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c212"
      id="hidden-fact-128"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c211"
      id="hidden-fact-129"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c211"
      id="hidden-fact-130"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c212"
      id="hidden-fact-131"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c212"
      id="hidden-fact-132"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <nnox:NumberOfSharebasedPaymentAwardsCancelled
      contextRef="c211"
      id="hidden-fact-133"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c211"
      id="hidden-fact-134"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="c4"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="c5"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c233"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c234"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c233"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c234"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c233"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c234"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c235"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c236"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c237"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c236"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c237"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:CurrentTotal
      contextRef="c236"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:CurrentTotal
      contextRef="c237"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c236"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c237"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c236"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c237"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="c239"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="c240"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:ProvisionForIncomeTaxes
      contextRef="c236"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <nnox:ProvisionForIncomeTaxes
      contextRef="c237"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="c4"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="c5"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome
      contextRef="c4"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome
      contextRef="c5"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c3"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c3"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="c3"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c242"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="c247"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="c248"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="c247"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="c248"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c247"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c248"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="c251"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="c252"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="c251"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="c252"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c251"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c252"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentOtherNet
      contextRef="c256"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001795251</dei:EntityCentralIndexKey>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" unitRef="pure" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" unitRef="pure" xsi:nil="true"/>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Less than 1 thousand US dollars.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-89"
          xlink:label="hidden-fact-89"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span>As of&#160;</xhtml:span>December
31, 2021,&#160;<xhtml:span>approximately $29,697 thousand of debt securities were classified under &#x201c;Cash
and Cash equivalents&#x201d; in the consolidated balance sheets as such securities met all applicable classification criteria.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-89"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-94"
          xlink:label="hidden-fact-94"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span>Since the loan was
originated in September 2021, the fair value of the long term loan approximates its carrying value.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-94"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">A 3 years Convertible Loan Agreement, dated August 9, 2021 between the Company and Nanox AI in the amount of $3 million, which bears an annual interest of 6% and shall be automatically converted into the Nanox AI&#x2019;s Preferred C Shares, at a price per share of $23.42. This loan is eliminated in the Consolidated financial statements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of December&#160;31, 2021, the Company&#x2019;s restricted
cash consisted of a bank deposit that was denominated in New Israeli Shekel. Restricted deposit is presented at cost including accrued
interest. This bank deposit is used as security for credit card use and collateralizing the Company&#x2019;s lease contracts</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes $415 thousand under long term deferred revenue in the Company&#x2019;s consolidated balance sheets as of December 31, 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On October 26, 2020, the Company entered into an amendment to a business development agreement (&#x201c;the Agreement&#x201d;) dated February 4, 2020 with two service providers pursuant to which the Company paid an aggregate one-time payment of $400 thousand plus VAT and issued to them warrants to purchase an aggregate of 650,000 ordinary shares at an exercise price of $18 per share with a graded vesting ending 10 weeks following the grant date (subject to a standard cashless exercise provision). As a result, the Company recorded an expense of $6.1 million for the warrants granted. The service providers waived any and all past, present and future compensation to which they are or may be entitled pursuant to the Agreement and all activities undertaking on behalf of the Company, including the right to a percentage from future revenues from any of the Company&#x2019;s systems and the issuance of warrants.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>103
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M9[W ?7OA'YH"Q1L?8_Z<[5P3\RD/4CZ9FVETUG,,$4]XJ(T$@W\;/N9)8I2
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MY+NYB,-R\I@$#XWDU#H_Q:WZ1]:QN0,+N8>@WLB)R\WX!E:+"1,8G T M%,
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M"5#6 -_/I30/$WN?M!\HP_]02P,$%     @ T$&B5#!%,_R>!0  #1<  !@
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MQN#KES/P!80)6&SHCN-DQ?MM(?N0(K67A_:N\_900WL0@7N:B T'?K(BJRI
M6W:^8(".#*Z1$7%,EA? AM\ LA#4=&CT]G1+DSY^<SKL&=C813WL#,]NP)LD
M2QJ3LA+@S^$S%TQ.C[\,Z$Z![F3H3@/ZW'_RIX^^KFQYHILEIHO%?@!MR^FW
M]Z=2&M'3)>J2;_&27+7D&L0)VY/6 .@T_3A.A7ZGH-\QTA_-@@68W0"###E
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MA:!Q=KLA>$58&B#_7U,JC@]I \4)^. _4$L#!!0    ( -!!HE1S.=XW20@
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MV)VQWGVIRDU]Q/>NK*IR77]<<;;D0@V W^]+V(F;+TK!_J3[Q7\!4$L#!!0
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M@=N'NV_@[G[^,%DOEI_!9+I>_%BL%_/51TL];EF/J^IQ6^I9BI02L30%(G6
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M-!"_;QG+WK[("LK+_#?_ U!+ P04    " #00:)4H9ERDS@*   7&0  &
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M*(6ZU?DJ4T"DO6=;9,A7=(8R.)_@$9=V8D]9MZ)+NO;!#_# &Q#NQJ*FK&/
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MGG"BLA5 4,VB(/P2U,*Z(E&L" 6-LL3CM,1)T##UG"O0Q3=5.9"Y#> ":^:
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MB[YLQ?$%E0OYI:93>L"%1@6+N:_ZHI;*!EO4_19\.9L1?E(>)6HC#U$VY+M
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M);**&IP]MN0"J]VB.[0\!)[#LJ?0,^B?SV07VIZB)B.@IVINXH:P. T77/2
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MXNJN)D;: 2XACTG"C7=V1)11KOA&*N!"00>_K$VH/.X$)0U2<KI5)")@QIV
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M*$QI3Q<53&5O&];)*I3"&-5X\ 3I8SX\PO-JB>1I#X%>W4<P750P5J,-^"A
M"6/>1W& >LDFC@YVA*X97!Q)32._>DZ>.M!LP;(1B%$#&GKBNLA$_OR0CX+3
MX8A-=%2B8$ L)$E!\=-3IDNY$/"3_9C3#?I==I&!!LTE92+ZV_%I<!*.V-_R
M/*'8>Q@&O4'?K&#&A,'HM&_<]":KPD$WZ/7'[#/@L<O6RNAGP[WT@T'8?V0,
M\6)O# &#;S"QP9-E.6:R__$<MNUVN^8H:4W-(!CVAN8X+5)&%HQ[^D2;ISVT
M\1 N/P$G0RD,]W?_F$=977%MEE=M7@W.O;P5 L*\C>*CBT]:<F>$^Y3R,!UU
M3VGK"(MI605'P50-JY$X>O2L61:+JC('4\(8'RPSUN22\6M[8G9CE_1<%E:8
M9_S*!(=12>[?U-%,F1%IZ_4[@Y[Q\BF>']$ME4NI:Q,NK_)@9@;/,@+Q&G#N
M;[!9BVSPP$XMF!6FAI*:",0]@#*[O-PP"#^OKM-@?<AQT ]'7L62I$!&L[OP
MR%H*CV'79KX72_1'[^2<8R.+=AGV@F&W^\!=VLJ;]2Z(9G-KW[0'V;@7=;HT
M#AB,60KH2%0"XDPKKY2+>^LZ]SH3Q9S"1HQC8LJG;/J4KPP2UU5CIU.3"P8*
M4.FG6VD4:&@^+Z(5T,*!BCF=:PUAR!(K_8K"*AWRN\-8MH#HP#_5I#HB4+W$
MW,9+F#_9_76P[%8RA@8L /0 (,-"(&D%1<8 9Z"#*PB9M@O%-O^PRII@^ D$
M)+[^R)8:<00+@&LCCV#F:F^+$4F18QKQ/8/<V^:7)H_]!.HL7UQJE_/^)_G3
M]X"*L"1PV,PT>:TQ21UG4'B%),D?'MF;Z2B2@IA"QN!B7!-PKR!,D;$$<97*
M2-6H12WRC:#7K:5++0#G@F))4F#,^VLEAO!P5B$DSW2NQ=#*O:5N =[\1 .$
M;<)^37J'GU?"-< 0?>:N;NH7P;V^2K!Q>M50)8TPK!5A?(>!, B4:, K(&#S
M^):!A:/^U3TLQWBJ,^,27LZ]C-:4^553C(BH>$Z!#PQD7DE,9OIN@HDD"W+_
M(NGPOZR=4@L%R$GE+T&'K)4 ]$GE^M\5=G=U90FH!K^*VH\ B.D@M@DS7:7C
M+F/QRB-,5YN^HJ,@4,[Q5+V8#M);&#1OU%N]V2\LTE)3@MHHI/<_B3N 0(=]
M@# #?]0;).#^A?PFM3)8:(%=:U9JJO<@"8F]:SJP&6EL5WL$TM4F6%D?R!:0
M*8 41+95$8CO<F&0P6)R3D#@@8)W;I\MM*TIH&KYH\J#?KKZ+O.+/R"2DNO6
M7I.LK593>T"_<62;])OP%<855.!RLO::4DC'.6@9M5KM;82 B ''Z/DKZNP-
M@G X;C0J%>HDJ&BZWBR/55D$$342"L+GI-:^>C.7V6O^HZ]Q;KU%B#LCJL@5
M(G<U^Q=1HJ5>M^)AQ-\CB*Z*-=-G[FKRVXBV)!GA--*!VJ]Z<@4= (;_:H0Z
M#FLV Q-E [I"O-#P@E2"6EN;5CFH(E)$CE77\3CX4\HA4)]FF$W':#Y3 -]
M5\68.1[$^/<[74)V[I)T9#,:,%?1C7;8C=C R 8>B!EDCQ((H!S9:!Y\B8L
M&<;[Z82*"FQ*L[*B&)06<[T(6,X*#2(#*@["=Y@IZUK_/OH-5IM>*C4#:V6#
M/-/Z>1!]JC4(9^"1,X&^5DM19@EU4&Z$[H:;ECV *4;B>Y73J7!L6Q[D&#W,
MH7%LGY;FL>&+V7<J(%K*C+\C.;(/AL7_0/2FNTA\^ROV[:J1A;*OIIES"&E5
M?]3',FPP''8I%R)8.N1')^.@.QCRY_CW"++',?S-IJWW:+Y=3;Y.SOD?>4HY
MLVXK>+&,>=YVH<6_3].SEU*VIQIGSG9>K.'->S4;!(;=[C,KF/I*2)-LC-.!
M<# 8U[G@MMF!RQPU*')$L+U7<J[HKLBE36RV\L4O<9G3T8<.:K>OW>@= WY>
M=/@G\).12/D_JE]@7I3RFC8!1G1QM)(E.2K<UAV1<@/_=HHYN>D"T 4;W+')
M;!,Y:8VD4H9-T)*]#&4[[Y>@&1Z.@W!0.PVJ2V'LAW\/3D?!$'2NB>_.W6U>
MU-A[NP; YC ,&TF6UMVL(F6[[\4/OO/BQV:CKWGA(ZD*,Y!M-OU6&,?11UOE
M\AB^T7[PN^#;H5-X$HP\9F[<,JA6IM9IZG$@DD87$17&='?;.\ZPUPST2:?:
M 7__[N+Z?$*2TIKGYU_P)^$KN![CN$P-Q_2$>UX;F.UM Z,VW''#P+15>ECX
M:<8D6O/O-WV$VL'JZ53V< 4/K4:>Y#?ZNUA5T#=T;B#97+84H*U8]7I[^\!T
MAX89=7#-YKKP;[OW*%:D]4@^W=YU#]I<#AQI+.I@S*_]Q':9*@RZ_4$SE&VI
M90U/:NDT(Y\[@UOVL."6LA=!_@_DZ(>P=!0RJFTWM-5>9CM[D/\?VLN& :W-
MY6WFZ-;R1OUZJ]%,<+ZOV<PU"OMUWHTV1=F.X*-@T!WNZ!J#O^P.>T_;-&Y1
MC__#EO')ANN:-)"_U^\,>\X#.W%LM92-=PT86N!XU!F,GSVN[[S+V=[51V7[
M:B68^2AE?=+M0J!WT4 'RD%A=XKE-E/&<?DX&!:P7]7U0>W<DL"U.1N%(V9:
MMUM9U'8AR6\M/DE+F_UF2YO?V=+^K=X@LRSS^X->%N<J*9/:,7L=Z<-P,*B1
MW12SZ&Z50YGFM2J+-A*KCHRB&*#1<OOR\E+W$XR+_2 2JO'\#2.'S+ !B]J8
M#]VO>\#:VWVM=;V='3Q<VL7NE[3L[IY>W>WTVWJ'O-_O[6C@A;V61AWD .')
MN&[4018V'#;[=/U=3;K>:3 ,3QFUIBB5COB\9B%871:O.8ANNU<V'-[9VAN/
M1O=O[06#8?_^MX-.A[T]?;JP"\EG;T>?SD3 ]U6).QM*_ D:2H7 F!K7@"@+
M&P-2Z;CE,!P'XW$=<@;F-2BP#%MFU]<2P%07<F4"K7ZOY]78,'03B"*Z615T
M3[V[^?A?HP5$VN-[$:^_PGZWOV*/M7:W]K5-[N")VLV3!9:[34/@!38$*%D/
M.^'8OS2Z;]W]#%S0->Z-]4=N>><FZAW8U@ZFKV"8WKIBV'-+/MYAL,?=@;K;
M85SO"AS;/<7C[D#QI[D#Q1Y[!XH_W1TH]OMWH/A3WX%B#[L#9;?7%1DM4Y-Q
M/NHR%+5U(,WZW>M0_-'7H=B378?BC[H.Q734^437H?AO78<ZKP1[\O;HW6%4
M>WN4/7%[E/]V>Y3]:]JC_*[VZ+FN!%)YEYDD4[^/8XK5]'Y>5"0Z!DYR4'E2
M1+0%XCB"D7ZQ@^X3I"Z^HQ+SNPG7-_&QS7X9K>.%P)IS 71H4<.?\R):ZBM+
MMHP-,;>M8://D]K(4"EIK$2= BRQJB.7JRAVG\Z^_'EQ_B(\!82&G9<RMD"R
M6;*=FG))!^-HKTP.&9TM/2)5;%(!2A>V28:<\TKEVJ3 )N4J2C<ZS9@Z?#17
MD3 K"71&!\>(P1&0X8 B$1HC%_$]>GJKQ13*Z^L>%^9:%5: "C(!71,O3'LW
M[$ Z_HSJ@W@1:^F\"$6U]JZUH62&6&KB@<FL%/;6M2WBM?2+;?G!7E,E!Y07
M<U@I,V[3[M#!EVH?V&YH5+1MU96LWNSA6M5F7?TV-&MD;Z[$_Z">_W;AFAV&
MIR=/W?._W.H!-BN%7D?6J_;X$J#>')H^]>< RE816M]4Q!$H$,Y:NRZA0VBS
MW-[6?.LE.&9>>YEX\%IWK#Z=__7^'?_X\:SYRGG?MHF\/=G>UI<70ZZ  <@A
MKX)OL-UN&.".#B+HJ[K;MO_=<UR(W:/1Y>X4F+N1S1HH$$:[NI:4PM>%:A^U
M\<;W:!",0^H7(?;9>A4SA4>@4[/QCD81)EG-8MM=;11^[S8*LQ<,Z;TK[S4[
MP_-:*$2D;K:=I7FE_>SV>WC;G1?SZMV=+]BQA_1&FAQY:&_DCG??V /??>/;
M[[X]@82P$?ZX/M8VMW^?Q>RQ+'[)C^3S?_E;AR^?O/WD7A\OMSJA&B ;3#:7
M:41K8<#\M $Z!Z3G!?Y^"#,_;6#>2P6S=Q=<O8N(2-S@Q+P^O1',81#7]L,H
MQ]Y/T] 5*OP!'D1^$+/^E1KWK?N-GXG^:9MZN/Z!H$]@PA)\5"IF,+7;&0\/
M(.&C']W1'\I\13]T,\W+,E_2GPL1@8KA '@^RX%0\P$W<+]\]/9_ %!+ P04
M    " #00:)4Q;?WTK($  !^"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6RE5E]SXC80?_>GT-#,33OC@FVP@1PP0R[I-3.Y)!-(,VVG#\)>8TUD
MRR<)2/KINY*,0QJ2/O3%UDJ[O_TO[60GY*,J #1Y*GFEIIU"Z_JTUU-I 255
M75%#A2>YD"752,IU3]42:&:%2MZ+@B#IE915G=G$[MW*V41L-&<5W$JB-F5)
MY?,9<+&;=L+.?N..K0MM-GJS24W7L !]7]]*I'HM2L9*J!03%9&03SOS\/1L
M8/@MPV\,=NI@38PG*R$>#7&933N!,0@XI-H@4/QMX0MP;H#0C.\-9J=5:00/
MUWOT7ZSOZ,N**O@B^ /+=#'MC#HD@YQNN+X3NU^A\2<V>*G@RG[)SO$.X@Y)
M-TJ+LA%&"TI6N3]]:N)P(# *WA&(&H'(VNT462O/J::SB10[(@TWHIF%==5*
MHW&L,DE9:(FG#.7T[*L0V8YQ3C[1LOY,+BM-JS5;<2!SI4 KGUR#GO0TJC("
MO;2!/7.PT3NP842^B4H7BEQ4&62O 7IH8VMHM#?T+/H0\1S2+NF'/HF"*/P
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MH#O$64:Z:<<16M1VPE@)C4U@EP4.B" - Y[G0N@]812T(^?L'U!+ P04
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MUV T&;L@^X[83[1H;1?*A,:>9H<5_HF@TAC@?BF$WDU,@/W?DOF_4$L#!!0
M   ( -!!HE3WT+LV?0,  *X'   9    >&PO=V]R:W-H965T<R]S:&5E=#$R
M+GAM;(556V_J1A!^]Z\8N5)U*E&,#0&4 A(!JA.I)TV!G#Y4?5CL,5YEO>NS
MNPXG_?6=70-QVH2\V'N9^6:^N>WDH/2C*1 M?"^%--.PL+:ZCB*3%E@RTU45
M2KK)E2Z9I:W>1Z;2R#*O5(HHZ?6&4<FX#&<3?W:O9Q-56\$EWFLP=5DR_7R#
M0AVF81R>#M9\7UAW$,TF%=OC!NU#=:]I%YU1,EZB-%Q)T)A/PWE\?3-P\E[@
M*\>#::W!,=DI]>@VM]DT[#F'4&!J'0*CWQ,N4 @'1&Y\.V*&9Y-.L;T^H?_J
MN1.7'3.X4.)/GMEB&HY#R#!GM;!K=?B,1SY7#B]5PO@O'!K9 0FGM;&J/"J3
M!R67S9]]/\:AI3#NO:.0'!42[W=CR'NY9);-)EH=0#MI0G,+3]5KDW-<NJ1L
MK*9;3GIVMF"FZ(#[PNI;S9^80&D-,)G!&HW5/+68^?M)9,F>TXK2(_9-@YV\
M@QTG\$5)6QA8R0RSUP 1.7KV-CEY>Y-<1%QBVH5^W(&DE\07\/IG]GV/U[_
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M:_)KMWRV?*#JJ!G7IIA#9AFVA5OSCHIB/]$RUVZ>(!51AA>H4\L<2((L 49
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M)L,^FP3A 2XWTHVVQZ&/OX-!\*(8?+:G69JC=-*84X^C$_Y6.175;A:#4W^
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MV -5C99J8^3*M7,L#0T'M\QH&J.R!G2_D-)L-C9 ,]\GOP%02P,$%     @
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MVX<"G^8&>,,S<WQQ=1T1S<]7; ]RL,I[!N"7(M.L4'(9'OG-&NK%E#14=-.
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MB697LJM5I3UR*J)HQ<4A(%9)VH.,XO-WZTZOR[9GD)^6O3.2$K'YNL-$1UI
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M;O:-Y[7S+D>WN(H/7JH0(1A%TS">C=D,,M2$S:(X^"1@]BY1W"[!>1C#B)2
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MK2KH<2,X1#5N@/654K9Y00;M/TZN_@-02P,$%     @ T$&B5!2I!.D]!@
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M=1"=#+M@F^'>++RIPD!=&$_C.;P6E!^T+$#G2V/\=L$7[+ZP)O\ 4$L#!!0
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M]E4 $3QP>>J!A3RPH'WS0K3+UUF;O?RQJ>_2!D?#;/@''96>ALT5%=[*3=O
MKP4\U[Z\6JWJKFJ+:I-^J,MB51@[29<'_G!(S_3+\Q\?MK </O1P)5._XJD7
M)Z:>+])W==5N;?JFRDT>3_ 0]NDVN]#-OEJ,SOC:K&;IH_DD75PLYB/S/7*'
M?T3S/?KVPZ?_<[6T;0/(\K\C"SQV"SRF!1Z?6."S-6F]3HUM"T @F+VHTG9K
M4B"@?=9DA)?P^[JHLFI59&5J6Q@&2-_:(7B/+H;T^\+NLY7YZ0',;TUS:QZ\
M3+-9^D_L(OUT/ X?7=65!8CE,"X??A#6@$'(-HKVD-P5[3;]/+N9I7^YNOH
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MNCJ:RO:Z4*#>B]T$5F,]!^@$N(5)"!*NDS<]H/32/VXE ]<GE/'#VC."YQV
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M)N^F.&4QF6!!8DG0].R"BLQTD[$[.-V$:;31CF9;V%;T,X'&$]![J;4['+R
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M3)4UP/<+B8=ZL[ )=I?OZ7]02P,$%     @ T$&B5(<6[L&? P  N0@  !D
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M<VFH&P_#FIX_5-: ]BLIS6%B TP/ZOI?4$L#!!0    ( -!!HE2 &Y#9%0,
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MV3BBYV02>R_AX*O[N5'5L#L"I8JA4J4R>@*W[>*X2.)1-*''-#T&R+G.[%4
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M0AL<Z+PVQF^-D&!\^1:_ 5!+ P04    " #00:)4C*&Y@0@#  #-!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R=56UOVC 0_LZO.&75!%)+2("6
M=H#4MVV56JDJ[:IIV@<G.8A5Q\YLI[3_?F<',JI1-.T#V&??/??J)^.ETD\F
M1[3P4@AI)D%N;7D2AB;-L6"FJTJ4=#-7NF"61+T(3:F19=ZH$&'<ZQV&!>,R
MF([]V:V>CE5E!9=XJ\%41<'TZQD*M9P$4; ^N..+W+J#<#HNV0)G:!_*6TU2
MV*!DO$!IN)*@<3X)3J.3LZ'3]PK?."[-QAY<)HE23TZXRB9!SP6$ E/K$!@M
MSWB.0C@@"N/7"C-H7#K#S?T:_;//G7))F,%S)1YY9O-), H@PSFKA+U3RZ^X
MRL<'F"IA_#\L:]T!>4PK8U6Q,B:YX+)>V<NJ#AL&H]X[!O'*(/9QUXY\E!?,
MLNE8JR5HITUH;N-3]=84')>N*3.KZ9:3G9W>H6 6,[AEVG(TT+YGB4#3&8>6
MT)U.F*Z0SFJD^!VD*(8;)6UNX%)FF+T%""FL)K9X'=M9O!/Q M,N]*-]B'MQ
MM .OW^3:]WC]?\CU%:XY2[C@M/MQFABK:3Y^[G R:)P,O)/!.TYF]&RR2B"H
M.0UM[;!T#K=5=">4>X\GIF0I3@)Z< ;U,P:N*%@DJ'UA-H56^T()P;0!+L'F
MJC),9J;3:K,.7%0(<ZT*N!*B*OCB5<(>].D7'[7:R<;](ST/0T\.X1[37"JA
M%FXJKFW6A2B":-!JIQOJ,_YR</F*<"4MZOJ!003M(73^TH/3*Q .I@\'K7ME
MF:BO-FOD7.U!-'+!'<*.9@R;9@S_JQG.$75<&N:YP6SKS4[D[;WYCDP#NNE_
MVQDWOVZ(>_07';?:#]U9%[9WZXZPF$YS()'8Y9E8LR0.M/#QPRB.HD]@$"&#
MQ+$IC'K0'PXA&@Y:7U!2!X0W8QD1!7<C[1NRMIR19;H/Z'7F*XAV=!Q!AY;#
M(UJ&^Z-XL+7PX0;%%*@7GD@-I*J2MF:;YK3AZM.:HOZHUT1_P_2"2P,"YV3:
MZQY1I75-GK5@5>D)*U&6Z,]O<_K>H'8*=#]7RJX%YZ#Y@DU_ U!+ P04
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M@XL1<B*[-MLMM&AM:UL*C8W23M?X90+2".#Y2@A]6!@'P[?.]!]02P,$%
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MYQ;(R/@]8'HCI0T\WY_0O[C<32XIU? H^0^68[7R/GDDAX*V')]E]Q6&?)S
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M_(WYF?+$0>-7*E@TB;OIE>>TB1K!6,G1+JH1#)C$WX.?J48<]$-Z\ABY=*V
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M?4(:0A#H<@RB4GXI%>_8NVB<$>B_CW3D?.R%]OECD3;Z5I%V[-:A/CB8(#T
M/3E1_3F!P1E15"BV+I)7"5^;Y8+Q!,^/RC@?L.M.X%8?>#RU/ZO-FWP]]C!J
M>=#/;=([+6)2FW2><=B"'[@+?F,/"<R7)S(;G?W'QSS'6<N[07[ "<&3"R<O
M"RQ!"-S%&Y8ST[O&L*@B"24'1KF;90_8P0-,,6@<$[DIP'M!8=TRF79&X6X;
M#E*1P%* P$T!7!H3=/_=W1TRH9Z@.P-;^8/9L^G.P)*!P$T&[B3/(K[3:M\(
MOB,J'_O<.3)MDM!?;2Q)"-QU?6 0OG7S);!L('B^PZ?0%OS07?"_<?,E[&
M%SW$+;0,('17[ _+/]Z]1>_?WYR2Z= B9_A\7P2$%@]#-XY=-RA&.9^&",[-
M@,7F-FQU:#@+QG,<&C*BZ45%,D>55H7*5:;8[.("PK .$5DQC.9V]@26!\R.
MN(JZV(F2_P!M@$*OH.Q!M[8<M,61#D1,ZMJ.4IZ #Y%I^"_)T.BX1<\CF'90
M9-E&U@0-HD,[>$WKR#+(<G/T)A%%R61*/^9,JW(A6D(TIW+#\HHH'!-D^ QP
MVKH?-!FIMA8[4CL+3^7G"D\R@BC4M<:97YFYF.GJ8BC-ZE": >&K#PN.!W'E
M44@%>KYG2(0^;XCI02%6'BA6R:6[70(YT@RGSF*])]],M]Z]^BXCI$\<VMD<
MD/6(-&E9*]O?GN+1_YOBU^@%?SF4>?0/,S]ZFOG79EJ^X.!*MWT0"4@%M#??
MVVDA\22Z2NZY@H&'0AY9YK&=&607#ED6%+J9S%.9I72W->CKB%_IM_6'A+P:
MW?KXJ*2W2-/;SH+@=AHL4 J,==M)H*:-K_'TQY8?8/WR3*&$K<&8-YD#G9+E
M]XOECUSLS =Z*Y$#T3>76P9L7.H7X/E:B/SX0W_S5W]%>O4W4$L#!!0    (
M -!!HE2?:!>(50,  ,$*   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM
M;-6636_;.!"&_\I Z*$%NI$H6_X(; -VW*(&DMT@3KJ'H@=:&EM$*=)+4G;R
M[SOZB.PTMI!B#XN]V"3%>>?AD#.8T5Z;'S9%=/"8267'7NK<]M+W;9QBQNV%
MWJ*B+VMM,NYH:C:^W1KD26F423\,@IZ?<:&\R:A<NS63D<Z=% IO#=@\R[AY
MFJ'4^[''O.>%.[%)7;'@3T9;OL$ENH?MK:&9WZ@D(D-EA59@<#WVINQRQJ+"
MH-SQ5>#>'HVA.,I*ZQ_%9)&,O: @0HFQ*R0X_>WP"J4LE(CCGUK4:WP6AL?C
M9_7/Y>'I,"MN\4K+OT7BTK$W\"#!-<^EN]/[+U@?J 2,M;3E+^SKO8$'<6Z=
MSFIC(LB$JO[Y8QV((X.0G3$(:X.PY*X<E91S[OAD9/0>3+&;U(I!>=32FN"$
M*FYEZ0Q]%63G)K/<THJU<*6SE5"\"I5*X"^7HH%[PY7E50#?S]%Q(>T'^ .6
M]#J27"+H-:RY,+#C,D>(-5U7@J:2<87Q&HW!!-Z!4'"?ZMR2N!WYCM@+ C^N
M.6<59WB&DX5PHY5++7Q2"28O!7PZ='/R\/GDL[!5<8[Q!7381PB#D#TLY_#^
MW8<6V4X3T$XIVSTC^R=7^A&F"[AV"7R[P6R%YGN+;K?1[9:ZG?_XHKY=DQM8
M.,QL&W;48$>MX;CB-H4M?Z)$=B>OO=6\J$F7=LMC''M4="R:'7H3:.'J-5R]
M5JZ%M3E7<1D7;1(*J'D"FW)R<HJR$HM*L:+0[2:#0<2"D;\[P=!O&/KML:$'
M+=2&(D.>M7'@T&2 W"@JGR %7PDIW-,IGOXKGLZ A</3/(.&9_!6'JG5YC=P
M!J]PPE[O3'2&#<VPE>9>.RY?/M13KH>O7%,<PN&94+#@4!>#5O</R^G== Y?
MM*3'L8&%HFKQAG1F1X67_9\2FH4'\/#?I71M?WPG?=;MG[F10V%E[97U-U.V
M5GOQ,E@4G'F5[%"'6?>M6?(RZ-P!6B>H4Z"H'Z[F)%OW%5NO&T1GT ZUEK47
MVS>F3*W2.T[7*(C"7]S[1UU%AF93]DZ6Y'/EJ@:C66WZLVG5E1RV5\W=#3<;
MH2Q(7)-I<-$G E/U2]7$Z6W9HZRTHXZG'*;48Z(I-M#WM=;N>5(X:+K6R4]0
M2P,$%     @ T$&B5! <@O_.!0  C!8  !D   !X;"]W;W)K<VAE971S+W-H
M965T-#(N>&ULW5C?;]LV$/Y7"*\;6B"-15+RC\PQX#C;&J#=@B3='HH]T!)M
M$95(EZ3BY+_?47(D-Y(8!WL9]F)+%'G?=R?>=R?.=DI_-2GG%CWDF33G@]3:
M[=EP:.*4Y\R<JBV7\&2M=,XLW.K-T&PU9TFY*,^&) A&PYP).9C/RK%K/9^I
MPF9"\FN-3)'G3#]>\$SMS@=X\#1P(S:I=0/#^6S+-OR6V\_;:PUWP]I*(G(N
MC5 2:;X^'RSPV9)&;D$YXT_!=^;@&CE75DI]=3=7R?D@<(QXQF/K3##XN^=+
MGF7.$O#XMC<ZJ#'=PL/K)^N_ELZ#,RMF^%)E?XG$IN>#R0 E?,V*S-ZHW0>^
M=Z@D&*O,E+]HMY\;#%!<&*OR_6)@D M9_;.'?2".64#V"\BS!9CV+*#[!;1T
MM&)6NG7)+)O/M-HA[6:#-7=1QJ9<#=X(Z5[CK=7P5, Z.[\H#(P8@Y8J7PG)
MJMC*!/UA4Z[1G6;2L"KB;R^Y92(S[]![= O;*2DRCM0:P42T+72<0C315HN8
M(ZL0,X9; Z_I6R$T3TJ;F6 KD0DKN''/BQS&WR AT5VJ"@,SS&QHP2E';1CO
M';BH'" ]#F""/BEI4X-^D0E/OC<PA&C4(2%/(;D@7HN7/#Y%%)\@$A#\^?82
MO7WSSF.6UI&FI=FPQ^SO3*H'M+A"'VV"OGSB^8KKOSUVP]IN6-JE_]4W^.4C
MX*,KRW/C\R>J_8F\<5HRDYZ@&'X1!^1[EG'I: #Z#3<6V%D =;.Z-DME>U3:
M=A)V/Q]-H]%L>-_!:%0S&GD9+>)8%8[##8\Y$%IEO'.C5E:B ^SIM!MY7"./
MO<C5*XP+K2$&^Q?2A3QN(8<TZ(:>U- 3+_25M$QN!/CJP9VT<,?3">X)][1&
MGGJ1?U,JV8DLZP*<M@ C3$+:#8B#1@2#(^+<[^=^^2$N'DW[8 ^T%WMA[Y1E
MV?,\Z\3';?PP('3<PX T#(A?E*!1@*+'M4MPRQX.$[R3"&D1H2'N"T0CC=BO
MC4M0<"$W;I.;5&F++-<YXDQ+Z#QJ3H^=C&B;T023GL3#C:KB\%A*F9*;]Z]@
M%+88D=&H)QUQ(XOX!5U4\IYK6V:D5)9W0D?M8 1! UW.6KX ] 7[9!PWJHG]
MLEDE5>;?3VW-#",2]<2JD4WLU\TJL3J*52>'MGI&>$SZ<JL14.Q74)=;Q^1V
M6T0GDPCW[9=&1;%?1C_?+FX6E^B#RA+8Q^A*0E=S1-M!&M$DP?^B\2"-'A._
M'A];Z$E;CJ>8=+\PTF@Q\6OQ4167M 688#SIV:RD46#B5V!?T25MB1T'44^2
MDD9AB5]A7RJZI*VCM*?2D$9%B5_<CBZYI"VE9!KAGKI"&E4D?E7\J)A$:ZUR
MQ-!&@:++O.SMH-+$G>6$M"42AV$/C48AB5\A7UOX25LDZ7C4T^F11B.)7R/_
M1>$G;=VD8=2W01K9)'[9?%;W7T.HW9S"CNF1!=K(+#VF-_674=KN3Z.H1Q-H
M(X?TF/;TR"I*.UK48#+N<[]11?IRAWI$NM*V+N+)*.R+P<%'^PN=J?L.=07H
M^0=I)PG:^OJDM"\"3B>_'VE$C+ZR0]O#^U<M$$6/L)-=P6Y:R5*/%AO-N=.A
M$Y0P]WF]*#:%L6A:'8*@%;<[SF59KZ':;YE\+(-2GVF(ZAG+7?UTE?T-13F4
M$RC^)VB7BC@%&PZ:N19!%K"OA(34@@]Z-WOT8VG.I"S+8")BA54Y-!0QW#^B
MN*(+M&"-*H&>@'_Z84+P^&>#KO63F"W1;<K \ EBL'/V7<464LBXX9(;H:<A
M.45WJ3"0Y$ )_GDF<M?$E"A[1Z51F:@"LH9G,A; VU@8<+$RIUU-Q_#@+"[G
M>E,>41I4-A;5(4@]6A^#+LK#OV?C%_ALB;O&R=FR:_Z"AF=+V%4=*VCT=-(Z
M;"A5Y[2?F-X("6'@:Z 7G(YA#^GJZ+.ZL6I;GAZNE(5W4EZFG"5<NPGP?*W@
M6V1_XP#J ^CY/U!+ P04    " #00:)4S\)\F94"    !@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6R-5%%OVC 0_BNGJ ^MM#8A(;2K *G IB&U
M757:[:'J@TD.8C6QJ>T ^_<[.R&C%-!>$M_YON^^.]O774GUIC-$ ^LB%[KG
M9<8LKGU?)QD63%_(!0K:F4E5,$.FFOMZH9"E#E3D?A@$';]@7'C]KO,]J'Y7
MEB;G A\4Z+(HF/HSP%RN>E[+VS@>^3PSUN'WNPLVQPF:Y\6#(LMO6%)>H-!<
M"E XZWDWK>MA;.-=P"^.*[VU!EO)5,HW:XS3GA=809AC8BP#H]\2AYCGEHAD
MO-><7I/2 K?7&_;OKG:J9<HT#F7^FZ<FZWE7'J0X8V5N'N7J!];U.(&)S+7[
MPJJ.#3Q(2FUD48-)0<%%]6?KN@];@%;G ""L >$NH'T $-6 R!5:*7-EC9AA
M_:Z2*U VFMCLPO7&H:D:+NPI3HRB74XXTQ^4FCQ:PU 64RY8U5N1PD^3H8(G
MQ81F5<=/1V@8S_49G,.$;E-:Y@AR1B?Q7G+-70R9]TS(-=R,*:I9WIH47NZP
MF*)Z)?_S9 2G)V=P ES 4R9+31EUUS=4D)7E)[7X024^/""^%<*=%";3\$VD
MF'XD\*D333O"33L&X5'&$287$+6^0!B$K3V"AO\/#X[(B9K3B1Q?=(!O**DN
MH3&%B6$&Z?48V^*Q2&2!,&0+VW0-+[>$@S$%Z-<C6=M-UK;+VCZ0]1&7*$K<
M=QX5L.. =D L^V'4B;K^<KM'GX-:<1PT01\TQ8VF^*BF>QIHN=1[+TG\*=_Y
MU670CG=D[0GK?+VZC'>$^5N/J4 U=S-&0R)+8:J+U'B;,7;C7N^.?T#CK9I&
M_VBJV7C'U)S3N>4X(\K@XI*DJ6K>5(:1"_=DI]+0 '#+C$8T*AM ^S,IS<:P
M"9JAW_\+4$L#!!0    ( -!!HE2J+*HI9P(  "P&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0T+GAM;*55VV[;, S]%<$8AA;8ZDLN[3K'0%)W6Q\Z%"VZ
M/0Q[4&PF%JJ+)S%QMZ^?)#M>VB9!@;W8(L5S#BF9=-HH_6 J "2/@DLS"2K$
M^CP,35&!H.9$U2#MSD)I0=&:>AF:6@,M/4CP,(FB<2@HDT&6>M^-SE*U0LXD
MW&AB5D)0_7L&7#63( XVCENVK- YPBRMZ1+N ._K&VVML&<IF0!IF))$PV(2
M3./S?.3B?< W!HW96A-7R5RI!V=<E9,@<@D!AP(= [6O-5P YX[(IO&KXPQZ
M20?<7F_8/_G:;2US:N!"\>^LQ&H2G 6DA 5=<;Q5S1?HZO$)%HH;_R1-&SL:
M!J18&52B ]L,!)/MFSYVY[ %B,=[ $D'2)X#]BD,.L#@M8!A!QCZDVE+\>>0
M4Z19JE5#M(NV;&[A#].C;?E,NFN_0VUWF<5A]EFILF&<D[=4U!_)E40JEVS.
M@4R- 33OR%?[[1WE@)1Q<TS>D_N[G!R].4Y#M/*.)"PZJ5DKE>R1BA-RK216
MAES*$LJG!*'-NT\^V20_2PXRYE"<D$'\CB11$N](Z.+U\&@'/'\U//YPH)I!
M?Q4#SS?XKZOX,9T;U+9=?AZ0'/:20R\YW"-Y:9#9WH&2+"C39$WY"G9=;,LR
M]BQND*RS.(K/DG$:KG>HCWKUT4'UJ5 :V1_J!\#EHYUD9J?ZZ*7ZZ?BLUVZO
M^F50]#0B/Q31YA]N]9$ O?3SR)!"K22V7V7O[4?>U'?Z,__,CL)V<OVC:>?H
M-=5+)@WAL+"4T<FIS4JWLZDU4-6^6^<*;>_[967'.6@78/<72N'&< +]#R+[
M"U!+ P04    " #00:)4-$CH:KL"  ";!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6RM56M/VS 4_2M6-$T@,?(H?<#:2"W= VE,B(Y-&N*#F]PF
M%GX$VVG9OY_MI*;;2M@'OK1^W'/NN<?.]7@CY+TJ 31Z9)2K25!J79V%H<I*
M8%@=BPJXV5D)R; V4UF$JI* <P=B-$RB:! R3'B0CMW:E4S'HM:4<+B22-6,
M8?EK!E1L)D$<;!>N25%JNQ"FXPH7L !]4UU),PL]2TX8<$4$1Q)6DV :G\UB
M!W 1WPELU,X8V5*60MS;R44^"2*K""ADVE)@\[>&<Z#4,AD=#RUIX'-:X.YX
MR_[1%6^*66(%YX+^(+DN)\$H0#FL<$WUM=A\AK:@ON7+!%7N%VW:V"A 6:VT
M8"W8*&"$-__XL35B!Y#$SP"2%I XW4TBIW*.-4['4FR0M-&&S0Y<J0YMQ!%N
M3V6AI=DE!J?33T+D&T(I>HM9]1Y=<(UY0984T%0IT.H(?357XV .&A.J#M$[
MM# 7(Z]-@%BA8HO&/$>Z!$2>\-CA#<"GN+T$M@1YA]Z8./2M%+4R.#4.M2G$
MR@FS5O2L$9T\(SI.T*7@NE3H \\A_Y,@- YX&Y*M#;.DDW$.V3'JQ4<HB9+X
M9C%'!V\..VA[WMV>H^V]Y.[M%[.#+C0P==?!>^)Y3QSOR3.\,R@(YX07YD92
MS#/8YV$GA?W:SU2%,Y@$YG-6(-<0I*A#6]]KZW=J,T?R@K &WW=XVS76:7^4
MG([&X7I/VH%/.^A,^Q.6$OLKUE''T!,.7_7L1IYWU"G4\ZZD8*8K/=1$$=NA
M]EDU^M>J.#GI[;?JU"LX[51PLYA>3^?_XU4</;61Z%7=BG<:5/QZ?K5<@QW#
MAE&__Y=?X4Z_9" +]RHHE(F:ZZ9U^E7_\DR;?OL4WCQ;EUB:3U$A"BL#C8Z'
MYJQD\Q(T$RTJUWV70IM>[H:E>3U!V@"SOQ)";R<V@7^/T]]02P,$%     @
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MZ=$<>,<SIQ\S.27$M$$['45[R[.B5"#D'JCY" F>L^CGA,!.Z\K.Y:7 G8\
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MD_#N.*V/O>)HD*3CUNV!T&$K='A6Z-'OO.+JE@Z'K49A.V3.SQ-]B;YVQ=:
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M5'8#_;Z4TNQ?K('FPVC^/U!+ P04    " #00:)4$W9"]'H"  !9!@  &0
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MO:%?<%%Z\<S-+74\4S5*4<)2,U,7!==OMR#5;NX%WOO$H]CD:"?\>%;Q#:P
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M-\SIL0)M'6@]4PK?#=M V^<O_@-02P,$%     @ T$&B5$RL5=[3 0  P@,
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MR9^?X"CY:%BJ_]LB:%@*&EI!PR<$K4'0C@A.YUQPLVN"TS$:6T98S1\NP=@
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MFF_,,E0C*' =H,X7C,G-1@\YY5#K?P%02P,$%     @ T$&B5%5I^$NB @
MV 8  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N>&ULC55=;]HP%/TK5E9-
MK=0V'R24=H!4RKKMH1(JZ_8P[<$D-\2J8V>V@>[?[]H)&>5+O(#MG'-\CV]\
MTE])]:H+ $/>2B[TP"N,J>Y\7Z<%E%1?RPH$/LFE*JG!J9K[NE) ,T<JN1\%
M0=<O*1/>L._6)FK8EPO#F8")(GI1EE3]'0&7JX$7>NN%9S8OC%WPA_V*SF$*
MYJ6:*)SYK4K&2A":24$4Y /O/KP;)Q;O #\8K/3&F%@G,RE?[>1;-O "6Q!P
M2(U5H/BWA ?@W IA&7\:3:_=TA(WQVOU1^<=O<RHA@?)?[+,% .OYY$,<KK@
MYEFNOD+CQQ682J[=+UDUV, CZ4(;639DK*!DHOZG;\TY;!#"[@%"U!"B;4)\
M@-!I")U3"7%#B-W)U%;<.8RIH<.^DBNB+!K5[, =IF.C?29LVZ=&X5.&/#-\
M!DX-9&1"E6&@R?D8#&5<7Y K,L5W+%MP(#+'#M>XJL$9186FKG<:H2_3,3D_
MNR!GA GRO9 +346F^[[!$NU&?MJ4,ZK+B0Z4$T;D20I3:/)99)"]%_#16VLP
M6AL<14<5QY!>DTYX2:(@"O<4]' Z/=A#'Y],#V^/N.FT[>HXO<X!O9-;\NM^
MIG$A-;^/[!JWN\9NU_C@2Z*!JK0@V%2\5$L,BPJOOB$?/_2B,/Q$- #)R,R&
MR+Z>U^I=IVYS:#GLX5DN-[NP"^DDR7O,>!<3)G&+>><L:9TE1YU] 0&*<F>,
M9GB_F#TU&T6MMREZ2R\).$Q^V&2R4]U5>!MNV=P'ZMYL^=P%);UHVZB_<>=+
M4'.7G9JD<B%,?3O:U3:>[UTJ;:V/,+;KE/TO4V?^$U5SAN\2AQPE@^L;+$S5
M.5I/C*Q<LLRDP9QRPP(_/: L )_G4IKUQ&[0?LR&_P!02P,$%     @ T$&B
M5-83:*8< @  UP0  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULC51M
M:]LP$/XKPG30PHC?DJTICB%I&!NT$)IU^S#V07$NCJ@L>=*Y;O_]3K)C,DC"
MOMAWTCW//7?2*6NU>;%[ &1OE51V%NP1Z[LPM,4>*FY'N@9%.SMM*H[DFC*T
MM0&^]:!*ADD4?0HK+E209WYM9?),-RB%@I5AMJDJ;MX7('4["^+@L/ DRCVZ
MA3#/:E["&O"Y7AGRPH%E*RI05FC%#.QFP3R^6TQ<O _X(:"U1S9SE6RT?G'.
MM^TLB)P@D%"@8^#T>X5[D-(1D8P_/6<PI'3 8_O _L773K5LN(5[+7^*+>YG
MP6W MK#CC<0GW7Z%OAXOL-#2^B]KN]AT&K"BL:BK'DP**J&Z/W_K^W $2.(S
M@*0')%YWE\BK7'+D>69TRXR+)C9G^%(]FL0)Y0YEC89V!>$P?]"J9-_!5.Q!
M<\6NEX!<2'O#KIA0[%%(2;VS68B4RR'"HN===+S)&=XUU".61A]9$B7Q\WK)
MKJ]N_F4)2>D@-QGD)IXV/4.[A VRI;"%U+8QP'[--Q8-'>WO"^3I0)YZ\O'9
M7E '>&D Z-8A0^K*J<(ODZ3L';BQ%^2,!SGC_Y!3Z4;A*1D=>.K!;O1>\W1T
MFX6O)S).AHR3BQGG2C5<TL%3Z6"1&8YP*O5EEG@4CZ<?3C4@/+JG;N0?N2F%
MLDS"CIBBT6<B-MT8=0[JVE_=C48:!&_NZ>4!XP)H?Z<U'APW#<-;EO\%4$L#
M!!0    ( -!!HE37Z1:O+ (  .H$   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8S+GAM;)U4W6_:,!#_5ZRH#ZTT$0C0M56(Q$>G[:$:*NKV,.W!))?$JC^8
M?9#VO]_9@8Q-P,->B,^^W\<=9Z>-L:^N!D#VIJ1VDZA&W#S$L<MK4-SUS 8T
MG93&*HX4VBIV&PN\"" EXZ3?OXT5%SK*TK"WM%EJMBB%AJ5E;JL4M^\SD*:9
M1(/HL/$LJAK]1IRE&U[!"O!EL[04Q1U+(11H)XQF%LI)-!T\S,8^/R1\$]"X
MHS7SE:R->?7!EV(2];TAD)"C9^#TV<$<I/1$9./7GC/J)#WP>'U@_Q1JIUK6
MW,'<R.^BP'H2W46L@))O)3Z;YC/LZPD&<R-=^&5-FSL>12S?.C1J#R8'2NCV
MR]_V?3@")(,S@&0/2(+O5BBX7'#D66I-PZS/)C:_"*4&-)D3VO\I*[1T*@B'
MV=PH)9"ZC(YQ7;"YT2AT!3H7X-CU I +Z6[8%1.:/0DIJ94NC9&D/4&<[V5F
MK4QR1F; GHBX=NQ1%U#\C8_)<N<[.?B>)1<)O^;88\G=!Y;TD\'+:L&NKVXN
MT Z[=@P#[?"_VO%CNG9H:9!^7I :=5*C(#4Z*Z4=C0ZQLQ+@9$];@MM X&_7
M+AND\>Z$YKC3'%_4?*1J4(*OCZ%A#;>6AU*5V6H\9:'ENS^RD-SWQO^XB(_F
M3X&MPBUS+/>D[2AVN]U%GK;S^R>]?06>N*V$=DQ"2=!^[R,9L.W-:@,TFS#-
M:X-T-\*RIL<(K$^@\](8/ 1>H'O>LM]02P,$%     @ T$&B5*(9+760!
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M,/:U;/P>+36S1 0IA+(,0=7?,ZPA3<M("L>W)JC6]EDZ'C^_1?^E(J_(;*B
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M@)<&ZON6,?G6*#MH+YM6_P%02P,$%     @ T$&B5$AOSQ<5!   9Q8  !D
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MB#W8SJUJ.TN W<G[OR&[0N@ !NZU=<U/FMPDDP^K:CO3R154?USEQ3O8LDM
MKLN=3(5"D:>ZVLFJ1^O=TB_E'N&[\06^659[G@U-M05[3^6:F0+AL#*4OCLV
M;2.K7<WJ1(NLW!A\%EJ+I#R,@9K"+2XPOZ^$T/N3X@;UWO+\7U!+ P04
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M?^21?$&_?0!)HUC\CJ[0HWIPPCP&Q%9(:.-03>K"A2BC+ZJA4B#)$"19S%X
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MJG1X?HV7OTBVSBZVYDQ*%F>/*Z !\-1 ?5\P)@\OZ03E9>KD/U!+ P04
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M)\I:(YH=.#&=-])GPN9]913N,O0SBP>1R1+($WTF;Y=@*./Z';DB*ZROO.9
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MV 6Z88&=/2AK@/L;*<W+Q![0_5=8_ 502P,$%     @ T$&B5 R256\N P
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M0J%R?PW9=[0H[4F^$AKO!;:9X=4-I G _VLA]&O'7 Z:R^#B+U!+ P04
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M/6IW@/:72MGMQ#GH_D'2'U!+ P04    " #00:)4AW/C=O\!   \!0  &0
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MHN"(+='O&\BIF@V./DQ!T#CA']$%FLFU%FT34"$Y;%@NZ%P]E='9"O$]AIJ
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M."_OO<L'P3;%3?"<"<'2XN,:: 2Y"I#?+QD3^P<U0/V_#Y/_ %!+ P04
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M;GOWNV37YB ]A#X0/D]482C,%,JY:2D27LQUQ4:RW(Q&8R;5H&66L9J%@>L
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M[%4PQO(6Q_#ULV':P .+ Y'^+-=XM?$.>;X/L)H^UR'83O%.Q':*YQH0?][
M(TG\U<;B@ =6!:QW(+X_#O24WR>*H*J8-NP)QI$DP1#H17^/QC&2G1@^_OI@
M3TD4)8D? <RO((HP!)Y&',$4@ 8,B:+J'-PYC\+U.15N?B,:_0902P,$%
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #00:)4?2.^#.\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #0
M0:)4F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( -!!HE1:X/MN4 8   P=   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #0
M0:)4L4-S+T0'  #C'0  &               @(&4#@  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ T$&B5#4LT#SP @  K @  !@
M         ("!#A8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( -!!HE0P13/\G@4   T7   8              " @309  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #00:)4<SG>-TD(  #U+@
M&               @($('P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ T$&B5%M2\GJX"0  V"\  !@              ("!AR<  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( -!!HE2AF7*3. H
M !<9   8              " @74Q  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " #00:)4MW))\5@G  !3>   &               @('C
M.P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ T$&B5),;
MJI^>%0  !4D  !@              ("!<6,  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( -!!HE3%M_?2L@0  'X*   9
M  " @45Y  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
MT$&B5--!JV,#!   H@@  !D              ("!+GX  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " #00:)4]]"[-GT#  "N!P  &0
M            @(%H@@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( -!!HE1@C9#YJ 8  $T2   9              " @1R&  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ T$&B5-W(;,B[ @
MZP4  !D              ("!^XP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " #00:)4>M1U?(L.  #@)@  &0              @('M
MCP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( -!!HE0/
M]YRS[0(   0&   9              " @:^>  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ T$&B5)Q*A'^=!P  N1$  !D
M     ("!TZ$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -!!HE0+Y%[QI 0  &T)   9              "
M@<;+  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ T$&B
M5#AG;[%$)P  "(   !D              ("!H=   'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " #00:)4_N%M!_$#  "J"   &0
M        @($<^   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( -!!HE32!96N9P0  (@+   9              " @43\  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ T$&B5(<6[L&? P  N0@
M !D              ("!X@ ! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " #00:)4%_D&Q"\#  !<!P  &0              @(&X! $
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -!!HE2 &Y#9
M%0,  ,8&   9              " @1X( 0!X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ T$&B5+::HG7W P  UPH  !D
M ("!:@L! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #0
M0:)4+4T1Q4P"   %!0  &0              @(&8#P$ >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -!!HE2,H;F!" ,  ,T&   9
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M970S-2YX;6Q02P$"% ,4    " #00:)4J:FJ4H("  "&!@  &0
M    @(%H*0$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M -!!HE1DM.KL- (  /,$   9              " @2$L 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ T$&B5'6JIIUA P  K!(  !D
M             ("!C"X! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " #00:)4^.QPT$T%  #2&0  &0              @($D,@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -!!HE03?U-5\PD
M %$J   9              " @:@W 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ T$&B5)]H%XA5 P  P0H  !D              ("!
MTD$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #00:)4
M$!R"_\X%  ",%@  &0              @(%>10$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( -!!HE3/PGR9E0(    &   9
M      " @6-+ 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ T$&B5*HLJBEG @  + 8  !D              ("!+TX! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #00:)4-$CH:KL"  ";!P
M&0              @('-4 $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( -!!HE1K2=65V00  + 8   9              " @;]3 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ T$&B5"99G/U^
M @  J08  !D              ("!SU@! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " #00:)4P/W5^W,"  #+!@  &0
M@(&$6P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( -!!
MHE1EH$&N/@,  -X2   9              " @2Y> 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ T$&B5,H5B8+B P  T!   !D
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M=#4T+GAM;%!+ 0(4 Q0    ( -!!HE0&H&P&(0,  *\)   9
M  " @8)S 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
MT$&B5-PX7_.7 @  "@<  !D              ("!VG8! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    " #00:)43*Q5WM,!  #" P  &0
M            @(&H>0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( -!!HE1]SU_@^ (   $(   9              " @;)[ 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ T$&B5!<TQ6*)"0
MAQX  !D              ("!X7X! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    " #00:)4OL@U)L$"  #@"@  &0              @(&A
MB $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( -!!HE15
M:?A+H@(  -@&   9              " @9F+ 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ T$&B5-83:*8< @  UP0  !D
M     ("!<HX! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -!!HE1(;\\7%00  &<6   9              "
M@1:? 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ T$&B
M5 I(GPN;"P  ^F,  !D              ("!8J,! 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    " #00:)4EAK,M',$  "%%   &0
M        @($TKP$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0
M   ( -!!HE2B)1;S( 4  ! .   9              " @=ZS 0!X;"]W;W)K
M<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ T$&B5!?0=9WR P  ZQ$
M !D              ("!-;D! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"% ,4    " #00:)4U"TBYS8$  !8%0  &0              @(%>O0$
M>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( -!!HE3*-S<-
MQ@,  #<,   9              " @<O! 0!X;"]W;W)K<VAE971S+W-H965T
M-S,N>&UL4$L! A0#%     @ T$&B5 R256\N P  & H  !D
M ("!R,4! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " #0
M0:)4,.HS780"  !-!@  &0              @($MR0$ >&PO=V]R:W-H965T
M<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( -!!HE2'<^-V_P$  #P%   9
M          " @>C+ 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#
M%     @ T$&B5)=C[+C=!   B1@  !D              ("!'LX! 'AL+W=O
M<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " #00:)4&DF2 ]L"  !I
M"P  &0              @($RTP$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM
M;%!+ 0(4 Q0    ( -!!HE0J$7>H>P(  *H&   9              " @436
M 0!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ T$&B5!'X
M[D06 P  :0@  !D              ("!]M@! 'AL+W=O<FMS:&5E=',O<VAE
M970X,"YX;6Q02P$"% ,4    " #00:)4!8C0E%4"  !I!@  &0
M    @(%#W $ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    (
M -!!HE1IGXV)*@,  # 2   -              "  <_> 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ T$&B5)>*NQS     $P(   L              ( !
M).(! %]R96QS+RYR96QS4$L! A0#%     @ T$&B5*(JJ@"3!0  2#4   \
M             ( !#>,! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( -!!
MHE2KG#%+;@(  -HO   :              "  <WH 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -!!HE1$Y-]8'@(  )<N   3
M          "  7/K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !9 %D
*9A@  ,+M 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>262</ContextCount>
  <ElementCount>449</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statement of Changes in Shareholders??? Equity (capital Deficiency)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statement of Changes in Shareholders??? Equity (capital Deficiency)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Business Combination and Other Transaction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/BusinessCombinationandOtherTransaction</Role>
      <ShortName>Business Combination and Other Transaction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Goodwill &amp; Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNet</Role>
      <ShortName>Goodwill &amp; Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Cash, Cash Equivalents and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/DeferredRevenue</Role>
      <ShortName>Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Long Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LongTermLoan</Role>
      <ShortName>Long Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Segments of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SegmentsofOperations</Role>
      <ShortName>Segments of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Business Combination and Other Transaction (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables</Role>
      <ShortName>Business Combination and Other Transaction (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/BusinessCombinationandOtherTransaction</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Goodwill &amp; Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill &amp; Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/Leases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Deferred Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/DeferredRevenueTables</Role>
      <ShortName>Deferred Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/DeferredRevenue</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/RelatedParties</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/IncomeTaxTables</Role>
      <ShortName>Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/IncomeTax</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Segments of Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SegmentsofOperationsTables</Role>
      <ShortName>Segments of Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SegmentsofOperations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LossPerShare</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/General</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Significant Accounting Policies (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Business Combination and Other Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails</Role>
      <ShortName>Business Combination and Other Transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure -  Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable</Role>
      <ShortName>Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure -  Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable</Role>
      <ShortName>Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure -  Business Combination and Other Transaction (Details) - Schedule of acquisition of Nanox AI</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable</Role>
      <ShortName>Business Combination and Other Transaction (Details) - Schedule of acquisition of Nanox AI</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Goodwill &amp; Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill &amp; Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Goodwill &amp; Intangible Assets, Net (Details) - Schedule of goodwill and the intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable</Role>
      <ShortName>Goodwill &amp; Intangible Assets, Net (Details) - Schedule of goodwill and the intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Goodwill &amp; Intangible Assets, Net (Details) - Schedule of intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable</Role>
      <ShortName>Goodwill &amp; Intangible Assets, Net (Details) - Schedule of intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Goodwill &amp; Intangible Assets, Net (Details) - Schedule of Amortization of intangible assets for each of the next five years and thereafter</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable</Role>
      <ShortName>Goodwill &amp; Intangible Assets, Net (Details) - Schedule of Amortization of intangible assets for each of the next five years and thereafter</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0</Role>
      <ShortName>Property and Equipment, Net (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Leases (Details) - Schedule of company's total lease costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable</Role>
      <ShortName>Leases (Details) - Schedule of company's total lease costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LeasesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental cash flow information related to operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LeasesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Leases (Details) - Schedule of supplemental balance sheet information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable</Role>
      <ShortName>Leases (Details) - Schedule of supplemental balance sheet information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LeasesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Leases (Details) - Schedule of maturities of operating lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of operating lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LeasesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/DeferredRevenueDetails</Role>
      <ShortName>Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/DeferredRevenueTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Deferred Revenue (Details) - Schedule of Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofDeferredRevenueTable</Role>
      <ShortName>Deferred Revenue (Details) - Schedule of Deferred Revenue</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/DeferredRevenueTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/RelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/RelatedPartiesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Related Parties (Details) - Schedule of related party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable</Role>
      <ShortName>Related Parties (Details) - Schedule of related party</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/RelatedPartiesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Related Parties (Details) - Schedule of related parties transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable</Role>
      <ShortName>Related Parties (Details) - Schedule of related parties transactions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/RelatedPartiesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Long Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LongTermLoanDetails</Role>
      <ShortName>Long Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LongTermLoan</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/CommitmentsandContingencies</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Shareholders' Equity (Details) - Schedule of issued and outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of issued and outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based awards to employees, officers and directors</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of share-based awards to employees, officers and directors</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Shareholders' Equity (Details) - Schedule of shared - based payments to employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of shared - based payments to employees</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based compensation expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of share-based compensation expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/ShareholdersEquityTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/IncomeTaxDetails</Role>
      <ShortName>Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/IncomeTaxTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Income Tax (Details) - Schedule of income (loss) before income taxes consisted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable</Role>
      <ShortName>Income Tax (Details) - Schedule of income (loss) before income taxes consisted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/IncomeTaxTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Income Tax (Details) - Schedule of reconciliation our theoretical income tax expense to actual income tax expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable</Role>
      <ShortName>Income Tax (Details) - Schedule of reconciliation our theoretical income tax expense to actual income tax expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/IncomeTaxTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Income Tax (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Tax (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/IncomeTaxTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Income Tax (Details) - Schedule of valuation allowance provided portion deferred</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofvaluationallowanceprovidedportiondeferredTable</Role>
      <ShortName>Income Tax (Details) - Schedule of valuation allowance provided portion deferred</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/IncomeTaxTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Segments of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SegmentsofOperationsDetails</Role>
      <ShortName>Segments of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SegmentsofOperationsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable</Role>
      <ShortName>Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SegmentsofOperationsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Segments of Operations (Details) - Schedule of property and equipment by geography</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable</Role>
      <ShortName>Segments of Operations (Details) - Schedule of property and equipment by geography</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SegmentsofOperationsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/LossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LossPerShareTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Loss Per Share (Details) - Schedule of basic loss per share is calculated by dividing the loss attributable to the company???s owners</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable</Role>
      <ShortName>Loss Per Share (Details) - Schedule of basic loss per share is calculated by dividing the loss attributable to the company???s owners</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/LossPerShareTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="f20f2021_nanoximaging.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nanox.vision.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nanox.vision.com/role/SubsequentEvents</ParentRole>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="f20f2021_nanoximaging.htm">f20f2021_nanoximaging.htm</File>
    <File>f20f2021ex12-1_nanox.htm</File>
    <File>f20f2021ex12-2_nanox.htm</File>
    <File>f20f2021ex13-1_nanox.htm</File>
    <File>f20f2021ex13-2_nanox.htm</File>
    <File>f20f2021ex15-1_nanox.htm</File>
    <File>f20f2021ex2-1_nanox.htm</File>
    <File>f20f2021ex4-1_nanox.htm</File>
    <File>f20f2021ex4-2_nanox.htm</File>
    <File>f20f2021ex4-3_nanox.htm</File>
    <File>f20f2021ex4-4_nanox.htm</File>
    <File>f20f2021ex8-1_nanox.htm</File>
    <File>nnox-20211231.xsd</File>
    <File>nnox-20211231_cal.xml</File>
    <File>nnox-20211231_def.xml</File>
    <File>nnox-20211231_lab.xml</File>
    <File>nnox-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="863">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>109
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f20f2021_nanoximaging.htm": {
   "axisCustom": 1,
   "axisStandard": 21,
   "contextCount": 262,
   "dts": {
    "calculationLink": {
     "local": [
      "nnox-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nnox-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f20f2021_nanoximaging.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nnox-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nnox-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nnox-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 708,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 134,
    "http://www.nanox.vision.com/20211231": 47,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 184
   },
   "keyCustom": 129,
   "keyStandard": 320,
   "memberCustom": 50,
   "memberStandard": 34,
   "nsprefix": "nnox",
   "nsuri": "http://www.nanox.vision.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.nanox.vision.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Goodwill & Intangible Assets, Net",
     "role": "http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNet",
     "shortName": "Goodwill & Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Property and Equipment, Net",
     "role": "http://www.nanox.vision.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:CashEquivalentsAndRestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Cash, Cash Equivalents and Restricted Cash",
     "role": "http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash",
     "shortName": "Cash, Cash Equivalents and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:CashEquivalentsAndRestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Leases",
     "role": "http://www.nanox.vision.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:DeferredRevenuesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Deferred Revenue",
     "role": "http://www.nanox.vision.com/role/DeferredRevenue",
     "shortName": "Deferred Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:DeferredRevenuesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:RelatedPartyLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Related Parties",
     "role": "http://www.nanox.vision.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:RelatedPartyLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Long Term Loan",
     "role": "http://www.nanox.vision.com/role/LongTermLoan",
     "shortName": "Long Term Loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Commitments and Contingencies",
     "role": "http://www.nanox.vision.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Shareholders' Equity",
     "role": "http://www.nanox.vision.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Income Tax",
     "role": "http://www.nanox.vision.com/role/IncomeTax",
     "shortName": "Income Tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "role": "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:SegmentsOfOperationsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Segments of Operations",
     "role": "http://www.nanox.vision.com/role/SegmentsofOperations",
     "shortName": "Segments of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:SegmentsOfOperationsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Loss Per Share",
     "role": "http://www.nanox.vision.com/role/LossPerShare",
     "shortName": "Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Subsequent Events",
     "role": "http://www.nanox.vision.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfFairValueConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Business Combination and Other Transaction (Tables)",
     "role": "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables",
     "shortName": "Business Combination and Other Transaction (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfFairValueConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Goodwill & Intangible Assets, Net (Tables)",
     "role": "http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables",
     "shortName": "Goodwill & Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfPropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.nanox.vision.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfPropertyPlantAndEquipmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)",
     "role": "http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Leases (Tables)",
     "role": "http://www.nanox.vision.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Deferred Revenue (Tables)",
     "role": "http://www.nanox.vision.com/role/DeferredRevenueTables",
     "shortName": "Deferred Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfRelatedPartyTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Related Parties (Tables)",
     "role": "http://www.nanox.vision.com/role/RelatedPartiesTables",
     "shortName": "Related Parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfRelatedPartyTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfIssuedAndOutstandingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.nanox.vision.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfIssuedAndOutstandingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfIncomelossBeforeIncomeTaxesConsisted",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Income Tax (Tables)",
     "role": "http://www.nanox.vision.com/role/IncomeTaxTables",
     "shortName": "Income Tax (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfIncomelossBeforeIncomeTaxesConsisted",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Segments of Operations (Tables)",
     "role": "http://www.nanox.vision.com/role/SegmentsofOperationsTables",
     "shortName": "Segments of Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Loss Per Share (Tables)",
     "role": "http://www.nanox.vision.com/role/LossPerShareTables",
     "shortName": "Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c37",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nnox:InitialPublicOfferingNetProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - General (Details)",
     "role": "http://www.nanox.vision.com/role/GeneralDetails",
     "shortName": "General (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c37",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nnox:InitialPublicOfferingNetProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nnox:TaxBenefitPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Significant Accounting Policies (Details)",
     "role": "http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nnox:TaxBenefitPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "nnox:ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c38",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Significant Accounting Policies (Details) - Schedule of property and equipment",
     "role": "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "nnox:ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c38",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:PropertyPlantAndEquipmentSalvageValuePercentageDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c49",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value",
     "role": "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c49",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "role": "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ServicePeriodsDecription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Business Combination and Other Transaction (Details)",
     "role": "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails",
     "shortName": "Business Combination and Other Transaction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:ServicePeriodsDecription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfFairValueConsiderationTransferred",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c54",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure -  Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred",
     "role": "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable",
     "shortName": "Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfFairValueConsiderationTransferred",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c54",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c64",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure -  Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed",
     "role": "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable",
     "shortName": "Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c64",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pf0:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c65",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure -  Business Combination and Other Transaction (Details) - Schedule of acquisition of Nanox AI",
     "role": "http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable",
     "shortName": "Business Combination and Other Transaction (Details) - Schedule of acquisition of Nanox AI",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pf0:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c65",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Goodwill & Intangible Assets, Net (Details)",
     "role": "http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetDetails",
     "shortName": "Goodwill & Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Goodwill & Intangible Assets, Net (Details) - Schedule of goodwill and the intangible assets",
     "role": "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable",
     "shortName": "Goodwill & Intangible Assets, Net (Details) - Schedule of goodwill and the intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c70",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nnox:FiniteLivedIntangibleAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Goodwill & Intangible Assets, Net (Details) - Schedule of intangible assets",
     "role": "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable",
     "shortName": "Goodwill & Intangible Assets, Net (Details) - Schedule of intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nnox:FiniteLivedIntangibleAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Goodwill & Intangible Assets, Net (Details) - Schedule of Amortization of intangible assets for each of the next five years and thereafter",
     "role": "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable",
     "shortName": "Goodwill & Intangible Assets, Net (Details) - Schedule of Amortization of intangible assets for each of the next five years and thereafter",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfPropertyPlantAndEquipmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c84",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nnox:PercentageOfPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment",
     "role": "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
     "shortName": "Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfPropertyPlantAndEquipmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c84",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "nnox:PercentageOfPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statement of Changes in Shareholders\u2019 Equity (capital Deficiency)",
     "role": "http://www.nanox.vision.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statement of Changes in Shareholders\u2019 Equity (capital Deficiency)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Property and Equipment, Net (Details) - Schedule of property and equipment",
     "role": "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0",
     "shortName": "Property and Equipment, Net (Details) - Schedule of property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash",
     "role": "http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable",
     "shortName": "Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of reconciliation of cash, cash equivalents and restricted cash",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "nnox:RestrictedBankDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c105",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Leases (Details)",
     "role": "http://www.nanox.vision.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c105",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Leases (Details) - Schedule of company's total lease costs",
     "role": "http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable",
     "shortName": "Leases (Details) - Schedule of company's total lease costs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Leases (Details) - Schedule of supplemental cash flow information related to operating leases",
     "role": "http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable",
     "shortName": "Leases (Details) - Schedule of supplemental cash flow information related to operating leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Leases (Details) - Schedule of supplemental balance sheet information",
     "role": "http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable",
     "shortName": "Leases (Details) - Schedule of supplemental balance sheet information",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Leases (Details) - Schedule of maturities of operating lease liabilities",
     "role": "http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of maturities of operating lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRevenueNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Deferred Revenue (Details)",
     "role": "http://www.nanox.vision.com/role/DeferredRevenueDetails",
     "shortName": "Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nnox:IncreaseDueToTheBusinessCombinations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Deferred Revenue (Details) - Schedule of Deferred Revenue",
     "role": "http://www.nanox.vision.com/role/ScheduleofDeferredRevenueTable",
     "shortName": "Deferred Revenue (Details) - Schedule of Deferred Revenue",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nnox:IncreaseDueToTheBusinessCombinations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c19",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Related Parties (Details)",
     "role": "http://www.nanox.vision.com/role/RelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c19",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.nanox.vision.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfRelatedPartyTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nnox:TotalDueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Related Parties (Details) - Schedule of related party",
     "role": "http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable",
     "shortName": "Related Parties (Details) - Schedule of related party",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfRelatedPartyTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "nnox:TotalDueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Related Parties (Details) - Schedule of related parties transactions",
     "role": "http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable",
     "shortName": "Related Parties (Details) - Schedule of related parties transactions",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c124",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Long Term Loan (Details)",
     "role": "http://www.nanox.vision.com/role/LongTermLoanDetails",
     "shortName": "Long Term Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c124",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c125",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nnox:ConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.nanox.vision.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c125",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "nnox:ConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c126",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:DescriptionOfSharebasedCompensationExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Shareholders' Equity (Details)",
     "role": "http://www.nanox.vision.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c126",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:DescriptionOfSharebasedCompensationExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfIssuedAndOutstandingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ExcessStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Shareholders' Equity (Details) - Schedule of issued and outstanding",
     "role": "http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of issued and outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfIssuedAndOutstandingTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ExcessStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based awards to employees, officers and directors",
     "role": "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of share-based awards to employees, officers and directors",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions",
     "role": "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c182",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards",
     "role": "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of information concerning outstanding and exercisable awards",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c182",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c209",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Shareholders' Equity (Details) - Schedule of shared - based payments to employees",
     "role": "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of shared - based payments to employees",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c210",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - General",
     "role": "http://www.nanox.vision.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherCostOfOperatingRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Shareholders' Equity (Details) - Schedule of share-based compensation expenses",
     "role": "http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of share-based compensation expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherCostOfOperatingRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Income Tax (Details)",
     "role": "http://www.nanox.vision.com/role/IncomeTaxDetails",
     "shortName": "Income Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c227",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfIncomelossBeforeIncomeTaxesConsisted",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c229",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071 - Disclosure - Income Tax (Details) - Schedule of income (loss) before income taxes consisted",
     "role": "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable",
     "shortName": "Income Tax (Details) - Schedule of income (loss) before income taxes consisted",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfIncomelossBeforeIncomeTaxesConsisted",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c229",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "072 - Disclosure - Income Tax (Details) - Schedule of reconciliation our theoretical income tax expense to actual income tax expense",
     "role": "http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable",
     "shortName": "Income Tax (Details) - Schedule of reconciliation our theoretical income tax expense to actual income tax expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "073 - Disclosure - Income Tax (Details) - Schedule of deferred tax assets and liabilities",
     "role": "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable",
     "shortName": "Income Tax (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "074 - Disclosure - Income Tax (Details) - Schedule of valuation allowance provided portion deferred",
     "role": "http://www.nanox.vision.com/role/ScheduleofvaluationallowanceprovidedportiondeferredTable",
     "shortName": "Income Tax (Details) - Schedule of valuation allowance provided portion deferred",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "nnox:IncreaseDueToBusinessCombinationinShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "075 - Disclosure - Segments of Operations (Details)",
     "role": "http://www.nanox.vision.com/role/SegmentsofOperationsDetails",
     "shortName": "Segments of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c242",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "076 - Disclosure - Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss",
     "role": "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable",
     "shortName": "Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c242",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentOtherNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "077 - Disclosure - Segments of Operations (Details) - Schedule of property and equipment by geography",
     "role": "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable",
     "shortName": "Segments of Operations (Details) - Schedule of property and equipment by geography",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "nnox:ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentOtherNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nnox:BasicAndDilutedShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "078 - Disclosure - Loss Per Share (Details)",
     "role": "http://www.nanox.vision.com/role/LossPerShareDetails",
     "shortName": "Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nnox:BasicAndDilutedShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Significant Accounting Policies",
     "role": "http://www.nanox.vision.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "079 - Disclosure - Loss Per Share (Details) - Schedule of basic loss per share is calculated by dividing the loss attributable to the company\u2019s owners",
     "role": "http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable",
     "shortName": "Loss Per Share (Details) - Schedule of basic loss per share is calculated by dividing the loss attributable to the company\u2019s owners",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c259",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nnox:AdditionalSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.nanox.vision.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c259",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "nnox:AdditionalSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:CertainTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Business Combination and Other Transaction",
     "role": "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransaction",
     "shortName": "Business Combination and Other Transaction",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_nanoximaging.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nnox:CertainTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 87,
   "tag": {
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ISRAEL",
        "terseLabel": "Israel [Member]"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan [Member]"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "Korea [Member]"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Unites States [Member]",
        "verboseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable",
      "http://www.nanox.vision.com/role/SegmentsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_KRW": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Korea (South), Won",
        "terseLabel": "South Korea [Member]"
       }
      }
     },
     "localname": "KRW",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nnox_AISolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AISolutionsMember",
        "terseLabel": "AI Solutions [Member]"
       }
      }
     },
     "localname": "AISolutionsMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_AcquisitionDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AcquisitionDate",
        "terseLabel": "Acquisition date"
       }
      }
     },
     "localname": "AcquisitionDate",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nnox_AcquisitionOfSharesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of shares percentage.",
        "label": "AcquisitionOfSharesPercentage",
        "terseLabel": "Acquisition of shares percentage"
       }
      }
     },
     "localname": "AcquisitionOfSharesPercentage",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_AdditionalCashConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional cash consideration.",
        "label": "AdditionalCashConsideration",
        "terseLabel": "Additional cash consideration"
       }
      }
     },
     "localname": "AdditionalCashConsideration",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_AdditionalConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional consideration.",
        "label": "AdditionalConsideration",
        "terseLabel": "Additional consideration"
       }
      }
     },
     "localname": "AdditionalConsideration",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6",
        "terseLabel": "Additional consideration with respect to an assets purchase agreement, see note 9a"
       }
      }
     },
     "localname": "AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreementSeeNote1cAndNote6",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional consideration with respect to an assets purchase agreement.",
        "label": "AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements",
        "terseLabel": "Additional consideration with respect to an assets purchase agreement"
       }
      }
     },
     "localname": "AdditionalConsiderationWithRespectToAnAssetsPurchaseAgreements",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_AdditionalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payment.",
        "label": "AdditionalPayment",
        "terseLabel": "Additional payment"
       }
      }
     },
     "localname": "AdditionalPayment",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_AdditionalSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares issued.",
        "label": "AdditionalSharesIssued",
        "terseLabel": "Additional shares issued"
       }
      }
     },
     "localname": "AdditionalSharesIssued",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AgreementAxis",
        "terseLabel": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_AgreementTerminateTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement terminate term.",
        "label": "AgreementTerminateTerm",
        "terseLabel": "Agreement terminate term"
       }
      }
     },
     "localname": "AgreementTerminateTerm",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nnox_AmortizationExpenseForThePeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization expense for the period",
        "label": "AmortizationExpenseForThePeriod",
        "terseLabel": "Amortization expense for the period"
       }
      }
     },
     "localname": "AmortizationExpenseForThePeriod",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_AnnualInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual interest rate.",
        "label": "AnnualInterestRate",
        "terseLabel": "Annual interest rate"
       }
      }
     },
     "localname": "AnnualInterestRate",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/LongTermLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_AssetsAcquisitionDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AssetsAcquisitionDescription",
        "terseLabel": "Assets acquisition, description"
       }
      }
     },
     "localname": "AssetsAcquisitionDescription",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_AwardsExercisableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AwardsExercisableMember",
        "terseLabel": "Awards exercisable [Member]"
       }
      }
     },
     "localname": "AwardsExercisableMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_AwardsOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AwardsOutstandingMember",
        "terseLabel": "Awards outstanding [Member]"
       }
      }
     },
     "localname": "AwardsOutstandingMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_BasicAndDilutedLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BasicAndDilutedLossPerShare",
        "terseLabel": "Basic and diluted loss per share"
       }
      }
     },
     "localname": "BasicAndDilutedLossPerShare",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nnox_BasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted share",
        "label": "BasicAndDilutedShare",
        "terseLabel": "Basic and diluted share"
       }
      }
     },
     "localname": "BasicAndDilutedShare",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/LossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_BlackScholesOptionpricingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BlackScholesOptionpricingMember",
        "terseLabel": "Black- Scholes option-pricing [Member]"
       }
      }
     },
     "localname": "BlackScholesOptionpricingMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_BusinessAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BusinessAcquisitionMember",
        "terseLabel": "Business Acquisition [Member]"
       }
      }
     },
     "localname": "BusinessAcquisitionMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_BusinessCombinationandOtherTransactionDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Other Transaction (Details) [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationandOtherTransactionDetailsLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Other Transaction (Details) - Schedule of fair value consideration transferred [Table]"
       }
      }
     },
     "localname": "BusinessCombinationandOtherTransactionDetailsScheduleoffairvalueconsiderationtransferredTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Other Transaction (Details) - Schedule of the purchase price to assets acquired and liabilities assumed [Table]"
       }
      }
     },
     "localname": "BusinessCombinationandOtherTransactionDetailsScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_BusinessCombinationandOtherTransactionDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Other Transaction (Details) [Table]"
       }
      }
     },
     "localname": "BusinessCombinationandOtherTransactionDetailsTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_CarryForwardLossYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carry forward loss years.",
        "label": "CarryForwardLossYears",
        "terseLabel": "Carry forward loss years"
       }
      }
     },
     "localname": "CarryForwardLossYears",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nnox_CashCashEquivalentsandRestrictedCashLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents and Restricted Cash [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsandRestrictedCashLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_CashCashEquivalentsandRestrictedCashTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents and Restricted Cash [Table]"
       }
      }
     },
     "localname": "CashCashEquivalentsandRestrictedCashTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_CashCashEquivalentsandRestrictedCashTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents and Restricted Cash Table[Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsandRestrictedCashTablesLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_CashCashEquivalentsandRestrictedCashTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents and Restricted Cash (Tables) [Table]"
       }
      }
     },
     "localname": "CashCashEquivalentsandRestrictedCashTablesTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_CashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents and Restricted Cash [Abstract]"
       }
      }
     },
     "localname": "CashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_CashEquivalentsAndRestrictedCashTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash equivalent and restricted cash.",
        "label": "CashEquivalentsAndRestrictedCashTextBlock",
        "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashEquivalentsAndRestrictedCashTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_CertainTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Other Transaction [Abstract]"
       }
      }
     },
     "localname": "CertainTransactionsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_CertainTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Transactions.",
        "label": "CertainTransactionsTextBlock",
        "terseLabel": "BUSINESS COMBINATION AND OTHER TRANSACTION"
       }
      }
     },
     "localname": "CertainTransactionsTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransaction"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ChangesDuringTheYearAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ChangesDuringTheYearAbstract",
        "terseLabel": "Changes during the year:"
       }
      }
     },
     "localname": "ChangesDuringTheYearAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ComputersAndElectronicEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ComputersAndElectronicEquipmentMember",
        "terseLabel": "Computers and electronic equipment [Member]"
       }
      }
     },
     "localname": "ComputersAndElectronicEquipmentMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_ConsiderationForServicesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration for services shares",
        "label": "ConsiderationForServicesShares",
        "terseLabel": "Consideration for services shares"
       }
      }
     },
     "localname": "ConsiderationForServicesShares",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_ConsultingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting fees.",
        "label": "ConsultingFees",
        "terseLabel": "Consulting fees"
       }
      }
     },
     "localname": "ConsultingFees",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_ContingentLongTermEarnoutLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent long term earnout liability.",
        "label": "ContingentLongTermEarnoutLiability",
        "terseLabel": "Contingent long term earnout liability"
       }
      }
     },
     "localname": "ContingentLongTermEarnoutLiability",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_ContingentLongtermEarnoutLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent long-term earnout liability.",
        "label": "ContingentLongtermEarnoutLiability",
        "terseLabel": "Contingent long-term earnout liability"
       }
      }
     },
     "localname": "ContingentLongtermEarnoutLiability",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_ContingentShortTermEarnoutLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent short term earnout liability.",
        "label": "ContingentShortTermEarnoutLiability",
        "terseLabel": "Contingent short term earnout liability"
       }
      }
     },
     "localname": "ContingentShortTermEarnoutLiability",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_ConversionOfRelatedPartyLiabilityToShareholdersEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of related party liability to shareholders\u2019 equity.",
        "label": "ConversionOfRelatedPartyLiabilityToShareholdersEquity",
        "terseLabel": "Conversion of related party liability to shareholders\u2019 equity"
       }
      }
     },
     "localname": "ConversionOfRelatedPartyLiabilityToShareholdersEquity",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_ConvertibleNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of convertible note.",
        "label": "ConvertibleNote",
        "terseLabel": "Convertible note"
       }
      }
     },
     "localname": "ConvertibleNote",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_CurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CurrentAbstract",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_CurrentMaturitiesOfOperatingLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CurrentMaturitiesOfOperatingLeases",
        "terseLabel": "Current maturities of operating leases"
       }
      }
     },
     "localname": "CurrentMaturitiesOfOperatingLeases",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_CurrentTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CurrentTotal",
        "negatedLabel": "Total"
       }
      }
     },
     "localname": "CurrentTotal",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_DeferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredAbstract",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_DeferredClosingConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred closing consideration.",
        "label": "DeferredClosingConsideration",
        "terseLabel": "Deferred closing consideration"
       }
      }
     },
     "localname": "DeferredClosingConsideration",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
        "negatedLabel": "Domestic"
       }
      }
     },
     "localname": "DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
        "negatedLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_DeferredOfferingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredOfferingCostsPolicyTextBlock",
        "terseLabel": "Offering Costs"
       }
      }
     },
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_DeferredRevenuesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "DeferredRevenuesDisclosureAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_DeferredRevenuesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredRevenuesDisclosureTextBlock",
        "terseLabel": "DEFERRED REVENUE"
       }
      }
     },
     "localname": "DeferredRevenuesDisclosureTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/DeferredRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_DeferredRevenuesTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenues Total.",
        "label": "DeferredRevenuesTotal",
        "terseLabel": "Change in deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenuesTotal",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofDeferredRevenueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_DeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredTaxAssetsAbstract",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_DescriptionOfNetAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DescriptionOfNetAssets",
        "terseLabel": "Description of net assets"
       }
      }
     },
     "localname": "DescriptionOfNetAssets",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_DescriptionOfSharebasedCompensationExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DescriptionOfSharebasedCompensationExpenses",
        "terseLabel": "Description of share-based compensation expenses"
       }
      }
     },
     "localname": "DescriptionOfSharebasedCompensationExpenses",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_DueToMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DueToMember",
        "terseLabel": "Due to [Member]"
       }
      }
     },
     "localname": "DueToMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_DueToOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DueToOneMember",
        "terseLabel": "Due to One [Member]"
       }
      }
     },
     "localname": "DueToOneMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_DueToThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DueToThreeMember",
        "terseLabel": "Due to Three [Member]"
       }
      }
     },
     "localname": "DueToThreeMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_DueToTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DueToTwoMember",
        "terseLabel": "Due to Two [Member]"
       }
      }
     },
     "localname": "DueToTwoMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_EmployeeOptionsAndRestrictedStockUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee options and restricted stock units.",
        "label": "EmployeeOptionsAndRestrictedStockUnits",
        "terseLabel": "Employee options and restricted stock units (in Shares)"
       }
      }
     },
     "localname": "EmployeeOptionsAndRestrictedStockUnits",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_EmployeesOfficersAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EmployeesOfficersAndDirectorsMember",
        "terseLabel": "Employees, Officers and Directors [Member]"
       }
      }
     },
     "localname": "EmployeesOfficersAndDirectorsMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_EmploymentAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of employment agreement.",
        "label": "EmploymentAgreementDescription",
        "terseLabel": "Employment Agreement description"
       }
      }
     },
     "localname": "EmploymentAgreementDescription",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_EntitlementToWarrantsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entitlement to warrants amount.",
        "label": "EntitlementToWarrantsAmount",
        "terseLabel": "Entitlement to warrants amount"
       }
      }
     },
     "localname": "EntitlementToWarrantsAmount",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_FabricationFacilityAndResearchDevelopmentalCenterDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fabrication facility and research developmental center description.",
        "label": "FabricationFacilityAndResearchDevelopmentalCenterDescription",
        "terseLabel": "Fabrication facility and research developmental center description"
       }
      }
     },
     "localname": "FabricationFacilityAndResearchDevelopmentalCenterDescription",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_FairValueOfContingentConsiderationAssumedInBusinessCombinations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration assumed in business combinations.",
        "label": "FairValueOfContingentConsiderationAssumedInBusinessCombinations",
        "terseLabel": "Fair value of contingent consideration assumed in business combinations"
       }
      }
     },
     "localname": "FairValueOfContingentConsiderationAssumedInBusinessCombinations",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_FairValueOfContingentConsiderationLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration liabilities.",
        "label": "FairValueOfContingentConsiderationLiabilities",
        "terseLabel": "Fair value of contingent consideration liabilities"
       }
      }
     },
     "localname": "FairValueOfContingentConsiderationLiabilities",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of ordinary shares issued as consideration for business combinations.",
        "label": "FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations",
        "terseLabel": "Fair value of ordinary shares issued as consideration for business combinations"
       }
      }
     },
     "localname": "FairValueOfOrdinarySharesIssuedAsConsiderationForBusinessCombinations",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of ordinary shares issued as consideration for purchase of assets.",
        "label": "FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets",
        "terseLabel": "Fair value of ordinary shares issued as consideration for purchase of assets"
       }
      }
     },
     "localname": "FairValueOfOrdinarySharesIssuedAsConsiderationForPurchaseOfAssets",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_FairValuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of fair value.",
        "label": "FairValuePercentage",
        "terseLabel": "Fair value percentage"
       }
      }
     },
     "localname": "FairValuePercentage",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_FederalTaxRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal tax rate percentage.",
        "label": "FederalTaxRatePercentage",
        "terseLabel": "Federal tax rate percentage"
       }
      }
     },
     "localname": "FederalTaxRatePercentage",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_FinancialExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of financial expense.",
        "label": "FinancialExpense",
        "terseLabel": "Financial expense"
       }
      }
     },
     "localname": "FinancialExpense",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_FinancialIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of financial income.",
        "label": "FinancialIncome",
        "terseLabel": "Financial income"
       }
      }
     },
     "localname": "FinancialIncome",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_FiniteLivedIntangibleAssetNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "FiniteLivedIntangibleAssetNet",
        "terseLabel": "Amount as of the merger/ acquisition date"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetNet",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_FortynineAndSixtyeightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FortynineAndSixtyeightMember",
        "terseLabel": "49.68 [Member]"
       }
      }
     },
     "localname": "FortynineAndSixtyeightMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_GeneralDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General (Details) [Line Items]"
       }
      }
     },
     "localname": "GeneralDetailsLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_GeneralDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General (Details) [Table]"
       }
      }
     },
     "localname": "GeneralDetailsTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_GeneralLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "localname": "GeneralLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/General"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_GeneralTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Table]"
       }
      }
     },
     "localname": "GeneralTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/General"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ImageBigDataMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ImageBigDataMember",
        "terseLabel": "Image big data [Member]"
       }
      }
     },
     "localname": "ImageBigDataMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_IncomeTaxDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax (Details) [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDetailsLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax (Details) - Schedule of income (loss) before income taxes consisted [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax (Details) - Schedule of income (loss) before income taxes consisted [Table]"
       }
      }
     },
     "localname": "IncomeTaxDetailsScheduleofincomelossbeforeincometaxesconsistedTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_IncomeTaxDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax (Details) [Table]"
       }
      }
     },
     "localname": "IncomeTaxDetailsTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_IncomeTaxExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomeTaxExpensesMember",
        "terseLabel": "Income Tax Expenses [Member]"
       }
      }
     },
     "localname": "IncomeTaxExpensesMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_IncomelossBeforeIncomeTaxesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomelossBeforeIncomeTaxesMember",
        "terseLabel": "Income (loss) Before Income Taxes [Member]"
       }
      }
     },
     "localname": "IncomelossBeforeIncomeTaxesMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_IncreaseDecreaseOperatingLease": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease.",
        "label": "IncreaseDecreaseOperatingLease",
        "terseLabel": "Operating lease assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseOperatingLease",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_IncreaseDecreaseRelatedPartyPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party prepaid expenses.",
        "label": "IncreaseDecreaseRelatedPartyPrepaidExpenses",
        "negatedLabel": "Related party prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseRelatedPartyPrepaidExpenses",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_IncreaseDueToBusinessCombinationinShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase due to business combination",
        "label": "IncreaseDueToBusinessCombinationinShares",
        "terseLabel": "Increase due to business combination"
       }
      }
     },
     "localname": "IncreaseDueToBusinessCombinationinShares",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofvaluationallowanceprovidedportiondeferredTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_IncreaseDueToTheBusinessCombinations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase due to the business combinations.",
        "label": "IncreaseDueToTheBusinessCombinations",
        "terseLabel": "Increase due to the business combinations"
       }
      }
     },
     "localname": "IncreaseDueToTheBusinessCombinations",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofDeferredRevenueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_InitialPublicOfferingNetProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering net proceeds .",
        "label": "InitialPublicOfferingNetProceeds",
        "terseLabel": "Proceeds received from the IPO"
       }
      }
     },
     "localname": "InitialPublicOfferingNetProceeds",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_InterestAccruesRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest accrues rate.",
        "label": "InterestAccruesRate",
        "terseLabel": "Interest accrues rate"
       }
      }
     },
     "localname": "InterestAccruesRate",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_IssuanceOfOrdinarySharePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ordinary share percentage.",
        "label": "IssuanceOfOrdinarySharePercentage",
        "terseLabel": "Issuance of ordinary share percentage"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharePercentage",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ordinary shares and warrants, net of issuance costs.",
        "label": "IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts",
        "terseLabel": "Issuance of ordinary shares and warrants, net of issuance costs"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ordinary shares and warrants, net of issuance shares.",
        "label": "IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares",
        "terseLabel": "Issuance of ordinary shares and warrants, net of issuance costs (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCostsShares",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions",
        "terseLabel": "Issuance of ordinary shares to employees and non-employees upon exercise of options"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptions",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares",
        "terseLabel": "Issuance of ordinary shares to employees and non-employees upon exercise of options (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesToEmployeesAndNonemployeesUponExerciseOfOptionsinShares",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets",
        "terseLabel": "Issuance of ordinary shares due to business combination and assets acquisition (refer to Note 3)"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssets",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin",
        "terseLabel": "Issuance of ordinary shares due to business combination and assets acquisition (refer to Note 3) (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesToInvestorsSueToBusinessCombinationAndPurchaseOfAssetsin",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ordinary shares to investors upon exercise of warrants.",
        "label": "IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants",
        "terseLabel": "Issuance of ordinary shares to investors upon exercise of warrants"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrants",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ordinary shares to investors upon exercise of warrants",
        "label": "IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares",
        "terseLabel": "Issuance of ordinary shares to investors upon exercise of warrants (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesToInvestorsUponExerciseOfWarrantsShares",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ordinary shares upon exercise of warrants.",
        "label": "IssuanceOfOrdinarySharesUponExerciseOfWarrants",
        "terseLabel": "Issuance of ordinary shares upon exercise of warrants"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesUponExerciseOfWarrants",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ordinary shares upon exercise of warrants.",
        "label": "IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares",
        "terseLabel": "Issuance of ordinary shares upon exercise of warrants (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfOrdinarySharesUponExerciseOfWarrantsinShares",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_IssuanceOfSharesInConsiderationOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares in consideration of assets.",
        "label": "IssuanceOfSharesInConsiderationOfAssets",
        "terseLabel": "Fair value of contingent consideration assumed in purchase of assets"
       }
      }
     },
     "localname": "IssuanceOfSharesInConsiderationOfAssets",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_IssuedDueToBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued due to business combination.",
        "label": "IssuedDueToBusinessCombination",
        "terseLabel": "Issued due to business combination"
       }
      }
     },
     "localname": "IssuedDueToBusinessCombination",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nnox_LeaseTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lease term.",
        "label": "LeaseTermDescription",
        "terseLabel": "Rent payment agreement, description"
       }
      }
     },
     "localname": "LeaseTermDescription",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_LeasedAdditionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LeasedAdditionTerm",
        "terseLabel": "Leased addition term"
       }
      }
     },
     "localname": "LeasedAdditionTerm",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nnox_LeasesTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement term, description",
        "label": "LeasesTermDescription",
        "terseLabel": "Vehicles lease, description"
       }
      }
     },
     "localname": "LeasesTermDescription",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_LegalAndOtherContingenciesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LegalAndOtherContingenciesPolicyTextBlock",
        "terseLabel": "Legal and other contingencies"
       }
      }
     },
     "localname": "LegalAndOtherContingenciesPolicyTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_LessValuationAllowanceForDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LessValuationAllowanceForDeferredTaxAssets",
        "terseLabel": "Less valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "LessValuationAllowanceForDeferredTaxAssets",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearFours": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueYearFours",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFours",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_LoanTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LoanTerm",
        "terseLabel": "Loan term"
       }
      }
     },
     "localname": "LoanTerm",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nnox_LongTermMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term marketable securities.",
        "label": "LongTermMarketableSecurities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "LongTermMarketableSecurities",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_MDWEBLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MDWEBLLCMember",
        "terseLabel": "MDWEB LLC [Member]"
       }
      }
     },
     "localname": "MDWEBLLCMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_MaximumAggregateAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum aggregate amount.",
        "label": "MaximumAggregateAmount",
        "terseLabel": "Maximum aggregate amount"
       }
      }
     },
     "localname": "MaximumAggregateAmount",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_NanoxAILtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NanoxAILtdMember",
        "terseLabel": "Nanox AI Ltd [Member]"
       }
      }
     },
     "localname": "NanoxAILtdMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails",
      "http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable",
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable",
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_NanoxARCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NanoxARCMember",
        "terseLabel": "Nanox ARC [Member]"
       }
      }
     },
     "localname": "NanoxARCMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_NanoxJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NanoxJapanMember",
        "terseLabel": "Nanox Japan [Member]"
       }
      }
     },
     "localname": "NanoxJapanMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_NanoxPLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NanoxPLCMember",
        "terseLabel": "Nanox PLC [Member]"
       }
      }
     },
     "localname": "NanoxPLCMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_NasdaqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NasdaqMember",
        "terseLabel": "Nasdaq [Member]"
       }
      }
     },
     "localname": "NasdaqMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_NetAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net assets acquired.",
        "label": "NetAssetsAcquired",
        "terseLabel": "Net assets acquired"
       }
      }
     },
     "localname": "NetAssetsAcquired",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_NetLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss",
        "label": "NetLoss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetLoss",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_NonCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NonCurrentAssetsAbstract",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "NonCurrentAssetsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_NonCurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NonCurrentLiabilitiesAbstract",
        "terseLabel": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "NonCurrentLiabilitiesAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_NoncurrentOperatingLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NoncurrentOperatingLeases",
        "terseLabel": "Non-current operating leases"
       }
      }
     },
     "localname": "NoncurrentOperatingLeases",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_NonemployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NonemployeesMember",
        "terseLabel": "Non-employees [Member]"
       }
      }
     },
     "localname": "NonemployeesMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_NumberOfSharebasedPaymentAwardsCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfSharebasedPaymentAwardsCancelled",
        "terseLabel": "Number of share-based payment awards, Cancelled"
       }
      }
     },
     "localname": "NumberOfSharebasedPaymentAwardsCancelled",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share-based payment awards, Outstanding at end of year.",
        "label": "NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear",
        "terseLabel": "Number of share-based payment awards, Outstanding at end of year"
       }
      }
     },
     "localname": "NumberOfSharebasedPaymentAwardsOutstandingAtEndOfYear",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_OfficeFurnitureAndLabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OfficeFurnitureAndLabEquipmentMember",
        "terseLabel": "Office furniture and lab equipment [Member]"
       }
      }
     },
     "localname": "OfficeFurnitureAndLabEquipmentMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_OneEightZeroZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OneEightZeroZeroMember",
        "terseLabel": "18.00 [Member]"
       }
      }
     },
     "localname": "OneEightZeroZeroMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_OneNinetyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OneNinetyTwoMember",
        "terseLabel": "1.92 [Member]"
       }
      }
     },
     "localname": "OneNinetyTwoMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_OnePointZeroZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OnePointZeroZeroMember",
        "terseLabel": "One Point Zero Zero [Member]"
       }
      }
     },
     "localname": "OnePointZeroZeroMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_OneSixZeroZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OneSixZeroZeroMember",
        "terseLabel": "16.00 [Member]"
       }
      }
     },
     "localname": "OneSixZeroZeroMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_OperatingLeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeaseCostAbstract",
        "terseLabel": "Operating lease cost:"
       }
      }
     },
     "localname": "OperatingLeaseCostAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_OperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeasesAbstract",
        "terseLabel": "Operating leases:"
       }
      }
     },
     "localname": "OperatingLeasesAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_OrdinaryShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ordinary shares.",
        "label": "OrdinaryShare",
        "terseLabel": "Ordinary shares (in Shares)"
       }
      }
     },
     "localname": "OrdinaryShare",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_OrdinarySharesIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued and outstanding.",
        "label": "OrdinarySharesIssuedAndOutstanding",
        "terseLabel": "Issued and Outstanding"
       }
      }
     },
     "localname": "OrdinarySharesIssuedAndOutstanding",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_OtherComprehensiveLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherComprehensiveLossAbstract",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveLossAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_OtherGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "OtherGeneralAndAdministrativeExpenses",
        "negatedLabel": "General and administrative \u2013 See c, e and f below"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_OtherNetLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of net loss.",
        "label": "OtherNetLoss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "OtherNetLoss",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_OtherOperationalPerformancebasedEarnoutsOver": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other operational performance-based earnouts over.",
        "label": "OtherOperationalPerformancebasedEarnoutsOver",
        "terseLabel": "Other operational performance-based earnouts over"
       }
      }
     },
     "localname": "OtherOperationalPerformancebasedEarnoutsOver",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nnox_OtherRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other revenue.",
        "label": "OtherRevenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "OtherRevenue",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_OutstandingSharesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding shares per share.",
        "label": "OutstandingSharesPerShare",
        "terseLabel": "Outstanding shares per share (in Dollars per share)"
       }
      }
     },
     "localname": "OutstandingSharesPerShare",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nnox_PPPLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PPPLoanMember",
        "terseLabel": "PPP Loan [Member]"
       }
      }
     },
     "localname": "PPPLoanMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_PaysApproximately": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PaysApproximately",
        "terseLabel": "pays approximately"
       }
      }
     },
     "localname": "PaysApproximately",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_PercentageOfPropertyPlantAndEquipment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of property plant and equipment.",
        "label": "PercentageOfPropertyPlantAndEquipment",
        "terseLabel": "Percentage of property plant and equipment"
       }
      }
     },
     "localname": "PercentageOfPropertyPlantAndEquipment",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_PresentValueOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lease liabilities.",
        "label": "PresentValueOfLeaseLiabilities",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "PresentValueOfLeaseLiabilities",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_PrincipalAmountOfThePPPLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount of the PPP Loan.",
        "label": "PrincipalAmountOfThePPPLoan",
        "terseLabel": "Principal amount of the PPP Loan"
       }
      }
     },
     "localname": "PrincipalAmountOfThePPPLoan",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts",
        "terseLabel": "Proceeds from issuance of ordinary shares and warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCosts",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_ProductionLineInConstructionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProductionLineInConstructionMember",
        "terseLabel": "Production line in construction [Member]"
       }
      }
     },
     "localname": "ProductionLineInConstructionMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_PropertyPlantAndEquipmentSalvageValuePercentageDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.",
        "label": "PropertyPlantAndEquipmentSalvageValuePercentageDescription",
        "terseLabel": "Property and equipment, percentage"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentageDescription",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net (Details) - Schedule of Percentage of property and equipment [Table]"
       }
      }
     },
     "localname": "PropertyandEquipmentNetDetailsScheduleofPercentageofpropertyandequipmentTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ProvisionForIncomeTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision for income taxes.",
        "label": "ProvisionForIncomeTaxes",
        "negatedLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "ProvisionForIncomeTaxes",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_PurchaseAggregateShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase aggregate shares",
        "label": "PurchaseAggregateShares",
        "terseLabel": "Purchase aggregate shares"
       }
      }
     },
     "localname": "PurchaseAggregateShares",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_PurchaseConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase consideration",
        "label": "PurchaseConsideration",
        "terseLabel": "Purchase consideration"
       }
      }
     },
     "localname": "PurchaseConsideration",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_PurchaseOfSharesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of shares percentage.",
        "label": "PurchaseOfSharesPercentage",
        "terseLabel": "Purchase of shares percentage"
       }
      }
     },
     "localname": "PurchaseOfSharesPercentage",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_RadiologistRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RadiologistRelationshipsMember",
        "terseLabel": "Radiologist relationships [Member]"
       }
      }
     },
     "localname": "RadiologistRelationshipsMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_RadiologyServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RadiologyServicesMember",
        "terseLabel": "Radiology Services [Member]"
       }
      }
     },
     "localname": "RadiologyServicesMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition of operating lease right-of-use asset against operating lease liabilities.",
        "label": "RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RecognitionOfOperatingLeaseRightofuseAssetAgainstOperatingLeaseLiabilities",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_RecordedAnExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recorded an expense.",
        "label": "RecordedAnExpense",
        "terseLabel": "Recorded expense (in Dollars)"
       }
      }
     },
     "localname": "RecordedAnExpense",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_RelatedPartiesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Details) [Line Items]"
       }
      }
     },
     "localname": "RelatedPartiesDetailsLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_RelatedPartiesDetailsScheduleofrelatedpartyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Details) - Schedule of related party [Line Items]"
       }
      }
     },
     "localname": "RelatedPartiesDetailsScheduleofrelatedpartyLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_RelatedPartiesDetailsScheduleofrelatedpartyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Details) - Schedule of related party [Table]"
       }
      }
     },
     "localname": "RelatedPartiesDetailsScheduleofrelatedpartyTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_RelatedPartiesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Details) [Table]"
       }
      }
     },
     "localname": "RelatedPartiesDetailsTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_RelatedPartyLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Liability [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyLiabilityAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_RelatedPartyLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RelatedPartyLiabilityTextBlock",
        "terseLabel": "RELATED PARTIES:"
       }
      }
     },
     "localname": "RelatedPartyLiabilityTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_RestrictedBankDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RestrictedBankDeposit",
        "terseLabel": "Restricted bank deposit"
       }
      }
     },
     "localname": "RestrictedBankDeposit",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations (non-cash):"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsNonCashAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfAcquisitionOfNanoxAiAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of acquisition of Nanox AI [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAcquisitionOfNanoxAiAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amortization of intangible assets for each of the next five years and thereafter [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAmortizationOfIntangibleAssetsForEachOfTheNextFiveYearsAndThereafterAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of basic loss per share is calculated by dividing the loss attributable to the company\u2019s owners [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfBasicLossPerShareIsCalculatedByDividingTheLossAttributableToTheCompanySOwnersAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfCompanysTotalLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of company's total lease costs [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfCompanysTotalLeaseCostsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDeferredRevenueAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax assets and liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfFairValueConsiderationTransferred": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfFairValueConsiderationTransferred",
        "terseLabel": "Schedule of fair value consideration transferred"
       }
      }
     },
     "localname": "ScheduleOfFairValueConsiderationTransferred",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ScheduleOfFairValueConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value consideration transferred [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFairValueConsiderationTransferredAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of financial assets and liabilities measured fair value [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFinancialAssetsAndLiabilitiesMeasuredFairValueAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfGoodwillAndTheIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of goodwill and the intangible assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillAndTheIntangibleAssetsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of income (loss) before income taxes consisted [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfIncomeLossBeforeIncomeTaxesConsistedAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfIncomelossBeforeIncomeTaxesConsisted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfIncomelossBeforeIncomeTaxesConsisted",
        "terseLabel": "Schedule of income (loss) before income taxes consisted"
       }
      }
     },
     "localname": "ScheduleOfIncomelossBeforeIncomeTaxesConsisted",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of information concerning outstanding and exercisable awards [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInformationConcerningOutstandingAndExercisableAwardsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfIssuedAndOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of issued and outstanding [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfIssuedAndOutstandingAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfIssuedAndOutstandingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfIssuedAndOutstandingTextBlock",
        "terseLabel": "Schedule of issued and outstanding"
       }
      }
     },
     "localname": "ScheduleOfIssuedAndOutstandingTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of maturities of operating lease liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of options valued using a Black-Scholes pricing model with assumptions [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOptionsValuedUsingABlackScholesPricingModelWithAssumptionsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfPercentageOfPropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Percentage of property and equipment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPercentageOfPropertyAndEquipmentAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfPropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Property and equipment are stated at cost, net of accumulated depreciation.",
        "label": "ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentAreStatedAtCostNetOfAccumulatedDepreciationTableTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ScheduleOfPropertyAndEquipmentByGeographyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment by geography [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentByGeographyAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock",
        "terseLabel": "Schedule of property and equipment by geography"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentByGeographyTableTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SegmentsofOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ScheduleOfPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfPropertyPlantAndEquipmentTableTextBlock",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of cash, cash equivalents and restricted cash [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation our theoretical income tax expense to actual income tax expense [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOurTheoreticalIncomeTaxExpenseToActualIncomeTaxExpenseAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfRelatedPartiesTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of related parties transactions [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartiesTransactionsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of related party [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfRelatedPartyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfRelatedPartyTableTextBlock",
        "terseLabel": "Schedule of related party"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTableTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reportable operating segments based on net sales and operating loss [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock",
        "terseLabel": "Schedule of reportable operating segments based on net sales and operating loss"
       }
      }
     },
     "localname": "ScheduleOfReportableOperatingSegmentsBasedOnNetSalesAndOperatingLossTableTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SegmentsofOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share-based awards to employees, officers and directors [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedAwardsToEmployeesOfficersAndDirectorsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfShareBasedCompensationExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share-based compensation expenses [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationExpensesAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfSharedBasedPaymentsToEmployeesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of shared - based payments to employees [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSharedBasedPaymentsToEmployeesAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfSupplementalBalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of supplemental balance sheet information [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfSupplementalBalanceSheetInformationTableTextBlock",
        "terseLabel": "Schedule of supplemental balance sheet information"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationTableTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of supplemental cash flow information related to operating leases [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the purchase price to assets acquired and liabilities assumed [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfThePurchasePriceToAssetsAcquiredAndLiabilitiesAssumedAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of valuation allowance provided portion deferred [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfValuationAllowanceProvidedPortionDeferredAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_SegmentsOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments Of Operations [Abstract]"
       }
      }
     },
     "localname": "SegmentsOfOperationsAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "xbrltype": "stringItemType"
    },
    "nnox_SegmentsOfOperationsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SegmentsOfOperationsTextBlock",
        "terseLabel": "SEGMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "SegmentsOfOperationsTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SegmentsofOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_SegmentsofOperationsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments of Operations (Details) [Line Items]"
       }
      }
     },
     "localname": "SegmentsofOperationsDetailsLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SegmentsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments of Operations (Details) - Schedule of property and equipment by geography [Line Items]"
       }
      }
     },
     "localname": "SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments of Operations (Details) - Schedule of property and equipment by geography [Table]"
       }
      }
     },
     "localname": "SegmentsofOperationsDetailsScheduleofpropertyandequipmentbygeographyTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss [Line Items]"
       }
      }
     },
     "localname": "SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments of Operations (Details) - Schedule of reportable operating segments based on net sales and operating loss [Table]"
       }
      }
     },
     "localname": "SegmentsofOperationsDetailsScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SegmentsofOperationsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments of Operations (Details) [Table]"
       }
      }
     },
     "localname": "SegmentsofOperationsDetailsTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SegmentsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ServicePeriodsDecription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service periods, decription",
        "label": "ServicePeriodsDecription",
        "terseLabel": "Service periods, decription"
       }
      }
     },
     "localname": "ServicePeriodsDecription",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SettledInCashPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settled in cash percentage.",
        "label": "SettledInCashPercentage",
        "terseLabel": "Settled in cash percentage"
       }
      }
     },
     "localname": "SettledInCashPercentage",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_SeventeenPointSixtyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SeventeenPointSixtyThreeMember",
        "terseLabel": "17.63 [Member]"
       }
      }
     },
     "localname": "SeventeenPointSixtyThreeMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_SeverancePayPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SeverancePayPolicyTextBlock",
        "terseLabel": "Severance pay"
       }
      }
     },
     "localname": "SeverancePayPolicyTextBlock",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nnox_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices",
        "periodEndLabel": "Weighted average exercise price, Outstanding at end of year",
        "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrices",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nnox_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SharePurchaseAgreementMember",
        "terseLabel": "Share purchase agreement [Member]"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_ShareholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of issued and outstanding [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofissuedandoutstandingLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ShareholdersEquityDetailsScheduleofissuedandoutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of issued and outstanding [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofissuedandoutstandingTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of options valued using a Black-Scholes pricing model with assumptions [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of shared - based payments to employees [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of shared - based payments to employees [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofsharedbasedpaymentstoemployeesTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ShareholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ShareholdersEquityTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Tables) [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityTablesLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_ShareholdersEquityTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Tables) [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityTablesTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of financial assets and liabilities measured fair value [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of property and equipment [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of property and equipment [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SixAIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SixAIMember",
        "terseLabel": "SixAI [Member]"
       }
      }
     },
     "localname": "SixAIMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_SixteenPointZeroZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SixteenPointZeroZeroMember",
        "terseLabel": "16.00 [Member]"
       }
      }
     },
     "localname": "SixteenPointZeroZeroMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_StockIssuedDuringPeriodSharesStockOptionsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssuedDuringPeriodSharesStockOptionsForfeited",
        "negatedLabel": "Number of share-based payment awards, Forfeited"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsForfeited",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_TaxBenefitPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax benefit percentage.",
        "label": "TaxBenefitPercentage",
        "terseLabel": "Tax benefit percentage"
       }
      }
     },
     "localname": "TaxBenefitPercentage",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nnox_TaxesOnIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TaxesOnIncomeMember",
        "terseLabel": "Taxes on Income [Member]"
       }
      }
     },
     "localname": "TaxesOnIncomeMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands",
        "terseLabel": "The weighted average of the number of ordinary shares (in thousands)"
       }
      }
     },
     "localname": "TheWeightedAverageOfTheNumberOfOrdinarySharesinThousands",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_ThirtyPointNineThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ThirtyPointNineThreeMember",
        "terseLabel": "30.93 [Member]"
       }
      }
     },
     "localname": "ThirtyPointNineThreeMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_TotalAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalAssetsAcquired",
        "terseLabel": "Total assets acquired"
       }
      }
     },
     "localname": "TotalAssetsAcquired",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_TotalDueFromRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Due from related parties.",
        "label": "TotalDueFromRelatedParties",
        "terseLabel": "Total Due from related parties"
       }
      }
     },
     "localname": "TotalDueFromRelatedParties",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_TotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalMember",
        "terseLabel": "Total [Member]"
       }
      }
     },
     "localname": "TotalMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_TotalOperatingLeaseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "TotalOperatingLeaseCost",
        "terseLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "TotalOperatingLeaseCost",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_TwentSixPointFiveSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwentSixPointFiveSixMember",
        "terseLabel": "26.56 [Member]"
       }
      }
     },
     "localname": "TwentSixPointFiveSixMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_TwoPointTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoPointTwoOneMember",
        "terseLabel": "2.21 [Member]"
       }
      }
     },
     "localname": "TwoPointTwoOneMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_TwoTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoTwentyOneMember",
        "terseLabel": "2.21 [Member]"
       }
      }
     },
     "localname": "TwoTwentyOneMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_USARADHoldingIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USARADHoldingIncMember",
        "terseLabel": "USARAD Holding Inc. [Member]"
       }
      }
     },
     "localname": "USARADHoldingIncMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails",
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable",
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_USARADMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USARADMember",
        "terseLabel": "USARAD [Member]"
       }
      }
     },
     "localname": "USARADMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_UnpaidOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid offering costs.",
        "label": "UnpaidOfferingCosts",
        "terseLabel": "Unpaid offering costs"
       }
      }
     },
     "localname": "UnpaidOfferingCosts",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_VehiclesLeasePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vehicle lease Payments.",
        "label": "VehiclesLeasePayments",
        "terseLabel": "Vehicle lease payment"
       }
      }
     },
     "localname": "VehiclesLeasePayments",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_VestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period",
        "label": "VestingPeriod",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "VestingPeriod",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nnox_WarrantsOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares warrants option.",
        "label": "WarrantsOption",
        "terseLabel": "Warrants option"
       }
      }
     },
     "localname": "WarrantsOption",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/LossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_WarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shrares warrants shares.",
        "label": "WarrantsShares",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsShares",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/LossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nnox_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageDiscountRateAbstract",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_WeightedAverageExercisePriceExercisableAtEndOfYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageExercisePriceExercisableAtEndOfYear",
        "terseLabel": "Weighted average exercise price, Exercisable at end of year"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceExercisableAtEndOfYear",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "nnox_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageRemainingLeaseTermAbstract",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"
     ],
     "xbrltype": "stringItemType"
    },
    "nnox_WellseseTechnologiesLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WellseseTechnologiesLtdMember",
        "terseLabel": "Wellsese Technologies Ltd.[Member]"
       }
      }
     },
     "localname": "WellseseTechnologiesLtdMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_ZebraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ZebraMember",
        "terseLabel": "Zebra [Member]"
       }
      }
     },
     "localname": "ZebraMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_ZeroPointZeroZeroOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ZeroPointZeroZeroOneMember",
        "terseLabel": "0.01 [Member]"
       }
      }
     },
     "localname": "ZeroPointZeroZeroOneMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_fortyAndTwentyoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "fortyAndTwentyoneMember",
        "terseLabel": "40.21 [Member]"
       }
      }
     },
     "localname": "fortyAndTwentyoneMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of ordinary shares to investor upon exercise of warrants.",
        "label": "issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants",
        "terseLabel": "issuance of ordinary shares to investor upon exercise of warrants"
       }
      }
     },
     "localname": "issuanceOfOrdinarySharesToInvestorUponExerciseOfWarrants",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nnox_thirtyAndSixtysixHundredthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "thirtyAndSixtysixHundredthsMember",
        "terseLabel": "30.66 [Member]"
       }
      }
     },
     "localname": "thirtyAndSixtysixHundredthsMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_twentythreeAndEightyfourHundredthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "twentythreeAndEightyfourHundredthsMember",
        "terseLabel": "23.84 [Member]"
       }
      }
     },
     "localname": "twentythreeAndEightyfourHundredthsMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "nnox_twentythreeAndNineteenHundredthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "twentythreeAndNineteenHundredthsMember",
        "terseLabel": "23.19 [Member]"
       }
      }
     },
     "localname": "twentythreeAndNineteenHundredthsMember",
     "nsuri": "http://www.nanox.vision.com/20211231",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CondensedStatementOfComprehensiveIncomeTable": {
     "auth_ref": [
      "r116",
      "r410",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.",
        "label": "Condensed Statement of Comprehensive Income [Table]"
       }
      }
     },
     "localname": "CondensedStatementOfComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedStatementOfComprehensiveIncomeTableTextBlock": {
     "auth_ref": [
      "r116",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.",
        "label": "Condensed Statement of Comprehensive Income [Table Text Block]",
        "terseLabel": "Schedule of acquisition of Nanox AI"
       }
      }
     },
     "localname": "CondensedStatementOfComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CondensedStatementOfIncomeCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Statement of Income Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedStatementOfIncomeCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r116",
      "r241",
      "r246",
      "r252",
      "r412",
      "r413",
      "r417",
      "r418",
      "r470",
      "r571",
      "r590",
      "r601",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable",
      "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r255",
      "r276",
      "r309",
      "r312",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r548",
      "r550",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails",
      "http://www.nanox.vision.com/role/RelatedPartiesDetails",
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r255",
      "r276",
      "r309",
      "r312",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r548",
      "r550",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails",
      "http://www.nanox.vision.com/role/RelatedPartiesDetails",
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r231",
      "r236",
      "r237",
      "r238",
      "r239",
      "r255",
      "r276",
      "r297",
      "r309",
      "r312",
      "r342",
      "r343",
      "r344",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r548",
      "r550",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails",
      "http://www.nanox.vision.com/role/RelatedPartiesDetails",
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r231",
      "r236",
      "r237",
      "r238",
      "r239",
      "r255",
      "r276",
      "r297",
      "r309",
      "r312",
      "r342",
      "r343",
      "r344",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r548",
      "r550",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails",
      "http://www.nanox.vision.com/role/RelatedPartiesDetails",
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r126",
      "r310",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r126",
      "r131",
      "r235",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r294",
      "r296",
      "r549",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r589",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable",
      "http://www.nanox.vision.com/role/SegmentsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r294",
      "r296",
      "r549",
      "r557",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r589",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable",
      "http://www.nanox.vision.com/role/SegmentsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r126",
      "r131",
      "r235",
      "r310",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r181",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Accounts receivables net of allowance for credit losses of $137 and o thousand as of December 31, 2021 and December 31,2020, respectively.",
        "verboseLabel": "Accounts Receivables"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r45",
      "r473"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r19",
      "r226"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r35",
      "r57",
      "r58",
      "r59",
      "r534",
      "r555",
      "r556"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive deficit"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r56",
      "r59",
      "r67",
      "r68",
      "r69",
      "r118",
      "r119",
      "r120",
      "r416",
      "r464",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive deficit"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Acquired Finite-Lived Intangible Asset, Residual Value",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetResidualValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r33",
      "r473"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r351",
      "r352",
      "r353",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r39",
      "r186",
      "r193"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivables net, credit losses (in Dollars)"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r98",
      "r210",
      "r218"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "terseLabel": "Private office space (in Square Meters)"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current.",
        "label": "Asset Acquisition, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent short term earnout liability"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable",
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.",
        "label": "Asset Acquisition, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent long-term earnout liability",
        "verboseLabel": "Contingent long term earnout liability"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable",
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r22",
      "r110",
      "r160",
      "r169",
      "r175",
      "r191",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r412",
      "r417",
      "r436",
      "r471",
      "r473",
      "r510",
      "r530"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r12",
      "r43",
      "r110",
      "r191",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r412",
      "r417",
      "r436",
      "r471",
      "r473"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r110",
      "r191",
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r412",
      "r417",
      "r436",
      "r471"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails",
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable",
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r308",
      "r311",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails",
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r308",
      "r311",
      "r394",
      "r395",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails",
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "General and administration expenses"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationAsset": {
     "auth_ref": [
      "r402",
      "r403",
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Asset",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Percentage of acquisition shares"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredInExcessOfPaymentsToAcquireBusiness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business.",
        "label": "Cash Acquired in Excess of Payments to Acquire Business",
        "terseLabel": "Cash payments"
       }
      }
     },
     "localname": "CashAcquiredInExcessOfPaymentsToAcquireBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r9",
      "r17",
      "r100"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
      "http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r94",
      "r100",
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE YEAR",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE YEAR",
        "terseLabel": "Cash, cash equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow",
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r94",
      "r437"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r291",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r51",
      "r516",
      "r538"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r240",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable",
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value (in New Shekels per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r32",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r32",
      "r473"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary Shares, par value NIS 0.01 per share 100,000,000 authorized at December 31, 2021 and December 31 2020, 51,791,441 and 46,100,173 issued and outstanding at September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r62",
      "r64",
      "r65",
      "r75",
      "r520",
      "r543"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "TOTAL COMPERHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers and electronic equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r150",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.",
        "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure",
        "terseLabel": "Contingent consideration at estimated fair value"
       }
      }
     },
     "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r81",
      "r110",
      "r191",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r436"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "COST OF REVENUE"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Loan expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r267",
      "r268",
      "r269",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG TERM LOAN"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LongTermLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r24",
      "r26",
      "r289",
      "r511",
      "r513",
      "r525",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument, Description",
        "terseLabel": "Share purchase agreement description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r254",
      "r271",
      "r272",
      "r447",
      "r448",
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt securities"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.",
        "label": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance",
        "terseLabel": "Number of share-based payment awards, Issued due to business combination"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DeferredFuelCostsMember": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate action of a regulator resulting in capitalization or accrual of fuel costs incurred.",
        "label": "Deferred Fuel Costs [Member]",
        "terseLabel": "Deferred Taxes [Member]"
       }
      }
     },
     "localname": "DeferredFuelCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r111",
      "r375",
      "r381",
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r28",
      "r29",
      "r366",
      "r512",
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Less deferred tax liabilities",
        "terseLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable",
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "periodEndLabel": "Balance at December 31, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofDeferredRevenueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue, by Arrangement, Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/DeferredRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Non-current deferred revenue",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
      "http://www.nanox.vision.com/role/DeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenuePeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred revenue.",
        "label": "Deferred Revenue, Period Increase (Decrease)",
        "terseLabel": "Increase"
       }
      }
     },
     "localname": "DeferredRevenuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofvaluationallowanceprovidedportiondeferredTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Tax loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Employee and payroll accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "periodEndLabel": "Valuation allowance, ending balance",
        "periodStartLabel": "Valuation allowance, beginning balance",
        "terseLabel": "Valuation allowance (in Dollars)"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails",
      "http://www.nanox.vision.com/role/ScheduleofvaluationallowanceprovidedportiondeferredTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Acquired intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r98",
      "r224"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r98",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r76",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r132",
      "r134",
      "r137",
      "r138",
      "r139",
      "r143",
      "r144",
      "r426",
      "r427",
      "r521",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r113",
      "r362",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory tax rate in Israel"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r362",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Direct expenses percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r362",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r67",
      "r68",
      "r69",
      "r118",
      "r119",
      "r120",
      "r122",
      "r128",
      "r130",
      "r146",
      "r192",
      "r288",
      "r290",
      "r351",
      "r352",
      "r353",
      "r377",
      "r378",
      "r425",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r464",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable",
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of excess stock shares permitted to be issued.",
        "label": "Excess Stock, Shares Authorized",
        "terseLabel": "Authorized"
       }
      }
     },
     "localname": "ExcessStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r428",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r264",
      "r271",
      "r272",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r429",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r431",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r264",
      "r298",
      "r299",
      "r304",
      "r307",
      "r429",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r264",
      "r271",
      "r272",
      "r298",
      "r299",
      "r304",
      "r307",
      "r429",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r264",
      "r271",
      "r272",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r429",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r264",
      "r271",
      "r272",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r433",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FilmMonetizedOnItsOwnAmortizationExpense": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for capitalized film cost for film predominantly monetized on its own.",
        "label": "Film, Monetized on Its Own, Amortization Expense",
        "terseLabel": "Amortization Expense"
       }
      }
     },
     "localname": "FilmMonetizedOnItsOwnAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Contingent short term earnout liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Contingent long-term earnout liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted Average Useful Life (in Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "2026 and thenafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Amortization of intangible assets for each of the next five years and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r211",
      "r213",
      "r217",
      "r219",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r211",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r217",
      "r492"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofAmortizationofintangibleassetsforeachofthenextfiveyearsandthereafterTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Intangible assets on straight-line basis over expected useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Functional currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r98",
      "r223",
      "r228"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Impairment of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r20",
      "r196",
      "r197",
      "r204",
      "r208",
      "r473",
      "r508"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
      "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable",
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r198",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill from acquisition"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill &amp; Intangible Assets, Net [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL &amp; INTANGIBLE ASSETS, NET"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r205",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill [Member]",
        "terseLabel": "Goodwill [Member]"
       }
      }
     },
     "localname": "GoodwillMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r79",
      "r110",
      "r160",
      "r168",
      "r171",
      "r174",
      "r176",
      "r191",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r436"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "GROSS LOSS"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairedIntangibleAssetDescription": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the finite or indefinite-lived intangible asset (excluding goodwill) that is impaired.",
        "label": "Impaired Intangible Asset, Description",
        "terseLabel": "Intangible asset, description"
       }
      }
     },
     "localname": "ImpairedIntangibleAssetDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r222",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r69",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "negatedLabel": "Loss before income taxes",
        "negatedTerseLabel": "Loss before taxes on income"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable",
      "http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r112",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "negatedLabel": "Domestic (Israel)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r72",
      "r160",
      "r168",
      "r171",
      "r174",
      "r176",
      "r506",
      "r517",
      "r522",
      "r545"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "OPERATING LOSS BEFORE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r112",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "negatedLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r388",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss before taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r113",
      "r363",
      "r364",
      "r371",
      "r379",
      "r386",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAX"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r129",
      "r130",
      "r159",
      "r361",
      "r380",
      "r387",
      "r546"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "INCOME TAX BENEFIT",
        "negatedTerseLabel": "Income tax expenses"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement",
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r357",
      "r358",
      "r364",
      "r365",
      "r370",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income tax"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Operating losses and other temporary differences for which valuation allowance was provided"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "negatedLabel": "Effect of different tax rates applicable in foreign jurisdictions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "negatedLabel": "Theoretical tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxExemptIncome": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount",
        "terseLabel": "Actual tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxExemptIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreconciliationourtheoreticalincometaxexpensetoactualincometaxexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of effects of businesses acquired:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "auth_ref": [
      "r1"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.",
        "label": "Intangible Assets, Current",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r209",
      "r215"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including amortization and accretion of premiums and discounts, on held-to-maturity securities.",
        "label": "Interest Income, Debt Securities, Held-to-Maturity",
        "negatedLabel": "Amortization of premium on marketable securities"
       }
      }
     },
     "localname": "InterestAndDividendIncomeSecuritiesHeldToMaturity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "FINANCIAL INCOME (EXPENSES), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r10",
      "r40",
      "r473"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "negatedLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent payment"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r459",
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Fixed payments"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of the compnay's total lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseIncome": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.",
        "label": "Lease Income",
        "terseLabel": "Relation to sub lease"
       }
      }
     },
     "localname": "LeaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvement [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvement [Member]"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofmaturitiesofoperatingleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r46",
      "r110",
      "r170",
      "r191",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r413",
      "r417",
      "r418",
      "r436",
      "r471",
      "r472"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r38",
      "r110",
      "r191",
      "r436",
      "r473",
      "r514",
      "r536"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r48",
      "r110",
      "r191",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r413",
      "r417",
      "r418",
      "r436",
      "r471",
      "r472",
      "r473"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r26",
      "r27",
      "r110",
      "r191",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r413",
      "r417",
      "r418",
      "r436",
      "r471",
      "r472"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "TOTAL NON-CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r26",
      "r263",
      "r270",
      "r271",
      "r272",
      "r513",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long term loan",
        "verboseLabel": "Loan amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LongTermLoanDetails",
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTerm": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Long-Term Debt, Term",
        "terseLabel": "Loan agreement term"
       }
      }
     },
     "localname": "LongTermDebtTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LongTermLoanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Equipment and machinery [Member]",
        "verboseLabel": "Machines [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManagementFeeExpense": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Management Fee Expense",
        "terseLabel": "management fee"
       }
      }
     },
     "localname": "ManagementFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable Securities - short term"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable Securities - long term"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "negatedLabel": "Investment in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketingRelatedIntangibleAssetsMember": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.",
        "label": "Marketing-Related Intangible Assets [Member]",
        "terseLabel": "Market platform [Member]"
       }
      }
     },
     "localname": "MarketingRelatedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredfairvalueTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r147",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r94",
      "r96",
      "r99"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r8",
      "r60",
      "r63",
      "r69",
      "r73",
      "r99",
      "r110",
      "r121",
      "r123",
      "r124",
      "r125",
      "r126",
      "r129",
      "r130",
      "r135",
      "r160",
      "r168",
      "r171",
      "r174",
      "r176",
      "r191",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r427",
      "r436",
      "r518",
      "r541"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss for the year",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow",
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement",
      "http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable",
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r132",
      "r133",
      "r136",
      "r139",
      "r160",
      "r168",
      "r171",
      "r174",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "negatedLabel": "Net loss attributable to Company\u2019s owners"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofbasiclosspershareiscalculatedbydividingthelossattributabletothecompanysownersTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Newly issued and recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office furniture and lab equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "TOTAL OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r160",
      "r168",
      "r171",
      "r174",
      "r176"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "OPERATING LOSS",
        "verboseLabel": "Segment operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement",
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturities of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r452",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r458",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r457",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalbalancesheetinformationTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Carry forward loss (in Dollars)"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r274",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r21",
      "r509",
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r42",
      "r473"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other assets.",
        "label": "Other Assets, Fair Value Disclosure",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "OtherAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCashEquivalentsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Other Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "OtherCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Prior completion"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r61",
      "r64",
      "r67",
      "r68",
      "r70",
      "r74",
      "r288",
      "r438",
      "r443",
      "r444",
      "r519",
      "r542"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r54",
      "r57",
      "r190"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized loss from available- for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r54",
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss from available- for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostOfOperatingRevenue": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other costs incurred during the reporting period related to other revenue generating activities.",
        "label": "Other Cost of Operating Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "OtherCostOfOperatingRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r83",
      "r98",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r85",
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "terseLabel": "Expense amount"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Amount as of December 31, 2021"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r473"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "verboseLabel": "Other labilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebtNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.",
        "label": "Other Long-Term Debt, Noncurrent",
        "terseLabel": "Long term loan"
       }
      }
     },
     "localname": "OtherLongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Research and development \u2013 see d below"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartiestransactionsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSellingAndMarketingExpense": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling and marketing expense classified as other.",
        "label": "Other Selling and Marketing Expense",
        "terseLabel": "Sales and Marketing"
       }
      }
     },
     "localname": "OtherSellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees",
        "terseLabel": "Payment for agreements"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromDepositOnLoan": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow from resulting from payment, receipt or drawdown of cash deposit to guarantee a loan during the period.",
        "label": "Payments for (Proceeds from) Deposit on Loan",
        "terseLabel": "Cash payment"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDepositOnLoan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForPurchaseOfOtherAssets1": {
     "auth_ref": [
      "r92",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid to purchase other assets as part of operating activities.",
        "label": "Payments for Purchase of Other Assets",
        "terseLabel": "Purchase of land"
       }
      }
     },
     "localname": "PaymentsForPurchaseOfOtherAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Payments for rent"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Cash paid for business combinations, net of cash and restricted cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r11",
      "r41",
      "r194",
      "r195"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering of ordinary shares, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Issuance of Other Long-Term Debt",
        "terseLabel": "Proceeds from long term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r89",
      "r350"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Issuance of ordinary shares to employees and non-employees upon exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from issuance of ordinary shares upon exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r8",
      "r60",
      "r63",
      "r69",
      "r93",
      "r110",
      "r121",
      "r129",
      "r130",
      "r160",
      "r168",
      "r171",
      "r174",
      "r176",
      "r191",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r411",
      "r414",
      "r415",
      "r419",
      "r420",
      "r427",
      "r436",
      "r522"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "NET LOSS"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r230",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r18",
      "r225"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r227",
      "r473",
      "r524",
      "r537"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other, Net",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentbygeographyTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r227",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RegulatoryAssetAxis": {
     "auth_ref": [
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of regulatory asset.",
        "label": "Regulatory Asset [Axis]"
       }
      }
     },
     "localname": "RegulatoryAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RegulatoryAssetDomain": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate action of a regulator resulting in capitalization of costs incurred.",
        "label": "Regulatory Asset [Domain]"
       }
      }
     },
     "localname": "RegulatoryAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r306",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails",
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r306",
      "r465",
      "r466",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails",
      "http://www.nanox.vision.com/role/RelatedPartiesDetails",
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable",
      "http://www.nanox.vision.com/role/ScheduleofincomelossbeforeincometaxesconsistedTable",
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable",
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable",
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails",
      "http://www.nanox.vision.com/role/RelatedPartiesDetails",
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
      "http://www.nanox.vision.com/role/ScheduleofrelatedpartyTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": {
     "auth_ref": [
      "r115",
      "r244",
      "r246",
      "r247",
      "r251",
      "r252",
      "r253",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Related Party Transaction, Due from (to) Related Party",
        "terseLabel": "Related party liability"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r306",
      "r465",
      "r469",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails",
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r356",
      "r489",
      "r578"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r17",
      "r104",
      "r507",
      "r533"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r17",
      "r100",
      "r104",
      "r507",
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofreconciliationofcashcashequivalentsandrestrictedcashTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r34",
      "r290",
      "r473",
      "r535",
      "r554",
      "r556"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r118",
      "r119",
      "r120",
      "r122",
      "r128",
      "r130",
      "r192",
      "r351",
      "r352",
      "r353",
      "r377",
      "r378",
      "r425",
      "r551",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Total revenue percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SegmentsofOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r71",
      "r110",
      "r157",
      "r158",
      "r167",
      "r172",
      "r173",
      "r177",
      "r178",
      "r180",
      "r191",
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r436",
      "r522"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Revenues",
        "terseLabel": "REVENUE",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement",
      "http://www.nanox.vision.com/role/ScheduleofacquisitionofNanoxAITable",
      "http://www.nanox.vision.com/role/ScheduleofreportableoperatingsegmentsbasedonnetsalesandoperatinglossTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesNetOfInterestExpense": {
     "auth_ref": [
      "r157",
      "r158",
      "r167",
      "r172",
      "r173",
      "r177",
      "r178",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income after deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues, Net of Interest Expense",
        "terseLabel": "Amounts of revenues"
       }
      }
     },
     "localname": "RevenuesNetOfInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r456",
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsupplementalcashflowinformationrelatedtooperatingleasesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "terseLabel": "Gross monthly base salary"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Stock consideration"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information related to operating leases"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in common stock outstanding.",
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of issued and outstanding"
       }
      }
     },
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic loss per share is calculated by dividing the loss attributable to the company\u2019s owners"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/LossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation our theoretical income tax expense to actual income tax expense"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets and liabilities measured fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r211",
      "r216",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r211",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofgoodwillandtheintangibleassetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill and the intangible assets"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GoodwillIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of the purchase price to assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related parties transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r104",
      "r507",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock awards granted to nonemployee directors that were outstanding at the beginning and end of the year, and the number of awards that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "Share-Based Payment Arrangement, Nonemployee Director Award Plan, Activity [Table Text Block]",
        "terseLabel": "Schedule of share-based awards to employees, officers and directors"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationNonemployeeDirectorStockAwardPlanActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Black-Scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r291",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of information concerning outstanding and exercisable awards"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity by class in any valuation allowance for impairment of recognized servicing assets - including beginning and ending balances, aggregate additions charged and recoveries credited to operations, and aggregate write-downs charged against allowance.",
        "label": "Schedule of Valuation Allowance for Impairment of Recognized Servicing Assets [Table Text Block]",
        "terseLabel": "Schedule of valuation allowance provided portion deferred"
       }
      }
     },
     "localname": "ScheduleOfValuationAllowanceForImpairmentOfRecognizedServicingAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/IncomeTaxTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and Marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Bisiness Acquisition [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Employees, officers awards to purchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "terseLabel": "Awards were exercised on a cashless"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of share-based payment awards, Exercisable at end of year",
        "verboseLabel": "Number of awards exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of share-based payment awards, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of share-based payment awards, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price. Cancelled",
        "verboseLabel": "Weighted average exercise price, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of share-based payment awards, Forfeited",
        "terseLabel": "Number of share-based payment awards, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of share-based payment awards, Granted",
        "verboseLabel": "Granted employees shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable",
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r318",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of share-based payment awards, Outstanding at end of year",
        "periodStartLabel": "Number of share-based payment awards, Outstanding at beginning of year",
        "terseLabel": "Number of share-based payment awards, Outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r318",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding at end of year",
        "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of year",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r318",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails",
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable",
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised",
        "verboseLabel": "Weighted average exercise price, Weighted average exercise price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r317",
      "r339",
      "r340",
      "r341",
      "r342",
      "r345",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Number of awards outstanding at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Awards agreement term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofinformationconcerningoutstandingandexercisableawardsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Contractual term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofoptionsvaluedusingaBlackScholespricingmodelwithassumptionsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Average exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Ordinary shares issued (in Shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/BusinessCombinationandOtherTransactionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r44",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Short-Term Bank Loans and Notes Payable",
        "terseLabel": "Loan from a government agency"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofthepurchasepricetoassetsacquiredandliabilitiesassumedTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r23",
      "r473",
      "r511",
      "r531"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Loan from a Government Agency"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r454",
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofcompanystotalleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r105",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r53",
      "r67",
      "r68",
      "r69",
      "r118",
      "r119",
      "r120",
      "r122",
      "r128",
      "r130",
      "r146",
      "r192",
      "r288",
      "r290",
      "r351",
      "r352",
      "r353",
      "r377",
      "r378",
      "r425",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r464",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofissuedandoutstandingTable",
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r146",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Granted, Value, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Share-based compensation expenses"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedcompensationexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r266",
      "r288",
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of related party liability to shareholders\u2019 equity, see note 9a (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r31",
      "r32",
      "r288",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Initial public offering of ordinary shares, net of offering costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r32",
      "r288",
      "r290",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of share-based payment awards, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofsharebasedawardstoemployeesofficersanddirectorsTable",
      "http://www.nanox.vision.com/role/ScheduleofsharedbasedpaymentstoemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r53",
      "r288",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Conversion of related party liability to shareholders\u2019 equity, see note 9a"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r31",
      "r32",
      "r288",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Initial public offering of ordinary shares, net of offering costs",
        "verboseLabel": "Issuance of ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleoffairvalueconsiderationtransferredTable",
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of ordinary shares to employees and non-employees upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r32",
      "r36",
      "r37",
      "r110",
      "r188",
      "r191",
      "r436",
      "r473"
     ],
     "calculation": {
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet",
      "http://www.nanox.vision.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r292",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r445",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r445",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r445",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r474",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivables"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade name [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofintangibleassetsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates in the preparation of financial statements"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UtilitiesOperatingExpenseProductsAndServices": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense for products and services of regulated operation.",
        "label": "Utilities Operating Expense, Products and Services",
        "terseLabel": "Services amount for per hour"
       }
      }
     },
     "localname": "UtilitiesOperatingExpenseProductsAndServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValueAddedTaxReceivableNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle), if longer of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.",
        "label": "Value Added Tax Receivable, Noncurrent",
        "terseLabel": "Plus VAT (in Dollars)"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles [Member]"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ScheduleofPercentageofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable",
      "http://www.nanox.vision.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Increase",
        "terseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r132",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "THE WEIGHTED AVERAGE OF THE NUMBER OF ORDINARY SHARES (in thousands) (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nanox.vision.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3095-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6411-128476"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=SL120155244-107959"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "340",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=123417213&loc=d3e43603-110378"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=6499975&loc=d3e44250-110382"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=6499975&loc=d3e44264-110382"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "715",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=6501251&loc=d3e52485-110419"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r579": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r580": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r581": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r582": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r583": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r584": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r585": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r586": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r587": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r588": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03"
  },
  "r589": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r590": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r591": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r592": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04"
  },
  "r593": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r594": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r595": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r596": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r597": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r598": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r599": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r600": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r601": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01"
  },
  "r602": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01"
  },
  "r603": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02"
  },
  "r604": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>110
<FILENAME>0001213900-22-022912-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-022912-xbrl.zip
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MMQV>?,K4@ERV^WN/23,<[H1/]Y\@CN$G+11>Y@1\YM@5LG%:SCQE1"D7EJH
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M-R<?7E$6T$*OS'.8EHA6%^ON/J4S2@D&>X\'N[N[K'',$_F?38Y4%QKF/I;
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M\TJ)J+:8G$>*>KD'=F+A)+M(43 '?=)F1,0<YE6#OE#*=+=L[5F)6"*ZK&S
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MHS+FKPWIV01P]*,M.'J-X.AG6W#TMP".7@$6#+%VKB!NM&XU,9?$5%+_*H2
MK-LI!-#N!&+:?SB]:3M(6GT8H9#CQX36- #-P  T*UNB.(XNBE('(9KO&7K]
MP<P;LFD304MG DV05TCDP+:()D(D18O94Q=>7+5BPC_JL\[ 66\^UVO.]]7]
MT;1L!%HVR'6;@U)4XO5/HGCA#X9A![SBJ]FH)>04VF9T(?*I,/L7AAMT)R5^
M^"!H,? 5AI8H0ACPD!/3>9$/2RS5)?&ST."Q M=@#J81HXI-$;6]MBP68"!1
M*((E%,,.A/7U1Q+ 24!.@,2[9(X)M2MCXT"%!I,(([(7 UL&ZD0,KW(>#5_^
MDX CDC1W4-Y!BUK EL'JW&JKV-72R;61)S,PXVK![H$U@ZA]#OL,T'B,.7HL
MJ36=PFJ7]2(%<[\8Z@7DDC<.8^ILG B*%5%FE)%X@ O2<DOB!CP0['=-D?"T
M#$WKBT *7K'"F,#G/2#WI?IRB=X*';U%H4Y'9W&9M:6-(VA\P'']RH->S"*V
M&WDIT0X7O*XI M>079MH]-.8 Z=QJ(;HVE)MK)GT5B#HJF[*>0[=[<G,;4LV
MZ:"-NJ")$,HK9QDQB$?\A9Q(O4"C3),_>G<SEQB"/)P_G]:@)_0H1:#Z3O@F
M6 ) 3(.,;]60$X>4TKL^8 (_BB71;C D>;3F%&HB8N=%_[+7S*_'9=_7,/[#
MI<:_)OCMJ'[/\F]]NZEF_UT7>GEUNIH<Q!'78,5I<L4A./#9[@P@I<O2M9S+
M/NCALD=5M)S*_CLV9\ZO-0$TF_K(,K,O)S[/Y/7L39SOGETQ*31-:(B!F'J:
M,H\J9=3+=%)0G9^EU\-4>N"@BZD2J'($PQR3/M^>2YX&8_:(*\V[FC/PGW!H
M58G0F0U\\C7SRL%8)5A=-H#EB82@F2.+1GJ6'EV:-8EBE*2/A80H%"W&E%A-
MV>'WU/2Q?.*3;B3"$J%]/AZW>!LE'NHV7Z B/>Z\$*[JO+"$R9+NH=DG+420
M%"-3:C(<@AIM(GT 4F(P.8F!Z!"!;YY+0:&3?USV2-G\TA>]7P=3_@DYART/
M":MQXF%T0F5+VI0LZ4EKX(N&@/-;5PBDK%^DZ'OBXNL^-,2"Q 8*L5)54MFI
MB8S"@^/P/BZW*K-%P#R:<.+_CQJ5T4^#\,/9P>F![0',1"OXX[>O_CSZE>F^
M' Y5M_!3@JL]V2+;E-L,BQ2XK(U$-O6SN*)$&+*<=]".+3$^X@]Q6/8>GECD
MMV%O61%?#5\\2%^NYQC1ZZCE9%W/6<JS^0[4*"%@##'8<C$*>L4H[(A1!+I)
MS8>9KEF;(5P_QX6)LD6=QI4<+0LM<?@3N#H1- (U]24;3V7*TD4;IJ)@B8#R
MDW$WE,2EGHA3P@ZSUE;H7,@)!Y8C6KC4\(8TN ,!DNK@293W4?AB(>A5-&OF
M6&3&[4PM?R7:/#"IX-DV<F(Q$[TN3]1<Z:8THO*79B<P3.Z&(NR"SAW+*J\/
M7/ 'D?F;+#);K6#Z-:0R'"$SL2J[1^/S0+Q-&WB*1W;M/PO0 B',')'+M.MK
M#4$D$[%0%ZW<'W+_.*4\F>'O;*5D5-%IH/@HLN8FY*A4T041H$FV$A1!'#>T
MM(6I-C<L.S01YME.J3PWSL+#!Y$VJF4F>*:MT2.!8XAY^2?=T=XBI9566>C7
M,8\@5Y4KVL!4<@K['@D U(Q*G]FUU#Q"O"Y6/>Z$[T$?XN)E- K8;$Q9/%*6
MSBLQ25CTH'-7OECU@Y(!NVC&-5^Z$JPFCC-T0V%0H*M4B7>Z)*)"F$%-&6@.
M@=:-L4,"CU:[<1F8LAVF./\0<<F QGU"Z)T<?GNWLH]1#1T;%A-[6[E3[Y'@
M09&E188G7<1,JK=9.SIQQ8 '@;,W9JKF4ODEYZXLBMR3V30$3=U-><E%I")7
M'[7X5=![UO8;8(/;'+G+<2";9I_=L9=]$&+C6#5+XT&HYBG]C22SJ2E9$_ &
M3'.J'4/W*4DK1(0.3-OZPY,_CE\-D?L4A<6UE_,KR*R-,6Q71*^!J50/6 ]$
M3GF1SE=XU(+E%66;W['S_;X9H4AP4A^Q Q7U0.+5T<M;.;YYH%>W2SFNO19G
ME7;"7\$US'..A0K-;23!0O0<4VEH<Y&6(!]YA-R]8$R=#0^+/X;[X?T*SW_<
MUTW-6/F4H#*+ -124A;4NZ$L\HA_O_\3A[_L1\;?0DEPY6T:86("&X$0BQIJ
MO1@)YRAN'L5@+G (D5H(NHKRN"HC8:\!20T>[[+7;1J?X(^H)P"J._T\,Y5(
MRJ NBNS"-)N0B" -*+.M/KIJS_)R4,6 <M5W8.,(0TW:_Z\&/=B:T1TPU3CE
M'CNZ;6<P]Z1 0O,SV*ILY_2_"0ZXO?@J"5HT=S C>N#8Z6,'27/!/(CP]0:Z
MQ+!W=)W3ICL&CBNK'$1,89@<&Y70P0OC<([=&=;58MOJH0D7E^F<3(V_%2 "
M*#.RK#@8+.7I-+EJD=UB6 >>&KX]>EM)U!N\@WDKV0#F-3V #0\;Y[8T0!SP
MKCA2Y P_; ^_R(<5=M]"8B2.(Y/RLZ8_$;+6BMQ7,?O@B-)DLN1L2!LQ6I0Y
M65*:PD.JV[T7U5L'U]D)2.N%;O'OM"A3W<IHFSX*7C54_T3O/?B\E:?*A#@5
M4B"7T+$V_;K:9$+P9%[G@*RG>5/&4Z(A0K@&6U$,>WJ%T*BIB1Q+/D[7[#2X
MO30HV4'AH>2X:>VW9U%TYD3_!TZ.C+O ]37.ULU$/#*C25:,VIQ&#J^E94@^
ME[AWB84:632B$@Z4?79UR. 9*96;B!2VDK)JD:==U+4E.Z#(=BJ]:L:&G)(3
M:CW=W]R^.RS\?O^4OO=F GT;=[-#U3%"T1;$)@/3\F]'-<8Q67@X-/TR.U9J
M2%7A#J-C &S::5-C$7(E#+VZ]AC9%HQ(:[BXWW&%^R937Z@O2$&[R>BIQUOT
MU!K14WN[6_C4)N\5K6^Y(H%/S-X32P[.JFT@D:)W&,+]<A8Q#^CDX< )14W8
MVW4.76/H8H0%(>348DH[]:19HUR<\3DV'"9;C8X$M!+@&,UCU:;U3IK2=;J=
MPQ=]:K<S+1^4.$@XZ<J):G>G)3->DO <"#06N@V#ZJ8]A6'%;UU*<P5R7%.\
MAN=S8))3LZ:V4ZH-/;0]H]QRGO!][J,-BC20E,J?XBTI>:5*Z0D22J>^5'LY
M!8;7?O(.W796+1U3)((&J/U*.9B\<PE= /A,,ZIPG3DH/,W;AX'AQ;(4D,3[
MX,@D9AA..UKN9NW2P-N:Q['I0)F5I?Z:(TD>.79PI6]\#>RW8\H*I_65-H.0
M<B6=QJ)!]_F&0<S96!@\Y1 DG]C+$FU^F*<32OA.SW?.5%MK3,<L8:\PR$WZ
M3 ==)<;+#/9DA22JN>,S&]I56/F,U(OMK>?L81?Y8L.E@Y[1R!8.W$2T:ZN9
M!S:HB.!F"N9B=5ZU/ZKGY%5[@GBDGWK"?N#)LN(9.)R_(/=ET;!"JS0+(FNB
MM*H:D^'+).[@#ZPR"0-X2C'3TQ1\R,DE/.,X@YTIOHPR".XF=/9UIZU$*[$N
MG/&67%5#*-MM+[H;;]/VQAT'-]%G,8XT:&PY4XDWL$ZIF,8T\3'@#HL4(T[B
M*3:+=1D:Q*FECIV7?C\[G3*S8@U>AM*\F4LZXP7MSGBZ?JV4A(54BO&&1EY.
M'"1!U_JZH#E=GN )'Q6B2B/=NI3?QJ&^,SE)<X(G:6F9F?VY2,'XN(A,N%R7
MX*)##/_FW$4;.S4"^9XA/!BV*+AMB*TDSQ/F2ND^Y*[*#_3^)4,$2T55^1V'
M;O'@;X.=7(DM87,G(+(ZW"BNJQ%6;LPA8FQ)MHV$HXH[%Z;,6OGI&A,#,UE/
M56'-5EI-!7/+U9("5Y8=@WUB.&6")X>T*F+B/#(V7*"E)4G1$+HVOAAT)P@L
M,X5UFNQ173!"08=F8!A4<U"=3I+:Z\3G#2+0H7!\BX;)$&98]#:?+L+[TOWQ
M\%PZ.O[D 5!S8EGC;LZ5RU6N%XL2I4AI'AI*\Y5DWD&7S-MP[_DU\I_+YGUN
M6RRC#>RO16 .D\(8CK[IQ)!BE_Z-8HQUBJD?@[ >X&D.ML.H8951&@)")-\<
MZ;AFE_352B*"Q1/J.%85FW8>W5618%85 P?$6*!6(^V.^ LA9&D#M0U47HOO
M;X((.)(NZS""%&.2<,G[*<ST'/[R.ROK0?@'^4P#L&_^F<*(BVJ:CB):A]_A
MD 6Y&&@W9*3J6I6AL\4"[W@PA$,1TGZ0539!]XC@UN6\8)9 (SL#:W81FI%H
M]UF=B,PX@'5]ZZ2@G _='/%^+ELKN1I+&GOIW^,/R9-#9SN-87^5 PDA*S"F
MP.KECN>.<L%P(@4F*9@X6GC-X3'KJ5% ,@MS#%^6W! \IRC];,X=_V@RZ$-'
M,^GVY[H49LP)!AX59:I(L0E@2>XV4N)K!P)]B*-R!,.&J2UT-WO.:!'QOC:-
M.<SI8O#]UQ[BU8E1EBV7M]V0P4/*]V!S'1"UELQ15A1.J0DLTJMW!V$%,Z-R
M4A(&1RNMVTCUFW9TFIBMI?[AI8*6:N6H ,7F$9@A5@2U%-25&VX\Q4,X]-0-
MC*PMR,Z*$S='XXX\6=@L,!%$Z^7K?B_2XIUZ?4V.K4U(@%8O=."U)[#SHCTA
MS!VU^RHO,:C\XIXQ&GX(4Y(3FTQ('4\R9@8*.G50O)P6%DTS+U!WL]DWSBA>
M::,\UB/AAO:KPPMD*<A3)XI/7KISA/;*=ZKSQ;'$Q1[H72NJ!)0;V\M.@=^4
M>EJ4Y"XZ+%V.>-KM%F=%DX@UXZ/C01*TVCH^=W>JM[3"1VS#+& >P!/(5F+A
M_"3MWM@TR46;>Z@C?09@NI](7":Y*!0!VOD<R/IR8TXX1D3H>>>!.1Z^4\FX
M66;FR38SL\[,S-XV,[/)>^6D*?N=3Z</#T;< C]0MFUR\\6)<0PL':UHR6!$
MEW#",^;205@P++"8N^PGCF5C8PF]=M26:VN35MVMUB>NARDNL1^ P2_&</IS
M,U>T@M,955%*6B$'#R#EU*429KAX,3#%Y9+22R\,&3.W3A#A0%A23PGZ5HR^
M)3%"#@PJX,$<=IV.%S:X3&7[XOAGB.GOAMVUA\6EBU3L+X)HZK5A'DLF5L L
M/=US*P&;) %<:J&K\FUM)_,MED5=(!F('_QQT\IZY>%,V2[LQBZL=O9T'[(^
M".%V^39I^20:)5EP"N'\JX$GC5/8G'-=R=5MQ;%=Q4U:152@&LF#?2YRAZH;
M4\5Y;3OU7&)62-MU>#"7*:P[[% OPV9(%+84I9NVV!726'DTRQHBXB1>"HE"
MAC#@J6$<8OS9LG0+ WSZ,CI2-OKCT7_^V6+;P(D\.+9T5S8_C5M+!82M<CH]
M.&Q,Z!A)/AV+0S%%B+=R*K3MS70D^"!-BIC6XH_C_]DY.!:<RD /!=-+F4H0
MP#(NXH:P2:"[$0A$\=A<'\A-.6%!J3I$(\+LYE#&.EZ6'7]4.C72DD 4_XMP
M"H+O<PTXD1J=;N2D%4Q*WP2V:HXD\QG^3J,RE4,NF<S!\? T2L)#'B%1IA"&
M1ZKZ*^3O+1#Z&F-4J1Z*1B."1,LXET1U1)7]NH(>;CM'KBE"(DRPAF$ZXP2<
M'M/AN91PP'NTX0(ZXU]Q?HD!6AJJP<8N?L&7!3KGR"7>K)%ELG(01BJ\QK+_
M[S52WK>[EA Q4-;4_\[.=1?W->A'UHS+:(*BJ1N-^L@P0D]YV;Z%HP?#9)%'
M6&BY$YS;7,^4>05Y4]NL=J)O;[:,(*91 [<*NKSXI]#IS]&;I6)IM,LL5X3M
MB8L\(OHJR@IJ#! #O& T=/J3^L^0S)R5^RS*,F3NSY3IZZ=I,"K*(K%B(FHB
MK#2:<&8(?VO21*8EA%-%';0Q,4Q]"7HAG?MY+M(D1SG6R,&6>#]=5/#*48YB
M8PDJ3LTJOQ=XO?>.U!:^8[@2BA-',TWGE>#FO69R7M\=A*6D8ZJ]J[GL\>[%
M?N/.L^-.' U555$S71_"JQGEU1M_P86C:UV)9>P!8V+=1+P!#7LH7NX$B<VH
MHQ)TYZ;IM;NGZ[4,IK8RA*I'&,JBJJ"G,+)3QTK%; N'_V$V+W*46[Q)Q<5[
M(/TI]QG(O?J4%:5QZ"N =H1!Z#LSJP-M8 \+ZQ=56#P_N_KP 3F-',XE AD>
M"N.I2;@<4@G+VF1*&%I%K1Y[I@9)&-X!E!V_@OW[!9#"AA4>PD&;$!>MR!5+
M'?A+K;&'O2$UC>H0JEK&-)GU,*PPUGQ52/L9F>2^A@9-LJBJ!(Y$Q@^<#WAD
M\D="Z,A )]H13 BC=$D6?>$5\(HUY SEA%),YK<,5T[1ADH431%!9FG74)I:
MN#Y]4M=@^089$[3!C$:K-[^4%TW2237@.)>!^C"9 AC7;^$M]W?W=WG)/,Y1
MJF120R)S(DH_>'#0:E&NQ\HG^.OBTQF6=<!K'FMJFB0\=YA6C_-X9T"]YD95
MFJ01HTS@=\BA9!"PKX_/CS4&MJ\:VUW[P)GP#X:148\W7#U>>,Z _JOAJ-P\
M3(DY+/?@SJ]<&,V:T(BH:+MB3&I!,Q-8=!JI/K]#-BE+A.[%<5$FI'M,80M8
M24/#ZZDW!+A)FD% *LR(W%?PTOA&X#3-B< Q(!M*!KEI)]8=/<U0>B77*_X/
MUEW\KR'%FA-=%_M[-PJ6_WPY=\ WR!=P #XP.:?>"4"5G4QAAN"(DI"MM ]A
M&BZQ^#Z?#()+A_YX@5X,TFXB7+F%V79J ^3.SL9F^BY31H"U7(+R+. WD\AA
M19/8A1T-CK_"8>@:4 E,>79A/^&;5]T4]>,)6L=BI=1''B/*#=>T(OC:.QG;
MFH,J;<3FZ+()".B=CU$$ G'U<%IZ4N!7Z6CZ\]1J^28B)*<VE#R.\X FF"II
M3#MC:3_&S>"%00MM+H<<=J0?.6"Z?^>37GY,Y#FG?I$>E-FVA@Q6O#@50M@#
MU;*BM_G2X:TWKNYL'8[;ACQT%;;PZ19;N$YLX?X66WB7@8_U(PTUJ^4UG.2@
MZR1[@7URE)T*@2TB\8OGP;!'K9L"@[?D (2E1!(R+:%/P"K6;=YZLY80O':P
MB&K5\BD7J)UH?XVYOEJ;34Q<2XD<(L4'XWR[I!NVI"XKGG7Z3$B9HXNZ/Y#K
M:^LF5.Q/;-=U8]=5*&*(_E[VKPG:V++%[0)N[ )2C'YA'>U29>J"FXN9X(7K
MH9K8A:^F):>^7>A-6FC-3GI)01CF'<VM^A7#-N$6C-NEVZ2ELWO4SYBYV]5T
MC],Q)1N!VR[F)BVF+=?7V5(F]:6F\5M8Y:8METUIJT_SHI*=9Q=QEE84SH?U
M\T+1F&_,D+*CX90JDJ@L?D"DI-\>:L8H*-]D4#I;A(S<@67DI@Z/U* 2!C".
M1J6X )HZ>X'[ADBZ-<BOA:PB;X(4H\E06YZL1+<&[?2M(:J:P&\+.HNJJB<S
MWN(0IQ%3&DN/4-.;],4D>M)?[?L%4>5G1(1$H-L5SDO\F]RI!8F0.1==.NPA
MDHGOAXZ\\IF5F6+/P5$Y_=9L2(PA&1W"<=WO6,\=IRV8;B#A>H*T( @H)B:8
M9= S2Z5E5^!,(G@7>2WLZ9RD\5^N\'+"W:R'(4HD8CT;\6N_3)N.4+]<T$_R
M:1L+"?.55*0Q@XETMJ5\88M\WNWP9+N/ZEY/--B4$FXX>6DM&6G;FI>82O1J
M=MBJ\)W$??[F<S!+&XEY=*[81HQ8[]JZIN3NO'$I-"=6\D5Q:XO8,F>-G,(T
MF'>DPZ6FP[+7&;GK/$ SJ%4.Q_^ G:*$JF&Y0X%AJ60,>,N6<R-;LGYX]"YQ
MQ'P629U2!1E5B6JS27J*UWGAH+M+OE-A.0<'B D%)*$:T2(:$$@L<,0 )V,(
M5G75F!HVYJ8E++%/"TF<*49G"O&^0Q;M-J66FM:%IOIQ.@6[W3#]P%=;0%G'
MX<\U39S&,,R*A"54Z6;:=%QA#:S0BU%JFU+IO$GHA'-$6.@8623<3F%Z4S&Q
MJPQE(!/X>&_W_L>?'%Y@I_^F4;CMAK$^UXR+DFA@R*5D^ -)8UL"5,Z,$;1+
M]UMQWLC?$-Q,R*&FD60  _:)(+KD_(])^//1@/JWEK,@, !#=S/I@"7G$4SG
M :?)L-U4!;>J'EH6*-EF(+LJ%$ 6M4'??WY*D,M3W?2D"'\S;6*"4]-(=D>@
M6QNV3^\>,(O+[X#C_1Y002?\!*IR)O31Z60J+<(9<2II(%&ZQ.AK^KW)>:L)
MP;E+K<M1G174S.[[!9:^XHGEHI5.3(^/+V1H\ZKQ1?^8,APJX1'=Y1I^M@7S
MV%#GZYN R>G\6-H/QVYKU9$4B1M]S&TX<;\VN3'[$;R/5(#L'6B&2:30%](R
MAEK5'5/>@?V\!<52,.Y-WXV;Z%5%G$:&'CM*HCF1U_9P4%A-3_I7.D.UZBIC
MXB;P?R@_*)M,DZ/6%1(4^JEH?!U-1,WD>DG R3'0)2GND*RXE'29>TZ1$E8I
M60?Z:"C[AB)1)I =NHG=4PZ9I\-O:D&[24"F;H6Y\006IDXS[KBH'6$F:OA$
MQ1:\">'KD?1F_;<@A!%>QVK/4$/H05:*SFYN2R1."9_B]KP+>/HLS7B%=/L'
MMCG1JM>2)Z9F^,0*2_"FVK:/=^1YH-L(2M4:.DP]M]>G=%P8JP!9."^1C;*_
M64U#!Q3R <-A8'<!F:P-N4[2A+X8CZLIGH:$X\+CL@^R9O#YNK4#5^+QA'OT
M"\Z\4UG'K$'RMEK9%[WH3<V:%]X)WGK?)HI)TK6%(AW%D[2BJB%L5Z$'Y=\6
M]82@R+4 2/M0J9VJT*O78E4J,.FS2AJZ!URVX%[?*E PYX'JL\W8@K@4/U#.
M?KAL#,>;6  >(;;G(!N.>:("1!4QZ*X(G?5/G^LJ&^-\ZL][=6<DS:IG([33
MA:/8L/SI@C6VT6)<O *;U%%G"L>2&^@R38HH5$[DRE\ ':UPN=#-D=A=+SEG
M6=5Z\9+ =ZZ$$M3Y4(ZG@>U0B]/!C?20VS2C_F<F-R5F9+<I%9N-TIW7J1@A
M$_**EH=]U.I$IM[,^<G+S+S1HM,4U<7"8\T%2,5<GQ:]YJ'&8SJ6B-WT.-RT
MU!6*4F;H )([(S*_;#?VV+SZJJ_"L/CS%@6Y3A3DPRT*\H;2>V?KI5_13O,7
M\]7N3N;0ZW/;4&MM[&E9]4E1=UF_SU(!IX_VT:XW!]_X$F[<\/]DRHMY4U8-
MVW6EPH[S6$P6Y0KKMEK+Q8')3[9IJUN0:))M8J%PW%SJ$=V:#RK",!6BVBT-
MW  6&;K:C)5F!ZG/("\UZC.*,GG#9![WLV94Q67Z?]E[U^:XC2Q;]'O^"L2<
MN"?L"(ACJ1]NC^9.A)J2N]73'OM*\O'Y"E9EL=!" =5XD*[^]3?W,W<"*)(E
MBZ9H82)FQF)5 8E$YL[]6'LM8K+\#OZNK9 %4V-P(E<P%U'GA#B7#^,V&W+=
M$H$?,SZ58- ,I(B^'MD/IFEE/,_0 >6XQ0@;_B.M2!0&34<2VY4@@155/C6C
M9[VORS"PTNAZ ,= S_X*MR2S\^R0[R!N8!Y@V2D@NZ=^K0BOUN[Q5.Q.T1%T
MSQ AEMCX KKTE!?TQ2Z;O5T^HI"5#B%D.N#WUG X5G*?9=..: (BNSE3(W!_
MN[DL20XWL3A JZR@G",[;>Z(EEOD3QOU/4UNH^E():T@(D5IY)WE)6$QZSB1
M$CWZ';2@>:HC2M,1A-2857M2P6CG?>:9B8:<FGG-$@&V):_\R[:Y[J-N;RS4
M8AN4_)C\W@;%1J"Y3Y@*8/TRGT4GTA#0O%9"Y0Y$P"79=S=E^O!"D'X$CI%'
M:H/O^0CYR(?]?Y9P:'"U=6(VF:K^((LM,7J)C$)5##7+>*92@[B!H<_1\WIA
MD1S#6\ST.S&H,N(YJ1.BI5JR?A2J18/)57?(K8SX",K_FG5+/L%W<O_+Y]'M
MJ#LL4#K7MV6%A:E@] NKJ8,)K8VPA47=.,IXSA$<A4%457,M!QU!:1SB(:B
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MWRL#2-W43\8?: V0HMHPM.VA@R)\3=5X#FPVK0^Q54':''+O3;'B6L!9]A8
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MVKE]Y$OCVZ$%?S5'#?>$P!'+8\('0L6QRLLW#I'/%34T5JNB8\DS7594);:
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MN#M IX/Z):-D6D9BKOT_!T!(L/XD"$T!OJ>JSK(7QT9/\E C_!G6R7\&/B?
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MX]-FEO\+6X"@E2O6UY"!X7W']8@[ >:.U+P>K1=!3M!O))Y.F)=P YG@"=<
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M+GLJ,WOJD2[&!ZR</0+K_>IG0E,X7#Z;:@"WCZONK"$(F_+'L[=GP9>JL+$
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MCN3,P5DNU1JL(9%QX<4"B>712^<"TOB1R+-70AKQ[.DZ3\+:;D0/>UZ%\<;
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MSAF4--CO06?&Y/_0DE%7XFVFG,\8IQ8 '$B H:5Y%,OCL2DK8-6\3B\D]'I
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M<",@5 ?G(J5D\'..EK.M?Z550P[//_:PJ ,>F^HP9/D[JRQC&XZ]%U,NV?*
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M0,)B'V["PB8+)Y@MP@?XM3T&;8H2DQUT\DEB,&:X771<4X=6.X2I_##"DZZ
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M]$OQL^G9UZ__ZY==Y]E'?Y'?_/'K;^*;_+ !?LP107XA.^%_@B,8G:FUWT%
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M@;T._76(+3",.&D0T!6Q'/C+3E]V^CT>^&G+D_9Y 39_!18 3OQKCXU8 NU
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MANL!>UUR-SX?PS1>1<@-/QE&%66SO:BJ>]O]5J1FRBPQD_,NT_XVU2E$-K4
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M:;_[K"YQ%-&11#!+FHL %2'E/@:8IV*$>!J1?UH\80J"4PSB:QR"6<<CLB6
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MEHHF.LO+730C0@_N+V;I:*-=T.%?'.].2+BH&CC"OMXUE3;TYH3)2HP"_:E
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MWSV=SR5HX(CH@4.6@4G CX,S7%:.")HQ+J,QHM9K1]E7L!NW@\92A*NL13$
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MG$L<DOCFX!\/$CY:Q,1KDET,V$V)=S"?(B)PDY; OA%QZM?\;*W78'Q+O%K
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MDQ/$?TG)@;E&_N5?%H%>GHCUMA6EQ.-M1L%P>=W"='A6KC)X_X)BU80]VC<
M<M62NUJPE[:ZL&4(UUT&TOS4=D'9UIJ#OM[>?#P9%@X]80[ [A,TI<I$[))%
MXPR%([ :#S1^]MOJI*.HR P']/B8+YCL)-M'V#D]!OSEW'H=K2L;>=B[W%(&
M6X)R:$V:<*LM.LZ9]W)>50OKZ>#@-"HE^QY]J 5N0XYP[=HQIA" $@<E:4\]
M44MR"CDFH"PJ8A.S$>,:X%U]6L!*@)Y'8-)<>(.?5!PT7$OY&V,2V&O?)VHF
MM<)U"VV(>]C6I7D*D+H"P:P[X8WI_.H5<K4X,KCLF:Y)43W--BOF^';:3IUX
M:/ #%3PB@GMFSBHW*/>NLL%$Z9<VMWWN' CMNK;"VN/<WFWPX,VR2Y_?9Y<^
M9G;IT7UVZ:.<E9,VGO8/$JKYGAJJQ9O#.L^]$),P&AO;*&?]+W9N3[[YK]KF
M7W]SK4C&!PY:Q0'\"U$D5P3.)C*CR F!$1S=C&O>(BWND.9I2D(QT >$6+&2
M*+4E(F:CCD7&W3U@V9.H4E,M&75//R,:S!4]-?,\*@ = 4B&2YMI?WCMU?P(
M.WG#_?Q0?#B[SN];:K_IXKD"R@[[-DS)>]V7XW5\5I_4O$FVOM(EE% C*,@@
MMA-U"*F]HI@@V%**#2H7#>R[74_1*O^5D0"0E\M5%]5">,BM&74F0BJ"V^&X
M$V^I)]#)&DT':[B5S8V)ASD.":0.!M/O!/<5_=2=-HI96EV%BC+3TEBW/$;R
M8$.V5;D>K$N0Y1@XWR_[KJQ6-:>H##DDS9QDF,)%:8"W*P[B@.Q5$Q3!6""%
M?XO-/6["-CA3G!4Y*[LU=_Y9NAWBDEW&6(D9!G:]2BB+<79EX)G/'GH"&3&4
MKI1NG1<6GJ-&XHP<+5<NZY#7B'::J]?BA_@H]<%0KK#C<!=IC@O$WWA]281)
MKQF7X&!Y>)2-3<2:1=(24)1[J@?;330:YI]IM"E-QIU8&PH>8F.5(M+M',!4
M,I1%#4ZU,W30N%4!C ]\;?TX>2/%Z[M#S]9F$22B3-)!U:3$:/\V;F$Z0Q5:
M&VN;-V%5XK(]8><_[=KS[=E=3C"TF:=9O:_F2KCI87I(\O%B8&U8^(F^S"VX
MAO!EL8&9Y6R1QO.Y>Z.RSDKVOJ]<P%\IN?K*U'W<86H8%X\CN87+W0J)(WZM
M]J?D-]-/DV]EJD#%J^B0&VYQ(6\F12\?D'F CKG=HL(H>!)UGRW+6A9/%'@6
MBFO$^;8VQI)10=94U[5KX9AK;H_F3+'0"B3#I')NVXG^B ;YJW/L)MDTKX##
M[B["&T(H76V:?V ]HVOQRQOF-'F@LJAH8FZ7S3MT45\)P_1%NW.TDFRP**CG
M@K/ZU'>:+)"[K,8281&OE1J56+]^N'1!"I4TG$I-ARV!I\TL?;!/DJ0N\P%P
M!0AQXD_W)76_>!U)R78=F>;Q^IK7&VB.B3T<Z][[.K/;OY&N;MZ9'C#.42Q2
M,P'(P,S.^@IHHH/=P9,+:L<R=C4)ZN9"VLGJ<3GUOL@YQ:44Y:S>].S0TC.W
M!'K;1ANACRM:T5CR=A-@YZ4("_Y6SJ,[U]?LAL+WBXX/<&\H][@7T=LDHMHZ
M5CLO8[_FX,TU@X\R8&NK]HZVW$\NM\=X2[V'X<GN&N1*NIG2/"N)DB(U0) 4
M[_@DT 3:D?P7>XKV<D^\9CWAR;.<NS8 1NA7KBZB6WXO8K=)Q.J^-[I] =OM
M-@NH0D/Z=!57?Y,F(82@_8+Z[T2_K=.L*F]PRKZI983>W%'!-O>[?[MVWUOY
MI#ZBG4J)]<R:(:^5NF%HI*,& +WNN9U,5\(JE2\R1$\C2FP#W^_X;=IQA3CT
M@LZ-1Y-)'I9 0+JP<<(C:-3A5N[D1]Y*64[>I3";7;E12&N.MN/QEYOW:?!Q
M%?=\[OCQYOU4.GB46/9_M3V6)._$XV_X1/'?B60&LA O?L("G6:ET&16Z*^*
M@8?JK@4TNSK0'AO0"6?:^!$L.JD%1Z)I?//B6?Z&;'800=J,6R.%OUM]LJC[
MS4X:I+"Z\/Z+%=@S6>>&P-\$Z>JH;V@F-.1]P>%)<D8IG2T[+9)Z&+4="_PU
MGX31 $S\^:QI5^WIQ:U46[];@?'>,3LTYBT@%Y<@>(OJA#\1/=:XZ>)U1%F1
M6JO[?;U-^TKT3V;YM1(ZUS"H*0=W+R P4D@!6,]<*')VY;/IJK"*5C)&J"K#
M^CTACQ/XY:B\((QC7H1V+R>W24ZVS._MO89IH;G?MMNT;>+*6WK1(J1:O'F_
M7;=INP;TKQ(D=.7HD@(FHY];C;I MT&(:,O[>RJSV[:Y JN;$6%J2Z4R&FB3
M?H%;X?+T1W5<CD"6U:JOT,KX+E."7>/5-T.Q?W&/8O^8*/;C>Q3[+3Q%>XGU
M.+A/!3Z%ZVK ,67X YNN.D@0RH.>" 8" R[)#: 6E73=>)HB 7(I:F*VV'DP
MA L;,(D<0?$4$+IM[S$1O_B%-(C-*",J$UH[ZH5!8,9CT3S%B?)8WIN4MVF3
ML[@>M^OFR)^4#J)L,W6>,"SU)!Q:(H#W.WR;=IB=\"%015NSV;F%=9GZO]YO
MXJW:Q"$23;BL=N;]I:L7L;1:^!PXV])VROT@#-F2]-W=[_*MVN7K8<QF XP9
M.LY0#X<<!T:4.N3XQY,-<ZYAFJ;X^Y_:J+UG5%A"2>)B-B]!:@U"I7HK$#6"
MC23EP)ZEI'/NA>8V"8V#DQEGLQ</M!PO$QT!=5TIHW-*,2' #:,@+!B-/""+
M</?^?;CHMFT[V5QMK[25UG!#,RA,J<'LA#DA12,%;C7#PY0CB)(S40]4OT,B
M>2E236UU4J]B(S$4+Q6<3:#8&[G%0IUEU.93&3-R=Y78"_2E5(174RUM(5UP
M5^"JX%"M8ID9:D[I] 3,+$+J7P@O&?I9R@73K0_X9E>5"V*TZ>-Q, */T=A0
MGY2QG#F>/$=XMJKC'4,<FF$ZPS/@) -N9-O.W^IB4;,U#G4R!."?9;\H_W?V
M%R8N^2ZM?;P&:>M.-8J=3)PZ"U $A!A0^4A]%*@@[_T6A**70^!P3O#==AGO
M-0Y2[!H%-X@S1,<,A)[EUM"TDSL2C"'?!DJ</W&/3KJV7.CT_1 \V9S6A#S0
M<E;@<\W@^]]=G'#5"8DF,6?%?Z9Q2&5"$32*3 TR%ZY1'!]R;8RF8ET,N\J!
M#;:P1G"6X77%_%GW!.9#CD_<I<(^??A#X<89T(2-SLVT&*$DO+15XT3Q6J,0
M=Y5/ZZ5HY[+?$BU-U4PN%Z]0L+:&5L,UD\0ZYX.HADL.-\2\UG8ZBQ&22Z!:
M'J=3GI;T!6L&0=VD<&0(7,QTR,%._!+-ICQ"5$=R@J8E6ZKN+L][$"K+@PDG
M@!Z@=%/5#67XG4J4;H&+:EDU!D"31\BY*H,^4MI#$)?>@IHF$IBYCT/1EA+&
MK0<&R*VR:8VJZN^H5-TL$_+E?2;D8V9"/KO/A/P6" &>]LQ9 ;XX:PQ)JJ\C
MM14(8E^]K];Q$<S"8;228-:0+CRD+TOTL:<(NG+R\6.$L:[B)M+4N'4KH$JN
M!$W-H(B9)JJXA@S1>=MMX+P)&1S*/#:H7I_C#N^WU'*'0'?ISB;@K;.U_!A]
M(VRV(H +)C/4X2_C1!IT#IC/Z3#3*$.FYID?A5MQNQ=/S/H.UPW_6$D1C:.+
M>?&>S2NT/@5U;],V!T1:&O16A1<^+6HPR(C1Y;^YZ0*)"W,27/##]GQM^OV%
M2AL+;L@$=]R*(1LZBS*Q*V>["_95VV(N,TL&L,<"/WCT4$'D6D061F]1XU(!
MYT2:6"<<:1SC>SR6BE4T92$4@#\G8YEJK2ONG%&JJ4/2?4KU+<1Z8\L3\N5Y
M<#P:XW@E^/2P&=U;M[<EI31E_E9:M11?BRMRVO/&4:4+7"XXGASZ]:K6G!LW
M29$W4(<4IKZ7DKSX;8 C%Q4SGW,-%W,;&9,0/?#!9SPG/IMCP0CYG  CJE?&
MGJFX_?C(Y(/8!!NB&EK'\W/P/]KQ&=Y 4\9-WV8EC<G5H<UA4@W'O%-04\\S
MT.N>5\S:H:2[1$#C(]=I'!ESCXSE\X._#US0Z3/20YHIRZQD2$&W40CPN;>J
MG&A]_/'1P;=Q?M'<CM?I$7,5E]%_Y$6E0<>5JLJH49=U/Y<&Y5"RJVIP6G0<
M>K0"<9.OR*7#PJUTC$;6=)WQQ:WX.W8N2L473ZXY/FP.=-+>P7$;CMF''N+G
MPR4,>X8(4JN]VPC3WU_'WZ=6?=\^SVC)M]P9P[$KZ8/ "[<NWW+K<&E-34&
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M?[Q30Z;!M*)/6 TYQ*YT8216BM\SSJ:,^BJ>AV$PELQN,&4'WRR#4=9Q0?
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M%QZ;7$ R'G6)8$5P/('#<?T9-WV.(U8#K44C0S*+!JLKX.C!"X*LF\9ZJ>]
MXUHY)K@MED8:0(!IGUSY,H75IV"W2'P)4G6SB0-CU*?'94"Z DAP"NU.VC9D
M1Y87_"H^"K3RV@6 ,'8RGSJC;1_#<Y\9L/8?Y3GUX(O^7C]"C;MRT( #"5GG
M\Y8IN*@QJAD%U(Z/OGZYK=:S+P_CE:'F]\N4-D/0[?CKI[R>9 24YGR*2Q(?
M_@J.XF4/>"ZO#J_18Q&O?O0U-]I)Q%,^7Q>O8FO]G';?NW^.SEW[Y]#1($E$
MEKQ\7TW,5/[]Z.@P/$UO'H_X1932\KW_S7_5W^AO:%!$UO_&188',^UUCM05
MZI)Y_L:#\-H'Z\=*_0D7;55';Z%N7!Z;-]T5\(<,F2*Q=44QB)91OWS0:*GN
M,Y\GJLXV!^];TR;$\IQ[V<97"I/B1 .QW^2.7)(6&:QP"C*DY47CM_%.2MP\
MN9S).?7YO2LBZQ9<7=2L[5W80:/.EBS[D36Z.^671HL'*"ZELRR[D[*I^H-7
M[U?5!2.(',$V^[&]Z_H;:JK/H@=S=:9*'4<,H'>SA<E'TEP*KTH(GCR-RF4=
M@#UHE0*W,LVQ#:,@"?*B_; ^X/*HU\3=\KQ=+ Z^C=OZ=O9CM 7#FVU'I^1[
MNJ#7>/HSQ%3B1KY.<$-:Y0?T=5&H[BF2K(G*[Z%=51I9&\<4IU;M,,!"8 '(
MZB@GYL91%(W\>G$\T$(1!YP3\RL?+F\O72ZJLL)U8U-%"DGY?FIYX*.  CI(
ML:FVD]"4U?1PZA?%8+MFL:L"E8:B>307^:4.1-SN6<,O@J$_Q'WD=&(Z?:GC
MD;=]1$F6F9HLUW1X%9LFMIV4RZR4BCY.$#5'$Y@&"Z_M#1)9K'8Z&H9?64@L
M_/LAL=FU0V+2]1D&M1PFB7:%FP7)+(],3!K2:#H%SK+P:;W5@5T6$0S7#)=M
MJG;#1CX1>%36 'D4-BO<[[F2>"O]YJ(N'"=/[FB436/!O+5JF?0M6?5Q->%>
M32F:D&.RAWH]ZT+)LK_G+M'+::JLKE#OV %]4W=(Q96OHA.0IV)&&O2R2*UT
MT*834J]663^X&\3F@^B_FNXA.DNREHH94I\K]4_!HQ@H4^EMK="F)7J,LC;<
MIT\'2M0%^,,K$^PIQ>=G> W%-S/%EVF['X;!$,V$2\A!EL4R![G3%A=BLHX2
M.^1[2SJ+Q_D,O+;@CI<E,Q-)9A>OUZB<*N&<(*L:"K4A1@*T9/4\,L,@A5/9
MICLELZF-3AA$8PLU&IO,@(^5X,6VU)SR%"UW=NC?'C_X6W=Y]FJ5%+L0NS:M
MD%G 7(%,$AB2=^2N;:98CL\X)UFNZ#[C<)A=P"9>P&^3[HY:O!< _M P?B/6
MVN.CQVHGJTD\@TD,:/D#U4C3VD*_"#,XFF50<0\I[J;U#DT[$["$KWQHU#:<
M+A.^.%07^<>H2_X#61NXE2<5E,/0V\DD<O8[D,@;99.>'-UGDSYF-NG)?3;I
M-I^5U[N.$,%0WI?HS!1&"*8RQ<44U;EH-WNLO=>LCIZ).GJ: B6OJ/R>:-EF
M_TT6#+$"E1SG$%U?]WF91C$(@(5! "P5<\!>T5A"XX@K '-N4AAAAOQ+,O,L
MU@*SQ[!C>Y^7PA0A"TP8E#[UL;[VJW.7DB-',%C5AS6SKFK.M$7!>S:.&!-A
M!CAQ)153[Q"+T^Y?<:Z+X<!M4O!?&T H/(3+%D5<>NDM[=LH9]SXL,_Y);R(
MR6Z[V2+IQO?<N=Q:SN&",P,W6*V910R\!Q/%E5[Z[*RNEBZ._TH<;,>[DB,S
M^JJIVZPZ/_=S(;HZ20)=2^F_S6[  4"6?YE%? :&.?QC-9&,3&D<B+BF01)R
M@T3MD52X\K=7__W& HI1OK>")#?*34TAL6- Q4TPF:S]"ME+Y'3DJ%MW%A;5
MIH(N"J[X44P7%TQ=UMW:^F]3UE8SL__1X9:9.HUW&%YVXA9P*&!D>KH/%YS.
M$G:K/2_7[M;L<Z;B+&$=D1EHT +L)@LE2PGC%MK4&!N?C)/8;257-,"FP39,
M;#,9^,WW'$W)4[7/L^BP?,WOD=K<Y*W.%FR;@[#"RO=,Y5BB2$)H'*%5P";Y
M;;O&6KN9GA*.#H>+3,%=R27K H<K=]<K)6(=UU0O_SC$("[:&2'DRHXZEHX6
M"T$K07@-^&*@Y-(V[=6SGS+*=D]O='ZVJP%J3$3:3?3#N7YT+%VH)8PC"&Z?
MU#>Z;9;]!\:^<'_T617-X5J3\]I?H%P)6/82<I]]'%AJLO@>E<X%FTSN)_]+
M5&$WK_O*"*AV6[J*<-E$S[8K-77<BL+$O8[RLTHK!\B\QSUK-=GZL.VP2\T=
M1NQ\BU)R#4H!LZ%E:!-</LQYH?* B##I,NX2CYC:7I1#M '65<GNOOWMI&O?
M,F T*[,34R:>X,:8CYP%344.X='CQ["BUKO5*;1MNE7S:HG"1[QT;@C'2V*6
M;G?C(QN^9X;W4/5 E.]X+8.VS:\('0*LPK*K^!B0JN[K]XKP;[9GO0T!F VY
M6[5(0FYC7\GNXBRS!XP"B5=\N=E$]:F D;:I4!;]\# :4JAX?7)<''UY5#P^
M.AHW:G('A"L\OD,+V,\>%;/CH^-CJ41]C^A('.+CX^*SHR^+)T>?CQZ5Z-PG
MZ10&I2JXO;I*5P?;O*RXBC^*!,=0L\)*DCFQHVS)#>U )D*<BX>FS'+P P^*
M-?_7@2^ZM9 23"R&@?OVSFA8?*,9M1.! S'8JX_BP+OK)2A.QR[)X$?&AHA6
MN0Z^DN!09O*E+LS94WP\#F;*U1O[>7'\^6?%5Y\_'I+WL;RJSHU;=E:MX&G*
M9F1GP#9DO+\+C'QJHZ;.5C0(LQIS.Z&^F/A,$$_.,/9U>+IKLCYT-]%"4+Y-
MIH.;AH:UV\1QZ.WA:HJ#W1IIW[_W*_T]>,UG3T_C//E8EJ FJZG2Z*1:M></
MQV"@1T=Q4RY# 3T[C-LE!NLS)?&5I45ZCH!Z_;RK-[[6-A<!#"R^)UIV/N6@
MJS!U 4]MQ%@.+V0M0Y0?6.P[!DA=;6D[&^ R@K^/9CU) &]5+;>WX8X=LBA,
M'%(X<EPLLCUOPZ0]@S1<_!JES\KXTY9I Z*F?G1</'[\V9@_$0Z52;NT[H@/
M0[ <&N4/C[X\/$+IF3#4Q)?\X?CH\,LOZ'=,\+1/L;@Q/RD>??:X>/)X?/'D
M)\_;;FRC6];>IG;)U17X<)(H'1\]^FKV@HD 7C9DRY$_^9J@L^.3R:#4.%0Z
M*^0D2Y5*OC0TH#\\.CY\]$5:#TY6/2J^/#HJOCCZS%TT83A.PMMV1+KNS&2S
M<*\S<([9)/.ULP%B 0U6+B&@Z%-&U4\EG I^67#)WG<M)^W /DS?=.A@N;A.
MZ16IE%!&*W;)LQ2M0$%TXJ%PF?YX+ZW:"TGO(V>Z(LW3!\[V$SDKZK7XR=;C
MDQ/'N0PX61>6@TURVVPYKFO!3\P@3%KT=U/U7/G^FZ5M'MVG;3YFVN;S^[3-
M;R$0@EBZWD]V5_@Z@:#UZ5(9T57+%8RA1.)- ?CJ#D<2?O"<\I.U^[PVX:1"
MK?Z\U!#P<)'@T:5"ALR2U)A2NM/H1D$:@/ZLZU]2I03?E;H56VF8HC3=4\V,
M[3.<$-JTX D&I%X+/(0 @LLMU*BIF2G<<>*,*-%M><*BK9C2I:DH<1$O[Q5=
MRF4G-K?@(N@^DY L4P$4KC#JI&W?RDB3[69<W1+-($,!8$0*\L;%(G.=V+%4
M$N^B%+Y<*CT4V6.P6,MHK5V 2;KN-:47[*\(&G,50'E"'FOJN&+9-P)J0F8N
MN/@ZFG/+\EW+40S4HD5#I$/4>Q&-D5-B9IQF-.<G89>"RC5X[.L-K!P%MS&7
M(\65*!TV?NEPR RUOO3X<0"<BG;BI.[H[O_@FE!?'H2. K!RC034:W5"LTC5
M(:0+]DH5PG?]69(>3;ZI^/#9U\^+41H4BL2&/G.9.742Q4CS$KT%6;A+ <%Y
M*T0.-3<Q2P]K.TEI6W!S*>FLB<0(PKEPD91];?HI(%[E**5UQI#9<XL,48XW
MEL) O@KEEV[Z39RBIC):->?BI.-^V5'DDQB87-"^P@>-E>C^,SX'@E7VG7/D
MERN0W_QITS*L01$ D0+MYO"H&T,8I#C5,'D<;I8\%EP$@0B0ZBZW-\P^GY=\
MSZ9J%P1?PO-X[Q+.0&,9CS1K2JGFC,O(QV\%NX'(XHT@)A/5LLD\"0JFV>4/
MD-.:.KHLNW*W&*2B,^8X/A]@ZHG#6E*5('/XY8]V^&5/50Q,BZ=/LT2XW8+6
M1D$4[!6AO3M<[?;"9&*<+]XG"M"U:O%=.*H2@/$70'K57 ,]^#)6/BK(]K3"
MOC$+VB)>2)2,<@5<>Y%18$DBV LS' ]$:G"H!V OLCW[_OI@D$E<E@S28 J!
M T^]&_,4%=D8Q3*[&L4R'/]^/$O8.X6]*F4S#>2[93B #U74Z= W&8K$UI=:
M!+8=%35&(:X2C*U@8C0I.Z);.2HCVB5L7&TUZ3F8A368S^R80J:*04'ER$[X
MTMI!#HFJ>RLN^^ .BNF>0BE%T\C.C0%'XGFFDDW_I/VR&*9EL9">"N^BNXB0
M-,%CYG6B$+N!Y!D+]X(24 MC\>,D3#BORK<DT^K'2KVA\E]J"@<>-RUC?%O)
M/P[@/^G=?:K")V.)IDQ(-VD'1;4%$NKNX,ZXICK869((I1L@UH1V/W8+]5*\
M[UF[TCV7&2]*1BV?T<CS-9;!PK21V2!)=<VK[+=MO$V_[3\PY?;IS5_8E*-A
MC$PY[2E/S:8HE;#T%"3-#I^EO,24;K=Z+KYA&TZ=;SJ /E94WD1??=NTYZMJ
M<5H5#@,8I)\#XPS87>AWJ</FT+R;JC0OQ*YC+FFBRDNZ=]HBU66KFG=UUS;
M:L-7]*#)OCKMJE/;S<5N6VL1%I^[\;Y<PZ9 VF_"N+8="<,=L7RQ4U5[U. E
M]G3)V$G.BI^P1N=<^Y-"<^_/W)C#:QNS0A8@TD/,.RQKS1K&9Z;N 7PL'QV?
M'!SO;:I2ZJM'D]1D?@V&&KT"+@I.FZU/E!.>=L9=$* ^NL&R(&Z$_>.L;,UN
M0AD%&C;EINW[6JE;F%+1AKJ.7F]"HT@XEM=F\C)@C#P[-&)*$GX3M8-4OD^
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M29JX</!$?X8BGXJL)Q]1WR1Q.Z&!IZDTN_F*S(;SJMRDI$LOXZX687X11?R
MG]/;_+0? >75N<#W8XXFZ&AFUQX-#0")MC/82WV4):2;EROV$LMUBT30MJO6
M)GG&:L:JQ*7W @X _9DVNTB23+\2,<1H=9.[ZH2ZK4"H2O=TPNM[::N;=^WJ
M'<U=SJ98O@CC=SOA%.I"M(2IA;8FL[>HF=NC5 RK$06M265'5R1R-!\^3MJ
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M%"$'7]_?7"^M\W<*39/OWW!(MF3<ST^[Q2G[N^+-[J1W]YYL:U.NE;9GR)M
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M["$:10][L A)1G.!+30^#&X1%$();.QV2SV9:@:\4$"!9YM2P(M%/+6](T3
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M0L5^D.T_?);M/=P?Z/:1>([O+ =V;SP@??(@VZ<16:V#N8:)+EL\,6[BK #
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M#@_^E-R3^@6:I(@^(617N!\D:QT% ^LQYC+ H?>,06RVENT %;6=>@';,]$
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M0>I_D\!L](O1U@HKDHPH&1:QKA#0"DBWP&/[[53C-QXN@/T\/NG7F)8.];I
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MXF')_'T'/RM "=Z_];/X$6;N2"+S,F/OR"BY>Q(%-I_MB;$OI/\T%RCSKL8
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ME7\!#+^"&P1R8_1&P#P-#2Q+6SDJ8S,AH* 3'C8'4/)F@D*;O")UO)Z0PK1
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M_\!37KX\=-&%7W[8%;/'2\Z$_-"R7>1]*6H#^TH'E9D@MC+$O*JXS"'&?I[
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M^6A=M47G'))Z@1F(3!70APCY5]X&+PH@5</5E^%JN4#T0H> S#GID0@C52^
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ME54(/U7.AC=9X?EQ50O'U52IN&@Y^%#*,SN444OGX98QWJ#^[I00"BVSP-'
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M@!&V(UEX#]K\2L2CG4MU:IH4NOPZ0D@]6_V: ' .#]#'3F&_',]07AW95[Q
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M\EK,?(F%^<2J#P9\FL))"Z8/T4#"A1-E&(#V\5^F\#]5I9'@F]CP\& &M6>
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M'V70&0;AT!?8@=TNQ5?COY3K*@HA/[U(1C$Z\'1:SL@5\#]EUW("_^&R:R@
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ME1LI'1BKW[% =+H!;VGV JE<1K2-NC8O+0L%8!CJ0D)GGZ5:R0!8-G6_("T
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M!2Q&-8>_TM30 6&/S:KE*2I:\Q4F3FZNN\-GUWB2X4,46.*IKG!C,MY*KJO
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MZHJ1H#)I:DTE=<" $O8%V6MA-'YXO/Y^GH<?4#J</L:,7D7=.LG%S[[ZUT^
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MRUF ]?;,7$O-__7\W:?+<W6LOYS^]Q;X:&"]'7^'D[;Y9QFLM^-N+<S](ZT
M6&^'WVV_/L%%W=IWVS>8];X"C+*7ZO_C^;N++QM_W/=_>-NE#:MO:R!N?_&3
M_?'\RT(!N/W';*7\D3],RWXLOG,G9SW(,M^.ZIG-V<OR,--EO>>^F.&VG7-?
MS&2;/_<VW-8.9LN4^J^G5Q=G_NG'M_[;B_=_?#E_2YZ[]./]J]]/+^\M"UOO
M0]_M]'Y052]G_IW*;E-GOMLYN9=B875J_CN.XB_]-U]^/_?_/+_X[7<XB*?_
M.K\\_>T<:C3A\X]_?/A5GDKY7Y\NWUY\/+W\'SJA5Q CQV&\M)D!-GL7]Z4^
MO+^:<\8V+N9SK/7\]PZ"PX,:P\"/,__>0= ]OC<]NL#\VQC;IMA1:S68E<?8
M'N=RKVB%9CC%<TR#50VDV4-]AH$TNXO/&<I_A/@0PAD(^S)Q UV ;H4?IWG>
MEHEMTF"66Y7Q7<']/Y),R*?]1PQ1CKACW6T8Q4!-N ,4ISO0+\+/Q:"D5F$;
M'_I]>;A;J\[Z@7*=;>A_ T+_2S[F7](BC)D]><[ML;%;VA[I]DAO.Q2+BF3.
M/GWX?'G^^_G'JXM_G6\+?+X7[._^T/"C%H"U7 "6VR_J&1F^Y_5L.FI[-JVR
M9U.O[=DT2X)GR^OW/_F7_IM?HC=GT%,@B_(T45WAI@*HCNN4ZS[PA2-3 %%I
M1V\6ZECSN)&I::_@!7#*YG0]^ *]OI'NOR_B],[/RS&T:?F/?#QUDL<>!=A<
M0O<HP 8CBZ]=H-I52;M>GK)-[R#R$\C1I;@522E(+#9[/@^6"^@RDM'\J;=(
M)H;>D!H-<S_I*!U"8QJ1@UX>/ON6;WD_BZ:;<$D<\X<_/? E"[:X.+^WQ473
M^V:876M Z;_"+>@M?PN:6F$L;[TW>%7F,G5MB10N]\1+%^F%/Q<.\O!!/6*M
M%DFJ6+(SY^O?^>NG#;_*>UK$TBP;1MC%4;=I>UQRZ<4">:5NL+M7@XLL-\>U
MR##H@?7_K07<5A=98V/@Z/!O/[TYO:B^]YFZ4/2.:BIL<UIH/$5+C(><.DI/
MK/(L-31W>?JS],@SLU L:R-]GW>6>SO+N\6&PIF #H[2^U'ND'237TA[8,\?
M1W$L765JJ!ARJ^$D383C.\]X^&['?VO<J7M'0:TIK6& ZRY%_)KZ-6.:'((=
MC3>%:OT<CK$O)4R@V]E5X^?.P^8AIQ=@+944!JC_=-=,?76=0ALE<R5>_EE*
MC7%_=&]_P.O \N4IK]]OO?Z-[V)YN*(FEO=[^.OK1ZUSH\.VB>7&2,UR3][]
MGG;K57]7WTCIR359&/,]["6Z3#5;_;[6D+N[:^+L/7#D3]OZT'+.5X2U[38U
MA'LFW._* B#KY#@W=N#;5,=YF_R(AWO.%=<"O<A>Y_A)'6B=Q*P.YGG<:$_^
M]'@1-[H.Y%L=[F*)[Y*.]6\9@/K?P__<XU0O[;V//!XK?O\]CO<UKA-60&@A
MQ5(($0YNI/!=0SN=1;WPU@G?J+QOFWI_]BUH4^]MZKU-O;=!@O5(O:]GWOU'
MS[A#A^ Z2^_<U]3.:9MO?Y*P07,SYSG[LZXA@Q\Z8A#:7A$YV@>SP@72#TI'
MD72J,RXC7RAV\$E[7OQS=+D<Q]_3CO\"C^SZ=V$.R7$=$+#?8>K;P>-S(@/W
M/-LSS[;68'6)]V<5E(?5,!VW-4RKK&':^V%JF%9:C/<$[W1Z,+\U/9C]<]V.
M<ANUQ;WE*\V=J3W5I--O(2YK$%UK(2[KOK0MQ*6%N&PTQ&7.@^^].N>SFVU!
MS&L^,.8JC.65*N\'6)\[:4RM 2CF,-C=KS'N; 0HIA?LGM3TWDJ!,;-#$%<W
MTH7>Z8>Y&*)#+:4=*[]7C%W9"WKU#BC/A*/9"_:.'QAO?>KX\^7_#<>3UV_]
M'0Q3B#R7.Q3&WQF(7GB!Y$D[6B"6]D2;=5@_]2M DB'-Y8KGT@V.#A;@)7V2
M=:UWDMS&L'#W*.CV5BS*BXSC).AUYV9!?\3X\.4,3]VW/?5,X%75GWHOCCHG
M&G55I/Z+[E&GJS^8$T^E6>F +<9C7YQT>HO\U@H=0]Q!#<B3ENRL0(,9/H1O
M)UD$T8EXZH=%D47]DOQZ.?[">AX'NX_TD(:E_LY89-=R('=1<>/_K^AG(9"N
M).%8#+V/89)^\T\O AR#>AC"SO*:!8?_:KQ.?#G..R'-@:2($GJQG -\?5Y
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M@FH=#O[.PNS=3F_I&WER>'2R3D P.,(8_5ST_Z2](#5(D693?=[)= 5^:NM
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M33B6[>W9WIY/'H8C@F'TH$=1K$+FTH0%GF,T:"=A@=GSR21F5F,,P!%B4/U
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MYERIH@TL*5)ALW3I.%(1R0\]T*:A1$$F8$54[7(9497 PK10L4'BV*+Q IC
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M3A?-84P.]%,'$2/)1BB]E UECI92$\XZMIF!D^+B?+*, DJ%J1.NK+ H)EA
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M2 X\>)(>5)X/U[]"45R@ ]HY3<)NU1'A)G<(V[@#UA*T,8?@H&<.&R(H3[/
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M__LJ:D>(08$7O)Q9!U?2</<TKD(YT,"%H+O$6MD@#HO $4#*0)YPII@-FU\
M/X+)DY\"]0Z@/];@3MZ7FO)3%>-%#JRG22Z1OG"*(GE+3C:0L6WDE& 8G &,
M/O;F/>@0,),HO)B!^-(Y754^5=5,7%GPT.7SD/$CV17,9O&67C$_?7'HSM#<
M&&&46,U]SLD.S+N4G )H] O\@$D9T>,&>OT?@ ^I\%V2)5XI$CL&(WV824,1
M^U2 ],"O<:XC)0UZ:4\<:;)Q&IMC;+*RZ ('''*JLU%"DN77G]]SG=;K-^A_
M&"?P09D45H)/XD)Y1S6#?:7 ;VS58(I7TTYJCD_B):=(%HZ'^6+3PN2:Q<#9
M418&954CL=,>B4X;>Z.Y9.Y"<S!AIFD#0T'#)H@::X+.P M'G\.3+U@[-H7[
M_"KY"W-WXY2]7<&''%CM/#P=O!J<AK3ZO9>\A?AYSC3[#?WM%Z"!D)A"CR%%
MHJ7R7V>=5>$;V ')+VBE<%K-V(G5OX>#^*@FH)$4VF49LB?#RP8&"R9,D68N
M6U[G!I)_N.1$(,S48D.KD>UK3Q7]A1;BP+C/2YOB6X:/3H_>G)P^=O(#9. (
MY7],*<,PO':M<BG3#IA_HQ'J7V=8FA2)HY5S$]-8<LI.LBE>R8 CHSC3C)Q'
MS6^=PBO9F(U*^NI ?\^E6MJ #OE'U%=PS@A(7"R)K0O5GED0:'R%U2*9.TW1
MO^]$P]=89JF!-]=+I>#*?A<&77$ /=L*4U:Q0"C1_#QNZ(T-W)Y!H!W\^*R)
M/$BJRZ&N%'MND]L]*"#\/K))K<IBN#UG:Z)"?F[ 5)XWU^#?_.!*?.Q'7?7G
M J2P8_ZC&F,&$::1+VB]\ONS)?"/W":[\V_?)=.Q^>%7O')>>(054<ITI_1+
MGQ>\BK//-F4O:GWFC/PIR$Y.,^ -;-9H#OH!>"RL+LE=<23I$#*GMW$&6G$R
MTJ&:D[-CFZ_/(1OC/>I(6Z2"2XU@TMQ]T%.MB\/?^U^!LN."4+1D)\'TJEFK
MECV-L[P"!= 6].%4W)PK/!]X\!21T4"3QZCGTAY!,B>+#<V]3%0#C0$%W\%M
M-_-V'23^$DPRU%55#V;JYC".3?*JQ@(21>2(!.[2J2)L)G*R5H%)V3_75*C8
MX(/5U5;09B"U*C:7 ]2$PNK-)X*63[1.N#FG2R6"\C+.%D#&S%9*J;AL0.H$
MZV;<+C!6O;7OD+Y'L[I4557V.;+WA:A(:+<DU%#IBA>+'!78<3A<=KG#*B?]
M_0K>,X)^D[J/@[U(,MAL6CCJZ5JB[.]R50A#\%[P /$?*(N :RE,Q'0\[&X,
M&9C_.?S+Q4D@OF,\'@,TJ4! H;?#I).YHV'B7* ]RSIYSEA29[-X!A<"(<(7
MK@]G3]?9D"G7'B!'IO/+6]29U%RGE#TZ._W_?L1??_H5-,ICP[81JX_G0XQ$
M^ZT2XG&Y9#M0/JIQ--&6FPE[*0W-48TJ_TX5F,P<6]0^+H;3G%14<XW_%V<R
M P8=@5UG,XA_65*5#+N0TF2B#-O@:FM34N0#O.EM[ZI]03MR/8.\:^_*'2N>
MUXO=[_6Q^]N,W3_K8_?;(6B'P$_N-]?TU2! O5]E)2F(MSOQV\7!OHNMO]T5
MN"=!L)+-S$B6?$XR\);J<UNNCH)R%I1YF.:,+7NAPC\Q)#19LI:)_!)DAM6'
MRK+&C. +PJ$.P70-"^#)2<'^-$K6E^ 7Y7T6^9=E6-18/QMSP? P5?CD;X,S
M,%1RF!OF\MNH6&"U**HPX(]S(-/[ /RN(,\I@MS"<(Y_-@<MN,1<8>O<U*2H
M]>5U.94Y^OH#S#8EG7663&?ITGX%5KKR'B4UD+(&AYZ,:RRB*&*)&1#4=AA/
M0<6:PNL1&(1E KH8VN;FM]XL'5TR( 5\!UX1I%[[S").8+(%U640[BR8#C4M
M'U?8,D=<G+4/T-.$VX-J=*C(HZZ+<YFFQ6C80WL@@,V'LTSF,%78C+^_&.SS
M0W.L-$-KW(-X:SR].S@(Y4&#8FX6?D$^/8Q3)V.L]0[CT:BHC7\?/=XA+A _
M'+#RC7770!J5I@RT4Q(8 ,OP5:8FE&5B-H:V&K7Z.=9S =$!C2#A:L^&B=17
M17R./J@"K/61WF0GR893!N3IP(U-C&L*Z"K$2<>'],CPJ60^Q"P!6HX^B<C2
MF9TP1G-RU.:==V 1=,I#)W#LQEJ MU*E,28Q$%71J1*@2YVF.^0U5%)X4893
MCO6G.D5G:YG6?8.$WOB"@!4$U',$R"'-+_ ^T%$*&P6K"[W7AJJ0>DHNCQ;R
M ?) >U"XVP2O?1?S$E!MMNG+\!%&BB@RA"%9IYB,?-KQQ6,@;C+K@;"(KQ<*
MDUE,*LFE[&,0_HY\'/$@Y!6:GF653+07,[ ]A6_7A0J24M]^JOS"$C$IWA 7
M^S%6%\ ?;=#(!&70X["H"[#-K<..M]=@1M3S.6XI;7>D/^GR5_F6R".%B0VE
M/@E@X7E6EWBB*)^J92M_]AD46%SSA%W:<*>79.Q+(GVV]-C60A5<WP>#4J(?
ML%^PXX$7S7(IBO,/O_0AM>%S%,^JXL\F"X?9*'W-$X?"C2<U1J,>;-8$G_T(
M-FB!,BJ;_L_?=O]&/V.VC?[YVDL42WV4IVF\*&$R^E\OX::,JQFE]O_PMQON
MV[497;M:NDMOVH3,-L&QX&__YV][S[_^E#O],1UMO6Y6"-U\M[!_#G]RTL)H
MKZ[Z?Q]!<2N,BK["AQ_M/6XFKVXD?=Q"3[VNNWEE"_T*SK^;ZRH+6B--E^$:
M0- E"Q J'\2C_6C_\=KK?<4UW?4=W__;+6W];5_(5Z!"_'-8_(/7=$:*QN8?
MP&;.ZB&1A>AX^J82B80?K([(JW]TL 6W=3-G]8"(Y3]QD:"N:_G(L6?2$*4\
MZ2FEIY03MEM1Z(S74LO3GEIZ:OF45W&Z^3M^AQK]O2]UTR;48FT_N;:U_9WM
MV<9-Z'*6==\SW+@MNP6>\Q)31C]CRELV1N]B7OP8%M/AH_W=)]'^P?-H_^G3
MQU_/EXQS\LGN#ZN1CIO<+(25PDD:1)MHI0^SA<1]DQ<(&=>!H_3HV7HUY!K+
MWOMA,UO<.Q.\W6/Y^TWMY(O&1(MD.KO1F1[N[T:[N[LW=_*WN[$WPJUZ.MT^
M.MT_.(R>]73:T^F&T^G>\YZ?]G2Z^73*:N[SP_V>4GM*W6A*?1H='#Z+GFPU
MI=Z& ?LMYNEM+I^ZN>+,N.6E1F%'4W2U;^M&^QTV<W]OB!'>KK9^^ )N[;??
MV(W?QYX -Y, 7^Q'>R\.>OKKZ>^>&.!N]/S@64]_/?W=#_T]?788'3[K&6!/
M@/<E@)_M1GO/GFP; 6Y?I/$V-^A?,?R9IO8Z+N+(V')GU/Z38HIGTF&VM^@>
M]GW>/[@9O_;&[V-/@)M)@ =/HN<O#GOZZ^GO?NCO<+_G?SW]]19=3X";NG&W
M;=&!P?+LV=ZV$>#W%'H[K?Z:Q9]I;N_B>(EO>#F?*YC+CPZ_->>SOZV;>5OW
M]_>BYT][?:4GP/O2EP^B_;VMDQ8]_3T4^GOR(GK:1^!Z^KLW>^WP:;3_O'=8
M]01X7_;:WHOH^?,^ K?5$;A/\3SF;,JC68Q]88[SF<HBL>?>Q<5G18VLQ)[K
MK_*#O,K[>T^B@Z>][Z\GP/LRYG:CPUZ9[NGOONAO[UET<+!UJDQ/?P^&_IX?
M1D]>]-[4G@#ORYOU_/DV%C1L5O#M;N&Z^LO6-L]OKSN]748?/7OV-'IZ^'3;
M;EI/?0^ ^I[N/H^>'?0^XY[V[I[V#D##.-SM;?R>]NZ>]IY%>P>'T=YA3WT]
M]=T]]8',?;H;[;[8.O^2MJ[^0<UW=$.>!])0Z!XZ#W^L4[7C-I+54_"Z^*XT
ML3W QK:"+;/_%(&%G%?=93NMA^E3+:U']*;0U%:[W*[,\.[WZY8:/=U*-R?8
MY1L <=T=[-\PZ5/[GF_GVC>:.LPXLO%H! 2*W1^Y$QUW04S"-+Z(J.DA=WC$
MKHN+O*BHH9W;^ZU0] M5S*DK'+;,T]TRN>7=DAJI%0J'X;>YFYXD)M,DRBJN
MJ*G;-3IH#B[GC#=T4>Z0!][]7;O2#?+N1<NJ;O"B[%]Z46YIY..X;/3QTY0/
M_#&G-H-,OJ.Z*!30+GP]M]UHD6:E_VZ*/5,O5(']9S/<7WK/]N?%OY=A7''/
M5NR].M6/8CTU-KE5FWD/G ;MO8BX:1%QL'$BXH@O $W%9_\)MM9-ZWEF&_[J
M9IN($>!TVW3:+L-[V#X:1A[371HNW?;3(' &X1DVT^SZ%,UC'B_UF)'N?0IJ
M3$LOZQ@^91HV1TY_4+AJ59$,:[SD-,@_N+^O]"=F&:2[(X=.=^3S6#H8TTQ&
M<#'A0?P??/F"G\%['*>J'"D4J3"H'9F^*UU&2YA7D53PURK^@NVVRW*G7MA'
M6WH9-W8#1RJ3$E=.TR'IC:)U6B=CD. 9[GU!7053;,0,POEBINB3W !5N-L,
M.!!H 54-B\">J2KC]LAF;V4'!V$O<'O.U<JYGFPEYS+MDW6#+Z]3D^X2C,P&
MKABV0N8NY'&1N4W$N6?Q+:FX_97KKUS[E7NZI5=N4:@2936+%FJ]WGUQONK2
MD""469BFZFL[BD]2> KUDS@M]:-A? &"LX1+,B8#%^9]GN1U2>.7($D3X XD
M.H$QX$JEH3M.D0V$BAX=<"IW6=;SA=$WPL]J"<H$<YTRK$MK50/MC>J4.1!(
M;$]2HZT]!LT"=!=^X=<<#(6]?6UOQZ!E5;2^C)Q+I&1U<:%(UL &/.E3]KCB
M+ -U0([Q#KG0PVQI_GUQIF<;QYE66B;!D1(C@'M3J@+5WY(=5NU]DD*XBYK7
MA)K-H',,[)EZ"FP@(?8TAQN3Y7!("M7T)!\CFRKQY7_5,.;!+IL-\/+^W=GL
M_8W:_AMUN'$W:@5V8OV-6D&A0$'S?E3E>*&NZ,-Z(!?B'H)<&#UZ"1_[LT:7
M!(ZY_Q)LGK3&?]NP$I$5O]P1"-O;QWA6(Q;VS(EQ=;92_=M7+7RU_:H9G0-S
M+=.Y8:>PNX]Z!U^&GY8+>.*HB(?)Z&7X:SQ7O,N_YKB=+PZ]")Y^C7;:(0NS
MU5U;/RQ4_'EGJ$"TP/<7=(KN\I^U+!^/R-ULAW8\[VW[X.ZT[S+FV.56WO2[
M_KL*%O&2/8V@K"/#R_)L1\T7:;Y4H*PG8-I4.3K[0;$O9^$$?@D/_OW@&4++
MH9K ]LPBK5'I#E%&HNH/G%)4<'R#W(:,NHK:1 S7#1L\@ADS3ZI*J0 _>1@]
ME2_2=,P?PT?P]M_WGM* VH@:8<=(>+9D*R.VCS\>A*=V'I&$!\FRL4$]XR-!
MC6JTC/ /0<?*X7\5^5_K!<Y]L<B3K$(+!%THBBPO^+TX&WEA,"/S/GQ;["9X
M9%$7,'.P&'$B-*VX6(;E#&R8DLT^V$,P)C%<,P(#"UB<#K.@,80?GA8Q#@T;
M]O3Y;G2X?Q"1 8<+_+..P68MTF68@VH FR):'#P\P0')\HO8SSJI,3(Z D5&
M%;P5M#RTO.KYG'Z#IP+3>???\7SQ\BC\! .7,:_V48Q!);#,K,V[O[OW(N3^
MX7  XG$*/Z1Q]GAPU\)DRV7AC4W_9#)!\CQ704SN\W_%<"6!X(P%<*$T0<-!
MGA3JK_"=2JN_D'CPRO_W?SW?W]]]^5J5(,+(&'\M9!W1G_9>ACXAD(>_+LH:
M:;3EO@7ZOM&#Z'Z<)7.7:7CART1\F*,856T,-4C$ (D=0_4K 4^\%MS-SK(F
M'.KO^[O\6_BDZTD)O+?-*^+*0),(/_GQ[#>ZO4/%MX_72E<*/@:SMA<OR<HJ
M3E,=IQ%?"+S@L2'Z.# PI(;/J@KXH@L#;K*%G">3QIB74,3TC3$P;7B<&"5M
MD<Q@$+[#_Y<S;%%IX[#E,%WS,+#FH=+4$S+UD%_%87_K;<[OY=)?L<7])6NX
MV17H@RUGR2(XFA:*/6;?R8ELW/1!RR)'*UD .I5B[)Q1&)LS8NGL*F2.)N&R
M5G9^TN6WN@K?\YPE\JHN,@@^.%\ K@*:B!TZXF'UT^$%7'#-[[0.4\,>%9?(
M^P$B.,(BR:-$C)6#N-J[S/%@\NCF%YGB'>A@?L-E<P]*4,Y$+IU6:AX> K^+
M_X !S_"-&=Q&5;"/^J-BUOL!6./255]*?']O_^61O!JXKPZT9.L9V/TQL!-2
MPY$J>_9U[]-O95\7!5I;H$V9DUIA8IA[*=?:Y&# +T@[* ?AIP;["1=%?IZ,
MV5KTW-"D?9P#5P .$HQKL5?(%%0%Y;6)[D?I:/J#R#O *(6GX!_XEP)LG7/D
M?2NSB73PBYEJ!?OAIX[H!V%A:4KI-TE6JP#V0:S#$-7)L(Q3Y%W(?'322\LZ
M*4B'WX@I%Z^LX!3@+5I^25S6\DNT24E'K<2<A?<F"1XTL$]DO?DD<#DM#AV7
MJ.&QA3J!TSK'I^&S@_"7_ )S@2)>'+X&*N(PD0_1;QL#NK/"Q"50@=-D3D$Z
M%@4V92G@_*<&>SX8A/]6*"','(7YOAZ$'Y/R<_@F)L8NO\5?E89SP_Z>:(/\
M70ST9I[[K3&X0X<XCY),&YPP$!).VN14\:)A&V%78CP-?*#*V8RHN$$,IAB1
MTTHON<[T^QA%I8T%HM;;A()W4N1S?>9HG@3T"QTC+JJD)/V^S.=&SY\PS+'V
M.)1:[B!=QV"?%Y3IQ.'2A4OAJP?7/+11&F-.QUU+L"WV@GF\+6YG:\S5/L:9
MC<-%<I)T%\"JM<H3I;_94^XRDD)'(0L\]A6%"1^W)*$;7@=+\^9 -^+P9>G-
M&4:_B"GE!ZVV?)@FTUC[J8 >R;(M=1\D)_+/?#>PCJ.]Y[MH;<+N>8,R(QR2
M4$BJE.^JYH4F!U",QB9OE Q"DQ<(;#!-5,V43'Q?W'P!K6$L8@ ]<,9Z1O>5
M'ZND>Y.%R7RNQ@DZRQSA0%S8.4D1->.51:'8XF3&< YD,L.$0IA](+-G<Q_F
M\/<G[$]@@7'!65:%L;?__HS_3#XU\E<Z?C7- )(L02X.6CT<SPA%C*)S@.TX
MJJ<@%T#'WMUED][,,2C(?L>\".0PN+V+O.1K#[/H"@ W;7G?$[1/QX+?<FB(
M3M@071A/*L6^5R") $E"",\_AL9TC:PL/3<$N6_A:NJM:#%5ME9=ZM+VKA38
M.N@#6[<9V'K>![8V[5ILR?2OI2,X3EC,4LO#62R^F3$[88V:4&)RKLW-0:=*
M1"4Z>99)9(F^V/"]!NM]KZN^VP:_'X2L0#<T#M=YC,+ D>U:*DI4C^4A1HA^
M._O["W:N-P)OZSZ6Z>]0]G'X:)R EJLH!J#M)Q*EL/PY"%4P^2@+!VQ..)[X
M<>B-&P5:;L,2T5VE)*N9(H-5F"ITG</S3Y[N>D%$DGP3&!HFPG[_25,(4N8G
M2S"T"PI*EV(EO((S=-^6:> ?02*7B:CG:"O#[\=%?,$!TO-8ZBK80LLH-%"S
ML69FY6Y/%);U\ _) R7%!_--06]4X2/0]"\0*OBQUA;IC2!ANX93O3L.^X*-
MG<8Q%1@>*?B8M$%>)E]8&S(B?P&BWACI&(BP.^9H70&IH5QBV?;=_4/6+1N*
M!*SD0CF:!VVW'<#15B=)47*6:F,2C]27D0*V "<=B#5ZC"91>]2J<>:N"IZ)
MAC="%3;+_85K'5BO#4//C;D[NZOU]*!-3_\J-=WHQ>X97E$Q#QJ*>;2BE9,K
M@8Q<M#Y&'!9KU]/#;]'3 T]//[V4]UT2=R+"UFYK=V/:PO '$A;4;N= W,YQ
M10S^BRI&:+G#J3.= Q/9/Q@\?W(E/[A.4,;P/%L.&)G'] <;+X03P(/'</W>
M,_W[$L.2<ZS0A..^A)-[S$$L#617F.FMLBFH"HXO+*[8Q:\3!C"G0#NH]/80
M_:"_+UA-$4#!%+,GHVG08& 1AAJ';Q/8BW%LT@0H0H%'C-Q%7[JK;!_<)M89
M8'Y!/,S1 \G/^4%BLA^UV,%=:+ESK6]ZDMB/G(YSQ1Q4WQP;H@Y6H\[^A^Y&
MT;D;R(YM#!W020<^+6VMVKGE6O/[+#@#.2R)YY'HMZ@2C('?D$JEUK  DD$H
MBZCN'!C=#OWV$;XE8KW[92WK0=S(L\YO'P^"3^N')KY2<9T.JJP3D%MC$ESF
M.=)DE]J'H3U^\"1H?NBGTWJ-<?%&7EJ81$*B@'AI6L44@P4%,2ES"6'2Y\D/
MK'/="A;L2S(K1)$JK8X 4T*%L<J-VAK&YL_Z^8*?T!XK/(2D"!2NL"IU]+A[
M.4,UB],)>\II#G.LXL%G@=?#).#K0PEG4 R#) #/7R)#^0++<FKT?_&<XQ%I
M4&$<P&L@;56%(BXA@PN$)S#XFB,I#4J@  !_0L_9/9'KGD3HGD1P R=!?T/U
MUQ'2OV44/CFKR)4[47 >H';!86!LH(J_/#S/UY9,'TQ\JLTORUJ)AO)5[(FU
MW^?1[I.]Z,7!LX[4!D]QB\=_U"5KM\DD6,18UU$C",<H7B05YL7-XFR*BBEI
M@WS9\#/F@5R*XIE&LYHXKFC*J]Y5"FR-%6O>BEW)'/7,Z7\'X?N&1NQ,-J^K
M$JX(W6TI,OR&W:IFH)7"3R4YXRK0B=67!<PSPB7Q"C,LMU'C*  &-5%T>YS8
MK](FQ3)$=@97DQUS\#^D/XL2/S:645QCQ)4J9U))142N!,NBC^C(&^>*8'EE
M55/%-"O8O"%8FDG.;+MRLT8:)YYB=!='.X^3E-P7.$LR3/H;?F7=]K871%_Z
MZ;6UK%NJ<YV42"\7B46DR Z&RQ&[4S8(K((JI\LY:;4^D5ZF4PSV<VKWP?YN
M]'1O=Y53<&8X#($X@NA#%,B=50/U[T^>#I[O428KO<SD?1B]V#OD--:K)7#Q
MMAR5Z.!K*1QL6\Q>M/_D,'K^='\EATL;XR*D5W-!:(YV6UNG&#1M:S31K[0C
M>V"P/^5]V(]>/#W@?="3N@KGBOAP';YG;W!_D3N ).]X06_R FY((UO"9&F8
M#&])/V\F$3X;F&1H&B-#+]^[.-/N$R2>$S=18V__Y?$@?$6"]4.!HF)D_^ F
MO!_KNA2=5_B=D,S7N09N% YM$#3.9YO=&MOOF*'#((&B;]IW<A4V;OKOZR)H
ML0D$]2-=ZC(;]#<CU]K=>XD88IF3G1&^(9.FD:&.#NPTF2P9=6BL%HJ6L"+;
MV4]=+'($"@RFZ/[.*"I&\I4L"@F&_1J7X_A/^W#H/%S4J4 :X9-VO)&)R)@L
M) 2AY4/;VSW:.=!?/_G"=E5X-.J5\ON:/@4G _+7S%GQQB-%OP\73J$MC >-
M08:2@E1LEU$<C.U<CXP[JQ^, 9CE(0'*$>SEA-S[,&*6!W,T&QD,4TG.&)B8
MR;R>TQ/S^ O]NVU4R11E>AJS>HI)>VA4X[LK)C8YR<[SRN2#EFX1PM:>YI83
M([)&Q\!#O**$,P4IZZ.:%: YCE(@1"G8198UG5)>"/UQAPQ(0A,>A"=4R(Q/
M-SBM\%<"%L[@A918)J<-I.CZF 1YIG:J6<(T3'#%9$JVT1Y^KDJJNM)&K"0G
MM&35A4<2 I0$@ZG*R/TX5TI7539I,:*\5%/H#(IQH7;LC^Y$)CG"2)I9H!_'
MR\VG," .08:?_JUS=2?L#FK9,KR[P5!)=G3C0_02NXU,O23O7<<R[43):=:Q
MN$B"E_AUNK]H_5)2 R5#1B:>VCY*U+'F/*,XL.I:IJQ$R,>D"N%QE/*9H(83
M3B]?9\MQ$C?BURGG #ZLC.<^IQR0<9TN;5UP!$\+N\359'6A-+"7N2IF\Y&6
M$W22^W5FDL2,KOJW\04.*M\$&9V?ZV16V2)*SM @84,%!]6SP]L$4WG2YYS>
M9L[IBS[G]/NZ?7>@C,3SG(2LJXW$6OZ6/S++Q=_S#IRZT4X?0\$'?<"JV01T
MV +CDSG6MY#<1=&AN3.+#HZV=LD<3]XP<,(,Z CCN"!"@=\TYW?9!(_2(E]&
MP9LT7X[#?\=5^9FUZE_S:0P_(SI7))E+-SK5_9?&OO2F>QITSM>O*,&W7\-O
MSFJ0=O";\<U.,^!I'O0"\KX05D!%"U;T6#@M2<)$35* XHVQA\_JHZ3,N3D6
MH3LUF/ @'OLBOT!-2O!FD9+D#X0(!/_1]('9K@Q0'\1#PE/'Z,SCI@+907B4
M%GQU]=&#L37YL8XJB0IO(/K@&MTQ_&;=$?Z$46_T_;0JDH/@-Q-)NKYK ?3?
M(C_GX%WSQ'1.>9E\J98[F!Y-7.(B9XNMQ/C;2!"BT*<0V(.%T4;X*M4D8S,!
M;W/E@)/,R3+A7)HOR_"1[4/ K@-*X51J_+B9N,V;X:;"&-H,7$W;$D[H$<[6
M7L<MYR9?ZPI;D^0A9ISS6RPB0$Z O2"D"4R7QRP*+,E)?4&;_P$SR=%,HP?6
M.<DP&PHG9>H 31VF@(BM73;E?ZP:_Z8FDVO\YZ -$/<T):R7>QX>E8]Q;J4.
M2>//6+)#O22H9P::P01J0@G0A(PF&[@$<UGIX=L631EA>&<I'<4Z'ELV2Q9\
MI<V@7)260V?98W-[!#Z.7(\X;2>1GMSPY(,P>#+$^2P<EZU3TA*-P074N.<1
M]\HCO"9G#(B(U1"K@!5T8PK$4^#?KG\8R5K*D77AAP91,'?6P"_";+5@:Z%#
M/91\1JO1MO*W?6+R5P>Z0>#I37%57(/@=-4E6DW0 NJ!8&^Q%.\8383ENM;)
M$%\?JUY<%6S58^9(5QO \M02#A:X;TG*:6#T"& 6N!S#\IB9.1"-.'<&Y[?N
M2<HW;BT3YXP6-W$NXD_:VVO14P)=D8,&(XW11,G4"@>RZ(32_3B-AS@?GRIZ
M+9$%ZI],]Z(N<FJ23N 30!?IO RO]EP7D6@"H<1@U)-CFYF%, LF%=GFYIJU
M7K*DERUT?.GT>/F$CFARB*5D/]!-$^26L(B)N<%3CDF/=,+).*$2K6%=.5JO
M)TF=FE)LZ>3,KN-K@_ #U;+!AJP!(Z!D_7R(4#5JO'(S=%JUH7':[G>Z!L8W
MA;WI#G/I]70%3H);WD5BS4O$=.Y>)8W#,DIASZU-T['>0>##%V!1:J'-"BGM
M3'1(X[I@"P9IX5)0A* #%&'+9=>63_\T"RS'[! $W<HX GI8M:QR8LM=JG*S
M;I90N&P[% I$<>TP)SH+T)"N]W70D0HUE9XLI8=2PU# !MR^ZXLH$=RW9CE%
MKSG=.A"4%S'_U;B6'G,HZB8@<ED8T<<2<GV3X/H,-DA$6G8,KT]GH!F?*[*V
M\;5DA(\N-:8L;;9).H=GAG6)_>%*9[K!G!&B.-S>TH%G$/YB>2>>AH,+A1(#
M:[M3KA$$#J>$T;?V\FE1;IBA5"H8JR$FJOB8AT!>F7+\)?:K+GH7@KFPNP>K
MMD% :WHQ=;\ME+)"(129,V<7=8HGW +R73)V$;F4=3]0&+"4^.5R(2<&-Z%+
MJRM'N3R%?TG5%PU-AGNUD/)1.(#W[7=C1B$_N1ICEB(7AO:MOP6#IC[MLLTG
M'04[*=GNALP8ON@YOF>Z4-5>HJWE4EO.9#\A^%J K"\#04X?$3,!*&B6+$JA
M5,>Y)4:]5M<=/YDAL>_&I[6)F9\G7RK,V4N#:V=^8FD3:&<WLYX'?O(;-WWV
M5+1H2"/S(U8]2F:G:UHC@J,6-50GB3^PRR,21YT&:@ ^P2H\L E$1T=SU=Y_
M,Q)CL\A+:4+&HB0*<8IIM*)M:<^ID3[514Z->@O7,\998&3&H6W-,"E&3%J;
M@U-4R>8(FC9'^/LL 37D E.F1DJ-I2Z:\\GHBP998]4WH=T9$K.PS2DF'1..
M*&H:<-1T-4")EDC+*F&%;]2PT';,WO?"3S=N^AK#-7##9(Y^3P79=3IM7*G.
M*^A>#+Y >#' C"5X6J[5K/+19Z1-+D)U+EC@Y&C_G.9#()EWU-(@0G/?*W'5
M7P2-DTTH^(Z4X.0+K&BM# "JMK7]P)^7T^W<3TVL@>\Q* 1#MO$1RAF'.<!T
MC%:-F^&8]>QDA$DZ/6BT:FLJB>R?&HX+.XT'#K]ZO22SIWV2V2TFF>WM[O99
M9KU ^5J,%N#98/ON/]>04DDF_6JHSD8;VF7#C]3AZ-(Y+\"BK\/? X>_M['W
M\);9>W U]N[J44T_+V_CP2K&8G/G.#M>Z8;*M"'DM5DC\3SD>4D!L]@"C#92
MYF%*MG'Y(UC!CU&C'.<4@R#'D&GHI ,"*,$=;5(?T"6P72M']SB"T6 XHYRR
M7GY%;<+),>C6)O#(80Q>$_F8EM8!9%Q"W35@VE%UC8-WR<;[%N\"K84,%<??
MX+A<91U$D8_=/R $#+X[SN<(PS8*"'"D$.^8[P&FNG/=N3M%R [3O*E538_<
MC,@6W9[#^"X54?0A<,,0^M)*%;\A"FJ/)R,^=H=$V&G*(C@]I2'U#UY2I[0R
MA\N"@4.;>:8RG:,1Z!P-@B-R7N <A>_%X-A$!\X1WAI;RGXOWIN;TZ^&YD2&
M5P9PV-BE&$8<H,3XZ/"IZRQOR^_,QDT?(X4-!>J:)KI3 D78EQ'*T::>=JD&
M%GRMA7T-#>P*.E=P/9/ZJIJ51&Q$C^H.83F3"30T7&,R$@SS]8IF%?G9R3%7
M'3BB_7L12QO+ /DP@K=2@=%SP,V8OG7^7PKA$+5AA&,:+]D,J,<V+JM?<&/]
M\^2!;\6=B +4>^%A4*KG-)8)%<.%3Q%6'F8682,E91[#H#!#\24+G9=+*4"%
M@E_'+LB0X,_IY$&39&7PAVW6AI-%X&($..#>C#'NY.HQT%AC9DZ>!E4M,S.V
M$?"Y12_J@]KW/?T6?4#;CYY$<9A7U"JGJ-"C7. %T)""C<!/U,"F1M*!^U8B
M4)I.LKO(B\\V$<[>%QI-RW=*K2O-16M7->!*@-#%E_1#;?DRXO'00AT3=P(S
MO"@7XI,H#? L2>/$;EBJII+8(:I47BR]'>NI^Q[K5#MX-.E-7I5F(]C8K#@=
M>!X,<DJ4)CE2%T6U.O'(?])6$>%G%Y%W$_.23 K9'_5XRC>'$H/<\3'O;57^
M6!)GSNJVD^!>DP&JBA:?:"9I\VV92FY>7/,SE\O.GN8WH/!S3OB899=SN5&<
M-S30@P[K=1J3M'I>@68;&%:/AH\?[3UF\S'X7L&L-M8J:7C,X,54]>;(_8JH
M#M&@6Q&T&1HSZL<"8J@2V*#"N 9$"<,F3XGJO/LB!I7N#(:R@>6"3F\2G\(5
M+:48@8;!E'$%BO903#0&N!V^,_^#LI E\J)^W-ICO80J*VX;!ANVP,3];/H_
M?]O]&_T,+XSTSS*1BV1<S?##NS_P2-=9[V79 55Q_9T\1Z-M%*<Z'P&&^-M/
MP3^K\?4_)6LSJ1O5^*=O^\[^C1_DBV>'+^Q)?MT$;W)&V&,-FS!1FE-XC?_C
M>RG%]'RW_2[E3:L+S!ED$:@>2&:@8]M/$E $!'G^.K-HM]6:1JA31NKO_3^J
M O^#]^>&60+_=W (!-3@#CNW058]?^CYPX;QA[RK(F?]!5WOZ(DLS[G6;#S_
M$+E3L:RGP7^XD=S8N)L6-6@HW >.G:'BA<1,!JE:)D7H6C.!#X%ZA9^1SH>)
M">:P5E5*:YV>4_6<JN=4=Z3)$)(M\06Z@PR4G.WX-U+<&@;:0+Q7:Y6<ZW&I
M!D-"1@2<9\<4GL.([1[JGEGTS*)G%G?$+)R&LTZ#+B?O5ASXB#^EHYT.+K(;
M#I)05']]^^O;7]_K7-_S1%U<]^Z2J3'WVQTUO10.LE-'E%<G+N22P5O6PWE"
M\ ]?8Q^=G1P3VD[/ 'H&T#. *\](:\37NG(@?'6)1E7$6<FM+W6S7A]=0>,7
M2?V(WRJB!;L_NKX[@FQ^G=&$&5A+;UJ#[Y EW,5:KE?0^:POZ+S5@LZ]OJ#S
M&XCY;FNACPSF(A<W=01=*3*4IP8.>B51A,.Q'-I-<(0$6*\QH)*"$]\$VE!0
M8DT:D]7?VC/AATO=WAS9-K6492>-;W&AY;8V+["LIU/%28'<@9TZMF.X>@3O
ML5>8.76WJYOA,ME'["7*Q&F9^R@<&)U'S])(C6NL+)1B"BH.D_[SV+E&DH&5
MUZ3S\"5G$6(N,6T8;$ FK7[H.YA>0TAC6$"3:$Q>HP?[:%>1K2)T%CU7()D$
MMJR2;\>3"3(S6@ 7*>AI-6 W6Z@@$!][6\$I9@>I2M(09+H=H- K<V]D(0EN
M"#VSY Y4['E/\G$R"BA#=($=K7&E>>DZ]7QZD0;:B-K4">#(8TEJD_DTX8>J
M+S'AX?E_DA;>A!]FS8@UH1.<@\R4<9,%)@*G5>4.N77G95$7C=+=-)V]'?AK
M#LMEB4UC-35(N(*"-GA-B=3\3>()^-4V+JD+4&EKF8R95L H:VX.[TH-C7_J
M)OW<E/"8^5Q&ALW=,0F4 1PU\16M,?J*FE8=:7-<71*3[B7O;0[/P^5)==(;
M$)[\!>99Q,W*TY:H$Z71F&1*XP5VV$176940J[>"59TW[E)Q30]!03;!RMF8
MCZ!*J&#)S&'P,'$_VFZ2R9-"7X#0,NSKI$[%TT<7&46?IDY+9, :L<\%4QF"
MP]0C\AX*BN]?R'$0W3>9QGQ U(B/D:D9[U$ F(A7Z!O2S,_:^L.@K,)_)C\=
M.6TI/JW0[4>YBQ]0*F##X^0GSCK<[L6OH<1&EXXU7 RO*I<@,.KW),&DORYV
M=5W35TN#I#"@YJ5N&6"@]9>$PQ!HL&U"_\286%FU2RB-(*V%->I;IE%A[$[X
M,K:E\3()7=A95,"HZ.T:XVKK (WRW#)5I2HK/-?@)JRPY*V_FMW4V5I>JT')
MFR>!1<$+!%D?)R4"QZFUZLYRE8;XNSX^.-(;:VA8 *=%M1; 'OCLYRR_R/"2
MS)*Y!O-UJGIQ2/5%5P,55B]<H4)' 1F$1RWS-'8.H=O++R7UA)\.I/"/18$[
M@@"::Z76(F^TC(,QI4P9)<@V&RCT9W2B[3 ?+^U-)5U4)K+2IL#Y(\,B/_T!
M/S@%.YM$H+UTD04FP0=T;R4R+PJ/-=@S,Y4BE(YCB["#=@Q<T8P:WV:@>*>W
M3\O>H 9+&38E2&4@.FX+Y.P6$ .\-$L6M&A&=4FRX.J':^-]C3,QO08FC"4]
M=^. PJ^XV6EL6F%1 R2M!\I' _>CJY]H&HH.1C5WXD(K8Q:GD_8Y.6<B<^%)
M4"/T1.C .>T CR[+6W=$[$I45QXHMSM%NX<+5GP8YR:;XY3[H'67XE P9JP-
MX-[]B&QMS8M<IL *9ZEWVKQL'1+:2T(P"G,"%>+4%C:W^744M6GR&:^#QM*.
M'5X)1(_\*&NUL BTO(I)WT1/ 5AM%=%;FL1:"8U"-U^E'330L[NTY>-M@M-1
MK3F)+E^ ).9(MX1Q@L"CZ-^8@QW$?1/TQ ;!$>PMER"U;' \QE1!(YF:X^O#
M]%ISN U7.KQ!#_-.&%5]DA2ZXUO+F36<8,VN+MW;MD(J<-<Z+T_X2"Y/U'E[
MX+R"J]P@/-?&+0J=6W0S-RAHO4&/K<QL9RPMFO5MV&)W3$A6X),F9]K(- 3>
M#+>\;#,OF+MZFAIM8E*:#@!H#%5X6K;W8P?9Z9KS%F-%%!$X_D?,I@*6"DU9
MW#$7LG76$/%CS5-,4\R*>94S;2O=N4<F2=U -W]:Z;7I+6M](2?Y7RV06Z3I
M^S*)'YZZ33ZO6#3:Z06^=%37));-\6\[Z"]P1*M=2_$ ';P+_-Y8I<E0MV]8
M,]4.9[6[64T2:,J80!J<*LT?7'.S4&0></$VU[C%V-K"-7'-\\TPP@/@ ,?B
MJ133$-NH$B?02_:Q#F'7EP%;VU[]0+[&X]D=TF]]Q[+A3I=#EZ)'7A3Y9EP4
M6++,\_8[IIC$8TDR1C+C,(H.S70._4#UB6L&Z _[ /VM!NCW^P#]9MP6@X-H
MHF .4N5#=7Z?KM:*K4487.W#<3,(@U^-X1_<*,)@%[COY0B#02O"X,,D&@-(
M?350MJ ;E*VK&4(7--M%[@%G8U=6#6:6B!]X-=58(GL!J\OL^I&COAP8A]"4
MNV99%P4;UPPRI=-*&'TM/T]*K>\VQPF:XXAO&(DR[PQ]/%!R^B37L)L.: \]
MQ*<H:")44R.VH[3()<&&,<?*-46R;E<\;_R)Y"[Y;$1ZA0))>#,)UH)+M:]K
M<PZR\8UKI!I3&+E=7 I,S4,.&K?(S369>F6PEAPPJ<4+G;+9R^V;RQ_O>P<W
ML8[@TNJ ]3G_C4Q^DW_/3_U$K9"D@&U-^'3E1!=@OXR6R#^NE:W>SF<B]E2@
MNH+1(G1A62Q/R@EH]B<V$4V3<7:=672V;K[:;D0F'ZJY+=>:A6PAQZ!C3/Y7
MF?7]E[.\3O&7I.MEMO\Y]JM0A=/!&;,-7MY):O]>6_IP?Z&^YD+5BS%G?N4W
M0421F ^8=X)?A/]EU4 GBU**)?:91>V*1NDI9H,H9JQ&&&TT;,7/-C:./8E>
MT,&ZCKT;8,',ADS_X$:26+LPEVK#GHPVE8R:)V<(B?XR2]0$FP&,:LG4(4JX
M7O49N[2IZ8Z3Q^ V6NS0'"*3%\SM"%"\D6#_FFH\"?AZV85#-8KK4M+D#3U?
MD%"%Y]C7(K%32JNG2ORVG;EF82#MXF!#K\7MF0B2&J^/G&R!<,[X2H[#K"ZZ
MND=A,(VB4//XL[(R5-QS\-D.SYH?!(DOY >GM"5$K@:G/"WBA^M:N&:LXWD?
MZ[C56,=!'^O8C-O2ZK_Y0#+HP?MM)+ED38%EK+&EQ)SFMCZ2,-%F\%^>FQ;&
MDXJJT4<J.>?<P[')F=%LNLG>I4*IPX>X6GO5-C4G6WQ5@S4)OWZRCJLRT##>
M=B2Z B\N38,%RJ)NS:* '7&R93@Q8^(GATE6L$G&X00.VJ1&)I$[L0!TQE3L
M?TZFEKHN)YTMLEABI,FK!%5 :FK)9$<OFMEY.<?-#!^<NAR):1ROIX(I4QCD
MP+S3M94=WB_P+;^OYI62<;IT1YH%SG*L*R[TSCUR<KB'I< [EH_1A80--WDK
MR*;**Q@CJS&E"(?B-<?3.,G*2H<U8).Q I"\E2L*IM%M, 5PE)*R:79[G*M2
M>M.'^S\X&XLSHU1UDWMK<L.E11=6VF!WCZ08U?.R0J]K&77=-5*:^$H&7?<"
MCGF!17]$B52#YT0 O269/,-,*W.ZQK++F\LE/)F=7N!-CPV22']X&)<)$1;8
M"G&") ULK+;]1IES8,I.S?7)=![=)@3G2Z\AF$ _N78/.JY=Y"1(#YE"=;*N
M7S3Z0#7*7_(+=,9&F+MO_*W:=XK5S^(VY3I",):XS#X0"X Y:<3UZ&6'.,'(
MZ/C<+P3N\,TB@>@ ?+=#VG2<RBEOKBX#-]PH-0_R172GKIN<E$EFZ$ #'E#-
M2ANE1^^=2P-H;V)[6B-1K;# "])Y.:D 0,WQ*H1 Q,D8-E;CZSM[=%D QL]G
M:^0I< DOF-L!F-LTB+B2=?_8IG?=+%"#XZ]=X0,E_Y58K1P':4A#8F9>K^9
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M?0_VOO_0I-/HY0"\H7_!.$[;E1B_2F[A4U+!@?P,YZ=.*+Q?2W/@DX'I?G5
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MT>N]5T=[>WOW?J\]RE(P17:B+. ,]_L!2?NA,;:1\IKCVR^O.64#ZD??9$8
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MN,@2&T("*KVR$I[O0IK^@OA**"$)SW5;THTO!1_TN[_R=ZU.L')!1HE[))R
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M+03BCL%J?9ZG"#@R89)W__A(24"G:2/8%'!<+E@448E%6'Z3QA[$,Z'@&AX
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M<)LA^/MHGBM0"<Y31B-'3AF,([)-3#G2SMMG23:.QGRK$&Q,7D&;A@F(&C\
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MH"X*LL1Z=E$L3=U0KHL'[B^Y!1 KO(KL;C>5*QU&WZF(G5S@B^FLN(@DO]'
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MOKO2E%<)C0O([B_)6TA2HGU @EIYS5QT1=@HZCF1R(L34E2X[-VVG\V>H6W
MDH4!$IN^H=>"OL@D)@Q^-"IA(C^I1_-:&RC(FTW_3&[091 ])XY%E:-T/,>'
MG<UA2#GH*^F=R%X3!O<S\)2Z42K..PRG<.Y\#*!8%1J-K]O5QDY//Q:9O-X)
M&N(MOOZ05WH;]G=Y.F';L&LM+JM6ONELWPS,1R'DP-ZC#?JX]36-X&NN@6P;
M__=N(N"_INCT15XU=_39RQQO,A1^IT7LK3/P2Q']7%YP7^X#;<OM#)*%5N8P
MH+V-\=W?<_!Z!Q7[[?3DUY.W<<"EQ- HKSKDE)HK?%*LV<D91JJI+P,WMOT%
M5"T-ZDA'Q6U:&MO29A';-[VM!M''#)Z4YM'_G?\GCGSL,R<@!<_//1V\06KO
M,?D<_SIB5LGZL:=WKM[SPVOO.3D#X#C8!A^\ULQ"CQ_X^/;W=S]>L?LG^.EU
M=E];Q1O-5/KCQ+?3VQY]'N[JC7K1LU%QD"O'O9*4\NJUU\6F]?N4$R0R^BC@
M 5[_D_D9NHJO[=FKU9KPSJ$;QO^7#JLDVBG*R^@+_*<P\/F?DZ+\&IU\V.4S
M]@F\ND6>HQ#]LQD/8FZ!*%%[@N+B*.A!%H>$WDVST./YN A$KNRB^>R']\2@
M!U977@OX79#8F%;43<*$>-@B/'HQ\/MZFS(X%*Y/^-\RC(WS*7D+SFQ>SI0H
MK_7Y(%"]Z8O\;J-O:X_7MYG0N%INCI$/\6<\L[<8#49I^'J:3C,XT>9#T:1G
M%1W$S^GHO"CS\@Q.V8=B-,!4Q!S[B,R)@LN>Y:=I.M^>'OV8+/C5!\>DT_8H
MX$9A?N5+3:QU:Y8L,GL\[S]\_N"WJ0^4:^)N,OP<_\PUB?:9Z.\EHR_@+7H9
M_52R]]F,]>4E7+SX7;\6)_80 ^5X/K($K"5"KJQ*QZMXBN"<.JTNLE$(0DB0
MG"^;8M89[+=X;V]/-/7IHB:O#MO,8,206-AH"(99TH@3E"8EL%'%4&+&@%HD
M2H0$7,V,KR2**&+K,)E K5E">4R>1_.:IXA$GA57<M9SK&K#-H!9P9$MR8\;
M)084))J_2066P@RB4UO<@%5KVA6X1A9Q5]=0D;4'3Z9AH#O:NZZZ?(/H4X7_
MJRA.8S]EJWUPF2QX2W&*-@SQ6G!A >9HDE7PI_3KC MST-.FL"U>P -O@89I
MD(RFP5N&1(Q%=&IM$P^E2FN9I15U*6-SS2_5ME$..V:2.8H4$A6RA/FP&6Y2
M9X(!I,%1+)DSW000X<EI:!$-$VH.B[!UE=#:C9MA$5)-)V.L9=JV4Z;=L=;7
M&+2#7RNK1K=3;1XC@ $)Y A<PLX/GVL/5E"U E,EY(=WA+V4MDO*<_K?ESV*
M!R;85]05"1L1+T%K>"K$TCA+70I+%8X(CUT/KT"@5P0P ],KTDM"<DZX"@:I
M%-"*LNI(RVJT7QZ5%359'L)8L66P99'4)GFTC1*ASZB"BU+N(!$(]2>>3V1'
M)FD3X1:C362<&Q&WYFZ4K'&1"F$CM8J=$FRCO4Z"U>&(N79##OL;(ZL=9BT9
M)\+300R LC19L8GX4_S+H$C#:10/ *M5 L$Z>0^FJ&!2?*GFLV:T8/:]&I'U
M2 '81>H/[@@$\+CNY&N"" ZV((*-@@A>;D$$C_:TW9KK0K[P[TE%O?FLU?O$
M.T^=<- J 5,C.N1PTT$L91B7^!_*AGI)OTM>(&O+AN#9]&M:C;(:;^8_8U85
M;ASY@N8C;1K6!F\DLL8,Q%R%*HP)5,8BZ:.3Y_],AG5T,K[(:O#KS7\ET]GW
M(/L%67X<5.$1N6Q2B;82@UC/B("AP((1LEFL;^ 7^Q_MD4?0 3&K72FS(WPG
M7<3F3_NOR&6@3WX?UK>W)@XO.OU'=(HF91J=3&%B<*.*6[N#\0RR,RF A-$A
M^.SG-,<JV.CSQ\_P,03[D6V E/"#77_@YB ^.#Z(7[PXO,;8HS\=[ U>O73#
MCWLPDU$7(O@2O?!_P;7?1M&87X7R^A.9#'[^0,(R/PZB*S]#'\"?L>TN-HB
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MN#&E]E;\NEIQM^8.H^;I+[@-V4AJ?)*H;\K2;B0BV "Q82G/,=)8QH8=J9)
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MF:<C;=0N2]/KY;46<X<?JE\&EQ77%N9)[>U0Z8UP<\>[L;$:G!=BDN$J6!<
M-$K,EW'2^&WKB'X)6Q4(Y87# ^5>,^%VW:#P-/F8T2IMYE5A7,"1[!C,"Q#C
M]F,1\<=U('_O,C&L&03<1@DVA'Y]L46_;A3]^GJ+?GV0I^WAA]Q?;D/N=Q +
M$1*Q)'<X@KH?2-!%$( ))O%WVB\_[OZR)^[N_<ZAL-K15[9(,'4+BH7,+#$P
M;?L9K-/JLS)#QMQA"HY)K)'#S-&EZ>0$MJ76KC<&"PLPRPS0[0V\R3A]KYQ0
M%#J!]_E28*O-DB:K&3#1$[A%9)I *@((B8N1+),M]5\D>5^EV(JA^%>YN#I
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M&2<5%,:MZI/OO(1.#'JMD;SY-./87JS3"PB*K J/G;U&=0<^UN"Q U0?I.)
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M .FL$) QRY.U;)('G\?;D-!Y,K6N2MP*WJH7C4KI^7VQENVQE;NMW-W*BR3
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M(9U F;<N2+B,RS-$79 ;A3VX<PR#N%AJ4+)X-4R5^@46&B!*T>]2O<NP:<I
M#-/F$BGIO5@2,B@Q^ ->;?CS[F4:O&WA!JD)HVU]A,>18R'( 8[*JI?67"8:
MT42[QH;O5AK]6$)A'^O#1FOYL)J9Y,X/?=[A1#.:5*&!*4[N-=KQ!0)OKMU6
M4N8E5X%358F="\VA:]EX=S[<9(BFP46C];%N@#<C8X6E[V'=2[O/(!O*$]EF
MBR8)@G_X>L%'THA"\\/M,\_,7'U[)CJ5GC%Q&Q^RU.QL6XZ';1*RS(?&8)M9
MSPSBI@Y7?Q;/"/[+VP*P=OTFB%Z4U?4Q-&K-M;W8B+S83UX)/IK=5*F0@:\'
M"]#7IB.&Z_TRI;X)63L"FJD%LV1-3#>PT#-/=+\ZQM":BT0PL"(P0W"))5PH
M$1^S0C:2*JNIY7%%_5W#R+4G&#=1?+ZQ8BT(TQV$31QUSZOW83%*Q:!IR6=]
M3AU!UG6)3=N$Z5T;W!AK2W:;+RRS:L) &'Z2!81?-J&&*B(?ZWH/NCZS$NUT
MXMJ?SI*1C5RM(\A;8^N:4(S76RC&1J$8+[90C#]@UOD3QYS,>]&W'QPUZ!MI
M9]]N7;=U93:A;D^,+='SLGRQM@3B3#3OB&2+T1/H2WBL%691(S1,2603(ZF4
MG6PW>GD4< N@9= ! M/PR"6@2'O-79;4YFM Y] O-+2IB>F*FD]'1R%[ =Z=
MQ%5@Y'7<L\YK5N<GU]NYY20"7ZZ"/V-7,K 0017L1N-YQ>VA=)B(_&DXMVR[
MW/-;R*@&LQ5=%PH 5:FQ'?$XD5.J^=&9T@ ;OG$YF:QQS"@%:O3&+] $!+/O
M-)+:1V>!/@AKX(6%_9TU^BYY$#[SK"S') ;.T9L7P[+\0B$K,'W(!J8E+$<9
M!:>9]82)?BSCB0<V0E,U=#2#0:!\A@,!\SW<5_=MMKDHG3\M$9\D9?Z($(C[
M6O7&454NDIS;U168K4$_8<>C!U!.Q+[/:2-@"=;))*41.@M'E^R%6Y0U81?A
MA#N3P8^,E=WE1!VG<&UGNA8&JKTLOZ?VB'J9@?*RX$[,U$VP(B:$QI*-L?A[
M.RR BM6?MV@0"DOS:OEU+C9#>4DP+EQZL$X;YA/!> '_1!V8<[!2F^@ 3CV1
MAQ!IB+Z'2$6V2:9-:/[?I44X)[,Y0\["$_<K> (O3AC18Q4B;_<499Q[49*_
MJCQA#$"DMI;H)\4N?(9W2JO5GLB4TUS;?5^Q[S\FM38UA_^7Y NYCEHK&=QM
M^#=>VF[J_1+!5I3N:?P;O8,]H/ZJT5MP-:=#./2'^S%V;]^G_I#GQ" 19,TE
MDWX&:JJ 6S$U$O,\!R\:LRDB3B!'<]8N;'C(A!AN0(,1[*J.2=%Q[;&AYFH/
M[B! 3UG)Y716D\%=-FG$ 1_ER%,ARL?A)3)J1P\"6W/:3A9,8GU+S:&E \5G
M4C9KCM,V_M]8C?=N39..S@LLM4%+(WP+S'*OE2+Z>>DV].7U\6EFG346 XY'
MWK+C)$:F45=?0U#)"RD<1<\X?</"JDH&]D2NW!C_1C! 7G_6/L\)"2C7/\;V
M%JQ^]"A00URVSIB4A'10[2FA7A74.CA&[]3W^7QD&V7*/2\@C5F5C=)EX7[.
M24YR=F=;<U]+8LK*8'$.><3A)M1V8>SQCH+C[6Q'-@J#:Q[DJ+;]1CW#=HB!
M(DU$R#'EF9J5,V7K))ORES(T2C]?M;PZ3HH$YS5A9KB1+P_D7+OBPC_ OLY&
M7\!8P*L*)XV/RC/XK;THHM\HA!82DUP2E <_7$D?7[:TG.49F-XM7P'^!\-G
MJ;:,O4CEJ)BUGN9;K=KF%B6>QG3IK3LW\$54*Y+ LDU.7A+;DAZ/#TXDJ[_@
M8@Y3C*'V2A&=*:^HBXUBFLI@>Y'>*JG'O,(SC5YD;+P#6?$9MVJ,A$,]A"[_
MCLWP4X@\[KUK&FG^C,=E= Z;FF)W;/+-10;XF<9S@IW/J\9][4LE5Y;/F:4O
M\4_IFBY>S$@"6\O("H\EC7) >?8%;K'SDAL:S&O6]'A!KZG^HF7J;VL8;JCZ
MZ:KKJ1VZT3@'2T"8%L-$5-U;V 3B1!7:K2PJ3.X+>M>FU12#LF$HGP20#?NY
M[\:=IW3SJEXNUF^ S2DI?&ZVRSM%9-Q?1S@VOQ+ .'OOB[T9 ^0NS]^]=)HF
MA!YK5100QD>6+ D7LH,&%B*?Z(P<>8Y%F'WTDO4NYUB36CQA60J]271.<UZE
MR^# 2!=!*<WZO,085F<Y;9(YA D;/:VMO96P!4;9W)*><1Y68 PW3B-^*+"[
M>L;Q28>:U*EZ\*U>\"2E!I=54# 0UD+EG91Q;BY$*%H4H8((DV%YD6Z5$@V6
M_SMPI?M6/7W#F,F\HTN%5!&=W"UOU9;2X2Y[CQ! %N\&$^AT4""DWS3PBN56
M(PJ]@B:!O5U$"-!<4ZU&2]3JEJ-G*^AW*>@,/31.EL7H"2-!D\@=BL#^B%?<
M[@D7<;8M2>LA]1P2TSHD,_AOI4.:9%7="E'YR8>EYNP.>B\>\2+81\_I#_@(
MN=AW7<I37F PGZ)GDSVL[=G<GLW[/IODB<NQ""*R7AX3\WF>B#O1[B\EQ0!]
MRB>+;6(X52E%Z.B2\C"_7-OM*H2I&CV98?:PRH@,F&\U>#"^>,NOOCTS=WUF
M--MO1F!.G?F @; HFKR]6;)@M#!><%1FQ.>DA8/ELQ)".M8ZAR8XAW?'@O5P
M?48!9=X1\]8#(/@ZW-NB2C>**CW:HDKO-[KQAX]Q7_JW3)LBP+199"1U%^;E
M"0KAOTYK2>$/HY2#N>P[!4,DZ^V*\>$CN9[%9!,<ZPC3-OC2:9HV-FQ<4Z._
MH(0&Q^ !,N(6/T@[-'Z><$D+(X2B):']V'1#^W&GGB6Y*#.P$(2&B&SA,?83
M3,4PM;QE'"1,SS G/41XP!>.N"M73PIS&9./JA%<'8A9@_. J]:&B\[^#*(/
M@E^Q*8NLIIDOR5)0_IW&TDA!7"V-%4VG>K#1S63K(T?,'#(L*9-#LLH+)OA(
MK\0G6B8S2;)*@0V,*" 4A(;O*=E-<_-6S_>. W9J%Z7U=I6CY-&)!=OX3[*2
M@#73V&::^XH(^Y,1D$@_+@U]FR6IPKBWNK"]R5X5M]VYRX2WSL<.&9_0Q55U
MRDIV*S$#W%&+Z'7Y$G5I8F 31'1[(I JPB%OT]P2@;OM0^.3X58KDR\]*^;7
M<(TQD8/*!D9I^K:0*[3@8"Z6E&DMR= 0CU!3P=Z#QER'+3!1Y@+#V7(NK<)]
M"/K+P.NL!N@;;]32@,L07?C@4$98*FLMA<\)W>9IK;M.5-\1I>UCN809:$0E
MK\,Z&V?X%\8C$YHLK\M>"$W<O7@Y>;@6K%JJMGN@S,)[Y3'O/&^R5*!W..FP
M0TP?6*260PA:M";(.!Z-GO$*%H-P4HE7<LA:=Y)6E51)<_DV.\<1.\>FK8[@
M>&AUQCYQ7XFFB9:DRTG9$+R$%0N3!H(B+"O;')C18/)>1/KUK0F6:QSL=I2J
M/+5>\MANWK@'4-,O%7:;G22:54#('A#D*JZF]9E/NSMOO/M"KH3.^+<9Z(U4
M2"$Q'Z*;E<[&9A[ *3PK<<L$N16J)=@WN;39JB(1H7H&O;$9SS)A\"73O3ES
M H\PX4W:1K-Q)DJ?O\ 5$VB))CW@&JH46OJ 7D?&<R=:] L6-R-5-U$W.4):
MAZ)B(=I% #5+[P"76.*">ZP^4XZ9MJ%J^FT6-M/%)4%^/.6T#PZQYF9[N#(4
MC-YWJSB "]>&8Z$2$E7H1W.N5^.I*Z&2/_^ET^L?2-_\[-B]%3$6#-P[]#66
MA*F.Q-+7NC/:>*(_D@SWI<L)"FN4#I^S$[,JO<C*>>U*L@BCHP!@=WGI]Y8X
MAFQXKD]NXJ^3"9 _0W]ID?1A0B0+J$@=4I*VC0=FZ1!6CF[),5M^9J\&*A$W
MR-7F:/=@BI\AWCKO#RH0JO5+1B/:F*;-\]*^[16>!NLBZ5;_L.([^D:S]DKX
M+K\Z)QWSQ:-3^3:^'6&-07*,?FUC'&:Z9=VU])B:DHX;9\GG\0/>&7*?U^/3
M\R6F%NH]3P4LF9B4MW:FMF;"!LP$T%-+@:N9YR(Z%KDEUH$EWG4M8JBSN@)"
MF<RC$D91J0&++(^O@7OE/"%XN!X6?H.0A+.Y@8?#9;[H[/6RA5Q%][J"XY7H
MC(61)13[S@SZG)_66HK;\_MYEE/]!!8WC+(9]SA;P1QK?&)67J0%CH$J*#HC
MB8/B-4OFQ&53=+UD:JJSQEOB7)+W(]$!OYK2M-3W,H$AA4'X><?B8P6H;;6%
MSB4;@6Y,EK/);8#!Q@H4P>RR,@Z(=X$C:8ZW417S2'=S>3"K/3J?-[[MX 75
M2]K1"$:88\DZKCPRH<$U4@1WF%<_'%UDG0N&;_G_G[VW[TX;R?:%_]>GT/&<
MG)O,$@[OMI/NK$5LG.:,@SV&=,_<9SVKEX#"UD1(C"3\,I_^UMY5)95 @ 02
M"*.SSJ03&Z2J7;OV^_YM#%;']L64Z+A2&.,0AU 0UW!"B$'+U-O\7.0 JB<<
M0T*;@#G"KH(8<:_S="H$=B9^70B@5.&,[@:@L>Q\?6>,91]\;E\88[T0-@E9
M>CB*SK^D/($"8EW.3T#S'/6K%J#9&;. 03JS1KY^H"+F[^UK3;:5;19Q?66W
MD'472;D;W!#]CAQM1W$A;7H"$[]XA$<)>HFHB)[H?G3')\/J20T\-13ZND7
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MW=W<QNQ(<I$M$*&W"<Y>#HVNFQ,QK,^#$U\8-1(1^;A#+L2I/$*AHC C54A
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M1(4H8/*Q&7U:!YP:R3^H\14JMB?TJB#J-AL9.O=B*N+.P^^%\23^'H/1<*,
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MGB'T8SE"(N,(PZBF-D<Z5O[ P&V1W@?U5C]QEBW+73HV-=A<C&_[C@UZ4>K
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M&.<'(S!R>7T/+7+1?R0*%$F!08[EP)&2 _.1EEWZA]J9Z _@]MUXHU-,MW-
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M(N*>2^JM7I5W&V/8938V>*SH2?4S%90H)3_!NSF0P3Y#*CD(E%R7-@J5O,%
MR7[\8?R#3>?CEO?R <J;>"D+BZ,O,"8/JFYZOYY0?]09_GIB3"@EZ,O/3O\U
M?3CYF$FP(LN( (J\F Z+,N^P9!6=R7;#?2;:O]JZ@[,H \P]\(5D@T6)'FQY
M>%L&+]7X<CLU+"RTLEDE790^4X &'%O%5!'SWC95FVI@Z>.,7R@YJ+?WY1"9
M8/&FP[AD%7N[='!J&90YXL5,J$Q^I7L-ST$=<'?,17=LZ0142DS(UX>0RM[#
MD[$3N_SYDCT>_U7Y_(&7L<TC+%;P03A+0!$@[ XQ<2&A586[<VS?M='@G\/
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M32?%&V^?L%?BT>-QN_<A-^0#KYWXH(B>4&Y?CGQ4D""NB6_CCD:0YV%OA(/
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M[EN!&H*9!6E3**4@IOW,C OV:\JW!GJ[",6)(FOF(#8GKW0));O6Q^=86!!
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MSA/+<$6YZ-RB5Z@0&4)!?N5BQRWD*VL^ZD5Y1T1Y1ZTH[T@/G2, -=L*GZ.
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MS7?9X(1D2,Y*72O7MH7%SXLV-NC68+3Z=#8PC2&5 F/B0/QP46;D6TR<;=H
M<CAB8I7IT6''>(>G>,L/<=5 G@NM5L_O:(>XA[XI'/?;4.*S*64K\D*<H<'R
MN$*COP6CFDOF-M_>JL:<YOK8[5N6 ?$IU:QMVV!Z.%; =I2J-#>!1\J'@N^L
M$!F>K9+)U+1?"7<" #XL^,F"1+&G6/_X%@1*S[.'/V_9?@0'K*ADK&FUC<#T
M<QO_R=5B#JA<2EPKO\7=MY%#]N_!YOIB&ULI-R0> \F65Q,?&\FRKQ6Z'5]3
M56<-*5G6./"U&&A^!UL9),257QLTY:EV=?"JC@6%WE)]T*[+@WPVBZY5F(N]
M:;48N"#')@UV71>4Z,BJ];)V<9%B._0Q'%H&-4&)#JU2T\Z;&9U9D78_+.<B
M5XO)54E0M]U7+W]K=;^UU4Y7Q0*A5O>*_:7]]Q^=WULW[6Z_AS^\;_?Z]YW+
M?IO]/F/29E?D"Z(%_@<EXT]4>%!3\=YOWL2N1FL4_H'TR3OJZ=FC1?2@H3D#
M\K9?AC@*ZU[W2!L'7,6I6JR?:>5*'N&W,U/+^SN#^7'6#:UQH.'B;31L7NA/
M=>!&C+\[;1Q+Y*;@GB62O6JKKWYM?^MTNU"]>7NM]G]KJ_]LM^[?MDU9VQ?'
MKQJP6M/.SE-$;CD&WZ!RD;^#!$F48LO'41SCWJRP%6-,]NWQI:1!ZIGKCS;]
M<0+-4=^$4>F7U)$]&YAD2SY=]J X;%K-'Y<VF]K9V7J[9SE3;"!K#O< WY#:
M/](3?#L*/\8!YL ?2:(X>C_N[F[:WZFJ:-W_4^UTKV_OO[?ZG=NN2O\_: Q3
MN[=]0%V[O?D=?(Z@EZSH&#NDQ62;EDQLM?RP$&<M605%ON5@W%* >NQ2@#>L
M-.(2:SE^U!$1*Y.^"'8#187XFD*)\PWPB?:N,3,06ZN*L#V;HZ[8SOJ"[(-D
MQ-AWZ1@OXL;]7L:2IJ2^W>'L](-RDRA4O1V+3J55R8WDX#-O^-3BZIKEB'^9
MBK:="*YKW7!4ZAK-(D47L" 9J3I@W5JN,4(@<\K@ (,[E> !PV.E#Y,;,ID8
M">3]':@[?XD[2-F6>RG3]=IV!.CB[7CMQ&&M45SG3:[S\H[T@E@+Q%K>!'\,
M9MWFTC$2)/RP628? E* CE]*=%TA),MEK5PIQ.0&-W\YJD)!K'EBG2_O+7]K
M)B)<>_H9 &4/2SUJ \XF#&2T$'Z)A=^E3]:0P&LQHG:L9&*O?J95+HIDU 87
M.?X8PH)8Y_'[_=Z^<1A'+A8N<PRA&&#Q<$/0"DG$.(YQ>8/>G.(ZG\?O12V(
M=9YJMBYG%M\]T*)DCTLS*JN8H%+M@:=3"P3E&.$%W>CI6N19&LUJ0N5WDHG3
M^>:&3"3</1G:#P#'!-+,GPYY Y1#RMMC2G>4<JT'2G/7"W\FUBSJPOS+/D&S
MDW/4RN?)2UB/]"0WSGGOXB0;,=#4CL%L;M$?PN9U<\Y0?C:\1YB:."5##Y+F
MNB5TCV\WZP\.(7$F3^6;A^/:&$612P)BI9JE/51B92(=@QL;\L3^H/?UGEW7
MOMVRF%LF\I<M<5-7!N>UZMEZ!*W#MZ<IV>C[73@1ZOD[Q-1A*NQ4AX%ZPE1^
M!9&'B:5'VZ0D=O_G+^?5RMEGG+;GO1XV6\:]PT5J-BM;-6#!V_$]8\ [X#]A
MNKSV[9[$?&UDNA57]TP[R\:>.=13B\OBF234/^(D65S$%T51^/.GXLG0(O!)
MK93I%OK&A+AJE_KL]_9$MS3V TWM$<<8?X8ANP\&?15\M!Q^^Y!*.N+0G;I3
M:IE)3RZYQG_()[4I'P]\ABYO*I;$5\3&]PZ):?+-_GI"O6CX-_W"4/P[\:J?
MC9'W"!\MOZ-F+CL]:N*:^M2E"Q-_.UFC$CQ[NJ@-^*.%)%^V>5CER9?W?_W@
M;UUBT#7?NH%,F?=(/U&A_[%G+J!N_NA1;J/K=MQ3^9'1)Y[2>>.?9XO*#2<)
M;G/L&3'BX$O_D?H$PZ$]H>]]A?"397L 6^H0\!X,^KD'!Z#+J:13J.;U'HE+
MT.N _E94PASOC'[(]>@/T&+YY>- WD1Z%^HD@C;_52JIUP8Q1Y_4._V!"I<>
M5?C$&@)[U,\_JY@?_*16U5*)?Q.YBGU9$CKL127*Q/2+53A$_A,A3IKPLW4]
MOR?2)A=I_EE-NG&VGG+$<I#UKTOR_L7./ZO]URG=<\NANFGX6>U2-<:HT[6!
M#&?RESZ*;R&!@+P^:9:1:N 0_6=I0*CNI,^=(M7EY38CE@LDE8DCG6O _DM?
M+J\7]A$<9HJL-?#7,8C@,_Q#5XT1?85A_5DN-X$;]2]97]%NJWM;^H?:^=[Z
M!FUB-_VKT^@%9K:"553)YJ7=VWZ[I_9OL9>:#U5KW:B]?JN/?76]G.R>66_=
MV80^<+@0W&8932C"HO;EGUW=FSG$CXY1&5H:EO^$S_Q9.5$)-12G(#.<&5D
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ME:!OWMIF'')9(Q@X[MF#'[AS$#\6-CE._>M=\VO:O^I/?PXQ?!KCGSMF(&F
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M_97M ##2L$,>'176PM^EP3SG3$"&ESRI,M88RBWJ>@]C8DT0E<]ZCP4QFHA
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MRE M< .+CGCX2$,14S)O+5=  5-F(\%.E%F1N;-88)G-+(/1G)1I)1B,5)4
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M#^C$_<G2Z&<ECTF69GX0^'"2+1$0%!<FB)OU+ VM2,.P66GX+<<J0%$@RX#
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M\0_ZV?GD#EZ4^^B#JNI@''8Y!\VOI@@.-+->3V?"@Q]MPL,?9\)?_<ARCZ8
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M)/J@ IF\'>#&@DE7<'X*:=8W\]%GQ4,='VNHP[Q65HU8]3@=K=>+!9+I+>(
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MNZ9F6<NO.Z&YAM>ASSXWX4DS/\1:@)D;HPQ@ 7T0PS"P.@!'U36_+N$KJ1'
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MC[UO6VX;21)]YU?4\79OV!L4EP#O=H<C:%GJT8PM:27U],[3!D0618Q)@ .
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MA@?%Q]K]>W'>:KP]Y?@-J9]YJ8TWLOZ%X_X>47^UP[P_RIYHFU>.Y]>M5::
M\OFB@^0UBN=7HT>FKNT.M8CLGT233.V0U73"'!83^1MAFGA\^GA\1D^<G\H?
MC@F-"%:H[Z.XP/>>X^9=6Q\_UZ\]DM_,FJ7B M7Y4-X;I IB-_'J4XM6'C9>
M?;XUV$@58'6<O*]2-JPJ+$]9$D(+WS[#-TWSHWUW3W:SV'.PP^_A>!Q?I'\D
M[BM\#4QN9 VD>)%U]-[!Y%?B&E,P]K6(2]B?5DM;YJL&*+,QEIAI)H-NTV]X
MD*N=A3AR?(MU79L.DPL"<7.BI[#J='-%>1R0*VV&T_KH5\K_>Z7=X)#T'?/M
M$!AE"(][3?/B 7R7@JC5[Y>RJJ_H3%[%LG<I9TU+@_CM;7GR/$U&YMAICAJ!
M^@9BZTW:Y6 Q\C_9PW X-VXH>\(9OFN%#]_=#=YMXN8'BIM7+$@NK'60?6;.
MF4EG'^=;XY4J1G1XUN&T*6>T.X?/W.TSH ?ECM0/F@<UCWL+L=@K%8O#46%8
M;$+950'F #Y\ EH%%,9<-6?8'T6 2VD%T58I8(H-N.;5,D=/*_1SI/OV).%7
MFPWO@ MOJ3'S3H8_DSV.\V9KT'>?!YU1?!PTB(-?*Y-D.";JQO%1RE#4';1&
M.-5V:7?/?)+I1J-FNI%HNM'PE*8;%3>#Q@-%,]>HF6M4X[E&H>*VA"AMRB5J
MT@&VJ(7V6$36<>P-!:AJ*T4J9(]RKO$(OL7M7+*+(5[KW;=04'RY5U!\N6IA
MXY3G2A<V?@.'%>T?$)1=Y\9$TH/%.,@'"<:.Q\)P%O"%7*V08'%E0(D$JC/"
MX>N6XGROAQ<]H@1E&)_^/\IL>D;'7F5"%V729VG0B%KE43^^./SHD<1]PO7K
M1CA[8WERJEWJ6R.B5$,^(-5R+'H 4@V<W8C@BR] &]6_O,\38,!,RYGZ\VRI
MSN<4/L+_>[8 BIQ)W?Z[SV>V<5R_JKNPPKG]%39UN8%I16=4F=1DD+>N_""W
M#X_ZD:CKS=9B8VO@]M%3W[-2&FO\H3FI*3J_^#F#CT[9(+^HA;$EU4:7*PB$
M!96W/#)!GC%*+1Q/>+IUF9GUO8TT%MF_6?C8Z3A5L_O9DI2EDP>+]B4>C/&5
M+JAAT/D=?:;P2W,W;%I4&!D^ "/!<PJ(!NZBK&/"-OI*G\C7B\N+N[N+K^3N
MXN\7UW]<N"'N4FMDLU;$IL&W,S\^'8T.$G-=Z*N5_H(V#8\!&M2WFYG/0L()
MK:VY#3Q\A$%O+RNGY'4WV=H)D9&>U"88-2HF*!MUF0N=<I.&0+T,1,TW77[O
M35]>IX:!Y$$[37Q-3S*N6YGZ4H<>/$9H4^6P!:?I[)K/=OT\4:S 5>UF\V)^
M2>+ )'83!Z%N8O$^Q"G4,A4?TG6Z9\@<)+RE,P'_N#55#:Q\N$SK1U7CDSUK
M%_?M)K=6W1:B+7W004M^L1%P[CF_:[-V@WLG"USG>A#O^)Q/<%4ULJ_D3]M#
M[F;DCWV5S\)#X0PAC>+;R2OD_9Z"8$SHRT?H0XF\_Z_8"4LE>/(!A5JN$Q_'
M]6CBJC__;_Q_J*%C#-+P&S <UJ*9,H&?D6A19/*BD'0.1TJ#OM#*Q;V%41%W
M$)XB0F0KJ/ZZ'1E<TW=AVI'_64R4R7 T22 ]KOAF$9/\4EJH=(^$N^$$$9NI
MI6#*RBTP@,_"?2<K'7URW L><+S!&4>S#*P1\&Q>6?AD] FM,XWI039KUC>-
MUB0*JYX*R+@.EUKL(OE"826&OO:JZZ7"(F!W?,SNK6)8KVZL.EWP*_H1A<:]
M)@3+"^\NODT?+KZ2V^G=P]7%_<=JQ[P28M@)=R4F2.F1KJF/_5N<_:5)FWCN
M$5RO&:K:.5&(#3EAH!,7=K20%<U>6X1/C)8JTL0G5@;I!I1[D/=@*)K)WP N
MR:6AKQ]T[]]=23,,FIZ=<5#4K-75"O[1)B]+=;;<C_DM%-7893?P-^92@0^
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M[ZU0\?DP;Z+GJ#)=+(%F);N3130!JD:G< _1K68_TJB$?B2G%2E'$U+QDY@
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MM_N!I6/0&>!ZU-4WP)=8 &V?N&6_ 'TSS?(H'WP-5Q>ZYUWPS!FK2D=;](-
M/SDE\/S@:_)+?]!UW_T$5  4(1LY"HK18Z&BO&NQ<FB5/]+#H:JY$P-NMA*_
MBP!C H]]VS[J;ID,J"#5WLV"_ R_GQO*"\/I_)DMK'%/JCFE]0!VRX7*0;VN
M;4W?FAZF.['J"&O@R?O92GG!^0@?'(.#?0/!!OU* "J-SC\%B;RG^V=;TP(A
M@SMRF'9ON=J=;[WC#JM*5NP,Z!^C_)]1P:WUB@+.YJJ&BQ/Y'RYN'#7-6P<,
MCVZ 3W',@$:? :<9+85@)1&*XL4674%D&N^V8R3THPZ/>_^"X0N\%@JJ3SRA
MPCH.6&T8 ($]"PB+XNT[8*3&53[P* QVH-(08*KUQ/@&NQK8D!]FA3G;@GK=
M;KO;[9(;9\G0/5\R]!Z/:TN<&_X]-WIB*WE\.MAX^&1FF6!;QS/*.H\!UQ]S
M2P;KG%IL]R (%0=&+S$9QW+1X%LKA#+,?K]-CD?J92>1%&4M !>LP)I<[:[F
MBDF$>=LQ=EEMGF7S^@I,;KQD-JJ\?''/,0Q:379$DL-// 1!'I2?-@(UC+,,
M1K)T)DV&$@>?_H1[KYI[2Y7L0[7<0_TB]SKCOG==D[O#BGV/X=ATSMSKGH%A
M3!0L&7RB80:+]_MP@NOI_=?I_[3]M>ISGK>W]U+!G76>=7$C-.YWC2ZO7M]#
MI*0[Y'Z+#3R\3V -\#Y2WHS@D!GNTR.N?V*"66G-%'.YPLB4BS.[3--<?]HS
MHD%JK7B+G4*&-I/9\#J5EK:%CN?9&>,\B#/B?L6^E^-8YHXGLO--0% :IL6;
M3N"!'H2\IS]G<'(&BGUASI6M&VQ$AI_SY@2G;T)L0+AAR!G>2TWG5'(@<2Z*
M@8T#H$P^? IVEQ98X9?-T2_/*$W982B-CQ]/RCZI#PSAGSS[[1F:%]/3'/(H
MN9_P4;'S^I:AL_Y"OI7I+4[Y_]1?_E_V),!!3--X/I9/Q;F30NOYKS1?SD!J
M[Q9OVJF%_=XNWWI"((#Q&E+M3RY!B,W)WQ3+_ '*:M]MN)E9.JM[<_H('!/'
M^S7;U#%Q01*'(J2D'X6V%TH&P#/X_6"]$TLQ?YCD"3ZO,9L(0S!HU/[0]!<P
M$)\0NI\;O( F'WS"?E(I4]8 K:V84+1R<X:G/P"_9Y9^AO^U]55K7[^&!M9
M5\&[.&"H@E5/+Q]?QNR,)+;M.$-?46\M.(FJ!6_Y3*0@0ATMR[!DYQ^8[XG:
MV V\I2@(2U=6^(>%S*U2\X:WT6I/=DG]K:%C"RF&:NR+;@H+#_E&#E'9(5I'
MX+&A6_:D@,EM<;_S68=G^5HV3!<3*W6M<D2W<$,G?MOD&W=?T8B@VERQ*^_:
M>^8U^Z1S'UR3Q0Z]^OHSVQ%$0)N&Y1H! TP>M.R-8/@:(.S=_1^F:W<"7,P%
M< '#,DN+%:3Z>B[A[[/MRG&F0>JH#.KWZ@=BO>B\A82'M?;?;C>#,L.FQ1C"
M?@7C/BQ2,FT#[;V*3W,V]X* ^4&MW0)?0$Y@,ZEW/Z]E* RD.;?MO&_JD"G@
MQP*C&3%A%U29+0=KH%,U=N.\.-V/H=IWUA]4D/K,JG/,P!<#6]HUQPX,1!V$
MS<2M0-JO@(:9')<)^U;QP@2Z4@(71AH*=C+;(N )I(CK.S"></SW^!+,/*6A
MMW8P_E(WX/+/*)V;.-3Z*P6O2[5NM&^ZHD5$F$<1M9G"H^%E:FUTP_&N&0NY
M#+&@U.PD":L6IX #]4W)BC%'W:884U2,.3FE8LS:5&,V9935*:-D_]N/W"0;
M/2'<[X#CPO6OJCE;Z1CD%/@CT2/%0[Y>@ ^S*^"4NN[XPF\WP&4/%W??X5_3
M:^*2O2!*8P(#OW^VC][]4$OR'!SS_>*17&[DQC9TO,-4T*SA0VG^!J)0<9)<
M+7N<3V1R3>[[; #<+/,1#$JTH0*%6KKV]  V&F( _^O9TN,@TZZY0DM@W\-4
M.' :^:)H/_:L\UVT'O_H&M ^5Y:L=.8>[$TKB<E&R_YL]"!=99KGP*YA,PPT
M$'<$IMH:[%^L%FBAI<L@?V28V26R5$8D='K@_XC!*_Q(SPFQ_^WF[NK+S1TS
MZ=(<,=D)62)UR@"YLN' ,4&10X Z4E\PXN978D<#6)F ?22W;(,UZV]9O%IQ
MRB P2::RT4S,]=T .\_4#6+$9)]U JN:NV29X0^] ^XX/"*/[!JCR +^SAPP
M/HK(\5SV_7O%-*D5:3$6*=4',M^M5(QDYR.]&$[!?3AG?WL":PG\\AP"/]U3
MB]4#$CDCYS??OU\]<#T[O?X*/U\_@.EQ 4KXXA[U03%+M</ID5T5%$(>IU<\
M,W7+U3273N2,.63PWS;Q5L1QKQUS9BT,VJR>><C#">2ME!=SRR:AP45>@6>W
MPHP,>HW84FN+?/BLZ=YX-P)AYY,QH;HU58V:9H?\17_!D1IM@M$HNP)--;W9
M0U5#,:19K:UF#PSAX]K8L#R6ZZ;X5!!0VY5EOQ/?8A"=!1) 9EH80\5S<;@6
M^PB KR@\7 &29LW")BZ$%4C9'(YS>_DXM^PN]+UA<ZS(^P7+=69@/+'Y++,5
MJ(.6JT_7FQ7RBSVV;J&N=@F^/S06<;RW6+WD5YQ]JP+#G0/Q+;=XXT(Q@7>T
MW9^!=_$8_]"-'VYT<Z\PR1EKT[+'B-@%_H9ICW=T@L1.(0D##?B=!]EPZ@A&
MW-#=YQ-E\(D*2T3C3R98#9__7&+]SG.'68?HVZV5)U24;*H/!;MC!:STN4W.
M%9.VKO4.D3[*W;/9\UFWWQL,6)4"95]X5G5>Z,[2 1X\XBWWSY;##/@&3H&?
M9?%Y+.U@2Z'P[CBU"G/WWKVP0/Z,9T*%@7E>H8<-^H:"P3K/ZYWYC-/MTQ8P
M+'OG]NPX .>&<BY@]4Z4_L S;36,I:L+%1XY5]98;LAF9+K3=D;.MT!N;72$
M>465.>&LHBX63/JL5=-D>.&<L\7*B4=#I0N;) 9=X^@B?6N9%OR,%89DRK 8
M$YO$@F--MX!'9\:6/>P5#"$3&^:YO )\:K9@Q5@8M[*!)32[Q,$I W[4GU'J
M+5 X8GG8CML[7GF^0S=&\VSQRFB&-'&_9,-%4&/R@*-J\1CY'%[!?O0\XEE]
MT@W0!JO7MR4?^_GD8Z_\H;I.2F_@\)["92+9EXDM+  ^K$3$SZJLZ)L+Q/9.
ML+6^S[XIVZ?E"BV-"+G&91JQ99K$9-I@((TXR[M7F#D%AL7T@;K>DV0)I%@K
M5(H%RW>"4HL/-AYY&I)L.2:-':I$"BO?45I,6-/=G;4O),X"!<Z8XX!<H @K
M0",+\!5Y^A3D%THU-BX-"<K]-IP6"]1S,BJ!-C?;Z&GOANMR-#&N4;%RJL4J
MY_AI@3;L4?K>D=NL7G(>YK"QI4V7NLX%Z5=C^T2\X^=US2M_PZ5J2R!527E2
M-5JHMESJ1$C4FHC3@TG303YI6D S:U)I*H\]XM0EL"M!6VDDZ#D6;  ;>B7H
M.;P8_JZIBDB&BAN-,%*"YN(9:R#"5D@PVA2#MM"65.>JTTO#(XB_JX_P4DLQ
MV(!KIT[=_:U;-\I\HV"5K1N6<40YB[J8K#3CA;+Z$%8RZNN6:?ED/[N&6TW%
M\"T7>.[D;=<>=<8KSK XC]U[6VWMVF(Q.\3+KT-FPSM2V"-! 8S=^=E-?=EO
M^P((Y:[4WQ.^+K+G8.[AK76J&;TUY!HO(=C!P@0,0^3NK:K6\@<X4S7BROX]
M'\/DP<!S%ZQ+ZDE,!Z*=P5TX3JR3NRTYH$T1NKS@]>*(V@?]3\7 @+$Y93@+
M!UV>= 2C'AWH VW2O+=W5YW-3 0Z=VK5&5DQ=FV_'>^V2\;DEK5'3(BL(J]N
M:"-7H!IE-P0CKD S=K-4SJC,7> %$<%1]KM^@)WQPZUWNS[?=\<9O%P-FEO6
M8 [LS!LE0&':)6^N/;1C7XR-Z"_4*<MVW]5V7Z;A$%66XS^ AAN$S6#Z)YA9
MZN*UT*K S-JM7/6$G/A5?59-NXSB0@,ZSGQ3:]'2:MWO#-3_5-:;3^3B)Y9K
M/]D+)9B9Y6LEN+\X=]6!;5=Q>>WK-47^4)W>%;9T *4P*_2BIN5I)IU37@!$
M6R]+:MMBZ%,O%6QGHKS(RQ^(8 5-=,Y4P5Y0PG<#&7CL&;PHG-4RZ;.MG:1
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MN45H<+ZZ/S0C(9V.54,79B1>@LIGX^X]<A-7BLQ PSOXO ,-[UJ*9[+'5-R
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M36A(U8.:D<)P5&UA&,V*D\YHG"9^6&TZ)5[1V(_#RYF+%'>/XXFB8E Z*MZ
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MOUVO<64(/-&;F)_N7GIKO[1C*RL?7U&>X[/%LE>:P@-1[N_XOQ54%SOMN!,
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M[A?%5&?[7R^\VH+][[#7&>]K$K%A4@9[]1*SEQQF(? JD3PHD)">#.6LYY&
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MX8(S,O([#J_(R&Q@X0Q"613*YC1@5OAFJBE ])9G%:(=[O33:ID,@D.+EJM
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MP:M@LBS!&"M+V-825*$/!$PR%JLVG*9"@$G&R@G'_)/K:B6:_>&_U]E:!L;
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M=)Z];L(KZE#,:Z9S8X&302--]/E!CTW*:<GBO(@%#+HBZ8>:U;!:QNO3N--
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MFYV9%)'SZ/9I0KESMYL-G_\/U'=F9R0W+IW1GY:XOS6A/TGY$U!+ P04
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M^_[&7!7G+V>'^V7%GBF4QZ]?DK9VOONYJ^"VK:W?&A>OD?7;YK\!4$L#!!0
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M89(7D?2\&I]+^P<I_Y+<7CA]7()HIUPT1^^S0'?46V'UFJC>)O\&4$L#!!0
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M\U5HJ= ZJTW9H.J"6CM!]5J*I0CY>D@&:A=@&2,I2I9(&T=%D1 .]<DI*)N
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MIL@8MZ(0<A-D4P >Y_[.TFC>"W+\QB?.WKF5*_ ^A0E;&)]U"M1U\I.!GUT
M>V]C? ;P@W3Z[N.@,$F@6U82!TXNHNQ)2;7;FL^9+<H=5-7,QU_Q#KMQ "%
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MQ*[]8(ZI%!=0DBD5]\;[NFP/66\+_N9ZV,"A;]QRYP<%;/R[O-L$D@JD_"L
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MC0RV09H$KZNJB5!EPA&ZEN%S>WO3L9*OXE5]D3WHV,E;.U4G-Y]J;)/3D[O
M# GG_<&<5[%*8!UP9Y*VOT\R(?O5!?#MYWT?=&/]ZY7+%]V<@5?H"-1WJL3@
MFC[)SM9LL?S;#[$]Z I:3!AE*;T(5I^D4WANO44R_OIOL>DF="3JZ_RO)H^_
M!:IW1.BK*BZ+B^!T5BJU7>[W]NC=D9[ ]%61YRK[RJG=C3"HN%1U5*[^559_
M-\73ZFMG]4YH_PI&SY>@?"> _[;(X7:+I:I)JUF&O]4WV93LW2C^'V>G[T]?
MBJ5FB@:^R+&]BN;MJ-YM\Z2?@?9ML;*1_=-C^TBEPQ;O<OOE/P\_H_%S2[FM
MAY_)^/D2FW'SQL^M;<(-&3]?@NHW:?S</+W;QD)+')VK'$ZF$3KOHG++8WKM
M4KVM*?ZH*W10K#9Q[99H8+JH*%&V;ET+>OUWVHSK'_44R!?Y-$6ED,(#ZM73
MX#3/X<;QUC;%[6?8'_4&N<Z*+(W3>MMHRBWE&A]UY0ZHY67$P:H M, 5N.>+
M9.Q.[D)R;I>=^\JR<W<D/[?YAU]EHF[[Y7^1C-W5<UV/.C987ZX+2^2WK'KQ
M4UVW5(']J!N9>EN([;Z=%KW]^I='/<&I>50JD.OQQX,_EK8;[;VJZC+=UL"_
M?TLEV(^Z(:I?FA(LY!)[T9H27:I;7?:ZG6@OU3/Q7^>)6N17X)[[MY2 >]PU
MY\^:\CP]C[:(PUY_L5NS^N.N]2ZTKE?!9'6U&,[M$;UCK'<63\FW+99^^[FW
MQUWSW964U#<M'<<OLBA=;'-B;RDH^[@;/G@197&3F3=X4U355K+F]F,@C[L:
M2[>NO\[/B^P<VQL_S-,RV3[ </W7V70C.II+-WBDV]3DWW_X!<C?45;@,%%=
M?CIIMI3ZUU[^IN3N:88X!YM@Z\J++T+P;B:%@WY?(Z%[&A_<9M$MEGS[0:7'
M/4T/I_''O+C(5#*CJ-A5U=4MM6T\[NE]^"W*<[ D0;A+D_?7O@?=*!FO&WN6
MP!#>1IS?/-G;@L1'\5#E(LU)I&Q11W3_]MLUGG3-8&?M7Q]?>T!Q&+0Y.(]
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MQW'$)#KA12>%V(-H0!&9<1.660/6!-ERQLABCTR4<&NO*DVS153!9L$58)N
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MS97BQW;"&,'1T4\/GO"BEX>+0U-V+:F(7'+.XH&_C,"G7;#UK2AFC\.P3#B
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M?ZD:<(GW3O>YQ;0LL)R]LBB^3M1;0KL=?6%AH?GG^#;P&A\)C!U1W5$(X"0
M 5] I;/WG!]HPKA7?B!&@W=!7-YS.[]J/'(&6/5I"<3>+1KL3S CKRK]BQZ$
M3F.G312>9,'REF!)SLWPP$[3EH$!0B!O]S8(DF\N5KF!$K\DZ-F7%MM9[^[6
M8UW;-A593E01BPUVU.RA)L@=R:EM43'8(NRN;+!#6/#H7H._N./2:Q%33V3<
MJF9PUV3;)>!X=$J0MMM49ST^/-Z+]N\\-VX2<WZRBSGKF//]7<SY6^'L/C%Q
MU>X!%!?W=^)B/5&O9&NY]$UV]!7Z6N+^%GU*%\TB8 773\T>"^'.4]#CT'=<
M:Q=L6@OOV:QH*,0[SNRE*]RY2/H#%+^D957;H>-\*8/B I6+/.E^I[-,'^9I
MV?EZ1_P6\;?J2> W0&;>84@YQ*1T)G@/<;RI^^")AH>'1WN3G6CH(6@/O)Z!
M1@@49Y'M[ ;$YO?24'7/",'34!++9.33OL#?>IY0-[M)TGX\DB2FI*TZ$WUX
MB$_8S7"KFQQT^7UL:L?'YAW5].YIW*/Y;#QAX[^.CQ^$]^[=8U+'48;CG"C+
M'%4\P)+"VD76+%1PH=+9G(8J8.)CQJ 6!'$YCS X#OO-Y?#O9-:%QGBF[RM]
MM[=1E41_R\)^HY1&@&7N].7)/2R!H,065=0/\M".#3PVP&KH;E(B%" D1C[A
MT<N)DBX&.Y,/9Y945;"7TI5FD*(^=<1A[I"8*(YI/(A!5H<M4J "$2M?I@PB
M*('9U*I9:&#S!-&$L0O$9"-DIHANO/#0:8-I62R\M;!.@,O3!).=B,EMIK<R
MF#\O?CSJ5,6TA!*56/029<=:'FM]L)2YBJW^>%</YA&U3J7ZRDKHK4U&$[C?
MD;:7M'\6)59+!"^B94ICMC8.1+?H^V!G27HD_D0SWH#"'9S<S2BZ2S3U$?/J
MX*[W=WZC0\]ER@;NYO@*#G-BH]TNJ6S)^<O+TXU2H X)W3+PHP<[Y>13,SAE
M> 3F4.R5FM'DQW<X7F"U);>V2+W#M'!(C;-+;M(&N/.TW20=?71OEX_6^>@'
MNWSTM\+:OMC(>;@158$7V598(CL9/$!,X]YN2<Y=2L0E9UG5XU$K^3;0038O
ME0KV3O89@CYN:#A9'&4J3R(<P)O7\\KK0MJU"UU"_E]/3]]YMC!3VQ_ +D..
ML5TGQA'0&"?G:"52<UGBL($E#1J/J.Y:QO1QA!/635%,^.^.YDSS_AEO_:C>
M')W$B755LRPC^R>J4GADR#T-.<_MFRK,A&0\/T*%P:+)J4N2^EVR HY*,#-/
M=P9ICD<THZ) 3QTOJII)DLHD;#/)'FXQ<Y9NQLKC''GLOO!G!D;ZO;"#"(P$
MG-5=)/B_\!;8O#]IP"AHW$8>H&'-TP M-!&G;RC*CU._:UXXCM;$B;<8;\_Y
M[?0 /WD*/Y.:@J93_D*R!9("0/K-BEU_6)<K^R<<69;4WR+KX>FVK6+ -O:/
M6D4+2JEX0^#=EJZ_@/QU@ -+&AR+B.-&8F[O\GX7CD>3+,HQF6::P+RF-)QY
M[WXBTU3C@CM+B1OMM^U&,NE-6>F_ZZCZJ/\-%^8SN9*:DCBE0^Q9ZW>:-MRN
M=J[F:9QARTM]H52^:7<2M3>YLWM=^1"<VF-DYNY2HXQ/>T[\1 ._I8FML?,(
M9Z/P*SD9=:K*_;YV&VR6P_]JX"S)9&E&P,F'58Q3VLCDB;.HJ10_#%Z,'C[9
MMP=Y420X1R9RY]KN#N4&JN)W9,/^,UDV/-0RNHC*!'DZ3EEZIOE?32XC6T%$
MSO@,M#*E$0V5Y*^<DV(.2 P?A=0OZ1R"THZ"T"42H<;!++ A.%'8[37,T;L]
MICU^G8,X4>/1A^A3_]["%_@7]MS1^;J8%YGBYE::](Q43NDFI**CE$ "RZ!*
M%VD&=C'^/ETL]92.+%6-5NH[P"V]!XF:@%T[,,2I3_C9(;,)?8]]Z4ECPJ A
MM[8WM6Z%]K :0=PY,V4Q?Q\YH]JY2 7\2*,6TGP\<E +4V>Y-)]K4I1E<0&_
M Q](K;R"ABSK%C5('8,5R<M229D"VF<J^JBQ(X6%>,ISA;4,V!:,L\=[>S*Q
M.Y0N-6_H+G7?T6$*^W!Q<#)R+_9O5RAH)FP+5.ZSK7U8.?/3+8PCS;O%E\ Z
M#8('L)W@:JI*/#5&YW,ASU1&^+H#UB<K?TOXGG9R^]* ?I7>4&$T9.N 9L9;
M2]K4!V'%C]+>DJ$?#W>'38DR=)BH/]F X:Z9'R^H"]A7&T?+NG%^U7X$KB/Y
M43\'KE.?EMQ.[7?<AG:4NX^,R68570[BGV9] WL*,"F7UM X]Z2,+G(>R<XX
M+F7"\^=Q1_>4-CJJ\0CQ0\%_9S!4@A*H6G/BS?0A+KPK58PJ*$&W,I98M_P.
MUHIO7"8TN)[X#UU9-J:F\M#VL9TU$5J&2E7$,ZT#21&&U5)A^*9CS536G-%3
MD>'=@FA2G"MCPSA<<:?EZD9!]:-=4%T'U1_N@NK?"FO[)H- <V+#1]D7P.FS
M&V(<A$(:*-5W$%?(+?KKKS?#)X0,;\BH.VU\4(Z>:*>S\RT9^B7/;D==QVM!
M6Y%&P8&%J&$9G*_32GZFDGT1W@/5< S_6I0&X%7 1\&!CSB"2Z",#!5TIR5D
MEXU69#OT\U'XF1B)$%PBL6E$9X/_APX$6%7 #PN7#Q"K?()Q#<T-NQTT.RAP
MX8@R"!:GZ@$U_=]"90@BGV;-/V'P;O[R*6Z-X-%0OH-L(?"@I]UK\0PVN;8<
MF_PBS3)*:A0$B(/864'?,FR; 8L+_9>!<RN5OB\R%7K^Y(OD;,JX,.OX4QU\
MSE9DFLURF@TY3<L%,RB:F,!$%<*LHBN 79IL:FG;JH/[-U2:0 3!F\*=INFT
M1K[;.WJP[TVG)K,-AU*GYT@- :TGD[)#0N!G(!H-QNPC66 H-DPMQC\BZ9L7
M%#Q1?#XBHH$E=GU1T"<5F"#FTH1_/QZ9WT9B+=,]^ Y$1OJ;OR+:NKO,6,2=
M9>^.HAS%JBEY##J5'ET%+OO!+CG;2\^RB)5*KD#/7>V 0T^+(DXD[<".F\DC
M/Q'&&F4R,'X1U1S_P'-/25?Z0(\E(A]6HCD@HDK%\I4'<I@!\\Y?L,0#5/AA
MH--\419BB(GBMW2C4AVH3Y&.$5<V#=C46-!+87R553*JGI* :8ZY'+1 2@+;
M+2/;"P,^-9!)O\A3!G3#X @BOQ'N&P&[!?SG>,2!DZ2DV L/;%)UD!0X>044
M$6U/5LR**I08"WW&O5Y%N2P04=3YK+L@EW1D1;F7Z+=].A[MO<!R@^6JQ ZQ
MZ]TLV'N)]UJ@7BQ!-TSKBP@37TE41TPD02ZDG\'EK_8M32U1*HS'U_I=\RD&
MTFK*?&K=F.;8S"C[KF$/F?3:B,@+Y #S"44Q#3XBJ<E2(38?Q6*6F.6!W0D)
MD/U@7ES 8N"@-%/$:>=L'=Q T #QOS&/NR>-J.)YGH)/6V'&N%)1B2J36.)<
M9<52.C*=%3?Y$H$EJSGQL)">EGE1$+-,=0T.+0/;[/02# F0II2@C/57<5&U
MGF,NQJ_M?999)-L:"R8B_5$UN,D8NH*=Y>^=NR&G_+*O6[[@9)>IJC&*)WQ#
M9U)LMKZ$EQNSQ:1*XMCB^!PDLI(^,L'%(U;DN\-?\,R:Q2]97'ZL%\X,>V[X
MS"RZJ'33VE^P>U62,BKS_E..G_U*'*]SDW64SU(DOEI,BB3UUK"3ZT:NESC>
MU!2'!;O:L!LB*U4\GZTJH.80&BF>IWE4)BQ-?;D:!AA37G)J@T11 6ICQ>DS
MF051\=V#IC+3/#":/0!06793^"0B"<J4K]5BPT52W1T5VM,WB#.,#JI)'F\8
M[K#YMG5%4:WZ)[<VJEL+!=J#C1?$-(XN0DF]Y*CH8K!N0DRK*]):1=88*ZJJ
MTUK^8I<S;-<^$6<M04F+HK&3(D,_%TX9_8 L+U-*Y>35P\Z=X-E+<ZM6%I_-
M#OE6,O' _CGH:$K-@]M-=^7\O)W$!N8(8QL #0B_P$RLH\22+2*9#A>8.$:0
M1!.\9)I7_7(ZG8(%296%]@L>O"9[#C3$ A<RCWG('/7DA<X\N 1(1$/?0EV>
M2!&LG+Y<@*KB?P!OS.A?=0F'4N&]S"0YWLPF0Q@(7LJ,=-N>E]S$P(%VRN7Q
M>HJ-787]I+48^P6OR?F;EV8_T.NRG]CEV;DY>IGZ$YR4 R8\A>X\H;4)_>]V
M^G^C--7Q+DVETU2/=FFJ;X6U'7W;VX#K(O_KJ($WU=,MB DY 4 "2=<]4K4&
MUM4""VA'H95/QWM_A'59#U27(F#-9/H)=-)X%$U(M:KV_%!PJJBZ@521_&$5
MGO["*, )JFGP:*7>]V 29508 "ZDJEDQ]E<64.6-7 W6 %U.Q3!26M%79.#4
M38/:PJ096('46,!:$U^<S)S@O:O*3]G2A\58'2H&  >.G3N-1_96NLKR3LOJ
M+D.O$&8"V+(7\:F=$>,,5H]I#]=VLZ08P'E35*8^):WA%^#ZGR.CEXJK&U>:
MC\3 !X.E-^T6_/S+[V\_N 0[J-)_%%/MAV>VVS70J3F\_AEGZ)Q1OWYU3L2@
M=0>\8"+$CC^$/U0^-.,$O@*?@ 8*AL%\M43RZG(]KEL#R5.4]2S"?V&'$1FW
M.I:"QG3<+*B!08E4M(-/*!2#>S,E),)239L*_8XEUM,NV::E:UB.@C=2KVQ5
MF7T&8A6F[-#H"28@GDE:X-QFMT#77X[4Z)GZ-);:;%P[55GP 1>IL7 FX8C(
M1;%;CYV3R/4*";'*V+U0 VA15$M^IDD6#EU.0\"F--DY('?:$-DLFVS]P1M0
MNF]9ZP=*W2NV#)QC+A);CDBIK;U)4YFB+;J0BN6&+EZ2).!J:O5)E7%*O0/M
M5]&KKV44.'Z,\T'+:IXNO:?=;:O;.:E$V)ZS2FXG0W,)W3*Z%",Z"SB:E=2Y
M<R18<5HDRMARL76.8&7@O' OL&H&@=)7N.MN72264%8JPXG'&"WV?LL?4&05
M]$ ME@ZLI)RD.M#/8>:FK/GJ?=](LG849CUR7/X;U^;2Y?D5'4J:EVQJ6_D\
MANT8/:RER,[U\3R5.G__T)J%8S5LGO@7$YD4AK$Y3CY45^0YH(/U1<8IE;"T
MCB*XHV%VS$_,_UN$(6-J $S @@"1\HJZ)OM; +BC4O<C 9.?2QN'S:"@ 9V6
MH ^PX%S*(#B$@.B(9/G.F'?(D*7J=/J3[XWI);Y[);>OO/M7[0=4&,Q>R%M@
M:ZB\AID<IPNG3R5VX_&ZR>!8=2>:J,EJ*<]=JM)Z$Y=-(<2^K8]4G 1,3!T2
MG0(;FD<^+R[@I4I= (53BG*I_#;$%6(SD;&Y:9C*<>0$C7GU>(Z,'C)I'MV'
MS&%K/+LRLI)WAY.WWI?\/A28D^)N*KO7/H]N:J;IB^2(8W(V"H3%-'\%/GL)
M:_T$DHT':D5Y#K>.=6\<E95PWZ29IREF@1ZZUS_STW>*%$8;H]C([TZVBW+$
M'*E$_2BEDCK?5H4FVX;_C'#&E#ONZ5RQC+2AO/%H+TVE[-MP%+ "O;1>TRPK
MP-4+$ VZ6- [TJ),,M$4NJ-]5B025"M-[3FG""N'Q[@IUK9'Z\<15"1Z(0V:
M$URO;B<F:C[&A=+T-&1FVVD ;Y(ZO7K2@TB%4&:EDRC_2 U?V"C!)A0^1J]P
MK]79FZ15V2S=9+335AMG\&#=1V"03EUS3@<0^?;D77W"9H[TO&^=& YGHSB0
MMF'^BMB7Z>(&M8UM9,/''>^9O&9RO??<1^K OY/-D0]L*S,2J/ E#;*+SZTJ
M1Y/?G'"G4D(/)?4[XN%%P%VO19QI3E(5/-!+^7<4=@O8$X4+& 6E)81])T6S
M-.4P@KD3ZL<4,0^TBU7/@X68"UQ:Q(W90)>R*$%*H'&*<4=JUNB\5,C!91LG
MQM^E=<'2U5K!?/22%(X>"H?8R ILUN$(.5&$GN*M15P9,9Q,7HZJ3RE0G:N,
MO)/NVF#?]9F HP-F1QJCGEJF^I_ X8J:>IN: H[X+9@D\[\;$*/PQQQ(!OQ
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MP(@^=SVP?$=KJDPQEMQ49D EE7.T,]BZCZ[=9-&SDZ'T1YH#:I8L&85<\>#
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M4[&/AV:AEFJ6VO*R1,59I/^0A@^\&KQ2JB6@9)[)5OQ*H]%PLU$A&_MN7=Q
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M:#S? _Z*QG &#^FCQ^8CD(A/Z*.C([D#93T5./N+@C)A0"7]7:@3JJ;2QKP
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MDCJA^_Y9&)T)QX!&]MPA4'@.'EAQ.5GK@+H='E% EV9FXA9(O/ K']K4+WR
MTX<3X'>_^@KWEE?1$Q%7\BRI\'8HL3/LS1:#2P2N] 7F:6$0T5JZ<;$11V>@
M9&<3$)Q)BOTX\G2*WBN:#TQYX%&=_ F+"ZPV/0^/5[QM.D<PE*?ZLJBD+-YU
M'+_]5$T-@5W1BH4CRV=NU3XQW2T)29/'K'D0+0ZAO=YNW1"?P46$46,CNAB/
M4?MS=*5G(FXU"X9@F7#9+<1UX8ZQ\@GV3\O2+-,35>9=97.E[2 Z*[;;2L.W
M&X65-V0:EL%S*U;*,SN4OA82@=<^_B$5Y]U.4#.,/@'^V%<>F_)PR991W?C2
MX-EE-@Y%4]O??0']FYM$7P7LJW[KZ<H?2 J7ESV,5R 5H^3?T%IAFV%U2:AA
M2K;JD'O\C 6)M+;"$UUO$_EXJ!M 6,Y0PCB;9A.<3'%;S<:T9;4IT-HT8&G1
M%8F"!;D-.R;>CV]M"K*C.C_FM58==CN-1Q+,(FJ.A.A:9#]I-Z0YR.GY@$K+
M#1-+[KG;:66 62+E*^S>"^OUHM9R/4JF4(T>V&!U0FZACF8@Z8WTT706UV>+
MWVWM;)U%^Z:A(=TX$VU'EF<[XG@AF/Z%(R,W/!7S&+7C>7S:')BVK#KN];H=
M??OE#2FI6VE[_Q](K=Y1FZ@CV+*11&_0R:[^F-,J8)*[/\5E@_6"A>%,H?_.
M%F>T"9?C$\,::R$?8V"!)R##?^T?/2[6-H=<YR@];Z;[+WZ@.;O%3/$1>6J0
M)T([TCM'WAF,Z9,%(6B): %/+[\$WE, $X6_22S\,R55#X+S4G)J%;F>T5^5
M #6&+.! @C&NUYG1%ZFM-4T&9F-R74$/<H,F\&3'9\Q;8XC+G>,R+6&OQG1V
M&%+^@3Q0\R:.B3^X!6EUQM%=)NB_.<S5>NV[.&IO;Q"P;;2QJ!OF((MT8H)B
MGL[*S6<EE H\HU7;E-:9(Z(VXHBU1$XXGH*03<\"%V1NSF=EGE67XG44HV',
MF0?^E.8!:2,"ED157A2\<$HMNDV/Z98',%R$&PY0H$.NT2MB?WK?]&X<PIB5
M@TN,D3@H 3TG?+U;U,7A]Q=%,90A\V10M&:P8%C.-KUM44J&9T,=.D@8"LM1
M YMT7'",CYFUP!D;&!)@;)R*B7(\EJX*.IW@>!M\I  "3-$9F'ZC:RZ ';JM
M4UT2 5)!Y%U#S+PSK?89FH/&.EZP!L9,)E_5$G<1%@XUC_;*$IWSW?LY]YIT
M>?J8='%)EQ<KFG1YX'*\S6TSW__^-IM*5H/V<;=S"W/C*9L;'-]GM(9$4I5K
M$;D2ER%5\$7%6B^ZG*Z-S7?3>G<6)A"5++TP_H1!XQOH@4POH,;-6\P 8U=5
MCL<T&B239,#  )Q3L&0:Z7C!N+@,2<$]$/P!@*#JV]15Q\O/27,2VUAWYU(Q
M+ST-9@QM,W+ZF3*$ J-"%+M8"KZ4I L^719<N6R3>L+0A:\O?]8+]0[+BR07
M>ERX?L_S"<YI^4*GK19%*^B2S!B[=)I@E"0#MSNC/E^$'+=!"MNR.N::OV:G
MM*G0B/J)I##(Y^Y&3%11Y"11]HMS%[LYC\XSL"6I)\=P!J9;&.SP>1\O#!C.
M$GD!9S"CU\)0"UHT2CY*6=+V6SD1BZ/V>RZ>-P*4W3QQ1@*7#]_(# >35Y1A
M*4%0"F\S9BMC/&UKGN9567R$5Y<3AV>> Y @7O@5GL28HN.<+W+WX:U*ES!4
MEE9%*@7U*%IXT0*GY^4TBQ+ZWU[>,4QJ6ML7MEJ=(L5G$ITU7;H"6?$.)HUU
MC;LDK0NJ57K;8(G-W"(T'P<@!Q--<>^&:%QZ"&YCO;O]>G _>I9T951BVDQX
M,S%'E=PCG<+#E[]G)'^*[90@WLF,&A6)0+::.L\:J43'Q8J3C8PP:UN;Z]$(
MH>/PN<>&U 1C36 >#%.] *%B8#,59<]2IF,^QV-R;<??KM(1+G<[UWMMW2$0
MIY_2$2%EL,T:3/,E^IM9@0F\H?2;HQ3A<7H.NQ%-]%?)B%*4)Y<I&(*H1C>B
MDPP_P?LMNHXB4"X:2SE1'KX6N\^Q)WF2J:C-82QK[+#*L4B,PD.N38$9 %^W
ML,C72*/Y&I.G(C]$858\?"[5"KJP#=$);RTV-#=)1KK9X+_C*II-"@7Y9I06
MQNTFD>1A41N/N>\J[3EF*Y%&2@7RIKY+IE/=;M_[1-PI3+[3Z-.K#,*FV3B*
M2T;@<I5Z(5Q% X@XX[ X)Z7>L(89#D_+Y*QD8FMN2<F XZH1SC']MXC]@KM#
M&63-95(.F>'"<%VXN&$MB^IHX3SWK##;X2!K['5NB':$',(S[XQ&@8QK)(U"
MI,$,)\QPBI9H K:U$^V^/HZ.$BP*>[&]^>3%LV<WC!V3>+<?/.8]B=X&(6&#
M45K)=%$K2@;QV1"DP8J8HH*P%1F5!39;D3U]:EYIZ^GFDZWMS?"5,N7:=N@4
M/V?[I[UCKY-:VI"=3.'MG.&])^8VG53P[9Z\Y2FQ[TDKLFK.C KIH@#DKYFD
MGDX,UI%&X@G?IB<6C<J[R<V[HXLS]>2]9&^3%T\KH3P]R)%(;J?#6N$Z:( S
M$4%#;8XSI@P'VULTO?^HX':_1B\W-S>>/GOY R6JOA#<?/LQ\NDBGR]7-/+Y
MS67[%N?P<S)-P&9-L):/4.'L ^PW?4<N$.2V4 CL%,QNS.SNKJS6<"IQ5LD#
M.TG3>,A(I3JJ%:#K:,/J%UGU593U>V#S=N& $R?8W=+H/#BFJ- =LS\A5VK8
M^LIDC([D 8@B=+<,&LDL=HGCP&_)V*G5D.<R<2ERYQ'C[UJ*=CL()*_U%.67
M<"9,[  ]!)5/E*H]C=ZD8,PC,0<L%]WR",P([2B!@^L-J#VF?N3:/O_\G-%7
M8Z2VX+;$W0X]UN)(I,@@IO5"!OE92556TW243B[1U^!.=7_#$885 !+QF.4*
M%&5(";/VDV^#>-\D&QDFLTNLWQ]5ZUKSH-U'NAU;ARAW8B[_-I;26CD$<?TU
M,YX9UNN""1$>Q'K\^O743S#S:"C()I?7%9I!QB*2CL[&<+M*W4SY>@B\R)5J
ML%6F'#/<#0!?7<4S,M(I?(:"@Q_23AW&9H :HQ/S\H:8CO02]F44VJ0\1G0@
M[3KN1MX*#1]BI>J,=0>(2]$*%V_JD89-]WG;IE8<@RMDJV/PNX8DDP#S@.%9
MY]Q"PH>!W8*AB^Y>Q%3+?/<NWBT.E!<</L)$/4&!*Q"+TJ?7?OB9V,*'KB7K
M[-S2/$3!-$BA9S(0)J%:]%,CH^Y[0LOG5[!YR#6ID8[X'-4G;C@]0[(/= LH
MU8,]I/,TY>87%\0Z2S57A;(11%<9O+=L(M@*"9.>UMDQ<&3H'7&Z@)&JPR9J
MAGUX[3K),2I'L)%27 BV/A$3: :2:H<&V431_[Y>A+@)_$"$8:2"4V>CS6O5
M1I>N-E?37#&[?5.BPHA]&)LGQ<2X'3^#9,R0IX7 .U1^=<Z1/&95"$9=.8XK
M+0 J0[H5)75O*Z_!#G'X7BV2\A4WR]:WVRIGZV$<B!:+\KZ5%["V?90Y\U$Y
M$-*AZF+*T+*QUR#$)[?Z/,7[C$B,L8EY:GXIMHQ*>%S/B5:I]&*WHD_] JF;
MY[SQ$D.K!IUQ0V1_<R :P<]3,&OF_)#2=MBZ2<%.;$V8,1UCB<'6LV=H#XQG
MHPM*[-03N2?N_="0^]%E2[2_-1WJ@C5WW[E0)%L8* >DE?FCN#V@%$XO69!L
M^S%<33H%#9#Y<#P)<N)A7T8F5*BXN>)YRZW%,&5B.8Z_QQC-QQ2&Y-RX8QK^
M] PL0DQ3IZ9!%$55_8'"2IIM>$H,4)W'8"X8 KM>D:X5W9<X9D:8#SP=LCPT
MV3YK0V-GT<_?T='G;NCVD_RN.SKZK U- (N6'1V6N P^J@5<S3VGO8F*#U6Q
M7JC V$18%3-N4#N;R/O '8*\6<S*A?L(Q2 (*=#Z[6QNH1T(<N'CUM%>L*3S
MU,>/KIVWEHZG/GN,I[IXZL\K&D]]P#*\-KRK]3I.KM'- YLB<?2 5.I84@S"
ML2>.1@6U?<8B?+CI+]^W9E@N*$X/9DO@]$T_.GG3.^Z?1,?](_A/_^"TO]?M
MO.D?]U_]&;WI_=&/#@Y/HU?]_@%<\:_]DU/X9B]Z?[#7/X[HU_W=]\?[I_MP
MA][N:73X.MKZ>7L[CGH'>_QS^FEO]_]]OX\_?'UX'.T?_-$_.7T'CZ*K\/X?
M]D_?1+WHC_W^A^CT,([H*ECVPX.#_N[I_N$!71'S$WMO^WC!'@SF>/_5>_KZ
M%$=\^'H#[A:=O-]]$YT>]PY.7L,@W_7^A#%$_=>OX4XP KS1X7M\M'RV#X/D
M5SONT;U.3GNG?1K><?]MC^:#;G]ZB(^%WQT>[1_@A?"RNX?O#T[Z;V&T,'QX
MN7<PO-/]D]<P%X?'?\*[T)!W#]\=]0[@GV]ZISR\X('[)S0)QWV9I'FSV^W(
M]&Z(K?8M!.=;2>S1:":X8]ZKCBRZVY$83]T@528,LE8#;FT.)[#5BM! ;^NJ
M[=>B4IQE[J-*IL5WC'ETC,!R\R&JXRT^(M=DB5U#9-#I\/YLCV^V9K<(5[ZD
M<"76:QZ2\W1<]VY@'3]0D B7+:A'U$A<PR%"?]']A,)0B1J&5#[D:H<LT(3O
M-&(Z62%P=Q[@GL^J*6:,"7&84+=!3&JPM;ZTGW!<'Z4:C"\1QXWI?YD\*GP;
MBI')RV M%S]/(6D8J2LQBS$_Y166&X0WC\R]"8<@K6&< ^H[TB&$S/5(M!E%
MA/N5;@)?*=I,FRT)BT)0*3BO^YVR E@1N$HK\PH,O^;88;CF7-[O)Q8'B)_
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M__BQV]O@-7<>XXL:7]S>?(PO/D0Y?K;!A>K"Z1D<;'V!(/G#S>L+:5>=.MV
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MTF3(R6EG;H<'R=S#WT$[M$#CG/:=-^PD@^?ML6#[V-L&Y-%+C3WZK*%CEY2
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MKWIH)B3LX]=I/Q@4QI"C*OL;7(M\>@E+6B CIT*Y7  KHPP+^R9"5RQ+,2(
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MG#HA/%!%;KTFS..(5:NTJAT4%SFU8J? /.7O$$J>82[G/!D0W27E[,$^2)_
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M@$=U%UYMX"@K8V#1:%!"BUG.R\;O[RW?IB(@RRT79&OBMH#T.DNEBVF &3;
MD//V&NP&-8BV'1;12Z-AD7(QMX2Z^&M_(T9N46/KDJC;_,BRO$ZGU$1K:UM
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MCN@W.]0YDG7#>-?FM=B"U801\&1A'QNU(?'$P:E:UPP3BJ[$A_U6R=UN( C
M;%Q3,(YE4'B#2=6!IKJ28N )]UQH442UW("#,KC"QS:[Q9P6:VDH 5Q@UWPR
MM7%H,8V">1FN4W07+YU3F^\,[2W?U\$T4*)4 9G;5+>XU Q(U>)Y>%0T5#]V
MC$#=3Q[H M4?U[S1EBFOJ?Z[SQ;(2AE^!@]T+LYMYF4CJI?RXWK;5A03+,Z@
M;U1D8^2C9.><L#9^T]=DRZI'S-#DFO]J:=I ;&2DB\U&D\W%A>EGO@RE=7S@
M?<D 5\:$72J4__PQE.]"^5N/H?P'*<?+$2F@^M^T5 H?4&=S_TUPW*[!"\B2
MD40;N#-J_W].L9<MMC@].CY\L_]J_Y0[H?:PE>HN%6N][7V(/KS9WWT3[?8.
M#J@9:O2AM_]'?R^.^CWX6'JW'O6.J97KF_YQ'VZ/_X$;T94GTN-6>]<>PJW>
MG_3=S[%KZLG[5R?[>_N]XWV^@GX82^/7/_H'O8-3Z7I[T-_GOKHX\*#S:G"/
MDS?8'A?;S1Z?1FO:C+=WTNT<O>WM'YSNOWX=1WO]U_V#O1[W\W4M>=>Y]>W^
MO]Z<TDP=8VM;>)G_>G^,+6?IV]>'Q^_?X3^.^]A1]E0[TG+[7[CQR>[Q_BN8
MS:"=L3NH?];"3_@)SMR?.F_O>G#O?6IF#&/:_]?^ ;75?7]PVC_&"ZF=+'QP
M]*=KBMQR>V%(H,;%^ BX ?RT=T*=B&'-H_X?^WO]@]V^:8-\<$)]C5_SLIR\
MA__CD8FPT(H<NRZWK;.S.F?+\GMRR^[)XW24H>$BR]^?#YI,/.5&Y9QAY(PB
MGJH,K86Q3=X[Q.RU!VB$>)P&V8[*(0-J) /'DF.LI,2S3<,DS)@NA,,5;;PW
MX'5=!_7%^ $9_GA^L<_6$BJ"R[L=>A-S.VL]&^*($. I7HK.XG*O3(ZU?6'R
M6CA B-YZV]O/:QNP,D*/L\50Y!.!!H,$L]GJ<9MM(AW(LO$AG* &>&]/2#],
MQG#.#ZU%&W.<JJ).:ISP*QG*>S:Z9D'.8?,,P7A!KTS2L_ 8# OSC=._LVK:
MPBXW5XKJ0+94D&22+6F-;A. ,RL=B%I3/B7_W.?V''\N?'65%12RV !7 >\&
MNP7?&.\NC'N19M?Q^?"Y[T]-(0_O5^B+:ZL\EQNC31.'RX.O)ND\#;A/BHI0
M0F?8UQ'C0E@$ET@^>YI\I-29A0V%2^A2/8@;G8XT)@5#_FN62]2%HA'Z3_+-
MP5NAY?"]@W5. KJC18M#64L.#/K4O%N$%BAW&V*;UZJ&:.0HT$9TLH #A^D$
MPR:'MH6X9RR<<OE"S)J,AIJETM\SB"J;Y<2);</A-_F-A$\J)@C$;#S#&;PB
MWUFY"D6$?+#<\D%@F-U(7%VLLM04C!A-+) T7?)V72"A_X4J0<4":1DISTFS
M^<^B;%])!D>B;R]=6U!*9T@I7@ZKRVQ2PW2:G,7YK.0XF7]X'&H&305)).W<
M".U5&LG@,)TP;W!9[F#=<E+I.6)D6Z*>A'VD1%KK)8TF#S':!)ZJ7T(Q.'B-
MN+-B:U6#B#U0-:DQU_:-TO+*!"<R[V7[>-A1:SQ9P0ZN<V> O)&@WDH=I-M"
M ]/ML)_&IR=XXJ[5 .7\,:3F*PE"CCFQ%%5>_T[+05:YIBS<7J%&D)*-)TDF
MS47Y @Q?&YR4HA:2B$)^)1TK&'L?_.\,MN\@99F. TF6!P;];F+7[2:>0_&E
M&C!77!9%!/',2XD%AC1&,FJ\F!D\AK=&LZ$->>->E%WM?JB%$T7IK$769G@3
MFG3WLE&]3T2SL8H>;<(T4R@S?V UAC>L@\-E/&N?PJ(M.637X[:;@@[2-CC$
MKLL/F.4$I??VA.#C3,E6RPNZI1?%X*7$O1W'1.7VE!1)QJGVO&E2"3&(22%5
M:KXG"#W&#(U 2F04-;R>:T$,7ZZ,#E@J.OGB,3KIHI-/'Z.3#U&.\2SCRJ4#
M7UE&0<>6@CYG!"+C-/UCD$TH28M=5*:C:SW,ZA69PS(Y)UW3]+ZC?6NO8?O5
M\5EV,2-&5CA%J(A9H %:\<)IT!(4I?A.F$Y.J[A1/J/*T(":*H3/T7#,J(W:
MTV*_G-R9:C:>.&_G; ;;,)?\$AI-='MZ-ISZ5\3$0L=^5KE_^M,>GG&5E=.9
M3[12LQHR<!?%0%8X6,&%-'M9A15-U'?358%ZF23HM1;24<\#BJTEFJO#&?6W
M,'6DSNWPM@!*WY#0P]*8RWDY8Q=FP(,0S6?S$%,XS\?A**M,\ZG6ISN3'<_5
MC'CFL.A*HU7\;JV_3(BKOD0.@"'9\4H9"V)>HDU?Y+86'TOL]((@I!9M:ZAP
M?B]#=8*'?B TRS1B!<Q4BL,0^6T?-6XKP82I6RHJ9(:!B07=%C,IX?-O4GN1
MY1L&;'.\M$8VJ'X4: )Y4=84P8!K%;Z!<V^'SNI#!I\QI/ASQAK"NUS(#?RX
M]$H#(4Z('*WN'48F30LKVT<RF4R(I([P&XB].D\P19ZWI-7Y2>QO)F?R)\D*
MW*0L)B4!K@=E455/2G!O2[IB*E#\55)K7-AS>IF5L'^/Z'!X184.@PP.$]5M
M!\7--<+>!N>:F,B5Q BJ/2P&;^0H7*T#G6\N..3<B8#M/&IOI^F[#/ S64%Y
M-\:-DLJ X9WU/+2O'.PN)_/^UIX+V^JREM@A[>QFBT)%9[ >:=Y,71T[25S%
M;Y_P2T,)M$80.3JKLP'>$_.FN'H6?6=1ER@AXYR8.F@?BB.'(Y5[K]3NX/JA
M-VE"A >N>B@%J>2/%IU8--.PDBG5.5 -[3E)MNH; C5Y%@.'0)/*=8RP%@2$
M&B*+/:@Z"O]R,(=Q.D+M,"@FJ0/D3=MJ09PX^JIUQ0[A Z:7SBX5Q-8X37(#
M\S/V[6J;@2\%R#ZC28'=6?W:[?1',)]ED6>#Z 3N06'QUKI(C6IKN;0L =,!
ML@SX&_.JB3LPS,Y);*9UO4DV%]'/I 0--C_7@!H'U^MV1NZK]\^EHDK0Z)5/
M&.B/I\4%1Y?J>$"TN=0PHZB.+Q"?6V=NJ\4#ZN&CO=<4_.&\@JU.BUPS2_]]
M[86T>J_Q,AP@0T.+TU&V@;.=!?/D5 P)L#ZHR$M-ZA],U#G2\M/O_]]O^[^?
M<I8KR;C(5#8YQCC<\:[DW=W.V2C)/VYX85=6Z U$DO__7WBTX93<$/5Z^1CU
M<E&O[<>HUWT <73XC,-YH&BA_9P47HX1]T^L 67$8;Z>S%/I5<W'>H6)Y:-9
M.;A$8+U7WA)<5]TMEF&*8!9M7F?HJ(@SGZ-*2/*/_C@8E6E)SK<8FT2%?YZ5
M&-;7^F&$SOQ@6G:)N/WWQ&7_^V^O?D<,WZOW?_:/?_GMGZ_JG*N[A_@6!__G
MIZ<U::4IX.J0H@0E,9M,TA++-W[">S9XW0]V-_CNLM'NQ"?LEG;N$,T%=Z<K
MEIE^OOD?/[4_L=8  "Y[=?U+^S4WG35N7;>?PVW^6?W3TJ_?WR3]3N='[;,O
M]*A3!'G4GW4$ZH3(XA[FTNL^..H=]P].;]P((."]@T,4\'>]?\&.CMZ>[FVX
M'SV\MVM=ISO+[$^_1R"HT3'8VWO@6*:C^Y?4UF^^T -;Y77W$O$[K\&7R >(
M-3CD$^^!KJ]([^[A.[C?GTN([[N]#_U72.Z_&ZT-"\+SS:J,# PXTN%;^FY]
MA40:);K)0?Z%-? 7?> "N>YSX3*8=NUR?7\LUI]KM+5Y5;<=R@W^%_C+SO<E
M#PNM8[*<NYVFZ8Q.\?WV+=[>>.H;%^NT/-G^4JW![_"XK[ (.\^^VENV 6R.
M9Z/TB?JI\R(*F\VA!V;Y3\$O;0K.1!WH3BWZ1^<>?6CY?^M#!P/\%L+PSU>'
M>W^B1OCGF]-W;W__OU!+ P04    " #00:)4JE&VC/Z/ 0#X(@D %P   &8R
M,&8R,#(Q97@T+3)?;F%N;W@N:'1M[+UK4]Q(MC;ZG0C^@]Z.F3E4A&"X&%_:
MO1V!#>YF;VSS N[>LT^<#ZHJ%:A;)=665&#FUY]UR\R5NA0(8VQ</N_9T[BJ
M)*4R5ZY<EV<]ZY??SMX=O5I=^>6W@[U]^&^ _]\O9X=G1P>O?ODG_Q>^_:=\
M_<OK#_O_"D[/_G5T\!\_3?*L^CG8VIQ5P5DRC<O@?7P5G.33* OY@S XC8MD
M\A-<")<>^]<-\W1\BXM?!M.H.$^RGP/\Z>;+H(H_5>M1FIS#1T5R?E']].K@
MTT4R3*K@R<;V+_\\_F)/&\59%1<_O?I'-BQG+Q_B27N_GAP<O#MX?Q;LO=\/
MCH_VW@<?W@;O#DY^/3AYB.?_\OH$GK&_=W:P'^R=PK,?[J%['W_]>'H6_/+V
M [R]>M;Z58R+_G.0Y<4T2G]Z]>*7?^)O7H7!]N;VUL,-\/6_:%'VWGUX_^OW
M)77O]]Y_6/_OX/#=WJ^'[W\-CL[V'VY6_^?@]<D>2/C^X9N]H^#WP]/##^]Q
M!!OAPXWA_<$?P?\<[!WA\O)>"TX_OL91/. @X.$/][#C@Y.3?QT=R5QW/;?W
M(^M"R__OLV^[L9MD]-?6QC;\*2]6%5%63D I_!S,9[.X&$5E+%\EV3C&)ZWS
M!?#6Y@W_S_IZ\#:)T_'/P7%T#K\_C?]W'F>C&(85K*_+@?C+_N'O9LP\DO4J
MG\%/MF>5&=OZ,*^J'![^%#\;YL4X+NQGK]-H]!<,=Q<&7>9I,H8A'/MWI'?3
M$_;+/^&I+0,8%G'TU_HPAE>%4<YHU'I03UO&A /M^T@U-?_$N>'I^":6KTL5
M-@7\9=!WD#R)FRV32)]UCA6F5Q]5BW[W^M59-$SCU95\$KR!X<%(RU_^^?J5
M'&3WMOWN?:+/]EX?'01O#HZ.3H_WWL#9\!\_;?Y$_S[>V]\W_^X]Z*MD7%W@
M3S?_;G?.*$_3:%:"A)N_?B+!_.7LQ#S@,BZJ9!2E9L5AX>!RV&CG13[/QGB+
MO  ;\7RXMKWY)-S>>1YN[^X.?C("?K8?O/F ;_+^/W[:^>D6"[>'STOCX##8
M/WA[^/[P#/3E*1D!)Q^/#M \@AN^/ST[^?@&OP+S>5\]:X&,+GCF#MT%_N?D
MCJ__QT52Q3\UQR&3OOMW_USX<UY6R>3:+7W;.Y@%V^ZZ^#0>54F>@>!M+;S#
ML\['[\>3)(O'P5E<3,N%]WC^]_:3[;-G;I'@M"SFK6;NAMG:[G'5&WB+"#;X
M23R)"SRR.J;IB\Q-EU3=]X3L]+CJ9)Z"EF&=6E;%G.[Q@'/R!13-87#VVX'U
M]^Y!G3QY' N_W:4WVA<^AL&7<7 Z'Y;).(F*Z^!=7)S'Q>T7_[/GY<&5Q78O
M97$PF>!UES$=O0\X+P\E+WT4!>@'%!B\D+3%=!9EU\'I153$Y<O@#.SK:@KO
MK[_\,*_**LK&278>'))VP5^4 7S4?L$?40$;L.K0R?7)8Q.S_1Q[C*+YI(]H
MEJ,BO[J]2.X^%I'<[2.2('SP=F'P^CJ-KL TWD\*N%%>L(A]F$R2$8CL[6?I
MZ2.4FJ=])BQ*1_,TJF03L[ZGDS\!]R'J=_1_]F0]E$@]ZS-#:5ZBND+Y,7\?
M1]?3N%,K?2]R]+R/]ODTNHBR\YAT-[X1;+2HBLN-VT_1B\<B/2_N(#W[<0I6
M0Y'T\2ZV-A^AT,B@;W?9<5Y6ZW??5%M;CT5DMOK8X>]S&#KMI"AX&R7IO(AA
M_,'>Z"(!"QT^?)> AU;E60\#=&O[,<I2']-\/REG<] XX,B?1P59F-5%;&;-
MV)5?:?(>3,[ZV.]_)-7%19[B5-U^+KY%[_XP.#DX/CDX/7A_MN>"B7_LG9SL
MO3\[Y(@B!@#>?'@'M__7O40 MAY)[&>G5PC@0W$>9<F_R>X+@X-/25EA2(R,
MGU_S?!R<BO?68_,\O@#B3J^8P'%^!28SSM#>O+K(BZ2Z?LC9>2@QZJ-9#C+8
M+Z,X&B9IO]EX?$[Z3B\G'1TKM'%>!N_S#,:<@7*YA ]ZN5F?/TL/)3.]7/=H
MEE3PX;][.IV/4F;ZN.@V'-O/>7@DSOA.+V?\;9)%V2B)4CR(JKBOO_#XO/"=
M7E[X1SB;RQ'X4_$X.$I8_288C#W,QO&PBL=97/:9KV>/18;ZN.1[91GWDIK/
MGH6O(#6]W/"SZ%,OU?+\L8A%+[<;SN;Q?$1>XNMYF?3;*MN?'8KX&D+2*T].
MQLJHS\[9?C3&;2^_^3@NIDFO>?!R+? ?Q/^\\K%)%G'4#<M2/[D-\&[[9?!A
MAN]7_HR8(7G9E\'O43I_2%Q>FV-]"XP8W$*]G'FME\'9]0Q&?X1.%Z&@P)2.
MIC&__OL<7RKQ,'?F2OSF<> !;R$*=T.R[6X\V[7@NWI<YQM#W2T:ZQHZ3DDV
MC\>#A;OD>X?==2LI.ZK=O_?6B^Z-MO_NZ<C;.[KV%L_P^4=@A)[W\NKL]<__
M7M>>W_0ITLO?S:>S-(E0,UTEU45P%%WU.5(>HRNSU<?M/8G!RSLN<M \?4)(
MGS\Q#R8M?1S?@^PR*?(,'5Z8EG=15?6",3Q.<>GC^A["BZ8I7#N_F]@\&E=W
MJX^ONQ]5$<Y&98R_XR*YC$8])F;G\26A=S:V^WB_AQBLGC($YBP>760P[/,^
M,_1(LM P+7W<X0,XGO+K. Y>QUD\Z>7O[#R^9#-,3B\<J$Q.^1+.;;#Y>LS-
MH_&)MWN!QN,TJN(Q>&$%1AR#,W0>(KI5'\%YC,?4=J\$$/R13^'L!D\=O*HT
MZ76,[SR:4VJ[CRE\F)7S BWAAYR)KR$I?>Q?C&J E!C(*B687T?97\'>: 3O
MT4L?/QZQZ6,3FXD(3N)1#&;-,.TC0)\=Q/X: M3'(GY=Y'_UTRZ/)JZ_W2O?
M,QH5\3C!T^DPNT3LE^RF_PNN0C))].??BOS<$0GU^RV 4,<?3][\MG=Z3X50
MCT5FGGQM&-0CU#=/'@X&]7C$Z"%@4#N?#87_"K+RX#"HSY^EAY*9/K9P_U/[
MP82E_02X<5X6GUF_][[RS8??#][#>?9%8+U/'DDP9[=G96]4YAD:R.@]] (V
M?/Z$/+@NVNUU;IU=) 7'+:X#HY<><GH>2E[Z'%P?9E+[AV 8K*+H#XAY\OAB
M@+O]SC#AC?@X&V.AVT/.S$.)3)]SZ^#3* 4AN>QEZ#QY?+4!N_VPNU@,CS4V
M4E0+[]UC=AX)SGNW%X07F6B2S&H7/4-[YT4<.T( '5.^5E\^Y Q^!?GJ$]N0
MW$QPG$99H&:VQQSI&?KE@:!I.\N 0OL!0_L!0UL*&-K=@I6_'P:>)W>_<<D'
M/3OO'VWWM(=[YX/M8"],$J0?3"(,.KEC\_;3JK!WC_  ?=K+^S/IM7\4Y?_.
M\Y=D=UC.&/.A*:7I8]G>O_S==9L=!O_YX1"4JMUM][/!/AN5^>"2\:Q7S.1-
M/IW"R\(V2J\#%4 YF,!<]#)"'PE^]5FOC?-V7E07:+.7DKM_T!GY$L?1(1Y(
M[_>%CO3L0_#FZ,/I(9*2W\=V>22PU.<]]T@V3LC?0((2#!0);YMHSC+X,$P%
M^]U'/AX?#.AY/\Y1;]Z.Y\7H J2DL+.&IY!0<9W.AU][,A]*\OI$*/\S3[(J
M:,J?X,_,R7VW&?L64_O_'1R^WS]X]_[P[>&;O7NC17[R2')H+WJII5_C+"ZB
M%"%VQ65R&:4]UO[QI5Y?]$QW@ GSOW,P9CGH9K<*EHA/,^9MP]O>;>L\&GGJ
MHVQ@:I++9(R5!7KJZE-V^VG:?7Q)M1>]DB-'R32I6'@"N/A>9&OWD2"G7_3*
MFS0/_V]DLKZ"A/6"QS))'OGK<>7G%-ZD4=+%=M\Z68\DT?*B7Z)%)[8??$:^
M@OCT <>J386FXSLN48V#_6@:G??Q97<?B7?_HA]'RAC_)-)$G)W/8@7^_!GZ
M"K+4BS^EKK%-+CP.3N)I/.X1-OP"TG0W?^._@[/H4]\ZTX6NQB,4@ZW-7F['
M<1'/(L'-X+GT-DF1A10.))S+D[B:%[V.\$>B66"6>O/(Y"E.R]X<O/<@+VA^
M^K,$P!0]OD 1S%:_'@OYK+_&?20A'YB+/DX%U11.8A*77D?TXZL5@YGIXT2P
M?IG B!]T6AY,2OHX!C@7""I"U7L7S-"7E98[GL:'P=G!R;O#]_<7^=M])!47
M6YV]SQ:%_GHL]^.KR]GJU^#L!/O\HAEO\&$]JB0?D93TJU8'LQS+U#_.<@\W
MUV-F'E^@&";I+@#G#Y3GY<Y7U!?N3O/UU.,1^>6!@(9/E@)H^ -I^ -I^ -I
MN,!Z.@P._N_'P[-__?;A:/_@Q"N2_OW@7LRIIY]-D_15\89;?3I%^H##O=D,
M<_&FP4I5RR^"7S(K8BQ\B+!OXNTG6Z$0/W]R'_ZL[==7TI9,W^,4/K!0?MYD
M]>0:2OJQQ3Q]?/G6K7[='^LAZ'L5HT>2>-WJURORX-,LSLHX> L#?<C)^"('
MW&& )SI&!_:.[AGI^_219$>W^K4Z<A %1"A(GUEJE@!F]1U4S./+F&[UZW-T
M.HM'J&"^RN0\F CU.8CVN=D&]N<['5W$XWD? JHO*S!W522_!^\.3]%#V'M_
M\.'C/2F0QY*.Z$<2I"@. SE+^C2$?82IJYZ$0/-AFHQZ5<T\(DGIHR<8J]1'
M.!YAQJH? ] !G+6@-GM7I\'</):0=#_>'R1"^B/"'L$/.15?0TQZM2='@L>X
MF$6]*JX>D8CT ?1)#^GK8'@='"#5>9%G8([1.31-RK)?//Y1RDX?B-]I#"_2
MNW#S$<E.+T ?<@V/J(#Q*+KZWL6D%WKO=4)4CI+A>FGXSK]+D>G5$&T/5,IY
MUO-T?H1IT2?]&J'MP8R,>X)*/G]:'DY$>K40)XN%DL(%=N6$D^D_YT4?=?LX
MY>4.9)>(P("Y2<IQ,NJ9.G]$PM/'Y+4!I>.XH!8<_6)*CU-R^EF_V01.;6(X
M/X\*.J5T$/][%:(^1O&O.0S?]$6"R<GA7?KP,G]1,6J=!N]5:P;MJ]_B")?Y
M<XZ65FC-W3 )FQN[249_;6ULPY\+PGSR%=A2,3YIG2^H0Q(6HW5VEP&M<_G(
MP3IWE*3O'YPB=S(#>(;8B"R+/P5[[9M9@RCVP>/(XC%!ZWJ4VRB,Q-[ZO3/1
MOC))C:"!P7WU7_%U8)L@W5Y9*7WXA32N'?/VQHNUX6 M20:UH=<I2D!P+K&4
M]+C(+[&\[<%?IWO>&S%55RX<O(EF"9QYTJ4@..O7_N0!%Z)!Q_SJ!)1>4H"X
M]^=;_D(SWGI.W]:&>; Y=5F];5 9^6A.H"LST3]F\9:2>?#I(ADF55TOOWH+
M%@VZLK_GE5<\\M7GU0SX=6W 4I>+W2[SLD_1P\/-\9N..3Z.KO,YR"XX,]&X
MO(CC;V>6]]O/B^!U#BX8N!A@0\[[^5X/-]T''=-MW@'S*66<!D?@3Z;!AUF2
M?847Z9SYMQVC?Q]E^?I_?QN#O\TJU"CC&N"\NY2E?>&I_ZVN6I(4.V)E=T&V
M/-Q$']:MH[RLUH,W:5Z2 F=4"]6L[)5E/DH\;"230^$/W^3%+.];9/N%%^0_
M.W=R1K>F3$X>9?=V3-UGV."^ZSAN6>WS= GB!S_"!ZTW'.;IN/]=VZMM]GX]
M.3AX=_#^C+KG'1_MO4=^ZG<')[\B.?67?_X][QW_(;:&PPO74:#OIU=GOQV>
M!JVOO[K"[Q^L51=)&?PC':/S_,O'5TK]?'SUCX(^'@3PDVDTCH.(E>_\')X:
M_+__&,[3].7_%P;;F]M;(2:+D"8CFN:@@^6,/YQ&YZB2CZIQ"-\&AV41Q6D2
MC-B 65U9<X^VOK!^=$BS\C]QE/HDFGC'C;9;\AB"JXL\3:_7\RL,PY3S89F,
MDZB@>@SG<ZN'\YU75^#6_N/_)QX6$3QXC-H_^#U!6$;WP]?P)')W%3O-OR,.
M\#@NBNNC(W<OT$1Q>ATD69!4Y>K**)I%B+7#&<=;%A[6']\B2GWVNK+^[(6U
M FX\&U]#,+_HEK 5@:]?'9\<'!UBG?W)O^ 1>V>T#TZYVN^+/OOK[?F]C>#L
M(EY=08P5ED1?Q$5<Y2!850QR!W_1"/'?.6R32H%>K_"GL(G5)KM*0,JF^&_X
ML[H@T:4K%3=P7>[X<D_D5U?H:GU1::TU_)0>482(W,=_(O\;L^;"SOTS'E6&
M#G;D"&++N J0N?L"]PPI,:NZ9)A!-!K!T8]IR, \'^8%PX(E,QE. LG=E,'.
MUI/UG>UGQICD8>+\'457P>ZSW1?K6R]>O+"V9H7D8O /WO\P!?EY3'75]D4+
M#.'02(KX?)X*-QD\?3I/D9ILO+J"%\1@/.*;^W-X^.;(UQD3T&;Y%4[7U44R
MNFBLT2@&A4:KB\U-6<?HZ:8?#6-04[%5C@$IQ]65#NUX7ZOQ_2F8A4]^O1'P
M!N3X LRH[3_@"]=U -/\<["6#(*Q,![&N&A159M %@Y9<;.P.4F;VKXE+D<5
M3V?<9 GV,=YE=47MBB(.)E$"5^6AV2)XJR%XAJ0?X(0@1H#0&R7]$CXO76>G
M\F6 @?@@FN%NHE'?-.#5E9M&S-J'6S; W6O3DL,V&B&%?V;G*/:&5)]<&5M]
M:+3K^DZF#&VY!/G-AI+CLB'(SHJJ&687$<QZ'(&26NLG(C<MP^H*KT/(PO?E
M-DVP<,^P!+5L&C4'=L^ 5:>E-'33]K)%R.$U0AP1T3*:LW&29'"$(1IKEI>)
MBGBLKN"QB3\;F=,J##+<*+:Y!=QK%!<9GPJEVSBML1)S2 1SOACVW&2>3O!#
MFCQ%L0D#<&\+$Y+3VW)?]AS5 V_BRQOVL#IKQ,ZM3YC_I-"(4]FVVN#3W&5;
M+]GYM+\1G"9@@U11%N?S,KU6QEG\*1[-+=_AV.#32=S\Z8;EBMSYW][U@ Q-
ME#&Q&!LF&MX$_)UL/!_1AV(1X593DE$_B_#?E'&$S8"2/!.,D&X]* ^/Q\;.
MO>0<4&2?7S-:FSDB9WVMKLA!.9&8'3I7'-;C9=S#7P>S>5'.(P8&LI%6SO%_
M]*A(-](@:#M4T5\@[0R;@T^,D,+C)MR.A6Q7.=B,AXIS0$;L6#0$:"?W7F*:
M.9M-&6DMZYADHW1.-R)E+0,HL%,CW9WOQKLN2MN&$HWSF5-*WAJ3.FWV$-$S
M$IKC?M!XIY'#69)L$IP;!!+[UIJ!)'XD'D;D7FT$NP V#LCO%:%:Z:("R;-*
M_67A ?!*HS+=.&BXI1$]^(#O@>/"(<ZG4_0%:-*5I@$7OG&R-,ZCU*=5+R-T
M&6#OSN9\%6V')%LR#76;T/"SE\$'$CNPH&$ XL;9>/'VHXX7[V&9RZ@9*]Y>
MSECQHQ#:@WLY5GVCVHN77&# SXO=C%3J*,744:3UNCVQ0"E65819/Q,+@G.W
M?H3])QUAC>AE=VY*!R>:)Y][#QGW)XP^D:&H7@J&.47B/M!UZ;4*<?ASUF9]
M--]=7G@&!L<HF<%1%4VQUA"O_MM.N+FY2?_'PPOMB3ZBJ$G3>\" MVE"$(]#
M:QG+8XU=(4>#'$;3'%P".$F2' ZO-.)3RO^)?7&8%#2B5E?DH-=:7\;6/?O?
MX'EP'_F2Q8>"IG?#9ZY?Q7@._PP>3S&-TI]>O14"MXW@YM_>8JLNVIVW=E?@
M>K:/T/9$8XD,*9;QACE,+LQ-WHHVV9Q%L7$#>=T77YZOD,T[_;YS=X>9C01X
M,(?IO)I'Z>I*S6X%'64I;S"& '9R9!JOVW-A89R637'X4OSF\SP?TT=@^"=C
M?S"A)*5&<3*KV \HY]AZ-0&+A$XV/@<P?")9!3"BLOPJC<?GJ%!)5ZL,!?X
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M(W(5RZK@T@-[]IOY$\!/%)QCX"T8XPNA5BA-_I?O@?[4XIN0!.+!7\*62$D
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MMK/^T>A$EX,.%,/#R'W!+4Q+G'A3S6U[O]AD?2A. Q'*8*4_'D4.5*!X:4B
M0'[GS/<X20JD710B8_2_4DTG6<H>$1R&<$_9Q\JW]K&*W9_G!G]M1E^K3'7I
M-T/\Z'(9]#C6]?;>I<=8;LHHO;'>>$ND/U>CM_?&3]T,D9-F(2AX-4@N7AYV
MO.F2G3VWRCAL?><9AZ<_,@[?K("B+?X>"24)(T]GW 3C+ O(P) W'MMF5,KI
M8?Q"$YFF* Y4NQ(&O;=YK-9V];TH53/MI\#EK%7G*_@^D^" V<+@/21DUH"]
M@K%$^%TRF+BQIOK>Q!\1V)6/L:D?G+4C%_U8")W'Q'R]P6N]K96Z+4*1I\1G
M7+LIIL"',,FX#*S@SU0#WH-/LQA./IL79QR(]0>)"1B/*CKL!09 ?IIC0TPR
M/G8-(  ;[@E]9MUFPG^KIZ^N^(]WC;DZ\LQDX;1[R+H>WMIR<.DL*KKJ%4U
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M;F&WTS-&ZP+:?=W4(2(O/P+\B#>$="J2TW$&F4-\F%^4WA'V(N:^P]4%"W[
MU#J%!;M3DXPQL<;@\S)[7;VA*,MW';IOE_L+K^3#K-I/K[2>%$:<TI1(8D(Z
MO8JNA:+0U"14H=0D-.I9W*D:/-^U1U"S,%[IUZ[Z]BY2'J:DUBDO4*A:(PSC
MZ@I'ZPF6//?C:7 Z'\+R)PAVH!><QE7GLWJ_H+2PO-T;MB?$O"Q8C=E5)^!Q
MFV"0FH3R*+H:?,N<^(^6O']+D?>_X4)@4A.O!0/,K3%5!Z!Z<LGO ;2UQ1V
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MPOZTZ(6$CEL%!4-899GU88*^C6$)9J /XD7QH(R%R%MGL6PKFEET+;@^;#H
M:KNL\M%?H=\N4K<'IH@$X?JZG6[9^#6!=N=&"89JY1#%K!J<JU>3>241PF@D
MMP9SQLB-IC@^ -4( S^4"LG28.1F4H(]QOB:$"E[81AS7-WV^>;5"&W8_7PS
M.K/5S.9CT)A$)G+S=%>IYDY(OJ_;C2$?PX;%W*0W! R+Y\8<)YRRDL6<>"84
M>;0G"#ZG>\\7=V.KO[.C&*&9G5K"!XY@(FY=9.44;X@X 7;CB(THFD4C8LHH
M:2:630_$ \Q_C&D.3:BI\.TS=Z;:C;KFAX%;VYL.;/=5- D0N5@R'!C-=^R+
M3N:^/)*^0J5 =$DF]LQ5W>/8: [;DG1>SJ7+[IV;QR_;0D\P4<]>%-L&V&-J
M<;=4Z18F8F"#$ UY2);/RCJ';3.?3&([FW9V$*%LZY<H&E3\_^R]ZW+;2)8M
M_)\1? ?$Q%S$"-CC>Y7;'1VALET]ZJFR?6Q7]YSO^P62H(02"+ !4BK.TY_<
MU]R9 "C*)5]*5,3$=%DD@40B<^>^K+W69B7F;].BG'P2_*)G?_4)<C#^"&B.
M8;5?8*(0\&E5NVDP"(9V&!9]"VC %P4 $A=E7<-Q5 #0"JSR.42O9(O_6H?'
MTX&]SKT*T<]N>R'ZX5TA^IM=H0 K) DW.JHAP]S4RP(]S-H*E-&WDN [J81P
MQ;)/A9!Y_A4LZ]/-R+A^V($2-KPX3SA;BZE_IV)&J;R3Y!-?R3LK<L<WP:XT
M-.'3_"PK%QT-/?*J5"B%6Z]7>GI/J0\X@3633=U!,3FT=_8K)QO%X<$B\68)
M_P'.+DSOZ29#)2=>\B?N"E,W>> W<LL6!+8IR7#/,>]%0@+X:P!SM!H^=GZL
MY5Q*=E)AG?@+^?#71@!%9-:=RX0AEW,LLHJ291<9<VJ;KDMLO3%Q)X7D[GHF
ME-.TYV$F/,]M9LPKO5**#)H7UVT?5Q3Z910S')R;6\J4@>W"B9I[8E+&-[X(
M/LFJ:L/BJ68NJ6?RA5N[]4JX'\V/?-=E^+L7(K8LY'^PESS;Q0MAQK'70XX<
M^ $(%IYRUMJHGT**NH ZPSR''2ERKH*V0.'-.6:,X+A, Y/MP5%JMRD?X\7B
M7'A;EQ="H6K+O)B6R7WRW%.\EMI773=&1)A^0-IX(H%7-_K,^J S$8[VC$%$
M+=5M*4TZW:2?W/L8E'JAS/N"FJNAY#;W<1&Y$&N1J,M8F1.>"B*A!20<=5H;
M;00NJG!F#FWC+2DMXT(Z2%2>(A6"2<\(M,2W5 /96 F+WL4);>S']>9G.@RU
MD-6U7-U7UW-3E4-$;(R,0T;1RAEUS8$PO8<D1PEN/L/5NJ!5)?OJ0[U87V9-
M=!C&5XC$V6=UM4""]"(+E=$LI=S;2T@6]X^7;C8>]1$>!.R;K,AVO !%1VQ9
MJD/M#-8)3HFP%W\PY<H;S*CA.?&E$&9'F;HOUQ6' ][Y<Q<MLU6;A]EF .D%
M%,GN_U OR3T\%]Y5LU(Y054AA.2L&OX#F":=R^XTN6GA>3JT/5N!.#7J;K'M
M"_*G%CHKLIMS8%B$I4]J74%V%$(R^MH]9R8A]9-;-LN6ZZFD:W6M77L%"@//
M,\_JX**)7SXD?ST^?G=H[[/>Y2\656_) E+85@A /<< .3V;.>>IH7JE.]]*
MQGU39R@FPQN1_.*3U[]L*G?,7=BP1<_*I\H)D+TBRULW/FD.J7TEB,ZB+BWL
M@Y/;N#$"(D;<%^[?1T+J]N!*(RN.(CL.EP9O1MP/33[,-![,\CH,*#YL5JU%
M;)U=4/)A%<4+8%/:C L\")Q/E5]B\8^NJS<)KGIH+^B?@BGR486%%QT=3Y)I
M76U:K# O0)!(^$%M2P9$!Q<Y9= %\\!\^"L29X8LP)J1EFE_7T>J^Q7P*U/W
M1.Z4#9A>TJ3*-V[9H)\?T(^2]2ZS:6T0#QY%3Q]L*L;7T+?]W1)S,^5[1QQ-
MBI;BZ(<) XG#^RDHF7GWL3,E#2A+0XX"6>SR?3B@\G)A,")RR50P.N"(@<(%
M<B<U S!I!@TYNZ??3KN72@9_S^F:L-8(%4$V9CE3I(LPS"=7#)FP'%&Y3$?C
M?OOHWU*]TYP9RDV_#\)D6-C 2"^,1RL61[80"CUD9(Z)Q\"?Q  *_\T-$%[V
M#_R==_C>R*#X>>CK=D"IX@N!OMC^6[=4.B>$QTRF'B^)?$\*F2R+<P@ZUG4:
M<4KZ$X[.%> ^5C$>[[Z_Q7UV:&:K8;-E;#_F<<TFE0HA^!%-L ?,QJ#M2*)
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MP!9](2F/?*UD6QNH8.9J&+3R>IDY:P'3A@A_W&Z+3>F682G^]+P6!FM$TD&
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M4NNAKZ/N! 8N)!K/UA)CLT1M#];/Q"JI()[:= #KUUH(5!OSHA[:VCB_(BS
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M/&(1[HM" ?@-IM\XHZY+^DN*,J-ZZY1K8<ZE<Z:"$HH%9G9%-6]0ZHYGAO0
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M]_\FD9\0W8G15X^J5/.BG95U2YF]*/:6V\SR^VZ^H!:D99G?.8JNLTFY#&[
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M.)*AY:*UE9AXK CN]^/C.J-58Z0:(#B(%5.UQ94U="R')R&ZA7H9O76\L,-
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MR]Q=OBK$13Y@/WBO#-MWMSW#]N@NP_;-KE"00S+N//0SN5-A;4NK[$0;;R$
MAL;IK[Y8/A<A&R,"F/_&_5;=:XY'%=?OKT2M@CM$!RGZYVIOH=T5S?6Z/J6_
M*-B8.[<N>/#X'VT@BN%/(RQE>=W8"8,HUVZ&R):*E)1ZF+[3%T !D :9NUF$
M<E :',#]HG4"218N9>;OI@X0=P;JB:F'KG>-8]/.F#NH#)4Y)G9P]N 8 ^B8
MLKS82Z?^PO!>+R$L($^$C+QS!8BI#<#'Y(Q$OBN%X3!N(T3]&69*&\F_P-L8
MG'QN/E<'GK]M8E>B.N)0U5T.IB=J9&P'WM^!G961\NV00?%I7Y6R75MB7]0Z
M;0-W"F!5T.+,'RW,&TS!6\JA*5R\5/X24L[.W9IW(YYQVQN]SCG1F3),M)UH
M]P&LJ7T@GD@ )OW'%M,#60:!.B-"NX5D+9B@2==O"_"?U\J\E .9E_L#O26[
M9]\G.W:2P40)5I+51'[?1F+B,L/G=F< 91J$3@71!;1)3<M#GYCP>'1,M?'U
MEI3/BM8W3*QHUG*?/ &[1.JQJ"T(X_ [\:(N-]6:4B7B7[O5LJS<$("ZAE,[
M 6%AI%(L[K,7%X8Q]\L?L_:&).094Y%:YYZ'"'%=Y^9G&#+ R_9!*[9-%P%&
M5]? Q^PWPOQ#[[4)[&A9!? =S2_<5:\^1_7J44_UJGTQ'OV434FG^M". 8+R
M D32+D/:SU?V3[&>1<.Y,5^V(;.;4"/6%J3/\2A'"6BL\)0PWPD0$9SG\B^6
MS0/*IZP\=Z=(FK1E?0GHM#19%;/SG*I#3;[8M$2W,VOJMN7/@)LO)PCP:H4\
M44U2UC.XD!X:,PBJ*;5D$Q9D[>KR0FHEN18V8V1HU. +$Z9DDW#20:9!C*4G
M\DBF[OTPRZ":D50+X2;+:PT<FD<DZH?G5@'K^89NQ]?DK'+&LXASS;AGR#M7
ML\) G^@[5HP[W=DM<1X<*_AK4 7NOT7WXD#S 9+LX(X%P*T8+A ZL.Z3HC&!
M@$^BVO< BU9>@;0D5EX<!GE/EX0FCJ!HH !WZL9('F3/L&E=V[>F#T(Y,K;P
M^CQ=,6T^8E9NT>(EP0_*RURQF)MJD14R9U*:2&9G[I;8DOBI?@YZ"%.2[S7L
MKL$QJ.?VH5F[:;=4_T@H:MH$['\6U.,Q*.8H1Y$MC)!]1Y6HAO3,N:^J12?'
M3348H*6[\%EI,KJ+9$G%&?>E7S[\:_(P??#@09+YU2,9W"CH#ZLU.T1L+HH,
MZ)^+!EML$178U*@H,2>=F!GE&A8E5BH8M5X@U1PO8K_K"+9,;XN^]6L]33#\
MH_J/.#RM 'Z15]?9W(Q(/Q"!:G:Q<_;;5C/1K>V,DD1"CF7LH:F&?0%D8%"6
MNR<98C"_]X@0$,FCZ@W4G>!TR4I0"B&&C:.7X-7KAK7 484M5A,W9C?D<)R<
MJ7&_7%->N;K'_V+WU2> 88_12"XSUJ"$X4 U:E.RM0W50/\+"H/PQO\!4P<_
M> ^V"\L4#Y\_?0@#DG> #29!<(PH4(F.E;O52X1R8:YH)6R?1_=W[Y3GJ^&5
M%US_"/+=W%? WX-7[*XZ<<>1+&\@4J;)9EWS:H/=LB57.R0'%%R:4QN\A)>I
MK@"ZY5G(2616BAL'>>/ QHC=>6XH^(O>ZUO<V;2N-MAIP^)G82K&K88+P/SJ
M=:FFLQ1),<L^/P'6/L#&^ND_,NPJ?S[YR[1P6]"] O?U[,S9IN6?__/D+_C"
MW(=N!MUF=GO\S%GCY68-GTW L9EMM(,&U$?YK84!CPFF 7">F48%\6A]M4(9
ME[?$$$B]O/B: )OG;&;!;\%\;!<=+%+?9G.&RQ4YR[(M1?'.]Z(L5\@=+.AM
M[+Z1U4>E+_P25E2YA(7WLS>\R+A8A7<9O+!9U;SH[(1!G[R]#I&ZT:+7VAG0
M%598[0^^2R-R%JW,J],UEL"YU,<5*M\)4W&2 A:RUGUB!P:A3^X-@4W\3;8S
M\)S64W=,\]#"UPM7/G?G%X/Y?Q-+S6Z2DIURZBLA74$E9:;MZ)D,*-L2Y,KH
M9="NLU/K1M/DED ,LR.F5A74 CG"2AX^$9].1(D_@& EQM+OW%IFD_;L<4>Y
MP5_@V-_$]IV-1T?61Q5LFJ8:U,I%8^Z_,BP6R$!J0701SH)]4CUX6>4=G2M[
M4]6\DL9F_)D<XW"*8Z=>X,SBNZ[8P83W$WW3K>%&WB"<2+\5>DPOZY9:N"%K
M']@[D\*VY\L\$[@A8CLH6JL7=%4XL7O>/VXM=\DRAST*:X?])4DZZV='F+<#
M5%^=<A/:.C\%3C]HR8.OI,:M"9HLZ *^'5P@/_(77<DREYIH:_+UIL%J,IQ%
M$]X>SM6@;751M-EX!( "L/7%PIS/7];;??ST_I.G827LR]][KY+H][>])/KX
MKB3Z3:_2:V3"'S&X/X6J)50&G'MF7#4"X,7 1"XLQ2T*<2 7.*$,1D:_JT$J
M\EXV(Q)!<L;X# X-JN/-1?^/SJ&B&2QI$11Q.+($2[Q"VDIH#>2PA/V6,"GP
M'S8=@',S&$21%>;,B8F)>D07X9^_?/"ZB]N]$*A3%(K4T2K;8$\J'GD#KS<$
M#_C#@X18-EI.BO@$FE+/>C4\Y]GP";0F)RT#SA"Y>7-/1^$+4,CMZQYH?8G)
M>7/#N$_]?J#OU)LCT"EW'O%UYMS$;[+L6/'%%U!,%$HII1+ TKB\)($! P[K
MM.-1=Z"X=3Q+3%GZA)S7P#9AA5! 7^;&(6< )%-71A#NQ/OA$H2WAN;_4^IC
M:A6"R50U1N?$4SR^-<V=Z[.FWIR>0?_CJK[$W*L[%0Z/B!$@YO\@..)XY)9
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MKXLUY TNW.3.N;$7(RG\JC1AFA2)BTJ4U")03/29N!:(O&S:RF=.K@8^(.I
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M\SM@6B-+HUJHL:6)MC+N8ER=6'*6C0L@@TO^=B:7PC,/?!_I7)I+LB>.WU!
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M;@PG$]H^]G%\\A2&;9A9E"6(H:WBK\ "L'SOJ31QH+PY#_"HWTI-$NHUE?X
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MI=R SF#D'FL)26\LZUFWV#W*1<$F<$<& N$E<!4M+8K7Y*6&CH:9R(1"R\#
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M^5RD3?3Y M%P0<AM6^>!1YO]QJM$TX.L$DE%89C&U9A"J1L<VB0MW'FY'H]
M_F2=?$]D7+ 6_SO?)J^U ?0,&QR7%.5P7^C<,_MJJ51(5(%-;$W)/7_VTO>'
M6XN@%VL\\LU8=@@#1(G)D?#QI,E9?>G,+^3CD2R!V23 '00O:+E!G2]/VAM<
MG?X#!VDK\L+XAG:B!;L 1CF8&K012-C394-\2+GDR?WD30^WD'83II)]H-.C
MC\X-YM_('X3SIJ^!' ?4%')/6KA(QC+PJ590Y^D-!RGI!GFZY.!9T5P=;TYA
M*A\_$!HH##@II@O8E89O$G351BH@-\X4],?8AJ=N&P(ZL%TW!76\BB-I/3IX
MT3\W]Y/76_<^/]9E/L^<T^'5:&3[H1.!JZ&_V<\X#%$9C2\^'NG5?8[V*D:N
M(#P_=&_CC..0*-R PG99NMD"XK5WV$T%9#AML@">,&P^*:%/G4687E?.A9A2
MBTT@]J%%QI^*O.)F&:2 KA?K2TB8T(OG3!5F45I1$-EC0(&CLP2FLD:B###M
MJPWULV*W\CWJ5G:68Y$C90Z<KK.L8F<''\S=U!W"2[=NQJ.W*[?T/F#/JQO%
MW.>$<%7UZ4CK&CVP1;17NN71;4^W?'>7;OEF5RB(O]J@ZC_:Y.59D2^2U^0+
M./O!U'/H0LZ .1 S#9"K;0JB"(GS(O!-N+#SH;:>3)#LV\G)<7(*F6&P-^X_
MEK9M'BHZS)H85AZ)Q.$%U6KPLAU="+@P'7(<JCDKATVUR&GKSD]LA37)'J**
M\#X/?W\2T'#$72#_T9*P4TX/ 3QG ;VP>R@W;I,D &&KU=H2>?D#V_NY,E9,
M^:"XY(7GV7)/EHY')%?O'QLK5EJ;PU\3J;"-5>GK:;)9&38%W]%9)_]?[@ZG
MY&,^.ZOJLCZ%O+]AZDIA"*B\A2=  6#;-E^O2TY*J&,SQ"1*ES\B]M&_P7MC
MM_-!*JX&$[%,5%'JLFB5<!.F Q:&<V.L:"!1F* WN_L!.I0JP(R,DT(2Q*;@
MA3,8,9M]WAWY9?;]O_SE8[#H*!+D%0:[%&&Q?V1F[O;W4'._\S5@N-ZFDJF8
M;D">X*+(+^$?-!.0@'53\=EGPCUJ.!,I#D=8]"'%FS496<I%<;IIB+\*8SAW
M@XNL9" ;DQC29$2.HTSALWO./UR?R==I+O^VJ7(-$>_0EU\0??G8H"__!DJZ
MJ& E;7ERAE ?OJRJ*]"6>I9*^_ZG]B12*7<'Q%*$*3ZIL9#+,2S#05X!, 34
M%27;$;L)6WD\$M?#L-X,IJ6NQ'<>(#03&%G;)LO+@J0@-NNZV2;_R&A6B="$
ME]+Q.J'<XM,'SA?;MC:T="9P!;DFSQ8!(I0D: [_8E#O.Q'UCO*-L!3?YZ<%
M!*?<YI')W1[O<[=,DL'A_?@4MP*9D?$[L#@4BJKNE4/+Q4_Y*>4)D&>P(&UP
MR&\F?P5BM@JV,=2M!,T*$S=#X5/8.[]NFJ*=%Q3<FU?C_ AZNAP\>$CF@M(U
M%23=*UINRE.- -R68TD)Q'!92M>SC&CT)!^U !422;?RRW6F!A\!P-QH(KH_
M6LG3P4JT7B6+T<H5K8BR)GI^9NUS4"HNY+'\TZ#;ST_RMIF+%W_S(T?UHKV&
M'J[^0UO:6-D%>_;A6(M#_A <\'M=U+<DH3[?94+VT(UGMFE(M]=O@H"&3078
MGKZ2J??&U/\:.20?/G_V_;='%_/'I]38YPFN(9;[]/%M3\)]?RN2<-_T>ONV
M=TP(._X?I: Y>?/J]<]O3GX\>7D,1#0W2#YS%^+UAGC/ \*9O^95WF3E"U <
M!9);>WA= ="-@KH Q=P#'Q(ETKQ9$_;98F#"Q!=)T1**SF=,4TT9-/E2W.XL
MF=>;*0*HPFNSRX1LPD)/':<@XI*6Z('1L"!IVBKHK5\&R(@8;_> 31WY8BB*
M+H#'!!VI-0[?MX"3UUM=Y%M(^V#]?SS"K&,O;W+FO&)T-C?X2[":LS/_AO;N
MG2 IH(19QH=>%G<^FGR[OBRM)$\1^NB>D"3>W"MX^"C!/$_;Y?9C-1&FPH8'
M9([H4%D#?@$)PQ_=O3**$X K,W@VT?'@"X2O#IZ;N99E?#XK/2>V/@H+GG%B
M;VBHF*_K,(?0' 1]4@^_1RKUH]XJZ>2&1OOX63"U3"=L!OPB^?/)7XSV%/Z2
M+.W)7]*D3[C*@$MX=-$BNWIA 89V_UZ5'R(LV@\[&BP?4//9Q^PWMT'[)^D9
MQ^]F1O+?5D431"Q&Y[;%+ 26&<IB6= 3!=A<A">Y*)2)]2%[Q$6=-96')F(U
M<<5:" ;4UXTL+#:%#&?'VAPW :%G(X,"Q*EN('VTD#UR90K^'= ,0,"(#-8(
MGQ6HM\JM"C/\!'N;I7<! 4=N";NH'-+)&+Y[ZT3F1Q (X1K!X)-6R-8;'M_1
M$SSI-4X,8X-X.4##A\)J3>>WH<"G'#068'#T -@"AENWT'.EW\=H%Y\-!#-;
M%\JM^_/YG]R1%'M&V'D6)"CM.N536NN:\$QS;C+IKIS]NYOB;?:<L&?04!K8
MCA0-FF+EP(*0'0+!<6+X7SM'IR_/NL]CT$'NPV86P%DC>HS?OJ:AK1*RY*)#
M!*[S#U[BRWM3NTG.#=B,WJE]H;@0[+=[=I1_!.<7#+X*,D%X/9R+K#6K#,$Z
MB)NGRG#%;,PN0+O(Y_>3$[3I;+ :6() 65&M.TET+E&:@?2;Y30\[ ?:&F[6
M:1/'Q\UO/2LP]Z;RL5/2PC(6(S,VHZ^C:Z\GF*").G/+GPP^]V_W&G:>/8+4
M^R271_.:I8IE[$\<4XK&'LO8(@2>[G7RM)W*\2>/ 5\&G8!?]&U J096Q!06
M]WPS@UHE:9YMH<@G?71[V;8>P]9OKNXGKWM8T#M")#",8*U3\T1+Z;BL60J1
MR+TRKT[=;2OG#*T+<7.<MW4:W@! C,MI/:>-F7/@5A"[.C9I^+.^K5?NYFO<
M34#IQ-=P^P9S@_L,X<4.%+0<VVA6K)PH+ODJ+[#0ZW_/RF6^R@V92KT0]NR4
M=->S8N5+* 0F).B>V4P<L;*[I _N=M6V%ATZ] P23&@"Y_9TL^7','\%H(=S
MF!M1MNO.AZD;BL:=@6N<.F\05'$D9&1G3;R2*_??3:6Q[Y(0 TD(R_*#"##;
M1Z.G^4D4Z78JS1_"8C"ORIM1L>UQS)Q!7^S@J _@2J;T@H= U O4^6X'_O[W
M&NLMQX8S;ATU'+62GO ^+1:R(,L'@%ET84W6894Q^ -*:F[[@,-%'>3X3:Q[
M$Q)$--O7X&^A2TR6Z2,*#+W#??^2(D.WQ4CUBW,4;:!T@VZ$,ZW'"RC.9@ K
M"7(Z5U#^]THX3M3J&;DQU2 #G@+0EPPTR-*@'IL&A]H%?KR9@0J R*"ZL]*M
M_C8B7UIRJT4!DA>K;%8(K0-.UY'O/3&]%\:%#5I/W ZQCW^:0?XG$>@:O*U7
MV3*#(ZMU.Y#B:'*FH==<_\1Z67TN,\ERP%=0'<K&[UA@I%,/P8AN& >(0T"W
M57D\MJ21M'\ *VS+]O@-NOEV)M3"ICZ-;G;$MFD2D1.95%@29<*^RIQ^78C!
M/F]S>,;V?9NI)&&&W^4^N=*;FZ4;G_8]&P>>W/::Y?-;4;/\^NOIFG *W,:\
M:Z/=P^<6PD>SH@3M]!ZY R_@0]DD_HH/5>$2/CX6MH:0K(9LLJ<V"$=R:-9U
MSJ\%?(NI"ULK]A;MU!=+-T_@X $E1!^^4GK,;/;Z-:N(*O=7");4W@YDXL'V
MA*I>@Y7'1MPY-<_.-PP?5>*P<K8I>\!)"9 (%G/&2,./)?\FY%0@-'JSW?,/
MD:KQT!9,S@MFIB'"^LQM:?=2 >9/?X2L&#!04+8?]UDC"'6(*=Q*2_KQDW*:
MGQ<5^L25"^&Q9S%;MS4EIF,_?8M-/<YOZKV!6!7RK^0G(?>4AD;9%.5=<Z([
M05"<>X8T*0MW:>HUJ4'RW?\[32 -4]&?\3]3%AJ02[)S3K8(8P!;"6%N-:[/
M68I*HZ@+M=%=4]H_E4 QXR./[H\EP.K4S@%-B!AH]:\6A=N(!:1TYINU9W/3
M*[C)=--5<7$4,TG!%R3# Z[P#.-WV((7-1'0+;(+&@6A;JE0V5MM'T:4<SY2
M6RY,N2H035'B?H!%3/L+^_\I2V9A,@_F6/%<!AXC0.?(D$! .#\P5IBC2>K9
M@V#1\/ONVU*)D<U.3?"77!G[4<TW/%+?95OX_@?G)&=S:CPA[]9S:THJ 2G/
M.D2;(2E) ">-L]N8"2[+>G:ET4XIF1*0PM&T1,/OM_A2E_#WXNIM3_UL: I\
MF<"<&D%%4*@??)81T9@P/>9O+[DDT&K^<E#=.=I]+]QL'MB!LN #!8O^L)@D
M.;+*MJ2-'"TI^B+N"Y9<;YV?@0!^-GCKLX#C?S#;A/O%I*^ RX_3Z)(56B!<
M>T*9&*/-"@SS[[@/BI);T.C'2SQ+/KCW/Y^[P;_3YB?<*EV*06,$D"?!+;7_
MQ]Z[-K>-)&FCWQ6A_X S9W>/& =6R]?N=N]V#"VKV]J5+;^2W#VS&_L!)$$)
M;1+@ 4C)G%]_\EJ5A0M%J65;8RIBM\<B0:!0E965ER>?7$@C=KP47Q[U.X7-
M\$"DCI:H]6$F],M8YL3_WIO&.>95=5SY4CZ99SBS!I>T4R,RTS/DV%1''OI.
M%CV!RI#5!U,A-5[UI9*OTTJ?/N5".DX4)#KS\ *V0!#_F@XT++;(LSGE#3#R
M/_,5/(&%6G'X!G23>\3J<B :OZ+P;_ 6K)&XRSL8QDR)4M0*5'$8'"M/B>.@
M]#'(&O0IL6<:7B@\8<3@18<PN9N-8#1J':K?DM2CU<&Q'(.7C>5)YO,R&RQ<
MU?"'',[GXAST$KP$7G<()RI[4171.1#Q6'$-PUP+8;[#?.U8==ZK^0"2AR93
M(9F2V&K E:<;+UA/&Z #L;U%W8P%=B?[8*>OE1:\1BTN2M2G9W-EQJM>("J!
M6[1#;W*M;W$'3-WJ7/0VS;LXE\-@7"8+LD!\15U!>WJ07B23\:967>%SS^J9
M(DVI2:8('2(+0K->[PVA0XW,GH.!_H$%I,P A%X9IO:#K:T%UIJR6$8'U; L
MKF2O2=Z,$D,!FB:W85E" 2F]F%IN'7>,^3X&#^;&*B-DHQ;1N3SX%J!>,*UQ
M&Q:,S+F6-\U*"P_4Y.:2BA[+(CI)YHF\CCO9,?#QA07W:XKM6I'GY]]XY/GY
MWF9&GK^6='X9Y,/VUH^[3__M__[1("Z/#. +=-&U:(<SCSFJJ7/W&ZNOFM7R
MV&=3B^(-VN7N4K^WG,I[T%DWT.JF2(.\?;20P0?A+C@2I?O3YAL<E=)30,'&
MA-3S*/_D_!S!&0CNG5IW38U=<,:$P7<9.K,6-DLV=CJJHG]YLK<7[^WM$4]F
MY*$* 8'MV04</OAO"U6(":!=X\9OFZ\Z%W6RM#@&Z\/2ZP4OU3X,QY[0#JC8
MA3>-P(7.V$]OGP!"=0M;)-8PSR<\/ ;_2NG-"-S^$59G<"3MSI;XJ2PQKJL#
ME.L"*HF+XCL;P^"UB_[E<>O*O<?X%EW7NFPNX6+ QXQ^'!4I\X%ZTF@O4_10
MG]YI>8B?4?:>YL554HZJKMQ+^\K^5$>6^X(4_CPL4O%39N.6S="F.MN+62'
M"[]'NG RY)HR:19[VSZF37>PB (3\EV!O@@I2FF6:)G7GB?L7*:S;8+-+8M1
M+^Y9/8V*ATPNBXP-5NS,PB5T5Q=ICD9P-,49)O97(;I*L7D9)^,8"F:*@+A'
M1DI_(^]B5:<OK\3HKMW5JPRGYD:<OLVEI0BVZ("EG3B1]]M#$DO:9J7>:H8"
M;5AMKW1="QCS#EZ5?DHP7!T' 6\3(XOF%"@@'#2,SL''!-[*,N\'B#!5XD)*
M(Q DC@.2Z.@/A3E)F?I'&/@8^1<S&YY^?\[!1YICU%!Z'4N_.C<MYP)6 <!C
MY8VJWLVD A^% J&24!#M%MY0MYTHH@Z%$'>H9RK&$35KE)#BV^P38I.'R$J0
MMA$8*DGIPO/F@,%$/E5GFJH?#W$,5!+CWM?7272?F\R<XJF[[XD :QY&FR;E
M,6-2@+$+DBX=DXH=+R;1-*N0O6@QY*0<!CPV)H[AH5U?W4)CS4E!I\Z3LB/F
M<,.M"#<R%8BC%&Z5#4Q5M1\C.13"S6^F@X6IUD/M09Q"QA;'/-AB8NL"TWDG
MY82B=>H)7*OKZN6_583B,_"-'N')8@)7U!Q"FG'@"9CKXU-D7%:;MS/_R5F5
MO+#G1Z!]G+:<9.W<GW;@3HN2F1_*M)^5]GPJ5313_9HG#26U'@RGK9R_>9G/
M_YLD&2G6,(2G 7FTO_@LH2]\\/].$3Q"PL_E;<7XIB=KL)VKMOU\%S[&4'R,
MNA8@&X(B!G@ EN&JU%3$>5G NN?I.6PB##?%JY1&ZSIOFB:A-O)![3SE_6!9
MF7.P0:N03JKTBLJ49$-R56"Y9*!BK2^@07/8]H%U-YK[,HB)K-?%8AJ[?AA=
M+8'4A(;138L\Q1PJX4K(/&FP>EQ+)K%#N*IQEF>UWH92XWW=#7HKR]_;&A^V
M&O_UJ)BO"-)];&=Q5:=*16AA4AVWE<63KZH-P"HZ[; 4M]V1;4(SU7]&(;24
M*AF82@7OEC#T@5U),QRI#'5J'N6P$5^JY7GQFO6F8=,T0MHCJI8,NV9/W6SX
M&LQDR-&QF ,+V!C916M%Q:9<+QR Q#+J 54K6*I#(AT<#:\>@(V!V>B4:I#A
M?Q%EI/9QQ@@: P70(C*ZQ56RY#,K%H2C]\>E?[WBL'&KTU&,>#,/36OCJ$$G
M2-"5=$W]%3MKF-K@V1LF5FLEQ5Y\ZTFQQP])L7LKH0C/>\>A$#Y05G3%HXIS
M:D[3]%B<*^\5"9E("$=R=)E4ON$A? &>RAU2C,!J:B%7N+YD8"55?0EZJU7_
M-( 1FZJ%$'73;>Z*D=NP:]M=SB \;G,RXF>O%<!9@4%Y>A^*6<_ZKXX.HOV#
MHZ/W_=>O#]_]^A]_V?L+_7WZOK^O?]]R="LU[$_@NHWF%WB_O7\%379VHH\A
M4.<PF>C[P%TZVC;@"[S6G\GM]G:_EP/I[/7/;5\_@:_#^TW2\9SZO-1_T_I0
M:0*(D,&2<?HS!':BUE"C5/J"A_@:::Z-J0A,>FL@@-Q?:C(E3!4.^"[9HZ*4
MA$:S-F&E^XN(.W@=F*/OSDYP.G"I:=7O+HM.0K6.]#U^D+W5LG<#X7.QOR9&
ME%NZNWC7>,*M=_'802(U*4);48.F:-$@A-8I2 ]"=,^$Z!92U 815PAS2^24
M;1:' DJ59T-27+YR!&R?!37UBV9@DP_%G[.*KCL LGN/!>X+-UCL2%I>:YS8
M);9!.BI=(,J46D%?D:=^!5K*R1IG63+OBM63@3S!>J2E24H$N=I6ZC 9E[5F
MD[Q&E],<V::9N%E/&86H\]JM[<_G4>!]T*;5Y2FNZDV_5X0_MK>"9(;GE@4;
MEZ-\-?)=3IX3GGE.<FN@&LT$Y5"SY4VL,OY__HA1U63JKP!IT[7U1C>^O5P+
MB !_$"6723;AC$V8\.D<*&(XU-;[2%D+<!1+"HHSJN6F-_1[77L[XTK(KRN%
MO 0PRH2:863%HIH@39GKB&>I(WM12PC,L8VZ^&H5C1:I,A\9TKMK1AU[5%<@
M8CXWK8'R6*LPL;J>+1@M7AZ!55NF^C@*YEJ'/(X$V:!RE.7,H(17'RMWFV#O
M@_Y'V"#))S2#K^CR6@IQD$AM5&<^<!50GJJWDHR&1QW-N)@8.S8MFY&(J@VL
M?ZOG[D8'[(;<@G9UO9R>T(T%I0XF+%&+EX0,MZP$M/MBE:8?&5E%%-1"(N4,
M$/V8$'-<^X?XFO/45Z/#@GKC@TP.#C0[,X1B+XBXLJVX&?CC&B:VAH4-MU%W
M/N8N<!PVAWL-'W:SFWK2O@:NL(ODZKPH1@C (H)$9,25=IBN%^<D^\@,%\1?
ML? EK&/7DB=S@ -K=ZR8-#\NW\7;_))%H,:"VUJK? =S_((.I-;@?]B3% 8X
MS&8$^/.I)I"QT:4B$DF9,UNZ)*'P"X%PTH;EVDJ7\$/7/W;).L0>8\2QO$SM
MU6YC$_MI93' (J)4".J:KH:,X4G>2E8:5H-B3E+/05JB"2D/MK[B=0<F: R#
M?4#5_3Y9,A]@&G1UMYF<#;/7UDJ,?/^M)T:>/"1&[H&$_N5G9NXF"A!ANL4-
MG"^TEKUF-5&)G]???  0LGZ0LDU#QF;SY!%FNQ$K.K;/HM9LAS<*VDH75<V0
M9F\4<:[T&P2)I:-U-EP(,FLS]]Z7> +!W+@Z=<\_ZHH>8;8_@E%UB=M6!['2
MYI2Y9N9YX9V1%,]N]$;)ZOE$%A(8<APHR-)<JNVME4_[\DNES47:ETILATK,
M&O!FU)CY3*NXO>66L3'MMD$WQN]Y%>HTLW>QRE3/)F+T3?3*[CCD;D>P_"PL
M-72SZ%&6UY8;_M+)S2OD&'7K\_8LQ!A!ORL:8D'1]YJ@_# 1'=?4H?+DAU7:
MAF'8TPH[KF'A$6G0"V,4-J=_)>=,W;PNX?!.>V7>"A[A!H7P#:F#@REJ90^V
M55:HI+\Z>_ ]*1R](_Y@OXV4@L:PQ=Z./SADK67&V<TCC1HTV$2[N-=:F$7K
M"W,7O*+D6J+-8'E%N\:4S*]I5>XC)@CYLY7?YMEW!"?M;9IK>;M3]WEXZG+
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MYMA@.IV.L<A(:DIF>XM?X$J["-+FILI@L B2"8DL#"FVZ3G*(LAQD!=RI;V
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M>Y[2752> N-/F V5_ )1(U@E7TQ D\#>WMY">@Q0!<C&F=@N;%4VS9!4W?<
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M!&%W/6>#25T[^%9)VR]7,?BQ8<-8Y)T@>*TDA(2[IFI5^3'#$RMOF="_*=2
M+3/XI#1<A38H;K *";5+I!@@QH;$<R&JPUX7NGGFD5R:[!8@5\V?E+H$#L '
M1A:5822.,4[J%&R9@A;?7ZD] GNNS-.E,01'KK8@82,B"!4-DQ)I_!>*D9C[
M?/ =Q86>;2!8[;8[N-;"C?(38[03R"?Q97Q5,L%1+M"<FLM%V# JF;B8M_E<
M)8#H!5AL::,0(9-T#W67L[LAOK]$ZE%Z4XK@:@W-*$6R;S@R*'(!9Y70^X*)
METR0@48+2MJ!N<V*A'5*!)06KUZ9$Y37[ R+R82IEI!3R?AG^H)N+GUSMD8J
MRFE*&P]KI?[0<&<7EZO@]*;)1ZJ81X(D4@0P\<:_C*6'F$QV@;VR+*VI!#P;
M_AG* IG$H:1<.VI%610H0UW$ )'A!6!#-:HU K7JDMK&) CL,M\;0C!7;J6,
MP=&OQ%1!DCF)#B@.9EXZ4%-*2X#S-%I(T4\ZR10%H25D;GT?%,Y:"J?>HR'Y
MA,0U"(55;2-G%7,=5/;<9922['TB*C"[O!CW(D>VZ;PM5#[G.1PA(V+]AC%=
M$'84JT(YU<+K2WA) ZEDI\V[A -*3?:"G<HVS>FBO.1& ?L"3*13G;-S(1&;
MCU\W Q^68F5[RQE*HK8H KP"(W;[9&8=NQ481Z!J?,*1.O\1BZE81]::<VZR
M+AM=35'ZU@P5Y<+4\^TNLI8,,\4[77E=FL-9T!K8K]B":42)DF4#L(WO0=5[
M6CZ2++F4D10&)I\7)6N1K)J7V6#AJ@!;5)N-$[@)8$;X)WN6$+X115HA0_Z2
M%EG:WG+"Y-QU%GK/*E]J98LEO[\!:YCC"@M2T+94R<05,,-1N5FN9)KOKLB_
MH4?"@DTPKK'/!)W5PG?"B'.#_D7Z$Z--2*I[OJ/LG6UMM"_H\&+>/R] : *A
MR<*BQM(7UEIY 7HX3M8Z3KYO.4Y.+XBZW90E>SL6)[CY?1P%1=#6O(.;QJ&H
M.2BDK9U3E4HP3MKK 1(B!N."ZP$L,J;LEC);*A>&?#T;FU,YC1?:-.%9)\#V
MY%L/L'W_$&"[OQ)Z2_568]YYO/?LC< F%^C2L5X[NR:R!J=>J;&UM>K->BZ[
MQL5N6CGAO>3#LSZ<;"&V;TQ1N^>]&KS/E?3Z\N(:&P<??^QQ$Z/+0MQ52CC$
M:'O@<8GJLXJ)")KX]+F\Q7$?HA),W0L;?=X"",A*-V&/]Y[P3\$4N+HH/#:>
M..>0"<)1$3#\$Z'R,D3.R:+-:;S^ XH%X*C>T&"LWT_F-9)A-N@T#ZLR >^2
MU'D[I;\M@\X, 32/OE8G[<N>Z\-1XD]NV+HBK,&%YF[A BX)S3.A/.H)>$P(
M#=0XU*'^WP]_UCGY[E!E-V)WS\DN7E2ZBWZB^^AU(N+DG#-49<+55EE5+4R3
ME;.^P@!Q-['AYW!V(,&/>*W"5A@#,*!+7 =M8X#3S%!$OY(TDD.Y4[CI=$%_
M\EA$;"J3H66 W5$IZIN4TCY<;HFBQH.1G\>2OQ6K&V.P!EBM$GH\XZU!+A39
MBS !"&DLY O,E8HTR"J4LAV<>6(,6]40X0/E8=M;?C_P Z^_H<E94Q/?C)D*
M'66KU#A%V12)FE"65-AQ)XDKH>-*A+/;7))(@&XBO:EEU;Q\*N^S8T30"6-!
MX4)*@5ZU3FTL\4"ZF>M?SK.\O:6W$T*%,@UTA[N%&4]23C)"L[Z,=CXQ*E1\
M,PI7!1LFF%F_J8E9QDMY?3#JA-@6*VVB 9/ZG5QYB\>YV[ .+^&$H\V]O64W
MR1.S-VR4,Y9R6A\<]>='?9.K4 9;[D0V;K@K53*X,LN>AD&(M0DK;&$X=IA/
M.A!%4T9O;):)#@M]IH)>6HX4ZFG=D7[A@\,?<UI/4$_:B-.J"$8,9&(-6K48
M2'<;"4[5XY6QQ."I+)M@.(IRER J*<I@WNR:_10%F)=(6^Y1O\EBF"4NK&Z\
M51JPAF2:]U8M7WF_J2UT1% )#*^2+]56';&KK1(U/('NES3Z=-UC(FUSV9)D
MW-X*;2$>SYI!:,]Q2@#.6A")0EM<WRJCEO3BJ&A<.RIR2D$BI>X%34S;\D5^
M]1K(P$ERM?:2QETI2+@1-3_G0R>Y+#+FND?D?;$8S#ORM/6MX<$?4\5P6KE0
M1E@XF[M)VQP2TT75NM_'X7SAB*WF9 UA>0.,R,EEL_^&WHY)R&3OQM$Y2!G]
MM 72%5PJAPD&5A>Y-&%O)PH@*ZD$M[^QRUT@J&.,S$$/S^2MA"TW9-A8OM^R
MK+(B:ZX0)YI;GFO:5&C,+_7Q/==X!-&_"U8]G(J;INF<%L3#:*56_?Z%'.X)
ME<VAY[(Y.'E[^*Y_=GC\[H'+Y@[\X\=U+IM?TQRKM@5\@GZQUCVW,4\IJD+X
M0]N XZ;B16TI(0'TE%B!U^0R4,Y?DAJQN^ !!%%Z0#:L*QJUZI,3QS5VIO%;
MC9ZTDF7>A&!3[#$;&&8K"E/Q87VCXV89+.5\U@8\W&('G:=:!YH_GRUYQG#0
MEYLE.,C?I!TII@MROUIJ@YJP!3E:O\J8OVYQ.,Z6I"E<EQ71GS4286__D4HE
M3N&2Y9[(\C":'#U^_/+YC_Q&L]WI;NS]?A@Q%1>_!A.8"C^?/HZC)WM/'GM7
M1(B4@M(#3T+1B%4YG/N?WRV@.K2!GR2?!>3LZ+/4CA726K+:%/P.7XT7DS%&
M*\C!&3<:.+6!\ATQH_B$68[ =ZU](\ 2!JS0Z/7L4PYO'ZX-^@BX'CC!5.=H
MU$^""U.A(X9!O0T3\;721$^_]331#P]IHGLKH5BD@DK8'TJ-J*3USH1HNAY3
M&5O-8^LS2Y/ED1+,JZ0D=SBM&DWB!/SCU+"RF)NP2Y 4^-.:]P=0O,G==4[]
MP>EQ@7Z[4$HL\"[1ZQ5,1X5LK]Z]KJM63X0T7&A_8YE]P?E(Y\6=IWL]"_AQ
M8)RQV'G;6Q1,]2NL)RW?KEZ%Y@O0^/..HC3NB$WK1#:DHR"OGS,5YSD*I6],
M_'+63-1P<<4LN(-%>7RW:^Q) &#X]05M C0V[,C#=L=J ZL0KZE2C(26BLT[
M70R,>FE&E8(K?8S+JR T8FZB@Z(OKH)4/ E'?(?R21'96Z@@*HWP:[%" SW=
M6ZEX.(D39/VE9,5Q[,C].&"-CQEUJB,0XQ9]%(C9#352=!N%!,.XMZ?.NAH)
M'KMA2BFM6SF21G*B,^:HLL\=X8(SNTS"+%DQS&S^"/93FK!+=EQ*!^F$*"*D
MX]UTEE)<NTZ>(3=#_EY&@V++TKQ:3*<N$W?#(%!7:^:;.K!W(-'DP:;&@XUN
MY\ RKN;N/-BH[L#2FFV>_-\VHEFCJSB1P/7VU@>L/SSSH6H.;!XV5"V2;?D8
MY=T2[8',B:GM];P/OS?A16YK"].!<E"%L.K1@BE;*9-VC0#6*A<\!*KC)O42
MCX3Z@WHZ<L6KL0GB9]<1*"1W;7W )#Z3233%_/#I<[8@[B(2_/CN;O7D[NPD
M#5&S^9,77?U_ZK!H:3=$=85ST5=S7[/;TC](&!'(FLS*X6**=1#(]'S.&&QM
M$EO/_C0-%ZIP(?4F#'OT3)]+7MGEJ'1-D!@+@C*;4?LY;R@E-8<]5DN9JUD*
M,.!Q^S:[/)G:1(90@M,I1VQ;QM]#JY1W4!CM:(KU7 A< C37]+Q,KSDJ\20?
MT*$NNT\ZK8P*M/W:MG(O]@17TIMWY4H$AYR\A1!7S,L%&UU$/45X'&0GR9=2
M^:(I?TSLH6E,IR.?U]I;T+$WH<7!JX,_%M5&>G9<(*F)9OE7#S8D T*=S$""
M(4Y+T V-<7W50BH KA^G[(.HO@WX@%]?'C%E^2<$4EPW/NT=F>/*66$0#97\
M^C[%CL&EZBJ2E]ISUV!CG*8*#4(3D.X4!Q4^ KE"0T@7<>FH7<VRF.,IFPZ0
M<HQ7!W\O[@C]MLOLR\8-Y+"YNXR Y@8O8K4W(393]Q'C,A;T;3G(YL+7B1PN
M<^9;(@8>^A17)1NYJJ+VM\'FV2-:1'DEV]:I-O>^1[2=/9<20II(5+=&&(F_
M=--RT^MD%)Y]ZQF%'Q\R"O=70F_I:]297=(2XW+;6\>D>@[(?:9(1M/MJ(47
MKS\10;%(>+D&#36Y^<IC5'$8=^:O;" F D_S[2W2XG1.5<5*XANQ#S&68A'<
M87\[XZX\YU":)D[R<88CR!(J7O2+_N^'/T\7:$: I8S_R$=9A4'$5L8)SR@C
MM#MBILY;B7H*+8\<X)E( -M1QH.-/:09!<Q5[1+;(IUNYDZ=1#LW" MAV4E*
MMZP4NHN7,4 "!^K<3>;:H2+S-O-(6PD7,^YUS>V =RQ9,7]%=KU.UVP!)O<0
M(< :^NEY"#EY412RP3)M*F79L-TPZ#%"O%M,E6IEBIAK^#^PD FK.Y26U1Q'
M_!RHK1?:R8CI%;!&^!I%>@^-K_L"P?48W(/_\^'P[.]OCH]>'YQ$)P?O3PY.
M#]Z=]<\.?SMXP.3>@>GPI([)[<]F!;B3TW2]MD]L1+RR[:(=1EY^+2E&3I0%
MEH2C_DG\0Z-D,;\HRNP?O&L<-97P;8>L;HV&YK$TKT8^MME<26C":DQM'&#Z
M8=D8:%OY21!M89)=RI+RL58B/?B0F)WD1:Z;-=>.Q%[C$[!M1<'J,ZL3#<O_
M: R'&BL<.%<FBXKN3(PH'2>A.[3H&2 2Q&N7#UL*?1OA4H;KO4(9.2C+HOR_
MX)W&,(7XZPK\7L1*8$QG7# =!F[.5S\S7I?XYZCOH9NK5!W_V43+E;00%$P;
M2VJLV1 A]U(;8I0F\PN*%B2S9,@4Z9,),8P3B8<RNGHI TVL/+Q(;N.RZ7:>
M[Z%2OH]*HX;6[O.>G2_75QD'24W\7>#1;">J_:FNW4UTRK.,D>'E1X.18:QX
MXI(^,0%!LH6"&3>UX1$K2E9>LS(3<K;:)N(Z3AM,C=>S,+>WC''H=-@&>C,(
M96JAJ8S#UK@-W1AKJ1XK=OT9QGJO_REGE2S+):R];39S/<5"K(REH%52*K,J
M4PZI2OM((S;U8'N0=MZP%1_(BN>CHJQ25V\IW*37+9PA"JQ\+%L/?XT\2($T
M+T2%AI^&/H,%W<G 9TPL[T1/6^IL*-ALR(N##!T@T;/%7'J=C$OTG@A_Q)\S
M$]:U&U3S>\0B%N2?6A/ XO=+!RBO0;>W7LM>_8FI&O+TO.#6)U+'B94X696N
M-R9]->='<^)8+#^12,])X"9 D)_RC9J2KOS,@S/D3FN^7>1?3K@HX U%(U[[
M0IPR-=SUB3]5'+5 @T^S'J)A?6A7'--1FR;](Y;^JR1LG;="DO;K<$:#?T0\
M0:W\[[?#PT,?7&M6K4D;KD*:\J"QLMXXR,;A?B45.SWT$D2GB.V,^)B#^TZ+
MD6M.4,4W..VH"'+%<==E,L4WV^EN+\1,Q%:GMFPU%7A3N].\E6%AM25'T3C<
M%!LF\FNEOYY_X^FO%WL/Z:][*Z$(-65[D6*V-S$Z%$QADE!"QMNFDC9LY^^,
M=5[/4:8<$"-6CE]RL[FY.OM(TFN2406-C@[.;B*T@2CV8C''!IFS8O@QG7M
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M;G*M( JDFV\=YM"JJ#OCM<)WKMHH)7&(54(=A8MA.EK8+M-W@EAXPNTG?+<
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MZ+T>=/IGT>D6*W@*_C9VZ]G>>N\!,!IS\'%9VE?"WE0RE1LQ0253=#(X\$2
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MLX?D^;T59F-(GIQVP5+K77.$*SMJ.Q4V3!F8^3L+8+T4+F/C.\#98FJBO_%
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M6CY$ZFC#SH<\U5+22ZQUG-TSD0A"#A(3GF']-.$)(HK6>*'^!;MT -[08JZ
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MU[3EQ>6Y\0&Q2[\#NUSHZ+K_M0ZLBYS.OOL#877HZ7]+?I:><(X.'6'H7^F
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M,$8]S8B*&2QBE"?YF8[R9 !\M@6'[SX)OG-\4?]"$<^3SMGIT?\#4$L#!!0
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MI74YYV7Y0^0@@$JS.LL3"(>#BRE0#BU@<,&7-Q8MN'3-:)JX\K!W-';S&4=
M!!"X6Q@&JR8Q'.#=K3'C;N1R+'.X!<<%[*K.55R))%D@FPB74JA)C[,687,M
MX?(6:7%7G\;J ?? ZK58RMR:-_K^X"3U(P+0@FFW@(,=IF^_:JEQ4&/;S@UG
M_GYV_/GXS7#P&RP"!H]#H,)H#V83O)&)N, UB;)\GN7LTVPQG=ZQI8<#KWP\
M_OCIT?\&[SX<_PJV&3SVX^N-'ZN[:3:6"I<7GXR/%FF&CYZ)"55$ES$].=+D
MD^43D:J_81/-2LD WED80B'O%WYX5^2XZ*V7G\+@FK)R[YZ=$(PV].A<Y$K@
MTXH9D/ CD+3%/3WRUDWH#V W*:P#ZKIG*E 8TX9S/"&5,BL"K<;$X".9@DB*
M%)Q8V46JSP$8C*&M8@HWT9=\H*FT<:"U2.V,KO:D=D\F=(.D%LL"D7[AU"E
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M4:B27$AQ%94</,4ITZD&?[-"%%I?!(72:I\1;H8;3P1I8@**GH_ZP4?CL4J
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M,2"YPH[6:2V8Q6NNKC-<'C<R7/RFWE*JWI.'GJKWS*?J_0"DO@WY-5<<(N=
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M$F -BPA$ %M<42*J0O++$'04WS#:K>7'+(LM(*@7"G><(W7TT'.DGOL<J1^
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M#;RQ&?)U3C\-_EZS*"G2R<)6[)O)8&TTGW(ZJA6L.&?"%E:.<[[2;/F%H';
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MH ?[>P=[SSS$X%U/8'DW@<^%!O=T?:-9%U VGBMY\Z) PT=C*BGR;]TCN4$
M1:"E5[!SFEU@$ 7KA5W0]ET01W#]8_:K!CMN9Z7=$&Y_'.R\%G-L*Z._?1F<
M5:-"@>Z:PYOA&KK]&=]. -[FNX,7_.6K/$- 9_[ZB1G0IT:)"0V/)>.9A@@Q
MU^N1-8;],CC!]-E(:C15[M=%ES_1CZ]!@\>ZI<JN%VF]8H)W\.19JL8*Y-85
MTBMX)5YX/_+=3V!I2U<&GSNZ57E5N0\3N&0+ SRI.F"Y3)&BP7%"B']13 -L
MII"@DO+/PZ-P?W_?;VX_-I<.P#6!.M\^KB\3J/=,84"NJ]1,_Q+\)D523JDL
MJ A>R5*"+C2I)C(-?IV-?M-@EZ^SO>"_?_5[VH\]13A23'](08/6]=/+8M4X
M>QF\M'%QP!HR?F_<T7YK;RG']/#!YY@>^1S3'X#6MR;&C 1:EF#4KI2<J8Q]
MH$4699X*;-M5$9;!/Y^&1_O[J"=B_6H258EP>N2,1*$LLH(-OO&3B!&]Y.L)
M-3#VTW!P!9PJJD37+NVBZ>@F'*JT"X=J%:R5)X1>$D+@H>CNZ03J+36^WD7#
M#M%-YW2"O6%RSLLWI02V)R,P.I91E2#Y9^)/ZF-EI+K3P U;IY%HGXIS0K!;
M,$(1S(S !DQ[[/.,\7_885QF#(K1\>Q1AE %"%+@!.F<$18HBA#) !]G #C&
M56K:\6FP"^J81V42\WFFN(+ O!),+=#+D^' %DK@@761,K:&B0/")QY"LN#.
M<?:3*53@M ]?@'#W$["$#Z*K2?%YT/BQ(Y+,!2X8VTT2[&[:2M<;2S3B$H+1
M**FU8I)%^%E#*.+)!O,B$)5L)IT.O(0/,L9NO</!),\*C78])X 9;MB+J!^H
M5\$S9F&02D0ZS['/)NM:()9EK"$^0L1Z0503KJ[A#G:(=F)AN>9B@73+E4+3
MS+2VM(TWPZ7^F/#KMXA&*M-SE6>Z<9W!^P"!7S$0&,Q]-L>73U11VD8;"?!X
MROY&6K\X?H1B1:5J5LU0<P@9HDM@,]1"%L6,2WE@6XBA)VZS/'S"7Q7HCH\:
M7T>@DF)'4NWL2@G3A+IGX@MLCUE=#P4[C&+!-M[34/)=B/2P&G,)"\@3A+$K
M#9U2(I68"2F.QR'N&KQ-S0C,KU6*Q4TD]V#=-?)/K(IY5;(T >E*#66#][:%
MH,'C<=JG,@V23]:JSB48?8AW%N5JQ&=NE C$^T$:-8ABZ/$E8P\SDW!(54+I
M2MQ-%Z0KU6EPMU$G>8%[0Z/9:C[-1GBRPZ)40/V4P0;D/9G CB/5 _E6<XL:
MVM0)J;FL,SW=RA.N8XX1(UA+)BU\*$AJ[-54-SU%*BRBJ13TLY;HP\%2 U#&
M?-N)URQE<+65I&;&O#O86C1:7M;AH+6N.P>[=FU-3U-)]$AM>*.(VKL:<JS;
M3.X<[M(W\ANZZ;D5Z0Q1<X!(1B 7V4L$MRD=7:,-F%.SUX7A%_TXLPUT!NFI
M^N.G+\</(L5ED90H<*Z2RO]\[\@KT'<]@>9&+MM M<*0TV^AAORB;+19R'IB
MC057F/(<N(SD&"%XCB2!CL7&K[)T:/$SW6;$( *<1NM-G-#"%)"0R"Y+$4VY
MW;'I;MPZ TD^@K%.X])-+SW5]87J"+7"DD(W[344U+"EH8:LG[;4T[K^NJET
M@2D4+4B5P7"%!B"D0Y-T'5)_,/715=] 6R!06(W?I_4N3T+](*&IRF^GZ*&@
M^HHU50_<S<G317_HXA'F:RVNT"W5)&WYDM$>3*#>RUS$FK]6G!#H@"=7_1=@
MQX^BB,5?P:])-@*1_X$ 1<GC!?8OBWM^GM_=ONRN00$?#EYE:55@*Q]2Z;K%
M^(BNJ2%CL3Y PB,06-!8Q@63PTBBC\IZ35K(P466H(AOF;S<3!6!7V9-%/75
M&.@6-T:73]1-UN%6[:9B9=9%MB=[UHS7$^,MI4<\?O#I$4]]>L0/0.M;%KPG
MWU"&=H8+0':-L2(,!"TB8*.LD_IJM+.K/&?7+TGC"U6LE+?HB,S25)M2Y T@
M'[><9*42VO1JXJ7CRZXHBVO3GX-64K;&#(] "*]")DMM2O3W%+#CNEBJIK3R
MW7;;&$M"+A#)\O/#X&C_O\A03#!:(6>JFKG'E1T'&)D8GBB-9P1?^(:R(3_!
M8:%@%*<@2:(%3BF0 N9"+;[UT( F)&4TZPW W(0JG0L5+_>9#79X@&9A\"=G
MT8+FJ6MG.^8ZP(YMI]>PP];=:+U<OH*E1PP^;I4+K^VF]=1;/7<]@:7=H]YZ
MJ^*X;JC4Q&=:T52*H)K8DW-19XS32M]\$>H.%"@P,(9I<@\X1AH8]RS(HPF'
M =F]2W+>]K*FSM5AX$0>D?3,61+J@Z41>,1L''3FU1%*$]["%]A.4-;=:R7@
MBN-E=<NAX*WV_8GS3,5"=RZ*LVI4AH%9?CW+.'.KF[$$<-$N8GY' 7&^WO-0
M3WA(BJ)"O'F-/;^Z=!6Q/#DJC]22Y>C?R^N;J-M(E4R(BO1QUTR<>",QO<:$
M9?F(Y;?;$'$\'+0;?;_.8N\R[ >Q_)X*4(^H"^5;"^QJ$><V@T3R+2=Z,0&[
MIW]P\3EF![7T(.9\4JNQ]%K7*B'_GTX7A8+-3[FJ\/VIW\L^[66SU$S_7,OQ
MK"H+79IOH =(K=#-'VMKE#+T_=;V:6NQ?\%B=9MYQZE*1R=6\K;*SA(,!NL$
M.;RFP?^456?41_T00U2<C6C<OW4FF/PF\XA\&M0?3)OU]5W4&0PSG)P!6O,;
M5 *,*8?!21'EV06/F*N4^4[6((/5Q<PPE++,%1CWZV<5-99A:6XZPYF+H"\4
MS& D,6V/'PVG&/RD_0+-9X<ZAQ#&$:$Q0$JR5O3)T5!#>NA:B&/: AJ&@?KT
M3-8/)LORKYV'($I#LJ$XW0'S>2B'4F/HUT#[!ATJV&'-. ]K99EA^!^5\/*&
M,W"7<R\-BCZHT7\B^UW08$)&VM=-(6-UKN**VC#&<BYI 3@]7>#[VUTB=<8'
M?*M Q+MP+Y[@>D-P%+?5T#S+4GU'[/)\J5^G)D%,OBG;O8J#'1)QW'=2!^[H
MBJR0?(?IS! DH)<#2<A983HF4[$>(0@9D62PH;&Q&%?RA(Y_%&4>R6H08K^Q
M-S2NAT?M-<>2? ZUS:^'C7! [WZ9J;0"/>7=+YALNS1#[++)>6Y*;CA/FQC7
M-4O1G&BP=IZ[SD39C6'<*\:9VSPD73_QB75QK_8>AW8F")PS@L.%>ZZ>GIX&
M[S,DEU6+B5 [=C6=%6KYOV.)I39D>^&)W\CLYF+,O4!37J )SQYY3O5F51A/
M>-W1 P]Y,/OF"?F]N4&K/N/G*(.PNW=0E3"NO]GR@V,;I)YY4)?5&&)!3J+<
MP5*7[)*'6O\,3VL?L6OWT<NX6PH8/WGP >-G/F#\ ]#Z]L]S$-3Y1'88:_]\
M?/0X/-Q_X654+_;M/]7?EV J;0IR5LQ -7H4B7D!\BR)KS[_]AQO?HOZ->3#
MO>& A_VE&8/?.JO<4P:Y\6$?[AW8/0#>.#5N07+'B$0:?;S&(ML+CDLWFX(5
MPJ(:_:D[TU%N.95_ZW05$\ULX)U2H=WQ))>ZN@_TN.& WH2.2./+*:9H?!02
MZUI-K%9KR0GFG9OWO:H6:#Z/L1J/WII(D1OWU'N%ONP=SC<IIR+5WYAZ3AV_
M<K%-L3S\C0[^+MDD9 *AGLJ^-:<</A$7Q:ZS7EQ=2'Z@* *=G@)DG^;X!IXA
MJ^(1*KEHYP?C"CZ2<D_9.O5=PX%[6XT4W7YL$31#:NXBD^%@^HU0&6';AVBW
M_Q3=>R^I*'+9"S8<K!]UXVH[5.-^V^8 &7L6BT(M$6B2L?[M<9[-@B6ZJK>(
M=S/ZFF87B8PG#%/"4TL:[L..I:;P*#I('0<H^0>;LZ G-CR2M7W:D6^_S,L%
M&%@L// <RV=&S!S>4&,U+RQ7"<O#3F%)Q,BR$<^QVEW>W'5;KNP*V6))R*YC
M$&VY_W3K2W?0P_V^1>V13B>>Q3)\Z@[N7:U?+@=B''5SUW6ZB$(75!5;WU#Z
M[Y,7:%#?4VZ^S1D@8]=ZT#^?$;@9_+_9XGL]N8>Q/8[D=1W*A#)7E&I&#-7E
M:[W7,W\8>_=X]=YI46KP NU.=OG9=?4\)W4W;)#&D;G<\O+)W@%HLBB%[_52
M/@QB>/)]Q-!*SG=(XG(:B#T-W/T,D :.7!J8)]VRW(TX<OK'2]28[_/<'\;N
M/5VY>T(G\]A66 N=:]/<VG8\DG<7C68I8S;.VY>P;_TE9CFX8H-=1M_W6C"P
M=,J22->]V]M<-S_H4Z*F>S7D>[G..R-KSYZARRZM#%#<"A!H/F=54528+# '
MN6Q4+ZJN(87LGP<'!ADZV'',W)$H:GSH)DP^A9*'@[8%O1I*WS&E7[+(6>%L
M:;74.K08M:;I%"P!?518A6Y2+A OB050/9IE-X^QY>^S1^/>NV2\J+C:H#=)
M[CAZ\,D=SW^XY(Z'3-/7/OZB73?P;.&RM$9H4O^Z+4HL#>842= W)=QZ ^V@
M_:9U;%K<V+2N>@>.QZUKQ1/:B]J;OF-W<Y<OHH"F$S4TD<P0.X=W1G/M%71_
M=QBTKLD@3:MV=E!)A*F&P/30UE<K"R2X,:F9ALGMY/<TBQG<$&BX+BS=-8.B
M6=^@&HFUI%\A4R%CM+2YCA((5XFZ8=[YLP+[;[RX.6995FI>!CT9^1>,33?5
M5QT>!P)Q,C9$C.\R$?AVWFV=SV'PD9VTC1I>9$7&;M,+QR"WP$ )4%4UF9H*
M<IMZM<+_DRW]:EE<IQ:';HD1*O6"D+"RU*E ;BX%)P\H#=\A"JK8,)=^9PS7
MA^1O+23_V W)?ZFE/\?CSS;(2V(07":@2-.5WLTKA.K1%=6(U7<;M8U8,#-C
M*;["FT!))N08:E.19ZF*+/Q$G?JT\_.[7Q0ZOO;@#TE_A,'>/ :['5:8T/&Q
MK\5$Y[5@8@ZBCB.T)S:TL!E-)C\E#LZ5".1,J&276" 'GBD9!4[G^ N&A=6X
MG]S>'I@US0)YCF-#&S^OG6<E(DT&.X]S/*U?85D!^M;>B(7[#+RP (8JQMJK
M#UQU(2BA*QO;*F2=-].9/F8-^Z<TT6=Z$QM97EP-4S\!=PA1\$R/$EZO0'"#
M]I$9DI+M\!)/NI7BMGK\E 3E#!P>IA^T&Q)VB"CY&CU6(&@NJB 2T/X'3F9:
M714ID,YP)2XP]PQ!C4K=>@G1/JSWT\A)I+&"WQ &G83)>*V-D[G-/4 =YZHP
M)9UUOWI^XE@WN]>@P"A-%WBG!:QJMH"RS:)*GCTM0UW-TL:& -:J]>_'FG,0
M@T1#%>KS@V\7=>)6@R6)BYT[$P4T;) '<^Y"0T5T%I0?.R+$1%#N@[QXOS7Q
M_L05[[9]&&=_*BWF7(#,FTFR]_&A*VQ8(Z.8Y=@F&[>45]P4@]H=S>QKTG\1
MCIRZHK  UU]+MO#L@7,SV54'&SDYG_:5(&YC^$[:G($0;)B@&*A3>/P:_0:K
MEQVX<7$.9PHK(""&"W,.Z1)%K-M@M8?M!W,2-N#WEHQE-V.<CH$Z^#?&@W7G
M:#=P]194A%1F,\W=#H;ANE[J.\HI=5UV5H2PCXW*6*5V@YWCW292PLZK7=<]
MT$!,V'F]NWJ>+FK"RV#GS8HL=,.!,)J=DT:NM_GE_A+??>>=D<L[EN3KU/$6
MG*AMV%=.43/<>7P%,KZ$#T%C;3)BJ'5<)$=3+XVXT3G"EV(3)(0+@S?%JN .
M7K9*@+0K!Y.F3OE9G\5'9=IR7G(G%)S!/Y\=4:01$1'@29+]MFPN92AG4I@E
MK 0[ $%%I#/E71KM&0 0XRKK<O?6W2T/CNXO#=UW%HCN/PM@$R]#_)>G.-[?
MO>H)J6T2Y7SZX*.<+WZX*.>/1N=;"**UT;[Q8!U7>:DQO5&&,91'3IYZVU_T
M&DJ[2"U02ZVR#P?+.KN1Y"TE_;MT],OE-!D%;4&]4E=N+)1%#=,-'-<%U>XO
MU=QWHI=MHF_#NCUD0[3#J+L9)YFGQ,LI<>S%[^7BUPT ;5(%<G_IX;Z3\V3)
MO]<EZZY,M.&&CJU[NW#W?=^G[7TWR4H32L6XUG8O^SC;(73S$I9E-Y^)[2GA
M<DI0&TJ !I'8]*&X<O,3]"FDP5PH8T=87,1E*C/?G@LX?:IB.(AD7JJQBK@Q
MKC"O*3!-"=3TJN[G4V="M%HSUQ$D=S#V568\A S;>>@U:@F::/C/J/KPQFK8
M/+5>3JU_KH]'79X2V64\7)IRVE&QCG0\'/#5+.Q\X/K. ]<-=!>C"R^'KF\N
MS<"S\%5"REWY K:9Z89I EG[Q-&'2;#16<(II/5ALN(,<>(3[K'A4I<Y-H+V
MJ<%3O<%.9)[FKA**/5YY\C?ICV*+#D@=F,Z2E1=CB;=T6S?C?UF_#4P6&C?C
M+?,LL4G-SHU&+S*^H(8/R+GP+7D&UHQ@UAY J&E[*I.86S?E$F-MW5#-K91Q
M:>=N,_$F&2Q,:MM2;KXVY@DW6D+P8QZ=F\3.GCWTV-GA_H\9._OAJ/U[%,5&
MS8%C0JQ2%CM3&SN 3J^DK_!IX),<[WKXCD;Z/BM(/X@EJ(C90L9<Y/=O1YD,
MQ'BL8G&NM">B(!-PGET@%5!ND^,S<RI-FIJJHDJDF8'>Q70J+&C"#HM9*D;)
MHBY/R/*F/]\[(/JA22[I;NN=8B[X<)?:=W_7Y+YO:=38T@VW<X67M-E9W;4Z
MK9'9=&;B2>%8JB@"UOLS30]WG46YHKAHM7]S14W\YJ#%-V/*WE/%Y1:TE:/5
MD,7!L2W\]:4S=SX#:F?D;E8=^GXE$C*NSZ92<C1D325T#43=S=SDF@ %8I)E
M,1;M@;W.C9NDBZP?4A<Z5PO5%\7N5=A1?3F/Q:T(O6(B;B H)Z&4*79DYPDM
MX4-=,OFZO%:6E-U@JT:M?D25AD(E[M%J(1J<A9'Z3>C(@&&8_FQ+;;9X>PK:
MGHYN >V.?)@"82YK)$M@NX =M=L-?[J38*^L>#@8877E0LK=Y0!I5[*$>4#3
MGT,%)VN0-?7;@LM?-ARL?LS2.^&E7?G]JV?2=77[J>>[P5(WGI4/[(8!;#Z2
MV@K 4QL@!*N'N Q5V7@<I=I0-3.*7MCX*$&^*GCD^EVA0Q1-?D<QH8<4[9JZ
M6>J79JY'I\,DXV8<%F"\HVW"<$!RGZ7#)IDUX27YZN&E91LKUWTXT$'^ECA;
M7LMVXY"U.!#!SC?-I+:\P\BM;D?E<$#=?W2M=JGKR.'MH6DXV-J\U@"N-NM@
MY:1!WC9F'7*+/-YGIU&>=;#RO!K[7(C9/)$=BR+*4B#V"M+8BCYZ#(<W'. "
M8/D:U<C8-4#+%-83M(6<3Q'0 [%["L9&BJ+"@ZU1W!U12T,"[O@$-BB""QX>
MA<'A_N&!IOB%NTWZ+2/)8(&T%FB\:JP&E8/RRT9NH0OD4:6&%:E/$O/J'2X4
M"JC6?],,,B?#H./BX<#*X([6B31_T_103SR-9$O \ZQC52"L2,Y:_I@[).)Z
MY4;EQ]#R1&J4!G1V$N'B";Q@L%,^9YO=7H_'8Y4H.J>X^W&JU7)++*]!$<%^
MM>VIW5!SV!].Z=O$=_[\P?O.#[SO_(>@]N\Q<0Z[ !U:QLOQ2B0:BS^#TH\!
M:%#&(2 -F!?E(MAYL;^+,"@@TL=LAK1U;"M$=1^K;E-HA?'#>AC=1V@HL>U"
MO\JCLVS/K$ &PG2@[[!B:$K6AH'!<7,S@Z@B2H/;TNPRW6''# ??:\CP";_&
MEKG4_-"V JCSG?J5J_);U:I+:0_;VMO556_X$77$'+9S9;![284<8X/X;:CL
M0:VQPV)<4=L%3@=5(+\I]7$X<%7'0&N.EVIWP1:5NX:6MD*GZS2F.Q2Y!D[U
MM14Y[B)^1=4N\)K=0SSK&G'B-ZJ85R ;/V9EHUU<!U,;RETCQ5<1=KA.J*X2
MIUV2M&&(@T!#6+HN&'<]Z%W+44CZ28BT&H&]2.$$>,)(,> #WX\@=3FUS*Q2
M75RTREVIC]G".4E36D%8)N<075Y=>X N53-9_R2A292+1US5].2HH3EH%^>B
M?<#5^[3!R8QKK>#RG6*7.)M,>_K06$?G[&?9ABI(S%-:'S,"D2C03N]8BSAX
M!X]L(KH=Z_'4@UDWDDPC9:29&0S!Y0M5U(B=S86_$A4$F@B8#QKM.WG30TZP
MY.^T.M8L4S,7K@MF:;VE^77!$A0.<R*_K$[OSN;8=+2"XYS>,!-?*>ENKL@+
MS&^Z (:!T<\)%A?Q24G"H^,@5R(!JJ:3)+?@H>UZ KUV'6=P![ I,Z"A+%@2
M,^8 WX]' G-L>X)&HVE4,-@$Q2FV.BC8QXOPA3!(ANI+RGIS5P_0H9.7J!/H
MC8@9&1N^0#+6,-DI5_21"L9@>P9(4'=?I?E89%I4&AV<592 ^/)<GBMY81PM
M'>1*4\R<8,:B39RDFJ#B&5<Y/BC-\AF(NY&)34RS2F^HJST10\89K"A&-Q2>
MW&-<+7L$\V.& _N<;*YS_UN;H">E]\ ?T+?F>GGQX%TOA][U\D-0^_>HHPTL
MS<\22+8RDET+RJ)62YO'QII0,AB'8'^0MI#C,\^EJQ>P$E(TO2Q@3[, ID3Q
M"WC>(M@Y9,<-'FH*+S2)C4N*6(=0QY.#3A9$'*L*QJBET>UH!9-.Z M5:.3<
MN.5/7SO/73R5.&.=#_+/-G;R9/^Y&=9;B15?"?U(<O\$#\34C!!.(P0DA],4
MU<.Z?_QP0(ZA((?;]MJKIA=T8U0).P^>E7:-K5GEIKI&Q06;Z&OONE2+%2."
MD[)BG=BA$-RP90IQ=G<XL HES8%VMWL282!5.=6^OL9!VSVB&=ZIG7<MDT*;
M"JS.[9"ALFQBG%6CF2(:Z[0VI@;>F2&%06$N\ 8V%9 ,<L3;IMJ'U@J@TI/7
M;*D'@Z8:V'8Q94)\QCHA*3=G4=:JZ/QA9X,(@$% CB,^F4PG@CT2('+*4E-,
M^ZW!\DM9+[]$,&AU7:$:/)O)/ +5.%FX1I(<H^E$JFRMW7>\F2F'2F 4H:U$
MI#W"*&!Q,U0CFW#E.ZN<Q(A.C@3T6#N)=QTO<5%OZ_+*VY$PLRO:J#GZ8A#*
MQ=KIQ$:N.Z]H"2VSU3LU1/?FN\ATM&9TPT$[_P9(>^? >,1KD8KW3]2Y@W2_
MDKC!:#QQ\#@V&"WZCP5"E32%T6HK+B12<>AB)(NR01QP:;+0%AL\Q+D4\QWA
MZL*(Q2YN(<:JK:;V_KG6'%HKF%DMN')WE&5?X;M<HLM7)VPK.&]%3E8T_+3>
M!-LQ9E&HP>=),.BA<!L"F)DB9S((BDO-DLNMD. R(X3RNISUWV6V[J)UXF(V
MNWC@&Y,WFZS$L$+?U7!A43I5]QFP[%Y71;/[TI&U,5VCL_8)=TS%QD4ZQH)A
M('B/I@<D$+)6&R.KC5/G2"5WKNT4L5X$T/(U'TDRBXB%SG='&[&C778YK6]R
M?+1W:%L<=FA*E]W\6'=GV?1LH76R*P-?JS+AS&-TFKBAKXU$JY:),SB>X'DD
M56EWFZ<RG:J[ :D$Y*DQKG*'H3>0Q_I,AFN:)+A$5R[CUO,H&HUT]),,;32U
ME.(Z9XQQDSC3 .7L"O-8R=66N)H,:11!&QUT-,[:!Z?;]0#O!DZM"?LZL=K%
MTJD>'8>\C#-G_6CX3*<<2![!N,I354R9 &37&<0\LT+OW*)JT/F&NJ67&4B3
M>1UZW%AN3L4YGGZ&96A?5Q-*B-%%7JL$3B4#ZE5$(/K-;1V">2<V"WP%'RV?
MYG]6\83W5VOD9MM(J68A(',]#C9Y*N90/.@D12#_A$.NB!7)'J;2L=3] *2)
MSNG5Z6(.RW>C#,PQ//8;2.O=87A**",9 K=,*2YL?('UK;JVREQ)TH:O;40&
MX5A%?PZZ,NR1@W+(\9%BB;8L=/,U]+'CD2TN1!YK8!BB9K8/1E+D-:"@S@Z,
MRHITY?I!6KTQ81-<7M.B*M1E8-'4='W30UE>5[MX==B3THE7+;9]L!NAM@]A
MLEYG)[X"I4UP,-,F#Q*/F["U<CC:<$Y+T%UD51(S9W"O%Q/<_N<! H 3"'@J
M&^C?SFZN/<$LKZYX(9;3;/Y&4UIC7GE%/43/CO?6V5Y\%<;+%D:P_M,T66Z^
MER(3Z4HEW6P^ NT]._HO^O7PZ+]"1TXEB]">/<NT0V+.!O95W:?)&KNPY7J"
MS06-U7A,Y8UY-KMT95Q*&SF8WO7:AZL=-V:2!2C5Y:J)H-A/%E242_8'YGAL
M:HBAF./62]CQ"P. B=0M@_XT+:G6Q<?<CGE.@,*(Y\VD/NM)MCI,VUO4H+MY
M:*\7\-3&&V\T*JR6+3J/HZT5:VV#&D+-!'D+=+LD;F9E%@"&8_T\\5)LB&1F
MV'B?#?EQPI=QS6"1Q7QA":S&CEBC.7'H!LOCHI*II.LJE,:.+VI9-X==0A64
MEI&]A23IU>I3*86#!7XC5Z-^;D$/'@Z:6O]8YW>P^L0+44^MM1/:9&; #Q\N
MNJUPT>/]!Q\N>NS#13\$M7]/N*A9.9H5Y2/CCUA?1KJ4OIN!Q=N=N]O(QB'1
M-U9C.'9VCGX^^_WTEW+Z\[_QWY6M)/4M2[I4N&$[6G9Y8+B@Z\<G[&@"H=Q9
M#+(VU6I%8="EF58[374,YU='(-[23#L'X\0@PG5WK*[/6[[MDM*[I1N&@TMK
MZVC"2^^YI'X.5($6Q3D=BZWN,Q,Q6?U,'(7'0[E[/!10F!K&>5'-* /]V/F.
M2:";< @Z<YZ8%FFOEF[KH)P:;A.[D;_[9>?UTEW=>9/-=FQOEH?=_8 VWS<?
M<U(_9CA8S57H_*]!UIMNB:Y%NZR^</7"@<185VO9'O_KSI=^QP)N5#6\9A4O
M+;VT1G!+9!@'9R[C*F*'B@7*&PXL4A[[>:=97HY1KK21Z-Q3\#,^B4:_JH28
M'K;VGEI\81?R5E,(4WMIS.8F/B!;>/@;G*+LK2HRF+/<")&OC5-2IS%BD@38
M<'7KWVO!? 0O]@[V&? XR^^M++OOHGCD1?%U1#$P1:V5>FE\@])8I5'.,*(D
MCX>#-G(IPX-^LP'S6CIR$9Y8-"_AVUL>V9W.6#&%)&#.!)$V-U5#))"' Z-0
MMKJ^)^B*I)BMK@Q:MAL(X&C7A)56-$RI8TOMN+@[';L<W]>?:+EC8J=STX,R
MW1HHT],&SH_(T^!351O/(HZIEE DMH" J</)BF=F:F $AFW&( ;5#S?Z!OGM
M*8^QH27H)(CE9 NBYF!'^_BY67#+*G7'7U>:?'%>'M:O#9VVJRIN,2JGE>D@
M%D?/V,:G;(DE&)#C.MIE2A*]D_2.W49/FQA6G]'/4\G *1:Q%-DJ^OY#"\RN
MBJRFPT>BJCINI 2\53D(9OOH4TH,97("6LX0;:7Y6Y-9EO&OUI9U!\*MYG9+
MKY;FZS(%!XSJBC%\OKF! &%>O?ORYEAS.1Q0K:ARYQR#=5/$3ELVT1@^)LA.
M%Y2 [<Z@.:J+J2Q--NT)/#>;J2CXH, \Q9[*;H["C!F2!^NFWS3'W1I6QTX/
M!YML=202^"CR '2#G"KT.%V.?MSF]B+=<(:=FEVZ3*CS?,S21\M+%5S@^D=3
M)3&#6P^6!2EOG2G=2SN$Z2H*@D>JSF6%?8EQN5!LEN[:T1OUDKT,;$)B,,TN
MY#FW/1 <"?W_V7NWYK:1+%WTG1'\#W@X>Q\Q M;HXNO4Q$2H;%6W][AL']O5
MM?L1(D$);1!@ Z1DU:\_ZYJY$A>2DFW)E!DQ,5T622 O*U>NZ_=-P8A85FFS
MXI(N!6?SX(IRG2G>38MLL234-LP,Z'&$KWN_$D;+6S%>5I(3<R^2NFUL^.*<
M E9:IER72DUJ876VRTWSSX<#YQGW@"^4%;=[65NLRPXS;UWSSFCU*T'U_8%9
MU=75!J')YY:_1XK@HN?CIJ*TJMD1\],X\NDUALREU5!3PG(>Y3F:<*3I];P[
MT&W^SR?F">T2>(Y]<-^%CD+:1VL[G+ZQF /479IE=VWNDJ8KUYPDEO+O09MI
M<MUT%6P5CJ(>R%>0\> RH2EW+E9"/*#C*CMCZRJTH[@T$QT+4&_40=%8&7S%
MJB469\KH-; 3*^J<7+&#8BH5<,N3QBA!88#2,'V3:VIDN.1A3+ +I1LNO[.M
MK A)0Z-(3MGP*#I-RYW!=F=9[<,'G]5^O,MJ_Q32_C7N28 _9=.@.WJE^T\8
MOE;(J0(LA"4:"<Y<<S!4?#'69#+Y>TY#(^Z2[G*&X'J<9M6,XV!H=09H#/I3
M[!MJ>'&,RM-QWWD;LP__JU:JK^X+.@ZZ,A+_P7#0-@'85A2[05N!]$;>R%A:
M9_]T%4YP(5U'L"4VUE+=;RX9"XD>3+9?&?HP^DB)-%EX37U\1>6XGB:-H:*Z
M7*=V.FYWMN\_ _7I(FT+GY43"1L0.D[#Q=7@97=BLT,TO<L'TD]-D$]@((UN
MG-5>FCH,TD#>;1P[ZYUJFG+GR"116X?L<>EG4-[N360TFE,<]6B%LEG=P?54
M*Y;0R:(:88)<P:%I^;A+-T^6*35%<!<'8?;5&U=!VSY_53_,4-<[*'0EZ36E
MCDV&-!Q0XR,C"X7'.^DZW')E$\Y@&''>1+CZ)8MP=6XK6E;3)FN\.)&GAO<7
M>KY=RG_3;8V^X:X.!VNVE1&EQIBZ=!T*V"G1N5V-6JW-3_-P<)DE-\Z )85+
M@(%?#AHN6;20%"AHQ<O1[(2@5FI7DR-ARE8B+V RZ)SUSL.]=YL_Q.'S6)TL
MP;\AUXW F;L 9D<2#$^/0;^DH,XA?K(K-;Q_SZ&5@K%%I[,T86!6[&;'#VMJ
MZ3\OLK\LPU:OT]%93ORWDY/WTNB.'?*FDXY9XGU_Z'*2+1 /UH*7KAPO?!';
M;&NX6T;4H</@,ZA2L"HB^2*X^S!$J= 87\ &X%\G2^K6Y'PNL@L2Q"Q<K*05
MZ0)(ON#L\R0C@!FT0[Q!#K_.L[\2>U5VK(MT3Q[QX"A3,E8T!X- "II^<057
MI.G7"EAR8[-:!O=TT<1G,""H#AR1.BKKNAQGB;9>]XUV9_Q_Y? W"2X>/?C@
MXI.?,[CX$\GY-W!RC<-"R?SV+01W%C4/9P6HS%2]453I%,,*\\-?M%<4AELE
M%#M!W*;S)"N(PB\O\1(8<9=ESG66?^!X&'B6FO$12H>K ILO<#]C!VT\TD'A
M%;'9;R;@^J 7@6K8X7G.T-?B2X00=CM_C\.7HD)\4,I#YCKFHBP>D4^!C\-_
MX(6UK"B!+C<=_IR7@5VB #EA@8 /C&N:3"8"1^"\;D38V6@#XEM8"1[IM"N0
MUK(9HC4F@\')ZXMLL@%+D;C+,N.WP2TZ*6$=J)$UPRJ$ST5YE:>3<P(@P$L4
MPY\43]7+%5>K[RJ/HSJM+LD)M1 #E>P&/,QU-3?;AG]_]:> HO7<W:[TK'MQ
M.U@("NR+)R\-1Y\BDKS94 ](PU;4Q.?L&SC[4F^C2!",2.2J0K7@[H^/$>*K
ME]?:2$[]N,2L6Z^PD=R(37.VC,=1$G2,9N<MWKNW^+@#M7V7(?I!_+S^&@4-
M1&X>B8UN&X@E3T\JR4CGM5 D!89R&M58Y0I#2SPA< LVWK"X4.<_CJGRL&'V
MUV%%#HYL.,"A]</?QVL20WRU<"4-S*I[?7O6T:\/C\)]LA^],N5NC3>[V[4?
MPI03?12[2^0]Y[*?JP 2&;-ENL3:&,;86XFHAU=@,UE%B']R13/H'V*^:^#4
MXKX[II6S:\VJR<- ]$E(%![HFMWLE#-\WUX</9B1ZYBXR&JXG[(Q-N4*%TF2
M6VS#:"\8+(IA@T&(3,M:[WG&H!@% 8.;SH7B .LF@Q'K_D-N4,<$^7$U5'S'
M$(>#KUWOW3UP_X[6:[:A&$: #EI?@FY"]J:BRC"6C-_4%GV%01M>J;:P2J!#
M!1'G>CKC'!8Y)5P[AYGLCN/R7[_^]]Y__<>O_^T@HGM%DA(Q*W0 F-'D"/$P
MZ">LX#T9AP#_Q.12)?-YFG#&1(Q:Q0@BB!K,H6E,W+U^)_AW$$D[?O"1M*>[
M2-H#E_-;*_AQMX+O5]A930!N'C?,M7YP8TR_L>CAR3L0R:=$Y*:!.$X*AM;S
MGL:*L*D&<6FE'4<([/@=LZ4 .9(!/_*1""Z%F-H:=GJ8%IUX>#)LQ6\X ;N,
MQKW)YZ19JGA["@3\/N/HU9[J2PG.UYLG:$QWVR??CPVAHQ['X=M]0UJ$FZX*
M'=:5Q D>.[$;UX+"/GOIZ&;T)VUNA>'@&Y K;$*ZLI9;83CX2G*%;P6@S,G?
M6Y,K>!#L)GQR1^?D&E:%'I-]+:U"=&M6A9;$^D.B!"<WYU>(OB6] D'.W(Y?
M(?K&] I"]G<C?H5.8(>O(UD8#KX!RT*#ZNWK2!:& WGT317C!C0,-WJN(^59
MS],0H&%LKMPVI10@@*(;<PI$WX52X+;;TT-A\15, W""O@G50"=4_0UG)SP2
MWXF!(+H) 0$GH7N6X.L8"%99?9WWIU":.N#^[X?!KY?T.@A^WJ>OP>!_<O"_
M5@++>$S] 'W?_(QKPSQ*_\)C[QN"X*ZAJ REILZY&]:]!1_BH1&Z@L1HM.,!
M6B0"O__D?U')0EFU*K&]1#CHE<,#F)Q2O=]@:5NHY-I O3DL>22HY*:,NP49
M'MT*,7PX^$Z0X='-$,,5\/R;0X:O-  ;KILN[7#P3;#"S2-_.(SPGR@PL$F
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M'<H:IF4],BP[NHUPL#V6()C7K19]@4CT&=E&08,>6@MTNJP,HL<*K'93J1-
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M&#L/[0Y\\[[EZW%?Q^_J2 3Z3" ?"WJ!]W+XWG?:NC=,T9'LP*L5O^PO@N&
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M5;LD HLS;6LC1<=IQ:5=9H;>O\P!D\_<!5Z8F#K=6PF5#%(5V^?FYYOTX+J
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MEW]Z\. 3<<<_72+NH<OU[8VAIZ;']JQ."245M,^;3.F1VEI5"I ;R39/M>0
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M%6]7F#I/"99[.(G"?TF5$CPI!G-+->ETD>62Y;MBJ\)RTP2(7WQ;L:HG!/R
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M&79"@VK\^0*<FC*Q6F"X7LD7B#UEW"X!?ZI#)^ NG-TL!^L5L@-ZF19S?<Q
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M<BXFL#G7%>4U'<"('2Q#[CF&>V"&49CR8B7I3O "\Y HT!/3!7U*OT(#LUS
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M6>2."HD^/,M%961/FG]'L9(71,9@;/5&,$0B]51LCW!7A^/)PNF,%0>VD*R
MV$V\","-6\V7!G@,UL$82:'7?(_B'46ADO!RG A^S?.)8.:;ZZ.,=>,,3;J2
M6\8IMQX\$":,Q&MXEEQ1/B(RI)#7EP4_B4$.W8_*)+B VG/*'88 *F07*X6'
M$DU3&&LX<TIB]L+E3XEJ4?-N$O4=:/C PXX%8SSB.#BV3(Q35X^U\R-(5C>=
M;ATDZI+O@+2;0'%C"LB[+FD_,$&RJNJ4X@JS;+J:9.(>^!HASTA'LP5W271
M.(?$U*>^^9=DL?SM@S\AH+D\*;9.U=308\%7 W>31A_*BR27BE@P7=^X<-0-
MAIM78N06/BUF52M/HHZ&#@>R?%J5!1NF!)P^TWUY&@R3BT.%_28_% [**R'
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MV9(KL7V\-<RQN4(-%E_ABTAV$8NNV0NR[WXT=8E^^H28AA7<F*[:2( U?ZM
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MX(Z6V!%<SL6J5-'*>]SY^WXWH+$L91(;-F0S[NNQBFH5;\7*XUDNKA?7NE/
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M-]Y$MX9>/*$"176(L"@T!"T&9_^F6\_Y8+CTY=YKV5XJ=[_!V.-[(:)J05\
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MX !=JI#-?N/<\<9YSALG+U10W:VB29)SC18"7:;6*'GZS!HE/C>FY@A)LES
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MD]7B2FD.%@4<20@_,H40&W7"38?VX,A;LV2>LR7S3PGIG>57Q?R*U ](H]H
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MKV!WL^XH9&O1'<P2A)[X(@65'TC=#P0/4.%!$DI+_>Q""L6H# (Q]\:ZM&R
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M!-3%*6GDB56?IRH?!(-"OJXH!HO3)Q?8\!IPJ^/S"('F,/B!V130[RB$6-_
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M<.L@/[4*V3G9EKISJ@QOZM-:4C,36(V"[(1S8,=@M/NI?!N5P70#G_I=FF8
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M4[:2\G"DLHR\.]I,R*'C?^T<.F>!*TLE'YX?G!Y^Q_\YZGPY_OC_4$L#!!0
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ME78!U:+-(4\?JD@/E'J <SR81U?,G#*6S%J0NLLH4PL0X&0.<5)T,CF5O6C
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M:7;)=#)T4';L?(.3P HB8417M>C7"-^%QRZUOZ1D.*'_,DQ_?&"7@!2?.!Q
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MJWAMCL_V>$)2)KU&*0\%0*EZ\+P(0@-CR\H(,Z\&DKQ(<A"Y8->?8Z-#JDM
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M2Q!%9.X?QSQ'Q$+&&S:A@VU>XIW9H] U5'97&8M5? =)X$IBS! 51RKK31/
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MK0!!>C%G'L5$0S8@BQ9K%FY"F7V3M1C>)[9L!Q)(9<?V*BW=-=IZMDU5O!5
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MQ*]"?*-$61ZB\\TVB'9$7#ZOHY 4?ZV2>;,5STL&&E$]7+/<E-H,+<0-]]H
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M45ZGG9$EH;08)(3=QK,/F[V<T'C;MH??2)W%BCZP?$B$SQ<0%K.C]F')?Y/
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MRJ]J-\L]P2V'*=CUMX%F_BY3)P-QAG&K4VWMCC/%:ZVF5'6XK-*]W&QP&J.
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MES96$Q"A])>VC9U ;QDX/JB\;:)SQTNE#KQ#(5_AOBJQP"@<X9OPFB3W#F,
M#_[N"Q>99S"P!@@(K;W+J]:(<P1^P^:.%?JPG>P^D6A%G>UZ6/V7'FQ[K5<,
M):S)NBD^L"S/MQ_4<V6N$^Y+[G --&\6YXKL9) FHS6OTJ/"JM_9)_*.6X<>
MFR<W8KQ82;3<'KHND,J3>+.B8&FGUC.2.'X0RY$W0F%R,PV(S[!B8C@)&A6
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M[:8[Q_/YMO7C1&#GU41K?]LJT(Z=U0/"RD,/J$W6QQZ<N2X/U/$(IPIG7S7
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M0GDXP Y(-\-M(I?NKZ<P(F&(0"1\02MR9G<>RG&<D>R_EZ$8MG(@X'#I ;:
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M[*774=PABBNY1N'%EO*2>::R:R;[:12*[&CJ!'PR^T<,+9_ JBP.D+*[&2;
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MF,ICX<XW[N7%H9TY+<W&[A.R+4F0IZR3W67(1$SBY'*O)+?,42)AXJR@WPF
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M(++TVA]N8\F8B#.-_"9-XH11RYR&;%=KO=3O_MI>EW6@_21A#&CW]+Q)D!B
MD\WLC/FP3E]L8R4A='YLJ]$YD 2ZF:(RMMLL7,KW7.D*>,HLJ>_E;9L$[=F,
M5>A(JBK:.>\J?1[W]B4W<K=3ZJZ9+UI!J^9VMWXYVS-'Q@VE#N!Z?"_&$Y\R
M2,RFZK-?"F#^_IN</[E _@ZZ%1:>)[CD!/K2Z/IV_H+HY$HN@W^ RN"S\^)O
MTLUBM:)DY22M-:U=097V3V=\OY1RI+AF2F.&VOS?>]R:5=MMW\W<WVIE1<%U
MP-O]&8D+5^YF65QTU&[S'9_.7>6[.%(P'^RRGAFX@^]UQO:7FKFO?3-G1[2=
M"06O@<:529Y?E5#GT>C3**YO (PG;EV(9[Q]3-A<2+K[_FY829I-FA1CM(K7
M=#ACCJ2H9NV!J3&SD"#4@+(L24F2YO3.KDQL_KLSWCG5-1<<A;UKE[;@S7(?
M1=-QL^009NYP];"GD$GW+=PX^&$H#<GGKR,,(A.#[.YM<EZ<.O$Z+TKQ^%#&
MDC8 'Q<R3#.V8$J,+*0GN;7KYTS*[935\B25+V9]0K=QH,@IPO>.$+(-/?X?
MWJ;@R0EX2<'^ILH'F3),:5T,,%M&">]L#9\!BPLY P8#!,7[R1A.P"SO,J(;
M)W2)&'5Y[M P2I/XYDFQ.$8+X,P="#WF%=*#F9M3CY4R]1D416Y\/^.3J9\W
MA2RDV?R!#=XJ*.^(2_PGXMU6%@%L-361S]YTZC*[D#I@Y8 @.[\MJ]O'XH.Y
M[['JZ@OV2NL"S#BL$QRH?/ J.%P/$WR$#1/<DR0)B'<9<D.I>27M^G;^/G8G
M5PHA2++S)E+@Y9S<<ZB-B]&41S^4^4M&@5.%C*0)^R'^5EY)K>EE%5_-W2JU
M\*'@.%AZ?M]>=+-U>&CADHDV7/F/ 1'IN5+.#MB+4D XWWN+#E>+BE>DC/_-
MDCEMO*D6TY^*^U84W?I$[<#7@SC[U*DF PLI LU7R.*UU ]=?^L$67&(&':6
M/Q)1"V1+OI^[;93RIA &;$5!D:!;N"Z#$M^I5A6T?3=?T];-BH+K,&-V!1XN
MS@="-TI\WO_R_'VOP[H+IDK2^$8NEJB]*9>'=!WT7=Z6#,#\!2#G3R$4^-+\
M"\XJ<L7#*C6?(;XC?.7L'&(6CR;^GV)MV;.!#\"^F2D5<S[T!TN@4 IIU&#L
MSJ.?HLA[]H.@OI1K[H0:S; L^%1 7H0-/AV2*4A-C?5PFU^*]OG63IVX([%H
MWB\\1>!5ZF*W^8K?2!LJ[V5T68W6R/_"#S:?HY"P#4Z\F_ RB6^>P_*.QZEV
M4T9KM>7(8#FK<W=Z;9QO:;0E--FQDX7GD+<\)%,UI$8*5X#E[0&210DVDO7L
MQS=@]X@C]XQL*7']K$ U],KB!5Y++SJ;1E%9L.4-TL] I$9;>8PQOHCHH5!,
M4)/M;V@GLQ^?W9X?1M)38*)BW]$Q#=L58726AEJ8J$\& \EDU8";%J\+,*)G
M!#N[ IQSO!V'O1Y6[7(IZVP'5S :@@E4/+"A&VYH_="J)]3-5\E*H7L.'U#%
MQEQM?#E%794M%'P$J$#V$UG[;D!B@;0PZTI<;?]RLESM6"AX(Y:6(_*"U'-/
MD%Z%@#Y1&]')C-ZN*R:IP$?JN\)YO'!<T6<GZYM$V%+69^2)!)%P;)S@E/#
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M"P6O)4T\=)E]Z2[I(O5\]J^+)"%QD@UB&QI0D("=Q:$K8TLA!>F]U]CZ%\F
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M"9MCX+Y1LV6E&7_WL&9P;C:67["XK[*XXZ'\O]YS\(].3/C:_W]02P,$%
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MEXV\U0*UD6R[U$3%5&ZB?8NAX/AJ;\X%(K$'SO?R! !9>2 8HXU9U104'M?
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M]VO> "#XT@_!=10$."<$^J R@^<KJ^>Y_Q'04\EHUC+ <J(D_97W,<''C,O
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M,"!7;V;Y.9N0=(H71/QYJA_]YPYY'YK<PYC<,X]T[<LD8[(.)XL)U@O(O#E
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MQL7;+Q^^ D4OF^)FB:$0-W5F"N+>Q@Z.NMR<]@]1,$C6S9',N@T:M%E"SMJ
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MD!A$!WRYG9/0;JSP:-G(XLEFAYW4D_0AUW5>U<OV!BT@Q%:NSYZI#S!U-S!
MOWY$8V<I^BK(Z@YF8!,R'LS 9(45S. $><JILH-M&Z5?;HTP!OZ,U<V8]S!$
MBBY  \^\O1_Z6,GA^^]Q,-1'S320>OAAH"GO1?#D-/I9?;<D*,HZK$3FK^&I
M7.5#&LM"JE&PEX&X8J+7)KI=;3:6@SK9PJ':0:W)C7 H$7G83.>&=I;?P,=]
MZY4A:CT5$U1IT<]5O:Z+$($8)FDV7/YQ+Z.P7!O]P?U")"UDV.UEBO'IWBR6
ML^758G8+%LNKU=T<?%D<:[YZ@\O?6$^X*RS@5L)=L051WP0*)V\1%'3I)+ZK
M&6QT&J;11>6" :?+V69Q16*SKQ>W'[?S:[(C +0_ !)X6R^?1(L4LX QKB#K
MH&*O@SJ*?H(XISWT9FB3<![A\H@#-U>[SFW\&.B2HVW!-2/%( .0VP]S\--\
M\?X#QN+L$[)3WL^Q<P__?OGQ[A(!$_VT6E\C/;C^.0/IAJ"TJ#N8?$5^S*A^
M9?MXI028.HKE%U76*412570O7/%N+Y5PI&<(@X 48(>? ZAQN8[MM1^LG*@D
M)%/F'!&8MJ+UQKJ3_QC&T EP9.2'*" I\AT_Q$17856C81;["?K3-?HQ?$0:
MV8^\2[B+8J@_*&0\/LT?Z<::"@/^U;@$]7G6T&?'#W!"WS-<^_4L<0((DI**
M;04[.BH[;PI'D\< [RMB(\9OL:]A]M]%V'UPM$9FW$T4OSBQ[GAC6>KFP[ D
M.63=-'Z8+=\C<^/ZXQH[3]Z>7WQO9V,8*/;FT4M^9<S7+E;@DN:,Z0CP[86U
M?&)V92A?V9A8%SB*'2=^6.V*X.K\=43H_>3$L1.F67A>T0[?=B="UJ/:R"9C
M$M399%5+RMN0'*;-6'7BTW_)!WQ3%&'WBPXN'M6.JV<X#$I357TMS6$W:S(>
M@O/QS:9C',#I.%"FGM@_"U W\3$,VK455O=0$<V?/3:J6YKD020Q7W5?Q_?2
MLQ$WULN5 H[3",#](8A., <UKE-6_>9XB$( 7V'L^@GI7V#>JH4H#(=.LH+>
MU5..6V,,G[NTS&&T3M!\_8Y>G@Q"=$H>4W%T"$"VO9P*1VRN/M]&B_ 9)JA7
M\A$M[CQ?V]6NT/*#+(?^T<V=I(<QJH9EOQA41+E.R P61D6OO2"VL,91K<$J
M%J4QF1.>(,.C(9VAHS\;S$M:RC++K1H&/<]WQDL8PIU/DGL5-\70PVY>&"8.
M?C*K.TY F*[QV %1SE@!KKCQV0-N36[1BN:VC0II23<"":061;'@0_4Z^RH*
M$]\C@2]1^).?/JVS;%#;:!9FI87OD=R?$/'98PPACB[;0+B,4GCA(M;P/[X5
M4LV:21K7U'KY[W_Y[]:I@!=$IDC4A56X$^;%JL$AIP6<@M@;D$"(C/$4@N\=
M>U?)XV"L5.4CR$/)T7?UA 0(D^P<@!.J284QL'N;CF!@<B)Z/?7VW&+<0J\4
M2MSPYSDDN2;#A[&$+^0OV@N#"M$T?_LIQ!?+< W1-XW3GAP? M]%!ND.XA$H
M=FSIVRW;M*XIIN-,H*- U 767#+SEZ'"O-&N0#D'D7]S2<E?>0HYEPPKDS;1
M"7G76ZR-I5 ^&V>E"FQI:ZC;T4X^#62B(563(/MLM?N(1&)R+^S2MA"M+,4@
MN[Q'W@[#-(992IR#$Z>GJ@8#/AP00.?Q&$46:TCB,AA'@TG!F0\8465,7]11
M='*=5/;OU'\(8!6+9U)7]S,S&8M0D&%#7P-+T4_GPY!$F[#^%Y. Y,F(ZVX=
MX?:*?65EWYFO[9:J_V)J*@[Z@3=1?==/(R/1#S7<.?4,/8T@+#Z3.B$ZZ:@K
M,1@HPK:QFHH.>_;%57%?D!!79EC&7S1Y61VP<W3H):H<K4GH7DFF#83!1!FE
MR7T#BE 2N%N5EX!>)2_)@1;MKTIS&MN"(O?FOIY)[R8#\:;[BQIW_RD#)S9'
MN(TNCX@<3-"98O^ FF'ZB,7B_FVUR^[C=,7RR)"<8FB/!/\*GY9WA/CS>LC'
MQR$2!8$LBU-V@>RXZ#"<D+M4\&6,*V+B7OA6%+R;XK<U!' R@4"RPM'Z3$2-
M#S^T\&7YH?&[:MT3L/1Q3>%N8504CO2Y^>&0NWK=SZI'JC8Q&ILV[O#&FLPX
MF07^#1(+\"I?C"H,Y>M#-,J5DSS=Q]&S[T'O\O0QP86YRZQP,URADK"0E<0]
MHM_E?T0V[DC)J#4Q9>'"40_GK+N7V>8#N+E=_;0!-^O5':A2/,ZNMHM/B^VB
MD?C:PO>D%TWUKT?CPJK>1LZ\?QZ3K$+T-EI#O!Q^ !%C5>;$;23(Y$@?SB@L
M&G\V-\8LF)&_)2D0X^O)&&U>R%2,"ZHD/(7L9NBW^-\NH@N../8=69%5PD^G
MI&BY9/68*&U6&AM)2$/RDYMXV,%^Q6'Z?E_KHPT;%^["KS/X3S&4E/D^BE/_
M5S+.:K<(4[18^/J=YBD;KI;YQ"S8*7R.6,JRUHGD=RB[Y>=NRYI/2*0-'=:_
M"JK&PC5$=K[KCZ& &D.;5SMU\@R@U)M8/N'1Y%"'0&<VBOKD&CN98KR_X=T/
M'<OR!,?Y>S+M$.!3,_VDL(<?)DRR7DB1X&X@=5XM!Z@+2K$)H/ZIJV=ZZ6;]
MJLPGHJ1&.DB(TS6?5UV0,]8A.GN(U++><[=QZ)5!C'XM-AWN=M!%?T?_+#S/
M,'<R(\G;KC4EC1%^6CG><NH$\LQUHR,Z/=P[)^P>W,:.I[L$C"!1&ZY9,=;8
MM5E)4W#(VDX.@#S9\M''7 7%V)06@1+<M_@GL6L[_A#&+^&X[+!27E>%22!Y
MM$S5=W8OPX0D55UM]2^#<@&3'DSB"D:N&Q^A=UNMG6G-16?"N*M.C4^V6L,-
M <S+(!)\9J70J2B=HJKC@D-*];%73FL.Z<)^':>Z;#^]:6R^+:[Z#BQQIWCS
M-,#($"8?=[2Y*]\G4NQ)<N]Y1!3"U*3"9-&=P(&%SAFW7$40A8]GB-:>L6%/
M GX]HNXY=W!61?W<P;@WS.)?3%S)*3 PG7MK#I>"=]2+Y:?YYG.XHQ9 A,!]
M=-^"J;J3&>1N_- )78LPYC$P'1ASN!2$<5Z2;_HP%D"$ (S[%DP5QHB."Z&7
MW*"IU((3L>:_11O<%NUOU_!!-W9%J1H_/0DRQL!HT3N+L\,& L@,A,@)K4)3
M4LIU/,JLB&I&5 8-S;4NAE,Q[5D:S+$03GU.=+=<00SC+BIMP"F]6'J67-'1
M12.>)^ZY)WE[5GE*'@/JF$[7]%%-F#,QI,LG06)C?2IZG N0/DW.7DOU UZ=
M3OZ=%$_Q=/L8N*1L^+%X# U6QI-+QRXC<182J:ND[.RJCTQRO>1//XOA==?@
MZZ=G&X54KOZ]7_=+@X&%3?;:J2>'.QX. 4F]ZP3XG'<31"^+<!?%^^R1USB^
M E&JYNNQB#'&"J']>']_.[^;+[>X*O5B>;-:W\VVB]42H/^KW )@N=IBM]?J
M]A/V%U2>!-MQ(I)@:,3?2BR<ZK'L8WAP?*^P"L0/6K1^9M,Y4#A@OI##+:>0
M/+=OR<LC"FMRBAD-_-XGJ0.RE"D/;C1GCBJ7#$SQ;+A:U1$A>\XT (>BH43I
MH#55"RVZ<?PXJY;6HIDE_)LEC03Y-U&LE(YC.!73;J3!'#-PCL<%SWA@&M)]
M,CAPDE8%![1'5;4:4#^;#Q7TPJ;$OIX%5TDT*4V9DFA@I,^ 2LFL6:"%9^T?
M RUUAMW(/ZTH4O\JF*NO:.G4&,B>)#\B\[E!%'U]QSV^;M/Q62C1,)Z=:2##
M0E^#6P[<@K^3#8U#__E?@<4O8 A4:-A77N6!>97R;RUL4%5,1,8?RU;J/BY7
MVH#*M5TL9BP2DB\E$5'_JBFJ6_P$_3'TL^&:T>!K__$IC7;')'O8.7MT_#!)
MFVV8D8D,=&HD9Q; ^AAG8)R,<A;MSH[50X/H(45C98B&KRYY@D6LD1"^U)YA
M98\3;,=ZCP2G\F/0+ $;M0C%OI&!) S7/1[&[9B5!2V>5O6@1$_UP&%UD.OE
M%M99V8I[7+6B^)Q.VVA3*UDQ)Z4JA&"N-K)QTUN)S?&J@%@L6C@$"55!0^7E
M5 V>)%%P2S0Y)WG*7IOG3\TU7]^QZ6AT)7Z?03:$CWCE>)=V3':X[R6*-V0V
M;X1[!=9)#\B<IBIFS*2CX*2AL  8N204B^75ZFX.MK._@LOY<GZSV%I_52.:
M>J(WY<0("[\5>.[$8HI:JK),_=']9"W=D^N1P/F F+8J ^BUGQRBQ&<[3P9_
MNWQ:VLZFXI\OER'61[P_.'Z,C41LCQQB?*1$!@@.',+6QJ%I15O E)!$Z\CJ
M7X5!KX"1J0B3=!9ZUSY^^!'FZ6NJA+,?8.!MHSLGQ3^?M.\7LO0MX%":2<&L
M:8<8[OWC'J"?]D[\"TSQ8^_II$16QD93+ZJLG=9W[6OH0O\9K^WX3XWKM*P@
ME<-07PJ9N&PZ@7VW7X;\-\3M>6M%U'T,<2A4OM4GQ& ?'5I4HM;L:@'FF''G
MI"DMMX>;O?EN7V], H$\F?.AR%P;/8F,ZBZ'%BFQVS6)\<S"398]UC5$PREU
M:,'/GO=)09#,I$=]JS+ :\!)SC#*,42(I*XPS2$ZK\L6UP^%WRTP%-PT-!Q;
MLN+I.@;=WI9/(9Q3GDU\EB56O"Q3+9)WCSCN//^+]G<U,J0M&'@R_+$\]CAM
M/5&!S""P\A4B27&/]V=LPL>^B]5H]KN<AET/F0I0&F]N9%=S@!5Y5Y[PJI//
M.B_W4ASQ-8-9B*1Y32K"%LN[0T*XB7?'[S\T6T"DC)3K2!1>$XU:]3YWCMVC
M)<;G\WGA'QM;I[()C^6KEE*I3/98!YI:8%:?PW$26K)7\%P=R5\>U0P$.975
MKDPX0WGWI0V*'3(6M_(V+WT9!UE/QJQBBR4W&I*H$U;863WH_Z,*6@U3QTWO
MX/Z!ZXI!^\37C]'S-ZAOAA?TCPHF[!$-/IUA,L$ 1M$6Y(WM*)M>86 D\*>F
MJ#JNHOT^"LF3Z5[QJ^B,[OCF*VUT>&"=-)O//ZP>,)ERJ>L$^L0T/\)\AO%#
MI+# M%OJU@J#OV?-_]NR'E9?[/,!5?"*$+Y[=)I<A%?.P4^=8)2/D$_+0ETZ
M#CO] :#X]'V&#C!NULWV=8N0()L5W_JF/^"@/'/=X_Y(W)FL0JGC0$R8KNED
M5,*<L6_XBO[%14M]!.#!G>_ZJ748R@J^ 4FI-5(_1:]A]GYA[L0A,F"34:#(
M(&+>[J S(@"S-J0LP(DOJ3IV.+-4M$F7.)@!EF\Z.H\XAR?A[1*PD?"IRP8#
M&^_GR_EZ=FM;Q;#ETDB%2Y^5>NXE_S'TT?> _259L 4NW1T%Z N!R1:^II>H
M_R^:$2)(U 9JQ%ACY5Y:O%\N;A97L^46S*ZN5A^7)*?X_>IV<;68;VQG5I(2
M=2.QDOBBJ,4-;-PGZ!T#A.O"@U=WWLUBN$FQZIZEV"E#KC]J"KU>''%+RC'1
M8<N(,1B+MN&'82--@X7TG-K4_,HFT%0&.HRYY /21M,]X!LG>'8>(7EP?P\1
M],(4_7@-$S?V#]WZKXR/9<#PQI^2J?/*SDI* ?H;<"C'L)SW>:#DZPF?AZR<
MJM.F^I[*U!!Y=<>P7EWJ#CH)LH&\%0ZD/,;XON'22?R$I_N'FRQ:>;-0AETG
M_P*;PBZ[1G$"1A4_L,\I@5V9;<)JE?<QL->PH;0+0"475K-:ZKF0SF_W,9VJ
MK46?=<(GK6QE+^4M;O6NG#(1Q4/\713"4Q:8<7,,O039&$X<GQ!:"+)T!^OT
M4#/M=.SAAX$0TBL/S $[W,_R@4Q0B(U8'(&9*Z;:*"J7T,)]A/0$=P#CUA^/
M&Q9 N#%;IK6)B#Q*U=([6U6;K+8UC92'FT;!^*49A0D&2&HM?[!IL' $4U<8
MK(D-N 0;L096I]"5813TE[.ZI1>PL@& GB)5M$I4AB,7VBS0@A9N(YQ4:(^=
MBI_3:@X(32 YLW"\8O9<FI'[L,S0DK]>T'VCK,B%A7*)BJRRDP(5Z0R3IRA.
MLX\9.G$8'=,J+9!ETW @2!JWSP.6SQ3&<4:92<"\QHB-VR=U=OO17M5F9H/]
M,T!Z%RI#P-Y:0.TFA\ F.8QEVI;:$OJ_AX8;4^XJ67"R]&HPQN$9V]@)$V19
MX^MXN<M'[@#FD^]QN&%%>'_<+);SS09<K>XN%\NLTM!L>0U6VP_S-=BN9\L-
MKCJT6EI,I2<@I2IC7M\:**6<IGA_&\ DY+)'%)*7UOWC&8>1!',B-PE5-NIF
M<M*T&F82E\W"DJ5<((LME*HY5G\KN@CGKRY,DM6.^<)4LPTF2]W"$P8Y#OF/
ME[-.MJ/)%$7>",E76!7%ZPQ*?G]V20"H^Y @2]T\0"4Y9 !T&Z7M#,\V+7]%
MH=<AJK(NRD^YJ.->!4Z2^#L?UVK)LN>6JOS:3]P@PK>YNA7J$%8L.'"&\-M_
MKFT5I4@!3%)_3R*]*:$%EEY #<=.\['4P 4='J&3EP?X%6T-'N(CITKNM_,M
MHQG7D)=R,12CHX<[\Y5?]4Y P+A.GV"5RO\0^RXD:?[SD)V<5"=V)Z_\8O4)
MYTA0I(?LZ!/'L'RH2(P^&C(C/<[% (N*#7<H@Q=F I:B-:4&D:4DI3R!M5*1
M,F>J_+:#/#8;)0]:?633P3\UVMR<9C9K:'(DT,FF/[RH%+'KF^I(R(E$ZV>V
MS!.% ^[9I;4QV7,I<I:\].ZP)J?^P+/(LU(F=&?6 QO\A7-)V=@+> PQ,+.$
M*7[LF:6FP;G[:36[+&@%$3'6U43OU&VDINICBAKK@5/!]$K$TFZM6RKJETKE
MZ6Z# Q1PU,D\N[PKKZ_$[I8$QC$=RRW DZ:X#>.73.)2JU=G$EH-E4C_:FP<
MNI0.!Q%S&+,F0S]#>D(A+%PEB8N,@B#N:JAKHF<8I_A8LHQ2* J81A\+&J9.
MGUL:CK0"(6IF\0*1L<BM$F[-"2GZL,EY8SR;L3.\E:-AOUV8G25X#BU;1\4>
MDX,Z/\5O&QG'"D?&;B_#S]P[#'!L?^9IT?@WSESL\BNGSVN MS#+-.0D3_@F
MX-D)\)WMN*_$1"A:N'T28(MWH8]]WR2M.*RZVSZJ2,BVHSX$5D+Y=J@P8B^=
M\!<<UX_?MN(]*[EW3M@5KON^IY>>E0PR?5PQ7Y8X(<!R!@YXC-"6'Y)<X@XR
M[EP[=6BEY=JX/!%:!K5T,4VK5\,!F3F,S;.-VN%X>A&_DB)CG&UXAV-)#"5Q
MB@?W< D:C^1HP5_::D?)RR=_7XT&K^DN]%.EM]3I&MPVE9D4N&UVJ@!M_./2
M06(&LX4E7 Z& 4;JL.4:8-^]CR+OQ0^"&2Y:V+P\K((]QHJTD"1N^APHQQXK
M+>!J=?W3XO86_-;9'_X(%LOM;/E^<7D[![/-9K[=O '+N>4JS&H8:!1PE5\I
M]>NK*IZB(#M^)%"7DLW<.QUN!)3F8]Z'G$1PO([/B7.P&HC#E"H]J(:^&(JN
MK1+(^?'Y^HA3Y]S#V(]TU^'BDK)QXN QQ%)N!:BR T>U+T]$H7&D2%5?K)FK
MYT6MGF;XH9_"6[2-=U2DJ8QCPAR8WF@5>!30>#P%9UG%28.!D0),:K74=UPV
MG8\)W!V#6W^GVRDC1-(T3D688@#S)^@_/N%@\MDSC)U'"+(> '<!7_HA^!F=
MLY.O;$-41M)U3 JOC.(U WO\9?L=#\-+PQ_!K(.&RPLK,1W);8(T61%OO8?Q
M(XR_:9R&/:=^!VG:.2,DI-(OT[\(BEA!*Q6G_J_D+4->(?@FBK=/D&;&,=#2
M-X8IS2/"#!LP9:^B%#2IATJ"]4E/BU=9@D*JDAX*K,&P".?V#MI1+'INMFAD
MC+\087$BHGNNH4N*1X!W%V\ _G(L9X#H$U[GZHHU[P%>-(XA1@'NJ/;^(%8L
MW*L.X5?@$-#0@K1# 5&)T'&?BGTU1*.#'2X:=,(F6>$OB:&S0Y.Q>H.F V9B
M5IO@VJM>\<H17D<!&N016\C;E\CJ]])B9?+?2Y-?QO>"U\2R$M<!"'5D4U;)
M/+(1GLT=HH68,>_B'L8P&][O;(;DZ8&$'G27RZ3H'U>F?(/ ,A5T$UZFXSL2
MX):-[-]-UV,D@0@MX"X7:@Q'9Q]MU&4R\,:\?#[P1EW8\/[]YPOO&B+TP+M8
M*%/PGN'SSB3 W>3$N+=D +-L9'];'"S#S^U<2<6%.L2[ZS7 $<,L.35^,),4
M:>,8EN&.5;=LO;J?K[<_D[R<\__ZN+B_FR^WS?@E"^!5$7D=K=(KHUI3KUOG
MKT-22]W)OE'-WG5)\Z>C5.04BD4*"I=3!E)DH13OR*JJ>QQR0O@3&\GP\RXA
MIEAJKNS;@-H!=V< SC38I*17E6,47I0Q-F#CV^X4-]O/M1ZNO'2%=EAM4>Q,
M"N_C2'LBXAYB%NX$^!QQGR_34?8&/.*>M@_?8F(5@EJU$DJ)U]O/'4-O#9,T
M]MT4>OAODNGZA4<S&F<BS!;K^=AL\^$-P/]+C@>?9K?H?+ AQX7U?+-=+ZZV
M\VOR=ZNFFK0LJZ=D4@ND(6BX.3RBU^+ 1 I440[L!0T+\RBPZ\80P\</_#)B
M +_:?M-YNTWT95P2)G^?R@,*:=2PLI7*+*OB0:0B@A_X7L-#E/AB!P]Z3Z,*
MD\H" V156_" &@,O:VWM#,%=^%+CL6>HK-WZ8*59E?62,W_+W<<2/^^^L#K"
M"<Y>0N"')*PI*1Z5%CH-[(+H);'J=Q:%0ET_"2V>XNTV3BP(X>I $J&'C[?0
M2>!H>VP/,0O'"#Y'K'P3\]EFOK%:<U-(:HTJG/T352YTC,>ZBA*N*U<#=NA4
M;#P;9/ BF#7>C?:'T#G]UD$[RQ\3D&8YM?"0Z$]):C7!:H\LFXAB+X):<I(F
M.O'0],+9#.N(T]VHB<3F@Y5UN^A00\$/-E..] NBM)9Z)JML,I7#C:5&+%1*
M+T@S8'#COR(SAE(&RZ8>X'[Y0WV89::CL:1-(6 UL54?!$C#++]JI0HLQRFS
MA41-6D4!AUI:_JYF$=H%6'V-UW)D,,(]Z424G<#:<;E'"LUL_8R)#B^7A,\Z
M-^C8MCD>#@$YS3E!%:9@*I& '!<6#C**K J8K$EMG.H4C<[8NRC>9R[#& :D
M:E@:M1&<V%9>PW!$]Q+*K[#R!<R]XWLW49R]1DP6H1L</1QBMGV"=VA]$;DL
M:1;YZNIEE&0,9RV$S)=<UL UOQZI[Y&7<DXV.D)\-GSA7MI7%/!WDFGL6F[D
M'ZQI;IW(:=P$:5EOU3VAN<44U50UJWP&$?,>4SHCO2?(RLV9)2B:F#[FR[#Q
M;ID]?Y6B#FN<BV2U^YCD4;FK!URK/"_/^X36$K^M)Z16#X'_2/:U9!F%Q.,J
MHTRU$#*N3'5PS;H%PD.?1;NS8U(^0([RX;$JA3D!HFLS)1I5-,"7812>851_
M9=4EHA,_U563KE575:DM!JCTFQ\B(T_P\#NK 9P8]^0,8%;,!6@]#$D#,!HW
M6 ,7;'C\>=U6OW30VKMP\P1ANJB.,8,BT>7'MQ63+LVI[!GQ(1L4)'C4^CG1
MFCVL 0:4F'6UA50,&FG=W VX&+%X9&,P(J@3?["7YJMG]1FW(6,<>UJ:E/*X
M;-0#D0!Y&PYV628%+^+BKNEJN2JN(A;8!RO!M5*L-I'58KYSTF-,_ "K7>L+
M$?-/]0]CN-I$+T,LQU+6$>S+GGCWG,@975)DE6-(;#54JVTAAC,"*M!A]S9=
M78_)":L,%S[VYG#A <0X0GH%4E7FXDY9,6!M$;HQ'N0:9O]=A"3#745AM")]
M,I1M;((2_$E=0DZD]K."X.O;GNSJJ.UX1<[C/.7Q&N[10;? /;X>ES+<Q4<S
M&N DS%9?8F@G3PP=%R/DB,,!$%9UG+082YTGMS;JZ5L;"K67Z,6HAP(!\O8/
M!?U,*KCFK!\!Q"7//@((KHP6A8BOR?'=X=I)X1!52!W'M$DGP).H!O3ROB"V
MFLY<0EHLC<=<!=7*RSRLUHGE;_U-:CH:^<EI.@J3_P::CB-Y84W'6ID!0<O=
M1Q;E149^/CZ-_$I"G@/3KU@5>!2X@N"Z5*AG&#NH'H"1OO<\(HNHGDF/2[&(
MS[@^PG%R5LM2-Q^P(\FA2&+JJ<&3+65A:#(60N/K12:I$;)-R].W\.I$DD61
ME-+3TYP\82N#LYXZ6LEY+4,-Y_(5<VK+CVKV>D2:OPGF>AXFOO)PI+84BE<E
MTMB>A=ZV+/.A'7H4$H9SX@WCEI.BF5DA9=(09<M<":^,%1OP'E"4NJ5=?"H)
M"FB\2=WH4-Z83GI''[*1#TQMP"'R,2R\=M";O[JH:?8NPB0ZF3S828N@P"DK
MQP9J\ /P]X=C2L+$$7&86,MWJP4/PNCE+I6:&_X>K1[Z(#XYP1%VG^<(;?T]
M0YAVOO/9826ZS3J!9]R+^FC+7H);(0E5F6W[IZ_R3.8:[F <0V\-GV%XA$EO
M#GD&6$3&,8T8 9X8L+F>W\S7ZSG.Z?AIOOPXMVCO20BHQ(KHQ!6=,*WA+T^S
M.,8Q_69J$,A2-^\8E.10P-==C CR(6UOBXH(J&^(*HNDHN#*,* CW$;HY')Y
M3/P0[;!7T?[!#[,75D(:3F@@HV$Y(APQP%5T!1[:%M.(/&]^R+OC?%5E?YNA
MJ3*B*W6?\**HV55MU4K.6TH[9-;3*&"H++ BE[,WFGX(O$+YQ%WE8WLW;"P_
M<_^KYJDF]'66[N+>B=-3:;3+V4<]0Y@VC?CLL![VSF]G.+OU_6R]7<PW/UBT
MBL0D4DOQVCM=E;VEGD>X(C#H62%G(*.J0H0CH5336:*8 ^YM$2\RDJ*\_.M9
M@P%)K] V=8/8K!$0/9YSNAM%"IL/KHL2]<@25M0ATHS6L)+_BBN09@HL]J2U
MI,6O00Y9QHGC$MO%4/XK0?)6DNM),BFIIG! 45H;;#H9[V4 P4IW+[Q@ZI'J
M^)IL#1.(9HES5U\C(RR(2(&2D1ZL]A,T'H31SQ,[A3[I0RX<O:H7^.UO_H!V
M@#^"!*)#&T#$HA?+3U.%Y=R(SQ1;F %WBM?PP8@7BD[%AD)D\,*Z:%DMWX/M
M?'T';E>SI=7<^#VB:KJ+V'-45E57T7[OI_N\SLU5%.*K&1BZOH ??#"")(F;
M#MJ58X_E1%C=W2VV=V6)I*O5<KM8OI\OKQ:U?/J6G)AJTJ^#4F&-U,-Q-RD:
MXRD*/"0Y7 LB/2VC%(Z/4W&ZQJLCB7+&L@ _S-;S#ZO;Z_EZ0[;7[_Y(BGIM
M?[:J%:4%W;#UI-9$,>ZL,B@727*$'@+_ZI@F*;)9T >@ZOK@CV4K>Q*7*X&C
MA4_Z$W,NJD:82!U?(?%1_"']BZ*NY[( "(+CS9.#1#L[ID]1[/\*/<V:C4?)
M_*TAAQL&S*H&5O65@,#J&JIOGBJ.V%6,$.C$IVQ &CJ%=)' ,&;54#]#K/N]
M2NNLJ%K'>$(M80E5N;7$)C_ HJHRNV$2ETX"D1&WQZ=0<D^XC$*X/P31":(-
M-(8N&HG =O;BQ!ZNOCIS4_]Y[!=^8W%I7L.--!.1=(68WMD#)@@</!JNP@0*
M8LD;U&;GNXC_S.V2$[?]<G!D?-)=A/I%HZ+0L]OGY/H88\OBB82?RZ6XYPU@
M/G4]AQON_7L"/-*'!&B<4"^K.9%%I%)E">N;LW*I$"I":^%#EZ>J21X83G"Z
M.A!G]WO4$.>ROX>Q'WEC5$\?@T,[98RTSX.5_.RX?X!Q6U7GSQ9RE?T&D/'J
MUJZ=\DBCP:]97VF<M=>^[3_#^"&R@J-S"I!RB%1[>P8HZR]?/F_4G ^QLOM8
M2J1X:J7TF+_"V/43>!_[KNZ+19.<6[#&S<U.-"D2S#N! ^Y%T?=3_'#UPU?J
M@]8L)<4G 8/9+#CY++]S.>9M%(LS.D/5S[T8Y#/_X)6@K/6;EY>6;K>F#J-0
M^RQI]F(O*'L:_"]H+8I3/<QR*+,W4;R#?HJK/WZ.&Y8L^Y^A=2HY1=4]*R?3
M<$I\E@I $=%:58"*S.P9K <_SIZ3?8X:0);]SU #2$Y1W6I%9#[_[5\)S9H-
M 'EYC?7UBRNJ6>A-7!6,.I<I'F;'G+":EO@:7.%J<4$P=3UA O<Z_=7#93G%
MD^_8DU8Z"%,0/%%3]W\<B!5.PN2*/KMUS6,^'MK<);5(JUDZ#[W5#M_A"X5?
MJ(UL/"Y#B<U!5]BU(8&3 HC#@G<DLL-F8,<@(%3EOY17TU8H2/XEX9BEC/F)
MV69=_HR_L= ]@T%?3VTTSM?S.6Y*3"3JW&CHPM!OPANP@:A3H=DU%;#RP$\H
M@*'_!9#4J@]XK:N1H\_HS"W*]><8]"<XMX&7Q/_&GZ_IXX>,P#0D-J'S0J+)
M<X9PCM-L#DERW!\X62Y&?&(Q@#F[25%T3$'@2<5EX+B_G*'?(/82$)%1SO W
MBD\V^\B#@>T;L5$0U_=H8N":CW>CS5("-XX?DZ3"-<9P)@X7J8%K_]GWD(;%
M]=*FLH,*\SO!&ZNA<V)E*\Z;@),/ \]&0FOC*-2R_TDMN^F;)AYSGZ( #8-S
M&'XN7V:+8^/YF Q,BO%Q%HW!<]GZ,WV_(H_(T;]2B@1LG$5I+*[]Y)>;&,)%
M7LEBZE\JE=_/? ^ES8F5=PTU/=NAMF7ID59EYG^#CY4'R=$^5:8,AFRH#VWF
MR&]KF20^AAZ,:_8W?J*<-(ZS:SR9VM$WM]-9M=%Q<B?\<O7H!+A"^MLQ/N4)
MS,I6.(?]J;.>85?- )K*'GR)74W)5[8/M]-8-*;VL,_:L'O%ZF1/S:?UDQ.3
M9U6K>(VY20PXIB3YL)K=0XY7D21:X2Z*]P1(@'P=,19Y/:$62=S1N-HAMSU6
M#\-#0<3P-2FLKM;#J^*G7$0'U,( \D_:B%FLG^OI7,YHGUOO)7U^EQKU1[-,
MQF@>#;;]IO,X\AGF*^[LT%W[OA/"DU.O\3,I<WG<&4S&-!YUFGW7LGE_4 X
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M%)KW +4NU _?!NYDY5T'H=3"* ,2*<QQ(%<-; -4)746;/!&04&)#8QT1-!
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MN]Z3FRBN(MP)P6SCUVUE]M.S\4:MERN!9PWH#YYE< D+LXXNL;DKOV^XA6A
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MA^/KS^'OO_=^_>[Y\>=3^/'Z^/+^N_C[[WY\^\^/VU,2?/?L_GH>_"7])MW
MO_SZW;M?7B_<V_3\;S<W;S<_?O/\>GGU\_FSMXD??O?TK??B_?SS3T[TSGF%
M#[]?[G:7;__V]O0A?KM[?'O_E^WZG\%W^^"[;__PE^?MS]'\M/[E+CC^QV(?
M_'/[KT_K?]W BZOYSW_YC_##Z\?_N/G%<Y>7RY]?OOWD/%TDB^WMS?GLQ\6/
M_W)A\FMR>DPWZW_^8?;3(4E_??[K^W<?#\_)_?F/+Q<OEW_S#H'SSTO_N^3Q
MXQ8^__-M?/.7CZOM^_>[C\=W5_^U>(Q_/-]_VBSNWOWR$AS\A^_2?_WZ]M*)
MWWWW[8_;K1,?_N/ESW_^;W"U69^=J9V!R<)?1?M##)_0XI>?Z37<^2'TBH*I
M"%BD3*X?Q7DE(9Q=]2J&GI_.8A]7;[@^XF*Z6739)41G2?RIC_'AC<BM!9MF
MY"FQ7V&@PSZB<PB@;2O($ 0[ZF;D15>.K8RAL]K=.J'VHEG5P#;*8I74V9!\
MQN4KHMT.UUE+#HZ;5=W;_.N(S?@[B&E\9=D9T95.([JQ.4FU@E;.*9D=#G'T
M2H(_@Y9K@?4FK-/+]$NP-@,,,1]0.^#4&UI,),I:ZNJA%W56 \[MY)XN4S9C
MA-/D(UL)HLEH\_P]^*HCC4!R?,BN6:W:I!1)= )G:E-2/XELG,")?8AK_/Z$
M#G:Z#R.=X2VDLVHPP*I($$=) O91F#X%)_PV ^EXW/-DT_9@R::5E*H[/\7H
MJ:SL,W;@S IGE.R]:<\0IF]&^>QP"WT35]R,ZY2S<+4I)J)6(6_N_!6O)S^F
M^4/S/)5C^)@?D._C"/M*,"!SLU2W3I$B;?SZ088[?C7?I'B$CJ\^<57G)\2M
MU5U)1>AU926]-@-L&5)@!8TWDI>M,[SQG,8M!G@/H;M%=:S AR621G9BVK34
MS9MZ)'H<N1!Z";[NNH:'*/'35=A-:Z'U.0*3I&FTB##%R9$_C;AR&6&RGB-P
M)Z^.L]LH?,SB6A_2;O:$X<>G]O#&SU M!GC:IKK);"=@L'*28DBF<9RBS4XU
M[W08'IV@2,HAG"2%TLU\%H8.#ZRGEJ0A\(MD*<TD*1;,8O:B5ZD6Z)-3\H+A
MI$O' -LOW1ADAGQ;7<SFOVD29^GYLA$.JTJL)="@+VXI1\I<5(^[8>JG =%4
MV^@G)XX=M$=(U&/F]3?LW^2PPCKD5CVPU^LE[].MSVS^B-LOENI\VS-OU517
MC=*P)%"'U"; ES+(*JV_OE:H[-LSGG&U+\&<6!5@DBDVKUKAUD:AG4-,HTM!
MLO2"P0(+I5S )]KOHY DFB=W@5GEHM4Q35(G])#FTWZ6[:-G(XJDERNQVD]V
MCRS"HFR>@45FKOR$B@QWV4;N#"O/+$+Y\E0UR<].,[1!>$N$>X)^7#<H/57Q
M?LG\%<:NCYKKOCX8DU7SN2;&G [+5,?=$_""K%ZD?O.V.!N50_*^!]!2=G^3
M8&S<EXPM D5_NC)?=\ZKOS_NE\?] XQKE20SUS_4?9$['I_&/?6C385[KX0.
M+6_R,)(8F=O9YXDL\"(0_//\&D51J.53%%K_(>6AJ*9=1F9V3)^B&*=D^AAZ
M:&LFFS31"S@@J]0%]S&2[QI/I+9M9^V2GR#. @B]V3.,G4?8Z'()'_T0)\6[
M= )<L$!WKIQ)3<U"H->4YL_:L;.^Y6X-#K@WN0#,2G#@L+/K* B<.*E^^Y5M
M/^N45I:I;2;"G[KG\1-,TC*D4\CUT.QAW+G0(,_,;D':8#"C1G;36E"6MY;.
MHCT7U1,^'8S=K>^AO?65-0!F27+<9]";Y^EC\<V%F?U""Z.3T?XZ9L,_?3%N
MQ":CI74"KU_G:EMOM<SIA2SP.'[HI% XVSVCJ^G*350N6 !L((^T;M_*&K^K
MXPJ@NJ]C3U/5J]^HE7)3/IM(,B- ^!J/,X3I^$8^.YR+OJHP#@XN2XJ LX[+
MU#P\Q(34N [L60%%CTRF?SP/:1SG-:OQZCP$<(GX/\:Q_I0L_?1L>.%[N6(]
MF F."?@TV]9/*[:?QPA+M+Z'B2V 6OZZ(CGJ[!$INT>DXB0T$:NO<0N?P4A?
M>ENG:#X%I=,CB.K%#6>NJF>!_-JZ<6)<A&Z,GWAH5C%<4C:T"X\AYL/QS\HM
M(B+=NKKI71$U38,S&L1(A\WH=048.J;;R["MVV& ^8 K:U=$&+!V'=-ZA;GL
MI4:ASW" \YJ>T2(K&'@D_JK<6-(=$2]!V/S-JSAS3*,Y/D0Q.3XYKU8#'M4%
MW9_XA+D@BC9T^<X#EVB_0JKMA(X;Q">B&7P<0J9#I=FL, /L41N0-P(!?HA(
M5U\VTA_T"K"1N8 _=?7P>I$T/9L4_6H6>K=HI*!LI_WASR!6+/@\A_#+ "SZ
M&W!)G@DK4<(Z02&;"XJ[4FJIC"'V7@0YM6X->WZ:8E9GL_'E+#98R86SYN5.
M2DTL9CYK<(\@JHS O-DJQJ(397F3*4NL/'^&2/6+>22I/8UFLJ>R(+[9G7!S
M>WDVN$M?^1F9<U2.PUS#9Q@>85D'$2$)K<L>WQ"O'@+_L2B(2%4(&I*XRE$W
M;[-+<LC:K"*<GSS.QJ)I&BNY7)4DWTSG*K\X*I55+IW$=]&&=^T'QQ1ZQ-\E
MI)>H'4W?C]"88."$-"4I[KVL<>9 LNJ6Y"U^J9F8<U01=_&&1L(1W>IBUO)H
M$F>(MFAD,[*$OK"E$"GS4+0DBI%6XDE;6EWL2'#%2\E2- *1W>+>],7M2''5
M2*^B(L69YY%ZX$Z0(6*1),?VZPI6E *]J^DH!2H7K"B%LG%^&01\TMQFE )7
M %64 GN: WRXM5*)923,M9^XR%P^MK=?/6E+V<1L91UE<L2L6-.M0FW',2LF
MO4[&3_Z$E7P+)$V<5V!4.,Z)TLWXK7*7!U;*"=(0.'E+JSDG>A:]60>O.SG5
M&^2/N+QJ48]=>[:MYN#F\VDUZ#- \#&KEPN+9L!'0'C"=\3PX.2!3NCO.S]$
M!R0?;S/8C]>JF68EHQ95=(V<6=WY#]A9;J(8^H_A%0E=<>N%0/[_]MZU-W(<
M213]*P066'0#KMGM/L"]%]A/+KO<XQU7V;!=TSC;& SD3*:M;5G*D92N\OSZ
MRR#UH,2GE,H(]9[S8:9=-DG%@X]X!Q1=DO]4I3"KNR)+Q0#^O?XHEOQ]X5TU
M'PY\.\1L6%TOU2'?--+.IEF3TAAQ])88-*T_BE8SO8P?#U6:\ZJZ*%Z?(%*T
M7W[A7>OY$+:7T0V*R[[13&#Z#%+?8IAM^LX*(#S?MPCUS<3>A/] :J\0(>%9
M..WU%_=-_*LN"BY?G3BPGT%>.>/]=-)--HF[@R(,T:28>6M]3LK?>0VQI ]<
MO .R+N9);BW/A[!O+3<HCDW53V#]#-(-%6;;L.V?%^'YMY9X2K?@B%:JXV8#
M)8^J/CSY)!LI[IOXMU847"[34S.<E=UXVOTUB;'Z5HNGPMR.M&6QYV7]#CFQ
M-91H%=>B['Q[VK<R^K,4/6PC87-V%5'3Y;/)V[EG+.?$;6XG<GI0;'4*2>9:
M/'XIBNVW-,O$^M=Y+4@*K=F4 >VTFW'"A_'OP7C@'/NQG\74M-%6)-F,TWFM
M;\>)-)EY-5Z_[I.TA%U^6UZFU;ZHDNQV!V5E;](WOL78F;- P-^C<\!T[=9N
M*;#M96*)#QFLP1*Y"*UA[Y@=H>_?V?2:X_U_X%"]0N!VE[Q[=ZO#<>";C^Q_
M](#B[+K0S(!BYW3A:!$\Z/P((23G)DK?\.<D:T5)E1/PS/--I[M,VQ7QJZ%&
M+4:#Y70\B?E2<BM@!;;1EZ#;/Y-YIWFEIA#D^+#'3?&<2P?8:1_&\/<H,A^#
M4#DSW50@HS:1N"U])#>MP8M>Y(_88147*(#Y[E)\*2ND_M&VFCF%923FBP3J
M:018SFVF9JJ R'XN<0GG&1P>[KLX>LQ52[N$D!.+^J[/H#OG79 X]4L8#GD?
MQ#IEB%$#"=R'X[%5)HWRERIT4&JK$+HM9'Q9@NXDM]8<"-#[-TZ'T27?.ZK2
M4X>+';$/PM54PX0Z(BDS*2'S "JORH^?]M(+?0U[8P;@<39(JK3J%-1;+Y*#
M@R3)"+3G;ZDN^O$S3R#TL;<;GS@<*?J[V-LL&K)@6"Q[[5>@E=XF<WD0832)
M($>$A13RQE3!@_=I]?N%S'B&GY8.!O%\B2 $Q V-NYY</P-,L6H&@RFD">(1
M+!RVW?!C/L>B>LEWO!3+W.[$?\6]*=M;SC&B12V$:C^+@<C5HJ69PN0<.EO9
M%.YH78 B\9YMO[CA5<6Y#!(_L=/(]R7\J\<#C2_XG]@6$<&M0:_) ))S^X?P
M9W@)[_F^*&61:@2I*>Z;!&UV8N!R>H'D7%:VDXDM%9/X.M 'HXDP<\=]X=^:
M*"-8O2QR\>-&Y51@;+[)GZ>P\D\%TK$IQ3+9>Y,3*2VR$*R6U^)WR;;80ZYZ
MTGV%[0>?(74.S-TB^CZ>1<+YO='$D\ZKV]UUODW?TNTAR;+WZU=(O2G3)&MC
MT,\W_SBDE71<5)\Y=*%9_&:="0:Z>6XFH*XDA;1)4M!FL-_4E+]16TN.W1O#
MV_D(NLW,*?^25-OD'[;]ZM Y!A.0XS?T;[MN13G$NCVP%0D;:3N%P4#E"*?!
M]=WM22Z<?EU\'U+[:9?3Z.[6Y#&%SVA,^H&3:(#$W+@;R[F?<%S=L]'+[K@@
M">6F>:]]].H[(6[T)7B\^,ZQ&]W=W=T4R13N#V?@5X'7/^\*=[^[8S#(<F6C
M%WRWT;<O\VX@,ZO\PN?+7S]]O+FYF,#%T13<4CS#C[LRLF 0$Z-6\?#:2=PQ
MTH+13.%).;NZ\O]-;YH)G/4N@'Y<?=#X_.==FU*MIY5E'Z 'S49PIX^:#>$^
MZ[!_2<3_WTTZ[*,IN(=]^'&GB"T&L;N5''8[B34YV\!HMJ8D_O\_D_VD!]B8
MA.J-&7_=RU Y;@WGUD7H(4_':,UK@?&0?C^_GG)A:^-16:E]V'45PX@52%$6
MDO:W[ B+>4S[E6=9Q2O^R#<O>9$5SRFO;NKM!#;Z5T"N=>B#Q57ZL)G#]$E,
MS/H3M5TLGD%]@<0@ >8';-SSJBY3Z! I^_=^S=.ZNG_X>A)SB?];Z"84+SBN
M".^'KQ7M%3*)<:,P[@"Z,PPPTL50OO_]+_>>O5+QS9^>B[=_:P:KK=+\H]\E
MVE)H6Z'_IH/??RE*GI :54P* U-'@,]T1K9!&5<'GLF C),<>]=7*%R+#E@<
MW&]',]FM8A7VU #+] /OPW6^J^_P5/%_'" !Y,VARA_OQ[-^ ]U)9X/")5IV
M8YD<O(JMXF75P*WFQ'2Z7%&5]=\?-CQ/RK2 LG:;I)JP2<1L;8.(?_6;P[,P
MVG/AAL$51]P,(O?&AMD"&R* W^Q+ ZJ9U.^085'D8H-=%M!^8>%+P_Z-A2^-
MS'-?6 %PM>.48UDWF/VFAI/>%UXN#;(9G)C.M!S]PG/5&^@IBVN3,9BPN(_=
MQF7CLP[.-D/8;W(0J>'/1M5.IS10F>M];1:Z27-^7?/7N.X7QB2$<VK]<(B+
MYT]":4HV-9T_U47?,2>'*,VS&T'9QE'IQB3?]HHC_"W^D,:OAL7]:(@\Q3K/
MF"S9J2TA8PO[1=3?S?./O7$F,U/KVC6%3*?;:M/NE&DK+A_<<=2N"UU(<7O.
MO*U6NN_<M]ET8LT)%(G>X=4)KKL*6VR9"-GQE]\/:K4?_TBW8'7D75@=+TK%
M?VOYFW&\[NJ>Y&J1*U(N9;\G5[PUC[LN;>2;_&B#:> QK3.N1U__FM8O][QI
M3?"2[A^+3WDM5,-X!3]@\)GZQ:4M0;9M.P,N5Y--6 52?_MU2 T!1_"XM1[-
M(<S,P 2(1WHILBTO*V60F/I@^U? V$IA,'Q19<V<?TWV1?4?K#$IK>CIC>+0
M,+[,2X9C8A M"T][0\.KG,"=-7G/A-[(F'T#:S"Y"&6,3"S3@OO'?/<6K>+^
M*":?Q)X=\T4<)78"1,[Z/?GS!UEY5PA@>JEL\[G#O:=FL#>J:ON((E-W';RD
M]X)0?#'/F;X:TD4U^JSK1JJ%:%#5Z4;(/EIM&NJ-X>! *^:,\9I5-CI]SM.=
M0%QLG3Y5%])R4UY=\CI)L^IA\\*WAXP7NWVSU81TW[4\F"#J+/0M+*UP(7B=
M@:#=ZJQ?GK7KLQ^:+_S(/K#V*R"F[ZV-)];@ZEEX+VGAJ,OQ86[\\;$03)3S
M%OP>HHUY0;"1#HU5S/P#'AR/1+HP3V8&^=E*OUV5,MYG,\%2<V1=P/$7<477
M"(A<B7N:3-+-L$HG:ZD)Z.!MJ!J@C1QSM27;^GV/[C^GO!0XON!M/O>WZ;>A
M$S9?:4HYGG43Y-WZY?ROEGVYDDT9Y'YH>_K)-"OW<-K]W'7!5GUR!,6S-'E*
M,]F<L"D2NMT)(&79T%.)YG.@P',TGAR7A663OK.Y D&>(PV(MOCKENWZ@K 6
M<7_E8LL16W>F,#.7M7,]IZ>$[I3ZPUQ(UJF'S\1F%8?:KH[\CSK82VDJQ[#Y
MB.XT65+S[5TB5*3',LFK9 ,NQ9.(D/YO83@&HR!Q-J&1<YB<Q+19-JV%)'$Q
M@I/#Q,40$8ZM''51O#Z)30VK)DTG+_U#Q@%H][; MDJW7-6^KF&&RKB*E_Y.
M"P&F2_*DF(0J8&D?E=>]_.Q@[SM?B_X-&$# -! ,D8^JIM9)]ZE1E^MTG)RE
MKIT*K&GRW>FAP%/73HX+];%U"'7_8\ZO6Z+#82WRNRO^WA;2VI?IAM=%(X%"
M 4$!W% 2%7\[O"*\Q4= ]0=XG^=C=[K#+P;V%=4D5*PN.FVO <Q0^QK8_JB/
M^?&;_]C+X<BM@/GHSP(511 X$K+5"P?'X;?:.^,/+DDL<QY(+I"C)0Z(U[H0
MXDR1I5NP(\CX<[!K+96DX%D<,=3.#86[ 5DW@;4S:#V(<:QJ@_ "&$\,EVA6
MW$)3XRU$)4JWX^T.RAR4_$7\.GWC;5=;0Z2<NW'B/X=@\I\*DWMCJ258MX;L
M;Z>OPIJFQH3"V%R&:]MO&J7F1 ';/J+6O4ADDUI7&L-B&]+U-9S(B8E03=N1
MS1YL5UG%*S^3Z;Y-Z:/5$4TUNH ,&<E?-;$:V]O\GF\.)?3X^YA4:?4U+YXJ
M7K[!,;C.]X?Z'HP+&_'(2[GAX[N<?@'.I-/& RT-)M+;?FH\'$=&I6?(<2OQ
M&YUZOUDCD$Y![/FU]QI)^G;W2U%LOZ69K6+2\=7W'%]!WN\.,%S! IJJUXZG
M%"XB63:HPN=!>/:6:9>:)"5,V"SF^B@6"N?G7?6<NBUA?^()=H:3,_J>L.,W
M-Q \S=.:RS2\Z[QN\O":"R[Y[Z*4]]27Y/4T^8Q3OXZZCR8"YPK-E:LTB8[]
M.BK5L3IC<JGF387%J)/<CMP8@P=S!@'G]NSM[DG/1T_[, 8_C+IYX^&*>#S]
M>]@,?B5]4V,W@/V9C:+6\G?MJ9[BJ$\BUD.-@6?61;J&8,TY?(Z\+VT*^F2_
MV5V?3=8EI7_AM6&2O^,E]$1.GH].,5[VBWA^KD7A=K7PTW,@NZ^<,?$=I\.J
M_]ZTU&-TE]1)MEK?5'!Q]LP-6ED*$L?]?^)CA?H$G 9R],-%_\R<=N,M?L@L
M3]=Q$KZ[P,I)Y?O 9W&31F/!"AR/,R:G#4_)RN3Y.';;I?D(XBQ>_.E4HGS$
M!S&S4,+@S-M[MOMU3<6?O!)\)%'F2AM:THLM!ZM4?][+G)AH&7WRHI@!JE.!
MBTA_\J4)-NLQN2!Y4.A<=G=/^"SJS0K)G/"E::+NK(7Q%,4YX"V[1QWRZ)HW
MJUOFG$W.V3GB1H%(XZ-I51UD&&)QJ*M:_#?-GX^I)SOA YBUHHZ <WI=4<?6
M5E^0$H'V#5)Y=+%=XJE).I'2L^H*SOOHM+OZZ(\0EE>>!NG)=SRQ%+SHGCEV
MYQ]K^^[40OC\QZ3B6XC(Y'DEXW'.RQ+J=LIR0A_?^S%WR3O\[OQ;4F[E_T'Y
M5B'2@VA_,G_X24#$U I/@8 K& TF,)BQDEBT4^ZO@7GC5#0^H1!5J#A3F4:Z
MA421Y^1CEFQ^%R,$=2O(_!"_>RVV//N6UB\RS4--6534.A8,VG+N2Z.SV"O6
MP*%RK[=,0L(2)F'YT ##&FB8!(<!/$P#:!5>*[R-/.5-7(++\VKAG1*VQ47+
M)4!!K(J'@M"Z3OA*7&>XVQKGI!]M#?$+%_*WU?FA?BG*])]\^S476#S4Q>;W
M6_E]$":J3]]YN4DK?@=IG+(8/J*,?!R$V&'LRZ/@ZBG=#&=R/),3UE$0]H0;
M+2PL'T_JV7YL&?1ZN_LU 7F]OBWOT^>7DWBN/1]"#/AS0^%*RY.1T.+):::P
MHF1R$G%+A7C^Z=LO@/Y\8X9UX5.YG@,?PPU]\ ,S?5?9I9*U["RONSF"%'/#
M&]0]>"WNQ>]\^UA<@UVNZZ%UJO96D1]%?JWCH')L/#69-;.AO(B:K\3NJI&[
MSQQV+()=.(WQ^FZ<0*>ENCL:$G0%0[9/\-[OE>&KJ@O^NL^*=WY<&\A9GUJ7
M R\"XL441O4M\4OY.=9^#PY ]T7R (ME-]0432^6%2?R]?D_O[AI)O9S:_+_
M1<*,?& <)I0_WLDYRDXRA3<S<V7:.BW?31>E_$M65-43WQ4E5_^ND^^\D@4R
MJWI*?<DEOH-GM5P 6L>!:<JNB*7=OG(UY ?XR(],?:;]I?P0Z[ZT"F_"@ENH
M.QQ+,6"NJ^^X[T][6);Z%E9NRT+P(AV0E1CC%]Y0"QT4RQ,R70SCS_)E*G:W
M^Z9FLBVB<5^4-1S+0@W*GZMFGGS>BCR'6H@9AXX:W1  ?H(N@P$(IJ:#@(]+
MK&N6@-/6?]P3JML"P;I/L!:,1M K<B8@81(4%0?6C01H5M%(%G$G]V(@%I=G
MJ5BG!6ZB H8%#)YZAH31BDXYN16:9%]CG?9C54*HHMB ^ LOGLMD_P+-Z1>K
M%NQ>&T6W\X+@JIZE#:0O$!QD3EL+TX_F3&-!U.ZUY48_O3\W@$Q(V%ON:ZCA
MC$M!O<RE[4CO?WIGW==68418?&M-NW*C&3(OP' !$$X@*T5_$3%<<$FX$4_0
M2JP,)]EHBYXDFX0RRW'?MF$XA_X)52I3 U0KA=/X[,/?0W;7!P$*]1/1)IZQ
M=NHZ@N:BF:O[Y>,(LD@3UI-W7J794B8$46U6;94\J9NKQG547:0P=0(56&10
M)>09W>Y.W:$WXH.HJ7!!<%SO<*(>6#EU%3%!\:P<A-[&$6"N*^H7GHO'-FL>
MVGCUR38/S;)E^;A3OY8C-?&+.EK&0_!.%'+A-U.Q'BXW3=1WS<54>ATPQ+/<
M(3\3\]XM"OL0/GVOOQ.U]43W<$V';LD>>>3E-N;S?%XSNN-\09,^->T*F[DT
MVFLV#[Y%]ZKM@ESU?G7?G4=0<^;S>OXL=$ P1-CD<<>>',]!O!9'GW;5A6A'
MD>M?/AIW7+<A-><:LI;..K(*(%JV6 "$R173J$7E,#/\)<^.:/+C7G3:VQ-8
M O'8^R&9OC?6(E/',<F_48QG8+EL@0629=:3!'-L<LLJ7(%1G K'T9\HNV3:
M]1*Q#'TV2.B2B=HYCNMF-;O'?>-$TF5^$O,]?SYD\'?5$_%$W@/;-Q SX*T
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M^0O/(51;P'2^?4WSM*I!IW_CH4BV/GSW6:T@694,UNBJXVXR\;S+KDR0+%+
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M3Y<5W?8=_0BI&+>Y$!D?DDS&%?2)TT*&G%Y1=YDOK:&<P%*XF(K/B1B#5D1
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M2,YC$)FQ'!^!.<J94I&XF_>__^7^5Q?!_U*4/&$_/!2'^N7',_8K51ZH#NM
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M[2'*"M7>ZD-VW%"K[FLM1L$JH958\38EZ[JQ2CN0-FL]35='Z+C>4"_VF*R
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M&\ZWL@3/KPG<GW5[$;HK5S5S5+);,ZM[B\ACU'TH.>22  F0BP'?W?IC"<6
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M]-88<!O%[<AAGX+>[G;%W8+JP/RH9!\83GS#C( /V!5[_% O;5/L;=LU"MA
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MOV3G9F?ZHF8T(X50.Y,65O'U*+HBFO:;ZB%7:?EZ[:Y!W51(@5'L^I*R,>4
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M>$)F40]Q5!.M&0)JXY *J=?/;P(X2UFI%ZN),_$'A> L6"<6+V#E8X'WY)&
M'@N(PL%[Q';=BMYWN/L5T)N.GV)B9)9U,-E1/+SC"L$OL &+[*^]D\CSO]+?
MH$@2=L^C/]OB $5/8;KAE[J=J6*:(K5P-E<.">;V(!)3"BI*QWR\9^J[A@FC
M(!>;T3U'%YT=-> :&7"5W'E['N"K**6IJ@\ MKF5F8^'J-UCG$;/[(_FRQD
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M%D)-)X-W0_ C/1:#D_WGA U9.33"6?AI^,C=HZZV?I86"T345&XT/=K1.,5
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MXZG2T$X&T!UT3FG@$T&N*0T7E(9?& UYO6Y!@^X[2DC4FG'''LWL,"BW.*)
MUHR,^R<\7HAYF!3WSQHMZ)&D?RLA*.!'8V/I&-6L\3QI*6)<OQ>8KIKELG)<
M?Z)-_@7.H",19K2X38I/5LUR.;EU9?6)IY],1LD8+6]*UB,GMX-YU8A?,%Y,
M0L7JE$SUUB6_3_45JB$3QW-L>FB'OX4/()MN=@Q<+TS#8ZPK^D0J0&\0\1GT
M-?WSCN =(NF>7L71;UFX8\_1#S=QO8OX$3S]<P&>FOKS$KSF)5L:K/K6NCDR
MX0".RKO5#4N.<3++@L6H?#9!H6_%O$99]-5$"DY5%9U9&F!5:]2FZIPG)44W
MD4=)KI!ULK^GGUNH2)7!Z.ADL6()JB>,%+=!:E/5^AIO=QGS3AA%$?)3@N/0
M/]"F4$XC!\EM_EY!X_/&Q5+,<?M$?;E:A3[JE9AY2J83A\O4FJ(D!Y@%/YU6
M388_HTWH1Y:*HAK G=[G-,76Y(_;X-$GCZXP1J1VY%NJ-15CFI4EE6*=?K0&
MI@G9%?(2M,%1<+FE)_LC;]!E9TOV89JE7'M9YW)XWQ7US>R(\ C8<2Q$5V05
MSC@:N<=Z ]UZ\5KZJC'0FNH(RX5K8NT&T6 31#,=/3');R0903E^*-&I?#5V
M=_CW6KS[%,;A-MN"<:\.SY'UZ65?8\5NWFMQ0KQG6-;7X$V2]?45S[C?C#5[
M:B$&6N]JHQB2[0@FMLYRN3"K%*1Y2[,5>.82E6,A8 VZHP2.4+^_U^[C 9FH
M&4[.&+;T$ K7;D./ ;3Z*5TA8$%^Q5X$OI9:<9I;D<RGJ"N'_G")MXR)U*,O
MN=WI)BD"*V]&G)4F'3(8YQEOD.*E?A>./+)_D9$X3#."%KSKEDX>2PK0C%(?
M<HQQTOOS+?D(EGQ\2X7,1:Z64R$ (?.W-,B+2X.\)9BU$LR.6FV\):T4DE9P
M#3.D*RB#S"_".^@R9L,M4I+_1,%CD0 SIXTDPY5"8#_"5=F\E-MN.Y)L./1.
MB.DC@1^P-H!LJI:F,Y(LRT"W-7\+W\^V&6_,=H8H>C^??4'_'"'.VCBH/H.0
MS"H8*P(861-U_GHU!DXF&G?QGW+=BM&:X3=[ZRVD#/Z142\JUY8>V'!4GQ'I
MW-9KSXC<9:!(;=H.7OE>LF'_0\>A[M1'HR2D)/2I+K)_,WQ65!_PLURQ&?+-
M.?)Q<'M R?Y-,X-EA$H_SLS!Q$$34WKJ$;(/XS4?,@.\]^1PNFZ6 "'[6@L^
M.4Z[.=Z/RSCQXJ_TY,!)**?!W5^Z?20%)3H!5QRWJ6C0W5(IX-TZB.ZE;=1A
M_H)&OAV=IO1'.R_>)_QT9UVS*!>3ZMACO1/SM ![SYT&!O:4@=4\%(>@,3/S
MU__^[;?O_N^73S__\?_]W__R=]GS+_$??PI^__%Q_<L^_GR6/7W\D?STXS\_
M_/OS_3Z)?GST?_\^^D?Z77J'_O'[CS]\?7[O7Z7?_^OBXL/=/[][?#XY_>7[
MQ^".//SGYD_!4_#++U\\_(/WC![^>+U:G7SXUX?]W\F'U?K#S3_N;_\=_;B-
M?OS3G__Q>/\+/M_??OT49?]QN8W^??_;S[>_7:#WI^>__.,_XK\_?_Z/BZ^!
M?WUR_<O3GW[V-N^3R_NKB^\7_[S\YV\^2GY/]NOT[O;??UY\V27I[X__]?&'
MS[O'Y.;[?SZ]?SKY5["+O'^?A#\FZ\_WZ/'?'\C%/SXO[S]^7'W.?CC]/Y=K
M\L_OMS_?77[ZX>M3]!_;BX?ES0__^67U\//G__-C\,/E^=7OB[_][?^].[V[
M_?9;Q;PF]28]UHC[P'@E*?9\[O9TD%11GL'L80%@2P;]9 DCR49JA,-U$@4<
MUKI6VB-G@HLVKX?0W(9>K^\1V=H22@<"5Y=4-0%U<<;5FT>^X=OD2UDST;>N
MI*!ESH0,@*S!<.3/)-EN%_&TIQ>QF_\JPD]AO,)DRQ&2?)A$BG&Y?.[S5/P=
M78_GKH*8>8H7%/'E$7$QQ>(>U_FNZQ&98M/8-@S-C1<&%Y@LMCBC'O!E[$=9
MP/K5W&]0,2V9D;1<<6Q7H?= W7$^:UUEE2"(W&](((7@E3@@K'?</*J^SAMO
MO[5P2Q4@<7,WA=PQM1X" DZZ<'WX7*SEZG-2]*I:/J1>&+,5GC_[&_9&B*Z>
MT[E\B,)U/G7B&L?*(5(01"_**L"PWG44J[Z(SC74>5%NDCUT@,N $B=7),BM
M5PM\F8@$-&X] 1_RP8N\V$?)!K%A9(=]"NLOGN1([AB2BC$ \ V'(&OX@28.
MK)0[ZMPN2XJC'1F:JK/5V-$=#2JMNF$2Z*<1Q5#PNF18ZJ1A_FE&V&(_>6E&
MN">Y7#46*7<)&P;C^)F>YHZ5X8^KR!0]G/V</!V1B;]V/MA"4U8]_(#*O>D8
M5WJ+(XR,,Y3_]S+F,W:.-!ZO<<!V507S;,]4+3:#-5I748@OB)T"*%@\4I+6
MZ!:Q-X2EDK)HMY)S) _-;>),4ZP*S *;$6ON.@U2_=ZJZR2!WM4^5U9^L3,E
MPV17>=8&;6=AXK-0WJV7(I/=W0EGKN>T%(^@7C2![^DJN44?ES'W=!?ZB>SI
M/F67WLV=[(6]'CN*$VT/=PB\JN<3HZ-K8EAZ++ZGZ*;7=&'K!R.N$+TB(T'(
ML$Q?G&7(SDA 5>RNZQBU)%XOAE%DM]NG1$KD6ACFIX[?<>!C7 4!'\FGI"0J
MI+*Q;G*1$G6H<Q6Y!O_ JIIMR9FK9&V &[C0.U"X.1:T]5]5^%U,=9S#D"7?
MT7G@ZK9FI!+JO'4]F:*7TL]Q4-PN4'#^[--?S0MMQE0)(0VN+G'V%43,=C?-
MH&YRYO*G<^U2*JG380#$'/?Z$%<@0^:.;N!G!=6WZ!'%&3*ORF@ U+Q8BZ 8
MF,$&2& #UX3N/! Y((>JI6IQ1M]MH?LLQ,%=ZI%4^]PZ9*VH.F+J39UD21C3
M;7R*MP]AG!=A2:F3%""WF2 )*<FQPTGSQP;U^<L)*=%T?SEY60@6[.3")]B]
MOWYOW[)-6T@]C-$_L'/#=AX'3;/FK(<'+W.F+$OWQKTY.*@;!DJ[YT8'"/5[
M:P4,]:]:<P7::Y:A4AFHQI&E@.-*:>JN%F#7\?<^A<J[0:B*N3$I5[/;PY&J
M>^+%B<<[VUEH^-Z'R8UL=#=6O9M##_\ ^KL#RM1*6_=^7$X;/4JHMH0DNQNX
MJSF$S$=5Z*!9_7V7_=@E&5A;GJ-G/YR&9=PYR*V/R\=/YJ"JS54Z\;#S&]>3
MLD(?/YD-JRNK=%('6EQN"5+6Z^I'<S$AM86"E6K.S*_0\YG->NOR^SH5P06E
MOHY?2N%Z/G>A>B:WCD,7"P$WYC]GK;+\D#4B.VS)0T&9\769%:=5X)I?GD4
MM2NQ6;G_+>4R52;6@.T,/:((\UZFEIZM#2-T7 @B+[Y:?:8$(QTE^SEI'U&,
MB!>Q!L7!-HQ#MI(T?$0%<7+F30[2A*(+$@*4Y Y<OV9W!B],D@P%7AS@+$U2
M^M\P7IOG\RXY5,JZY1&JIJ'K!:5QFM]MJ+JP42UT^["VDNF^=0:*>2)%N@D"
M]9VLB4XMHFB,Q+']EM%'MO'-E ,BX'A'.<-?@N3H67LQ'+-R PLAQWY<;D0&
ML#MK#?#ZV0DS85)+T V"K$0?NW&XO/!*J7=5@ (VZ<^+/#0$Q]LMCN]2['^U
M,G*I#=_M< MESG<P2'^[/"+R@-MQGAE:%O/SMA6-T#(?O/Z/2X=3E"RR=(-)
M^/O1%X0R(CV8'+GU0"Y/S<[T\=-)1Y$EH41[9)^3T^7!R-W/AL',:3]V"E&&
M55"9%X?]L=CJ'KR$LN3)(T&28K3=17B/V$-(-NN7L DL04B03[7)] 4DY^4)
MP[;@V.[Q>8EM66!C(8T2FV[3+$TL^H;SB)$=@?0F7R@[82W6\CEWQU\I:GTY
M;<L=CQ=4E.HZL^ WP-/GN&V%F1[5NUF#B\Z)9;>PGL;C[_-G1/PP03>$,GBZ
M"MI+]00:Z4Q2=?M%K7_,051AG_)&E<E91ICKO.$/)-2:4/<!>!$:T<\BE_VU
M3'7T(_U%UFOYABN2C8&C-BATI50R6P72@G1*9]K'7Z*TI"D=@8"4.^JA#JV=
MD+($O,IIQ.>Q_S6_8>;,R0G.;Y[\'XL%E31#AV,T"'!4YZ.L0QJLU3@OQ2G8
M\2U8N9)9&C$UXN>BA".+%*QPTLT5] *3%0K3C!S7.S&?KXO"U^+S=4I'HW14
M-&7<D=_7L:PYV4U5\E^)!Z@L59>=+4UWYOGS+B3Y,^R)VLTN"E^+W>R43J%N
M?YJOW>Q8UISLIBKYK\1N*DNU4.0?YV@W*X?$(@ZF;T6'Z7TA6FHNMT(M_PQA
M7R>IFE.RM5;7\E*N^G8%7NC[3R/?_//,=Y'*>F@NK9IH7*3G<;!<,39*Y>[T
M(+^(I)XF4Z&"/Q,N/@#O+#1F^<&\E=*!I/6?)0M;)3FXFO-%L>JY219XM>E[
M*_ 2BPXJ2.1:%6?D/,I2_2)._M%%K1&&FMX(%YPO^I'UR U8:\JU=Q)Y_E?Z
M&_07DQU=*OW9%@<H>@K3C9<DV3;_Y/@V5:^LN6 W[\X;?&:8%U7,-SGF3PSS
M%XIY<<2L6>$,@%#1PY.HK#?EOQ0+[)-AY_FO/E57T(]J(4AQ_?0>;L=)/K\R
M5N[F.UZMLY\;]WOZBQ8>[M9A.SM'1[,SU8.VP5>(%[SC)F.."XB#F\B+K[TM
MLO+ZUPJ)3IN3=>XIF&1*GU0:O0V5]*6J[KDE+)1>H679$ R7#[J%(AE<N*L)
M)PE)?[UE^B!KF.D'E>U&_W;<:G583N[AHQKA!N_T7RM$FM'K P'R;_9EQ%=]
MH>_ OG6J9(W?C4VC98H8L$]A'&ZS+1CWZO <)7YZV==8,9S546:]]PS+^AJ\
M2;*^OF+H(44OULJ.=4>MI)]<Q-LOO)#P6V'ERL>:J_DI"L["QS! <<"F%T\E
MO"E-[PO4T59D R3V*:\!KL;06UWBSSBB8-A,L;FH>8/BJ38.F9.>-Y7 R4PF
M*RN\#9.O%P2ARYA2AI)TZDK>2>^;+0?7 #@_T$#)'YI+S)\9'KL^?8XIE957
MARPHE-1R<=SOK>3MBD!W(WUWBU@0B8KB%,<\FIUYT3TBVP\VML($5N5JAJ';
M'3,!Q@,^)738CCA>8;+EP'WZ?XBPI5;:?]'_CXXLROM@&3:ZNCRB/#V@K%;L
ML=K. \J\4$"WE[$)*OU4U&E$=7FY^N(Q*YXNR2W3J(Y$KGG/2S$BW2Z=71 %
M:58[Y#<2J4Z[& -H:JW#9X]>O.5 E=(@PUO,<@Y323ZMJF2%9)3H6]<2$":B
MA(MUTOPFIZ:R3959W_YVXJSO6*S32^YKGNFH9Z]DIC@:)0'?QCC.?XSC-8X/
M_6@5C%K'9Z[MF21+NQ;LHC75BTTN*LK#:LH1,IXJ%1LXV;>C S9F@%B@T/7^
M53O<K,A(/Q:CZ=(#K*:]EA'+$LTH=*UQ%O<YD*J*A6MPY"]C=!W&B%IEI7FW
M'9^]< %V,<K)'8CBOW^BO-BK#8/N^.R%2ZR+44[F25/\=^'SOQ#![']JNZS]
MH6-/SOXVZ^"5HQ:+*5>?E$UM7L0!W_X(Q7_/XH"B3S<J=R1)4"]\2\HR%&PV
MMKZTSYG'N5_AC #(NP?8R][.\CP%>^6M>)IN0GHEO<%AG#)U5!U%W_.YTQE]
MED_6'J8!/FY6V[V<)JID]/A(]TGXK+=M!Z&\= L]S$:HYG-*XEWAG*S<H\-*
MKJ_HVQ<N2B'+--JTF0OP@E$34VM1ZA8OBE&08B^ %R[*?N:!M2%3D2=SS_D)
M4/KJ:M?1GL]?\,'9Q[0RF&"<S%:\FG*G3.]RVO6IXQ&YUF^GG>PJ93=N)(A2
M4U,F->%U??K2A=?)KE)XXP:%[I]R2T#_JQS(:W_XLF^1W;PJY081%5(K/*4G
M,$*Q[M[K^?P%'WU]3"LE:1SO49(B>J0<*4GB7I7J[7\ Q,O>E$/\*X4*$=%1
MM*R(T\/IN@@?64!9R;X*/W_!V[./::4DC6,ZK[?'AUI=0W>/#@WK&.GNH;<F
M'6]-.EY"DPZYWM6JE703XWQSP? E<Y.UE+*/C"K9I;=1[R]IU+O:*S.7\]RG
M-*%9L]ZLG)%067K!C"D7&/90_5*TUH(\W3>Q:#W(;N_-UIR.P;WI]BV_W14X
MCC=H*O/88@;TCMYF6TQUMH4[MT \P$(C3DV5^0$WC*FCM@X)6W3 =^(N7W62
MXL/CJ6-/?]T>#IRI096KU5D.FMT:)('::4(OPS&IY<"@4C=9QHA;&\WN.J]J
M?1Y<#R61UF7)?I%2ZM3L^:!S0N6&[)*W:0GN\6629 >J+'6"D$(YT=[,"MN\
M>L[(<7GLWO@OYP6PBA8// 4&;%DY:]6%/ \J7K@[7[IR?YBD+]VF;Y8V<*PP
M7,/?UMBV^0C#N]0CJ5X 8Z2@HH)#-08Q4VTBJZ&6XPE0_V@WUE*HO?>17:H/
MLY(_$IR,$P@VHW"V![)5.]HI2^A^_V,-:.I<TY2R;H"43[:]L4UEAI0\V.-B
M'1T_*_ )ULG&Z=$[#&NDGWE1,\US@0F[UW@QN *#D?42M1-.9D[>.?.K<'"6
MH7M\PGHHHR2A*WD(8[X0*<]R ,1T&TAK2'V(76['4[,<;TDAH4YG;O!RI:LD
M@ _)WP#ZI%,GX$5IAXD@-)Y*_Y1K3HS6K)V:9>]_Z) MES)+#TN-^)>ILR,K
M@/[#\:X\J'Q,1G9KTJ-YA<*T:2-%T15UL"]*BW38JO'R7&3Q'-F\8C$9F:?5
M4R7_);KOX^N DP?Z4(&ACM5.+,C71>%;D$]:EF"-!US9Y//G74CX1[.TR:KD
MO]ED"!V :]F@5F!1E%QWU[4FIRPN%$62+J@TL!?E>,JS$*ZS@^N3E\\%FK25
ML[J6%Z6_TV"I2?N,UG5\&M4[<H\]7=?OO.FQC!P-6H+DY1'G<:"IGV.5@#35
M=0I5/"]&.<<4HD&G$U-=?7M5-']5M?_RR+QSBY)2]FV8ZG3+E.K]<O4+\N2*
MS#7 OBB3IL/64@',F_6Z?GK&6>57-@9Z9G\$>WK6VGCG!7R3IV?#0 TF4RW3
M#2*G.$F7JR4]1RC\>'W+FG)ET)>_/DR./%I-X=5>X/3Q#^KIA]Y8Q(1N7G]#
M;W5GE)X([YA]H+<Z@JG' 3_ALA^;DX,60+R#7(1K462P?^]0%.5SGS]YY"MB
M.E@LSL8>[L$V5S$/<M'U $%.X$<44PL340(7P3:,0[:>-'Q$%F4]A'+6 A_D
M)^#$(/W"/%Z%7"^/^-F+,G2,7%<7;^7]A"X9<]4.?;Z#U>(Z]97#F/Z0'G9)
M\H!6F*#\[ZGWC!*?WA'I1D%!Z3'K><N7'.(5Q7#",>1_OV<83DL,FCZS$FCE
MLN<26.LN)L\SF>5 X%&. YDA;5TW+2[PJMJDP:&)T5%C7@X.H4;U-@V H],M
M]&;HP^3F\@>XDR7FJL,U8M#:TU&7ABJT9AB&XKI3@^1L< EVN+BT'\@HO1-E
MV;2_G95$.I8.=;-6ZOK.%&$9YS2IM'OO^,[)>W9%YG>N%WB\[7QM.I@_U.Q3
MHG-6'UV-"[I6UI$PC#/>:Q,5%1LMBW9&_Y"DH0]\EIM0,D.UZ$VW&4E%XZ01
M/F082:4N&)/6L7N-*@EQ=<I-2Z<.8M$X-"%? S8/\Q,4HU686E&7-I87JPL=
M#-4XI.N"OM=/S9]FA+%"*3[3_,914MV"J%K<<#1GOJ#C'J=>I"*2_ ,WEW"!
M)E786BP'\*A4X6G9I$%)U5L?N8A165#T-C. H]W*8@'SB0<D:>KQCB]^D>)6
MY3A+W]6 ^$[?%5[R%<_TI8A].NXEFQ:(R?X:P?N4%=#3V[/='#!V K6"9#<$
MYZE#UH7HJ"12^TKT[0MRW87LT>CQ ]NWX+CS%VE*PH<L91&O>WS#V6/M3M^)
M[.7X_[+<!6S4X[(V@"#*#C^,0@X?9R3=(,HNZA1XT9%G^6TUQ?G0E.;/C]6V
M>M4#MS4:EAFY/]+0O#'?XP6GH?ESS>H"4-2::=NW?6Q9%S2VM;XC? _1_N!\
MM4(^JUT[+.V6PJ[S9I%>H( 5O-U1$67,B:C],K#>0%#DNBS<MFZ!2 VP MDH
MY%LG6Q"X'%<'86E[Z=H(+$DWEY.!Q10WV1JI9R'=AHS]83-P:DL!!ZEX):>J
MAG@T@NLV+E$MRD\W[('E95Q>XNDO+!+J 2>L9CB7713A)PM=E@$(<EM$Z4C7
ME"0&%^D&U+D;$F+"GF@*HS"VE*L3L[-N::XUJ5L.8"V=896&KQ1M=VG^[^/H
M2Q/IJU65%O<UHD(3?# 2%(2GWK/';:@7!W3%#W39:7A\7:T7[6D9Z$4<7!V!
M:P9R9*'JIHR/<'5RQ^VOG;N$BF*HIIPZ>.%TGGV+KL/3;1;G.?4(V:\PX8W@
M@.VC"F971G)0@[O&6$BQ$G 4(HC8#^^XNY]YVY;]$/IY*L @4QT'K%H$\VQ0
M_K/B8&>4DT?>$6_A^X0>_0G_+ZH:/-O:H4N6V^2UGLYHB\#M;+&V\6//RJT?
M&1S)',5<L >N0!)$:#:>S N0N XA:_AP0VP#L^8FLCS<MNS;YTY4[N^S )+M
M9B)<&!_LP*[0!U\(-H3-;:P4<@,WV0AEEE5D?$7]Q':\]0*3%K52UV<%<#,T
MQ2K, BS--MRSE45]Q#AX"B/6<>>2\CM>AZS58'%KJ/_=WJ[6I&>.\1= :0!'
MLQW%*1_+W>.5NV?'JC4IR!TF[.?!@5,F$<OV)KTIT-SD:+3>E9C !XN464]G
M2N8KW>Y%;0'W'L@]B4>-D%G7@'?%GA0$>0D2#2T-XWQ*FY3N2@.;MVCE>3:)
M:U/1J#1O;G:@'>7_M;2O^W&Z]LI -_8 >X'[;( ;=O!)&-,O11G+KE<:_FM<
MM]K]_ET^!V">$_.6<)GX2=":MR+G/1)Q'+-T<(182OCP*^R9A?DC@!+S(>5T
M5V#F31^7,;W5WC',U,&M9:6T2_^-$2H>P25XO#H^SFL]7#&5@!03QB!$_;9I
MF:PKI8Z&HQ'CI(>.C7W'1ZR,HN)OK1*-9#^B&1JWEZ+2T$5V$BYN3Q7:PC4^
MF4-'N.8JG=3IW'I!B".\WM\A\L@&)"GP7/3M3-HA"I?NHAWBXO(.1QG?[PH2
M:'_EQFPI<KYCL:ZZ_O.F-RKM)RN_[^("I=IULKH\\&Y)+_A@',_?;7:LU/29
M>/P#WD$JP#K+NH]\[:C[1"5/31X>ZT6$2QH.3OWQ;32PB+LPN+GV.!1U)YOU
MW8#FO%T5R5^$L1?[H1=UCIH1G$JMCYS$]AP(L,TM-V6*!SJZGOH,":WV4N=U
MB:WQ-L?<-3%OSGL6LBXTK%,7"HX<N4;I<G7O/0-;7R74K\XLJPG&>1T.1>H7
MG23B8+%E:8S?^5_!DSMB3"\R;-6K)+U\!ZNET=$(EH/RV2VM=SP6L')((GV-
M#KVL/. >BKI+%NX(XTNZIPQ"OV4A?P_TL%\CO";>;K,W*[JZ*8#3[79> C_9
M?RR!:R;]9*&J;D<IE9/B%UAN2@J;1C0+ KF%5)PT1M<U*8J*+1THDM.N>NI,
M2? )27]EW8'XW/F27O; 7C9K1@%43A?ZM^/)T@][P@Z'RIYFHAQ@HH.18IRB
M?*E5>L[PU@NEO,HAL0IANQ&KE!H?1"5F3"5@IWR5]W$6IV3_Z^55#X,3Y/]A
MC1^_*WXYYW'QER.+*Z"<W-VDV5E=LY-R29^/(/#WO_[S]HL,VXM?+_A>_*W"
M^"JXB:MR?>F >3 =I?]\!Z;T%-0\E)ZMV4G\J23@'S=@3*>@YL%TMF:P@,W+
M<#^ G?=67E$KAE%ZQ#>1%Z=5MY@_,(=_$SJ,;]*1"]6[534\(<%JP(&ICN(2
M#UX2^BQ20Y>:L#!,F% KX6>\FN%A'X2/81#&:[IB]DM>I0]TBND/*<2=%^\3
M_!33[P]US7IAC!-&"XLNWR#"0T*7R>F!EI/]64'+_::C)S7]X6E.R]V2TZ(9
M]+!#@WX4FZI9I0WW(]7N'!=%M,7Q78K]KQL<42U,..7 NU\5N^MX@54-JMH&
M9;% #@U2K*C:H"\H7&_8//9':BC7E$_T9]<9*T):KI:$<L0C^_QU5AC?;W#&
MPKARX29MX&X?NUC7$WVF.VH1Q3G"VE6%4<:TK<(;*47H^_[%6X5>Y@%74H[J
M)WQ$,>MS7KA5WVB?8DNR]N(B"7A*_30<A4&9(+RIT+U<'2H1#K<7P4EN7F@%
M0I/J';/.4?DT1M=W9KC5\@JB;UW7EH-J%MO+G0(R?T13OHA>^/06D826'M"(
ML+B24H^V5[TI(7-&?^G21Q'[(T%(/MAO*+@Z/M<;;4"!A\398%XC(: CHCM$
M0I0L5Y<QOZ1F7A3M+[=;NK<)W>0=-'0^Y#"6G#89+E\K* A3G\UPGBS@J\7D
M9%_]E_$>,78A=N,82QIE%0;J^[B15J2^BT8K=KD#@6M#K*[8(JEV&V.UAZ%)
MX/VF]"RT\L$DW\8-\+&^8L#+NMX9F#TD].[*(@D>N^GRP),%FR;&XZA(7M*&
M]?!'/\.H73URH.I(R[6W99&AH_I9L6(2")T^T!Y4XYI,);C7K#?1?(=PL[3B
M,A[ASH?K%5Y ^W73,1O" $DE,Z[KJG2T1+M+T:[B.+/\8KJ_C"F74))>'NY,
M-XCXC#]KZ-)T$)*F$5KH3>3"L-Y).XC+.&3#_VZRARCTEVP:8!BOKU'*YTP@
MR23-() I;,9."0XO']08C9N##]=QN I]5ES@\S(<NK8;3!=*[]O'B+O60Y<6
M/$LQ]!Y$BC>)>^^YF*XJ,G>B#&37AXZ\4GG^\QQAYY(=3X=ZH-:/DIJQ^/B%
MYZ/%EJT$6&V$:)SZ0W)2&V85; 9W5)O4<5)Z<<#KG:I>=C4=J*1GIXC03^/J
M=5NI3J?O>^5(H=)BY3-U&F UTO4J2-0R?9J@G6Q="7WB^7D-21L\_GEKG&>R
MN:;;!F^ *NL!Z(E%;21;7DERS2 CF#?NN[Q* ^4&A96/9M ]K+U01]5BG^\6
MMXNSO^,HR'OT*/!=\.DD<P%-_HN6[:I9WJ>S+^<G5U<J?3D;G\S!@#17Z;0W
MS>NLXX$YS8?*?(S2QV]U/B^LSJ<#NH*=$W_M.#8DP=^>E3L>(+Q@TZSOZ2]:
ML'EUV/.V= T^P>2:M5+-G9UU%H0N99W7P)[LC[]SX^W9SSCUQR7$ 7L!QW*M
M=I+3-DAT&TCLVB6U%+85J9@T6;BYN;G"GHJ!K7_A^M02LKRQ,.!F"K,Q3+KQ
MPD;BV\ ()9=)DAT#TI#&HP0]@TA7*Q3;,@L'/CE)!)UO=Q'>([3<Y<'4.+A%
M24I"GW5I8_4AG^-0<B"M)*A9'/2=8I/EE>LBP0LO)&P.%[I&*9_*50Y"W0-O
MQAY$+H)K<!NSCX-0L1\5R2ZS-$GI6MC\(6XSE)YJBK]V=#4R%U0/0YQ$BXH)
M)OGXPX3-/0RYD9"2C_#CZ?L=G<(1,P.JX8S659;MX\H-FST>#(.BD0A?64X.
M]"U7%NUL]Z(Z@X$';,M?>C+B;^@-JT:9W.6G\\MY'G("+H VW94623E ]#3"
M=%UK=<GT IBOK]G/ET)6/XZ]@19!P+>V%ZD+2O3M?&4DY$8AGC^/GA[TGL-M
MMEVLUX3WD.FJY1.E";L_G>L-6\2)0C(_C1Q./]PG%&M=N[Z;J5/8R8+RICQN
MS.,,):5+NER5-SRY&(?@T[EN$Q$G2KF,'L*HN(]G=-O*'2R-;V;K2+<67XIA
MY%E*/<]H*B06Q1RG.&GN'1OOE$2(Y[KS='A<J@/ _$B]*LA\'!\?^%,^G;(S
M0Z47U7P=1CE.EF(>>XX2I:8]WE!43%G\[ERWWV&M);-'CT54=OER=8AAJCB'
M_1!FZB8.L*44EWF40B=NI"FHGL_G'4'JDQ!$;$+GE#KUDDU1E!:PH745A0(^
MI/HPS=4N2G&Q%#% ?$,I"5;MH2J7^*I],5^_H;'RDO_&40SM_14'[#_L$?VC
M%['RI</MGLV(C'"2-24$L]ND\,[3IFKPM\Q$CQL]X8LZ=.#W(FK\5YALO=A'
M?#;@N4=BG*7)\E&RL$P)X$S=&C6FE8(==P10)9Q-E<\HP-_Z?J[G82]/2C&-
M_@RHHS-2C;1;Y*/P$04WM75"5^*I(9^W55;E=*D:XU:A\)45P05YTUM^,-<]
M6E]UR7F(Z(DZ\U5B*+4/9LW\9C3EP^C1E#N4IA$*+F-FIA6OYZ)OYWM?$'*C
ME(]Q^$2II5629,S1:4S!4)32,)3YRDN"0Z7DC,,J>AYA\21%T0\LOYJK<>M8
M?RF'T6L[#GT9MSN/164N*1/C=?@0(9ZTK61R@?T\"80SO92IL+24.T3EB%[I
MR')%/4_6K(KRH^:#EK7I(9+S.]0@SC:;KLBXLFS</)BBEEH@8>R'.R_**Y3X
MT*CB"9M<;J'G^[F:W5Z>E'(:O32ES-,N?)]D*+F5+4_I^FZF!K.3!:5 S*,@
M*M)@RG"/R%9*!(=?GJ^+>%QOR6_CT(*2)\@+PZH%2B)_0^04]@&8KUCZ^5**
MRLE[EXLP#E-TQ:)3#<<FN47L 3D]$:F!)6DQ3"M_KO,>V'O4I6*V;H<Q^TNE
M,8ZAC-U+]"/&P5,81<WE7C-7VG">8 E[$;>X><R(6>IYK(;;H-=*F6\7:LXM
M2OA )N[6 J]2%;O;_FU:^E![K*;*;,#)WQJF/-I^PC&BM@(%R_@R399/<=5X
MV*G"E$;KN,.2L3+(\W?&K9[+Z?9>9;!]TS1K:6<)F+6G21<5Z);L\3 ^@_ :
M/^K/$!6 '^8Z' =530!>RR ZMV966K35W33,0K!.)YH*FP=SDPM,CI6,G.K<
M:$#[P,/X7'=3TI*S!!N!.Z&,:B^O$%U04C6/.KJ60[%D"1O =5N<<C"\FPUE
M863'E^C&X;(%<[=DJ@HNX(LCZ\6I82$@U=!+YX>.738Q\[N7Z:JE4DZG-M=;
M7TY3X06K=-'IZ&>T"?T()9RD\H218GCWE]-DN&"54*V+#)VB"]3,)$*Z0!SZ
M9,V/D!U0K8M4L[\/)/0Y:RX\GW<@R]O.(;K8S1EZ1!'FCIH7G2*6G5$U4T8(
M)BM%,[:Y:D_4H7NWK:(;R*UX>RC.F:(0A>QPTZFH).>3%WMYTUYJ&.PXRYTH
M)B^G;L; M2H:^P)8MF J2HLK-T&=!E?EF^^A=(6P\<@@&-WK7P/T-8[]C!!X
MPR/&XTBUY453GP,H9)?^S? 1D0?<J(485=DKHUFTIY%6Q[L<&J8J:7D_!%4%
M[UR3_%R_GL\5?>Q.2%=*0_H&0#C:05(29YNG3Q2-P7N:Q_)KGKTWK.CCSMB#
M%.#;D#V70_9NE&:--3Z9 Q^;JP2>%R'Y>BE\7EPJ\+GZ^RX#7)(\KBT/<'2>
M"HN_H"BB]Q=TC_Q-C".\IH92;7YD/X0YZ/H #YR.V1,L(3G95_]EO-.\"_&,
M#_=./KJ;PE>EQ?H!/Y$Y>^H:+I)K]^&N?+;_P]LI#8!J?33!HV> F^UU.YJO
MMU@3Q$-E;8LF*J"O?>%*F>6,46-U3@Z6 PU=]F6(QS63,3J3.Y6CQE>("7#Y
M$^.B<.< 6<4+[0/@2D&%O.M?KB,SD)#TUULV U#6L:$?5(X_^K?CT5>'Y<(V
MRQF'QIKU\ZJ1EETXH._2='VF.U;[3D6J<;NAZ5HF@P'[%,:LLSX8]^KP'%G<
M7O8U5@QG*I19GP\U@&-]#=XD65]?,5SL8**V<2A14*E,T"SS$<4+,\3:?-[C
MZK^/%'3M1.TDGB*7IY$)OW:S$[!R5#/3^Y!>QDE*,NY$6FL9(L;C/D\E*=@>
M5D$= #H2/%^M$-6P1W09^WB+[KUG]@C_%ODX9F5.G)?7F.5_,_IKU+K8*5#1
M)F,R;FFO\/6Y#'9":;]=*DB!#I/684\J_- KR@9/P$(1!A)B(^ )VE"*#AIV
MAE9T$<$)BND?4C[G':4W),2DF*7))H"<4E+#=$%"-A#N+"/T_^>/QD_0"A.F
MI39D;I':V1P&UL7F="XJ0=YR=>7%X)-/CX!G(^DJ,Z#*@)7:07G[9+';$4SO
M/93TJ.&#BYI M;Z:T"6GD]\=ZX2KZC5X!9?O:^"-4(4\#P>HQ@NP"E[-%M<>
MH50OXN"+MP9W:UK@YR&?-E? 1HZJ".E\NXLP+\X_9B84WY\,@)C\P3'$ KB!
MHSJ[YW-:]#<L1@_$Z\(5OB&8W5V8 A6N"O3.4D(]DVB/&CO!AIOJ2)Z/#&0O
M^>U<!UO@YV$WVUP!G'1JVHJ"8!^A(&&!PS.TPTF8+N-V'U#0;A1"E/,0IQSW
M8*>HCMN# L=K]BR;+<2XAQH+:5IOEB9 HKU!2@XPN.U^G^:N>1.\RYJF?@'5
M_/,65\!2"Z9"LB@@Q\V0],1CDB]HO0I3W$2+.,Z\J.S:*]VQN.,SU\63P[SO
M6BM@ XM1S?XIWF[#E!]M7AP<NI?[8;T?D:9C>("]:,*V?3BHX58/L[/N[EG$
M@+9;6 ATO?&)TS)^+=$PW6^NVU6>^9Q2G$;\$GR/OWB$>&PIO(F[7#"@YWNW
MME];-+TL 2TE&M5"\6K*#8XH_0EK%I?NS?M(\NEJ-9C7.+5EB@:0J=L>(4?D
M'QP/@ "DJ76KTJ/KJO;^V-GFE%.<0Q%PCY":3Y&U\FE/'@GNZ2]:>*Q4A^W*
M*9-3]5I:K<X3=X^,.>DG;.(J2^>B."GX15@%(C?O)_OC[Q3Q!4[]<0EQP#.]
MWA99>;IDA42G^[-S1]32&5:D8E+I?*SOHT8D]%,4<"/S.0[3Y/;NLWP)KE)]
M9!^N:4MP@$^P)7.3-'4R9VWE/JINPBIII>6*8WMH[ICN8+^PHY \O,F=-)UA
M824.N:[%93<*'//=PLN+.+W),DN3E-[YZ>W"PMV[']\\A*S /S<O-:0/-=&9
M=DW5ERMQSHQC%7)R_HR('R8(NE++*JEN+NYZ2F579DZ+@[675KS!N<[845[8
MU>0&D;SR 4$72]FCTXD'-;(>#@O+<05T][&<T[G(T@TF; ;+YY@2F=MVOJN8
M:W_823?4T43\R5C%VN>_EWQ!X7I#O=#%(R+>&M4^.4'K,&9CMTZ\B$U;AA[S
M,*FE.2J<,E#WJ7 .L-.SVA;YF=ZA#L7A4BY\_8MY^&^-5;KNM=RM>FU+^]"T
MM(?QPHLDR;:YHK';!;L#L]SO.-8%A- 78"M@!.:J!/U0.LKH8&,GD?1H6\&G
M<W"Z1:N&ZQ@]KJ-<G#8?>8KOLACH^9'@!+QHW0*%\S@\K,I(OX3>M$ZG-I7^
MXO!Z+,D](.DZAAX0LS#Q0VP JZ77,0OYT1$$]+#PGF^1C\)'%@*VUBU]&-^\
MMJP$_\ *YA6WW[$K%#V1UO0<4MAWHF_G(1SARL'*XG6V6E$F4[NG7<8^88_2
M@'=9+ZIYR%".:X!%\(JM[WV&.EATSR@6[*KV5W-P:#O66K(=(MPV>I'7H?N%
MWCB(4C&/8&S7E_9A4L[C-%<O7\?5_:6B,6P":6F<$@E7M4HMAY4$$LK MI*
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M+FAT;5!+ 0(4 Q0    ( -!!HE3FF5NB%@<  ,(A   8              "
M <VT! !F,C!F,C R,65X,3(M,5]N86YO>"YH=&U02P$"% ,4    " #00:)4
M%_M[90X'  "9(@  &               @ $9O 0 9C(P9C(P,C%E>#$R+3)?
M;F%N;W@N:'1M4$L! A0#%     @ T$&B5'6X( 77 P  =!8  !@
M     ( !7<,$ &8R,&8R,#(Q97@Q,RTQ7VYA;F]X+FAT;5!+ 0(4 Q0    (
M -!!HE1,%<L5J ,  %0.   8              "  6K'! !F,C!F,C R,65X
M,3,M,E]N86YO>"YH=&U02P$"% ,4    " #00:)4-:Q(I/\"  "W"@  &
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M,&8R,#(Q97@T+3)?;F%N;W@N:'1M4$L! A0#%     @ T$&B5%-&UU(+%0
M68<  !<              ( !)F@' &8R,&8R,#(Q97@T+3-?;F%N;W@N:'1M
M4$L! A0#%     @ T$&B5-8/+RI'D0$ $D0, !<              ( !9GT'
M &8R,&8R,#(Q97@T+31?;F%N;W@N:'1M4$L! A0#%     @ T$&B5-C0@8.?
M @  $QL  !<              ( !X@X) &8R,&8R,#(Q97@X+3%?;F%N;W@N
M:'1M4$L! A0#%     @ T$&B5)EH<T'K!P  * D   T              ( !
MMA$) &EM86=E7S P-RYJ<&=02P$"% ,4    " #00:)4V$?K+B@C  !?J0$
M$0              @ ',&0D ;FYO>"TR,#(Q,3(S,2YX<V102P$"% ,4
M" #00:)4L$6KA&L-   /GP  %0              @ $C/0D ;FYO>"TR,#(Q
M,3(S,5]C86PN>&UL4$L! A0#%     @ T$&B5,0\J=K'80  RA$& !4
M         ( !P4H) &YN;W@M,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    (
M -!!HE3D4V(<@N(  (QJ"P 5              "  ;NL"0!N;F]X+3(P,C$Q
M,C,Q7VQA8BYX;6Q02P$"% ,4    " #00:)4;GNOLVAB  #31 8 %0
M        @ %PCPH ;FYO>"TR,#(Q,3(S,5]P<F4N>&UL4$L%!@     2 !(
*R00   OR"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
